ID   5HT1A_HUMAN             Reviewed;         422 AA.
AC   P08908; Q6LAE7;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1993, sequence version 3.
DT   02-MAR-2010, entry version 108.
DE   RecName: Full=5-hydroxytryptamine receptor 1A;
DE            Short=5-HT-1A;
DE            Short=5-HT1A;
DE   AltName: Full=Serotonin receptor 1A;
DE   AltName: Full=G-21;
GN   Name=HTR1A; Synonyms=ADRB2RL1, ADRBRL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=87315369; PubMed=3041227; DOI=10.1038/329075a0;
RA   Kobilka B.K., Frielle T., Collins S., Yang-Feng T.L., Kobilka T.S.,
RA   Francke U., Lefkowitz R.J., Caron M.G.;
RT   "An intronless gene encoding a potential member of the family of
RT   receptors coupled to guanine nucleotide regulatory proteins.";
RL   Nature 329:75-79(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Saltzman A.G., Morse B., Felder S.;
RT   "Nucleotide and deduced amino acid sequence of the human serotonin 5-
RT   HT1a receptor gene.";
RL   Submitted (FEB-1991) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Levy F.O., Gudermann T., Birnbaumer M., Kaumann A.J., Birnbaumer L.;
RL   Submitted (MAY-1992) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=15014171; DOI=10.1093/molbev/msh100;
RA   Kitano T., Liu Y.-H., Ueda S., Saitou N.;
RT   "Human-specific amino acid changes found in 103 protein-coding
RT   genes.";
RL   Mol. Biol. Evol. 21:936-944(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction
RT   sequenced by the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-9.
RX   MEDLINE=92115564; PubMed=1766875; DOI=10.1093/nar/19.25.7155;
RA   Parks C.L., Chang L.S., Shenk T.;
RT   "A polymerase chain reaction mediated by a single primer: cloning of
RT   genomic sequences adjacent to a serotonin receptor protein coding
RT   region.";
RL   Nucleic Acids Res. 19:7155-7160(1991).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 200-365.
RX   MEDLINE=93329096; PubMed=8393041;
RA   Aune T.M., McGrath K.M., Sarr T., Bombara M.P., Kelley K.A.;
RT   "Expression of 5HT1a receptors on activated human T cells. Regulation
RT   of cyclic AMP levels and T cell proliferation by 5-
RT   hydroxytryptamine.";
RL   J. Immunol. 151:1175-1183(1993).
RN   [9]
RP   FUNCTION.
RX   MEDLINE=88334700; PubMed=3138543; DOI=10.1038/335358a0;
RA   Fargin A., Raymond J.R., Lohse M.L., Kobilka B.K., Caron M.G.,
RA   Lefkowitz R.J.;
RT   "The genomic clone G-21 which resembles a beta-adrenergic receptor
RT   sequence encodes the 5-HT1A receptor.";
RL   Nature 335:358-360(1988).
RN   [10]
RP   UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-334, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Lung adenocarcinoma;
RX   PubMed=17203973; DOI=10.1021/pr060438j;
RA   Vasilescu J., Zweitzig D.R., Denis N.J., Smith J.C., Ethier M.,
RA   Haines D.S., Figeys D.;
RT   "The proteomic reactor facilitates the analysis of affinity-purified
RT   proteins by mass spectrometry: application for identifying
RT   ubiquitinated proteins in human cells.";
RL   J. Proteome Res. 6:298-305(2007).
RN   [11]
RP   VARIANTS SER-22 AND VAL-28.
RX   MEDLINE=95275307; PubMed=7755630; DOI=10.1006/bbrc.1995.1692;
RA   Nakhai B., Nielsen D.A., Linnoila M., Goldman D.;
RT   "Two naturally occurring amino acid substitutions in the human 5-HT1A
RT   receptor: glycine 22 to serine 22 and isoleucine 28 to valine 28.";
RL   Biochem. Biophys. Res. Commun. 210:530-536(1995).
RN   [12]
RP   VARIANTS LEU-16 AND ASP-273.
RX   MEDLINE=98425601; PubMed=9754630;
RX   DOI=10.1002/(SICI)1096-8628(19980907)81:5<434::AID-AJMG13>3.0.CO;2-D;
RA   Kawanishi Y., Harada S., Tachikawa H., Okubo T., Shiraishi H.;
RT   "Novel mutations in the promoter and coding region of the human 5-HT1A
RT   receptor gene and association analysis in schizophrenia.";
RL   Am. J. Med. Genet. 81:434-439(1998).
CC   -!- FUNCTION: This is one of the several different receptors for 5-
CC       hydroxytryptamine (serotonin), a biogenic hormone that functions
CC       as a neurotransmitter, a hormone, and a mitogen. The activity of
CC       this receptor is mediated by G proteins that inhibit adenylate
CC       cyclase activity.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M28269; AAA36440.1; -; Genomic_DNA.
DR   EMBL; X13556; CAA31908.1; -; Genomic_DNA.
DR   EMBL; X57829; CAA40962.1; -; Genomic_DNA.
DR   EMBL; M83181; AAA66493.1; -; Genomic_DNA.
DR   EMBL; AB041403; BAA94488.1; -; Genomic_DNA.
DR   EMBL; AF498978; AAM21125.1; -; mRNA.
DR   EMBL; BC069159; AAH69159.1; -; mRNA.
DR   EMBL; Z11168; CAA77560.1; -; Genomic_DNA.
DR   IPI; IPI00031686; -.
DR   PIR; I38209; I38209.
DR   RefSeq; NP_000515.2; -.
DR   UniGene; Hs.247940; -.
DR   SMR; P08908; 40-421.
DR   STRING; P08908; -.
DR   PhosphoSite; P08908; -.
DR   PRIDE; P08908; -.
DR   Ensembl; ENST00000323865; ENSP00000316244; ENSG00000178394; Homo sapiens.
DR   GeneID; 3350; -.
DR   KEGG; hsa:3350; -.
DR   UCSC; uc003jtg.1; human.
DR   CTD; 3350; -.
DR   GeneCards; GC05M063292; -.
DR   H-InvDB; HIX0032004; -.
DR   HGNC; HGNC:5286; HTR1A.
DR   HPA; HPA018073; -.
DR   MIM; 109760; gene.
DR   PharmGKB; PA192; -.
DR   HOGENOM; HBG445348; -.
DR   HOVERGEN; HBG106962; -.
DR   InParanoid; P08908; -.
DR   OMA; NERNAEA; -.
DR   OrthoDB; EOG9Q2H0X; -.
DR   PhylomeDB; P08908; -.
DR   Reactome; REACT_14797; Signaling by GPCR.
DR   DrugBank; DB00866; Alprenolol.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB00490; Buspirone.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB00216; Eletriptan.
DR   DrugBank; DB01049; Ergoloid mesylate.
DR   DrugBank; DB00176; Fluvoxamine.
DR   DrugBank; DB00589; Lisuride.
DR   DrugBank; DB00247; Methysergide.
DR   DrugBank; DB00370; Mirtazapine.
DR   DrugBank; DB00960; Pindolol.
DR   DrugBank; DB00571; Propranolol.
DR   DrugBank; DB01224; Quetiapine.
DR   DrugBank; DB01104; Sertraline.
DR   DrugBank; DB01079; Tegaserod.
DR   DrugBank; DB00656; Trazodone.
DR   DrugBank; DB00285; Venlafaxine.
DR   DrugBank; DB00246; Ziprasidone.
DR   NextBio; 13248; -.
DR   ArrayExpress; P08908; -.
DR   Bgee; P08908; -.
DR   CleanEx; HS_HTR1A; -.
DR   Genevestigator; P08908; -.
DR   GermOnline; ENSG00000178394; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0004993; F:serotonin receptor activity; TAS:ProtInc.
DR   GO; GO:0007610; P:behavior; TAS:ProtInc.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; TAS:ProtInc.
DR   InterPro; IPR000610; 5HT1A_rcpt.
DR   InterPro; IPR002231; 5HT_rcpt.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   PANTHER; PTHR19266:SF64; 5HT1A_rcpt; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00512; 5HT1ARECEPTR.
DR   PRINTS; PR01101; 5HTRECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Complete proteome; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Isopeptide bond; Membrane;
KW   Polymorphism; Receptor; Transducer; Transmembrane; Ubl conjugation.
FT   CHAIN         1    422       5-hydroxytryptamine receptor 1A.
FT                                /FTId=PRO_0000068903.
FT   TOPO_DOM      1     36       Extracellular (By similarity).
FT   TRANSMEM     37     62       1 (By similarity).
FT   TOPO_DOM     63     73       Cytoplasmic (By similarity).
FT   TRANSMEM     74     98       2 (By similarity).
FT   TOPO_DOM     99    109       Extracellular (By similarity).
FT   TRANSMEM    110    132       3 (By similarity).
FT   TOPO_DOM    133    152       Cytoplasmic (By similarity).
FT   TRANSMEM    153    178       4 (By similarity).
FT   TOPO_DOM    179    191       Extracellular (By similarity).
FT   TRANSMEM    192    217       5 (By similarity).
FT   TOPO_DOM    218    345       Cytoplasmic (By similarity).
FT   TRANSMEM    346    367       6 (By similarity).
FT   TOPO_DOM    368    378       Extracellular (By similarity).
FT   TRANSMEM    379    403       7 (By similarity).
FT   TOPO_DOM    404    422       Cytoplasmic (By similarity).
FT   CARBOHYD     10     10       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     11     11       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     24     24       N-linked (GlcNAc...) (Potential).
FT   DISULFID    109    187       By similarity.
FT   CROSSLNK    334    334       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   VARIANT      16     16       P -> L (in dbSNP:rs1800041).
FT                                /FTId=VAR_003446.
FT   VARIANT      22     22       G -> S (in dbSNP:rs1799920).
FT                                /FTId=VAR_011826.
FT   VARIANT      28     28       I -> V (in dbSNP:rs1799921).
FT                                /FTId=VAR_011827.
FT   VARIANT     184    184       P -> L (in dbSNP:rs1800043).
FT                                /FTId=VAR_011828.
FT   VARIANT     220    220       R -> L (in dbSNP:rs1800044).
FT                                /FTId=VAR_011829.
FT   VARIANT     273    273       G -> D (in dbSNP:rs1800042).
FT                                /FTId=VAR_011830.
FT   CONFLICT    152    154       RAA -> PR (in Ref. 1; AAA36440/CAA31908).
FT   CONFLICT    172    172       M -> I (in Ref. 1; AAA36440/CAA31908).
FT   CONFLICT    200    202       TFG -> RPR (in Ref. 8).
FT   CONFLICT    228    228       K -> R (in Ref. 8).
FT   CONFLICT    244    244       A -> AA (in Ref. 8).
FT   CONFLICT    355    355       I -> T (in Ref. 8).
FT   CONFLICT    363    365       IVA -> MRP (in Ref. 8).
FT   CONFLICT    418    418       K -> N (in Ref. 1; AAA36440/CAA31908).
SQ   SEQUENCE   422 AA;  46107 MW;  762664FCF62CFD8F CRC64;
     MDVLSPGQGN NTTSPPAPFE TGGNTTGISD VTVSYQVITS LLLGTLIFCA VLGNACVVAA
     IALERSLQNV ANYLIGSLAV TDLMVSVLVL PMAALYQVLN KWTLGQVTCD LFIALDVLCC
     TSSILHLCAI ALDRYWAITD PIDYVNKRTP RRAAALISLT WLIGFLISIP PMLGWRTPED
     RSDPDACTIS KDHGYTIYST FGAFYIPLLL MLVLYGRIFR AARFRIRKTV KKVEKTGADT
     RHGASPAPQP KKSVNGESGS RNWRLGVESK AGGALCANGA VRQGDDGAAL EVIEVHRVGN
     SKEHLPLPSE AGPTPCAPAS FERKNERNAE AKRKMALARE RKTVKTLGII MGTFILCWLP
     FFIVALVLPF CESSCHMPTL LGAIINWLGY SNSLLNPVIY AYFNKDFQNA FKKIIKCKFC
     RQ
//
ID   5HT1B_HUMAN             Reviewed;         390 AA.
AC   P28222; Q4VAY7;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-1992, sequence version 1.
DT   02-MAR-2010, entry version 99.
DE   RecName: Full=5-hydroxytryptamine receptor 1B;
DE            Short=5-HT-1B;
DE            Short=5-HT1B;
DE   AltName: Full=Serotonin receptor 1B;
DE   AltName: Full=Serotonin 1D beta receptor;
DE            Short=5-HT-1D-beta;
DE   AltName: Full=S12;
GN   Name=HTR1B; Synonyms=HTR1DB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=92246962; PubMed=1315531; DOI=10.1016/0006-291X(92)90654-4;
RA   Hamblin M.W., Metcalf M.A., McGuffin R.W., Karpells S.;
RT   "Molecular cloning and functional characterization of a human 5-HT1B
RT   serotonin receptor: a homologue of the rat 5-HT1B receptor with 5-
RT   HT1D-like pharmacological specificity.";
RL   Biochem. Biophys. Res. Commun. 184:752-759(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=92304270; PubMed=1610347; DOI=10.1016/0006-291X(92)91655-A;
RA   Mochizuki D., Yuyama Y., Tsujita R., Komaki H., Sagai H.;
RT   "Cloning and expression of the human 5-HT1B-type receptor gene.";
RL   Biochem. Biophys. Res. Commun. 185:517-523(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=92210526; PubMed=1348246;
RA   Jin H., Oksenberg D., Ashkenazi A., Peroutka S.J., Duncan A.M.V.,
RA   Rozmahel R., Yang Y., Mengod G., Palacios J.M., O'Dowd B.F.;
RT   "Characterization of the human 5-hydroxytryptamine1B receptor.";
RL   J. Biol. Chem. 267:5735-5738(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=92218412; PubMed=1559993;
RA   Levy F.O., Gudermann T., Perez-Reyes E., Birnbaumer M., Kaumann A.J.,
RA   Birnbaumer L.;
RT   "Molecular cloning of a human serotonin receptor (S12) with a
RT   pharmacological profile resembling that of the 5-HT1D subtype.";
RL   J. Biol. Chem. 267:7553-7562(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   MEDLINE=92228840; PubMed=1565658; DOI=10.1073/pnas.89.8.3630;
RA   Weinshank R.L., Zgombick J.M., Macchi M.J., Branchek T.A.,
RA   Hartig P.R.;
RT   "Human serotonin 1D receptor is encoded by a subfamily of two distinct
RT   genes: 5-HT1D alpha and 5-HT1D beta.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:3630-3634(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=92302275; PubMed=1351684; DOI=10.1073/pnas.89.12.5522;
RA   Demchyshyn L., Sunahara R.K., Miller K., Teitler M., Hoffman B.J.,
RA   Kennedy J.L., Seeman P., van Tol H.H.M., Niznik H.B.;
RT   "A human serotonin 1D receptor variant (5HT1D beta) encoded by an
RT   intronless gene on chromosome 6.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:5522-5526(1992).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=93024334; PubMed=1328844;
RA   Veldman S.A., Bienkowski M.J.;
RT   "Cloning and pharmacological characterization of a novel human 5-
RT   hydroxytryptamine1D receptor subtype.";
RL   Mol. Pharmacol. 42:439-444(1992).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=15014171; DOI=10.1093/molbev/msh100;
RA   Kitano T., Liu Y.-H., Ueda S., Saitou N.;
RT   "Human-specific amino acid changes found in 103 protein-coding
RT   genes.";
RL   Mol. Biol. Evol. 21:936-944(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "Isolation of complete coding sequence for 5-hydroxytryptamine
RT   (serotonin) receptor 1B (HTR1B).";
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   MEDLINE=22935763; PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   PALMITOYLATION, AND PHOSPHORYLATION.
RX   MEDLINE=94032297; PubMed=8218242; DOI=10.1021/bi00094a032;
RA   Ng G.Y.K., George S.R., Zastawny R.L., Caron M., Bouvier M.,
RA   Dennis M., O'Dowd B.F.;
RT   "Human serotonin1B receptor expression in Sf9 cells: phosphorylation,
RT   palmitoylation, and adenylyl cyclase inhibition.";
RL   Biochemistry 32:11727-11733(1993).
RN   [13]
RP   VARIANT CYS-124.
RX   MEDLINE=95100945; PubMed=7802650; DOI=10.1006/bbrc.1994.2792;
RA   Nothen M.M., Erdmann J., Shimron-Abarbanell D., Propping P.;
RT   "Identification of genetic variation in the human serotonin 1D beta
RT   receptor gene.";
RL   Biochem. Biophys. Res. Commun. 205:1194-1200(1994).
CC   -!- FUNCTION: This is one of the several different receptors for 5-
CC       hydroxytryptamine (serotonin), a biogenic hormone that functions
CC       as a neurotransmitter, a hormone, and a mitogen. The activity of
CC       this receptor is mediated by G proteins that inhibit adenylate
CC       cyclase activity.
CC   -!- INTERACTION:
CC       Q9Y2Q3:GSTK1; NbExp=1; IntAct=EBI-1056863, EBI-1053767;
CC       P22392:NME2; NbExp=1; IntAct=EBI-1056863, EBI-713693;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- PTM: Phosphorylated. Desensitization of the receptor may be
CC       mediated by its phosphorylation.
CC   -!- PTM: Palmitoylated.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M89478; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; D10995; BAA01763.1; -; Genomic_DNA.
DR   EMBL; M83180; AAA36029.1; -; Genomic_DNA.
DR   EMBL; L09732; AAA36030.1; -; Genomic_DNA.
DR   EMBL; M81590; AAA60316.1; -; mRNA.
DR   EMBL; M75128; AAA58675.1; -; Genomic_DNA.
DR   EMBL; AB041370; BAA94455.1; -; Genomic_DNA.
DR   EMBL; AY225227; AAO67712.1; -; Genomic_DNA.
DR   EMBL; AL049595; CAB51537.1; -; Genomic_DNA.
DR   EMBL; BC069065; AAH69065.1; -; mRNA.
DR   EMBL; BC096206; AAH96206.1; -; mRNA.
DR   EMBL; BC096207; AAH96207.1; -; mRNA.
DR   EMBL; BC096208; AAH96208.1; -; mRNA.
DR   IPI; IPI00002184; -.
DR   PIR; JN0268; JN0268.
DR   RefSeq; NP_000854.1; -.
DR   UniGene; Hs.123016; -.
DR   PDB; 2G1X; Model; -; A=1-390.
DR   PDBsum; 2G1X; -.
DR   SMR; P28222; 31-388.
DR   IntAct; P28222; 2.
DR   STRING; P28222; -.
DR   PhosphoSite; P28222; -.
DR   PRIDE; P28222; -.
DR   Ensembl; ENST00000369947; ENSP00000358963; ENSG00000135312; Homo sapiens.
DR   GeneID; 3351; -.
DR   KEGG; hsa:3351; -.
DR   UCSC; uc003pil.1; human.
DR   CTD; 3351; -.
DR   GeneCards; GC06M078228; -.
DR   H-InvDB; HIX0032923; -.
DR   HGNC; HGNC:5287; HTR1B.
DR   MIM; 182131; gene.
DR   PharmGKB; PA29549; -.
DR   eggNOG; prNOG04701; -.
DR   HOGENOM; HBG445348; -.
DR   HOVERGEN; HBG106962; -.
DR   InParanoid; P28222; -.
DR   OMA; ALPWKVL; -.
DR   OrthoDB; EOG9Q2H0X; -.
DR   PhylomeDB; P28222; -.
DR   Reactome; REACT_14797; Signaling by GPCR.
DR   DrugBank; DB00918; Almotriptan.
DR   DrugBank; DB01191; Dexfenfluramine.
DR   DrugBank; DB00320; Dihydroergotamine.
DR   DrugBank; DB00216; Eletriptan.
DR   DrugBank; DB00696; Ergotamine.
DR   DrugBank; DB00998; Frovatriptan.
DR   DrugBank; DB00952; Naratriptan.
DR   DrugBank; DB00960; Pindolol.
DR   DrugBank; DB00571; Propranolol.
DR   DrugBank; DB00953; Rizatriptan.
DR   DrugBank; DB00669; Sumatriptan.
DR   DrugBank; DB00285; Venlafaxine.
DR   DrugBank; DB00315; Zolmitriptan.
DR   NextBio; 13252; -.
DR   ArrayExpress; P28222; -.
DR   Bgee; P28222; -.
DR   CleanEx; HS_HTR1B; -.
DR   Genevestigator; P28222; -.
DR   GermOnline; ENSG00000135312; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0004993; F:serotonin receptor activity; TAS:ProtInc.
DR   GO; GO:0007187; P:G-protein signaling, coupled to cyclic nucl...; TAS:ProtInc.
DR   GO; GO:0007268; P:synaptic transmission; TAS:ProtInc.
DR   InterPro; IPR002147; 5HT1B_rcpt.
DR   InterPro; IPR002231; 5HT_rcpt.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   PANTHER; PTHR19266:SF67; 5HT1B_rcpt; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00513; 5HT1BRECEPTR.
DR   PRINTS; PR01101; 5HTRECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Complete proteome; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane;
KW   Palmitate; Phosphoprotein; Polymorphism; Receptor; Transducer;
KW   Transmembrane.
FT   CHAIN         1    390       5-hydroxytryptamine receptor 1B.
FT                                /FTId=PRO_0000068916.
FT   TOPO_DOM      1     49       Extracellular (By similarity).
FT   TRANSMEM     50     73       1 (By similarity).
FT   TOPO_DOM     74     86       Cytoplasmic (By similarity).
FT   TRANSMEM     87    109       2 (By similarity).
FT   TOPO_DOM    110    119       Extracellular (By similarity).
FT   TRANSMEM    120    145       3 (By similarity).
FT   TOPO_DOM    146    165       Cytoplasmic (By similarity).
FT   TRANSMEM    166    187       4 (By similarity).
FT   TOPO_DOM    188    205       Extracellular (By similarity).
FT   TRANSMEM    206    229       5 (By similarity).
FT   TOPO_DOM    230    315       Cytoplasmic (By similarity).
FT   TRANSMEM    316    340       6 (By similarity).
FT   TOPO_DOM    341    347       Extracellular (By similarity).
FT   TRANSMEM    348    373       7 (By similarity).
FT   TOPO_DOM    374    390       Cytoplasmic (By similarity).
FT   LIPID       388    388       S-palmitoyl cysteine (Potential).
FT   CARBOHYD     24     24       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     32     32       N-linked (GlcNAc...) (Potential).
FT   DISULFID    122    199       By similarity.
FT   VARIANT     124    124       F -> C (in dbSNP:rs130060).
FT                                /FTId=VAR_011715.
FT   VARIANT     219    219       F -> L (in dbSNP:rs130061).
FT                                /FTId=VAR_011831.
FT   VARIANT     367    367       I -> V (in dbSNP:rs130063).
FT                                /FTId=VAR_011832.
FT   VARIANT     374    374       E -> K (in dbSNP:rs130064).
FT                                /FTId=VAR_011833.
SQ   SEQUENCE   390 AA;  43568 MW;  CD874DC7EB44CF12 CRC64;
     MEEPGAQCAP PPPAGSETWV PQANLSSAPS QNCSAKDYIY QDSISLPWKV LLVMLLALIT
     LATTLSNAFV IATVYRTRKL HTPANYLIAS LAVTDLLVSI LVMPISTMYT VTGRWTLGQV
     VCDFWLSSDI TCCTASILHL CVIALDRYWA ITDAVEYSAK RTPKRAAVMI ALVWVFSISI
     SLPPFFWRQA KAEEEVSECV VNTDHILYTV YSTVGAFYFP TLLLIALYGR IYVEARSRIL
     KQTPNRTGKR LTRAQLITDS PGSTSSVTSI NSRVPDVPSE SGSPVYVNQV KVRVSDALLE
     KKKLMAARER KATKTLGIIL GAFIVCWLPF FIISLVMPIC KDACWFHLAI FDFFTWLGYL
     NSLINPIIYT MSNEDFKQAF HKLIRFKCTS
//
ID   5HT1E_CAVPO             Reviewed;         365 AA.
AC   Q6VB83;
DT   23-OCT-2007, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   02-MAR-2010, entry version 39.
DE   RecName: Full=5-hydroxytryptamine receptor 1E;
DE            Short=5-HT-1E;
DE            Short=5-HT1E;
DE   AltName: Full=Serotonin receptor 1E;
GN   Name=5HT1E;
OS   Cavia porcellus (Guinea pig).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
OC   Hystricognathi; Caviidae; Cavia.
OX   NCBI_TaxID=10141;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], CHARACTERIZATION, AND TISSUE SPECIFICITY.
RC   STRAIN=Hartley;
RX   PubMed=14744596; DOI=10.1016/j.ejphar.2003.11.019;
RA   Bai F., Yin T., Johnstone E.M., Su C., Varga G., Little S.P.,
RA   Nelson D.L.;
RT   "Molecular cloning and pharmacological characterization of the guinea
RT   pig 5-HT1E receptor.";
RL   Eur. J. Pharmacol. 484:127-139(2004).
CC   -!- FUNCTION: This is one of the several different receptors for 5-
CC       hydroxytryptamine (serotonin), a biogenic hormone that functions
CC       as a neurotransmitter, a hormone, and a mitogen. The activity of
CC       this receptor is mediated by G proteins that inhibit adenylate
CC       cyclase activity.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Detected in the brain with the greatest
CC       abundance in the hippocampus, followed by the olfactory bulb.
CC       Lower levels are detected in the cortex, thalamus, pons,
CC       hypothalamus, midbrain, striatum, and cerebellum.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY344643; AAR05654.1; -; mRNA.
DR   HSSP; P08913; 1HLL.
DR   SMR; Q6VB83; 30-365.
DR   Ensembl; ENSCPOT00000003711; ENSCPOP00000015883; ENSCPOG00000003667; Cavia porcellus.
DR   HOVERGEN; HBG106962; -.
DR   InParanoid; Q6VB83; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0007186; P:G-protein coupled receptor protein signalin...; IEA:UniProtKB-KW.
DR   InterPro; IPR000450; 5HT1F_rcpt.
DR   InterPro; IPR002231; 5HT_rcpt.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   PANTHER; PTHR19266:SF65; 5HT1F_rcpt; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00515; 5HT1FRECEPTR.
DR   PRINTS; PR01101; 5HTRECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Membrane; Receptor; Transducer; Transmembrane.
FT   CHAIN         1    365       5-hydroxytryptamine receptor 1E.
FT                                /FTId=PRO_0000307929.
FT   TOPO_DOM      1     23       Extracellular (By similarity).
FT   TRANSMEM     24     44       1 (By similarity).
FT   TOPO_DOM     45     63       Cytoplasmic (By similarity).
FT   TRANSMEM     64     84       2 (By similarity).
FT   TOPO_DOM     85     96       Extracellular (By similarity).
FT   TRANSMEM     97    117       3 (By similarity).
FT   TOPO_DOM    118    139       Cytoplasmic (By similarity).
FT   TRANSMEM    140    160       4 (By similarity).
FT   TOPO_DOM    161    179       Extracellular (By similarity).
FT   TRANSMEM    180    200       5 (By similarity).
FT   TOPO_DOM    201    293       Cytoplasmic (By similarity).
FT   TRANSMEM    294    314       6 (By similarity).
FT   TOPO_DOM    315    324       Extracellular (By similarity).
FT   TRANSMEM    325    345       7 (By similarity).
FT   TOPO_DOM    346    365       Cytoplasmic (By similarity).
FT   CARBOHYD      2      2       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD      5      5       N-linked (GlcNAc...) (Potential).
FT   DISULFID     95    173       By similarity.
SQ   SEQUENCE   365 AA;  41653 MW;  B07177BAF21A74F6 CRC64;
     MNITNCTTDA SMVVRPKTVT EKMLICMTLV IITTLTMLLN SAVIMAICTT KKLHQPANYL
     ICSLAVTDLL VAVLVMPLSI MYIVMDSWRL GYFICEVWLS VDMTCCTCSI LHLCVIALDR
     YWAITNAIEY ARKRTAKRAG LMILTVWTIS IFISMPPLFW RSHRQLSPPP SQCTIQHDHV
     IYTIYSTFGA FYIPLTLILI LYYRIYHAAK SLYQKRGSSR HLSNRSTDSQ NSFASCKLTQ
     TFCVSDFSTS DPTTEFEKIH ASIRIPPFDN DLDHPGERQQ ISSTRERKAA RILGLILGAF
     ILSWLPFFIK ELIVGLSIYT VSSEVGDFLT WLGYVNSLIN PLLYTSFNED FKLAFKKLIR
     CREHT
//
ID   5HT1E_HUMAN             Reviewed;         365 AA.
AC   P28566; Q9P1Y1;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-1992, sequence version 1.
DT   02-MAR-2010, entry version 100.
DE   RecName: Full=5-hydroxytryptamine receptor 1E;
DE            Short=5-HT-1E;
DE            Short=5-HT1E;
DE   AltName: Full=Serotonin receptor 1E;
DE   AltName: Full=S31;
GN   Name=HTR1E;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   MEDLINE=92302274; PubMed=1608964; DOI=10.1073/pnas.89.12.5517;
RA   McAllister G., Charlesworth A., Snodin C., Beer M.S., Noble A.J.,
RA   Middlemiss D.N., Iversen L.L., Whiting P.;
RT   "Molecular cloning of a serotonin receptor from human brain (5HT1E): a
RT   fifth 5HT1-like subtype.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:5517-5521(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=92128546; PubMed=1733778; DOI=10.1016/0014-5793(92)80379-U;
RA   Levy F.O., Gudermann T., Birnbaumer M., Kaumann A.J., Birnbaumer L.;
RT   "Molecular cloning of a human gene (S31) encoding a novel serotonin
RT   receptor mediating inhibition of adenylyl cyclase.";
RL   FEBS Lett. 296:201-206(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=92382553; PubMed=1513320;
RA   Zgombick J.M., Schechter L.E., Macchi M., Hartig P.R., Branchek T.A.,
RA   Weinshank R.L.;
RT   "Human gene S31 encodes the pharmacologically defined serotonin 5-
RT   hydroxytryptamine1E receptor.";
RL   Mol. Pharmacol. 42:180-185(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction
RT   sequenced by the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   MEDLINE=22935763; PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-363.
RX   PubMed=15014171; DOI=10.1093/molbev/msh100;
RA   Kitano T., Liu Y.-H., Ueda S., Saitou N.;
RT   "Human-specific amino acid changes found in 103 protein-coding
RT   genes.";
RL   Mol. Biol. Evol. 21:936-944(2004).
RN   [8]
RP   VARIANT PHE-262.
RX   MEDLINE=99318093; PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [9]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
CC   -!- FUNCTION: This is one of the several different receptors for 5-
CC       hydroxytryptamine (serotonin), a biogenic hormone that functions
CC       as a neurotransmitter, a hormone, and a mitogen. The activity of
CC       this receptor is mediated by G proteins that inhibit adenylate
CC       cyclase activity.
CC   -!- INTERACTION:
CC       P17980:PSMC3; NbExp=1; IntAct=EBI-1043151, EBI-359720;
CC       P43686:PSMC4; NbExp=1; IntAct=EBI-1043151, EBI-743997;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M91467; AAA58353.1; -; mRNA.
DR   EMBL; Z11166; CAA77558.1; -; Genomic_DNA.
DR   EMBL; M92826; AAA58355.1; -; Genomic_DNA.
DR   EMBL; AF498980; AAM21127.1; -; mRNA.
DR   EMBL; AL157777; CAC10582.1; -; Genomic_DNA.
DR   EMBL; BC069751; AAH69751.1; -; mRNA.
DR   EMBL; AB041373; BAA94458.1; -; Genomic_DNA.
DR   IPI; IPI00003932; -.
DR   PIR; S20579; A45260.
DR   RefSeq; NP_000856.1; -.
DR   UniGene; Hs.1611; -.
DR   SMR; P28566; 23-362.
DR   IntAct; P28566; 2.
DR   STRING; P28566; -.
DR   PRIDE; P28566; -.
DR   Ensembl; ENST00000305344; ENSP00000307766; ENSG00000168830; Homo sapiens.
DR   Ensembl; ENST00000369584; ENSP00000358597; ENSG00000168830; Homo sapiens.
DR   GeneID; 3354; -.
DR   KEGG; hsa:3354; -.
DR   UCSC; uc003plg.1; human.
DR   CTD; 3354; -.
DR   GeneCards; GC06P087704; -.
DR   H-InvDB; HIX0032800; -.
DR   HGNC; HGNC:5291; HTR1E.
DR   HPA; HPA004931; -.
DR   MIM; 182132; gene.
DR   PharmGKB; PA29552; -.
DR   eggNOG; prNOG09215; -.
DR   HOGENOM; HBG445348; -.
DR   HOVERGEN; HBG106962; -.
DR   InParanoid; P28566; -.
DR   OMA; FNEDFKL; -.
DR   OrthoDB; EOG9Q2H0X; -.
DR   PhylomeDB; P28566; -.
DR   Reactome; REACT_14797; Signaling by GPCR.
DR   DrugBank; DB00216; Eletriptan.
DR   NextBio; 13262; -.
DR   ArrayExpress; P28566; -.
DR   Bgee; P28566; -.
DR   CleanEx; HS_HTR1E; -.
DR   Genevestigator; P28566; -.
DR   GermOnline; ENSG00000168830; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0051378; F:serotonin binding; IDA:MGI.
DR   GO; GO:0004993; F:serotonin receptor activity; IDA:MGI.
DR   GO; GO:0007187; P:G-protein signaling, coupled to cyclic nucl...; TAS:ProtInc.
DR   GO; GO:0007268; P:synaptic transmission; TAS:ProtInc.
DR   InterPro; IPR000450; 5HT1F_rcpt.
DR   InterPro; IPR002231; 5HT_rcpt.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   PANTHER; PTHR19266:SF65; 5HT1F_rcpt; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01101; 5HTRECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Complete proteome; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Polymorphism;
KW   Receptor; Transducer; Transmembrane.
FT   CHAIN         1    365       5-hydroxytryptamine receptor 1E.
FT                                /FTId=PRO_0000068933.
FT   TOPO_DOM      1     22       Extracellular (By similarity).
FT   TRANSMEM     23     47       1 (By similarity).
FT   TOPO_DOM     48     59       Cytoplasmic (By similarity).
FT   TRANSMEM     60     81       2 (By similarity).
FT   TOPO_DOM     82     96       Extracellular (By similarity).
FT   TRANSMEM     97    118       3 (By similarity).
FT   TOPO_DOM    119    138       Cytoplasmic (By similarity).
FT   TRANSMEM    139    159       4 (By similarity).
FT   TOPO_DOM    160    179       Extracellular (By similarity).
FT   TRANSMEM    180    201       5 (By similarity).
FT   TOPO_DOM    202    291       Cytoplasmic (By similarity).
FT   TRANSMEM    292    314       6 (By similarity).
FT   TOPO_DOM    315    324       Extracellular (By similarity).
FT   TRANSMEM    325    347       7 (By similarity).
FT   TOPO_DOM    348    365       Cytoplasmic (By similarity).
FT   CARBOHYD      2      2       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD      5      5       N-linked (GlcNAc...) (Potential).
FT   DISULFID     95    173       By similarity.
FT   VARIANT     208    208       A -> T (in dbSNP:rs3828741).
FT                                /FTId=VAR_022061.
FT   VARIANT     262    262       S -> F (in dbSNP:rs6303).
FT                                /FTId=VAR_014165.
SQ   SEQUENCE   365 AA;  41682 MW;  4C31DD783A3F7483 CRC64;
     MNITNCTTEA SMAIRPKTIT EKMLICMTLV VITTLTTLLN LAVIMAIGTT KKLHQPANYL
     ICSLAVTDLL VAVLVMPLSI IYIVMDRWKL GYFLCEVWLS VDMTCCTCSI LHLCVIALDR
     YWAITNAIEY ARKRTAKRAA LMILTVWTIS IFISMPPLFW RSHRRLSPPP SQCTIQHDHV
     IYTIYSTLGA FYIPLTLILI LYYRIYHAAK SLYQKRGSSR HLSNRSTDSQ NSFASCKLTQ
     TFCVSDFSTS DPTTEFEKFH ASIRIPPFDN DLDHPGERQQ ISSTRERKAA RILGLILGAF
     ILSWLPFFIK ELIVGLSIYT VSSEVADFLT WLGYVNSLIN PLLYTSFNED FKLAFKKLIR
     CREHT
//
ID   5HT2A_HUMAN             Reviewed;         471 AA.
AC   P28223; B2RAC5; Q5T8C0;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 2.
DT   02-MAR-2010, entry version 105.
DE   RecName: Full=5-hydroxytryptamine receptor 2A;
DE            Short=5-HT-2A;
DE            Short=5-HT-2;
DE   AltName: Full=Serotonin receptor 2A;
GN   Name=HTR2A; Synonyms=HTR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain stem;
RX   MEDLINE=92109767; PubMed=1722404; DOI=10.1016/0006-291X(91)92105-S;
RA   Saltzman A.G., Morse B., Whitman M.M., Ivanshchenko Y., Jaye M.,
RA   Felder S.;
RT   "Cloning of the human serotonin 5-HT2 and 5-HT1C receptor subtypes.";
RL   Biochem. Biophys. Res. Commun. 181:1469-1478(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=92356792; PubMed=1323014; DOI=10.1016/0169-328X(92)90005-V;
RA   Chen K., Yang W., Grimsby J., Shih J.C.;
RT   "The human 5-HT2 receptor is encoded by a multiple intron-exon gene.";
RL   Brain Res. Mol. Brain Res. 14:20-26(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=94308772; PubMed=8035173;
RA   Cook E.H. Jr., Fletcher K.E., Wainwright M., Marks N., Yan S.Y.,
RA   Leventhal B.L.;
RT   "Primary structure of the human platelet serotonin 5-HT2A receptor:
RT   identify with frontal cortex serotonin 5-HT2A receptor.";
RL   J. Neurochem. 63:465-469(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction
RT   sequenced by the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E.,
RA   Griffiths-Jones S., Jones M.C., Keenan S.J., Oliver K., Scott C.E.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Andrews D.T.,
RA   Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., Bannerjee R.,
RA   Barlow K.F., Bates K., Beasley H., Bird C.P., Bray-Allen S.,
RA   Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M.,
RA   Clegg S.C., Cobley V., Collins J.E., Corby N., Coville G.J.,
RA   Deloukas P., Dhami P., Dunham I., Dunn M., Earthrowl M.E.,
RA   Ellington A.G., Faulkner L., Frankish A.G., Frankland J., French L.,
RA   Garner P., Garnett J., Gilbert J.G.R., Gilson C.J., Ghori J.,
RA   Grafham D.V., Gribble S.M., Griffiths C., Hall R.E., Hammond S.,
RA   Harley J.L., Hart E.A., Heath P.D., Howden P.J., Huckle E.J.,
RA   Hunt P.J., Hunt A.R., Johnson C., Johnson D., Kay M., Kimberley A.M.,
RA   King A., Laird G.K., Langford C.J., Lawlor S., Leongamornlert D.A.,
RA   Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., Martin S.,
RA   Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K.M., Rice C.M., Searle S.,
RA   Sehra H.K., Shownkeen R., Skuce C.D., Smith M., Steward C.A.,
RA   Sycamore N., Tester J., Thomas D.W., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., Whitehead S.L., Willey D.L.,
RA   Wilming L., Wray P.W., Wright M.W., Young L., Coulson A., Durbin R.M.,
RA   Hubbard T., Sulston J.E., Beck S., Bentley D.R., Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 9-464.
RC   TISSUE=Brain;
RA   Tritch R.J., Robinson D.L., Sahagan B.G., Horlick R.A.;
RT   "Cloning and nucleotide sequence of the human(5HT) type 2 receptor.";
RL   Submitted (MAY-1992) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 105-218.
RX   MEDLINE=93049882; PubMed=1330647; DOI=10.1016/0922-4106(92)90123-D;
RA   Stam N.J., van Huizen F., van Alebeek C., Brands J., Dijkema R.,
RA   Tonnaer J.A., Olijve W.;
RT   "Genomic organization, coding sequence and functional expression of
RT   human 5-HT2 and 5-HT1A receptor genes.";
RL   Eur. J. Pharmacol. 227:153-162(1992).
RN   [11]
RP   INTERACTION WITH MPDZ.
RX   MEDLINE=21201137; PubMed=11150294; DOI=10.1074/jbc.M008089200;
RA   Becamel C., Figge A., Poliak S., Dumuis A., Peles E., Bockaert J.,
RA   Luebbert H., Ullmer C.;
RT   "Interaction of serotonin 5-hydroxytryptamine type 2C receptors with
RT   PDZ10 of the multi-PDZ domain protein MUPP1.";
RL   J. Biol. Chem. 276:12974-12982(2001).
RN   [12]
RP   INTERACTION WITH INADL; MPP3; PRDX6; DLG4; DLG1; CASK; APBA1 AND
RP   MAGI2, AND MUTAGENESIS OF GLY-463; ASN-465; CYS-470 AND VAL-471.
RX   PubMed=14988405; DOI=10.1074/jbc.M312106200;
RA   Becamel C., Gavarini S., Chanrion B., Alonso G., Galeotti N.,
RA   Dumuis A., Bockaert J., Marin P.;
RT   "The serotonin 5-HT2A and 5-HT2C receptors interact with specific sets
RT   of PDZ proteins.";
RL   J. Biol. Chem. 279:20257-20266(2004).
RN   [13]
RP   VARIANTS ASN-25 AND TYR-452.
RX   MEDLINE=96209907; PubMed=8655141; DOI=10.1007/s004390050104;
RA   Erdmann J., Shimron-Abarbanell D., Rietschel M., Albus M., Maier W.,
RA   Koerner J., Bondy B., Chen K., Shih J.C., Knapp M., Propping P.,
RA   Noethen M.M.;
RT   "Systematic screening for mutations in the human serotonin-2A (5-HT2A)
RT   receptor gene: identification of two naturally occurring receptor
RT   variants and association analysis in schizophrenia.";
RL   Hum. Genet. 97:614-619(1996).
RN   [14]
RP   VARIANTS ASN-25 AND TYR-452.
RX   MEDLINE=20049881; PubMed=10581480;
RX   DOI=10.1002/(SICI)1096-8628(19991215)88:6<621::AID-AJMG9>3.0.CO;2-H;
RA   Marshall S.E., Bird T.G., Hart K., Welsh K.I.;
RT   "Unified approach to the analysis of genetic variation in serotonergic
RT   pathways.";
RL   Am. J. Med. Genet. 88:621-627(1999).
RN   [15]
RP   VARIANTS VAL-197; VAL-447 AND TYR-452.
RX   MEDLINE=99318093; PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [16]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
CC   -!- FUNCTION: This is one of the several different receptors for 5-
CC       hydroxytryptamine (serotonin), a biogenic hormone that functions
CC       as a neurotransmitter, a hormone, and a mitogen. This receptor
CC       mediates its action by association with G proteins that activate a
CC       phosphatidylinositol-calcium second messenger system. This
CC       receptor is involved in tracheal smooth muscle contraction,
CC       bronchoconstriction, and control of aldosterone production.
CC   -!- SUBUNIT: Interacts with MPDZ and INADL. May interact with MPP3,
CC       PRDX6, DLG4, DLG1, CASK, APBA1 and MAGI2.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein
CC       (By similarity). Note=Localizes to the post-synaptic thickening of
CC       axo-dendritic synapses (By similarity).
CC   -!- DOMAIN: The PDZ domain-binding motif is involved in the
CC       interaction with INADL, CASK, APBA1, DLG1 and DLG4.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=HTR2A";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X57830; CAA40963.1; -; mRNA.
DR   EMBL; S42168; AAB22791.2; -; Genomic_DNA.
DR   EMBL; S42165; AAB22791.2; JOINED; Genomic_DNA.
DR   EMBL; S42167; AAB22791.2; JOINED; Genomic_DNA.
DR   EMBL; S71229; AAB31320.1; -; mRNA.
DR   EMBL; AF498982; AAM21129.1; -; mRNA.
DR   EMBL; AK314132; BAG36822.1; -; mRNA.
DR   EMBL; AL160397; CAI16877.1; -; Genomic_DNA.
DR   EMBL; AL136958; CAI16877.1; JOINED; Genomic_DNA.
DR   EMBL; AL136958; CAI12227.1; -; Genomic_DNA.
DR   EMBL; AL160397; CAI12227.1; JOINED; Genomic_DNA.
DR   EMBL; CH471075; EAX08770.1; -; Genomic_DNA.
DR   EMBL; BC069356; AAH69356.1; -; mRNA.
DR   EMBL; BC069576; AAH69576.1; -; mRNA.
DR   EMBL; BC074848; AAH74848.1; -; mRNA.
DR   EMBL; BC074849; AAH74849.1; -; mRNA.
DR   EMBL; BC096839; AAH96839.1; -; mRNA.
DR   EMBL; M86841; AAA58354.1; -; mRNA.
DR   EMBL; S50130; AAB24166.2; -; Genomic_DNA.
DR   EMBL; S49737; AAB24166.2; JOINED; Genomic_DNA.
DR   EMBL; S50113; AAB24166.2; JOINED; Genomic_DNA.
DR   IPI; IPI00002185; -.
DR   PIR; A43956; A43956.
DR   RefSeq; NP_000612.1; -.
DR   UniGene; Hs.654586; -.
DR   SMR; P28223; 78-399.
DR   STRING; P28223; -.
DR   PhosphoSite; P28223; -.
DR   PRIDE; P28223; -.
DR   Ensembl; ENST00000378688; ENSP00000367959; ENSG00000102468; Homo sapiens.
DR   GeneID; 3356; -.
DR   KEGG; hsa:3356; -.
DR   UCSC; uc001vbq.2; human.
DR   CTD; 3356; -.
DR   GeneCards; GC13M046305; -.
DR   H-InvDB; HIX0026550; -.
DR   HGNC; HGNC:5293; HTR2A.
DR   HPA; HPA014011; -.
DR   MIM; 182135; gene.
DR   PharmGKB; PA193; -.
DR   eggNOG; prNOG08127; -.
DR   HOGENOM; HBG445348; -.
DR   HOVERGEN; HBG107487; -.
DR   InParanoid; P28223; -.
DR   OMA; MDILCEE; -.
DR   OrthoDB; EOG9ZSCNH; -.
DR   PhylomeDB; P28223; -.
DR   Reactome; REACT_14797; Signaling by GPCR.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB00477; Chlorpromazine.
DR   DrugBank; DB01239; Chlorprothixene.
DR   DrugBank; DB00604; Cisapride.
DR   DrugBank; DB01242; Clomipramine.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB00924; Cyclobenzaprine.
DR   DrugBank; DB00434; Cyproheptadine.
DR   DrugBank; DB00320; Dihydroergotamine.
DR   DrugBank; DB00843; Donepezil.
DR   DrugBank; DB00751; Epinastine.
DR   DrugBank; DB00696; Ergotamine.
DR   DrugBank; DB00176; Fluvoxamine.
DR   DrugBank; DB00933; Mesoridazine.
DR   DrugBank; DB00247; Methysergide.
DR   DrugBank; DB06148; Mianserin.
DR   DrugBank; DB00805; Minaprine.
DR   DrugBank; DB00370; Mirtazapine.
DR   DrugBank; DB01149; Nefazodone.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB01267; Paliperidone.
DR   DrugBank; DB00715; Paroxetine.
DR   DrugBank; DB00433; Prochlorperazine.
DR   DrugBank; DB00420; Promazine.
DR   DrugBank; DB01069; Promethazine.
DR   DrugBank; DB00777; Propiomazine.
DR   DrugBank; DB01224; Quetiapine.
DR   DrugBank; DB00734; Risperidone.
DR   DrugBank; DB06144; Sertindole.
DR   DrugBank; DB00372; Thiethylperazine.
DR   DrugBank; DB00679; Thioridazine.
DR   DrugBank; DB00752; Tranylcypromine.
DR   DrugBank; DB00656; Trazodone.
DR   DrugBank; DB00285; Venlafaxine.
DR   DrugBank; DB00246; Ziprasidone.
DR   NextBio; 13270; -.
DR   ArrayExpress; P28223; -.
DR   Bgee; P28223; -.
DR   CleanEx; HS_HTR2A; -.
DR   Genevestigator; P28223; -.
DR   GermOnline; ENSG00000102468; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0051378; F:serotonin binding; IDA:MGI.
DR   GO; GO:0004993; F:serotonin receptor activity; IDA:MGI.
DR   GO; GO:0007268; P:synaptic transmission; TAS:ProtInc.
DR   InterPro; IPR000455; 5HT2A_rcpt.
DR   InterPro; IPR002231; 5HT_rcpt.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00516; 5HT2ARECEPTR.
DR   PRINTS; PR01101; 5HTRECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Complete proteome; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Polymorphism;
KW   Receptor; Transducer; Transmembrane.
FT   CHAIN         1    471       5-hydroxytryptamine receptor 2A.
FT                                /FTId=PRO_0000068946.
FT   TOPO_DOM      1     75       Extracellular (By similarity).
FT   TRANSMEM     76     99       1 (By similarity).
FT   TOPO_DOM    100    110       Cytoplasmic (By similarity).
FT   TRANSMEM    111    132       2 (By similarity).
FT   TOPO_DOM    133    147       Extracellular (By similarity).
FT   TRANSMEM    148    171       3 (By similarity).
FT   TOPO_DOM    172    191       Cytoplasmic (By similarity).
FT   TRANSMEM    192    215       4 (By similarity).
FT   TOPO_DOM    216    233       Extracellular (By similarity).
FT   TRANSMEM    234    254       5 (By similarity).
FT   TOPO_DOM    255    324       Cytoplasmic (By similarity).
FT   TRANSMEM    325    346       6 (By similarity).
FT   TOPO_DOM    347    362       Extracellular (By similarity).
FT   TRANSMEM    363    384       7 (By similarity).
FT   TOPO_DOM    385    471       Cytoplasmic (By similarity).
FT   MOTIF       469    471       PDZ-binding.
FT   CARBOHYD      8      8       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     38     38       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     44     44       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     51     51       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     54     54       N-linked (GlcNAc...) (Potential).
FT   DISULFID    148    227       By similarity.
FT   VARIANT      25     25       T -> N (in dbSNP:rs1805055).
FT                                /FTId=VAR_003448.
FT   VARIANT     197    197       I -> V (in dbSNP:rs6304).
FT                                /FTId=VAR_013901.
FT   VARIANT     447    447       A -> V (in dbSNP:rs6308).
FT                                /FTId=VAR_013902.
FT   VARIANT     452    452       H -> Y (in dbSNP:rs6314).
FT                                /FTId=VAR_003449.
FT   MUTAGEN     463    463       G->V: Loss of interaction with INADL.
FT   MUTAGEN     465    465       N->S: No effect on interaction with
FT                                INADL. Acquires the binding properties of
FT                                HTR2C; when associated with S-470.
FT   MUTAGEN     470    470       C->S: No effect on interaction with
FT                                INADL. Acquires the binding properties of
FT                                HTR2C; when associated with S-465.
FT   MUTAGEN     471    471       V->A: Loss of interaction with INADL,
FT                                CASK, APBA1, DLG1 and DLG4.
SQ   SEQUENCE   471 AA;  52603 MW;  EF8AAC0BC5379DA2 CRC64;
     MDILCEENTS LSSTTNSLMQ LNDDTRLYSN DFNSGEANTS DAFNWTVDSE NRTNLSCEGC
     LSPSCLSLLH LQEKNWSALL TAVVIILTIA GNILVIMAVS LEKKLQNATN YFLMSLAIAD
     MLLGFLVMPV SMLTILYGYR WPLPSKLCAV WIYLDVLFST ASIMHLCAIS LDRYVAIQNP
     IHHSRFNSRT KAFLKIIAVW TISVGISMPI PVFGLQDDSK VFKEGSCLLA DDNFVLIGSF
     VSFFIPLTIM VITYFLTIKS LQKEATLCVS DLGTRAKLAS FSFLPQSSLS SEKLFQRSIH
     REPGSYTGRR TMQSISNEQK ACKVLGIVFF LFVVMWCPFF ITNIMAVICK ESCNEDVIGA
     LLNVFVWIGY LSSAVNPLVY TLFNKTYRSA FSRYIQCQYK ENKKPLQLIL VNTIPALAYK
     SSQLQMGQKK NSKQDAKTTD NDCSMVALGK QHSEEASKDN SDGVNEKVSC V
//
ID   5HT2B_HUMAN             Reviewed;         481 AA.
AC   P41595; B2R9D5; Q53TI1; Q62221; Q6P523;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   02-MAR-2010, entry version 98.
DE   RecName: Full=5-hydroxytryptamine receptor 2B;
DE            Short=5-HT-2B;
DE            Short=5-HT2B;
DE   AltName: Full=Serotonin receptor 2B;
GN   Name=HTR2B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=94192809; PubMed=8143856; DOI=10.1016/0014-5793(94)80590-3;
RA   Schmuck K., Ullmer C., Engels P., Luebbert H.;
RT   "Cloning and functional characterization of the human 5-HT2B serotonin
RT   receptor.";
RL   FEBS Lett. 342:85-90(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   MEDLINE=95010749; PubMed=7926008; DOI=10.1016/0014-5793(94)00968-6;
RA   Choi D.S., Birraux G., Launay J.-M., Maroteaux L.;
RT   "The human serotonin 5-HT2B receptor: pharmacological link between 5-
RT   HT2 and 5-HT1D receptors.";
RL   FEBS Lett. 352:393-399(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Uterus;
RX   MEDLINE=94359485; PubMed=8078486;
RA   Kursar J.D., Nelson D.L., Wainscott D.B., Baez M.;
RT   "Molecular cloning, functional expression, and mRNA tissue
RT   distribution of the human 5-hydroxytryptamine2B receptor.";
RL   Mol. Pharmacol. 46:227-234(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=20189989; PubMed=10722792; DOI=10.1006/mcpr.1999.0281;
RA   Kim S.J., Veenstra-VanderWeele J., Hanna G.L., Gonen D.,
RA   Leventhal B.L., Cook E.H. Jr.;
RT   "Mutation screening of human 5-HT(2B) receptor gene in early-onset
RT   obsessive-compulsive disorder.";
RL   Mol. Cell. Probes 14:47-52(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction
RT   sequenced by the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   INTERACTION WITH MPDZ.
RX   MEDLINE=21201137; PubMed=11150294; DOI=10.1074/jbc.M008089200;
RA   Becamel C., Figge A., Poliak S., Dumuis A., Peles E., Bockaert J.,
RA   Luebbert H., Ullmer C.;
RT   "Interaction of serotonin 5-hydroxytryptamine type 2C receptors with
RT   PDZ10 of the multi-PDZ domain protein MUPP1.";
RL   J. Biol. Chem. 276:12974-12982(2001).
CC   -!- FUNCTION: This is one of the several different receptors for 5-
CC       hydroxytryptamine (serotonin), a biogenic hormone that functions
CC       as a neurotransmitter, a hormone, and a mitogen. This receptor
CC       mediates its action by association with G proteins that activate a
CC       phosphatidylinositol-calcium second messenger system.
CC   -!- SUBUNIT: Interacts with MPDZ.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Detected in most peripheral organs. Only low
CC       expression levels were found in the brain.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X77307; CAA54513.1; -; mRNA.
DR   EMBL; Z36748; CAA85319.1; -; mRNA.
DR   EMBL; AF156160; AAD39259.1; -; Genomic_DNA.
DR   EMBL; AF156158; AAD39259.1; JOINED; Genomic_DNA.
DR   EMBL; AF156159; AAD39259.1; JOINED; Genomic_DNA.
DR   EMBL; AY136751; AAN01277.1; -; mRNA.
DR   EMBL; AC009407; AAX93128.1; -; Genomic_DNA.
DR   EMBL; AK313741; BAG36482.1; -; mRNA.
DR   EMBL; CH471063; EAW70949.1; -; Genomic_DNA.
DR   EMBL; BC063123; AAH63123.1; -; mRNA.
DR   IPI; IPI00015134; -.
DR   PIR; S43687; S43687.
DR   PIR; S49442; S49442.
DR   RefSeq; NP_000858.3; -.
DR   UniGene; Hs.421649; -.
DR   SMR; P41595; 64-399.
DR   STRING; P41595; -.
DR   PRIDE; P41595; -.
DR   Ensembl; ENST00000258400; ENSP00000258400; ENSG00000135914; Homo sapiens.
DR   GeneID; 3357; -.
DR   KEGG; hsa:3357; -.
DR   CTD; 3357; -.
DR   GeneCards; GC02M231681; -.
DR   H-InvDB; HIX0029887; -.
DR   HGNC; HGNC:5294; HTR2B.
DR   HPA; CAB011448; -.
DR   HPA; HPA012867; -.
DR   MIM; 601122; gene.
DR   PharmGKB; PA29554; -.
DR   eggNOG; prNOG17666; -.
DR   HOGENOM; HBG445348; -.
DR   HOVERGEN; HBG107487; -.
DR   InParanoid; P41595; -.
DR   OMA; NKPPQRL; -.
DR   OrthoDB; EOG9ZSCNH; -.
DR   PhylomeDB; P41595; -.
DR   Reactome; REACT_14797; Signaling by GPCR.
DR   DrugBank; DB01239; Chlorprothixene.
DR   DrugBank; DB00216; Eletriptan.
DR   DrugBank; DB00574; Fenfluramine.
DR   DrugBank; DB01403; Methotrimeprazine.
DR   DrugBank; DB00805; Minaprine.
DR   DrugBank; DB01224; Quetiapine.
DR   DrugBank; DB00669; Sumatriptan.
DR   DrugBank; DB01079; Tegaserod.
DR   DrugBank; DB00508; Triflupromazine.
DR   NextBio; 13274; -.
DR   ArrayExpress; P41595; -.
DR   Bgee; P41595; -.
DR   CleanEx; HS_HTR2B; -.
DR   Genevestigator; P41595; -.
DR   GermOnline; ENSG00000135914; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0051378; F:serotonin binding; IDA:MGI.
DR   GO; GO:0004993; F:serotonin receptor activity; IDA:MGI.
DR   GO; GO:0007200; P:activation of phospholipase C activity by G...; TAS:ProtInc.
DR   GO; GO:0008015; P:blood circulation; TAS:ProtInc.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-k...; IEP:UniProtKB.
DR   InterPro; IPR000482; 5HT2B_rcpt.
DR   InterPro; IPR002231; 5HT_rcpt.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00651; 5HT2BRECEPTR.
DR   PRINTS; PR01101; 5HTRECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Complete proteome; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane;
KW   Palmitate; Polymorphism; Receptor; Transducer; Transmembrane.
FT   CHAIN         1    481       5-hydroxytryptamine receptor 2B.
FT                                /FTId=PRO_0000068953.
FT   TOPO_DOM      1     56       Extracellular (By similarity).
FT   TRANSMEM     57     79       1 (By similarity).
FT   TOPO_DOM     80     91       Cytoplasmic (By similarity).
FT   TRANSMEM     92    113       2 (By similarity).
FT   TOPO_DOM    114    129       Extracellular (By similarity).
FT   TRANSMEM    130    151       3 (By similarity).
FT   TOPO_DOM    152    171       Cytoplasmic (By similarity).
FT   TRANSMEM    172    192       4 (By similarity).
FT   TOPO_DOM    193    216       Extracellular (By similarity).
FT   TRANSMEM    217    239       5 (By similarity).
FT   TOPO_DOM    240    324       Cytoplasmic (By similarity).
FT   TRANSMEM    325    345       6 (By similarity).
FT   TOPO_DOM    346    360       Extracellular (By similarity).
FT   TRANSMEM    361    383       7 (By similarity).
FT   TOPO_DOM    384    481       Cytoplasmic (By similarity).
FT   MOTIF       479    481       PDZ-binding.
FT   LIPID       397    397       S-palmitoyl cysteine (Potential).
FT   CARBOHYD     30     30       N-linked (GlcNAc...) (Potential).
FT   DISULFID    128    207       By similarity.
FT   VARIANT     421    421       M -> V (in dbSNP:rs6736017).
FT                                /FTId=VAR_055907.
FT   CONFLICT    452    452       T -> P (in Ref. 2; CAA85319).
FT   CONFLICT    477    477       Q -> R (in Ref. 9; AAH63123).
SQ   SEQUENCE   481 AA;  54298 MW;  CDA4447ECDBA3B46 CRC64;
     MALSYRVSEL QSTIPEHILQ STFVHVISSN WSGLQTESIP EEMKQIVEEQ GNKLHWAALL
     ILMVIIPTIG GNTLVILAVS LEKKLQYATN YFLMSLAVAD LLVGLFVMPI ALLTIMFEAM
     WPLPLVLCPA WLFLDVLFST ASIMHLCAIS VDRYIAIKKP IQANQYNSRA TAFIKITVVW
     LISIGIAIPV PIKGIETDVD NPNNITCVLT KERFGDFMLF GSLAAFFTPL AIMIVTYFLT
     IHALQKKAYL VKNKPPQRLT WLTVSTVFQR DETPCSSPEK VAMLDGSRKD KALPNSGDET
     LMRRTSTIGK KSVQTISNEQ RASKVLGIVF FLFLLMWCPF FITNITLVLC DSCNQTTLQM
     LLEIFVWIGY VSSGVNPLVY TLFNKTFRDA FGRYITCNYR ATKSVKTLRK RSSKIYFRNP
     MAENSKFFKK HGIRNGINPA MYQSPMRLRS STIQSSSIIL LDTLLLTENE GDKTEEQVSY
     V
//
ID   5HT2C_HUMAN             Reviewed;         458 AA.
AC   P28335; Q5VUF8; Q9NP28;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-1992, sequence version 1.
DT   02-MAR-2010, entry version 109.
DE   RecName: Full=5-hydroxytryptamine receptor 2C;
DE            Short=5-HTR2C;
DE            Short=5-HT-2C;
DE            Short=5-HT2C;
DE   AltName: Full=5-hydroxytryptamine receptor 1C;
DE            Short=5-HT-1C;
DE            Short=5-HT1C;
DE   AltName: Full=Serotonin receptor 2C;
GN   Name=HTR2C; Synonyms=HTR1C;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   MEDLINE=92109767; PubMed=1722404; DOI=10.1016/0006-291X(91)92105-S;
RA   Saltzman A.G., Morse B., Whitman M.M., Ivanshchenko Y., Jaye M.,
RA   Felder S.;
RT   "Cloning of the human serotonin 5-HT2 and 5-HT1C receptor subtypes.";
RL   Biochem. Biophys. Res. Commun. 181:1469-1478(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND FUNCTION.
RC   TISSUE=Hippocampus, and Placenta;
RX   MEDLINE=95203331; PubMed=7895773; DOI=10.1016/0922-4106(94)90042-6;
RA   Stam N.J., Vanderheyden P., Van Alebeek C., Klomp J., De Boer T.,
RA   Van Delft A.M.L., Olijve W.;
RT   "Genomic organisation and functional expression of the gene encoding
RT   the human serotonin 5-HT2C receptor.";
RL   Eur. J. Pharmacol. 269:339-348(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   MEDLINE=97001158; PubMed=8812491; DOI=10.1006/geno.1996.0397;
RA   Xie E., Zhao L., Levine A.J., Shenk T., Chang L.-S.;
RT   "The human serotonin 5-HT2C receptor: complete cDNA, genomic
RT   structure, and alternatively spliced variant.";
RL   Genomics 35:551-561(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND RNA EDITING OF POSITIONS 156; 158 AND
RP   160.
RC   TISSUE=Brain;
RX   MEDLINE=99127198; PubMed=9928237;
RX   DOI=10.1111/j.1749-6632.1998.tb10171.x;
RA   Niswender C.M., Sanders-Bush E., Emeson R.B.;
RT   "Identification and characterization of RNA editing events within the
RT   5-HT2C receptor.";
RL   Ann. N. Y. Acad. Sci. 861:38-48(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction
RT   sequenced by the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   INTERACTION WITH MPDZ, DOMAIN, MUTAGENESIS OF SER-456; SER-457 AND
RP   VAL-458, AND GLYCOSYLATION.
RX   MEDLINE=21201137; PubMed=11150294; DOI=10.1074/jbc.M008089200;
RA   Becamel C., Figge A., Poliak S., Dumuis A., Peles E., Bockaert J.,
RA   Luebbert H., Ullmer C.;
RT   "Interaction of serotonin 5-hydroxytryptamine type 2C receptors with
RT   PDZ10 of the multi-PDZ domain protein MUPP1.";
RL   J. Biol. Chem. 276:12974-12982(2001).
RN   [9]
RP   INTERACTION WITH ARRB2, AND MUTAGENESIS OF PRO-159.
RX   PubMed=16319069; DOI=10.1074/jbc.M508074200;
RA   Marion S., Oakley R.H., Kim K.-M., Caron M.G., Barak L.S.;
RT   "A beta-arrestin binding determinant common to the second
RT   intracellular loops of rhodopsin family G protein-coupled receptors.";
RL   J. Biol. Chem. 281:2932-2938(2006).
RN   [10]
RP   VARIANT SER-23.
RX   MEDLINE=96044432; PubMed=7557992; DOI=10.1006/geno.1995.1042;
RA   Lappalainen J., Zhang L., Dean M., Oz M., Ozaki N., Yu D.,
RA   Virkkunen M., Weight F., Linnoila M., Goldman D.;
RT   "Identification, expression, and pharmacology of a Cys23-Ser23
RT   substitution in the human 5-HT2c receptor gene (HTR2C).";
RL   Genomics 27:274-279(1995).
RN   [11]
RP   VARIANT SER-23.
RX   MEDLINE=99221071; PubMed=10206230;
RX   DOI=10.1002/(SICI)1096-8628(19990416)88:2<126::AID-AJMG6>3.3.CO;2-D;
RA   Samochowiec J., Smolka M., Winterer G., Rommelspacher H.,
RA   Schmidt L.G., Sander T.;
RT   "Association analysis between a Cys23Ser substitution polymorphism of
RT   the human 5-HT2c receptor gene and neuronal hyperexcitability.";
RL   Am. J. Med. Genet. 88:126-130(1999).
RN   [12]
RP   VARIANT SER-23.
RX   MEDLINE=20049881; PubMed=10581480;
RX   DOI=10.1002/(SICI)1096-8628(19991215)88:6<621::AID-AJMG9>3.0.CO;2-H;
RA   Marshall S.E., Bird T.G., Hart K., Welsh K.I.;
RT   "Unified approach to the analysis of genetic variation in serotonergic
RT   pathways.";
RL   Am. J. Med. Genet. 88:621-627(1999).
RN   [13]
RP   VARIANT SER-23.
RX   MEDLINE=99318093; PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [14]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
CC   -!- FUNCTION: This is one of the several different receptors for 5-
CC       hydroxytryptamine (serotonin), a biogenic hormone that functions
CC       as a neurotransmitter, a hormone, and a mitogen. This receptor
CC       mediates its action by association with G proteins that activate a
CC       phosphatidylinositol-calcium second messenger system.
CC   -!- SUBUNIT: Interacts with MPDZ. Interacts with ARRB2.
CC   -!- INTERACTION:
CC       Q91YI4:Arrb2 (xeno); NbExp=1; IntAct=EBI-994141, EBI-994161;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- DOMAIN: The PDZ domain-binding motif is involved in the
CC       interaction with MPDZ.
CC   -!- PTM: N-glycosylated.
CC   -!- RNA EDITING: Modified_positions=156, 158, 160; Note=Partially
CC       edited. RNA editing generates receptor isoforms that differ in
CC       their ability to interact with the phospholipase C signaling
CC       cascade in a transfected cell line, suggesting that this RNA
CC       processing event may contribute to the modulation of serotonergic
CC       neurotransmission in the central nervous system.
CC   -!- POLYMORPHISM: Position 23 is polymorphic; the frequencies in
CC       unrelated Caucasians are 0.87 for Cys and 0.13 for Ser.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M81778; AAA60317.1; -; mRNA.
DR   EMBL; X80763; CAB59978.1; -; Genomic_DNA.
DR   EMBL; U49516; AAB40898.1; -; mRNA.
DR   EMBL; AF208053; AAF35842.1; -; mRNA.
DR   EMBL; AF498983; AAM21130.1; -; mRNA.
DR   EMBL; AC004822; AAC71658.1; -; Genomic_DNA.
DR   EMBL; AL355812; CAI41335.1; -; Genomic_DNA.
DR   EMBL; AL590097; CAI41335.1; JOINED; Genomic_DNA.
DR   EMBL; AC004822; CAI41335.1; JOINED; Genomic_DNA.
DR   EMBL; AL590097; CAH70193.1; -; Genomic_DNA.
DR   EMBL; AC004822; CAH70193.1; JOINED; Genomic_DNA.
DR   EMBL; AL355812; CAH70193.1; JOINED; Genomic_DNA.
DR   EMBL; BC095543; AAH95543.1; -; mRNA.
DR   IPI; IPI00002876; -.
DR   PIR; JS0616; JS0616.
DR   RefSeq; NP_000859.1; -.
DR   UniGene; Hs.149037; -.
DR   SMR; P28335; 60-387.
DR   IntAct; P28335; 1.
DR   STRING; P28335; -.
DR   PhosphoSite; P28335; -.
DR   PRIDE; P28335; -.
DR   Ensembl; ENST00000276198; ENSP00000276198; ENSG00000147246; Homo sapiens.
DR   Ensembl; ENST00000371951; ENSP00000361019; ENSG00000147246; Homo sapiens.
DR   GeneID; 3358; -.
DR   KEGG; hsa:3358; -.
DR   UCSC; uc004epu.1; human.
DR   CTD; 3358; -.
DR   GeneCards; GC0XP113641; -.
DR   H-InvDB; HIX0028341; -.
DR   HGNC; HGNC:5295; HTR2C.
DR   HPA; CAB006857; -.
DR   HPA; HPA003133; -.
DR   MIM; 312861; gene.
DR   PharmGKB; PA194; -.
DR   eggNOG; prNOG18115; -.
DR   HOGENOM; HBG445348; -.
DR   HOVERGEN; HBG107487; -.
DR   InParanoid; P28335; -.
DR   OMA; NPSNVVS; -.
DR   OrthoDB; EOG9ZSCNH; -.
DR   PhylomeDB; P28335; -.
DR   Reactome; REACT_14797; Signaling by GPCR.
DR   DrugBank; DB01239; Chlorprothixene.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB01191; Dexfenfluramine.
DR   DrugBank; DB00574; Fenfluramine.
DR   DrugBank; DB00247; Methysergide.
DR   DrugBank; DB06148; Mianserin.
DR   DrugBank; DB00805; Minaprine.
DR   DrugBank; DB00370; Mirtazapine.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB00420; Promazine.
DR   DrugBank; DB00777; Propiomazine.
DR   DrugBank; DB01224; Quetiapine.
DR   DrugBank; DB06144; Sertindole.
DR   DrugBank; DB00372; Thiethylperazine.
DR   DrugBank; DB00193; Tramadol.
DR   DrugBank; DB00246; Ziprasidone.
DR   NextBio; 13278; -.
DR   ArrayExpress; P28335; -.
DR   Bgee; P28335; -.
DR   CleanEx; HS_HTR2C; -.
DR   Genevestigator; P28335; -.
DR   GermOnline; ENSG00000147246; Homo sapiens.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0051378; F:serotonin binding; IDA:MGI.
DR   GO; GO:0004993; F:serotonin receptor activity; IDA:MGI.
DR   GO; GO:0007631; P:feeding behavior; TAS:ProtInc.
DR   GO; GO:0007186; P:G-protein coupled receptor protein signalin...; EXP:Reactome.
DR   GO; GO:0007268; P:synaptic transmission; TAS:ProtInc.
DR   InterPro; IPR000377; 5HT2C_rcpt.
DR   InterPro; IPR002231; 5HT_rcpt.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00517; 5HT2CRECEPTR.
DR   PRINTS; PR01101; 5HTRECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Complete proteome; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Polymorphism;
KW   Receptor; RNA editing; Transducer; Transmembrane.
FT   CHAIN         1    458       5-hydroxytryptamine receptor 2C.
FT                                /FTId=PRO_0000068958.
FT   TOPO_DOM      1     52       Extracellular (By similarity).
FT   TRANSMEM     53     78       1 (By similarity).
FT   TOPO_DOM     79     89       Cytoplasmic (By similarity).
FT   TRANSMEM     90    110       2 (By similarity).
FT   TOPO_DOM    111    127       Extracellular (By similarity).
FT   TRANSMEM    128    150       3 (By similarity).
FT   TOPO_DOM    151    170       Cytoplasmic (By similarity).
FT   TRANSMEM    171    193       4 (By similarity).
FT   TOPO_DOM    194    213       Extracellular (By similarity).
FT   TRANSMEM    214    235       5 (By similarity).
FT   TOPO_DOM    236    311       Cytoplasmic (By similarity).
FT   TRANSMEM    312    333       6 (By similarity).
FT   TOPO_DOM    334    348       Extracellular (By similarity).
FT   TRANSMEM    349    371       7 (By similarity).
FT   TOPO_DOM    372    458       Cytoplasmic (By similarity).
FT   MOTIF       456    458       PDZ-binding.
FT   CARBOHYD     39     39       N-linked (GlcNAc...) (Probable).
FT   DISULFID    127    207       By similarity.
FT   VARIANT      23     23       C -> S (in dbSNP:rs6318).
FT                                /FTId=VAR_003450.
FT   VARIANT     156    156       I -> V (in RNA edited version).
FT                                /FTId=VAR_010166.
FT   VARIANT     158    158       N -> S (in RNA edited version).
FT                                /FTId=VAR_010167.
FT   VARIANT     160    160       I -> V (in RNA edited version).
FT                                /FTId=VAR_010168.
FT   MUTAGEN     159    159       P->A: Decreases interaction with ARRB2.
FT   MUTAGEN     456    456       S->A: Loss of interaction with MPDZ.
FT   MUTAGEN     456    456       S->T: No effect on interaction with MPDZ.
FT   MUTAGEN     457    457       S->A: No effect on interaction with MPDZ.
FT   MUTAGEN     458    458       V->A: Loss of interaction with MPDZ.
SQ   SEQUENCE   458 AA;  51821 MW;  9E76B3FFD3E09C93 CRC64;
     MVNLRNAVHS FLVHLIGLLV WQCDISVSPV AAIVTDIFNT SDGGRFKFPD GVQNWPALSI
     VIIIIMTIGG NILVIMAVSM EKKLHNATNY FLMSLAIADM LVGLLVMPLS LLAILYDYVW
     PLPRYLCPVW ISLDVLFSTA SIMHLCAISL DRYVAIRNPI EHSRFNSRTK AIMKIAIVWA
     ISIGVSVPIP VIGLRDEEKV FVNNTTCVLN DPNFVLIGSF VAFFIPLTIM VITYCLTIYV
     LRRQALMLLH GHTEEPPGLS LDFLKCCKRN TAEEENSANP NQDQNARRRK KKERRPRGTM
     QAINNERKAS KVLGIVFFVF LIMWCPFFIT NILSVLCEKS CNQKLMEKLL NVFVWIGYVC
     SGINPLVYTL FNKIYRRAFS NYLRCNYKVE KKPPVRQIPR VAATALSGRE LNVNIYRHTN
     EPVIEKASDN EPGIEMQVEN LELPVNPSSV VSERISSV
//
ID   5HT2C_RAT               Reviewed;         460 AA.
AC   P08909;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1988, sequence version 1.
DT   02-MAR-2010, entry version 93.
DE   RecName: Full=5-hydroxytryptamine receptor 2C;
DE            Short=5-HTR2C;
DE            Short=5-HT-2C;
DE            Short=5-HT2C;
DE   AltName: Full=5-hydroxytryptamine receptor 1C;
DE            Short=5-HT-1C;
DE            Short=5-HT1C;
DE   AltName: Full=Serotonin receptor 2C;
GN   Name=Htr2c; Synonyms=5ht1c, Htr1c;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=88290673; PubMed=3399891; DOI=10.1126/science.3399891;
RA   Julius D., McDermott A.B., Axel R., Jessell T.M.;
RT   "Molecular characterization of a functional cDNA encoding the
RT   serotonin 1c receptor.";
RL   Science 241:558-564(1988).
RN   [2]
RP   INTERACTION WITH MPDZ, AND MUTAGENESIS OF SER-458 AND SER-459.
RX   MEDLINE=22679206; PubMed=12682077; DOI=10.1074/jbc.M210973200;
RA   Parker L.L., Backstrom J.R., Sanders-Bush E., Shieh B.H.;
RT   "Agonist-induced phosphorylation of the serotonin 5-HT2C receptor
RT   regulates its interaction with multiple PDZ protein 1.";
RL   J. Biol. Chem. 278:21576-21583(2003).
CC   -!- FUNCTION: This is one of the several different receptors for 5-
CC       hydroxytryptamine (serotonin), a biogenic hormone that functions
CC       as a neurotransmitter, a hormone, and a mitogen. This receptor
CC       mediates its action by association with G proteins that activate a
CC       phosphatidylinositol-calcium second messenger system.
CC   -!- SUBUNIT: Interacts with MPDZ. Interacts with ARRB2 (By
CC       similarity).
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- DOMAIN: The PDZ domain-binding motif is involved in the
CC       interaction with MPDZ.
CC   -!- PTM: N-glycosylated (By similarity).
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M21410; AAA42177.1; -; Genomic_DNA.
DR   IPI; IPI00187680; -.
DR   PIR; A32605; A32605.
DR   RefSeq; NP_036897.2; -.
DR   UniGene; Rn.9935; -.
DR   SMR; P08909; 46-389.
DR   STRING; P08909; -.
DR   PhosphoSite; P08909; -.
DR   Ensembl; ENSRNOT00000065293; ENSRNOP00000060345; ENSRNOG00000030877; Rattus norvegicus.
DR   GeneID; 25187; -.
DR   KEGG; rno:25187; -.
DR   UCSC; U35315; rat.
DR   CTD; 25187; -.
DR   RGD; 2848; Htr2c.
DR   eggNOG; roNOG05307; -.
DR   HOVERGEN; HBG107487; -.
DR   InParanoid; P08909; -.
DR   NextBio; 605689; -.
DR   ArrayExpress; P08909; -.
DR   Genevestigator; P08909; -.
DR   GermOnline; ENSRNOG00000030877; Rattus norvegicus.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:MGI.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:RGD.
DR   GO; GO:0004993; F:serotonin receptor activity; IDA:MGI.
DR   GO; GO:0007208; P:activation of phospholipase C activity by s...; IDA:RGD.
DR   GO; GO:0031583; P:activation of phospholipase D activity by G...; IMP:RGD.
DR   GO; GO:0035095; P:behavioral response to nicotine; IMP:RGD.
DR   GO; GO:0007631; P:feeding behavior; IMP:RGD.
DR   GO; GO:0007187; P:G-protein signaling, coupled to cyclic nucl...; TAS:RGD.
DR   GO; GO:0048016; P:inositol phosphate-mediated signaling; IDA:MGI.
DR   GO; GO:0045963; P:negative regulation of dopamine metabolic p...; IMP:RGD.
DR   GO; GO:0040013; P:negative regulation of locomotion; IMP:RGD.
DR   GO; GO:0031100; P:organ regeneration; IEP:RGD.
DR   GO; GO:0014057; P:positive regulation of acetylcholine secretion; IMP:RGD.
DR   GO; GO:0014054; P:positive regulation of gamma-aminobutyric a...; IMP:RGD.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IMP:RGD.
DR   GO; GO:0051930; P:regulation of sensory perception of pain; IMP:RGD.
DR   GO; GO:0042493; P:response to drug; IMP:RGD.
DR   InterPro; IPR000377; 5HT2C_rcpt.
DR   InterPro; IPR002231; 5HT_rcpt.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00517; 5HT2CRECEPTR.
DR   PRINTS; PR01101; 5HTRECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Membrane; Receptor; Transducer; Transmembrane.
FT   CHAIN         1    460       5-hydroxytryptamine receptor 2C.
FT                                /FTId=PRO_0000068961.
FT   TOPO_DOM      1     53       Extracellular (By similarity).
FT   TRANSMEM     54     79       1 (By similarity).
FT   TOPO_DOM     80     90       Cytoplasmic (By similarity).
FT   TRANSMEM     91    111       2 (By similarity).
FT   TOPO_DOM    112    128       Extracellular (By similarity).
FT   TRANSMEM    129    151       3 (By similarity).
FT   TOPO_DOM    152    171       Cytoplasmic (By similarity).
FT   TRANSMEM    172    194       4 (By similarity).
FT   TOPO_DOM    195    214       Extracellular (By similarity).
FT   TRANSMEM    215    236       5 (By similarity).
FT   TOPO_DOM    237    313       Cytoplasmic (By similarity).
FT   TRANSMEM    314    335       6 (By similarity).
FT   TOPO_DOM    336    350       Extracellular (By similarity).
FT   TRANSMEM    351    373       7 (By similarity).
FT   TOPO_DOM    374    460       Cytoplasmic (By similarity).
FT   MOTIF       458    460       PDZ-binding.
FT   CARBOHYD     39     39       N-linked (GlcNAc...) (By similarity).
FT   CARBOHYD    204    204       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    205    205       N-linked (GlcNAc...) (Potential).
FT   DISULFID    128    208       By similarity.
FT   MUTAGEN     458    458       S->A,D: Loss of interaction with MPDZ.
FT   MUTAGEN     459    459       S->D: No effect on interaction with MPDZ.
SQ   SEQUENCE   460 AA;  51917 MW;  D44E977D8F80047E CRC64;
     MVNLGNAVRS LLMHLIGLLV WQFDISISPV AAIVTDTFNS SDGGRLFQFP DGVQNWPALS
     IVVIIIMTIG GNILVIMAVS MEKKLHNATN YFLMSLAIAD MLVGLLVMPL SLLAILYDYV
     WPLPRYLCPV WISLDVLFST ASIMHLCAIS LDRYVAIRNP IEHSRFNSRT KAIMKIAIVW
     AISIGVSVPI PVIGLRDESK VFVNNTTCVL NDPNFVLIGS FVAFFIPLTI MVITYFLTIY
     VLRRQTLMLL RGHTEEELAN MSLNFLNCCC KKNGGEEENA PNPNPDQKPR RKKKEKRPRG
     TMQAINNEKK ASKVLGIVFF VFLIMWCPFF ITNILSVLCG KACNQKLMEK LLNVFVWIGY
     VCSGINPLVY TLFNKIYRRA FSKYLRCDYK PDKKPPVRQI PRVAATALSG RELNVNIYRH
     TNERVARKAN DPEPGIEMQV ENLELPVNPS NVVSERISSV
//
ID   5HT4R_MOUSE             Reviewed;         388 AA.
AC   P97288; O89003; O89004; Q9R2A4;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1999, sequence version 2.
DT   02-MAR-2010, entry version 86.
DE   RecName: Full=5-hydroxytryptamine receptor 4;
DE            Short=5-HT-4;
DE            Short=5-HT4;
DE   AltName: Full=Serotonin receptor 4;
GN   Name=Htr4;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Swiss; TISSUE=Brain;
RX   MEDLINE=97102706; PubMed=8946946; DOI=10.1016/S0014-5793(96)01132-5;
RA   Claeysen S., Sebben M., Journot L., Bockaert J., Dumuis A.;
RT   "Cloning, expression and pharmacology of the mouse 5-HT(4L)
RT   receptor.";
RL   FEBS Lett. 398:19-25(1996).
RN   [2]
RP   SEQUENCE REVISION TO C-TERMINUS.
RA   Dumuis A.;
RL   Submitted (SEP-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5-HT4(A) AND 5-HT4(E)).
RC   STRAIN=Swiss; TISSUE=Brain;
RX   MEDLINE=99127199; PubMed=9928238;
RX   DOI=10.1111/j.1749-6632.1998.tb10172.x;
RA   Claeysen S., Faye P., Sebben M., Taviaux S., Bockaert J., Dumuis A.;
RT   "5-HT4 receptors: cloning and expression of new splice variants.";
RL   Ann. N. Y. Acad. Sci. 861:49-56(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5-HT4(F)).
RC   TISSUE=Brain;
RX   MEDLINE=99238795; PubMed=10220570;
RA   Claeysen S., Sebben M., Becamel C., Bockaert J., Dumuis A.;
RT   "Novel brain-specific 5-HT4 receptor splice variants show marked
RT   constitutive activity: role of the C-terminal intracellular domain.";
RL   Mol. Pharmacol. 55:910-920(1999).
RN   [5]
RP   INTERACTION WITH INADL; MAGI2; MPP3; NOS1; SEC23A; SLC9A3R1 AND SNX27.
RX   PubMed=15466885; DOI=10.1242/jcs.01379;
RA   Joubert L., Hanson B., Barthet G., Sebben M., Claeysen S., Hong W.,
RA   Marin P., Dumuis A., Bockaert J.;
RT   "New sorting nexin (SNX27) and NHERF specifically interact with the 5-
RT   HT4a receptor splice variant: roles in receptor targeting.";
RL   J. Cell Sci. 117:5367-5379(2004).
CC   -!- FUNCTION: This is one of the several different receptors for 5-
CC       hydroxytryptamine (serotonin), a biogenic hormone that functions
CC       as a neurotransmitter, a hormone, and a mitogen. The activity of
CC       this receptor is mediated by G proteins that stimulate adenylate
CC       cyclase (By similarity).
CC   -!- SUBUNIT: Isoform 5-HT4(A) interacts with MAGI2, MPP3, SLC9A3R1 and
CC       SNX27 isoforms 1 and 2. Isoform 5-HT4(E) interacts with INADL,
CC       NOS1 and SEC23A. Isoform 5-HT4(A) forms a complex including
CC       SLC9A3R1 and EZR.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC       Endosome. Note=Interaction with SNX27 mediates recruitment to
CC       early endosomes, while interaction with SLC9A3R1 and EZR might
CC       target the protein to specialized subcellular regions, such as
CC       microvilli.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=P97288-1; Sequence=Displayed;
CC       Name=5-HT4(A);
CC         IsoId=P97288-2; Sequence=VSP_001851;
CC       Name=5-HT4(E);
CC         IsoId=P97288-3; Sequence=VSP_001852;
CC       Name=5-HT4(F);
CC         IsoId=P97288-4; Sequence=VSP_001853;
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y09585; CAA70773.1; -; mRNA.
DR   EMBL; Y09587; CAA70775.1; -; mRNA.
DR   EMBL; Y09588; CAA70776.1; -; mRNA.
DR   EMBL; AJ011369; CAA09598.1; -; mRNA.
DR   IPI; IPI00122961; -.
DR   IPI; IPI00223494; -.
DR   IPI; IPI00223495; -.
DR   IPI; IPI00223496; -.
DR   UniGene; Mm.20440; -.
DR   SMR; P97288; 21-329.
DR   STRING; P97288; -.
DR   PRIDE; P97288; -.
DR   Ensembl; ENSMUST00000027560; ENSMUSP00000027560; ENSMUSG00000026322; Mus musculus.
DR   Ensembl; ENSMUST00000115214; ENSMUSP00000110869; ENSMUSG00000026322; Mus musculus.
DR   Ensembl; ENSMUST00000115215; ENSMUSP00000110870; ENSMUSG00000026322; Mus musculus.
DR   UCSC; uc008fdb.1; mouse.
DR   UCSC; uc008fdc.1; mouse.
DR   MGI; MGI:109246; Htr4.
DR   eggNOG; roNOG09543; -.
DR   HOGENOM; HBG445348; -.
DR   HOVERGEN; HBG106962; -.
DR   InParanoid; P97288; -.
DR   ArrayExpress; P97288; -.
DR   Bgee; P97288; -.
DR   CleanEx; MM_HTR4; -.
DR   Genevestigator; P97288; -.
DR   GermOnline; ENSMUSG00000026322; Mus musculus.
DR   GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   InterPro; IPR001520; 5HT4_rcpt.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01059; 5HT4RECEPTR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Disulfide bond; Endosome;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane;
KW   Palmitate; Receptor; Transducer; Transmembrane.
FT   CHAIN         1    388       5-hydroxytryptamine receptor 4.
FT                                /FTId=PRO_0000068966.
FT   TOPO_DOM      1     19       Extracellular (By similarity).
FT   TRANSMEM     20     40       1 (By similarity).
FT   TOPO_DOM     41     58       Cytoplasmic (By similarity).
FT   TRANSMEM     59     79       2 (By similarity).
FT   TOPO_DOM     80     93       Extracellular (By similarity).
FT   TRANSMEM     94    116       3 (By similarity).
FT   TOPO_DOM    117    137       Cytoplasmic (By similarity).
FT   TRANSMEM    138    158       4 (By similarity).
FT   TOPO_DOM    159    192       Extracellular (By similarity).
FT   TRANSMEM    193    213       5 (By similarity).
FT   TOPO_DOM    214    260       Cytoplasmic (By similarity).
FT   TRANSMEM    261    281       6 (By similarity).
FT   TOPO_DOM    282    294       Extracellular (By similarity).
FT   TRANSMEM    295    315       7 (By similarity).
FT   TOPO_DOM    316    388       Cytoplasmic (By similarity).
FT   LIPID       329    329       S-palmitoyl cysteine (By similarity).
FT   CARBOHYD      7      7       N-linked (GlcNAc...) (Potential).
FT   DISULFID     93    184       By similarity.
FT   VAR_SEQ     359    388       RDAVECGGQWESRCHLTATSPLVAAQPSDT -> SFPLLFR
FT                                NRPVPV (in isoform 5-HT4(E)).
FT                                /FTId=VSP_001852.
FT   VAR_SEQ     360    388       DAVECGGQWESRCHLTATSPLVAAQPSDT -> YTVLHSGH
FT                                HQELEKLPIHNDPESLESCF (in isoform 5-
FT                                HT4(A)).
FT                                /FTId=VSP_001851.
FT   VAR_SEQ     360    388       DAVECGGQWESRCHLTATSPLVAAQPSDT -> PVPV (in
FT                                isoform 5-HT4(F)).
FT                                /FTId=VSP_001853.
SQ   SEQUENCE   388 AA;  43932 MW;  F84163F39BA115B0 CRC64;
     MDKLDANVSS NEGFRSVEKV VLLTFLAVVI LMAILGNLLV MVAVCRDRQL RKIKTNYFIV
     SLAFADLLVS VLVMPFGAIE LVQDIWAYGE MFCLVRTSLD VLLTTASIFH LCCISLDRYY
     AICCQPLVYR NKMTPLRIAL MLGGCWVLPM FISFLPIMQG WNNIGIVDVI EKRKFSHNSN
     STWCVFMVNK PYAITCSVVA FYIPFLLMVL AYYRIYVTAK EHAQQIQMLQ RAGATSESRP
     QPADQHSTHR MRTETKAAKT LCVIMGCFCF CWAPFFVTNI VDPFIDYTVP EQVWTAFLWL
     GYINSGLNPF LYAFLNKSFR RAFLIILCCD DERYKRPPIL GQTVPCSTTT INGSTHVLRD
     AVECGGQWES RCHLTATSPL VAAQPSDT
//
ID   5HT5A_MOUSE             Reviewed;         357 AA.
AC   P30966;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1993, sequence version 1.
DT   02-MAR-2010, entry version 80.
DE   RecName: Full=5-hydroxytryptamine receptor 5A;
DE            Short=5-HT-5A;
DE            Short=5-HT5A;
DE            Short=5-HT-5;
DE   AltName: Full=Serotonin receptor 5A;
GN   Name=Htr5a; Synonyms=5ht5a;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Brain;
RX   MEDLINE=93099851; PubMed=1464308;
RA   Plassat J.-L., Boschert U., Amlaiky N., Hen R.;
RT   "The mouse 5HT5 receptor reveals a remarkable heterogeneity within the
RT   5HT1D receptor family.";
RL   EMBO J. 11:4779-4786(1992).
RN   [2]
RP   CHARACTERIZATION.
RC   TISSUE=Brain;
RX   MEDLINE=93196607; PubMed=8450829;
RA   Matthes H., Boschert U., Amlaiky N., Grailhe R., Plassat J.-L.,
RA   Muscatelli F., Mattei M.-G., Hen R.;
RT   "Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors
RT   define a new family of serotonin receptors: cloning, functional
RT   expression, and chromosomal localization.";
RL   Mol. Pharmacol. 43:313-319(1993).
CC   -!- FUNCTION: This is one of the several different receptors for 5-
CC       hydroxytryptamine (serotonin), a biogenic hormone that functions
CC       as a neurotransmitter, a hormone, and a mitogen. The activity of
CC       this receptor is mediated by G proteins.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Expressed predominantly in the central nervous
CC       system; in the cerebral cortex, hippocampus, habenula, olfactory
CC       bulb and granular layer of the cerebellum.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z18278; CAA79155.1; -; Genomic_DNA.
DR   IPI; IPI00135792; -.
DR   PIR; S28058; S28058.
DR   UniGene; Mm.4835; -.
DR   SMR; P30966; 9-354.
DR   STRING; P30966; -.
DR   PRIDE; P30966; -.
DR   Ensembl; ENSMUST00000036227; ENSMUSP00000038884; ENSMUSG00000039106; Mus musculus.
DR   MGI; MGI:96283; Htr5a.
DR   eggNOG; roNOG09158; -.
DR   HOGENOM; HBG445348; -.
DR   HOVERGEN; HBG106962; -.
DR   InParanoid; P30966; -.
DR   ArrayExpress; P30966; -.
DR   Bgee; P30966; -.
DR   CleanEx; MM_HTR5A; -.
DR   Genevestigator; P30966; -.
DR   GermOnline; ENSMUSG00000039106; Mus musculus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0019933; P:cAMP-mediated signaling; IDA:MGI.
DR   GO; GO:0007186; P:G-protein coupled receptor protein signalin...; IEA:UniProtKB-KW.
DR   InterPro; IPR001397; 5HT5A_rcpt.
DR   InterPro; IPR002231; 5HT_rcpt.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   PANTHER; PTHR19266:SF81; 5HT5A_rcpt; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00518; 5HT5ARECEPTR.
DR   PRINTS; PR01101; 5HTRECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Membrane; Receptor; Transducer; Transmembrane.
FT   CHAIN         1    357       5-hydroxytryptamine receptor 5A.
FT                                /FTId=PRO_0000068970.
FT   TOPO_DOM      1     40       Extracellular (By similarity).
FT   TRANSMEM     41     63       1 (By similarity).
FT   TOPO_DOM     64     78       Cytoplasmic (By similarity).
FT   TRANSMEM     79     99       2 (By similarity).
FT   TOPO_DOM    100    115       Extracellular (By similarity).
FT   TRANSMEM    116    137       3 (By similarity).
FT   TOPO_DOM    138    158       Cytoplasmic (By similarity).
FT   TRANSMEM    159    181       4 (By similarity).
FT   TOPO_DOM    182    198       Extracellular (By similarity).
FT   TRANSMEM    199    219       5 (By similarity).
FT   TOPO_DOM    220    282       Cytoplasmic (By similarity).
FT   TRANSMEM    283    303       6 (By similarity).
FT   TOPO_DOM    304    320       Extracellular (By similarity).
FT   TRANSMEM    321    341       7 (By similarity).
FT   TOPO_DOM    342    357       Cytoplasmic (By similarity).
FT   CARBOHYD      6      6       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     21     21       N-linked (GlcNAc...) (Potential).
FT   DISULFID    120    192       By similarity.
SQ   SEQUENCE   357 AA;  40805 MW;  5F5D856AC477BFAC CRC64;
     MDLPVNLTSF SLSTPSSLEP NRSLDTEVLR PSRPFLSAFR VLVLTLLGFL AAATFTWNLL
     VLATILKVRT FHRVPHNLVA SMAISDVLVA VLVMPLSLVH ELSGRRWQLG RRLCQLWIAC
     DVLCCTASIW NVTAIALDRY WSITRHLEYT LRTRKRVSNV MILLTWALST VISLAPLLFG
     WGETYSEPSE ECQVSREPSY TVFSTVGAFY LPLWLVLFVY WKIYRAAKFR MGSRKTNSVS
     PVPEAVEVKN ATQHPQMVFT ARHATVTFQT EGDTWREQKE QRAALMVGIL IGVFVLCWFP
     FFVTELISPL CSWDVPAIWK SIFLWLGYSN SFFNPLIYTA FNRSYSSAFK VFFSKQQ
//
ID   5HT6R_HUMAN             Reviewed;         440 AA.
AC   P50406; Q13640; Q5TGZ1;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   02-MAR-2010, entry version 84.
DE   RecName: Full=5-hydroxytryptamine receptor 6;
DE            Short=5-HT-6;
DE            Short=5-HT6;
DE   AltName: Full=Serotonin receptor 6;
GN   Name=HTR6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Corpus striatum;
RX   MEDLINE=96102917; PubMed=8522988;
RA   Kohen R., Metcalf M.A., Khan N., Druck T., Huebner K., Lachowicz J.E.,
RA   Sibley D.R., Roth B., Hamblin M.W.;
RT   "Cloning, characterization, and chromosomal localization of a human 5-
RT   HT6 serotonin receptor.";
RL   J. Neurochem. 66:47-56(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction
RT   sequenced by the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Fetal brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 215-280.
RC   TISSUE=Corpus striatum;
RX   MEDLINE=95385798; PubMed=7656980; DOI=10.1016/0014-5793(95)00828-W;
RA   Ullmer C., Schmuck K., Kalkman H.O., Luebbert H.;
RT   "Expression of serotonin receptor mRNAs in blood vessels.";
RL   FEBS Lett. 370:215-221(1995).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-125, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=T-cell;
RX   PubMed=16094384; DOI=10.1038/nmeth776;
RA   Tao W.A., Wollscheid B., O'Brien R., Eng J.K., Li X.-J.,
RA   Bodenmiller B., Watts J.D., Hood L., Aebersold R.;
RT   "Quantitative phosphoproteome analysis using a dendrimer conjugation
RT   chemistry and tandem mass spectrometry.";
RL   Nat. Methods 2:591-598(2005).
CC   -!- FUNCTION: This is one of the several different receptors for 5-
CC       hydroxytryptamine (serotonin), a biogenic hormone that functions
CC       as a neurotransmitter, a hormone, and a mitogen. The activity of
CC       this receptor is mediated by G proteins that stimulate adenylate
CC       cyclase. It has a high affinity for tricyclic psychotropic drugs.
CC   -!- INTERACTION:
CC       P06241:FYN; NbExp=7; IntAct=EBI-1182222, EBI-515315;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Expressed in several human brain regions, most
CC       prominently in the caudate nucleus.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L41147; AAA92622.1; -; mRNA.
DR   EMBL; AY429105; AAR07900.1; -; mRNA.
DR   EMBL; AL031727; CAI19020.1; -; Genomic_DNA.
DR   EMBL; CH471134; EAW94896.1; -; Genomic_DNA.
DR   EMBL; BC074995; AAH74995.1; -; mRNA.
DR   EMBL; BC074996; AAH74996.1; -; mRNA.
DR   EMBL; Z49119; CAA88929.1; -; mRNA.
DR   IPI; IPI00032009; -.
DR   PIR; JC5520; JC5520.
DR   RefSeq; NP_000862.1; -.
DR   UniGene; Hs.22180; -.
DR   IntAct; P50406; 2.
DR   STRING; P50406; -.
DR   PhosphoSite; P50406; -.
DR   PRIDE; P50406; -.
DR   Ensembl; ENST00000289753; ENSP00000289753; ENSG00000158748; Homo sapiens.
DR   GeneID; 3362; -.
DR   KEGG; hsa:3362; -.
DR   UCSC; uc001bcl.1; human.
DR   CTD; 3362; -.
DR   GeneCards; GC01P019864; -.
DR   H-InvDB; HIX0028515; -.
DR   HGNC; HGNC:5301; HTR6.
DR   MIM; 601109; gene.
DR   PharmGKB; PA29560; -.
DR   eggNOG; prNOG17733; -.
DR   HOGENOM; HBG445348; -.
DR   HOVERGEN; HBG106962; -.
DR   InParanoid; P50406; -.
DR   OMA; RMTPPRA; -.
DR   OrthoDB; EOG9QC3RX; -.
DR   PhylomeDB; P50406; -.
DR   Reactome; REACT_14797; Signaling by GPCR.
DR   DrugBank; DB00889; Granisetron.
DR   DrugBank; DB00904; Ondansetron.
DR   DrugBank; DB06144; Sertindole.
DR   NextBio; 13308; -.
DR   ArrayExpress; P50406; -.
DR   Bgee; P50406; -.
DR   CleanEx; HS_HTR6; -.
DR   Genevestigator; P50406; -.
DR   GermOnline; ENSG00000158748; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0004969; F:histamine receptor activity; TAS:ProtInc.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0007187; P:G-protein signaling, coupled to cyclic nucl...; TAS:ProtInc.
DR   GO; GO:0007268; P:synaptic transmission; TAS:ProtInc.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Complete proteome; Disulfide bond;
KW   G-protein coupled receptor; Membrane; Phosphoprotein; Receptor;
KW   Transducer; Transmembrane.
FT   CHAIN         1    440       5-hydroxytryptamine receptor 6.
FT                                /FTId=PRO_0000068974.
FT   TOPO_DOM      1     34       Extracellular (By similarity).
FT   TRANSMEM     35     57       1 (By similarity).
FT   TOPO_DOM     58     64       Cytoplasmic (By similarity).
FT   TRANSMEM     65     85       2 (By similarity).
FT   TOPO_DOM     86    100       Extracellular (By similarity).
FT   TRANSMEM    101    122       3 (By similarity).
FT   TOPO_DOM    123    144       Cytoplasmic (By similarity).
FT   TRANSMEM    145    166       4 (By similarity).
FT   TOPO_DOM    167    184       Extracellular (By similarity).
FT   TRANSMEM    185    208       5 (By similarity).
FT   TOPO_DOM    209    265       Cytoplasmic (By similarity).
FT   TRANSMEM    266    290       6 (By similarity).
FT   TOPO_DOM    291    295       Extracellular (By similarity).
FT   TRANSMEM    296    320       7 (By similarity).
FT   TOPO_DOM    321    440       Cytoplasmic (By similarity).
FT   MOD_RES     125    125       Phosphotyrosine.
FT   DISULFID     99    180       By similarity.
FT   CONFLICT    247    247       V -> M (in Ref. 6; CAA88929).
SQ   SEQUENCE   440 AA;  46954 MW;  C888F47650C1D2EF CRC64;
     MVPEPGPTAN STPAWGAGPP SAPGGSGWVA AALCVVIALT AAANSLLIAL ICTQPALRNT
     SNFFLVSLFT SDLMVGLVVM PPAMLNALYG RWVLARGLCL LWTAFDVMCC SASILNLCLI
     SLDRYLLILS PLRYKLRMTP LRALALVLGA WSLAALASFL PLLLGWHELG HARPPVPGQC
     RLLASLPFVL VASGLTFFLP SGAICFTYCR ILLAARKQAV QVASLTTGMA SQASETLQVP
     RTPRPGVESA DSRRLATKHS RKALKASLTL GILLGMFFVT WLPFFVANIV QAVCDCISPG
     LFDVLTWLGY CNSTMNPIIY PLFMRDFKRA LGRFLPCPRC PRERQASLAS PSLRTSHSGP
     RPGLSLQQVL PLPLPPDSDS DSDAGSGGSS GLRLTAQLLL PGEATQDPPL PTRAAAAVNF
     FNIDPAEPEL RPHPLGIPTN
//
ID   5HT7R_HUMAN             Reviewed;         479 AA.
AC   P34969; B5BUP6; P78336; P78372; P78516; Q5VX01; Q5VX02;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   30-MAY-2000, sequence version 2.
DT   02-MAR-2010, entry version 102.
DE   RecName: Full=5-hydroxytryptamine receptor 7;
DE            Short=5-HT-7;
DE            Short=5-HT7;
DE   AltName: Full=5-HT-X;
DE   AltName: Full=Serotonin receptor 7;
GN   Name=HTR7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], ALTERNATIVE SPLICING, AND
RP   TISSUE SPECIFICITY.
RX   MEDLINE=97238071; PubMed=9084407;
RA   Heidmann D.E.A., Metcalf M.A., Kohen R., Hamblin M.W.;
RT   "Four 5-hydroxytryptamine7 (5-HT7) receptor isoforms in human and rat
RT   produced by alternative splicing: species differences due to altered
RT   intron-exon organization.";
RL   J. Neurochem. 68:1372-1381(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RC   TISSUE=Fetal brain, and Placenta;
RX   MEDLINE=94043137; PubMed=8226867;
RA   Bard J.A., Zgombick J.M., Adham N., Vaysse P., Branchek T.A.,
RA   Weinshank R.L.;
RT   "Cloning of a novel human serotonin receptor (5-HT7) positively linked
RT   to adenylate cyclase.";
RL   J. Biol. Chem. 268:23422-23426(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM B).
RC   TISSUE=Brain;
RA   King M.M., Aronstam R.S., Sharma S.V.;
RT   "Isolation of cDNA coding for 5-hydroxytryptamine receptor 7,
RT   transcript variant b (HTR7B).";
RL   Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM B).
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H.,
RA   Maruyama Y., Matsuo K., Minami K., Mitsubori M., Mori M.,
RA   Morishita R., Murase A., Nishikawa A., Nishikawa S., Okamoto T.,
RA   Sakagami N., Sakamoto Y., Sasaki Y., Seki T., Sono S., Sugiyama A.,
RA   Sumiya T., Takayama T., Takayama Y., Takeda H., Togashi T., Yahata K.,
RA   Yamada H., Yanagisawa Y., Endo Y., Imamoto F., Kisu Y., Tanaka S.,
RA   Isogai T., Imai J., Watanabe S., Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in
RT   vitro-expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM A).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   VARIANTS LYS-92 AND LEU-279.
RX   MEDLINE=97298817; PubMed=9154233;
RA   Erdmann J., Nothen M.M., Shimron-Abarbanell D., Rietschel M.,
RA   Albus M., Borrmann M., Maier W., Franzek E., Korner J., Weigelt B.,
RA   Fimmers R., Propping P.;
RT   "The human serotonin 7 (5-HT7) receptor gene: genomic organization and
RT   systematic mutation screening in schizophrenia and bipolar affective
RT   disorder.";
RL   Mol. Psychiatry 1:392-397(1996).
CC   -!- FUNCTION: This is one of the several different receptors for 5-
CC       hydroxytryptamine (serotonin), a biogenic hormone that functions
CC       as a neurotransmitter, a hormone, and a mitogen. The activity of
CC       this receptor is mediated by G proteins that stimulate adenylate
CC       cyclase.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC         Comment=Isoform A and isoform B appear to be expressed at higher
CC         levels;
CC       Name=D;
CC         IsoId=P34969-1; Sequence=Displayed;
CC       Name=A;
CC         IsoId=P34969-2; Sequence=VSP_001857;
CC       Name=B;
CC         IsoId=P34969-3; Sequence=VSP_001856;
CC   -!- TISSUE SPECIFICITY: Isoform A is the predominant isoform in
CC       spleen, caudate and hippocampus. Isoform B is expressed at lower
CC       levels. Isoform D is a minor isoform in term of expression.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U68487; AAB48393.1; -; mRNA.
DR   EMBL; U68488; AAB48394.1; -; mRNA.
DR   EMBL; U68492; AAF07218.1; -; Genomic_DNA.
DR   EMBL; U68493; AAF07217.1; -; Genomic_DNA.
DR   EMBL; U68492; AAF07217.1; JOINED; Genomic_DNA.
DR   EMBL; U68493; AAB48397.2; -; Genomic_DNA.
DR   EMBL; U68492; AAB48397.2; JOINED; Genomic_DNA.
DR   EMBL; L21195; AAC37538.1; -; mRNA.
DR   EMBL; AY493988; AAR87480.1; -; mRNA.
DR   EMBL; AB451482; BAG70296.1; -; mRNA.
DR   EMBL; AL360011; CAH69967.1; -; Genomic_DNA.
DR   EMBL; AL360011; CAH69968.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW50118.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW50119.1; -; Genomic_DNA.
DR   EMBL; BC047526; AAH47526.1; -; mRNA.
DR   IPI; IPI00003048; -.
DR   IPI; IPI00015395; -.
DR   IPI; IPI00553192; -.
DR   PIR; A48881; A48881.
DR   RefSeq; NP_000863.1; -.
DR   RefSeq; NP_062873.1; -.
DR   RefSeq; NP_062874.1; -.
DR   UniGene; Hs.73739; -.
DR   SMR; P34969; 81-404.
DR   STRING; P34969; -.
DR   PRIDE; P34969; -.
DR   Ensembl; ENST00000336152; ENSP00000337949; ENSG00000148680; Homo sapiens.
DR   GeneID; 3363; -.
DR   KEGG; hsa:3363; -.
DR   UCSC; uc001kha.1; human.
DR   UCSC; uc001khb.1; human.
DR   CTD; 3363; -.
DR   GeneCards; GC10M092490; -.
DR   H-InvDB; HIX0025953; -.
DR   HGNC; HGNC:5302; HTR7.
DR   HPA; CAB022708; -.
DR   MIM; 182137; gene.
DR   PharmGKB; PA29561; -.
DR   eggNOG; prNOG05985; -.
DR   HOGENOM; HBG445348; -.
DR   HOVERGEN; HBG106962; -.
DR   InParanoid; P34969; -.
DR   OMA; APTWDAP; -.
DR   OrthoDB; EOG91ZHX6; -.
DR   PhylomeDB; P34969; -.
DR   Reactome; REACT_14797; Signaling by GPCR.
DR   DrugBank; DB00216; Eletriptan.
DR   DrugBank; DB00247; Methysergide.
DR   DrugBank; DB00246; Ziprasidone.
DR   NextBio; 13312; -.
DR   ArrayExpress; P34969; -.
DR   Bgee; P34969; -.
DR   CleanEx; HS_HTR7; -.
DR   Genevestigator; P34969; -.
DR   GermOnline; ENSG00000148680; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0004993; F:serotonin receptor activity; TAS:ProtInc.
DR   GO; GO:0008015; P:blood circulation; TAS:ProtInc.
DR   GO; GO:0007623; P:circadian rhythm; TAS:ProtInc.
DR   GO; GO:0007268; P:synaptic transmission; TAS:ProtInc.
DR   InterPro; IPR001069; 5HT_7_rcpt.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   PANTHER; PTHR19266:SF47; 5HT_7_rcpt; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00652; 5HT7RECEPTR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Complete proteome;
KW   Disulfide bond; G-protein coupled receptor; Glycoprotein; Lipoprotein;
KW   Membrane; Palmitate; Polymorphism; Receptor; Transducer;
KW   Transmembrane.
FT   CHAIN         1    479       5-hydroxytryptamine receptor 7.
FT                                /FTId=PRO_0000068979.
FT   TOPO_DOM      1     83       Extracellular (By similarity).
FT   TRANSMEM     84    104       1 (By similarity).
FT   TOPO_DOM    105    117       Cytoplasmic (By similarity).
FT   TRANSMEM    118    138       2 (By similarity).
FT   TOPO_DOM    139    157       Extracellular (By similarity).
FT   TRANSMEM    158    178       3 (By similarity).
FT   TOPO_DOM    179    201       Cytoplasmic (By similarity).
FT   TRANSMEM    202    222       4 (By similarity).
FT   TOPO_DOM    223    236       Extracellular (By similarity).
FT   TRANSMEM    237    257       5 (By similarity).
FT   TOPO_DOM    258    325       Cytoplasmic (By similarity).
FT   TRANSMEM    326    346       6 (By similarity).
FT   TOPO_DOM    347    367       Extracellular (By similarity).
FT   TRANSMEM    368    388       7 (By similarity).
FT   TOPO_DOM    389    479       Cytoplasmic (By similarity).
FT   LIPID       401    401       S-palmitoyl cysteine (Potential).
FT   CARBOHYD      5      5       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     66     66       N-linked (GlcNAc...) (Potential).
FT   DISULFID    155    231       By similarity.
FT   VAR_SEQ     433    479       RACTRRVLLRPEKRPPVSVWVLQSPDHHNWLADKMLTTVEK
FT                                KVMIHD -> QNADYCRKKGHDS (in isoform A).
FT                                /FTId=VSP_001857.
FT   VAR_SEQ     433    479       Missing (in isoform B).
FT                                /FTId=VSP_001856.
FT   VARIANT      92     92       T -> K.
FT                                /FTId=VAR_012995.
FT   VARIANT     279    279       P -> L.
FT                                /FTId=VAR_012996.
FT   VARIANT     448    448       P -> Q (in dbSNP:rs33954285).
FT                                /FTId=VAR_049365.
SQ   SEQUENCE   479 AA;  53555 MW;  1F62E985EADE1F23 CRC64;
     MMDVNSSGRP DLYGHLRSFL LPEVGRGLPD LSPDGGADPV AGSWAPHLLS EVTASPAPTW
     DAPPDNASGC GEQINYGRVE KVVIGSILTL ITLLTIAGNC LVVISVCFVK KLRQPSNYLI
     VSLALADLSV AVAVMPFVSV TDLIGGKWIF GHFFCNVFIA MDVMCCTASI MTLCVISIDR
     YLGITRPLTY PVRQNGKCMA KMILSVWLLS ASITLPPLFG WAQNVNDDKV CLISQDFGYT
     IYSTAVAFYI PMSVMLFMYY QIYKAARKSA AKHKFPGFPR VEPDSVIALN GIVKLQKEVE
     ECANLSRLLK HERKNISIFK REQKAATTLG IIVGAFTVCW LPFFLLSTAR PFICGTSCSC
     IPLWVERTFL WLGYANSLIN PFIYAFFNRD LRTTYRSLLQ CQYRNINRKL SAAGMHEALK
     LAERPERPEF VLRACTRRVL LRPEKRPPVS VWVLQSPDHH NWLADKMLTT VEKKVMIHD
//
ID   AA2BR_RAT               Reviewed;         332 AA.
AC   P29276;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-1992, sequence version 1.
DT   02-MAR-2010, entry version 74.
DE   RecName: Full=Adenosine receptor A2b;
GN   Name=Adora2b;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   MEDLINE=92261592; PubMed=1584214; DOI=10.1210/me.6.3.384;
RA   Stehle J.H., Rivkees S.A., Lee J.J., Weaver D.R., Deeds J.D.,
RA   Reppert S.M.;
RT   "Molecular cloning and expression of the cDNA for a novel A2-adenosine
RT   receptor subtype.";
RL   Mol. Endocrinol. 6:384-393(1992).
RN   [2]
RP   CHARACTERIZATION.
RX   MEDLINE=93078793; PubMed=1333049; DOI=10.1210/me.6.10.1598;
RA   Rivkees S.A., Reppert S.M.;
RT   "RFL9 encodes an A2b-adenosine receptor.";
RL   Mol. Endocrinol. 6:1598-1604(1992).
CC   -!- FUNCTION: Receptor for adenosine. The activity of this receptor is
CC       mediated by G proteins which activate adenylyl cyclase.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M91466; AAA20981.1; -; mRNA.
DR   IPI; IPI00202683; -.
DR   PIR; A42171; A42171.
DR   RefSeq; NP_058857.1; -.
DR   UniGene; Rn.89544; -.
DR   SMR; P29276; 16-312.
DR   STRING; P29276; -.
DR   Ensembl; ENSRNOT00000003966; ENSRNOP00000003966; ENSRNOG00000002922; Rattus norvegicus.
DR   GeneID; 29316; -.
DR   KEGG; rno:29316; -.
DR   UCSC; NM_017161; rat.
DR   CTD; 29316; -.
DR   RGD; 2050; Adora2b.
DR   eggNOG; roNOG12536; -.
DR   HOVERGEN; HBG106962; -.
DR   InParanoid; P29276; -.
DR   NextBio; 608760; -.
DR   ArrayExpress; P29276; -.
DR   Genevestigator; P29276; -.
DR   GermOnline; ENSRNOG00000002922; Rattus norvegicus.
DR   GO; GO:0009986; C:cell surface; IDA:RGD.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IDA:RGD.
DR   GO; GO:0001609; F:adenosine receptor activity, G-protein coupled; IMP:RGD.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IMP:RGD.
DR   GO; GO:0032966; P:negative regulation of collagen biosyntheti...; IMP:RGD.
DR   GO; GO:0030819; P:positive regulation of cAMP biosynthetic pr...; IMP:RGD.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:RGD.
DR   GO; GO:0010701; P:positive regulation of norepinephrine secre...; IMP:RGD.
DR   GO; GO:0010893; P:positive regulation of steroid biosynthetic...; IMP:RGD.
DR   GO; GO:0045909; P:positive regulation of vasodilation; IMP:RGD.
DR   GO; GO:0045765; P:regulation of angiogenesis; IMP:RGD.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR001435; Adeno_A2B_rcpt.
DR   InterPro; IPR001634; Adenosn_rcpt.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00554; ADENOSINA2BR.
DR   PRINTS; PR00424; ADENOSINER.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Lipoprotein; Membrane; Palmitate; Receptor; Transducer;
KW   Transmembrane.
FT   CHAIN         1    332       Adenosine receptor A2b.
FT                                /FTId=PRO_0000069005.
FT   TOPO_DOM      1      8       Extracellular (By similarity).
FT   TRANSMEM      9     33       1 (By similarity).
FT   TOPO_DOM     34     43       Cytoplasmic (By similarity).
FT   TRANSMEM     44     67       2 (By similarity).
FT   TOPO_DOM     68     78       Extracellular (By similarity).
FT   TRANSMEM     79    101       3 (By similarity).
FT   TOPO_DOM    102    121       Cytoplasmic (By similarity).
FT   TRANSMEM    122    144       4 (By similarity).
FT   TOPO_DOM    145    178       Extracellular (By similarity).
FT   TRANSMEM    179    203       5 (By similarity).
FT   TOPO_DOM    204    235       Cytoplasmic (By similarity).
FT   TRANSMEM    236    259       6 (By similarity).
FT   TOPO_DOM    260    267       Extracellular (By similarity).
FT   TRANSMEM    268    291       7 (By similarity).
FT   TOPO_DOM    292    332       Cytoplasmic (By similarity).
FT   REGION      173    182       Agonist binding (By similarity).
FT   REGION      247    254       Agonist binding (By similarity).
FT   REGION      266    276       Agonist binding (By similarity).
FT   LIPID       311    311       S-palmitoyl cysteine (Potential).
FT   CARBOHYD    153    153       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    163    163       N-linked (GlcNAc...) (Potential).
FT   DISULFID     78    171       By similarity.
SQ   SEQUENCE   332 AA;  36367 MW;  F0ABAB5CCACA8858 CRC64;
     MQLETQDALY VALELVIAAL AVAGNVLVCA AVGASSALQT PTNYFLVSLA TADVAVGLFA
     IPFAITISLG FCTDFHSCLF LACFVLVLTQ SSIFSLLAVA VDRYLAIRVP LRYKGLVTGT
     RARGIIAVLW VLAFGIGLTP FLGWNSKDRA TSNCTEPGDG ITNKSCCPVK CLFENVVPMS
     YMVYFNFFGC VLPPLLIMMV IYIKIFMVAC KQLQHMELME HSRTTLQREI HAAKSLAMIV
     GIFALCWLPV HAINCITLFH PALAKDKPKW VMNVAILLSH ANSVVNPIVY AYRNRDFRYS
     FHRIISRYVL CQTDTKGGSG QAGGQSTFSL SL
//
ID   AA3R_RAT                Reviewed;         320 AA.
AC   P28647; Q63792;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 3.
DT   02-MAR-2010, entry version 91.
DE   RecName: Full=Adenosine receptor A3;
DE   AltName: Full=TGPCR1;
GN   Name=Adora3;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A), AND CHARACTERIZATION.
RC   TISSUE=Brain;
RX   MEDLINE=92366475; PubMed=1323836; DOI=10.1073/pnas.89.16.7432;
RA   Zhou Q.Y., Li C.Y., Olah M.E., Johnson R.A., Stiles G.L., Civelli O.;
RT   "Molecular cloning and characterization of an adenosine receptor: the
RT   A3 adenosine receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:7432-7436(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RC   STRAIN=Wistar; TISSUE=Testis;
RX   MEDLINE=91285122; PubMed=1647979; DOI=10.1016/0014-5793(91)80674-R;
RA   Meyerhof W., Mueller-Brechlin R., Richter D.;
RT   "Molecular cloning of a novel putative G-protein coupled receptor
RT   expressed during rat spermiogenesis.";
RL   FEBS Lett. 284:155-160(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B).
RC   TISSUE=Brain;
RX   MEDLINE=96196578; PubMed=8612733; DOI=10.1016/0014-5793(96)00150-0;
RA   Sajjadi F.G., Boyle D.L., Domingo R.C., Firestein G.S.;
RT   "cDNA cloning and characterization of A3i, an alternatively spliced
RT   rat A3 adenosine receptor variant.";
RL   FEBS Lett. 382:125-129(1996).
RN   [4]
RP   PHOSPHORYLATION AT THR-307; THR-318 AND THR-319, AND MUTAGENESIS OF
RP   302-CYS--CYS-305; THR-307; THR-318 AND THR-319.
RX   MEDLINE=20159069; PubMed=10692494;
RA   Palmer T.M., Stiles G.L.;
RT   "Identification of threonine residues controlling the agonist-
RT   dependent phosphorylation and desensitization of the rat A(3)
RT   adenosine receptor.";
RL   Mol. Pharmacol. 57:539-545(2000).
CC   -!- FUNCTION: Receptor for adenosine. The activity of this receptor is
CC       mediated by G proteins which inhibits adenylyl cyclase. Possible
CC       role in reproduction.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=A;
CC         IsoId=P28647-1; Sequence=Displayed;
CC       Name=B; Synonyms=A3i;
CC         IsoId=P28647-2; Sequence=VSP_001859;
CC   -!- TISSUE SPECIFICITY: Testis, particularly in spermatocytes and
CC       spermatids but not in spermatogonia. Low levels in the brain.
CC   -!- DEVELOPMENTAL STAGE: Expressed during spermiogenesis.
CC   -!- PTM: Phosphorylation on Thr-318 and Thr-319 may be crucial for
CC       rapid desensitization. Phosphorylation on Thr-318 may be necessary
CC       for phosphorylation on Thr-319 to occur.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X59249; CAA41937.1; -; mRNA.
DR   EMBL; M94152; AAA40680.1; -; mRNA.
DR   EMBL; X93219; CAA63702.1; -; mRNA.
DR   IPI; IPI00202795; -.
DR   IPI; IPI00231943; -.
DR   PIR; A46152; A46152.
DR   PIR; S17177; S17177.
DR   PIR; S68678; S68678.
DR   RefSeq; NP_037028.2; -.
DR   UniGene; Rn.10457; -.
DR   UniGene; Rn.205912; -.
DR   SMR; P28647; 22-311.
DR   DIP; DIP-217N; -.
DR   STRING; P28647; -.
DR   PhosphoSite; P28647; -.
DR   Ensembl; ENSRNOT00000021236; ENSRNOP00000021236; ENSRNOG00000015788; Rattus norvegicus.
DR   GeneID; 25370; -.
DR   KEGG; rno:25370; -.
DR   UCSC; NM_012896; rat.
DR   CTD; 25370; -.
DR   RGD; 2051; Adora3.
DR   eggNOG; roNOG14435; -.
DR   HOVERGEN; HBG106962; -.
DR   OMA; MVYFSFF; -.
DR   PhylomeDB; P28647; -.
DR   NextBio; 606381; -.
DR   ArrayExpress; P28647; -.
DR   Genevestigator; P28647; -.
DR   GermOnline; ENSRNOG00000015788; Rattus norvegicus.
DR   GO; GO:0042734; C:presynaptic membrane; IDA:RGD.
DR   GO; GO:0001609; F:adenosine receptor activity, G-protein coupled; IDA:RGD.
DR   GO; GO:0014061; P:regulation of norepinephrine secretion; IMP:RGD.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR000466; Adeno_A3_rcpt.
DR   InterPro; IPR001634; Adenosn_rcpt.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00555; ADENOSINEA3R.
DR   PRINTS; PR00424; ADENOSINER.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane;
KW   Palmitate; Phosphoprotein; Receptor; Transducer; Transmembrane.
FT   CHAIN         1    320       Adenosine receptor A3.
FT                                /FTId=PRO_0000069013.
FT   TOPO_DOM      1     16       Extracellular (By similarity).
FT   TRANSMEM     17     39       1 (By similarity).
FT   TOPO_DOM     40     50       Cytoplasmic (By similarity).
FT   TRANSMEM     51     74       2 (By similarity).
FT   TOPO_DOM     75     86       Extracellular (By similarity).
FT   TRANSMEM     87    108       3 (By similarity).
FT   TOPO_DOM    109    128       Cytoplasmic (By similarity).
FT   TRANSMEM    129    150       4 (By similarity).
FT   TOPO_DOM    151    179       Extracellular (By similarity).
FT   TRANSMEM    180    200       5 (By similarity).
FT   TOPO_DOM    201    233       Cytoplasmic (By similarity).
FT   TRANSMEM    234    257       6 (By similarity).
FT   TOPO_DOM    258    263       Extracellular (By similarity).
FT   TRANSMEM    264    286       7 (By similarity).
FT   TOPO_DOM    287    320       Cytoplasmic (By similarity).
FT   MOD_RES     307    307       Phosphothreonine (Probable).
FT   MOD_RES     318    318       Phosphothreonine (Probable).
FT   MOD_RES     319    319       Phosphothreonine (Probable).
FT   LIPID       305    305       S-palmitoyl cysteine (Potential).
FT   CARBOHYD      4      4       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD      5      5       N-linked (GlcNAc...) (Potential).
FT   DISULFID     85    168       By similarity.
FT   VAR_SEQ     119    119       R -> RLSFLVVNLPFSSPHSNR (in isoform B).
FT                                /FTId=VSP_001859.
FT   MUTAGEN     302    305       CRLC->ARLA: Promotes agonist-independent
FT                                phosphorylation.
FT   MUTAGEN     307    307       T->A: Small decrease in agonist-
FT                                stimulated phosphorylation.
FT   MUTAGEN     318    318       T->A,E: Strong decrease in agonist-
FT                                stimulated phosphorylation.
FT   MUTAGEN     319    319       T->A: 50% decrease in agonist-stimulated
FT                                phosphorylation.
FT   CONFLICT     18     18       I -> V (in Ref. 1; AAA40680).
FT   CONFLICT     68     68       I -> V (in Ref. 3; CAA63702).
FT   CONFLICT     74     83       VSLEVQMHFY -> SAWRSRCTSM (in Ref. 2;
FT                                CAA41937).
FT   CONFLICT    132    132       F -> L (in Ref. 3; CAA63702).
FT   CONFLICT    172    172       S -> F (in Ref. 1; AAA40680).
FT   CONFLICT    288    288       I -> N (in Ref. 1).
FT   CONFLICT    291    295       FKETY -> VQRNH (in Ref. 1).
SQ   SEQUENCE   320 AA;  36629 MW;  59DBA40C594ACDAB CRC64;
     MKANNTTTSA LWLQITYITM EAAIGLCAVV GNMLVIWVVK LNRTLRTTTF YFIVSLALAD
     IAVGVLVIPL AIAVSLEVQM HFYACLFMSC VLLVFTHASI MSLLAIAVDR YLRVKLTVRY
     RTVTTQRRIW LFLGLCWLVS FLVGLTPMFG WNRKVTLELS QNSSTLSCHF RSVVGLDYMV
     FFSFITWILI PLVVMCIIYL DIFYIIRNKL SQNLTGFRET RAFYGREFKT AKSLFLVLFL
     FALCWLPLSI INFVSYFNVK IPEIAMCLGI LLSHANSMMN PIVYACKIKK FKETYFVILR
     ACRLCQTSDS LDSNLEQTTE
//
ID   ABC2_SCHPO              Reviewed;        1478 AA.
AC   Q10185;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   02-MAR-2010, entry version 82.
DE   RecName: Full=ATP-binding cassette transporter abc2;
DE            Short=ABC transporter abc2;
DE            EC=3.6.3.44;
DE   AltName: Full=Glutathione S-conjugate-transporting ATPase abc2;
DE   AltName: Full=ATP-energized glutathione S-conjugate pump abc2;
GN   Name=abc2; ORFNames=SPAC3F10.11c;
OS   Schizosaccharomyces pombe (Fission yeast).
OC   Eukaryota; Fungi; Dikarya; Ascomycota; Taphrinomycotina;
OC   Schizosaccharomycetes; Schizosaccharomycetales;
OC   Schizosaccharomycetaceae; Schizosaccharomyces.
OX   NCBI_TaxID=4896;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 38366 / 972;
RX   MEDLINE=21848401; PubMed=11859360; DOI=10.1038/nature724;
RA   Wood V., Gwilliam R., Rajandream M.A., Lyne M.H., Lyne R., Stewart A.,
RA   Sgouros J.G., Peat N., Hayles J., Baker S.G., Basham D., Bowman S.,
RA   Brooks K., Brown D., Brown S., Chillingworth T., Churcher C.M.,
RA   Collins M., Connor R., Cronin A., Davis P., Feltwell T., Fraser A.,
RA   Gentles S., Goble A., Hamlin N., Harris D.E., Hidalgo J., Hodgson G.,
RA   Holroyd S., Hornsby T., Howarth S., Huckle E.J., Hunt S., Jagels K.,
RA   James K.D., Jones L., Jones M., Leather S., McDonald S., McLean J.,
RA   Mooney P., Moule S., Mungall K.L., Murphy L.D., Niblett D., Odell C.,
RA   Oliver K., O'Neil S., Pearson D., Quail M.A., Rabbinowitsch E.,
RA   Rutherford K.M., Rutter S., Saunders D., Seeger K., Sharp S.,
RA   Skelton J., Simmonds M.N., Squares R., Squares S., Stevens K.,
RA   Taylor K., Taylor R.G., Tivey A., Walsh S.V., Warren T., Whitehead S.,
RA   Woodward J.R., Volckaert G., Aert R., Robben J., Grymonprez B.,
RA   Weltjens I., Vanstreels E., Rieger M., Schaefer M., Mueller-Auer S.,
RA   Gabel C., Fuchs M., Duesterhoeft A., Fritzc C., Holzer E., Moestl D.,
RA   Hilbert H., Borzym K., Langer I., Beck A., Lehrach H., Reinhardt R.,
RA   Pohl T.M., Eger P., Zimmermann W., Wedler H., Wambutt R., Purnelle B.,
RA   Goffeau A., Cadieu E., Dreano S., Gloux S., Lelaure V., Mottier S.,
RA   Galibert F., Aves S.J., Xiang Z., Hunt C., Moore K., Hurst S.M.,
RA   Lucas M., Rochet M., Gaillardin C., Tallada V.A., Garzon A., Thode G.,
RA   Daga R.R., Cruzado L., Jimenez J., Sanchez M., del Rey F., Benito J.,
RA   Dominguez A., Revuelta J.L., Moreno S., Armstrong J., Forsburg S.L.,
RA   Cerutti L., Lowe T., McCombie W.R., Paulsen I., Potashkin J.,
RA   Shpakovski G.V., Ussery D., Barrell B.G., Nurse P.;
RT   "The genome sequence of Schizosaccharomyces pombe.";
RL   Nature 415:871-880(2002).
RN   [2]
RP   FUNCTION, SUBCELLULAR LOCATION, AND DISRUPTION PHENOTYPE.
RX   PubMed=16849797; DOI=10.1099/mic.0.28952-0;
RA   Iwaki T., Giga-Hama Y., Takegawa K.;
RT   "A survey of all 11 ABC transporters in fission yeast: two novel ABC
RT   transporters are required for red pigment accumulation in a
RT   Schizosaccharomyces pombe adenine biosynthetic mutant.";
RL   Microbiology 152:2309-2321(2006).
RN   [3]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-839; SER-843 AND
RP   SER-863, AND MASS SPECTROMETRY.
RX   PubMed=18257517; DOI=10.1021/pr7006335;
RA   Wilson-Grady J.T., Villen J., Gygi S.P.;
RT   "Phosphoproteome analysis of fission yeast.";
RL   J. Proteome Res. 7:1088-1097(2008).
CC   -!- FUNCTION: Involved in detoxification of xenobiotics, and vacuolar
CC       sequestration of glutathione S-conjugates. Together with abc4,
CC       required for accumulation of a red pigment (ade pigment) in the
CC       vacuole of a mutant affected in the adenine biosynthetic pathway.
CC   -!- CATALYTIC ACTIVITY: ATP + H(2)O + xenobiotic(In) = ADP + phosphate
CC       + xenobiotic(Out).
CC   -!- SUBCELLULAR LOCATION: Vacuole membrane; Multi-pass membrane
CC       protein (Potential).
CC   -!- DISRUPTION PHENOTYPE: Cells lacking both abc2 and abc4 show
CC       sensitivity to cycloheximide (CHX) and 4-nitroquinoline oxide (4-
CC       NQO), and decreased accumulation of monochlorobimane-glutathione
CC       (MCIB-GS).
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCC
CC       family. Conjugate transporter (TC 3.A.1.208) subfamily.
CC   -!- SIMILARITY: Contains 2 ABC transmembrane type-1 domains.
CC   -!- SIMILARITY: Contains 2 ABC transporter domains.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; CU329670; CAA93309.1; -; Genomic_DNA.
DR   PIR; T38712; T38712.
DR   RefSeq; NP_593943.2; -.
DR   SMR; Q10185; 262-813, 985-1474.
DR   STRING; Q10185; -.
DR   TCDB; 3.A.1.208.16; ATP-binding cassette (ABC) superfamily.
DR   GeneID; 2543193; -.
DR   GenomeReviews; CU329670_GR; abc2.
DR   KEGG; spo:SPAC3F10.11c; -.
DR   NMPDR; fig|4896.1.peg.3913; -.
DR   GeneDB_Spombe; SPAC3F10.11c; -.
DR   HOGENOM; HBG758042; -.
DR   OMA; FANDIST; -.
DR   OrthoDB; EOG9RV47X; -.
DR   PhylomeDB; Q10185; -.
DR   ArrayExpress; Q10185; -.
DR   GO; GO:0000329; C:fungal-type vacuole membrane; IDA:GeneDB_SPombe.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:GeneDB_SPombe.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0015431; F:glutathione S-conjugate-exporting ATPase ac...; IMP:GeneDB_SPombe.
DR   GO; GO:0008559; F:xenobiotic-transporting ATPase activity; IEA:EC.
DR   GO; GO:0009636; P:response to toxin; IEA:UniProtKB-KW.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   GO; GO:0007034; P:vacuolar transport; IMP:GeneDB_SPombe.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR017940; ABC_transporter_type1.
DR   InterPro; IPR001140; ABC_transptr_TM_dom.
DR   InterPro; IPR011527; ABC_transptrTM_dom_typ1.
DR   InterPro; IPR003593; ATPase_AAA+_core.
DR   Pfam; PF00664; ABC_membrane; 2.
DR   Pfam; PF00005; ABC_tran; 2.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF90123; ABC_TM_1; 2.
DR   PROSITE; PS50929; ABC_TM1F; 2.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
PE   1: Evidence at protein level;
KW   ATP-binding; Complete proteome; Detoxification; Glycoprotein;
KW   Hydrolase; Membrane; Nucleotide-binding; Phosphoprotein; Repeat;
KW   Transmembrane; Transport; Vacuole.
FT   CHAIN         1   1478       ATP-binding cassette transporter abc2.
FT                                /FTId=PRO_0000093468.
FT   TOPO_DOM      1     25       Vacuolar (By similarity).
FT   TRANSMEM     26     46       1 (By similarity).
FT   TOPO_DOM     47     65       Cytoplasmic (By similarity).
FT   TRANSMEM     66     85       2 (By similarity).
FT   TOPO_DOM     86     90       Vacuolar (By similarity).
FT   TRANSMEM     91    104       3 (By similarity).
FT   TOPO_DOM    105    116       Cytoplasmic (By similarity).
FT   TRANSMEM    117    137       4 (By similarity).
FT   TOPO_DOM    138    154       Vacuolar (By similarity).
FT   TRANSMEM    155    175       5 (By similarity).
FT   TOPO_DOM    176    259       Cytoplasmic (By similarity).
FT   TRANSMEM    260    280       6 (By similarity).
FT   TOPO_DOM    281    310       Vacuolar (By similarity).
FT   TRANSMEM    311    331       7 (By similarity).
FT   TOPO_DOM    332    387       Cytoplasmic (By similarity).
FT   TRANSMEM    388    408       8 (By similarity).
FT   TOPO_DOM    409    411       Vacuolar (By similarity).
FT   TRANSMEM    412    432       9 (By similarity).
FT   TOPO_DOM    433    495       Cytoplasmic (By similarity).
FT   TRANSMEM    496    516       10 (By similarity).
FT   TOPO_DOM    517    539       Vacuolar (By similarity).
FT   TRANSMEM    540    560       11 (By similarity).
FT   TOPO_DOM    561    910       Cytoplasmic (By similarity).
FT   TRANSMEM    911    931       12 (By similarity).
FT   TOPO_DOM    932    968       Vacuolar (By similarity).
FT   TRANSMEM    969    990       13 (By similarity).
FT   TOPO_DOM    991   1033       Cytoplasmic (By similarity).
FT   TRANSMEM   1034   1054       14 (By similarity).
FT   TOPO_DOM   1055   1055       Vacuolar (By similarity).
FT   TRANSMEM   1056   1076       15 (By similarity).
FT   TOPO_DOM   1077   1147       Cytoplasmic (By similarity).
FT   TRANSMEM   1148   1168       16 (By similarity).
FT   TOPO_DOM   1169   1172       Vacuolar (By similarity).
FT   TRANSMEM   1173   1193       17 (By similarity).
FT   TOPO_DOM   1194   1478       Cytoplasmic (By similarity).
FT   DOMAIN      268    557       ABC transmembrane type-1 1.
FT   DOMAIN      593    821       ABC transporter 1.
FT   DOMAIN      918   1202       ABC transmembrane type-1 2.
FT   DOMAIN     1239   1473       ABC transporter 2.
FT   NP_BIND     631    638       ATP 1 (Potential).
FT   NP_BIND    1273   1280       ATP 2 (Potential).
FT   MOD_RES     839    839       Phosphoserine.
FT   MOD_RES     843    843       Phosphoserine.
FT   MOD_RES     863    863       Phosphoserine.
FT   CARBOHYD     86     86       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    139    139       N-linked (GlcNAc...) (Potential).
SQ   SEQUENCE   1478 AA;  166938 MW;  6C59F43105EB7187 CRC64;
     MVLEQDLDPF VGGNWMNSAY KGFTFLSATW LAPNIYLLIS GCLQYFYEVR KRSHYFHFRR
     FWTIWLKSLV IMVLLFTHIY DCYKTNESVW NVLSIITYFL ALFLHVVEQP TLRIPMASLL
     MFWLFKFLAS ALVLLLRPNY TMFPMLNVVP SITFFCSLVC LLAEIYVPPA NRVWYPDDAA
     ELEETGLRPS RFTYANIFSR ISFGWLSPLM KFGYRNYLTE SDAWSLPPAE RSSNLTIVFE
     KNWISHAKKK KSSLYMWGVL FLNHWKLTVV IIVLKLVQDV VAFIQPNLIR KIVIFVSSYS
     SEHPQPPQVG FSLAIAMFLT NVVQTALLQQ YFQLGMVLGM RWRSELITAI YRKSLRLSSA
     ARQSRSVGDI VNYMSVDTQK VCDLTMFLFV IVSGPFQIVL ALTNLYHLVG YGALSGAFVT
     FLLFPCNVVI ASIFKRFQNR QMKNKDARSQ FMTEIINNIR SIKLYAWENI FLQKLLQLRN
     TRELRMLKKI GIVNTIGNFT WLFAPILVSA ATFGTFIVLY GKTRVLSVDI VFACLSLFNL
     LQFPLTMLPI VVSSVLEASV AISRIYGFLT AGELDSNAVQ RYPANKEPSG VCLEIKKGTF
     SWSGPGQNAA EPTLRDIDFV ARRGELCCIV GKVGMGKSSL LEACLGNMQK HSGSVFRCGS
     IAYAAQQPWI LNATIQENIL FGLELDPEFY EKTIRACCLL RDFEILADGD QTEVGEKGIS
     LSGGQKARIS LARAVYSRSD IYLLDDILSA VDQHVNRDLV RNLLGSKGLL RSRCVILSTN
     SLTVLKEASM IYMLRNGKII ESGSFTQLSS SPDSQLFQLL SEFSKKDTAS STGADTPLSR
     SQSVITSSTD VTSSASRSSD TVSNYPKATI KGTGRIRKRL TDEDNVKATG QAAEKMERGK
     VKWKVYWTYF KACSLFLIFL YFLFIIGGIG MNVGTNVWLK HWSEVNTQLG YNPKPYFYLG
     IYTLFGLLSC ALISLSSLTI TVFCAIKSCR YLHDSMVKAV LRAPMSFFET TPTGRILNRF
     SSDVYRVDEV ISRVFMFFFR NLFQIVFVLA VICYSSPMFM ILIVPLFFLY RYNQVYYTQT
     SRELKRLDSV TRSPLYAHFQ ESLGGLSTIR AYDMEDTFIS ENDIRVDTNH RIWFLYFSSN
     RWQAIRVEAI GALVVFSSAF FGVLSAVRGN PNSGLVGLSL SYAVQITQSL TFVVRQSVDV
     ETNIVSVERM LEYIGLPSEA PSIIPDHRPP EGWPSHGAIK FDHYSVRYRE NLPLVLNDIS
     VNIKPQEKIG IVGRTGAGKS TLTLALFRLI EPTSGDIQLD DINITSIGLH DLRSRLAIIP
     QENQAFEGTI RENLDPNANA TDEEIWHALE AASLKQFIQT LDGGLYSRVT EGGANLSSGQ
     RQLMCLTRAL LTPTRVLLLD EATAAVDVET DAIVQRTIRE RFNDRTILTI AHRINTVMDS
     NRILVLDHGK VVEFDSTKKL LENKASLFYS LAKESGLI
//
ID   ABCC8_CRICR             Reviewed;        1582 AA.
AC   Q09427;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 73.
DE   RecName: Full=ATP-binding cassette transporter sub-family C member 8;
DE   AltName: Full=Sulfonylurea receptor 1;
GN   Name=ABCC8; Synonyms=SUR;
OS   Cricetus cricetus (Black-bellied hamster).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Cricetidae; Cricetinae; Cricetus.
OX   NCBI_TaxID=10034;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Pancreatic islet;
RX   MEDLINE=95232532; PubMed=7716547; DOI=10.1126/science.7716547;
RA   Aguilar-Bryan L., Nichols C.G., Wechsler S.W., Clement J.P. IV,
RA   Boyd A.E. III, Gonzalez G., Herrera-Sosa H., Nguy K., Bryan J.,
RA   Nelson D.A.;
RT   "Cloning of the beta cell high-affinity sulfonylurea receptor: a
RT   regulator of insulin secretion.";
RL   Science 268:423-426(1995).
RN   [2]
RP   GLYCOSYLATION AT ASN-10.
RX   MEDLINE=97098100; PubMed=8942641; DOI=10.1021/bi960777y;
RA   Nelson D.A., Bryan J., Wechsler S., Clement J.P. IV, Aguilar-Bryan L.;
RT   "The high-affinity sulfonylurea receptor: distribution, glycosylation,
RT   purification, and immunoprecipitation of two forms from endocrine and
RT   neuroendocrine cell lines.";
RL   Biochemistry 35:14793-14799(1996).
RN   [3]
RP   TOPOLOGY, AND GLYCOSYLATION AT ASN-10.
RX   MEDLINE=99436117; PubMed=10506167; DOI=10.1074/jbc.274.41.29122;
RA   Raab-Graham K.F., Cirilo L.J., Boettcher A.A., Radeke C.M.,
RA   Vandenberg C.A.;
RT   "Membrane topology of the amino-terminal region of the sulfonylurea
RT   receptor.";
RL   J. Biol. Chem. 274:29122-29129(1999).
CC   -!- FUNCTION: Putative subunit of the beta-cell ATP-sensitive
CC       potassium channel (KATP). Regulator of ATP-sensitive potassium
CC       channels and insulin release.
CC   -!- SUBUNIT: Associates with KCNJ11 (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCC
CC       family. Conjugate transporter (TC 3.A.1.208) subfamily.
CC   -!- SIMILARITY: Contains 2 ABC transmembrane type-1 domains.
CC   -!- SIMILARITY: Contains 2 ABC transporter domains.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L40623; AAA99201.1; -; mRNA.
DR   SMR; Q09427; 285-921, 1078-1579.
DR   HOVERGEN; HBG101342; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042626; F:ATPase activity, coupled to transmembrane m...; IEA:InterPro.
DR   GO; GO:0008281; F:sulfonylurea receptor activity; IEA:InterPro.
DR   GO; GO:0006813; P:potassium ion transport; IEA:InterPro.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR017940; ABC_transporter_type1.
DR   InterPro; IPR001140; ABC_transptr_TM_dom.
DR   InterPro; IPR011527; ABC_transptrTM_dom_typ1.
DR   InterPro; IPR003593; ATPase_AAA+_core.
DR   InterPro; IPR000388; Sulphorea_rcpt_N.
DR   InterPro; IPR000844; Surea_rcpt_1_N.
DR   Pfam; PF00664; ABC_membrane; 2.
DR   Pfam; PF00005; ABC_tran; 2.
DR   PRINTS; PR01093; SULFNYLUR1.
DR   PRINTS; PR01092; SULFNYLUREAR.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF90123; ABC_TM_1; 2.
DR   PROSITE; PS50929; ABC_TM1F; 2.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 2.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
PE   1: Evidence at protein level;
KW   ATP-binding; Direct protein sequencing; Glycoprotein; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Receptor; Repeat; Transmembrane;
KW   Transport.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2   1582       ATP-binding cassette transporter sub-
FT                                family C member 8.
FT                                /FTId=PRO_0000093399.
FT   TOPO_DOM      2     34       Extracellular.
FT   TRANSMEM     35     55       1.
FT   TOPO_DOM     56     75       Cytoplasmic.
FT   TRANSMEM     76     96       2.
FT   TOPO_DOM     97    101       Extracellular.
FT   TRANSMEM    102    122       3.
FT   TOPO_DOM    123    134       Cytoplasmic.
FT   TRANSMEM    135    154       4.
FT   TOPO_DOM    155    167       Extracellular.
FT   TRANSMEM    168    194       5.
FT   TOPO_DOM    195    311       Cytoplasmic.
FT   TRANSMEM    312    331       6 (By similarity).
FT   TOPO_DOM    332    355       Extracellular (By similarity).
FT   TRANSMEM    356    376       7 (By similarity).
FT   TOPO_DOM    377    434       Cytoplasmic (By similarity).
FT   TRANSMEM    435    455       8 (By similarity).
FT   TOPO_DOM    456    458       Extracellular (By similarity).
FT   TRANSMEM    459    479       9 (By similarity).
FT   TOPO_DOM    480    541       Cytoplasmic (By similarity).
FT   TRANSMEM    542    562       10 (By similarity).
FT   TOPO_DOM    563    584       Extracellular (By similarity).
FT   TRANSMEM    585    605       11 (By similarity).
FT   TOPO_DOM    606   1005       Cytoplasmic.
FT   TRANSMEM   1006   1026       12.
FT   TOPO_DOM   1027   1073       Extracellular.
FT   TRANSMEM   1074   1094       13 (By similarity).
FT   TOPO_DOM   1095   1138       Cytoplasmic (By similarity).
FT   TRANSMEM   1139   1159       14 (By similarity).
FT   TOPO_DOM   1160   1160       Extracellular (By similarity).
FT   TRANSMEM   1161   1181       15 (By similarity).
FT   TOPO_DOM   1182   1252       Cytoplasmic (By similarity).
FT   TRANSMEM   1253   1273       16 (By similarity).
FT   TOPO_DOM   1274   1277       Extracellular.
FT   TRANSMEM   1278   1298       17.
FT   TOPO_DOM   1299   1582       Cytoplasmic.
FT   DOMAIN      299    602       ABC transmembrane type-1 1.
FT   DOMAIN      679    930       ABC transporter 1.
FT   DOMAIN     1013   1307       ABC transmembrane type-1 2.
FT   DOMAIN     1345   1579       ABC transporter 2.
FT   NP_BIND     713    720       ATP 1 (Potential).
FT   NP_BIND    1379   1386       ATP 2 (Potential).
FT   CARBOHYD     10     10       N-linked (GlcNAc...).
FT   CARBOHYD   1050   1050       N-linked (GlcNAc...).
SQ   SEQUENCE   1582 AA;  177147 MW;  B7FFDFD8E7124BA4 CRC64;
     MPLAFCGTEN HSAAYRVDQG VLNNGCFVDA LNVVPHVFLL FITFPILFIG WGSQSSKVHI
     HHSTWLHFPG HNLRWILTFI LLFVLVCEIA EGILSDGVTE SRHLHLYMPA GMAFMAAITS
     VVYYHNIETS NFPKLLIALL IYWTLAFITK TIKFVKFYDH AIGFSQLRFC LTGLLVILYG
     MLLLVEVNVI RVRRYIFFKT PREVKPPEDL QDLGVRFLQP FVNLLSKGTY WWMNAFIKTA
     HKKPIDLRAI AKLPIAMRAL TNYQRLCVAF DAQARKDTQS PQGARAIWRA LCHAFGRRLI
     LSSTFRILAD LLGFAGPLCI FGIVDHLGKE NHVFQPKTQF LGVYFVSSQE FLGNAYVLAV
     LLFLALLLQR TFLQASYYVA IETGINLRGA IQTKIYNKIM HMSTSNLSMG EMTAGQICNL
     VAIDTNQLMW FFFLCPNLWT MPVQIIVGVI LLYYILGVSA LIGAAVIILL APVQYFVATK
     LSQAQRTTLE HSNERLKQTN EMLRGMKLLK LYAWESIFCS RVEVTRRKEM TSLRAFAVYT
     SISIFMNTAI PIAAVLITFV GHVSFFKESD LSPSVAFASL SLFHILVTPL FLLSSVVRST
     VKALVSVQKL SEFLSSAEIR EEQCAPREPA PQGQAGKYQA VPLKVVNRKR PAREEVRDLL
     GPLQRLAPSM DGDADNFCVQ IIGGFFTWTP DGIPTLSNIT IRIPRGQLTM IVGQVGCGKS
     SLLLATLGEM QKVSGAVFWN SNLPDSEGED PSSPERETAA GSDIRSRGPV AYASQKPWLL
     NATVEENITF ESPFNKQRYK MVIEACSLQP DIDILPHGDQ TQIGERGINL SGGQRQRISV
     ARALYQQTNV VFLDDPFSAL DVHLSDHLMQ AGILELLRDD KRTVVLVTHK LQYLPHADWI
     IAMKDGTIQR EGTLKDFQRS ECQLFEHWKT LMNRQDQELE KETVMERKAS EPSQGLPRAM
     SSRDGLLLDE EEEEEEAAES EEDDNLSSVL HQRAKIPWRA CTKYLSSAGI LLLSLLVFSQ
     LLKHMVLVAI DYWLAKWTDS ALVLSPAARN CSLSQECDLD QSVYAMVFTL LCSLGIVLCL
     VTSVTVEWTG LKVAKRLHRS LLNRIILAPM RFFETTPLGS ILNRFSSDCN TIDQHIPSTL
     ECLSRSTLLC VSALTVISYV TPVFLVALLP LAVVCYFIQK YFRVASRDLQ QLDDTTQLPL
     VSHFAETVEG LTTIRAFRYE ARFQQKLLEY TDSNNIASLF LTAANRWLEV CMEYIGACVV
     LIAAATSISN SLHRELSAGL VGLGLTYALM VSNYLNWMVR NLADMEIQLG AVKRIHALLK
     TEAESYEGLL APSLIPKNWP DQGKIQIQNL SVRYDSSLKP VLKHVNTLIS PGQKIGICGR
     TGSGKSSFSL AFFRMVDMFE GRIIIDGIDI AKLPLHTLRS RLSIILQDPV LFSGTIRFNL
     DPEKKCSDST LWEALEIAQL KLVVKALPGG LDAIITEGGE NFSQGQRQLF CLARAFVRKT
     SIFIMDEATA SIDMATENIL QKVVMTAFAD RTVVTIAHRV HTILSADLVM VLKRGAILEF
     DKPETLLSQK DSVFASFVRA DK
//
ID   ABCC8_HUMAN             Reviewed;        1581 AA.
AC   Q09428; A6NMX8; O75948; Q16583;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 5.
DT   02-MAR-2010, entry version 106.
DE   RecName: Full=ATP-binding cassette transporter sub-family C member 8;
DE   AltName: Full=Sulfonylurea receptor 1;
GN   Name=ABCC8; Synonyms=HRINS, SUR, SUR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND ALTERNATIVE SPLICING.
RC   TISSUE=Pancreatic islet;
RA   Gonzalez G., Aguilar-Bryan L., Bryan J.;
RT   "Human beta cell sulfonylurea receptor, SUR1, expression.";
RL   Submitted (JUN-1996) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1).
RC   TISSUE=Brain, and Foreskin;
RA   Thomas P.T., Wohllk N., Huang E., Gagel R.F., Cote G.J.;
RL   Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Pancreas;
RA   Nishimura M., Miki T., Aizawa T., Seino S.;
RL   Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ALA-1369.
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1187-1581.
RC   TISSUE=Pancreatic islet;
RX   MEDLINE=95232533; PubMed=7716548; DOI=10.1126/science.7716548;
RA   Thomas P.M., Cote G.J., Wohllk N., Haddad B., Mathew P.M., Rabl W.,
RA   Aguilar-Bryan L., Gagel R.F., Bryan J.;
RT   "Mutations in the sulfonylurea receptor gene in familial persistent
RT   hyperinsulinemic hypoglycemia of infancy.";
RL   Science 268:426-429(1995).
RN   [6]
RP   TOPOLOGY.
RX   MEDLINE=99436117; PubMed=10506167; DOI=10.1074/jbc.274.41.29122;
RA   Raab-Graham K.F., Cirilo L.J., Boettcher A.A., Radeke C.M.,
RA   Vandenberg C.A.;
RT   "Membrane topology of the amino-terminal region of the sulfonylurea
RT   receptor.";
RL   J. Biol. Chem. 274:29122-29129(1999).
RN   [7]
RP   REVIEW.
RX   MEDLINE=99220315; PubMed=10204114; DOI=10.1210/er.20.2.101;
RA   Aguilar-Bryan L., Bryan J.;
RT   "Molecular biology of adenosine triphosphate-sensitive potassium
RT   channels.";
RL   Endocr. Rev. 20:101-135(1999).
RN   [8]
RP   REVIEW ON VARIANTS.
RX   MEDLINE=99268411; PubMed=10338089;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:5<351::AID-HUMU3>3.3.CO;2-I;
RA   Meissner T., Beinbrech B., Mayatepek E.;
RT   "Congenital hyperinsulinism: molecular basis of a heterogeneous
RT   disease.";
RL   Hum. Mutat. 13:351-361(1999).
RN   [9]
RP   VARIANT HHF1 VAL-716.
RX   MEDLINE=96354544; PubMed=8751851;
RA   Thomas P.M., Wohllk N., Huang E., Kuhnle U., Rabl W., Gagel R.F.,
RA   Cote G.J.;
RT   "Inactivation of the first nucleotide-binding fold of the sulfonylurea
RT   receptor, and familial persistent hyperinsulinemic hypoglycemia of
RT   infancy.";
RL   Am. J. Hum. Genet. 59:510-518(1996).
RN   [10]
RP   VARIANT ALA-1369.
RX   MEDLINE=96220088; PubMed=8635661;
RA   Inoue H., Ferrer J., Welling C.M., Elbein S.C., Hoffman M.,
RA   Mayorga R., Warren-Perry M., Zhang Y., Millns H., Turner R.,
RA   Province M., Bryan J., Permutt M.A., Aguilar-Bryan L.;
RT   "Sequence variants in the sulfonylurea receptor (SUR) gene are
RT   associated with NIDDM in Caucasians.";
RL   Diabetes 45:825-831(1996).
RN   [11]
RP   VARIANT HHF1 PHE-1387 DEL, AND VARIANTS GLY-1360; ALA-1369 AND
RP   ILE-1572.
RX   MEDLINE=97081768; PubMed=8923011; DOI=10.1093/hmg/5.11.1813;
RA   Nestorowicz A., Wilson B.A., Schoor K.P., Inoue H., Glaser B.,
RA   Landau H., Stanley C.A., Thornton P.S., Clement J.P. IV, Bryan J.,
RA   Aguilar-Bryan L., Permutt M.A.;
RT   "Mutations in the sulfonylurea receptor gene are associated with
RT   familial hyperinsulinism in Ashkenazi Jews.";
RL   Hum. Mol. Genet. 5:1813-1822(1996).
RN   [12]
RP   CHARACTERIZATION OF VARIANT HHF1 ARG-1478.
RX   MEDLINE=96256476; PubMed=8650576; DOI=10.1126/science.272.5269.1785;
RA   Nichols C.G., Shyng S.-L., Nestorowicz A., Glaser B., Clement J.P. IV,
RA   Gonzalez G., Aguilar-Bryan L., Permutt M.A., Bryan J.;
RT   "Adenosine diphosphate as an intracellular regulator of insulin
RT   secretion.";
RL   Science 272:1785-1787(1996).
RN   [13]
RP   VARIANTS GLN-275; MET-560; ASN-810; CYS-834 AND ALA-1369.
RX   MEDLINE=98178572; PubMed=9519757;
RA   Ohta Y., Tanizawa Y., Inoue H., Hosaka T., Ueda K., Matsutani A.,
RA   Repunte V.P., Yamada M., Kurachi Y., Bryan J., Aguilar-Bryan L.,
RA   Permutt M.A., Oka Y.;
RT   "Identification and functional analysis of sulfonylurea receptor 1
RT   variants in Japanese patients with NIDDM.";
RL   Diabetes 47:476-481(1998).
RN   [14]
RP   VARIANTS ASN-673 AND ALA-1369.
RX   MEDLINE=98227644; PubMed=9568693;
RA   Hansen T., Echwald S.M., Hansen L., Moeller A.M., Almind K.,
RA   Clausen J.O., Urhammer S.A., Inoue H., Ferrer J., Bryan J.,
RA   Aguilar-Bryan L., Permutt M.A., Pedersen O.;
RT   "Decreased tolbutamide-stimulated insulin secretion in healthy
RT   subjects with sequence variants in the high-affinity sulfonylurea
RT   receptor gene.";
RL   Diabetes 47:598-605(1998).
RN   [15]
RP   CHARACTERIZATION OF VARIANTS HHF1 GLN-125; SER-188; LEU-591; MET-1138;
RP   GLN-1214; SER-1381; PHE-1387 DEL AND HIS-1393.
RX   MEDLINE=98311174; PubMed=9648840;
RA   Shyng S.-L., Ferrigni T., Shepard J.B., Nestorowicz A., Glaser B.,
RA   Permutt M.A., Nichols C.G.;
RT   "Functional analyses of novel mutations in the sulfonylurea receptor 1
RT   associated with persistent hyperinsulinemic hypoglycemia of infancy.";
RL   Diabetes 47:1145-1151(1998).
RN   [16]
RP   VARIANTS HHF1 GLN-74; GLN-125; SER-188; ASP-406; LEU-591; MET-1138;
RP   GLN-1214; ARG-1378; SER-1381; PHE-1387 DEL AND HIS-1393.
RX   MEDLINE=98282238; PubMed=9618169; DOI=10.1093/hmg/7.7.1119;
RA   Nestorowicz A., Glaser B., Wilson B.A., Shyng S.-L., Nichols C.G.,
RA   Stanley C.A., Thornton P.S., Permutt M.A.;
RT   "Genetic heterogeneity in familial hyperinsulinism.";
RL   Hum. Mol. Genet. 7:1119-1128(1998).
RN   [17]
RP   VARIANTS HHF1 PRO-1352; CYS-1420 AND TRP-1493.
RX   MEDLINE=98443218; PubMed=9769320; DOI=10.1172/JCI4495;
RA   Verkarre V., Fournet J.-C., de Lonlay P., Gross-Morand M.-S.,
RA   Devillers M., Rahier J., Brunelle F., Robert J.-J., Nihoul-Fekete C.,
RA   Saudubray J.-M., Junien C.;
RT   "Paternal mutation of the sulfonylurea receptor (SUR1) gene and
RT   maternal loss of 11p15 imprinted genes lead to persistent
RT   hyperinsulinism in focal adenomatous hyperplasia.";
RL   J. Clin. Invest. 102:1286-1291(1998).
RN   [18]
RP   VARIANT HHF1 ASP-187.
RX   MEDLINE=99265491; PubMed=10334322;
RA   Otonkoski T., Aemmaelae C., Huopio H., Cote G.J., Chapman J.,
RA   Cosgrove K., Ashfield R., Huang E., Komulainen J., Ashcroft F.M.,
RA   Dunne M.J., Kere J., Thomas P.M.;
RT   "A point mutation inactivating the sulfonylurea receptor causes the
RT   severe form of persistent hyperinsulinemic hypoglycemia of infancy in
RT   Finland.";
RL   Diabetes 48:408-415(1999).
RN   [19]
RP   VARIANTS ALA-1369 AND ILE-1572.
RX   MEDLINE=99374921; PubMed=10447255;
RX   DOI=10.1002/(SICI)1098-1004(1999)14:1<23::AID-HUMU3>3.0.CO;2-#;
RA   Glaser B., Furth J., Stanley C.A., Baker L., Thornton P.S., Landau H.,
RA   Permutt M.A.;
RT   "Intragenic single nucleotide polymorphism haplotype analysis of SUR1
RT   mutations in familial hyperinsulinism.";
RL   Hum. Mutat. 14:23-29(1999).
RN   [20]
RP   VARIANTS HHF1 GLY-841; CYS-1420 AND TRP-1493.
RX   PubMed=10202168; DOI=10.1056/NEJM199904153401505;
RA   de Lonlay-Debeney P., Poggi-Travert F., Fournet J.-C., Sempoux C.,
RA   Vici C.D., Brunelle F., Touati G., Rahier J., Junien C.,
RA   Nihoul-Fekete C., Robert J.-J., Saudubray J.-M.;
RT   "Clinical features of 52 neonates with hyperinsulinism.";
RL   N. Engl. J. Med. 340:1169-1175(1999).
RN   [21]
RP   CHARACTERIZATION OF VARIANTS HHF1 CYS-1420 AND GLN-1436, AND VARIANT
RP   ALA-1369.
RX   MEDLINE=20081704; PubMed=10615958;
RA   Tanizawa Y., Matsuda K., Matsuo M., Ohta Y., Ochi N., Adachi M.,
RA   Koga M., Mizuno S., Kajita M., Tanaka Y., Tachibana K., Inoue H.,
RA   Furukawa S., Amachi T., Ueda K., Oka Y.;
RT   "Genetic analysis of Japanese patients with persistent
RT   hyperinsulinemic hypoglycemia of infancy: nucleotide-binding fold-2
RT   mutation impairs cooperative binding of adenine nucleotides to
RT   sulfonylurea receptor 1.";
RL   Diabetes 49:114-120(2000).
RN   [22]
RP   CHARACTERIZATION OF VARIANT HHF1 LYS-1506.
RX   MEDLINE=20472673; PubMed=11018078; DOI=10.1172/JCI9804;
RA   Huopio H., Reimann F., Ashfield R., Komulainen J., Lenko H.-L.,
RA   Rahier J., Vauhkonen I., Kere J., Laakso M., Ashcroft F.,
RA   Otonkoski T.;
RT   "Dominantly inherited hyperinsulinism caused by a mutation in the
RT   sulfonylurea receptor type 1.";
RL   J. Clin. Invest. 106:897-906(2000).
RN   [23]
RP   CHARACTERIZATION OF VARIANT HHF1 PHE-1387 DEL.
RX   MEDLINE=21126980; PubMed=11226335; DOI=10.1073/pnas.051499698;
RA   Cartier E.A., Conti L.R., Vandenberg C.A., Shyng S.-L.;
RT   "Defective trafficking and function of KATP channels caused by a
RT   sulfonylurea receptor 1 mutation associated with persistent
RT   hyperinsulinemic hypoglycemia of infancy.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:2882-2887(2001).
RN   [24]
RP   CHARACTERIZATION OF VARIANT HHF1 PRO-1543.
RX   MEDLINE=21988132; PubMed=11867634; DOI=10.1074/jbc.M200363200;
RA   Taschenberger G., Mougey A., Shen S., Lester L.B., LaFranchi S.,
RA   Shyng S.-L.;
RT   "Identification of a familial hyperinsulinism-causing mutation in the
RT   sulfonylurea receptor 1 that prevents normal trafficking and function
RT   of KATP channels.";
RL   J. Biol. Chem. 277:17139-17146(2002).
RN   [25]
RP   VARIANTS HHF1 ASP-187; THR-1457; LYS-1506; ASP-1550 AND VAL-1551.
RX   PubMed=12364426; DOI=10.1210/jc.2002-020378;
RA   Huopio H., Jaeaeskelaeinen J., Komulainen J., Miettinen R.,
RA   Kaerkkaeinen P., Laakso M., Tapanainen P., Voutilainen R.,
RA   Otonkoski T.;
RT   "Acute insulin response tests for the differential diagnosis of
RT   congenital hyperinsulinism.";
RL   J. Clin. Endocrinol. Metab. 87:4502-4507(2002).
RN   [26]
RP   VARIANT HHF1 SER-1385 DEL, AND CHARACTERIZATION OF VARIANT HHF1
RP   SER-1385 DEL.
RX   PubMed=12941782;
RA   Thornton P.S., MacMullen C., Ganguly A., Ruchelli E., Steinkrauss L.,
RA   Crane A., Aguilar-Bryan L., Stanley C.A.;
RT   "Clinical and molecular characterization of a dominant form of
RT   congenital hyperinsulinism caused by a mutation in the high-affinity
RT   sulfonylurea receptor.";
RL   Diabetes 52:2403-2410(2003).
RN   [27]
RP   VARIANT LIH HIS-1352, AND CHARACTERIZATION OF VARIANT LIH HIS-1352.
RX   PubMed=15356046; DOI=10.1210/jc.2004-0441;
RA   Magge S.N., Shyng S.-L., MacMullen C., Steinkrauss L., Ganguly A.,
RA   Katz L.E.L., Stanley C.A.;
RT   "Familial leucine-sensitive hypoglycemia of infancy due to a dominant
RT   mutation of the beta-cell sulfonylurea receptor.";
RL   J. Clin. Endocrinol. Metab. 89:4450-4456(2004).
RN   [28]
RP   VARIANTS HHF1 GLU-70; ARG-111; GLU-1342; HIS-1418 AND TRP-1493, AND
RP   CHARACTERIZATION OF VARIANTS HHF1 GLU-70; ARG-111; GLU-1342; HIS-1418
RP   AND TRP-1493.
RX   PubMed=15579781; DOI=10.1210/jc.2004-1233;
RA   Tornovsky S., Crane A., Cosgrove K.E., Hussain K., Lavie J.,
RA   Heyman M., Nesher Y., Kuchinski N., Ben-Shushan E., Shatz O.,
RA   Nahari E., Potikha T., Zangen D., Tenenbaum-Rakover Y., de Vries L.,
RA   Argente J., Gracia R., Landau H., Eliakim A., Lindley K., Dunne M.J.,
RA   Aguilar-Bryan L., Glaser B.;
RT   "Hyperinsulinism of infancy: novel ABCC8 and KCNJ11 mutations and
RT   evidence for additional locus heterogeneity.";
RL   J. Clin. Endocrinol. Metab. 89:6224-6234(2004).
RN   [29]
RP   VARIANTS HHF1 GLN-1384 AND LYS-1486, AND VARIANT ALA-1369.
RX   PubMed=15807877; DOI=10.1111/j.1365-2265.2005.02242.x;
RA   Ohkubo K., Nagashima M., Naito Y., Taguchi T., Suita S., Okamoto N.,
RA   Fujinaga H., Tsumura K., Kikuchi K., Ono J.;
RT   "Genotypes of the pancreatic beta-cell K-ATP channel and clinical
RT   phenotypes of Japanese patients with persistent hyperinsulinaemic
RT   hypoglycaemia of infancy.";
RL   Clin. Endocrinol. (Oxf.) 62:458-465(2005).
RN   [30]
RP   VARIANTS HHF1 SER-27; TRP-74; SER-188; GLN-495; LYS-501; SER-686;
RP   TRP-1214; GLN-1214; ASN-1336; PHE-1387 DEL; HIS-1471 AND ASN-1471.
RX   PubMed=15562009; DOI=10.1210/jc.2004-1604;
RA   Henwood M.J., Kelly A., MacMullen C., Bhatia P., Ganguly A.,
RA   Thornton P.S., Stanley C.A.;
RT   "Genotype-phenotype correlations in children with congenital
RT   hyperinsulinism due to recessive mutations of the adenosine
RT   triphosphate-sensitive potassium channel genes.";
RL   J. Clin. Endocrinol. Metab. 90:789-794(2005).
RN   [31]
RP   VARIANT PNDM LEU-132, AND CHARACTERIZATION OF VARIANT PNDM LEU-132.
RX   PubMed=16613899; DOI=10.1093/hmg/ddl101;
RA   Proks P., Arnold A.L., Bruining J., Girard C., Flanagan S.E.,
RA   Larkin B., Colclough K., Hattersley A.T., Ashcroft F.M., Ellard S.;
RT   "A heterozygous activating mutation in the sulphonylurea receptor SUR1
RT   (ABCC8) causes neonatal diabetes.";
RL   Hum. Mol. Genet. 15:1793-1800(2006).
RN   [32]
RP   VARIANTS HHF1 TRP-74; ARG-111; SER-188; ARG-233; ASN-310; ARG-551;
RP   THR-719; PRO-1130; ARG-1147; LYS-1295 AND PRO-1450, AND VARIANTS
RP   ALA-1369 AND ILE-1572.
RX   PubMed=16429405; DOI=10.1002/humu.9401;
RA   Fernandez-Marmiesse A., Salas A., Vega A., Fernandez-Lorenzo J.R.,
RA   Barreiro J., Carracedo A.;
RT   "Mutation spectra of ABCC8 gene in Spanish patients with
RT   Hyperinsulinism of Infancy (HI).";
RL   Hum. Mutat. 27:214-214(2006).
RN   [33]
RP   VARIANTS HHF1 ARG-7; ASP-21; SER-27; TRP-74; LYS-501; PRO-503;
RP   SER-686; TRP-1214; TRP-1214; GLN-1349; ARG-1378; PHE-1387 DEL;
RP   ARG-1400 AND GLN-1493.
RX   PubMed=16357843; DOI=10.1038/modpathol.3800497;
RA   Suchi M., MacMullen C.M., Thornton P.S., Adzick N.S., Ganguly A.,
RA   Ruchelli E.D., Stanley C.A.;
RT   "Molecular and immunohistochemical analyses of the focal form of
RT   congenital hyperinsulinism.";
RL   Mod. Pathol. 19:122-129(2006).
RN   [34]
RP   VARIANTS PNDM ARG-213 AND VAL-1424, VARIANTS TNDM2 ARG-435; VAL-582;
RP   TYR-1023; GLN-1182 AND CYS-1379, CHARACTERIZATION OF VARIANT PNDM
RP   VAL-1424, AND CHARACTERIZATION OF VARIANT TNDM2 TYR-1023.
RX   PubMed=16885549; DOI=10.1056/NEJMoa055068;
RA   Babenko A.P., Polak M., Cave H., Busiah K., Czernichow P.,
RA   Scharfmann R., Bryan J., Aguilar-Bryan L., Vaxillaire M., Froguel P.;
RT   "Activating mutations in the ABCC8 gene in neonatal diabetes
RT   mellitus.";
RL   N. Engl. J. Med. 355:456-466(2006).
RN   [35]
RP   VARIANT PNDM ALA-86.
RX   PubMed=17213273; DOI=10.1210/jc.2006-2490;
RA   Stanik J., Gasperikova D., Paskova M., Barak L., Javorkova J.,
RA   Jancova E., Ciljakova M., Hlava P., Michalek J., Flanagan S.E.,
RA   Pearson E., Hattersley A.T., Ellard S., Klimes I.;
RT   "Prevalence of permanent neonatal diabetes in Slovakia and successful
RT   replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8
RT   mutation carriers.";
RL   J. Clin. Endocrinol. Metab. 92:1276-1282(2007).
CC   -!- FUNCTION: Putative subunit of the beta-cell ATP-sensitive
CC       potassium channel (KATP). Regulator of ATP-sensitive K(+) channels
CC       and insulin release.
CC   -!- SUBUNIT: Associates with KCNJ11.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q09428-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q09428-2; Sequence=VSP_000055;
CC   -!- DISEASE: Defects in ABCC8 are a cause of leucine-induced
CC       hypoglycemia (LIH) [MIM:240800]; also known as leucine-sensitive
CC       hypoglycemia of infancy. LIH is a rare cause of hypoglycemia and
CC       is described as a condition in which symptomatic hypoglycemia is
CC       provoked by high protein feedings. Hypoglycemia is also elicited
CC       by administration of oral or intravenous infusions of a single
CC       amino acid, leucine.
CC   -!- DISEASE: Defects in ABCC8 are the cause of familial
CC       hyperinsulinemic hypoglycemia type 1 (HHF1) [MIM:256450]; also
CC       known as persistent hyperinsulinemic hypoglycemia of infancy
CC       (PHHI) or congenital hyperinsulinism. HHF is the most common cause
CC       of persistent hypoglycemia in infancy and is due to defective
CC       negative feedback regulation of insulin secretion by low glucose
CC       levels. It causes nesidioblastosis, a diffuse abnormality of the
CC       pancreas in which there is extensive, often disorganized formation
CC       of new islets. Unless early and aggressive intervention is
CC       undertaken, brain damage from recurrent episodes of hypoglycemia
CC       may occur.
CC   -!- DISEASE: Defects in ABCC8 are a cause of permanent neonatal
CC       diabetes mellitus (PNDM) [MIM:606176]; also known as permanent
CC       diabetes mellitus of infancy (PDMI). PNDM is a rare form of
CC       diabetes characterized by insulin-requiring hyperglycemia that is
CC       diagnosed within the first months of life. Permanent neonatal
CC       diabetes requires lifelong therapy.
CC   -!- DISEASE: Defects in ABCC8 are the cause of transient neonatal
CC       diabetes mellitus type 2 (TNDM2) [MIM:610374]. Neonatal diabetes
CC       is a form of diabetes mellitus defined by the onset of mild-to-
CC       severe hyperglycemia within the first months of life. Transient
CC       neonatal diabetes remits early, with a possible relapse during
CC       adolescence.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCC
CC       family. Conjugate transporter (TC 3.A.1.208) subfamily.
CC   -!- SIMILARITY: Contains 2 ABC transmembrane type-1 domains.
CC   -!- SIMILARITY: Contains 2 ABC transporter domains.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/ABCC8";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L78207; AAB02278.1; -; mRNA.
DR   EMBL; L78243; AAB02417.1; -; Genomic_DNA.
DR   EMBL; L78208; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78209; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78210; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78211; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78212; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78255; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78213; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78214; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78215; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78216; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78217; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78218; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78219; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78220; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78221; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78222; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78223; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78225; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78254; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78226; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78227; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78228; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78229; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78230; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78231; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78232; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78233; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78234; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78235; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78236; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78237; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78238; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78239; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78240; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78241; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78242; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78243; AAB02418.1; -; Genomic_DNA.
DR   EMBL; L78208; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78209; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78210; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78211; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78212; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78255; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78213; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78214; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78215; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78216; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78217; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78218; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78219; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78220; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78221; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78222; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78224; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78225; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78254; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78226; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78227; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78228; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78229; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78230; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78231; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78232; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78233; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78234; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78235; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78236; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78237; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78238; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78239; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78240; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78241; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78242; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; U63421; AAB36699.1; -; mRNA.
DR   EMBL; U63455; AAB36700.1; -; Genomic_DNA.
DR   EMBL; U63422; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63423; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63424; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63425; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63426; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63427; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63428; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63429; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63430; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63431; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63432; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63433; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63434; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63435; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63436; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63437; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63438; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63439; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63441; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63442; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63443; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63444; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63445; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63446; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63447; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63448; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63449; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63450; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63451; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63452; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63453; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63454; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; AF087138; AAC36724.1; -; mRNA.
DR   EMBL; AC124798; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; L40625; AAA99227.1; -; mRNA.
DR   IPI; IPI00219696; -.
DR   IPI; IPI00871283; -.
DR   RefSeq; NP_000343.2; -.
DR   UniGene; Hs.54470; -.
DR   STRING; Q09428; -.
DR   TCDB; 3.A.1.208.4; ATP-binding cassette (ABC) superfamily.
DR   PhosphoSite; Q09428; -.
DR   Ensembl; ENST00000389817; ENSP00000374467; ENSG00000006071; Homo sapiens.
DR   GeneID; 6833; -.
DR   KEGG; hsa:6833; -.
DR   CTD; 6833; -.
DR   GeneCards; GC11M017373; -.
DR   H-InvDB; HIX0035864; -.
DR   HGNC; HGNC:59; ABCC8.
DR   HPA; CAB011451; -.
DR   MIM; 240800; phenotype.
DR   MIM; 256450; phenotype.
DR   MIM; 600509; gene.
DR   MIM; 602485; phenotype.
DR   MIM; 606176; phenotype.
DR   MIM; 610374; phenotype.
DR   Orphanet; 224; Diabetes mellitus, neonatal.
DR   Orphanet; 99885; Diabetes mellitus, neonatal, permanent.
DR   Orphanet; 99886; Diabetes mellitus, neonatal, transient.
DR   Orphanet; 165988; Diffuse hyperinsulinism, diazoxide-resistant.
DR   Orphanet; 165985; Diffuse hyperinsulinism, diazoxide-sensitive.
DR   Orphanet; 79298; Hyperinsulinism due to focal adenomatous hyperplasia.
DR   Orphanet; 657; Persistent hyperinsulinemic hypoglycemia of infancy.
DR   PharmGKB; PA24395; -.
DR   eggNOG; prNOG04894; -.
DR   HOVERGEN; HBG101342; -.
DR   Pathway_Interaction_DB; hnf3bpathway; FOXA2 and FOXA3 transcription factor networks.
DR   Reactome; REACT_1505; Integration of energy metabolism.
DR   Reactome; REACT_15380; Diabetes pathways.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   DrugBank; DB01016; Glibenclamide.
DR   DrugBank; DB01120; Gliclazide.
DR   DrugBank; DB01252; Mitiglinide.
DR   DrugBank; DB00731; Nateglinide.
DR   DrugBank; DB00912; Repaglinide.
DR   NextBio; 26675; -.
DR   ArrayExpress; Q09428; -.
DR   Bgee; Q09428; -.
DR   CleanEx; HS_ABCC8; -.
DR   Genevestigator; Q09428; -.
DR   GermOnline; ENSG00000006071; Homo sapiens.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; TAS:ProtInc.
DR   GO; GO:0042626; F:ATPase activity, coupled to transmembrane m...; IEA:InterPro.
DR   GO; GO:0015079; F:potassium ion transmembrane transporter act...; TAS:ProtInc.
DR   GO; GO:0008281; F:sulfonylurea receptor activity; TAS:ProtInc.
DR   GO; GO:0005975; P:carbohydrate metabolic process; NAS:ProtInc.
DR   GO; GO:0006813; P:potassium ion transport; TAS:ProtInc.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR017940; ABC_transporter_type1.
DR   InterPro; IPR001140; ABC_transptr_TM_dom.
DR   InterPro; IPR011527; ABC_transptrTM_dom_typ1.
DR   InterPro; IPR003593; ATPase_AAA+_core.
DR   InterPro; IPR000388; Sulphorea_rcpt_N.
DR   InterPro; IPR000844; Surea_rcpt_1_N.
DR   Pfam; PF00664; ABC_membrane; 2.
DR   Pfam; PF00005; ABC_tran; 2.
DR   PRINTS; PR01093; SULFNYLUR1.
DR   PRINTS; PR01092; SULFNYLUREAR.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF90123; ABC_TM_1; 2.
DR   PROSITE; PS50929; ABC_TM1F; 2.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 2.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Complete proteome;
KW   Diabetes mellitus; Disease mutation; Glycoprotein; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Receptor; Repeat;
KW   Transmembrane; Transport.
FT   INIT_MET      1      1       Removed (By similarity).
FT   CHAIN         2   1581       ATP-binding cassette transporter sub-
FT                                family C member 8.
FT                                /FTId=PRO_0000093400.
FT   TOPO_DOM      2     34       Extracellular (By similarity).
FT   TRANSMEM     35     55       1 (By similarity).
FT   TOPO_DOM     56     75       Cytoplasmic (By similarity).
FT   TRANSMEM     76     96       2 (By similarity).
FT   TOPO_DOM     97    101       Extracellular (By similarity).
FT   TRANSMEM    102    122       3 (By similarity).
FT   TOPO_DOM    123    134       Cytoplasmic (By similarity).
FT   TRANSMEM    135    154       4 (By similarity).
FT   TOPO_DOM    155    167       Extracellular (By similarity).
FT   TRANSMEM    168    194       5 (By similarity).
FT   TOPO_DOM    195    311       Cytoplasmic (By similarity).
FT   TRANSMEM    312    331       6 (By similarity).
FT   TOPO_DOM    332    355       Extracellular (By similarity).
FT   TRANSMEM    356    376       7 (By similarity).
FT   TOPO_DOM    377    434       Cytoplasmic (By similarity).
FT   TRANSMEM    435    455       8 (By similarity).
FT   TOPO_DOM    456    458       Extracellular (By similarity).
FT   TRANSMEM    459    479       9 (By similarity).
FT   TOPO_DOM    480    541       Cytoplasmic (By similarity).
FT   TRANSMEM    542    562       10 (By similarity).
FT   TOPO_DOM    563    584       Extracellular (By similarity).
FT   TRANSMEM    585    605       11 (By similarity).
FT   TOPO_DOM    606   1004       Cytoplasmic (By similarity).
FT   TRANSMEM   1005   1025       12 (By similarity).
FT   TOPO_DOM   1026   1072       Extracellular (By similarity).
FT   TRANSMEM   1073   1093       13 (By similarity).
FT   TOPO_DOM   1094   1137       Cytoplasmic (By similarity).
FT   TRANSMEM   1138   1158       14 (By similarity).
FT   TOPO_DOM   1159   1159       Extracellular (By similarity).
FT   TRANSMEM   1160   1180       15 (By similarity).
FT   TOPO_DOM   1181   1251       Cytoplasmic (By similarity).
FT   TRANSMEM   1252   1272       16 (By similarity).
FT   TOPO_DOM   1273   1276       Extracellular (By similarity).
FT   TRANSMEM   1277   1297       17 (By similarity).
FT   TOPO_DOM   1298   1581       Cytoplasmic (By similarity).
FT   DOMAIN      299    602       ABC transmembrane type-1 1.
FT   DOMAIN      679    929       ABC transporter 1.
FT   DOMAIN     1012   1306       ABC transmembrane type-1 2.
FT   DOMAIN     1344   1578       ABC transporter 2.
FT   NP_BIND     713    720       ATP 1 (Potential).
FT   NP_BIND    1378   1385       ATP 2 (Potential).
FT   CARBOHYD     10     10       N-linked (GlcNAc...) (By similarity).
FT   CARBOHYD   1049   1049       N-linked (GlcNAc...) (By similarity).
FT   VAR_SEQ     740    740       S -> SS (in isoform 2).
FT                                /FTId=VSP_000055.
FT   VARIANT       7      7       G -> R (in HHF1).
FT                                /FTId=VAR_031349.
FT   VARIANT      21     21       V -> D (in HHF1).
FT                                /FTId=VAR_031350.
FT   VARIANT      27     27       F -> S (in HHF1).
FT                                /FTId=VAR_031351.
FT   VARIANT      70     70       G -> E (in HHF1; altered intracellular
FT                                trafficking).
FT                                /FTId=VAR_031352.
FT   VARIANT      74     74       R -> Q (in HHF1).
FT                                /FTId=VAR_008639.
FT   VARIANT      74     74       R -> W (in HHF1).
FT                                /FTId=VAR_031353.
FT   VARIANT      86     86       V -> A (in PNDM).
FT                                /FTId=VAR_031354.
FT   VARIANT     104    104       L -> V (in dbSNP:rs10400391).
FT                                /FTId=VAR_029777.
FT   VARIANT     111    111       G -> R (in HHF1; altered intracellular
FT                                trafficking).
FT                                /FTId=VAR_031355.
FT   VARIANT     116    116       A -> P (in HHF1).
FT                                /FTId=VAR_031356.
FT   VARIANT     125    125       H -> Q (in HHF1; mild; dbSNP:rs60637558).
FT                                /FTId=VAR_008640.
FT   VARIANT     132    132       F -> L (in PNDM; with neurologic
FT                                features; reduces the sensitivity of the
FT                                K(ATP) channel to inhibition by MgATP;
FT                                increases whole-cell K(ATP) current).
FT                                /FTId=VAR_029778.
FT   VARIANT     187    187       V -> D (in HHF1; severe; high prevalence
FT                                in Finland; loss of channel activity).
FT                                /FTId=VAR_008641.
FT   VARIANT     188    188       N -> S (in HHF1; severe).
FT                                /FTId=VAR_008642.
FT   VARIANT     213    213       L -> R (in PNDM).
FT                                /FTId=VAR_029779.
FT   VARIANT     233    233       M -> R (in HHF1).
FT                                /FTId=VAR_031357.
FT   VARIANT     275    275       R -> Q.
FT                                /FTId=VAR_008643.
FT   VARIANT     310    310       D -> N (in HHF1).
FT                                /FTId=VAR_031358.
FT   VARIANT     406    406       N -> D (in HHF1).
FT                                /FTId=VAR_008644.
FT   VARIANT     418    418       C -> R (in HHF1).
FT                                /FTId=VAR_031359.
FT   VARIANT     435    435       C -> R (in TNDM2).
FT                                /FTId=VAR_029780.
FT   VARIANT     495    495       R -> Q (in HHF1).
FT                                /FTId=VAR_031360.
FT   VARIANT     501    501       E -> K (in HHF1).
FT                                /FTId=VAR_031361.
FT   VARIANT     503    503       L -> P (in HHF1).
FT                                /FTId=VAR_031362.
FT   VARIANT     508    508       L -> P (in HHF1).
FT                                /FTId=VAR_031363.
FT   VARIANT     551    551       P -> R (in HHF1).
FT                                /FTId=VAR_031364.
FT   VARIANT     560    560       V -> M (in dbSNP:rs4148619).
FT                                /FTId=VAR_008645.
FT   VARIANT     582    582       L -> V (in TNDM2).
FT                                /FTId=VAR_029781.
FT   VARIANT     591    591       F -> L (in HHF1).
FT                                /FTId=VAR_008646.
FT   VARIANT     620    620       R -> C (in HHF1; dbSNP:rs58241708).
FT                                /FTId=VAR_031365.
FT   VARIANT     673    673       D -> N.
FT                                /FTId=VAR_015006.
FT   VARIANT     686    686       F -> S (in HHF1).
FT                                /FTId=VAR_031366.
FT   VARIANT     716    716       G -> V (in HHF1).
FT                                /FTId=VAR_000100.
FT   VARIANT     719    719       K -> T (in HHF1).
FT                                /FTId=VAR_031367.
FT   VARIANT     810    810       D -> N.
FT                                /FTId=VAR_008647.
FT   VARIANT     834    834       R -> C.
FT                                /FTId=VAR_008648.
FT   VARIANT     841    841       R -> G (in HHF1).
FT                                /FTId=VAR_031368.
FT   VARIANT     889    889       K -> T (in HHF1).
FT                                /FTId=VAR_031369.
FT   VARIANT     956    956       S -> F (in HHF1).
FT                                /FTId=VAR_031370.
FT   VARIANT    1023   1023       H -> Y (in TNDM2; overactive channel).
FT                                /FTId=VAR_029782.
FT   VARIANT    1130   1130       T -> P (in HHF1).
FT                                /FTId=VAR_031371.
FT   VARIANT    1138   1138       T -> M (in HHF1).
FT                                /FTId=VAR_008649.
FT   VARIANT    1147   1147       L -> R (in HHF1).
FT                                /FTId=VAR_031372.
FT   VARIANT    1182   1182       R -> Q (in TNDM2).
FT                                /FTId=VAR_029783.
FT   VARIANT    1214   1214       R -> Q (in HHF1; severe).
FT                                /FTId=VAR_008650.
FT   VARIANT    1214   1214       R -> W (in HHF1).
FT                                /FTId=VAR_031373.
FT   VARIANT    1295   1295       N -> K (in HHF1).
FT                                /FTId=VAR_031374.
FT   VARIANT    1336   1336       K -> N (in HHF1).
FT                                /FTId=VAR_031375.
FT   VARIANT    1342   1342       G -> E (in HHF1; altered intracellular
FT                                trafficking).
FT                                /FTId=VAR_031376.
FT   VARIANT    1349   1349       L -> Q (in HHF1).
FT                                /FTId=VAR_031377.
FT   VARIANT    1352   1352       R -> H (in LIH; partially impairs ATP-
FT                                dependent potassium channel function).
FT                                /FTId=VAR_029784.
FT   VARIANT    1352   1352       R -> P (in HHF1; dbSNP:rs28936370).
FT                                /FTId=VAR_008537.
FT   VARIANT    1360   1360       V -> G.
FT                                /FTId=VAR_008651.
FT   VARIANT    1360   1360       V -> M (in HHF1).
FT                                /FTId=VAR_015007.
FT   VARIANT    1369   1369       S -> A (common polymorphism;
FT                                dbSNP:rs757110).
FT                                /FTId=VAR_008652.
FT   VARIANT    1378   1378       G -> R (in HHF1).
FT                                /FTId=VAR_008653.
FT   VARIANT    1379   1379       R -> C (in TNDM2).
FT                                /FTId=VAR_029785.
FT   VARIANT    1381   1381       G -> S (in HHF1).
FT                                /FTId=VAR_008654.
FT   VARIANT    1384   1384       K -> Q (in HHF1).
FT                                /FTId=VAR_031378.
FT   VARIANT    1385   1385       Missing (in HHF1; does not alter surface
FT                                expression but channels are not
FT                                functional).
FT                                /FTId=VAR_029786.
FT   VARIANT    1386   1386       S -> F (in HHF1).
FT                                /FTId=VAR_031379.
FT   VARIANT    1387   1387       Missing (in HHF1; severe; high frequency
FT                                in Ashkenazi Jewish patients; defective
FT                                trafficking and lack of surface
FT                                expression).
FT                                /FTId=VAR_008538.
FT   VARIANT    1393   1393       R -> H (in HHF1; severe; loss of channel
FT                                activity).
FT                                /FTId=VAR_008655.
FT   VARIANT    1400   1400       G -> R (in HHF1).
FT                                /FTId=VAR_031380.
FT   VARIANT    1418   1418       R -> H (in HHF1; altered intracellular
FT                                trafficking).
FT                                /FTId=VAR_031381.
FT   VARIANT    1420   1420       R -> C (in HHF1; modest impairment of
FT                                channel function; dbSNP:rs28938469).
FT                                /FTId=VAR_008539.
FT   VARIANT    1424   1424       I -> V (in PNDM; overactive channel).
FT                                /FTId=VAR_029787.
FT   VARIANT    1436   1436       R -> Q (in HHF1; cannot form a functional
FT                                channel, due to protein instability or
FT                                defective transport to the membrane).
FT                                /FTId=VAR_015008.
FT   VARIANT    1450   1450       L -> P (in HHF1).
FT                                /FTId=VAR_031382.
FT   VARIANT    1457   1457       A -> T (in HHF1).
FT                                /FTId=VAR_031383.
FT   VARIANT    1471   1471       D -> H (in HHF1).
FT                                /FTId=VAR_031384.
FT   VARIANT    1471   1471       D -> N (in HHF1).
FT                                /FTId=VAR_031385.
FT   VARIANT    1478   1478       G -> R (in HHF1; channels insensitive to
FT                                metabolic inhibition and to activation by
FT                                ADP).
FT                                /FTId=VAR_008656.
FT   VARIANT    1486   1486       R -> K (in HHF1).
FT                                /FTId=VAR_031386.
FT   VARIANT    1493   1493       R -> Q (in HHF1).
FT                                /FTId=VAR_031387.
FT   VARIANT    1493   1493       R -> W (in HHF1; altered intracellular
FT                                trafficking; dbSNP:rs28936371).
FT                                /FTId=VAR_008540.
FT   VARIANT    1506   1506       E -> K (in HHF1; mild; dominantly
FT                                inherited; channels insensitive to
FT                                metabolic inhibition and to activation by
FT                                ADP).
FT                                /FTId=VAR_015009.
FT   VARIANT    1507   1507       A -> AAS (in HHF1).
FT                                /FTId=VAR_008657.
FT   VARIANT    1543   1543       L -> P (in HHF1; reduced channels surface
FT                                expression and response to ADP).
FT                                /FTId=VAR_015010.
FT   VARIANT    1550   1550       V -> D (in HHF1).
FT                                /FTId=VAR_031388.
FT   VARIANT    1551   1551       L -> V (in HHF1).
FT                                /FTId=VAR_031389.
FT   VARIANT    1572   1572       V -> I (in dbSNP:rs8192690).
FT                                /FTId=VAR_008658.
FT   CONFLICT     30     30       A -> V (in Ref. 1; AAB02278/AAB02417/
FT                                AAB02418).
FT   CONFLICT    157    157       F -> L (in Ref. 2; AAB36699/AAB36700).
FT   CONFLICT    163    163       G -> A (in Ref. 1; AAB02278/AAB02417/
FT                                AAB02418).
FT   CONFLICT    167    167       L -> V (in Ref. 1; AAB02278/AAB02417/
FT                                AAB02418).
FT   CONFLICT    225    225       L -> P (in Ref. 2; AAB36699/AAB36700).
FT   CONFLICT    256    256       A -> V (in Ref. 2; AAB36699/AAB36700).
FT   CONFLICT    487    487       S -> T (in Ref. 1; AAB02278/AAB02417/
FT                                AAB02418).
FT   CONFLICT   1069   1070       VL -> AV (in Ref. 1; AAB02278/AAB02417/
FT                                AAB02418).
FT   CONFLICT   1172   1172       I -> V (in Ref. 2; AAB36699/AAB36700).
FT   CONFLICT   1410   1410       A -> R (in Ref. 2; AAB36699/AAB36700).
FT   CONFLICT   1418   1418       R -> P (in Ref. 2; AAB36699/AAB36700).
SQ   SEQUENCE   1581 AA;  177008 MW;  98E4C38854950F1D CRC64;
     MPLAFCGSEN HSAAYRVDQG VLNNGCFVDA LNVVPHVFLL FITFPILFIG WGSQSSKVHI
     HHSTWLHFPG HNLRWILTFM LLFVLVCEIA EGILSDGVTE SHHLHLYMPA GMAFMAAVTS
     VVYYHNIETS NFPKLLIALL VYWTLAFITK TIKFVKFLDH AIGFSQLRFC LTGLLVILYG
     MLLLVEVNVI RVRRYIFFKT PREVKPPEDL QDLGVRFLQP FVNLLSKGTY WWMNAFIKTA
     HKKPIDLRAI GKLPIAMRAL TNYQRLCEAF DAQVRKDIQG TQGARAIWQA LSHAFGRRLV
     LSSTFRILAD LLGFAGPLCI FGIVDHLGKE NDVFQPKTQF LGVYFVSSQE FLANAYVLAV
     LLFLALLLQR TFLQASYYVA IETGINLRGA IQTKIYNKIM HLSTSNLSMG EMTAGQICNL
     VAIDTNQLMW FFFLCPNLWA MPVQIIVGVI LLYYILGVSA LIGAAVIILL APVQYFVATK
     LSQAQRSTLE YSNERLKQTN EMLRGIKLLK LYAWENIFRT RVETTRRKEM TSLRAFAIYT
     SISIFMNTAI PIAAVLITFV GHVSFFKEAD FSPSVAFASL SLFHILVTPL FLLSSVVRST
     VKALVSVQKL SEFLSSAEIR EEQCAPHEPT PQGPASKYQA VPLRVVNRKR PAREDCRGLT
     GPLQSLVPSA DGDADNCCVQ IMGGYFTWTP DGIPTLSNIT IRIPRGQLTM IVGQVGCGKS
     SLLLAALGEM QKVSGAVFWS SLPDSEIGED PSPERETATD LDIRKRGPVA YASQKPWLLN
     ATVEENIIFE SPFNKQRYKM VIEACSLQPD IDILPHGDQT QIGERGINLS GGQRQRISVA
     RALYQHANVV FLDDPFSALD IHLSDHLMQA GILELLRDDK RTVVLVTHKL QYLPHADWII
     AMKDGTIQRE GTLKDFQRSE CQLFEHWKTL MNRQDQELEK ETVTERKATE PPQGLSRAMS
     SRDGLLQDEE EEEEEAAESE EDDNLSSMLH QRAEIPWRAC AKYLSSAGIL LLSLLVFSQL
     LKHMVLVAID YWLAKWTDSA LTLTPAARNC SLSQECTLDQ TVYAMVFTVL CSLGIVLCLV
     TSVTVEWTGL KVAKRLHRSL LNRIILAPMR FFETTPLGSI LNRFSSDCNT IDQHIPSTLE
     CLSRSTLLCV SALAVISYVT PVFLVALLPL AIVCYFIQKY FRVASRDLQQ LDDTTQLPLL
     SHFAETVEGL TTIRAFRYEA RFQQKLLEYT DSNNIASLFL TAANRWLEVR MEYIGACVVL
     IAAVTSISNS LHRELSAGLV GLGLTYALMV SNYLNWMVRN LADMELQLGA VKRIHGLLKT
     EAESYEGLLA PSLIPKNWPD QGKIQIQNLS VRYDSSLKPV LKHVNALISP GQKIGICGRT
     GSGKSSFSLA FFRMVDTFEG HIIIDGIDIA KLPLHTLRSR LSIILQDPVL FSGTIRFNLD
     PERKCSDSTL WEALEIAQLK LVVKALPGGL DAIITEGGEN FSQGQRQLFC LARAFVRKTS
     IFIMDEATAS IDMATENILQ KVVMTAFADR TVVTIAHRVH TILSADLVIV LKRGAILEFD
     KPEKLLSRKD SVFASFVRAD K
//
ID   ABCC8_RAT               Reviewed;        1582 AA.
AC   Q09429; O54989; P70532; Q9EQT0;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   02-MAR-2010, entry version 87.
DE   RecName: Full=ATP-binding cassette transporter sub-family C member 8;
DE   AltName: Full=Sulfonylurea receptor 1;
GN   Name=Abcc8; Synonyms=Sur, Sur1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM C).
RC   TISSUE=Pancreatic islet;
RX   MEDLINE=95232532; PubMed=7716547; DOI=10.1126/science.7716547;
RA   Aguilar-Bryan L., Nichols C.G., Wechsler S.W., Clement J.P. IV,
RA   Boyd A.E. III, Gonzalez G., Herrera-Sosa H., Nguy K., Bryan J.,
RA   Nelson D.A.;
RT   "Cloning of the beta cell high-affinity sulfonylurea receptor: a
RT   regulator of insulin secretion.";
RL   Science 268:423-426(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RC   TISSUE=Pancreatic islet;
RA   Faure C., Partiseti M., Gouhier C., Graham D.;
RL   Submitted (APR-1996) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B).
RC   TISSUE=Pancreatic islet;
RA   Blache P., Peyrollier K., Gros L., Bataille D.;
RT   "Identification of two forms of sulfonylurea receptors (SUR 1A and SUR
RT   1B) by means of polymerase chain reaction, subcloning, DNA sequencing
RT   and tissue distribution.";
RL   Submitted (DEC-1997) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RC   TISSUE=Vascular smooth muscle;
RA   Cao K., Wang R.;
RL   Submitted (DEC-2000) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   GLYCOSYLATION AT ASN-10.
RX   MEDLINE=97098100; PubMed=8942641; DOI=10.1021/bi960777y;
RA   Nelson D.A., Bryan J., Wechsler S., Clement J.P. IV, Aguilar-Bryan L.;
RT   "The high-affinity sulfonylurea receptor: distribution, glycosylation,
RT   purification, and immunoprecipitation of two forms from endocrine and
RT   neuroendocrine cell lines.";
RL   Biochemistry 35:14793-14799(1996).
CC   -!- FUNCTION: Putative subunit of the beta-cell ATP-sensitive
CC       potassium channel (KATP). Regulator of ATP-sensitive K(+) channels
CC       and insulin release.
CC   -!- SUBUNIT: Associates with KCNJ11 (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC         Comment=Experimental confirmation may be lacking for some
CC         isoforms;
CC       Name=A;
CC         IsoId=Q09429-1; Sequence=Displayed;
CC       Name=B;
CC         IsoId=Q09429-2; Sequence=VSP_000057;
CC       Name=C;
CC         IsoId=Q09429-3; Sequence=VSP_000056;
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCC
CC       family. Conjugate transporter (TC 3.A.1.208) subfamily.
CC   -!- SIMILARITY: Contains 2 ABC transmembrane type-1 domains.
CC   -!- SIMILARITY: Contains 2 ABC transporter domains.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L40624; AAA99237.1; -; mRNA.
DR   EMBL; X97279; CAA65934.1; -; mRNA.
DR   EMBL; AF039595; AAB96684.1; -; mRNA.
DR   EMBL; AB052294; BAB19011.1; -; mRNA.
DR   IPI; IPI00204427; -.
DR   IPI; IPI00476240; -.
DR   IPI; IPI00851131; -.
DR   RefSeq; NP_037171.2; -.
DR   UniGene; Rn.11187; -.
DR   SMR; Q09429; 285-921, 1078-1579.
DR   STRING; Q09429; -.
DR   Ensembl; ENSRNOT00000028696; ENSRNOP00000028696; ENSRNOG00000021130; Rattus norvegicus.
DR   GeneID; 25559; -.
DR   KEGG; rno:25559; -.
DR   CTD; 25559; -.
DR   RGD; 3786; Abcc8.
DR   eggNOG; maNOG08054; -.
DR   HOVERGEN; HBG101342; -.
DR   PhylomeDB; Q09429; -.
DR   NextBio; 607139; -.
DR   ArrayExpress; Q09429; -.
DR   Genevestigator; Q09429; -.
DR   GermOnline; ENSRNOG00000021130; Rattus norvegicus.
DR   GO; GO:0008282; C:ATP-sensitive potassium channel complex; IMP:RGD.
DR   GO; GO:0042383; C:sarcolemma; IDA:RGD.
DR   GO; GO:0030672; C:synaptic vesicle membrane; IMP:RGD.
DR   GO; GO:0005524; F:ATP binding; IMP:RGD.
DR   GO; GO:0042626; F:ATPase activity, coupled to transmembrane m...; IEA:InterPro.
DR   GO; GO:0005267; F:potassium channel activity; IMP:RGD.
DR   GO; GO:0008281; F:sulfonylurea receptor activity; TAS:RGD.
DR   GO; GO:0019905; F:syntaxin binding; IPI:RGD.
DR   GO; GO:0046676; P:negative regulation of insulin secretion; IDA:RGD.
DR   GO; GO:0043268; P:positive regulation of potassium ion transport; IDA:RGD.
DR   GO; GO:0006813; P:potassium ion transport; IEA:InterPro.
DR   GO; GO:0042493; P:response to drug; IEP:RGD.
DR   GO; GO:0032868; P:response to insulin stimulus; IEP:RGD.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEP:RGD.
DR   GO; GO:0009268; P:response to pH; IDA:RGD.
DR   GO; GO:0010043; P:response to zinc ion; IDA:RGD.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR017940; ABC_transporter_type1.
DR   InterPro; IPR001140; ABC_transptr_TM_dom.
DR   InterPro; IPR011527; ABC_transptrTM_dom_typ1.
DR   InterPro; IPR003593; ATPase_AAA+_core.
DR   InterPro; IPR000388; Sulphorea_rcpt_N.
DR   InterPro; IPR000844; Surea_rcpt_1_N.
DR   Pfam; PF00664; ABC_membrane; 2.
DR   Pfam; PF00005; ABC_tran; 2.
DR   PRINTS; PR01093; SULFNYLUR1.
DR   PRINTS; PR01092; SULFNYLUREAR.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF90123; ABC_TM_1; 2.
DR   PROSITE; PS50929; ABC_TM1F; 2.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 2.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Glycoprotein; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Receptor; Repeat; Transmembrane;
KW   Transport.
FT   INIT_MET      1      1       Removed (By similarity).
FT   CHAIN         2   1582       ATP-binding cassette transporter sub-
FT                                family C member 8.
FT                                /FTId=PRO_0000093401.
FT   TOPO_DOM      2     34       Extracellular (By similarity).
FT   TRANSMEM     35     55       1 (By similarity).
FT   TOPO_DOM     56     75       Cytoplasmic (By similarity).
FT   TRANSMEM     76     96       2 (By similarity).
FT   TOPO_DOM     97    101       Extracellular (By similarity).
FT   TRANSMEM    102    122       3 (By similarity).
FT   TOPO_DOM    123    134       Cytoplasmic (By similarity).
FT   TRANSMEM    135    154       4 (By similarity).
FT   TOPO_DOM    155    168       Extracellular (By similarity).
FT   TRANSMEM    169    194       5 (By similarity).
FT   TOPO_DOM    195    311       Cytoplasmic (By similarity).
FT   TRANSMEM    312    331       6 (By similarity).
FT   TOPO_DOM    332    355       Extracellular (By similarity).
FT   TRANSMEM    356    376       7 (By similarity).
FT   TOPO_DOM    377    434       Cytoplasmic (By similarity).
FT   TRANSMEM    435    455       8 (By similarity).
FT   TOPO_DOM    456    458       Extracellular (By similarity).
FT   TRANSMEM    459    479       9 (By similarity).
FT   TOPO_DOM    480    541       Cytoplasmic (By similarity).
FT   TRANSMEM    542    562       10 (By similarity).
FT   TOPO_DOM    563    584       Extracellular (By similarity).
FT   TRANSMEM    585    605       11 (By similarity).
FT   TOPO_DOM    606   1005       Cytoplasmic (By similarity).
FT   TRANSMEM   1006   1026       12 (By similarity).
FT   TOPO_DOM   1027   1073       Extracellular (By similarity).
FT   TRANSMEM   1074   1094       13 (By similarity).
FT   TOPO_DOM   1095   1138       Cytoplasmic (By similarity).
FT   TRANSMEM   1139   1159       14 (By similarity).
FT   TOPO_DOM   1160   1160       Extracellular (By similarity).
FT   TRANSMEM   1161   1181       15 (By similarity).
FT   TOPO_DOM   1182   1252       Cytoplasmic (By similarity).
FT   TRANSMEM   1253   1273       16 (By similarity).
FT   TOPO_DOM   1274   1277       Extracellular (By similarity).
FT   TRANSMEM   1278   1298       17 (By similarity).
FT   TOPO_DOM   1299   1582       Cytoplasmic (By similarity).
FT   DOMAIN      299    602       ABC transmembrane type-1 1.
FT   DOMAIN      679    930       ABC transporter 1.
FT   DOMAIN     1013   1307       ABC transmembrane type-1 2.
FT   DOMAIN     1345   1579       ABC transporter 2.
FT   NP_BIND     713    720       ATP 1 (Potential).
FT   NP_BIND    1379   1386       ATP 2 (Potential).
FT   CARBOHYD     10     10       N-linked (GlcNAc...).
FT   CARBOHYD   1050   1050       N-linked (GlcNAc...) (By similarity).
FT   VAR_SEQ     741    741       Missing (in isoform C).
FT                                /FTId=VSP_000056.
FT   VAR_SEQ    1252   1289       Missing (in isoform B).
FT                                /FTId=VSP_000057.
FT   CONFLICT    487    487       S -> T (in Ref. 1; AAA99237).
FT   CONFLICT    699    699       I -> T (in Ref. 4; BAB19011).
FT   CONFLICT    836    837       QR -> PG (in Ref. 1; AAA99237).
FT   CONFLICT   1314   1314       R -> G (in Ref. 1; AAA99237).
SQ   SEQUENCE   1582 AA;  177185 MW;  7C57A1CFC86B9214 CRC64;
     MPLAFCGTEN HSAAYRVDQG VLNNGCFVDA LNVVPHVFLL FITFPILFIG WGSQSSKVHI
     HHSTWLHFPG HNLRWILTFI LLFVLVCEIA EGILSDGVTE SRHLHLYMPA GMAFMAAITS
     VVYYHNIETS NFPKLLIALL IYWTLAFITK TIKFVKFYDH AIGFSQLRFC LTGLLVILYG
     MLLLVEVNVI RVRRYVFFKT PREVKPPEDL QDLGVRFLQP FVNLLSKGTY WWMNAFIKTA
     HKKPIDLRAI GKLPIAMRAL TNYQRLCLAF DAQARKDTQS QQGARAIWRA LCHAFGRRLV
     LSSTFRILAD LLGFAGPLCI FGIVDHLGKE NHVFQPKTQF LGVYFVSSQE FLGNAYVLAV
     LLFLALLLQR TFLQASYYVA IETGINLRGA IQTKIYNKIM HLSTSNLSMG EMTAGQICNL
     VAIDTNQLMW FFFLCPNLWA MPVQIIVGVI LLYYILGVSA LIGAAVIILL APVQYFVATK
     LSQAQRSTLE YSNERLKQTN EMLRGIKLLK LYAWENIFCS RVEKTRRKEM TSLRAFAVYT
     SISIFMNTAI PIAAVLITFV GHVSFFKESD FSPSVAFASL SLFHILVTPL FLLSSVVRST
     VKALVSVQKL SEFLSSAEIR EEQCAPREPA PQGQAGKYQA VPLKVVNRKR PAREEVRDLL
     GPLQRLTPST DGDADNFCVQ IIGGFFTWTP DGIPTLSNIT IRIPRGQLTM IVGQVGCGKS
     SLLLATLGEM QKVSGAVFWN SSLPDSEGED PSNPERETAA DSDARSRGPV AYASQKPWLL
     NATVEENITF ESPFNKQRYK MVIEACSLQP DIDILPHGDQ TQIGERGINL SGGQRQRISV
     ARALYQHTNV VFLDDPFSAL DVHLSDHLMQ AGILELLRDD KRTVVLVTHK LQYLPHADWI
     IAMKDGTIQR EGTLKDFQRS ECQLFEHWKT LMNRQDQELE KETVMERKAP EPSQGLPRAM
     SSRDGLLLDE DEEEEEAAES EEDDNLSSVL HQRAKIPWRA CTKYLSSAGI LLLSLLVFSQ
     LLKHMVLVAI DYWLAKWTDS ALVLSPAARN CSLSQECALD QSVYAMVFTV LCSLGIALCL
     VTSVTVEWTG LKVAKRLHRS LLNRIILAPM RFFETTPLGS ILNRFSSDCN TIDQHIPSTL
     ECLSRSTLLC VSALAVISYV TPVFLVALLP LAVVCYFIQK YFRVASRDLQ QLDDTTQLPL
     LSHFAETVEG LTTIRAFRYE ARFQQKLLEY TDSNNIASLF LTAANRWLEV RMEYIGACVV
     LIAAATSISN SLHRELSAGL VGLGLTYALM VSNYLNWMVR NLADMEIQLG AVKRIHTLLK
     TEAESYEGLL APSLIPKNWP DQGKIQIQNL SVRYDSSLKP VLKHVNALIS PGQKIGICGR
     TGSGKSSFSL AFFRMVDMFE GRIIIDGIDI AKLPLHTLRS RLSIILQDPV LFSGTIRFNL
     DPEKKCSDST LWEALEIAQL KLVVKALPGG LDAIITEGGE NFSQGQRQLF CLARAFVRKT
     SIFIMDEATA SIDMATENIL QKVVMTAFAD RTVVTIAHRV HTILSADLVM VLKRGAILEF
     DKPEKLLSQK DSVFASFVRA DK
//
ID   ACM1_HUMAN              Reviewed;         460 AA.
AC   P11229;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1990, sequence version 2.
DT   02-MAR-2010, entry version 116.
DE   RecName: Full=Muscarinic acetylcholine receptor M1;
GN   Name=CHRM1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=88096607; PubMed=3697105; DOI=10.1093/nar/15.24.10604;
RA   Allard W.J., Sigal I.S., Dixon R.A.F.;
RT   "Sequence of the gene encoding the human M1 muscarinic acetylcholine
RT   receptor.";
RL   Nucleic Acids Res. 15:10604-10604(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=90245684; PubMed=2336407; DOI=10.1093/nar/18.8.2191;
RA   Chapman C.G., Browne M.J.;
RT   "Isolation of the human ml (Hml) muscarinic acetylcholine receptor
RT   gene by PCR amplification.";
RL   Nucleic Acids Res. 18:2191-2191(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=88166632; PubMed=3443095;
RA   Peralta E.G., Ashkenazi A., Winslow J.W., Smith D.H., Ramachandran J.,
RA   Capon D.J.;
RT   "Distinct primary structures, ligand-binding properties and tissue-
RT   specific expression of four human muscarinic acetylcholine
RT   receptors.";
RL   EMBO J. 6:3923-3929(1987).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction
RT   sequenced by the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   MUTAGENESIS.
RX   MEDLINE=93075202; PubMed=1445347; DOI=10.1016/0006-291X(92)91346-R;
RA   Arden J.R., Nagata O., Shockley M.S., Philip M., Lameh J., Sadee W.;
RT   "Mutational analysis of third cytoplasmic loop domains in G-protein
RT   coupling of the HM1 muscarinic receptor.";
RL   Biochem. Biophys. Res. Commun. 188:1111-1115(1992).
RN   [7]
RP   INTERACTION WITH GPRASP2.
RX   PubMed=15086532; DOI=10.1111/j.1471-4159.2004.02411.x;
RA   Simonin F., Karcher P., Boeuf J.J.-M., Matifas A., Kieffer B.L.;
RT   "Identification of a novel family of G protein-coupled receptor
RT   associated sorting proteins.";
RL   J. Neurochem. 89:766-775(2004).
CC   -!- FUNCTION: The muscarinic acetylcholine receptor mediates various
CC       cellular responses, including inhibition of adenylate cyclase,
CC       breakdown of phosphoinositides and modulation of potassium
CC       channels through the action of G proteins. Primary transducing
CC       effect is Pi turnover.
CC   -!- SUBUNIT: Interacts with GPRASP2.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC       Cell junction, synapse, postsynaptic cell membrane; Multi-pass
CC       membrane protein.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y00508; CAA68560.1; -; Genomic_DNA.
DR   EMBL; X52068; CAA36291.1; -; Genomic_DNA.
DR   EMBL; X15263; CAA33334.1; -; Genomic_DNA.
DR   EMBL; AF498915; AAM18938.1; -; mRNA.
DR   EMBL; BC007740; AAH07740.1; -; mRNA.
DR   EMBL; BC022984; AAH22984.1; -; mRNA.
DR   IPI; IPI00298980; -.
DR   PIR; S09508; S09508.
DR   RefSeq; NP_000729.2; -.
DR   UniGene; Hs.632119; -.
DR   SMR; P11229; 10-437.
DR   STRING; P11229; -.
DR   PRIDE; P11229; -.
DR   Ensembl; ENST00000306960; ENSP00000306490; ENSG00000168539; Homo sapiens.
DR   GeneID; 1128; -.
DR   KEGG; hsa:1128; -.
DR   UCSC; uc001nwi.1; human.
DR   CTD; 1128; -.
DR   GeneCards; GC11M062432; -.
DR   H-InvDB; HIX0009731; -.
DR   HGNC; HGNC:1950; CHRM1.
DR   HPA; HPA014101; -.
DR   MIM; 118510; gene.
DR   PharmGKB; PA26484; -.
DR   eggNOG; prNOG11440; -.
DR   HOGENOM; HBG713567; -.
DR   HOVERGEN; HBG105720; -.
DR   InParanoid; P11229; -.
DR   OMA; RPTRKGR; -.
DR   OrthoDB; EOG93NB01; -.
DR   PhylomeDB; P11229; -.
DR   Reactome; REACT_14797; Signaling by GPCR.
DR   DrugBank; DB00517; Anisotropine Methylbromide.
DR   DrugBank; DB00572; Atropine.
DR   DrugBank; DB00767; Benzquinamide.
DR   DrugBank; DB00245; Benztropine.
DR   DrugBank; DB01019; Bethanechol.
DR   DrugBank; DB00810; Biperiden.
DR   DrugBank; DB00354; Buclizine.
DR   DrugBank; DB00411; Carbachol.
DR   DrugBank; DB00748; Carbinoxamine.
DR   DrugBank; DB00185; Cevimeline.
DR   DrugBank; DB00771; Clidinium.
DR   DrugBank; DB00785; Cryptenamine.
DR   DrugBank; DB01176; Cyclizine.
DR   DrugBank; DB00979; Cyclopentolate.
DR   DrugBank; DB00942; Cycrimine.
DR   DrugBank; DB01151; Desipramine.
DR   DrugBank; DB00804; Dicyclomine.
DR   DrugBank; DB01231; Diphenidol.
DR   DrugBank; DB00366; Doxylamine.
DR   DrugBank; DB00392; Ethopropazine.
DR   DrugBank; DB01148; Flavoxate.
DR   DrugBank; DB00986; Glycopyrrolate.
DR   DrugBank; DB00725; Homatropine Methylbromide.
DR   DrugBank; DB00424; Hyoscyamine.
DR   DrugBank; DB00332; Ipratropium.
DR   DrugBank; DB00940; Methantheline.
DR   DrugBank; DB01403; Methotrimeprazine.
DR   DrugBank; DB00462; Methylscopolamine.
DR   DrugBank; DB00340; Metixene.
DR   DrugBank; DB01233; Metoclopramide.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB01062; Oxybutynin.
DR   DrugBank; DB00383; Oxyphencyclimine.
DR   DrugBank; DB00219; Oxyphenonium.
DR   DrugBank; DB01085; Pilocarpine.
DR   DrugBank; DB00670; Pirenzepine.
DR   DrugBank; DB00387; Procyclidine.
DR   DrugBank; DB00420; Promazine.
DR   DrugBank; DB01069; Promethazine.
DR   DrugBank; DB00782; Propantheline.
DR   DrugBank; DB00777; Propiomazine.
DR   DrugBank; DB01103; Quinacrine.
DR   DrugBank; DB00747; Scopolamine.
DR   DrugBank; DB01591; Solifenacin.
DR   DrugBank; DB00202; Succinylcholine.
DR   DrugBank; DB00372; Thiethylperazine.
DR   DrugBank; DB01036; Tolterodine.
DR   DrugBank; DB00505; Tridihexethyl.
DR   DrugBank; DB00508; Triflupromazine.
DR   DrugBank; DB00376; Trihexyphenidyl.
DR   DrugBank; DB00209; Trospium.
DR   NextBio; 4676; -.
DR   ArrayExpress; P11229; -.
DR   Bgee; P11229; -.
DR   CleanEx; HS_CHRM1; -.
DR   Genevestigator; P11229; -.
DR   GermOnline; ENSG00000168539; Homo sapiens.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0005624; C:membrane fraction; TAS:ProtInc.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004981; F:muscarinic acetylcholine receptor activity; TAS:ProtInc.
DR   GO; GO:0004435; F:phosphoinositide phospholipase C activity; TAS:ProtInc.
DR   GO; GO:0007207; P:activation of phospholipase C activity by m...; TAS:ProtInc.
DR   GO; GO:0007205; P:activation of protein kinase C activity by ...; TAS:ProtInc.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0007399; P:nervous system development; TAS:ProtInc.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; TAS:ProtInc.
DR   GO; GO:0006464; P:protein modification process; TAS:ProtInc.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   InterPro; IPR002228; Musac_M1_rcpt.
DR   InterPro; IPR000995; Musac_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00243; MUSCARINICR.
DR   PRINTS; PR00538; MUSCRINICM1R.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell junction; Cell membrane; Complete proteome; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Phosphoprotein;
KW   Postsynaptic cell membrane; Receptor; Synapse; Transducer;
KW   Transmembrane.
FT   CHAIN         1    460       Muscarinic acetylcholine receptor M1.
FT                                /FTId=PRO_0000069015.
FT   TOPO_DOM      1     24       Extracellular (Potential).
FT   TRANSMEM     25     47       1 (By similarity).
FT   TOPO_DOM     48     61       Cytoplasmic (Potential).
FT   TRANSMEM     62     82       2 (By similarity).
FT   TOPO_DOM     83     99       Extracellular (Potential).
FT   TRANSMEM    100    121       3 (By similarity).
FT   TOPO_DOM    122    141       Cytoplasmic (Potential).
FT   TRANSMEM    142    164       4 (By similarity).
FT   TOPO_DOM    165    186       Extracellular (Potential).
FT   TRANSMEM    187    209       5 (By similarity).
FT   TOPO_DOM    210    366       Cytoplasmic (Potential).
FT   TRANSMEM    367    387       6 (By similarity).
FT   TOPO_DOM    388    401       Extracellular (Potential).
FT   TRANSMEM    402    421       7 (By similarity).
FT   TOPO_DOM    422    460       Cytoplasmic (Potential).
FT   MOD_RES     428    428       Phosphothreonine (Potential).
FT   MOD_RES     451    451       Phosphoserine (Potential).
FT   MOD_RES     455    455       Phosphothreonine (Potential).
FT   MOD_RES     457    457       Phosphoserine (Potential).
FT   CARBOHYD      2      2       N-linked (GlcNAc...) (Probable).
FT   CARBOHYD     12     12       N-linked (GlcNAc...) (Probable).
FT   DISULFID     98    178       By similarity.
FT   CONFLICT    173    173       V -> M (in Ref. 3; CAA33334).
SQ   SEQUENCE   460 AA;  51421 MW;  567C20F63541C8D0 CRC64;
     MNTSAPPAVS PNITVLAPGK GPWQVAFIGI TTGLLSLATV TGNLLVLISF KVNTELKTVN
     NYFLLSLACA DLIIGTFSMN LYTTYLLMGH WALGTLACDL WLALDYVASN ASVMNLLLIS
     FDRYFSVTRP LSYRAKRTPR RAALMIGLAW LVSFVLWAPA ILFWQYLVGE RTVLAGQCYI
     QFLSQPIITF GTAMAAFYLP VTVMCTLYWR IYRETENRAR ELAALQGSET PGKGGGSSSS
     SERSQPGAEG SPETPPGRCC RCCRAPRLLQ AYSWKEEEEE DEGSMESLTS SEGEEPGSEV
     VIKMPMVDPE AQAPTKQPPR SSPNTVKRPT KKGRDRAGKG QKPRGKEQLA KRKTFSLVKE
     KKAARTLSAI LLAFILTWTP YNIMVLVSTF CKDCVPETLW ELGYWLCYVN STINPMCYAL
     CNKAFRDTFR LLLLCRWDKR RWRKIPKRPG SVHRTPSRQC
//
ID   ACM1_RAT                Reviewed;         460 AA.
AC   P08482;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1988, sequence version 1.
DT   02-MAR-2010, entry version 88.
DE   RecName: Full=Muscarinic acetylcholine receptor M1;
GN   Name=Chrm1; Synonyms=Chrm-1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=87263421; PubMed=3037705; DOI=10.1126/science.3037705;
RA   Bonner T.I., Buckley N.J., Young A.C., Brann M.R.;
RT   "Identification of a family of muscarinic acetylcholine receptor
RT   genes.";
RL   Science 237:527-532(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=92101806; PubMed=1759615;
RA   Lai J., Smith T.L., Mei L., Ikeda M., Fujiwara Y., Gomez J.,
RA   Halonen M., Roeske W.R., Yamamura H.I.;
RT   "The molecular properties of the M1 muscarinic receptor and its
RT   regulation of cytosolic calcium in a eukaryotic gene expression
RT   system.";
RL   Adv. Exp. Med. Biol. 287:313-330(1991).
RN   [3]
RP   PROTEIN SEQUENCE OF 63-124.
RX   MEDLINE=90337982; PubMed=2380182;
RA   Kurtenbach E., Curtis C.A.M., Pedder E.K., Aitken A., Harris A.C.M.,
RA   Hulme E.C.;
RT   "Muscarinic acetylcholine receptors. Peptide sequencing identifies
RT   residues involved in antagonist binding and disulfide bond
RT   formation.";
RL   J. Biol. Chem. 265:13702-13708(1990).
RN   [4]
RP   MUTAGENESIS OF CYSTEINE RESIDUES.
RX   MEDLINE=92283857; PubMed=1317867;
RA   Savarese T.M., Wang C.-D., Fraser C.M.;
RT   "Site-directed mutagenesis of the rat m1 muscarinic acetylcholine
RT   receptor. Role of conserved cysteines in receptor function.";
RL   J. Biol. Chem. 267:11439-11448(1992).
CC   -!- FUNCTION: The muscarinic acetylcholine receptor mediates various
CC       cellular responses, including inhibition of adenylate cyclase,
CC       breakdown of phosphoinositides and modulation of potassium
CC       channels through the action of G proteins. Primary transducing
CC       effect is Pi turnover.
CC   -!- SUBUNIT: Interacts with GPRASP2 (By similarity).
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC       Cell junction, synapse, postsynaptic cell membrane; Multi-pass
CC       membrane protein.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M16406; AAA40660.1; -; Genomic_DNA.
DR   EMBL; S73971; AAB20705.1; -; Genomic_DNA.
DR   IPI; IPI00211363; -.
DR   PIR; A94518; A29514.
DR   RefSeq; NP_542951.1; -.
DR   UniGene; Rn.119395; -.
DR   SMR; P08482; 10-437.
DR   STRING; P08482; -.
DR   Ensembl; ENSRNOT00000024785; ENSRNOP00000024785; ENSRNOG00000018385; Rattus norvegicus.
DR   GeneID; 25229; -.
DR   KEGG; rno:25229; -.
DR   CTD; 25229; -.
DR   RGD; 2342; Chrm1.
DR   eggNOG; roNOG04436; -.
DR   HOVERGEN; HBG105720; -.
DR   InParanoid; P08482; -.
DR   OMA; RPTRKGR; -.
DR   OrthoDB; EOG93NB01; -.
DR   PhylomeDB; P08482; -.
DR   NextBio; 605783; -.
DR   ArrayExpress; P08482; -.
DR   Genevestigator; P08482; -.
DR   GermOnline; ENSRNOG00000018385; Rattus norvegicus.
DR   GO; GO:0032279; C:asymmetric synapse; IDA:RGD.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0043679; C:axon terminus; IDA:RGD.
DR   GO; GO:0014069; C:postsynaptic density; IDA:RGD.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0008144; F:drug binding; IDA:RGD.
DR   GO; GO:0004981; F:muscarinic acetylcholine receptor activity; IDA:RGD.
DR   GO; GO:0007213; P:muscarinic acetylcholine receptor signaling...; IDA:RGD.
DR   GO; GO:0007274; P:neuromuscular synaptic transmission; IDA:RGD.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   InterPro; IPR002228; Musac_M1_rcpt.
DR   InterPro; IPR000995; Musac_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00243; MUSCARINICR.
DR   PRINTS; PR00538; MUSCRINICM1R.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell junction; Cell membrane; Direct protein sequencing;
KW   Disulfide bond; G-protein coupled receptor; Glycoprotein; Membrane;
KW   Phosphoprotein; Postsynaptic cell membrane; Receptor; Synapse;
KW   Transducer; Transmembrane.
FT   CHAIN         1    460       Muscarinic acetylcholine receptor M1.
FT                                /FTId=PRO_0000069019.
FT   TOPO_DOM      1     24       Extracellular (Potential).
FT   TRANSMEM     25     47       1 (By similarity).
FT   TOPO_DOM     48     61       Cytoplasmic (Potential).
FT   TRANSMEM     62     82       2 (By similarity).
FT   TOPO_DOM     83     99       Extracellular (Potential).
FT   TRANSMEM    100    121       3 (By similarity).
FT   TOPO_DOM    122    141       Cytoplasmic (Potential).
FT   TRANSMEM    142    164       4 (By similarity).
FT   TOPO_DOM    165    186       Extracellular (Potential).
FT   TRANSMEM    187    209       5 (By similarity).
FT   TOPO_DOM    210    366       Cytoplasmic (Potential).
FT   TRANSMEM    367    387       6 (By similarity).
FT   TOPO_DOM    388    401       Extracellular (Potential).
FT   TRANSMEM    402    421       7 (By similarity).
FT   TOPO_DOM    422    460       Cytoplasmic (Potential).
FT   BINDING     105    105       Antagonist.
FT   MOD_RES     428    428       Phosphothreonine (Potential).
FT   MOD_RES     451    451       Phosphoserine (Potential).
FT   MOD_RES     455    455       Phosphothreonine (Potential).
FT   MOD_RES     457    457       Phosphoserine (Potential).
FT   CARBOHYD      2      2       N-linked (GlcNAc...) (Probable).
FT   CARBOHYD     12     12       N-linked (GlcNAc...) (Probable).
FT   DISULFID     98    178       Probable.
SQ   SEQUENCE   460 AA;  51369 MW;  527573ED8FF7C317 CRC64;
     MNTSVPPAVS PNITVLAPGK GPWQVAFIGI TTGLLSLATV TGNLLVLISF KVNTELKTVN
     NYFLLSLACA DLIIGTFSMN LYTTYLLMGH WALGTLACDL WLALDYVASN ASVMNLLLIS
     FDRYFSVTRP LSYRAKRTPR RAALMIGLAW LVSFVLWAPA ILFWQYLVGE RTVLAGQCYI
     QFLSQPIITF GTAMAAFYLP VTVMCTLYWR IYRETENRAR ELAALQGSET PGKGGGSSSS
     SERSQPGAEG SPESPPGRCC RCCRAPRLLQ AYSWKEEEEE DEGSMESLTS SEGEEPGSEV
     VIKMPMVDSE AQAPTKQPPK SSPNTVKRPT KKGRDRGGKG QKPRGKEQLA KRKTFSLVKE
     KKAARTLSAI LLAFILTWTP YNIMVLVSTF CKDCVPETLW ELGYWLCYVN STVNPMCYAL
     CNKAFRDTFR LLLLCRWDKR RWRKIPKRPG SVHRTPSRQC
//
ID   ACM2_HUMAN              Reviewed;         466 AA.
AC   P08172; Q4VBK6; Q9P1X9;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1988, sequence version 1.
DT   02-MAR-2010, entry version 111.
DE   RecName: Full=Muscarinic acetylcholine receptor M2;
GN   Name=CHRM2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=87263421; PubMed=3037705; DOI=10.1126/science.3037705;
RA   Bonner T.I., Buckley N.J., Young A.C., Brann M.R.;
RT   "Identification of a family of muscarinic acetylcholine receptor
RT   genes.";
RL   Science 237:527-532(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=88166632; PubMed=3443095;
RA   Peralta E.G., Ashkenazi A., Winslow J.W., Smith D.H., Ramachandran J.,
RA   Capon D.J.;
RT   "Distinct primary structures, ligand-binding properties and tissue-
RT   specific expression of four human muscarinic acetylcholine
RT   receptors.";
RL   EMBO J. 6:3923-3929(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction
RT   sequenced by the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 27-466.
RX   PubMed=15014171; DOI=10.1093/molbev/msh100;
RA   Kitano T., Liu Y.-H., Ueda S., Saitou N.;
RT   "Human-specific amino acid changes found in 103 protein-coding
RT   genes.";
RL   Mol. Biol. Evol. 21:936-944(2004).
RN   [6]
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=7822302; DOI=10.1074/jbc.270.2.720;
RA   Gurevich V.V., Dion S.B., Onorato J.J., Ptasienski J., Kim C.M.,
RA   Sterne-Marr R., Hosey M.M., Benovic J.L.;
RT   "Arrestin interactions with G protein-coupled receptors. Direct
RT   binding studies of wild type and mutant arrestins with rhodopsin, beta
RT   2-adrenergic, and m2 muscarinic cholinergic receptors.";
RL   J. Biol. Chem. 270:720-731(1995).
RN   [7]
RP   INDUCTION, AND MASS SPECTROMETRY.
RX   PubMed=16548883; DOI=10.1111/j.1462-5822.2005.00644.x;
RA   Leong W.F., Chow V.T.;
RT   "Transcriptomic and proteomic analyses of rhabdomyosarcoma cells
RT   reveal differential cellular gene expression in response to
RT   enterovirus 71 infection.";
RL   Cell. Microbiol. 8:565-580(2006).
RN   [8]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO ALCOHOLISM AND MAJOR DEPRESSIVE
RP   DISORDER.
RX   PubMed=15229186; DOI=10.1093/hmg/ddh194;
RA   Wang J.C., Hinrichs A.L., Stock H., Budde J., Allen R., Bertelsen S.,
RA   Kwon J.M., Wu W., Dick D.M., Rice J., Jones K., Nurnberger J.I. Jr.,
RA   Tischfield J., Porjesz B., Edenberg H.J., Hesselbrock V., Crowe R.,
RA   Schuckit M., Begleiter H., Reich T., Goate A.M., Bierut L.J.;
RT   "Evidence of common and specific genetic effects: association of the
RT   muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol
RT   dependence and major depressive syndrome.";
RL   Hum. Mol. Genet. 13:1903-1911(2004).
CC   -!- FUNCTION: The muscarinic acetylcholine receptor mediates various
CC       cellular responses, including inhibition of adenylate cyclase,
CC       breakdown of phosphoinositides and modulation of potassium
CC       channels through the action of G proteins. Primary transducing
CC       effect is adenylate cyclase inhibition.
CC   -!- SUBUNIT: Interacts with ARRB1 and ARRB2.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC       Cell junction, synapse, postsynaptic cell membrane; Multi-pass
CC       membrane protein.
CC   -!- INDUCTION: Up-regulated in response to enterovirus 71 (EV71)
CC       infection.
CC   -!- POLYMORPHISM: Genetic variations in CHRM2 can influence
CC       susceptibility to alcoholism [MIM:103780].
CC   -!- DISEASE: Genetic variations in CHRM2 can influence susceptibility
CC       to major depressive disorder (MDD) [MIM:608516]. MDD is one of the
CC       most common psychiatric disorders. MDD is a complex trait
CC       characterized by one or more major depressive episodes without a
CC       history of manic, mixed, or hypomanic episodes. A major depressive
CC       episode is characterized by at least 2 weeks during which there is
CC       a new onset or clear worsening of either depressed mood or loss of
CC       interest or pleasure in nearly all activities. Four additional
CC       symptoms must also be present including changes in appetite,
CC       weight, sleep, and psychomotor activity; decreased energy;
CC       feelings of worthlessness or guilt; difficulty thinking,
CC       concentrating, or making decisions; or recurrent thoughts of death
CC       or suicidal ideation, plans, or attempts. The episode must be
CC       accompanied by distress or impairment in social, occupational, or
CC       other important areas of functioning.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M16404; AAA51570.1; -; Genomic_DNA.
DR   EMBL; X15264; CAA33335.1; -; Genomic_DNA.
DR   EMBL; AF498916; AAM18939.1; -; mRNA.
DR   EMBL; BC095547; AAH95547.1; -; mRNA.
DR   EMBL; BC106741; AAI06742.1; -; mRNA.
DR   EMBL; BC106742; AAI06743.1; -; mRNA.
DR   EMBL; AB041391; BAA94476.1; -; Genomic_DNA.
DR   IPI; IPI00027473; -.
DR   PIR; S10126; S10126.
DR   RefSeq; NP_000730.1; -.
DR   RefSeq; NP_001006627.1; -.
DR   RefSeq; NP_001006628.1; -.
DR   RefSeq; NP_001006629.1; -.
DR   RefSeq; NP_001006630.1; -.
DR   RefSeq; NP_001006631.1; -.
DR   RefSeq; NP_001006632.1; -.
DR   RefSeq; NP_001006633.1; -.
DR   UniGene; Hs.535891; -.
DR   PDB; 1LUB; Model; -; A=1-50.
DR   PDBsum; 1LUB; -.
DR   STRING; P08172; -.
DR   PhosphoSite; P08172; -.
DR   PRIDE; P08172; -.
DR   Ensembl; ENST00000320658; ENSP00000319984; ENSG00000181072; Homo sapiens.
DR   Ensembl; ENST00000397608; ENSP00000380733; ENSG00000181072; Homo sapiens.
DR   Ensembl; ENST00000401861; ENSP00000384401; ENSG00000181072; Homo sapiens.
DR   Ensembl; ENST00000402486; ENSP00000384937; ENSG00000181072; Homo sapiens.
DR   Ensembl; ENST00000402594; ENSP00000385652; ENSG00000181072; Homo sapiens.
DR   Ensembl; ENST00000406605; ENSP00000384346; ENSG00000181072; Homo sapiens.
DR   Ensembl; ENST00000435017; ENSP00000406474; ENSG00000181072; Homo sapiens.
DR   Ensembl; ENST00000445907; ENSP00000399745; ENSG00000181072; Homo sapiens.
DR   Ensembl; ENST00000453373; ENSP00000415386; ENSG00000181072; Homo sapiens.
DR   GeneID; 1129; -.
DR   KEGG; hsa:1129; -.
DR   UCSC; uc003vtf.1; human.
DR   CTD; 1129; -.
DR   GeneCards; GC07P136115; -.
DR   H-InvDB; HIX0007117; -.
DR   HGNC; HGNC:1951; CHRM2.
DR   MIM; 103780; phenotype.
DR   MIM; 118493; gene.
DR   MIM; 608516; phenotype.
DR   PharmGKB; PA111; -.
DR   HOGENOM; HBG713567; -.
DR   HOVERGEN; HBG105720; -.
DR   InParanoid; P08172; -.
DR   OMA; NNNMPGS; -.
DR   OrthoDB; EOG92RGSR; -.
DR   PhylomeDB; P08172; -.
DR   Pathway_Interaction_DB; arf6_traffickingpathway; Arf6 trafficking events.
DR   Reactome; REACT_14797; Signaling by GPCR.
DR   DrugBank; DB00517; Anisotropine Methylbromide.
DR   DrugBank; DB00572; Atropine.
DR   DrugBank; DB00767; Benzquinamide.
DR   DrugBank; DB00411; Carbachol.
DR   DrugBank; DB00785; Cryptenamine.
DR   DrugBank; DB01176; Cyclizine.
DR   DrugBank; DB01151; Desipramine.
DR   DrugBank; DB01231; Diphenidol.
DR   DrugBank; DB01334; Doxacurium.
DR   DrugBank; DB01135; Doxacurium chloride.
DR   DrugBank; DB01148; Flavoxate.
DR   DrugBank; DB00483; Gallamine Triethiodide.
DR   DrugBank; DB00725; Homatropine Methylbromide.
DR   DrugBank; DB00424; Hyoscyamine.
DR   DrugBank; DB00332; Ipratropium.
DR   DrugBank; DB01403; Methotrimeprazine.
DR   DrugBank; DB00340; Metixene.
DR   DrugBank; DB01336; Metocurine.
DR   DrugBank; DB01226; Mivacurium.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB01062; Oxybutynin.
DR   DrugBank; DB00383; Oxyphencyclimine.
DR   DrugBank; DB01085; Pilocarpine.
DR   DrugBank; DB00387; Procyclidine.
DR   DrugBank; DB00420; Promazine.
DR   DrugBank; DB01069; Promethazine.
DR   DrugBank; DB00777; Propiomazine.
DR   DrugBank; DB00728; Rocuronium.
DR   DrugBank; DB00372; Thiethylperazine.
DR   DrugBank; DB01036; Tolterodine.
DR   DrugBank; DB00505; Tridihexethyl.
DR   DrugBank; DB00508; Triflupromazine.
DR   NextBio; 4680; -.
DR   ArrayExpress; P08172; -.
DR   Bgee; P08172; -.
DR   CleanEx; HS_CHRM2; -.
DR   Genevestigator; P08172; -.
DR   GermOnline; ENSG00000181072; Homo sapiens.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004981; F:muscarinic acetylcholine receptor activity; TAS:ProtInc.
DR   GO; GO:0007207; P:activation of phospholipase C activity by m...; TAS:ProtInc.
DR   GO; GO:0007188; P:G-protein signaling, coupled to cAMP nucleo...; TAS:ProtInc.
DR   GO; GO:0007399; P:nervous system development; TAS:ProtInc.
DR   GO; GO:0008016; P:regulation of heart contraction; TAS:ProtInc.
DR   GO; GO:0009615; P:response to virus; IEP:UniProtKB.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   InterPro; IPR001065; Musac_M2_rcpt.
DR   InterPro; IPR000995; Musac_rcpt.
DR   PANTHER; PTHR19266:SF32; Musac_M2_rcpt; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00243; MUSCARINICR.
DR   PRINTS; PR00539; MUSCRINICM2R.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell junction; Cell membrane; Complete proteome;
KW   Disulfide bond; G-protein coupled receptor; Glycoprotein; Membrane;
KW   Phosphoprotein; Postsynaptic cell membrane; Receptor; Synapse;
KW   Transducer; Transmembrane.
FT   CHAIN         1    466       Muscarinic acetylcholine receptor M2.
FT                                /FTId=PRO_0000069021.
FT   TOPO_DOM      1     22       Extracellular (By similarity).
FT   TRANSMEM     23     45       1 (By similarity).
FT   TOPO_DOM     46     59       Cytoplasmic (By similarity).
FT   TRANSMEM     60     80       2 (By similarity).
FT   TOPO_DOM     81     97       Extracellular (By similarity).
FT   TRANSMEM     98    119       3 (By similarity).
FT   TOPO_DOM    120    139       Cytoplasmic (By similarity).
FT   TRANSMEM    140    162       4 (By similarity).
FT   TOPO_DOM    163    184       Extracellular (By similarity).
FT   TRANSMEM    185    207       5 (By similarity).
FT   TOPO_DOM    208    388       Cytoplasmic (By similarity).
FT   TRANSMEM    389    409       6 (By similarity).
FT   TOPO_DOM    410    423       Extracellular (By similarity).
FT   TRANSMEM    424    443       7 (By similarity).
FT   TOPO_DOM    444    466       Cytoplasmic (By similarity).
FT   MOD_RES     232    232       Phosphoserine (By similarity).
FT   MOD_RES     234    234       Phosphoserine (By similarity).
FT   MOD_RES     446    446       Phosphothreonine (Potential).
FT   MOD_RES     450    450       Phosphothreonine (Potential).
FT   MOD_RES     465    465       Phosphothreonine (Potential).
FT   CARBOHYD      2      2       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD      3      3       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD      6      6       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD      9      9       N-linked (GlcNAc...) (Potential).
FT   DISULFID     96    176       By similarity.
FT   STRAND        5      7
FT   STRAND       10     14
FT   HELIX        16     18
FT   TURN         24     26
FT   TURN         30     32
FT   HELIX        35     49
SQ   SEQUENCE   466 AA;  51715 MW;  2FC2FD7748C22BEC CRC64;
     MNNSTNSSNN SLALTSPYKT FEVVFIVLVA GSLSLVTIIG NILVMVSIKV NRHLQTVNNY
     FLFSLACADL IIGVFSMNLY TLYTVIGYWP LGPVVCDLWL ALDYVVSNAS VMNLLIISFD
     RYFCVTKPLT YPVKRTTKMA GMMIAAAWVL SFILWAPAIL FWQFIVGVRT VEDGECYIQF
     FSNAAVTFGT AIAAFYLPVI IMTVLYWHIS RASKSRIKKD KKEPVANQDP VSPSLVQGRI
     VKPNNNNMPS SDDGLEHNKI QNGKAPRDPV TENCVQGEEK ESSNDSTSVS AVASNMRDDE
     ITQDENTVST SLGHSKDENS KQTCIRIGTK TPKSDSCTPT NTTVEVVGSS GQNGDEKQNI
     VARKIVKMTK QPAKKKPPPS REKKVTRTIL AILLAFIITW APYNVMVLIN TFCAPCIPNT
     VWTIGYWLCY INSTINPACY ALCNATFKKT FKHLLMCHYK NIGATR
//
ID   ACM2_MOUSE              Reviewed;         466 AA.
AC   Q9ERZ4;
DT   01-JUN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 1.
DT   02-MAR-2010, entry version 61.
DE   RecName: Full=Muscarinic acetylcholine receptor M2;
GN   Name=Chrm2; Synonyms=Chrm-2;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Gomeza J., Wess J.;
RT   "Isolation, sequence and functional expression of mouse muscarinic
RT   acetylcholine receptor genes.";
RL   Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-232 AND SER-234, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Brain cortex;
RX   PubMed=17114649; DOI=10.1074/mcp.M600046-MCP200;
RA   Munton R.P., Tweedie-Cullen R., Livingstone-Zatchej M., Weinandy F.,
RA   Waidelich M., Longo D., Gehrig P., Potthast F., Rutishauser D.,
RA   Gerrits B., Panse C., Schlapbach R., Mansuy I.M.;
RT   "Qualitative and quantitative analyses of protein phosphorylation in
RT   naive and stimulated mouse synaptosomal preparations.";
RL   Mol. Cell. Proteomics 6:283-293(2007).
CC   -!- FUNCTION: The muscarinic acetylcholine receptor mediates various
CC       cellular responses, including inhibition of adenylate cyclase,
CC       breakdown of phosphoinositides and modulation of potassium
CC       channels through the action of G proteins. Primary transducing
CC       effect is adenylate cyclase inhibition.
CC   -!- SUBUNIT: Interacts with ARRB1 and ARRB2 (By similarity).
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC       Cell junction, synapse, postsynaptic cell membrane; Multi-pass
CC       membrane protein.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF264049; AAG14343.1; -; Genomic_DNA.
DR   IPI; IPI00112942; -.
DR   UniGene; Mm.448632; -.
DR   STRING; Q9ERZ4; -.
DR   PhosphoSite; Q9ERZ4; -.
DR   PRIDE; Q9ERZ4; -.
DR   Ensembl; ENSMUST00000062520; ENSMUSP00000062955; ENSMUSG00000045613; Mus musculus.
DR   KEGG; mmu:243764; -.
DR   UCSC; uc009biy.1; mouse.
DR   CTD; 243764; -.
DR   MGI; MGI:88397; Chrm2.
DR   HOGENOM; HBG713567; -.
DR   HOVERGEN; HBG105720; -.
DR   InParanoid; Q9ERZ4; -.
DR   NextBio; 385914; -.
DR   Bgee; Q9ERZ4; -.
DR   CleanEx; MM_CHRM2; -.
DR   Genevestigator; Q9ERZ4; -.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004981; F:muscarinic acetylcholine receptor activity; IMP:MGI.
DR   GO; GO:0007213; P:muscarinic acetylcholine receptor signaling...; IMP:MGI.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   InterPro; IPR001065; Musac_M2_rcpt.
DR   InterPro; IPR000995; Musac_rcpt.
DR   PANTHER; PTHR19266:SF32; Musac_M2_rcpt; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00243; MUSCARINICR.
DR   PRINTS; PR00539; MUSCRINICM2R.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell junction; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Phosphoprotein;
KW   Postsynaptic cell membrane; Receptor; Synapse; Transducer;
KW   Transmembrane.
FT   CHAIN         1    466       Muscarinic acetylcholine receptor M2.
FT                                /FTId=PRO_0000069022.
FT   TOPO_DOM      1     22       Extracellular (By similarity).
FT   TRANSMEM     23     45       1 (By similarity).
FT   TOPO_DOM     46     59       Cytoplasmic (By similarity).
FT   TRANSMEM     60     80       2 (By similarity).
FT   TOPO_DOM     81     97       Extracellular (By similarity).
FT   TRANSMEM     98    119       3 (By similarity).
FT   TOPO_DOM    120    139       Cytoplasmic (By similarity).
FT   TRANSMEM    140    162       4 (By similarity).
FT   TOPO_DOM    163    184       Extracellular (By similarity).
FT   TRANSMEM    185    207       5 (By similarity).
FT   TOPO_DOM    208    388       Cytoplasmic (By similarity).
FT   TRANSMEM    389    409       6 (By similarity).
FT   TOPO_DOM    410    423       Extracellular (By similarity).
FT   TRANSMEM    424    443       7 (By similarity).
FT   TOPO_DOM    444    466       Cytoplasmic (By similarity).
FT   MOD_RES     232    232       Phosphoserine.
FT   MOD_RES     234    234       Phosphoserine.
FT   MOD_RES     446    446       Phosphothreonine (Potential).
FT   MOD_RES     450    450       Phosphothreonine (Potential).
FT   MOD_RES     465    465       Phosphothreonine (Potential).
FT   CARBOHYD      2      2       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD      3      3       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD      6      6       N-linked (GlcNAc...) (Potential).
FT   DISULFID     96    176       By similarity.
SQ   SEQUENCE   466 AA;  51515 MW;  CDCF281AD28276F8 CRC64;
     MNNSTNSSNN GLAITSPYKT FEVVFIVLVA GSLSLVTIIG NILVMVSIKV NRHLQTVNNY
     FLFSLACADL IIGVFSMNLY TLYTVIGYWP LGPVVCDLWL ALDYVVSNAS VMNLLIISFD
     RYFCVTKPLT YPVKRTTKMA GMMIAAAWVL SFILWAPAIL FWQFIVGVRT VEDGECYIQF
     FSNAAVTFGT AIAAFYLPVI IMTVLYWHIS RASKSRIKKE KKEPVANQDP VSPSLVQGRI
     VKPNNNNMPG GDGGLEHNKI QNGKALRDGG TENCVQGEEK ESSNDSTSVS AVASNMRDDE
     ITQDENTVST SLGHSKDDNS RQTCIKIVTK TQKGDACTPT STTVELVGSS GQNGDEKQNI
     VARKIVKMTK QPAKKKPPPS REKKVTRTIL AILLAFIITW APYNVMVLIN TFCAPCIPNT
     VWTIGYWLCY INSTINPACY ALCNATFKKT FKHLLMCHYK NIGATR
//
ID   ACM3_CAEEL              Reviewed;         611 AA.
AC   Q9U7D5; Q7JKV1; Q9XW31;
DT   19-SEP-2003, integrated into UniProtKB/Swiss-Prot.
DT   23-NOV-2004, sequence version 2.
DT   02-MAR-2010, entry version 68.
DE   RecName: Full=Muscarinic acetylcholine receptor gar-3;
DE   AltName: Full=G-protein-linked acetylcholine receptor 3;
GN   Name=gar-3; ORFNames=Y40H4A.1;
OS   Caenorhabditis elegans.
OC   Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidea;
OC   Rhabditidae; Peloderinae; Caenorhabditis.
OX   NCBI_TaxID=6239;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A), AND FUNCTION.
RC   STRAIN=Bristol N2;
RX   MEDLINE=20100976; PubMed=10635059;
RA   Hwang J.M., Chang D.-J., Kim U.S., Lee Y.-S., Park Y.-S., Kaang B.-K.,
RA   Cho N.J.;
RT   "Cloning and functional characterization of a Caenorhabditis elegans
RT   muscarinic acetylcholine receptor.";
RL   Recept. Channels 6:415-424(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS A AND B), FUNCTION, AND
RP   DEVELOPMENTAL STAGE.
RX   MEDLINE=22808153; PubMed=12927813; DOI=10.1016/S0006-291X(03)01508-0;
RA   Park Y.-S., Kim S., Shin Y., Choi B., Cho N.J.;
RT   "Alternative splicing of the muscarinic acetylcholine receptor GAR-3
RT   in Caenorhabditis elegans.";
RL   Biochem. Biophys. Res. Commun. 308:961-965(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Bristol N2;
RX   MEDLINE=99069613; PubMed=9851916; DOI=10.1126/science.282.5396.2012;
RG   The C. elegans sequencing consortium;
RT   "Genome sequence of the nematode C. elegans: a platform for
RT   investigating biology.";
RL   Science 282:2012-2018(1998).
RN   [4]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-28 AND ASN-33, AND MASS
RP   SPECTROMETRY.
RX   PubMed=17761667; DOI=10.1074/mcp.M600392-MCP200;
RA   Kaji H., Kamiie J., Kawakami H., Kido K., Yamauchi Y., Shinkawa T.,
RA   Taoka M., Takahashi N., Isobe T.;
RT   "Proteomics reveals N-linked glycoprotein diversity in Caenorhabditis
RT   elegans and suggests an atypical translocation mechanism for integral
RT   membrane proteins.";
RL   Mol. Cell. Proteomics 6:2100-2109(2007).
CC   -!- FUNCTION: The muscarinic acetylcholine receptor mediates various
CC       cellular responses, including inhibition of adenylate cyclase,
CC       breakdown of phosphoinositides and modulation of potassium
CC       channels through the action of G proteins. Primary transducing
CC       effect is Pi turnover.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=b; Synonyms=GAR-3a;
CC         IsoId=Q9U7D5-1; Sequence=Displayed;
CC       Name=a; Synonyms=GAR-3b;
CC         IsoId=Q9U7D5-2; Sequence=VSP_012003;
CC   -!- DEVELOPMENTAL STAGE: Isoform a and isoform b are expressed at all
CC       developmental stages examined, isoform a is more abundant at
CC       embryonic and early larval stages and isoform b at first larval
CC       instar.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF139093; AAD48771.1; -; mRNA.
DR   EMBL; AY221631; AAP97492.1; -; mRNA.
DR   EMBL; AL034391; CAA22301.2; -; Genomic_DNA.
DR   EMBL; Z81486; CAA22301.2; JOINED; Genomic_DNA.
DR   EMBL; AL034391; CAE47471.1; -; Genomic_DNA.
DR   EMBL; Z81486; CAE47471.1; JOINED; Genomic_DNA.
DR   EMBL; Z81486; CAC42272.1; -; Genomic_DNA.
DR   EMBL; AL034391; CAC42272.1; JOINED; Genomic_DNA.
DR   EMBL; Z81486; CAE47465.1; -; Genomic_DNA.
DR   EMBL; AL034391; CAE47465.1; JOINED; Genomic_DNA.
DR   PIR; T20171; T20171.
DR   PIR; T26789; T26789.
DR   RefSeq; NP_001024235.1; -.
DR   RefSeq; NP_001024236.1; -.
DR   UniGene; Cel.19494; -.
DR   SMR; Q9U7D5; 69-602.
DR   PRIDE; Q9U7D5; -.
DR   Ensembl; Y40H4A.1b.1; Y40H4A.1b.1; Y40H4A.1; Caenorhabditis elegans.
DR   Ensembl; Y40H4A.1b.2; Y40H4A.1b.2; Y40H4A.1; Caenorhabditis elegans.
DR   GeneID; 179962; -.
DR   KEGG; cel:Y40H4A.1; -.
DR   UCSC; Y40H4A.1b.1; c. elegans.
DR   CTD; 179962; -.
DR   WormBase; WBGene00001519; gar-3.
DR   WormPep; Y40H4A.1a; CE27783.
DR   WormPep; Y40H4A.1b; CE35800.
DR   eggNOG; meNOG05512; -.
DR   HOGENOM; HBG713567; -.
DR   InParanoid; Q9U7D5; -.
DR   OMA; NNNMPGS; -.
DR   PhylomeDB; Q9U7D5; -.
DR   NextBio; 907558; -.
DR   ArrayExpress; Q9U7D5; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004981; F:muscarinic acetylcholine receptor activity; IEA:InterPro.
DR   GO; GO:0007186; P:G-protein coupled receptor protein signalin...; IEA:UniProtKB-KW.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   InterPro; IPR000995; Musac_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00243; MUSCARINICR.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Complete proteome;
KW   Disulfide bond; G-protein coupled receptor; Glycoprotein; Membrane;
KW   Receptor; Transducer; Transmembrane.
FT   CHAIN         1    611       Muscarinic acetylcholine receptor gar-3.
FT                                /FTId=PRO_0000069050.
FT   TOPO_DOM      1     67       Extracellular (By similarity).
FT   TRANSMEM     68     88       1 (By similarity).
FT   TOPO_DOM     89    101       Cytoplasmic (By similarity).
FT   TRANSMEM    102    122       2 (By similarity).
FT   TOPO_DOM    123    140       Extracellular (By similarity).
FT   TRANSMEM    141    161       3 (By similarity).
FT   TOPO_DOM    162    181       Cytoplasmic (By similarity).
FT   TRANSMEM    182    202       4 (By similarity).
FT   TOPO_DOM    203    227       Extracellular (By similarity).
FT   TRANSMEM    228    248       5 (By similarity).
FT   TOPO_DOM    249    525       Cytoplasmic (By similarity).
FT   TRANSMEM    526    546       6 (By similarity).
FT   TOPO_DOM    547    557       Extracellular (By similarity).
FT   TRANSMEM    558    578       7 (By similarity).
FT   TOPO_DOM    579    611       Cytoplasmic (By similarity).
FT   CARBOHYD     28     28       N-linked (GlcNAc...).
FT   CARBOHYD     33     33       N-linked (GlcNAc...).
FT   DISULFID    138    218       By similarity.
FT   VAR_SEQ     271    296       Missing (in isoform a).
FT                                /FTId=VSP_012003.
SQ   SEQUENCE   611 AA;  69563 MW;  F1DD615020CA3180 CRC64;
     MQSSSLGNAD DPRFRQTHLF QMLVKVINTS AENATKTAIA TSSTSTPSFV DTYSTSSLLG
     EEGRMVMIVV IGAMFALVTS LGNLMVMVSF KIDKQLQTIS NYFLFSLAVA DIAIGVISIP
     MFTYYTAIQK WDLGYTMCQF WLCIDYLMSN ASVLNLLLIS FDRYFSVTRP LSYRPRRTTK
     KALTMIACTY IISLILWPPW IISWPYIEGK FTAEPGTCVV QFLQTNPYVT VGTAVAAFYL
     PVTIMCILYT RVYWETQKRQ KEFGKLQATQ TWASDVVDRP STQSFRNSKM WKKVKKFSRR
     SMKRDVSSTS IIKSSGSMRK KNNQDGYVED SVTPCTSSRN SKRKSWLRNC TGKSNSSSED
     SSEAVAMNLD DTSLSSSHFA LSGSRRRNIS PPCTPMPTNF EDEEQTDAGA SMRNGSARFR
     SRPSDTGKNN NSDTYTVLIE LNDEGSRPSV RLSSCEPYLD EPISTRNRSK SDCNSEIDER
     RHSLLNKQSP FKNGRILKNF SSQERKSEKE QRKNERKQES KAAKTLSAIL CAFIATWTPY
     NLIVCWEAFF PNTVPNVLWT FSYFLCYINS TINPLCYALC NARFRHTYMR ILRCKFKAER
     PTMNQGYVRR N
//
ID   ACM3_HUMAN              Reviewed;         590 AA.
AC   P20309; Q0VAJ8; Q4QRI3; Q5VXY2; Q9HB60;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1991, sequence version 1.
DT   02-MAR-2010, entry version 108.
DE   RecName: Full=Muscarinic acetylcholine receptor M3;
GN   Name=CHRM3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=88166632; PubMed=3443095;
RA   Peralta E.G., Ashkenazi A., Winslow J.W., Smith D.H., Ramachandran J.,
RA   Capon D.J.;
RT   "Distinct primary structures, ligand-binding properties and tissue-
RT   specific expression of four human muscarinic acetylcholine
RT   receptors.";
RL   EMBO J. 6:3923-3929(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=90166521; PubMed=3272174; DOI=10.1016/0896-6273(88)90190-0;
RA   Bonner T.I., Young A.C., Brann M.R., Buckley N.J.;
RT   "Cloning and expression of the human and rat m5 muscarinic
RT   acetylcholine receptor genes.";
RL   Neuron 1:403-410(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=15014171; DOI=10.1093/molbev/msh100;
RA   Kitano T., Liu Y.-H., Ueda S., Saitou N.;
RT   "Human-specific amino acid changes found in 103 protein-coding
RT   genes.";
RL   Mol. Biol. Evol. 21:936-944(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction
RT   sequenced by the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-384.
RC   TISSUE=Teratocarcinoma;
RX   MEDLINE=21137218; PubMed=11238933;
RX   DOI=10.1128/MCB.21.6.1973-1985.2001;
RA   Speek M.;
RT   "Antisense promoter of human L1 retrotransposon drives transcription
RT   of adjacent cellular genes.";
RL   Mol. Cell. Biol. 21:1973-1985(2001).
RN   [8]
RP   STRUCTURE BY NMR OF 271-289, MUTAGENESIS OF GLU-276; PHE-280 AND
RP   VAL-281, AND SUBCELLULAR LOCATION.
RX   PubMed=15870063; DOI=10.1074/jbc.M501264200;
RA   Iverson H.A., Fox D. III, Nadler L.S., Klevit R.E., Nathanson N.M.;
RT   "Identification and structural determination of the M(3) muscarinic
RT   acetylcholine receptor basolateral sorting signal.";
RL   J. Biol. Chem. 280:24568-24575(2005).
CC   -!- FUNCTION: The muscarinic acetylcholine receptor mediates various
CC       cellular responses, including inhibition of adenylate cyclase,
CC       breakdown of phosphoinositides and modulation of potassium
CC       channels through the action of G proteins. Primary transducing
CC       effect is Pi turnover.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC       Cell junction, synapse, postsynaptic cell membrane; Multi-pass
CC       membrane protein. Basolateral cell membrane; Multi-pass membrane
CC       protein.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X15266; CAA33337.1; -; Genomic_DNA.
DR   EMBL; U29589; AAA70337.1; -; Genomic_DNA.
DR   EMBL; AB041395; BAA94480.1; -; Genomic_DNA.
DR   EMBL; AF498917; AAM18940.1; -; mRNA.
DR   EMBL; AL356361; CAH72987.1; -; Genomic_DNA.
DR   EMBL; BC096844; AAH96844.1; -; mRNA.
DR   EMBL; BC121026; AAI21027.1; -; mRNA.
DR   EMBL; AF279779; AAG30036.1; -; mRNA.
DR   IPI; IPI00023456; -.
DR   PIR; S10128; S10128.
DR   RefSeq; NP_000731.1; -.
DR   UniGene; Hs.7138; -.
DR   PDB; 2CSA; NMR; -; A=271-289.
DR   PDBsum; 2CSA; -.
DR   SMR; P20309; 52-562.
DR   STRING; P20309; -.
DR   PRIDE; P20309; -.
DR   Ensembl; ENST00000255380; ENSP00000255380; ENSG00000133019; Homo sapiens.
DR   Ensembl; ENST00000436707; ENSP00000413585; ENSG00000133019; Homo sapiens.
DR   GeneID; 1131; -.
DR   KEGG; hsa:1131; -.
DR   UCSC; uc001hyp.1; human.
DR   CTD; 1131; -.
DR   GeneCards; GC01P237858; -.
DR   H-InvDB; HIX0021237; -.
DR   HGNC; HGNC:1952; CHRM3.
DR   HPA; CAB010409; -.
DR   HPA; HPA024106; -.
DR   MIM; 118494; gene.
DR   PharmGKB; PA112; -.
DR   eggNOG; prNOG05498; -.
DR   HOGENOM; HBG713567; -.
DR   HOVERGEN; HBG105720; -.
DR   InParanoid; P20309; -.
DR   OMA; FIQFLSE; -.
DR   OrthoDB; EOG93NB01; -.
DR   PhylomeDB; P20309; -.
DR   Reactome; REACT_14797; Signaling by GPCR.
DR   Reactome; REACT_15380; Diabetes pathways.
DR   DrugBank; DB00517; Anisotropine Methylbromide.
DR   DrugBank; DB00572; Atropine.
DR   DrugBank; DB00767; Benzquinamide.
DR   DrugBank; DB00185; Cevimeline.
DR   DrugBank; DB00785; Cryptenamine.
DR   DrugBank; DB01176; Cyclizine.
DR   DrugBank; DB00496; Darifenacin.
DR   DrugBank; DB00729; Diphemanil Methylsulfate.
DR   DrugBank; DB01231; Diphenidol.
DR   DrugBank; DB00725; Homatropine Methylbromide.
DR   DrugBank; DB01403; Methotrimeprazine.
DR   DrugBank; DB00340; Metixene.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB01062; Oxybutynin.
DR   DrugBank; DB00383; Oxyphencyclimine.
DR   DrugBank; DB00420; Promazine.
DR   DrugBank; DB01069; Promethazine.
DR   DrugBank; DB00777; Propiomazine.
DR   DrugBank; DB01591; Solifenacin.
DR   DrugBank; DB00372; Thiethylperazine.
DR   DrugBank; DB01409; Tiotropium.
DR   DrugBank; DB01036; Tolterodine.
DR   DrugBank; DB00505; Tridihexethyl.
DR   NextBio; 4702; -.
DR   ArrayExpress; P20309; -.
DR   Bgee; P20309; -.
DR   CleanEx; HS_CHRM3; -.
DR   Genevestigator; P20309; -.
DR   GermOnline; ENSG00000133019; Homo sapiens.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004981; F:muscarinic acetylcholine receptor activity; TAS:ProtInc.
DR   GO; GO:0004435; F:phosphoinositide phospholipase C activity; TAS:ProtInc.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0007399; P:nervous system development; TAS:ProtInc.
DR   GO; GO:0006464; P:protein modification process; TAS:ProtInc.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   InterPro; IPR001183; Musac_M3_rcpt.
DR   InterPro; IPR000995; Musac_rcpt.
DR   PANTHER; PTHR19266:SF37; Musac_M3_rcpt; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00243; MUSCARINICR.
DR   PRINTS; PR00540; MUSCRINICM3R.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell junction; Cell membrane; Complete proteome;
KW   Disulfide bond; G-protein coupled receptor; Glycoprotein; Membrane;
KW   Phosphoprotein; Polymorphism; Postsynaptic cell membrane; Receptor;
KW   Synapse; Transducer; Transmembrane.
FT   CHAIN         1    590       Muscarinic acetylcholine receptor M3.
FT                                /FTId=PRO_0000069029.
FT   TOPO_DOM      1     67       Extracellular (By similarity).
FT   TRANSMEM     68     91       1 (By similarity).
FT   TOPO_DOM     92    104       Cytoplasmic (By similarity).
FT   TRANSMEM    105    125       2 (By similarity).
FT   TOPO_DOM    126    142       Extracellular (By similarity).
FT   TRANSMEM    143    164       3 (By similarity).
FT   TOPO_DOM    165    184       Cytoplasmic (By similarity).
FT   TRANSMEM    185    207       4 (By similarity).
FT   TOPO_DOM    208    229       Extracellular (By similarity).
FT   TRANSMEM    230    252       5 (By similarity).
FT   TOPO_DOM    253    492       Cytoplasmic (By similarity).
FT   TRANSMEM    493    513       6 (By similarity).
FT   TOPO_DOM    514    527       Extracellular (By similarity).
FT   TRANSMEM    528    547       7 (By similarity).
FT   TOPO_DOM    548    590       Cytoplasmic (By similarity).
FT   MOTIF       275    281       Basolateral sorting signal.
FT   CARBOHYD      5      5       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD      6      6       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     15     15       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     41     41       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     48     48       N-linked (GlcNAc...) (Potential).
FT   DISULFID    141    221       By similarity.
FT   VARIANT      65     65       V -> I (in dbSNP:rs2067481).
FT                                /FTId=VAR_033461.
FT   VARIANT     431    431       L -> P (in dbSNP:rs16839102).
FT                                /FTId=VAR_049368.
FT   MUTAGEN     276    276       E->A: Loss of basolateral sorting.
FT   MUTAGEN     276    276       E->D: Loss of basolateral sorting. No
FT                                effect on basolateral sorting; when
FT                                associated with L-280 and L-281.
FT   MUTAGEN     280    280       F->A: Loss of basolateral sorting.
FT   MUTAGEN     280    280       F->L: No effect on basolateral sorting.
FT   MUTAGEN     281    281       V->A: Loss of basolateral sorting.
FT   MUTAGEN     281    281       V->L: No effect on basolateral sorting.
FT   CONFLICT    382    384       KLP -> RLS (in Ref. 7; AAG30036).
FT   STRAND      280    283
SQ   SEQUENCE   590 AA;  66128 MW;  5CB473C57B9526E9 CRC64;
     MTLHNNSTTS PLFPNISSSW IHSPSDAGLP PGTVTHFGSY NVSRAAGNFS SPDGTTDDPL
     GGHTVWQVVF IAFLTGILAL VTIIGNILVI VSFKVNKQLK TVNNYFLLSL ACADLIIGVI
     SMNLFTTYII MNRWALGNLA CDLWLAIDYV ASNASVMNLL VISFDRYFSI TRPLTYRAKR
     TTKRAGVMIG LAWVISFVLW APAILFWQYF VGKRTVPPGE CFIQFLSEPT ITFGTAIAAF
     YMPVTIMTIL YWRIYKETEK RTKELAGLQA SGTEAETENF VHPTGSSRSC SSYELQQQSM
     KRSNRRKYGR CHFWFTTKSW KPSSEQMDQD HSSSDSWNNN DAAASLENSA SSDEEDIGSE
     TRAIYSIVLK LPGHSTILNS TKLPSSDNLQ VPEEELGMVD LERKADKLQA QKSVDDGGSF
     PKSFSKLPIQ LESAVDTAKT SDVNSSVGKS TATLPLSFKE ATLAKRFALK TRSQITKRKR
     MSLVKEKKAA QTLSAILLAF IITWTPYNIM VLVNTFCDSC IPKTFWNLGY WLCYINSTVN
     PVCYALCNKT FRTTFKMLLL CQCDKKKRRK QQYQQRQSVI FHKRAPEQAL
//
ID   ACM3_RAT                Reviewed;         589 AA.
AC   P08483; Q9QWK9;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1988, sequence version 1.
DT   02-MAR-2010, entry version 93.
DE   RecName: Full=Muscarinic acetylcholine receptor M3;
GN   Name=Chrm3; Synonyms=Chrm-3;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RX   MEDLINE=87263421; PubMed=3037705; DOI=10.1126/science.3037705;
RA   Bonner T.I., Buckley N.J., Young A.C., Brann M.R.;
RT   "Identification of a family of muscarinic acetylcholine receptor
RT   genes.";
RL   Science 237:527-532(1987).
RN   [2]
RP   SEQUENCE REVISION TO 184.
RX   MEDLINE=90166521; PubMed=3272174; DOI=10.1016/0896-6273(88)90190-0;
RA   Bonner T.I., Young A.C., Brann M.R., Buckley N.J.;
RT   "Cloning and expression of the human and rat m5 muscarinic
RT   acetylcholine receptor genes.";
RL   Neuron 1:403-410(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   MEDLINE=88077068; PubMed=3120722; DOI=10.1016/0006-291X(87)91613-5;
RA   Braun T., Schofield P.R., Shivers B.D., Pritchett D.B., Seeburg P.H.;
RT   "A novel subtype of muscarinic receptor identified by homology
RT   screening.";
RL   Biochem. Biophys. Res. Commun. 149:125-132(1987).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Iris;
RX   MEDLINE=99138467; PubMed=9972520;
RA   Furuta M., Ohya S., Imaizumi Y., Watanabe M.;
RT   "Molecular cloning of m3 muscarinic acetylcholine receptor in rat
RT   iris.";
RL   J. Smooth Muscle Res. 34:111-122(1998).
RN   [5]
RP   PROTEIN SEQUENCE OF 104-166.
RX   MEDLINE=90337982; PubMed=2380182;
RA   Kurtenbach E., Curtis C.A.M., Pedder E.K., Aitken A., Harris A.C.M.,
RA   Hulme E.C.;
RT   "Muscarinic acetylcholine receptors. Peptide sequencing identifies
RT   residues involved in antagonist binding and disulfide bond
RT   formation.";
RL   J. Biol. Chem. 265:13702-13708(1990).
RN   [6]
RP   MUTAGENESIS OF TYR-148; THR-231; THR-234; TYR-506; TYR-529 AND
RP   TYR-533.
RX   MEDLINE=92037535; PubMed=1657592;
RA   Wess J., Gdula D., Brann M.R.;
RT   "Site-directed mutagenesis of the m3 muscarinic receptor:
RT   identification of a series of threonine and tyrosine residues involved
RT   in agonist but not antagonist binding.";
RL   EMBO J. 10:3729-3734(1991).
RN   [7]
RP   MUTAGENESIS OF THR-234 AND TYR-506.
RX   MEDLINE=92406875; PubMed=1527051;
RA   Wess J., Maggio R., Palmer J.R., Vogel Z.;
RT   "Role of conserved threonine and tyrosine residues in acetylcholine
RT   binding and muscarinic receptor activation. A study with m3 muscarinic
RT   receptor point mutants.";
RL   J. Biol. Chem. 267:19313-19319(1992).
CC   -!- FUNCTION: The muscarinic acetylcholine receptor mediates various
CC       cellular responses, including inhibition of adenylate cyclase,
CC       breakdown of phosphoinositides and modulation of potassium
CC       channels through the action of G proteins. Primary transducing
CC       effect is Pi turnover.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein
CC       (By similarity). Cell junction, synapse, postsynaptic cell
CC       membrane; Multi-pass membrane protein (By similarity). Basolateral
CC       cell membrane; Multi-pass membrane protein (By similarity).
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M16407; AAA40661.1; ALT_SEQ; mRNA.
DR   EMBL; M16408; AAA40662.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; M18088; AAA40659.1; -; mRNA.
DR   EMBL; M62826; AAA41553.1; -; Genomic_DNA.
DR   EMBL; AB017656; BAA36839.1; -; mRNA.
DR   IPI; IPI00327521; -.
DR   PIR; A29476; A29476.
DR   PIR; B94518; B29514.
DR   RefSeq; NP_036659.1; -.
DR   UniGene; Rn.87735; -.
DR   PDB; 2AMK; Model; -; A=56-560.
DR   PDBsum; 2AMK; -.
DR   SMR; P08483; 65-561.
DR   STRING; P08483; -.
DR   Ensembl; ENSRNOT00000019662; ENSRNOP00000019662; ENSRNOG00000014639; Rattus norvegicus.
DR   GeneID; 24260; -.
DR   KEGG; rno:24260; -.
DR   UCSC; NM_012527; rat.
DR   CTD; 24260; -.
DR   RGD; 2343; Chrm3.
DR   eggNOG; maNOG13832; -.
DR   HOVERGEN; HBG105720; -.
DR   InParanoid; P08483; -.
DR   OMA; FIQFLSE; -.
DR   OrthoDB; EOG93NB01; -.
DR   PhylomeDB; P08483; -.
DR   NextBio; 602805; -.
DR   ArrayExpress; P08483; -.
DR   Genevestigator; P08483; -.
DR   GermOnline; ENSRNOG00000014639; Rattus norvegicus.
DR   GO; GO:0032279; C:asymmetric synapse; IDA:RGD.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0043679; C:axon terminus; IDA:RGD.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0008144; F:drug binding; IDA:RGD.
DR   GO; GO:0004981; F:muscarinic acetylcholine receptor activity; IDA:RGD.
DR   GO; GO:0007213; P:muscarinic acetylcholine receptor signaling...; IDA:RGD.
DR   GO; GO:0045987; P:positive regulation of smooth muscle contra...; IMP:RGD.
DR   GO; GO:0003056; P:regulation of vascular smooth muscle contra...; IMP:RGD.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   InterPro; IPR001183; Musac_M3_rcpt.
DR   InterPro; IPR000995; Musac_rcpt.
DR   PANTHER; PTHR19266:SF37; Musac_M3_rcpt; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00243; MUSCARINICR.
DR   PRINTS; PR00540; MUSCRINICM3R.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell junction; Cell membrane; Direct protein sequencing;
KW   Disulfide bond; G-protein coupled receptor; Glycoprotein; Membrane;
KW   Phosphoprotein; Postsynaptic cell membrane; Receptor; Synapse;
KW   Transducer; Transmembrane.
FT   CHAIN         1    589       Muscarinic acetylcholine receptor M3.
FT                                /FTId=PRO_0000069034.
FT   TOPO_DOM      1     66       Extracellular (By similarity).
FT   TRANSMEM     67     90       1 (By similarity).
FT   TOPO_DOM     91    103       Cytoplasmic (By similarity).
FT   TRANSMEM    104    124       2 (By similarity).
FT   TOPO_DOM    125    141       Extracellular (By similarity).
FT   TRANSMEM    142    163       3 (By similarity).
FT   TOPO_DOM    164    183       Cytoplasmic (By similarity).
FT   TRANSMEM    184    206       4 (By similarity).
FT   TOPO_DOM    207    228       Extracellular (By similarity).
FT   TRANSMEM    229    251       5 (By similarity).
FT   TOPO_DOM    252    491       Cytoplasmic (By similarity).
FT   TRANSMEM    492    512       6 (By similarity).
FT   TOPO_DOM    513    526       Extracellular (By similarity).
FT   TRANSMEM    527    546       7 (By similarity).
FT   TOPO_DOM    547    589       Cytoplasmic (By similarity).
FT   MOTIF       274    280       Basolateral sorting signal (By
FT                                similarity).
FT   BINDING     147    147       Antagonist (By similarity).
FT   CARBOHYD      6      6       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     15     15       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     41     41       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     48     48       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     52     52       N-linked (GlcNAc...) (Potential).
FT   DISULFID    140    220       By similarity.
FT   MUTAGEN     148    148       Y->A: Decreased affinity for
FT                                acetylcholine.
FT   MUTAGEN     231    231       T->A: Decreased affinity for
FT                                acetylcholine.
FT   MUTAGEN     234    234       T->A: Strongly decreased affinity for
FT                                acetylcholine.
FT   MUTAGEN     506    506       Y->F: Decreased affinity for
FT                                acetylcholine.
FT   MUTAGEN     529    529       Y->F: Decreased affinity for
FT                                acetylcholine.
FT   MUTAGEN     533    533       Y->F: Decreased affinity for
FT                                acetylcholine.
FT   CONFLICT    184    184       A -> R (in Ref. 1; AAA40661/AAA40662 and
FT                                4; BAA36839).
FT   CONFLICT    516    516       C -> R (in Ref. 3; AAA40659).
FT   CONFLICT    556    556       T -> M (in Ref. 3; AAA40659).
SQ   SEQUENCE   589 AA;  66066 MW;  9A5EF2FA653C830A CRC64;
     MTLHSNSTTS PLFPNISSSW VHSPSEAGLP LGTVTQLGSY NISQETGNFS SNDTSSDPLG
     GHTIWQVVFI AFLTGFLALV TIIGNILVIV AFKVNKQLKT VNNYFLLSLA CADLIIGVIS
     MNLFTTYIIM NRWALGNLAC DLWLSIDYVA SNASVMNLLV ISFDRYFSIT RPLTYRAKRT
     TKRAGVMIGL AWVISFVLWA PAILFWQYFV GKRTVPPGEC FIQFLSEPTI TFGTAIAAFY
     MPVTIMTILY WRIYKETEKR TKELAGLQAS GTEAEAENFV HPTGSSRSCS SYELQQQGVK
     RSSRRKYGRC HFWFTTKSWK PSAEQMDQDH SSSDSWNNND AAASLENSAS SDEEDIGSET
     RAIYSIVLKL PGHSSILNST KLPSSDNLQV SNEDLGTVDV ERNAHKLQAQ KSMGDGDNCQ
     KDFTKLPIQL ESAVDTGKTS DTNSSADKTT ATLPLSFKEA TLAKRFALKT RSQITKRKRM
     SLIKEKKAAQ TLSAILLAFI ITWTPYNIMV LVNTFCDSCI PKTYWNLGYW LCYINSTVNP
     VCYALCNKTF RTTFKTLLLC QCDKRKRRKQ QYQQRQSVIF HKRVPEQAL
//
ID   ACM5_RAT                Reviewed;         531 AA.
AC   P08911;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1988, sequence version 1.
DT   02-MAR-2010, entry version 85.
DE   RecName: Full=Muscarinic acetylcholine receptor M5;
GN   Name=Chrm5; Synonyms=Chrm-5;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=90166521; PubMed=3272174; DOI=10.1016/0896-6273(88)90190-0;
RA   Bonner T.I., Young A.C., Brann M.R., Buckley N.J.;
RT   "Cloning and expression of the human and rat m5 muscarinic
RT   acetylcholine receptor genes.";
RL   Neuron 1:403-410(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RX   MEDLINE=89214170; PubMed=2540186;
RA   Liao C.-F., Themmen A.P.N., Joho R., Barberis C., Birnbaumer M.,
RA   Birnbaumer L.;
RT   "Molecular cloning and expression of a fifth muscarinic acetylcholine
RT   receptor.";
RL   J. Biol. Chem. 264:7328-7337(1989).
RN   [3]
RP   PROTEIN SEQUENCE OF 66-128.
RX   MEDLINE=90337982; PubMed=2380182;
RA   Kurtenbach E., Curtis C.A.M., Pedder E.K., Aitken A., Harris A.C.M.,
RA   Hulme E.C.;
RT   "Muscarinic acetylcholine receptors. Peptide sequencing identifies
RT   residues involved in antagonist binding and disulfide bond
RT   formation.";
RL   J. Biol. Chem. 265:13702-13708(1990).
CC   -!- FUNCTION: The muscarinic acetylcholine receptor mediates various
CC       cellular responses, including inhibition of adenylate cyclase,
CC       breakdown of phosphoinositides and modulation of potassium
CC       channels through the action of G proteins. Primary transducing
CC       effect is Pi turnover.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC       Cell junction, synapse, postsynaptic cell membrane; Multi-pass
CC       membrane protein.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M22926; AAA40658.1; -; mRNA.
DR   EMBL; M22925; AAA41572.1; -; Genomic_DNA.
DR   IPI; IPI00187712; -.
DR   PIR; JT0531; JT0531.
DR   RefSeq; NP_059058.1; -.
DR   UniGene; Rn.44293; -.
DR   SMR; P08911; 26-512.
DR   STRING; P08911; -.
DR   Ensembl; ENSRNOT00000008387; ENSRNOP00000008387; ENSRNOG00000006397; Rattus norvegicus.
DR   GeneID; 53949; -.
DR   KEGG; rno:53949; -.
DR   UCSC; NM_017362; rat.
DR   CTD; 53949; -.
DR   RGD; 620027; Chrm5.
DR   eggNOG; roNOG08249; -.
DR   HOVERGEN; HBG105720; -.
DR   InParanoid; P08911; -.
DR   OMA; RKPAHRA; -.
DR   OrthoDB; EOG93NB01; -.
DR   PhylomeDB; P08911; -.
DR   NextBio; 610614; -.
DR   ArrayExpress; P08911; -.
DR   Genevestigator; P08911; -.
DR   GermOnline; ENSRNOG00000006397; Rattus norvegicus.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004981; F:muscarinic acetylcholine receptor activity; IDA:RGD.
DR   GO; GO:0007186; P:G-protein coupled receptor protein signalin...; IEA:UniProtKB-KW.
DR   GO; GO:0060304; P:regulation of phosphoinositide dephosphoryl...; IMP:RGD.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   InterPro; IPR000502; Musac_M5_rcpt.
DR   InterPro; IPR000995; Musac_rcpt.
DR   PANTHER; PTHR19266:SF36; Musac_M5_rcpt; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00243; MUSCARINICR.
DR   PRINTS; PR00542; MUSCRINICM5R.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell junction; Cell membrane; Direct protein sequencing;
KW   Disulfide bond; G-protein coupled receptor; Glycoprotein; Membrane;
KW   Phosphoprotein; Postsynaptic cell membrane; Receptor; Synapse;
KW   Transducer; Transmembrane.
FT   CHAIN         1    531       Muscarinic acetylcholine receptor M5.
FT                                /FTId=PRO_0000069046.
FT   TOPO_DOM      1     28       Extracellular (By similarity).
FT   TRANSMEM     29     52       1 (By similarity).
FT   TOPO_DOM     53     65       Cytoplasmic (By similarity).
FT   TRANSMEM     66     86       2 (By similarity).
FT   TOPO_DOM     87    103       Extracellular (By similarity).
FT   TRANSMEM    104    125       3 (By similarity).
FT   TOPO_DOM    126    145       Cytoplasmic (By similarity).
FT   TRANSMEM    146    168       4 (By similarity).
FT   TOPO_DOM    169    190       Extracellular (By similarity).
FT   TRANSMEM    191    213       5 (By similarity).
FT   TOPO_DOM    214    442       Cytoplasmic (By similarity).
FT   TRANSMEM    443    463       6 (By similarity).
FT   TOPO_DOM    464    477       Extracellular (By similarity).
FT   TRANSMEM    478    497       7 (By similarity).
FT   TOPO_DOM    498    531       Cytoplasmic (By similarity).
FT   BINDING     109    109       Antagonist (By similarity).
FT   MOD_RES     500    500       Phosphothreonine (Potential).
FT   MOD_RES     504    504       Phosphothreonine (Potential).
FT   CARBOHYD      7      7       N-linked (GlcNAc...) (Potential).
FT   DISULFID    102    182       By similarity.
SQ   SEQUENCE   531 AA;  60137 MW;  647CE0D5D75A2BB1 CRC64;
     MEGESYNEST VNGTPVNHQA LERHGLWEVI TIAVVTAVVS LMTIVGNVLV MISFKVNSQL
     KTVNNYYLLS LACADLIIGI FSMNLYTTYI LMGRWVLGSL ACDLWLALDY VASNASVMNL
     LVISFDRYFS ITRPLTYRAK RTPKRAGIMI GLAWLVSFIL WAPAILCWQY LVGKRTVPPD
     ECQIQFLSEP TITFGTAIAA FYIPVSVMTI LYCRIYRETE KRTKDLADLQ GSDSVAEAKK
     REPAQRTLLR SFFSCPRPSL AQRERNQASW SSSRRSTSTT GKTTQATDLS ADWEKAEQVT
     TCSSYPSSED EAKPTTDPVF QMVYKSEAKE SPGKESNTQE TKETVVNTRT ENSDYDTPKY
     FLSPAAAHRL KSQKCVAYKF RLVVKADGTQ ETNNGCRKVK IMPCSFPVSK DPSTKGPDPN
     LSHQMTKRKR MVLVKERKAA QTLSAILLAF IITWTPYNIM VLVSTFCDKC VPVTLWHLGY
     WLCYVNSTIN PICYALCNRT FRKTFKLLLL CRWKKKKVEE KLYWQGNSKL P
//
ID   ACTHR_HUMAN             Reviewed;         297 AA.
AC   Q01718; Q3MI45; Q504X6;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1993, sequence version 1.
DT   02-MAR-2010, entry version 98.
DE   RecName: Full=Adrenocorticotropic hormone receptor;
DE            Short=ACTH receptor;
DE            Short=ACTH-R;
DE   AltName: Full=Adrenocorticotropin receptor;
DE   AltName: Full=Melanocortin receptor 2;
DE            Short=MC2-R;
GN   Name=MC2R; Synonyms=ACTHR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Skin;
RX   MEDLINE=92390715; PubMed=1325670; DOI=10.1126/science.1325670;
RA   Mountjoy K.G., Robbins L.S., Mortrud M., Cone R.D.;
RT   "The cloning of a family of genes that encode the melanocortin
RT   receptors.";
RL   Science 257:1248-1251(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Suwa M., Sato T., Okouchi I., Arita M., Futami K., Matsumoto S.,
RA   Tsutsumi S., Aburatani H., Asai K., Akiyama Y.;
RT   "Genome-wide discovery and analysis of human seven transmembrane helix
RT   receptor genes.";
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction
RT   sequenced by the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-293.
RX   MEDLINE=93216807; PubMed=8463333;
RA   Gantz I., Konda Y., Tashiro T., Shimoto Y., Miwa H., Munzert G.,
RA   Watson S.J., Delvalle J., Yamada T.;
RT   "Molecular cloning of a novel melanocortin receptor.";
RL   J. Biol. Chem. 268:8246-8250(1993).
RN   [6]
RP   INTERACTION WITH FALP.
RX   PubMed=15654338; DOI=10.1038/ng1501;
RA   Metherell L.A., Chapple J.P., Cooray S., David A., Becker C.,
RA   Rueschendorf F., Naville D., Begeot M., Khoo B., Nuernberg P.,
RA   Huebner A., Cheetham M.E., Clark A.J.L.;
RT   "Mutations in MRAP, encoding a new interacting partner of the ACTH
RT   receptor, cause familial glucocorticoid deficiency type 2.";
RL   Nat. Genet. 37:166-170(2005).
RN   [7]
RP   REVIEW ON GCCD1 VARIANTS.
RA   Clark A.J.L., Weber A.;
RT   "Molecular insights into inherited ACTH resistance syndromes.";
RL   Trends Endocrinol. Metab. 5:209-214(1994).
RN   [8]
RP   VARIANT GCCD1 ILE-74.
RX   MEDLINE=93164774; PubMed=8094489; DOI=10.1016/0140-6736(93)90208-X;
RA   Clark A.J.L., McLoughlin L., Grossman A.;
RT   "Familial glucocorticoid deficiency associated with point mutation in
RT   the adrenocorticotropin receptor.";
RL   Lancet 341:461-462(1993).
RN   [9]
RP   VARIANT GCCD1 ARG-120.
RX   MEDLINE=94043766; PubMed=8227361; DOI=10.1172/JCI116853;
RA   Tsigos C., Arai K., Hung W., Chrousos G.P.;
RT   "Hereditary isolated glucocorticoid deficiency is associated with
RT   abnormalities of the adrenocorticotropin receptor gene.";
RL   J. Clin. Invest. 92:2458-2461(1993).
RN   [10]
RP   VARIANTS GCCD1 ASN-107 AND PHE-251.
RX   MEDLINE=96186146; PubMed=8636348; DOI=10.1210/jc.81.4.1442;
RA   Naville D., Barjhoux L., Jaillard C., Faury D., Despert F., Esteva B.,
RA   Durand P., Saez J.M., Begeot M.;
RT   "Demonstration by transfection studies that mutations in the
RT   adrenocorticotropin receptor gene are one cause of the hereditary
RT   syndrome of glucocorticoid deficiency.";
RL   J. Clin. Endocrinol. Metab. 81:1442-1448(1996).
RN   [11]
RP   VARIANTS GCCD1 ASN-103 AND TRP-137.
RX   MEDLINE=20428356; PubMed=10971458;
RX   DOI=10.1046/j.1365-2265.2000.01040.x;
RA   Ishii T., Ogata T., Sasaki G., Sato S., Kinoshita E.I., Matsuo N.;
RT   "Novel mutations of the ACTH receptor gene in a female adult patient
RT   with adrenal unresponsiveness to ACTH.";
RL   Clin. Endocrinol. (Oxf.) 53:389-392(2000).
RN   [12]
RP   VARIANTS GCCD1 ILE-74; TRP-137 AND CYS-254.
RX   MEDLINE=22202419; PubMed=12213892; DOI=10.1210/jc.2002-020501;
RA   Fluck C.E., Martens J.W.M., Conte F.A., Miller W.L.;
RT   "Clinical, genetic, and functional characterization of
RT   adrenocorticotropin receptor mutations using a novel receptor assay.";
RL   J. Clin. Endocrinol. Metab. 87:4318-4323(2002).
CC   -!- FUNCTION: Receptor for ACTH. This receptor is mediated by G
CC       proteins (G(s)) which activate adenylate cyclase.
CC   -!- SUBUNIT: Interacts with FALP/MRAP.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Melanocytes and corticoadrenal tissue.
CC   -!- DISEASE: Defects in MC2R are the cause of glucocorticoid
CC       deficiency type 1 (GCCD1) [MIM:202200]; also known as familial
CC       glucocorticoid deficiency type 1 (FGD1). GCCD1 is an autosomal
CC       recessive disorder due to congenital insensitivity or resistance
CC       to adrenocorticotropin (ACTH). It is characterized by progressive
CC       primary adrenal insufficiency, without mineralocorticoid
CC       deficiency.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/MC2R";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X65633; CAA46587.1; -; Genomic_DNA.
DR   EMBL; AB065915; BAC06130.1; -; Genomic_DNA.
DR   EMBL; BC069074; AAH69074.1; -; mRNA.
DR   EMBL; BC094710; AAH94710.1; -; mRNA.
DR   EMBL; BC104169; AAI04170.1; -; mRNA.
DR   EMBL; BC104170; AAI04171.1; -; mRNA.
DR   EMBL; AY225229; AAO67714.1; -; Genomic_DNA.
DR   IPI; IPI00009312; -.
DR   PIR; C43265; C43265.
DR   RefSeq; NP_000520.1; -.
DR   UniGene; Hs.248144; -.
DR   SMR; Q01718; 8-296.
DR   DIP; DIP-29949N; -.
DR   STRING; Q01718; -.
DR   PhosphoSite; Q01718; -.
DR   Ensembl; ENST00000327606; ENSP00000333821; ENSG00000185231; Homo sapiens.
DR   Ensembl; ENST00000399821; ENSP00000382718; ENSG00000185231; Homo sapiens.
DR   GeneID; 4158; -.
DR   KEGG; hsa:4158; -.
DR   UCSC; uc002ksp.1; human.
DR   CTD; 4158; -.
DR   GeneCards; GC18M013874; -.
DR   H-InvDB; HIX0039742; -.
DR   HGNC; HGNC:6930; MC2R.
DR   MIM; 202200; phenotype.
DR   MIM; 607397; gene.
DR   Orphanet; 361; Glucocorticoid deficiency, familial.
DR   PharmGKB; PA30674; -.
DR   eggNOG; prNOG16349; -.
DR   HOGENOM; HBG717691; -.
DR   HOVERGEN; HBG108148; -.
DR   InParanoid; Q01718; -.
DR   OMA; ARNNSDC; -.
DR   OrthoDB; EOG95XBFV; -.
DR   PhylomeDB; Q01718; -.
DR   Reactome; REACT_14797; Signaling by GPCR.
DR   DrugBank; DB01285; Corticotropin.
DR   DrugBank; DB01284; Cosyntropin.
DR   NextBio; 16382; -.
DR   ArrayExpress; Q01718; -.
DR   Bgee; Q01718; -.
DR   CleanEx; HS_MC2R; -.
DR   Genevestigator; Q01718; -.
DR   GermOnline; ENSG00000185231; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0004978; F:adrenocorticotropin receptor activity; TAS:ProtInc.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0007187; P:G-protein signaling, coupled to cyclic nucl...; TAS:ProtInc.
DR   GO; GO:0030819; P:positive regulation of cAMP biosynthetic pr...; IDA:UniProtKB.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR001168; ACTH_rcpt.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   InterPro; IPR001671; Melcrt_ACTH_rcpt.
DR   PANTHER; PTHR22750:SF3; ACTH_rcpt; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00520; ACTROPHINR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00534; MCRFAMILY.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Complete proteome; Disease mutation;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane;
KW   Palmitate; Phosphoprotein; Polymorphism; Receptor; Transducer;
KW   Transmembrane.
FT   CHAIN         1    297       Adrenocorticotropic hormone receptor.
FT                                /FTId=PRO_0000069054.
FT   TOPO_DOM      1     23       Extracellular (By similarity).
FT   TRANSMEM     24     49       1 (By similarity).
FT   TOPO_DOM     50     58       Cytoplasmic (By similarity).
FT   TRANSMEM     59     79       2 (By similarity).
FT   TOPO_DOM     80    104       Extracellular (By similarity).
FT   TRANSMEM    105    126       3 (By similarity).
FT   TOPO_DOM    127    147       Cytoplasmic (By similarity).
FT   TRANSMEM    148    168       4 (By similarity).
FT   TOPO_DOM    169    180       Extracellular (By similarity).
FT   TRANSMEM    181    199       5 (By similarity).
FT   TOPO_DOM    200    217       Cytoplasmic (By similarity).
FT   TRANSMEM    218    244       6 (By similarity).
FT   TOPO_DOM    245    256       Extracellular (By similarity).
FT   TRANSMEM    257    278       7 (By similarity).
FT   TOPO_DOM    279    297       Cytoplasmic (By similarity).
FT   LIPID       293    293       S-palmitoyl cysteine (Potential).
FT   CARBOHYD     12     12       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     17     17       N-linked (GlcNAc...) (Potential).
FT   VARIANT      27     27       P -> R (in dbSNP:rs28926178).
FT                                /FTId=VAR_003509.
FT   VARIANT      74     74       S -> I (in GCCD1; complete loss of
FT                                activity).
FT                                /FTId=VAR_003510.
FT   VARIANT     103    103       D -> N (in GCCD1).
FT                                /FTId=VAR_010702.
FT   VARIANT     107    107       D -> N (in GCCD1).
FT                                /FTId=VAR_015095.
FT   VARIANT     120    120       S -> R (in GCCD1).
FT                                /FTId=VAR_003511.
FT   VARIANT     128    128       R -> C (in GCCD1).
FT                                /FTId=VAR_003512.
FT   VARIANT     137    137       R -> W (in GCCD1; partial loss of
FT                                ACTIVITY).
FT                                /FTId=VAR_010703.
FT   VARIANT     146    146       R -> H (in GCCD1).
FT                                /FTId=VAR_003513.
FT   VARIANT     251    251       C -> F (in GCCD1).
FT                                /FTId=VAR_015096.
FT   VARIANT     254    254       Y -> C (in GCCD1; complete loss of
FT                                activity; dbSNP:rs28940892).
FT                                /FTId=VAR_015295.
FT   VARIANT     278    278       F -> C (in dbSNP:rs28926182).
FT                                /FTId=VAR_049369.
SQ   SEQUENCE   297 AA;  33927 MW;  66EE31961ABB8773 CRC64;
     MKHIINSYEN INNTARNNSD CPRVVLPEEI FFTISIVGVL ENLIVLLAVF KNKNLQAPMY
     FFICSLAISD MLGSLYKILE NILIILRNMG YLKPRGSFET TADDIIDSLF VLSLLGSIFS
     LSVIAADRYI TIFHALRYHS IVTMRRTVVV LTVIWTFCTG TGITMVIFSH HVPTVITFTS
     LFPLMLVFIL CLYVHMFLLA RSHTRKISTL PRANMKGAIT LTILLGVFIF CWAPFVLHVL
     LMTFCPSNPY CACYMSLFQV NGMLIMCNAV IDPFIYAFRS PELRDAFKKM IFCSRYW
//
ID   ADA1A_MOUSE             Reviewed;         466 AA.
AC   P97718; O54913;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   11-FEB-2002, sequence version 2.
DT   02-MAR-2010, entry version 79.
DE   RecName: Full=Alpha-1A adrenergic receptor;
DE   AltName: Full=Alpha-1A adrenoreceptor;
DE            Short=Alpha-1A adrenoceptor;
DE   AltName: Full=Alpha-1C adrenergic receptor;
GN   Name=Adra1a; Synonyms=Adra1c;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CHARACTERIZATION.
RC   STRAIN=CD-1; TISSUE=Brain, and Kidney;
RX   MEDLINE=98292316; PubMed=9630362; DOI=10.1038/sj.bjp.0701812;
RA   Xiao L., Scofield M.A., Jeffries W.B.;
RT   "Molecular cloning, expression and characterization of cDNA encoding a
RT   mouse alpha1a-adrenoceptor.";
RL   Br. J. Pharmacol. 124:213-221(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 197-280.
RC   TISSUE=Brain;
RX   MEDLINE=96064818; PubMed=7595531;
RA   Alonso-Llamazares A., Zamanillo D., Casanova E., Ovalle S., Calvo P.,
RA   Chinchetru M.A.;
RT   "Molecular cloning of alpha 1d-adrenergic receptor and tissue
RT   distribution of three alpha 1-adrenergic receptor subtypes in mouse.";
RL   J. Neurochem. 65:2387-2392(1995).
CC   -!- FUNCTION: This alpha-adrenergic receptor mediates its action by
CC       association with G proteins that activate a phosphatidylinositol-
CC       calcium second messenger system. Its effect is mediated by G(q)
CC       and G(11) proteins.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- PTM: Carboxyl-terminal Ser or Thr residues may be phosphorylated
CC       (By similarity).
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF031431; AAC02658.1; -; mRNA.
DR   EMBL; S80220; AAB47044.1; ALT_INIT; mRNA.
DR   IPI; IPI00128843; -.
DR   UniGene; Mm.57064; -.
DR   SMR; P97718; 23-344.
DR   STRING; P97718; -.
DR   PhosphoSite; P97718; -.
DR   PRIDE; P97718; -.
DR   Ensembl; ENSMUST00000054661; ENSMUSP00000053703; ENSMUSG00000045875; Mus musculus.
DR   MGI; MGI:104773; Adra1a.
DR   eggNOG; roNOG12277; -.
DR   HOGENOM; HBG445348; -.
DR   HOVERGEN; HBG106962; -.
DR   InParanoid; P97718; -.
DR   ArrayExpress; P97718; -.
DR   Bgee; P97718; -.
DR   CleanEx; MM_ADRA1A; -.
DR   Genevestigator; P97718; -.
DR   GermOnline; ENSMUSG00000045875; Mus musculus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005624; C:membrane fraction; IDA:MGI.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004937; F:alpha1-adrenergic receptor activity; IDA:MGI.
DR   GO; GO:0007200; P:activation of phospholipase C activity by G...; IDA:MGI.
DR   GO; GO:0007512; P:adult heart development; IGI:MGI.
DR   GO; GO:0016049; P:cell growth; IGI:MGI.
DR   GO; GO:0001985; P:negative regulation of heart rate involved ...; IMP:MGI.
DR   GO; GO:0001994; P:norepinephrine-epinephrine vasoconstriction...; IMP:MGI.
DR   GO; GO:0035265; P:organ growth; IGI:MGI.
DR   GO; GO:0001996; P:positive regulation of heart rate by epinep...; IGI:MGI.
DR   GO; GO:0043410; P:positive regulation of MAPKKK cascade; IGI:MGI.
DR   GO; GO:0001997; P:positive regulation of the force of heart c...; IGI:MGI.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR001004; Adrene_rcpt_A1Cs.
DR   InterPro; IPR002233; Adrnrgc_rcpt.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   PANTHER; PTHR19266:SF89; Adrene_rcpt_A1Cs; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01103; ADRENERGICR.
DR   PRINTS; PR00557; ADRENRGCA1AR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Lipoprotein; Membrane; Palmitate; Phosphoprotein;
KW   Receptor; Transducer; Transmembrane.
FT   CHAIN         1    466       Alpha-1A adrenergic receptor.
FT                                /FTId=PRO_0000069064.
FT   TOPO_DOM      1     27       Extracellular (By similarity).
FT   TRANSMEM     28     51       1 (By similarity).
FT   TOPO_DOM     52     64       Cytoplasmic (By similarity).
FT   TRANSMEM     65     88       2 (By similarity).
FT   TOPO_DOM     89     99       Extracellular (By similarity).
FT   TRANSMEM    100    122       3 (By similarity).
FT   TOPO_DOM    123    143       Cytoplasmic (By similarity).
FT   TRANSMEM    144    167       4 (By similarity).
FT   TOPO_DOM    168    181       Extracellular (By similarity).
FT   TRANSMEM    182    205       5 (By similarity).
FT   TOPO_DOM    206    273       Cytoplasmic (By similarity).
FT   TRANSMEM    274    297       6 (By similarity).
FT   TOPO_DOM    298    305       Extracellular (By similarity).
FT   TRANSMEM    306    329       7 (By similarity).
FT   TOPO_DOM    330    466       Cytoplasmic (By similarity).
FT   MOD_RES     215    215       Phosphoserine; by PKA (Potential).
FT   LIPID       345    345       S-palmitoyl cysteine (Potential).
FT   CARBOHYD      7      7       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     13     13       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     22     22       N-linked (GlcNAc...) (Potential).
FT   DISULFID     99    176       By similarity.
SQ   SEQUENCE   466 AA;  51763 MW;  3649A5A53DBD34DA CRC64;
     MVLLSENASE GSNCTHPPAQ VNISKAILLG VILGGLIIFG VLGNILVILS VACHRHLHSV
     THYYIVNLAV ADLLLTSTVL PFSAIFEILG YWAFGRVFCN IWAAVDVLCC TASIMGLCII
     SIDRYIGVSY PLRYPTIVTQ RRGVRALLCV WALSLVISIG PLFGWRQQAP EDETICQINE
     EPGYVLFSAL GSFYVPLTII LVMYCRVYVV AKRESRGLKS GLKTDKSDSE QVTLRIHRKN
     VPAEGSGVSS AKNKTHFSVR LLKFSREKKA AKTLGIVVGC FVLCWLPFFL VMPIGSFFPN
     FKPPETVFKI VFWLGYLNSC INPIIYPCSS QEFKKAFQNV LRIQCLRRRQ SSKHALGYTL
     HPPSQAVEEQ HRGMVRIPVG SGETFYKISK TDGVCEWKFF SSMPQGSARI TMPKDQSACT
     TARVRSKSFL QVCCCVGSST PRPEENHQVP TIKIHTISLG ENGEEV
//
ID   ADA1B_MESAU             Reviewed;         515 AA.
AC   P18841;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1990, sequence version 1.
DT   02-MAR-2010, entry version 73.
DE   RecName: Full=Alpha-1B adrenergic receptor;
DE   AltName: Full=Alpha-1B adrenoreceptor;
DE            Short=Alpha-1B adrenoceptor;
GN   Name=ADRA1B;
OS   Mesocricetus auratus (Golden hamster).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Cricetidae; Cricetinae; Mesocricetus.
OX   NCBI_TaxID=10036;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=89017157; PubMed=2845398; DOI=10.1073/pnas.85.19.7159;
RA   Cotecchia S., Schwinn D.A., Randall R.R., Lefkowitz R.J., Caron M.G.,
RA   Kobilka B.K.;
RT   "Molecular cloning and expression of the cDNA for the hamster alpha 1-
RT   adrenergic receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:7159-7163(1988).
RN   [2]
RP   MUTAGENESIS OF ALA-293.
RX   MEDLINE=92112850; PubMed=1346134;
RA   Kjelsberg M.A., Cotecchia S., Ostrowski J., Caron M.G.,
RA   Lefkowitz R.J.;
RT   "Constitutive activation of the alpha 1B-adrenergic receptor by all
RT   amino acid substitutions at a single site. Evidence for a region which
RT   constrains receptor activation.";
RL   J. Biol. Chem. 267:1430-1433(1992).
CC   -!- FUNCTION: This alpha-adrenergic receptor mediates its action by
CC       association with G proteins that activate a phosphatidylinositol-
CC       calcium second messenger system.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J04084; AAA58964.1; -; mRNA.
DR   PIR; A40491; A40491.
DR   SMR; P18841; 36-372.
DR   HOVERGEN; HBG106962; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004937; F:alpha1-adrenergic receptor activity; IEA:InterPro.
DR   GO; GO:0007186; P:G-protein coupled receptor protein signalin...; IEA:UniProtKB-KW.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR001115; Adrene_rcpt_A1B.
DR   InterPro; IPR002233; Adrnrgc_rcpt.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01103; ADRENERGICR.
DR   PRINTS; PR00556; ADRENRGCA1BR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Lipoprotein; Membrane; Palmitate; Phosphoprotein;
KW   Receptor; Transducer; Transmembrane.
FT   CHAIN         1    515       Alpha-1B adrenergic receptor.
FT                                /FTId=PRO_0000069070.
FT   TOPO_DOM      1     45       Extracellular (By similarity).
FT   TRANSMEM     46     70       1 (By similarity).
FT   TOPO_DOM     71     83       Cytoplasmic (By similarity).
FT   TRANSMEM     84    105       2 (By similarity).
FT   TOPO_DOM    106    115       Extracellular (By similarity).
FT   TRANSMEM    116    141       3 (By similarity).
FT   TOPO_DOM    142    161       Cytoplasmic (By similarity).
FT   TRANSMEM    162    184       4 (By similarity).
FT   TOPO_DOM    185    201       Extracellular (By similarity).
FT   TRANSMEM    202    224       5 (By similarity).
FT   TOPO_DOM    225    295       Cytoplasmic (By similarity).
FT   TRANSMEM    296    319       6 (By similarity).
FT   TOPO_DOM    320    326       Extracellular (By similarity).
FT   TRANSMEM    327    351       7 (By similarity).
FT   TOPO_DOM    352    515       Cytoplasmic (By similarity).
FT   COMPBIAS    371    378       Poly-Arg.
FT   MOD_RES     264    264       Phosphothreonine (By similarity).
FT   MOD_RES     267    267       Phosphoserine (By similarity).
FT   LIPID       365    365       S-palmitoyl cysteine (Potential).
FT   CARBOHYD     10     10       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     24     24       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     34     34       N-linked (GlcNAc...) (Potential).
FT   DISULFID    118    195       By similarity.
FT   MUTAGEN     293    293       A->X: Confers constitutive activity.
SQ   SEQUENCE   515 AA;  56493 MW;  6DAF1576D1C1CE2D CRC64;
     MNPDLDTGHN TSAPAQWGEL KDANFTGPNQ TSSNSTLPQL DVTRAISVGL VLGAFILFAI
     VGNILVILSV ACNRHLRTPT NYFIVNLAIA DLLLSFTVLP FSATLEVLGY WVLGRIFCDI
     WAAVDVLCCT ASILSLCAIS IDRYIGVRYS LQYPTLVTRR KAILALLSVW VLSTVISIGP
     LLGWKEPAPN DDKECGVTEE PFYALFSSLG SFYIPLAVIL VMYCRVYIVA KRTTKNLEAG
     VMKEMSNSKE LTLRIHSKNF HEDTLSSTKA KGHNPRSSIA VKLFKFSREK KAAKTLGIVV
     GMFILCWLPF FIALPLGSLF STLKPPDAVF KVVFWLGYFN SCLNPIIYPC SSKEFKRAFM
     RILGCQCRSG RRRRRRRRLG ACAYTYRPWT RGGSLERSQS RKDSLDDSGS CMSGSQRTLP
     SASPSPGYLG RGAQPPLELC AYPEWKSGAL LSLPEPPGRR GRLDSGPLFT FKLLGEPESP
     GTEGDASNGG CDATTDLANG QPGFKSNMPL APGHF
//
ID   ADA1B_MOUSE             Reviewed;         514 AA.
AC   P97717;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 2.
DT   02-MAR-2010, entry version 76.
DE   RecName: Full=Alpha-1B adrenergic receptor;
DE   AltName: Full=Alpha-1B adrenoreceptor;
DE            Short=Alpha-1B adrenoceptor;
GN   Name=Adra1b;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=BALB/c; TISSUE=Brain;
RA   Cotecchia S., Lattion-Zellweger A.;
RL   Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 238-276.
RX   MEDLINE=96064818; PubMed=7595531;
RA   Alonso-Llamazares A., Zamanillo D., Casanova E., Ovalle S., Calvo P.,
RA   Chinchetru M.A.;
RT   "Molecular cloning of alpha 1d-adrenergic receptor and tissue
RT   distribution of three alpha 1-adrenergic receptor subtypes in mouse.";
RL   J. Neurochem. 65:2387-2392(1995).
RN   [3]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-263 AND SER-266, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=17242355; DOI=10.1073/pnas.0609836104;
RA   Villen J., Beausoleil S.A., Gerber S.A., Gygi S.P.;
RT   "Large-scale phosphorylation analysis of mouse liver.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:1488-1493(2007).
CC   -!- FUNCTION: This alpha-adrenergic receptor mediates its action by
CC       association with G proteins that activate a phosphatidylinositol-
CC       calcium second messenger system.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y12738; CAA73272.1; -; mRNA.
DR   EMBL; S80219; AAB47043.1; -; mRNA.
DR   IPI; IPI00314429; -.
DR   UniGene; Mm.39086; -.
DR   SMR; P97717; 45-369.
DR   STRING; P97717; -.
DR   PhosphoSite; P97717; -.
DR   PRIDE; P97717; -.
DR   Ensembl; ENSMUST00000055899; ENSMUSP00000057822; ENSMUSG00000050541; Mus musculus.
DR   Ensembl; ENSMUST00000067258; ENSMUSP00000070200; ENSMUSG00000050541; Mus musculus.
DR   MGI; MGI:104774; Adra1b.
DR   eggNOG; roNOG13643; -.
DR   HOVERGEN; HBG106962; -.
DR   InParanoid; P97717; -.
DR   ArrayExpress; P97717; -.
DR   Bgee; P97717; -.
DR   CleanEx; MM_ADRA1B; -.
DR   Genevestigator; P97717; -.
DR   GermOnline; ENSMUSG00000050541; Mus musculus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0000299; C:integral to membrane of membrane fraction; IDA:MGI.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004937; F:alpha1-adrenergic receptor activity; IDA:MGI.
DR   GO; GO:0007512; P:adult heart development; IGI:MGI.
DR   GO; GO:0048148; P:behavioral response to cocaine; IMP:MGI.
DR   GO; GO:0001974; P:blood vessel remodeling; IMP:MGI.
DR   GO; GO:0016049; P:cell growth; IGI:MGI.
DR   GO; GO:0007186; P:G-protein coupled receptor protein signalin...; IEA:UniProtKB-KW.
DR   GO; GO:0042593; P:glucose homeostasis; IMP:MGI.
DR   GO; GO:0007626; P:locomotory behavior; IMP:MGI.
DR   GO; GO:0045818; P:negative regulation of glycogen catabolic p...; IMP:MGI.
DR   GO; GO:0035265; P:organ growth; IGI:MGI.
DR   GO; GO:0045819; P:positive regulation of glycogen catabolic p...; IMP:MGI.
DR   GO; GO:0001996; P:positive regulation of heart rate by epinep...; IGI:MGI.
DR   GO; GO:0001997; P:positive regulation of the force of heart c...; IGI:MGI.
DR   GO; GO:0001975; P:response to amphetamine; IMP:MGI.
DR   GO; GO:0043278; P:response to morphine; IMP:MGI.
DR   GO; GO:0001987; P:vasoconstriction of artery involved in baro...; IMP:MGI.
DR   GO; GO:0008542; P:visual learning; IMP:MGI.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR001115; Adrene_rcpt_A1B.
DR   InterPro; IPR002233; Adrnrgc_rcpt.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01103; ADRENERGICR.
DR   PRINTS; PR00556; ADRENRGCA1BR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Lipoprotein; Membrane; Palmitate; Phosphoprotein;
KW   Receptor; Transducer; Transmembrane.
FT   CHAIN         1    514       Alpha-1B adrenergic receptor.
FT                                /FTId=PRO_0000069071.
FT   TOPO_DOM      1     45       Extracellular (By similarity).
FT   TRANSMEM     46     69       1 (By similarity).
FT   TOPO_DOM     70     82       Cytoplasmic (By similarity).
FT   TRANSMEM     83    104       2 (By similarity).
FT   TOPO_DOM    105    114       Extracellular (By similarity).
FT   TRANSMEM    115    140       3 (By similarity).
FT   TOPO_DOM    141    160       Cytoplasmic (By similarity).
FT   TRANSMEM    161    183       4 (By similarity).
FT   TOPO_DOM    184    200       Extracellular (By similarity).
FT   TRANSMEM    201    223       5 (By similarity).
FT   TOPO_DOM    224    294       Cytoplasmic (By similarity).
FT   TRANSMEM    295    318       6 (By similarity).
FT   TOPO_DOM    319    325       Extracellular (By similarity).
FT   TRANSMEM    326    350       7 (By similarity).
FT   TOPO_DOM    351    514       Cytoplasmic (By similarity).
FT   COMPBIAS    370    377       Poly-Arg.
FT   MOD_RES     263    263       Phosphothreonine.
FT   MOD_RES     266    266       Phosphoserine.
FT   LIPID       364    364       S-palmitoyl cysteine (Potential).
FT   CARBOHYD     10     10       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     24     24       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     29     29       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     34     34       N-linked (GlcNAc...) (Potential).
FT   DISULFID    117    194       By similarity.
SQ   SEQUENCE   514 AA;  56418 MW;  17CFD10123DC2B29 CRC64;
     MNPDLDTGHN TSAPAHWGEL KDANFTGPNQ TSSNSTLPQL DVTRAISVGC LGAFILFAIV
     GNILVILSVA CNRHLRTPTN YFIVNLAIAD LLLSFTDLPF SATLEVLGYW VLGRIFCDIW
     AAVDVLCCTA SILSLCAISI DRYIGVRYSL QYPTLVTRRK AILALLSVWV LSTVISIGPL
     LGWKEPAPND DKECGVTEEP FYALFSSLGS FYIPLAVILV MYCRVYIVAK RTTKNLEAGV
     MKEMSNSKEL TLRIHSKNFH EDTLSSTKAK GHNPRSSIAV KLFKFSREKK AAKTLGIVVG
     MFILCWLPFF IALPLGSLFS TLKPPDAVFK VVFWLGYFNS CLNPIIYPCS SKEFKRAFMR
     ILGCQCRGGR RRRRRRRLGA CAYTYRPWTR GGSLERSQSR KDSLDDSGSC MSGSQRTLPS
     ASPSPGYLGR GTQPPVELCA FPEWKPGALL SLPEPPGRRG RLDSGPLFTF KLLGEPESPG
     TEGDASNGGC DTTTDLANGQ PGFKSNMPLA PGHF
//
ID   ADA2A_HUMAN             Reviewed;         450 AA.
AC   P08913; B0LPF6; Q2I8G2; Q2XN99; Q86TH8; Q9BZK1;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 3.
DT   02-MAR-2010, entry version 124.
DE   RecName: Full=Alpha-2A adrenergic receptor;
DE   AltName: Full=Alpha-2A adrenoreceptor;
DE            Short=Alpha-2A adrenoceptor;
DE            Short=Alpha-2AAR;
DE   AltName: Full=Alpha-2 adrenergic receptor subtype C10;
GN   Name=ADRA2A; Synonyms=ADRA2R, ADRAR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Platelet;
RX   MEDLINE=88042789; PubMed=2823383; DOI=10.1126/science.2823383;
RA   Kobilka B.K., Matsui H., Kobilka T.S., Yang-Feng T.L., Francke U.,
RA   Caron M.G., Lefkowitz R.J., Regan J.W.;
RT   "Cloning, sequencing, and expression of the gene coding for the human
RT   platelet alpha 2-adrenergic receptor.";
RL   Science 238:650-656(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=89308571; PubMed=2568356;
RA   Fraser C.M., Arakawa S., McCombie W.R., Venter J.C.;
RT   "Cloning, sequence analysis, and permanent expression of a human alpha
RT   2-adrenergic receptor in Chinese hamster ovary cells. Evidence for
RT   independent pathways of receptor coupling to adenylate cyclase
RT   attenuation and activation.";
RL   J. Biol. Chem. 264:11754-11761(1989).
RN   [3]
RP   SEQUENCE REVISION TO 333-365.
RX   MEDLINE=91009167; PubMed=2170371;
RA   Guyer C.A., Horstman D.A., Wilson A.L., Clark J.D., Kragoe E.J. Jr.,
RA   Limbird L.E.;
RT   "Cloning, sequencing, and expression of the gene encoding the porcine
RT   alpha 2-adrenergic receptor. Allosteric modulation by Na+, H+, and
RT   amiloride analogs.";
RL   J. Biol. Chem. 265:17307-17317(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-251.
RX   PubMed=10948191; DOI=10.1074/jbc.M004550200;
RA   Small K.M., Forbes S.L., Brown K.M., Liggett S.B.;
RT   "An Asn to Lys polymorphism in the third intracellular loop of the
RT   human alpha 2A-adrenergic receptor imparts enhanced agonist-promoted
RT   Gi coupling.";
RL   J. Biol. Chem. 275:38518-38523(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-251.
RX   PubMed=16567612; DOI=10.1073/pnas.0601345103;
RA   Small K.M., Brown K.M., Seman C.A., Theiss C.T., Liggett S.B.;
RT   "Complex haplotypes derived from noncoding polymorphisms of the
RT   intronless alpha-2A-adrenergic gene diversify receptor expression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:5472-5477(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Mao Z.-M., Tang K., Li B.-M., Jing N.-H.;
RT   "Cloning and expression of human alpha-2A adrenergic receptor in SY5Y
RT   cells.";
RL   Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Castellano M., Giacche' M., Rossi F., Rivadossi F., Perani C.,
RA   Beschi M., Agabiti Rosei E.;
RT   "A search for genetic variability in the human alpha-2 adrenergic
RT   receptor on chromosome 10.";
RL   Submitted (AUG-2000) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Liu L., Yuan L.;
RT   "Human alpha-2A adrenergic receptor gene and the genotype of -1296
RT   nucleotide and motionsickness.";
RL   Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-251.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (NOV-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=PNS, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 77-209.
RX   MEDLINE=91192139; PubMed=1849485; DOI=10.1016/0014-5793(91)80301-I;
RA   Chhajlani V., Rangel N., Uhlen S., Wikberg J.E.S.;
RT   "Identification of an additional gene belonging to the alpha 2
RT   adrenergic receptor family in the human genome by PCR.";
RL   FEBS Lett. 280:241-244(1991).
RN   [14]
RP   MUTAGENESIS OF PHE-412.
RX   MEDLINE=91332079; PubMed=1678390;
RA   Suryanarayana S., Daunt D.A., von Zastrow M., Kobilka B.K.;
RT   "A point mutation in the seventh hydrophobic domain of the alpha 2
RT   adrenergic receptor increases its affinity for a family of beta
RT   receptor antagonists.";
RL   J. Biol. Chem. 266:15488-15492(1991).
RN   [15]
RP   MUTAGENESIS OF ASPARTIC ACID AND SERINE RESIDUES.
RX   MEDLINE=91342598; PubMed=1678850;
RA   Wang C.-D., Buck M.A., Fraser C.M.;
RT   "Site-directed mutagenesis of alpha 2a-adrenergic receptors:
RT   Identification of amino acids involved in ligand binding and receptor
RT   activation by agonists.";
RL   Mol. Pharmacol. 40:168-179(1991).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-297; SER-298 AND
RP   SER-299, AND MASS SPECTROMETRY.
RC   TISSUE=Epithelium;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [17]
RP   STRUCTURE BY NMR OF 118-149, AND PROBABLE MEMBRANE TOPOLOGY.
RX   MEDLINE=21885815; PubMed=11888275; DOI=10.1021/bi015811+;
RA   Chung D.A., Zuiderweg E.R.P., Fowler C.B., Soyer O.S., Mosberg H.I.,
RA   Neubig R.R.;
RT   "NMR structure of the second intracellular loop of the alpha 2A
RT   adrenergic receptor: evidence for a novel cytoplasmic helix.";
RL   Biochemistry 41:3596-3604(2002).
CC   -!- FUNCTION: Alpha-2 adrenergic receptors mediate the catecholamine-
CC       induced inhibition of adenylate cyclase through the action of G
CC       proteins. The rank order of potency for agonists of this receptor
CC       is oxymetazoline > clonidine > epinephrine > norepinephrine >
CC       phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin =
CC       p-octopamine. For antagonists, the rank order is yohimbine >
CC       phentolamine = mianserine > chlorpromazine = spiperone = prazosin
CC       > propanolol > alprenolol = pindolol.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/adra2a/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M18415; AAA51664.1; -; Genomic_DNA.
DR   EMBL; M23533; AAA51665.1; -; Genomic_DNA.
DR   EMBL; AF281308; AAF91441.1; -; Genomic_DNA.
DR   EMBL; AF316894; AAK01634.1; -; Genomic_DNA.
DR   EMBL; DQ149926; AAZ73101.1; -; Genomic_DNA.
DR   EMBL; AF284095; AAK26743.1; -; mRNA.
DR   EMBL; AF262016; AAG00447.2; -; Genomic_DNA.
DR   EMBL; AY032736; AAK51162.1; -; Genomic_DNA.
DR   EMBL; DQ285607; ABB72683.1; -; Genomic_DNA.
DR   EMBL; EU332846; ABY87535.1; -; Genomic_DNA.
DR   EMBL; AL158163; CAH72817.1; -; Genomic_DNA.
DR   EMBL; BC035047; AAH35047.1; -; mRNA.
DR   EMBL; BC050414; AAH50414.4; -; mRNA.
DR   IPI; IPI00943254; -.
DR   PIR; A34169; A34169.
DR   RefSeq; NP_000672.3; -.
DR   UniGene; Hs.249159; -.
DR   PDB; 1HLL; NMR; -; A=118-149.
DR   PDB; 1HO9; NMR; -; A=118-149.
DR   PDB; 1HOD; NMR; -; A=118-149.
DR   PDB; 1HOF; NMR; -; A=118-149.
DR   PDBsum; 1HLL; -.
DR   PDBsum; 1HO9; -.
DR   PDBsum; 1HOD; -.
DR   PDBsum; 1HOF; -.
DR   SMR; P08913; 9-447.
DR   STRING; P08913; -.
DR   PhosphoSite; P08913; -.
DR   PRIDE; P08913; -.
DR   Ensembl; ENST00000280155; ENSP00000280155; ENSG00000150594; Homo sapiens.
DR   Ensembl; ENST00000449894; ENSP00000397995; ENSG00000150594; Homo sapiens.
DR   GeneID; 150; -.
DR   KEGG; hsa:150; -.
DR   UCSC; uc001kzo.1; human.
DR   CTD; 150; -.
DR   GeneCards; GC10P112826; -.
DR   H-InvDB; HIX0025918; -.
DR   HGNC; HGNC:281; ADRA2A.
DR   MIM; 104210; gene.
DR   PharmGKB; PA35; -.
DR   eggNOG; prNOG15068; -.
DR   HOGENOM; HBG445348; -.
DR   HOVERGEN; HBG106962; -.
DR   InParanoid; P08913; -.
DR   PhylomeDB; P08913; -.
DR   Reactome; REACT_14797; Signaling by GPCR.
DR   Reactome; REACT_15380; Diabetes pathways.
DR   Reactome; REACT_604; Hemostasis.
DR   DrugBank; DB00321; Amitriptyline.
DR   DrugBank; DB00182; Amphetamine.
DR   DrugBank; DB00964; Apraclonidine.
DR   DrugBank; DB00865; Benzphetamine.
DR   DrugBank; DB00217; Bethanidine.
DR   DrugBank; DB00484; Brimonidine.
DR   DrugBank; DB00575; Clonidine.
DR   DrugBank; DB04840; Debrisoquin.
DR   DrugBank; DB00633; Dexmedetomidine.
DR   DrugBank; DB00449; Dipivefrin.
DR   DrugBank; DB00751; Epinastine.
DR   DrugBank; DB00696; Ergotamine.
DR   DrugBank; DB00800; Fenoldopam.
DR   DrugBank; DB00629; Guanabenz.
DR   DrugBank; DB00226; Guanadrel Sulfate.
DR   DrugBank; DB01170; Guanethidine.
DR   DrugBank; DB01018; Guanfacine.
DR   DrugBank; DB04948; Lofexidine.
DR   DrugBank; DB00968; Methyldopa.
DR   DrugBank; DB06148; Mianserin.
DR   DrugBank; DB00370; Mirtazapine.
DR   DrugBank; DB00368; Norepinephrine.
DR   DrugBank; DB00935; Oxymetazoline.
DR   DrugBank; DB00692; Phentolamine.
DR   DrugBank; DB00397; Phenylpropanolamine.
DR   DrugBank; DB00852; Pseudoephedrine.
DR   DrugBank; DB00697; Tizanidine.
DR   DrugBank; DB00656; Trazodone.
DR   DrugBank; DB01392; Yohimbine.
DR   NextBio; 595; -.
DR   ArrayExpress; P08913; -.
DR   Bgee; P08913; -.
DR   CleanEx; HS_ADRA2A; -.
DR   Genevestigator; P08913; -.
DR   GermOnline; ENSG00000150594; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0004938; F:alpha2-adrenergic receptor activity; TAS:ProtInc.
DR   GO; GO:0015459; F:potassium channel regulator activity; TAS:ProtInc.
DR   GO; GO:0030036; P:actin cytoskeleton organization; TAS:ProtInc.
DR   GO; GO:0000187; P:activation of MAPK activity; TAS:ProtInc.
DR   GO; GO:0006928; P:cellular component movement; TAS:ProtInc.
DR   GO; GO:0007186; P:G-protein coupled receptor protein signalin...; EXP:Reactome.
DR   GO; GO:0007194; P:negative regulation of adenylate cyclase ac...; TAS:ProtInc.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; TAS:ProtInc.
DR   GO; GO:0007266; P:Rho protein signal transduction; TAS:ProtInc.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR001946; Adren_rcpt_A2A.
DR   InterPro; IPR015695; Adren_rcpt_A2A/B/C.
DR   InterPro; IPR002233; Adrnrgc_rcpt.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   PANTHER; PTHR19266:SF56; Alpha-2A_Recept; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01103; ADRENERGICR.
DR   PRINTS; PR00558; ADRENRGCA2AR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Complete proteome;
KW   Direct protein sequencing; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Lipoprotein; Membrane; Palmitate; Phosphoprotein;
KW   Polymorphism; Receptor; Transducer; Transmembrane.
FT   CHAIN         1    450       Alpha-2A adrenergic receptor.
FT                                /FTId=PRO_0000069080.
FT   TOPO_DOM      1     33       Extracellular (By similarity).
FT   TRANSMEM     34     59       1 (By similarity).
FT   TOPO_DOM     60     70       Cytoplasmic (By similarity).
FT   TRANSMEM     71     96       2 (By similarity).
FT   TOPO_DOM     97    106       Extracellular (By similarity).
FT   TRANSMEM    107    129       3 (By similarity).
FT   TOPO_DOM    130    151       Cytoplasmic (By similarity).
FT   TRANSMEM    152    172       4 (By similarity).
FT   TOPO_DOM    173    194       Extracellular (By similarity).
FT   TRANSMEM    195    217       5 (By similarity).
FT   TOPO_DOM    218    374       Cytoplasmic (By similarity).
FT   TRANSMEM    375    395       6 (By similarity).
FT   TOPO_DOM    396    409       Extracellular (By similarity).
FT   TRANSMEM    410    429       7 (By similarity).
FT   TOPO_DOM    430    450       Cytoplasmic (By similarity).
FT   SITE        113    113       Implicated in ligand binding.
FT   SITE        200    200       Implicated in catechol agonist binding
FT                                and receptor activation.
FT   SITE        204    204       Implicated in catechol agonist binding
FT                                and receptor activation.
FT   MOD_RES     297    297       Phosphoserine.
FT   MOD_RES     298    298       Phosphoserine.
FT   MOD_RES     299    299       Phosphoserine.
FT   LIPID       442    442       S-palmitoyl cysteine (By similarity).
FT   CARBOHYD     10     10       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     14     14       N-linked (GlcNAc...) (Potential).
FT   DISULFID    106    188       By similarity.
FT   VARIANT     251    251       N -> K (rare polymorphism; frequency in
FT                                Caucasians 0.004 and in African-Americans
FT                                0.05; 40% increase in agonist-promoted Gi
FT                                coupling; dbSNP:rs1800035).
FT                                /FTId=VAR_014957.
FT   VARIANT     386    386       C -> S (in dbSNP:rs35658213).
FT                                /FTId=VAR_055908.
FT   MUTAGEN      79     79       D->N: No change in binding affinity.
FT                                eliminates guanine nucleotide-sensitive
FT                                agonist binding.
FT   MUTAGEN     113    113       D->N: No binding to yohimbine. Increase
FT                                in adenylate cyclase activity.
FT   MUTAGEN     130    130       D->N: Lower affinity for agonists.
FT                                Eliminates guanine nucleotide-sensitive
FT                                agonist binding.
FT   MUTAGEN     200    200       S->A: Lower affinity for agonists. No
FT                                change in guanine nucleotide-sensitive
FT                                agonist binding.
FT   MUTAGEN     204    204       S->A: Lower affinity for agonists.
FT                                Reduced guanine nucleotide-sensitive
FT                                agonist binding.
FT   MUTAGEN     412    412       F->N: 350-fold reduced affinity for
FT                                alpha-2 antagonist yohimbine, 3000-fold
FT                                increase for beta-antagonist alprenolol.
FT   CONFLICT    104    104       A -> T (in Ref. 1; AAA51664).
FT   CONFLICT    124    124       L -> P (in Ref. 13).
FT   CONFLICT    157    157       V -> C (in Ref. 1; AAA51664).
FT   CONFLICT    333    365       PRRGPGATGIGTPAAGPGEERVGAAKASRWRGR -> RGAG
FT                                RGRRGSGRRLQGRGRSASGLPRRRAGAGG (in Ref. 1;
FT                                AAA51664 and 2; AAA51665).
FT   CONFLICT    368    368       R -> L (in Ref. 1; AAA51664).
FT   HELIX       119    128
FT   HELIX       130    139
FT   HELIX       140    142
SQ   SEQUENCE   450 AA;  48957 MW;  A703CF262F04E8AC CRC64;
     MGSLQPDAGN ASWNGTEAPG GGARATPYSL QVTLTLVCLA GLLMLLTVFG NVLVIIAVFT
     SRALKAPQNL FLVSLASADI LVATLVIPFS LANEVMGYWY FGKAWCEIYL ALDVLFCTSS
     IVHLCAISLD RYWSITQAIE YNLKRTPRRI KAIIITVWVI SAVISFPPLI SIEKKGGGGG
     PQPAEPRCEI NDQKWYVISS CIGSFFAPCL IMILVYVRIY QIAKRRTRVP PSRRGPDAVA
     APPGGTERRP NGLGPERSAG PGGAEAEPLP TQLNGAPGEP APAGPRDTDA LDLEESSSSD
     HAERPPGPRR PERGPRGKGK ARASQVKPGD SLPRRGPGAT GIGTPAAGPG EERVGAAKAS
     RWRGRQNREK RFTFVLAVVI GVFVVCWFPF FFTYTLTAVG CSVPRTLFKF FFWFGYCNSS
     LNPVIYTIFN HDFRRAFKKI LCRGDRKRIV
//
ID   ADA2A_MOUSE             Reviewed;         450 AA.
AC   Q01338;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1993, sequence version 1.
DT   02-MAR-2010, entry version 88.
DE   RecName: Full=Alpha-2A adrenergic receptor;
DE   AltName: Full=Alpha-2A adrenoreceptor;
DE            Short=Alpha-2A adrenoceptor;
DE            Short=Alpha-2AAR;
GN   Name=Adra2a;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=92342131; PubMed=1353249;
RA   Link R.E., Daunt D.A., Barsh G., Chruscinski A.J., Kobilka B.K.;
RT   "Cloning of two mouse genes encoding alpha 2-adrenergic receptor
RT   subtypes and identification of a single amino acid in the mouse alpha
RT   2-C10 homolog responsible for an interspecies variation in antagonist
RT   binding.";
RL   Mol. Pharmacol. 42:16-27(1992).
CC   -!- FUNCTION: Alpha-2 adrenergic receptors mediate the catecholamine-
CC       induced inhibition of adenylate cyclase through the action of G
CC       proteins.
CC   -!- INTERACTION:
CC       Q14232:EIF2B1 (xeno); NbExp=1; IntAct=EBI-491073, EBI-491065;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M99377; AAA37213.1; -; Genomic_DNA.
DR   IPI; IPI00122276; -.
DR   PIR; I49481; I49481.
DR   UniGene; Mm.235195; -.
DR   SMR; Q01338; 8-447.
DR   IntAct; Q01338; 1.
DR   STRING; Q01338; -.
DR   PhosphoSite; Q01338; -.
DR   PRIDE; Q01338; -.
DR   Ensembl; ENSMUST00000036700; ENSMUSP00000036203; ENSMUSG00000033717; Mus musculus.
DR   UCSC; uc008hxi.1; mouse.
DR   MGI; MGI:87934; Adra2a.
DR   eggNOG; maNOG17874; -.
DR   HOVERGEN; HBG106962; -.
DR   InParanoid; Q01338; -.
DR   PhylomeDB; Q01338; -.
DR   NextBio; 279038; -.
DR   ArrayExpress; Q01338; -.
DR   Bgee; Q01338; -.
DR   CleanEx; MM_ADRA2A; -.
DR   Genevestigator; Q01338; -.
DR   GermOnline; ENSMUSG00000033717; Mus musculus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004938; F:alpha2-adrenergic receptor activity; TAS:MGI.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0042596; P:fear response; IMP:MGI.
DR   GO; GO:0007186; P:G-protein coupled receptor protein signalin...; IDA:MGI.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR001946; Adren_rcpt_A2A.
DR   InterPro; IPR015695; Adren_rcpt_A2A/B/C.
DR   InterPro; IPR002233; Adrnrgc_rcpt.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   PANTHER; PTHR19266:SF56; Alpha-2A_Recept; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01103; ADRENERGICR.
DR   PRINTS; PR00558; ADRENRGCA2AR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Lipoprotein; Membrane; Palmitate; Phosphoprotein;
KW   Receptor; Transducer; Transmembrane.
FT   CHAIN         1    450       Alpha-2A adrenergic receptor.
FT                                /FTId=PRO_0000069081.
FT   TOPO_DOM      1     33       Extracellular (By similarity).
FT   TRANSMEM     34     59       1 (By similarity).
FT   TOPO_DOM     60     70       Cytoplasmic (By similarity).
FT   TRANSMEM     71     96       2 (By similarity).
FT   TOPO_DOM     97    106       Extracellular (By similarity).
FT   TRANSMEM    107    129       3 (By similarity).
FT   TOPO_DOM    130    149       Cytoplasmic (By similarity).
FT   TRANSMEM    150    173       4 (By similarity).
FT   TOPO_DOM    174    192       Extracellular (By similarity).
FT   TRANSMEM    193    217       5 (By similarity).
FT   TOPO_DOM    218    374       Cytoplasmic (By similarity).
FT   TRANSMEM    375    399       6 (By similarity).
FT   TOPO_DOM    400    409       Extracellular (By similarity).
FT   TRANSMEM    410    430       7 (By similarity).
FT   TOPO_DOM    431    450       Cytoplasmic (By similarity).
FT   SITE        113    113       Implicated in ligand binding (By
FT                                similarity).
FT   SITE        200    200       Implicated in catechol agonist binding
FT                                (By similarity).
FT   SITE        204    204       Implicated in catechol agonist binding
FT                                (By similarity).
FT   MOD_RES     297    297       Phosphoserine (By similarity).
FT   MOD_RES     298    298       Phosphoserine (By similarity).
FT   MOD_RES     299    299       Phosphoserine (By similarity).
FT   LIPID       442    442       S-palmitoyl cysteine (By similarity).
FT   CARBOHYD     10     10       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     14     14       N-linked (GlcNAc...) (Potential).
FT   DISULFID    106    188       By similarity.
SQ   SEQUENCE   450 AA;  48865 MW;  F07E225393AFA93B CRC64;
     MGSLQPDAGN SSWNGTEAPG GGTRATPYSL QVTLTLVCLA GLLMLFTVFG NVLVIIAVFT
     SRALKAPQNL FLVSLASADI LVATLVIPFS LANEVMGYWY FGKVWCEIYL ALDVLFCTSS
     IVHLCAISLD RYWSITQAIE YNLKRTPRRI KAIIVTVWVI SAVISFPPLI SIEKKGAGGG
     QQPAEPSCKI NDQKWYVISS SIGSFFAPCL IMILVYVRIY QIAKRRTRVP PSRRGPDACS
     APPGGADRRP NGLGPERGAG PTGAEAEPLP TQLNGAPGEP APAGPRDGDA LDLEESSSSE
     HAERPPGPRR PDRGPRAKGK TRASQVKPGD SLPRRGPGAA GPGASGSGHG EERGGGAKAS
     RWRGRQNREK RFTFVLAVVI GVFVVCWFPF FFTYTLIAVG CPVPSQLFNF FFWFGYCNSS
     LNPVIYTIFN HDFRRAFKKI LCRGDRKRIV
//
ID   ADA2A_PIG               Reviewed;         450 AA.
AC   P18871;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1990, sequence version 1.
DT   02-MAR-2010, entry version 80.
DE   RecName: Full=Alpha-2A adrenergic receptor;
DE   AltName: Full=Alpha-2A adrenoreceptor;
DE            Short=Alpha-2A adrenoceptor;
DE            Short=Alpha-2AAR;
GN   Name=ADRA2A; Synonyms=A2AR;
OS   Sus scrofa (Pig).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Suina; Suidae;
OC   Sus.
OX   NCBI_TaxID=9823;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 212-232.
RC   TISSUE=Liver;
RX   MEDLINE=91009167; PubMed=2170371;
RA   Guyer C.A., Horstman D.A., Wilson A.L., Clark J.D., Kragoe E.J. Jr.,
RA   Limbird L.E.;
RT   "Cloning, sequencing, and expression of the gene encoding the porcine
RT   alpha 2-adrenergic receptor. Allosteric modulation by Na+, H+, and
RT   amiloride analogs.";
RL   J. Biol. Chem. 265:17307-17317(1990).
RN   [2]
RP   MUTAGENESIS OF CYS-442.
RX   MEDLINE=93216775; PubMed=8385131;
RA   Kennedy M.E., Limbird L.E.;
RT   "Mutations of the alpha 2A-adrenergic receptor that eliminate
RT   detectable palmitoylation do not perturb receptor-G-protein
RT   coupling.";
RL   J. Biol. Chem. 268:8003-8011(1993).
CC   -!- FUNCTION: Alpha-2 adrenergic receptors mediate the catecholamine-
CC       induced inhibition of adenylate cyclase through the action of G
CC       proteins.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- MISCELLANEOUS: Alpha2-adrenergic receptor shows an allosteric
CC       modulation by Na(+), H(+) and amiloride analogs.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J05652; AAA30984.1; -; Genomic_DNA.
DR   PIR; A38316; A38316.
DR   RefSeq; NP_999565.1; -.
DR   UniGene; Ssc.27594; -.
DR   SMR; P18871; 37-441.
DR   Ensembl; ENSSSCT00000011625; ENSSSCP00000011323; ENSSSCG00000010629; Sus scrofa.
DR   GeneID; 399501; -.
DR   KEGG; ssc:399501; -.
DR   CTD; 399501; -.
DR   HOVERGEN; HBG106962; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004938; F:alpha2-adrenergic receptor activity; IEA:InterPro.
DR   GO; GO:0007186; P:G-protein coupled receptor protein signalin...; IEA:UniProtKB-KW.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR001946; Adren_rcpt_A2A.
DR   InterPro; IPR015695; Adren_rcpt_A2A/B/C.
DR   InterPro; IPR002233; Adrnrgc_rcpt.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   PANTHER; PTHR19266:SF56; Alpha-2A_Recept; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01103; ADRENERGICR.
DR   PRINTS; PR00558; ADRENRGCA2AR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Direct protein sequencing; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane;
KW   Palmitate; Phosphoprotein; Receptor; Transducer; Transmembrane.
FT   CHAIN         1    450       Alpha-2A adrenergic receptor.
FT                                /FTId=PRO_0000069082.
FT   TOPO_DOM      1     33       Extracellular (By similarity).
FT   TRANSMEM     34     59       1 (By similarity).
FT   TOPO_DOM     60     70       Cytoplasmic (By similarity).
FT   TRANSMEM     71     96       2 (By similarity).
FT   TOPO_DOM     97    106       Extracellular (By similarity).
FT   TRANSMEM    107    129       3 (By similarity).
FT   TOPO_DOM    130    149       Cytoplasmic (By similarity).
FT   TRANSMEM    150    173       4 (By similarity).
FT   TOPO_DOM    174    192       Extracellular (By similarity).
FT   TRANSMEM    193    217       5 (By similarity).
FT   TOPO_DOM    218    374       Cytoplasmic (By similarity).
FT   TRANSMEM    375    399       6 (By similarity).
FT   TOPO_DOM    400    409       Extracellular (By similarity).
FT   TRANSMEM    410    430       7 (By similarity).
FT   TOPO_DOM    431    450       Cytoplasmic (By similarity).
FT   SITE        113    113       Implicated in ligand binding (By
FT                                similarity).
FT   SITE        200    200       Implicated in catechol agonist binding
FT                                (By similarity).
FT   SITE        204    204       Implicated in catechol agonist binding
FT                                (By similarity).
FT   MOD_RES     297    297       Phosphoserine (By similarity).
FT   MOD_RES     298    298       Phosphoserine (By similarity).
FT   MOD_RES     299    299       Phosphoserine (By similarity).
FT   LIPID       442    442       S-palmitoyl cysteine.
FT   CARBOHYD     10     10       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     14     14       N-linked (GlcNAc...) (Potential).
FT   DISULFID    106    188       By similarity.
FT   MUTAGEN     442    442       C->A,S: Loss of palmitoylation.
SQ   SEQUENCE   450 AA;  48976 MW;  79D7D5B47372074E CRC64;
     MGSLQPEAGN ASWNGTEAPG GGARATPYSL QVTLTLVCLA GLLMLFTVFG NVLVIIAVFT
     SRALKAPQNL FLVSLASADI LVATLVIPFS LANEVMGYWY FGKAWCEIYL ALDVLFCTSS
     IVHLCAISLD RYWSITQAIE YNLKRTPRRI KAIIVTVWVI SAVISFPPLI SIEKKAGGGG
     QQPAEPRCEI NDQKWYVISS CIGSFFAPCL IMILVYVRIY QIAKRRTRVP PSRRGPDAAA
     ALPGGAERRP NGLGPERGVG RVGAEAEPLP VQLNGAPGEP APAGPRDADG LDLEESSSSE
     HAERPPGPRR SERGPRAKSK ARASQVKPGD SLPRRGPGAP GPGAPATGAG EERGGVAKAS
     RWRGRQNREK RFTFVLAVVI GVFVVCWFPF FFTYTLTAVG CSVPPTLFKF FFWFGYCNSS
     LNPVIYTIFN HDFRRAFKKI LCRGDRKRIV
//
ID   ADA2B_MOUSE             Reviewed;         450 AA.
AC   P30545;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   21-JUN-2005, sequence version 2.
DT   02-MAR-2010, entry version 93.
DE   RecName: Full=Alpha-2B adrenergic receptor;
DE   AltName: Full=Alpha-2B adrenoreceptor;
DE            Short=Alpha-2B adrenoceptor;
DE            Short=Alpha-2BAR;
GN   Name=Adra2b;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=DBA/2; TISSUE=Liver;
RX   MEDLINE=93129625; PubMed=1336396; DOI=10.1016/0167-4781(92)90126-K;
RA   Chen W.-M., Chang A.C., Shie B.J., Chang Y.-H., Chang N.-C.A.;
RT   "Molecular cloning and characterization of a mouse alpha 2C2
RT   adrenoceptor subtype gene.";
RL   Biochim. Biophys. Acta 1171:219-223(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=92378586; PubMed=1354956; DOI=10.1016/S0006-291X(05)81544-X;
RA   Chruscinski A.J., Link R.E., Daunt D.A., Barsh G.S., Kobilka B.K.;
RT   "Cloning and expression of the mouse homolog of the human alpha 2-C2
RT   adrenergic receptor.";
RL   Biochem. Biophys. Res. Commun. 186:1280-1287(1992).
CC   -!- FUNCTION: Alpha-2 adrenergic receptors mediate the catecholamine-
CC       induced inhibition of adenylate cyclase through the action of G
CC       proteins.
CC   -!- INTERACTION:
CC       Q14232:EIF2B1 (xeno); NbExp=1; IntAct=EBI-491084, EBI-491065;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M94583; AAA73895.1; ALT_INIT; Genomic_DNA.
DR   EMBL; L00979; AAA37131.1; -; Genomic_DNA.
DR   IPI; IPI00469442; -.
DR   PIR; S28221; S28221.
DR   UniGene; Mm.347390; -.
DR   SMR; P30545; 16-443.
DR   IntAct; P30545; 1.
DR   STRING; P30545; -.
DR   PRIDE; P30545; -.
DR   Ensembl; ENSMUST00000071902; ENSMUSP00000071798; ENSMUSG00000058620; Mus musculus.
DR   Ensembl; ENSMUST00000104934; ENSMUSP00000100539; ENSMUSG00000058620; Mus musculus.
DR   MGI; MGI:87935; Adra2b.
DR   eggNOG; maNOG18122; -.
DR   HOGENOM; HBG445348; -.
DR   HOVERGEN; HBG106962; -.
DR   InParanoid; P30545; -.
DR   ArrayExpress; P30545; -.
DR   Bgee; P30545; -.
DR   CleanEx; MM_ADRA2B; -.
DR   Genevestigator; P30545; -.
DR   GermOnline; ENSMUSG00000058620; Mus musculus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004938; F:alpha2-adrenergic receptor activity; IDA:MGI.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0001525; P:angiogenesis; IMP:MGI.
DR   GO; GO:0007186; P:G-protein coupled receptor protein signalin...; IDA:MGI.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR015695; Adren_rcpt_A2A/B/C.
DR   InterPro; IPR000207; Adren_rcpt_A2B.
DR   InterPro; IPR002233; Adrnrgc_rcpt.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   PANTHER; PTHR19266:SF56; Alpha-2A_Recept; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01103; ADRENERGICR.
DR   PRINTS; PR00559; ADRENRGCA2BR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Lipoprotein; Membrane; Palmitate; Phosphoprotein; Receptor;
KW   Transducer; Transmembrane.
FT   CHAIN         1    450       Alpha-2B adrenergic receptor.
FT                                /FTId=PRO_0000069096.
FT   TOPO_DOM      1     12       Extracellular (By similarity).
FT   TRANSMEM     13     37       1 (By similarity).
FT   TOPO_DOM     38     49       Cytoplasmic (By similarity).
FT   TRANSMEM     50     75       2 (By similarity).
FT   TOPO_DOM     76     85       Extracellular (By similarity).
FT   TRANSMEM     86    108       3 (By similarity).
FT   TOPO_DOM    109    130       Cytoplasmic (By similarity).
FT   TRANSMEM    131    153       4 (By similarity).
FT   TOPO_DOM    154    169       Extracellular (By similarity).
FT   TRANSMEM    170    193       5 (By similarity).
FT   TOPO_DOM    194    372       Cytoplasmic (By similarity).
FT   TRANSMEM    373    396       6 (By similarity).
FT   TOPO_DOM    397    405       Extracellular (By similarity).
FT   TRANSMEM    406    429       7 (By similarity).
FT   TOPO_DOM    430    450       Cytoplasmic (By similarity).
FT   COMPBIAS    301    311       Asp/Glu-rich (acidic).
FT   SITE         92     92       Implicated in ligand binding (By
FT                                similarity).
FT   SITE        176    176       Implicated in catechol agonist binding
FT                                (By similarity).
FT   SITE        180    180       Implicated in catechol agonist binding
FT                                (By similarity).
FT   LIPID       442    442       S-palmitoyl cysteine (Potential).
FT   DISULFID     85    164       By similarity.
FT   CONFLICT    197    197       V -> L (in Ref. 1; AAA73895).
FT   CONFLICT    224    225       Missing (in Ref. 2).
SQ   SEQUENCE   450 AA;  50172 MW;  A95DA296CA12A992 CRC64;
     MVHQEPYSVQ ATAAIASAIT FLILFTIFGN ALVILAVLTS RSLRAPQNLF LVSLAAADIL
     VATLIIPFSL ANELLGYWYF WRAWCEVYLA LDVLFCTSSI VHLCAISLDR YWAVSRALEY
     NSKRTPRRIK CIILTVWLIA AVISLPPLIY KGDQRPEPHG LPQCELNQEA WYILASSIGS
     FFAPCLIMIL VYLRIYVIAK RSHCRGLGAK RGSGEGESKK PRPGPAAGGV PASAKVPTLV
     SPLSSVGEAN GHPKPPREKE EGETPEDPEA RALPPNWSAL PRSVQDQKKG TSGATAEKGA
     EEDEEEVEEC EPQTLPASPA SVFNPPLQQP QTSRVLATLR GQVLLSKNVG VASGQWWRRR
     TQLSREKRFT FVLAVVIGVF VVCWFPFFFS YSLGAICPQH CKVPHGLFQF FFWIGYCNSS
     LNPVIYTIFN QDFRRAFRRI LCRQWTQTGW
//
ID   ADA2C_MOUSE             Reviewed;         458 AA.
AC   Q01337;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1993, sequence version 1.
DT   02-MAR-2010, entry version 83.
DE   RecName: Full=Alpha-2C adrenergic receptor;
DE   AltName: Full=Alpha-2C adrenoreceptor;
DE            Short=Alpha-2C adrenoceptor;
DE            Short=Alpha-2CAR;
DE   AltName: Full=Alpha-2 adrenergic receptor subtype C4;
GN   Name=Adra2c;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=92342131; PubMed=1353249;
RA   Link R.E., Daunt D.A., Barsh G., Chruscinski A.J., Kobilka B.K.;
RT   "Cloning of two mouse genes encoding alpha 2-adrenergic receptor
RT   subtypes and identification of a single amino acid in the mouse alpha
RT   2-C10 homolog responsible for an interspecies variation in antagonist
RT   binding.";
RL   Mol. Pharmacol. 42:16-27(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=DBA/2;
RX   MEDLINE=93250567; PubMed=8387367;
RA   Chang Y.-H., Chang A.C., Chen W.-M., Chang N.-C.A.;
RT   "Molecular characterization of a murine homologue of alpha 2C4
RT   adrenoceptor subtype gene.";
RL   Biochem. Mol. Biol. Int. 29:467-474(1993).
CC   -!- FUNCTION: Alpha-2 adrenergic receptors mediate the catecholamine-
CC       induced inhibition of adenylate cyclase through the action of G
CC       proteins.
CC   -!- INTERACTION:
CC       Q14232:EIF2B1 (xeno); NbExp=1; IntAct=EBI-491121, EBI-491065;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M99376; AAA37212.1; -; Genomic_DNA.
DR   EMBL; M97516; AAA37183.1; -; Genomic_DNA.
DR   IPI; IPI00850891; -.
DR   PIR; A48392; A48392.
DR   PIR; I49480; I49480.
DR   RefSeq; NP_031444.2; -.
DR   RefSeq; XP_001475607.1; -.
DR   UniGene; Mm.407152; -.
DR   UniGene; Mm.57205; -.
DR   SMR; Q01337; 53-452.
DR   IntAct; Q01337; 1.
DR   STRING; Q01337; -.
DR   PRIDE; Q01337; -.
DR   Ensembl; ENSMUST00000049545; ENSMUSP00000059705; ENSMUSG00000045318; Mus musculus.
DR   GeneID; 100045767; -.
DR   GeneID; 11553; -.
DR   KEGG; mmu:100045767; -.
DR   KEGG; mmu:11553; -.
DR   UCSC; uc009vdd.1; mouse.
DR   CTD; 11553; -.
DR   MGI; MGI:87936; Adra2c.
DR   eggNOG; maNOG18808; -.
DR   HOGENOM; HBG445348; -.
DR   HOVERGEN; HBG106962; -.
DR   InParanoid; Q01337; -.
DR   OMA; SRSVEFF; -.
DR   OrthoDB; EOG9S7N8H; -.
DR   PhylomeDB; Q01337; -.
DR   NextBio; 459225; -.
DR   ArrayExpress; Q01337; -.
DR   Bgee; Q01337; -.
DR   CleanEx; MM_ADRA2C; -.
DR   Genevestigator; Q01337; -.
DR   GermOnline; ENSMUSG00000045318; Mus musculus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004938; F:alpha2-adrenergic receptor activity; TAS:MGI.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0007186; P:G-protein coupled receptor protein signalin...; IDA:MGI.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR015695; Adren_rcpt_A2A/B/C.
DR   InterPro; IPR000735; Adren_rcpt_A2C.
DR   InterPro; IPR002233; Adrnrgc_rcpt.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   PANTHER; PTHR19266:SF56; Alpha-2A_Recept; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01103; ADRENERGICR.
DR   PRINTS; PR00560; ADRENRGCA2CR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Membrane; Phosphoprotein; Receptor; Transducer;
KW   Transmembrane.
FT   CHAIN         1    458       Alpha-2C adrenergic receptor.
FT                                /FTId=PRO_0000069106.
FT   TOPO_DOM      1     51       Extracellular (By similarity).
FT   TRANSMEM     52     76       1 (By similarity).
FT   TOPO_DOM     77     88       Cytoplasmic (By similarity).
FT   TRANSMEM     89    114       2 (By similarity).
FT   TOPO_DOM    115    124       Extracellular (By similarity).
FT   TRANSMEM    125    147       3 (By similarity).
FT   TOPO_DOM    148    168       Cytoplasmic (By similarity).
FT   TRANSMEM    169    191       4 (By similarity).
FT   TOPO_DOM    192    207       Extracellular (By similarity).
FT   TRANSMEM    208    231       5 (By similarity).
FT   TOPO_DOM    232    379       Cytoplasmic (By similarity).
FT   TRANSMEM    380    403       6 (By similarity).
FT   TOPO_DOM    404    416       Extracellular (By similarity).
FT   TRANSMEM    417    437       7 (By similarity).
FT   TOPO_DOM    438    458       Cytoplasmic (By similarity).
FT   COMPBIAS    291    305       Arg-rich (basic).
FT   SITE        131    131       Implicated in ligand binding (By
FT                                similarity).
FT   SITE        214    214       Implicated in catechol agonist binding
FT                                and receptor activation (By similarity).
FT   SITE        218    218       Implicated in catechol agonist binding
FT                                and receptor activation (By similarity).
FT   CARBOHYD     19     19       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     33     33       N-linked (GlcNAc...) (Potential).
FT   DISULFID    124    202       By similarity.
FT   CONFLICT    196    196       G -> V (in Ref. 2; AAA37183).
FT   CONFLICT    296    296       G -> A (in Ref. 2).
FT   CONFLICT    298    298       L -> V (in Ref. 2).
SQ   SEQUENCE   458 AA;  49906 MW;  C0A8BDF0302BF1FB CRC64;
     MASPALAAAL AAAAAEGPNG SDAGEWGSGG GANASGTDWV PPPGQYSAGA VAGLAAVVGF
     LIVFTVVGNV LVVIAVLTSR ALRAPQNLFL VSLASADILV ATLVMPFSLA NELMAYWYFG
     QVWCGVYLAL DVLFCTSSIV HLCAISLDRY WSVTQAVEYN LKRTPRRVKA TIVAVWLISA
     VISFPPLVSF YRRPDGAAYP QCGLNDETWY ILSSCIGSFF APCLIMGLVY ARIYRVAKLR
     TRTLSEKRGP AGPDGASPTT ENGLGKAAGE NGHCAPPRTE VEPDESSAAE RRRRRGALRR
     GGRRREGAEG DTGSADGPGP GLAAEQGART ASRSPGPGGR LSRASSRSVE FFLSRRRRAR
     SSVCRRKVAQ AREKRFTFVL AVVMGVFVLC WFPFFFSYSL YGICREACQL PEPLFKFFFW
     IGYCNSSLNP VIYTVFNQDF RRSFKHILFR RRRRGFRQ
//
ID   ADRB1_HUMAN             Reviewed;         477 AA.
AC   P08588; B0LPE2; Q5T5Y4; Q9UKG7; Q9UKG8;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   07-JUN-2004, sequence version 2.
DT   02-MAR-2010, entry version 117.
DE   RecName: Full=Beta-1 adrenergic receptor;
DE   AltName: Full=Beta-1 adrenoreceptor;
DE            Short=Beta-1 adrenoceptor;
GN   Name=ADRB1; Synonyms=ADRB1R, B1AR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   MEDLINE=88068509; PubMed=2825170; DOI=10.1073/pnas.84.22.7920;
RA   Frielle T., Collins S., Daniel K.W., Caron M.G., Lefkowitz R.J.,
RA   Kobilka B.K.;
RT   "Cloning of the cDNA for the human beta 1-adrenergic receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:7920-7924(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLY-49 AND GLY-389.
RX   MEDLINE=99407229; PubMed=10477438;
RX   DOI=10.1002/(SICI)1098-1004(1999)14:3<271::AID-HUMU14>3.3.CO;2-H;
RA   Moore J.D., Mason D.A., Green S.A., Hsu J., Liggett S.B.;
RT   "Racial differences in the frequencies of cardiac beta(1)-adrenergic
RT   receptor polymorphisms: analysis of c145A>G and c1165G>C.";
RL   Hum. Mutat. 14:271-271(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLY-49; GLY-389 AND
RP   LEU-389.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (MAR-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT GLY-389.
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [6]
RP   INTERACTION WITH GOPC AND DLG4, MUTAGENESIS OF GLU-474; SER-475;
RP   LYS-476 AND VAL-477, AND SUBCELLULAR LOCATION.
RX   PubMed=15358775; DOI=10.1074/jbc.M404876200;
RA   He J., Bellini M., Xu J., Castleberry A.M., Hall R.A.;
RT   "Interaction with cystic fibrosis transmembrane conductance regulator-
RT   associated ligand (CAL) inhibits beta1-adrenergic receptor surface
RT   expression.";
RL   J. Biol. Chem. 279:50190-50196(2004).
RN   [7]
RP   VARIANT GLY-389.
RX   MEDLINE=99230291; PubMed=10212248; DOI=10.1074/jbc.274.18.12670;
RA   Mason D.A., Moore J.D., Green S.A., Liggett S.B.;
RT   "A gain-of-function polymorphism in a G-protein coupling domain of the
RT   human beta1-adrenergic receptor.";
RL   J. Biol. Chem. 274:12670-12674(1999).
RN   [8]
RP   VARIANT GLY-49.
RX   MEDLINE=20507547; PubMed=11052857; DOI=10.1053/euhj.1999.1994;
RA   Borjesson M., Magnusson Y., Hjalmarson A., Andersson B.;
RT   "A novel polymorphism in the gene coding for the beta(1)-adrenergic
RT   receptor associated with survival in patients with heart failure.";
RL   Eur. Heart J. 21:1853-1858(2000).
RN   [9]
RP   VARIANT GLY-49.
RX   MEDLINE=21881226; PubMed=11854867; DOI=10.1086/339621;
RA   Ranade K., Jorgenson E., Sheu W.H.-H., Pei D., Hsiung C.A.,
RA   Chiang F.-T., Chen Y.-D.I., Pratt R., Olshen R.A., Curb D., Cox D.R.,
RA   Botstein D., Risch N.;
RT   "A polymorphism in the beta1 adrenergic receptor is associated with
RT   resting heart rate.";
RL   Am. J. Hum. Genet. 70:935-942(2002).
CC   -!- FUNCTION: Beta-adrenergic receptors mediate the catecholamine-
CC       induced activation of adenylate cyclase through the action of G
CC       proteins. This receptor binds epinephrine and norepinephrine with
CC       approximately equal affinity.
CC   -!- SUBUNIT: Interacts with GOPC, MAGI3 and DLG4.
CC   -!- INTERACTION:
CC       Q62696:Dlg1 (xeno); NbExp=1; IntAct=EBI-991009, EBI-389325;
CC       P31016:Dlg4 (xeno); NbExp=1; IntAct=EBI-991009, EBI-375655;
CC       Q9Z254:Gipc1 (xeno); NbExp=1; IntAct=EBI-991009, EBI-991162;
CC       Q9HD26:GOPC; NbExp=1; IntAct=EBI-991009, EBI-349832;
CC       Q96QZ7:MAGI1; NbExp=1; IntAct=EBI-991009, EBI-924464;
CC       Q86UL8:MAGI2; NbExp=1; IntAct=EBI-991009, EBI-311035;
CC       Q5TCQ9:MAGI3; NbExp=4; IntAct=EBI-991009, EBI-310506;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC       Note=Localized at the plasma membrane. Found in the Golgi upon
CC       GOPC overexpression.
CC   -!- DOMAIN: The PDZ domain-binding motif mediates competitive
CC       interactions with GOPC, MAGI3 and DLG4 and plays a role in
CC       subcellular location of the receptor.
CC   -!- PTM: Homologous desensitization of the receptor is mediated by its
CC       phosphorylation by beta-adrenergic receptor kinase.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/adrb1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J03019; AAA51667.1; -; mRNA.
DR   EMBL; AF169006; AAD53696.1; -; Genomic_DNA.
DR   EMBL; AF169007; AAD53697.1; -; Genomic_DNA.
DR   EMBL; AY567837; AAS66983.1; -; Genomic_DNA.
DR   EMBL; EU332832; ABY87521.1; -; Genomic_DNA.
DR   EMBL; AL355543; CAI16920.1; -; Genomic_DNA.
DR   IPI; IPI00029278; -.
DR   PIR; A39911; QRHUB1.
DR   RefSeq; NP_000675.1; -.
DR   UniGene; Hs.99913; -.
DR   SMR; P08588; 56-257, 57-391.
DR   IntAct; P08588; 7.
DR   STRING; P08588; -.
DR   PhosphoSite; P08588; -.
DR   PRIDE; P08588; -.
DR   Ensembl; ENST00000369295; ENSP00000358301; ENSG00000043591; Homo sapiens.
DR   GeneID; 153; -.
DR   KEGG; hsa:153; -.
DR   CTD; 153; -.
DR   GeneCards; GC10P115793; -.
DR   H-InvDB; HIX0035626; -.
DR   HGNC; HGNC:285; ADRB1.
DR   MIM; 109630; gene.
DR   MIM; 607276; phenotype.
DR   PharmGKB; PA38; -.
DR   eggNOG; prNOG14235; -.
DR   HOGENOM; HBG445348; -.
DR   HOVERGEN; HBG106962; -.
DR   InParanoid; P08588; -.
DR   OrthoDB; EOG92NMJH; -.
DR   Reactome; REACT_14797; Signaling by GPCR.
DR   DrugBank; DB01193; Acebutolol.
DR   DrugBank; DB00866; Alprenolol.
DR   DrugBank; DB01118; Amiodarone.
DR   DrugBank; DB01102; Arbutamine.
DR   DrugBank; DB00335; Atenolol.
DR   DrugBank; DB00195; Betaxolol.
DR   DrugBank; DB01295; Bevantolol.
DR   DrugBank; DB00612; Bisoprolol.
DR   DrugBank; DB01158; Bretylium.
DR   DrugBank; DB00521; Carteolol.
DR   DrugBank; DB01136; Carvedilol.
DR   DrugBank; DB01151; Desipramine.
DR   DrugBank; DB00841; Dobutamine.
DR   DrugBank; DB00988; Dopamine.
DR   DrugBank; DB00668; Epinephrine.
DR   DrugBank; DB00187; Esmolol.
DR   DrugBank; DB00221; Isoetharine.
DR   DrugBank; DB01064; Isoproterenol.
DR   DrugBank; DB00598; Labetalol.
DR   DrugBank; DB01210; Levobunolol.
DR   DrugBank; DB01214; Metipranolol.
DR   DrugBank; DB00264; Metoprolol.
DR   DrugBank; DB01203; Nadolol.
DR   DrugBank; DB00368; Norepinephrine.
DR   DrugBank; DB01580; Oxprenolol.
DR   DrugBank; DB01359; Penbutolol.
DR   DrugBank; DB00960; Pindolol.
DR   DrugBank; DB01297; Practolol.
DR   DrugBank; DB00571; Propranolol.
DR   DrugBank; DB00734; Risperidone.
DR   DrugBank; DB00373; Timolol.
DR   DrugBank; DB00246; Ziprasidone.
DR   ArrayExpress; P08588; -.
DR   Bgee; P08588; -.
DR   CleanEx; HS_ADRB1; -.
DR   Genevestigator; P08588; -.
DR   GermOnline; ENSG00000043591; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0004940; F:beta1-adrenergic receptor activity; TAS:ProtInc.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR000507; Adrgc_rcpt_B1.
DR   InterPro; IPR002233; Adrnrgc_rcpt.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01103; ADRENERGICR.
DR   PRINTS; PR00561; ADRENRGCB1AR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Complete proteome; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane;
KW   Palmitate; Phosphoprotein; Polymorphism; Receptor; Transducer;
KW   Transmembrane.
FT   CHAIN         1    477       Beta-1 adrenergic receptor.
FT                                /FTId=PRO_0000069118.
FT   TOPO_DOM      1     55       Extracellular (By similarity).
FT   TRANSMEM     56     84       1 (By similarity).
FT   TOPO_DOM     85     93       Cytoplasmic (By similarity).
FT   TRANSMEM     94    120       2 (By similarity).
FT   TOPO_DOM    121    132       Extracellular (By similarity).
FT   TRANSMEM    133    154       3 (By similarity).
FT   TOPO_DOM    155    172       Cytoplasmic (By similarity).
FT   TRANSMEM    173    196       4 (By similarity).
FT   TOPO_DOM    197    222       Extracellular (By similarity).
FT   TRANSMEM    223    248       5 (By similarity).
FT   TOPO_DOM    249    319       Cytoplasmic (By similarity).
FT   TRANSMEM    320    349       6 (By similarity).
FT   TOPO_DOM    350    354       Extracellular (By similarity).
FT   TRANSMEM    355    377       7 (By similarity).
FT   TOPO_DOM    378    477       Cytoplasmic (By similarity).
FT   REGION      218    232       Agonist and antagonist binding (By
FT                                similarity).
FT   REGION      337    344       Agonist and antagonist binding (By
FT                                similarity).
FT   REGION      363    367       Agonist and antagonist binding (By
FT                                similarity).
FT   MOTIF       474    477       PDZ-Binding.
FT   BINDING     138    138       Agonist or antagonist (By similarity).
FT   BINDING     143    143       Agonist or antagonist (By similarity).
FT   MOD_RES     312    312       Phosphoserine; by PKA (Potential).
FT   MOD_RES     412    412       Phosphoserine; by PKA (Potential).
FT   LIPID       392    392       S-palmitoyl cysteine (By similarity).
FT   CARBOHYD     15     15       N-linked (GlcNAc...) (Probable).
FT   DISULFID    131    216       By similarity.
FT   DISULFID    209    215       By similarity.
FT   VARIANT      26     26       A -> V (in dbSNP:rs34844626).
FT                                /FTId=VAR_055909.
FT   VARIANT      29     29       A -> T (in dbSNP:rs35720093).
FT                                /FTId=VAR_055910.
FT   VARIANT      31     31       R -> Q (in dbSNP:rs35230616).
FT                                /FTId=VAR_055911.
FT   VARIANT      49     49       S -> G (associated with high mean resting
FT                                heart rate; dbSNP:rs1801252).
FT                                /FTId=VAR_009879.
FT   VARIANT     389    389       R -> G (reduced binding to G proteins;
FT                                dbSNP:rs1801253).
FT                                /FTId=VAR_009880.
FT   VARIANT     389    389       R -> L.
FT                                /FTId=VAR_018742.
FT   VARIANT     399    399       R -> H (in dbSNP:rs36052953).
FT                                /FTId=VAR_055912.
FT   VARIANT     405    405       H -> Y (in dbSNP:rs35705839).
FT                                /FTId=VAR_055913.
FT   MUTAGEN     474    474       E->A,D: Loss of interaction with GOPC.
FT   MUTAGEN     474    474       E->K: Loss of interaction with GOPC; when
FT                                associated with A-477.
FT   MUTAGEN     475    475       S->A: Loss of interaction with GOPC.
FT   MUTAGEN     475    475       S->T: Partial loss of interaction with
FT                                GOPC.
FT   MUTAGEN     476    476       K->A: Partial loss of interaction with
FT                                GOPC.
FT   MUTAGEN     477    477       V->A,F,L,I,M: Loss of interaction with
FT                                GOPC.
SQ   SEQUENCE   477 AA;  51323 MW;  0950F2684E4721B8 CRC64;
     MGAGVLVLGA SEPGNLSSAA PLPDGAATAA RLLVPASPPA SLLPPASESP EPLSQQWTAG
     MGLLMALIVL LIVAGNVLVI VAIAKTPRLQ TLTNLFIMSL ASADLVMGLL VVPFGATIVV
     WGRWEYGSFF CELWTSVDVL CVTASIETLC VIALDRYLAI TSPFRYQSLL TRARARGLVC
     TVWAISALVS FLPILMHWWR AESDEARRCY NDPKCCDFVT NRAYAIASSV VSFYVPLCIM
     AFVYLRVFRE AQKQVKKIDS CERRFLGGPA RPPSPSPSPV PAPAPPPGPP RPAAAAATAP
     LANGRAGKRR PSRLVALREQ KALKTLGIIM GVFTLCWLPF FLANVVKAFH RELVPDRLFV
     FFNWLGYANS AFNPIIYCRS PDFRKAFQRL LCCARRAARR RHATHGDRPR ASGCLARPGP
     PPSPGAASDD DDDDVVGATP PARLLEPWAG CNGGAAADSD SSLDEPCRPG FASESKV
//
ID   ADRB1_MOUSE             Reviewed;         466 AA.
AC   P34971;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1994, sequence version 1.
DT   02-MAR-2010, entry version 89.
DE   RecName: Full=Beta-1 adrenergic receptor;
DE   AltName: Full=Beta-1 adrenoreceptor;
DE            Short=Beta-1 adrenoceptor;
GN   Name=Adrb1; Synonyms=Adrb1r;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=129/Sv;
RX   MEDLINE=93372116; PubMed=8395893; DOI=10.1016/0167-4889(93)90209-8;
RA   Jasper J.R., Link R.E., Chruscinski A.J., Kobilka B.K., Bernstein D.;
RT   "Primary structure of the mouse beta 1-adrenergic receptor gene.";
RL   Biochim. Biophys. Acta 1178:307-309(1993).
RN   [2]
RP   PROTEIN SEQUENCE OF 303-307, AND MASS SPECTROMETRY.
RC   STRAIN=OF1; TISSUE=Hippocampus;
RA   Lubec G., Sunyer B., Chen W.-Q.;
RL   Submitted (JAN-2009) to UniProtKB.
CC   -!- FUNCTION: Beta-adrenergic receptors mediate the catecholamine-
CC       induced activation of adenylate cyclase through the action of G
CC       proteins. This receptor binds epinephrine and norepinephrine with
CC       approximately equal affinity.
CC   -!- SUBUNIT: Interacts with GOPC, MAGI3 and DLG4 (By similarity).
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein
CC       (By similarity). Note=Localized at the plasma membrane. Found in
CC       the Golgi upon GOPC overexpression (By similarity).
CC   -!- DOMAIN: The PDZ domain-binding motif mediates competitive
CC       interactions with GOPC, MAGI3 and DLG4 and plays a role in
CC       subcellular location of the receptor (By similarity).
CC   -!- PTM: Homologous desensitization of the receptor is mediated by its
CC       phosphorylation by beta-adrenergic receptor kinase.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L10084; AAA02929.1; -; Genomic_DNA.
DR   IPI; IPI00119827; -.
DR   PIR; S36794; S36794.
DR   UniGene; Mm.46797; -.
DR   SMR; P34971; 56-380.
DR   STRING; P34971; -.
DR   PhosphoSite; P34971; -.
DR   PRIDE; P34971; -.
DR   Ensembl; ENSMUST00000038949; ENSMUSP00000040847; ENSMUSG00000035283; Mus musculus.
DR   UCSC; uc008hze.1; mouse.
DR   MGI; MGI:87937; Adrb1.
DR   eggNOG; maNOG04780; -.
DR   HOGENOM; HBG445348; -.
DR   HOVERGEN; HBG106962; -.
DR   InParanoid; P34971; -.
DR   ArrayExpress; P34971; -.
DR   Bgee; P34971; -.
DR   CleanEx; MM_ADRB1; -.
DR   Genevestigator; P34971; -.
DR   GermOnline; ENSMUSG00000035283; Mus musculus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004940; F:beta1-adrenergic receptor activity; IDA:MGI.
DR   GO; GO:0007189; P:activation of adenylate cyclase activity by...; IMP:MGI.
DR   GO; GO:0050873; P:brown fat cell differentiation; IGI:MGI.
DR   GO; GO:0002024; P:diet induced thermogenesis; IGI:MGI.
DR   GO; GO:0042596; P:fear response; IMP:MGI.
DR   GO; GO:0031649; P:heat generation; IGI:MGI.
DR   GO; GO:0040015; P:negative regulation of multicellular organi...; IGI:MGI.
DR   GO; GO:0001996; P:positive regulation of heart rate by epinep...; IMP:MGI.
DR   GO; GO:0001997; P:positive regulation of the force of heart c...; IDA:MGI.
DR   GO; GO:0009409; P:response to cold; IGI:MGI.
DR   GO; GO:0002025; P:vasodilation by norepinephrine-epinephrine ...; IGI:MGI.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR000507; Adrgc_rcpt_B1.
DR   InterPro; IPR002233; Adrnrgc_rcpt.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01103; ADRENERGICR.
DR   PRINTS; PR00561; ADRENRGCB1AR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Direct protein sequencing; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane;
KW   Palmitate; Phosphoprotein; Receptor; Transducer; Transmembrane.
FT   CHAIN         1    466       Beta-1 adrenergic receptor.
FT                                /FTId=PRO_0000069122.
FT   TOPO_DOM      1     55       Extracellular (By similarity).
FT   TRANSMEM     56     84       1 (By similarity).
FT   TOPO_DOM     85     93       Cytoplasmic (By similarity).
FT   TRANSMEM     94    120       2 (By similarity).
FT   TOPO_DOM    121    132       Extracellular (By similarity).
FT   TRANSMEM    133    154       3 (By similarity).
FT   TOPO_DOM    155    172       Cytoplasmic (By similarity).
FT   TRANSMEM    173    196       4 (By similarity).
FT   TOPO_DOM    197    222       Extracellular (By similarity).
FT   TRANSMEM    223    248       5 (By similarity).
FT   TOPO_DOM    249    308       Cytoplasmic (By similarity).
FT   TRANSMEM    309    338       6 (By similarity).
FT   TOPO_DOM    339    343       Extracellular (By similarity).
FT   TRANSMEM    344    366       7 (By similarity).
FT   TOPO_DOM    367    466       Cytoplasmic (By similarity).
FT   REGION      218    232       Agonist and antagonist binding (By
FT                                similarity).
FT   REGION      326    333       Agonist and antagonist binding (By
FT                                similarity).
FT   REGION      352    356       Agonist and antagonist binding (By
FT                                similarity).
FT   MOTIF       463    466       PDZ-Binding (By similarity).
FT   BINDING     138    138       Agonist or antagonist (By similarity).
FT   BINDING     143    143       Agonist or antagonist (By similarity).
FT   MOD_RES     296    296       Phosphoserine; by PKA (Potential).
FT   MOD_RES     301    301       Phosphoserine; by PKA (Potential).
FT   MOD_RES     401    401       Phosphoserine; by PKA (Potential).
FT   LIPID       381    381       S-palmitoyl cysteine (By similarity).
FT   CARBOHYD     15     15       N-linked (GlcNAc...) (Probable).
FT   DISULFID    131    216       By similarity.
FT   DISULFID    209    215       By similarity.
SQ   SEQUENCE   466 AA;  50480 MW;  753CD44C42BC9211 CRC64;
     MGAGALALGA SEPCNLSSAA PLPDGAATAA RLLVLASPPA SLLPPASEGS APLSQQWTAG
     MGLLVALIVL LIVVGNVLVI VAIAKTPRLQ TLTNLFIMSL ASADLVMGLL VVPFGATIVV
     WGRWEYGSFF CELWTSVDVL CVTASIETLC VIALDRYLAI TSPFRYQSLL TRARARALVC
     TVWAISALVS FLPILMHWWR AESDEARRCY NDPKCCDFVT NRAYAIASSV VSFYVPLCIM
     AFVYLRVFRE AQKQVKKIDS CERRFLGGPA RPPSPEPSPS PGPPRPADSL ANGRSSKRRP
     SRLVALREQK ALKTLGIIMG VFTLCWLPFF LANVVKAFHR DLVPDRLFVF FNWLGYANSA
     FNPIIYCRSP DFRKAFQRLL CCARRAACRR RAAHGDRPRA SGCLARAGPP PSPGAPSDDD
     DDDAGTTPPA RLLEPWTGCN GGTTTVDSDS SLDEPGRQGF SSESKV
//
ID   ADRB1_RAT               Reviewed;         466 AA.
AC   P18090;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1990, sequence version 1.
DT   02-MAR-2010, entry version 96.
DE   RecName: Full=Beta-1 adrenergic receptor;
DE   AltName: Full=Beta-1 adrenoreceptor;
DE            Short=Beta-1 adrenoceptor;
GN   Name=Adrb1; Synonyms=Adrb1r;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=90330633; PubMed=1695899;
RA   Machida C.A., Bunzow J.R., Searles R.P., van Tol H.H.M., Tester B.,
RA   Neve K.A., Teal P., Nipper V., Civelli O.;
RT   "Molecular cloning and expression of the rat beta 1-adrenergic
RT   receptor gene.";
RL   J. Biol. Chem. 265:12960-12965(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=90356399; PubMed=2167473; DOI=10.1093/nar/18.15.4591;
RA   Shimomura H., Terada A.;
RT   "Primary structure of the rat beta-1 adrenergic receptor gene.";
RL   Nucleic Acids Res. 18:4591-4591(1990).
RN   [3]
RP   INTERACTION WITH MAGI3, AND MUTAGENESIS OF VAL-466.
RX   PubMed=16316992; DOI=10.1074/jbc.M509503200;
RA   He J., Bellini M., Inuzuka H., Xu J., Xiong Y., Yang X.,
RA   Castleberry A.M., Hall R.A.;
RT   "Proteomic analysis of beta1-adrenergic receptor interactions with PDZ
RT   scaffold proteins.";
RL   J. Biol. Chem. 281:2820-2827(2006).
CC   -!- FUNCTION: Beta-adrenergic receptors mediate the catecholamine-
CC       induced activation of adenylate cyclase through the action of G
CC       proteins. This receptor binds epinephrine and norepinephrine with
CC       approximately equal affinity.
CC   -!- SUBUNIT: Interacts with GOPC, MAGI3 and DLG4.
CC   -!- INTERACTION:
CC       Q9JK71:Magi3; NbExp=3; IntAct=EBI-991303, EBI-696226;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein
CC       (By similarity). Note=Localized at the plasma membrane. Found in
CC       the Golgi upon GOPC overexpression (By similarity).
CC   -!- DOMAIN: The PDZ domain-binding motif mediates competitive
CC       interactions with GOPC, MAGI3 and DLG4 and plays a role in
CC       subcellular location of the receptor.
CC   -!- PTM: Homologous desensitization of the receptor is mediated by its
CC       phosphorylation by beta-adrenergic receptor kinase.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J05561; AAA40792.1; -; Genomic_DNA.
DR   EMBL; D00634; BAA00527.1; -; Genomic_DNA.
DR   IPI; IPI00188184; -.
DR   PIR; S12591; S12591.
DR   RefSeq; NP_036833.1; -.
DR   UniGene; Rn.87064; -.
DR   PDB; 2FF9; Model; -; A=34-384.
DR   PDBsum; 2FF9; -.
DR   SMR; P18090; 56-380.
DR   IntAct; P18090; 1.
DR   STRING; P18090; -.
DR   Ensembl; ENSRNOT00000022813; ENSRNOP00000022813; ENSRNOG00000017002; Rattus norvegicus.
DR   GeneID; 24925; -.
DR   KEGG; rno:24925; -.
DR   UCSC; NM_012701; rat.
DR   CTD; 24925; -.
DR   RGD; 2059; Adrb1.
DR   eggNOG; maNOG04780; -.
DR   HOVERGEN; HBG106962; -.
DR   InParanoid; P18090; -.
DR   NextBio; 604879; -.
DR   ArrayExpress; P18090; -.
DR   Genevestigator; P18090; -.
DR   GermOnline; ENSRNOG00000017002; Rattus norvegicus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005792; C:microsome; IDA:RGD.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004940; F:beta1-adrenergic receptor activity; IDA:RGD.
DR   GO; GO:0035240; F:dopamine binding; IDA:RGD.
DR   GO; GO:0008144; F:drug binding; IDA:RGD.
DR   GO; GO:0051379; F:epinephrine binding; IDA:RGD.
DR   GO; GO:0051380; F:norepinephrine binding; IDA:RGD.
DR   GO; GO:0030165; F:PDZ domain binding; IPI:RGD.
DR   GO; GO:0007189; P:activation of adenylate cyclase activity by...; TAS:RGD.
DR   GO; GO:0048167; P:regulation of synaptic plasticity; TAS:RGD.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR000507; Adrgc_rcpt_B1.
DR   InterPro; IPR002233; Adrnrgc_rcpt.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01103; ADRENERGICR.
DR   PRINTS; PR00561; ADRENRGCB1AR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane;
KW   Palmitate; Phosphoprotein; Receptor; Transducer; Transmembrane.
FT   CHAIN         1    466       Beta-1 adrenergic receptor.
FT                                /FTId=PRO_0000069124.
FT   TOPO_DOM      1     55       Extracellular (By similarity).
FT   TRANSMEM     56     84       1 (By similarity).
FT   TOPO_DOM     85     93       Cytoplasmic (By similarity).
FT   TRANSMEM     94    120       2 (By similarity).
FT   TOPO_DOM    121    132       Extracellular (By similarity).
FT   TRANSMEM    133    154       3 (By similarity).
FT   TOPO_DOM    155    172       Cytoplasmic (By similarity).
FT   TRANSMEM    173    196       4 (By similarity).
FT   TOPO_DOM    197    222       Extracellular (By similarity).
FT   TRANSMEM    223    248       5 (By similarity).
FT   TOPO_DOM    249    308       Cytoplasmic (By similarity).
FT   TRANSMEM    309    338       6 (By similarity).
FT   TOPO_DOM    339    343       Extracellular (By similarity).
FT   TRANSMEM    344    366       7 (By similarity).
FT   TOPO_DOM    367    466       Cytoplasmic (By similarity).
FT   REGION      218    232       Agonist and antagonist binding (By
FT                                similarity).
FT   REGION      326    333       Agonist and antagonist binding (By
FT                                similarity).
FT   REGION      352    356       Agonist and antagonist binding (By
FT                                similarity).
FT   MOTIF       463    466       PDZ-Binding (By similarity).
FT   BINDING     138    138       Agonist or antagonist (By similarity).
FT   BINDING     143    143       Agonist or antagonist (By similarity).
FT   MOD_RES     296    296       Phosphoserine; by PKA (Potential).
FT   MOD_RES     301    301       Phosphoserine; by PKA (Potential).
FT   MOD_RES     401    401       Phosphoserine; by PKA (Potential).
FT   LIPID       381    381       S-palmitoyl cysteine (By similarity).
FT   CARBOHYD     15     15       N-linked (GlcNAc...) (Probable).
FT   DISULFID    131    216       By similarity.
FT   DISULFID    209    215       By similarity.
FT   MUTAGEN     466    466       V->A: Abolishes interaction with MAGI3.
FT   CONFLICT    162    162       L -> S (in Ref. 2; BAA00527).
FT   CONFLICT    267    267       T -> S (in Ref. 2; BAA00527).
SQ   SEQUENCE   466 AA;  50472 MW;  2955CB024944A12B CRC64;
     MGAGALALGA SEPCNLSSAA PLPDGAATAA RLLVLASPPA SLLPPASEGS APLSQQWTAG
     MGLLLALIVL LIVVGNVLVI VAIAKTPRLQ TLTNLFIMSL ASADLVMGLL VVPFGATIVV
     WGRWEYGSFF CELWTSVDVL CVTASIETLC VIALDRYLAI TLPFRYQSLL TRARARALVC
     TVWAISALVS FLPILMHWWR AESDEARRCY NDPKCCDFVT NRAYAIASSV VSFYVPLCIM
     AFVYLRVFRE AQKQVKKIDS CERRFLTGPP RPPSPAPSPS PGPPRPADSL ANGRSSKRRP
     SRLVALREQK ALKTLGIIMG VFTLCWLPFF LANVVKAFHR DLVPDRLFVF FNWLGYANSA
     FNPIIYCRSP DFRKAFQRLL CCARRAACRR RAAHGDRPRA SGCLARAGPP PSPGAPSDDD
     DDDAGATPPA RLLEPWAGCN GGTTTVDSDS SLDEPGRQGF SSESKV
//
ID   ADRB2_MESAU             Reviewed;         418 AA.
AC   P04274;
DT   20-MAR-1987, integrated into UniProtKB/Swiss-Prot.
DT   20-MAR-1987, sequence version 1.
DT   02-MAR-2010, entry version 83.
DE   RecName: Full=Beta-2 adrenergic receptor;
DE   AltName: Full=Beta-2 adrenoreceptor;
DE            Short=Beta-2 adrenoceptor;
GN   Name=ADRB2;
OS   Mesocricetus auratus (Golden hamster).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Cricetidae; Cricetinae; Mesocricetus.
OX   NCBI_TaxID=10036;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lung;
RX   MEDLINE=86203654; PubMed=3010132; DOI=10.1038/321075a0;
RA   Dixon R.A.F., Kobilka B.K., Strader D.J., Benovic J.L., Dohlman H.G.,
RA   Frielle T., Bolanowski M.A., Bennett C.D., Rands E., Diehl R.E.,
RA   Mumford R.A., Slater E.E., Sigal I.S., Caron M.G., Lefkowitz R.J.,
RA   Strader C.D.;
RT   "Cloning of the gene and cDNA for mammalian beta-adrenergic receptor
RT   and homology with rhodopsin.";
RL   Nature 321:75-79(1986).
RN   [2]
RP   MUTAGENESIS TO CONFIRM GLYCOSYLATION SITES.
RX   MEDLINE=90285215; PubMed=2162359;
RA   Rands E., Candelore M.R., Cheung A.H., Will W.S., Strader C.D.,
RA   Dixon R.A.F.;
RT   "Mutational analysis of beta-adrenergic receptor glycosylation.";
RL   J. Biol. Chem. 265:10759-10764(1990).
RN   [3]
RP   MUTAGENESIS OF SER-204 AND SER-207.
RX   MEDLINE=89340434; PubMed=2547766;
RA   Strader C.D., Candelore M.R., Hill W.S., Sigal I.S., Dixon R.A.F.;
RT   "Identification of two serine residues involved in agonist activation
RT   of the beta-adrenergic receptor.";
RL   J. Biol. Chem. 264:13572-13578(1989).
RN   [4]
RP   MUTAGENESIS OF ASP-79 AND ASP-113.
RX   MEDLINE=88273123; PubMed=2899076;
RA   Strader C.D., Sigal I.S., Candelore M.R., Rands E., Hill W.S.,
RA   Dixon R.A.F.;
RT   "Conserved aspartic acid residues 79 and 113 of the beta-adrenergic
RT   receptor have different roles in receptor function.";
RL   J. Biol. Chem. 263:10267-10271(1988).
RN   [5]
RP   3D-STRUCTURE MODELING.
RX   MEDLINE=92292166; PubMed=1318386; DOI=10.1016/0022-2836(92)90406-A;
RA   Huss K.M., Lybrand T.P.;
RT   "Three-dimensional structure for the beta 2 adrenergic receptor
RT   protein based on computer modeling studies.";
RL   J. Mol. Biol. 225:859-871(1992).
CC   -!- FUNCTION: Beta-adrenergic receptors mediate the catecholamine-
CC       induced activation of adenylate cyclase through the action of G
CC       proteins. The beta-2-adrenergic receptor binds epinephrine with an
CC       approximately 30-fold greater affinity than it does
CC       norepinephrine.
CC   -!- SUBUNIT: Binds SLC9A3R1 and GPRASP1. Interacts with ARRB1 and
CC       ARRB2. Interacts with SRC, USP20 and USP33 (By similarity).
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- PTM: Palmitoylated; may reduce accessibility of Ser-345 and Ser-
CC       346 by anchoring Cys-341 to the plasma membrane. Agonist
CC       stimulation promotes depalmitoylation and further allows Ser-345
CC       and Ser-346 phosphorylation (By similarity).
CC   -!- PTM: Phosphorylated by PKA and BARK upon agonist stimulation,
CC       which mediates homologous desensitization of the receptor. PKA-
CC       mediated phosphorylation seems to facilitate phosphorylation by
CC       BARK (By similarity).
CC   -!- PTM: Phosphorylation of Tyr-141 is induced by insulin and leads to
CC       supersensitization of the receptor (By similarity).
CC   -!- PTM: Ubiquitinated. Agonist-induced ubiquitination leads to sort
CC       internalized receptors to the lysosomes for degradation.
CC       Deubiquitination by USP20 and USP33, leads to ADRB2 recycling and
CC       resensitization after prolonged agonist stimulation. USP20 and
CC       USP33 are constitutively associated and are dissociated
CC       immediately after agonist stimulation (By similarity).
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X03804; CAA27430.1; -; mRNA.
DR   SMR; P04274; 8-349.
DR   HOVERGEN; HBG106962; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0043235; C:receptor complex; ISS:HGNC.
DR   GO; GO:0004941; F:beta2-adrenergic receptor activity; ISS:HGNC.
DR   GO; GO:0051380; F:norepinephrine binding; ISS:HGNC.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:HGNC.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; ISS:HGNC.
DR   GO; GO:0002032; P:desensitization of G-protein coupled recept...; ISS:HGNC.
DR   GO; GO:0007186; P:G-protein coupled receptor protein signalin...; IEA:UniProtKB-KW.
DR   GO; GO:0043410; P:positive regulation of MAPKKK cascade; ISS:HGNC.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; ISS:HGNC.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR000332; Adrgc_rcpt_B2.
DR   InterPro; IPR002233; Adrnrgc_rcpt.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   PANTHER; PTHR19266:SF42; Adrgc_rcpt_B2; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01103; ADRENERGICR.
DR   PRINTS; PR00562; ADRENRGCB2AR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Lipoprotein; Membrane; Palmitate; Phosphoprotein;
KW   Receptor; Transducer; Transmembrane; Ubl conjugation.
FT   CHAIN         1    418       Beta-2 adrenergic receptor.
FT                                /FTId=PRO_0000069133.
FT   TOPO_DOM      1     34       Extracellular (By similarity).
FT   TRANSMEM     35     58       1 (By similarity).
FT   TOPO_DOM     59     71       Cytoplasmic (By similarity).
FT   TRANSMEM     72     95       2 (By similarity).
FT   TOPO_DOM     96    106       Extracellular (By similarity).
FT   TRANSMEM    107    129       3 (By similarity).
FT   TOPO_DOM    130    150       Cytoplasmic (By similarity).
FT   TRANSMEM    151    174       4 (By similarity).
FT   TOPO_DOM    175    196       Extracellular (By similarity).
FT   TRANSMEM    197    220       5 (By similarity).
FT   TOPO_DOM    221    274       Cytoplasmic (By similarity).
FT   TRANSMEM    275    298       6 (By similarity).
FT   TOPO_DOM    299    305       Extracellular (By similarity).
FT   TRANSMEM    306    329       7 (By similarity).
FT   TOPO_DOM    330    418       Cytoplasmic (By similarity).
FT   REGION      193    207       Agonist and antagonist binding (By
FT                                similarity).
FT   REGION      286    293       Agonist and antagonist binding (By
FT                                similarity).
FT   REGION      312    316       Agonist and antagonist binding (By
FT                                similarity).
FT   BINDING     113    113       Agonist or antagonist (By similarity).
FT   BINDING     118    118       Agonist or antagonist (By similarity).
FT   MOD_RES     141    141       Phosphotyrosine (By similarity).
FT   MOD_RES     261    261       Phosphoserine; by PKA (Potential).
FT   MOD_RES     262    262       Phosphoserine; by PKA (Potential).
FT   MOD_RES     345    345       Phosphoserine; by PKA (By similarity).
FT   MOD_RES     346    346       Phosphoserine; by PKA (By similarity).
FT   MOD_RES     355    355       Phosphoserine; by BARK (Probable).
FT   MOD_RES     356    356       Phosphoserine; by BARK (Probable).
FT   LIPID       341    341       S-palmitoyl cysteine (By similarity).
FT   CARBOHYD      6      6       N-linked (GlcNAc...).
FT   CARBOHYD     15     15       N-linked (GlcNAc...).
FT   DISULFID    106    191       By similarity.
FT   DISULFID    184    190       By similarity.
FT   MUTAGEN      79     79       D->A: Small decrease in agonist binding.
FT                                No effect on antagonist binding.
FT   MUTAGEN     113    113       D->A: Drastic decrease in agonist and
FT                                antagonist binding. Stimulates adenylyl
FT                                cyclase activity.
FT   MUTAGEN     204    204       S->A: Decrease in catechol agonist
FT                                binding.
FT   MUTAGEN     207    207       S->A: Decrease in catechol agonist
FT                                binding.
SQ   SEQUENCE   418 AA;  46861 MW;  9B20478F91FB284E CRC64;
     MGPPGNDSDF LLTTNGSHVP DHDVTEERDE AWVVGMAILM SVIVLAIVFG NVLVITAIAK
     FERLQTVTNY FITSLACADL VMGLAVVPFG ASHILMKMWN FGNFWCEFWT SIDVLCVTAS
     IETLCVIAVD RYIAITSPFK YQSLLTKNKA RMVILMVWIV SGLTSFLPIQ MHWYRATHQK
     AIDCYHKETC CDFFTNQAYA IASSIVSFYV PLVVMVFVYS RVFQVAKRQL QKIDKSEGRF
     HSPNLGQVEQ DGRSGHGLRR SSKFCLKEHK ALKTLGIIMG TFTLCWLPFF IVNIVHVIQD
     NLIPKEVYIL LNWLGYVNSA FNPLIYCRSP DFRIAFQELL CLRRSSSKAY GNGYSSNSNG
     KTDYMGEASG CQLGQEKESE RLCEDPPGTE SFVNCQGTVP SLSLDSQGRN CSTNDSPL
//
ID   ADRB2_MOUSE             Reviewed;         418 AA.
AC   P18762;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1990, sequence version 1.
DT   02-MAR-2010, entry version 99.
DE   RecName: Full=Beta-2 adrenergic receptor;
DE   AltName: Full=Beta-2 adrenoreceptor;
DE            Short=Beta-2 adrenoceptor;
GN   Name=Adrb2; Synonyms=Adrb2r;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=88196072; PubMed=2834198;
RA   Allen J.M., Baetge E.E., Abrass I.B., Palmiter R.D.;
RT   "Isoproterenol response following transfection of the mouse beta 2-
RT   adrenergic receptor gene into Y1 cells.";
RL   EMBO J. 7:133-138(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=89374066; PubMed=2549959;
RA   Nakada M.T., Haskell K.M., Ecker D.J., Stadel J.M., Crooke S.T.;
RT   "Genetic regulation of beta 2-adrenergic receptors in 3T3-L1
RT   fibroblasts.";
RL   Biochem. J. 260:53-59(1989).
CC   -!- FUNCTION: Beta-adrenergic receptors mediate the catecholamine-
CC       induced activation of adenylate cyclase through the action of G
CC       proteins. The beta-2-adrenergic receptor binds epinephrine with an
CC       approximately 30-fold greater affinity than it does
CC       norepinephrine.
CC   -!- SUBUNIT: Binds SLC9A3R1 and GPRASP1. Interacts with ARRB1 and
CC       ARRB2. Interacts with SRC, USP20 and USP33 (By similarity).
CC   -!- INTERACTION:
CC       Q14232:EIF2B1 (xeno); NbExp=1; IntAct=EBI-491143, EBI-491065;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- PTM: Palmitoylated; may reduce accessibility of Ser-345 and Ser-
CC       346 by anchoring Cys-341 to the plasma membrane. Agonist
CC       stimulation promotes depalmitoylation and further allows Ser-345
CC       and Ser-346 phosphorylation (By similarity).
CC   -!- PTM: Phosphorylated by PKA and BARK upon agonist stimulation,
CC       which mediates homologous desensitization of the receptor. PKA-
CC       mediated phosphorylation seems to facilitate phosphorylation by
CC       BARK. Phosphorylated upon DNA damage, probably by ATM or ATR (By
CC       similarity).
CC   -!- PTM: Phosphorylation of Tyr-141 is induced by insulin and leads to
CC       supersensitization of the receptor (By similarity).
CC   -!- PTM: Ubiquitinated. Agonist-induced ubiquitination leads to sort
CC       internalized receptors to the lysosomes for degradation.
CC       Deubiquitination by USP20 and USP33, leads to ADRB2 recycling and
CC       resensitization after prolonged agonist stimulation. USP20 and
CC       USP33 are constitutively associated and are dissociated
CC       immediately after agonist stimulation (By similarity).
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X15643; CAA33664.1; -; Genomic_DNA.
DR   IPI; IPI00221716; -.
DR   PIR; S00260; S00260.
DR   UniGene; Mm.5598; -.
DR   SMR; P18762; 8-350.
DR   IntAct; P18762; 1.
DR   STRING; P18762; -.
DR   PhosphoSite; P18762; -.
DR   PRIDE; P18762; -.
DR   Ensembl; ENSMUST00000053640; ENSMUSP00000062256; ENSMUSG00000045730; Mus musculus.
DR   MGI; MGI:87938; Adrb2.
DR   eggNOG; maNOG17463; -.
DR   HOGENOM; HBG445348; -.
DR   HOVERGEN; HBG106962; -.
DR   InParanoid; P18762; -.
DR   ArrayExpress; P18762; -.
DR   Bgee; P18762; -.
DR   CleanEx; MM_ADRB2; -.
DR   Genevestigator; P18762; -.
DR   GermOnline; ENSMUSG00000045730; Mus musculus.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:MGI.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0043235; C:receptor complex; ISS:HGNC.
DR   GO; GO:0008179; F:adenylate cyclase binding; IDA:UniProtKB.
DR   GO; GO:0004941; F:beta2-adrenergic receptor activity; IDA:MGI.
DR   GO; GO:0051380; F:norepinephrine binding; ISS:HGNC.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:HGNC.
DR   GO; GO:0007189; P:activation of adenylate cyclase activity by...; IDA:MGI.
DR   GO; GO:0045453; P:bone resorption; IMP:MGI.
DR   GO; GO:0050873; P:brown fat cell differentiation; IGI:MGI.
DR   GO; GO:0002032; P:desensitization of G-protein coupled recept...; ISS:HGNC.
DR   GO; GO:0002024; P:diet induced thermogenesis; IGI:MGI.
DR   GO; GO:0031649; P:heat generation; IGI:MGI.
DR   GO; GO:0040015; P:negative regulation of multicellular organi...; IGI:MGI.
DR   GO; GO:0045986; P:negative regulation of smooth muscle contra...; IGI:MGI.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; IMP:MGI.
DR   GO; GO:0043410; P:positive regulation of MAPKKK cascade; ISS:HGNC.
DR   GO; GO:0045944; P:positive regulation of transcription from R...; IGI:MGI.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; ISS:HGNC.
DR   GO; GO:0009409; P:response to cold; IGI:MGI.
DR   GO; GO:0002025; P:vasodilation by norepinephrine-epinephrine ...; IGI:MGI.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR000332; Adrgc_rcpt_B2.
DR   InterPro; IPR002233; Adrnrgc_rcpt.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   PANTHER; PTHR19266:SF42; Adrgc_rcpt_B2; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01103; ADRENERGICR.
DR   PRINTS; PR00562; ADRENRGCB2AR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Lipoprotein; Membrane; Palmitate; Phosphoprotein;
KW   Receptor; Transducer; Transmembrane; Ubl conjugation.
FT   CHAIN         1    418       Beta-2 adrenergic receptor.
FT                                /FTId=PRO_0000069134.
FT   TOPO_DOM      1     34       Extracellular (By similarity).
FT   TRANSMEM     35     58       1 (By similarity).
FT   TOPO_DOM     59     71       Cytoplasmic (By similarity).
FT   TRANSMEM     72     95       2 (By similarity).
FT   TOPO_DOM     96    106       Extracellular (By similarity).
FT   TRANSMEM    107    129       3 (By similarity).
FT   TOPO_DOM    130    150       Cytoplasmic (By similarity).
FT   TRANSMEM    151    174       4 (By similarity).
FT   TOPO_DOM    175    196       Extracellular (By similarity).
FT   TRANSMEM    197    220       5 (By similarity).
FT   TOPO_DOM    221    274       Cytoplasmic (By similarity).
FT   TRANSMEM    275    298       6 (By similarity).
FT   TOPO_DOM    299    305       Extracellular (By similarity).
FT   TRANSMEM    306    329       7 (By similarity).
FT   TOPO_DOM    330    418       Cytoplasmic (By similarity).
FT   REGION      193    207       Agonist and antagonist binding (By
FT                                similarity).
FT   REGION      286    293       Agonist and antagonist binding (By
FT                                similarity).
FT   REGION      312    316       Agonist and antagonist binding (By
FT                                similarity).
FT   BINDING     113    113       Agonist or antagonist (By similarity).
FT   BINDING     118    118       Agonist or antagonist (By similarity).
FT   MOD_RES     141    141       Phosphotyrosine (By similarity).
FT   MOD_RES     246    246       Phosphoserine (By similarity).
FT   MOD_RES     261    261       Phosphoserine; by PKA (Potential).
FT   MOD_RES     262    262       Phosphoserine; by PKA (Potential).
FT   MOD_RES     345    345       Phosphoserine; by PKA (By similarity).
FT   MOD_RES     346    346       Phosphoserine; by PKA (By similarity).
FT   MOD_RES     355    355       Phosphoserine; by BARK (Probable).
FT   MOD_RES     356    356       Phosphoserine; by BARK (Probable).
FT   LIPID       341    341       S-palmitoyl cysteine (By similarity).
FT   CARBOHYD      6      6       N-linked (GlcNAc...) (Probable).
FT   CARBOHYD     15     15       N-linked (GlcNAc...) (Probable).
FT   DISULFID    106    191       By similarity.
FT   DISULFID    184    190       By similarity.
FT   CONFLICT     21     21       D -> H (in Ref. 2; CAA33664).
FT   CONFLICT     94     95       IL -> TS (in Ref. 2; CAA33664).
FT   CONFLICT    213    213       C -> V (in Ref. 2; CAA33664).
FT   CONFLICT    254    254       S -> T (in Ref. 2; CAA33664).
FT   CONFLICT    347    348       SK -> FE (in Ref. 2; CAA33664).
SQ   SEQUENCE   418 AA;  47002 MW;  457AE2877C6B3DE2 CRC64;
     MGPHGNDSDF LLAPNGSRAP DHDVTQERDE AWVVGMAILM SVIVLAIVFG NVLVITAIAK
     FERLQTVTNY FIISLACADL VMGLAVVPFG ASHILMKMWN FGNFWCEFWT SIDVLCVTAS
     IETLCVIAVD RYVAITSPFK YQSLLTKNKA RVVILMVWIV SGLTSFLPIQ MHWYRATHKK
     AIDCYTEETC CDFFTNQAYA IASSIVSFYV PLCVMVFVYS RVFQVAKRQL QKIDKSEGRF
     HAQNLSQVEQ DGRSGHGLRR SSKFCLKEHK ALKTLGIIMG TFTLCWLPFF IVNIVHVIRD
     NLIPKEVYIL LNWLGYVNSA FNPLIYCRSP DFRIAFQELL CLRRSSSKTY GNGYSSNSNG
     RTDYTGEPNT CQLGQEREQE LLCEDPPGME GFVNCQGTVP SLSVDSQGRN CSTNDSPL
//
ID   ADT1_ARATH              Reviewed;         381 AA.
AC   P31167; Q9M9K2;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2000, sequence version 2.
DT   02-MAR-2010, entry version 92.
DE   RecName: Full=ADP,ATP carrier protein 1, mitochondrial;
DE   AltName: Full=ADP/ATP translocase 1;
DE   AltName: Full=Adenine nucleotide translocator 1;
DE            Short=ANT 1;
DE   Flags: Precursor;
GN   Name=ANT1; OrderedLocusNames=At3g08580; ORFNames=F17O14.5;
OS   Arabidopsis thaliana (Mouse-ear cress).
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
OC   rosids; malvids; Brassicales; Brassicaceae; Arabidopsis.
OX   NCBI_TaxID=3702;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=cv. Columbia;
RX   MEDLINE=21016720; PubMed=11130713; DOI=10.1038/35048706;
RA   Salanoubat M., Lemcke K., Rieger M., Ansorge W., Unseld M.,
RA   Fartmann B., Valle G., Bloecker H., Perez-Alonso M., Obermaier B.,
RA   Delseny M., Boutry M., Grivell L.A., Mache R., Puigdomenech P.,
RA   De Simone V., Choisne N., Artiguenave F., Robert C., Brottier P.,
RA   Wincker P., Cattolico L., Weissenbach J., Saurin W., Quetier F.,
RA   Schaefer M., Mueller-Auer S., Gabel C., Fuchs M., Benes V.,
RA   Wurmbach E., Drzonek H., Erfle H., Jordan N., Bangert S.,
RA   Wiedelmann R., Kranz H., Voss H., Holland R., Brandt P., Nyakatura G.,
RA   Vezzi A., D'Angelo M., Pallavicini A., Toppo S., Simionati B.,
RA   Conrad A., Hornischer K., Kauer G., Loehnert T.-H., Nordsiek G.,
RA   Reichelt J., Scharfe M., Schoen O., Bargues M., Terol J., Climent J.,
RA   Navarro P., Collado C., Perez-Perez A., Ottenwaelder B., Duchemin D.,
RA   Cooke R., Laudie M., Berger-Llauro C., Purnelle B., Masuy D.,
RA   de Haan M., Maarse A.C., Alcaraz J.-P., Cottet A., Casacuberta E.,
RA   Monfort A., Argiriou A., Flores M., Liguori R., Vitale D.,
RA   Mannhaupt G., Haase D., Schoof H., Rudd S., Zaccaria P., Mewes H.-W.,
RA   Mayer K.F.X., Kaul S., Town C.D., Koo H.L., Tallon L.J., Jenkins J.,
RA   Rooney T., Rizzo M., Walts A., Utterback T., Fujii C.Y., Shea T.P.,
RA   Creasy T.H., Haas B., Maiti R., Wu D., Peterson J., Van Aken S.,
RA   Pai G., Militscher J., Sellers P., Gill J.E., Feldblyum T.V.,
RA   Preuss D., Lin X., Nierman W.C., Salzberg S.L., White O., Venter J.C.,
RA   Fraser C.M., Kaneko T., Nakamura Y., Sato S., Kato T., Asamizu E.,
RA   Sasamoto S., Kimura T., Idesawa K., Kawashima K., Kishida Y.,
RA   Kiyokawa C., Kohara M., Matsumoto M., Matsuno A., Muraki A.,
RA   Nakayama S., Nakazaki N., Shinpo S., Takeuchi C., Wada T.,
RA   Watanabe A., Yamada M., Yasuda M., Tabata S.;
RT   "Sequence and analysis of chromosome 3 of the plant Arabidopsis
RT   thaliana.";
RL   Nature 408:820-822(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=cv. Columbia;
RX   MEDLINE=22954850; PubMed=14593172; DOI=10.1126/science.1088305;
RA   Yamada K., Lim J., Dale J.M., Chen H., Shinn P., Palm C.J.,
RA   Southwick A.M., Wu H.C., Kim C.J., Nguyen M., Pham P.K., Cheuk R.F.,
RA   Karlin-Newmann G., Liu S.X., Lam B., Sakano H., Wu T., Yu G.,
RA   Miranda M., Quach H.L., Tripp M., Chang C.H., Lee J.M., Toriumi M.J.,
RA   Chan M.M., Tang C.C., Onodera C.S., Deng J.M., Akiyama K., Ansari Y.,
RA   Arakawa T., Banh J., Banno F., Bowser L., Brooks S.Y., Carninci P.,
RA   Chao Q., Choy N., Enju A., Goldsmith A.D., Gurjal M., Hansen N.F.,
RA   Hayashizaki Y., Johnson-Hopson C., Hsuan V.W., Iida K., Karnes M.,
RA   Khan S., Koesema E., Ishida J., Jiang P.X., Jones T., Kawai J.,
RA   Kamiya A., Meyers C., Nakajima M., Narusaka M., Seki M., Sakurai T.,
RA   Satou M., Tamse R., Vaysberg M., Wallender E.K., Wong C., Yamamura Y.,
RA   Yuan S., Shinozaki K., Davis R.W., Theologis A., Ecker J.R.;
RT   "Empirical analysis of transcriptional activity in the Arabidopsis
RT   genome.";
RL   Science 302:842-846(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 3-381.
RC   STRAIN=cv. Columbia;
RX   PubMed=16653021;
RA   Saint-Guily A., Lim P.Y., Chevalier C., Yamaguchi J., Akazawa T.;
RT   "Complementary DNA sequence of an adenylate translocator from
RT   Arabidopsis thaliana.";
RL   Plant Physiol. 100:1069-1071(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 83-190.
RC   STRAIN=cv. Columbia;
RX   MEDLINE=96158348; PubMed=8580968;
RX   DOI=10.1046/j.1365-313X.1996.09010101.x;
RA   Cooke R., Raynal M., Laudie M., Grellet F., Delseny M., Morris P.-C.,
RA   Guerrier D., Giraudat J., Quigley F., Clabault G., Li Y.-F., Mache R.,
RA   Krivitzky M., Gy I.J.-J., Kreis M., Lecharny A., Parmentier Y.,
RA   Marbach J., Fleck J., Clement B., Philipps G., Herve C., Bardet C.,
RA   Tremousaygue D., Lescure B., Lacomme C., Roby D., Jourjon M.-F.,
RA   Chabrier P., Charpenteau J.-L., Desprez T., Amselem J., Chiapello H.,
RA   Hoefte H.;
RT   "Further progress towards a catalogue of all Arabidopsis genes:
RT   analysis of a set of 5000 non-redundant ESTs.";
RL   Plant J. 9:101-124(1996).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS], AND
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RX   PubMed=14671022; DOI=10.1105/tpc.016055;
RA   Heazlewood J.L., Tonti-Filippini J.S., Gout A.M., Day D.A., Whelan J.,
RA   Millar A.H.;
RT   "Experimental analysis of the Arabidopsis mitochondrial proteome
RT   highlights signaling and regulatory components, provides assessment of
RT   targeting prediction programs, and indicates plant-specific
RT   mitochondrial proteins.";
RL   Plant Cell 16:241-256(2004).
CC   -!- FUNCTION: Catalyzes the exchange of ADP and ATP across the
CC       mitochondrial inner membrane.
CC   -!- SUBUNIT: Homodimer (By similarity).
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane; Multi-pass
CC       membrane protein.
CC   -!- MISCELLANEOUS: The transmembrane helices are not perpendicular to
CC       the plane of the membrane, but cross the membrane at an angle. At
CC       least 2 of the odd-numbered transmembrane helices exhibit a sharp
CC       kink, due to the presence of a conserved proline residue (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the mitochondrial carrier family.
CC   -!- SIMILARITY: Contains 3 Solcar repeats.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AC012562; AAG51358.1; -; Genomic_DNA.
DR   EMBL; AY034933; AAK59440.1; -; mRNA.
DR   EMBL; AY042814; AAK68754.1; -; mRNA.
DR   EMBL; AY054248; AAL06907.1; -; mRNA.
DR   EMBL; AY074529; AAL69497.1; -; mRNA.
DR   EMBL; BT000381; AAN15700.1; -; mRNA.
DR   EMBL; BT002387; AAO00747.1; -; mRNA.
DR   EMBL; X65549; CAA46518.1; -; mRNA.
DR   EMBL; Z26399; CAA81237.1; -; mRNA.
DR   IPI; IPI00546691; -.
DR   PIR; S21313; S21313.
DR   RefSeq; NP_187470.1; -.
DR   RefSeq; NP_850541.1; -.
DR   UniGene; At.23909; -.
DR   UniGene; At.67047; -.
DR   UniGene; At.71535; -.
DR   UniGene; Rra.4062; -.
DR   UniGene; Rsa.6929; -.
DR   SMR; P31167; 80-367.
DR   STRING; P31167; -.
DR   TCDB; 2.A.29.1.5; mitochondrial carrier (MC) family.
DR   PRIDE; P31167; -.
DR   GeneID; 820005; -.
DR   GenomeReviews; BA000014_GR; AT3G08580.
DR   KEGG; ath:AT3G08580; -.
DR   GeneFarm; 3730; 374.
DR   TAIR; At3g08580; -.
DR   eggNOG; KOG0749; -.
DR   HOGENOM; HBG610399; -.
DR   InParanoid; P31167; -.
DR   OMA; AKDEGSK; -.
DR   PhylomeDB; P31167; -.
DR   ArrayExpress; P31167; -.
DR   Genevestigator; P31167; -.
DR   GermOnline; AT3G08580; Arabidopsis thaliana.
DR   GO; GO:0005618; C:cell wall; IDA:TAIR.
DR   GO; GO:0009941; C:chloroplast envelope; IDA:TAIR.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005730; C:nucleolus; IDA:TAIR.
DR   GO; GO:0005886; C:plasma membrane; IDA:TAIR.
DR   GO; GO:0005773; C:vacuole; IDA:TAIR.
DR   GO; GO:0005471; F:ATP:ADP antiporter activity; IDA:TAIR.
DR   GO; GO:0005507; F:copper ion binding; IDA:TAIR.
DR   GO; GO:0015865; P:purine nucleotide transport; IDA:TAIR.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR002113; Aden_trnslctor.
DR   InterPro; IPR002067; Mit_carrier.
DR   InterPro; IPR001993; Mitochondria_substrate_carrier.
DR   InterPro; IPR018108; Mitochondrial_sb/sol_carrier.
DR   PANTHER; PTHR11896; Mitoch_carrier; 1.
DR   Pfam; PF00153; Mito_carr; 3.
DR   PRINTS; PR00927; ADPTRNSLCASE.
DR   PRINTS; PR00926; MITOCARRIER.
DR   SUPFAM; SSF103506; Mitoch_carrier; 1.
DR   PROSITE; PS50920; SOLCAR; 3.
PE   1: Evidence at protein level;
KW   Complete proteome; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Repeat; Transit peptide; Transmembrane;
KW   Transport.
FT   TRANSIT       1     70       Mitochondrion (Potential).
FT   CHAIN        71    381       ADP,ATP carrier protein 1, mitochondrial.
FT                                /FTId=PRO_0000019245.
FT   TRANSMEM     77    111       1 (By similarity).
FT   TRANSMEM    148    172       2 (By similarity).
FT   TRANSMEM    181    215       3 (By similarity).
FT   TRANSMEM    251    278       4 (By similarity).
FT   TRANSMEM    283    317       5 (By similarity).
FT   TRANSMEM    346    371       6 (By similarity).
FT   REPEAT       78    171       Solcar 1.
FT   REPEAT      183    276       Solcar 2.
FT   REPEAT      284    370       Solcar 3.
FT   MOTIF       311    316       Substrate recognition (By similarity).
FT   BINDING     153    153       Nucleotide (By similarity).
FT   CONFLICT      3      3       D -> H (in Ref. 3; CAA46518).
FT   CONFLICT    319    319       G -> N (in Ref. 3; CAA46518).
FT   CONFLICT    368    368       Q -> T (in Ref. 3; CAA46518).
SQ   SEQUENCE   381 AA;  41476 MW;  FF39C3D1E1ED5B58 CRC64;
     MVDQVQHPTI AQKAAGQFMR SSVSKDVQVG YQRPSMYQRH ATYGNYSNAA FQFPPTSRML
     ATTASPVFVQ TPGEKGFTNF ALDFLMGGVS AAVSKTAAAP IERVKLLIQN QDEMIKAGRL
     SEPYKGIGDC FGRTIKDEGF GSLWRGNTAN VIRYFPTQAL NFAFKDYFKR LFNFKKDRDG
     YWKWFAGNLA SGGAAGASSL LFVYSLDYAR TRLANDAKAA KKGGGGRQFD GLVDVYRKTL
     KTDGIAGLYR GFNISCVGII VYRGLYFGLY DSVKPVLLTG DLQDSFFASF ALGWVITNGA
     GLASYPIDTV RRRMMMTSGE AVKYKSSLDA FKQILKNEGA KSLFKGAGAN ILRAVAGAGV
     LSGYDKLQLI VFGKKYGSGG A
//
ID   ADT1_HUMAN              Reviewed;         298 AA.
AC   P12235;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   02-MAR-2010, entry version 127.
DE   RecName: Full=ADP/ATP translocase 1;
DE   AltName: Full=Adenine nucleotide translocator 1;
DE            Short=ANT 1;
DE   AltName: Full=ADP,ATP carrier protein 1;
DE   AltName: Full=Solute carrier family 25 member 4;
DE   AltName: Full=ADP,ATP carrier protein, heart/skeletal muscle isoform T1;
GN   Name=SLC25A4; Synonyms=ANT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=88041149; PubMed=2823266; DOI=10.1073/pnas.84.21.7580;
RA   Neckelmann N., Li K., Wade R.P., Shuster R., Wallace D.C.;
RT   "cDNA sequence of a human skeletal muscle ADP/ATP translocator: lack
RT   of a leader peptide, divergence from a fibroblast translocator cDNA,
RT   and coevolution with mitochondrial DNA genes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:7580-7584(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=89236396; PubMed=2541251; DOI=10.1016/0022-2836(89)90477-4;
RA   Cozens A.L., Runswick M.J., Walker J.E.;
RT   "DNA sequences of two expressed nuclear genes for human mitochondrial
RT   ADP/ATP translocase.";
RL   J. Mol. Biol. 206:261-280(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=89340499; PubMed=2547778;
RA   Li K., Warner C.K., Hodge J.A., Minoshima S., Kudoh J., Fukuyama R.,
RA   Maekawa M., Shimizu Y., Shimizu N., Wallace D.C.;
RT   "A human muscle adenine nucleotide translocator gene has four exons,
RT   is located on chromosome 4, and is differentially expressed.";
RL   J. Biol. Chem. 264:13998-14004(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye, Mammary gland, and PNS;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-37.
RC   TISSUE=Liver;
RX   MEDLINE=88124845; PubMed=2829183; DOI=10.1073/pnas.85.2.377;
RA   Houldsworth J., Attardi G.;
RT   "Two distinct genes for ADP/ATP translocase are expressed at the mRNA
RT   level in adult human liver.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:377-381(1988).
RN   [6]
RP   PROTEIN SEQUENCE OF 2-31; 34-43; 64-92; 141-147; 189-199 AND 273-296,
RP   CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT GLY-2, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=B-cell lymphoma;
RA   Bienvenut W.V.;
RL   Submitted (OCT-2004) to UniProtKB.
RN   [7]
RP   INTERACTION WITH HIV-1 VPR.
RX   PubMed=16120388; DOI=10.1016/j.mito.2004.06.012;
RA   Deniaud A., Brenner C., Kroemer G.;
RT   "Mitochondrial membrane permeabilization by HIV-1 Vpr.";
RL   Mitochondrion 4:223-233(2004).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-191, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Lung;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [9]
RP   IDENTIFICATION [LARGE SCALE ANALYSIS], AND MASS SPECTROMETRY.
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [10]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-96, AND MASS SPECTROMETRY.
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [11]
RP   VARIANTS PEOA2 PRO-114 AND MET-289.
RX   MEDLINE=20385067; PubMed=10926541; DOI=10.1126/science.289.5480.782;
RA   Kaukonen J., Juselius J.K., Tiranti V., Kyttala A., Zeviani M.,
RA   Comi G.P., Keranen J., Peltonen L., Suomalainen A.;
RT   "Role of adenine nucleotide translocator 1 in mtDNA maintenance.";
RL   Science 289:782-785(2000).
RN   [12]
RP   VARIANT PEOA2 PRO-98.
RX   MEDLINE=21630143; PubMed=11756613;
RA   Napoli L., Bordoni A., Zeviani M., Hadjigeorgiou G.M., Sciacco M.,
RA   Tiranti V., Terentiou A., Moggio M., Papadimitriou A., Scarlato G.,
RA   Comi G.P.;
RT   "A novel missense adenine nucleotide translocator-1 gene mutation in a
RT   Greek adPEO family.";
RL   Neurology 57:2295-2298(2001).
RN   [13]
RP   VARIANT PEOA2 GLY-104.
RX   MEDLINE=22104981; PubMed=12112115; DOI=10.1002/ana.10172;
RA   Komaki H., Fukazawa T., Houzen H., Yoshida K., Nonaka I., Goto Y.;
RT   "A novel D104G mutation in the adenine nucleotide translocator 1 gene
RT   in autosomal dominant progressive external ophthalmoplegia patients
RT   with mitochondrial DNA with multiple deletions.";
RL   Ann. Neurol. 51:645-648(2002).
RN   [14]
RP   VARIANT PEO MET-289.
RX   PubMed=12707443;
RA   Agostino A., Valletta L., Chinnery P.F., Ferrari G., Carrara F.,
RA   Taylor R.W., Schaefer A.M., Turnbull D.M., Tiranti V., Zeviani M.;
RT   "Mutations of ANT1, Twinkle, and POLG1 in sporadic progressive
RT   external ophthalmoplegia (PEO).";
RL   Neurology 60:1354-1356(2003).
RN   [15]
RP   VARIANT HYPERTROPHIC CARDIOMYOPATHY ASP-123.
RX   PubMed=16155110; DOI=10.1093/hmg/ddi341;
RA   Palmieri L., Alberio S., Pisano I., Lodi T., Meznaric-Petrusa M.,
RA   Zidar J., Santoro A., Scarcia P., Fontanesi F., Lamantea E.,
RA   Ferrero I., Zeviani M.;
RT   "Complete loss-of-function of the heart/muscle-specific adenine
RT   nucleotide translocator is associated with mitochondrial myopathy and
RT   cardiomyopathy.";
RL   Hum. Mol. Genet. 14:3079-3088(2005).
RN   [16]
RP   VARIANT PEOA2 ASP-90.
RX   PubMed=15792871; DOI=10.1016/j.nmd.2004.12.004;
RA   Deschauer M., Hudson G., Mueller T., Taylor R.W., Chinnery P.F.,
RA   Zierz S.;
RT   "A novel ANT1 gene mutation with probable germline mosaicism in
RT   autosomal dominant progressive external ophthalmoplegia.";
RL   Neuromuscul. Disord. 15:311-315(2005).
CC   -!- FUNCTION: Catalyzes the exchange of ADP and ATP across the
CC       mitochondrial inner membrane.
CC   -!- SUBUNIT: Homodimer. Interacts with HIV-1 Vpr.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane; Multi-pass
CC       membrane protein.
CC   -!- DISEASE: Defects in SLC25A4 are a cause of progressive external
CC       ophthalmoplegia with mitochondrial DNA deletions autosomal
CC       dominant type 2 (PEOA2) [MIM:609283]. Progressive external
CC       ophthalmoplegia is characterized by progressive weakness of ocular
CC       muscles and levator muscle of the upper eyelid. In a minority of
CC       cases, it is associated with skeletal myopathy, which
CC       predominantly involves axial or proximal muscles and which causes
CC       abnormal fatigability and even permanent muscle weakness. Ragged-
CC       red fibers and atrophy are found on muscle biopsy. A large
CC       proportion of chronic ophthalmoplegias are associated with other
CC       symptoms, leading to a multisystemic pattern of this disease.
CC       Additional symptoms are variable, and may include cataracts,
CC       hearing loss, sensory axonal neuropathy, ataxia, depression,
CC       hypogonadism, and parkinsonism.
CC   -!- MISCELLANEOUS: The transmembrane helices are not perpendicular to
CC       the plane of the membrane, but cross the membrane at an angle.
CC       Odd-numbered transmembrane helices exhibit a sharp kink, due to
CC       the presence of a conserved proline residue (By similarity).
CC   -!- SIMILARITY: Belongs to the mitochondrial carrier family.
CC   -!- SIMILARITY: Contains 3 Solcar repeats.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/SLC25A4";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J02966; AAA61223.1; -; mRNA.
DR   EMBL; J04982; AAA51736.1; -; Genomic_DNA.
DR   EMBL; BC008664; AAH08664.1; -; mRNA.
DR   EMBL; BC061589; AAH61589.1; -; mRNA.
DR   EMBL; BC063643; AAH63643.1; -; mRNA.
DR   EMBL; J03593; AAA36751.1; -; mRNA.
DR   IPI; IPI00022891; -.
DR   PIR; A44778; A44778.
DR   RefSeq; NP_001142.2; -.
DR   UniGene; Hs.246506; -.
DR   UniGene; Hs.655925; -.
DR   SMR; P12235; 3-294.
DR   IntAct; P12235; 2.
DR   STRING; P12235; -.
DR   TCDB; 2.A.29.1.2; mitochondrial carrier (MC) family.
DR   PhosphoSite; P12235; -.
DR   PRIDE; P12235; -.
DR   Ensembl; ENST00000281456; ENSP00000281456; ENSG00000151729; Homo sapiens.
DR   GeneID; 291; -.
DR   KEGG; hsa:291; -.
DR   UCSC; uc003ixd.1; human.
DR   CTD; 291; -.
DR   GeneCards; GC04P186301; -.
DR   HGNC; HGNC:10990; SLC25A4.
DR   MIM; 103220; gene.
DR   MIM; 609283; phenotype.
DR   Orphanet; 663; Progressive external ophthalmoplegia.
DR   PharmGKB; PA35866; -.
DR   eggNOG; prNOG12573; -.
DR   HOGENOM; HBG610399; -.
DR   HOVERGEN; HBG108348; -.
DR   InParanoid; P12235; -.
DR   OMA; AKDEGSK; -.
DR   OrthoDB; EOG9JMB7V; -.
DR   PhylomeDB; P12235; -.
DR   Reactome; REACT_1505; Integration of energy metabolism.
DR   Reactome; REACT_15380; Diabetes pathways.
DR   Reactome; REACT_1698; Metabolism of nucleotides.
DR   Reactome; REACT_6185; HIV Infection.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   DrugBank; DB00720; Clodronate.
DR   NextBio; 1187; -.
DR   ArrayExpress; P12235; -.
DR   Bgee; P12235; -.
DR   CleanEx; HS_SLC25A4; -.
DR   Genevestigator; P12235; -.
DR   GermOnline; ENSG00000151729; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0005743; C:mitochondrial inner membrane; EXP:Reactome.
DR   GO; GO:0015207; F:adenine transmembrane transporter activity; TAS:ProtInc.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0006091; P:generation of precursor metabolites and energy; TAS:ProtInc.
DR   GO; GO:0044419; P:interspecies interaction between organisms; IEA:UniProtKB-KW.
DR   GO; GO:0000002; P:mitochondrial genome maintenance; TAS:ProtInc.
DR   GO; GO:0060547; P:negative regulation of necrotic cell death; IMP:UniProtKB.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR002113; Aden_trnslctor.
DR   InterPro; IPR002067; Mit_carrier.
DR   InterPro; IPR001993; Mitochondria_substrate_carrier.
DR   InterPro; IPR018108; Mitochondrial_sb/sol_carrier.
DR   PANTHER; PTHR11896; Mitoch_carrier; 1.
DR   Pfam; PF00153; Mito_carr; 3.
DR   PRINTS; PR00927; ADPTRNSLCASE.
DR   PRINTS; PR00926; MITOCARRIER.
DR   SUPFAM; SSF103506; Mitoch_carrier; 1.
DR   PROSITE; PS50920; SOLCAR; 3.
PE   1: Evidence at protein level;
KW   Acetylation; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Host-virus interaction; Isopeptide bond; Membrane;
KW   Mitochondrion; Mitochondrion inner membrane; Phosphoprotein;
KW   Progressive external ophthalmoplegia; Repeat; Transmembrane;
KW   Transport; Ubl conjugation.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    298       ADP/ATP translocase 1.
FT                                /FTId=PRO_0000090574.
FT   TRANSMEM      5     39       1 (By similarity).
FT   TRANSMEM     75    100       2 (By similarity).
FT   TRANSMEM    109    143       3 (By similarity).
FT   TRANSMEM    176    202       4 (By similarity).
FT   TRANSMEM    207    241       5 (By similarity).
FT   TRANSMEM    273    298       6 (By similarity).
FT   REPEAT        6     98       Solcar 1.
FT   REPEAT      111    201       Solcar 2.
FT   REPEAT      212    297       Solcar 3.
FT   MOTIF       235    240       Substrate recognition (By similarity).
FT   BINDING      80     80       Nucleotide (By similarity).
FT   MOD_RES       2      2       N-acetylglycine.
FT   MOD_RES      96     96       N6-acetyllysine.
FT   MOD_RES     126    126       Phosphothreonine (By similarity).
FT   MOD_RES     127    127       Phosphoserine (By similarity).
FT   MOD_RES     191    191       Phosphotyrosine.
FT   MOD_RES     195    195       Phosphotyrosine (By similarity).
FT   CROSSLNK     10     10       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
FT   VARIANT      90     90       A -> D (in PEOA2).
FT                                /FTId=VAR_038814.
FT   VARIANT      98     98       L -> P (in PEOA2).
FT                                /FTId=VAR_022459.
FT   VARIANT     104    104       D -> G (in PEOA2; dbSNP:rs28999114).
FT                                /FTId=VAR_022460.
FT   VARIANT     114    114       A -> P (in PEOA2).
FT                                /FTId=VAR_012111.
FT   VARIANT     123    123       A -> D (in hypertrophic cardiomyopathy;
FT                                sporadic patient with mild myopathy,
FT                                exercise intolerance and lactic acidosis
FT                                but no ophthalmoplegia).
FT                                /FTId=VAR_038815.
FT   VARIANT     289    289       V -> M (in PEOA2; also found in a
FT                                sporadic case affected by PEO).
FT                                /FTId=VAR_012112.
FT   CONFLICT     16     16       G -> A (in Ref. 1; AAA61223).
FT   CONFLICT    147    149       KGA -> RR (in Ref. 1; AAA61223).
FT   CONFLICT    227    227       V -> L (in Ref. 1; AAA61223).
SQ   SEQUENCE   298 AA;  33064 MW;  59F0DFAEC4E7CFBB CRC64;
     MGDHAWSFLK DFLAGGVAAA VSKTAVAPIE RVKLLLQVQH ASKQISAEKQ YKGIIDCVVR
     IPKEQGFLSF WRGNLANVIR YFPTQALNFA FKDKYKQLFL GGVDRHKQFW RYFAGNLASG
     GAAGATSLCF VYPLDFARTR LAADVGKGAA QREFHGLGDC IIKIFKSDGL RGLYQGFNVS
     VQGIIIYRAA YFGVYDTAKG MLPDPKNVHI FVSWMIAQSV TAVAGLVSYP FDTVRRRMMM
     QSGRKGADIM YTGTVDCWRK IAKDEGAKAF FKGAWSNVLR GMGGAFVLVL YDEIKKYV
//
ID   ADT1_MOUSE              Reviewed;         298 AA.
AC   P48962; Q62164;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   02-MAR-2010, entry version 96.
DE   RecName: Full=ADP/ATP translocase 1;
DE   AltName: Full=Adenine nucleotide translocator 1;
DE            Short=ANT 1;
DE   AltName: Full=ADP,ATP carrier protein 1;
DE   AltName: Full=Solute carrier family 25 member 4;
DE   AltName: Full=ADP,ATP carrier protein, heart/skeletal muscle isoform T1;
DE   AltName: Full=mANC1;
GN   Name=Slc25a4; Synonyms=Anc1, Ant1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=C57BL/6; TISSUE=Brain;
RX   MEDLINE=97059403; PubMed=8903724; DOI=10.1007/s003359900007;
RA   Ellison J.W., Li X., Francke U., Shapiro L.J.;
RT   "Rapid evolution of human pseudoautosomal genes and their mouse
RT   homologs.";
RL   Mamm. Genome 7:25-30(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=BALB/c; TISSUE=Muscle;
RA   Laplace C., Costet P.;
RL   Submitted (SEP-1993) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=20432087; PubMed=10974536; DOI=10.1016/S0378-1119(00)00252-3;
RA   Levy S.E., Chen Y.-S., Graham B.H., Wallace D.C.;
RT   "Expression and sequence analysis of the mouse adenine nucleotide
RT   translocase 1 and 2 genes.";
RL   Gene 254:57-66(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PROTEIN SEQUENCE OF 81-92, AND MASS SPECTROMETRY.
RC   STRAIN=OF1; TISSUE=Hippocampus;
RA   Lubec G., Sunyer B., Chen W.-Q.;
RL   Submitted (JAN-2009) to UniProtKB.
RN   [6]
RP   UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-10, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Heart;
RX   PubMed=17451654; DOI=10.1016/j.bbrc.2007.04.015;
RA   Jeon H.B., Choi E.S., Yoon J.H., Hwang J.H., Chang J.W., Lee E.K.,
RA   Choi H.W., Park Z.-Y., Yoo Y.J.;
RT   "A proteomics approach to identify the ubiquitinated proteins in mouse
RT   heart.";
RL   Biochem. Biophys. Res. Commun. 357:731-736(2007).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-195, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Brain;
RX   PubMed=18034455; DOI=10.1021/pr0701254;
RA   Ballif B.A., Carey G.R., Sunyaev S.R., Gygi S.P.;
RT   "Large-scale identification and evolution indexing of tyrosine
RT   phosphorylation sites from murine brain.";
RL   J. Proteome Res. 7:311-318(2008).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-191, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Brain cortex;
RX   PubMed=17114649; DOI=10.1074/mcp.M600046-MCP200;
RA   Munton R.P., Tweedie-Cullen R., Livingstone-Zatchej M., Weinandy F.,
RA   Waidelich M., Longo D., Gehrig P., Potthast F., Rutishauser D.,
RA   Gerrits B., Panse C., Schlapbach R., Mansuy I.M.;
RT   "Qualitative and quantitative analyses of protein phosphorylation in
RT   naive and stimulated mouse synaptosomal preparations.";
RL   Mol. Cell. Proteomics 6:283-293(2007).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-126 AND SER-127, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Brain;
RA   Lubec G., Kang S.;
RL   Submitted (APR-2007) to UniProtKB.
CC   -!- FUNCTION: Catalyzes the exchange of ADP and ATP across the
CC       mitochondrial inner membrane.
CC   -!- SUBUNIT: Homodimer.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane; Multi-pass
CC       membrane protein.
CC   -!- MISCELLANEOUS: The transmembrane helices are not perpendicular to
CC       the plane of the membrane, but cross the membrane at an angle.
CC       Odd-numbered transmembrane helices exhibit a sharp kink, due to
CC       the presence of a conserved proline residue (By similarity).
CC   -!- SIMILARITY: Belongs to the mitochondrial carrier family.
CC   -!- SIMILARITY: Contains 3 Solcar repeats.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U27315; AAC52837.1; -; mRNA.
DR   EMBL; X74510; CAA52616.1; -; mRNA.
DR   EMBL; AF240002; AAF64470.1; -; Genomic_DNA.
DR   EMBL; BC003791; AAH03791.1; -; mRNA.
DR   EMBL; BC026925; AAH26925.1; -; mRNA.
DR   IPI; IPI00115564; -.
DR   PIR; S37210; S37210.
DR   RefSeq; NP_031476.3; -.
DR   UniGene; Mm.16228; -.
DR   SMR; P48962; 3-294.
DR   STRING; P48962; -.
DR   PhosphoSite; P48962; -.
DR   PRIDE; P48962; -.
DR   Ensembl; ENSMUST00000034049; ENSMUSP00000034049; ENSMUSG00000031633; Mus musculus.
DR   GeneID; 11739; -.
DR   KEGG; mmu:11739; -.
DR   UCSC; uc009lpz.1; mouse.
DR   CTD; 11739; -.
DR   MGI; MGI:1353495; Slc25a4.
DR   eggNOG; roNOG15102; -.
DR   HOGENOM; HBG610399; -.
DR   HOVERGEN; HBG108348; -.
DR   InParanoid; P48962; -.
DR   OMA; AKDEGSK; -.
DR   OrthoDB; EOG9JMB7V; -.
DR   PhylomeDB; P48962; -.
DR   NextBio; 279463; -.
DR   ArrayExpress; P48962; -.
DR   Bgee; P48962; -.
DR   Genevestigator; P48962; -.
DR   GermOnline; ENSMUSG00000031633; Mus musculus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IDA:MGI.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR002113; Aden_trnslctor.
DR   InterPro; IPR002067; Mit_carrier.
DR   InterPro; IPR001993; Mitochondria_substrate_carrier.
DR   InterPro; IPR018108; Mitochondrial_sb/sol_carrier.
DR   PANTHER; PTHR11896; Mitoch_carrier; 1.
DR   Pfam; PF00153; Mito_carr; 3.
DR   PRINTS; PR00927; ADPTRNSLCASE.
DR   PRINTS; PR00926; MITOCARRIER.
DR   SUPFAM; SSF103506; Mitoch_carrier; 1.
DR   PROSITE; PS50920; SOLCAR; 3.
PE   1: Evidence at protein level;
KW   Acetylation; Direct protein sequencing; Isopeptide bond; Membrane;
KW   Mitochondrion; Mitochondrion inner membrane; Phosphoprotein; Repeat;
KW   Transmembrane; Transport; Ubl conjugation.
FT   INIT_MET      1      1       Removed (By similarity).
FT   CHAIN         2    298       ADP/ATP translocase 1.
FT                                /FTId=PRO_0000090575.
FT   TRANSMEM      5     39       1 (By similarity).
FT   TRANSMEM     75    100       2 (By similarity).
FT   TRANSMEM    109    143       3 (By similarity).
FT   TRANSMEM    176    202       4 (By similarity).
FT   TRANSMEM    207    241       5 (By similarity).
FT   TRANSMEM    273    298       6 (By similarity).
FT   REPEAT        6     98       Solcar 1.
FT   REPEAT      111    201       Solcar 2.
FT   REPEAT      212    297       Solcar 3.
FT   MOTIF       235    240       Substrate recognition (By similarity).
FT   BINDING      80     80       Nucleotide (By similarity).
FT   MOD_RES       2      2       N-acetylglycine (By similarity).
FT   MOD_RES      96     96       N6-acetyllysine (By similarity).
FT   MOD_RES     126    126       Phosphothreonine.
FT   MOD_RES     127    127       Phosphoserine.
FT   MOD_RES     191    191       Phosphotyrosine.
FT   MOD_RES     195    195       Phosphotyrosine.
FT   CROSSLNK     10     10       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   CONFLICT    136    136       F -> L (in Ref. 1; AAC52837).
SQ   SEQUENCE   298 AA;  32904 MW;  3A849FEAB0981462 CRC64;
     MGDQALSFLK DFLAGGIAAA VSKTAVAPIE RVKLLLQVQH ASKQISAEKQ YKGIIDCVVR
     IPKEQGFLSF WRGNLANVIR YFPTQALNFA FKDKYKQIFL GGVDRHKQFW RYFAGNLASG
     GAAGATSLCF VYPLDFARTR LAADVGKGSS QREFNGLGDC LTKIFKSDGL KGLYQGFSVS
     VQGIIIYRAA YFGVYDTAKG MLPDPKNVHI IVSWMIAQSV TAVAGLVSYP FDTVRRRMMM
     QSGRKGADIM YTGTLDCWRK IAKDEGANAF FKGAWSNVLR GMGGAFVLVL YDEIKKYV
//
ID   ADT1_RAT                Reviewed;         298 AA.
AC   Q05962;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 84.
DE   RecName: Full=ADP/ATP translocase 1;
DE   AltName: Full=Adenine nucleotide translocator 1;
DE            Short=ANT 1;
DE   AltName: Full=ADP,ATP carrier protein 1;
DE   AltName: Full=Solute carrier family 25 member 4;
GN   Name=Slc25a4; Synonyms=Ant1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RC   STRAIN=Sprague-Dawley, and Wistar; TISSUE=Heart, and Liver;
RX   MEDLINE=94002161; PubMed=8399300; DOI=10.1016/0005-2736(93)90248-X;
RA   Shinohara Y., Kamida M., Yamazaki N., Terada H.;
RT   "Isolation and characterization of cDNA clones and a genomic clone
RT   encoding rat mitochondrial adenine nucleotide translocator.";
RL   Biochim. Biophys. Acta 1152:192-196(1993).
RN   [2]
RP   PROTEIN SEQUENCE OF 2-31; 34-43; 73-80 AND 273-280, CLEAVAGE OF
RP   INITIATOR METHIONINE, ACETYLATION AT GLY-2, AND MASS SPECTROMETRY.
RC   TISSUE=Pheochromocytoma;
RA   Bienvenut W.V., von Kriegsheim A.F., Kolch W.;
RL   Submitted (AUG-2006) to UniProtKB.
CC   -!- FUNCTION: Catalyzes the exchange of ADP and ATP across the
CC       mitochondrial inner membrane.
CC   -!- SUBUNIT: Homodimer.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane; Multi-pass
CC       membrane protein.
CC   -!- TISSUE SPECIFICITY: In heart, skeletal muscle and to a lesser
CC       extent, in brain and kidney.
CC   -!- MISCELLANEOUS: The transmembrane helices are not perpendicular to
CC       the plane of the membrane, but cross the membrane at an angle.
CC       Odd-numbered transmembrane helices exhibit a sharp kink, due to
CC       the presence of a conserved proline residue (By similarity).
CC   -!- SIMILARITY: Belongs to the mitochondrial carrier family.
CC   -!- SIMILARITY: Contains 3 Solcar repeats.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X61667; CAA43842.1; -; Genomic_DNA.
DR   EMBL; D12770; BAA02237.1; -; mRNA.
DR   IPI; IPI00231927; -.
DR   PIR; I60173; I60173.
DR   RefSeq; NP_445967.1; -.
DR   UniGene; Rn.4092; -.
DR   SMR; Q05962; 3-294.
DR   STRING; Q05962; -.
DR   PhosphoSite; Q05962; -.
DR   PRIDE; Q05962; -.
DR   Ensembl; ENSRNOT00000014704; ENSRNOP00000014704; ENSRNOG00000010830; Rattus norvegicus.
DR   GeneID; 85333; -.
DR   KEGG; rno:85333; -.
DR   UCSC; NM_053515; rat.
DR   CTD; 85333; -.
DR   RGD; 620352; Slc25a4.
DR   eggNOG; roNOG15102; -.
DR   HOVERGEN; HBG108348; -.
DR   InParanoid; Q05962; -.
DR   PhylomeDB; Q05962; -.
DR   NextBio; 617472; -.
DR   ArrayExpress; Q05962; -.
DR   Genevestigator; Q05962; -.
DR   GermOnline; ENSRNOG00000010830; Rattus norvegicus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IDA:MGI.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IDA:MGI.
DR   GO; GO:0000295; F:adenine nucleotide transmembrane transporte...; TAS:RGD.
DR   GO; GO:0005471; F:ATP:ADP antiporter activity; IDA:RGD.
DR   GO; GO:0005515; F:protein binding; IPI:RGD.
DR   GO; GO:0015866; P:ADP transport; IDA:RGD.
DR   GO; GO:0015867; P:ATP transport; IDA:RGD.
DR   GO; GO:0051935; P:glutamate uptake during transmission of ner...; IEP:RGD.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR002113; Aden_trnslctor.
DR   InterPro; IPR002067; Mit_carrier.
DR   InterPro; IPR001993; Mitochondria_substrate_carrier.
DR   InterPro; IPR018108; Mitochondrial_sb/sol_carrier.
DR   PANTHER; PTHR11896; Mitoch_carrier; 1.
DR   Pfam; PF00153; Mito_carr; 3.
DR   PRINTS; PR00927; ADPTRNSLCASE.
DR   PRINTS; PR00926; MITOCARRIER.
DR   SUPFAM; SSF103506; Mitoch_carrier; 1.
DR   PROSITE; PS50920; SOLCAR; 3.
PE   1: Evidence at protein level;
KW   Acetylation; Direct protein sequencing; Isopeptide bond; Membrane;
KW   Mitochondrion; Mitochondrion inner membrane; Phosphoprotein; Repeat;
KW   Transmembrane; Transport; Ubl conjugation.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    298       ADP/ATP translocase 1.
FT                                /FTId=PRO_0000090577.
FT   TRANSMEM      5     39       1 (By similarity).
FT   TRANSMEM     75    100       2 (By similarity).
FT   TRANSMEM    109    143       3 (By similarity).
FT   TRANSMEM    176    202       4 (By similarity).
FT   TRANSMEM    207    241       5 (By similarity).
FT   TRANSMEM    273    298       6 (By similarity).
FT   REPEAT        6     98       Solcar 1.
FT   REPEAT      111    201       Solcar 2.
FT   REPEAT      212    297       Solcar 3.
FT   MOTIF       235    240       Substrate recognition (By similarity).
FT   BINDING      80     80       Nucleotide (By similarity).
FT   MOD_RES       2      2       N-acetylglycine.
FT   MOD_RES      96     96       N6-acetyllysine (By similarity).
FT   MOD_RES     126    126       Phosphothreonine (By similarity).
FT   MOD_RES     127    127       Phosphoserine (By similarity).
FT   MOD_RES     191    191       Phosphotyrosine (By similarity).
FT   MOD_RES     195    195       Phosphotyrosine (By similarity).
FT   CROSSLNK     10     10       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
SQ   SEQUENCE   298 AA;  32989 MW;  66704FF78C6BC320 CRC64;
     MGDQALSFLK DFLAGGIAAA VSKTAVAPIE RVKLLLQVQH ASKQISAEKQ YKGIIDCVVR
     IPKEQGFLSF WRGNLANVIR YFPTQALNFA FKDKYKQIFL GGVDRHKQFW RYFAGNLASG
     GAAGATSLCF VYPLDFARTR LAADVGKGSS QREFNGLGDC LTKIFKSDGL KGLYQGFSVS
     VQGIIIYRAA YFGVYDTAKG MLPDPKNVHI IVSWMIAQSV TAVAGLVSYP FDTVRRRMMM
     QSGRKGADIM YTGTVDCWRK IAKDEGRKAF FKGAWSNVLR GMGGAFVLVL YDEIKKYV
//
ID   ADT1_YEAST              Reviewed;         309 AA.
AC   P04710;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   13-AUG-1987, sequence version 1.
DT   02-MAR-2010, entry version 91.
DE   RecName: Full=ADP,ATP carrier protein 1;
DE   AltName: Full=ADP/ATP translocase 1;
DE   AltName: Full=Adenine nucleotide translocator 1;
DE            Short=ANT 1;
GN   Name=AAC1; OrderedLocusNames=YMR056C; ORFNames=YM9796.09C;
OS   Saccharomyces cerevisiae (Baker's yeast).
OC   Eukaryota; Fungi; Dikarya; Ascomycota; Saccharomycotina;
OC   Saccharomycetes; Saccharomycetales; Saccharomycetaceae; Saccharomyces.
OX   NCBI_TaxID=4932;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=87064348; PubMed=3023860;
RA   Adrian G.S., McCammon M.T., Montgomery D.L., Douglas M.G.;
RT   "Sequences required for delivery and localization of the ADP/ATP
RT   translocator to the mitochondrial inner membrane.";
RL   Mol. Cell. Biol. 6:626-634(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 204511 / S288c / AB972;
RX   MEDLINE=97313268; PubMed=9169872;
RA   Bowman S., Churcher C.M., Badcock K., Brown D., Chillingworth T.,
RA   Connor R., Dedman K., Devlin K., Gentles S., Hamlin N., Hunt S.,
RA   Jagels K., Lye G., Moule S., Odell C., Pearson D., Rajandream M.A.,
RA   Rice P., Skelton J., Walsh S.V., Whitehead S., Barrell B.G.;
RT   "The nucleotide sequence of Saccharomyces cerevisiae chromosome
RT   XIII.";
RL   Nature 387:90-93(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 265-309.
RC   STRAIN=ATCC 204508 / S288c;
RX   MEDLINE=91330299; PubMed=1651171; DOI=10.1016/0092-8674(81)90014-3;
RA   Hoyt M.A., Totis L., Roberts B.T.;
RT   "S. cerevisiae genes required for cell cycle arrest in response to
RT   loss of microtubule function.";
RL   Cell 66:507-517(1991).
CC   -!- FUNCTION: Catalyzes the exchange of ADP and ATP across the
CC       mitochondrial inner membrane.
CC   -!- SUBUNIT: Homodimer.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane; Multi-pass
CC       membrane protein.
CC   -!- MISCELLANEOUS: The transmembrane helices are not perpendicular to
CC       the plane of the membrane, but cross the membrane at an angle. At
CC       least 2 of the odd-numbered transmembrane helices exhibit a sharp
CC       kink, due to the presence of a conserved proline residue (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the mitochondrial carrier family.
CC   -!- SIMILARITY: Contains 3 Solcar repeats.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M12514; AAA97486.1; -; Genomic_DNA.
DR   EMBL; Z49703; CAA89766.1; -; Genomic_DNA.
DR   EMBL; M64706; AAA16884.1; -; Genomic_DNA.
DR   PIR; A24849; A24849.
DR   RefSeq; NP_013772.1; -.
DR   SMR; P04710; 10-299.
DR   DIP; DIP-2551N; -.
DR   IntAct; P04710; 4.
DR   STRING; P04710; -.
DR   TCDB; 2.A.29.1.3; mitochondrial carrier (MC) family.
DR   PeptideAtlas; P04710; -.
DR   Ensembl; YMR056C; YMR056C; YMR056C; Saccharomyces cerevisiae.
DR   GeneID; 855078; -.
DR   GenomeReviews; Z71257_GR; YMR056C.
DR   KEGG; sce:YMR056C; -.
DR   NMPDR; fig|4932.3.peg.4819; -.
DR   CYGD; YMR056c; -.
DR   SGD; S000004660; AAC1.
DR   eggNOG; fuNOG06875; -.
DR   HOGENOM; HBG610399; -.
DR   OMA; TATHEGI; -.
DR   OrthoDB; EOG9P2RKS; -.
DR   PhylomeDB; P04710; -.
DR   NextBio; 978360; -.
DR   ArrayExpress; P04710; -.
DR   Genevestigator; P04710; -.
DR   GermOnline; YMR056C; Saccharomyces cerevisiae.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005743; C:mitochondrial inner membrane; TAS:SGD.
DR   GO; GO:0005471; F:ATP:ADP antiporter activity; IDA:SGD.
DR   GO; GO:0005488; F:binding; IEA:InterPro.
DR   GO; GO:0009060; P:aerobic respiration; IGI:SGD.
DR   GO; GO:0006783; P:heme biosynthetic process; IGI:SGD.
DR   GO; GO:0006839; P:mitochondrial transport; IGI:SGD.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR002113; Aden_trnslctor.
DR   InterPro; IPR002067; Mit_carrier.
DR   InterPro; IPR001993; Mitochondria_substrate_carrier.
DR   InterPro; IPR018108; Mitochondrial_sb/sol_carrier.
DR   PANTHER; PTHR11896; Mitoch_carrier; 1.
DR   Pfam; PF00153; Mito_carr; 3.
DR   PRINTS; PR00927; ADPTRNSLCASE.
DR   PRINTS; PR00926; MITOCARRIER.
DR   SUPFAM; SSF103506; Mitoch_carrier; 1.
DR   PROSITE; PS50920; SOLCAR; 3.
PE   1: Evidence at protein level;
KW   Complete proteome; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Repeat; Transmembrane; Transport.
FT   CHAIN         1    309       ADP,ATP carrier protein 1.
FT                                /FTId=PRO_0000090593.
FT   TRANSMEM     10     44       1 (By similarity).
FT   TRANSMEM     81    105       2 (By similarity).
FT   TRANSMEM    114    148       3 (By similarity).
FT   TRANSMEM    183    210       4 (By similarity).
FT   TRANSMEM    215    249       5 (By similarity).
FT   TRANSMEM    278    303       6 (By similarity).
FT   REPEAT       11    104       Solcar 1.
FT   REPEAT      116    208       Solcar 2.
FT   REPEAT      216    302       Solcar 3.
FT   MOTIF       243    248       Substrate recognition (By similarity).
FT   BINDING      86     86       Nucleotide (By similarity).
SQ   SEQUENCE   309 AA;  34121 MW;  BEC8999DFBB1CA51 CRC64;
     MSHTETQTQQ SHFGVDFLMG GVSAAIAKTG AAPIERVKLL MQNQEEMLKQ GSLDTRYKGI
     LDCFKRTATH EGIVSFWRGN TANVLRYFPT QALNFAFKDK IKSLLSYDRE RDGYAKWFAG
     NLFSGGAAGG LSLLFVYSLD YARTRLAADA RGSKSTSQRQ FNGLLDVYKK TLKTDGLLGL
     YRGFVPSVLG IIVYRGLYFG LYDSFKPVLL TGALEGSFVA SFLLGWVITM GASTASYPLD
     TVRRRMMMTS GQTIKYDGAL DCLRKIVQKE GAYSLFKGCG ANIFRGVAAA GVISLYDQLQ
     LIMFGKKFK
//
ID   ADT2_ARATH              Reviewed;         385 AA.
AC   P40941; Q9FY52;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   06-JUN-2002, sequence version 2.
DT   02-MAR-2010, entry version 81.
DE   RecName: Full=ADP,ATP carrier protein 2, mitochondrial;
DE   AltName: Full=ADP/ATP translocase 2;
DE   AltName: Full=Adenine nucleotide translocator 2;
DE            Short=ANT 2;
DE   Flags: Precursor;
GN   Name=ANT2; OrderedLocusNames=At5g13490; ORFNames=T6I14_20;
OS   Arabidopsis thaliana (Mouse-ear cress).
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
OC   rosids; malvids; Brassicales; Brassicaceae; Arabidopsis.
OX   NCBI_TaxID=3702;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=cv. Columbia;
RX   MEDLINE=93176813; PubMed=8439563; DOI=10.1016/0167-4781(93)90296-P;
RA   Schuster W., Kloska S., Brennicke A.;
RT   "An adenine nucleotide translocator gene from Arabidopsis thaliana.";
RL   Biochim. Biophys. Acta 1172:205-208(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=cv. Columbia;
RX   MEDLINE=21016721; PubMed=11130714; DOI=10.1038/35048507;
RA   Tabata S., Kaneko T., Nakamura Y., Kotani H., Kato T., Asamizu E.,
RA   Miyajima N., Sasamoto S., Kimura T., Hosouchi T., Kawashima K.,
RA   Kohara M., Matsumoto M., Matsuno A., Muraki A., Nakayama S.,
RA   Nakazaki N., Naruo K., Okumura S., Shinpo S., Takeuchi C., Wada T.,
RA   Watanabe A., Yamada M., Yasuda M., Sato S., de la Bastide M.,
RA   Huang E., Spiegel L., Gnoj L., O'Shaughnessy A., Preston R.,
RA   Habermann K., Murray J., Johnson D., Rohlfing T., Nelson J.,
RA   Stoneking T., Pepin K., Spieth J., Sekhon M., Armstrong J., Becker M.,
RA   Belter E., Cordum H., Cordes M., Courtney L., Courtney W., Dante M.,
RA   Du H., Edwards J., Fryman J., Haakensen B., Lamar E., Latreille P.,
RA   Leonard S., Meyer R., Mulvaney E., Ozersky P., Riley A., Strowmatt C.,
RA   Wagner-McPherson C., Wollam A., Yoakum M., Bell M., Dedhia N.,
RA   Parnell L., Shah R., Rodriguez M., Hoon See L., Vil D., Baker J.,
RA   Kirchoff K., Toth K., King L., Bahret A., Miller B., Marra M.A.,
RA   Martienssen R., McCombie W.R., Wilson R.K., Murphy G., Bancroft I.,
RA   Volckaert G., Wambutt R., Duesterhoeft A., Stiekema W., Pohl T.,
RA   Entian K.-D., Terryn N., Hartley N., Bent E., Johnson S.,
RA   Langham S.-A., McCullagh B., Robben J., Grymonprez B., Zimmermann W.,
RA   Ramsperger U., Wedler H., Balke K., Wedler E., Peters S.,
RA   van Staveren M., Dirkse W., Mooijman P., Klein Lankhorst R.,
RA   Weitzenegger T., Bothe G., Rose M., Hauf J., Berneiser S., Hempel S.,
RA   Feldpausch M., Lamberth S., Villarroel R., Gielen J., Ardiles W.,
RA   Bents O., Lemcke K., Kolesov G., Mayer K.F.X., Rudd S., Schoof H.,
RA   Schueller C., Zaccaria P., Mewes H.-W., Bevan M., Fransz P.F.;
RT   "Sequence and analysis of chromosome 5 of the plant Arabidopsis
RT   thaliana.";
RL   Nature 408:823-826(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=cv. Columbia;
RX   MEDLINE=22954850; PubMed=14593172; DOI=10.1126/science.1088305;
RA   Yamada K., Lim J., Dale J.M., Chen H., Shinn P., Palm C.J.,
RA   Southwick A.M., Wu H.C., Kim C.J., Nguyen M., Pham P.K., Cheuk R.F.,
RA   Karlin-Newmann G., Liu S.X., Lam B., Sakano H., Wu T., Yu G.,
RA   Miranda M., Quach H.L., Tripp M., Chang C.H., Lee J.M., Toriumi M.J.,
RA   Chan M.M., Tang C.C., Onodera C.S., Deng J.M., Akiyama K., Ansari Y.,
RA   Arakawa T., Banh J., Banno F., Bowser L., Brooks S.Y., Carninci P.,
RA   Chao Q., Choy N., Enju A., Goldsmith A.D., Gurjal M., Hansen N.F.,
RA   Hayashizaki Y., Johnson-Hopson C., Hsuan V.W., Iida K., Karnes M.,
RA   Khan S., Koesema E., Ishida J., Jiang P.X., Jones T., Kawai J.,
RA   Kamiya A., Meyers C., Nakajima M., Narusaka M., Seki M., Sakurai T.,
RA   Satou M., Tamse R., Vaysberg M., Wallender E.K., Wong C., Yamamura Y.,
RA   Yuan S., Shinozaki K., Davis R.W., Theologis A., Ecker J.R.;
RT   "Empirical analysis of transcriptional activity in the Arabidopsis
RT   genome.";
RL   Science 302:842-846(2003).
RN   [4]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS], AND
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RX   PubMed=14671022; DOI=10.1105/tpc.016055;
RA   Heazlewood J.L., Tonti-Filippini J.S., Gout A.M., Day D.A., Whelan J.,
RA   Millar A.H.;
RT   "Experimental analysis of the Arabidopsis mitochondrial proteome
RT   highlights signaling and regulatory components, provides assessment of
RT   targeting prediction programs, and indicates plant-specific
RT   mitochondrial proteins.";
RL   Plant Cell 16:241-256(2004).
CC   -!- FUNCTION: Catalyzes the exchange of ADP and ATP across the
CC       mitochondrial inner membrane.
CC   -!- SUBUNIT: Homodimer (By similarity).
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane; Multi-pass
CC       membrane protein.
CC   -!- MISCELLANEOUS: The transmembrane helices are not perpendicular to
CC       the plane of the membrane, but cross the membrane at an angle. At
CC       least 2 of the odd-numbered transmembrane helices exhibit a sharp
CC       kink, due to the presence of a conserved proline residue (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the mitochondrial carrier family.
CC   -!- SIMILARITY: Contains 3 Solcar repeats.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X68592; CAA48579.1; -; mRNA.
DR   EMBL; AL391710; CAC05426.1; -; Genomic_DNA.
DR   EMBL; AY050857; AAK92794.1; -; mRNA.
DR   EMBL; AY079407; AAL85138.1; -; mRNA.
DR   IPI; IPI00537792; -.
DR   PIR; S29852; S29852.
DR   RefSeq; NP_001031876.1; -.
DR   RefSeq; NP_196853.1; -.
DR   UniGene; At.127; -.
DR   UniGene; Rra.4062; -.
DR   SMR; P40941; 84-371.
DR   STRING; P40941; -.
DR   PRIDE; P40941; -.
DR   GeneID; 831193; -.
DR   GenomeReviews; BA000015_GR; AT5G13490.
DR   KEGG; ath:AT5G13490; -.
DR   NMPDR; fig|3702.1.peg.23467; -.
DR   GeneFarm; 3732; 374.
DR   TAIR; At5g13490; -.
DR   eggNOG; KOG0749; -.
DR   HOGENOM; HBG610399; -.
DR   InParanoid; P40941; -.
DR   OMA; FGRTIRD; -.
DR   PhylomeDB; P40941; -.
DR   ArrayExpress; P40941; -.
DR   Genevestigator; P40941; -.
DR   GermOnline; AT5G13490; Arabidopsis thaliana.
DR   GO; GO:0009941; C:chloroplast envelope; IDA:TAIR.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:TAIR.
DR   GO; GO:0005471; F:ATP:ADP antiporter activity; IDA:TAIR.
DR   GO; GO:0005507; F:copper ion binding; IDA:TAIR.
DR   GO; GO:0005515; F:protein binding; IPI:TAIR.
DR   GO; GO:0015865; P:purine nucleotide transport; IDA:TAIR.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR002113; Aden_trnslctor.
DR   InterPro; IPR002067; Mit_carrier.
DR   InterPro; IPR001993; Mitochondria_substrate_carrier.
DR   InterPro; IPR018108; Mitochondrial_sb/sol_carrier.
DR   PANTHER; PTHR11896; Mitoch_carrier; 1.
DR   Pfam; PF00153; Mito_carr; 3.
DR   PRINTS; PR00927; ADPTRNSLCASE.
DR   PRINTS; PR00926; MITOCARRIER.
DR   SUPFAM; SSF103506; Mitoch_carrier; 1.
DR   PROSITE; PS50920; SOLCAR; 3.
PE   1: Evidence at protein level;
KW   Complete proteome; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Repeat; Transit peptide; Transmembrane;
KW   Transport.
FT   TRANSIT       1     74       Mitochondrion (Potential).
FT   CHAIN        75    385       ADP,ATP carrier protein 2, mitochondrial.
FT                                /FTId=PRO_0000019246.
FT   TRANSMEM     81    115       1 (By similarity).
FT   TRANSMEM    152    176       2 (By similarity).
FT   TRANSMEM    185    219       3 (By similarity).
FT   TRANSMEM    255    282       4 (By similarity).
FT   TRANSMEM    287    321       5 (By similarity).
FT   TRANSMEM    350    375       6 (By similarity).
FT   REPEAT       82    175       Solcar 1.
FT   REPEAT      187    280       Solcar 2.
FT   REPEAT      288    374       Solcar 3.
FT   MOTIF       315    320       Substrate recognition (By similarity).
FT   BINDING     157    157       Nucleotide (By similarity).
FT   CONFLICT    228    228       G -> R (in Ref. 1; CAA48579).
SQ   SEQUENCE   385 AA;  41746 MW;  87ADF762213207BA CRC64;
     MVEQTQHPTI LQKVSGQLLS SSVSQDIRGY ASASKRPATY QKHAAYGNYS NAAFQYPLVA
     ASQIATTTSP VFVQAPGEKG FTNFAIDFMM GGVSAAVSKT AAAPIERVKL LIQNQDEMLK
     AGRLTEPYKG IRDCFGRTIR DEGIGSLWRG NTANVIRYFP TQALNFAFKD YFKRLFNFKK
     DKDGYWKWFA GNLASGGAAG ASSLLFVYSL DYARTRLAND SKSAKKGGGE RQFNGLVDVY
     KKTLKSDGIA GLYRGFNISC AGIIVYRGLY FGLYDSVKPV LLTGDLQDSF FASFALGWLI
     TNGAGLASYP IDTVRRRMMM TSGEAVKYKS SFDAFSQIVK KEGAKSLFKG AGANILRAVA
     GAGVLAGYDK LQLIVFGKKY GSGGA
//
ID   ADT2_HUMAN              Reviewed;         298 AA.
AC   P05141; O43350;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 6.
DT   02-MAR-2010, entry version 120.
DE   RecName: Full=ADP/ATP translocase 2;
DE   AltName: Full=Adenine nucleotide translocator 2;
DE            Short=ANT 2;
DE   AltName: Full=ADP,ATP carrier protein 2;
DE   AltName: Full=Solute carrier family 25 member 5;
DE   AltName: Full=ADP,ATP carrier protein, fibroblast isoform;
GN   Name=SLC25A5; Synonyms=ANT2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RX   MEDLINE=90375457; PubMed=2168878;
RA   Ku D.-H., Kagan J., Chen S.-T., Chang C.-D., Baserga R., Wurzel J.;
RT   "The human fibroblast adenine nucleotide translocator gene. Molecular
RT   cloning and sequence.";
RL   J. Biol. Chem. 265:16060-16063(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=87166056; PubMed=3031073;
RA   Battini R., Ferrari S., Kaczmarek L., Calabretta B., Chen S.T.,
RA   Baserga R.;
RT   "Molecular cloning of a cDNA for a human ADP/ATP carrier which is
RT   growth-regulated.";
RL   J. Biol. Chem. 262:4355-4358(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8918809; DOI=10.1093/nar/24.20.4034;
RA   Chen C.N., Su Y., Baybayan P., Siruno A., Nagaraja R., Mazzarella R.,
RA   Schlessinger D., Chen E.;
RT   "Ordered shotgun sequencing of a 135 kb Xq25 YAC containing ANT2 and
RT   four possible genes, including three confirmed by EST matches.";
RL   Nucleic Acids Res. 24:4034-4041(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT LEU-111.
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 2-31; 34-43; 64-92; 141-147; 189-199 AND 273-296,
RP   CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT THR-2, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=B-cell lymphoma;
RA   Bienvenut W.V.;
RL   Submitted (OCT-2004) to UniProtKB.
RN   [7]
RP   PROTEIN SEQUENCE OF 2-23; 32-43; 50-60; 64-92; 81-92; 97-106; 112-138;
RP   172-199; 207-235; 245-259 AND 281-295, CLEAVAGE OF INITIATOR
RP   METHIONINE, ACETYLATION AT THR-2, METHYLATION AT LYS-52, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RA   Bienvenut W.V., Waridel P., Quadroni M.;
RL   Submitted (MAR-2009) to UniProtKB.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 46-297, AND VARIANT LEU-111.
RC   TISSUE=Liver;
RX   MEDLINE=88124845; PubMed=2829183; DOI=10.1073/pnas.85.2.377;
RA   Houldsworth J., Attardi G.;
RT   "Two distinct genes for ADP/ATP translocase are expressed at the mRNA
RT   level in adult human liver.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:377-381(1988).
RN   [9]
RP   INTERACTION WITH HIV-1 VPR.
RX   PubMed=16120388; DOI=10.1016/j.mito.2004.06.012;
RA   Deniaud A., Brenner C., Kroemer G.;
RT   "Mitochondrial membrane permeabilization by HIV-1 Vpr.";
RL   Mitochondrion 4:223-233(2004).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-191 AND TYR-195, AND
RP   MASS SPECTROMETRY.
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [11]
RP   IDENTIFICATION [LARGE SCALE ANALYSIS], AND MASS SPECTROMETRY.
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [12]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-23; LYS-105; LYS-163 AND
RP   LYS-199, AND MASS SPECTROMETRY.
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
CC   -!- FUNCTION: Catalyzes the exchange of ADP and ATP across the
CC       mitochondrial inner membrane.
CC   -!- SUBUNIT: Homodimer. Interacts with HIV-1 Vpr.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane; Multi-pass
CC       membrane protein.
CC   -!- MISCELLANEOUS: The transmembrane helices are not perpendicular to
CC       the plane of the membrane, but cross the membrane at an angle.
CC       Odd-numbered transmembrane helices exhibit a sharp kink, due to
CC       the presence of a conserved proline residue (By similarity).
CC   -!- SIMILARITY: Belongs to the mitochondrial carrier family.
CC   -!- SIMILARITY: Contains 3 Solcar repeats.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M57424; AAA51737.1; -; Genomic_DNA.
DR   EMBL; J02683; AAA35579.1; -; mRNA.
DR   EMBL; L78810; AAB39266.1; -; Genomic_DNA.
DR   EMBL; AC004000; AAB96347.1; -; Genomic_DNA.
DR   EMBL; BC056160; AAH56160.1; -; mRNA.
DR   EMBL; J03591; AAA36749.1; -; mRNA.
DR   IPI; IPI00007188; -.
DR   PIR; A29132; A29132.
DR   RefSeq; NP_001143.2; -.
DR   UniGene; Hs.632282; -.
DR   SMR; P05141; 2-294.
DR   IntAct; P05141; 15.
DR   STRING; P05141; -.
DR   TCDB; 2.A.29.1.1; mitochondrial carrier (MC) family.
DR   PhosphoSite; P05141; -.
DR   PRIDE; P05141; -.
DR   Ensembl; ENST00000317881; ENSP00000360671; ENSG00000005022; Homo sapiens.
DR   GeneID; 292; -.
DR   KEGG; hsa:292; -.
DR   CTD; 292; -.
DR   GeneCards; GC0XP118486; -.
DR   HGNC; HGNC:10991; SLC25A5.
DR   MIM; 300150; gene.
DR   PharmGKB; PA35867; -.
DR   eggNOG; prNOG18664; -.
DR   HOVERGEN; HBG108348; -.
DR   InParanoid; P05141; -.
DR   OrthoDB; EOG9JMB7V; -.
DR   PhylomeDB; P05141; -.
DR   Reactome; REACT_1505; Integration of energy metabolism.
DR   Reactome; REACT_15380; Diabetes pathways.
DR   Reactome; REACT_1698; Metabolism of nucleotides.
DR   Reactome; REACT_6185; HIV Infection.
DR   DrugBank; DB00720; Clodronate.
DR   NextBio; 1191; -.
DR   ArrayExpress; P05141; -.
DR   Bgee; P05141; -.
DR   CleanEx; HS_SLC25A5; -.
DR   Genevestigator; P05141; -.
DR   GermOnline; ENSG00000005022; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0005743; C:mitochondrial inner membrane; EXP:Reactome.
DR   GO; GO:0042645; C:mitochondrial nucleoid; IDA:UniProtKB.
DR   GO; GO:0015207; F:adenine transmembrane transporter activity; TAS:ProtInc.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0044419; P:interspecies interaction between organisms; IEA:UniProtKB-KW.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR002113; Aden_trnslctor.
DR   InterPro; IPR002067; Mit_carrier.
DR   InterPro; IPR001993; Mitochondria_substrate_carrier.
DR   InterPro; IPR018108; Mitochondrial_sb/sol_carrier.
DR   PANTHER; PTHR11896; Mitoch_carrier; 1.
DR   Pfam; PF00153; Mito_carr; 3.
DR   PRINTS; PR00927; ADPTRNSLCASE.
DR   PRINTS; PR00926; MITOCARRIER.
DR   SUPFAM; SSF103506; Mitoch_carrier; 1.
DR   PROSITE; PS50920; SOLCAR; 3.
PE   1: Evidence at protein level;
KW   Acetylation; Complete proteome; Direct protein sequencing;
KW   Host-virus interaction; Membrane; Methylation; Mitochondrion;
KW   Mitochondrion inner membrane; Phosphoprotein; Polymorphism; Repeat;
KW   Transmembrane; Transport.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    298       ADP/ATP translocase 2.
FT                                /FTId=PRO_0000090579.
FT   TRANSMEM      5     39       1 (By similarity).
FT   TRANSMEM     75    100       2 (By similarity).
FT   TRANSMEM    109    143       3 (By similarity).
FT   TRANSMEM    176    202       4 (By similarity).
FT   TRANSMEM    207    241       5 (By similarity).
FT   TRANSMEM    273    298       6 (By similarity).
FT   REPEAT        6     98       Solcar 1.
FT   REPEAT      111    201       Solcar 2.
FT   REPEAT      212    297       Solcar 3.
FT   MOTIF       235    240       Substrate recognition (By similarity).
FT   BINDING      80     80       Nucleotide (By similarity).
FT   MOD_RES       2      2       N-acetylthreonine.
FT   MOD_RES      23     23       N6-acetyllysine.
FT   MOD_RES      42     42       Phosphoserine (By similarity).
FT   MOD_RES      52     52       N6,N6-dimethyllysine; alternate.
FT   MOD_RES      52     52       N6-methyllysine; alternate.
FT   MOD_RES      92     92       N6-acetyllysine (By similarity).
FT   MOD_RES     105    105       N6-acetyllysine.
FT   MOD_RES     163    163       N6-acetyllysine.
FT   MOD_RES     166    166       N6-acetyllysine (By similarity).
FT   MOD_RES     191    191       Phosphotyrosine.
FT   MOD_RES     195    195       Phosphotyrosine.
FT   MOD_RES     199    199       N6-acetyllysine.
FT   VARIANT     111    111       R -> L (in dbSNP:rs371749).
FT                                /FTId=VAR_030039.
FT   CONFLICT      6      6       V -> L (in Ref. 2; AAA35579).
FT   CONFLICT     66     66       G -> E (in Ref. 2; AAA35579).
FT   CONFLICT    162    162       V -> G (in Ref. 8; AAA36749).
SQ   SEQUENCE   298 AA;  32895 MW;  F973C3AED92C49D3 CRC64;
     MTDAAVSFAK DFLAGGVAAA ISKTAVAPIE RVKLLLQVQH ASKQITADKQ YKGIIDCVVR
     IPKEQGVLSF WRGNLANVIR YFPTQALNFA FKDKYKQIFL GGVDKRTQFW RYFAGNLASG
     GAAGATSLCF VYPLDFARTR LAADVGKAGA EREFRGLGDC LVKIYKSDGI KGLYQGFNVS
     VQGIIIYRAA YFGIYDTAKG MLPDPKNTHI VISWMIAQTV TAVAGLTSYP FDTVRRRMMM
     QSGRKGTDIM YTGTLDCWRK IARDEGGKAF FKGAWSNVLR GMGGAFVLVL YDEIKKYT
//
ID   ADT2_MOUSE              Reviewed;         298 AA.
AC   P51881; Q61311;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 98.
DE   RecName: Full=ADP/ATP translocase 2;
DE   AltName: Full=Adenine nucleotide translocator 2;
DE            Short=ANT 2;
DE   AltName: Full=ADP,ATP carrier protein 2;
DE   AltName: Full=Solute carrier family 25 member 5;
GN   Name=Slc25a5; Synonyms=Ant2;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=C57BL/6; TISSUE=Brain;
RX   MEDLINE=97059403; PubMed=8903724; DOI=10.1007/s003359900007;
RA   Ellison J.W., Li X., Francke U., Shapiro L.J.;
RT   "Rapid evolution of human pseudoautosomal genes and their mouse
RT   homologs.";
RL   Mamm. Genome 7:25-30(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Skeletal muscle;
RA   Sheldon J.G.;
RL   Thesis (1995), University of Cambridge, United Kingdom.
RN   [3]
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=129/Sv;
RA   Costet P., Laplace C.;
RL   Submitted (FEB-1993) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   SEQUENCE REVISION.
RA   Laplace C.;
RL   Submitted (FEB-1997) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=20432087; PubMed=10974536; DOI=10.1016/S0378-1119(00)00252-3;
RA   Levy S.E., Chen Y.-S., Graham B.H., Wallace D.C.;
RT   "Expression and sequence analysis of the mouse adenine nucleotide
RT   translocase 1 and 2 genes.";
RL   Gene 254:57-66(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6, and FVB/N; TISSUE=Brain, and Mammary gland;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 2-31; 34-43; 64-72; 81-92; 97-106 AND 189-199,
RP   CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT THR-2, AND MASS
RP   SPECTROMETRY.
RC   STRAIN=C57BL/6; TISSUE=Liver;
RA   Bienvenut W.V.;
RL   Submitted (JUL-2005) to UniProtKB.
RN   [8]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-23; LYS-92; LYS-155;
RP   LYS-163; LYS-166 AND LYS-199, AND MASS SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=16916647; DOI=10.1016/j.molcel.2006.06.026;
RA   Kim S.C., Sprung R., Chen Y., Xu Y., Ball H., Pei J., Cheng T.,
RA   Kho Y., Xiao H., Xiao L., Grishin N.V., White M., Yang X.-J., Zhao Y.;
RT   "Substrate and functional diversity of lysine acetylation revealed by
RT   a proteomics survey.";
RL   Mol. Cell 23:607-618(2006).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-191 AND TYR-195, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Brain;
RX   PubMed=18034455; DOI=10.1021/pr0701254;
RA   Ballif B.A., Carey G.R., Sunyaev S.R., Gygi S.P.;
RT   "Large-scale identification and evolution indexing of tyrosine
RT   phosphorylation sites from murine brain.";
RL   J. Proteome Res. 7:311-318(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-42, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=17208939; DOI=10.1074/mcp.M600218-MCP200;
RA   Lee J., Xu Y., Chen Y., Sprung R., Kim S.C., Xie S., Zhao Y.;
RT   "Mitochondrial phosphoproteome revealed by an improved IMAC method and
RT   MS/MS/MS.";
RL   Mol. Cell. Proteomics 6:669-676(2007).
CC   -!- FUNCTION: Catalyzes the exchange of ADP and ATP across the
CC       mitochondrial inner membrane.
CC   -!- SUBUNIT: Homodimer.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane; Multi-pass
CC       membrane protein.
CC   -!- MISCELLANEOUS: The transmembrane helices are not perpendicular to
CC       the plane of the membrane, but cross the membrane at an angle.
CC       Odd-numbered transmembrane helices exhibit a sharp kink, due to
CC       the presence of a conserved proline residue (By similarity).
CC   -!- SIMILARITY: Belongs to the mitochondrial carrier family.
CC   -!- SIMILARITY: Contains 3 Solcar repeats.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U27316; AAC52838.1; -; mRNA.
DR   EMBL; U10404; AAA19009.1; -; mRNA.
DR   EMBL; X70847; CAA50196.1; -; mRNA.
DR   EMBL; AF240003; AAF64471.1; -; Genomic_DNA.
DR   EMBL; BC004570; AAH04570.1; -; mRNA.
DR   EMBL; BC086756; AAH86756.1; -; mRNA.
DR   IPI; IPI00127841; -.
DR   PIR; S31814; S31814.
DR   RefSeq; NP_031477.1; -.
DR   UniGene; Mm.371544; -.
DR   UniGene; Mm.658; -.
DR   SMR; P51881; 2-294.
DR   STRING; P51881; -.
DR   PhosphoSite; P51881; -.
DR   PRIDE; P51881; -.
DR   Ensembl; ENSMUST00000016463; ENSMUSP00000016463; ENSMUSG00000016319; Mus musculus.
DR   GeneID; 11740; -.
DR   KEGG; mmu:11740; -.
DR   UCSC; uc009sxs.1; mouse.
DR   CTD; 11740; -.
DR   MGI; MGI:1353496; Slc25a5.
DR   eggNOG; roNOG06425; -.
DR   HOGENOM; HBG610399; -.
DR   HOVERGEN; HBG108348; -.
DR   InParanoid; P51881; -.
DR   OMA; KNTHILV; -.
DR   OrthoDB; EOG9JMB7V; -.
DR   PhylomeDB; P51881; -.
DR   NextBio; 279467; -.
DR   ArrayExpress; P51881; -.
DR   Bgee; P51881; -.
DR   Genevestigator; P51881; -.
DR   GermOnline; ENSMUSG00000016319; Mus musculus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IDA:MGI.
DR   GO; GO:0005488; F:binding; IEA:InterPro.
DR   GO; GO:0005215; F:transporter activity; IEA:InterPro.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR002113; Aden_trnslctor.
DR   InterPro; IPR002067; Mit_carrier.
DR   InterPro; IPR001993; Mitochondria_substrate_carrier.
DR   InterPro; IPR018108; Mitochondrial_sb/sol_carrier.
DR   PANTHER; PTHR11896; Mitoch_carrier; 1.
DR   Pfam; PF00153; Mito_carr; 3.
DR   PRINTS; PR00927; ADPTRNSLCASE.
DR   PRINTS; PR00926; MITOCARRIER.
DR   SUPFAM; SSF103506; Mitoch_carrier; 1.
DR   PROSITE; PS50920; SOLCAR; 3.
PE   1: Evidence at protein level;
KW   Acetylation; Direct protein sequencing; Membrane; Methylation;
KW   Mitochondrion; Mitochondrion inner membrane; Phosphoprotein; Repeat;
KW   Transmembrane; Transport.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    298       ADP/ATP translocase 2.
FT                                /FTId=PRO_0000090580.
FT   TRANSMEM      5     39       1 (By similarity).
FT   TRANSMEM     75    100       2 (By similarity).
FT   TRANSMEM    109    143       3 (By similarity).
FT   TRANSMEM    176    202       4 (By similarity).
FT   TRANSMEM    207    241       5 (By similarity).
FT   TRANSMEM    273    298       6 (By similarity).
FT   REPEAT        6     98       Solcar 1.
FT   REPEAT      111    201       Solcar 2.
FT   REPEAT      212    297       Solcar 3.
FT   MOTIF       235    240       Substrate recognition (By similarity).
FT   BINDING      80     80       Nucleotide (By similarity).
FT   MOD_RES       2      2       N-acetylthreonine.
FT   MOD_RES      23     23       N6-acetyllysine.
FT   MOD_RES      42     42       Phosphoserine.
FT   MOD_RES      52     52       N6,N6-dimethyllysine; alternate (By
FT                                similarity).
FT   MOD_RES      52     52       N6-methyllysine; alternate (By
FT                                similarity).
FT   MOD_RES      92     92       N6-acetyllysine.
FT   MOD_RES     105    105       N6-acetyllysine (By similarity).
FT   MOD_RES     155    155       N6-acetyllysine.
FT   MOD_RES     163    163       N6-acetyllysine.
FT   MOD_RES     166    166       N6-acetyllysine.
FT   MOD_RES     191    191       Phosphotyrosine.
FT   MOD_RES     195    195       Phosphotyrosine.
FT   MOD_RES     199    199       N6-acetyllysine.
SQ   SEQUENCE   298 AA;  32931 MW;  0798E04B987EFE20 CRC64;
     MTDAAVSFAK DFLAGGVAAA ISKTAVAPIE RVKLLLQVQH ASKQITADKQ YKGIIDCVVR
     IPKEQGVLSF WRGNLANVIR YFPTQALNFA FKDKYKQIFL GGVDKRTQFW RYFAGNLASG
     GAAGATSLCF VYPLDFARTR LAADVGKAGA EREFKGLGDC LVKIYKSDGI KGLYQGFNVS
     VQGIIIYRAA YFGIYDTAKG MLPDPKNTHI FISWMIAQSV TAVAGLTSYP FDTVRRRMMM
     QSGRKGTDIM YTGTLDCWRK IARDEGSKAF FKGAWSNVLR GMGGAFVLVL YDEIKKYT
//
ID   ADT2_RAT                Reviewed;         298 AA.
AC   Q09073;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 81.
DE   RecName: Full=ADP/ATP translocase 2;
DE   AltName: Full=Adenine nucleotide translocator 2;
DE            Short=ANT 2;
DE   AltName: Full=ADP,ATP carrier protein 2;
DE   AltName: Full=Solute carrier family 25 member 5;
GN   Name=Slc25a5; Synonyms=Ant2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Liver;
RX   MEDLINE=94002161; PubMed=8399300; DOI=10.1016/0005-2736(93)90248-X;
RA   Shinohara Y., Kamida M., Yamazaki N., Terada H.;
RT   "Isolation and characterization of cDNA clones and a genomic clone
RT   encoding rat mitochondrial adenine nucleotide translocator.";
RL   Biochim. Biophys. Acta 1152:192-196(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pituitary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   PROTEIN SEQUENCE OF 2-31; 34-43; 73-80 AND 273-280, CLEAVAGE OF
RP   INITIATOR METHIONINE, ACETYLATION AT THR-2, AND MASS SPECTROMETRY.
RC   TISSUE=Pheochromocytoma;
RA   Bienvenut W.V., von Kriegsheim A.F., Kolch W.;
RL   Submitted (AUG-2006) to UniProtKB.
CC   -!- FUNCTION: Catalyzes the exchange of ADP and ATP across the
CC       mitochondrial inner membrane.
CC   -!- SUBUNIT: Homodimer.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane; Multi-pass
CC       membrane protein.
CC   -!- TISSUE SPECIFICITY: Present in kidney, brain, heart, liver and
CC       skeletal muscle.
CC   -!- MISCELLANEOUS: The transmembrane helices are not perpendicular to
CC       the plane of the membrane, but cross the membrane at an angle.
CC       Odd-numbered transmembrane helices exhibit a sharp kink, due to
CC       the presence of a conserved proline residue (By similarity).
CC   -!- SIMILARITY: Belongs to the mitochondrial carrier family.
CC   -!- SIMILARITY: Contains 3 Solcar repeats.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D12771; BAA02238.1; -; mRNA.
DR   EMBL; BC059108; AAH59108.1; -; mRNA.
DR   IPI; IPI00200466; -.
DR   PIR; I56602; I56602.
DR   RefSeq; NP_476443.1; -.
DR   UniGene; Rn.102263; -.
DR   SMR; Q09073; 2-294.
DR   STRING; Q09073; -.
DR   PhosphoSite; Q09073; -.
DR   PRIDE; Q09073; -.
DR   Ensembl; ENSRNOT00000015085; ENSRNOP00000015913; ENSRNOG00000039980; Rattus norvegicus.
DR   GeneID; 25176; -.
DR   KEGG; rno:25176; -.
DR   UCSC; NM_057102; rat.
DR   CTD; 25176; -.
DR   RGD; 620353; Slc25a5.
DR   eggNOG; roNOG06425; -.
DR   HOVERGEN; HBG108348; -.
DR   InParanoid; Q09073; -.
DR   OMA; KNTHILV; -.
DR   OrthoDB; EOG9JMB7V; -.
DR   PhylomeDB; Q09073; -.
DR   NextBio; 605657; -.
DR   Genevestigator; Q09073; -.
DR   GermOnline; ENSRNOG00000039980; Rattus norvegicus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IDA:RGD.
DR   GO; GO:0005515; F:protein binding; IPI:RGD.
DR   GO; GO:0005215; F:transporter activity; IEA:InterPro.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR002113; Aden_trnslctor.
DR   InterPro; IPR002067; Mit_carrier.
DR   InterPro; IPR001993; Mitochondria_substrate_carrier.
DR   InterPro; IPR018108; Mitochondrial_sb/sol_carrier.
DR   PANTHER; PTHR11896; Mitoch_carrier; 1.
DR   Pfam; PF00153; Mito_carr; 3.
DR   PRINTS; PR00927; ADPTRNSLCASE.
DR   PRINTS; PR00926; MITOCARRIER.
DR   SUPFAM; SSF103506; Mitoch_carrier; 1.
DR   PROSITE; PS50920; SOLCAR; 3.
PE   1: Evidence at protein level;
KW   Acetylation; Direct protein sequencing; Membrane; Methylation;
KW   Mitochondrion; Mitochondrion inner membrane; Phosphoprotein; Repeat;
KW   Transmembrane; Transport.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    298       ADP/ATP translocase 2.
FT                                /FTId=PRO_0000090582.
FT   TRANSMEM      5     39       1 (By similarity).
FT   TRANSMEM     75    100       2 (By similarity).
FT   TRANSMEM    109    143       3 (By similarity).
FT   TRANSMEM    176    202       4 (By similarity).
FT   TRANSMEM    207    241       5 (By similarity).
FT   TRANSMEM    273    298       6 (By similarity).
FT   REPEAT        6     98       Solcar 1.
FT   REPEAT      111    201       Solcar 2.
FT   REPEAT      212    297       Solcar 3.
FT   MOTIF       235    240       Substrate recognition (By similarity).
FT   BINDING      80     80       Nucleotide (By similarity).
FT   MOD_RES       2      2       N-acetylthreonine.
FT   MOD_RES      23     23       N6-acetyllysine (By similarity).
FT   MOD_RES      42     42       Phosphoserine (By similarity).
FT   MOD_RES      52     52       N6,N6-dimethyllysine; alternate (By
FT                                similarity).
FT   MOD_RES      52     52       N6-methyllysine; alternate (By
FT                                similarity).
FT   MOD_RES      92     92       N6-acetyllysine (By similarity).
FT   MOD_RES     105    105       N6-acetyllysine (By similarity).
FT   MOD_RES     155    155       N6-acetyllysine (By similarity).
FT   MOD_RES     163    163       N6-acetyllysine (By similarity).
FT   MOD_RES     166    166       N6-acetyllysine (By similarity).
FT   MOD_RES     191    191       Phosphotyrosine (By similarity).
FT   MOD_RES     195    195       Phosphotyrosine (By similarity).
FT   MOD_RES     199    199       N6-acetyllysine (By similarity).
SQ   SEQUENCE   298 AA;  32901 MW;  6A59204B987EFE35 CRC64;
     MTDAAVSFAK DFLAGGVAAA ISKTAVAPIE RVKLLLQVQH ASKQITADKQ YKGIIDCVVR
     IPKEQGVLSF WRGNLANVIR YFPTQALNFA FKDKYKQIFL GGVDKRTQFW RYFAGNLASG
     GAAGATSLCF VYPLDFARTR LAADVGKAGA EREFKGLGDC LVKIYKSDGI KGLYQGFNVS
     VQGIIIYRAA YFGIYDTAKG MLPDPKNTHI FISWMIAQSV TAVAGLTSYP FDTVRRRMMM
     QSGRKGTDIM YTGTLDCWRK IARDEGGKAF FKGAWSNVLR GMGGAFVLVL YDEIKKYT
//
ID   ADT2_YEAST              Reviewed;         318 AA.
AC   P18239;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1994, sequence version 2.
DT   02-MAR-2010, entry version 91.
DE   RecName: Full=ADP,ATP carrier protein 2;
DE   AltName: Full=ADP/ATP translocase 2;
DE   AltName: Full=Adenine nucleotide translocator 2;
DE            Short=ANT 2;
GN   Name=AAC2; Synonyms=PET9; OrderedLocusNames=YBL030C; ORFNames=YBL0421;
OS   Saccharomyces cerevisiae (Baker's yeast).
OC   Eukaryota; Fungi; Dikarya; Ascomycota; Saccharomycotina;
OC   Saccharomycetes; Saccharomycetales; Saccharomycetaceae; Saccharomyces.
OX   NCBI_TaxID=4932;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=89008354; PubMed=2844786;
RA   Lawson J.E., Douglas M.G.;
RT   "Separate genes encode functionally equivalent ADP/ATP carrier
RT   proteins in Saccharomyces cerevisiae. Isolation and analysis of
RT   AAC2.";
RL   J. Biol. Chem. 263:14812-14818(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=90324269; PubMed=2165073;
RA   Kolarov J., Kolarova N., Nelson N.;
RT   "A third ADP/ATP translocator gene in yeast.";
RL   J. Biol. Chem. 265:12711-12716(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=ATCC 204508 / S288c;
RA   Trezeguet V., le Saux A., Lauquin G.;
RL   Submitted (AUG-1993) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=ATCC 204508 / S288c;
RX   MEDLINE=95242843; PubMed=7725803; DOI=10.1002/yea.320101217;
RA   van Dyck L., Jonniaux J.-L., Barreiros T.D.M., Kleine K., Goffeau A.;
RT   "Analysis of a 17.4 kb DNA segment of yeast chromosome II encompassing
RT   the ribosomal protein L19 as well as proteins with homologies to
RT   components of the hnRNP and snRNP complexes and to the human
RT   proliferation-associated p120 antigen.";
RL   Yeast 10:1663-1673(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 204508 / S288c;
RX   MEDLINE=95112788; PubMed=7813418;
RA   Feldmann H., Aigle M., Aljinovic G., Andre B., Baclet M.C., Barthe C.,
RA   Baur A., Becam A.-M., Biteau N., Boles E., Brandt T., Brendel M.,
RA   Brueckner M., Bussereau F., Christiansen C., Contreras R., Crouzet M.,
RA   Cziepluch C., Demolis N., Delaveau T., Doignon F., Domdey H.,
RA   Duesterhus S., Dubois E., Dujon B., El Bakkoury M., Entian K.-D.,
RA   Feuermann M., Fiers W., Fobo G.M., Fritz C., Gassenhuber J.,
RA   Glansdorff N., Goffeau A., Grivell L.A., de Haan M., Hein C.,
RA   Herbert C.J., Hollenberg C.P., Holmstroem K., Jacq C., Jacquet M.,
RA   Jauniaux J.-C., Jonniaux J.-L., Kallesoee T., Kiesau P., Kirchrath L.,
RA   Koetter P., Korol S., Liebl S., Logghe M., Lohan A.J.E., Louis E.J.,
RA   Li Z.Y., Maat M.J., Mallet L., Mannhaupt G., Messenguy F., Miosga T.,
RA   Molemans F., Mueller S., Nasr F., Obermaier B., Perea J., Pierard A.,
RA   Piravandi E., Pohl F.M., Pohl T.M., Potier S., Proft M., Purnelle B.,
RA   Ramezani Rad M., Rieger M., Rose M., Schaaff-Gerstenschlaeger I.,
RA   Scherens B., Schwarzlose C., Skala J., Slonimski P.P., Smits P.H.M.,
RA   Souciet J.-L., Steensma H.Y., Stucka R., Urrestarazu L.A.,
RA   van der Aart Q.J.M., Van Dyck L., Vassarotti A., Vetter I.,
RA   Vierendeels F., Vissers S., Wagner G., de Wergifosse P., Wolfe K.H.,
RA   Zagulski M., Zimmermann F.K., Mewes H.-W., Kleine K.;
RT   "Complete DNA sequence of yeast chromosome II.";
RL   EMBO J. 13:5795-5809(1994).
RN   [6]
RP   MUTAGENESIS.
RX   MEDLINE=93253777; PubMed=8487299; DOI=10.1006/jmbi.1993.1233;
RA   Nelson D.R., Lawson J.E., Klingenberg M., Douglas M.G.;
RT   "Site-directed mutagenesis of the yeast mitochondrial ADP/ATP
RT   translocator. Six arginines and one lysine are essential.";
RL   J. Mol. Biol. 230:1159-1170(1993).
RN   [7]
RP   MUTAGENESIS, AND TOPOLOGY.
RX   MEDLINE=93253778; PubMed=7683726; DOI=10.1006/jmbi.1993.1234;
RA   Nelson D.R., Douglas M.G.;
RT   "Function-based mapping of the yeast mitochondrial ADP/ATP
RT   translocator by selection for second site revertants.";
RL   J. Mol. Biol. 230:1171-1182(1993).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-39 AND SER-42, AND MASS
RP   SPECTROMETRY.
RX   PubMed=17761666; DOI=10.1074/mcp.M700098-MCP200;
RA   Reinders J., Wagner K., Zahedi R.P., Stojanovski D., Eyrich B.,
RA   van der Laan M., Rehling P., Sickmann A., Pfanner N., Meisinger C.;
RT   "Profiling phosphoproteins of yeast mitochondria reveals a role of
RT   phosphorylation in assembly of the ATP synthase.";
RL   Mol. Cell. Proteomics 6:1896-1906(2007).
CC   -!- FUNCTION: Catalyzes the exchange of ADP and ATP across the
CC       mitochondrial inner membrane.
CC   -!- SUBUNIT: Homodimer.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane; Multi-pass
CC       membrane protein.
CC   -!- MISCELLANEOUS: The transmembrane helices are not perpendicular to
CC       the plane of the membrane, but cross the membrane at an angle. At
CC       least 2 of the odd-numbered transmembrane helices exhibit a sharp
CC       kink, due to the presence of a conserved proline residue (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the mitochondrial carrier family.
CC   -!- SIMILARITY: Contains 3 Solcar repeats.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X77291; CAA54501.1; -; Genomic_DNA.
DR   EMBL; J04021; AAA34381.1; -; Genomic_DNA.
DR   EMBL; M34075; AAA97484.1; -; Genomic_DNA.
DR   EMBL; X74427; CAA52446.1; -; Genomic_DNA.
DR   EMBL; Z35791; CAA84850.1; -; Genomic_DNA.
DR   PIR; A31978; A31978.
DR   RefSeq; NP_009523.1; -.
DR   SMR; P18239; 22-308.
DR   DIP; DIP-2917N; -.
DR   IntAct; P18239; 89.
DR   STRING; P18239; -.
DR   TCDB; 2.A.29.1.7; mitochondrial carrier (MC) family.
DR   PeptideAtlas; P18239; -.
DR   PRIDE; P18239; -.
DR   Ensembl; YBL030C; YBL030C; YBL030C; Saccharomyces cerevisiae.
DR   GeneID; 852250; -.
DR   GenomeReviews; Y13134_GR; YBL030C.
DR   KEGG; sce:YBL030C; -.
DR   NMPDR; fig|4932.3.peg.215; -.
DR   CYGD; YBL030c; -.
DR   SGD; S000000126; PET9.
DR   eggNOG; fuNOG06875; -.
DR   HOGENOM; HBG610399; -.
DR   OMA; ISPEAQY; -.
DR   OrthoDB; EOG9WWT2K; -.
DR   PhylomeDB; P18239; -.
DR   NextBio; 970820; -.
DR   ArrayExpress; P18239; -.
DR   Genevestigator; P18239; -.
DR   GermOnline; YBL030C; Saccharomyces cerevisiae.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IDA:SGD.
DR   GO; GO:0005471; F:ATP:ADP antiporter activity; IDA:SGD.
DR   GO; GO:0005488; F:binding; IEA:InterPro.
DR   GO; GO:0015866; P:ADP transport; IDA:SGD.
DR   GO; GO:0009060; P:aerobic respiration; IMP:SGD.
DR   GO; GO:0009061; P:anaerobic respiration; IGI:SGD.
DR   GO; GO:0006915; P:apoptosis; IMP:SGD.
DR   GO; GO:0015867; P:ATP transport; IDA:SGD.
DR   GO; GO:0006783; P:heme biosynthetic process; IGI:SGD.
DR   GO; GO:0006839; P:mitochondrial transport; IMP:SGD.
DR   GO; GO:0055085; P:transmembrane transport; IDA:SGD.
DR   InterPro; IPR002113; Aden_trnslctor.
DR   InterPro; IPR002067; Mit_carrier.
DR   InterPro; IPR001993; Mitochondria_substrate_carrier.
DR   InterPro; IPR018108; Mitochondrial_sb/sol_carrier.
DR   PANTHER; PTHR11896; Mitoch_carrier; 1.
DR   Pfam; PF00153; Mito_carr; 3.
DR   PRINTS; PR00927; ADPTRNSLCASE.
DR   PRINTS; PR00926; MITOCARRIER.
DR   SUPFAM; SSF103506; Mitoch_carrier; 1.
DR   PROSITE; PS50920; SOLCAR; 3.
PE   1: Evidence at protein level;
KW   Complete proteome; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Phosphoprotein; Repeat; Transmembrane;
KW   Transport.
FT   CHAIN         1    318       ADP,ATP carrier protein 2.
FT                                /FTId=PRO_0000090594.
FT   TRANSMEM     20     54       1 (By similarity).
FT   TRANSMEM     91    115       2 (By similarity).
FT   TRANSMEM    123    157       3 (By similarity).
FT   TRANSMEM    192    219       4 (By similarity).
FT   TRANSMEM    224    258       5 (By similarity).
FT   TRANSMEM    287    312       6 (By similarity).
FT   REPEAT       21    114       Solcar 1.
FT   REPEAT      125    217       Solcar 2.
FT   REPEAT      225    311       Solcar 3.
FT   MOTIF       252    257       Substrate recognition (By similarity).
FT   BINDING      96     96       Nucleotide (By similarity).
FT   MOD_RES      39     39       Phosphothreonine.
FT   MOD_RES      42     42       Phosphoserine.
FT   CONFLICT     58     58       L -> I (in Ref. 2; AAA97484).
FT   CONFLICT     65     65       R -> K (in Ref. 2; AAA97484).
FT   CONFLICT     68     68       A -> S (in Ref. 2; AAA97484).
FT   CONFLICT     71     71       L -> V (in Ref. 2; AAA97484).
FT   CONFLICT     79     79       T -> K (in Ref. 2; AAA97484).
FT   CONFLICT     83     83       V -> L (in Ref. 2; AAA97484).
FT   CONFLICT    113    113       A -> L (in Ref. 2; AAA97484).
FT   CONFLICT    124    124       A -> G (in Ref. 2; AAA97484).
SQ   SEQUENCE   318 AA;  34426 MW;  A9805DC33D9E24AC CRC64;
     MSSNAQVKTP LPPAPAPKKE SNFLIDFLMG GVSAAVAKTA ASPIERVKLL IQNQDEMLKQ
     GTLDRKYAGI LDCFKRTATQ EGVISFWRGN TANVIRYFPT QALNFAFKDK IKAMFGFKKE
     EGYAKWFAGN LASGGAAGAL SLLFVYSLDY ARTRLAADSK SSKKGGARQF NGLIDVYKKT
     LKSDGVAGLY RGFLPSVVGI VVYRGLYFGM YDSLKPLLLT GSLEGSFLAS FLLGWVVTTG
     ASTCSYPLDT VRRRMMMTSG QAVKYDGAFD CLRKIVAAEG VGSLFKGCGA NILRGVAGAG
     VISMYDQLQM ILFGKKFK
//
ID   ADT3_HUMAN              Reviewed;         298 AA.
AC   P12236; Q96C49;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   02-MAR-2010, entry version 124.
DE   RecName: Full=ADP/ATP translocase 3;
DE   AltName: Full=Adenine nucleotide translocator 3;
DE            Short=ANT 3;
DE   AltName: Full=ADP,ATP carrier protein 3;
DE   AltName: Full=Solute carrier family 25 member 6;
DE   AltName: Full=ADP,ATP carrier protein, isoform T2;
DE            Short=ANT 2;
GN   Name=SLC25A6; Synonyms=ANT3; ORFNames=CDABP0051;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=89236396; PubMed=2541251; DOI=10.1016/0022-2836(89)90477-4;
RA   Cozens A.L., Runswick M.J., Walker J.E.;
RT   "DNA sequences of two expressed nuclear genes for human mitochondrial
RT   ADP/ATP translocase.";
RL   J. Mol. Biol. 206:261-280(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT PHE-242.
RC   TISSUE=Leukemia;
RA   Zhou J., Yu W., Tang H., Mei G., Tsang Y.T.M., Bouck J., Gibbs R.A.,
RA   Margolin J.F.;
RT   "Pediatric leukemia cDNA sequencing project.";
RL   Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, Cervix, Eye, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PROTEIN SEQUENCE OF 2-10, ACETYLATION AT THR-2, AND MASS SPECTROMETRY.
RC   TISSUE=B-cell lymphoma;
RA   Bienvenut W.V.;
RL   Submitted (JUL-2004) to UniProtKB.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 36-298.
RC   TISSUE=Liver;
RX   MEDLINE=88124845; PubMed=2829183; DOI=10.1073/pnas.85.2.377;
RA   Houldsworth J., Attardi G.;
RT   "Two distinct genes for ADP/ATP translocase are expressed at the mRNA
RT   level in adult human liver.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:377-381(1988).
RN   [6]
RP   FUNCTION IN APOPTOSIS.
RX   PubMed=15033708; DOI=10.1196/annals.1299.022;
RA   Verrier F., Mignotte B., Jan G., Brenner C.;
RT   "Study of PTPC composition during apoptosis for identification of
RT   viral protein target.";
RL   Ann. N. Y. Acad. Sci. 1010:126-142(2003).
RN   [7]
RP   INTERACTION WITH HIV-1 VPR.
RX   PubMed=16120388; DOI=10.1016/j.mito.2004.06.012;
RA   Deniaud A., Brenner C., Kroemer G.;
RT   "Mitochondrial membrane permeabilization by HIV-1 Vpr.";
RL   Mitochondrion 4:223-233(2004).
RN   [8]
RP   INTERACTION WITH INFLUENZA A VIRUS PB1-F2.
RX   PubMed=16201016; DOI=10.1371/journal.ppat.0010004;
RA   Zamarin D., Garcia-Sastre A., Xiao X., Wang R., Palese P.;
RT   "Influenza virus PB1-F2 protein induces cell death through
RT   mitochondrial ANT3 and VDAC1.";
RL   PLoS Pathog. 1:40-54(2005).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-191, AND MASS
RP   SPECTROMETRY.
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-148, AND MASS
RP   SPECTROMETRY.
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [11]
RP   IDENTIFICATION [LARGE SCALE ANALYSIS], AND MASS SPECTROMETRY.
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [12]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-23; LYS-96; LYS-105; LYS-268
RP   AND LYS-272, AND MASS SPECTROMETRY.
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
CC   -!- FUNCTION: Catalyzes the exchange of ADP and ATP across the
CC       mitochondrial inner membrane. May participate in the formation of
CC       the permeability transition pore complex (PTPC) responsible for
CC       the release of mitochondrial products that triggers apoptosis.
CC   -!- SUBUNIT: Homodimer. Interacts with influenza A virus PB1-F2
CC       protein and HIV-1 Vpr.
CC   -!- INTERACTION:
CC       Q92597:NDRG1; NbExp=1; IntAct=EBI-356254, EBI-716486;
CC       P62073:Timm10 (xeno); NbExp=1; IntAct=EBI-356254, EBI-1200663;
CC       Q9WV98:Timm9 (xeno); NbExp=1; IntAct=EBI-356254, EBI-1200652;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane; Multi-pass
CC       membrane protein.
CC   -!- MISCELLANEOUS: The transmembrane helices are not perpendicular to
CC       the plane of the membrane, but cross the membrane at an angle.
CC       Odd-numbered transmembrane helices exhibit a sharp kink, due to
CC       the presence of a conserved proline residue (By similarity).
CC   -!- MISCELLANEOUS: The gene encoding for this protein is located in
CC       the pseudoautosomal region 1 (PAR1) of X and Y chromosomes.
CC   -!- SIMILARITY: Belongs to the mitochondrial carrier family.
CC   -!- SIMILARITY: Contains 3 Solcar repeats.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY007135; AAG01998.1; -; mRNA.
DR   EMBL; BC007295; AAH07295.1; -; mRNA.
DR   EMBL; BC007850; AAH07850.1; -; mRNA.
DR   EMBL; BC008737; AAH08737.1; -; mRNA.
DR   EMBL; BC008935; AAH08935.1; -; mRNA.
DR   EMBL; BC014775; AAH14775.1; -; mRNA.
DR   EMBL; BC031912; AAH31912.1; -; mRNA.
DR   EMBL; J03592; AAA36750.1; -; mRNA.
DR   IPI; IPI00291467; -.
DR   PIR; S03894; S03894.
DR   RefSeq; NP_001627.2; -.
DR   UniGene; Hs.350927; -.
DR   SMR; P12236; 2-294.
DR   IntAct; P12236; 24.
DR   STRING; P12236; -.
DR   PhosphoSite; P12236; -.
DR   PeptideAtlas; P12236; -.
DR   PRIDE; P12236; -.
DR   Ensembl; ENST00000381401; ENSP00000370808; ENSG00000169100; Homo sapiens.
DR   GeneID; 293; -.
DR   KEGG; hsa:293; -.
DR   UCSC; uc004cpt.2; human.
DR   CTD; 293; -.
DR   GeneCards; GC0XM001548; -.
DR   H-InvDB; HIX0016624; -.
DR   H-InvDB; HIX0034763; -.
DR   H-InvDB; HIX0159624; -.
DR   HGNC; HGNC:10992; SLC25A6.
DR   MIM; 300151; gene.
DR   MIM; 403000; gene.
DR   PharmGKB; PA35868; -.
DR   HOVERGEN; HBG108348; -.
DR   InParanoid; P12236; -.
DR   OMA; FGRTIRD; -.
DR   OrthoDB; EOG9JMB7V; -.
DR   PhylomeDB; P12236; -.
DR   Reactome; REACT_1505; Integration of energy metabolism.
DR   Reactome; REACT_15380; Diabetes pathways.
DR   Reactome; REACT_1698; Metabolism of nucleotides.
DR   Reactome; REACT_6167; Influenza Infection.
DR   Reactome; REACT_6185; HIV Infection.
DR   DrugBank; DB00720; Clodronate.
DR   NextBio; 1195; -.
DR   ArrayExpress; P12236; -.
DR   Bgee; P12236; -.
DR   CleanEx; HS_SLC25A6; -.
DR   Genevestigator; P12236; -.
DR   GermOnline; ENSG00000169100; Homo sapiens.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005744; C:mitochondrial inner membrane presequence tr...; TAS:UniProtKB.
DR   GO; GO:0005471; F:ATP:ADP antiporter activity; NAS:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0044419; P:interspecies interaction between organisms; IEA:UniProtKB-KW.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR002113; Aden_trnslctor.
DR   InterPro; IPR002067; Mit_carrier.
DR   InterPro; IPR001993; Mitochondria_substrate_carrier.
DR   InterPro; IPR018108; Mitochondrial_sb/sol_carrier.
DR   PANTHER; PTHR11896; Mitoch_carrier; 1.
DR   Pfam; PF00153; Mito_carr; 3.
DR   PRINTS; PR00927; ADPTRNSLCASE.
DR   PRINTS; PR00926; MITOCARRIER.
DR   SUPFAM; SSF103506; Mitoch_carrier; 1.
DR   PROSITE; PS50920; SOLCAR; 3.
PE   1: Evidence at protein level;
KW   Acetylation; Apoptosis; Complete proteome; Direct protein sequencing;
KW   Host-virus interaction; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Phosphoprotein; Polymorphism; Repeat;
KW   Transmembrane; Transport.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    298       ADP/ATP translocase 3.
FT                                /FTId=PRO_0000090584.
FT   TRANSMEM      5     39       1 (By similarity).
FT   TRANSMEM     75    100       2 (By similarity).
FT   TRANSMEM    109    143       3 (By similarity).
FT   TRANSMEM    176    202       4 (By similarity).
FT   TRANSMEM    207    241       5 (By similarity).
FT   TRANSMEM    273    298       6 (By similarity).
FT   REPEAT        6     98       Solcar 1.
FT   REPEAT      111    201       Solcar 2.
FT   REPEAT      212    297       Solcar 3.
FT   MOTIF       235    240       Substrate recognition (By similarity).
FT   BINDING      80     80       Nucleotide (By similarity).
FT   MOD_RES       2      2       N-acetylthreonine.
FT   MOD_RES      23     23       N6-acetyllysine.
FT   MOD_RES      96     96       N6-acetyllysine.
FT   MOD_RES     105    105       N6-acetyllysine.
FT   MOD_RES     148    148       Phosphoserine.
FT   MOD_RES     191    191       Phosphotyrosine.
FT   MOD_RES     268    268       N6-acetyllysine.
FT   MOD_RES     272    272       N6-acetyllysine.
FT   VARIANT     242    242       S -> F (in dbSNP:rs17851235).
FT                                /FTId=VAR_054819.
FT   CONFLICT    105    108       KHTQ -> RHA (in Ref. 5; AAA36750).
SQ   SEQUENCE   298 AA;  32866 MW;  18534E9F0E49672F CRC64;
     MTEQAISFAK DFLAGGIAAA ISKTAVAPIE RVKLLLQVQH ASKQIAADKQ YKGIVDCIVR
     IPKEQGVLSF WRGNLANVIR YFPTQALNFA FKDKYKQIFL GGVDKHTQFW RYFAGNLASG
     GAAGATSLCF VYPLDFARTR LAADVGKSGT EREFRGLGDC LVKITKSDGI RGLYQGFSVS
     VQGIIIYRAA YFGVYDTAKG MLPDPKNTHI VVSWMIAQTV TAVAGVVSYP FDTVRRRMMM
     QSGRKGADIM YTGTVDCWRK IFRDEGGKAF FKGAWSNVLR GMGGAFVLVL YDELKKVI
//
ID   ADT3_YEAST              Reviewed;         307 AA.
AC   P18238;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1990, sequence version 1.
DT   02-MAR-2010, entry version 89.
DE   RecName: Full=ADP,ATP carrier protein 3;
DE   AltName: Full=ADP/ATP translocase 3;
DE   AltName: Full=Adenine nucleotide translocator 3;
DE            Short=ANT 3;
GN   Name=AAC3; OrderedLocusNames=YBR085W; ORFNames=YBR0753;
OS   Saccharomyces cerevisiae (Baker's yeast).
OC   Eukaryota; Fungi; Dikarya; Ascomycota; Saccharomycotina;
OC   Saccharomycetes; Saccharomycetales; Saccharomycetaceae; Saccharomyces.
OX   NCBI_TaxID=4932;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=90324269; PubMed=2165073;
RA   Kolarov J., Kolarova N., Nelson N.;
RT   "A third ADP/ATP translocator gene in yeast.";
RL   J. Biol. Chem. 265:12711-12716(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 204508 / S288c;
RX   MEDLINE=95112788; PubMed=7813418;
RA   Feldmann H., Aigle M., Aljinovic G., Andre B., Baclet M.C., Barthe C.,
RA   Baur A., Becam A.-M., Biteau N., Boles E., Brandt T., Brendel M.,
RA   Brueckner M., Bussereau F., Christiansen C., Contreras R., Crouzet M.,
RA   Cziepluch C., Demolis N., Delaveau T., Doignon F., Domdey H.,
RA   Duesterhus S., Dubois E., Dujon B., El Bakkoury M., Entian K.-D.,
RA   Feuermann M., Fiers W., Fobo G.M., Fritz C., Gassenhuber J.,
RA   Glansdorff N., Goffeau A., Grivell L.A., de Haan M., Hein C.,
RA   Herbert C.J., Hollenberg C.P., Holmstroem K., Jacq C., Jacquet M.,
RA   Jauniaux J.-C., Jonniaux J.-L., Kallesoee T., Kiesau P., Kirchrath L.,
RA   Koetter P., Korol S., Liebl S., Logghe M., Lohan A.J.E., Louis E.J.,
RA   Li Z.Y., Maat M.J., Mallet L., Mannhaupt G., Messenguy F., Miosga T.,
RA   Molemans F., Mueller S., Nasr F., Obermaier B., Perea J., Pierard A.,
RA   Piravandi E., Pohl F.M., Pohl T.M., Potier S., Proft M., Purnelle B.,
RA   Ramezani Rad M., Rieger M., Rose M., Schaaff-Gerstenschlaeger I.,
RA   Scherens B., Schwarzlose C., Skala J., Slonimski P.P., Smits P.H.M.,
RA   Souciet J.-L., Steensma H.Y., Stucka R., Urrestarazu L.A.,
RA   van der Aart Q.J.M., Van Dyck L., Vassarotti A., Vetter I.,
RA   Vierendeels F., Vissers S., Wagner G., de Wergifosse P., Wolfe K.H.,
RA   Zagulski M., Zimmermann F.K., Mewes H.-W., Kleine K.;
RT   "Complete DNA sequence of yeast chromosome II.";
RL   EMBO J. 13:5795-5809(1994).
RN   [3]
RP   LEVEL OF PROTEIN EXPRESSION [LARGE SCALE ANALYSIS].
RX   MEDLINE=22923965; PubMed=14562106; DOI=10.1038/nature02046;
RA   Ghaemmaghami S., Huh W.-K., Bower K., Howson R.W., Belle A.,
RA   Dephoure N., O'Shea E.K., Weissman J.S.;
RT   "Global analysis of protein expression in yeast.";
RL   Nature 425:737-741(2003).
CC   -!- FUNCTION: Catalyzes the exchange of ADP and ATP across the
CC       mitochondrial inner membrane.
CC   -!- SUBUNIT: Homodimer.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane; Multi-pass
CC       membrane protein.
CC   -!- MISCELLANEOUS: The transmembrane helices are not perpendicular to
CC       the plane of the membrane, but cross the membrane at an angle. At
CC       least 2 of the odd-numbered transmembrane helices exhibit a sharp
CC       kink, due to the presence of a conserved proline residue (By
CC       similarity).
CC   -!- MISCELLANEOUS: Present with 1080 molecules/cell in log phase SD
CC       medium.
CC   -!- SIMILARITY: Belongs to the mitochondrial carrier family.
CC   -!- SIMILARITY: Contains 3 Solcar repeats.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M34076; AAA97485.1; -; Genomic_DNA.
DR   EMBL; Z35954; CAA85031.1; -; Genomic_DNA.
DR   PIR; A36582; A36582.
DR   RefSeq; NP_009642.1; -.
DR   SMR; P18238; 9-297.
DR   DIP; DIP-6289N; -.
DR   IntAct; P18238; 18.
DR   STRING; P18238; -.
DR   PeptideAtlas; P18238; -.
DR   PRIDE; P18238; -.
DR   Ensembl; YBR085W; YBR085W; YBR085W; Saccharomyces cerevisiae.
DR   GeneID; 852380; -.
DR   GenomeReviews; Y13134_GR; YBR085W.
DR   KEGG; sce:YBR085W; -.
DR   NMPDR; fig|4932.3.peg.340; -.
DR   CYGD; YBR085w; -.
DR   SGD; S000000289; AAC3.
DR   eggNOG; fuNOG06875; -.
DR   HOGENOM; HBG610399; -.
DR   OMA; KKSEMVY; -.
DR   OrthoDB; EOG98SJBJ; -.
DR   PhylomeDB; P18238; -.
DR   NextBio; 971180; -.
DR   ArrayExpress; P18238; -.
DR   Genevestigator; P18238; -.
DR   GermOnline; YBR085W; Saccharomyces cerevisiae.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005488; F:binding; IEA:InterPro.
DR   GO; GO:0005215; F:transporter activity; IEA:InterPro.
DR   GO; GO:0009061; P:anaerobic respiration; IGI:SGD.
DR   GO; GO:0006783; P:heme biosynthetic process; IGI:SGD.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR002113; Aden_trnslctor.
DR   InterPro; IPR002067; Mit_carrier.
DR   InterPro; IPR001993; Mitochondria_substrate_carrier.
DR   InterPro; IPR018108; Mitochondrial_sb/sol_carrier.
DR   PANTHER; PTHR11896; Mitoch_carrier; 1.
DR   Pfam; PF00153; Mito_carr; 3.
DR   PRINTS; PR00927; ADPTRNSLCASE.
DR   PRINTS; PR00926; MITOCARRIER.
DR   SUPFAM; SSF103506; Mitoch_carrier; 1.
DR   PROSITE; PS50920; SOLCAR; 3.
PE   1: Evidence at protein level;
KW   Complete proteome; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Repeat; Transmembrane; Transport.
FT   CHAIN         1    307       ADP,ATP carrier protein 3.
FT                                /FTId=PRO_0000090595.
FT   TRANSMEM      9     43       1 (By similarity).
FT   TRANSMEM     80    104       2 (By similarity).
FT   TRANSMEM    112    146       3 (By similarity).
FT   TRANSMEM    181    208       4 (By similarity).
FT   TRANSMEM    213    247       5 (By similarity).
FT   TRANSMEM    276    301       6 (By similarity).
FT   REPEAT       10    103       Solcar 1.
FT   REPEAT      114    206       Solcar 2.
FT   REPEAT      214    300       Solcar 3.
FT   MOTIF       241    246       Substrate recognition (By similarity).
FT   BINDING      85     85       Nucleotide (By similarity).
SQ   SEQUENCE   307 AA;  33313 MW;  D0C1329FEC1B4DC8 CRC64;
     MSSDAKQQET NFAINFLMGG VSAAIAKTAA SPIERVKILI QNQDEMIKQG TLDKKYSGIV
     DCFKRTAKQE GLISFWRGNT ANVIRYFPTQ ALNFAFKDKI KLMFGFKKEE GYGKWFAGNL
     ASGGAAGALS LLFVYSLDFA RTRLAADAKS SKKGGARQFN GLTDVYKKTL KSDGIAGLYR
     GFMPSVVGIV VYRGLYFGMF DSLKPLVLTG SLDGSFLASF LLGWVVTTGA STCSYPLDTV
     RRRMMMTSGQ AVKYNGAIDC LKKIVASEGV GSLFKGCGAN ILRSVAGAGV ISMYDQLQMI
     LFGKKFK
//
ID   AL5AP_MOUSE             Reviewed;         161 AA.
AC   P30355; Q9D138;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   11-OCT-2005, sequence version 2.
DT   02-MAR-2010, entry version 68.
DE   RecName: Full=Arachidonate 5-lipoxygenase-activating protein;
DE   AltName: Full=FLAP;
DE   AltName: Full=MK-886-binding protein;
GN   Name=Alox5ap; Synonyms=Flap;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Embryo;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Mammary gland;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-153.
RX   PubMed=1480129;
RA   Vickers P.J., O'Neill G.P., Mancini J.A., Charleson S., Abramovitz M.;
RT   "Cross-species comparison of 5-lipoxygenase-activating protein.";
RL   Mol. Pharmacol. 42:1014-1019(1992).
RN   [4]
RP   SUBCELLULAR LOCATION, FUNCTION, AND INTERACTION WITH ALOX5.
RX   PubMed=19075240; DOI=10.1073/pnas.0808211106;
RA   Mandal A.K., Jones P.B., Bair A.M., Christmas P., Miller D.,
RA   Yamin T.-T., Wisniewski D., Menke J., Evans J.F., Hyman B.T.,
RA   Bacskai B., Chen M., Lee D.M., Nikolic B., Soberman R.J.;
RT   "The nuclear membrane organization of leukotriene synthesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:20434-20439(2008).
CC   -!- FUNCTION: Required for leukotriene biosynthesis by ALOX5 (5-
CC       lipoxygenase). Anchors ALOX5 to the membrane. Binds arachidonic
CC       acid, and could play an essential role in the transfer of
CC       arachidonic acid to ALOX5. Binds to MK-886, a compound that blocks
CC       the biosynthesis of leukotrienes (By similarity). unstructured (By
CC       similarity).
CC   -!- SUBUNIT: Homotrimer. Interacts with LTC4S and ALOX5.
CC   -!- SUBCELLULAR LOCATION: Nucleus membrane; Multi-pass membrane
CC       protein. Endoplasmic reticulum membrane; Multi-pass membrane
CC       protein (By similarity).
CC   -!- DOMAIN: The C-terminal part after residue 140 is mostly disordered
CC       (By similarity).
CC   -!- SIMILARITY: Belongs to the MAPEG family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK004002; BAB23117.1; -; mRNA.
DR   EMBL; BC026209; AAH26209.1; -; mRNA.
DR   EMBL; M96554; AAA37632.1; -; mRNA.
DR   IPI; IPI00129296; -.
DR   RefSeq; NP_033793.1; -.
DR   UniGene; Mm.19844; -.
DR   SMR; P30355; 1-149.
DR   STRING; P30355; -.
DR   PRIDE; P30355; -.
DR   Ensembl; ENSMUST00000071130; ENSMUSP00000071130; ENSMUSG00000060063; Mus musculus.
DR   GeneID; 11690; -.
DR   KEGG; mmu:11690; -.
DR   UCSC; uc009app.1; mouse.
DR   CTD; 11690; -.
DR   MGI; MGI:107505; Alox5ap.
DR   eggNOG; roNOG16061; -.
DR   HOGENOM; HBG283139; -.
DR   HOVERGEN; HBG107295; -.
DR   InParanoid; P30355; -.
DR   OMA; EHESKTQ; -.
DR   OrthoDB; EOG98PQ4N; -.
DR   NextBio; 279343; -.
DR   ArrayExpress; P30355; -.
DR   Bgee; P30355; -.
DR   CleanEx; MM_ALOX5AP; -.
DR   Genevestigator; P30355; -.
DR   GermOnline; ENSMUSG00000060063; Mus musculus.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0031965; C:nuclear membrane; ISS:UniProtKB.
DR   GO; GO:0050544; F:arachidonic acid binding; ISS:UniProtKB.
DR   GO; GO:0008047; F:enzyme activator activity; IEA:InterPro.
DR   GO; GO:0019370; P:leukotriene biosynthetic process; IEA:UniProtKB-KW.
DR   InterPro; IPR001446; 5_LipOase_AP.
DR   InterPro; IPR018295; FLAP/GST2/LTC4S_CS.
DR   InterPro; IPR001129; Membr-assoc_MAPEG.
DR   Pfam; PF01124; MAPEG; 1.
DR   PRINTS; PR00488; 5LPOXGNASEAP.
DR   PROSITE; PS01297; FLAP_GST2_LTC4S; 1.
PE   1: Evidence at protein level;
KW   Endoplasmic reticulum; Leukotriene biosynthesis; Membrane; Nucleus;
KW   Transmembrane.
FT   CHAIN         1    161       Arachidonate 5-lipoxygenase-activating
FT                                protein.
FT                                /FTId=PRO_0000217753.
FT   TOPO_DOM      1      8       Lumenal (By similarity).
FT   TRANSMEM      9     30       By similarity.
FT   TOPO_DOM     31     52       Cytoplasmic (By similarity).
FT   TRANSMEM     53     77       By similarity.
FT   TOPO_DOM     78     80       Lumenal (By similarity).
FT   TRANSMEM     81    102       By similarity.
FT   TOPO_DOM    103    107       Cytoplasmic (By similarity).
FT   TOPO_DOM    108    115       In membrane (By similarity).
FT   TRANSMEM    116    128       By similarity.
FT   TOPO_DOM    129    161       Lumenal (By similarity).
FT   REGION       20     27       Inhibitor binding (By similarity).
FT   REGION      112    123       Inhibitor binding (By similarity).
FT   CONFLICT    142    142       D -> Y (in Ref. 3; AAA37632).
SQ   SEQUENCE   161 AA;  18136 MW;  28DA042AA18D17C8 CRC64;
     MDQEAVGNVV LLALVTLISV VQNAFFAHKV EHESKAHNGR SFQRTGTLAF ERVYTANQNC
     VDAYPTFLVV LWTAGLLCSQ VPAAFAGLMY LFVRQKYFVG YLGERTQSTP GYIFGKRIIL
     FLFLMSFAGI LNHYLIFFFG SDFENYIRTV STTISPLLLI P
//
ID   AL5AP_RAT               Reviewed;         161 AA.
AC   P20291; Q5RJL3;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2007, sequence version 2.
DT   02-MAR-2010, entry version 73.
DE   RecName: Full=Arachidonate 5-lipoxygenase-activating protein;
DE   AltName: Full=FLAP;
DE   AltName: Full=MK-886-binding protein;
GN   Name=Alox5ap; Synonyms=Flap;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=90136904; PubMed=2300173; DOI=10.1038/343282a0;
RA   Dixon R.A.F., Diehl R.E., Opas E., Rands E., Vickers P.J., Evans J.F.,
RA   Gillard J.W., Miller D.K.;
RT   "Requirement of a 5-lipoxygenase-activating protein for leukotriene
RT   synthesis.";
RL   Nature 343:282-284(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   PROTEIN SEQUENCE OF 1-39; 90-121 AND 126-146.
RX   MEDLINE=90136903; PubMed=2300172; DOI=10.1038/343278a0;
RA   Miller D.K., Gillard J.W., Vickers P.J., Sadowski S., Leveille C.,
RA   Mancini J.A., Charleson P., Dixon R.A.F., Ford-Hutchinson A.W.,
RA   Fortin R., Gauthier J.Y., Rodkey J., Rosen R., Rouzer C., Sigal I.S.,
RA   Strader C.D., Evans J.F.;
RT   "Identification and isolation of a membrane protein necessary for
RT   leukotriene production.";
RL   Nature 343:278-281(1990).
CC   -!- FUNCTION: Required for leukotriene biosynthesis by ALOX5 (5-
CC       lipoxygenase). Anchors ALOX5 to the membrane. Binds arachidonic
CC       acid, and could play an essential role in the transfer of
CC       arachidonic acid to ALOX5. Binds to MK-886, a compound that blocks
CC       the biosynthesis of leukotrienes. unstructured (By similarity).
CC   -!- SUBUNIT: Homotrimer. Interacts with LTC4S and ALOX5 (By
CC       similarity).
CC   -!- SUBCELLULAR LOCATION: Nucleus membrane; Multi-pass membrane
CC       protein (By similarity). Endoplasmic reticulum membrane; Multi-
CC       pass membrane protein (By similarity).
CC   -!- DOMAIN: The C-terminal part after residue 140 is mostly disordered
CC       (By similarity).
CC   -!- SIMILARITY: Belongs to the MAPEG family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X52196; CAA36442.1; -; mRNA.
DR   EMBL; BC086593; AAH86593.1; -; mRNA.
DR   IPI; IPI00324979; -.
DR   PIR; S08206; S08206.
DR   RefSeq; NP_058956.1; -.
DR   UniGene; Rn.18399; -.
DR   SMR; P20291; 1-149.
DR   STRING; P20291; -.
DR   Ensembl; ENSRNOT00000001207; ENSRNOP00000001207; ENSRNOG00000000907; Rattus norvegicus.
DR   GeneID; 29624; -.
DR   KEGG; rno:29624; -.
DR   UCSC; NM_017260; rat.
DR   CTD; 29624; -.
DR   RGD; 2097; Alox5ap.
DR   eggNOG; roNOG16061; -.
DR   HOVERGEN; HBG107295; -.
DR   InParanoid; P20291; -.
DR   OMA; EHESKTQ; -.
DR   OrthoDB; EOG98PQ4N; -.
DR   PhylomeDB; P20291; -.
DR   NextBio; 609834; -.
DR   ArrayExpress; P20291; -.
DR   Genevestigator; P20291; -.
DR   GermOnline; ENSRNOG00000000907; Rattus norvegicus.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0031965; C:nuclear membrane; ISS:UniProtKB.
DR   GO; GO:0050544; F:arachidonic acid binding; ISS:UniProtKB.
DR   GO; GO:0008047; F:enzyme activator activity; IEP:RGD.
DR   GO; GO:0019899; F:enzyme binding; IPI:RGD.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:RGD.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:RGD.
DR   GO; GO:0019370; P:leukotriene biosynthetic process; IDA:RGD.
DR   GO; GO:0019372; P:lipoxygenase pathway; IDA:RGD.
DR   GO; GO:0070207; P:protein homotrimerization; IDA:RGD.
DR   InterPro; IPR001446; 5_LipOase_AP.
DR   InterPro; IPR018295; FLAP/GST2/LTC4S_CS.
DR   InterPro; IPR001129; Membr-assoc_MAPEG.
DR   Pfam; PF01124; MAPEG; 1.
DR   PRINTS; PR00488; 5LPOXGNASEAP.
DR   PROSITE; PS01297; FLAP_GST2_LTC4S; 1.
PE   1: Evidence at protein level;
KW   Direct protein sequencing; Endoplasmic reticulum;
KW   Leukotriene biosynthesis; Membrane; Nucleus; Transmembrane.
FT   CHAIN         1    161       Arachidonate 5-lipoxygenase-activating
FT                                protein.
FT                                /FTId=PRO_0000217756.
FT   TOPO_DOM      1      8       Lumenal (By similarity).
FT   TRANSMEM      9     30       By similarity.
FT   TOPO_DOM     31     52       Cytoplasmic (By similarity).
FT   TRANSMEM     53     77       By similarity.
FT   TOPO_DOM     78     80       Lumenal (By similarity).
FT   TRANSMEM     81    102       By similarity.
FT   TOPO_DOM    103    107       Cytoplasmic (By similarity).
FT   TOPO_DOM    108    115       In membrane (By similarity).
FT   TRANSMEM    116    128       By similarity.
FT   TOPO_DOM    129    161       Lumenal (By similarity).
FT   REGION       20     27       Inhibitor binding (By similarity).
FT   REGION      112    123       Inhibitor binding (By similarity).
FT   CONFLICT     32     32       L -> I (in Ref. 3; AA sequence).
FT   CONFLICT    127    127       L -> I (in Ref. 3; AA sequence).
SQ   SEQUENCE   161 AA;  18070 MW;  9CCD6F8B3AA3B87E CRC64;
     MDQEAVGNVV LLAIVTLISV VQNAFFAHKV ELESKAQSGR SFQRTGTLAF ERVYTANQNC
     VDAYPTFLVV LWTAGLLCSQ VPAAFAGLMY LFVRQKYFVG YLGERTQSTP GYIFGKRIIL
     FLFLMSLAGI LNHYLIFFFG SDFENYIRTI TTTISPLLLI P
//
ID   AOFA_MOUSE              Reviewed;         526 AA.
AC   Q64133; Q8K0Z8;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   25-OCT-2004, sequence version 2.
DT   02-MAR-2010, entry version 80.
DE   RecName: Full=Amine oxidase [flavin-containing] A;
DE            EC=1.4.3.4;
DE   AltName: Full=Monoamine oxidase type A;
DE            Short=MAO-A;
GN   Name=Maoa;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=FVB/N; TISSUE=Mammary tumor;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 19-40.
RX   MEDLINE=95312871; PubMed=7792602; DOI=10.1126/science.7792602;
RA   Cases O., Seif I., Grimsby J., Gaspar P., Chen K., Pournin S.,
RA   Mueller U., Aguet M., Babinet C., Shih J.C., de Maeyer E.;
RT   "Aggressive behavior and altered amounts of brain serotonin and
RT   norepinephrine in mice lacking MAOA.";
RL   Science 268:1763-1766(1995).
RN   [3]
RP   PROTEIN SEQUENCE OF 137-147; 207-217; 268-280 AND 380-395, AND MASS
RP   SPECTROMETRY.
RC   STRAIN=C57BL/6; TISSUE=Brain;
RA   Lubec G., Kang S.U.;
RL   Submitted (APR-2007) to UniProtKB.
CC   -!- FUNCTION: Catalyzes the oxidative deamination of biogenic and
CC       xenobiotic amines and has important functions in the metabolism of
CC       neuroactive and vasoactive amines in the central nervous system
CC       and peripheral tissues. MAOA preferentially oxidizes biogenic
CC       amines such as 5-hydroxytryptamine (5-HT), norepinephrine and
CC       epinephrine (By similarity).
CC   -!- CATALYTIC ACTIVITY: RCH(2)NHR' + H(2)O + O(2) = RCHO + R'NH(2) +
CC       H(2)O(2).
CC   -!- COFACTOR: FAD.
CC   -!- SUBUNIT: Monomer, homo- or heterodimer (containing two subunits of
CC       similar size). Each subunit contains a covalently bound flavin.
CC       Enzymatically active as monomer (By similarity).
CC   -!- SUBCELLULAR LOCATION: Mitochondrion outer membrane; Single-pass
CC       type IV membrane protein; Cytoplasmic side.
CC   -!- SIMILARITY: Belongs to the flavin monoamine oxidase family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; BC029100; AAH29100.1; -; mRNA.
DR   EMBL; S78615; AAB34677.1; -; Genomic_DNA.
DR   EMBL; S78606; AAB34677.1; JOINED; Genomic_DNA.
DR   IPI; IPI00169711; -.
DR   UniGene; Mm.21108; -.
DR   SMR; Q64133; 11-520.
DR   STRING; Q64133; -.
DR   PhosphoSite; Q64133; -.
DR   PRIDE; Q64133; -.
DR   Ensembl; ENSMUST00000026013; ENSMUSP00000026013; ENSMUSG00000025037; Mus musculus.
DR   MGI; MGI:96915; Maoa.
DR   HOGENOM; HBG556224; -.
DR   HOVERGEN; HBG004255; -.
DR   InParanoid; Q64133; -.
DR   BRENDA; 1.4.3.4; 244.
DR   ArrayExpress; Q64133; -.
DR   Bgee; Q64133; -.
DR   CleanEx; MM_MAOA; -.
DR   Genevestigator; Q64133; -.
DR   GermOnline; ENSMUSG00000025037; Mus musculus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0008131; F:amine oxidase activity; IEA:EC.
DR   GO; GO:0042420; P:dopamine catabolic process; IDA:MGI.
DR   GO; GO:0042135; P:neurotransmitter catabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0055114; P:oxidation reduction; IEA:UniProtKB-KW.
DR   InterPro; IPR001613; Amineoxid_fl.
DR   InterPro; IPR002937; Amino_oxidase.
DR   Pfam; PF01593; Amino_oxidase; 1.
DR   PRINTS; PR00757; AMINEOXDASEF.
PE   1: Evidence at protein level;
KW   Catecholamine metabolism; Direct protein sequencing; FAD;
KW   Flavoprotein; Membrane; Mitochondrion; Mitochondrion outer membrane;
KW   Neurotransmitter degradation; Oxidoreductase; Transmembrane.
FT   CHAIN         1    526       Amine oxidase [flavin-containing] A.
FT                                /FTId=PRO_0000099851.
FT   TOPO_DOM      1    497       Cytoplasmic (By similarity).
FT   TRANSMEM    498    518       Anchor for type IV membrane protein (By
FT                                similarity).
FT   TOPO_DOM    519    526       Mitochondrial intermembrane (By
FT                                similarity).
FT   REGION      520    522       Interaction with membrane phospholipid
FT                                headgroups (By similarity).
FT   SITE        335    335       Important for substrate specificity (By
FT                                similarity).
FT   SITE        374    374       Important for catalytic activity (By
FT                                similarity).
FT   MOD_RES     406    406       S-8alpha-FAD cysteine (By similarity).
SQ   SEQUENCE   526 AA;  59588 MW;  47FACA3581758217 CRC64;
     MTDLEKPSIT GHMFDVVVIG GGISGLAAAK LLSEYKINVL VLEARDRVGG RTYTVRNEHV
     KWVDVGGAYV GPTQNRILRL SKDLGIETYK VNVNERLVQY VKGKTYPFRG AFPPVWNPLA
     YLDYNNLWRT MDDMGKEIPV DAPWQARHAE EWDKITMKDL IDKICWTKTA REFAYLFVNI
     NVTSEPHEVS ALWFLWYVRQ CGGTSRIFSV TNGGQERKFV GGSGQISEQI MVLLGDKVKL
     SSPVTYIDQT DDNIIIETLN HEHYECKYVI SAIPPVLTAK IHFKPELPPE RNQLIQRLPM
     GAVIKCMVYY KEAFWKKKDY CGCMIIEDEE APISITLDDT KPDGSMPAIM GFILARKAER
     LAKLHKDIRK RKICELYAKV LGSQEALSPV HYEEKNWCEE QYSGGCYTAY FPPGIMTLYG
     RVIRQPVGRI YFAGTETATQ WSGYMEGAVE AGERAAREVL NALGKVAKKD IWVQEPESKD
     VPALEITHTF LERNLPSVPG LLKITGFSTS VALLCFVLYK FKQPQS
//
ID   AOFB_BOVIN              Reviewed;         520 AA.
AC   P56560; Q0P5K2; Q864W3;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   02-MAR-2010, entry version 72.
DE   RecName: Full=Amine oxidase [flavin-containing] B;
DE            EC=1.4.3.4;
DE   AltName: Full=Monoamine oxidase type B;
DE            Short=MAO-B;
GN   Name=MAOB;
OS   Bos taurus (Bovine).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Ruminantia;
OC   Pecora; Bovidae; Bovinae; Bos.
OX   NCBI_TaxID=9913;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Chung P.P., Vaidyanathan G., Lanier S.M.;
RL   Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=Hereford; TISSUE=Basal ganglia;
RG   NIH - Mammalian Gene Collection (MGC) project;
RL   Submitted (AUG-2006) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   PROTEIN SEQUENCE OF 2-17, ACETYLATION AT SER-2, AND MASS SPECTROMETRY.
RX   MEDLINE=20504172; PubMed=11049757; DOI=10.1006/prep.2000.1309;
RA   Newton-Vinson P., Hubalek F., Edmondson D.E.;
RT   "High-level expression of human liver monoamine oxidase B in Pichia
RT   pastoris.";
RL   Protein Expr. Purif. 20:334-345(2000).
RN   [4]
RP   PROTEIN SEQUENCE OF 22-36; 53-70; 101-120; 259-279; 289-323; 327-346;
RP   362-403; 420-431 AND 456-485.
RX   MEDLINE=89246344; PubMed=2719656;
RA   Powell J.F., Hsu Y.-P.P., Weyler W., Chen S.A., Salach J.,
RA   Andrikopoulos K., Mallet J., Breakefield X.O.;
RT   "The primary structure of bovine monoamine oxidase type A. Comparison
RT   with peptide sequences of bovine monoamine oxidase type B and other
RT   flavoenzymes.";
RL   Biochem. J. 259:407-413(1989).
RN   [5]
RP   DETERMINATION OF PROTEIN-FAD RATIO.
RC   TISSUE=Liver;
RX   MEDLINE=89350874; PubMed=2764901;
RA   Weyler W.;
RT   "Monoamine oxidase A from human placenta and monoamine oxidase B from
RT   bovine liver both have one FAD per subunit.";
RL   Biochem. J. 260:725-729(1989).
CC   -!- FUNCTION: Catalyzes the oxidative deamination of biogenic and
CC       xenobiotic amines and has important functions in the metabolism of
CC       neuroactive and vasoactive amines in the central nervous system
CC       and peripheral tissues. MAOB preferentially degrades benzylamine
CC       and phenylethylamine (By similarity).
CC   -!- CATALYTIC ACTIVITY: RCH(2)NHR' + H(2)O + O(2) = RCHO + R'NH(2) +
CC       H(2)O(2).
CC   -!- COFACTOR: FAD.
CC   -!- SUBUNIT: Monomer, homo- or heterodimer (containing two subunits of
CC       similar size). Each subunit contains a covalently bound flavin.
CC       Enzymatically active as monomer.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion outer membrane; Single-pass
CC       type IV membrane protein; Cytoplasmic side.
CC   -!- MASS SPECTROMETRY: Mass=59163.5; Mass_error=10.0;
CC       Method=Electrospray; Range=2-520; Source=PubMed:11049757;
CC   -!- SIMILARITY: Belongs to the flavin monoamine oxidase family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF217955; AAF23179.1; -; mRNA.
DR   EMBL; BC119941; AAI19942.1; -; mRNA.
DR   IPI; IPI00705282; -.
DR   PIR; S07573; S07573.
DR   RefSeq; NP_808813.2; -.
DR   UniGene; Bt.22460; -.
DR   SMR; P56560; 3-501.
DR   STRING; P56560; -.
DR   Ensembl; ENSBTAT00000001698; ENSBTAP00000001698; ENSBTAG00000001288; Bos taurus.
DR   GeneID; 338445; -.
DR   KEGG; bta:338445; -.
DR   CTD; 338445; -.
DR   eggNOG; maNOG07443; -.
DR   HOVERGEN; HBG004255; -.
DR   InParanoid; P56560; -.
DR   BRENDA; 1.4.3.4; 251.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0008131; F:amine oxidase activity; IEA:EC.
DR   GO; GO:0055114; P:oxidation reduction; IEA:UniProtKB-KW.
DR   InterPro; IPR001613; Amineoxid_fl.
DR   InterPro; IPR002937; Amino_oxidase.
DR   Pfam; PF01593; Amino_oxidase; 1.
DR   PRINTS; PR00757; AMINEOXDASEF.
PE   1: Evidence at protein level;
KW   Acetylation; Direct protein sequencing; FAD; Flavoprotein; Membrane;
KW   Mitochondrion; Mitochondrion outer membrane; Oxidoreductase;
KW   Transmembrane.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    520       Amine oxidase [flavin-containing] B.
FT                                /FTId=PRO_0000099856.
FT   TOPO_DOM      2    489       Cytoplasmic (By similarity).
FT   TRANSMEM    490    516       Anchor for type IV membrane protein (By
FT                                similarity).
FT   TOPO_DOM    517    520       Mitochondrial intermembrane (By
FT                                similarity).
FT   COMPBIAS     36     52       Arg/Lys-rich (basic).
FT   SITE        156    156       Important for catalytic activity (By
FT                                similarity).
FT   SITE        365    365       Important for catalytic activity (By
FT                                similarity).
FT   SITE        382    382       Important for catalytic activity (By
FT                                similarity).
FT   MOD_RES       2      2       N-acetylserine.
FT   MOD_RES      52     52       N6-acetyllysine (By similarity).
FT   MOD_RES     397    397       S-8alpha-FAD cysteine (By similarity).
FT   CONFLICT      3      3       S -> N (in Ref. 1; AAF23179).
FT   CONFLICT    270    270       M -> G (in Ref. 4; AA sequence).
FT   CONFLICT    286    286       I -> T (in Ref. 1; AAF23179).
FT   CONFLICT    297    299       SIV -> PIM (in Ref. 4; AA sequence).
FT   CONFLICT    307    307       R -> K (in Ref. 4; AA sequence).
FT   CONFLICT    341    341       I -> L (in Ref. 4; AA sequence).
FT   CONFLICT    344    344       I -> K (in Ref. 4; AA sequence).
FT   CONFLICT    400    400       S -> A (in Ref. 4; AA sequence).
FT   CONFLICT    478    485       TTTFLQRH -> STSSMMMP (in Ref. 4; AA
FT                                sequence).
FT   CONFLICT    509    509       F -> Y (in Ref. 2; AAI19942).
FT   CONFLICT    520    520       I -> V (in Ref. 1; AAF23179).
SQ   SEQUENCE   520 AA;  58421 MW;  A594889B4495C410 CRC64;
     MSSKCDVVVV GGGISGMAAA KLLHDSGLNV IVLEARDRVG GRTYTLRNQK VKYVDLGGSY
     VGPTQNHILR LSKELGLETY KVNEVERLIH HTKGKSYPFR GSFPSVWNPI TYLDHNNLWR
     TMDDMGREIP SDAPWKAPLA EQWDLMTMKE LLDKICWTES SKQLAILFVN LCVTAEIHEV
     SALWFLWYVK QCGGTTRIFS TSNGGQERKF VGGSGQVSER IMDLLGDRVK LERPVIHIDQ
     TGENVLVETL NHELYEAKYV ISAVPPVLGM KIHFNPPLPM MRNQLITRVP LGSVIKSIVY
     YKEPFWRNMD YCGSMIIEGE EAPVAYALDD TKPDGSYPAI IGFILAHKAR KLARLTKEER
     LKKLCDLYAK VLGSQEALHP VHYEEKNWCE EQYSGGCYTS YFPPGIMTQY GRVLRQPVGR
     IYFAGTETAT HWSGYMEGAV EAGERAAREI LHAMGKIPED EIWLPEPESV DVPAKPITTT
     FLQRHLPSVP GLLKLIGLTT IFSATALGFL AHKRGLLVRI
//
ID   AOFB_MOUSE              Reviewed;         520 AA.
AC   Q8BW75; Q8C0B2;
DT   25-OCT-2004, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 58.
DE   RecName: Full=Amine oxidase [flavin-containing] B;
DE            EC=1.4.3.4;
DE   AltName: Full=Monoamine oxidase type B;
DE            Short=MAO-B;
GN   Name=Maob;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Medulla oblongata, and Oviduct;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [2]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-52, AND MASS SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=16916647; DOI=10.1016/j.molcel.2006.06.026;
RA   Kim S.C., Sprung R., Chen Y., Xu Y., Ball H., Pei J., Cheng T.,
RA   Kho Y., Xiao H., Xiao L., Grishin N.V., White M., Yang X.-J., Zhao Y.;
RT   "Substrate and functional diversity of lysine acetylation revealed by
RT   a proteomics survey.";
RL   Mol. Cell 23:607-618(2006).
CC   -!- FUNCTION: Catalyzes the oxidative deamination of biogenic and
CC       xenobiotic amines and has important functions in the metabolism of
CC       neuroactive and vasoactive amines in the central nervous system
CC       and peripheral tissues. MAOB preferentially degrades benzylamine
CC       and phenylethylamine (By similarity).
CC   -!- CATALYTIC ACTIVITY: RCH(2)NHR' + H(2)O + O(2) = RCHO + R'NH(2) +
CC       H(2)O(2).
CC   -!- COFACTOR: FAD (By similarity).
CC   -!- SUBUNIT: Monomer, homo- or heterodimer (containing two subunits of
CC       similar size). Each subunit contains a covalently bound flavin.
CC       Enzymatically active as monomer (By similarity).
CC   -!- SUBCELLULAR LOCATION: Mitochondrion outer membrane; Single-pass
CC       type IV membrane protein; Cytoplasmic side (By similarity).
CC   -!- SIMILARITY: Belongs to the flavin monoamine oxidase family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK031833; BAC27571.1; -; mRNA.
DR   EMBL; AK054050; BAC35634.1; -; mRNA.
DR   IPI; IPI00226140; -.
DR   RefSeq; NP_766366.2; -.
DR   UniGene; Mm.241656; -.
DR   SMR; Q8BW75; 3-495.
DR   STRING; Q8BW75; -.
DR   PhosphoSite; Q8BW75; -.
DR   PRIDE; Q8BW75; -.
DR   Ensembl; ENSMUST00000040820; ENSMUSP00000040550; ENSMUSG00000040147; Mus musculus.
DR   GeneID; 109731; -.
DR   KEGG; mmu:109731; -.
DR   UCSC; uc009ssb.1; mouse.
DR   CTD; 109731; -.
DR   MGI; MGI:96916; Maob.
DR   HOGENOM; HBG556224; -.
DR   HOVERGEN; HBG004255; -.
DR   InParanoid; Q8BW75; -.
DR   BRENDA; 1.4.3.4; 244.
DR   NextBio; 362651; -.
DR   ArrayExpress; Q8BW75; -.
DR   Bgee; Q8BW75; -.
DR   CleanEx; MM_MAOB; -.
DR   Genevestigator; Q8BW75; -.
DR   GermOnline; ENSMUSG00000040147; Mus musculus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IDA:MGI.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0008131; F:amine oxidase activity; IEA:EC.
DR   GO; GO:0055114; P:oxidation reduction; IEA:UniProtKB-KW.
DR   InterPro; IPR001613; Amineoxid_fl.
DR   InterPro; IPR002937; Amino_oxidase.
DR   Pfam; PF01593; Amino_oxidase; 1.
DR   PRINTS; PR00757; AMINEOXDASEF.
PE   1: Evidence at protein level;
KW   Acetylation; FAD; Flavoprotein; Membrane; Mitochondrion;
KW   Mitochondrion outer membrane; Oxidoreductase; Transmembrane.
FT   INIT_MET      1      1       Removed (By similarity).
FT   CHAIN         2    520       Amine oxidase [flavin-containing] B.
FT                                /FTId=PRO_0000099860.
FT   TOPO_DOM      2    489       Cytoplasmic (By similarity).
FT   TRANSMEM    490    516       Anchor for type IV membrane protein (By
FT                                similarity).
FT   TOPO_DOM    517    520       Mitochondrial intermembrane (By
FT                                similarity).
FT   COMPBIAS     36     52       Arg/Lys-rich (basic).
FT   SITE        156    156       Important for catalytic activity (By
FT                                similarity).
FT   SITE        365    365       Important for catalytic activity (By
FT                                similarity).
FT   SITE        382    382       Important for catalytic activity (By
FT                                similarity).
FT   MOD_RES       2      2       N-acetylserine (By similarity).
FT   MOD_RES      52     52       N6-acetyllysine.
FT   MOD_RES     397    397       S-8alpha-FAD cysteine (By similarity).
FT   CONFLICT    408    408       S -> T (in Ref. 1; BAC27571).
FT   CONFLICT    482    482       L -> M (in Ref. 1; BAC27571).
SQ   SEQUENCE   520 AA;  58544 MW;  D7CD7EBBF5C4B837 CRC64;
     MSNKSDVIVV GGGISGMAAA KLLHDCGLSV VVLEARDRVG GRTYTIRNKN VKYVDLGGSY
     VGPTQNRILR LAKELGLETY KVNEVERLIH FVKGKSYAFR GPFPPVWNPI TYLDNNNLWR
     TMDEMGQEIP SDAPWKAPLA EEWDYMTMKE LLDKICWTKS TKQIATLFVN LCVTAETHEV
     SALWFLWYVK QCGGTTRIIS TTNGGQERKF IGGSGQVSER IKDILGDRVK LERPVIHIDQ
     TGENVIVKTL NHEIYEAKYV ISAIPPALGM KIHYSPPLPM LRNQLISRVP LGSVIKCMVY
     YKEPFWRKKD FCGTMVIEGE EAPIAYTLDD TKPDGTYAAI MGFILAHKAR KLVRLTKEER
     LRKLCELYAK VLNSQEALQP VHYEEKNWCE EQYSGGCYTT YFPPGILSQY GRVLRQPVGK
     IFFAGTETAS HWSGYMEGAV EAGERAAREI LHAIGKIPED EIWQPEPESL DVPARPITST
     FLERHLPSVP GLLKLFGLTT ILSATALGFL AHKRGLFVHF
//
ID   AOFB_RAT                Reviewed;         520 AA.
AC   P19643; Q5EBB5;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 82.
DE   RecName: Full=Amine oxidase [flavin-containing] B;
DE            EC=1.4.3.4;
DE   AltName: Full=Monoamine oxidase type B;
DE            Short=MAO-B;
GN   Name=Maob;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   MEDLINE=89087490; PubMed=2974701; DOI=10.1016/S0006-291X(88)80969-0;
RA   Ito A., Kuwahara T., Inadome S., Sagara Y.;
RT   "Molecular cloning of a cDNA for rat liver monoamine oxidase B.";
RL   Biochem. Biophys. Res. Commun. 157:970-976(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   MUTAGENESIS OF ILE-199.
RX   MEDLINE=97306298; PubMed=9162023; DOI=10.1074/jbc.272.22.14033;
RA   Tsugeno Y., Ito A.;
RT   "A key amino acid responsible for substrate selectivity of monoamine
RT   oxidase A and B.";
RL   J. Biol. Chem. 272:14033-14036(1997).
CC   -!- FUNCTION: Catalyzes the oxidative deamination of biogenic and
CC       xenobiotic amines and has important functions in the metabolism of
CC       neuroactive and vasoactive amines in the central nervous system
CC       and peripheral tissues. MAOB preferentially degrades benzylamine
CC       and phenylethylamine.
CC   -!- CATALYTIC ACTIVITY: RCH(2)NHR' + H(2)O + O(2) = RCHO + R'NH(2) +
CC       H(2)O(2).
CC   -!- COFACTOR: FAD.
CC   -!- SUBUNIT: Monomer, homo- or heterodimer (containing two subunits of
CC       similar size). Each subunit contains a covalently bound flavin.
CC       Enzymatically active as monomer (By similarity).
CC   -!- SUBCELLULAR LOCATION: Mitochondrion outer membrane; Single-pass
CC       type IV membrane protein; Cytoplasmic side.
CC   -!- SIMILARITY: Belongs to the flavin monoamine oxidase family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M23601; AAA41566.1; -; mRNA.
DR   EMBL; BC089814; AAH89814.1; -; mRNA.
DR   IPI; IPI00231774; -.
DR   PIR; A31870; A31870.
DR   RefSeq; NP_037330.1; -.
DR   UniGene; Rn.6656; -.
DR   SMR; P19643; 3-501.
DR   STRING; P19643; -.
DR   Ensembl; ENSRNOT00000044009; ENSRNOP00000043466; ENSRNOG00000029778; Rattus norvegicus.
DR   GeneID; 25750; -.
DR   KEGG; rno:25750; -.
DR   UCSC; NM_013198; rat.
DR   CTD; 25750; -.
DR   RGD; 3041; Maob.
DR   eggNOG; roNOG11531; -.
DR   HOVERGEN; HBG004255; -.
DR   InParanoid; P19643; -.
DR   BRENDA; 1.4.3.4; 248.
DR   NextBio; 607939; -.
DR   ArrayExpress; P19643; -.
DR   Genevestigator; P19643; -.
DR   GermOnline; ENSRNOG00000029778; Rattus norvegicus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005741; C:mitochondrial outer membrane; TAS:RGD.
DR   GO; GO:0008131; F:amine oxidase activity; TAS:RGD.
DR   GO; GO:0042135; P:neurotransmitter catabolic process; TAS:RGD.
DR   GO; GO:0055114; P:oxidation reduction; IEA:UniProtKB-KW.
DR   InterPro; IPR001613; Amineoxid_fl.
DR   InterPro; IPR002937; Amino_oxidase.
DR   Pfam; PF01593; Amino_oxidase; 1.
DR   PRINTS; PR00757; AMINEOXDASEF.
PE   1: Evidence at protein level;
KW   Acetylation; FAD; Flavoprotein; Membrane; Mitochondrion;
KW   Mitochondrion outer membrane; Oxidoreductase; Transmembrane.
FT   INIT_MET      1      1       Removed (By similarity).
FT   CHAIN         2    520       Amine oxidase [flavin-containing] B.
FT                                /FTId=PRO_0000099863.
FT   TOPO_DOM      2    489       Cytoplasmic (By similarity).
FT   TRANSMEM    490    516       Anchor for type IV membrane protein (By
FT                                similarity).
FT   TOPO_DOM    517    520       Mitochondrial intermembrane (By
FT                                similarity).
FT   COMPBIAS     36     52       Arg/Lys-rich (basic).
FT   SITE        156    156       Important for catalytic activity (By
FT                                similarity).
FT   SITE        365    365       Important for catalytic activity (By
FT                                similarity).
FT   SITE        382    382       Important for catalytic activity (By
FT                                similarity).
FT   MOD_RES       2      2       N-acetylserine (By similarity).
FT   MOD_RES      52     52       N6-acetyllysine (By similarity).
FT   MOD_RES     397    397       S-8alpha-FAD cysteine (By similarity).
FT   MUTAGEN     139    139       L->H: No change in substrate affinity.
FT   MUTAGEN     199    199       I->F: Increased affinity for serotonin
FT                                and tyramine.
FT   CONFLICT     38     38       R -> C (in Ref. 1; AAA41566).
FT   CONFLICT    335    336       GS -> AG (in Ref. 1; AAA41566).
SQ   SEQUENCE   520 AA;  58459 MW;  F2C230BC6CDE5840 CRC64;
     MSNKCDVIVV GGGISGMAAA KLLHDCGLSV VVLEARDRVG GRTYTIRNKN VKYVDLGGSY
     VGPTQNRILR LAKELGLETY KVNEVERLIH FVKGKSYAFR GPFPPVWNPI TYLDYNNLWR
     TMDEMGQEIP SDAPWKAPLA EEWDYMTMKE LLDKICWTNS TKQIATLFVN LCVTAETHEV
     SALWFLWYVK QCGGTTRIIS TTNGGQERKF IGGSGQVSER IKDILGDRVK LERPVIHIDQ
     TGENVVVKTL NHEIYEAKYV ISAIPPVLGM KIHHSPPLPI LRNQLITRVP LGSVIKCMVY
     YKEPFWRKKD FCGTMVIEGE EAPIAYTLDD TKPDGSCAAI MGFILAHKAR KLVRLTKEER
     LRKLCELYAK VLNSQEALQP VHYEEKNWCE EQYSGGCYTA YFPPGILTQY GRVLRQPVGK
     IFFAGTETAS HWSGYMEGAV EAGERAAREI LHAIGKIPED EIWQPEPESV DVPARPITNT
     FLERHLPSVP GLLKLLGLTT ILSATALGFL AHKKGLFVRF
//
ID   AQP1_MOUSE              Reviewed;         269 AA.
AC   Q02013; Q542P1; Q91VY8;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 92.
DE   RecName: Full=Aquaporin-1;
DE            Short=AQP-1;
DE   AltName: Full=Aquaporin-CHIP;
DE   AltName: Full=Water channel protein for red blood cells and kidney proximal tubule;
DE   AltName: Full=Delayed early response protein 2;
DE            Short=DER2;
GN   Name=Aqp1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=BALB/c;
RX   MEDLINE=92375060; PubMed=1508193;
RA   Lanahan A.A., Williams J.B., Sanders L.K., Nathans D.;
RT   "Growth factor-induced delayed early response genes.";
RL   Mol. Cell. Biol. 12:3919-3929(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J, and NOD; TISSUE=Head, Inner ear, and Spleen;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Mammary tumor;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-262, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=17203969; DOI=10.1021/pr0604155;
RA   Dai J., Jin W.-H., Sheng Q.-H., Shieh C.-H., Wu J.-R., Zeng R.;
RT   "Protein phosphorylation and expression profiling by Yin-yang
RT   multidimensional liquid chromatography (Yin-yang MDLC) mass
RT   spectrometry.";
RL   J. Proteome Res. 6:250-262(2007).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-246 AND SER-247, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=17242355; DOI=10.1073/pnas.0609836104;
RA   Villen J., Beausoleil S.A., Gerber S.A., Gygi S.P.;
RT   "Large-scale phosphorylation analysis of mouse liver.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:1488-1493(2007).
CC   -!- FUNCTION: Forms a water-specific channel that provides the plasma
CC       membranes of red cells and kidney proximal tubules with high
CC       permeability to water, thereby permitting water to move in the
CC       direction of an osmotic gradient.
CC   -!- SUBUNIT: Homotetramer (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Erythrocytes and renal tubules.
CC   -!- DOMAIN: Aquaporins contain two tandem repeats each containing
CC       three membrane-spanning domains and a pore-forming loop with the
CC       signature motif Asn-Pro-Ala (NPA).
CC   -!- MISCELLANEOUS: Pharmacologically inhibited by submillimolar
CC       concentrations of mercury.
CC   -!- SIMILARITY: Belongs to the MIP/aquaporin (TC 1.A.8) family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L02914; AAB53928.1; -; mRNA.
DR   EMBL; AK081886; BAC38360.1; -; mRNA.
DR   EMBL; AK086688; BAC39719.1; -; mRNA.
DR   EMBL; AK157333; BAE34051.1; -; mRNA.
DR   EMBL; AK158226; BAE34412.1; -; mRNA.
DR   EMBL; AK158389; BAE34482.1; -; mRNA.
DR   EMBL; AK171627; BAE42573.1; -; mRNA.
DR   EMBL; AK172361; BAE42966.1; -; mRNA.
DR   EMBL; BC007125; AAH07125.1; -; mRNA.
DR   IPI; IPI00123183; -.
DR   PIR; B44499; B44499.
DR   RefSeq; NP_031498.1; -.
DR   UniGene; Mm.18625; -.
DR   SMR; Q02013; 1-247.
DR   STRING; Q02013; -.
DR   PhosphoSite; Q02013; -.
DR   Ensembl; ENSMUST00000004774; ENSMUSP00000004774; ENSMUSG00000004655; Mus musculus.
DR   GeneID; 11826; -.
DR   KEGG; mmu:11826; -.
DR   UCSC; uc009caq.1; mouse.
DR   CTD; 11826; -.
DR   MGI; MGI:103201; Aqp1.
DR   eggNOG; roNOG11397; -.
DR   HOGENOM; HBG705794; -.
DR   HOVERGEN; HBG000312; -.
DR   InParanoid; Q02013; -.
DR   OMA; PLERNQT; -.
DR   OrthoDB; EOG9GQSRK; -.
DR   PhylomeDB; Q02013; -.
DR   NextBio; 279727; -.
DR   ArrayExpress; Q02013; -.
DR   Bgee; Q02013; -.
DR   CleanEx; MM_AQP1; -.
DR   Genevestigator; Q02013; -.
DR   GermOnline; ENSMUSG00000004655; Mus musculus.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:MGI.
DR   GO; GO:0015250; F:water channel activity; TAS:MGI.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   GO; GO:0006833; P:water transport; TAS:MGI.
DR   InterPro; IPR012269; Aquaporin.
DR   InterPro; IPR000425; MIP.
DR   Gene3D; G3DSA:1.20.1080.10; MIP; 1.
DR   PANTHER; PTHR19139; MIP; 1.
DR   Pfam; PF00230; MIP; 1.
DR   PRINTS; PR00783; MINTRINSICP.
DR   SUPFAM; SSF81338; MIP; 1.
DR   TIGRFAMs; TIGR00861; MIP; 1.
DR   PROSITE; PS00221; MIP; 1.
PE   1: Evidence at protein level;
KW   Glycoprotein; Membrane; Phosphoprotein; Repeat; Transmembrane;
KW   Transport.
FT   INIT_MET      1      1       Removed (By similarity).
FT   CHAIN         2    269       Aquaporin-1.
FT                                /FTId=PRO_0000063921.
FT   TOPO_DOM      2      7       Cytoplasmic (By similarity).
FT   TRANSMEM      8     36       Helix 1 (By similarity).
FT   TOPO_DOM     37     48       Extracellular (By similarity).
FT   TRANSMEM     49     66       Helix 2 (By similarity).
FT   TOPO_DOM     67     70       Cytoplasmic (By similarity).
FT   TOPO_DOM     71     76       In membrane (By similarity).
FT   TRANSMEM     77     84       Helix B (By similarity).
FT   TOPO_DOM     85     94       Cytoplasmic (By similarity).
FT   TRANSMEM     95    115       Helix 3 (By similarity).
FT   TOPO_DOM    116    136       Extracellular (By similarity).
FT   TRANSMEM    137    155       Helix 4 (By similarity).
FT   TOPO_DOM    156    166       Cytoplasmic (By similarity).
FT   TRANSMEM    167    183       Helix 5 (By similarity).
FT   TOPO_DOM    184    186       Extracellular (By similarity).
FT   TOPO_DOM    187    192       In membrane (By similarity).
FT   TRANSMEM    193    200       Helix E (By similarity).
FT   TOPO_DOM    201    207       Extracellular (By similarity).
FT   TRANSMEM    208    228       Helix 6 (By similarity).
FT   TOPO_DOM    229    269       Cytoplasmic (By similarity).
FT   MOTIF        76     78       NPA 1.
FT   MOTIF       192    194       NPA 2.
FT   COMPBIAS    159    162       Poly-Arg.
FT   SITE         56     56       Substrate discrimination (By similarity).
FT   SITE        180    180       Substrate discrimination (By similarity).
FT   SITE        189    189       Hg(2+)-sensitive residue (By similarity).
FT   SITE        195    195       Substrate discrimination (By similarity).
FT   MOD_RES     246    246       Phosphothreonine.
FT   MOD_RES     247    247       Phosphoserine.
FT   MOD_RES     262    262       Phosphoserine.
FT   CARBOHYD    205    205       N-linked (GlcNAc...) (Potential).
FT   CONFLICT    190    190       G -> S (in Ref. 3; AAH07125).
SQ   SEQUENCE   269 AA;  28793 MW;  F0499724AD4AB5F6 CRC64;
     MASEIKKKLF WRAVVAEFLA MTLFVFISIG SALGFNYPLE RNQTLVQDNV KVSLAFGLSI
     ATLAQSVGHI SGAHLNPAVT LGLLLSCQIS ILRAVMYIIA QCVGAIVATA ILSGITSSLV
     DNSLGRNDLA HGVNSGQGLG IEIIGTLQLV LCVLATTDRR RRDLGGSAPL AIGLSVALGH
     LLAIDYTGCG INPARSFGSA VLTRNFSNHW IFWVGPFIGG ALAVLIYDFI LAPRSSDFTD
     RMKVWTSGQV EEYDLDADDI NSRVEMKPK
//
ID   AT2A1_HUMAN             Reviewed;        1001 AA.
AC   O14983; A8K5J9; O14984;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   02-MAR-2010, entry version 109.
DE   RecName: Full=Sarcoplasmic/endoplasmic reticulum calcium ATPase 1;
DE            Short=SR Ca(2+)-ATPase 1;
DE            Short=SERCA1;
DE            EC=3.6.3.8;
DE   AltName: Full=Calcium pump 1;
DE   AltName: Full=Calcium-transporting ATPase sarcoplasmic reticulum type, fast twitch skeletal muscle isoform;
DE   AltName: Full=Endoplasmic reticulum class 1/2 Ca(2+) ATPase;
GN   Name=ATP2A1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS SERCA1A AND
RP   SERCA1B).
RC   TISSUE=Skeletal muscle;
RX   MEDLINE=96423024; PubMed=8825625; DOI=10.1006/geno.1995.1259;
RA   Zhang Y., Fujii J., Phillips M.S., Chen H.-S., Karpati G., Yee W.-C.,
RA   Schrank B., Cornblath D.R., Boylan K.B., Maclennan D.H.;
RT   "Characterization of cDNA and genomic DNA encoding SERCA1, the Ca(2+)-
RT   ATPase of human fast-twitch skeletal muscle sarcoplasmic reticulum,
RT   and its elimination as a candidate gene for Brody disease.";
RL   Genomics 30:415-424(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SERCA1A).
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   DISULFIDE BOND.
RX   PubMed=11438520; DOI=10.1074/jbc.M101229200;
RA   Daiho T., Yamasaki K., Saino T., Kamidochi M., Satoh K., Iizuka H.,
RA   Suzuki H.;
RT   "Mutations of either or both Cys876 and Cys888 residues of
RT   sarcoplasmic reticulum Ca2+-ATPase result in a complete loss of Ca2+
RT   transport activity without a loss of Ca2+-dependent ATPase activity.
RT   Role of the Cys876-Cys888 disulfide bond.";
RL   J. Biol. Chem. 276:32771-32778(2001).
RN   [4]
RP   VARIANT BRM LEU-789.
RX   MEDLINE=20370349; PubMed=10914677; DOI=10.1007/s004390000297;
RA   Odermatt A., Barton K., Khanna V.K., Mathieu J., Escolar D.,
RA   Kuntzer T., Karpati G., MacLennan D.H.;
RT   "The mutation of Pro(789) to Leu reduces the activity of the fast-
RT   twitch skeletal muscle sarco(endo)plasmic reticulum Ca(2+) ATPase
RT   (SERCA1) and is associated with Brody disease.";
RL   Hum. Genet. 106:482-491(2000).
CC   -!- FUNCTION: This magnesium-dependent enzyme catalyzes the hydrolysis
CC       of ATP coupled with the translocation of calcium from the cytosol
CC       to the sarcoplasmic reticulum lumen. Contributes to calcium
CC       sequestration involved in muscular excitation/contraction.
CC   -!- CATALYTIC ACTIVITY: ATP + H(2)O + Ca(2+)(Cis) = ADP + phosphate +
CC       Ca(2+)(Trans).
CC   -!- ENZYME REGULATION: Reversibly inhibited by phospholamban (PLN) at
CC       low calcium concentrations. Dephosphorylated PLN decreases the
CC       apparent affinity of the ATPase for calcium. This inhibition is
CC       regulated by the phosphorylation of PLN (By similarity).
CC   -!- SUBUNIT: Associated with sarcolipin (SLN) and phospholamban (PLN)
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Multi-pass
CC       membrane protein. Sarcoplasmic reticulum membrane; Multi-pass
CC       membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=SERCA1B; Synonyms=ATP2A1B, Neonatal;
CC         IsoId=O14983-1; Sequence=Displayed;
CC       Name=SERCA1A; Synonyms=ATP2A1A, Adult;
CC         IsoId=O14983-2; Sequence=VSP_000355;
CC   -!- TISSUE SPECIFICITY: Skeletal muscle, fast twitch muscle (type II)
CC       fibers.
CC   -!- DEVELOPMENTAL STAGE: Isoform SERCA1A accounts for more than 99% of
CC       SERCA1 isoforms expressed in adult, while isoform SERCA1B
CC       predominates in neo-natal fibers.
CC   -!- INDUCTION: Increased contractile activity leads to decrease SERCA1
CC       expression, while decreased contractile activity leads to increase
CC       of SERCA1 expression.
CC   -!- DISEASE: Defects in ATP2A1 are the cause of Brody myopathy (BRM)
CC       [MIM:601003]. An autosomal recessive myopathy characterized by
CC       increasing impairment of relaxation of fast twist skeletal muscle
CC       during exercise.
CC   -!- SIMILARITY: Belongs to the cation transport ATPase (P-type)
CC       family. Type IIA subfamily.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U96781; AAB53113.1; -; Genomic_DNA.
DR   EMBL; U96773; AAB53113.1; JOINED; Genomic_DNA.
DR   EMBL; U96774; AAB53113.1; JOINED; Genomic_DNA.
DR   EMBL; U96775; AAB53113.1; JOINED; Genomic_DNA.
DR   EMBL; U96776; AAB53113.1; JOINED; Genomic_DNA.
DR   EMBL; U96777; AAB53113.1; JOINED; Genomic_DNA.
DR   EMBL; U96778; AAB53113.1; JOINED; Genomic_DNA.
DR   EMBL; U96779; AAB53113.1; JOINED; Genomic_DNA.
DR   EMBL; U96780; AAB53113.1; JOINED; Genomic_DNA.
DR   EMBL; U96781; AAB53112.1; -; Genomic_DNA.
DR   EMBL; U96773; AAB53112.1; JOINED; Genomic_DNA.
DR   EMBL; U96774; AAB53112.1; JOINED; Genomic_DNA.
DR   EMBL; U96775; AAB53112.1; JOINED; Genomic_DNA.
DR   EMBL; U96776; AAB53112.1; JOINED; Genomic_DNA.
DR   EMBL; U96777; AAB53112.1; JOINED; Genomic_DNA.
DR   EMBL; U96778; AAB53112.1; JOINED; Genomic_DNA.
DR   EMBL; U96779; AAB53112.1; JOINED; Genomic_DNA.
DR   EMBL; U96780; AAB53112.1; JOINED; Genomic_DNA.
DR   EMBL; AK291314; BAF84003.1; -; mRNA.
DR   IPI; IPI00024804; -.
DR   IPI; IPI00396118; -.
DR   RefSeq; NP_004311.1; -.
DR   RefSeq; NP_775293.1; -.
DR   UniGene; Hs.657344; -.
DR   SMR; O14983; 1-993.
DR   IntAct; O14983; 1.
DR   STRING; O14983; -.
DR   PhosphoSite; O14983; -.
DR   PRIDE; O14983; -.
DR   Ensembl; ENST00000357084; ENSP00000349595; ENSG00000196296; Homo sapiens.
DR   GeneID; 487; -.
DR   KEGG; hsa:487; -.
DR   UCSC; uc002drn.1; human.
DR   UCSC; uc002dro.1; human.
DR   CTD; 487; -.
DR   GeneCards; GC16P028798; -.
DR   GeneCards; GC16P028799; -.
DR   H-InvDB; HIX0023254; -.
DR   HGNC; HGNC:811; ATP2A1.
DR   HPA; CAB002310; -.
DR   MIM; 108730; gene.
DR   MIM; 601003; phenotype.
DR   Orphanet; 53347; Brody myopathy.
DR   PharmGKB; PA25105; -.
DR   eggNOG; prNOG08565; -.
DR   HOGENOM; HBG456486; -.
DR   HOVERGEN; HBG105648; -.
DR   OMA; QVKRNLE; -.
DR   OrthoDB; EOG9G1Q1V; -.
DR   PhylomeDB; O14983; -.
DR   BRENDA; 3.6.3.8; 247.
DR   NextBio; 2023; -.
DR   ArrayExpress; O14983; -.
DR   Bgee; O14983; -.
DR   CleanEx; HS_ATP2A1; -.
DR   Genevestigator; O14983; -.
DR   GermOnline; ENSG00000196296; Homo sapiens.
DR   GO; GO:0034704; C:calcium channel complex; IC:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0005793; C:ER-Golgi intermediate compartment; ISS:UniProtKB.
DR   GO; GO:0031673; C:H zone; IDA:UniProtKB.
DR   GO; GO:0031674; C:I band; IDA:UniProtKB.
DR   GO; GO:0005792; C:microsome; IMP:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0016529; C:sarcoplasmic reticulum; ISS:UniProtKB.
DR   GO; GO:0033017; C:sarcoplasmic reticulum membrane; TAS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IMP:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; ISS:UniProtKB.
DR   GO; GO:0005388; F:calcium-transporting ATPase activity; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0070059; P:apoptosis in response to endoplasmic reticu...; IMP:UniProtKB.
DR   GO; GO:0008637; P:apoptotic mitochondrial changes; IMP:UniProtKB.
DR   GO; GO:0006754; P:ATP biosynthetic process; IEA:InterPro.
DR   GO; GO:0006200; P:ATP catabolic process; ISS:UniProtKB.
DR   GO; GO:0070509; P:calcium ion import; IMP:UniProtKB.
DR   GO; GO:0006816; P:calcium ion transport; IDA:UniProtKB.
DR   GO; GO:0032470; P:elevation of endoplasmic reticulum calcium ...; IMP:UniProtKB.
DR   GO; GO:0051561; P:elevation of mitochondrial calcium ion conc...; IMP:UniProtKB.
DR   GO; GO:0051659; P:maintenance of mitochondrion location; IMP:UniProtKB.
DR   GO; GO:0045988; P:negative regulation of striated muscle cont...; IMP:UniProtKB.
DR   GO; GO:0031448; P:positive regulation of fast-twitch skeletal...; IDA:UniProtKB.
DR   GO; GO:0032471; P:reduction of endoplasmic reticulum calcium ...; IMP:UniProtKB.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; IMP:UniProtKB.
DR   InterPro; IPR008250; ATPase_P-typ_ATPase-assoc-dom.
DR   InterPro; IPR005782; ATPase_P-typ_Ca-transp.
DR   InterPro; IPR006068; ATPase_P-typ_cation-transptr_C.
DR   InterPro; IPR004014; ATPase_P-typ_cation-transptr_N.
DR   InterPro; IPR000695; ATPase_P-typ_H-transp.
DR   InterPro; IPR001757; ATPase_P-typ_ion-transptr.
DR   InterPro; IPR018303; ATPase_P-typ_P_site.
DR   InterPro; IPR005834; Dehalogen-like_hydro.
DR   PANTHER; PTHR11939; ATPase_P; 1.
DR   Pfam; PF00689; Cation_ATPase_C; 1.
DR   Pfam; PF00690; Cation_ATPase_N; 1.
DR   Pfam; PF00122; E1-E2_ATPase; 1.
DR   Pfam; PF00702; Hydrolase; 1.
DR   PRINTS; PR00119; CATATPASE.
DR   PRINTS; PR00120; HATPASE.
DR   SMART; SM00831; Cation_ATPase_N; 1.
DR   TIGRFAMs; TIGR01116; ATPase-IIA1_Ca; 1.
DR   TIGRFAMs; TIGR01494; ATPase_P-type; 4.
DR   PROSITE; PS00154; ATPASE_E1_E2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Calcium; Calcium transport;
KW   Complete proteome; Disease mutation; Disulfide bond;
KW   Endoplasmic reticulum; Hydrolase; Ion transport; Magnesium; Membrane;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein;
KW   Sarcoplasmic reticulum; Transmembrane; Transport.
FT   CHAIN         1   1001       Sarcoplasmic/endoplasmic reticulum
FT                                calcium ATPase 1.
FT                                /FTId=PRO_0000046187.
FT   TOPO_DOM      1     48       Cytoplasmic (By similarity).
FT   TRANSMEM     49     69       1 (By similarity).
FT   TOPO_DOM     70     89       Lumenal (By similarity).
FT   TRANSMEM     90    110       2 (By similarity).
FT   TOPO_DOM    111    253       Cytoplasmic (By similarity).
FT   TRANSMEM    254    273       3 (By similarity).
FT   TOPO_DOM    274    295       Lumenal (By similarity).
FT   TRANSMEM    296    313       4 (By similarity).
FT   TOPO_DOM    314    757       Cytoplasmic (By similarity).
FT   TRANSMEM    758    777       5 (By similarity).
FT   TOPO_DOM    778    787       Lumenal (By similarity).
FT   TRANSMEM    788    808       6 (By similarity).
FT   TOPO_DOM    809    828       Cytoplasmic (By similarity).
FT   TRANSMEM    829    851       7 (By similarity).
FT   TOPO_DOM    852    897       Lumenal (By similarity).
FT   TRANSMEM    898    917       8 (By similarity).
FT   TOPO_DOM    918    930       Cytoplasmic (By similarity).
FT   TRANSMEM    931    949       9 (By similarity).
FT   TOPO_DOM    950    964       Lumenal (By similarity).
FT   TRANSMEM    965    985       10 (By similarity).
FT   TOPO_DOM    986   1001       Cytoplasmic (By similarity).
FT   REGION      370    400       Interacts with phospholamban 1 (By
FT                                similarity).
FT   REGION      788    808       Interacts with phospholamban 2 (By
FT                                similarity).
FT   ACT_SITE    351    351       4-aspartylphosphate intermediate (By
FT                                similarity).
FT   METAL       304    304       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       305    305       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       307    307       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       309    309       Calcium 2 (By similarity).
FT   METAL       703    703       Magnesium (By similarity).
FT   METAL       707    707       Magnesium (By similarity).
FT   METAL       768    768       Calcium 1 (By similarity).
FT   METAL       771    771       Calcium 1 (By similarity).
FT   METAL       796    796       Calcium 2 (By similarity).
FT   METAL       799    799       Calcium 1 (By similarity).
FT   METAL       800    800       Calcium 1 (By similarity).
FT   METAL       800    800       Calcium 2 (By similarity).
FT   METAL       908    908       Calcium 1 (By similarity).
FT   DISULFID    876    888
FT   VAR_SEQ     994   1001       DPEDERRK -> G (in isoform SERCA1A).
FT                                /FTId=VSP_000355.
FT   VARIANT     789    789       P -> L (in BRM; almost complete loss of
FT                                Ca(2+) transport activity because of
FT                                reduced Ca(2+) affinity).
FT                                /FTId=VAR_015588.
SQ   SEQUENCE   1001 AA;  110252 MW;  C8F33809B56FDDEE CRC64;
     MEAAHAKTTE ECLAYFGVSE TTGLTPDQVK RNLEKYGLNE LPAEEGKTLW ELVIEQFEDL
     LVRILLLAAC ISFVLAWFEE GEETITAFVE PFVILLILIA NAIVGVWQER NAENAIEALK
     EYEPEMGKVY RADRKSVQRI KARDIVPGDI VEVAVGDKVP ADIRILAIKS TTLRVDQSIL
     TGESVSVIKH TEPVPDPRAV NQDKKNMLFS GTNIAAGKAL GIVATTGVGT EIGKIRDQMA
     ATEQDKTPLQ QKLDEFGEQL SKVISLICVA VWLINIGHFN DPVHGGSWFR GAIYYFKIAV
     ALAVAAIPEG LPAVITTCLA LGTRRMAKKN AIVRSLPSVE TLGCTSVICS DKTGTLTTNQ
     MSVCKMFIID KVDGDICLLN EFSITGSTYA PEGEVLKNDK PVRPGQYDGL VELATICALC
     NDSSLDFNEA KGVYEKVGEA TETALTTLVE KMNVFNTDVR SLSKVERANA CNSVIRQLMK
     KEFTLEFSRD RKSMSVYCSP AKSSRAAVGN KMFVKGAPEG VIDRCNYVRV GTTRVPLTGP
     VKEKIMAVIK EWGTGRDTLR CLALATRDTP PKREEMVLDD SARFLEYETD LTFVGVVGML
     DPPRKEVTGS IQLCRDAGIR VIMITGDNKG TAIAICRRIG IFGENEEVAD RAYTGREFDD
     LPLAEQREAC RRACCFARVE PSHKSKIVEY LQSYDEITAM TGDGVNDAPA LKKAEIGIAM
     GSGTAVAKTA SEMVLADDNF STIVAAVEEG RAIYNNMKQF IRYLISSNVG EVVCIFLTAA
     LGLPEALIPV QLLWVNLVTD GLPATALGFN PPDLDIMDRP PRSPKEPLIS GWLFFRYMAI
     GGYVGAATVG AAAWWFLYAE DGPHVNYSQL THFMQCTEDN THFEGIDCEV FEAPEPMTMA
     LSVLVTIEMC NALNSLSENQ SLLRMPPWVN IWLLGSICLS MSLHFLILYV DPLPMIFKLR
     ALDLTQWLMV LKISLPVIGL DEILKFVARN YLEDPEDERR K
//
ID   AT2A2_HUMAN             Reviewed;        1042 AA.
AC   P16615; P16614;
DT   01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1990, sequence version 1.
DT   02-MAR-2010, entry version 132.
DE   RecName: Full=Sarcoplasmic/endoplasmic reticulum calcium ATPase 2;
DE            Short=SR Ca(2+)-ATPase 2;
DE            Short=SERCA2;
DE            EC=3.6.3.8;
DE   AltName: Full=Calcium pump 2;
DE   AltName: Full=Calcium-transporting ATPase sarcoplasmic reticulum type, slow twitch skeletal muscle isoform;
DE   AltName: Full=Endoplasmic reticulum class 1/2 Ca(2+) ATPase;
GN   Name=ATP2A2; Synonyms=ATP2B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS SERCA2A AND
RP   SERCA2B).
RC   TISSUE=Kidney;
RX   MEDLINE=89008384; PubMed=2844796;
RA   Lytton J., Maclennan D.H.;
RT   "Molecular cloning of cDNAs from human kidney coding for two
RT   alternatively spliced products of the cardiac Ca2+-ATPase gene.";
RL   J. Biol. Chem. 263:15024-15031(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SERCA2B).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   INTERACTION WITH TRAM2.
RX   PubMed=14749390; DOI=10.1128/MCB.24.4.1758-1768.2004;
RA   Stefanovic B., Stefanovic L., Schnabl B., Bataller R., Brenner D.A.;
RT   "TRAM2 protein interacts with endoplasmic reticulum Ca2+ pump Serca2b
RT   and is necessary for collagen type I synthesis.";
RL   Mol. Cell. Biol. 24:1758-1768(2004).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-663, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Epithelium;
RX   PubMed=15302935; DOI=10.1073/pnas.0404720101;
RA   Beausoleil S.A., Jedrychowski M., Schwartz D., Elias J.E., Villen J.,
RA   Li J., Cohn M.A., Cantley L.C., Gygi S.P.;
RT   "Large-scale characterization of HeLa cell nuclear phosphoproteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:12130-12135(2004).
RN   [5]
RP   NITRATION AT TYR-294 AND TYR-295.
RX   PubMed=16399855; DOI=10.1152/ajpheart.01293.2005;
RA   Xu S., Ying J., Jiang B., Guo W., Adachi T., Sharov V., Lazar H.,
RA   Menzoian J., Knyushko T.V., Bigelow D., Schoeneich C., Cohen R.A.;
RT   "Detection of sequence-specific tyrosine nitration of manganese SOD
RT   and SERCA in cardiovascular disease and aging.";
RL   Am. J. Physiol. 290:H2220-H2227(2006).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-663, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Epithelium;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-663, AND MASS
RP   SPECTROMETRY.
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-663, AND MASS
RP   SPECTROMETRY.
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   IDENTIFICATION [LARGE SCALE ANALYSIS], AND MASS SPECTROMETRY.
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [10]
RP   INTERACTION WITH HAX1.
RX   PubMed=18971376; DOI=10.1091/mbc.E08-06-0587;
RA   Vafiadaki E., Arvanitis D.A., Pagakis S.N., Papalouka V., Sanoudou D.,
RA   Kontrogianni-Konstantopoulos A., Kranias E.G.;
RT   "The anti-apoptotic protein HAX-1 interacts with SERCA2 and regulates
RT   its protein levels to promote cell survival.";
RL   Mol. Biol. Cell 20:306-318(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-663, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-464, AND MASS SPECTROMETRY.
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [13]
RP   VARIANTS DD.
RX   MEDLINE=99371767; PubMed=10441323; DOI=10.1093/hmg/8.9.1611;
RA   Sakuntabhai A., Burge S., Monk S., Hovnanian A.;
RT   "Spectrum of novel ATP2A2 mutations in patients with Darier's
RT   disease.";
RL   Hum. Mol. Genet. 8:1611-1619(1999).
RN   [14]
RP   VARIANTS DD, AND TISSUE SPECIFICITY.
RX   MEDLINE=99371768; PubMed=10441324; DOI=10.1093/hmg/8.9.1621;
RA   Ruiz-Perez V.L., Carter S.A., Healy E., Todd C., Rees J.L.,
RA   Steijlen P.M., Carmichael A.J., Lewis H.M., Hohl D., Itin P.,
RA   Vahlquist A., Gobello T., Mazzanti C., Reggazini R., Nagy G.,
RA   Munro C.S., Strachan T.;
RT   "ATP2A2 mutations in Darier's disease: variant cutaneous phenotypes
RT   are associated with missense mutations, but neuropsychiatric features
RT   are independent of mutation class.";
RL   Hum. Mol. Genet. 8:1621-1630(1999).
RN   [15]
RP   VARIANTS DD THR-39; ARG-560 AND LEU-765.
RX   MEDLINE=99371769; PubMed=10441325; DOI=10.1093/hmg/8.9.1631;
RA   Jacobsen N.J.O., Lyons I., Hoogendoorn B., Burge S., Kwok P.-Y.,
RA   O'Donovan M.C., Craddock N., Owen M.J.;
RT   "ATP2A2 mutations in Darier's disease and their relationship to
RT   neuropsychiatric phenotypes.";
RL   Hum. Mol. Genet. 8:1631-1636(1999).
RN   [16]
RP   VARIANTS DD GLU-23; LYS-357; PHE-495 AND ARG-749.
RX   MEDLINE=99178263; PubMed=10080178; DOI=10.1038/6784;
RA   Sakuntabhai A., Ruiz-Perez V., Carter S., Jacobsen N., Burge S.,
RA   Monk S., Smith M., Munro C.S., O'Donovan M.C., Craddock N.,
RA   Kucherlapati R., Rees J.L., Owen M.J., Lathrop G.M., Monaco A.P.,
RA   Strachan T., Hovnanian A.;
RT   "Mutations in ATP2A2, encoding a Ca2+ pump, cause Darier disease.";
RL   Nat. Genet. 21:271-277(1999).
RN   [17]
RP   VARIANT AKV LEU-602.
RX   MEDLINE=22432103; PubMed=12542527;
RX   DOI=10.1046/j.1523-1747.2003.t01-1-12045.x;
RA   Dhitavat J., Macfarlane S., Dode L., Leslie N., Sakuntabhai A.,
RA   MacSween R., Saihan E., Hovnanian A.;
RT   "Acrokeratosis verruciformis of Hopf is caused by mutation in ATP2A2:
RT   evidence that it is allelic to Darier's disease.";
RL   J. Invest. Dermatol. 120:229-232(2003).
CC   -!- FUNCTION: This magnesium-dependent enzyme catalyzes the hydrolysis
CC       of ATP coupled with the translocation of calcium from the cytosol
CC       to the sarcoplasmic reticulum lumen. Isoform SERCA2A is involved
CC       in the regulation of the contraction/relaxation cycle.
CC   -!- CATALYTIC ACTIVITY: ATP + H(2)O + Ca(2+)(Cis) = ADP + phosphate +
CC       Ca(2+)(Trans).
CC   -!- ENZYME REGULATION: Reversibly inhibited by phospholamban (PLN) at
CC       low calcium concentrations. Dephosphorylated PLN decreases the
CC       apparent affinity of the ATPase for calcium. This inhibition is
CC       regulated by the phosphorylation of PLN (By similarity).
CC   -!- SUBUNIT: Associated with phospholamban (PLN) (By similarity).
CC       Isoform SERCA2B interacts with TRAM2 (via C-terminus). Interacts
CC       with HAX1.
CC   -!- INTERACTION:
CC       O75365:PTP4A3; NbExp=1; IntAct=EBI-358933, EBI-1043866;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Multi-pass
CC       membrane protein. Sarcoplasmic reticulum membrane; Multi-pass
CC       membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC         Comment=SERCA2 transcripts differ only in their 3'-UTR region
CC         and are expressed in a tissue-specific manner;
CC       Name=SERCA2B; Synonyms=ATP2A2B, Class 2-4, HK1;
CC         IsoId=P16615-1; Sequence=Displayed;
CC         Note=Ubiquitous housekeeping isoform;
CC       Name=SERCA2A; Synonyms=ATP2A2A, Class 1, HK2;
CC         IsoId=P16615-2; Sequence=VSP_000358;
CC         Note=Cardiac/slow twitch, muscle specific isoform. Has a lower
CC         affinity for calcium and a higher catalytic turnover rate;
CC   -!- TISSUE SPECIFICITY: Isoform SERCA2A is highly expressed in heart
CC       and slow twitch skeletal muscle. Isoform SERCA2B is widely
CC       expressed, in smooth muscle and nonmuscle tissues such as in adult
CC       skin epidermis.
CC   -!- PTM: Nitrated under oxidative stress. Nitration on the two
CC       tyrosine residues inhibits catalytic activity.
CC   -!- DISEASE: Defects in ATP2A2 are a cause of acrokeratosis
CC       verruciformis (AKV) [MIM:101900]; also known as Hopf disease. AKV
CC       is a localized disorder of keratinization, which is inherited as
CC       an autosomal dominant trait. Its onset is early in life with
CC       multiple flat-topped, flesh-colored papules on the hands and feet,
CC       punctate keratoses on the palms and soles, with varying degrees of
CC       nail involvement. The histopathology shows a distinctive pattern
CC       of epidermal features with hyperkeratosis, hypergranulosis, and
CC       acanthosis together with papillomatosis. These changes are
CC       frequently associated with circumscribed elevations of the
CC       epidermis that are said to resemble church spires. There are no
CC       features of dyskeratosis or acantholysis, the typical findings in
CC       lesions of Darier disease.
CC   -!- DISEASE: Defects in ATP2A2 are the cause of Darier disease (DD)
CC       [MIM:124200]; also known as Darier-White disease (DAR). DD is an
CC       autosomal dominantly inherited skin disorder characterized by loss
CC       of adhesion between epidermal cells (acantholysis) and abnormal
CC       keratinization. Patients with mild disease may have no more than a
CC       few scattered keratotic papules or subtle nail changes, whereas
CC       those with severe disease are handicapped by widespread malodorous
CC       keratotic plaques. In a few families, neuropsychiatric
CC       abnormalities such as mild mental retardation, schizophrenia,
CC       bipolar disorder and epilepsy have been reported. Stress, UV
CC       exposure, heat, sweat, friction, and oral contraception exacerbate
CC       disease symptoms. Prevalence has been estimated at 1 in 50000.
CC   -!- SIMILARITY: Belongs to the cation transport ATPase (P-type)
CC       family. Type IIA subfamily.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/ATP2A2";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M23114; AAA53193.1; -; mRNA.
DR   EMBL; M23116; AAA52757.1; -; Genomic_DNA.
DR   EMBL; M23115; AAA53194.1; -; mRNA.
DR   EMBL; M23278; AAA52758.1; -; Genomic_DNA.
DR   EMBL; M23116; AAA52758.1; JOINED; Genomic_DNA.
DR   EMBL; BC035588; AAH35588.1; -; mRNA.
DR   IPI; IPI00177817; -.
DR   IPI; IPI00219078; -.
DR   PIR; A31981; A31981.
DR   PIR; B31981; B31981.
DR   RefSeq; NP_001129237.1; -.
DR   RefSeq; NP_001672.1; -.
DR   RefSeq; NP_733765.1; -.
DR   UniGene; Hs.506759; -.
DR   SMR; P16615; 1-992.
DR   IntAct; P16615; 9.
DR   STRING; P16615; -.
DR   TCDB; 3.A.3.2.7; P-type ATPase (P-ATPase) superfamily.
DR   PhosphoSite; P16615; -.
DR   HSC-2DPAGE; P16614; -.
DR   PRIDE; P16615; -.
DR   Ensembl; ENST00000313432; ENSP00000324892; ENSG00000174437; Homo sapiens.
DR   GeneID; 488; -.
DR   KEGG; hsa:488; -.
DR   UCSC; uc001tqk.2; human.
DR   UCSC; uc001tql.2; human.
DR   CTD; 488; -.
DR   GeneCards; GC12P109182; -.
DR   HGNC; HGNC:812; ATP2A2.
DR   MIM; 101900; phenotype.
DR   MIM; 108740; gene.
DR   MIM; 124200; phenotype.
DR   Orphanet; 79151; Acrokeratosis verruciformis of Hopf.
DR   Orphanet; 218; Darier disease.
DR   PharmGKB; PA71; -.
DR   eggNOG; prNOG08565; -.
DR   HOGENOM; HBG456486; -.
DR   HOVERGEN; HBG105648; -.
DR   InParanoid; P16615; -.
DR   OMA; PNKPSRT; -.
DR   PhylomeDB; P16615; -.
DR   BRENDA; 3.6.3.8; 247.
DR   NextBio; 2031; -.
DR   ArrayExpress; P16615; -.
DR   Bgee; P16615; -.
DR   CleanEx; HS_ATP2A2; -.
DR   Genevestigator; P16615; -.
DR   GermOnline; ENSG00000174437; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0005792; C:microsome; TAS:ProtInc.
DR   GO; GO:0033017; C:sarcoplasmic reticulum membrane; TAS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005509; F:calcium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005388; F:calcium-transporting ATPase activity; TAS:ProtInc.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
DR   GO; GO:0048155; F:S100 alpha binding; IPI:UniProtKB.
DR   GO; GO:0006754; P:ATP biosynthetic process; IEA:InterPro.
DR   GO; GO:0007155; P:cell adhesion; TAS:ProtInc.
DR   GO; GO:0008544; P:epidermis development; TAS:ProtInc.
DR   GO; GO:0070296; P:sarcoplasmic reticulum calcium ion transport; TAS:UniProtKB.
DR   InterPro; IPR008250; ATPase_P-typ_ATPase-assoc-dom.
DR   InterPro; IPR005782; ATPase_P-typ_Ca-transp.
DR   InterPro; IPR006068; ATPase_P-typ_cation-transptr_C.
DR   InterPro; IPR004014; ATPase_P-typ_cation-transptr_N.
DR   InterPro; IPR000695; ATPase_P-typ_H-transp.
DR   InterPro; IPR001757; ATPase_P-typ_ion-transptr.
DR   InterPro; IPR018303; ATPase_P-typ_P_site.
DR   InterPro; IPR005834; Dehalogen-like_hydro.
DR   PANTHER; PTHR11939; ATPase_P; 1.
DR   Pfam; PF00689; Cation_ATPase_C; 1.
DR   Pfam; PF00690; Cation_ATPase_N; 1.
DR   Pfam; PF00122; E1-E2_ATPase; 1.
DR   Pfam; PF00702; Hydrolase; 1.
DR   PRINTS; PR00119; CATATPASE.
DR   PRINTS; PR00120; HATPASE.
DR   SMART; SM00831; Cation_ATPase_N; 1.
DR   TIGRFAMs; TIGR01116; ATPase-IIA1_Ca; 1.
DR   TIGRFAMs; TIGR01494; ATPase_P-type; 4.
DR   PROSITE; PS00154; ATPASE_E1_E2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; ATP-binding; Calcium;
KW   Calcium transport; Complete proteome; Disease mutation;
KW   Endoplasmic reticulum; Epilepsy; Hydrolase; Ion transport;
KW   Isopeptide bond; Magnesium; Membrane; Metal-binding; Nitration;
KW   Nucleotide-binding; Phosphoprotein; Sarcoplasmic reticulum;
KW   Transmembrane; Transport; Ubl conjugation.
FT   CHAIN         1   1042       Sarcoplasmic/endoplasmic reticulum
FT                                calcium ATPase 2.
FT                                /FTId=PRO_0000046196.
FT   TOPO_DOM      1     48       Cytoplasmic (By similarity).
FT   TRANSMEM     49     69       1 (By similarity).
FT   TOPO_DOM     70     89       Lumenal (By similarity).
FT   TRANSMEM     90    110       2 (By similarity).
FT   TOPO_DOM    111    253       Cytoplasmic (By similarity).
FT   TRANSMEM    254    273       3 (By similarity).
FT   TOPO_DOM    274    295       Lumenal (By similarity).
FT   TRANSMEM    296    313       4 (By similarity).
FT   TOPO_DOM    314    756       Cytoplasmic (By similarity).
FT   TRANSMEM    757    776       5 (By similarity).
FT   TOPO_DOM    777    786       Lumenal (By similarity).
FT   TRANSMEM    787    807       6 (By similarity).
FT   TOPO_DOM    808    827       Cytoplasmic (By similarity).
FT   TRANSMEM    828    850       7 (By similarity).
FT   TOPO_DOM    851    896       Lumenal (By similarity).
FT   TRANSMEM    897    916       8 (By similarity).
FT   TOPO_DOM    917    929       Cytoplasmic (By similarity).
FT   TRANSMEM    930    948       9 (By similarity).
FT   TOPO_DOM    949    963       Lumenal (By similarity).
FT   TRANSMEM    964    984       10 (By similarity).
FT   TOPO_DOM    985   1042       Cytoplasmic (By similarity).
FT   REGION      370    400       Interacts with phospholamban 1 (By
FT                                similarity).
FT   REGION      575    594       Interacts with HAX1.
FT   REGION      787    807       Interacts with phospholamban 2 (By
FT                                similarity).
FT   ACT_SITE    351    351       4-aspartylphosphate intermediate (By
FT                                similarity).
FT   METAL       304    304       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       305    305       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       307    307       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       309    309       Calcium 2 (By similarity).
FT   METAL       702    702       Magnesium (By similarity).
FT   METAL       706    706       Magnesium (By similarity).
FT   METAL       767    767       Calcium 1 (By similarity).
FT   METAL       770    770       Calcium 1 (By similarity).
FT   METAL       795    795       Calcium 2 (By similarity).
FT   METAL       798    798       Calcium 1 (By similarity).
FT   METAL       799    799       Calcium 1 (By similarity).
FT   METAL       799    799       Calcium 2 (By similarity).
FT   METAL       907    907       Calcium 1 (By similarity).
FT   MOD_RES     294    294       Nitrated tyrosine.
FT   MOD_RES     295    295       Nitrated tyrosine.
FT   MOD_RES     464    464       N6-acetyllysine.
FT   MOD_RES     537    537       Phosphothreonine (By similarity).
FT   MOD_RES     663    663       Phosphoserine.
FT   CROSSLNK    143    143       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
FT   VAR_SEQ     994   1042       GKECVQPATKSCSFSACTDGISWPFVLLIMPLVIWVYSTDT
FT                                NFSDMFWS -> AILE (in isoform SERCA2A).
FT                                /FTId=VSP_000358.
FT   VARIANT      23     23       G -> E (in DD; dbSNP:rs28929478).
FT                                /FTId=VAR_008608.
FT   VARIANT      39     39       N -> T (in DD).
FT                                /FTId=VAR_008609.
FT   VARIANT      47     47       K -> KMFLTGK (in DD).
FT                                /FTId=VAR_008610.
FT   VARIANT      65     65       L -> S (in DD; severe form).
FT                                /FTId=VAR_008611.
FT   VARIANT     131    131       R -> Q (in DD).
FT                                /FTId=VAR_008612.
FT   VARIANT     160    160       P -> L (in DD).
FT                                /FTId=VAR_008613.
FT   VARIANT     186    186       S -> P (in DD).
FT                                /FTId=VAR_008614.
FT   VARIANT     211    211       G -> D (in DD; severe form).
FT                                /FTId=VAR_008615.
FT   VARIANT     223    223       V -> M (in DD).
FT                                /FTId=VAR_008616.
FT   VARIANT     268    268       C -> F (in DD; haemorrhagic lesions).
FT                                /FTId=VAR_008617.
FT   VARIANT     310    310       G -> V (in DD).
FT                                /FTId=VAR_008618.
FT   VARIANT     318    318       C -> R (in DD; severe form).
FT                                /FTId=VAR_008619.
FT   VARIANT     348    348       I -> T (in DD).
FT                                /FTId=VAR_008620.
FT   VARIANT     357    357       T -> K (in DD).
FT                                /FTId=VAR_009508.
FT   VARIANT     412    412       E -> G (in DD).
FT                                /FTId=VAR_008621.
FT   VARIANT     495    495       S -> F (in DD).
FT                                /FTId=VAR_008622.
FT   VARIANT     560    560       C -> R (in DD; neuropsychiatric
FT                                phenotype).
FT                                /FTId=VAR_008623.
FT   VARIANT     602    602       P -> L (in AKV; loss of activity).
FT                                /FTId=VAR_017532.
FT   VARIANT     675    675       F -> S (in DD; multiple neuropsychiatric
FT                                features).
FT                                /FTId=VAR_008624.
FT   VARIANT     683    683       K -> E (in DD; depression).
FT                                /FTId=VAR_008625.
FT   VARIANT     702    702       D -> N (in DD; moderate form).
FT                                /FTId=VAR_008626.
FT   VARIANT     745    745       A -> D (in DD; moderate form).
FT                                /FTId=VAR_008627.
FT   VARIANT     749    749       G -> R (in DD).
FT                                /FTId=VAR_009509.
FT   VARIANT     754    754       Missing (in DD).
FT                                /FTId=VAR_008628.
FT   VARIANT     765    765       S -> L (in DD).
FT                                /FTId=VAR_008629.
FT   VARIANT     767    767       N -> S (in DD; haemorrhagic lesions and
FT                                neuropsychiatric phenotype).
FT                                /FTId=VAR_008630.
FT   VARIANT     769    769       G -> R (in DD).
FT                                /FTId=VAR_008631.
FT   VARIANT     803    803       A -> T (in DD; mild/moderate form).
FT                                /FTId=VAR_008632.
FT   VARIANT     838    838       A -> P (in DD; severe form; petit mal
FT                                epilepsy).
FT                                /FTId=VAR_008633.
FT   VARIANT     843    843       V -> F (in DD; depression).
FT                                /FTId=VAR_008634.
FT   VARIANT     875    875       C -> G (in DD; retinitis pigmentosa).
FT                                /FTId=VAR_008635.
FT   VARIANT     920    920       S -> Y (in DD; mild/moderate/severe form;
FT                                one patient with epilepsy).
FT                                /FTId=VAR_008636.
FT   VARIANT     943    943       H -> R (in DD; learning difficulties).
FT                                /FTId=VAR_008637.
FT   VARIANT     975    975       P -> R (in DD).
FT                                /FTId=VAR_008638.
SQ   SEQUENCE   1042 AA;  114757 MW;  5462FF2DA7FB630A CRC64;
     MENAHTKTVE EVLGHFGVNE STGLSLEQVK KLKERWGSNE LPAEEGKTLL ELVIEQFEDL
     LVRILLLAAC ISFVLAWFEE GEETITAFVE PFVILLILVA NAIVGVWQER NAENAIEALK
     EYEPEMGKVY RQDRKSVQRI KAKDIVPGDI VEIAVGDKVP ADIRLTSIKS TTLRVDQSIL
     TGESVSVIKH TDPVPDPRAV NQDKKNMLFS GTNIAAGKAM GVVVATGVNT EIGKIRDEMV
     ATEQERTPLQ QKLDEFGEQL SKVISLICIA VWIINIGHFN DPVHGGSWIR GAIYYFKIAV
     ALAVAAIPEG LPAVITTCLA LGTRRMAKKN AIVRSLPSVE TLGCTSVICS DKTGTLTTNQ
     MSVCRMFILD RVEGDTCSLN EFTITGSTYA PIGEVHKDDK PVNCHQYDGL VELATICALC
     NDSALDYNEA KGVYEKVGEA TETALTCLVE KMNVFDTELK GLSKIERANA CNSVIKQLMK
     KEFTLEFSRD RKSMSVYCTP NKPSRTSMSK MFVKGAPEGV IDRCTHIRVG STKVPMTSGV
     KQKIMSVIRE WGSGSDTLRC LALATHDNPL RREEMHLEDS ANFIKYETNL TFVGCVGMLD
     PPRIEVASSV KLCRQAGIRV IMITGDNKGT AVAICRRIGI FGQDEDVTSK AFTGREFDEL
     NPSAQRDACL NARCFARVEP SHKSKIVEFL QSFDEITAMT GDGVNDAPAL KKAEIGIAMG
     SGTAVAKTAS EMVLADDNFS TIVAAVEEGR AIYNNMKQFI RYLISSNVGE VVCIFLTAAL
     GFPEALIPVQ LLWVNLVTDG LPATALGFNP PDLDIMNKPP RNPKEPLISG WLFFRYLAIG
     CYVGAATVGA AAWWFIAADG GPRVSFYQLS HFLQCKEDNP DFEGVDCAIF ESPYPMTMAL
     SVLVTIEMCN ALNSLSENQS LLRMPPWENI WLVGSICLSM SLHFLILYVE PLPLIFQITP
     LNVTQWLMVL KISLPVILMD ETLKFVARNY LEPGKECVQP ATKSCSFSAC TDGISWPFVL
     LIMPLVIWVY STDTNFSDMF WS
//
ID   AT2A2_MOUSE             Reviewed;        1044 AA.
AC   O55143; Q9R2A9; Q9WUT5;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2000, sequence version 2.
DT   02-MAR-2010, entry version 112.
DE   RecName: Full=Sarcoplasmic/endoplasmic reticulum calcium ATPase 2;
DE            Short=SR Ca(2+)-ATPase 2;
DE            Short=SERCA2;
DE            EC=3.6.3.8;
DE   AltName: Full=Calcium pump 2;
DE   AltName: Full=Calcium-transporting ATPase sarcoplasmic reticulum type, slow twitch skeletal muscle isoform;
DE   AltName: Full=Endoplasmic reticulum class 1/2 Ca(2+) ATPase;
GN   Name=Atp2a2;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS SERCA2A AND
RP   SERCA2B).
RC   STRAIN=129/SvJ;
RX   MEDLINE=20122169; PubMed=10656932; DOI=10.1007/s003350010030;
RA   Ver Heyen M., Reed T.D., Blough R.E., Zilberman A.L., Loukianov E.,
RA   Van Baelen K., Raeymaekers L., Periasamy M., Wutack F.;
RT   "Structure and organization of the mouse Atp2a2 gene encoding the
RT   sarco(endo)plasmic reticulum Ca(2+)-ATPase 2 (SERCA2) isoforms.";
RL   Mamm. Genome 11:159-163(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SERCA2B).
RC   STRAIN=C57BL/6; TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   PROTEIN SEQUENCE OF 604-611 AND 638-655, AND MASS SPECTROMETRY.
RC   STRAIN=C57BL/6, and OF1; TISSUE=Brain, and Hippocampus;
RA   Lubec G., Kang S.U., Sunyer B., Chen W.-Q.;
RL   Submitted (JAN-2009) to UniProtKB.
RN   [4]
RP   INTERACTION WITH TRAM2.
RX   PubMed=14749390; DOI=10.1128/MCB.24.4.1758-1768.2004;
RA   Stefanovic B., Stefanovic L., Schnabl B., Bataller R., Brenner D.A.;
RT   "TRAM2 protein interacts with endoplasmic reticulum Ca2+ pump Serca2b
RT   and is necessary for collagen type I synthesis.";
RL   Mol. Cell. Biol. 24:1758-1768(2004).
RN   [5]
RP   UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-143, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Heart;
RX   PubMed=17451654; DOI=10.1016/j.bbrc.2007.04.015;
RA   Jeon H.B., Choi E.S., Yoon J.H., Hwang J.H., Chang J.W., Lee E.K.,
RA   Choi H.W., Park Z.-Y., Yoo Y.J.;
RT   "A proteomics approach to identify the ubiquitinated proteins in mouse
RT   heart.";
RL   Biochem. Biophys. Res. Commun. 357:731-736(2007).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-537, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=17203969; DOI=10.1021/pr0604155;
RA   Dai J., Jin W.-H., Sheng Q.-H., Shieh C.-H., Wu J.-R., Zeng R.;
RT   "Protein phosphorylation and expression profiling by Yin-yang
RT   multidimensional liquid chromatography (Yin-yang MDLC) mass
RT   spectrometry.";
RL   J. Proteome Res. 6:250-262(2007).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-663, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Brain cortex;
RX   PubMed=17114649; DOI=10.1074/mcp.M600046-MCP200;
RA   Munton R.P., Tweedie-Cullen R., Livingstone-Zatchej M., Weinandy F.,
RA   Waidelich M., Longo D., Gehrig P., Potthast F., Rutishauser D.,
RA   Gerrits B., Panse C., Schlapbach R., Mansuy I.M.;
RT   "Qualitative and quantitative analyses of protein phosphorylation in
RT   naive and stimulated mouse synaptosomal preparations.";
RL   Mol. Cell. Proteomics 6:283-293(2007).
CC   -!- FUNCTION: This magnesium-dependent enzyme catalyzes the hydrolysis
CC       of ATP coupled with the translocation of calcium from the cytosol
CC       to the sarcoplasmic reticulum lumen. Isoform SERCA2A is involved
CC       in the regulation of the contraction/relaxation cycle (By
CC       similarity).
CC   -!- CATALYTIC ACTIVITY: ATP + H(2)O + Ca(2+)(Cis) = ADP + phosphate +
CC       Ca(2+)(Trans).
CC   -!- ENZYME REGULATION: Reversibly inhibited by phospholamban (PLN) at
CC       low calcium concentrations. Dephosphorylated PLN decreases the
CC       apparent affinity of the ATPase for calcium. This inhibition is
CC       regulated by the phosphorylation of PLN (By similarity).
CC   -!- SUBUNIT: Associated with phospholamban (PLN) (By similarity).
CC       Isoform SERCA2B interacts with TRAM2 (via C-terminus). Interacts
CC       with HAX1 (By similarity).
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Multi-pass
CC       membrane protein. Sarcoplasmic reticulum membrane; Multi-pass
CC       membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=SERCA2B; Synonyms=ATP2A2B;
CC         IsoId=O55143-1; Sequence=Displayed;
CC       Name=SERCA2A; Synonyms=ATP2A2A;
CC         IsoId=O55143-2; Sequence=VSP_000359;
CC   -!- TISSUE SPECIFICITY: Isoform SERCA2A is highly expressed in heart
CC       and slow twitch skeletal muscle. Isoform SERCA2B is widely
CC       expressed.
CC   -!- PTM: Nitrated under oxidative stress. Nitration on the two
CC       tyrosine residues inhibits catalytic activity (By similarity).
CC   -!- SIMILARITY: Belongs to the cation transport ATPase (P-type)
CC       family. Type IIA subfamily.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ131821; CAB72436.1; -; mRNA.
DR   EMBL; AJ223584; CAA11450.1; -; mRNA.
DR   EMBL; AF029982; AAD01889.1; -; Genomic_DNA.
DR   EMBL; AJ131870; CAB41017.1; -; Genomic_DNA.
DR   EMBL; AJ131870; CAB41018.1; -; Genomic_DNA.
DR   EMBL; BC054531; AAH54531.1; -; mRNA.
DR   EMBL; BC054748; AAH54748.1; -; mRNA.
DR   IPI; IPI00338964; -.
DR   IPI; IPI00468900; -.
DR   RefSeq; NP_001103610.1; -.
DR   RefSeq; NP_033852.1; -.
DR   UniGene; Mm.227583; -.
DR   SMR; O55143; 1-992.
DR   STRING; O55143; -.
DR   PhosphoSite; O55143; -.
DR   PRIDE; O55143; -.
DR   Ensembl; ENSMUST00000031423; ENSMUSP00000031423; ENSMUSG00000029467; Mus musculus.
DR   Ensembl; ENSMUST00000100740; ENSMUSP00000098306; ENSMUSG00000029467; Mus musculus.
DR   GeneID; 11938; -.
DR   KEGG; mmu:11938; -.
DR   UCSC; uc008zli.1; mouse.
DR   CTD; 11938; -.
DR   MGI; MGI:88110; Atp2a2.
DR   HOVERGEN; HBG105648; -.
DR   InParanoid; O55143; -.
DR   OMA; PNKPSRT; -.
DR   OrthoDB; EOG9G1Q1V; -.
DR   PhylomeDB; O55143; -.
DR   BRENDA; 3.6.3.8; 244.
DR   NextBio; 280039; -.
DR   ArrayExpress; O55143; -.
DR   Bgee; O55143; -.
DR   Genevestigator; O55143; -.
DR   GermOnline; ENSMUSG00000029467; Mus musculus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005792; C:microsome; IDA:MGI.
DR   GO; GO:0033017; C:sarcoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005509; F:calcium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005388; F:calcium-transporting ATPase activity; IDA:MGI.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
DR   GO; GO:0006754; P:ATP biosynthetic process; IEA:InterPro.
DR   GO; GO:0006816; P:calcium ion transport; IEA:UniProtKB-KW.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IDA:MGI.
DR   GO; GO:0006984; P:ER-nuclear signaling pathway; IMP:MGI.
DR   GO; GO:0045822; P:negative regulation of heart contraction; IGI:MGI.
DR   GO; GO:0006937; P:regulation of muscle contraction; TAS:MGI.
DR   GO; GO:0002026; P:regulation of the force of heart contraction; IGI:MGI.
DR   InterPro; IPR008250; ATPase_P-typ_ATPase-assoc-dom.
DR   InterPro; IPR005782; ATPase_P-typ_Ca-transp.
DR   InterPro; IPR006068; ATPase_P-typ_cation-transptr_C.
DR   InterPro; IPR004014; ATPase_P-typ_cation-transptr_N.
DR   InterPro; IPR000695; ATPase_P-typ_H-transp.
DR   InterPro; IPR001757; ATPase_P-typ_ion-transptr.
DR   InterPro; IPR018303; ATPase_P-typ_P_site.
DR   InterPro; IPR005834; Dehalogen-like_hydro.
DR   PANTHER; PTHR11939; ATPase_P; 1.
DR   Pfam; PF00689; Cation_ATPase_C; 1.
DR   Pfam; PF00690; Cation_ATPase_N; 1.
DR   Pfam; PF00122; E1-E2_ATPase; 1.
DR   Pfam; PF00702; Hydrolase; 1.
DR   PRINTS; PR00119; CATATPASE.
DR   PRINTS; PR00120; HATPASE.
DR   SMART; SM00831; Cation_ATPase_N; 1.
DR   TIGRFAMs; TIGR01116; ATPase-IIA1_Ca; 1.
DR   TIGRFAMs; TIGR01494; ATPase_P-type; 4.
DR   PROSITE; PS00154; ATPASE_E1_E2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; ATP-binding; Calcium;
KW   Calcium transport; Direct protein sequencing; Endoplasmic reticulum;
KW   Hydrolase; Ion transport; Isopeptide bond; Magnesium; Membrane;
KW   Metal-binding; Nitration; Nucleotide-binding; Phosphoprotein;
KW   Sarcoplasmic reticulum; Transmembrane; Transport; Ubl conjugation.
FT   CHAIN         1   1044       Sarcoplasmic/endoplasmic reticulum
FT                                calcium ATPase 2.
FT                                /FTId=PRO_0000046197.
FT   TOPO_DOM      1     48       Cytoplasmic (By similarity).
FT   TRANSMEM     49     69       1 (By similarity).
FT   TOPO_DOM     70     89       Lumenal (By similarity).
FT   TRANSMEM     90    110       2 (By similarity).
FT   TOPO_DOM    111    253       Cytoplasmic (By similarity).
FT   TRANSMEM    254    273       3 (By similarity).
FT   TOPO_DOM    274    295       Lumenal (By similarity).
FT   TRANSMEM    296    313       4 (By similarity).
FT   TOPO_DOM    314    756       Cytoplasmic (By similarity).
FT   TRANSMEM    757    776       5 (By similarity).
FT   TOPO_DOM    777    786       Lumenal (By similarity).
FT   TRANSMEM    787    807       6 (By similarity).
FT   TOPO_DOM    808    827       Cytoplasmic (By similarity).
FT   TRANSMEM    828    850       7 (By similarity).
FT   TOPO_DOM    851    896       Lumenal (By similarity).
FT   TRANSMEM    897    916       8 (By similarity).
FT   TOPO_DOM    917    929       Cytoplasmic (By similarity).
FT   TRANSMEM    930    948       9 (By similarity).
FT   TOPO_DOM    949    963       Lumenal (By similarity).
FT   TRANSMEM    964    984       10 (By similarity).
FT   TOPO_DOM    985   1044       Cytoplasmic (By similarity).
FT   REGION      370    400       Interacts with phospholamban 1 (By
FT                                similarity).
FT   REGION      575    594       Interacts with HAX1 (By similarity).
FT   REGION      787    807       Interacts with phospholamban 2 (By
FT                                similarity).
FT   ACT_SITE    351    351       4-aspartylphosphate intermediate (By
FT                                similarity).
FT   METAL       304    304       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       305    305       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       307    307       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       309    309       Calcium 2 (By similarity).
FT   METAL       702    702       Magnesium (By similarity).
FT   METAL       706    706       Magnesium (By similarity).
FT   METAL       767    767       Calcium 1 (By similarity).
FT   METAL       770    770       Calcium 1 (By similarity).
FT   METAL       795    795       Calcium 2 (By similarity).
FT   METAL       798    798       Calcium 1 (By similarity).
FT   METAL       799    799       Calcium 1 (By similarity).
FT   METAL       799    799       Calcium 2 (By similarity).
FT   METAL       907    907       Calcium 1 (By similarity).
FT   MOD_RES     294    294       Nitrated tyrosine (By similarity).
FT   MOD_RES     295    295       Nitrated tyrosine (By similarity).
FT   MOD_RES     464    464       N6-acetyllysine (By similarity).
FT   MOD_RES     537    537       Phosphothreonine.
FT   MOD_RES     663    663       Phosphoserine.
FT   CROSSLNK    143    143       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   VAR_SEQ     995   1044       GKECVQPATKSSCSLSACTDGISWPFVLLIMPLVVWVYSTD
FT                                TNFSDMFWS -> AILE (in isoform SERCA2A).
FT                                /FTId=VSP_000359.
SQ   SEQUENCE   1044 AA;  114858 MW;  06A753982116C421 CRC64;
     MENAHTKTVE EVLGHFGVNE STGLSLEQVK KLKERWGSNE LPAEEGKTLL ELVIEQFEDL
     LVRILLLAAC ISFVLAWFEE GEETITAFVE PFVILLILVA NAIVGVWQER NAENAIEALK
     EYEPEMGKVY RQDRKSVQRI KAKDIVPGDI VEIAVGDKVP ADIRLTSIKS TTLRVDQSIL
     TGESVSVIKH TDPVPDPRAV NQDKKNMLFS GTNIAAGKAM GVVVATGVNT EIGKIRDEMV
     ATEQERTPLQ QKLDEFGEQL SKVISLICIA VWIINIGHFN DPVHGGSWIR GAIYYFKIAV
     ALAVAAIPEG LPAVITTCLA LGTRRMAKKN AIVRSLPSVE TLGCTSVICS DKTGTLTTNQ
     MSVCRMFILD KVEGDTCSLN EFSITGSTYA PIGEVQKDDK PVKCHQYDGL VELATICALC
     NDSALDYNEA KGVYEKVGEA TETALTCLVE KMNVFDTELK GLSKIERANA CNSVIKQLMK
     KEFTLEFSRD RKSMSVYCTP NKPSRTSMSK MFVKGAPEGV IDRCTHIRVG STKVPMTPGV
     KQKIMSVIRE WGSGSDTLRC LALATHDNPL KREEMHLEDS ANFIKYETNL TFVGCVGMLD
     PPRIEVASSV KLCRQAGIRV IMITGDNKGT AVAICRRIGI FGQDEDVTSK AFTGREFDEL
     SPSAQRDACL NARCFARVEP SHKSKIVEFL QSFDEITAMT GDGVNDAPAL KKSEIGIAMG
     SGTAVAKTAS EMVLADDNFS TIVAAVEEGR AIYNNMKQFI RYLISSNVGE VVCIFLTAAL
     GFPEALIPVQ LLWVNLVTDG LPATALGFNP PDLDIMNKPP RNPKEPLISG WLFFRYLAIG
     CYVGAATVGA AAWWFIAADG GPRVSFYQLS HFLQCKEDNP DFDGVDCAIF ESPYPMTMAL
     SVLVTIEMCN ALNSLSENQS LLRMPPWENI WLVGSICLSM SLHFLILYVE PLPLIFQITP
     LNLTQWLMVL KISLPVILMD ETLKFVARNY LEQPGKECVQ PATKSSCSLS ACTDGISWPF
     VLLIMPLVVW VYSTDTNFSD MFWS
//
ID   AT2A2_RABIT             Reviewed;        1042 AA.
AC   P20647; P04192;
DT   20-MAR-1987, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1999, sequence version 2.
DT   02-MAR-2010, entry version 103.
DE   RecName: Full=Sarcoplasmic/endoplasmic reticulum calcium ATPase 2;
DE            Short=SR Ca(2+)-ATPase 2;
DE            Short=SERCA2;
DE            EC=3.6.3.8;
DE   AltName: Full=Calcium pump 2;
DE   AltName: Full=Calcium-transporting ATPase sarcoplasmic reticulum type, slow twitch skeletal muscle isoform;
DE   AltName: Full=Endoplasmic reticulum class 1/2 Ca(2+) ATPase;
GN   Name=ATP2A2;
OS   Oryctolagus cuniculus (Rabbit).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Lagomorpha; Leporidae;
OC   Oryctolagus.
OX   NCBI_TaxID=9986;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SERCA2B).
RC   TISSUE=Smooth muscle;
RX   MEDLINE=89214129; PubMed=2523389;
RA   Lytton J., Zarain-Herzberg A., Periasamy M., McLennan D.H.;
RT   "Molecular cloning of the mammalian smooth muscle sarco(endo)plasmic
RT   reticulum Ca2+-ATPase.";
RL   J. Biol. Chem. 264:7059-7065(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SERCA2B).
RC   TISSUE=Smooth muscle;
RX   MEDLINE=90326561; PubMed=2165260; DOI=10.1093/nar/18.13.4026;
RA   Khan I., Grover A.K.;
RT   "Cloning of internal Ca pump from rabbit stomach smooth muscle.";
RL   Nucleic Acids Res. 18:4026-4026(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SERCA2A).
RX   MEDLINE=85296300; PubMed=2993904; DOI=10.1038/316696a0;
RA   McLennan D.H., Brandl C.J., Korczak B., Green N.M.;
RT   "Amino-acid sequence of a Ca2+ + Mg2+-dependent ATPase from rabbit
RT   muscle sarcoplasmic reticulum, deduced from its complementary DNA
RT   sequence.";
RL   Nature 316:696-700(1985).
CC   -!- FUNCTION: This magnesium-dependent enzyme catalyzes the hydrolysis
CC       of ATP coupled with the translocation of calcium from the cytosol
CC       to the sarcoplasmic reticulum lumen. Isoform SERCA2A is involved
CC       in the regulation of the contraction/relaxation cycle.
CC   -!- CATALYTIC ACTIVITY: ATP + H(2)O + Ca(2+)(Cis) = ADP + phosphate +
CC       Ca(2+)(Trans).
CC   -!- ENZYME REGULATION: Reversibly inhibited by phospholamban (PLN) at
CC       low calcium concentrations. Dephosphorylated PLN decreases the
CC       apparent affinity of the ATPase for calcium. This inhibition is
CC       regulated by the phosphorylation of PLN.
CC   -!- SUBUNIT: Associated with phospholamban (PLN). Isoform SERCA2B
CC       interacts with TRAM2 (via C-terminus). Interacts with HAX1 (By
CC       similarity).
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Multi-pass
CC       membrane protein. Sarcoplasmic reticulum membrane; Multi-pass
CC       membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=SERCA2B; Synonyms=ATP2A2B;
CC         IsoId=P20647-1; Sequence=Displayed;
CC       Name=SERCA2A; Synonyms=ATP2A2A;
CC         IsoId=P20647-2; Sequence=VSP_000361;
CC   -!- TISSUE SPECIFICITY: Isoform SERCA2A is highly expressed in heart
CC       and slow twitch skeletal muscle. Isoform SERCA2B is widely
CC       expressed.
CC   -!- PTM: Nitrated under oxidative stress. Nitration on the two
CC       tyrosine residues inhibits catalytic activity (By similarity).
CC   -!- SIMILARITY: Belongs to the cation transport ATPase (P-type)
CC       family. Type IIA subfamily.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J04703; AAA31150.1; -; mRNA.
DR   EMBL; X52496; CAA36737.1; -; mRNA.
DR   EMBL; X02814; CAA26583.1; -; mRNA.
DR   PIR; A01076; PWRBSC.
DR   PIR; A33881; A33881.
DR   PIR; S10335; PWRBMC.
DR   RefSeq; NP_001082789.1; -.
DR   RefSeq; NP_001082790.1; -.
DR   UniGene; Ocu.3251; -.
DR   UniGene; Ocu.6938; -.
DR   SMR; P20647; 1-992.
DR   STRING; P20647; -.
DR   GeneID; 100037721; -.
DR   GeneID; 100038308; -.
DR   CTD; 100037721; -.
DR   HOVERGEN; HBG105648; -.
DR   BRENDA; 3.6.3.8; 255.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0033017; C:sarcoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005509; F:calcium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005388; F:calcium-transporting ATPase activity; IEA:EC.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006754; P:ATP biosynthetic process; IEA:InterPro.
DR   GO; GO:0006816; P:calcium ion transport; IEA:UniProtKB-KW.
DR   InterPro; IPR008250; ATPase_P-typ_ATPase-assoc-dom.
DR   InterPro; IPR005782; ATPase_P-typ_Ca-transp.
DR   InterPro; IPR006068; ATPase_P-typ_cation-transptr_C.
DR   InterPro; IPR004014; ATPase_P-typ_cation-transptr_N.
DR   InterPro; IPR000695; ATPase_P-typ_H-transp.
DR   InterPro; IPR001757; ATPase_P-typ_ion-transptr.
DR   InterPro; IPR018303; ATPase_P-typ_P_site.
DR   InterPro; IPR005834; Dehalogen-like_hydro.
DR   PANTHER; PTHR11939; ATPase_P; 1.
DR   Pfam; PF00689; Cation_ATPase_C; 1.
DR   Pfam; PF00690; Cation_ATPase_N; 1.
DR   Pfam; PF00122; E1-E2_ATPase; 1.
DR   Pfam; PF00702; Hydrolase; 1.
DR   PRINTS; PR00119; CATATPASE.
DR   PRINTS; PR00120; HATPASE.
DR   SMART; SM00831; Cation_ATPase_N; 1.
DR   TIGRFAMs; TIGR01116; ATPase-IIA1_Ca; 1.
DR   TIGRFAMs; TIGR01494; ATPase_P-type; 4.
DR   PROSITE; PS00154; ATPASE_E1_E2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; ATP-binding; Calcium;
KW   Calcium transport; Endoplasmic reticulum; Hydrolase; Ion transport;
KW   Isopeptide bond; Magnesium; Membrane; Metal-binding; Nitration;
KW   Nucleotide-binding; Phosphoprotein; Sarcoplasmic reticulum;
KW   Transmembrane; Transport; Ubl conjugation.
FT   CHAIN         1   1042       Sarcoplasmic/endoplasmic reticulum
FT                                calcium ATPase 2.
FT                                /FTId=PRO_0000046199.
FT   TOPO_DOM      1     48       Cytoplasmic (By similarity).
FT   TRANSMEM     49     69       1 (By similarity).
FT   TOPO_DOM     70     89       Lumenal (By similarity).
FT   TRANSMEM     90    110       2 (By similarity).
FT   TOPO_DOM    111    253       Cytoplasmic (By similarity).
FT   TRANSMEM    254    273       3 (By similarity).
FT   TOPO_DOM    274    295       Lumenal (By similarity).
FT   TRANSMEM    296    313       4 (By similarity).
FT   TOPO_DOM    314    756       Cytoplasmic (By similarity).
FT   TRANSMEM    757    776       5 (By similarity).
FT   TOPO_DOM    777    786       Lumenal (By similarity).
FT   TRANSMEM    787    807       6 (By similarity).
FT   TOPO_DOM    808    827       Cytoplasmic (By similarity).
FT   TRANSMEM    828    850       7 (By similarity).
FT   TOPO_DOM    851    896       Lumenal (By similarity).
FT   TRANSMEM    897    916       8 (By similarity).
FT   TOPO_DOM    917    929       Cytoplasmic (By similarity).
FT   TRANSMEM    930    948       9 (By similarity).
FT   TOPO_DOM    949    963       Lumenal (By similarity).
FT   TRANSMEM    964    984       10 (By similarity).
FT   TOPO_DOM    985   1042       Cytoplasmic (By similarity).
FT   REGION      370    400       Interacts with phospholamban 1 (By
FT                                similarity).
FT   REGION      575    594       Interacts with HAX1 (By similarity).
FT   REGION      787    807       Interacts with phospholamban 2 (By
FT                                similarity).
FT   ACT_SITE    351    351       4-aspartylphosphate intermediate (By
FT                                similarity).
FT   METAL       304    304       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       305    305       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       307    307       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       309    309       Calcium 2 (By similarity).
FT   METAL       702    702       Magnesium (By similarity).
FT   METAL       706    706       Magnesium (By similarity).
FT   METAL       767    767       Calcium 1 (By similarity).
FT   METAL       770    770       Calcium 1 (By similarity).
FT   METAL       795    795       Calcium 2 (By similarity).
FT   METAL       798    798       Calcium 1 (By similarity).
FT   METAL       799    799       Calcium 1 (By similarity).
FT   METAL       799    799       Calcium 2 (By similarity).
FT   METAL       907    907       Calcium 1 (By similarity).
FT   MOD_RES     294    294       Nitrated tyrosine.
FT   MOD_RES     295    295       Nitrated tyrosine.
FT   MOD_RES     464    464       N6-acetyllysine (By similarity).
FT   MOD_RES     537    537       Phosphothreonine (By similarity).
FT   MOD_RES     663    663       Phosphoserine (By similarity).
FT   CROSSLNK    143    143       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
FT   VAR_SEQ     994   1042       GKECVQPAPQSCSLWACTEGVSWPFVLLIVPLVMWVYSTDT
FT                                NFSDLLWS -> AILE (in isoform SERCA2A).
FT                                /FTId=VSP_000361.
FT   CONFLICT    578    578       K -> E (in Ref. 1; AAA31150).
SQ   SEQUENCE   1042 AA;  114705 MW;  4243836D67431575 CRC64;
     MENAHTKTVE EVLGHFGVNE STGLSLEQVK KLKERWGSNE LPAEEGKTLL ELVIEQFEDL
     LVRILLLAAC ISFVLAWFEE GEETITAFVE PFVILLILVA NAIVGVWQER NAENAIEALK
     EYEPEMGKVY RQDRKSVQRI KAKDIVPGDI VEIAVGDKVP ADIRLTSIKS TTLRVDQSIL
     TGESVSVIKH TDPVPDPRAV NQDKKNMLFS GTNIAAGKAM GVVVATGVNT EIGKIRDEMV
     ATEQERTPLQ QKLDEFGEQL SKVISLICIA VWIINIGHFN DPVHGGSWIR GAIYYFKIAV
     ALAVAAIPEG LPAVITTCLA LGTRRMAKKN AIVRSLPSVE TLGCTSVICS DKTGTLTTNQ
     MSVCRMFILD KVDGDTCSLN EFTITGSTYA PIGEVHKDDK PVKCHQYDGL VELATICALC
     NDSALDYNEA KGVYEKVGEA TETALTCLVE KMNVFDTELK GLSKIERANA CNSVIKQLMK
     KEFTLEFSRD RKSMSVYCTP NKPSRTSMSK MFVKGAPEGV IDRCTHIRVG STKVPMTAGV
     KQKIMSVIRE WGSGSDTLRC LALATHDNPL RREEMHLKDS ANFIKYETNL TFVGCVGMLD
     PPRIEVASSV KLCRQAGIRV IMITGDNKGT AVAICRRIGI FGQEEDVTAK AFTGREFDEL
     NPSAQRDACL NARCFARVEP SHKSKIVEFL QSFDEITAMT GDGVNDAPAL KKAEIGIAMG
     SGTAVAKTAS EMVLADDNFS TIVAAVEEGR AIYNNMKQFI RYLISSNVGE VVCIFLTAAL
     GFPEALIPVQ LLWVNLVTDG LPATALGFNP PDLDIMNKPP RNPKEPLISG WLFFRYLAIG
     CYVGAATVGA AAWWFIAADG GPRVSFYQLS HFLQCKEDNP DFEGVDCAIF ESPYPMTMAL
     SVLVTIEMCN ALNSLSENQS LLRMPPWENI WLVGSICLSM SLHFLILYVE PLPLIFQITP
     LNVTQWLMVL KISLPVILMD ETLKFVARNY LEPGKECVQP APQSCSLWAC TEGVSWPFVL
     LIVPLVMWVY STDTNFSDLL WS
//
ID   AT2A2_RAT               Reviewed;        1043 AA.
AC   P11507; P11508;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1989, sequence version 1.
DT   02-MAR-2010, entry version 108.
DE   RecName: Full=Sarcoplasmic/endoplasmic reticulum calcium ATPase 2;
DE            Short=SR Ca(2+)-ATPase 2;
DE            Short=SERCA2;
DE            EC=3.6.3.8;
DE   AltName: Full=Calcium pump 2;
DE   AltName: Full=Calcium-transporting ATPase sarcoplasmic reticulum type, slow twitch skeletal muscle isoform;
DE   AltName: Full=Endoplasmic reticulum class 1/2 Ca(2+) ATPase;
GN   Name=Atp2a2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS SERCA2A AND SERCA2B).
RC   TISSUE=Brain;
RX   MEDLINE=89008385; PubMed=2844797;
RA   Gunteski-Hamblin A.-M., Greeb J., Shull G.E.;
RT   "A novel Ca2+ pump expressed in brain, kidney, and stomach is encoded
RT   by an alternative transcript of the slow-twitch muscle sarcoplasmic
RT   reticulum Ca-ATPase gene. Identification of cDNAs encoding Ca2+ and
RT   other cation-transporting ATPases using an oligonucleotide probe
RT   derived from the ATP-binding site.";
RL   J. Biol. Chem. 263:15032-15040(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SERCA2A).
RC   TISSUE=Heart;
RX   MEDLINE=89252068; PubMed=2542094; DOI=10.1016/0014-5793(89)80010-9;
RA   Lompre A.M., de la Bastie D., Boheler K.R., Schwartz K.;
RT   "Characterization and expression of the rat heart sarcoplasmic
RT   reticulum Ca2+-ATPase mRNA.";
RL   FEBS Lett. 249:35-41(1989).
RN   [3]
RP   NITRATION.
RX   PubMed=10359649; DOI=10.1042/0264-6021:3400657;
RA   Viner R.I., Ferrington D.A., Williams T.D., Bigelow D.J.,
RA   Schoeneich C.;
RT   "Protein modification during biological aging: selective tyrosine
RT   nitration of the SERCA2a isoform of the sarcoplasmic reticulum Ca2+-
RT   ATPase in skeletal muscle.";
RL   Biochem. J. 340:657-669(1999).
RN   [4]
RP   NITRATION AT TYR-294 AND TYR-295.
RX   PubMed=16399855; DOI=10.1152/ajpheart.01293.2005;
RA   Xu S., Ying J., Jiang B., Guo W., Adachi T., Sharov V., Lazar H.,
RA   Menzoian J., Knyushko T.V., Bigelow D., Schoeneich C., Cohen R.A.;
RT   "Detection of sequence-specific tyrosine nitration of manganese SOD
RT   and SERCA in cardiovascular disease and aging.";
RL   Am. J. Physiol. 290:H2220-H2227(2006).
CC   -!- FUNCTION: This magnesium-dependent enzyme catalyzes the hydrolysis
CC       of ATP coupled with the translocation of calcium from the cytosol
CC       to the sarcoplasmic reticulum lumen. Isoform SERCA2A is involved
CC       in the regulation of the contraction/relaxation cycle (By
CC       similarity).
CC   -!- CATALYTIC ACTIVITY: ATP + H(2)O + Ca(2+)(Cis) = ADP + phosphate +
CC       Ca(2+)(Trans).
CC   -!- ENZYME REGULATION: Reversibly inhibited by phospholamban (PLN) at
CC       low calcium concentrations. Dephosphorylated PLN decreases the
CC       apparent affinity of the ATPase for calcium. This inhibition is
CC       regulated by the phosphorylation of PLN (By similarity).
CC   -!- SUBUNIT: Associated with phospholamban (PLN) (By similarity).
CC       Isoform SERCA2B interacts with TRAM2 (via C-terminus). Interacts
CC       with HAX1 (By similarity).
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Multi-pass
CC       membrane protein. Sarcoplasmic reticulum membrane; Multi-pass
CC       membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=SERCA2B; Synonyms=ATP2A2B;
CC         IsoId=P11507-1; Sequence=Displayed;
CC       Name=SERCA2A; Synonyms=ATP2A2A;
CC         IsoId=P11507-2; Sequence=VSP_000362;
CC   -!- TISSUE SPECIFICITY: Isoform SERCA2A is highly expressed in heart
CC       and slow twitch skeletal muscle. Isoform SERCA2B is widely
CC       expressed.
CC   -!- PTM: Nitrated under oxidative stress. Nitration on the two
CC       tyrosine residues inhibits catalytic activity (By similarity).
CC   -!- SIMILARITY: Belongs to the cation transport ATPase (P-type)
CC       family. Type IIA subfamily.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J04022; AAA40785.1; -; mRNA.
DR   EMBL; J04024; AAA40787.1; -; mRNA.
DR   EMBL; J04023; AAA40786.1; -; mRNA.
DR   EMBL; X15635; CAA33645.1; -; mRNA.
DR   IPI; IPI00190020; -.
DR   IPI; IPI00231369; -.
DR   PIR; A31982; A31982.
DR   PIR; B31982; B31982.
DR   RefSeq; NP_001103609.1; -.
DR   RefSeq; NP_001104293.1; -.
DR   UniGene; Rn.2305; -.
DR   SMR; P11507; 1-992.
DR   STRING; P11507; -.
DR   PhosphoSite; P11507; -.
DR   PRIDE; P11507; -.
DR   Ensembl; ENSRNOT00000024347; ENSRNOP00000024347; ENSRNOG00000001285; Rattus norvegicus.
DR   GeneID; 29693; -.
DR   KEGG; rno:29693; -.
DR   CTD; 29693; -.
DR   RGD; 2174; Atp2a2.
DR   eggNOG; maNOG06423; -.
DR   HOVERGEN; HBG105648; -.
DR   InParanoid; P11507; -.
DR   PhylomeDB; P11507; -.
DR   BRENDA; 3.6.3.8; 248.
DR   NextBio; 610084; -.
DR   ArrayExpress; P11507; -.
DR   Genevestigator; P11507; -.
DR   GermOnline; ENSRNOG00000001285; Rattus norvegicus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0043234; C:protein complex; IDA:RGD.
DR   GO; GO:0033017; C:sarcoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IDA:RGD.
DR   GO; GO:0005509; F:calcium ion binding; IDA:RGD.
DR   GO; GO:0005388; F:calcium-transporting ATPase activity; IDA:RGD.
DR   GO; GO:0031775; F:lutropin-choriogonadotropic hormone recepto...; IPI:RGD.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0006754; P:ATP biosynthetic process; IEA:InterPro.
DR   GO; GO:0006816; P:calcium ion transport; IDA:RGD.
DR   GO; GO:0006937; P:regulation of muscle contraction; TAS:RGD.
DR   GO; GO:0043434; P:response to peptide hormone stimulus; IDA:UniProtKB.
DR   InterPro; IPR008250; ATPase_P-typ_ATPase-assoc-dom.
DR   InterPro; IPR005782; ATPase_P-typ_Ca-transp.
DR   InterPro; IPR006068; ATPase_P-typ_cation-transptr_C.
DR   InterPro; IPR004014; ATPase_P-typ_cation-transptr_N.
DR   InterPro; IPR000695; ATPase_P-typ_H-transp.
DR   InterPro; IPR001757; ATPase_P-typ_ion-transptr.
DR   InterPro; IPR018303; ATPase_P-typ_P_site.
DR   InterPro; IPR005834; Dehalogen-like_hydro.
DR   PANTHER; PTHR11939; ATPase_P; 1.
DR   Pfam; PF00689; Cation_ATPase_C; 1.
DR   Pfam; PF00690; Cation_ATPase_N; 1.
DR   Pfam; PF00122; E1-E2_ATPase; 1.
DR   Pfam; PF00702; Hydrolase; 1.
DR   PRINTS; PR00119; CATATPASE.
DR   PRINTS; PR00120; HATPASE.
DR   SMART; SM00831; Cation_ATPase_N; 1.
DR   TIGRFAMs; TIGR01116; ATPase-IIA1_Ca; 1.
DR   TIGRFAMs; TIGR01494; ATPase_P-type; 4.
DR   PROSITE; PS00154; ATPASE_E1_E2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; ATP-binding; Calcium;
KW   Calcium transport; Endoplasmic reticulum; Hydrolase; Ion transport;
KW   Isopeptide bond; Magnesium; Membrane; Metal-binding; Nitration;
KW   Nucleotide-binding; Phosphoprotein; Sarcoplasmic reticulum;
KW   Transmembrane; Transport; Ubl conjugation.
FT   CHAIN         1   1043       Sarcoplasmic/endoplasmic reticulum
FT                                calcium ATPase 2.
FT                                /FTId=PRO_0000046200.
FT   TOPO_DOM      1     48       Cytoplasmic (By similarity).
FT   TRANSMEM     49     69       1 (By similarity).
FT   TOPO_DOM     70     89       Lumenal (By similarity).
FT   TRANSMEM     90    110       2 (By similarity).
FT   TOPO_DOM    111    253       Cytoplasmic (By similarity).
FT   TRANSMEM    254    273       3 (By similarity).
FT   TOPO_DOM    274    295       Lumenal (By similarity).
FT   TRANSMEM    296    313       4 (By similarity).
FT   TOPO_DOM    314    756       Cytoplasmic (By similarity).
FT   TRANSMEM    757    776       5 (By similarity).
FT   TOPO_DOM    777    786       Lumenal (By similarity).
FT   TRANSMEM    787    807       6 (By similarity).
FT   TOPO_DOM    808    827       Cytoplasmic (By similarity).
FT   TRANSMEM    828    850       7 (By similarity).
FT   TOPO_DOM    851    896       Lumenal (By similarity).
FT   TRANSMEM    897    916       8 (By similarity).
FT   TOPO_DOM    917    929       Cytoplasmic (By similarity).
FT   TRANSMEM    930    948       9 (By similarity).
FT   TOPO_DOM    949    963       Lumenal (By similarity).
FT   TRANSMEM    964    984       10 (By similarity).
FT   TOPO_DOM    985   1043       Cytoplasmic (By similarity).
FT   REGION      370    400       Interacts with phospholamban 1 (By
FT                                similarity).
FT   REGION      575    594       Interacts with HAX1 (By similarity).
FT   REGION      787    807       Interacts with phospholamban 2 (By
FT                                similarity).
FT   ACT_SITE    351    351       4-aspartylphosphate intermediate (By
FT                                similarity).
FT   METAL       304    304       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       305    305       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       307    307       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       309    309       Calcium 2 (By similarity).
FT   METAL       702    702       Magnesium (By similarity).
FT   METAL       706    706       Magnesium (By similarity).
FT   METAL       767    767       Calcium 1 (By similarity).
FT   METAL       770    770       Calcium 1 (By similarity).
FT   METAL       795    795       Calcium 2 (By similarity).
FT   METAL       798    798       Calcium 1 (By similarity).
FT   METAL       799    799       Calcium 1 (By similarity).
FT   METAL       799    799       Calcium 2 (By similarity).
FT   METAL       907    907       Calcium 1 (By similarity).
FT   MOD_RES     294    294       Nitrated tyrosine.
FT   MOD_RES     295    295       Nitrated tyrosine.
FT   MOD_RES     464    464       N6-acetyllysine (By similarity).
FT   MOD_RES     537    537       Phosphothreonine (By similarity).
FT   MOD_RES     663    663       Phosphoserine (By similarity).
FT   CROSSLNK    143    143       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
FT   VAR_SEQ     994   1043       GKECAQPATKPSCSLSACTDGISWPFVLLIMPLVVWVYSTD
FT                                TNFSDMFWS -> AILE (in isoform SERCA2A).
FT                                /FTId=VSP_000362.
FT   CONFLICT    272    272       W -> T (in Ref. 2).
FT   CONFLICT    288    288       W -> T (in Ref. 2).
FT   CONFLICT    557    557       T -> Q (in Ref. 2).
SQ   SEQUENCE   1043 AA;  114768 MW;  4B0B476BFD97F390 CRC64;
     MENAHTKTVE EVLGHFGVNE STGLSLEQVK KLKERWGSNE LPAEEGKTLL ELVIEQFEDL
     LVRILLLAAC ISFVLAWFEE GEETITAFVE PFVILLILVA NAIVGVWQER NAENAIEALK
     EYEPEMGKVY RQDRKSVQRI KAKDIVPGDI VEIAVGDKVP ADIRLTSIKS TTLRVDQSIL
     TGESVSVIKH TDPVPDPRAV NQDKKNMLFS GTNIAAGKAM GVVVATGVNT EIGKIRDEMV
     ATEQERTPLQ QKLDEFGEQL SKVISLICIA VWIINIGHFN DPVHGGSWIR GAIYYFKIAV
     ALAVAAIPEG LPAVITTCLA LGTRRMAKKN AIVRSLPSVE TLGCTSVICS DKTGTLTTNQ
     MSVCRMFILD KVEGDTCSLN EFTITGSTYA PIGEVQKDDK PVKCHQYDGL VELATICALC
     NDSALDYNEA KGVYEKVGEA TETALTCLVE KMNVFDTELK GLSKIERANA CNSVIKQLMK
     KEFTLEFSRD RKSMSVYCTP NKPSRTSMSK MFVKGAPEGV IDRCTHIRVG STKVPMTPGV
     KQKIMSVIRE WGSGSDTLRC LALATHDNPL RREEMHLEDS ANFIKYETNL TFVGCVGMLD
     PPRIEVASSV KLCRQAGIRV IMITGDNKGT AVAICRRIGI FGQDEDVTSK AFTGREFDEL
     SPSAQRDACL NARCFARVEP SHKSKIVEFL QSFDEITAMT GDGVNDAPAL KKSEIGIAMG
     SGTAVAKTAS EMVLADDNFS TIVAAVEEGR AIYNNMKQFI RYLISSNVGE VVCIFLTAAL
     GFPEALIPVQ LLWVNLVTDG LPATALGFNP PDLDIMNKPP RNPKEPLISG WLFFRYLAIG
     CYVGAATVGA AAWWFIAADG GPRVSFYQLS HFLQCKEDNP DFEGVDCAIF ESPYPMTMAL
     SVLVTIEMCN ALNSLSENQS LLRMPPWENI WLVGSICLSM SLHFLILYVE PLPLIFQITP
     LNLTQWLMVL KISLPVILMD ETLKFVARNY LEPGKECAQP ATKPSCSLSA CTDGISWPFV
     LLIMPLVVWV YSTDTNFSDM FWS
//
ID   AT2A3_HUMAN             Reviewed;        1043 AA.
AC   Q93084; A8MZG0; O60900; O60901; O75501; O75502; Q16115; Q8TEX5;
AC   Q8TEX6;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   18-OCT-2001, sequence version 2.
DT   02-MAR-2010, entry version 106.
DE   RecName: Full=Sarcoplasmic/endoplasmic reticulum calcium ATPase 3;
DE            Short=SR Ca(2+)-ATPase 3;
DE            Short=SERCA3;
DE            EC=3.6.3.8;
DE   AltName: Full=Calcium pump 3;
GN   Name=ATP2A3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM SERCA3A).
RC   TISSUE=Leukemic T-cell;
RX   MEDLINE=96404924; PubMed=8809064;
RA   Dode L., Wuytack F., Kools P.F.J., Baba-Aissa F., Raeymaekers L.,
RA   Brik F., van de Ven W.J.M., Casteels R.;
RT   "cDNA cloning, expression and chromosomal localization of the human
RT   sarco/endoplasmic reticulum Ca(2+)-ATPase 3 gene.";
RL   Biochem. J. 318:689-699(1996).
RN   [2]
RP   ERRATUM.
RA   Dode L., Wuytack F., Kools P.F.J., Baba-Aissa F., Raeymaekers L.,
RA   Brik F., van de Ven W.J.M., Casteels R.;
RL   Biochem. J. 319:1008-1008(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS SERCA3B AND SERCA3C).
RX   MEDLINE=98256332; PubMed=9593748; DOI=10.1074/jbc.273.22.13982;
RA   Dode L., De Greef C., Mountian I., Attard M., Town M.M., Casteels R.,
RA   Wuytack F.;
RT   "Structure of the human sarco/endoplasmic reticulum Ca2+-ATPase 3
RT   gene. Promoter analysis and alternative splicing of the SERCA3 pre-
RT   mRNA.";
RL   J. Biol. Chem. 273:13982-13994(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS SERCA3A; SERCA3C AND SERCA3D).
RC   TISSUE=Kidney, and Leukemic T-cell;
RX   MEDLINE=99061551; PubMed=9843705;
RA   Poch E., Leach S., Snape S., Cacic T., McLennan D.H., Lytton J.;
RT   "Functional characterization of alternatively spliced human SERCA3
RT   transcripts.";
RL   Am. J. Physiol. 275:C1449-C1458(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SERCA3A).
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 1-14, AND ACETYLATION AT MET-1.
RC   TISSUE=Platelet;
RX   MEDLINE=22608298; PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [9]
RP   PROTEIN SEQUENCE OF 1-33; 111-120; 219-234; 482-489; 516-524; 549-560
RP   AND 657-667, ACETYLATION AT MET-1, AND MASS SPECTROMETRY.
RC   TISSUE=Platelet;
RA   Bienvenut W.V., Claeys D.;
RL   Submitted (NOV-2005) to UniProtKB.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 454-509.
RX   MEDLINE=94117459; PubMed=8288608;
RA   Wuytack F., Papp B., Verboomen H., Raeymaekers L., Dode L., Bobe R.,
RA   Enouf J., Bokkala S., Authi K.S., Casteels R.;
RT   "A sarco/endoplasmic reticulum Ca(2+)-ATPase 3-type Ca2+ pump is
RT   expressed in platelets, in lymphoid cells, and in mast cells.";
RL   J. Biol. Chem. 269:1410-1416(1994).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 892-1043 (ISOFORMS SERCA3E AND SERCA3F).
RA   Martin V., Bredoux R., Corvazier E., van Gorp R., Kovacs T.,
RA   Gelebart P., Papp B., Enouf J.;
RT   "Splicing of sarco/endoplasmic reticulum Ca2+ ATPase 3 genes generates
RT   multiple and species-specific variants of Ca2+ transporting pumps.";
RL   Submitted (DEC-2001) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   VARIANT [LARGE SCALE ANALYSIS] HIS-674.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: This magnesium-dependent enzyme catalyzes the hydrolysis
CC       of ATP coupled with the transport of calcium. Transports calcium
CC       ions from the cytosol into the sarcoplasmic/endoplasmic reticulum
CC       lumen. Contributes to calcium sequestration involved in muscular
CC       excitation/contraction.
CC   -!- CATALYTIC ACTIVITY: ATP + H(2)O + Ca(2+)(Cis) = ADP + phosphate +
CC       Ca(2+)(Trans).
CC   -!- INTERACTION:
CC       P16333:NCK1; NbExp=1; IntAct=EBI-1046185, EBI-389883;
CC       Q9P2S5:WDR8; NbExp=1; IntAct=EBI-1046185, EBI-1054904;
CC   -!- SUBCELLULAR LOCATION: Nucleus membrane; Multi-pass membrane
CC       protein. Endoplasmic reticulum membrane; Multi-pass membrane
CC       protein. Sarcoplasmic reticulum membrane; Multi-pass membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC         Comment=The same names have been attributed to different
CC         isoforms;
CC       Name=SERCA3B;
CC         IsoId=Q93084-1; Sequence=Displayed;
CC       Name=SERCA3A; Synonyms=HuS3-II;
CC         IsoId=Q93084-2; Sequence=VSP_000364;
CC       Name=SERCA3C; Synonyms=HuS3-IV;
CC         IsoId=Q93084-3; Sequence=VSP_000366;
CC       Name=SERCA3D; Synonyms=HuS3-I;
CC         IsoId=Q93084-4; Sequence=VSP_000365;
CC       Name=SERCA3E;
CC         IsoId=Q93084-5; Sequence=VSP_000367;
CC       Name=SERCA3F;
CC         IsoId=Q93084-6; Sequence=VSP_000368;
CC   -!- TISSUE SPECIFICITY: Found in most tissues. Most abundant in
CC       thymus, trachea, salivary gland, spleen, bone marrow, lymph node,
CC       peripheral leukocytes, pancreas and colon. Also detected in fetal
CC       tissues.
CC   -!- SIMILARITY: Belongs to the cation transport ATPase (P-type)
CC       family. Type IIA subfamily.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z69881; CAA93737.1; -; mRNA.
DR   EMBL; Z69880; CAA93736.1; -; Genomic_DNA.
DR   EMBL; Y15724; CAA75739.1; -; Genomic_DNA.
DR   EMBL; Y15725; CAA75739.1; JOINED; Genomic_DNA.
DR   EMBL; Y15726; CAA75739.1; JOINED; Genomic_DNA.
DR   EMBL; Y15727; CAA75739.1; JOINED; Genomic_DNA.
DR   EMBL; Y15728; CAA75739.1; JOINED; Genomic_DNA.
DR   EMBL; Y15729; CAA75739.1; JOINED; Genomic_DNA.
DR   EMBL; Y15730; CAA75739.1; JOINED; Genomic_DNA.
DR   EMBL; Y15738; CAA75748.1; -; Genomic_DNA.
DR   EMBL; Y15737; CAA75747.1; -; Genomic_DNA.
DR   EMBL; AF068220; AAC24525.1; -; mRNA.
DR   EMBL; AF068221; AAC24526.1; -; mRNA.
DR   EMBL; AC005940; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471108; EAW90468.1; -; Genomic_DNA.
DR   EMBL; BC035729; AAH35729.1; -; mRNA.
DR   EMBL; S68239; AAB29700.1; -; mRNA.
DR   EMBL; AF458228; AAL78967.1; -; mRNA.
DR   EMBL; AF458229; AAL78968.1; -; mRNA.
DR   IPI; IPI00004092; -.
DR   IPI; IPI00218440; -.
DR   IPI; IPI00218442; -.
DR   IPI; IPI00303760; -.
DR   IPI; IPI00478023; -.
DR   IPI; IPI00748794; -.
DR   PIR; I55399; I55399.
DR   PIR; S72267; S72267.
DR   RefSeq; NP_005164.2; -.
DR   RefSeq; NP_777613.1; -.
DR   RefSeq; NP_777614.1; -.
DR   RefSeq; NP_777615.1; -.
DR   RefSeq; NP_777616.1; -.
DR   RefSeq; NP_777617.1; -.
DR   RefSeq; NP_777618.1; -.
DR   UniGene; Hs.513870; -.
DR   SMR; Q93084; 1-992.
DR   IntAct; Q93084; 6.
DR   STRING; Q93084; -.
DR   PRIDE; Q93084; -.
DR   Ensembl; ENST00000352011; ENSP00000301387; ENSG00000074370; Homo sapiens.
DR   GeneID; 489; -.
DR   KEGG; hsa:489; -.
DR   UCSC; uc002fwx.1; human.
DR   UCSC; uc002fwy.1; human.
DR   UCSC; uc002fwz.1; human.
DR   UCSC; uc002fxb.1; human.
DR   UCSC; uc002fxc.1; human.
DR   UCSC; uc002fxd.1; human.
DR   CTD; 489; -.
DR   GeneCards; GC17M003761; -.
DR   HGNC; HGNC:813; ATP2A3.
DR   HPA; CAB010882; -.
DR   HPA; HPA007180; -.
DR   MIM; 601929; gene.
DR   PharmGKB; PA25106; -.
DR   eggNOG; prNOG18350; -.
DR   HOVERGEN; HBG105648; -.
DR   PhylomeDB; Q93084; -.
DR   BRENDA; 3.6.3.8; 247.
DR   NextBio; 2037; -.
DR   ArrayExpress; Q93084; -.
DR   Bgee; Q93084; -.
DR   CleanEx; HS_ATP2A3; -.
DR   Genevestigator; Q93084; -.
DR   GermOnline; ENSG00000074370; Homo sapiens.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0031965; C:nuclear membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0033017; C:sarcoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005509; F:calcium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005388; F:calcium-transporting ATPase activity; TAS:ProtInc.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0006754; P:ATP biosynthetic process; IEA:InterPro.
DR   GO; GO:0006816; P:calcium ion transport; TAS:UniProtKB.
DR   InterPro; IPR008250; ATPase_P-typ_ATPase-assoc-dom.
DR   InterPro; IPR005782; ATPase_P-typ_Ca-transp.
DR   InterPro; IPR006068; ATPase_P-typ_cation-transptr_C.
DR   InterPro; IPR004014; ATPase_P-typ_cation-transptr_N.
DR   InterPro; IPR000695; ATPase_P-typ_H-transp.
DR   InterPro; IPR001757; ATPase_P-typ_ion-transptr.
DR   InterPro; IPR018303; ATPase_P-typ_P_site.
DR   InterPro; IPR005834; Dehalogen-like_hydro.
DR   PANTHER; PTHR11939; ATPase_P; 1.
DR   Pfam; PF00689; Cation_ATPase_C; 1.
DR   Pfam; PF00690; Cation_ATPase_N; 1.
DR   Pfam; PF00122; E1-E2_ATPase; 1.
DR   Pfam; PF00702; Hydrolase; 1.
DR   PRINTS; PR00119; CATATPASE.
DR   PRINTS; PR00120; HATPASE.
DR   SMART; SM00831; Cation_ATPase_N; 1.
DR   TIGRFAMs; TIGR01116; ATPase-IIA1_Ca; 1.
DR   TIGRFAMs; TIGR01494; ATPase_P-type; 4.
DR   PROSITE; PS00154; ATPASE_E1_E2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; ATP-binding; Calcium;
KW   Calcium transport; Complete proteome; Direct protein sequencing;
KW   Endoplasmic reticulum; Hydrolase; Ion transport; Magnesium; Membrane;
KW   Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Sarcoplasmic reticulum; Transmembrane; Transport.
FT   CHAIN         1   1043       Sarcoplasmic/endoplasmic reticulum
FT                                calcium ATPase 3.
FT                                /FTId=PRO_0000046202.
FT   TOPO_DOM      1     48       Cytoplasmic (By similarity).
FT   TRANSMEM     49     69       1 (By similarity).
FT   TOPO_DOM     70     89       Lumenal (By similarity).
FT   TRANSMEM     90    110       2 (By similarity).
FT   TOPO_DOM    111    253       Cytoplasmic (By similarity).
FT   TRANSMEM    254    273       3 (By similarity).
FT   TOPO_DOM    274    295       Lumenal (By similarity).
FT   TRANSMEM    296    313       4 (By similarity).
FT   TOPO_DOM    314    757       Cytoplasmic (By similarity).
FT   TRANSMEM    758    777       5 (By similarity).
FT   TOPO_DOM    778    787       Lumenal (By similarity).
FT   TRANSMEM    788    808       6 (By similarity).
FT   TOPO_DOM    809    828       Cytoplasmic (By similarity).
FT   TRANSMEM    829    851       7 (By similarity).
FT   TOPO_DOM    852    897       Lumenal (By similarity).
FT   TRANSMEM    898    917       8 (By similarity).
FT   TOPO_DOM    918    930       Cytoplasmic (By similarity).
FT   TRANSMEM    931    949       9 (By similarity).
FT   TOPO_DOM    950    964       Lumenal (By similarity).
FT   TRANSMEM    965    985       10 (By similarity).
FT   TOPO_DOM    986   1043       Cytoplasmic (By similarity).
FT   ACT_SITE    351    351       4-aspartylphosphate intermediate (By
FT                                similarity).
FT   METAL       304    304       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       305    305       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       307    307       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       309    309       Calcium 2 (By similarity).
FT   METAL       703    703       Magnesium (By similarity).
FT   METAL       707    707       Magnesium (By similarity).
FT   METAL       768    768       Calcium 1 (By similarity).
FT   METAL       771    771       Calcium 1 (By similarity).
FT   METAL       796    796       Calcium 2 (By similarity).
FT   METAL       799    799       Calcium 1 (By similarity).
FT   METAL       800    800       Calcium 1 (By similarity).
FT   METAL       800    800       Calcium 2 (By similarity).
FT   METAL       908    908       Calcium 1 (By similarity).
FT   BINDING     515    515       ATP (By similarity).
FT   MOD_RES       1      1       N-acetylmethionine.
FT   VAR_SEQ     994   1043       ACLYPGLLRTVSQAWSRQPLTTSWTPDHTGRNEPEVSAGNR
FT                                VESPVCTSD -> EEMSQK (in isoform SERCA3A).
FT                                /FTId=VSP_000364.
FT   VAR_SEQ     994   1043       ACLYPGLLRTVSQAWSRQPLTTSWTPDHTGRNEPEVSAGNR
FT                                VESPVCTSD -> EMSQK (in isoform SERCA3D).
FT                                /FTId=VSP_000365.
FT   VAR_SEQ    1024   1043       RNEPEVSAGNRVESPVCTSD -> LASLKK (in
FT                                isoform SERCA3C).
FT                                /FTId=VSP_000366.
FT   VAR_SEQ    1024   1043       RNEPEVSAGNRVESPVCTSD -> LASLGQGHSIVSLSELL
FT                                REGGSREE (in isoform SERCA3E).
FT                                /FTId=VSP_000367.
FT   VAR_SEQ    1024   1043       RNEPEVSAGNRVESPVCTSD -> ARDTASSRCQSCSEREE
FT                                AGK (in isoform SERCA3F).
FT                                /FTId=VSP_000368.
FT   VARIANT     674    674       R -> H (in a breast cancer sample;
FT                                somatic mutation).
FT                                /FTId=VAR_036498.
FT   VARIANT     869    869       Q -> H (in dbSNP:rs11654827).
FT                                /FTId=VAR_048372.
FT   CONFLICT    673    673       A -> T (in Ref. 4; AAC24525).
FT   CONFLICT    802    802       L -> H (in Ref. 3; CAA75739).
FT   CONFLICT    817    817       M -> I (in Ref. 1; CAA93737).
SQ   SEQUENCE   1043 AA;  113977 MW;  CB6514B36E00E091 CRC64;
     MEAAHLLPAA DVLRHFSVTA EGGLSPAQVT GARERYGPNE LPSEEGKSLW ELVLEQFEDL
     LVRILLLAAL VSFVLAWFEE GEETTTAFVE PLVIMLILVA NAIVGVWQER NAESAIEALK
     EYEPEMGKVI RSDRKGVQRI RARDIVPGDI VEVAVGDKVP ADLRLIEIKS TTLRVDQSIL
     TGESVSVTKH TEAIPDPRAV NQDKKNMLFS GTNITSGKAV GVAVATGLHT ELGKIRSQMA
     AVEPERTPLQ RKLDEFGRQL SHAISVICVA VWVINIGHFA DPAHGGSWLR GAVYYFKIAV
     ALAVAAIPEG LPAVITTCLA LGTRRMARKN AIVRSLPSVE TLGCTSVICS DKTGTLTTNQ
     MSVCRMFVVA EADAGSCLLH EFTISGTTYT PEGEVRQGDQ PVRCGQFDGL VELATICALC
     NDSALDYNEA KGVYEKVGEA TETALTCLVE KMNVFDTDLQ ALSRVERAGA CNTVIKQLMR
     KEFTLEFSRD RKSMSVYCTP TRPHPTGQGS KMFVKGAPES VIERCSSVRV GSRTAPLTPT
     SREQILAKIR DWGSGSDTLR CLALATRDAP PRKEDMELDD CSKFVQYETD LTFVGCVGML
     DPPRPEVAAC ITRCYQAGIR VVMITGDNKG TAVAICRRLG IFGDTEDVAG KAYTGREFDD
     LSPEQQRQAC RTARCFARVE PAHKSRIVEN LQSFNEITAM TGDGVNDAPA LKKAEIGIAM
     GSGTAVAKSA AEMVLSDDNF ASIVAAVEEG RAIYSNMKQF IRYLISSNVG EVVCIFLTAI
     LGLPEALIPV QLLWVNLVTD GLPATALGFN PPDLDIMEKL PRSPREALIS GWLFFRYLAI
     GVYVGLATVA AATWWFVYDA EGPHINFYQL RNFLKCSEDN PLFAGIDCEV FESRFPTTMA
     LSVLVTIEMC NALNSVSENQ SLLRMPPWMN PWLLVAVAMS MALHFLILLV PPLPLIFQVT
     PLSGRQWVVV LQISLPVILL DEALKYLSRN HMHACLYPGL LRTVSQAWSR QPLTTSWTPD
     HTGRNEPEVS AGNRVESPVC TSD
//
ID   AT2A3_RAT               Reviewed;         999 AA.
AC   P18596;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1990, sequence version 1.
DT   02-MAR-2010, entry version 98.
DE   RecName: Full=Sarcoplasmic/endoplasmic reticulum calcium ATPase 3;
DE            Short=SR Ca(2+)-ATPase 3;
DE            Short=SERCA3;
DE            EC=3.6.3.8;
DE   AltName: Full=Calcium pump 3;
GN   Name=Atp2a3;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], CHARACTERIZATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Kidney;
RX   MEDLINE=90036958; PubMed=2553713;
RA   Burk S.E., Lytton J., McLennan D.H., Shull G.E.;
RT   "cDNA cloning, functional expression, and mRNA tissue distribution of
RT   a third organellar Ca2+ pump.";
RL   J. Biol. Chem. 264:18561-18568(1989).
CC   -!- FUNCTION: This magnesium-dependent enzyme catalyzes the hydrolysis
CC       of ATP coupled with the transport of the calcium. Transports
CC       calcium ions from the cytosol into the sarcoplasmic/endoplasmic
CC       reticulum lumen. Contributes to calcium sequestration involved in
CC       muscular excitation/contraction.
CC   -!- CATALYTIC ACTIVITY: ATP + H(2)O + Ca(2+)(Cis) = ADP + phosphate +
CC       Ca(2+)(Trans).
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Multi-pass
CC       membrane protein (By similarity). Nucleus membrane; Multi-pass
CC       membrane protein (By similarity).
CC   -!- TISSUE SPECIFICITY: Found in most tissues. Most abundant in large
CC       and small intestine, spleen and lung.
CC   -!- SIMILARITY: Belongs to the cation transport ATPase (P-type)
CC       family. Type IIA subfamily.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M30581; AAA42131.1; -; mRNA.
DR   IPI; IPI00950187; -.
DR   PIR; A34307; A34307.
DR   RefSeq; NP_037046.1; -.
DR   UniGene; Rn.9920; -.
DR   SMR; P18596; 1-993.
DR   STRING; P18596; -.
DR   PRIDE; P18596; -.
DR   Ensembl; ENSRNOT00000064840; ENSRNOP00000060512; ENSRNOG00000017912; Rattus norvegicus.
DR   GeneID; 25391; -.
DR   KEGG; rno:25391; -.
DR   UCSC; NM_012914; rat.
DR   CTD; 25391; -.
DR   RGD; 2175; Atp2a3.
DR   eggNOG; maNOG16465; -.
DR   HOVERGEN; HBG105648; -.
DR   InParanoid; P18596; -.
DR   PhylomeDB; P18596; -.
DR   BRENDA; 3.6.3.8; 248.
DR   NextBio; 606461; -.
DR   ArrayExpress; P18596; -.
DR   Genevestigator; P18596; -.
DR   GermOnline; ENSRNOG00000017912; Rattus norvegicus.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:RGD.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0031965; C:nuclear membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005509; F:calcium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005388; F:calcium-transporting ATPase activity; IDA:RGD.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006754; P:ATP biosynthetic process; IEA:InterPro.
DR   GO; GO:0006816; P:calcium ion transport; IDA:RGD.
DR   InterPro; IPR008250; ATPase_P-typ_ATPase-assoc-dom.
DR   InterPro; IPR005782; ATPase_P-typ_Ca-transp.
DR   InterPro; IPR006068; ATPase_P-typ_cation-transptr_C.
DR   InterPro; IPR004014; ATPase_P-typ_cation-transptr_N.
DR   InterPro; IPR001757; ATPase_P-typ_ion-transptr.
DR   InterPro; IPR018303; ATPase_P-typ_P_site.
DR   InterPro; IPR005834; Dehalogen-like_hydro.
DR   PANTHER; PTHR11939; ATPase_P; 1.
DR   Pfam; PF00689; Cation_ATPase_C; 1.
DR   Pfam; PF00690; Cation_ATPase_N; 1.
DR   Pfam; PF00122; E1-E2_ATPase; 1.
DR   Pfam; PF00702; Hydrolase; 1.
DR   PRINTS; PR00119; CATATPASE.
DR   SMART; SM00831; Cation_ATPase_N; 1.
DR   TIGRFAMs; TIGR01116; ATPase-IIA1_Ca; 1.
DR   TIGRFAMs; TIGR01494; ATPase_P-type; 4.
DR   PROSITE; PS00154; ATPASE_E1_E2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; ATP-binding; Calcium; Calcium transport;
KW   Endoplasmic reticulum; Hydrolase; Ion transport; Magnesium; Membrane;
KW   Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Transmembrane; Transport.
FT   CHAIN         1    999       Sarcoplasmic/endoplasmic reticulum
FT                                calcium ATPase 3.
FT                                /FTId=PRO_0000046205.
FT   TOPO_DOM      1     48       Cytoplasmic (By similarity).
FT   TRANSMEM     49     69       1 (By similarity).
FT   TOPO_DOM     70     89       Lumenal (By similarity).
FT   TRANSMEM     90    110       2 (By similarity).
FT   TOPO_DOM    111    253       Cytoplasmic (By similarity).
FT   TRANSMEM    254    273       3 (By similarity).
FT   TOPO_DOM    274    295       Lumenal (By similarity).
FT   TRANSMEM    296    313       4 (By similarity).
FT   TOPO_DOM    314    757       Cytoplasmic (By similarity).
FT   TRANSMEM    758    777       5 (By similarity).
FT   TOPO_DOM    778    787       Lumenal (By similarity).
FT   TRANSMEM    788    808       6 (By similarity).
FT   TOPO_DOM    809    828       Cytoplasmic (By similarity).
FT   TRANSMEM    829    851       7 (By similarity).
FT   TOPO_DOM    852    897       Lumenal (By similarity).
FT   TRANSMEM    898    917       8 (By similarity).
FT   TOPO_DOM    918    930       Cytoplasmic (By similarity).
FT   TRANSMEM    931    949       9 (By similarity).
FT   TOPO_DOM    950    964       Lumenal (By similarity).
FT   TRANSMEM    965    985       10 (By similarity).
FT   TOPO_DOM    986    999       Cytoplasmic (By similarity).
FT   ACT_SITE    351    351       4-aspartylphosphate intermediate (By
FT                                similarity).
FT   METAL       304    304       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       305    305       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       307    307       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       309    309       Calcium 2 (By similarity).
FT   METAL       703    703       Magnesium (By similarity).
FT   METAL       707    707       Magnesium (By similarity).
FT   METAL       768    768       Calcium 1 (By similarity).
FT   METAL       771    771       Calcium 1 (By similarity).
FT   METAL       796    796       Calcium 2 (By similarity).
FT   METAL       799    799       Calcium 1 (By similarity).
FT   METAL       800    800       Calcium 1 (By similarity).
FT   METAL       800    800       Calcium 2 (By similarity).
FT   METAL       908    908       Calcium 1 (By similarity).
FT   BINDING     515    515       ATP (By similarity).
FT   MOD_RES       1      1       N-acetylmethionine (By similarity).
SQ   SEQUENCE   999 AA;  109359 MW;  8A6AEE29021AA379 CRC64;
     MEEAHLLSAA DVLRRFSVTA EGGLTLEQVT DARERYGPNE LPTEEGKSLW ELVVEQFEDL
     LVRILLLAAL VSFVLAWFEE GEETTTAFVE PLVIMLILVA NAIVGVWQER NAESAIEALK
     EYEPEMGKVI RSDRKGVQRI RARDIVPGDI VEVAVGDKVP ADLRLIEIKS TTLRVDQSIL
     TGESVSVTKH TDAIPDPRAV NQDKKNMLFS GTNIASGKAL GVAVATGLHT ELGKIRSQMA
     AVEPERTPLQ RKLDEFGRQL SHAISVICVA VWVINIGHFA DPAHGGSWLR GAVYYFKIAV
     ALAVAAIPEG LPAVITTCLA LGTRRMARKN AIVRSLPSVE TLGCTSVICS DKTGTLTTNQ
     MSVCRMFVVA EAEAGACRLH EFTISGTTYT PEGEVRQGEQ LVRCGQFDGL VELATICALC
     NDSALDYNEA KGVYEKVGEA TETALTCLVE KMNVFDTDLK GLSRVERAGA CNSVIKQLMQ
     KEFTLEFSRD RKSMSVYCTP TRADPKAQGS KMFVKGAPES VIERCSSVRV GSRTVPLSAT
     SREHILAKIR DWGSGSHTLR CLALATRDTP PRKEDMQLDD CSQFVQYETG LTFVGCVGML
     DPPRPEVAAC ITRCSRAGIR VVMITGDNKG TAVAICRRLG IFGDTEDVLG KAYTGREFDD
     LSPEQQRQAC RTARCFARVE PAHKSRIVEN LQSFNEITAM TGDGVNDAPA LKKAEIGIAM
     GSGTAVAKSA AEMVLSDDNF ASIVAAVEEG RAIYNNMKQF IRYLISSNVG EVVCIFLTAI
     LGLPEALIPV QLLWVNLVTD GLPATALGFN PPDLDIMEKL PRNPREALIS GWLFFRYLAI
     GVYVGLATVA AATWWFLYDA EGPQVTFHQL RNFLKCSEDN PLFAGIDCEV FESRFPTTMA
     LSVLVTIEMC NALNSVSENQ SLLRMPPWLN PWLLGAVVMS MALHFLILLV PPLPLIFQVT
     PLSGRQWGVV LQMSLPVILL DEALKYLSRH HVDEKKDLK
//
ID   AT2C1_HUMAN             Reviewed;         919 AA.
AC   P98194; B2RAT7; O76005; Q86V72; Q86V73; Q8N6V1; Q8NCJ7;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   21-JUN-2005, sequence version 3.
DT   02-MAR-2010, entry version 111.
DE   RecName: Full=Calcium-transporting ATPase type 2C member 1;
DE            Short=ATPase 2C1;
DE            EC=3.6.3.8;
DE   AltName: Full=ATP-dependent Ca(2+) pump PMR1;
GN   Name=ATP2C1; Synonyms=KIAA1347, PMR1L; ORFNames=HUSSY-28;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND VARIANTS HHD
RP   THR-304; PRO-318; ARG-641; ARG-645; MET-709 AND ARG-744.
RX   MEDLINE=20082810; PubMed=10615129; DOI=10.1038/71701;
RA   Hu Z., Bonifas J.M., Beech J., Bench G., Shigihara T., Ogawa H.,
RA   Ikeda S., Mauro T., Epstein E.H. Jr.;
RT   "Mutations in ATP2C1, encoding a calcium pump, cause Hailey-Hailey
RT   disease.";
RL   Nat. Genet. 24:61-65(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 4), AND VARIANTS HHD
RP   LEU-201; TYR-344 AND ILE-570.
RC   TISSUE=Keratinocyte;
RX   MEDLINE=20231541; PubMed=10767338; DOI=10.1093/hmg/9.7.1131;
RA   Sudbrak R., Brown J., Dobson-Stone C., Carter S., Ramser J., White J.,
RA   Healy E., Dissanayake M., Larregue M., Perrussel M., Lehrach H.,
RA   Munro C.S., Strachan T., Burge S., Hovnanian A., Monaco A.P.;
RT   "Hailey-Hailey disease is caused by mutations in ATP2C1 encoding a
RT   novel Ca(2+) pump.";
RL   Hum. Mol. Genet. 9:1131-1140(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5 AND 6), SUBCELLULAR LOCATION,
RP   AND MUTAGENESIS.
RC   TISSUE=Keratinocyte;
RX   MEDLINE=22716216; PubMed=12707275; DOI=10.1074/jbc.M300509200;
RA   Fairclough R.J., Dode L., Vanoevelen J., Andersen J.P., Missiaen L.,
RA   Raeymaekers L., Wuytack F., Hovnanian A.;
RT   "Effect of Hailey-Hailey Disease mutations on the function of a new
RT   variant of human secretory pathway Ca2+/Mn2+-ATPase (hSPCA1).";
RL   J. Biol. Chem. 278:24721-24730(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   MEDLINE=20181126; PubMed=10718198; DOI=10.1093/dnares/7.1.65;
RA   Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XVI.
RT   The complete sequences of 150 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 7:65-73(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 6), AND
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 360-919 (ISOFORM 1).
RC   TISSUE=Mammary gland, and Neuron;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Blood;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 424-919.
RX   MEDLINE=21064499; PubMed=11124703;
RX   DOI=10.1002/1097-0061(200101)18:1<69::AID-YEA647>3.3.CO;2-8;
RA   Stanchi F., Bertocco E., Toppo S., Dioguardi R., Simionati B.,
RA   Cannata N., Zimbello R., Lanfranchi G., Valle G.;
RT   "Characterization of 16 novel human genes showing high similarity to
RT   yeast sequences.";
RL   Yeast 18:69-80(2001).
RN   [9]
RP   VARIANTS HHD CYS-309; PRO-341; ARG-411; VAL-580; TYR-742 AND ARG-789.
RX   PubMed=11841554; DOI=10.1046/j.0022-202x.2001.01675.x;
RA   Dobson-Stone C., Fairclough R., Dunne E., Brown J., Dissanayake M.,
RA   Munro C.S., Strachan T., Burge S., Sudbrak R., Monaco A.P.,
RA   Hovnanian A.;
RT   "Hailey-Hailey disease: molecular and clinical characterization of
RT   novel mutations in the ATP2C1 gene.";
RL   J. Invest. Dermatol. 118:338-343(2002).
RN   [10]
RP   VARIANTS HHD PHE-490 AND PRO-584.
RX   PubMed=11874499; DOI=10.1046/j.0022-202x.2001.01686.x;
RA   Yokota K., Yasukawa K., Shimizu H.;
RT   "Analysis of ATP2C1 gene mutation in 10 unrelated Japanese families
RT   with Hailey-Hailey disease.";
RL   J. Invest. Dermatol. 118:550-551(2002).
CC   -!- FUNCTION: This magnesium-dependent enzyme catalyzes the hydrolysis
CC       of ATP coupled with the transport of the calcium.
CC   -!- CATALYTIC ACTIVITY: ATP + H(2)O + Ca(2+)(Cis) = ADP + phosphate +
CC       Ca(2+)(Trans).
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus membrane; Multi-pass
CC       membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC         Comment=Isoform 1 and isoform 2 are expressed in the same
CC         tissues;
CC       Name=1; Synonyms=ATP2C1A;
CC         IsoId=P98194-1; Sequence=Displayed;
CC       Name=2; Synonyms=ATP2C1B, ATP2C1C;
CC         IsoId=P98194-2; Sequence=VSP_000409;
CC       Name=3; Synonyms=ATP2C1B;
CC         IsoId=P98194-3; Sequence=VSP_000408, VSP_000410;
CC       Name=4; Synonyms=ATP2C1A;
CC         IsoId=P98194-4; Sequence=VSP_000408;
CC       Name=5; Synonyms=ATP2C1B;
CC         IsoId=P98194-5; Sequence=VSP_000410;
CC       Name=6; Synonyms=ATP2C1D;
CC         IsoId=P98194-6; Sequence=VSP_014102;
CC   -!- TISSUE SPECIFICITY: Found in most tissues except colon, thymus,
CC       spleen and leukocytes. Most abundant in keratinocytes and kidney.
CC   -!- DISEASE: Defects in ATP2C1 are the cause of Hailey-Hailey disease
CC       (HHD) [MIM:169600]; also known as benign familial pemphigus. HHD
CC       is an autosomal dominant disorder characterized by persistent
CC       blisters and suprabasal cell separation (acantholysis) of the
CC       epidermis, due to impaired keratinocyte adhesion. Patients lacking
CC       all isoforms except isoform 2 have HHD.
CC   -!- SIMILARITY: Belongs to the cation transport ATPase (P-type)
CC       family. Type IIA subfamily.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA92585.1; Type=Frameshift; Positions=8;
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/ATP2C1";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF181120; AAF26295.1; -; mRNA.
DR   EMBL; AF181121; AAF26296.1; -; mRNA.
DR   EMBL; AF189723; AAF27813.2; -; mRNA.
DR   EMBL; AF225981; AAF35375.1; -; mRNA.
DR   EMBL; AY268374; AAP30008.1; -; mRNA.
DR   EMBL; AY268375; AAP30009.1; -; mRNA.
DR   EMBL; AB037768; BAA92585.1; ALT_FRAME; mRNA.
DR   EMBL; AK001684; BAA91835.1; -; mRNA.
DR   EMBL; AK074692; BAC11142.1; ALT_INIT; mRNA.
DR   EMBL; AK314342; BAG36984.1; -; mRNA.
DR   EMBL; CH471052; EAW79219.1; -; Genomic_DNA.
DR   EMBL; BC028139; AAH28139.1; -; mRNA.
DR   EMBL; AJ010953; CAA09425.1; -; mRNA.
DR   IPI; IPI00220473; -.
DR   IPI; IPI00413116; -.
DR   IPI; IPI00419957; -.
DR   IPI; IPI00607568; -.
DR   IPI; IPI00607812; -.
DR   IPI; IPI00745171; -.
DR   RefSeq; NP_001001485.1; -.
DR   RefSeq; NP_001001486.1; -.
DR   RefSeq; NP_001001487.1; -.
DR   RefSeq; NP_055197.2; -.
DR   UniGene; Hs.584884; -.
DR   SMR; P98194; 26-901.
DR   STRING; P98194; -.
DR   TCDB; 3.A.3.2.5; P-type ATPase (P-ATPase) superfamily.
DR   PhosphoSite; P98194; -.
DR   PRIDE; P98194; -.
DR   Ensembl; ENST00000359644; ENSP00000352665; ENSG00000017260; Homo sapiens.
DR   Ensembl; ENST00000428331; ENSP00000395809; ENSG00000017260; Homo sapiens.
DR   GeneID; 27032; -.
DR   KEGG; hsa:27032; -.
DR   UCSC; uc003enk.1; human.
DR   UCSC; uc003enl.1; human.
DR   UCSC; uc003enm.1; human.
DR   UCSC; uc003enn.1; human.
DR   CTD; 27032; -.
DR   GeneCards; GC03P132095; -.
DR   H-InvDB; HIX0003679; -.
DR   HGNC; HGNC:13211; ATP2C1.
DR   HPA; CAB010207; -.
DR   MIM; 169600; phenotype.
DR   MIM; 604384; gene.
DR   Orphanet; 2841; Pemphigus, benign chronic familial.
DR   PharmGKB; PA25111; -.
DR   eggNOG; prNOG17631; -.
DR   HOVERGEN; HBG106478; -.
DR   PhylomeDB; P98194; -.
DR   BRENDA; 3.6.3.8; 247.
DR   DrugBank; DB01169; Arsenic trioxide.
DR   DrugBank; DB01189; Desflurane.
DR   DrugBank; DB00228; Enflurane.
DR   DrugBank; DB01159; Halothane.
DR   DrugBank; DB00753; Isoflurane.
DR   DrugBank; DB01028; Methoxyflurane.
DR   DrugBank; DB01110; Miconazole.
DR   DrugBank; DB01236; Sevoflurane.
DR   NextBio; 49568; -.
DR   ArrayExpress; P98194; -.
DR   Bgee; P98194; -.
DR   CleanEx; HS_ATP2C1; -.
DR   Genevestigator; P98194; -.
DR   GermOnline; ENSG00000017260; Homo sapiens.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral to membrane; NAS:UniProtKB.
DR   GO; GO:0005802; C:trans-Golgi network; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005388; F:calcium-transporting ATPase activity; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0030145; F:manganese ion binding; IDA:UniProtKB.
DR   GO; GO:0015410; F:manganese-transporting ATPase activity; IDA:UniProtKB.
DR   GO; GO:0004871; F:signal transducer activity; IMP:UniProtKB.
DR   GO; GO:0031532; P:actin cytoskeleton reorganization; IMP:UniProtKB.
DR   GO; GO:0006754; P:ATP biosynthetic process; IEA:InterPro.
DR   GO; GO:0006816; P:calcium ion transport; IDA:UniProtKB.
DR   GO; GO:0016339; P:calcium-dependent cell-cell adhesion; IMP:UniProtKB.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IDA:UniProtKB.
DR   GO; GO:0030026; P:cellular manganese ion homeostasis; IDA:UniProtKB.
DR   GO; GO:0008544; P:epidermis development; IMP:UniProtKB.
DR   GO; GO:0032468; P:Golgi calcium ion homeostasis; IMP:UniProtKB.
DR   GO; GO:0032472; P:Golgi calcium ion transport; IMP:UniProtKB.
DR   GO; GO:0006828; P:manganese ion transport; IDA:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-k...; IMP:UniProtKB.
DR   InterPro; IPR008250; ATPase_P-typ_ATPase-assoc-dom.
DR   InterPro; IPR006413; ATPase_P-typ_Ca-transp_PMR1.
DR   InterPro; IPR006068; ATPase_P-typ_cation-transptr_C.
DR   InterPro; IPR004014; ATPase_P-typ_cation-transptr_N.
DR   InterPro; IPR000695; ATPase_P-typ_H-transp.
DR   InterPro; IPR001757; ATPase_P-typ_ion-transptr.
DR   InterPro; IPR018303; ATPase_P-typ_P_site.
DR   InterPro; IPR005834; Dehalogen-like_hydro.
DR   PANTHER; PTHR11939; ATPase_P; 1.
DR   Pfam; PF00689; Cation_ATPase_C; 1.
DR   Pfam; PF00690; Cation_ATPase_N; 1.
DR   Pfam; PF00122; E1-E2_ATPase; 1.
DR   Pfam; PF00702; Hydrolase; 1.
DR   PRINTS; PR00119; CATATPASE.
DR   PRINTS; PR00120; HATPASE.
DR   SMART; SM00831; Cation_ATPase_N; 1.
DR   TIGRFAMs; TIGR01522; ATPase-IIA2_Ca; 1.
DR   TIGRFAMs; TIGR01494; ATPase_P-type; 4.
DR   PROSITE; PS00154; ATPASE_E1_E2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Calcium; Calcium transport;
KW   Complete proteome; Disease mutation; Golgi apparatus; Hydrolase;
KW   Ion transport; Magnesium; Membrane; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Transmembrane; Transport.
FT   CHAIN         1    919       Calcium-transporting ATPase type 2C
FT                                member 1.
FT                                /FTId=PRO_0000046223.
FT   TOPO_DOM      1     70       Cytoplasmic (By similarity).
FT   TRANSMEM     71     91       1 (By similarity).
FT   TOPO_DOM     92    104       Lumenal (By similarity).
FT   TRANSMEM    105    123       2 (By similarity).
FT   TOPO_DOM    124    262       Cytoplasmic (By similarity).
FT   TRANSMEM    263    282       3 (By similarity).
FT   TOPO_DOM    283    294       Lumenal (By similarity).
FT   TRANSMEM    295    312       4 (By similarity).
FT   TOPO_DOM    313    699       Cytoplasmic (By similarity).
FT   TRANSMEM    700    719       5 (By similarity).
FT   TOPO_DOM    720    729       Lumenal (By similarity).
FT   TRANSMEM    730    750       6 (By similarity).
FT   TOPO_DOM    751    770       Cytoplasmic (By similarity).
FT   TRANSMEM    771    793       7 (By similarity).
FT   TOPO_DOM    794    808       Lumenal (By similarity).
FT   TRANSMEM    809    828       8 (By similarity).
FT   TOPO_DOM    829    841       Cytoplasmic (By similarity).
FT   TRANSMEM    842    860       9 (By similarity).
FT   TOPO_DOM    861    875       Lumenal (By similarity).
FT   TRANSMEM    876    896       10 (By similarity).
FT   TOPO_DOM    897    919       Cytoplasmic (By similarity).
FT   ACT_SITE    350    350       4-aspartylphosphate intermediate (By
FT                                similarity).
FT   METAL       303    303       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       304    304       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       306    306       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       308    308       Calcium 2 (By similarity).
FT   METAL       644    644       Magnesium (By similarity).
FT   METAL       648    648       Magnesium (By similarity).
FT   METAL       738    738       Calcium 2 (By similarity).
FT   METAL       742    742       Calcium 2 (By similarity).
FT   VAR_SEQ       1     16       Missing (in isoform 3 and isoform 4).
FT                                /FTId=VSP_000408.
FT   VAR_SEQ     877    919       DLLFLLGLTSSVCIVAEIIKKVERSREKIQKHVSSTSSSFL
FT                                EV -> GLALGEEWTAAG (in isoform 2).
FT                                /FTId=VSP_000409.
FT   VAR_SEQ     910    919       SSTSSSFLEV -> WLWERSGQQLVEIHPHLETGLPLTEDV
FT                                SCV (in isoform 3 and isoform 5).
FT                                /FTId=VSP_000410.
FT   VAR_SEQ     919    919       V -> VSSTSSSFLEVWLWERSGQQLVEIHPHLETGLPLTE
FT                                DVSCV (in isoform 6).
FT                                /FTId=VSP_014102.
FT   VARIANT     201    201       P -> L (in HHD).
FT                                /FTId=VAR_010130.
FT   VARIANT     304    304       A -> T (in HHD).
FT                                /FTId=VAR_008803.
FT   VARIANT     309    309       G -> C (in HHD; unable to bind manganese,
FT                                reduced affinity for calcium).
FT                                /FTId=VAR_022672.
FT   VARIANT     318    318       L -> P (in HHD).
FT                                /FTId=VAR_008804.
FT   VARIANT     341    341       L -> P (in HHD; unstable protein).
FT                                /FTId=VAR_022673.
FT   VARIANT     344    344       C -> Y (in HDD; unstable protein).
FT                                /FTId=VAR_010131.
FT   VARIANT     411    411       C -> R (in HDD; unstable protein).
FT                                /FTId=VAR_022674.
FT   VARIANT     450    450       A -> T (in dbSNP:rs41434650).
FT                                /FTId=VAR_048373.
FT   VARIANT     490    490       C -> F (in HHD).
FT                                /FTId=VAR_019523.
FT   VARIANT     570    570       T -> I (in HDD; unstable protein).
FT                                /FTId=VAR_010132.
FT   VARIANT     580    580       I -> V (in HDD; unable to undergo
FT                                conformational change necessary for ion
FT                                transport).
FT                                /FTId=VAR_022675.
FT   VARIANT     584    584       L -> P (in HHD).
FT                                /FTId=VAR_019524.
FT   VARIANT     641    641       M -> R (in HHD).
FT                                /FTId=VAR_008805.
FT   VARIANT     645    645       G -> R (in HHD).
FT                                /FTId=VAR_008806.
FT   VARIANT     709    709       T -> M (in HHD).
FT                                /FTId=VAR_008807.
FT   VARIANT     742    742       D -> Y (in HDD; unable to bind calcium or
FT                                manganese).
FT                                /FTId=VAR_022676.
FT   VARIANT     744    744       P -> R (in HHD).
FT                                /FTId=VAR_008808.
FT   VARIANT     789    789       G -> R (in HDD; unstable protein).
FT                                /FTId=VAR_022677.
FT   CONFLICT     62     62       E -> K (in Ref. 1; AAF26295/AAF26296).
FT   CONFLICT    112    112       I -> F (in Ref. 2; AAF35375).
FT   CONFLICT    150    150       T -> I (in Ref. 5; BAC11142).
FT   CONFLICT    373    373       A -> T (in Ref. 1; AAF26295/AAF26296).
FT   CONFLICT    516    516       R -> H (in Ref. 8; CAA09425).
FT   CONFLICT    713    713       A -> T (in Ref. 5; BAC11142).
FT   CONFLICT    901    901       S -> G (in Ref. 5; BAC11142).
SQ   SEQUENCE   919 AA;  100577 MW;  4C1495D58FDA7EA1 CRC64;
     MKVARFQKIP NGENETMIPV LTSKKASELP VSEVASILQA DLQNGLNKCE VSHRRAFHGW
     NEFDISEDEP LWKKYISQFK NPLIMLLLAS AVISVLMHQF DDAVSITVAI LIVVTVAFVQ
     EYRSEKSLEE LSKLVPPECH CVREGKLEHT LARDLVPGDT VCLSVGDRVP ADLRLFEAVD
     LSIDESSLTG ETTPCSKVTA PQPAATNGDL ASRSNIAFMG TLVRCGKAKG VVIGTGENSE
     FGEVFKMMQA EEAPKTPLQK SMDLLGKQLS FYSFGIIGII MLVGWLLGKD ILEMFTISVS
     LAVAAIPEGL PIVVTVTLAL GVMRMVKKRA IVKKLPIVET LGCCNVICSD KTGTLTKNEM
     TVTHIFTSDG LHAEVTGVGY NQFGEVIVDG DVVHGFYNPA VSRIVEAGCV CNDAVIRNNT
     LMGKPTEGAL IALAMKMGLD GLQQDYIRKA EYPFSSEQKW MAVKCVHRTQ QDRPEICFMK
     GAYEQVIKYC TTYQSKGQTL TLTQQQRDVY QQEKARMGSA GLRVLALASG PELGQLTFLG
     LVGIIDPPRT GVKEAVTTLI ASGVSIKMIT GDSQETAVAI ASRLGLYSKT SQSVSGEEID
     AMDVQQLSQI VPKVAVFYRA SPRHKMKIIK SLQKNGSVVA MTGDGVNDAV ALKAADIGVA
     MGQTGTDVCK EAADMILVDD DFQTIMSAIE EGKGIYNNIK NFVRFQLSTS IAALTLISLA
     TLMNFPNPLN AMQILWINII MDGPPAQSLG VEPVDKDVIR KPPRNWKDSI LTKNLILKIL
     VSSIIIVCGT LFVFWRELRD NVITPRDTTM TFTCFVFFDM FNALSSRSQT KSVFEIGLCS
     NRMFCYAVLG SIMGQLLVIY FPPLQKVFQT ESLSILDLLF LLGLTSSVCI VAEIIKKVER
     SREKIQKHVS STSSSFLEV
//
ID   ATC1_DROME              Reviewed;        1020 AA.
AC   P22700; A4UZU0; Q2MGN2; Q95TX1; Q9W1G2; Q9W1G3;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2000, sequence version 2.
DT   02-MAR-2010, entry version 111.
DE   RecName: Full=Calcium-transporting ATPase sarcoplasmic/endoplasmic reticulum type;
DE            EC=3.6.3.8;
DE   AltName: Full=Calcium pump;
GN   Name=Ca-P60A; ORFNames=CG3725;
OS   Drosophila melanogaster (Fruit fly).
OC   Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC   Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC   Ephydroidea; Drosophilidae; Drosophila; Sophophora.
OX   NCBI_TaxID=7227;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RX   MEDLINE=91097592; PubMed=2148477; DOI=10.1016/S0006-291X(05)80867-8;
RA   Magyar A., Varadi A.;
RT   "Molecular cloning and chromosomal localization of a sarco/endoplasmic
RT   reticulum-type Ca2(+)-ATPase of Drosophila melanogaster.";
RL   Biochem. Biophys. Res. Commun. 173:872-877(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Berkeley;
RX   MEDLINE=20196006; PubMed=10731132; DOI=10.1126/science.287.5461.2185;
RA   Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA   Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA   George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA   Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
RA   Brandon R.C., Rogers Y.-H.C., Blazej R.G., Champe M., Pfeiffer B.D.,
RA   Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,
RA   Abril J.F., Agbayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,
RA   Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA   Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,
RA   Borkova D., Botchan M.R., Bouck J., Brokstein P., Brottier P.,
RA   Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA   Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
RA   de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA   Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA   Durbin K.J., Evangelista C.C., Ferraz C., Ferriera S., Fleischmann W.,
RA   Fosler C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,
RA   Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA   Harris N.L., Harvey D.A., Heiman T.J., Hernandez J.R., Houck J.,
RA   Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwam C.,
RA   Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
RA   Kimmel B.E., Kodira C.D., Kraft C.L., Kravitz S., Kulp D., Lai Z.,
RA   Lasko P., Lei Y., Levitsky A.A., Li J.H., Li Z., Liang Y., Lin X.,
RA   Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,
RA   Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,
RA   Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA   Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacleb J.M.,
RA   Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA   Reinert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,
RA   Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.J.,
RA   Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA   Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA   Wang Z.-Y., Wassarman D.A., Weinstock G.M., Weissenbach J.,
RA   Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,
RA   Ye J., Yeh R.-F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA   Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S.C., Zhu X.,
RA   Smith H.O., Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RT   "The genome sequence of Drosophila melanogaster.";
RL   Science 287:2185-2195(2000).
RN   [3]
RP   GENOME REANNOTATION, AND ALTERNATIVE SPLICING.
RX   MEDLINE=22426069; PubMed=12537572;
RA   Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,
RA   Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochnik S.E.,
RA   Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,
RA   Bettencourt B.R., Celniker S.E., de Grey A.D.N.J., Drysdale R.A.,
RA   Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,
RA   Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,
RA   Lewis S.E.;
RT   "Annotation of the Drosophila melanogaster euchromatic genome: a
RT   systematic review.";
RL   Genome Biol. 3:RESEARCH0083.1-RESEARCH0083.22(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM B).
RC   STRAIN=Berkeley; TISSUE=Head;
RX   MEDLINE=22426066; PubMed=12537569;
RA   Stapleton M., Carlson J.W., Brokstein P., Yu C., Champe M.,
RA   George R.A., Guarin H., Kronmiller B., Pacleb J.M., Park S., Wan K.H.,
RA   Rubin G.M., Celniker S.E.;
RT   "A Drosophila full-length cDNA resource.";
RL   Genome Biol. 3:RESEARCH0080.1-RESEARCH0080.8(2002).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 357-513.
RX   MEDLINE=90092469; PubMed=2557235; DOI=10.1016/0014-5793(89)81653-9;
RA   Varadi A., Gilmore-Heber M., Benz E.J. Jr.;
RT   "Amplification of the phosphorylation site-ATP-binding site cDNA
RT   fragment of the Na+,K(+)-ATPase and the Ca2(+)-ATPase of Drosophila
RT   melanogaster by polymerase chain reaction.";
RL   FEBS Lett. 258:203-207(1989).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-240, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryo;
RX   PubMed=18327897; DOI=10.1021/pr700696a;
RA   Zhai B., Villen J., Beausoleil S.A., Mintseris J., Gygi S.P.;
RT   "Phosphoproteome analysis of Drosophila melanogaster embryos.";
RL   J. Proteome Res. 7:1675-1682(2008).
CC   -!- FUNCTION: This magnesium-dependent enzyme catalyzes the hydrolysis
CC       of ATP coupled with the transport of calcium.
CC   -!- CATALYTIC ACTIVITY: ATP + H(2)O + Ca(2+)(Cis) = ADP + phosphate +
CC       Ca(2+)(Trans).
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Multi-pass
CC       membrane protein. Sarcoplasmic reticulum membrane; Multi-pass
CC       membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=B; Synonyms=C, D, E, F, G, H;
CC         IsoId=P22700-1; Sequence=Displayed;
CC         Note=No experimental confirmation available;
CC       Name=A;
CC         IsoId=P22700-2; Sequence=VSP_010297;
CC   -!- SIMILARITY: Belongs to the cation transport ATPase (P-type)
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M62892; AAB00735.1; -; mRNA.
DR   EMBL; AE013599; AAF47101.1; -; Genomic_DNA.
DR   EMBL; AE013599; AAF47102.1; -; Genomic_DNA.
DR   EMBL; AE013599; AAF47103.1; -; Genomic_DNA.
DR   EMBL; AE013599; AAM68278.1; -; Genomic_DNA.
DR   EMBL; AE013599; AAM68279.1; -; Genomic_DNA.
DR   EMBL; AE013599; AAM68280.1; -; Genomic_DNA.
DR   EMBL; AE013599; AAM68281.1; -; Genomic_DNA.
DR   EMBL; AY058465; AAL13694.1; -; mRNA.
DR   EMBL; X17472; CAA35505.1; -; mRNA.
DR   PIR; A36691; A36691.
DR   RefSeq; NP_476832.1; -.
DR   RefSeq; NP_726381.1; -.
DR   RefSeq; NP_726382.1; -.
DR   RefSeq; NP_726383.1; -.
DR   RefSeq; NP_726384.1; -.
DR   RefSeq; NP_726385.1; -.
DR   RefSeq; NP_726386.1; -.
DR   RefSeq; NP_726387.1; -.
DR   UniGene; Dm.3812; -.
DR   SMR; P22700; 1-989.
DR   DIP; DIP-20129N; -.
DR   IntAct; P22700; 8.
DR   STRING; P22700; -.
DR   Ensembl; FBtr0072211; FBpp0072120; FBgn0004551; Drosophila melanogaster.
DR   Ensembl; FBtr0072212; FBpp0072121; FBgn0004551; Drosophila melanogaster.
DR   Ensembl; FBtr0072213; FBpp0072122; FBgn0004551; Drosophila melanogaster.
DR   Ensembl; FBtr0072214; FBpp0072123; FBgn0004551; Drosophila melanogaster.
DR   Ensembl; FBtr0072215; FBpp0072124; FBgn0004551; Drosophila melanogaster.
DR   Ensembl; FBtr0072216; FBpp0072125; FBgn0004551; Drosophila melanogaster.
DR   Ensembl; FBtr0072217; FBpp0072126; FBgn0004551; Drosophila melanogaster.
DR   Ensembl; FBtr0072218; FBpp0072127; FBgn0004551; Drosophila melanogaster.
DR   GeneID; 49297; -.
DR   KEGG; dme:Dmel_CG3725; -.
DR   CTD; 49297; -.
DR   FlyBase; FBgn0004551; Ca-P60A.
DR   eggNOG; inNOG09096; -.
DR   InParanoid; P22700; -.
DR   OMA; QVKRNLE; -.
DR   OrthoDB; EOG9R241C; -.
DR   PhylomeDB; P22700; -.
DR   BioCyc; DMEL-XXX-02:DMEL-XXX-02-006337-MONOMER; -.
DR   BioCyc; DMEL-XXX-02:DMEL-XXX-02-006338-MONOMER; -.
DR   BioCyc; DMEL-XXX-02:DMEL-XXX-02-006339-MONOMER; -.
DR   BioCyc; DMEL-XXX-02:DMEL-XXX-02-006340-MONOMER; -.
DR   BioCyc; DMEL-XXX-02:DMEL-XXX-02-006342-MONOMER; -.
DR   BioCyc; DMEL-XXX-02:DMEL-XXX-02-006343-MONOMER; -.
DR   BioCyc; DMEL-XXX-02:DMEL-XXX-02-006344-MONOMER; -.
DR   BRENDA; 3.6.3.8; 48.
DR   NextBio; 839728; -.
DR   ArrayExpress; P22700; -.
DR   Bgee; P22700; -.
DR   GermOnline; CG3725; Drosophila melanogaster.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005811; C:lipid particle; IDA:FlyBase.
DR   GO; GO:0005635; C:nuclear envelope; IDA:FlyBase.
DR   GO; GO:0033017; C:sarcoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005509; F:calcium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005388; F:calcium-transporting ATPase activity; IEA:EC.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:FlyBase.
DR   GO; GO:0006754; P:ATP biosynthetic process; IEA:InterPro.
DR   GO; GO:0006816; P:calcium ion transport; IEA:UniProtKB-KW.
DR   GO; GO:0007274; P:neuromuscular synaptic transmission; IMP:FlyBase.
DR   GO; GO:0051282; P:regulation of sequestering of calcium ion; IMP:FlyBase.
DR   InterPro; IPR008250; ATPase_P-typ_ATPase-assoc-dom.
DR   InterPro; IPR005782; ATPase_P-typ_Ca-transp.
DR   InterPro; IPR006068; ATPase_P-typ_cation-transptr_C.
DR   InterPro; IPR004014; ATPase_P-typ_cation-transptr_N.
DR   InterPro; IPR001757; ATPase_P-typ_ion-transptr.
DR   InterPro; IPR018303; ATPase_P-typ_P_site.
DR   InterPro; IPR005834; Dehalogen-like_hydro.
DR   PANTHER; PTHR11939; ATPase_P; 1.
DR   Pfam; PF00689; Cation_ATPase_C; 1.
DR   Pfam; PF00690; Cation_ATPase_N; 1.
DR   Pfam; PF00122; E1-E2_ATPase; 1.
DR   Pfam; PF00702; Hydrolase; 1.
DR   PRINTS; PR00119; CATATPASE.
DR   SMART; SM00831; Cation_ATPase_N; 1.
DR   TIGRFAMs; TIGR01116; ATPase-IIA1_Ca; 1.
DR   TIGRFAMs; TIGR01494; ATPase_P-type; 3.
DR   PROSITE; PS00154; ATPASE_E1_E2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Calcium; Calcium transport;
KW   Complete proteome; Endoplasmic reticulum; Hydrolase; Ion transport;
KW   Magnesium; Membrane; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Sarcoplasmic reticulum; Transmembrane; Transport.
FT   CHAIN         1   1020       Calcium-transporting ATPase
FT                                sarcoplasmic/endoplasmic reticulum type.
FT                                /FTId=PRO_0000046208.
FT   TOPO_DOM      1     48       Cytoplasmic (By similarity).
FT   TRANSMEM     49     69       1 (By similarity).
FT   TOPO_DOM     70     89       Lumenal (By similarity).
FT   TRANSMEM     90    110       2 (By similarity).
FT   TOPO_DOM    111    253       Cytoplasmic (By similarity).
FT   TRANSMEM    254    273       3 (By similarity).
FT   TOPO_DOM    274    295       Lumenal (By similarity).
FT   TRANSMEM    296    313       4 (By similarity).
FT   TOPO_DOM    314    757       Cytoplasmic (By similarity).
FT   TRANSMEM    758    777       5 (By similarity).
FT   TOPO_DOM    778    787       Lumenal (By similarity).
FT   TRANSMEM    788    808       6 (By similarity).
FT   TOPO_DOM    809    828       Cytoplasmic (By similarity).
FT   TRANSMEM    829    851       7 (By similarity).
FT   TOPO_DOM    852    897       Lumenal (By similarity).
FT   TRANSMEM    898    917       8 (By similarity).
FT   TOPO_DOM    918    930       Cytoplasmic (By similarity).
FT   TRANSMEM    931    949       9 (By similarity).
FT   TOPO_DOM    950    964       Lumenal (By similarity).
FT   TRANSMEM    965    985       10 (By similarity).
FT   TOPO_DOM    986   1020       Cytoplasmic (By similarity).
FT   ACT_SITE    351    351       4-aspartylphosphate intermediate (By
FT                                similarity).
FT   METAL       304    304       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       305    305       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       307    307       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       309    309       Calcium 2 (By similarity).
FT   METAL       703    703       Magnesium (By similarity).
FT   METAL       707    707       Magnesium (By similarity).
FT   METAL       768    768       Calcium 1 (By similarity).
FT   METAL       771    771       Calcium 1 (By similarity).
FT   METAL       796    796       Calcium 2 (By similarity).
FT   METAL       799    799       Calcium 1 (By similarity).
FT   METAL       800    800       Calcium 1 (By similarity).
FT   METAL       800    800       Calcium 2 (By similarity).
FT   METAL       908    908       Calcium 1 (By similarity).
FT   MOD_RES     240    240       Phosphoserine.
FT   VAR_SEQ     994   1020       GESPIYKMHGIVLMWAVFFGLLYAMML -> VPDVVVDRM
FT                                (in isoform A).
FT                                /FTId=VSP_010297.
FT   CONFLICT    158    158       K -> R (in Ref. 4; AAL13694).
FT   CONFLICT    302    302       L -> V (in Ref. 1; AAB00735).
FT   CONFLICT    357    357       T -> L (in Ref. 5; CAA35505).
FT   CONFLICT    495    495       S -> P (in Ref. 4; AAL13694).
SQ   SEQUENCE   1020 AA;  111701 MW;  6A62D350BF316984 CRC64;
     MEDGHSKTVE QSLNFFGTDP ERGLTLDQIK ANQKKYGPNE LPTEEGKSIW QLVLEQFDDL
     LVKILLLAAI ISFVLALFEE HEETFTAFVE PLVILLILIA NAVVGVWQER NAESAIEALK
     EYEPEMGKVV RQDKSGIQKV RAKEIVPGDL VEVSVGDKIP ADIRITHIYS TTLRIDQSIL
     TGESVSVIKH TDAIPDPRAV NQDKKNILFS GTNVAAGKAR GVVIGTGLST AIGKIRTEMS
     ETEEIKTPLQ QKLDEFGEQL SKVISVICVA VWAINIGHFN DPAHGGSWIK GAIYYFKIAV
     ALAVAAIPEG LPAVITTCLA LGTRRMAKKN AIVRSLPSVE TLGCTSVICS DKTGTLTTNQ
     MSVSRMFIFD KVEGNDSSFL EFEMTGSTYE PIGEVFLNGQ RIKAADYDTL QELSTICIMC
     NDSAIDYNEF KQAFEKVGEA TETALIVLAE KLNSFSVNKS GLDRRSAAIA CRGEIETKWK
     KEFTLEFSRD RKSMSSYCTP LKASRLGTGP KLFVKGAPEG VLERCTHARV GTTKVPLTSA
     LKAKILALTG QYGTGRDTLR CLALAVADSP MKPDEMDLGD STKFYQYEVN LTFVGVVGML
     DPPRKEVFDS IVRCRAAGIR VIVITGDNKA TAEAICRRIG VFAEDEDTTG KSYSGREFDD
     LSPTEQKAAV ARSRLFSRVE PQHKSKIVEF LQSMNEISAM TGDGVNDAPA LKKAEIGIAM
     GSGTAVAKSA AEMVLADDNF SSIVSAVEEG RAIYNNMKQF IRYLISSNIG EVVSIFLTAA
     LGLPEALIPV QLLWVNLVTD GLPATALGFN PPDLDIMEKP PRKADEGLIS GWLFFRYMAI
     GFYVGAATVG AAAWWFVFSD EGPKLSYWQL THHLSCLGGG DEFKGVDCKI FSDPHAMTMA
     LSVLVTIEML NAMNSLSENQ SLITMPPWCN LWLIGSMALS FTLHFVILYV DVLSTVFQVT
     PLSAEEWITV MKFSIPVVLL DETLKFVARK IADGESPIYK MHGIVLMWAV FFGLLYAMML
//
ID   ATCL_BACSU              Reviewed;         890 AA.
AC   O34431; Q799L2;
DT   20-JAN-2009, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   02-MAR-2010, entry version 77.
DE   RecName: Full=Calcium-transporting ATPase;
DE            EC=3.6.3.8;
DE   AltName: Full=Calcium pump;
GN   Name=yloB; OrderedLocusNames=BSU15650;
OS   Bacillus subtilis.
OC   Bacteria; Firmicutes; Bacillales; Bacillaceae; Bacillus.
OX   NCBI_TaxID=1423;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=168;
RX   MEDLINE=98195738; PubMed=9534248;
RA   Foulger D., Errington J.;
RT   "A 28 kbp segment from the spoVM region of the Bacillus subtilis 168
RT   genome.";
RL   Microbiology 144:801-805(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=168;
RX   MEDLINE=98044033; PubMed=9384377; DOI=10.1038/36786;
RA   Kunst F., Ogasawara N., Moszer I., Albertini A.M., Alloni G.,
RA   Azevedo V., Bertero M.G., Bessieres P., Bolotin A., Borchert S.,
RA   Borriss R., Boursier L., Brans A., Braun M., Brignell S.C., Bron S.,
RA   Brouillet S., Bruschi C.V., Caldwell B., Capuano V., Carter N.M.,
RA   Choi S.-K., Codani J.-J., Connerton I.F., Cummings N.J., Daniel R.A.,
RA   Denizot F., Devine K.M., Duesterhoeft A., Ehrlich S.D., Emmerson P.T.,
RA   Entian K.-D., Errington J., Fabret C., Ferrari E., Foulger D.,
RA   Fritz C., Fujita M., Fujita Y., Fuma S., Galizzi A., Galleron N.,
RA   Ghim S.-Y., Glaser P., Goffeau A., Golightly E.J., Grandi G.,
RA   Guiseppi G., Guy B.J., Haga K., Haiech J., Harwood C.R., Henaut A.,
RA   Hilbert H., Holsappel S., Hosono S., Hullo M.-F., Itaya M.,
RA   Jones L.-M., Joris B., Karamata D., Kasahara Y., Klaerr-Blanchard M.,
RA   Klein C., Kobayashi Y., Koetter P., Koningstein G., Krogh S.,
RA   Kumano M., Kurita K., Lapidus A., Lardinois S., Lauber J.,
RA   Lazarevic V., Lee S.-M., Levine A., Liu H., Masuda S., Mauel C.,
RA   Medigue C., Medina N., Mellado R.P., Mizuno M., Moestl D., Nakai S.,
RA   Noback M., Noone D., O'Reilly M., Ogawa K., Ogiwara A., Oudega B.,
RA   Park S.-H., Parro V., Pohl T.M., Portetelle D., Porwollik S.,
RA   Prescott A.M., Presecan E., Pujic P., Purnelle B., Rapoport G.,
RA   Rey M., Reynolds S., Rieger M., Rivolta C., Rocha E., Roche B.,
RA   Rose M., Sadaie Y., Sato T., Scanlan E., Schleich S., Schroeter R.,
RA   Scoffone F., Sekiguchi J., Sekowska A., Seror S.J., Serror P.,
RA   Shin B.-S., Soldo B., Sorokin A., Tacconi E., Takagi T., Takahashi H.,
RA   Takemaru K., Takeuchi M., Tamakoshi A., Tanaka T., Terpstra P.,
RA   Tognoni A., Tosato V., Uchiyama S., Vandenbol M., Vannier F.,
RA   Vassarotti A., Viari A., Wambutt R., Wedler E., Wedler H.,
RA   Weitzenegger T., Winters P., Wipat A., Yamamoto H., Yamane K.,
RA   Yasumoto K., Yata K., Yoshida K., Yoshikawa H.-F., Zumstein E.,
RA   Yoshikawa H., Danchin A.;
RT   "The complete genome sequence of the Gram-positive bacterium Bacillus
RT   subtilis.";
RL   Nature 390:249-256(1997).
RN   [3]
RP   FUNCTION, CATALYTIC ACTIVITY, DEVELOPMENTAL STAGE, AND DISRUPTION
RP   PHENOTYPE.
RC   STRAIN=168 / PS832;
RX   PubMed=12161109; DOI=10.1016/S0143-4160(02)00125-2;
RA   Raeymaekers L., Wuytack E., Willems I., Michiels C.W., Wuytack F.;
RT   "Expression of a P-type Ca(2+)-transport ATPase in Bacillus subtilis
RT   during sporulation.";
RL   Cell Calcium 32:93-93(2002).
CC   -!- FUNCTION: This magnesium-dependent enzyme catalyzes the hydrolysis
CC       of ATP coupled with the transport of calcium.
CC   -!- CATALYTIC ACTIVITY: ATP + H(2)O + Ca(2+)(Cis) = ADP + phosphate +
CC       Ca(2+)(Trans).
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- DEVELOPMENTAL STAGE: Expressed from 4 hours and peaks at 9 hours
CC       after onset of sporulation.
CC   -!- DISRUPTION PHENOTYPE: Spores are less resistant to heat and
CC       germinate at a slower rate.
CC   -!- SIMILARITY: Belongs to the cation transport ATPase (P-type)
CC       family. Type IIA subfamily.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y13937; CAA74269.1; -; Genomic_DNA.
DR   EMBL; AL009126; CAB13439.1; -; Genomic_DNA.
DR   PIR; H69877; H69877.
DR   RefSeq; NP_389448.1; -.
DR   HSSP; P04191; 1WPG.
DR   SMR; O34431; 2-877.
DR   GeneID; 936954; -.
DR   GenomeReviews; AL009126_GR; BSU15650.
DR   KEGG; bsu:BSU15650; -.
DR   NMPDR; fig|224308.1.peg.1567; -.
DR   SubtiList; BG13384; yloB.
DR   HOGENOM; HBG456486; -.
DR   OMA; ARGLGWK; -.
DR   PhylomeDB; O34431; -.
DR   ProtClustDB; CLSK873333; -.
DR   BioCyc; SUBTI:BSU15650-MONOMER; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005509; F:calcium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005388; F:calcium-transporting ATPase activity; IEA:EC.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006754; P:ATP biosynthetic process; IEA:InterPro.
DR   GO; GO:0006816; P:calcium ion transport; IEA:UniProtKB-KW.
DR   InterPro; IPR008250; ATPase_P-typ_ATPase-assoc-dom.
DR   InterPro; IPR006068; ATPase_P-typ_cation-transptr_C.
DR   InterPro; IPR004014; ATPase_P-typ_cation-transptr_N.
DR   InterPro; IPR000695; ATPase_P-typ_H-transp.
DR   InterPro; IPR001757; ATPase_P-typ_ion-transptr.
DR   InterPro; IPR018303; ATPase_P-typ_P_site.
DR   InterPro; IPR005834; Dehalogen-like_hydro.
DR   PANTHER; PTHR11939; ATPase_P; 1.
DR   Pfam; PF00689; Cation_ATPase_C; 1.
DR   Pfam; PF00690; Cation_ATPase_N; 1.
DR   Pfam; PF00122; E1-E2_ATPase; 1.
DR   Pfam; PF00702; Hydrolase; 1.
DR   PRINTS; PR00119; CATATPASE.
DR   PRINTS; PR00120; HATPASE.
DR   SMART; SM00831; Cation_ATPase_N; 1.
DR   TIGRFAMs; TIGR01494; ATPase_P-type; 4.
DR   PROSITE; PS00154; ATPASE_E1_E2; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Calcium; Calcium transport; Cell membrane;
KW   Complete proteome; Hydrolase; Ion transport; Magnesium; Membrane;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Transmembrane;
KW   Transport.
FT   CHAIN         1    890       Calcium-transporting ATPase.
FT                                /FTId=PRO_0000360851.
FT   TOPO_DOM      1     47       Cytoplasmic (By similarity).
FT   TRANSMEM     48     68       1 (By similarity).
FT   TOPO_DOM     69     78       Extracellular (By similarity).
FT   TRANSMEM     79     99       2 (By similarity).
FT   TOPO_DOM    100    238       Cytoplasmic (By similarity).
FT   TRANSMEM    239    258       3 (By similarity).
FT   TOPO_DOM    259    270       Extracellular (By similarity).
FT   TRANSMEM    271    288       4 (By similarity).
FT   TOPO_DOM    289    688       Cytoplasmic (By similarity).
FT   TRANSMEM    689    708       5 (By similarity).
FT   TOPO_DOM    709    718       Extracellular (By similarity).
FT   TRANSMEM    719    739       6 (By similarity).
FT   TOPO_DOM    740    759       Cytoplasmic (By similarity).
FT   TRANSMEM    760    782       7 (By similarity).
FT   TOPO_DOM    783    798       Extracellular (By similarity).
FT   TRANSMEM    799    818       8 (By similarity).
FT   TOPO_DOM    819    830       Cytoplasmic (By similarity).
FT   TRANSMEM    831    849       9 (By similarity).
FT   TOPO_DOM    850    864       Extracellular (By similarity).
FT   TRANSMEM    865    885       10 (By similarity).
FT   TOPO_DOM    886    890       Cytoplasmic (By similarity).
FT   ACT_SITE    326    326       4-aspartylphosphate intermediate (By
FT                                similarity).
FT   METAL       279    279       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       280    280       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       282    282       Calcium 2; via carbonyl oxygen (By
FT                                similarity).
FT   METAL       284    284       Calcium 2 (By similarity).
FT   METAL       633    633       Magnesium (By similarity).
FT   METAL       637    637       Magnesium (By similarity).
FT   METAL       699    699       Calcium 1 (By similarity).
FT   METAL       702    702       Calcium 1 (By similarity).
FT   METAL       727    727       Calcium 2 (By similarity).
FT   METAL       730    730       Calcium 1 (By similarity).
FT   METAL       731    731       Calcium 1 (By similarity).
FT   METAL       731    731       Calcium 2 (By similarity).
SQ   SEQUENCE   890 AA;  97293 MW;  43CB25F7A9BA31A6 CRC64;
     MKFHEMGQTD LLEATNTSMK QGLTEKEVKK RLDKHGPNEL QEGKKTSALL LFFAQFKDFM
     VLVLLAATLI SGFLGEYVDA VAIIAIVFVN GILGFFQERR AEQSLQALKE LSTPHVMALR
     EGSWTKIPSK ELVPGDIVKF TSGDRIGADV RIVEARSLEI EESALTGESI PVVKHADKLK
     KPDVSLGDIT NMAFMGTIVT RGSGVGVVVG TGMNTAMGKI ADMLESAGTL STPLQRRLEQ
     LGKILIVVAL LLTVLVVAVG VIQGHDLYSM FLAGVSLAVA AIPEGLPAIV TVALSLGVQR
     MIKQKSIVRK LPAVETLGCA SIICSDKTGT MTQNKMTVTH VWSGGKTWRV AGAGYEPKGS
     FTLNEKEISV NEHKPLQQML LFGALCNNSN IEKRDGEYVL DGDPTEGALL TAARKGGFSK
     EFVESNYRVI EEFPFDSARK MMTVIVENQD RKRYIITKGA PDVLMQRSSR IYYDGSAALF
     SNERKAETEA VLRHLASQAL RTIAVAYRPI KAGETPSMEQ AEKDLTMLGL SGIIDPPRPE
     VRQAIKECRE AGIKTVMITG DHVETAKAIA KDLRLLPKSG KIMDGKMLNE LSQEELSHVV
     EDVYVFARVS PEHKLKIVKA YQENGHIVAM TGDGVNDAPA IKQADIGVSM GITGTDVAKE
     ASSLVLVDDN FATIKSAIKE GRNIYENIRK FIRYLLASNV GEILVMLFAM LLALPLPLVP
     IQILWVNLVT DGLPAMALGM DQPEGDVMKR KPRHPKEGVF ARKLGWKVVS RGFLIGVATI
     LAFIIVYHRN PENLAYAQTI AFATLVLAQL IHVFDCRSET SVFSRNPFQN LYLIGAVLSS
     ILLMLVVIYY PPLQPIFHTV AITPGDWMLV IGMSAIPTFL LAGSLLTRKK
//
ID   ATZN_SYNY3              Reviewed;         721 AA.
AC   Q59998;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   02-MAR-2010, entry version 82.
DE   RecName: Full=Zinc-transporting ATPase;
DE            EC=3.6.3.5;
DE   AltName: Full=Zn(2+)-translocating P-type ATPase;
GN   Name=ziaA; OrderedLocusNames=slr0798;
OS   Synechocystis sp. (strain PCC 6803).
OC   Bacteria; Cyanobacteria; Chroococcales; Synechocystis.
OX   NCBI_TaxID=1148;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   MEDLINE=96127529; PubMed=8590279; DOI=10.1093/dnares/2.4.153;
RA   Kaneko T., Tanaka A., Sato S., Kotani H., Sazuka T., Miyajima N.,
RA   Sugiura M., Tabata S.;
RT   "Sequence analysis of the genome of the unicellular cyanobacterium
RT   Synechocystis sp. strain PCC6803. I. Sequence features in the 1 Mb
RT   region from map positions 64% to 92% of the genome.";
RL   DNA Res. 2:153-166(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   MEDLINE=97061201; PubMed=8905231; DOI=10.1093/dnares/3.3.109;
RA   Kaneko T., Sato S., Kotani H., Tanaka A., Asamizu E., Nakamura Y.,
RA   Miyajima N., Hirosawa M., Sugiura M., Sasamoto S., Kimura T.,
RA   Hosouchi T., Matsuno A., Muraki A., Nakazaki N., Naruo K., Okumura S.,
RA   Shimpo S., Takeuchi C., Wada T., Watanabe A., Yamada M., Yasuda M.,
RA   Tabata S.;
RT   "Sequence analysis of the genome of the unicellular cyanobacterium
RT   Synechocystis sp. strain PCC6803. II. Sequence determination of the
RT   entire genome and assignment of potential protein-coding regions.";
RL   DNA Res. 3:109-136(1996).
RN   [3]
RP   CHARACTERIZATION.
RX   MEDLINE=98393713; PubMed=9724772; DOI=10.1073/pnas.95.18.10728;
RA   Thelwell C., Robinson N.J., Turner-Cavet J.S.;
RT   "An SmtB-like repressor from Synechocystis PCC 6803 regulates a zinc
RT   exporter.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:10728-10733(1998).
CC   -!- CATALYTIC ACTIVITY: ATP + H(2)O + Zn(2+)(In) = ADP + phosphate +
CC       Zn(2+)(Out).
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the cation transport ATPase (P-type)
CC       family. Type IB subfamily.
CC   -!- SIMILARITY: Contains 1 HMA domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; BA000022; BAA10707.1; -; Genomic_DNA.
DR   PIR; S77015; S77015.
DR   RefSeq; NP_442636.1; -.
DR   PDB; 2OFG; NMR; -; X=1-111.
DR   PDB; 2OFH; NMR; -; X=1-111.
DR   PDBsum; 2OFG; -.
DR   PDBsum; 2OFH; -.
DR   SMR; Q59998; 172-707.
DR   IntAct; Q59998; 26.
DR   STRING; Q59998; -.
DR   GeneID; 952488; -.
DR   GenomeReviews; BA000022_GR; slr0798.
DR   KEGG; syn:slr0798; -.
DR   NMPDR; fig|1148.1.peg.2737; -.
DR   eggNOG; COG2217; -.
DR   HOGENOM; HBG507745; -.
DR   OMA; NIRPEYA; -.
DR   PhylomeDB; Q59998; -.
DR   ProtClustDB; CLSK342750; -.
DR   BioCyc; SSP1148:SLR0798-MONOMER; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005261; F:cation channel activity; IEA:InterPro.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0016463; F:zinc-exporting ATPase activity; IEA:EC.
DR   GO; GO:0006754; P:ATP biosynthetic process; IEA:InterPro.
DR   GO; GO:0006829; P:zinc ion transport; IEA:UniProtKB-KW.
DR   InterPro; IPR008250; ATPase_P-typ_ATPase-assoc-dom.
DR   InterPro; IPR001366; ATPase_P-typ_Cd-transp.
DR   InterPro; IPR006404; ATPase_P-typ_Cd/Co/Hg/Pb/Zn.
DR   InterPro; IPR006416; ATPase_P-typ_heavy-metal.
DR   InterPro; IPR001757; ATPase_P-typ_ion-transptr.
DR   InterPro; IPR018303; ATPase_P-typ_P_site.
DR   InterPro; IPR005834; Dehalogen-like_hydro.
DR   InterPro; IPR017969; Heavy-metal-associated_CS.
DR   InterPro; IPR006121; HeavyMe_transpt.
DR   PANTHER; PTHR11939; ATPase_P; 1.
DR   Pfam; PF00122; E1-E2_ATPase; 1.
DR   Pfam; PF00403; HMA; 1.
DR   Pfam; PF00702; Hydrolase; 1.
DR   PRINTS; PR00119; CATATPASE.
DR   PRINTS; PR00941; CDATPASE.
DR   SUPFAM; SSF55008; HeavyMe_transpt; 1.
DR   TIGRFAMs; TIGR01512; ATPase-IB2_Cd; 1.
DR   TIGRFAMs; TIGR01525; ATPase-IB_hvy; 1.
DR   TIGRFAMs; TIGR01494; ATPase_P-type; 2.
DR   PROSITE; PS00154; ATPASE_E1_E2; 1.
DR   PROSITE; PS01047; HMA_1; 1.
DR   PROSITE; PS50846; HMA_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell membrane; Complete proteome;
KW   Hydrolase; Ion transport; Magnesium; Membrane; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Transmembrane; Transport; Zinc;
KW   Zinc transport.
FT   CHAIN         1    721       Zinc-transporting ATPase.
FT                                /FTId=PRO_0000046333.
FT   TOPO_DOM      1    107       Cytoplasmic (By similarity).
FT   TRANSMEM    108    128       By similarity.
FT   TOPO_DOM    129    140       Extracellular (By similarity).
FT   TRANSMEM    141    160       By similarity.
FT   TOPO_DOM    161    167       Cytoplasmic (By similarity).
FT   TRANSMEM    168    187       By similarity.
FT   TOPO_DOM    188    190       Extracellular (By similarity).
FT   TRANSMEM    191    210       By similarity.
FT   TOPO_DOM    211    344       Cytoplasmic (By similarity).
FT   TRANSMEM    345    363       By similarity.
FT   TOPO_DOM    364    369       Extracellular (By similarity).
FT   TRANSMEM    370    387       By similarity.
FT   TOPO_DOM    388    671       Cytoplasmic (By similarity).
FT   TRANSMEM    672    693       By similarity.
FT   TOPO_DOM    694    701       Extracellular (By similarity).
FT   TRANSMEM    702    717       By similarity.
FT   TOPO_DOM    718    721       Cytoplasmic (By similarity).
FT   DOMAIN        9     75       HMA.
FT   ACT_SITE    425    425       4-aspartylphosphate intermediate (By
FT                                similarity).
FT   METAL        19     19       Zinc (Potential).
FT   METAL        22     22       Zinc (Potential).
FT   METAL       618    618       Magnesium (By similarity).
FT   METAL       622    622       Magnesium (By similarity).
FT   STRAND        8     13
FT   HELIX        19     21
FT   HELIX        23     26
FT   HELIX        30     32
FT   STRAND       38     41
FT   STRAND       48     52
FT   TURN         54     56
FT   HELIX        59     67
SQ   SEQUENCE   721 AA;  76884 MW;  BE187EB3900EC58B CRC64;
     MTQSSPLKTQ QMQVGGMDCT SCKLKIEGSL ERLKGVAEAS VTVATGRLTV TYDPKQVSEI
     TIQERIAALG YTLAEPKSSV TLNGHKHPHS HREEGHSHSH GAGEFNLKQE LLPVLTAIAL
     FTIAILFEQP LHNTPGQIAE FAVIIPAYLL SGWTVLKTAG RNILRGQIFD ENFLMTIATL
     GALAIHQLPE AVAVMLFFRV GELFQEYSVG RSRRSIKALL EARPDTANLK RNGTVQQVSP
     ETVQVDDLIL VKPGEKVPLD GEILGGTSQV DTSALTGESV PGTVKPGDTI LAGMINQSGV
     LTIRVTKLFS ESSIAKVLDL VENASSKKAS TEKFITQFAR YYTPVIVFLS LAVALLPPLF
     IPGADRADWV YRALVLLVIS CPCGLVISIP LGYFGGIGGA AKHGILIKGS TFLDSLTAVK
     TVVFDKTGTL TKGTFKVTQV VTKNGFSESE LLTLAAKAES HSTHPIALSI REAYAQSIAD
     SEVADYEEIA GHGIRAVVQN QVVIAGNDRL LHREKIDHDT CDVAGTVVHL AVDGRYGGYI
     LIADEIKEDA VQAIRDLKRM GVEKTVMLTG DSEIVAQSVA QQIGLDAFVA ELLPEEKVDE
     IEQLLDPSGK AKLAFVGDGI NDAPVIARAD VGIAMGGLGS DAAIETADVV LMTDAPSKVA
     EAIHVARKTR QIVVQNIVLA LGIKALFIAL GTIGLATLWE AVFADVGVAL LAILNATRIA
     K
//
ID   BACH_HALHP              Reviewed;         276 AA.
AC   Q48315;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   02-MAR-2010, entry version 57.
DE   RecName: Full=Halorhodopsin;
DE            Short=HR;
DE   Flags: Precursor;
GN   Name=hop;
OS   Halobacterium halobium (strain port).
OC   Archaea; Euryarchaeota; Halobacteria; Halobacteriales;
OC   Halobacteriaceae; Halobacterium.
OX   NCBI_TaxID=33004;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=96130249; PubMed=8541296; DOI=10.1016/0005-2736(95)00211-1;
RA   Otomo J., Muramatsu T.;
RT   "Over-expression of a new photo-active halorhodopsin in Halobacterium
RT   salinarium.";
RL   Biochim. Biophys. Acta 1240:248-256(1995).
CC   -!- FUNCTION: Light-driven chloride pump.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Absorption:
CC         Abs(max)=578 nm;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the archaeal/bacterial/fungal opsin family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D43766; BAA07823.1; -; Genomic_DNA.
DR   PIR; T48843; T48843.
DR   SMR; Q48315; 24-260.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005216; F:ion channel activity; IEA:InterPro.
DR   GO; GO:0009881; F:photoreceptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0006811; P:ion transport; IEA:UniProtKB-KW.
DR   GO; GO:0007602; P:phototransduction; IEA:UniProtKB-KW.
DR   GO; GO:0018298; P:protein-chromophore linkage; IEA:UniProtKB-KW.
DR   InterPro; IPR001425; Rhodopsin_bac.
DR   InterPro; IPR018229; Rhodopsin_retinal_BS.
DR   Pfam; PF01036; Bac_rhodopsin; 1.
DR   PRINTS; PR00251; BACTRLOPSIN.
DR   PROSITE; PS00950; BACTERIAL_OPSIN_1; 1.
DR   PROSITE; PS00327; BACTERIAL_OPSIN_RET; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Chromophore; Ion transport; Membrane;
KW   Photoreceptor protein; Receptor; Retinal protein;
KW   Sensory transduction; Transmembrane; Transport.
FT   PROPEP        1     21       By similarity.
FT                                /FTId=PRO_0000020240.
FT   CHAIN        22    276       Halorhodopsin.
FT                                /FTId=PRO_0000020241.
FT   TOPO_DOM     22     25       Extracellular (By similarity).
FT   TRANSMEM     26     51       Helix A (By similarity).
FT   TOPO_DOM     52     57       Cytoplasmic (By similarity).
FT   TRANSMEM     58     81       Helix B (By similarity).
FT   TOPO_DOM     82    105       Extracellular (By similarity).
FT   TRANSMEM    106    127       Helix C (By similarity).
FT   TOPO_DOM    128    130       Cytoplasmic (By similarity).
FT   TRANSMEM    131    154       Helix D (By similarity).
FT   TOPO_DOM    155    157       Extracellular (By similarity).
FT   TRANSMEM    158    180       Helix E (By similarity).
FT   TOPO_DOM    181    192       Cytoplasmic (By similarity).
FT   TRANSMEM    193    216       Helix F (By similarity).
FT   TOPO_DOM    217    225       Extracellular (By similarity).
FT   TRANSMEM    226    254       Helix G (By similarity).
FT   TOPO_DOM    255    276       Cytoplasmic (By similarity).
FT   MOD_RES     241    241       N6-(retinylidene)lysine (By similarity).
SQ   SEQUENCE   276 AA;  29045 MW;  A2D024F474E593D7 CRC64;
     MTAASTTATT MLQATQSDVL QEIQSNFLLN SSIWVNIALA GVVILLFVAM GRDIESPRAK
     LIWVATMLVP LVSISSYAGL ASGLTVGFLQ MPPGHALAGQ EVLSPWGRYL TWTFSTPMIL
     LALGLLADTD IASLFTAITM DIGMCVTGLA AALITSSHLL RWVFYGISCA FFVAVLYVLL
     VQWPADAEAA GTSEIFGTLK ILTVVLWLGY PILWALGSEG VALLSVGVTS WGYSGLDILA
     KYVFAFLLLR WVAANEGAVS GSGMSIGSGG AAPADD
//
ID   BACH_HALHS              Reviewed;         276 AA.
AC   Q48314;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   02-MAR-2010, entry version 57.
DE   RecName: Full=Halorhodopsin;
DE            Short=HR;
DE   Flags: Precursor;
GN   Name=hop;
OS   Halobacterium halobium (strain shark).
OC   Archaea; Euryarchaeota; Halobacteria; Halobacteriales;
OC   Halobacteriaceae; Halobacterium.
OX   NCBI_TaxID=33005;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=96130249; PubMed=8541296; DOI=10.1016/0005-2736(95)00211-1;
RA   Otomo J., Muramatsu T.;
RT   "Over-expression of a new photo-active halorhodopsin in Halobacterium
RT   salinarium.";
RL   Biochim. Biophys. Acta 1240:248-256(1995).
CC   -!- FUNCTION: Halorhodopsin is a light-driven anion pump.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Absorption:
CC         Abs(max)=~596 nm;
CC         Note=In the presence of anions, the maximum absorption shifts to
CC         about 575 nm;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the archaeal/bacterial/fungal opsin family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D43765; BAA07822.1; -; Genomic_DNA.
DR   SMR; Q48314; 24-260.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005216; F:ion channel activity; IEA:InterPro.
DR   GO; GO:0009881; F:photoreceptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0006811; P:ion transport; IEA:UniProtKB-KW.
DR   GO; GO:0007602; P:phototransduction; IEA:UniProtKB-KW.
DR   GO; GO:0018298; P:protein-chromophore linkage; IEA:UniProtKB-KW.
DR   InterPro; IPR001425; Rhodopsin_bac.
DR   InterPro; IPR018229; Rhodopsin_retinal_BS.
DR   Pfam; PF01036; Bac_rhodopsin; 1.
DR   PRINTS; PR00251; BACTRLOPSIN.
DR   PROSITE; PS00950; BACTERIAL_OPSIN_1; 1.
DR   PROSITE; PS00327; BACTERIAL_OPSIN_RET; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Chromophore; Ion transport; Membrane;
KW   Photoreceptor protein; Receptor; Retinal protein;
KW   Sensory transduction; Transmembrane; Transport.
FT   PROPEP        1     21       By similarity.
FT                                /FTId=PRO_0000020242.
FT   CHAIN        22    276       Halorhodopsin.
FT                                /FTId=PRO_0000020243.
FT   TOPO_DOM     22     25       Extracellular (By similarity).
FT   TRANSMEM     26     51       Helix A (By similarity).
FT   TOPO_DOM     52     57       Cytoplasmic (By similarity).
FT   TRANSMEM     58     81       Helix B (By similarity).
FT   TOPO_DOM     82    105       Extracellular (By similarity).
FT   TRANSMEM    106    127       Helix C (By similarity).
FT   TOPO_DOM    128    130       Cytoplasmic (By similarity).
FT   TRANSMEM    131    154       Helix D (By similarity).
FT   TOPO_DOM    155    157       Extracellular (By similarity).
FT   TRANSMEM    158    180       Helix E (By similarity).
FT   TOPO_DOM    181    192       Cytoplasmic (By similarity).
FT   TRANSMEM    193    216       Helix F (By similarity).
FT   TOPO_DOM    217    225       Extracellular (By similarity).
FT   TRANSMEM    226    254       Helix G (By similarity).
FT   TOPO_DOM    255    276       Cytoplasmic (By similarity).
FT   MOD_RES     241    241       N6-(retinylidene)lysine (By similarity).
SQ   SEQUENCE   276 AA;  29041 MW;  A0D6C12BE96967E5 CRC64;
     MTAVSTTATT VLQATQSDVL QEIQSNFLLN SSIWVNIALA GVVILLFVAM GRDLESPRAK
     LIWVATMLVP LVSISSYAGL ASGLTVGFLQ MPPGHALAGQ EVLSPWGRYL TWTFSTPMIL
     LALGLLADTD IASLFTAITM DIGMCVTGLA AALITSSHLL RWVFYGISCA FFVAVLYVLL
     VQWPADAEAA GTSEIFGTLK ILTVVLWLGY PILWALGSEG VALLSVGVTS WGYSGLDILA
     KYVFAFLLLR WVAANEGTVS GSGMGIGSGG AAPADD
//
ID   BACH_NATPH              Reviewed;         291 AA.
AC   P15647;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 1.
DT   02-MAR-2010, entry version 75.
DE   RecName: Full=Halorhodopsin;
DE            Short=HR;
DE   AltName: Full=NpHR;
GN   Name=hop;
OS   Natronomonas pharaonis (Natronobacterium pharaonis).
OC   Archaea; Euryarchaeota; Halobacteria; Halobacteriales;
OC   Halobacteriaceae; Natronomonas.
OX   NCBI_TaxID=2257;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PARTIAL PROTEIN SEQUENCE.
RC   STRAIN=SP-1 / 28, and SP-1W;
RX   MEDLINE=90110172; PubMed=2104837;
RA   Lanyi J.K., Duschl A., Hatfield G.W., May K., Oesterhelt D.;
RT   "The primary structure of a halorhodopsin from Natronobacterium
RT   pharaonis. Structural, functional and evolutionary implications for
RT   bacterial rhodopsins and halorhodopsins.";
RL   J. Biol. Chem. 265:1253-1260(1990).
RN   [2]
RP   SPECTROPHOTOMETRIC STUDIES.
RC   STRAIN=SP-1 / 28;
RX   MEDLINE=94263943; PubMed=8204571; DOI=10.1021/bi00187a002;
RA   Scharf B., Engelhard M.;
RT   "Blue halorhodopsin from Natronobacterium pharaonis: wavelength
RT   regulation by anions.";
RL   Biochemistry 33:6387-6393(1994).
CC   -!- FUNCTION: Halorhodopsin is a light-driven anion pump. Binding
CC       affinity for the anions is in the order, bromide > chloride >
CC       nitrate > azide > bromate and binding is pH dependent.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Absorption:
CC         Abs(max)=~600 nm;
CC         Note=In the presence of anions, the maximum absorption shifts to
CC         about 577 nm;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the archaeal/bacterial/fungal opsin family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J05199; AAA72222.1; -; Genomic_DNA.
DR   PIR; A35002; A35002.
DR   SMR; P15647; 31-274.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005216; F:ion channel activity; IEA:InterPro.
DR   GO; GO:0009881; F:photoreceptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0006811; P:ion transport; IEA:UniProtKB-KW.
DR   GO; GO:0007602; P:phototransduction; IEA:UniProtKB-KW.
DR   GO; GO:0018298; P:protein-chromophore linkage; IEA:UniProtKB-KW.
DR   InterPro; IPR001425; Rhodopsin_bac.
DR   InterPro; IPR018229; Rhodopsin_retinal_BS.
DR   Pfam; PF01036; Bac_rhodopsin; 1.
DR   PRINTS; PR00251; BACTRLOPSIN.
DR   PROSITE; PS00950; BACTERIAL_OPSIN_1; 1.
DR   PROSITE; PS00327; BACTERIAL_OPSIN_RET; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Chromophore; Direct protein sequencing; Ion transport;
KW   Membrane; Photoreceptor protein; Receptor; Retinal protein;
KW   Sensory transduction; Transmembrane; Transport.
FT   CHAIN         1    291       Halorhodopsin.
FT                                /FTId=PRO_0000196268.
FT   TOPO_DOM      1     30       Extracellular (By similarity).
FT   TRANSMEM     31     56       Helix A (By similarity).
FT   TOPO_DOM     57     62       Cytoplasmic (By similarity).
FT   TRANSMEM     63     86       Helix B (By similarity).
FT   TOPO_DOM     87    120       Extracellular (By similarity).
FT   TRANSMEM    121    142       Helix C (By similarity).
FT   TOPO_DOM    143    145       Cytoplasmic (By similarity).
FT   TRANSMEM    146    169       Helix D (By similarity).
FT   TOPO_DOM    170    172       Extracellular (By similarity).
FT   TRANSMEM    173    195       Helix E (By similarity).
FT   TOPO_DOM    196    207       Cytoplasmic (By similarity).
FT   TRANSMEM    208    231       Helix F (By similarity).
FT   TOPO_DOM    232    240       Extracellular (By similarity).
FT   TRANSMEM    241    269       Helix G (By similarity).
FT   TOPO_DOM    270    291       Cytoplasmic (By similarity).
FT   MOD_RES     256    256       N6-(retinylidene)lysine (By similarity).
SQ   SEQUENCE   291 AA;  31080 MW;  454832C666655FEA CRC64;
     MTETLPPVTE SAVALQAEVT QRELFEFVLN DPLLASSLYI NIALAGLSIL LFVFMTRGLD
     DPRAKLIAVS TILVPVVSIA SYTGLASGLT ISVLEMPAGH FAEGSSVMLG GEEVDGVVTM
     WGRYLTWALS TPMILLALGL LAGSNATKLF TAITFDIAMC VTGLAAALTT SSHLMRWFWY
     AISCACFLVV LYILLVEWAQ DAKAAGTADM FNTLKLLTVV MWLGYPIVWA LGVEGIAVLP
     VGVTSWGYSF LDIVAKYIFA FLLLNYLTSN ESVVSGSILD VPSASGTPAD D
//
ID   BACR1_HALS1             Reviewed;         260 AA.
AC   P69051; P19585;
DT   01-FEB-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-2005, sequence version 1.
DT   02-MAR-2010, entry version 37.
DE   RecName: Full=Archaerhodopsin-1;
DE            Short=AR 1;
DE   Flags: Precursor;
OS   Halobacterium sp. (strain aus-1).
OC   Archaea; Euryarchaeota; Halobacteria; Halobacteriales;
OC   Halobacteriaceae; Halobacterium.
OX   NCBI_TaxID=2244;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PARTIAL PROTEIN SEQUENCE.
RX   MEDLINE=90078169; PubMed=2592356;
RA   Sugiyama Y., Maeda M., Futai M., Mukohata Y.;
RT   "Isolation of a gene that encodes a new retinal protein,
RT   archaerhodopsin, from Halobacterium sp. aus-1.";
RL   J. Biol. Chem. 264:20859-20862(1989).
RN   [2]
RP   PROTEIN SEQUENCE OF 7-39.
RX   MEDLINE=88183467; PubMed=2833260; DOI=10.1016/S0006-291X(88)80509-6;
RA   Mukohata Y., Sugiyama Y., Ihara K., Yoshida M.;
RT   "An Australian halobacterium contains a novel proton pump retinal
RT   protein: archaerhodopsin.";
RL   Biochem. Biophys. Res. Commun. 151:1339-1345(1988).
RN   [3]
RP   X-RAY CRYSTALLOGRAPHY (3.4 ANGSTROMS) OF 21-260.
RA   Enami N., Okumua H., Kouyama T.;
RT   "X-ray crystallographic studies of archaerhodopsin.";
RL   J. Photosci. 9:320-322(2002).
CC   -!- FUNCTION: Light-driven proton pump. It may interact with
CC       bacterioruberin in the claret membrane.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the archaeal/bacterial/fungal opsin family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J05165; AAA72220.1; -; Genomic_DNA.
DR   PIR; A34178; A34178.
DR   PDB; 1UAZ; X-ray; 3.40 A; A/B=7-260.
DR   PDBsum; 1UAZ; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005216; F:ion channel activity; IEA:InterPro.
DR   GO; GO:0009881; F:photoreceptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0007602; P:phototransduction; IEA:UniProtKB-KW.
DR   GO; GO:0018298; P:protein-chromophore linkage; IEA:UniProtKB-KW.
DR   GO; GO:0015992; P:proton transport; IEA:UniProtKB-KW.
DR   InterPro; IPR001425; Rhodopsin_bac.
DR   InterPro; IPR018229; Rhodopsin_retinal_BS.
DR   Pfam; PF01036; Bac_rhodopsin; 1.
DR   PRINTS; PR00251; BACTRLOPSIN.
DR   PROSITE; PS00950; BACTERIAL_OPSIN_1; 1.
DR   PROSITE; PS00327; BACTERIAL_OPSIN_RET; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Chromophore; Direct protein sequencing;
KW   Hydrogen ion transport; Ion transport; Membrane;
KW   Photoreceptor protein; Receptor; Retinal protein;
KW   Sensory transduction; Transmembrane; Transport.
FT   PROPEP        1      6
FT                                /FTId=PRO_0000020248.
FT   CHAIN         7    260       Archaerhodopsin-1.
FT                                /FTId=PRO_0000020249.
FT   TOPO_DOM      7     20       Extracellular (By similarity).
FT   TRANSMEM     21     42       Helix A (By similarity).
FT   TOPO_DOM     43     51       Cytoplasmic (By similarity).
FT   TRANSMEM     52     73       Helix B (By similarity).
FT   TOPO_DOM     74     91       Extracellular (By similarity).
FT   TRANSMEM     92    113       Helix C (By similarity).
FT   TOPO_DOM    114    116       Cytoplasmic (By similarity).
FT   TRANSMEM    117    139       Helix D (By similarity).
FT   TOPO_DOM    140    143       Extracellular (By similarity).
FT   TRANSMEM    144    172       Helix E (By similarity).
FT   TOPO_DOM    173    176       Cytoplasmic (By similarity).
FT   TRANSMEM    177    204       Helix F (By similarity).
FT   TOPO_DOM    205    212       Extracellular (By similarity).
FT   TRANSMEM    213    245       Helix G (By similarity).
FT   TOPO_DOM    246    260       Cytoplasmic (By similarity).
FT   MOD_RES     228    228       N6-(retinylidene)lysine.
FT   STRAND       16     18
FT   HELIX        22     43
FT   HELIX        51     74
FT   TURN         75     77
FT   STRAND       78     83
FT   STRAND       86     91
FT   HELIX        93    111
FT   TURN        112    114
FT   HELIX       117    138
FT   HELIX       143    165
FT   HELIX       167    171
FT   HELIX       177    203
FT   TURN        205    208
FT   HELIX       213    236
SQ   SEQUENCE   260 AA;  27852 MW;  64E1277EA641EB91 CRC64;
     MDPIALTAAV GADLLGDGRP ETLWLGIGTL LMLIGTFYFI VKGWGVTDKE AREYYSITIL
     VPGIASAAYL SMFFGIGLTE VQVGSEMLDI YYARYADWLF TTPLLLLDLA LLAKVDRVSI
     GTLVGVDALM IVTGLVGALS HTPLARYTWW LFSTICMIVV LYFLATSLRA AAKERGPEVA
     STFNTLTALV LVLWTAYPIL WIIGTEGAGV VGLGIETLLF MVLDVTAKVG FGFILLRSRA
     ILGDTEAPEP SAGAEASAAD
//
ID   BACR1_HALSS             Reviewed;         260 AA.
AC   P69052; P19585;
DT   01-FEB-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-2005, sequence version 1.
DT   02-MAR-2010, entry version 32.
DE   RecName: Full=Archaerhodopsin-1;
DE            Short=AR 1;
DE   AltName: Full=Bacterio-opsin;
DE   Flags: Precursor;
GN   Name=bop;
OS   Halobacterium sp. (strain SG1).
OC   Archaea; Euryarchaeota; Halobacteria; Halobacteriales;
OC   Halobacteriaceae; Halobacterium.
OX   NCBI_TaxID=33006;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=93239699; PubMed=8478333;
RA   Soppa J., Duschl J., Oesterhelt D.;
RT   "Bacterioopsin, haloopsin, and sensory opsin I of the halobacterial
RT   isolate Halobacterium sp. strain SG1: three new members of a growing
RT   family.";
RL   J. Bacteriol. 175:2720-2726(1993).
CC   -!- FUNCTION: Light-driven proton pump. It may interact with
CC       bacterioruberin in the claret membrane.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the archaeal/bacterial/fungal opsin family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X70291; CAA49772.1; -; Genomic_DNA.
DR   PIR; A34178; A34178.
DR   SMR; P69052; 7-242.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005216; F:ion channel activity; IEA:InterPro.
DR   GO; GO:0009881; F:photoreceptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0007602; P:phototransduction; IEA:UniProtKB-KW.
DR   GO; GO:0018298; P:protein-chromophore linkage; IEA:UniProtKB-KW.
DR   GO; GO:0015992; P:proton transport; IEA:UniProtKB-KW.
DR   InterPro; IPR001425; Rhodopsin_bac.
DR   InterPro; IPR018229; Rhodopsin_retinal_BS.
DR   Pfam; PF01036; Bac_rhodopsin; 1.
DR   PRINTS; PR00251; BACTRLOPSIN.
DR   PROSITE; PS00950; BACTERIAL_OPSIN_1; 1.
DR   PROSITE; PS00327; BACTERIAL_OPSIN_RET; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Chromophore; Hydrogen ion transport; Ion transport;
KW   Membrane; Photoreceptor protein; Receptor; Retinal protein;
KW   Sensory transduction; Transmembrane; Transport.
FT   PROPEP        1      6       By similarity.
FT                                /FTId=PRO_0000020250.
FT   CHAIN         7    260       Archaerhodopsin-1.
FT                                /FTId=PRO_0000020251.
FT   TOPO_DOM      7     20       Extracellular (By similarity).
FT   TRANSMEM     21     42       Helix A (By similarity).
FT   TOPO_DOM     43     51       Cytoplasmic (By similarity).
FT   TRANSMEM     52     73       Helix B (By similarity).
FT   TOPO_DOM     74     91       Extracellular (By similarity).
FT   TRANSMEM     92    113       Helix C (By similarity).
FT   TOPO_DOM    114    116       Cytoplasmic (By similarity).
FT   TRANSMEM    117    139       Helix D (By similarity).
FT   TOPO_DOM    140    143       Extracellular (By similarity).
FT   TRANSMEM    144    172       Helix E (By similarity).
FT   TOPO_DOM    173    176       Cytoplasmic (By similarity).
FT   TRANSMEM    177    204       Helix F (By similarity).
FT   TOPO_DOM    205    212       Extracellular (By similarity).
FT   TRANSMEM    213    245       Helix G (By similarity).
FT   TOPO_DOM    246    260       Cytoplasmic (By similarity).
FT   MOD_RES     228    228       N6-(retinylidene)lysine.
SQ   SEQUENCE   260 AA;  27852 MW;  64E1277EA641EB91 CRC64;
     MDPIALTAAV GADLLGDGRP ETLWLGIGTL LMLIGTFYFI VKGWGVTDKE AREYYSITIL
     VPGIASAAYL SMFFGIGLTE VQVGSEMLDI YYARYADWLF TTPLLLLDLA LLAKVDRVSI
     GTLVGVDALM IVTGLVGALS HTPLARYTWW LFSTICMIVV LYFLATSLRA AAKERGPEVA
     STFNTLTALV LVLWTAYPIL WIIGTEGAGV VGLGIETLLF MVLDVTAKVG FGFILLRSRA
     ILGDTEAPEP SAGAEASAAD
//
ID   BACR2_HALS2             Reviewed;         259 AA.
AC   P29563;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1993, sequence version 1.
DT   02-MAR-2010, entry version 74.
DE   RecName: Full=Archaerhodopsin-2;
DE            Short=AR 2;
DE   Flags: Precursor;
OS   Halobacterium sp. (strain aus-2).
OC   Archaea; Euryarchaeota; Halobacteria; Halobacteriales;
OC   Halobacteriaceae; Halobacterium.
OX   NCBI_TaxID=29285;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PARTIAL PROTEIN SEQUENCE.
RX   MEDLINE=91378274; PubMed=1654776; DOI=10.1016/0003-9861(91)90014-A;
RA   Uegaki K., Sugiyama Y., Mukohata Y.;
RT   "Archaerhodopsin-2, from Halobacterium sp. aus-2 further reveals
RT   essential amino acid residues for light-driven proton pumps.";
RL   Arch. Biochem. Biophys. 286:107-110(1991).
CC   -!- FUNCTION: Light-driven proton pump. It may interact with
CC       bacterioruberin in the claret membrane.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the archaeal/bacterial/fungal opsin family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; S56354; AAB19870.2; -; Genomic_DNA.
DR   PIR; S14731; S14731.
DR   PDB; 1VGO; X-ray; 2.50 A; A/B=7-259.
DR   PDB; 2EI4; X-ray; 2.10 A; A=7-259.
DR   PDB; 2Z55; X-ray; 2.50 A; A/B/D/E=7-259.
DR   PDBsum; 1VGO; -.
DR   PDBsum; 2EI4; -.
DR   PDBsum; 2Z55; -.
DR   TCDB; 3.E.1.1.2; ion-translocating microbial rhodopsin (MR) family.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005216; F:ion channel activity; IEA:InterPro.
DR   GO; GO:0009881; F:photoreceptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0007602; P:phototransduction; IEA:UniProtKB-KW.
DR   GO; GO:0018298; P:protein-chromophore linkage; IEA:UniProtKB-KW.
DR   GO; GO:0015992; P:proton transport; IEA:UniProtKB-KW.
DR   InterPro; IPR001425; Rhodopsin_bac.
DR   InterPro; IPR018229; Rhodopsin_retinal_BS.
DR   Pfam; PF01036; Bac_rhodopsin; 1.
DR   PRINTS; PR00251; BACTRLOPSIN.
DR   PROSITE; PS00950; BACTERIAL_OPSIN_1; 1.
DR   PROSITE; PS00327; BACTERIAL_OPSIN_RET; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Chromophore; Direct protein sequencing;
KW   Hydrogen ion transport; Ion transport; Membrane;
KW   Photoreceptor protein; Pyrrolidone carboxylic acid; Receptor;
KW   Retinal protein; Sensory transduction; Transmembrane; Transport.
FT   PROPEP        1      6
FT                                /FTId=PRO_0000020252.
FT   CHAIN         7    259       Archaerhodopsin-2.
FT                                /FTId=PRO_0000020253.
FT   TOPO_DOM      7     18       Extracellular (By similarity).
FT   TRANSMEM     19     40       Helix A (By similarity).
FT   TOPO_DOM     41     49       Cytoplasmic (By similarity).
FT   TRANSMEM     50     71       Helix B (By similarity).
FT   TOPO_DOM     72     90       Extracellular (By similarity).
FT   TRANSMEM     91    112       Helix C (By similarity).
FT   TOPO_DOM    113    115       Cytoplasmic (By similarity).
FT   TRANSMEM    116    138       Helix D (By similarity).
FT   TOPO_DOM    139    142       Extracellular (By similarity).
FT   TRANSMEM    143    171       Helix E (By similarity).
FT   TOPO_DOM    172    174       Cytoplasmic (By similarity).
FT   TRANSMEM    175    203       Helix F (By similarity).
FT   TOPO_DOM    204    211       Extracellular (By similarity).
FT   TRANSMEM    212    244       Helix G (By similarity).
FT   TOPO_DOM    245    259       Cytoplasmic (By similarity).
FT   MOD_RES       7      7       Pyrrolidone carboxylic acid (By
FT                                similarity).
FT   MOD_RES     227    227       N6-(retinylidene)lysine (By similarity).
FT   STRAND       14     16
FT   HELIX        20     41
FT   HELIX        47     72
FT   STRAND       77     80
FT   STRAND       86     89
FT   HELIX        92    112
FT   HELIX       116    137
FT   HELIX       142    164
FT   HELIX       166    171
FT   HELIX       176    202
FT   TURN        204    207
FT   HELIX       212    236
FT   HELIX       238    240
SQ   SEQUENCE   259 AA;  27938 MW;  918F368373DFED84 CRC64;
     MDPIALQAGF DLLNDGRPET LWLGIGTLLM LIGTFYFIAR GWGVTDKEAR EYYAITILVP
     GIASAAYLAM FFGIGVTEVE LASGTVLDIY YARYADWLFT TPLLLLDLAL LAKVDRVTIG
     TLIGVDALMI VTGLIGALSK TPLARYTWWL FSTIAFLFVL YYLLTSLRSA AAKRSEEVRS
     TFNTLTALVA VLWTAYPILW IVGTEGAGVV GLGIETLAFM VLDVTAKVGF GFVLLRSRAI
     LGETEAPEPS AGADASAAD
//
ID   BACR_HALAR              Reviewed;         250 AA.
AC   Q57101;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   02-MAR-2010, entry version 62.
DE   RecName: Full=Cruxrhodopsin-1;
DE            Short=CR-1;
DE            Short=COP-1;
GN   Name=cop1;
OS   Haloarcula argentinos (Haloarcula sp. (strain arg-1)).
OC   Archaea; Euryarchaeota; Halobacteria; Halobacteriales;
OC   Halobacteriaceae; Haloarcula.
OX   NCBI_TaxID=43776;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 1-10.
RX   MEDLINE=95070153; PubMed=7979388; DOI=10.1006/abbi.1994.1480;
RA   Tateno M., Ihara K., Mukohata Y.;
RT   "The novel ion pump rhodopsins from Haloarcula form a family
RT   independent from both the bacteriorhodopsin and archaerhodopsin
RT   families/tribes.";
RL   Arch. Biochem. Biophys. 315:127-132(1994).
CC   -!- FUNCTION: Light-driven proton pump.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the archaeal/bacterial/fungal opsin family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D31880; BAA06678.1; -; Genomic_DNA.
DR   SMR; Q57101; 6-228.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005216; F:ion channel activity; IEA:InterPro.
DR   GO; GO:0009881; F:photoreceptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0007602; P:phototransduction; IEA:UniProtKB-KW.
DR   GO; GO:0018298; P:protein-chromophore linkage; IEA:UniProtKB-KW.
DR   GO; GO:0015992; P:proton transport; IEA:UniProtKB-KW.
DR   InterPro; IPR001425; Rhodopsin_bac.
DR   InterPro; IPR018229; Rhodopsin_retinal_BS.
DR   Pfam; PF01036; Bac_rhodopsin; 1.
DR   PRINTS; PR00251; BACTRLOPSIN.
DR   PROSITE; PS00950; BACTERIAL_OPSIN_1; 1.
DR   PROSITE; PS00327; BACTERIAL_OPSIN_RET; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Chromophore; Direct protein sequencing;
KW   Hydrogen ion transport; Ion transport; Membrane;
KW   Photoreceptor protein; Receptor; Retinal protein;
KW   Sensory transduction; Transmembrane; Transport.
FT   CHAIN         1    250       Cruxrhodopsin-1.
FT                                /FTId=PRO_0000196273.
FT   TOPO_DOM      1      8       Extracellular (By similarity).
FT   TRANSMEM      9     27       Helix A (By similarity).
FT   TOPO_DOM     28     41       Cytoplasmic (By similarity).
FT   TRANSMEM     42     60       Helix B (By similarity).
FT   TOPO_DOM     61     76       Extracellular (By similarity).
FT   TRANSMEM     77     94       Helix C (By similarity).
FT   TOPO_DOM     95    105       Cytoplasmic (By similarity).
FT   TRANSMEM    106    125       Helix D (By similarity).
FT   TOPO_DOM    126    138       Extracellular (By similarity).
FT   TRANSMEM    139    158       Helix E (By similarity).
FT   TOPO_DOM    159    176       Cytoplasmic (By similarity).
FT   TRANSMEM    177    195       Helix F (By similarity).
FT   TOPO_DOM    196    207       Extracellular (By similarity).
FT   TRANSMEM    208    227       Helix G (By similarity).
FT   TOPO_DOM    228    250       Cytoplasmic (By similarity).
FT   SITE         83     83       Primary proton acceptor (By similarity).
FT   MOD_RES     220    220       N6-(retinylidene)lysine (By similarity).
SQ   SEQUENCE   250 AA;  27010 MW;  C415FA3AB6606021 CRC64;
     MPEPGSEAIW LWLGTAGMFL GMLYFIARGW GETDSRRQKF YIATILITAI AFVNYLAMAL
     GFGLTIVEFA GEEHPIYWAR YSDWLFTTPL LLYDLGLLAG ADRNTITSLV SLDVLMIGTG
     LVATLSPGSG VLSAGAERLV WWGISTAFLL VLLYFLFSSL SGRVADLPSD TRSTFKTLRN
     LVTVVWLVYP VWWLIGTEGI GLVGIGIETA GFMVIDLTAK VGFGIILLRS HGVLDGAAET
     TGTGATPADD
//
ID   BACR_HALSR              Reviewed;         255 AA.
AC   Q53496;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   02-MAR-2010, entry version 63.
DE   RecName: Full=Cruxrhodopsin-2;
DE            Short=CR-2;
DE            Short=COP-2;
GN   Name=cop2;
OS   Haloarcula sp. (strain arg-2 / Andes heights).
OC   Archaea; Euryarchaeota; Halobacteria; Halobacteriales;
OC   Halobacteriaceae; Haloarcula.
OX   NCBI_TaxID=69009;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 47-67.
RX   MEDLINE=95101679; PubMed=7803445; DOI=10.1016/0005-2728(94)90047-7;
RA   Sugiyama Y., Yamada N., Mukohata Y.;
RT   "The light-driven proton pump, cruxrhodopsin-2 in Haloarcula sp. arg-2
RT   (bR+, hR-), and its coupled ATP formation.";
RL   Biochim. Biophys. Acta 1188:287-292(1994).
CC   -!- FUNCTION: Light-driven proton pump. May generate a protonmotive
CC       force sufficient to synthesize ATP in the light.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- PTM: The N-terminus is blocked.
CC   -!- SIMILARITY: Belongs to the archaeal/bacterial/fungal opsin family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; S76743; AAB32951.1; -; Genomic_DNA.
DR   SMR; Q53496; 13-235.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005216; F:ion channel activity; IEA:InterPro.
DR   GO; GO:0009881; F:photoreceptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0007602; P:phototransduction; IEA:UniProtKB-KW.
DR   GO; GO:0018298; P:protein-chromophore linkage; IEA:UniProtKB-KW.
DR   GO; GO:0015992; P:proton transport; IEA:UniProtKB-KW.
DR   InterPro; IPR001425; Rhodopsin_bac.
DR   InterPro; IPR018229; Rhodopsin_retinal_BS.
DR   Pfam; PF01036; Bac_rhodopsin; 1.
DR   PRINTS; PR00251; BACTRLOPSIN.
DR   PROSITE; PS00950; BACTERIAL_OPSIN_1; 1.
DR   PROSITE; PS00327; BACTERIAL_OPSIN_RET; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Chromophore; Direct protein sequencing;
KW   Hydrogen ion transport; Ion transport; Membrane;
KW   Photoreceptor protein; Receptor; Retinal protein;
KW   Sensory transduction; Transmembrane; Transport.
FT   CHAIN         1    255       Cruxrhodopsin-2.
FT                                /FTId=PRO_0000196274.
FT   TOPO_DOM      1     15       Extracellular (By similarity).
FT   TRANSMEM     16     34       Helix A (By similarity).
FT   TOPO_DOM     35     48       Cytoplasmic (By similarity).
FT   TRANSMEM     49     67       Helix B (By similarity).
FT   TOPO_DOM     68     83       Extracellular (By similarity).
FT   TRANSMEM     84    101       Helix C (By similarity).
FT   TOPO_DOM    102    112       Cytoplasmic (By similarity).
FT   TRANSMEM    113    132       Helix D (By similarity).
FT   TOPO_DOM    133    145       Extracellular (By similarity).
FT   TRANSMEM    146    165       Helix E (By similarity).
FT   TOPO_DOM    166    183       Cytoplasmic (By similarity).
FT   TRANSMEM    184    202       Helix F (By similarity).
FT   TOPO_DOM    203    214       Extracellular (By similarity).
FT   TRANSMEM    215    234       Helix G (By similarity).
FT   TOPO_DOM    235    255       Cytoplasmic (By similarity).
FT   SITE         90     90       Primary proton acceptor (By similarity).
FT   MOD_RES     227    227       N6-(retinylidene)lysine (By similarity).
SQ   SEQUENCE   255 AA;  27545 MW;  E665DDE946475708 CRC64;
     MLQSGMSTYV PGGESIFLWV GTAGMFLGML YFIARGWSVS DQRRQKFYIA TIMIAAIAFV
     NYLSMALGFG VTTIELGGEE RAIYWARYTD WLFTTPLLLY DLALLAGADR NTIYSLVGLD
     VLMIGTGALA TLSAGSGVLP AGAERLVWWG ISTGFLLVLL YFLFSNLTDR ASELSGDLQS
     KFSTLRNLVL VLWLVYPVLW LVGTEGLGLV GLPIETAAFM VLDLTAKIGF GIILLQSHAV
     LDEGQTASEG AAVAD
//
ID   BACS1_HALSA             Reviewed;         239 AA.
AC   P25964; Q9HPF5;
DT   01-MAY-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1992, sequence version 1.
DT   02-MAR-2010, entry version 90.
DE   RecName: Full=Sensory rhodopsin-1;
DE   AltName: Full=Sensory rhodopsin I;
DE            Short=SR-I;
GN   Name=sop1; Synonyms=sopI; OrderedLocusNames=VNG_1660G;
OS   Halobacterium salinarium (Halobacterium halobium).
OC   Archaea; Euryarchaeota; Halobacteria; Halobacteriales;
OC   Halobacteriaceae; Halobacterium.
OX   NCBI_TaxID=2242;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PARTIAL PROTEIN SEQUENCE.
RX   MEDLINE=90076116; PubMed=2591367;
RA   Blanck A., Oesterhelt D., Ferrando E., Schegk E.S., Lottspeich F.;
RT   "Primary structure of sensory rhodopsin I, a prokaryotic
RT   photoreceptor.";
RL   EMBO J. 8:3963-3971(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=Flx5R;
RX   MEDLINE=93101637; PubMed=1465418; DOI=10.1073/pnas.89.24.11915;
RA   Yao V.J., Spudich J.L.;
RT   "Primary structure of an archaebacterial transducer, a methyl-
RT   accepting protein associated with sensory rhodopsin I.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:11915-11919(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 700922 / JCM 11081 / NRC-1;
RX   MEDLINE=20504483; PubMed=11016950; DOI=10.1073/pnas.190337797;
RA   Ng W.V., Kennedy S.P., Mahairas G.G., Berquist B., Pan M.,
RA   Shukla H.D., Lasky S.R., Baliga N.S., Thorsson V., Sbrogna J.,
RA   Swartzell S., Weir D., Hall J., Dahl T.A., Welti R., Goo Y.A.,
RA   Leithauser B., Keller K., Cruz R., Danson M.J., Hough D.W.,
RA   Maddocks D.G., Jablonski P.E., Krebs M.P., Angevine C.M., Dale H.,
RA   Isenbarger T.A., Peck R.F., Pohlschroder M., Spudich J.L., Jung K.-H.,
RA   Alam M., Freitas T., Hou S., Daniels C.J., Dennis P.P., Omer A.D.,
RA   Ebhardt H., Lowe T.M., Liang P., Riley M., Hood L., DasSarma S.;
RT   "Genome sequence of Halobacterium species NRC-1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:12176-12181(2000).
RN   [4]
RP   SPECTROSCOPY.
RX   MEDLINE=91242452; PubMed=2036407; DOI=10.1021/bi00236a010;
RA   Bosuche O., Spudich E.N., Pudich J.L., Rotschild K.J.;
RT   "Conformational changes in sensory rhodopsin I: similarities and
RT   differences with bacteriorhodopsin, halorhodopsin, and rhodopsin.";
RL   Biochemistry 30:5395-5400(1991).
RN   [5]
RP   3D-STRUCTURE MODELING.
RX   MEDLINE=97297615; PubMed=9153084; DOI=10.1093/protein/10.3.197;
RA   Lin S.L., Yan B.;
RT   "Three-dimensional model of sensory rhodopsin I reveals important
RT   restraints between the protein and the chromophore.";
RL   Protein Eng. 10:197-206(1997).
CC   -!- FUNCTION: Involved in the control of phototaxis. Mediates both
CC       photoattractant (in the red) and photophobic (in the near UV)
CC       responses. Seems to activate a methyl-accepting protein (HTR-I).
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the archaeal/bacterial/fungal opsin family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X51682; CAA35984.1; -; Genomic_DNA.
DR   EMBL; L05603; AAA72316.1; -; Genomic_DNA.
DR   EMBL; AE004437; AAG19914.1; -; Genomic_DNA.
DR   PIR; F84318; F84318.
DR   PIR; S09277; S09277.
DR   RefSeq; NP_280434.1; -.
DR   PDB; 1SR1; Model; -; A=1-239.
DR   PDBsum; 1SR1; -.
DR   SMR; P25964; 5-218.
DR   TCDB; 3.E.1.3.1; ion-translocating microbial rhodopsin (MR) family.
DR   GeneID; 1448214; -.
DR   GenomeReviews; AE004437_GR; VNG_1660G.
DR   KEGG; hal:VNG1660G; -.
DR   NMPDR; fig|64091.1.peg.1455; -.
DR   HOGENOM; HBG206176; -.
DR   OMA; WINQTID; -.
DR   ProtClustDB; CLSK348875; -.
DR   BioCyc; HSP64091:VNG1660G-MONOMER; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005216; F:ion channel activity; IEA:InterPro.
DR   GO; GO:0009881; F:photoreceptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0006811; P:ion transport; IEA:InterPro.
DR   GO; GO:0007602; P:phototransduction; IEA:UniProtKB-KW.
DR   GO; GO:0018298; P:protein-chromophore linkage; IEA:UniProtKB-KW.
DR   InterPro; IPR001425; Rhodopsin_bac.
DR   InterPro; IPR018229; Rhodopsin_retinal_BS.
DR   Pfam; PF01036; Bac_rhodopsin; 1.
DR   PRINTS; PR00251; BACTRLOPSIN.
DR   PROSITE; PS00950; BACTERIAL_OPSIN_1; 1.
DR   PROSITE; PS00327; BACTERIAL_OPSIN_RET; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Chromophore; Complete proteome;
KW   Direct protein sequencing; Membrane; Photoreceptor protein; Receptor;
KW   Retinal protein; Sensory transduction; Transmembrane.
FT   CHAIN         1    239       Sensory rhodopsin-1.
FT                                /FTId=PRO_0000196276.
FT   TOPO_DOM      1      3       Extracellular (By similarity).
FT   TRANSMEM      4     25       Helix A (By similarity).
FT   TOPO_DOM     26     34       Cytoplasmic (By similarity).
FT   TRANSMEM     35     56       Helix B (By similarity).
FT   TOPO_DOM     57     70       Extracellular (By similarity).
FT   TRANSMEM     71     92       Helix C (By similarity).
FT   TOPO_DOM     93     95       Cytoplasmic (By similarity).
FT   TRANSMEM     96    118       Helix D (By similarity).
FT   TOPO_DOM    119    122       Extracellular (By similarity).
FT   TRANSMEM    123    150       Helix E (By similarity).
FT   TOPO_DOM    151    153       Cytoplasmic (By similarity).
FT   TRANSMEM    154    181       Helix F (By similarity).
FT   TOPO_DOM    182    189       Extracellular (By similarity).
FT   TRANSMEM    190    222       Helix G (By similarity).
FT   TOPO_DOM    223    239       Cytoplasmic (By similarity).
FT   MOD_RES     205    205       N6-(retinylidene)lysine.
FT   HELIX         6     27
FT   HELIX        38     50
FT   HELIX        53     56
FT   HELIX        66     90
FT   HELIX       100    117
FT   TURN        128    130
FT   TURN        134    136
FT   HELIX       139    145
FT   HELIX       156    179
FT   HELIX       192    213
SQ   SEQUENCE   239 AA;  25501 MW;  2496161B60425DE3 CRC64;
     MDAVATAYLG GAVALIVGVA FVWLLYRSLD GSPHQSALAP LAIIPVFAGL SYVGMAYDIG
     TVIVNGNQIV GLRYIDWLVT TPILVGYVGY AAGASRRSII GVMVADALMI AVGAGAVVTD
     GTLKWALFGV SSIFHLSLFA YLYVIFPRVV PDVPEQIGLF NLLKNHIGLL WLAYPLVWLF
     GPAGIGEATA AGVALTYVFL DVLAKVPYVY FFYARRRVFM HSESPPAPEQ ATVEATAAD
//
ID   BACS1_HALSS             Reviewed;         247 AA.
AC   P33743;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1994, sequence version 1.
DT   02-MAR-2010, entry version 64.
DE   RecName: Full=Sensory rhodopsin-1;
DE   AltName: Full=Sensory rhodopsin I;
DE            Short=SR-I;
GN   Name=sop1; Synonyms=sopI;
OS   Halobacterium sp. (strain SG1).
OC   Archaea; Euryarchaeota; Halobacteria; Halobacteriales;
OC   Halobacteriaceae; Halobacterium.
OX   NCBI_TaxID=33006;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=93239699; PubMed=8478333;
RA   Soppa J., Duschl J., Oesterhelt D.;
RT   "Bacterioopsin, haloopsin, and sensory opsin I of the halobacterial
RT   isolate Halobacterium sp. strain SG1: three new members of a growing
RT   family.";
RL   J. Bacteriol. 175:2720-2726(1993).
CC   -!- FUNCTION: Involved in the control of phototaxis. Mediates both
CC       photoattractant (in the red) and photophobic (in the near UV)
CC       responses. Seems to activate a methyl-accepting protein (HTR-I).
CC       Photoreceptor for green-red and UV light.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the archaeal/bacterial/fungal opsin family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X70290; CAA49771.1; -; Genomic_DNA.
DR   PIR; S78782; S29989.
DR   SMR; P33743; 4-219.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005216; F:ion channel activity; IEA:InterPro.
DR   GO; GO:0009881; F:photoreceptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0006811; P:ion transport; IEA:InterPro.
DR   GO; GO:0007602; P:phototransduction; IEA:UniProtKB-KW.
DR   GO; GO:0018298; P:protein-chromophore linkage; IEA:UniProtKB-KW.
DR   InterPro; IPR001425; Rhodopsin_bac.
DR   InterPro; IPR018229; Rhodopsin_retinal_BS.
DR   Pfam; PF01036; Bac_rhodopsin; 1.
DR   PRINTS; PR00251; BACTRLOPSIN.
DR   PROSITE; PS00950; BACTERIAL_OPSIN_1; 1.
DR   PROSITE; PS00327; BACTERIAL_OPSIN_RET; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Chromophore; Membrane; Photoreceptor protein; Receptor;
KW   Retinal protein; Sensory transduction; Transmembrane.
FT   CHAIN         1    247       Sensory rhodopsin-1.
FT                                /FTId=PRO_0000196277.
FT   TOPO_DOM      1      4       Extracellular (By similarity).
FT   TRANSMEM      5     26       Helix A (By similarity).
FT   TOPO_DOM     27     35       Cytoplasmic (By similarity).
FT   TRANSMEM     36     57       Helix B (By similarity).
FT   TOPO_DOM     58     71       Extracellular (By similarity).
FT   TRANSMEM     72     93       Helix C (By similarity).
FT   TOPO_DOM     94     96       Cytoplasmic (By similarity).
FT   TRANSMEM     97    119       Helix D (By similarity).
FT   TOPO_DOM    120    123       Extracellular (By similarity).
FT   TRANSMEM    124    151       Helix E (By similarity).
FT   TOPO_DOM    152    154       Cytoplasmic (By similarity).
FT   TRANSMEM    155    182       Helix F (By similarity).
FT   TOPO_DOM    183    190       Extracellular (By similarity).
FT   TRANSMEM    191    223       Helix G (By similarity).
FT   TOPO_DOM    224    247       Cytoplasmic (By similarity).
FT   MOD_RES     206    206       N6-(retinylidene)lysine.
SQ   SEQUENCE   247 AA;  25748 MW;  807295627F0E6185 CRC64;
     MTGAVSAAYW IAAVAFLVGL GITAALYAKL GESEDRGRLA ALAVIPGFAG LAYAGMALGI
     GTVTVNGAEL VGLRYVDWIV TTPLLVGFIG YVAGASRRAI AGVMLADALM IAFGAGAVVT
     GGTLKWVLFG VSSIFHVTLF AYLYVVFPRA VPDDPMQRGL FSLLKNHVGL LWLAYPFVWL
     MGPAGIGFTT GVGAALTYAF LDVLAKVPYV YFFYARRQAF TDVVSAATAD REDATDAVGD
     GAPTAAD
//
ID   BACS_HALSD              Reviewed;         254 AA.
AC   O93743;
DT   01-JUN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   02-MAR-2010, entry version 56.
DE   RecName: Full=Sensory rhodopsin;
DE            Short=SR;
GN   Name=sop;
OS   Halorubrum sodomense.
OC   Archaea; Euryarchaeota; Halobacteria; Halobacteriales;
OC   Halobacteriaceae; Halorubrum.
OX   NCBI_TaxID=35743;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=99096913; PubMed=9878396; DOI=10.1006/jmbi.1998.2286;
RA   Ihara K., Umemura T., Katagiri I., Kitajima-Ihara T., Sugiyama Y.,
RA   Kimura Y., Mukohata Y.;
RT   "Evolution of the archaeal rhodopsins: evolution rate changes by gene
RT   duplication and functional differentiation.";
RL   J. Mol. Biol. 285:163-174(1999).
CC   -!- FUNCTION: Involved in the control of phototaxis (By similarity).
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the archaeal/bacterial/fungal opsin family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB009623; BAA75203.1; -; Genomic_DNA.
DR   PIR; T43843; T43843.
DR   SMR; O93743; 4-219.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005216; F:ion channel activity; IEA:InterPro.
DR   GO; GO:0009881; F:photoreceptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0006811; P:ion transport; IEA:InterPro.
DR   GO; GO:0007602; P:phototransduction; IEA:UniProtKB-KW.
DR   GO; GO:0018298; P:protein-chromophore linkage; IEA:UniProtKB-KW.
DR   InterPro; IPR001425; Rhodopsin_bac.
DR   InterPro; IPR018229; Rhodopsin_retinal_BS.
DR   Pfam; PF01036; Bac_rhodopsin; 1.
DR   PRINTS; PR00251; BACTRLOPSIN.
DR   PROSITE; PS00950; BACTERIAL_OPSIN_1; 1.
DR   PROSITE; PS00327; BACTERIAL_OPSIN_RET; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Chromophore; Membrane; Photoreceptor protein; Receptor;
KW   Retinal protein; Sensory transduction; Transmembrane.
FT   CHAIN         1    254       Sensory rhodopsin.
FT                                /FTId=PRO_0000196278.
FT   TOPO_DOM      1      4       Extracellular (By similarity).
FT   TRANSMEM      5     26       Helix A (By similarity).
FT   TOPO_DOM     27     35       Cytoplasmic (By similarity).
FT   TRANSMEM     36     57       Helix B (By similarity).
FT   TOPO_DOM     58     71       Extracellular (By similarity).
FT   TRANSMEM     72     93       Helix C (By similarity).
FT   TOPO_DOM     94     96       Cytoplasmic (By similarity).
FT   TRANSMEM     97    119       Helix D (By similarity).
FT   TOPO_DOM    120    123       Extracellular (By similarity).
FT   TRANSMEM    124    151       Helix E (By similarity).
FT   TOPO_DOM    152    154       Cytoplasmic (By similarity).
FT   TRANSMEM    155    182       Helix F (By similarity).
FT   TOPO_DOM    183    190       Extracellular (By similarity).
FT   TRANSMEM    191    223       Helix G (By similarity).
FT   TOPO_DOM    224    254       Cytoplasmic (By similarity).
FT   MOD_RES     206    206       N6-(retinylidene)lysine.
SQ   SEQUENCE   254 AA;  26282 MW;  92F5428824AD56D7 CRC64;
     MTGAVTSAYW LAAVAFLIGV GITAALYAKL EGSRARTRLA ALAVIPGFAG LSYVGMALGI
     GTVTVNGAEL VGLRYVDWVV TTPLLVGFIG YNAGASRRAI AGVMIADALM IVFGAAAVVS
     GGTLKWALFG VSALFHVSLF AYLYVIFPGG IPDDPMQRGL FSLLKNHVGL LWLAYPFVWL
     MGPAGIGFTG AVGAALTYAF LDVLAKVPYV YFFYARRQAF IDVTDSRAAA KGDGPAVGGE
     APVATGDDAP TAAD
//
ID   C560_BOVIN              Reviewed;         169 AA.
AC   P35720; Q1JP77; Q3T194; Q9T2T6;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 2.
DT   02-MAR-2010, entry version 77.
DE   RecName: Full=Succinate dehydrogenase cytochrome b560 subunit, mitochondrial;
DE   AltName: Full=Succinate dehydrogenase complex subunit C;
DE   AltName: Full=Integral membrane protein CII-3;
DE   AltName: Full=QPs-1;
DE            Short=QPs1;
DE   Flags: Precursor;
GN   Name=SDHC; Synonyms=CYB560;
OS   Bos taurus (Bovine).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Ruminantia;
OC   Pecora; Bovidae; Bovinae; Bos.
OX   NCBI_TaxID=9913;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 30-36.
RC   TISSUE=Heart;
RX   MEDLINE=95034971; PubMed=7947903; DOI=10.1016/0005-2728(94)90035-3;
RA   Cochran B., Capaldi R.A., Ackrell B.A.;
RT   "The cDNA sequence of beef heart CII-3, a membrane-intrinsic subunit
RT   of succinate-ubiquinone oxidoreductase.";
RL   Biochim. Biophys. Acta 1188:162-166(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=Crossbred X Angus; TISSUE=Ileum;
RG   NIH - Mammalian Gene Collection (MGC) project;
RL   Submitted (AUG-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2-169.
RX   PubMed=16305752; DOI=10.1186/1471-2164-6-166;
RA   Harhay G.P., Sonstegard T.S., Keele J.W., Heaton M.P., Clawson M.L.,
RA   Snelling W.M., Wiedmann R.T., Van Tassell C.P., Smith T.P.L.;
RT   "Characterization of 954 bovine full-CDS cDNA sequences.";
RL   BMC Genomics 6:166-166(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 38-169.
RC   TISSUE=Heart;
RX   MEDLINE=93077541; PubMed=1447196;
RA   Yu L., Wei Y.-Y., Usui S., Yu C.-A.;
RT   "Cytochrome b560 (QPs1) of mitochondrial succinate-ubiquinone
RT   reductase. Immunochemistry, cloning, and nucleotide sequencing.";
RL   J. Biol. Chem. 267:24508-24515(1992).
RN   [5]
RP   PROTEIN SEQUENCE OF 30-169.
RC   TISSUE=Heart;
RX   MEDLINE=95197652; PubMed=7890754; DOI=10.1074/jbc.270.11.6193;
RA   Lee G.Y., He D.Y., Yu L., Yu C.A.;
RT   "Identification of the ubiquinone-binding domain in QPs1 of succinate-
RT   ubiquinone reductase.";
RL   J. Biol. Chem. 270:6193-6198(1995).
CC   -!- FUNCTION: Membrane-anchoring subunit of succinate dehydrogenase
CC       (SDH) that is involved in complex II of the mitochondrial electron
CC       transport chain and is responsible for transferring electrons from
CC       succinate to ubiquinone (coenzyme Q).
CC   -!- COFACTOR: Heme group. The heme is bound between the two
CC       transmembrane subunits SDHC and SDHD (By similarity).
CC   -!- PATHWAY: Carbohydrate metabolism; tricarboxylic acid cycle.
CC   -!- SUBUNIT: Component of complex II composed of four subunits: the
CC       flavoprotein (FP) SDHA, iron-sulfur protein (IP) SDHB, and a
CC       cytochrome b560 composed of SDHC and SDHD.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane; Multi-pass
CC       membrane protein.
CC   -!- PTM: The N-terminus is blocked.
CC   -!- SIMILARITY: Belongs to the cytochrome b560 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; S74803; AAB32390.1; -; mRNA.
DR   EMBL; BC102062; AAI02063.1; -; mRNA.
DR   EMBL; BT025477; ABF57433.1; -; mRNA.
DR   EMBL; M76747; AAA21608.1; -; mRNA.
DR   IPI; IPI00700619; -.
DR   PIR; A45159; A45159.
DR   RefSeq; NP_787008.1; -.
DR   UniGene; Bt.89093; -.
DR   SMR; P35720; 32-169.
DR   STRING; P35720; -.
DR   Ensembl; ENSBTAT00000021075; ENSBTAP00000021075; ENSBTAG00000015853; Bos taurus.
DR   GeneID; 327696; -.
DR   KEGG; bta:327696; -.
DR   CTD; 327696; -.
DR   eggNOG; maNOG16227; -.
DR   HOVERGEN; HBG003187; -.
DR   InParanoid; P35720; -.
DR   OMA; VMSICHR; -.
DR   OrthoDB; EOG99GP1W; -.
DR   PhylomeDB; P35720; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005749; C:mitochondrial respiratory chain complex II; ISS:UniProtKB.
DR   GO; GO:0009055; F:electron carrier activity; IEA:InterPro.
DR   GO; GO:0020037; F:heme binding; ISS:UniProtKB.
DR   GO; GO:0000104; F:succinate dehydrogenase activity; IEA:InterPro.
DR   GO; GO:0022900; P:electron transport chain; IEA:UniProtKB-KW.
DR   GO; GO:0006810; P:transport; IEA:UniProtKB-KW.
DR   GO; GO:0006099; P:tricarboxylic acid cycle; IEA:UniProtKB-KW.
DR   InterPro; IPR018495; Succ_DH_cyt_bsu_CS.
DR   InterPro; IPR014314; Succ_DH_cytb556.
DR   InterPro; IPR014361; Succ_DH_cytb560.
DR   InterPro; IPR000701; Succ_DH_Fumarate_Rdtase_TM-su.
DR   Pfam; PF01127; Sdh_cyt; 1.
DR   PIRSF; PIRSF000178; SDH_cyt_b560; 1.
DR   TIGRFAMs; TIGR02970; succ_dehyd_cytB; 1.
DR   PROSITE; PS01000; SDH_CYT_1; 1.
DR   PROSITE; PS01001; SDH_CYT_2; 1.
PE   1: Evidence at protein level;
KW   Direct protein sequencing; Electron transport; Heme; Iron; Membrane;
KW   Metal-binding; Mitochondrion; Mitochondrion inner membrane;
KW   Transit peptide; Transmembrane; Transport; Tricarboxylic acid cycle.
FT   TRANSIT       1     29       Mitochondrion.
FT   CHAIN        30    169       Succinate dehydrogenase cytochrome b560
FT                                subunit, mitochondrial.
FT                                /FTId=PRO_0000003632.
FT   TOPO_DOM     30     62       Mitochondrial matrix (By similarity).
FT   TRANSMEM     63     92       By similarity.
FT   TOPO_DOM     93    112       Mitochondrial intermembrane (By
FT                                similarity).
FT   TRANSMEM    113    137       By similarity.
FT   TOPO_DOM    138    144       Mitochondrial matrix (By similarity).
FT   TRANSMEM    145    166       By similarity.
FT   TOPO_DOM    167    169       Mitochondrial intermembrane (By
FT                                similarity).
FT   METAL       127    127       Iron (heme axial ligand); shared with
FT                                SDHD (By similarity).
SQ   SEQUENCE   169 AA;  18389 MW;  CC2CFAD4380C4E27 CRC64;
     MAALLLRHVG RHCLRAHLSP QLCIRNAVPL GTTAKEEMER FWSKNTTLNR PLSPHISIYG
     WSLPMAMSIC HRGTGIALSA GVSLFGLSAL LVPGSFESHL EFVKSLCLGP ALIHTAKFAL
     VFPLMYHTWN GIRHLMWDLG KGLTISQLHQ SGVAVLVLTV LSSVGLAAM
//
ID   C560_HUMAN              Reviewed;         169 AA.
AC   Q99643; Q5VTH3;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1997, sequence version 1.
DT   02-MAR-2010, entry version 109.
DE   RecName: Full=Succinate dehydrogenase cytochrome b560 subunit, mitochondrial;
DE   AltName: Full=Succinate dehydrogenase complex subunit C;
DE   AltName: Full=Integral membrane protein CII-3;
DE   AltName: Full=QPs-1;
DE            Short=QPs1;
DE   AltName: Full=Succinate-ubiquinone oxidoreductase cytochrome B large subunit;
DE            Short=CYBL;
DE   Flags: Precursor;
GN   Name=SDHC; Synonyms=CYB560, SDH3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Au H.C., Raval P.J., Scheffler I.E.;
RT   "The cDNA sequence of human CII-3, an integral membrane protein
RT   subunit of complex II of the mitochondria electron transport chain.";
RL   Submitted (MAY-1996) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   MEDLINE=98194224; PubMed=9533030;
RA   Hirawake H., Taniwaki M., Tamura A., Kojima S., Kita K.;
RT   "Cytochrome b in human complex II (succinate-ubiquinone
RT   oxidoreductase): cDNA cloning of the components in liver mitochondria
RT   and chromosome assignment of the genes for the large (SDHC) and small
RT   (SDHD) subunits to 1q21 and 11q23.";
RL   Cytogenet. Cell Genet. 79:132-138(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=98372071; PubMed=9714607; DOI=10.1016/S0378-1119(98)00186-3;
RA   Elbehti-Green A., Au H.C., Mascarello J.T., Ream-Robinson D.,
RA   Scheffler I.E.;
RT   "Characterization of the human SDHC gene encoding one of the integral
RT   membrane proteins of succinate-quinone oxidoreductase in
RT   mitochondria.";
RL   Gene 213:133-140(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, Mammary gland, and Skeletal muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   IDENTIFICATION [LARGE SCALE ANALYSIS], AND MASS SPECTROMETRY.
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [8]
RP   INVOLVEMENT IN PGL3.
RX   MEDLINE=20517329; PubMed=11062460; DOI=10.1038/81551;
RA   Niemann S., Mueller U.;
RT   "Mutations in SDHC cause autosomal dominant paraganglioma, type 3.";
RL   Nat. Genet. 26:268-270(2000).
RN   [9]
RP   INVOLVEMENT IN PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA.
RX   PubMed=17804857; DOI=10.1056/NEJMc071191;
RA   McWhinney S.R., Pasini B., Stratakis C.A.;
RT   "Familial gastrointestinal stromal tumors and germ-line mutations.";
RL   N. Engl. J. Med. 357:1054-1056(2007).
CC   -!- FUNCTION: Membrane-anchoring subunit of succinate dehydrogenase
CC       (SDH) that is involved in complex II of the mitochondrial electron
CC       transport chain and is responsible for transferring electrons from
CC       succinate to ubiquinone (coenzyme Q).
CC   -!- COFACTOR: Heme group. The heme is bound between the two
CC       transmembrane subunits SDHC and SDHD (By similarity).
CC   -!- PATHWAY: Carbohydrate metabolism; tricarboxylic acid cycle.
CC   -!- SUBUNIT: Component of complex II composed of four subunits: the
CC       flavoprotein (FP) SDHA, iron-sulfur protein (IP) SDHB, and a
CC       cytochrome b560 composed of SDHC and SDHD.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane; Multi-pass
CC       membrane protein.
CC   -!- DISEASE: Defects in SDHC are the cause of autosomal dominant non-
CC       chromaffin paragangliomas type 3 (PGL3) [MIM:605373]. Non-
CC       chromaffin paragangliomas are usually benign, neural crest derived
CC       tumors of parasympathetic ganglia.
CC   -!- DISEASE: Defects in SDHC are a cause of paraganglioma and gastric
CC       stromal sarcoma [MIM:606864]; also known as Carney-Stratakis
CC       syndrome. Gastrointestinal stromal tumors may be sporadic or
CC       inherited in an autosomal dominant manner, alone or as a component
CC       of a syndrome associated with other tumors, such as in the context
CC       of neurofibromatosis type 1 (NF1). Patients have both
CC       gastrointestinal stromal tumors and paragangliomas. Susceptibility
CC       to the tumors was inherited in an apparently autosomal dominant
CC       manner, with incomplete penetrance.
CC   -!- SIMILARITY: Belongs to the cytochrome b560 family.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/SDHCID389.html";
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/SDHC";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=SDHC entry;
CC       URL="http://en.wikipedia.org/wiki/SDHC_%28gene%29";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U57877; AAB41838.1; -; mRNA.
DR   EMBL; D49737; BAA31998.1; -; mRNA.
DR   EMBL; AF039594; AAC27993.1; -; Genomic_DNA.
DR   EMBL; AF039589; AAC27993.1; JOINED; Genomic_DNA.
DR   EMBL; AF039590; AAC27993.1; JOINED; Genomic_DNA.
DR   EMBL; AF039591; AAC27993.1; JOINED; Genomic_DNA.
DR   EMBL; AF039592; AAC27993.1; JOINED; Genomic_DNA.
DR   EMBL; AF039593; AAC27993.1; JOINED; Genomic_DNA.
DR   EMBL; AL592295; CAH70271.1; -; Genomic_DNA.
DR   EMBL; CH471121; EAW52600.1; -; Genomic_DNA.
DR   EMBL; BC020808; AAH20808.1; -; mRNA.
DR   EMBL; BC033626; AAH33626.1; -; mRNA.
DR   EMBL; BC066329; AAH66329.1; -; mRNA.
DR   IPI; IPI00016968; -.
DR   RefSeq; NP_001030588.1; -.
DR   RefSeq; NP_001030589.1; -.
DR   RefSeq; NP_001030590.1; -.
DR   RefSeq; NP_002992.1; -.
DR   UniGene; Hs.444472; -.
DR   SMR; Q99643; 32-169.
DR   STRING; Q99643; -.
DR   PRIDE; Q99643; -.
DR   Ensembl; ENST00000367975; ENSP00000356953; ENSG00000143252; Homo sapiens.
DR   GeneID; 6391; -.
DR   KEGG; hsa:6391; -.
DR   NMPDR; fig|9606.3.peg.2487; -.
DR   UCSC; uc001gag.1; human.
DR   CTD; 6391; -.
DR   GeneCards; GC01P159550; -.
DR   H-InvDB; HIX0001245; -.
DR   HGNC; HGNC:10682; SDHC.
DR   MIM; 602413; gene.
DR   MIM; 605373; phenotype.
DR   MIM; 606864; phenotype.
DR   Orphanet; 97286; Carney-Stratakis syndrome.
DR   Orphanet; 29072; Hereditary pheochromocytoma-paraganglioma syndrome.
DR   PharmGKB; PA35607; -.
DR   HOGENOM; HBG734972; -.
DR   HOVERGEN; HBG003187; -.
DR   InParanoid; Q99643; -.
DR   OMA; VMSICHR; -.
DR   PhylomeDB; Q99643; -.
DR   BioCyc; MetaCyc:ENSG00000143252-MONOMER; -.
DR   Reactome; REACT_1046; Pyruvate metabolism and TCA cycle.
DR   Reactome; REACT_1505; Integration of energy metabolism.
DR   Reactome; REACT_15380; Diabetes pathways.
DR   DrugBank; DB00139; Succinic acid.
DR   NextBio; 24828; -.
DR   ArrayExpress; Q99643; -.
DR   Bgee; Q99643; -.
DR   CleanEx; HS_SDHC; -.
DR   Genevestigator; Q99643; -.
DR   GermOnline; ENSG00000143252; Homo sapiens.
DR   GO; GO:0016021; C:integral to membrane; TAS:UniProtKB.
DR   GO; GO:0005749; C:mitochondrial respiratory chain complex II; ISS:UniProtKB.
DR   GO; GO:0009055; F:electron carrier activity; IEA:InterPro.
DR   GO; GO:0020037; F:heme binding; ISS:UniProtKB.
DR   GO; GO:0000104; F:succinate dehydrogenase activity; IEA:InterPro.
DR   GO; GO:0022900; P:electron transport chain; IEA:UniProtKB-KW.
DR   GO; GO:0006810; P:transport; IEA:UniProtKB-KW.
DR   GO; GO:0006099; P:tricarboxylic acid cycle; TAS:UniProtKB.
DR   InterPro; IPR018495; Succ_DH_cyt_bsu_CS.
DR   InterPro; IPR014314; Succ_DH_cytb556.
DR   InterPro; IPR014361; Succ_DH_cytb560.
DR   InterPro; IPR000701; Succ_DH_Fumarate_Rdtase_TM-su.
DR   Pfam; PF01127; Sdh_cyt; 1.
DR   PIRSF; PIRSF000178; SDH_cyt_b560; 1.
DR   TIGRFAMs; TIGR02970; succ_dehyd_cytB; 1.
DR   PROSITE; PS01000; SDH_CYT_1; 1.
DR   PROSITE; PS01001; SDH_CYT_2; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Electron transport; Heme; Iron; Membrane;
KW   Metal-binding; Mitochondrion; Mitochondrion inner membrane;
KW   Transit peptide; Transmembrane; Transport; Tricarboxylic acid cycle.
FT   TRANSIT       1     29       Mitochondrion (By similarity).
FT   CHAIN        30    169       Succinate dehydrogenase cytochrome b560
FT                                subunit, mitochondrial.
FT                                /FTId=PRO_0000003634.
FT   TOPO_DOM     30     62       Mitochondrial matrix (By similarity).
FT   TRANSMEM     63     92       By similarity.
FT   TOPO_DOM     93    112       Mitochondrial intermembrane (By
FT                                similarity).
FT   TRANSMEM    113    137       By similarity.
FT   TOPO_DOM    138    144       Mitochondrial matrix (By similarity).
FT   TRANSMEM    145    166       By similarity.
FT   TOPO_DOM    167    169       Mitochondrial intermembrane (By
FT                                similarity).
FT   METAL       127    127       Iron (heme axial ligand); shared with
FT                                SDHD (By similarity).
SQ   SEQUENCE   169 AA;  18610 MW;  DF7CBD6D0CD49500 CRC64;
     MAALLLRHVG RHCLRAHFSP QLCIRNAVPL GTTAKEEMER FWNKNIGSNR PLSPHITIYS
     WSLPMAMSIC HRGTGIALSA GVSLFGMSAL LLPGNFESYL ELVKSLCLGP ALIHTAKFAL
     VFPLMYHTWN GIRHLMWDLG KGLKIPQLYQ SGVVVLVLTV LSSMGLAAM
//
ID   CADA_BACSU              Reviewed;         702 AA.
AC   O32219;
DT   20-JAN-2009, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   02-MAR-2010, entry version 80.
DE   RecName: Full=Cadmium, zinc and cobalt-transporting ATPase;
DE            EC=3.6.3.3;
DE            EC=3.6.3.5;
GN   Name=cadA; Synonyms=yvgW; OrderedLocusNames=BSU33490;
OS   Bacillus subtilis.
OC   Bacteria; Firmicutes; Bacillales; Bacillaceae; Bacillus.
OX   NCBI_TaxID=1423;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=168;
RX   MEDLINE=98044033; PubMed=9384377; DOI=10.1038/36786;
RA   Kunst F., Ogasawara N., Moszer I., Albertini A.M., Alloni G.,
RA   Azevedo V., Bertero M.G., Bessieres P., Bolotin A., Borchert S.,
RA   Borriss R., Boursier L., Brans A., Braun M., Brignell S.C., Bron S.,
RA   Brouillet S., Bruschi C.V., Caldwell B., Capuano V., Carter N.M.,
RA   Choi S.-K., Codani J.-J., Connerton I.F., Cummings N.J., Daniel R.A.,
RA   Denizot F., Devine K.M., Duesterhoeft A., Ehrlich S.D., Emmerson P.T.,
RA   Entian K.-D., Errington J., Fabret C., Ferrari E., Foulger D.,
RA   Fritz C., Fujita M., Fujita Y., Fuma S., Galizzi A., Galleron N.,
RA   Ghim S.-Y., Glaser P., Goffeau A., Golightly E.J., Grandi G.,
RA   Guiseppi G., Guy B.J., Haga K., Haiech J., Harwood C.R., Henaut A.,
RA   Hilbert H., Holsappel S., Hosono S., Hullo M.-F., Itaya M.,
RA   Jones L.-M., Joris B., Karamata D., Kasahara Y., Klaerr-Blanchard M.,
RA   Klein C., Kobayashi Y., Koetter P., Koningstein G., Krogh S.,
RA   Kumano M., Kurita K., Lapidus A., Lardinois S., Lauber J.,
RA   Lazarevic V., Lee S.-M., Levine A., Liu H., Masuda S., Mauel C.,
RA   Medigue C., Medina N., Mellado R.P., Mizuno M., Moestl D., Nakai S.,
RA   Noback M., Noone D., O'Reilly M., Ogawa K., Ogiwara A., Oudega B.,
RA   Park S.-H., Parro V., Pohl T.M., Portetelle D., Porwollik S.,
RA   Prescott A.M., Presecan E., Pujic P., Purnelle B., Rapoport G.,
RA   Rey M., Reynolds S., Rieger M., Rivolta C., Rocha E., Roche B.,
RA   Rose M., Sadaie Y., Sato T., Scanlan E., Schleich S., Schroeter R.,
RA   Scoffone F., Sekiguchi J., Sekowska A., Seror S.J., Serror P.,
RA   Shin B.-S., Soldo B., Sorokin A., Tacconi E., Takagi T., Takahashi H.,
RA   Takemaru K., Takeuchi M., Tamakoshi A., Tanaka T., Terpstra P.,
RA   Tognoni A., Tosato V., Uchiyama S., Vandenbol M., Vannier F.,
RA   Vassarotti A., Viari A., Wambutt R., Wedler E., Wedler H.,
RA   Weitzenegger T., Winters P., Wipat A., Yamamoto H., Yamane K.,
RA   Yasumoto K., Yata K., Yoshida K., Yoshikawa H.-F., Zumstein E.,
RA   Yoshikawa H., Danchin A.;
RT   "The complete genome sequence of the Gram-positive bacterium Bacillus
RT   subtilis.";
RL   Nature 390:249-256(1997).
RN   [2]
RP   DISRUPTION PHENOTYPE.
RC   STRAIN=168 / PY79;
RX   PubMed=11267663; DOI=10.1016/S0167-4781(01)00182-8;
RA   Yazgan A., Oezcengiz G., Marahiel M.A.;
RT   "Tn10 insertional mutations of Bacillus subtilis that block the
RT   biosynthesis of bacilysin.";
RL   Biochim. Biophys. Acta 1518:87-94(2001).
RN   [3]
RP   CATALYTIC ACTIVITY.
RC   STRAIN=168;
RX   PubMed=11934502; DOI=10.1111/j.1574-6968.2002.tb11068.x;
RA   Solovieva I.M., Entian K.D.;
RT   "Investigation of the yvgW Bacillus subtilis chromosomal gene involved
RT   in Cd(2+) ion resistance.";
RL   FEMS Microbiol. Lett. 208:105-109(2002).
RN   [4]
RP   CATALYTIC ACTIVITY, FUNCTION, AND INDUCTION.
RC   STRAIN=168 / CU1065;
RX   PubMed=12779235; DOI=10.1023/A:1023425321617;
RA   Gaballa A., Helmann J.D.;
RT   "Bacillus subtilis CPx-type ATPases: characterization of Cd, Zn, Co
RT   and Cu efflux systems.";
RL   BioMetals 16:497-505(2003).
RN   [5]
RP   DEVELOPMENTAL STAGE.
RC   STRAIN=168 / PY79;
RX   PubMed=16901659; DOI=10.1016/j.gene.2006.06.014;
RA   Irigul O., Yazgan-Karatas A.;
RT   "Sporulation-specific expression of the yvgW (cadA) gene and the
RT   effect of blockage on spore properties in Bacillus subtilis.";
RL   Gene 382:71-78(2006).
CC   -!- FUNCTION: Couples the hydrolysis of ATP with the transport of
CC       cadmium, zinc and cobalt out of the cell. Does not seem to
CC       transport copper.
CC   -!- CATALYTIC ACTIVITY: ATP + H(2)O + Cd(2+)(In) = ADP + phosphate +
CC       Cd(2+)(Out).
CC   -!- CATALYTIC ACTIVITY: ATP + H(2)O + Zn(2+)(In) = ADP + phosphate +
CC       Zn(2+)(Out).
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- DEVELOPMENTAL STAGE: Expression increases rapidly at 5 hours and
CC       peaks at 7 hours after onset of sporulation.
CC   -!- INDUCTION: By heat-shock, ethanol stress, zinc, cobalt and
CC       cadmium.
CC   -!- DISRUPTION PHENOTYPE: Arrested in competence development and
CC       sporulation.
CC   -!- SIMILARITY: Belongs to the cation transport ATPase (P-type)
CC       family. Type IB subfamily.
CC   -!- SIMILARITY: Contains 1 HMA domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AL009126; CAB15354.2; ALT_INIT; Genomic_DNA.
DR   PIR; D70041; D70041.
DR   RefSeq; NP_391229.2; -.
DR   HSSP; Q60048; 2AJ1.
DR   SMR; O32219; 3-68, 163-688.
DR   TCDB; 3.A.3.6.10; P-type ATPase (P-ATPase) superfamily.
DR   GeneID; 936034; -.
DR   GenomeReviews; AL009126_GR; BSU33490.
DR   KEGG; bsu:BSU33490; -.
DR   NMPDR; fig|224308.1.peg.3355; -.
DR   SubtiList; BG14105; cadA.
DR   HOGENOM; HBG507745; -.
DR   OMA; CANCAMK; -.
DR   PhylomeDB; O32219; -.
DR   ProtClustDB; CLSK887878; -.
DR   BioCyc; SUBTI:BSU33490-MONOMER; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046870; F:cadmium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008551; F:cadmium-exporting ATPase activity; IEA:EC.
DR   GO; GO:0005261; F:cation channel activity; IEA:InterPro.
DR   GO; GO:0050897; F:cobalt ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005507; F:copper ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0016463; F:zinc-exporting ATPase activity; IEA:EC.
DR   GO; GO:0006754; P:ATP biosynthetic process; IEA:InterPro.
DR   GO; GO:0006824; P:cobalt ion transport; IEA:UniProtKB-KW.
DR   GO; GO:0006825; P:copper ion transport; IEA:UniProtKB-KW.
DR   GO; GO:0046686; P:response to cadmium ion; IEA:UniProtKB-KW.
DR   GO; GO:0006950; P:response to stress; IEA:UniProtKB-KW.
DR   GO; GO:0006829; P:zinc ion transport; IEA:UniProtKB-KW.
DR   InterPro; IPR008250; ATPase_P-typ_ATPase-assoc-dom.
DR   InterPro; IPR001366; ATPase_P-typ_Cd-transp.
DR   InterPro; IPR006404; ATPase_P-typ_Cd/Co/Hg/Pb/Zn.
DR   InterPro; IPR006416; ATPase_P-typ_heavy-metal.
DR   InterPro; IPR001757; ATPase_P-typ_ion-transptr.
DR   InterPro; IPR018303; ATPase_P-typ_P_site.
DR   InterPro; IPR005834; Dehalogen-like_hydro.
DR   InterPro; IPR017969; Heavy-metal-associated_CS.
DR   InterPro; IPR006121; HeavyMe_transpt.
DR   PANTHER; PTHR11939; ATPase_P; 1.
DR   Pfam; PF00122; E1-E2_ATPase; 1.
DR   Pfam; PF00403; HMA; 1.
DR   Pfam; PF00702; Hydrolase; 1.
DR   PRINTS; PR00119; CATATPASE.
DR   PRINTS; PR00941; CDATPASE.
DR   SUPFAM; SSF55008; HeavyMe_transpt; 1.
DR   TIGRFAMs; TIGR01512; ATPase-IB2_Cd; 1.
DR   TIGRFAMs; TIGR01525; ATPase-IB_hvy; 1.
DR   TIGRFAMs; TIGR01494; ATPase_P-type; 2.
DR   PROSITE; PS00154; ATPASE_E1_E2; 1.
DR   PROSITE; PS01047; HMA_1; 1.
DR   PROSITE; PS50846; HMA_2; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Cadmium; Cadmium resistance; Cell membrane; Cobalt;
KW   Cobalt transport; Complete proteome; Copper; Copper transport;
KW   Hydrolase; Ion transport; Magnesium; Membrane; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Stress response; Transmembrane;
KW   Transport; Zinc; Zinc transport.
FT   CHAIN         1    702       Cadmium, zinc and cobalt-transporting
FT                                ATPase.
FT                                /FTId=PRO_0000360852.
FT   TOPO_DOM      1     86       Cytoplasmic (By similarity).
FT   TRANSMEM     87    107       By similarity.
FT   TOPO_DOM    108    116       Extracellular (By similarity).
FT   TRANSMEM    117    136       By similarity.
FT   TOPO_DOM    137    143       Cytoplasmic (By similarity).
FT   TRANSMEM    144    163       By similarity.
FT   TOPO_DOM    164    166       Extracellular (By similarity).
FT   TRANSMEM    167    186       By similarity.
FT   TOPO_DOM    187    320       Cytoplasmic (By similarity).
FT   TRANSMEM    321    339       By similarity.
FT   TOPO_DOM    340    345       Extracellular (By similarity).
FT   TRANSMEM    346    363       By similarity.
FT   TOPO_DOM    364    648       Cytoplasmic (By similarity).
FT   TRANSMEM    649    670       By similarity.
FT   TOPO_DOM    671    678       Extracellular (By similarity).
FT   TRANSMEM    679    694       By similarity.
FT   TOPO_DOM    695    702       Cytoplasmic (By similarity).
FT   DOMAIN        5     73       HMA.
FT   ACT_SITE    401    401       4-aspartylphosphate intermediate (By
FT                                similarity).
FT   METAL        15     15       Cadmium or zinc or cobalt (Potential).
FT   METAL        18     18       Cadmium or zinc or cobalt (Potential).
FT   METAL       595    595       Magnesium (By similarity).
FT   METAL       599    599       Magnesium (By similarity).
SQ   SEQUENCE   702 AA;  75405 MW;  C149EDADA4C4297D CRC64;
     MRLVKQEYVL DGLDCSNCAR KIENGVKGIK GINGCAVNFA ASTLTVSADG KEEQWVTNKV
     EKKVKSIDPH VTVRQKHIKK SADDGYRNRM VNMLIRMAAA VILGAAAYLV QSGTIEFFLF
     LGAYLIIGGD IIIRAVKNII RGQVFDEHFL MALATIGAFL IQQYPEGVAV MLFYQIGELF
     QGAAVSRSRK SISALMDIRP DYANLKTKNG IEQVSSEDVQ TGDIIVVNPG ESIPLDGKVV
     QGSAMVDTSA LTGESVPRKA AEGQDVMSGF INQNGVLHIE VTKGYQESAV SKILDLVQNA
     SSRKARTENF ITKFAKYYTP AVVIIAVLLA FVPPLVLSGA ALSDWVYRAL IFLVISCPCA
     LVVSIPLGFF GGIGAASKAG VLVKGSNYLE ALNQVKYAVF DKTGTLTKGS FEVTEIKPAE
     GFTKDRLLEA AAYAELHSQH PIAESVRKAY GKMLSSDEIE SYEEISGHGI FAKVNGTEIL
     AGNKKLMERE QIEDVPDENA GTIVHVAVDQ RYAGAIIIAD EIKEDAAQAV ADLKSLGIKQ
     TAMLTGDSKQ TGEAVGKQLG IGEVYAELLP QDKVAQVEAL EAKLLPSEKL IFVGDGINDT
     PVLARADIGV AMGGLGSDAA VEAADIVLMT DQPSKIAEAI RIAKRTRRIV WQNIGFALGV
     KAIFLILGAF GIATMWEAVF SDVGVTLLAV ANAMRVMRLK NK
//
ID   CAPSD_BPF1              Reviewed;          73 AA.
AC   P69540; P03617;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   21-JUL-1986, sequence version 1.
DT   02-MAR-2010, entry version 35.
DE   RecName: Full=Capsid protein G8P;
DE   AltName: Full=Gene 8 protein;
DE            Short=G8P;
DE   AltName: Full=Coat protein B;
DE   AltName: Full=Major coat protein;
DE   Flags: Precursor;
GN   Name=VIII;
OS   Enterobacteria phage f1 (Bacteriophage f1).
OC   Viruses; ssDNA viruses; Inoviridae; Inovirus.
OX   NCBI_TaxID=10863;
OH   NCBI_TaxID=562; Escherichia coli.
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=82211801; PubMed=6282703; DOI=10.1016/0378-1119(81)90059-7;
RA   Beck E., Zink B.;
RT   "Nucleotide sequence and genome organisation of filamentous
RT   bacteriophages f1 and fd.";
RL   Gene 16:35-58(1981).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=80185134; PubMed=7373712;
RA   Hill D.F., Petersen G.B.;
RT   "Nucleotide sequences in bacteriophage f1 DNA: nucleotide sequence of
RT   genes V, VII, and VIII.";
RL   J. Virol. 34:40-50(1980).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=83059882; PubMed=6292494;
RA   Hill D.F., Petersen G.B.;
RT   "Nucleotide sequence of bacteriophage f1 DNA.";
RL   J. Virol. 44:32-46(1982).
RN   [4]
RP   PROTEIN SEQUENCE OF 24-73.
RX   MEDLINE=77140968; PubMed=321454;
RA   Bailey G.S., Gillett D., Hill D.F., Petersen G.B.;
RT   "Automated sequencing of insoluble peptides using detergent.
RT   Bacteriophage f1 coat protein.";
RL   J. Biol. Chem. 252:2218-2225(1977).
CC   -!- FUNCTION: Self assembles to form a helical capsid wrapping up the
CC       viral genomic DNA. The capsid displays a filamentous structure
CC       with a length of 760-1950 nm and a width of 6-8 nm. The virion
CC       assembly and budding take place at the host inner membrane (By
CC       similarity).
CC   -!- SUBUNIT: Homomultimerizes. There are several thousands of this
CC       protein in the phage capsid (By similarity).
CC   -!- SUBCELLULAR LOCATION: Virion (Potential). Host membrane; Single-
CC       pass type I membrane protein. Note=prior to assembly, the major
CC       capsid protein is found associated with the bacterial host inner
CC       membrane (By similarity).
CC   -!- SIMILARITY: Belongs to the inovirus capsid protein family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; V00606; CAA23871.1; -; Genomic_DNA.
DR   EMBL; J02450; AAA32220.1; -; Genomic_DNA.
DR   EMBL; J02448; AAA32214.1; -; Genomic_DNA.
DR   PIR; E04226; VCBPF1.
DR   SMR; P69540; 24-73.
DR   GO; GO:0033644; C:host cell membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   InterPro; IPR008033; Phage_coat_Gp8.
DR   Pfam; PF05371; Phage_Coat_Gp8; 1.
DR   PIRSF; PIRSF004117; Phage_coat_B; 1.
PE   1: Evidence at protein level;
KW   Capsid protein; Direct protein sequencing; Host membrane; Membrane;
KW   Signal; Transmembrane; Virion.
FT   SIGNAL        1     23
FT   CHAIN        24     73       Capsid protein G8P.
FT                                /FTId=PRO_0000003297.
FT   TOPO_DOM     24     44       Periplasmic (By similarity).
FT   TRANSMEM     45     65       By similarity.
FT   TOPO_DOM     66     73       Cytoplasmic (By similarity).
SQ   SEQUENCE   73 AA;  7626 MW;  53ACF68DB18E6A52 CRC64;
     MKKSLVLKAS VAVATLVPML SFAAEGDDPA KAAFDSLQAS ATEYIGYAWA MVVVIVGATI
     GIKLFKKFTS KAS
//
ID   CAPSD_BPFD              Reviewed;          73 AA.
AC   P69539; P03617;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   21-JUL-1986, sequence version 1.
DT   02-MAR-2010, entry version 40.
DE   RecName: Full=Capsid protein G8P;
DE   AltName: Full=Gene 8 protein;
DE            Short=G8P;
DE   AltName: Full=Coat protein B;
DE   AltName: Full=Major coat protein;
DE   Flags: Precursor;
GN   Name=VIII;
OS   Enterobacteria phage fd (Bacteriophage fd).
OC   Viruses; ssDNA viruses; Inoviridae; Inovirus.
OX   NCBI_TaxID=10864;
OH   NCBI_TaxID=562; Escherichia coli.
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=478 / Heidelberg;
RX   MEDLINE=79136480; PubMed=745987; DOI=10.1093/nar/5.12.4495;
RA   Beck E., Sommer R., Auerswald E.A., Kurz C., Zink B., Osterburg G.,
RA   Schaller H., Sugimoto K., Sugisaki H., Okamoto T., Takanami M.;
RT   "Nucleotide sequence of bacteriophage fd DNA.";
RL   Nucleic Acids Res. 5:4495-4503(1978).
RN   [2]
RP   PROTEIN SEQUENCE OF 24-73.
RC   STRAIN=478 / Heidelberg;
RX   MEDLINE=70028989; PubMed=5349375;
RA   Asbeck F., Beyreuther K., Kohler H., von Wettstein G., Braunitzer G.;
RT   "Virus proteins. IV. Constitution of the coat protein of the fd
RT   phage.";
RL   Hoppe-Seyler's Z. Physiol. Chem. 350:1047-1066(1969).
RN   [3]
RP   PROTEIN SEQUENCE OF 24-73, AND SEQUENCE REVISION.
RX   MEDLINE=75097503; PubMed=4449122; DOI=10.1016/0022-2836(74)90410-0;
RA   Nakashima Y., Konigsberg W.;
RT   "Reinvestigation of a region of the fd bacteriophage coat protein
RT   sequence.";
RL   J. Mol. Biol. 88:598-600(1974).
RN   [4]
RP   STRUCTURE BY NMR.
RX   MEDLINE=97392441; PubMed=9237913; DOI=10.1006/jmbi.1997.1114;
RA   Almeida F.C., Opella S.J.;
RT   "fd coat protein structure in membrane environments: structural
RT   dynamics of the loop between the hydrophobic trans-membrane helix and
RT   the amphipathic in-plane helix.";
RL   J. Mol. Biol. 270:481-495(1997).
RN   [5]
RP   X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS).
RX   MEDLINE=94118269; PubMed=8289247; DOI=10.1016/S0022-2836(05)80032-4;
RA   Marvin D.A., Hale R.D., Nave C., Citterich M.H.;
RT   "Molecular models and structural comparisons of native and mutant
RT   class I filamentous bacteriophages Ff (fd, f1, M13), If1 and IKe.";
RL   J. Mol. Biol. 235:260-286(1994).
CC   -!- FUNCTION: Self assembles to form a helical capsid wrapping up the
CC       viral genomic DNA. The capsid displays a filamentous structure
CC       with a length of 760-1950 nm and a width of 6-8 nm. The virion
CC       assembly and budding take place at the host inner membrane (By
CC       similarity).
CC   -!- SUBUNIT: Homomultimerizes. There are several thousands of this
CC       protein in the phage capsid (By similarity).
CC   -!- SUBCELLULAR LOCATION: Virion (Potential). Host membrane; Single-
CC       pass type I membrane protein. Note=prior to assembly, the major
CC       capsid protein is found associated with the bacterial host inner
CC       membrane (By similarity).
CC   -!- SIMILARITY: Belongs to the inovirus capsid protein family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J02451; AAA32308.1; -; Genomic_DNA.
DR   PIR; A04226; VCBPFD.
DR   PDB; 1FDM; NMR; -; A=24-73.
DR   PDB; 1IFD; Fiber; 4.00 A; A=24-73.
DR   PDB; 1IFI; Fiber; 3.30 A; A=24-73.
DR   PDB; 1IFJ; Fiber; 3.30 A; A=24-73.
DR   PDB; 1MZT; NMR; -; A=24-73.
DR   PDB; 2C0W; X-ray; 3.20 A; A=24-73.
DR   PDB; 2C0X; NMR; -; A=24-73.
DR   PDB; 2HI5; EM; 8.00 A; A=24-73.
DR   PDBsum; 1FDM; -.
DR   PDBsum; 1IFD; -.
DR   PDBsum; 1IFI; -.
DR   PDBsum; 1IFJ; -.
DR   PDBsum; 1MZT; -.
DR   PDBsum; 2C0W; -.
DR   PDBsum; 2C0X; -.
DR   PDBsum; 2HI5; -.
DR   GenomeReviews; J02451_GR; VIII.
DR   GO; GO:0033644; C:host cell membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   InterPro; IPR008033; Phage_coat_Gp8.
DR   Pfam; PF05371; Phage_Coat_Gp8; 1.
DR   PIRSF; PIRSF004117; Phage_coat_B; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Capsid protein; Direct protein sequencing;
KW   Host membrane; Membrane; Signal; Transmembrane; Virion.
FT   SIGNAL        1     23
FT   CHAIN        24     73       Capsid protein G8P.
FT                                /FTId=PRO_0000003296.
FT   TOPO_DOM     24     44       Periplasmic.
FT   TRANSMEM     45     65       By similarity.
FT   TOPO_DOM     66     73       Cytoplasmic.
FT   HELIX        27     35
FT   HELIX        42     69
SQ   SEQUENCE   73 AA;  7626 MW;  53ACF68DB18E6A52 CRC64;
     MKKSLVLKAS VAVATLVPML SFAAEGDDPA KAAFDSLQAS ATEYIGYAWA MVVVIVGATI
     GIKLFKKFTS KAS
//
ID   CICH_TORCA              Reviewed;         810 AA.
AC   P35522;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 65.
DE   RecName: Full=Chloride channel protein;
DE   AltName: Full=ClC-0;
OS   Torpedo californica (Pacific electric ray).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Chondrichthyes;
OC   Elasmobranchii; Squalea; Hypnosqualea; Pristiorajea; Batoidea;
OC   Torpediniformes; Torpedinoidei; Torpedinidae; Torpedo.
OX   NCBI_TaxID=7787;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Electric organ;
RX   MEDLINE=92096455; PubMed=1721838; DOI=10.1016/0167-4781(91)90228-E;
RA   O'Neill G.P., Grygorczyk R., Adam M., Ford-Hutchinson A.W.;
RT   "The nucleotide sequence of a voltage-gated chloride channel from the
RT   electric organ of Torpedo californica.";
RL   Biochim. Biophys. Acta 1129:131-134(1991).
RN   [2]
RP   PROTEIN SEQUENCE OF 2-11, AND CHARACTERIZATION.
RC   TISSUE=Electric organ;
RX   MEDLINE=95034750; PubMed=7947726; DOI=10.1021/bi00249a005;
RA   Middleton R.E., Pheasant D.J., Miller C.;
RT   "Purification, reconstitution, and subunit composition of a voltage-
RT   gated chloride channel from Torpedo electroplax.";
RL   Biochemistry 33:13189-13198(1994).
RN   [3]
RP   CHARACTERIZATION, AND MUTAGENESIS OF GLU-166.
RX   PubMed=12649487; DOI=10.1126/science.1082708;
RA   Dutzler R., Campbell E.B., MacKinnon R.;
RT   "Gating the selectivity filter in ClC chloride channels.";
RL   Science 300:108-112(2003).
CC   -!- FUNCTION: Voltage-gated chloride channel. This channel is thought
CC       to ensure the high conductance of the non-innervated membrane of
CC       the electrocyte necessary for efficient current generation caused
CC       by sodium influx through the acetylcholine receptor at the
CC       innervated membrane.
CC   -!- SUBUNIT: Homodimer. Each subunit has channel activity ("Double
CC       barreled channel").
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- MISCELLANEOUS: The CLC channel family contains both chloride
CC       channels and proton-coupled anion transporters that exchange
CC       chloride or another anion for protons. The absence of conserved
CC       gating glutamate residues is typical for family members that
CC       function as channels (By similarity).
CC   -!- SIMILARITY: Belongs to the chloride channel (TC 2.A.49) family.
CC   -!- SIMILARITY: Contains 2 CBS domains.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X60433; CAA42960.1; -; mRNA.
DR   PIR; S19725; S19725.
DR   SMR; P35522; 51-517, 527-775.
DR   DIP; DIP-29258N; -.
DR   HOVERGEN; HBG005332; -.
DR   GO; GO:0034707; C:chloride channel complex; IEA:UniProtKB-KW.
DR   GO; GO:0031404; F:chloride ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005247; F:voltage-gated chloride channel activity; IEA:InterPro.
DR   GO; GO:0006821; P:chloride transport; IEA:InterPro.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR014743; Cl-channel_core.
DR   InterPro; IPR001807; Cl-channel_volt.
DR   InterPro; IPR002242; Cl_channel0.
DR   InterPro; IPR000644; Cysta_beta_synth_core.
DR   Gene3D; G3DSA:1.10.3080.10; Cl-channel_core; 1.
DR   PANTHER; PTHR11689; Cl-channel_volt; 1.
DR   Pfam; PF00571; CBS; 1.
DR   Pfam; PF00654; Voltage_CLC; 1.
DR   PRINTS; PR00762; CLCHANNEL.
DR   PRINTS; PR01111; CLCHANNEL0.
DR   SMART; SM00116; CBS; 2.
DR   SUPFAM; SSF81340; Cl-channel_core; 1.
DR   PROSITE; PS51371; CBS; 2.
PE   1: Evidence at protein level;
KW   CBS domain; Chloride; Chloride channel; Direct protein sequencing;
KW   Glycoprotein; Ion transport; Ionic channel; Membrane; Repeat;
KW   Transmembrane; Transport; Voltage-gated channel.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    810       Chloride channel protein.
FT                                /FTId=PRO_0000094463.
FT   TOPO_DOM      2     48       Cytoplasmic (By similarity).
FT   TRANSMEM     49     86       By similarity.
FT   TRANSMEM     93    116       By similarity.
FT   TRANSMEM    141    160       By similarity.
FT   TRANSMEM    166    184       By similarity.
FT   TRANSMEM    237    254       By similarity.
FT   TRANSMEM    283    311       By similarity.
FT   TRANSMEM    320    339       By similarity.
FT   TRANSMEM    389    408       By similarity.
FT   TRANSMEM    416    439       By similarity.
FT   TRANSMEM    490    506       By similarity.
FT   TOPO_DOM    507    810       Cytoplasmic (By similarity).
FT   DOMAIN      543    601       CBS 1.
FT   DOMAIN      724    781       CBS 2.
FT   REGION      125    132       In-membrane helix (By similarity).
FT   REGION      201    213       In-membrane helix (By similarity).
FT   REGION      217    225       In-membrane helix (By similarity).
FT   REGION      456    470       In-membrane helix (By similarity).
FT   REGION      471    472       In-membrane loop between two helices (By
FT                                similarity).
FT   REGION      473    484       In-membrane helix (By similarity).
FT   REGION      485    489       In-membrane loop between two helices (By
FT                                similarity).
FT   MOTIF       122    126       Selectivity filter part_1 (By
FT                                similarity).
FT   MOTIF       164    168       Selectivity filter part_2 (By
FT                                similarity).
FT   MOTIF       416    420       Selectivity filter part_3 (By
FT                                similarity).
FT   BINDING     123    123       Chloride (By similarity).
FT   BINDING     418    418       Chloride; via amide nitrogen (By
FT                                similarity).
FT   BINDING     512    512       Chloride (By similarity).
FT   SITE        166    166       Gate.
FT   CARBOHYD    365    365       N-linked (GlcNAc...).
FT   MUTAGEN     166    166       E->A,Q,V: Gating function is lost. The
FT                                channel is always open.
SQ   SEQUENCE   810 AA;  89447 MW;  BD3954973D6C99EA CRC64;
     MSHEKNEASG NPEAQSWKAQ EAMLGVKTEV SRWRAVKNCL YRHLVKVLGE DWIFLLLLGA
     LMALVSWAMD FIGSRGLRFY KYLFAMVEGN LGLQYLVWVC YPLILILFSS LFCQIVSPQA
     VGSGIPELKT IIRGAVLHEY LTLRTFVAKT VGLTVALSAG FPLGKEGPFV HIASICATLL
     NQLLCFISGR REEPYYLRAD ILTVGCALGI SCCFGTPLAG VLFSIEVTCS HFGVRSYWRG
     FLGGAFSAFI FRVLSVWVKD TVTLTALFKT NFRGDIPFDL QELPAFAIIG IASGFFGALF
     VYLNRQIIVF MRKKNFVTKI LKKQRLIYPA VVTFVLATLR FPPGVGQFFG AGLMPRETIN
     SLFDNYTWTK TIDPRGLGNS AQWFIPHLNI FIVMALYFVM HFWMAALAVT MPVPCGAFVP
     VFNLGAVLGR FVGELMALLF PDGLVSNGNL YHILPGEYAV IGAAAMTGAV THAVSTAVIC
     FELTGQISHV LPMMVAVILA NMVAQGLQPS LYDSIIQIKK LPYLPELSWS SANKYNIQVG
     DIMVRDVTSI ASTSTYGDLL HVLRQTKLKF FPFVDTPETN TLLGSIERTE VEGLLQRRIS
     AYRRQPATAA EAEEEGRNGE RGASFTGDVP GEAETSFAYI DQEEAEGQQQ REGLEAVKVQ
     TEDPRPPSPV PAEEPTQTSG IYQKKHKGTG QVASRFEEML TLEEIYQWEQ REKNVVVNFE
     TCRIDQSPFQ LVEGTSLQKT HTLFSLLGLD RAYVTSMGKL VGVVALAEIQ AAIEGSYQKG
     FRLPPPLASF RDAKNARNSG RTATSNSSGK
//
ID   CICH_TORMA              Reviewed;         805 AA.
AC   P21564;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1991, sequence version 1.
DT   02-MAR-2010, entry version 70.
DE   RecName: Full=Chloride channel protein;
DE   AltName: Full=ClC-0;
OS   Torpedo marmorata (Marbled electric ray).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Chondrichthyes;
OC   Elasmobranchii; Squalea; Hypnosqualea; Pristiorajea; Batoidea;
OC   Torpediniformes; Torpedinoidei; Torpedinidae; Torpedo.
OX   NCBI_TaxID=7788;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Electric organ;
RX   MEDLINE=91061906; PubMed=2174129; DOI=10.1038/348510a0;
RA   Jentsch T.J., Steinmeyer K., Schwarz G.;
RT   "Primary structure of Torpedo marmorata chloride channel isolated by
RT   expression cloning in Xenopus oocytes.";
RL   Nature 348:510-514(1990).
RN   [2]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 525-774, MASS SPECTROMETRY,
RP   AND SUBUNIT.
RX   PubMed=16472749; DOI=10.1016/j.str.2005.10.008;
RA   Meyer S., Dutzler R.;
RT   "Crystal structure of the cytoplasmic domain of the chloride channel
RT   ClC-0.";
RL   Structure 14:299-307(2006).
CC   -!- FUNCTION: Voltage-gated chloride channel. This channel is thought
CC       to ensure the high conductance of the non-innervated membrane of
CC       the electrocyte necessary for efficient current generation caused
CC       by sodium influx through the acetylcholine receptor at the
CC       innervated membrane.
CC   -!- SUBUNIT: Homodimer. Each subunit contains a channel ("Double
CC       barreled channel").
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- MISCELLANEOUS: The CLC channel family contains both chloride
CC       channels and proton-coupled anion transporters that exchange
CC       chloride or another anion for protons. The absence of conserved
CC       gating glutamate residues is typical for family members that
CC       function as channels (By similarity).
CC   -!- SIMILARITY: Belongs to the chloride channel (TC 2.A.49) family.
CC   -!- SIMILARITY: Contains 2 CBS domains.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X56758; CAA40078.1; -; mRNA.
DR   PIR; S13410; S13410.
DR   PDB; 2D4Z; X-ray; 3.10 A; A/B=525-774.
DR   PDBsum; 2D4Z; -.
DR   SMR; P21564; 51-517.
DR   DIP; DIP-29086N; -.
DR   HOVERGEN; HBG005332; -.
DR   GO; GO:0034707; C:chloride channel complex; IEA:UniProtKB-KW.
DR   GO; GO:0031404; F:chloride ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005247; F:voltage-gated chloride channel activity; IEA:InterPro.
DR   GO; GO:0006821; P:chloride transport; IEA:InterPro.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR014743; Cl-channel_core.
DR   InterPro; IPR001807; Cl-channel_volt.
DR   InterPro; IPR002242; Cl_channel0.
DR   InterPro; IPR000644; Cysta_beta_synth_core.
DR   Gene3D; G3DSA:1.10.3080.10; Cl-channel_core; 1.
DR   PANTHER; PTHR11689; Cl-channel_volt; 1.
DR   Pfam; PF00571; CBS; 1.
DR   Pfam; PF00654; Voltage_CLC; 1.
DR   PRINTS; PR00762; CLCHANNEL.
DR   PRINTS; PR01111; CLCHANNEL0.
DR   SMART; SM00116; CBS; 2.
DR   SUPFAM; SSF81340; Cl-channel_core; 1.
DR   PROSITE; PS51371; CBS; 2.
PE   1: Evidence at protein level;
KW   3D-structure; CBS domain; Chloride; Chloride channel; Glycoprotein;
KW   Ion transport; Ionic channel; Membrane; Repeat; Transmembrane;
KW   Transport; Voltage-gated channel.
FT   CHAIN         1    805       Chloride channel protein.
FT                                /FTId=PRO_0000094464.
FT   TOPO_DOM      1     48       Cytoplasmic (By similarity).
FT   TRANSMEM     49     86       By similarity.
FT   TRANSMEM     93    116       By similarity.
FT   TRANSMEM    141    159       By similarity.
FT   TRANSMEM    166    184       By similarity.
FT   TRANSMEM    237    256       By similarity.
FT   TRANSMEM    283    311       By similarity.
FT   TRANSMEM    320    339       By similarity.
FT   TRANSMEM    388    408       By similarity.
FT   TRANSMEM    416    439       By similarity.
FT   TRANSMEM    490    507       By similarity.
FT   TOPO_DOM    508    805       Cytoplasmic (By similarity).
FT   DOMAIN      543    601       CBS 1.
FT   DOMAIN      719    776       CBS 2.
FT   REGION      125    132       In-membrane helix (By similarity).
FT   REGION      201    213       In-membrane helix (By similarity).
FT   REGION      217    225       In-membrane helix (By similarity).
FT   REGION      456    470       In-membrane helix (By similarity).
FT   REGION      471    472       In-membrane loop between two helices (By
FT                                similarity).
FT   REGION      473    484       In-membrane helix (By similarity).
FT   REGION      485    489       In-membrane loop between two helices (By
FT                                similarity).
FT   MOTIF       122    126       Selectivity filter part_1 (By
FT                                similarity).
FT   MOTIF       164    168       Selectivity filter part_2 (By
FT                                similarity).
FT   MOTIF       416    420       Selectivity filter part_3 (By
FT                                similarity).
FT   BINDING     123    123       Chloride (By similarity).
FT   BINDING     418    418       Chloride; via amide nitrogen (By
FT                                similarity).
FT   BINDING     512    512       Chloride (By similarity).
FT   CARBOHYD    365    365       N-linked (GlcNAc...) (Potential).
FT   STRAND      541    546
FT   HELIX       556    565
FT   STRAND      569    575
FT   TURN        577    579
FT   STRAND      581    587
FT   HELIX       588    600
FT   STRAND      603    605
FT   HELIX       697    707
FT   HELIX       732    742
FT   STRAND      745    751
FT   STRAND      754    760
FT   HELIX       761    769
SQ   SEQUENCE   805 AA;  88888 MW;  4CD2FA48AE06FC6D CRC64;
     MSHEKNEASG YPEAQSWKSQ EAMLGARTEV SRWRAVKNCL YRHLVKVLGE DWIFLLLLGA
     LMALVSWAMD FIGSRGLRFY KYLFALVEGN IGLQYLVWVC YPLALILFSS LFCQIVSPQA
     VGSGIPELKT IIRGAVLHEY LTLRTFVAKT VGLTVALSAG FPLGKEGPFV HIASICATLL
     NQLLCFISGR REEPYYLRAD ILTVGCALGI SCCFGTPLAG VLFSIEVTCS HFGVRSYWRG
     FLGGAFSAFI FRVLSVWVKD TVTLTALFKT NFRGDIPFDL QEMPAFAIIG IASGFFGALF
     VYLNRQIIVF MRKKNFVTKI LKKQRLIYPA VVTFVLATLR FPPGVGQFFG AGLMPRETIN
     SLFDNYTWTK TIDPRGLGNS AQWFIPHLNI FIVMALYFVM HFWMAALAVT MPVPCGAFVP
     VFNLGAVLGR FVGELMALLF PDGLVSNGNL YHILPGEYAV IGAAAMTGAV THAVSTAVIC
     FELTGQISHV LPMMVAVILA NMVAQGLQPS LYDSIIQIKK LPYLPELSWS SANKYNIQVG
     DIMVRDVTSI ASTSTYGDLL HVLRQTKLKF FPFVDTPDTN TLLGSIDRTE VEGLLQRRIS
     AYRRQPAAAA EADEEGRNGE TGASFTGEAE SSFAYIDQED AEGQQREGLE AVKVQTEDPR
     PPSPVPAEEP TQTSGIYQKK QKGTGQVASR FEEMLTLEEI YRWEQREKNV VVNFETCRID
     QSPFQLVEGT SLQKTHTLFS LLGLDRAYVT SMGKLVGVVA LAEIQAAIEG SYQKGFRLPP
     PLASFRDVKH ARNSGRTATS NSSGK
//
ID   CLCN1_CANFA             Reviewed;         976 AA.
AC   Q9MZT1;
DT   26-APR-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   02-MAR-2010, entry version 51.
DE   RecName: Full=Chloride channel protein 1;
DE            Short=ClC-1;
DE   AltName: Full=Chloride channel protein, skeletal muscle;
GN   Name=CLCN1;
OS   Canis familiaris (Dog).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Carnivora; Caniformia; Canidae;
OC   Canis.
OX   NCBI_TaxID=9615;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT MCR MET-268.
RC   STRAIN=Miniature Schnauzer;
RX   MEDLINE=99379598; PubMed=10452529; DOI=10.1016/S0014-5793(99)00926-6;
RA   Rhodes T.H., Vite C.H., Giger U., Patterson D.F., Fahlke C.,
RA   George A.L. Jr.;
RT   "A missense mutation in canine C1C-1 causes recessive myotonia
RT   congenita in the dog.";
RL   FEBS Lett. 456:54-58(1999).
CC   -!- FUNCTION: Voltage-gated chloride channel. Chloride channels have
CC       several functions including the regulation of cell volume;
CC       membrane potential stabilization, signal transduction and
CC       transepithelial transport (By similarity).
CC   -!- SUBUNIT: Homotetramer (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- DISEASE: Defects in CLCN1 are the cause of autosomal recessive
CC       myotonia congenita (MCR). MCR is a disorder of sarcolemmal
CC       excitation leading to delayed relaxation of skeletal muscle
CC       following contractions. The disease has been identified in the
CC       miniature Schnauzer breed.
CC   -!- MISCELLANEOUS: The CLC channel family contains both chloride
CC       channels and proton-coupled anion transporters that exchange
CC       chloride or another anion for protons. The absence of conserved
CC       gating glutamate residues is typical for family members that
CC       function as channels (By similarity).
CC   -!- SIMILARITY: Belongs to the chloride channel (TC 2.A.49) family.
CC   -!- SIMILARITY: Contains 2 CBS domains.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF162445; AAF82606.1; -; mRNA.
DR   RefSeq; NP_001003124.1; -.
DR   RefSeq; XP_855566.1; -.
DR   UniGene; Cfa.3588; -.
DR   SMR; Q9MZT1; 117-583, 593-867.
DR   Ensembl; ENSCAFT00000020333; ENSCAFP00000018866; ENSCAFG00000003619; Canis familiaris.
DR   GeneID; 403723; -.
DR   KEGG; cfa:403723; -.
DR   CTD; 403723; -.
DR   HOVERGEN; HBG005332; -.
DR   InParanoid; Q9MZT1; -.
DR   GO; GO:0034707; C:chloride channel complex; IEA:UniProtKB-KW.
DR   GO; GO:0031404; F:chloride ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005247; F:voltage-gated chloride channel activity; IEA:InterPro.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR014743; Cl-channel_core.
DR   InterPro; IPR001807; Cl-channel_volt.
DR   InterPro; IPR002243; Cl_channel1.
DR   InterPro; IPR000644; Cysta_beta_synth_core.
DR   Gene3D; G3DSA:1.10.3080.10; Cl-channel_core; 1.
DR   PANTHER; PTHR11689; Cl-channel_volt; 1.
DR   Pfam; PF00571; CBS; 1.
DR   Pfam; PF00654; Voltage_CLC; 1.
DR   PRINTS; PR00762; CLCHANNEL.
DR   PRINTS; PR01112; CLCHANNEL1.
DR   SUPFAM; SSF81340; Cl-channel_core; 1.
DR   PROSITE; PS51371; CBS; 2.
PE   1: Evidence at protein level;
KW   CBS domain; Chloride; Chloride channel; Disease mutation;
KW   Ion transport; Ionic channel; Membrane; Repeat; Transmembrane;
KW   Transport; Voltage-gated channel.
FT   CHAIN         1    976       Chloride channel protein 1.
FT                                /FTId=PRO_0000094428.
FT   TOPO_DOM      1    114       Cytoplasmic (By similarity).
FT   TRANSMEM    115    152       By similarity.
FT   TRANSMEM    159    182       By similarity.
FT   TRANSMEM    207    225       By similarity.
FT   TRANSMEM    232    250       By similarity.
FT   TRANSMEM    302    321       By similarity.
FT   TRANSMEM    348    376       By similarity.
FT   TRANSMEM    385    404       By similarity.
FT   TRANSMEM    454    474       By similarity.
FT   TRANSMEM    482    505       By similarity.
FT   TRANSMEM    556    573       By similarity.
FT   TOPO_DOM    574    976       Cytoplasmic (By similarity).
FT   DOMAIN      609    668       CBS 1.
FT   DOMAIN      816    871       CBS 2.
FT   REGION      191    198       In-membrane helix (By similarity).
FT   REGION      266    278       In-membrane helix (By similarity).
FT   REGION      282    290       In-membrane helix (By similarity).
FT   REGION      522    536       In-membrane helix (By similarity).
FT   REGION      537    538       In-membrane loop between two helices (By
FT                                similarity).
FT   REGION      539    550       In-membrane helix (By similarity).
FT   REGION      551    555       In-membrane loop between two helices (By
FT                                similarity).
FT   MOTIF       188    192       Selectivity filter part_1 (By
FT                                similarity).
FT   MOTIF       230    234       Selectivity filter part_2 (By
FT                                similarity).
FT   MOTIF       482    486       Selectivity filter part_3 (By
FT                                similarity).
FT   BINDING     189    189       Chloride (By similarity).
FT   BINDING     484    484       Chloride; via amide nitrogen (By
FT                                similarity).
FT   BINDING     578    578       Chloride (By similarity).
FT   VARIANT     268    268       T -> M (in MCR; profound effect on the
FT                                voltage-dependence of activation such
FT                                that mutant channels have a greatly
FT                                reduced open probability at voltages near
FT                                the resting membrane potential of
FT                                skeletal muscle).
SQ   SEQUENCE   976 AA;  108053 MW;  8F85593E7C858F6E CRC64;
     MQPSQSLRRG GEQSWWGSAP QYQYMPFEHC TSYGLPSENG ALQHRLHRDA GLRANTRPTQ
     IYGHYKQQFS DKEQDTGMSK KMGSSESMDS KDEDHYSKCQ GCVRRLGHVV RRKLGEDWIF
     LVLLGLLMAL VSWSMDYVSA KSLQAYKWSY YQMQPNLPLQ YLVWVTFPLT LILFSAVFCH
     LISPQAVGSG IPEMKTILRG VILKEYLTLK AFVAKVVALT AGLGSGIPVG KEGPFVHIAS
     ICAAVLSKFM SMFCGVYEQP YYYTDMLTVG CAVGVGCCFG TPLGGVLFSI EVTSTYFAVR
     NYWRGFFAAT FSAFVFRVLA VWNKDAVTIT ALFRTNFRMD FPFDLQELPA FAIIGICCGF
     LGAVFVYLHR QVMLGVRKHK ALSQFLAKHR LLYPGIVTFI IASFTFPPGI GQFMAGELMP
     REAISTLFDN NTWVKHVGDP ESLGRSAVWI HPRVNVIIII FLFFIMKFWM SIVATTMPIP
     CGGFMPVFVL GAAFGRLVGE IMAMLFPDGI LFDDIIYKIL PGGYAVIGAA ALTGAVSHTV
     STAVICFELT GQIAHILPMM VAVILANMVA QSLQPSLYDS IIQVKKLPYL PDLGWNQLSK
     FTIFVEDIMV RDVKFVSATC TYGELRTLLQ TTTVKTLPLV DSKDSMILLG SVERSELQSL
     LQRHLGPERR LRVAQDMARK LSELPYDGKG HQGISPEGRR ESFAFVDEDE DEDLSGKPEL
     PPLPPPHPLP SAPLSSEESN GPLPSHKQQP EAPEPADQRP SVFRSLLRCL LGRPRPTKKK
     TTQESMDLVD NMSPEEIEAW EQEQLSQPVC FDYCCIDQSP FQLVEQTSLH KTHTLFSLLG
     LHLAYVTSMG KLRGVLALEE LQKAIEGHTK SGVQLRPPLA SFRSTTSTRK NPGGPPPPTE
     AWSLPEDGTG APASPEPPAP SPSPAPLLSE APAKVEGELE ELELGESPGL EEELADILQG
     PSLRSTDEED EDELIL
//
ID   CLCN1_HUMAN             Reviewed;         988 AA.
AC   P35523; A4D2H5; Q2M202;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 2.
DT   02-MAR-2010, entry version 102.
DE   RecName: Full=Chloride channel protein 1;
DE            Short=ClC-1;
DE   AltName: Full=Chloride channel protein, skeletal muscle;
GN   Name=CLCN1; Synonyms=CLC1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND VARIANT MCD LEU-480.
RX   MEDLINE=94155836; PubMed=8112288;
RA   Steinmeyer K., Lorenz C., Pusch M., Koch M.C., Jentsch T.J.;
RT   "Multimeric structure of ClC-1 chloride channel revealed by mutations
RT   in dominant myotonia congenita (Thomsen).";
RL   EMBO J. 13:737-743(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT GLY-118.
RX   MEDLINE=22616434; PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S.,
RA   Kwasnicka D., Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z.,
RA   Lu F., Zeesman S., Nowaczyk M.J., Teshima I., Chitayat D., Shuman C.,
RA   Weksberg R., Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J.,
RA   Rahman N., Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F.,
RA   Belloni E., Shaffer L.G., Pober B., Morton C.C., Gusella J.F.,
RA   Bruns G.A.P., Korf B.R., Quade B.J., Ligon A.H., Ferguson H.,
RA   Higgins A.W., Leach N.T., Herrick S.R., Lemyre E., Farra C.G.,
RA   Kim H.-G., Summers A.M., Gripp K.W., Roberts W., Szatmari P.,
RA   Winsor E.J.T., Grzeschik K.-H., Teebi A., Minassian B.A., Kere J.,
RA   Armengol L., Pujana M.A., Estivill X., Wilson M.D., Koop B.F.,
RA   Tosi S., Moore G.E., Boright A.P., Zlotorynski E., Kerem B.,
RA   Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W.,
RA   Mural R.J., Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 171-988, AND VARIANT MCR CYS-413.
RX   MEDLINE=92358240; PubMed=1379744; DOI=10.1126/science.1379744;
RA   Koch M.C., Steinmeyer K., Lorenz C., Ricker K., Wolf F., Otto M.,
RA   Zoll B., Lehmann-Horn F., Grzeschik K.-H., Jentsch T.J.;
RT   "The skeletal muscle chloride channel in dominant and recessive human
RT   myotonia.";
RL   Science 257:797-800(1992).
RN   [5]
RP   PARTIAL NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND VARIANT MCD
RP   GLU-230.
RX   MEDLINE=95072653; PubMed=7981750; DOI=10.1038/ng0493-305;
RA   George A.L. Jr., Crackower M.A., Abdalla J.A., Hudson A.J.,
RA   Ebers G.C.;
RT   "Molecular basis of Thomsen's disease (autosomal dominant myotonia
RT   congenita).";
RL   Nat. Genet. 3:305-310(1993).
RN   [6]
RP   VARIANT MCR SER-496.
RX   MEDLINE=95038751; PubMed=7951242; DOI=10.1093/hmg/3.6.941;
RA   Lorenz C., Meyer-Kleine C., Steinmeyer K., Koch M.C., Jentsch T.J.;
RT   "Genomic organization of the human muscle chloride channel CIC-1 and
RT   analysis of novel mutations leading to Becker-type myotonia.";
RL   Hum. Mol. Genet. 3:941-946(1994).
RN   [7]
RP   VARIANT MCR GLY-136.
RX   MEDLINE=95072577; PubMed=7981681; DOI=10.1093/hmg/3.7.1123;
RA   Heine R., George A.L. Jr., Pika U., Deymeer F., Ruedel R.,
RA   Lehmann-Horn F.;
RT   "Proof of a non-functional muscle chloride channel in recessive
RT   myotonia congenita (Becker) by detection of a 4 base pair deletion.";
RL   Hum. Mol. Genet. 3:1123-1128(1994).
RN   [8]
RP   VARIANTS MCR LEU-167 AND GLN-338, AND VARIANT GLN-300.
RX   MEDLINE=95179131; PubMed=7874130;
RA   George A.L. Jr., Sloan-Brown K., Fenichel G.M., Mitchell G.A.,
RA   Spiegel R., Pascuzzi R.M.;
RT   "Nonsense and missense mutations of the muscle chloride channel gene
RT   in patients with myotonia congenita.";
RL   Hum. Mol. Genet. 3:2071-2072(1994).
RN   [9]
RP   VARIANTS MCR AND MCD.
RX   MEDLINE=96065020; PubMed=8533761;
RA   Meyer-Kleine C., Steinmeyer K., Ricker K., Jentsch T.J., Koch M.C.;
RT   "Spectrum of mutations in the major human skeletal muscle chloride
RT   channel gene (CLCN1) leading to myotonia.";
RL   Am. J. Hum. Genet. 57:1325-1334(1995).
RN   [10]
RP   VARIANT MCD MET-290, VARIANT MYOTONIA LEVIOR ARG-552, AND VARIANT
RP   GLY-118.
RX   MEDLINE=96090261; PubMed=7581380; DOI=10.1093/hmg/4.8.1397;
RA   Lehmann-Horn F., Mailaender V., Heine R., George A.L. Jr.;
RT   "Myotonia levior is a chloride channel disorder.";
RL   Hum. Mol. Genet. 4:1397-1402(1995).
RN   [11]
RP   VARIANTS MCR CYS-150; ARG-200; CYS-261 AND VAL-415.
RX   MEDLINE=96152128; PubMed=8571958;
RA   Mailaender V., Heine R., Deymeer F., Lehmann-Horn F.;
RT   "Novel muscle chloride channel mutations and their effects on
RT   heterozygous carriers.";
RL   Am. J. Hum. Genet. 58:317-324(1996).
RN   [12]
RP   VARIANTS MCD/MCR LEU-236; GLU-285; ALA-286; SER-307; VAL-485 AND
RP   ASN-556.
RX   MEDLINE=98409504; PubMed=9736777; DOI=10.1093/hmg/7.11.1753;
RA   Kubisch C., Schmidt-Rose T., Fontaine B., Bretag A.H., Jentsch T.J.;
RT   "ClC-1 chloride channel mutations in myotonia congenita: variable
RT   penetrance of mutations shifting the voltage dependence.";
RL   Hum. Mol. Genet. 7:1753-1760(1998).
RN   [13]
RP   VARIANTS MCR ILE-563 AND LEU-708.
RX   PubMed=10215406;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:4<331::AID-HUMU13>3.3.CO;2-S;
RA   Sangiuolo F., Botta A., Mesoraca A., Servidei S., Merlini L.,
RA   Fratta G., Novelli G., Dallapiccola B.;
RT   "Identification of five new mutations and three novel polymorphisms in
RT   the muscle chloride channel gene (CLCN1) in 20 Italian patients with
RT   dominant and recessive myotonia congenita.";
RL   Hum. Mutat. 11:331-331(1998).
RN   [14]
RP   VARIANTS MCD/MCR VAL-161; THR-313 AND ASN-556.
RX   MEDLINE=98226073; PubMed=9566422;
RA   Plassart-Schiess E., Gervais A., Eymard B., Lagueny A., Pouget J.,
RA   Warter J.-M., Fardeau M., Jentsch T.J., Fontaine B.;
RT   "Novel muscle chloride channel (CLCN1) mutations in myotonia congenita
RT   with various modes of inheritance including incomplete dominance and
RT   penetrance.";
RL   Neurology 50:1176-1179(1998).
RN   [15]
RP   VARIANT [LARGE SCALE ANALYSIS] LYS-548.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Voltage-gated chloride channel. Chloride channels have
CC       several functions including the regulation of cell volume;
CC       membrane potential stabilization, signal transduction and
CC       transepithelial transport.
CC   -!- SUBUNIT: Homotetramer (Probable).
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in skeletal muscles.
CC   -!- DISEASE: Defects in CLCN1 are the cause of autosomal dominant
CC       myotonia congenita (MCD) [MIM:160800]; also known as Thomsen
CC       disease. MCD is characterized by skeletal muscle stiffness
CC       (delayed relaxation), due to membrane hyperexcitability. A variant
CC       form of Thomsen disease is myotonia levior that is characterized
CC       by milder symptoms, later onset and absence of muscle hypo- and
CC       hypertrophy.
CC   -!- DISEASE: Defects in CLCN1 are the cause of autosomal recessive
CC       myotonia congenita (MCR) [MIM:255700]; also known as Becker
CC       disease.
CC   -!- MISCELLANEOUS: The CLC channel family contains both chloride
CC       channels and proton-coupled anion transporters that exchange
CC       chloride or another anion for protons. The absence of conserved
CC       gating glutamate residues is typical for family members that
CC       function as channels.
CC   -!- SIMILARITY: Belongs to the chloride channel (TC 2.A.49) family.
CC   -!- SIMILARITY: Contains 2 CBS domains.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/CLCN1";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z25587; CAA80996.1; -; Genomic_DNA.
DR   EMBL; Z25884; CAA81103.1; -; mRNA.
DR   EMBL; CH236959; EAL23786.1; -; Genomic_DNA.
DR   EMBL; BC112156; AAI12157.1; -; mRNA.
DR   EMBL; BC113495; AAI13496.1; -; mRNA.
DR   EMBL; M97820; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; L08261; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; L08262; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; L08263; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; L08264; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; L08265; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z25753; CAB56792.1; -; Genomic_DNA.
DR   EMBL; Z25754; CAB56792.1; JOINED; Genomic_DNA.
DR   EMBL; Z25755; CAB56792.1; JOINED; Genomic_DNA.
DR   EMBL; Z25756; CAB56792.1; JOINED; Genomic_DNA.
DR   EMBL; Z25757; CAB56792.1; JOINED; Genomic_DNA.
DR   EMBL; Z25758; CAB56792.1; JOINED; Genomic_DNA.
DR   EMBL; Z25759; CAB56792.1; JOINED; Genomic_DNA.
DR   EMBL; Z25760; CAB56792.1; JOINED; Genomic_DNA.
DR   EMBL; Z25761; CAB56792.1; JOINED; Genomic_DNA.
DR   EMBL; Z25762; CAB56792.1; JOINED; Genomic_DNA.
DR   EMBL; Z25763; CAB56792.1; JOINED; Genomic_DNA.
DR   EMBL; Z25764; CAB56792.1; JOINED; Genomic_DNA.
DR   EMBL; Z25765; CAB56792.1; JOINED; Genomic_DNA.
DR   EMBL; Z25766; CAB56792.1; JOINED; Genomic_DNA.
DR   EMBL; Z25767; CAB56792.1; JOINED; Genomic_DNA.
DR   EMBL; Z25752; CAB56792.1; JOINED; Genomic_DNA.
DR   EMBL; Z25768; CAB56814.1; -; Genomic_DNA.
DR   EMBL; Z25872; CAB56814.1; JOINED; Genomic_DNA.
DR   IPI; IPI00293558; -.
DR   PIR; S37078; S37078.
DR   RefSeq; NP_000074.2; -.
DR   UniGene; Hs.121483; -.
DR   SMR; P35523; 117-583, 593-872.
DR   STRING; P35523; -.
DR   TCDB; 2.A.49.2.1; chloride carrier/channel (ClC) family.
DR   PhosphoSite; P35523; -.
DR   PRIDE; P35523; -.
DR   Ensembl; ENST00000343257; ENSP00000339867; ENSG00000188037; Homo sapiens.
DR   GeneID; 1180; -.
DR   KEGG; hsa:1180; -.
DR   CTD; 1180; -.
DR   GeneCards; GC07P142723; -.
DR   H-InvDB; HIX0033595; -.
DR   HGNC; HGNC:2019; CLCN1.
DR   MIM; 118425; gene.
DR   MIM; 160800; phenotype.
DR   MIM; 255700; phenotype.
DR   Orphanet; 614; Thomsen and Becker disease.
DR   PharmGKB; PA26546; -.
DR   eggNOG; prNOG05438; -.
DR   HOGENOM; HBG755253; -.
DR   HOVERGEN; HBG005332; -.
DR   InParanoid; P35523; -.
DR   ArrayExpress; P35523; -.
DR   Bgee; P35523; -.
DR   CleanEx; HS_CLCN1; -.
DR   Genevestigator; P35523; -.
DR   GermOnline; ENSG00000188037; Homo sapiens.
DR   GO; GO:0034707; C:chloride channel complex; IEA:UniProtKB-KW.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0031404; F:chloride ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005247; F:voltage-gated chloride channel activity; TAS:ProtInc.
DR   GO; GO:0006936; P:muscle contraction; TAS:ProtInc.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR014743; Cl-channel_core.
DR   InterPro; IPR001807; Cl-channel_volt.
DR   InterPro; IPR002243; Cl_channel1.
DR   InterPro; IPR000644; Cysta_beta_synth_core.
DR   Gene3D; G3DSA:1.10.3080.10; Cl-channel_core; 1.
DR   PANTHER; PTHR11689; Cl-channel_volt; 1.
DR   Pfam; PF00571; CBS; 1.
DR   Pfam; PF00654; Voltage_CLC; 1.
DR   PRINTS; PR00762; CLCHANNEL.
DR   PRINTS; PR01112; CLCHANNEL1.
DR   SUPFAM; SSF81340; Cl-channel_core; 1.
DR   PROSITE; PS51371; CBS; 2.
PE   1: Evidence at protein level;
KW   CBS domain; Chloride; Chloride channel; Complete proteome;
KW   Disease mutation; Ion transport; Ionic channel; Membrane;
KW   Polymorphism; Repeat; Transmembrane; Transport; Voltage-gated channel.
FT   CHAIN         1    988       Chloride channel protein 1.
FT                                /FTId=PRO_0000094429.
FT   TOPO_DOM      1    114       Cytoplasmic (By similarity).
FT   TRANSMEM    115    152       By similarity.
FT   TRANSMEM    159    182       By similarity.
FT   TRANSMEM    207    225       By similarity.
FT   TRANSMEM    232    250       By similarity.
FT   TRANSMEM    302    321       By similarity.
FT   TRANSMEM    348    376       By similarity.
FT   TRANSMEM    385    404       By similarity.
FT   TRANSMEM    454    474       By similarity.
FT   TRANSMEM    482    505       By similarity.
FT   TRANSMEM    556    573       By similarity.
FT   TOPO_DOM    574    988       Cytoplasmic (By similarity).
FT   DOMAIN      609    668       CBS 1.
FT   DOMAIN      821    876       CBS 2.
FT   REGION      191    198       In-membrane helix (By similarity).
FT   REGION      266    278       In-membrane helix (By similarity).
FT   REGION      282    290       In-membrane helix (By similarity).
FT   REGION      522    536       In-membrane helix (By similarity).
FT   REGION      537    538       In-membrane loop between two helices (By
FT                                similarity).
FT   REGION      539    550       In-membrane helix (By similarity).
FT   REGION      551    555       In-membrane loop between two helices (By
FT                                similarity).
FT   MOTIF       188    192       Selectivity filter part_1 (By
FT                                similarity).
FT   MOTIF       230    234       Selectivity filter part_2 (By
FT                                similarity).
FT   MOTIF       482    486       Selectivity filter part_3 (By
FT                                similarity).
FT   BINDING     189    189       Chloride (By similarity).
FT   BINDING     484    484       Chloride; via amide nitrogen (By
FT                                similarity).
FT   BINDING     578    578       Chloride (By similarity).
FT   VARIANT     105    105       R -> C (in MCR).
FT                                /FTId=VAR_001582.
FT   VARIANT     118    118       W -> G (in dbSNP:rs10282312).
FT                                /FTId=VAR_001583.
FT   VARIANT     136    136       D -> G (in MCR).
FT                                /FTId=VAR_001584.
FT   VARIANT     150    150       Y -> C (in MCR).
FT                                /FTId=VAR_001585.
FT   VARIANT     161    161       F -> V (in MCD and MCR).
FT                                /FTId=VAR_001586.
FT   VARIANT     165    165       V -> G (in MCR).
FT                                /FTId=VAR_001587.
FT   VARIANT     167    167       F -> L (in MCR).
FT                                /FTId=VAR_001588.
FT   VARIANT     200    200       G -> R (in MCD and MCR).
FT                                /FTId=VAR_001589.
FT   VARIANT     230    230       G -> E (in MCD and MCR).
FT                                /FTId=VAR_001590.
FT   VARIANT     236    236       V -> L (in MCR).
FT                                /FTId=VAR_001591.
FT   VARIANT     261    261       Y -> C (in MCR).
FT                                /FTId=VAR_001592.
FT   VARIANT     285    285       G -> E (in MCR).
FT                                /FTId=VAR_001593.
FT   VARIANT     286    286       V -> A (in MCD).
FT                                /FTId=VAR_001594.
FT   VARIANT     290    290       I -> M (in MCD).
FT                                /FTId=VAR_001595.
FT   VARIANT     291    291       E -> K (in MCR).
FT                                /FTId=VAR_001596.
FT   VARIANT     300    300       R -> Q.
FT                                /FTId=VAR_001597.
FT   VARIANT     307    307       F -> S (in MCD).
FT                                /FTId=VAR_001598.
FT   VARIANT     313    313       A -> T (in MCD and MCR).
FT                                /FTId=VAR_001599.
FT   VARIANT     317    317       R -> Q (in MCD).
FT                                /FTId=VAR_001600.
FT   VARIANT     327    327       V -> I (in MCR).
FT                                /FTId=VAR_001601.
FT   VARIANT     329    329       I -> T (in MCR).
FT                                /FTId=VAR_001602.
FT   VARIANT     338    338       R -> Q (in MCD and MCR).
FT                                /FTId=VAR_001603.
FT   VARIANT     413    413       F -> C (in MCR).
FT                                /FTId=VAR_001604.
FT   VARIANT     415    415       A -> V (in MCR).
FT                                /FTId=VAR_001605.
FT   VARIANT     437    437       A -> T (in dbSNP:rs41276054).
FT                                /FTId=VAR_001606.
FT   VARIANT     480    480       P -> L (in MCD).
FT                                /FTId=VAR_001607.
FT   VARIANT     482    482       G -> R (in MCR).
FT                                /FTId=VAR_001608.
FT   VARIANT     485    485       M -> V (in MCR).
FT                                /FTId=VAR_001609.
FT   VARIANT     496    496       R -> S (in MCR).
FT                                /FTId=VAR_001610.
FT   VARIANT     548    548       E -> K (in a breast cancer sample;
FT                                somatic mutation).
FT                                /FTId=VAR_036300.
FT   VARIANT     552    552       Q -> R (in MCD, MCR and in myotonia
FT                                levior).
FT                                /FTId=VAR_001611.
FT   VARIANT     556    556       I -> N (in MCD and MCR; mild form).
FT                                /FTId=VAR_001612.
FT   VARIANT     563    563       V -> I (in MCR).
FT                                /FTId=VAR_001613.
FT   VARIANT     708    708       F -> L (in MCR).
FT                                /FTId=VAR_001614.
FT   VARIANT     727    727       P -> L (in dbSNP:rs13438232).
FT                                /FTId=VAR_047779.
FT   CONFLICT    697    697       L -> P (in Ref. 1; CAA80996/CAA81103).
SQ   SEQUENCE   988 AA;  108756 MW;  088A71B4112182F7 CRC64;
     MEQSRSQQRG GEQSWWGSDP QYQYMPFEHC TSYGLPSENG GLQHRLRKDA GPRHNVHPTQ
     IYGHHKEQFS DREQDIGMPK KTGSSSTVDS KDEDHYSKCQ DCIHRLGQVV RRKLGEDWIF
     LVLLGLLMAL VSWSMDYVSA KSLQAYKWSY AQMQPSLPLQ FLVWVTFPLV LILFSALFCH
     LISPQAVGSG IPEMKTILRG VVLKEYLTMK AFVAKVVALT AGLGSGIPVG KEGPFVHIAS
     ICAAVLSKFM SVFCGVYEQP YYYSDILTVG CAVGVGCCFG TPLGGVLFSI EVTSTYFAVR
     NYWRGFFAAT FSAFVFRVLA VWNKDAVTIT ALFRTNFRMD FPFDLKELPA FAAIGICCGL
     LGAVFVYLHR QVMLGVRKHK ALSQFLAKHR LLYPGIVTFV IASFTFPPGM GQFMAGELMP
     REAISTLFDN NTWVKHAGDP ESLGQSAVWI HPRVNVVIII FLFFVMKFWM SIVATTMPIP
     CGGFMPVFVL GAAFGRLVGE IMAMLFPDGI LFDDIIYKIL PGGYAVIGAA ALTGAVSHTV
     STAVICFELT GQIAHILPMM VAVILANMVA QSLQPSLYDS IIQVKKLPYL PDLGWNQLSK
     YTIFVEDIMV RDVKFVSASY TYGELRTLLQ TTTVKTLPLV DSKDSMILLG SVERSELQAL
     LQRHLCPERR LRAAQEMARK LSELPYDGKA RLAGEGLPGA PPGRPESFAF VDEDEDEDLS
     GKSELPPSLA LHPSTTAPLS PEEPNGPLPG HKQQPEAPEP AGQRPSIFQS LLHCLLGRAR
     PTKKKTTQDS TDLVDNMSPE EIEAWEQEQL SQPVCFDSCC IDQSPFQLVE QTTLHKTHTL
     FSLLGLHLAY VTSMGKLRGV LALEELQKAI EGHTKSGVQL RPPLASFRNT TSTRKSTGAP
     PSSAENWNLP EDRPGATGTG DVIAASPETP VPSPSPEPPL SLAPGKVEGE LEELELVESP
     GLEEELADIL QGPSLRSTDE EDEDELIL
//
ID   CLCN2_HUMAN             Reviewed;         898 AA.
AC   P51788; O14864; Q6IPA9; Q8WU13;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   09-FEB-2010, sequence version 2.
DT   02-MAR-2010, entry version 96.
DE   RecName: Full=Chloride channel protein 2;
DE            Short=ClC-2;
GN   Name=CLCN2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT SER-668.
RC   TISSUE=Placenta;
RX   MEDLINE=95315938; PubMed=7795595; DOI=10.1093/hmg/4.3.407;
RA   Cid L.P., Montrose-Rafizadeh C., Smith D.I., Guggino W.B.,
RA   Cutting G.R.;
RT   "Cloning of a putative human voltage-gated chloride channel (ClC-2)
RT   cDNA widely expressed in human tissues.";
RL   Hum. Mol. Genet. 4:407-413(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Lens epithelium;
RA   Rae J.L., Shepard A.R.;
RL   Submitted (SEP-1997) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Lung, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   TISSUE SPECIFICITY.
RC   TISSUE=Aortic endothelium, and Vascular smooth muscle;
RX   MEDLINE=99222497; PubMed=10198195; DOI=10.1006/jmcc.1998.0901;
RA   Lamb F.S., Clayton G.H., Liu B.-X., Smith R.L., Barna T.J.,
RA   Schutte B.C.;
RT   "Expression of CLCN voltage-gated chloride channel genes in human
RT   blood vessels.";
RL   J. Mol. Cell. Cardiol. 31:657-666(1999).
RN   [5]
RP   FUNCTION.
RX   PubMed=19153159; DOI=10.1113/jphysiol.2008.167353;
RA   Niemeyer M.I., Cid L.P., Yusef Y.R., Briones R., Sepulveda F.V.;
RT   "Voltage-dependent and -independent titration of specific residues
RT   accounts for complex gating of a ClC chloride channel by extracellular
RT   protons.";
RL   J. Physiol. (Lond.) 587:1387-1400(2009).
RN   [6]
RP   VARIANT JAE GLU-715.
RX   MEDLINE=22552710; PubMed=12612585; DOI=10.1038/ng1121;
RA   Haug K., Warnstedt M., Alekov A.K., Sander T., Ramirez A., Poser B.,
RA   Maljevic S., Hebeisen S., Kubisch C., Rebstock J., Horvath S.,
RA   Hallmann K., Dullinger J.S., Rau B., Haverkamp F., Beyenburg S.,
RA   Schulz H., Janz D., Giese B., Mueller-Newen G., Propping P.,
RA   Elger C.E., Fahlke C., Lerche H., Heils A.;
RT   "Mutations in CLCN2 encoding a voltage-gated chloride channel are
RT   associated with idiopathic generalized epilepsies.";
RL   Nat. Genet. 33:527-532(2003).
RN   [7]
RP   VARIANTS ARG-48; HIS-68; ALA-199; GLN-646; SER-668; TRP-725 AND
RP   HIS-747, AND CHARACTERIZATION OF VARIANTS ARG-48; HIS-68; ALA-199;
RP   GLN-646; TRP-725 AND HIS-747.
RX   PubMed=17762171; DOI=10.1159/000107528;
RA   Paul J., Jeyaraj S., Huber S.M., Seebohm G., Boehmer C., Lang F.,
RA   Kremsner P.G., Kun J.F.J.;
RT   "Alterations in the cytoplasmic domain of CLCN2 result in altered
RT   gating kinetics.";
RL   Cell. Physiol. Biochem. 20:441-454(2007).
RN   [8]
RP   VARIANT ECA3 LEU-719.
RX   PubMed=19200853; DOI=10.1016/j.brainresbull.2009.01.008;
RA   Combi R., Grioni D., Contri M., Redaelli S., Redaelli F., Bassi M.T.,
RA   Barisani D., Lavitrano M.L., Tredici G., Tenchini M.L., Bertolini M.,
RA   Dalpra L.;
RT   "Clinical and genetic familial study of a large cohort of Italian
RT   children with idiopathic epilepsy.";
RL   Brain Res. Bull. 79:89-96(2009).
RN   [9]
RP   VARIANTS GLN-235; GLN-577 AND CYS-644, CHARACTERIZATION OF VARIANTS
RP   GLN-235; GLN-577 AND CYS-644, AND FUNCTION.
RX   PubMed=19191339; DOI=10.1002/humu.20876;
RA   Saint-Martin C., Gauvain G., Teodorescu G., Gourfinkel-An I.,
RA   Fedirko E., Weber Y.G., Maljevic S., Ernst J.-P., Garcia-Olivares J.,
RA   Fahlke C., Nabbout R., LeGuern E., Lerche H., Christophe Poncer J.,
RA   Depienne C.;
RT   "Two novel CLCN2 mutations accelerating chloride channel deactivation
RT   are associated with idiopathic generalized epilepsy.";
RL   Hum. Mutat. 30:397-405(2009).
CC   -!- FUNCTION: Voltage-gated chloride channel. Chloride channels have
CC       several functions including the regulation of cell volume;
CC       membrane potential stabilization, signal transduction and
CC       transepithelial transport.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P51788-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P51788-2; Sequence=VSP_007831, VSP_007832, VSP_036455;
CC         Note=May be produced at very low levels due to a premature stop
CC         codon in the mRNA, leading to nonsense-mediated mRNA decay;
CC       Name=3;
CC         IsoId=P51788-3; Sequence=VSP_036456;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed. Moderately expressed
CC       in aortic and coronary vascular smooth muscle cells and expressed
CC       at a low level in aortic endothelial cells.
CC   -!- DISEASE: Defects in CLCN2 may be the cause of epilepsy with grand
CC       mal seizures on awakening (EGMA) [MIM:607628]. EGMA is a subtype
CC       of idiopathic generalized epilepsy (IGE) characterized by
CC       generalized tonic-clonic seizures (GTCS) occurring predominantly
CC       on awakening. The GTCS can be the only symptom or they can be
CC       combined with the other subsyndromes of IGE in childhood or
CC       adolescence.
CC   -!- DISEASE: Defects in CLCN2 are the cause of childhood absence
CC       epilepsy type 3 (ECA3) [MIM:607682]. ECA3 is a subtype of
CC       idiopathic generalized epilepsy (IGE) characterized by onset at
CC       age 6-7 years, frequent absence seizures (several per day) and
CC       bilateral, synchronous, symmetric 3 Hz spike waves on EEG. During
CC       adolescence, tonic-clonic and myoclonic seizures develop.
CC   -!- DISEASE: Defects in CLCN2 are a cause of juvenile absence epilepsy
CC       (JAE) [MIM:607631]. JAE is a subtype of idiopathic generalized
CC       epilepsy (IGE) characterized by onset occurring around puberty,
CC       absence seizures, generalized tonic-clonic seizures (GTCS), GTCS
CC       on awakening and myoclonic seizures.
CC   -!- MISCELLANEOUS: The CLC channel family contains both chloride
CC       channels and proton-coupled anion transporters that exchange
CC       chloride or another anion for protons. The absence of conserved
CC       gating glutamate residues is typical for family members that
CC       function as channels (By similarity).
CC   -!- SIMILARITY: Belongs to the chloride channel (TC 2.A.49) family.
CC   -!- SIMILARITY: Contains 2 CBS domains.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH21578.1; Type=Erroneous translation; Note=Wrong choice of frame;
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/CLCN2";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; S77770; AAB34722.2; -; mRNA.
DR   EMBL; AF026004; AAB88807.1; -; mRNA.
DR   EMBL; BC021578; AAH21578.1; ALT_SEQ; mRNA.
DR   EMBL; BC072004; AAH72004.1; -; mRNA.
DR   IPI; IPI00020504; -.
DR   IPI; IPI00290972; -.
DR   IPI; IPI00922766; -.
DR   RefSeq; NP_001164558.1; -.
DR   RefSeq; NP_004357.3; -.
DR   UniGene; Hs.436847; -.
DR   SMR; P51788; 90-559, 568-841.
DR   STRING; P51788; -.
DR   PRIDE; P51788; -.
DR   Ensembl; ENST00000265593; ENSP00000265593; ENSG00000114859; Homo sapiens.
DR   GeneID; 1181; -.
DR   KEGG; hsa:1181; -.
DR   UCSC; uc003foh.2; human.
DR   UCSC; uc003foi.2; human.
DR   CTD; 1181; -.
DR   GeneCards; GC03M185546; -.
DR   H-InvDB; HIX0003908; -.
DR   HGNC; HGNC:2020; CLCN2.
DR   HPA; CAB009397; -.
DR   HPA; HPA014545; -.
DR   HPA; HPA024108; -.
DR   MIM; 600570; gene.
DR   MIM; 607628; phenotype.
DR   MIM; 607631; phenotype.
DR   MIM; 607682; phenotype.
DR   PharmGKB; PA26547; -.
DR   eggNOG; prNOG10115; -.
DR   HOGENOM; HBG755253; -.
DR   HOVERGEN; HBG005332; -.
DR   InParanoid; P51788; -.
DR   DrugBank; DB01046; Lubiprostone.
DR   NextBio; 4880; -.
DR   ArrayExpress; P51788; -.
DR   Bgee; P51788; -.
DR   CleanEx; HS_CLCN2; -.
DR   Genevestigator; P51788; -.
DR   GermOnline; ENSG00000114859; Homo sapiens.
DR   GO; GO:0034707; C:chloride channel complex; IEA:UniProtKB-KW.
DR   GO; GO:0031404; F:chloride ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005247; F:voltage-gated chloride channel activity; TAS:ProtInc.
DR   GO; GO:0006821; P:chloride transport; IEA:InterPro.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR002244; Cl-channel2.
DR   InterPro; IPR014743; Cl-channel_core.
DR   InterPro; IPR001807; Cl-channel_volt.
DR   InterPro; IPR000644; Cysta_beta_synth_core.
DR   Gene3D; G3DSA:1.10.3080.10; Cl-channel_core; 1.
DR   PANTHER; PTHR11689; Cl-channel_volt; 1.
DR   Pfam; PF00571; CBS; 1.
DR   Pfam; PF00654; Voltage_CLC; 1.
DR   PRINTS; PR00762; CLCHANNEL.
DR   PRINTS; PR01113; CLCHANNEL2.
DR   SMART; SM00116; CBS; 1.
DR   SUPFAM; SSF81340; Cl-channel_core; 1.
DR   PROSITE; PS51371; CBS; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; CBS domain; Chloride; Chloride channel;
KW   Complete proteome; Disease mutation; Epilepsy; Ion transport;
KW   Ionic channel; Membrane; Polymorphism; Repeat; Transmembrane;
KW   Transport; Voltage-gated channel.
FT   CHAIN         1    898       Chloride channel protein 2.
FT                                /FTId=PRO_0000094433.
FT   TOPO_DOM      1     87       Cytoplasmic (By similarity).
FT   TRANSMEM     88    121       By similarity.
FT   TRANSMEM    130    155       By similarity.
FT   TRANSMEM    180    198       By similarity.
FT   TRANSMEM    205    223       By similarity.
FT   TRANSMEM    275    295       By similarity.
FT   TRANSMEM    321    349       By similarity.
FT   TRANSMEM    358    377       By similarity.
FT   TRANSMEM    429    449       By similarity.
FT   TRANSMEM    457    480       By similarity.
FT   TRANSMEM    531    548       By similarity.
FT   TOPO_DOM    549    898       Cytoplasmic (By similarity).
FT   DOMAIN      584    642       CBS 1.
FT   DOMAIN      790    850       CBS 2.
FT   REGION      164    171       In-membrane helix (Potential).
FT   REGION      239    251       In-membrane helix (By similarity).
FT   REGION      255    263       In-membrane helix (By similarity).
FT   REGION      497    511       In-membrane helix (By similarity).
FT   REGION      512    513       In-membrane loop between two helices (By
FT                                similarity).
FT   REGION      514    525       In-membrane helix (By similarity).
FT   REGION      526    530       In-membrane loop between two helices (By
FT                                similarity).
FT   MOTIF       161    165       Selectivity filter part_1 (By
FT                                similarity).
FT   MOTIF       203    207       Selectivity filter part_2 (By
FT                                similarity).
FT   MOTIF       457    461       Selectivity filter part_3 (By
FT                                similarity).
FT   COMPBIAS      2      6       Poly-Ala.
FT   BINDING     162    162       Chloride (By similarity).
FT   BINDING     459    459       Chloride; via amide nitrogen (By
FT                                similarity).
FT   BINDING     553    553       Chloride (By similarity).
FT   VAR_SEQ       1    359       Missing (in isoform 2).
FT                                /FTId=VSP_007831.
FT   VAR_SEQ     443    485       FWMSALATTIPVPCGAFMPVFVIGAAFGRLVGESMAAWFPD
FT                                GI -> HLGVWWVKAWLPGSQMEFIRTAAPTGLCLGATLWS
FT                                GQLRWQER (in isoform 2).
FT                                /FTId=VSP_007832.
FT   VAR_SEQ     466    482       Missing (in isoform 3).
FT                                /FTId=VSP_036456.
FT   VAR_SEQ     486    898       Missing (in isoform 2).
FT                                /FTId=VSP_036455.
FT   VARIANT      48     48       P -> R (reduces channel activity).
FT                                /FTId=VAR_057886.
FT   VARIANT      68     68       R -> H (reduces channel activity).
FT                                /FTId=VAR_057887.
FT   VARIANT     199    199       G -> A (no effect).
FT                                /FTId=VAR_057888.
FT   VARIANT     235    235       R -> Q (no effect on channel activation,
FT                                but alters channel deactivation).
FT                                /FTId=VAR_057889.
FT   VARIANT     577    577       R -> Q (no effect on channel activation,
FT                                but alters channel deactivation).
FT                                /FTId=VAR_057890.
FT   VARIANT     644    644       R -> C (no effect).
FT                                /FTId=VAR_057891.
FT   VARIANT     646    646       R -> Q (reduces channel activity).
FT                                /FTId=VAR_057892.
FT   VARIANT     668    668       T -> S (in dbSNP:rs9820367).
FT                                /FTId=VAR_054550.
FT   VARIANT     715    715       G -> E (in JAE; dbSNP:rs28938470).
FT                                /FTId=VAR_015989.
FT   VARIANT     718    718       E -> D (in dbSNP:rs2228292).
FT                                /FTId=VAR_054551.
FT   VARIANT     719    719       S -> L (in ECA3).
FT                                /FTId=VAR_058426.
FT   VARIANT     725    725       R -> W (slightly faster channel
FT                                activation).
FT                                /FTId=VAR_057893.
FT   VARIANT     747    747       R -> H (slightly faster channel
FT                                activation).
FT                                /FTId=VAR_057894.
FT   CONFLICT     17     17       Y -> H (in Ref. 1; AAB34722).
FT   CONFLICT    537    537       A -> V (in Ref. 3; AAH21578).
SQ   SEQUENCE   898 AA;  98535 MW;  5F20FA8713C0C74E CRC64;
     MAAAAAEEGM EPRALQYEQT LMYGRYTQDL GAFAKEEAAR IRLGGPEPWK GPPSSRAAPE
     LLEYGRSRCA RCRVCSVRCH KFLVSRVGED WIFLVLLGLL MALVSWVMDY AIAACLQAQQ
     WMSRGLNTSI LLQYLAWVTY PVVLITFSAG FTQILAPQAV GSGIPEMKTI LRGVVLKEYL
     TLKTFIAKVI GLTCALGSGM PLGKEGPFVH IASMCAALLS KFLSLFGGIY ENESRNTEML
     AAACAVGVGC CFAAPIGGVL FSIEVTSTFF AVRNYWRGFF AATFSAFIFR VLAVWNRDEE
     TITALFKTRF RLDFPFDLQE LPAFAVIGIA SGFGGALFVY LNRKIVQVMR KQKTINRFLM
     RKRLLFPALV TLLISTLTFP PGFGQFMAGQ LSQKETLVTL FDNRTWVRQG LVEELEPPST
     SQAWNPPRAN VFLTLVIFIL MKFWMSALAT TIPVPCGAFM PVFVIGAAFG RLVGESMAAW
     FPDGIHTDSS TYRIVPGGYA VVGAAALAGA VTHTVSTAVI VFELTGQIAH ILPVMIAVIL
     ANAVAQSLQP SLYDSIIRIK KLPYLPELGW GRHQQYRVRV EDIMVRDVPH VALSCTFRDL
     RLALHRTKGR MLALVESPES MILLGSIERS QVVALLGAQL SPARRRQHMQ ERRATQTSPL
     SDQEGPPTPE ASVCFQVNTE DSAFPAARGE THKPLKPALK RGPSVTRNLG ESPTGSAESA
     GIALRSLFCG SPPPEAASEK LESCEKRKLK RVRISLASDA DLEGEMSPEE ILEWEEQQLD
     EPVNFSDCKI DPAPFQLVER TSLHKTHTIF SLLGVDHAYV TSIGRLIGIV TLKELRKAIE
     GSVTAQGVKV RPPLASFRDS ATSSSDTETT EVHALWGPHS RHGLPREGSP SDSDDKCQ
//
ID   CLCN3_HUMAN             Reviewed;         818 AA.
AC   P51790; O14918; Q86Z21;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   14-APR-2009, sequence version 2.
DT   02-MAR-2010, entry version 91.
DE   RecName: Full=H(+)/Cl(-) exchange transporter 3;
DE   AltName: Full=Chloride transporter ClC-3;
DE   AltName: Full=Chloride channel protein 3;
DE            Short=ClC-3;
GN   Name=CLCN3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Retina;
RX   MEDLINE=95394449; PubMed=7665160; DOI=10.1006/geno.1995.1015;
RA   Borsani G., Rugarli E.I., Taglialatela M., Wong C., Ballabio A.;
RT   "Characterization of a human and murine gene (CLCN3) sharing
RT   similarities to voltage-gated chloride channels and to a yeast
RT   integral membrane protein.";
RL   Genomics 27:131-141(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Lens epithelium;
RX   MEDLINE=98341556; PubMed=9678416; DOI=10.1076/ceyr.17.7.708.5162;
RA   Shepard A.R., Rae J.L.;
RT   "Ion transporters and receptors in cDNA libraries from lens and cornea
RT   epithelia.";
RL   Curr. Eye Res. 17:708-719(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), GLYCOSYLATION, SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF GLY-280.
RC   TISSUE=Colon tumor;
RX   MEDLINE=21282914; PubMed=11274166; DOI=10.1074/jbc.M009376200;
RA   Huang P., Liu J., Di A., Robinson N.C., Musch M.W., Kaetzel M.A.,
RA   Nelson D.J.;
RT   "Regulation of human CLC-3 channels by multifunctional
RT   Ca2+/calmodulin-dependent protein kinase.";
RL   J. Biol. Chem. 276:20093-20100(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY,
RP   INTERACTION WITH SLC9A3R1, DOMAIN, AND FUNCTION.
RX   PubMed=11967229; DOI=10.1096/fj.01-0845fje;
RA   Ogura T., Furukawa T., Toyozaki T., Yamada K., Zheng Y.-J.,
RA   Katayama Y., Nakaya H., Inagaki N.;
RT   "ClC-3B, a novel ClC-3 splicing variant that interacts with EBP50 and
RT   facilitates expression of CFTR-regulated ORCC.";
RL   FASEB J. 16:863-865(2002).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   TISSUE SPECIFICITY.
RC   TISSUE=Aortic endothelium, Fetal lung, and Vascular smooth muscle;
RX   MEDLINE=99222497; PubMed=10198195; DOI=10.1006/jmcc.1998.0901;
RA   Lamb F.S., Clayton G.H., Liu B.-X., Smith R.L., Barna T.J.,
RA   Schutte B.C.;
RT   "Expression of CLCN voltage-gated chloride channel genes in human
RT   blood vessels.";
RL   J. Mol. Cell. Cardiol. 31:657-666(1999).
RN   [7]
RP   INTERACTION WITH GOPC; PDZK1 AND SLC9A3R1, GLYCOSYLATION, TISSUE
RP   SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=12471024; DOI=10.1074/jbc.M211050200;
RA   Gentzsch M., Cui L., Mengos A., Chang X.-B., Chen J.-H., Riordan J.R.;
RT   "The PDZ-binding chloride channel ClC-3B localizes to the Golgi and
RT   associates with cystic fibrosis transmembrane conductance regulator-
RT   interacting PDZ proteins.";
RL   J. Biol. Chem. 278:6440-6449(2003).
CC   -!- FUNCTION: Mediates the exchange of chloride ions against protons.
CC       Functions as antiporter and contributes to the acidification of
CC       the endosome and synaptic vesicle lumen, and may thereby affect
CC       vesicle trafficking and exocytosis. May play an important role in
CC       neuronal cell function through regulation of membrane excitability
CC       by protein kinase C. It could help neuronal cells to establish
CC       short-term memory.
CC   -!- SUBUNIT: Homo- or heterodimer. Isoform 2 interacts with GOPC,
CC       PDZK1 and SLC9A3R1/EBP50.
CC   -!- INTERACTION:
CC       Q9HD26:GOPC; NbExp=1; IntAct=EBI-349797, EBI-349832;
CC       Q5T2W1:PDZK1; NbExp=1; IntAct=EBI-349797, EBI-349819;
CC       O14745:SLC9A3R1; NbExp=1; IntAct=EBI-349797, EBI-349787;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Membrane; Multi-pass membrane
CC       protein. Early endosome membrane; Multi-pass membrane protein.
CC       Late endosome membrane; Multi-pass membrane protein. Cytoplasmic
CC       vesicle, secretory vesicle membrane; Multi-pass membrane protein
CC       (By similarity). Note=Isoform 1 is localized mainly in early and
CC       late endosomes.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Membrane; Multi-pass membrane
CC       protein. Early endosome membrane; Multi-pass membrane protein.
CC       Late endosome membrane; Multi-pass membrane protein. Golgi
CC       apparatus membrane; Multi-pass membrane protein. Note=Isoform 2
CC       partially colocalized with isoform 1 but is mainly enriched in the
CC       Golgi.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=ClC-3A;
CC         IsoId=P51790-1; Sequence=Displayed;
CC       Name=2; Synonyms=ClC-3B;
CC         IsoId=P51790-2; Sequence=VSP_016073;
CC   -!- TISSUE SPECIFICITY: Expressed primarily in tissues derived from
CC       neuroectoderm. Within the brain, its expression is particularly
CC       evident in the hippocampus, olfactory cortex, and olfactory bulb.
CC       Highly expressed in aortic and coronary vascular smooth muscle
CC       cells, and aortic endothelial cells. Also expressed in tracheal
CC       and alveolar epithelial cells, and intima and media of the
CC       pulmonary vessels. Expressed in bronchus and colon (at protein
CC       level).
CC   -!- DOMAIN: Isoform 2 contains a C-terminal PDZ-binding motif
CC       mediating the interaction with GOPC.
CC   -!- PTM: N-glycosylated.
CC   -!- MISCELLANEOUS: The CLC channel family contains both chloride
CC       channels and proton-coupled anion transporters that exchange
CC       chloride or another anion for protons. The presence of conserved
CC       gating glutamate residues is typical for family members that
CC       function as antiporters (By similarity).
CC   -!- SIMILARITY: Belongs to the chloride channel (TC 2.A.49) family.
CC   -!- SIMILARITY: Contains 2 CBS domains.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X78520; CAA55280.1; -; mRNA.
DR   EMBL; X78520; CAA55281.1; ALT_INIT; mRNA.
DR   EMBL; AF029346; AAB95161.1; -; mRNA.
DR   EMBL; AF172729; AAD51034.1; -; mRNA.
DR   EMBL; AB019542; BAC54560.1; ALT_INIT; mRNA.
DR   EMBL; AC084724; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC106878; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   IPI; IPI00398349; -.
DR   IPI; IPI00413568; -.
DR   PIR; I37240; I37240.
DR   RefSeq; NP_001820.2; -.
DR   RefSeq; NP_776297.2; -.
DR   UniGene; Hs.481186; -.
DR   IntAct; P51790; 3.
DR   STRING; P51790; -.
DR   PhosphoSite; P51790; -.
DR   PRIDE; P51790; -.
DR   Ensembl; ENST00000360642; ENSP00000353857; ENSG00000109572; Homo sapiens.
DR   GeneID; 1182; -.
DR   KEGG; hsa:1182; -.
DR   UCSC; uc003ish.1; human.
DR   UCSC; uc003isi.1; human.
DR   UCSC; uc003isj.1; human.
DR   CTD; 1182; -.
DR   GeneCards; GC04P170778; -.
DR   H-InvDB; HIX0025817; -.
DR   HGNC; HGNC:2021; CLCN3.
DR   MIM; 600580; gene.
DR   PharmGKB; PA26548; -.
DR   eggNOG; prNOG14051; -.
DR   OMA; ILRHMAQ; -.
DR   OrthoDB; EOG9NGK64; -.
DR   PhylomeDB; P51790; -.
DR   NextBio; 4884; -.
DR   ArrayExpress; P51790; -.
DR   Bgee; P51790; -.
DR   CleanEx; HS_CLCN3; -.
DR   Genevestigator; P51790; -.
DR   GermOnline; ENSG00000109572; Homo sapiens.
DR   GO; GO:0009986; C:cell surface; NAS:UniProtKB.
DR   GO; GO:0031901; C:early endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; TAS:UniProtKB.
DR   GO; GO:0031902; C:late endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0030667; C:secretory granule membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0015297; F:antiporter activity; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0031404; F:chloride ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0030165; F:PDZ domain binding; IDA:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; NAS:UniProtKB.
DR   GO; GO:0005247; F:voltage-gated chloride channel activity; TAS:ProtInc.
DR   GO; GO:0006821; P:chloride transport; IEA:InterPro.
DR   GO; GO:0048388; P:endosomal lumen acidification; TAS:UniProtKB.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR014743; Cl-channel_core.
DR   InterPro; IPR001807; Cl-channel_volt.
DR   InterPro; IPR002245; Cl_channel3.
DR   InterPro; IPR000644; Cysta_beta_synth_core.
DR   Gene3D; G3DSA:1.10.3080.10; Cl-channel_core; 1.
DR   PANTHER; PTHR11689; Cl-channel_volt; 1.
DR   Pfam; PF00571; CBS; 2.
DR   Pfam; PF00654; Voltage_CLC; 1.
DR   PRINTS; PR00762; CLCHANNEL.
DR   PRINTS; PR01114; CLCHANNEL3.
DR   SMART; SM00116; CBS; 2.
DR   SUPFAM; SSF81340; Cl-channel_core; 1.
DR   PROSITE; PS51371; CBS; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; Antiport; ATP-binding; CBS domain; Chloride;
KW   Complete proteome; Cytoplasmic vesicle; Endosome; Glycoprotein;
KW   Golgi apparatus; Ion transport; Membrane; Nucleotide-binding; Repeat;
KW   Transmembrane; Transport.
FT   CHAIN         1    818       H(+)/Cl(-) exchange transporter 3.
FT                                /FTId=PRO_0000094438.
FT   TOPO_DOM      1    125       Cytoplasmic (By similarity).
FT   TRANSMEM    126    163       By similarity.
FT   TRANSMEM    209    232       By similarity.
FT   TRANSMEM    258    276       By similarity.
FT   TRANSMEM    282    301       By similarity.
FT   TRANSMEM    349    367       By similarity.
FT   TRANSMEM    391    416       By similarity.
FT   TRANSMEM    423    443       By similarity.
FT   TRANSMEM    500    520       By similarity.
FT   TRANSMEM    525    544       By similarity.
FT   TRANSMEM    606    624       By similarity.
FT   TOPO_DOM    625    818       Cytoplasmic (By similarity).
FT   DOMAIN      658    722       CBS 1.
FT   DOMAIN      755    812       CBS 2.
FT   NP_BIND     689    691       ATP (By similarity).
FT   NP_BIND     796    799       ATP (By similarity).
FT   REGION      241    248       In-membrane helix (By similarity).
FT   REGION      313    325       In-membrane helix (By similarity).
FT   REGION      329    337       In-membrane helix (By similarity).
FT   REGION      572    586       In-membrane helix (By similarity).
FT   REGION      590    601       In-membrane helix (By similarity).
FT   REGION      602    605       In-membrane loop between two helices (By
FT                                similarity).
FT   MOTIF       238    242       Selectivity filter part_1 (By
FT                                similarity).
FT   MOTIF       280    284       Selectivity filter part_2 (By
FT                                similarity).
FT   MOTIF       525    529       Selectivity filter part_3 (By
FT                                similarity).
FT   BINDING     239    239       Chloride (By similarity).
FT   BINDING     527    527       Chloride; via amide nitrogen (By
FT                                similarity).
FT   BINDING     630    630       Chloride (By similarity).
FT   SITE        282    282       Mediates proton transfer from the outer
FT                                aqueous phase to the interior of the
FT                                protein; involved in linking H(+) and
FT                                Cl(-) transport (By similarity).
FT   SITE        339    339       Mediates proton transfer from the protein
FT                                to the inner aqueous phase (By
FT                                similarity).
FT   CARBOHYD    177    177       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    451    451       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    479    479       N-linked (GlcNAc...) (Potential).
FT   VAR_SEQ     790    818       RLLGIITKKDILRHMAQTANQDPASIMFN -> IVLGIITK
FT                                KNILEHLEQLKQHVEPLAPPWHYNKKRYPPAYGPDGKPRPR
FT                                FNNVQLNLTDEEREETEEEVYLLNSTTL (in isoform
FT                                2).
FT                                /FTId=VSP_016073.
FT   MUTAGEN     280    280       G->E: Changes channel selectivity from
FT                                I(-)>Cl(-) to Cl(-)>I(-).
FT   CONFLICT    646    646       E -> EEF (in Ref. 1; CAA55280/CAA55281
FT                                and 4; BAC54560).
SQ   SEQUENCE   818 AA;  90966 MW;  30FF0A6A2D6EF3B8 CRC64;
     MESEQLFHRG YYRNSYNSIT SASSDEELLD GAGVIMDFQT SEDDNLLDGD TAVGTHYTMT
     NGGSINSSTH LLDLLDEPIP GVGTYDDFHT IDWVREKCKD RERHRRINSK KKESAWEMTK
     SLYDAWSGWL VVTLTGLASG ALAGLIDIAA DWMTDLKEGI CLSALWYNHE QCCWGSNETT
     FEERDKCPQW KTWAELIIGQ AEGPGSYIMN YIMYIFWALS FAFLAVSLVK VFAPYACGSG
     IPEIKTILSG FIIRGYLGKW TLMIKTITLV LAVASGLSLG KEGPLVHVAC CCGNIFSYLF
     PKYSTNEAKK REVLSAASAA GVSVAFGAPI GGVLFSLEEV SYYFPLKTLW RSFFAALVAA
     FVLRSINPFG NSRLVLFYVE YHTPWYLFEL FPFILLGVFG GLWGAFFIRA NIAWCRRRKS
     TKFGKYPVLE VIIVAAITAV IAFPNPYTRL NTSELIKELF TDCGPLESSS LCDYRNDMNA
     SKIVDDIPDR PAGIGVYSAI WQLCLALIFK IIMTVFTFGI KVPSGLFIPS MAIGAIAGRI
     VGIAVEQLAY YHHDWFIFKE WCEVGADCIT PGLYAMVGAA ACLGGVTRMT VSLVVIVFEL
     TGGLEYIVPL MAAVMTSKWV GDAFGREGIY EAHIRLNGYP FLDAKEEFTH TTLAADVMRP
     RRNDPPLAVL TQDNMTVDDI ENMINETSYN GFPVIMSKES QRLVGFALRR DLTIAIESAR
     KKQEGIVGSS RVCFAQHTPS LPAESPRPLK LRSILDMSPF TVTDHTPMEI VVDIFRKLGL
     RQCLVTHNGR LLGIITKKDI LRHMAQTANQ DPASIMFN
//
ID   CLCN3_MOUSE             Reviewed;         818 AA.
AC   P51791; Q8K4X0;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   14-APR-2009, sequence version 2.
DT   02-MAR-2010, entry version 81.
DE   RecName: Full=H(+)/Cl(-) exchange transporter 3;
DE   AltName: Full=Chloride transporter ClC-3;
DE   AltName: Full=Chloride channel protein 3;
DE            Short=ClC-3;
GN   Name=Clcn3; Synonyms=Clc3;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Thymus;
RX   MEDLINE=95394449; PubMed=7665160; DOI=10.1006/geno.1995.1015;
RA   Borsani G., Rugarli E.I., Taglialatela M., Wong C., Ballabio A.;
RT   "Characterization of a human and murine gene (CLCN3) sharing
RT   similarities to voltage-gated chloride channels and to a yeast
RT   integral membrane protein.";
RL   Genomics 27:131-141(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Lens epithelium;
RX   MEDLINE=98341556; PubMed=9678416; DOI=10.1076/ceyr.17.7.708.5162;
RA   Shepard A.R., Rae J.L.;
RT   "Ion transporters and receptors in cDNA libraries from lens and cornea
RT   epithelia.";
RL   Curr. Eye Res. 17:708-719(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=129/Sv;
RA   Schutte B.C., Zimmerman C.K., Swarz S., Malik M.I., Barna T.J.,
RA   Lamb F.S.;
RT   "Diversity at the N- and C-termini for the predicted protein product
RT   of the mouse Clcn3 chloride channel gene is caused by alternative
RT   splicing.";
RL   Submitted (JAN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   STRAIN=C57BL/6J; TISSUE=Bone, and Cerebellum;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15504734; DOI=10.1074/jbc.M407030200;
RA   Hara-Chikuma M., Yang B., Sonawane N.D., Sasaki S., Uchida S.,
RA   Verkman A.S.;
RT   "ClC-3 chloride channels facilitate endosomal acidification and
RT   chloride accumulation.";
RL   J. Biol. Chem. 280:1241-1247(2005).
RN   [7]
RP   SUBCELLULAR LOCATION.
RX   PubMed=16222710; DOI=10.1002/jcp.20516;
RA   Suzuki T., Rai T., Hayama A., Sohara E., Suda S., Itoh T., Sasaki S.,
RA   Uchida S.;
RT   "Intracellular localization of ClC chloride channels and their ability
RT   to form hetero-oligomers.";
RL   J. Cell. Physiol. 206:792-798(2006).
RN   [8]
RP   FUNCTION, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=18923035; DOI=10.1523/JNEUROSCI.3750-08.2008;
RA   Maritzen T., Keating D.J., Neagoe I., Zdebik A.A., Jentsch T.J.;
RT   "Role of the vesicular chloride transporter ClC-3 in neuroendocrine
RT   tissue.";
RL   J. Neurosci. 28:10587-10598(2008).
CC   -!- FUNCTION: Mediates the exchange of chloride ions against protons.
CC       Functions as antiporter and contributes to the acidification of
CC       the endosome and synaptic vesicle lumen, and may thereby affect
CC       vesicle trafficking and exocytosis. May play an important role in
CC       neuronal cell function through regulation of membrane excitability
CC       by protein kinase C. It could help neuronal cells to establish
CC       short-term memory.
CC   -!- SUBCELLULAR LOCATION: Early endosome membrane; Multi-pass membrane
CC       protein. Late endosome membrane; Multi-pass membrane protein.
CC       Cytoplasmic vesicle, secretory vesicle membrane; Multi-pass
CC       membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=b;
CC         IsoId=P51791-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P51791-2; Sequence=VSP_036899;
CC   -!- TISSUE SPECIFICITY: Detected in kidney, in the apical part of
CC       proximal tubule cells (at protein level). Expressed at high levels
CC       in the kidney while a low level expression is seen in the brain.
CC       Within the brain, it is prominent in the hippocampus, cerebral
CC       cortex and olfactory bulb.
CC   -!- DEVELOPMENTAL STAGE: At 10.5 days of development it is expressed
CC       throughout the embryo. Later in development (12.5 to 14.5 days of
CC       gestation), expression is progressively up-regulated in neurons of
CC       the brain and the spinal cord, in all cranial sensory ganglia and
CC       in the sympathetic dorsal root ganglia.
CC   -!- PTM: N-glycosylated (By similarity).
CC   -!- SIMILARITY: Belongs to the chloride channel (TC 2.A.49) family.
CC   -!- SIMILARITY: Contains 2 CBS domains.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X78874; CAA55476.1; -; mRNA.
DR   EMBL; AF029347; AAB95162.1; -; mRNA.
DR   EMBL; AF347688; AAM89113.1; -; Genomic_DNA.
DR   EMBL; AF347682; AAM89113.1; JOINED; Genomic_DNA.
DR   EMBL; AF347683; AAM89113.1; JOINED; Genomic_DNA.
DR   EMBL; AF347684; AAM89113.1; JOINED; Genomic_DNA.
DR   EMBL; AF347685; AAM89113.1; JOINED; Genomic_DNA.
DR   EMBL; AF347686; AAM89113.1; JOINED; Genomic_DNA.
DR   EMBL; AK141136; BAE24568.1; -; mRNA.
DR   EMBL; AK159698; BAE35298.1; -; mRNA.
DR   EMBL; AK162639; BAE37002.1; -; mRNA.
DR   EMBL; CH466569; EDL28642.1; -; Genomic_DNA.
DR   IPI; IPI00126619; -.
DR   IPI; IPI00830653; -.
DR   PIR; I48295; S55473.
DR   RefSeq; NP_031737.1; -.
DR   RefSeq; NP_776298.1; -.
DR   UniGene; Mm.25263; -.
DR   UniGene; Mm.259751; -.
DR   SMR; P51791; 123-636, 650-811.
DR   STRING; P51791; -.
DR   PhosphoSite; P51791; -.
DR   PRIDE; P51791; -.
DR   Ensembl; ENSMUST00000110301; ENSMUSP00000105930; ENSMUSG00000004319; Mus musculus.
DR   GeneID; 12725; -.
DR   KEGG; mmu:12725; -.
DR   UCSC; uc009ltl.1; mouse.
DR   CTD; 12725; -.
DR   MGI; MGI:103555; Clcn3.
DR   eggNOG; roNOG09341; -.
DR   HOVERGEN; HBG050984; -.
DR   OrthoDB; EOG9NGK64; -.
DR   PhylomeDB; P51791; -.
DR   NextBio; 282016; -.
DR   ArrayExpress; P51791; -.
DR   Bgee; P51791; -.
DR   CleanEx; MM_CLCN3; -.
DR   Genevestigator; P51791; -.
DR   GermOnline; ENSMUSG00000004319; Mus musculus.
DR   GO; GO:0031901; C:early endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:UniProtKB.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0031902; C:late endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0030667; C:secretory granule membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0015297; F:antiporter activity; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0031404; F:chloride ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0030165; F:PDZ domain binding; ISS:UniProtKB.
DR   GO; GO:0005247; F:voltage-gated chloride channel activity; ISS:UniProtKB.
DR   GO; GO:0006821; P:chloride transport; IEA:InterPro.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR014743; Cl-channel_core.
DR   InterPro; IPR001807; Cl-channel_volt.
DR   InterPro; IPR002245; Cl_channel3.
DR   InterPro; IPR000644; Cysta_beta_synth_core.
DR   Gene3D; G3DSA:1.10.3080.10; Cl-channel_core; 1.
DR   PANTHER; PTHR11689; Cl-channel_volt; 1.
DR   Pfam; PF00571; CBS; 2.
DR   Pfam; PF00654; Voltage_CLC; 1.
DR   PRINTS; PR00762; CLCHANNEL.
DR   PRINTS; PR01114; CLCHANNEL3.
DR   SMART; SM00116; CBS; 2.
DR   SUPFAM; SSF81340; Cl-channel_core; 1.
DR   PROSITE; PS51371; CBS; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; Antiport; ATP-binding; CBS domain; Chloride;
KW   Cytoplasmic vesicle; Endosome; Glycoprotein; Ion transport; Membrane;
KW   Nucleotide-binding; Repeat; Transmembrane; Transport.
FT   CHAIN         1    818       H(+)/Cl(-) exchange transporter 3.
FT                                /FTId=PRO_0000094439.
FT   TOPO_DOM      1    125       Cytoplasmic (By similarity).
FT   TRANSMEM    126    163       By similarity.
FT   TRANSMEM    209    232       By similarity.
FT   TRANSMEM    258    276       By similarity.
FT   TRANSMEM    282    301       By similarity.
FT   TRANSMEM    349    367       By similarity.
FT   TRANSMEM    391    416       By similarity.
FT   TRANSMEM    423    443       By similarity.
FT   TRANSMEM    500    520       By similarity.
FT   TRANSMEM    525    544       By similarity.
FT   TRANSMEM    606    624       By similarity.
FT   TOPO_DOM    625    818       Cytoplasmic (By similarity).
FT   DOMAIN      658    722       CBS 1.
FT   DOMAIN      755    812       CBS 2.
FT   NP_BIND     689    691       ATP (By similarity).
FT   NP_BIND     796    799       ATP (By similarity).
FT   REGION      241    248       In-membrane helix (By similarity).
FT   REGION      313    325       In-membrane helix (By similarity).
FT   REGION      329    337       In-membrane helix (By similarity).
FT   REGION      572    586       In-membrane helix (By similarity).
FT   REGION      590    601       In-membrane helix (By similarity).
FT   REGION      602    605       In-membrane loop between two helices (By
FT                                similarity).
FT   MOTIF       238    242       Selectivity filter part_1 (By
FT                                similarity).
FT   MOTIF       280    284       Selectivity filter part_2 (By
FT                                similarity).
FT   MOTIF       525    529       Selectivity filter part_3 (By
FT                                similarity).
FT   BINDING     239    239       Chloride (By similarity).
FT   BINDING     527    527       Chloride; via amide nitrogen (By
FT                                similarity).
FT   BINDING     630    630       Chloride (By similarity).
FT   SITE        282    282       Mediates proton transfer from the outer
FT                                aqueous phase to the interior of the
FT                                protein; involved in linking H(+) and
FT                                Cl(-) transport (By similarity).
FT   SITE        339    339       Mediates proton transfer from the protein
FT                                to the inner aqueous phase (By
FT                                similarity).
FT   CARBOHYD    177    177       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    451    451       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    479    479       N-linked (GlcNAc...) (Potential).
FT   VAR_SEQ       1     58       Missing (in isoform 2).
FT                                /FTId=VSP_036899.
SQ   SEQUENCE   818 AA;  90869 MW;  8DD21FD156A5B29E CRC64;
     MESEQLFHRG YYRNSYNSIT SASSDEELLD GAGAIMDFQT SEDDNLLDGD TAAGTHYTMT
     NGGSINSSTH LLDLLDEPIP GVGTYDDFHT IDWVREKCKD RERHRRINSK KKESAWEMTK
     SLYDAWSGWL VVTLTGLASG ALAGLIDIAA DWMTDLKEGI CLSALWYNHE QCCWGSNETT
     FEERDKCPQW KTWAELIIGQ AEGPGSYIMN YIMYIFWALS FAFLAVSLVK VFAPYACGSG
     IPEIKTILSG FIIRGYLGKW TLMIKTITLV LAVASGLSLG KEGPLVHVAC CCGNIFSYLF
     PKYSTNEAKK REVLSAASAA GVSVAFGAPI GGVLFSLEEV SYYFPLKTLW RSFFAALVAA
     FVLRSINPFG NSRLVLFYVE YHTPWYLFEL FPFILLGVFG GLWGAFFIRA NIAWCRRRKS
     TKFGKYPVLE VIIVAAITAV IAFPNPYTRL NTSELIKELF TDCGPLESSS LCDYRNDMNA
     SKIVDDIPDR PAGVGVYSAI WQLCLALIFK IIMTVFTFGI KVPSGLFIPS MAIGAIAGRI
     VGIAVEQLAY YHHDWFIFKE WCEVGADCIT PGLYAMVGAA ACLGGVTRMT VSLVVIVFEL
     TGGLEYIVPL MAAVMTSKWV GDAFGREGIY EAHIRLNGYP FLDAKEEFTH TTLAADVMRP
     RRSDPPLAVL TQDNMTVDDI ENMINETSYN GFPVIMSKES QRLVGFALRR DLTIAIESAR
     KKQEGIVGSS RVCFAQHTPS LPAESPRPLK LRSILDMSPF TVTDHTPMEI VVDIFRKLGL
     RQCLVTHNGR LLGIITKKDI LRHMAQTANQ DPASIMFN
//
ID   CLCN4_HUMAN             Reviewed;         760 AA.
AC   P51793; Q9UBU1;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   11-FEB-2002, sequence version 2.
DT   02-MAR-2010, entry version 87.
DE   RecName: Full=H(+)/Cl(-) exchange transporter 4;
DE   AltName: Full=Chloride transporter ClC-4;
DE   AltName: Full=Chloride channel protein 4;
DE            Short=ClC-4;
GN   Name=CLCN4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Retina;
RX   MEDLINE=94348498; PubMed=8069296; DOI=10.1093/hmg/3.4.547;
RA   van Slegtenhorst M.A., Bassi M.T., Borsani G., Wapenaar M.C.,
RA   Ferrero G.B., de Conciliis L., Rugarli E.I., Grillo A., Franco B.,
RA   Zoghbi H.Y., Ballabio A.;
RT   "A gene from the Xp22.3 region shares homology with voltage-gated
RT   chloride channels.";
RL   Hum. Mol. Genet. 3:547-552(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Skeletal muscle;
RX   MEDLINE=20035030; PubMed=10564087;
RA   Kawasaki M., Fukuma T., Yamauchi K., Sakamoto H., Marumo F.,
RA   Sasaki S.;
RT   "Identification of an acid-activated Cl- channel from human skeletal
RT   muscles.";
RL   Am. J. Physiol. 277:C948-C954(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lens epithelium;
RA   Rae J.L.;
RT   "A chloride channel (ClC-4) in human lens epithelium.";
RL   Submitted (JUL-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   FUNCTION, AND MUTAGENESIS OF GLU-224 AND GLU-281.
RX   PubMed=18063579; DOI=10.1074/jbc.M708368200;
RA   Zdebik A.A., Zifarelli G., Bergsdorf E.-Y., Soliani P., Scheel O.,
RA   Jentsch T.J., Pusch M.;
RT   "Determinants of anion-proton coupling in mammalian endosomal CLC
RT   proteins.";
RL   J. Biol. Chem. 283:4219-4227(2008).
CC   -!- FUNCTION: Proton-coupled chloride transporter. Functions as
CC       antiport system and exchanges chloride ions against protons.
CC   -!- SUBCELLULAR LOCATION: Early endosome membrane; Multi-pass membrane
CC       protein (By similarity). Late endosome membrane; Multi-pass
CC       membrane protein (By similarity).
CC   -!- TISSUE SPECIFICITY: Abundant in skeletal muscle and also
CC       detectable in brain and heart.
CC   -!- MISCELLANEOUS: The CLC channel family contains both chloride
CC       channels and proton-coupled anion transporters that exchange
CC       chloride or another anion for protons. The presence of conserved
CC       gating glutamate residues is typical for family members that
CC       function as antiporters.
CC   -!- SIMILARITY: Belongs to the chloride channel (TC 2.A.49) family.
CC   -!- SIMILARITY: Contains 2 CBS domains.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X77197; CAA54417.1; -; mRNA.
DR   EMBL; AB019432; BAA77327.1; -; mRNA.
DR   EMBL; AF170492; AAD50981.1; -; mRNA.
DR   IPI; IPI00294055; -.
DR   PIR; I37242; I37242.
DR   RefSeq; NP_001821.2; -.
DR   UniGene; Hs.495674; -.
DR   SMR; P51793; 66-578, 592-753.
DR   STRING; P51793; -.
DR   TCDB; 2.A.49.2.8; chloride carrier/channel (ClC) family.
DR   PRIDE; P51793; -.
DR   Ensembl; ENST00000380833; ENSP00000370213; ENSG00000073464; Homo sapiens.
DR   GeneID; 1183; -.
DR   KEGG; hsa:1183; -.
DR   UCSC; uc004csy.2; human.
DR   CTD; 1183; -.
DR   GeneCards; GC0XP010085; -.
DR   HGNC; HGNC:2022; CLCN4.
DR   MIM; 302910; gene.
DR   PharmGKB; PA26549; -.
DR   HOGENOM; HBG735070; -.
DR   HOVERGEN; HBG050984; -.
DR   InParanoid; P51793; -.
DR   OMA; CPQWQKW; -.
DR   OrthoDB; EOG93BQ73; -.
DR   PhylomeDB; P51793; -.
DR   NextBio; 4890; -.
DR   ArrayExpress; P51793; -.
DR   Bgee; P51793; -.
DR   CleanEx; HS_CLCN4; -.
DR   Genevestigator; P51793; -.
DR   GermOnline; ENSG00000073464; Homo sapiens.
DR   GO; GO:0031901; C:early endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0031902; C:late endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0015297; F:antiporter activity; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0031404; F:chloride ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005247; F:voltage-gated chloride channel activity; TAS:ProtInc.
DR   GO; GO:0006821; P:chloride transport; IDA:MGI.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR014743; Cl-channel_core.
DR   InterPro; IPR001807; Cl-channel_volt.
DR   InterPro; IPR002246; Cl_channel4.
DR   InterPro; IPR000644; Cysta_beta_synth_core.
DR   Gene3D; G3DSA:1.10.3080.10; Cl-channel_core; 1.
DR   PANTHER; PTHR11689; Cl-channel_volt; 1.
DR   Pfam; PF00571; CBS; 2.
DR   Pfam; PF00654; Voltage_CLC; 1.
DR   PRINTS; PR00762; CLCHANNEL.
DR   PRINTS; PR01115; CLCHANNEL4.
DR   SMART; SM00116; CBS; 2.
DR   SUPFAM; SSF81340; Cl-channel_core; 1.
DR   PROSITE; PS51371; CBS; 2.
PE   1: Evidence at protein level;
KW   Antiport; ATP-binding; CBS domain; Chloride; Complete proteome;
KW   Endosome; Ion transport; Membrane; Nucleotide-binding; Repeat;
KW   Transmembrane; Transport.
FT   CHAIN         1    760       H(+)/Cl(-) exchange transporter 4.
FT                                /FTId=PRO_0000094443.
FT   TOPO_DOM      1     67       Cytoplasmic (By similarity).
FT   TRANSMEM     68    105       By similarity.
FT   TRANSMEM    151    174       By similarity.
FT   TRANSMEM    200    218       By similarity.
FT   TRANSMEM    224    243       By similarity.
FT   TRANSMEM    291    309       By similarity.
FT   TRANSMEM    333    358       By similarity.
FT   TRANSMEM    365    385       By similarity.
FT   TRANSMEM    442    462       By similarity.
FT   TRANSMEM    467    486       By similarity.
FT   TRANSMEM    548    566       By similarity.
FT   TOPO_DOM    567    760       Cytoplasmic (By similarity).
FT   DOMAIN      600    666       CBS 1.
FT   DOMAIN      697    755       CBS 2.
FT   NP_BIND     631    633       ATP (By similarity).
FT   NP_BIND     738    741       ATP (By similarity).
FT   REGION      183    190       In-membrane helix (By similarity).
FT   REGION      255    267       In-membrane helix (By similarity).
FT   REGION      271    279       In-membrane helix (By similarity).
FT   REGION      514    528       In-membrane helix (By similarity).
FT   REGION      532    543       In-membrane helix (By similarity).
FT   REGION      544    547       In-membrane loop between two helices (By
FT                                similarity).
FT   MOTIF       180    184       Selectivity filter part_1 (By
FT                                similarity).
FT   MOTIF       222    226       Selectivity filter part_2 (By
FT                                similarity).
FT   MOTIF       467    471       Selectivity filter part_3 (By
FT                                similarity).
FT   BINDING     181    181       Chloride (By similarity).
FT   BINDING     469    469       Chloride; via amide nitrogen (By
FT                                similarity).
FT   BINDING     572    572       Chloride (By similarity).
FT   BINDING     610    610       ATP; via amide nitrogen and carbonyl
FT                                oxygen (By similarity).
FT   SITE        224    224       Mediates proton transfer from the outer
FT                                aqueous phase to the interior of the
FT                                protein; involved in linking H(+) and
FT                                Cl(-) transport.
FT   SITE        281    281       Mediates proton transfer from the protein
FT                                to the inner aqueous phase.
FT   MUTAGEN     224    224       E->A: Restores chloride translocation,
FT                                but not proton transport; when associated
FT                                with A-281.
FT   MUTAGEN     281    281       E->A: Abolishes translocation of protons
FT                                and chloride ions.
FT   CONFLICT    178    178       A -> R (in Ref. 1; CAA54417).
FT   CONFLICT    498    499       II -> YY (in Ref. 1; CAA54417).
FT   CONFLICT    659    659       K -> N (in Ref. 1; CAA54417).
SQ   SEQUENCE   760 AA;  84917 MW;  3A5A25D1FEF3F217 CRC64;
     MVNAGAMSGS GNLMDFLDEP FPDVGTYEDF HTIDWLREKS RDTDRHRKIT SKSKESIWEF
     IKSLLDAWSG WVVMLLIGLL AGTLAGVIDL AVDWMTDLKE GVCLSAFWYS HEQCCWTSNE
     TTFEDRDKCP LWQKWSELLV NQSEGASAYI LNYLMYILWA LLFAFLAVSL VRVFAPYACG
     SGIPEIKTIL SGFIIRGYLG KWTLLIKTVT LVLVVSSGLS LGKEGPLVHV ACCCGNFFSS
     LFSKYSKNEG KRREVLSAAA AAGVSVAFGA PIGGVLFSLE EVSYYFPLKT LWRSFFAALV
     AAFTLRSINP FGNSRLVLFY VEYHTPWYMA ELFPFILLGV FGGLWGTLFI RCNIAWCRRR
     KTTRLGKYPV LEVIVVTAIT AIIAYPNPYT RQSTSELISE LFNDCGALES SQLCDYINDP
     NMTRPVDDIP DRPAGVGVYT AMWQLALALI FKIVVTIFTF GMKIPSGLFI PSMAVGAIAG
     RMVGIGVEQL AYHHHDWIIF RNWCRPGADC VTPGLYAMVG AAACLGGVTR MTVSLVVIMF
     ELTGGLEYIV PLMAAAVTSK WVADAFGKEG IYEAHIHLNG YPFLDVKDEF THRTLATDVM
     RPRRGEPPLS VLTQDSMTVE DVETLIKETD YNGFPVVVSR DSERLIGFAQ RRELILAIKN
     ARQRQEGIVS NSIMYFTEEP PELPANSPHP LKLRRILNLS PFTVTDHTPM ETVVDIFRKL
     GLRQCLVTRS GRLLGIITKK DVLRHMAQMA NQDPESIMFN
//
ID   CLCN5_HUMAN             Reviewed;         746 AA.
AC   P51795; A1L475; Q5JQD5;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   02-MAR-2010, entry version 99.
DE   RecName: Full=H(+)/Cl(-) exchange transporter 5;
DE   AltName: Full=Chloride transporter ClC-5;
DE   AltName: Full=Chloride channel protein 5;
DE            Short=ClC-5;
GN   Name=CLCN5; Synonyms=CLCK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Kidney;
RX   MEDLINE=96121370; PubMed=8575751; DOI=10.1006/geno.1995.9960;
RA   Fisher S.E., van Bakel I., Lloyd S.E., Pearce S.H.S., Thakker R.V.,
RA   Craig I.W.;
RT   "Cloning and characterization of CLCN5, the human kidney chloride
RT   channel gene implicated in Dent disease (an X-linked hereditary
RT   nephrolithiasis).";
RL   Genomics 29:598-606(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 487-746.
RC   TISSUE=Kidney;
RX   MEDLINE=95179126; PubMed=7874126;
RA   Fisher S., Black G.C.M., Lloyd S.E., Hatchwell E., Wrong O.,
RA   Thakker R.V., Craig I.W.;
RT   "Isolation and partial characterization of a chloride channel gene
RT   which is expressed in kidney and is a candidate for Dent's disease (an
RT   X-linked hereditary nephrolithiasis).";
RL   Hum. Mol. Genet. 3:2053-2059(1994).
RN   [5]
RP   TISSUE SPECIFICITY.
RC   TISSUE=Aortic endothelium, and Vascular smooth muscle;
RX   MEDLINE=99222497; PubMed=10198195; DOI=10.1006/jmcc.1998.0901;
RA   Lamb F.S., Clayton G.H., Liu B.-X., Smith R.L., Barna T.J.,
RA   Schutte B.C.;
RT   "Expression of CLCN voltage-gated chloride channel genes in human
RT   blood vessels.";
RL   J. Mol. Cell. Cardiol. 31:657-666(1999).
RN   [6]
RP   INTERACTION WITH NEDD4 AND NEDD4L, UBIQUITINATION, AND MUTAGENESIS OF
RP   TYR-672.
RX   PubMed=15489223; DOI=10.1074/jbc.M411491200;
RA   Hryciw D.H., Ekberg J., Lee A., Lensink I.L., Kumar S., Guggino W.B.,
RA   Cook D.I., Pollock C.A., Poronnik P.;
RT   "Nedd4-2 functionally interacts with ClC-5: involvement in
RT   constitutive albumin endocytosis in proximal tubule cells.";
RL   J. Biol. Chem. 279:54996-55007(2004).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 570-746 IN COMPLEXES WITH ATP
RP   AND ADP, AND MUTAGENESIS OF GLU-211; TYR-617; SER-618 AND ASP-727.
RX   PubMed=17195847; DOI=10.1038/nsmb1188;
RA   Meyer S., Savaresi S., Forster I.C., Dutzler R.;
RT   "Nucleotide recognition by the cytoplasmic domain of the human
RT   chloride transporter ClC-5.";
RL   Nat. Struct. Mol. Biol. 14:60-67(2007).
RN   [8]
RP   VARIANT XLRH LEU-244, VARIANT NPHL1 GLU-506, AND VARIANTS NPHL2
RP   ARG-200 AND PRO-520.
RX   MEDLINE=96158876; PubMed=8559248; DOI=10.1038/379445a0;
RA   Lloyd S.E., Pearce S.H.S., Fisher S.E., Steinmeyer K., Schwappach B.,
RA   Schelnman S.J., Harding B., Bolino A., Devoto M., Goodyer P.,
RA   Rigden S.P.A., Wrong O., Jentsch T.J., Craig I.W., Thakker R.V.;
RT   "A common molecular basis for three inherited kidney stone diseases.";
RL   Nature 379:445-449(1996).
RN   [9]
RP   VARIANT NPHL2 LEU-244.
RX   MEDLINE=97331341; PubMed=9187673; DOI=10.1007/s004390050448;
RA   Oudet C., Martin-Coignard D., Pannetier S., Praud E., Champion G.,
RA   Hanauer A.;
RT   "A second family with XLRH displays the mutation S244L in the CLCN5
RT   gene.";
RL   Hum. Genet. 99:781-784(1997).
RN   [10]
RP   VARIANTS NPHL2 HIS-30 INS; VAL-57; ARG-512 AND ASP-527.
RX   MEDLINE=97402204; PubMed=9259268; DOI=10.1093/hmg/6.8.1233;
RA   Lloyd S.E., Guenther W., Pearce S.H.S., Thomson A., Bianchi M.L.,
RA   Bosio M., Craig I.W., Fisher S.E., Scheinman S.J., Wrong O.,
RA   Jentsch T.J., Thakker R.V.;
RT   "Characterisation of renal chloride channel, CLCN5, mutations in
RT   hypercalciuric nephrolithiasis (kidney stones) disorders.";
RL   Hum. Mol. Genet. 6:1233-1239(1997).
RN   [11]
RP   VARIANT LMWPHN PRO-280.
RX   PubMed=9062355; DOI=10.1172/JCI119262;
RA   Lloyd S.E., Pearce S.H.S., Guenther W., Kawaguchi H., Igarashi T.,
RA   Jentsch T.J., Thakker R.V.;
RT   "Idiopathic low molecular weight proteinuria associated with
RT   hypercalciuric nephrocalcinosis in Japanese children is due to
RT   mutations of the renal chloride channel (CLCN5).";
RL   J. Clin. Invest. 99:967-974(1997).
RN   [12]
RP   VARIANT NPHL2 VAL-57.
RX   PubMed=9602200; DOI=10.1016/S0022-3476(98)70318-X;
RA   Schurman S.J., Norden A.G., Scheinman S.J.;
RT   "X-linked recessive nephrolithiasis: presentation and diagnosis in
RT   children.";
RL   J. Pediatr. 132:859-862(1998).
RN   [13]
RP   CHARACTERIZATION OF VARIANTS NPHL2 VAL-57 AND ASP-527,
RP   CHARACTERIZATION OF VARIANT LMWPHN PRO-280, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF SER-270; GLY-513; ARG-516 AND ILE-524.
RX   PubMed=19019917; DOI=10.1152/ajprenal.90526.2008;
RA   Smith A.J., Reed A.A., Loh N.Y., Thakker R.V., Lippiat J.D.;
RT   "Characterization of Dent's disease mutations of CLC-5 reveals a
RT   correlation between functional and cell biological consequences and
RT   protein structure.";
RL   Am. J. Physiol. 296:F390-F397(2009).
CC   -!- FUNCTION: Proton-coupled chloride transporter. Functions as
CC       antiport system and exchanges chloride ions against protons.
CC       Important for normal acidification of the endosome lumen. May play
CC       an important role in renal tubular function.
CC   -!- SUBUNIT: Interacts with NEDD4 and NEDD4L.
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus membrane; Multi-pass
CC       membrane protein. Endosome membrane; Multi-pass membrane protein.
CC       Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Kidney. Moderately expressed in aortic
CC       vascular smooth muscle and endothelial cells, and at a slightly
CC       higher level in the coronary vascular smooth muscle.
CC   -!- PTM: Ubiquitinated by NEDD4L in the presence of albumin; which
CC       promotes endocytosis and proteasomal degradation.
CC   -!- DISEASE: Defects in CLCN5 are a cause of hypophosphatemic rickets
CC       X-linked recessive (XLRH) [MIM:300554]. XLRH is a renal disease
CC       belonging to the 'Dent disease complex', a group of disorders
CC       characterized by proximal renal tubular defect, hypercalciuria,
CC       nephrocalcinosis, and renal insufficiency. The spectrum of
CC       phenotypic features is remarkably similar in the various
CC       disorders, except for differences in the severity of bone
CC       deformities and renal impairment. XLRH patients present with
CC       rickets or osteomalacia, hypophosphatemia due to decreased renal
CC       tubular phosphate reabsorption, hypercalciuria, and low molecular
CC       weight proteinuria. Patients develop nephrocalcinosis with
CC       progressive renal failure in adulthood. Female carriers may have
CC       asymptomatic hypercalciuria or hypophosphatemia only.
CC   -!- DISEASE: Defects in CLCN5 are the cause of nephrolithiasis type 2
CC       (NPHL2) [MIM:300009]; also known as Dent disease 1. NPHL2 is an X-
CC       linked recessive renal disease belonging to the 'Dent disease
CC       complex'. NPHL2 patients manifest hypercalciuria,
CC       hypophosphatemia, aminoaciduria, nephrocalcinosis and
CC       nephrolithiasis, renal insufficiency leading to renal failure in
CC       adulthood, rickets (33% of patients) and osteomalacia.
CC   -!- DISEASE: Defects in CLCN5 are the cause of nephrolithiasis type 1
CC       (NPHL1) [MIM:310468]; also designated XRN. NPHL1 is an X-linked
CC       recessive renal disease belonging to the 'Dent disease complex'.
CC       NPHL1 presents with hypercalciuria, nephrocalcinosis, renal stones
CC       and renal insufficiency. Patients lack urinary acidification
CC       defects, rickets, and osteomalacia.
CC   -!- DISEASE: Defects in CLCN5 are the cause of low molecular weight
CC       proteinuria with hypercalciuria and nephrocalcinosis (LMWPHN)
CC       [MIM:308990]. LMWPHN is an X-linked renal disease belonging to the
CC       'Dent disease complex'. Patients tend to have hypercalciuric
CC       nephrocalcinosis without rickets or renal failure.
CC   -!- MISCELLANEOUS: The CLC channel family contains both chloride
CC       channels and proton-coupled anion transporters that exchange
CC       chloride or another anion for protons. The absence of conserved
CC       gating glutamate residues is typical for family members that
CC       function as channels.
CC   -!- SIMILARITY: Belongs to the chloride channel (TC 2.A.49) family.
CC   -!- SIMILARITY: Contains 2 CBS domains.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/CLCN5";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X91906; CAA63000.1; -; mRNA.
DR   EMBL; AL663118; CAI41555.1; -; Genomic_DNA.
DR   EMBL; BC130429; AAI30430.1; -; mRNA.
DR   EMBL; BC130431; AAI30432.1; -; mRNA.
DR   EMBL; X81836; CAA57430.1; -; mRNA.
DR   IPI; IPI00294056; -.
DR   PIR; I37277; I37277.
DR   RefSeq; NP_000075.1; -.
DR   UniGene; Hs.166486; -.
DR   PDB; 2J9L; X-ray; 2.30 A; A/B/C/D/E/F=571-746.
DR   PDB; 2JA3; X-ray; 3.05 A; A/B/C/D/E/F=571-746.
DR   PDBsum; 2J9L; -.
DR   PDBsum; 2JA3; -.
DR   SMR; P51795; 54-564, 520-741.
DR   DIP; DIP-29263N; -.
DR   STRING; P51795; -.
DR   PhosphoSite; P51795; -.
DR   Ensembl; ENST00000307367; ENSP00000304257; ENSG00000171365; Homo sapiens.
DR   Ensembl; ENST00000376088; ENSP00000365256; ENSG00000171365; Homo sapiens.
DR   Ensembl; ENST00000376091; ENSP00000365259; ENSG00000171365; Homo sapiens.
DR   Ensembl; ENST00000376108; ENSP00000365276; ENSG00000171365; Homo sapiens.
DR   Ensembl; ENST00000427844; ENSP00000410148; ENSG00000171365; Homo sapiens.
DR   Ensembl; ENST00000432101; ENSP00000393633; ENSG00000171365; Homo sapiens.
DR   Ensembl; ENST00000450422; ENSP00000400415; ENSG00000171365; Homo sapiens.
DR   GeneID; 1184; -.
DR   KEGG; hsa:1184; -.
DR   UCSC; uc004dos.1; human.
DR   CTD; 1184; -.
DR   GeneCards; GC0XP049573; -.
DR   H-InvDB; HIX0016806; -.
DR   HGNC; HGNC:2023; CLCN5.
DR   HPA; HPA000401; -.
DR   MIM; 300008; gene.
DR   MIM; 300009; phenotype.
DR   MIM; 300554; phenotype.
DR   MIM; 308990; phenotype.
DR   MIM; 310468; phenotype.
DR   Orphanet; 1652; Dent syndrome.
DR   PharmGKB; PA26550; -.
DR   eggNOG; prNOG06499; -.
DR   HOVERGEN; HBG050984; -.
DR   InParanoid; P51795; -.
DR   PhylomeDB; P51795; -.
DR   NextBio; 4894; -.
DR   ArrayExpress; P51795; -.
DR   Bgee; P51795; -.
DR   CleanEx; HS_CLCN5; -.
DR   Genevestigator; P51795; -.
DR   GermOnline; ENSG00000171365; Homo sapiens.
DR   GO; GO:0045177; C:apical part of cell; IDA:UniProtKB.
DR   GO; GO:0010008; C:endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0015297; F:antiporter activity; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0031404; F:chloride ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005247; F:voltage-gated chloride channel activity; IEA:InterPro.
DR   GO; GO:0006821; P:chloride transport; IEA:InterPro.
DR   GO; GO:0007588; P:excretion; TAS:ProtInc.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR014743; Cl-channel_core.
DR   InterPro; IPR001807; Cl-channel_volt.
DR   InterPro; IPR002247; Cl_channel5.
DR   InterPro; IPR000644; Cysta_beta_synth_core.
DR   Gene3D; G3DSA:1.10.3080.10; Cl-channel_core; 1.
DR   PANTHER; PTHR11689; Cl-channel_volt; 1.
DR   Pfam; PF00571; CBS; 2.
DR   Pfam; PF00654; Voltage_CLC; 1.
DR   PRINTS; PR00762; CLCHANNEL.
DR   PRINTS; PR01116; CLCHANNEL5.
DR   SMART; SM00116; CBS; 2.
DR   SUPFAM; SSF81340; Cl-channel_core; 1.
DR   PROSITE; PS51371; CBS; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Antiport; ATP-binding; CBS domain; Cell membrane;
KW   Chloride; Complete proteome; Disease mutation; Endosome;
KW   Golgi apparatus; Ion transport; Membrane; Nucleotide-binding;
KW   Polymorphism; Repeat; Transmembrane; Transport; Ubl conjugation.
FT   CHAIN         1    746       H(+)/Cl(-) exchange transporter 5.
FT                                /FTId=PRO_0000094446.
FT   TOPO_DOM      1     54       Cytoplasmic (By similarity).
FT   TRANSMEM     55     92       By similarity.
FT   TRANSMEM    138    161       By similarity.
FT   TRANSMEM    186    205       By similarity.
FT   TRANSMEM    211    230       By similarity.
FT   TRANSMEM    278    296       By similarity.
FT   TRANSMEM    319    345       By similarity.
FT   TRANSMEM    352    372       By similarity.
FT   TRANSMEM    428    448       By similarity.
FT   TRANSMEM    453    472       By similarity.
FT   TRANSMEM    535    552       By similarity.
FT   TOPO_DOM    553    746       Cytoplasmic (By similarity).
FT   DOMAIN      586    650       CBS 1.
FT   DOMAIN      682    742       CBS 2.
FT   NP_BIND     617    619       ATP.
FT   NP_BIND     724    727       ATP.
FT   REGION      170    177       In-membrane helix (By similarity).
FT   REGION      242    254       In-membrane helix (By similarity).
FT   REGION      258    266       In-membrane helix (By similarity).
FT   REGION      500    514       In-membrane helix (By similarity).
FT   REGION      515    517       In-membrane loop between two helices (By
FT                                similarity).
FT   REGION      518    529       In-membrane helix (By similarity).
FT   REGION      530    534       In-membrane loop between two helices (By
FT                                similarity).
FT   MOTIF       167    171       Selectivity filter part_1 (By
FT                                similarity).
FT   MOTIF       209    213       Selectivity filter part_2 (By
FT                                similarity).
FT   MOTIF       453    457       Selectivity filter part_3 (By
FT                                similarity).
FT   BINDING     168    168       Chloride (By similarity).
FT   BINDING     455    455       Chloride; via amide nitrogen (By
FT                                similarity).
FT   BINDING     558    558       Chloride (By similarity).
FT   BINDING     596    596       ATP; via amide nitrogen and carbonyl
FT                                oxygen.
FT   SITE        211    211       Mediates proton transfer from the outer
FT                                aqueous phase to the interior of the
FT                                protein; involved in linking H(+) and
FT                                Cl(-) transport (By similarity).
FT   SITE        268    268       Mediates proton transfer from the protein
FT                                to the inner aqueous phase (By
FT                                similarity).
FT   VARIANT      30     30       R -> RH (in NPHL2).
FT                                /FTId=VAR_001615.
FT   VARIANT      57     57       G -> V (in NPHL2; alters targeting to
FT                                endosomes).
FT                                /FTId=VAR_001616.
FT   VARIANT     142    142       M -> I (in dbSNP:rs34800648).
FT                                /FTId=VAR_048694.
FT   VARIANT     200    200       L -> R (in NPHL2).
FT                                /FTId=VAR_001617.
FT   VARIANT     244    244       S -> L (in XLRH).
FT                                /FTId=VAR_001618.
FT   VARIANT     280    280       R -> P (in LMWPHN; 70% reduction in
FT                                chloride transport activity and alters
FT                                targeting to endosomes).
FT                                /FTId=VAR_001619.
FT   VARIANT     506    506       G -> E (in NPHL1).
FT                                /FTId=VAR_001620.
FT   VARIANT     512    512       G -> R (in NPHL2; abolishes the chloride
FT                                currents).
FT                                /FTId=VAR_001621.
FT   VARIANT     520    520       S -> P (in NPHL2).
FT                                /FTId=VAR_001622.
FT   VARIANT     527    527       E -> D (in NPHL2; abolishes the chloride
FT                                currents; total loss of function).
FT                                /FTId=VAR_001623.
FT   MUTAGEN     211    211       E->A: Abolishes proton transport, but not
FT                                chloride transport.
FT   MUTAGEN     270    270       S->R: Causes retention in the endoplasmic
FT                                reticulum and alters protein stability;
FT                                total loss of function.
FT   MUTAGEN     513    513       G->E: Causes retention in the endoplasmic
FT                                reticulum and alters protein stability;
FT                                total loss of function.
FT   MUTAGEN     516    516       R->W: Causes retention in the endoplasmic
FT                                reticulum and alters protein stability;
FT                                total loss of function.
FT   MUTAGEN     524    524       I->K: Causes retention in the endoplasmic
FT                                reticulum and alters protein stability;
FT                                total loss of function.
FT   MUTAGEN     617    617       Y->A: Strongly decreased affinity for
FT                                ATP, but no effect on chloride transport.
FT   MUTAGEN     618    618       S->A: No effect ATP binding or chloride
FT                                transport.
FT   MUTAGEN     672    672       Y->A: Abolishes interaction with NEDD4
FT                                and NEDD4L.
FT   MUTAGEN     727    727       D->A: Strongly decreased affinity for
FT                                ATP, but no effect on chloride transport.
FT   HELIX       582    585
FT   STRAND      586    588
FT   STRAND      598    601
FT   HELIX       605    614
FT   STRAND      618    624
FT   TURN        626    628
FT   STRAND      630    636
FT   HELIX       637    648
FT   STRAND      659    661
FT   STRAND      663    665
FT   HELIX       680    682
FT   STRAND      683    686
FT   STRAND      689    691
FT   HELIX       696    706
FT   STRAND      709    715
FT   STRAND      718    724
FT   HELIX       725    735
SQ   SEQUENCE   746 AA;  83147 MW;  EF913C5BA40C85D8 CRC64;
     MDFLEEPIPG VGTYDDFNTI DWVREKSRDR DRHREITNKS KESTWALIHS VSDAFSGWLL
     MLLIGLLSGS LAGLIDISAH WMTDLKEGIC TGGFWFNHEH CCWNSEHVTF EERDKCPEWN
     SWSQLIISTD EGAFAYIVNY FMYVLWALLF AFLAVSLVKV FAPYACGSGI PEIKTILSGF
     IIRGYLGKWT LVIKTITLVL AVSSGLSLGK EGPLVHVACC CGNILCHCFN KYRKNEAKRR
     EVLSAAAAAG VSVAFGAPIG GVLFSLEEVS YYFPLKTLWR SFFAALVAAF TLRSINPFGN
     SRLVLFYVEF HTPWHLFELV PFILLGIFGG LWGALFIRTN IAWCRKRKTT QLGKYPVIEV
     LVVTAITAIL AFPNEYTRMS TSELISELFN DCGLLDSSKL CDYENRFNTS KGGELPDRPA
     GVGVYSAMWQ LALTLILKIV ITIFTFGMKI PSGLFIPSMA VGAIAGRLLG VGMEQLAYYH
     QEWTVFNSWC SQGADCITPG LYAMVGAAAC LGGVTRMTVS LVVIMFELTG GLEYIVPLMA
     AAMTSKWVAD ALGREGIYDA HIRLNGYPFL EAKEEFAHKT LAMDVMKPRR NDPLLTVLTQ
     DSMTVEDVET IISETTYSGF PVVVSRESQR LVGFVLRRDL IISIENARKK QDGVVSTSII
     YFTEHSPPLP PYTPPTLKLR NILDLSPFTV TDLTPMEIVV DIFRKLGLRQ CLVTHNGRLL
     GIITKKDVLK HIAQMANQDP DSILFN
//
ID   CLCN6_HUMAN             Reviewed;         869 AA.
AC   P51797; A8K1T4; O60818; O60819; O60820; O60821; P78520; P78521;
AC   Q17R81; Q5SNW2; Q5SNW3; Q5SNX1; Q5SNX2; Q5SNX3; Q99427; Q99428;
AC   Q99429;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   02-MAR-2010, entry version 95.
DE   RecName: Full=Chloride transport protein 6;
DE   AltName: Full=Chloride channel protein 6;
DE            Short=ClC-6;
GN   Name=CLCN6; Synonyms=KIAA0046;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A), AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   MEDLINE=96130311; PubMed=8543009; DOI=10.1016/0014-5793(95)01298-2;
RA   Brandt S., Jentsch T.J.;
RT   "ClC-6 and ClC-7 are two novel broadly expressed members of the CLC
RT   chloride channel family.";
RL   FEBS Lett. 377:15-20(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS B; C AND D),
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-409 (ISOFORM A), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Chronic myeloid leukemia cell;
RX   MEDLINE=97344267; PubMed=9224655;
RA   Eggermont J., Buyse G., Voets T., Tytgat J., De Smedt H.,
RA   Droogmans G., Nilius B.;
RT   "Alternative splicing of ClC-6 (a member of the ClC chloride-channel
RT   family) transcripts generates three truncated isoforms one of which,
RT   ClC-6c, is kidney-specific.";
RL   Biochem. J. 325:269-276(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM A).
RX   MEDLINE=99431565; PubMed=10500249; DOI=10.1016/S0167-4781(99)00128-1;
RA   Kornak U., Boesl M.R., Kubisch C.;
RT   "Complete genomic structure of the CLCN6 and CLCN7 putative chloride
RT   channel genes.";
RL   Biochim. Biophys. Acta 1447:100-106(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM A).
RC   TISSUE=Bone marrow;
RX   MEDLINE=96051398; PubMed=7584044; DOI=10.1093/dnares/1.5.223;
RA   Nomura N., Nagase T., Miyajima N., Sazuka T., Tanaka A., Sato S.,
RA   Seki N., Kawarabayasi Y., Ishikawa K., Tabata S.;
RT   "Prediction of the coding sequences of unidentified human genes. II.
RT   The coding sequences of 40 new genes (KIAA0041-KIAA0080) deduced by
RT   analysis of cDNA clones from human cell line KG-1.";
RL   DNA Res. 1:223-229(1994).
RN   [5]
RP   SEQUENCE REVISION.
RX   MEDLINE=22158633; PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM A).
RC   TISSUE=Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT GLU-198.
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM A).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   TISSUE SPECIFICITY.
RC   TISSUE=Aortic endothelium, and Vascular smooth muscle;
RX   MEDLINE=99222497; PubMed=10198195; DOI=10.1006/jmcc.1998.0901;
RA   Lamb F.S., Clayton G.H., Liu B.-X., Smith R.L., Barna T.J.,
RA   Schutte B.C.;
RT   "Expression of CLCN voltage-gated chloride channel genes in human
RT   blood vessels.";
RL   J. Mol. Cell. Cardiol. 31:657-666(1999).
RN   [11]
RP   SUBCELLULAR LOCATION, GLYCOSYLATION, AND MUTAGENESIS OF ASN-410;
RP   ASN-422 AND ASN-432.
RX   PubMed=17534424; DOI=10.1371/journal.pone.0000474;
RA   Ignoul S., Simaels J., Hermans D., Annaert W., Eggermont J.;
RT   "Human ClC-6 is a late endosomal glycoprotein that associates with
RT   detergent-resistant lipid domains.";
RL   PLoS ONE 2:E474-E474(2007).
CC   -!- FUNCTION: Chloride transport protein, initially identified as
CC       voltage-gated chloride channel. The presence of the conserved
CC       gating glutamate residues suggests that is functions as
CC       antiporter.
CC   -!- SUBCELLULAR LOCATION: Endosome membrane; Multi-pass membrane
CC       protein. Note=Detected in detergent-resistant lipid rafts.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=A; Synonyms=Clc-6a;
CC         IsoId=P51797-1; Sequence=Displayed;
CC       Name=B; Synonyms=ClC-6b, D2-A1;
CC         IsoId=P51797-2; Sequence=VSP_001043, VSP_001044;
CC       Name=C; Synonyms=ClC-6c, D1-A1;
CC         IsoId=P51797-3; Sequence=VSP_001045, VSP_001046;
CC       Name=D; Synonyms=ClC-6d, D1-A2;
CC         IsoId=P51797-4; Sequence=VSP_001047, VSP_001048;
CC       Name=E;
CC         IsoId=P51797-5; Sequence=VSP_017188;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Testis, ovary, small intestine, brain and
CC       skeletal muscle. Low level expression in aortic and coronary
CC       vascular smooth muscle cells, and aortic endothelial cells.
CC       Isoform C is only detected in kidney.
CC   -!- PTM: N-glycosylated on several asparagine residues.
CC   -!- MISCELLANEOUS: The CLC channel family contains both chloride
CC       channels and proton-coupled anion transporters that exchange
CC       chloride or another anion for protons. The presence of conserved
CC       gating glutamate residues is typical for family members that
CC       function as antiporters (By similarity).
CC   -!- SIMILARITY: Belongs to the chloride channel (TC 2.A.49) family.
CC   -!- SIMILARITY: Contains 2 CBS domains.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X83378; CAA58292.1; -; mRNA.
DR   EMBL; X96391; CAA65255.1; -; mRNA.
DR   EMBL; X99472; CAA67835.1; -; Genomic_DNA.
DR   EMBL; X99473; CAA67836.1; -; mRNA.
DR   EMBL; X99474; CAA67837.1; -; mRNA.
DR   EMBL; X99475; CAA67838.1; -; mRNA.
DR   EMBL; AF009257; AAB69287.1; -; Genomic_DNA.
DR   EMBL; AF009247; AAB69287.1; JOINED; Genomic_DNA.
DR   EMBL; AF009248; AAB69287.1; JOINED; Genomic_DNA.
DR   EMBL; AF009249; AAB69287.1; JOINED; Genomic_DNA.
DR   EMBL; AF009250; AAB69287.1; JOINED; Genomic_DNA.
DR   EMBL; AF009251; AAB69287.1; JOINED; Genomic_DNA.
DR   EMBL; AF009252; AAB69287.1; JOINED; Genomic_DNA.
DR   EMBL; AF009253; AAB69287.1; JOINED; Genomic_DNA.
DR   EMBL; AF009254; AAB69287.1; JOINED; Genomic_DNA.
DR   EMBL; AF009255; AAB69287.1; JOINED; Genomic_DNA.
DR   EMBL; AF009256; AAB69287.1; JOINED; Genomic_DNA.
DR   EMBL; D28475; BAA05836.4; -; mRNA.
DR   EMBL; AK289999; BAF82688.1; -; mRNA.
DR   EMBL; AL953897; CAI15891.1; -; Genomic_DNA.
DR   EMBL; AL021155; CAI15891.1; JOINED; Genomic_DNA.
DR   EMBL; AL953897; CAI15892.1; -; Genomic_DNA.
DR   EMBL; AL021155; CAI15892.1; JOINED; Genomic_DNA.
DR   EMBL; AL953897; CAI15893.1; -; Genomic_DNA.
DR   EMBL; AL021155; CAI15893.1; JOINED; Genomic_DNA.
DR   EMBL; AL953897; CAI15894.1; -; Genomic_DNA.
DR   EMBL; AL021155; CAI15894.1; JOINED; Genomic_DNA.
DR   EMBL; AL953897; CAI15895.1; -; Genomic_DNA.
DR   EMBL; AL021155; CAI15895.1; JOINED; Genomic_DNA.
DR   EMBL; AL021155; CAI23402.1; -; Genomic_DNA.
DR   EMBL; AL953897; CAI23402.1; JOINED; Genomic_DNA.
DR   EMBL; AL021155; CAI23403.1; -; Genomic_DNA.
DR   EMBL; AL953897; CAI23403.1; JOINED; Genomic_DNA.
DR   EMBL; AL021155; CAI23404.1; -; Genomic_DNA.
DR   EMBL; AL953897; CAI23404.1; JOINED; Genomic_DNA.
DR   EMBL; AL021155; CAI23405.1; -; Genomic_DNA.
DR   EMBL; AL953897; CAI23405.1; JOINED; Genomic_DNA.
DR   EMBL; AL021155; CAI23406.1; -; Genomic_DNA.
DR   EMBL; AL953897; CAI23406.1; JOINED; Genomic_DNA.
DR   EMBL; CH471130; EAW71715.1; -; Genomic_DNA.
DR   EMBL; BC117420; AAI17421.1; -; mRNA.
DR   EMBL; BC117424; AAI17425.1; -; mRNA.
DR   IPI; IPI00180121; -.
DR   IPI; IPI00305252; -.
DR   IPI; IPI00395741; -.
DR   IPI; IPI00414669; -.
DR   IPI; IPI00642888; -.
DR   PIR; S68428; S68428.
DR   RefSeq; NP_001277.1; -.
DR   RefSeq; NP_068503.1; -.
DR   RefSeq; NP_068504.1; -.
DR   RefSeq; NP_068505.1; -.
DR   UniGene; Hs.193043; -.
DR   SMR; P51797; 77-579, 588-854.
DR   STRING; P51797; -.
DR   PRIDE; P51797; -.
DR   Ensembl; ENST00000346436; ENSP00000234488; ENSG00000011021; Homo sapiens.
DR   GeneID; 1185; -.
DR   KEGG; hsa:1185; -.
DR   UCSC; uc001ate.2; human.
DR   UCSC; uc009vnf.1; human.
DR   UCSC; uc009vng.1; human.
DR   UCSC; uc009vnh.1; human.
DR   CTD; 1185; -.
DR   GeneCards; GC01P011800; -.
DR   H-InvDB; HIX0000129; -.
DR   HGNC; HGNC:2024; CLCN6.
DR   MIM; 602726; gene.
DR   PharmGKB; PA26551; -.
DR   eggNOG; prNOG17595; -.
DR   HOVERGEN; HBG050985; -.
DR   NextBio; 4898; -.
DR   ArrayExpress; P51797; -.
DR   Bgee; P51797; -.
DR   Genevestigator; P51797; -.
DR   GO; GO:0010008; C:endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; NAS:UniProtKB.
DR   GO; GO:0015297; F:antiporter activity; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0031404; F:chloride ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005247; F:voltage-gated chloride channel activity; NAS:UniProtKB.
DR   GO; GO:0006884; P:cell volume homeostasis; NAS:UniProtKB.
DR   GO; GO:0006821; P:chloride transport; NAS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; NAS:UniProtKB.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR014743; Cl-channel_core.
DR   InterPro; IPR001807; Cl-channel_volt.
DR   InterPro; IPR002248; Cl_channel6.
DR   InterPro; IPR000644; Cysta_beta_synth_core.
DR   Gene3D; G3DSA:1.10.3080.10; Cl-channel_core; 1.
DR   PANTHER; PTHR11689; Cl-channel_volt; 1.
DR   Pfam; PF00571; CBS; 2.
DR   Pfam; PF00654; Voltage_CLC; 1.
DR   PRINTS; PR00762; CLCHANNEL.
DR   PRINTS; PR01117; CLCHANNEL6.
DR   SMART; SM00116; CBS; 2.
DR   SUPFAM; SSF81340; Cl-channel_core; 1.
DR   PROSITE; PS51371; CBS; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; Antiport; ATP-binding; CBS domain; Chloride;
KW   Complete proteome; Endosome; Glycoprotein; Ion transport; Membrane;
KW   Nucleotide-binding; Polymorphism; Repeat; Transmembrane; Transport.
FT   CHAIN         1    869       Chloride transport protein 6.
FT                                /FTId=PRO_0000094449.
FT   TOPO_DOM      1     80       Cytoplasmic (By similarity).
FT   TRANSMEM     81    113       By similarity.
FT   TRANSMEM    128    150       By similarity.
FT   TRANSMEM    176    194       By similarity.
FT   TRANSMEM    200    217       By similarity.
FT   TRANSMEM    277    294       By similarity.
FT   TRANSMEM    335    364       By similarity.
FT   TRANSMEM    371    392       By similarity.
FT   TRANSMEM    462    481       By similarity.
FT   TRANSMEM    487    511       By similarity.
FT   TRANSMEM    553    571       By similarity.
FT   TOPO_DOM    572    869       Cytoplasmic (By similarity).
FT   DOMAIN      605    662       CBS 1.
FT   DOMAIN      807    868       CBS 2.
FT   NP_BIND     630    632       ATP (By similarity).
FT   NP_BIND     849    852       ATP (By similarity).
FT   REGION      159    166       In-membrane helix (By similarity).
FT   REGION      241    253       In-membrane helix (By similarity).
FT   REGION      257    265       In-membrane helix (By similarity).
FT   REGION      519    533       In-membrane helix (By similarity).
FT   REGION      534    536       In-membrane loop between two helices (By
FT                                similarity).
FT   REGION      537    548       In-membrane helix (By similarity).
FT   REGION      549    552       In-membrane loop between two helices (By
FT                                similarity).
FT   MOTIF       156    160       Selectivity filter part_1 (By
FT                                similarity).
FT   MOTIF       198    202       Selectivity filter part_2 (By
FT                                similarity).
FT   MOTIF       487    491       Selectivity filter part_3 (By
FT                                similarity).
FT   COMPBIAS      4     18       Cys-rich.
FT   BINDING     157    157       Chloride (By similarity).
FT   BINDING     489    489       Chloride; via amide nitrogen (By
FT                                similarity).
FT   BINDING     576    576       Chloride (By similarity).
FT   SITE        200    200       Mediates proton transfer from the outer
FT                                aqueous phase to the interior of the
FT                                protein; involved in linking H(+) and
FT                                Cl(-) transport (By similarity).
FT   SITE        267    267       Mediates proton transfer from the protein
FT                                to the inner aqueous phase (By
FT                                similarity).
FT   CARBOHYD    410    410       N-linked (GlcNAc...).
FT   CARBOHYD    422    422       N-linked (GlcNAc...).
FT   CARBOHYD    432    432       N-linked (GlcNAc...).
FT   VAR_SEQ     237    320       DKRDFVSAGAAAGVAAAFGAPIGGTLFSLEEGSSFWNQGLT
FT                                WKVLFCSMSATFTLNFFRSGIQFGSWGSFQLPGLLNFGEFK
FT                                CS -> YGKRQERLCISRSGCWSCCSFRGANRGYLVQSRGG
FT                                FVLLEPRAHVESALLFHVCHLHPQLLPFWDSVWKLGFLPAP
FT                                WIAELWRV (in isoform B).
FT                                /FTId=VSP_001043.
FT   VAR_SEQ     237    308       DKRDFVSAGAAAGVAAAFGAPIGGTLFSLEEGSSFWNQGLT
FT                                WKVLFCSMSATFTLNFFRSGIQFGSWGSFQL -> SGCWSC
FT                                CSFRGANRGYLVQSRGGFVLLEPRAHVESALLFHVCHLHPQ
FT                                LLPFWDSVWKLGFLPAPWIAELWRV (in isoform D).
FT                                /FTId=VSP_001047.
FT   VAR_SEQ     309    869       Missing (in isoform D).
FT                                /FTId=VSP_001048.
FT   VAR_SEQ     319    353       CSDSDKKCHLWTAMDLGFFVVMGVIGGLLGATFNC -> SL
FT                                REPPCVSGNHRGGVCGLDGVRRMPTDVLFESNR (in
FT                                isoform C).
FT                                /FTId=VSP_001045.
FT   VAR_SEQ     321    869       Missing (in isoform B).
FT                                /FTId=VSP_001044.
FT   VAR_SEQ     354    869       Missing (in isoform C).
FT                                /FTId=VSP_001046.
FT   VAR_SEQ     844    869       IVGIITRHNLTYEFLQARLRQHYQTI -> VSEAPALPPPL
FT                                REDPLARCCLCTQASHQKRRHPTRRGECGPTLALNPARLPC
FT                                TRDPFPCLPADGTSVPLAVLSSQSRASTRLCLPPEMLLFTP
FT                                YHWCSLVLHLRRDLRIR (in isoform E).
FT                                /FTId=VSP_017188.
FT   VARIANT     198    198       G -> E (in dbSNP:rs198400).
FT                                /FTId=VAR_023051.
FT   MUTAGEN     410    410       N->A: Abolishes N-glycosylation; when
FT                                associated with A-422 and A-432.
FT   MUTAGEN     422    422       N->A: Abolishes N-glycosylation; when
FT                                associated with A-410 and A-432.
FT   MUTAGEN     432    432       N->A: Abolishes N-glycosylation; when
FT                                associated with A-410 and A-422.
SQ   SEQUENCE   869 AA;  97217 MW;  E4273777D9FF4328 CRC64;
     MAGCRGSLCC CCRWCCCCGE RETRTPEELT ILGETQEEED EILPRKDYES LDYDRCINDP
     YLEVLETMDN KKGRRYEAVK WMVVFAIGVC TGLVGLFVDF FVRLFTQLKF GVVQTSVEEC
     SQKGCLALSL LELLGFNLTF VFLASLLVLI EPVAAGSGIP EVKCYLNGVK VPGIVRLRTL
     LCKVLGVLFS VAGGLFVGKE GPMIHSGSVV GAGLPQFQSI SLRKIQFNFP YFRSDRDKRD
     FVSAGAAAGV AAAFGAPIGG TLFSLEEGSS FWNQGLTWKV LFCSMSATFT LNFFRSGIQF
     GSWGSFQLPG LLNFGEFKCS DSDKKCHLWT AMDLGFFVVM GVIGGLLGAT FNCLNKRLAK
     YRMRNVHPKP KLVRVLESLL VSLVTTVVVF VASMVLGECR QMSSSSQIGN DSFQLQVTED
     VNSSIKTFFC PNDTYNDMAT LFFNPQESAI LQLFHQDGTF SPVTLALFFV LYFLLACWTY
     GISVPSGLFV PSLLCGAAFG RLVANVLKSY IGLGHIYSGT FALIGAAAFL GGVVRMTISL
     TVILIESTNE ITYGLPIMVT LMVAKWTGDF FNKGIYDIHV GLRGVPLLEW ETEVEMDKLR
     ASDIMEPNLT YVYPHTRIQS LVSILRTTVH HAFPVVTENR GNEKEFMKGN QLISNNIKFK
     KSSILTRAGE QRKRSQSMKS YPSSELRNMC DEHIASEEPA EKEDLLQQML ERRYTPYPNL
     YPDQSPSEDW TMEERFRPLT FHGLILRSQL VTLLVRGVCY SESQSSASQP RLSYAEMAED
     YPRYPDIHDL DLTLLNPRMI VDVTPYMNPS PFTVSPNTHV SQVFNLFRTM GLRHLPVVNA
     VGEIVGIITR HNLTYEFLQA RLRQHYQTI
//
ID   CLCN6_MOUSE             Reviewed;         870 AA.
AC   O35454;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   02-MAR-2010, entry version 80.
DE   RecName: Full=Chloride transport protein 6;
DE   AltName: Full=Chloride channel protein 6;
DE            Short=ClC-6;
GN   Name=Clcn6; Synonyms=Clc6;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Kornak U., Boesl M.R., Jentsch T.J.;
RL   Submitted (OCT-1997) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   TISSUE SPECIFICITY, AND ALTERNATIVE SPLICING.
RC   TISSUE=Chronic myeloid leukemia cell;
RX   MEDLINE=97344267; PubMed=9224655;
RA   Eggermont J., Buyse G., Voets T., Tytgat J., De Smedt H.,
RA   Droogmans G., Nilius B.;
RT   "Alternative splicing of ClC-6 (a member of the ClC chloride-channel
RT   family) transcripts generates three truncated isoforms one of which,
RT   ClC-6c, is kidney-specific.";
RL   Biochem. J. 325:269-276(1997).
RN   [3]
RP   FUNCTION, SUBCELLULAR LOCATION, DISRUPTION PHENOTYPE, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=16950870; DOI=10.1073/pnas.0606137103;
RA   Poet M., Kornak U., Schweizer M., Zdebik A.A., Scheel O., Hoelter S.,
RA   Wurst W., Schmitt A., Fuhrmann J.C., Planells-Cases R., Mole S.E.,
RA   Huebner C.A., Jentsch T.J.;
RT   "Lysosomal storage disease upon disruption of the neuronal chloride
RT   transport protein ClC-6.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:13854-13859(2006).
CC   -!- FUNCTION: Chloride transport protein, initially identified as
CC       voltage-gated chloride channel. The presence of the conserved
CC       gating glutamate residues suggests that is functions as
CC       antiporter.
CC   -!- SUBCELLULAR LOCATION: Endosome membrane; Multi-pass membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=ClC-6a;
CC         IsoId=O35454-1; Sequence=Displayed;
CC       Name=ClC-6c;
CC         IsoId=O35454-2; Sequence=Not described;
CC   -!- TISSUE SPECIFICITY: Detected in whole brain and in hippocampus
CC       neurons (at protein level). Detected in brain, trigeminus, dorsal
CC       root ganglion, spinal cord, eye, kidney, testis, skeletal muscle,
CC       thymus and pancreas. Isoform ClC-6c is expressed only in kidney.
CC   -!- PTM: N-glycosylated on several asparagine residues (By
CC       similarity).
CC   -!- DISRUPTION PHENOTYPE: Reduced pain sensitivity and moderate
CC       behavorial abnormalities, but have normal fertility and are
CC       generally not very different from wild-type.
CC   -!- MISCELLANEOUS: The CLC channel family contains both chloride
CC       channels and proton-coupled anion transporters that exchange
CC       chloride or another anion for protons. The presence of conserved
CC       gating glutamate residues is typical for family members that
CC       function as antiporters (By similarity).
CC   -!- SIMILARITY: Belongs to the chloride channel (TC 2.A.49) family.
CC   -!- SIMILARITY: Contains 2 CBS domains.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF030106; AAC17702.1; -; Genomic_DNA.
DR   EMBL; AF030101; AAC17702.1; JOINED; Genomic_DNA.
DR   EMBL; AF030102; AAC17702.1; JOINED; Genomic_DNA.
DR   EMBL; AF030103; AAC17702.1; JOINED; Genomic_DNA.
DR   EMBL; AF030104; AAC17702.1; JOINED; Genomic_DNA.
DR   EMBL; AF030105; AAC17702.1; JOINED; Genomic_DNA.
DR   IPI; IPI00875404; -.
DR   RefSeq; NP_036059.1; -.
DR   UniGene; Mm.89987; -.
DR   SMR; O35454; 77-581, 805-857.
DR   STRING; O35454; -.
DR   PRIDE; O35454; -.
DR   Ensembl; ENSMUST00000030879; ENSMUSP00000030879; ENSMUSG00000029016; Mus musculus.
DR   GeneID; 26372; -.
DR   KEGG; mmu:26372; -.
DR   UCSC; uc008vts.1; mouse.
DR   CTD; 26372; -.
DR   MGI; MGI:1347049; Clcn6.
DR   HOVERGEN; HBG050985; -.
DR   PhylomeDB; O35454; -.
DR   NextBio; 304269; -.
DR   ArrayExpress; O35454; -.
DR   Bgee; O35454; -.
DR   CleanEx; MM_CLCN6; -.
DR   Genevestigator; O35454; -.
DR   GermOnline; ENSMUSG00000029016; Mus musculus.
DR   GO; GO:0010008; C:endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0015297; F:antiporter activity; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0031404; F:chloride ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005247; F:voltage-gated chloride channel activity; IEA:InterPro.
DR   GO; GO:0006821; P:chloride transport; IEA:InterPro.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR014743; Cl-channel_core.
DR   InterPro; IPR001807; Cl-channel_volt.
DR   InterPro; IPR002248; Cl_channel6.
DR   InterPro; IPR000644; Cysta_beta_synth_core.
DR   Gene3D; G3DSA:1.10.3080.10; Cl-channel_core; 1.
DR   PANTHER; PTHR11689; Cl-channel_volt; 1.
DR   Pfam; PF00571; CBS; 2.
DR   Pfam; PF00654; Voltage_CLC; 1.
DR   PRINTS; PR00762; CLCHANNEL.
DR   PRINTS; PR01117; CLCHANNEL6.
DR   SMART; SM00116; CBS; 2.
DR   SUPFAM; SSF81340; Cl-channel_core; 1.
DR   PROSITE; PS51371; CBS; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; Antiport; ATP-binding; CBS domain; Chloride;
KW   Endosome; Glycoprotein; Ion transport; Membrane; Nucleotide-binding;
KW   Repeat; Transmembrane; Transport.
FT   CHAIN         1    870       Chloride transport protein 6.
FT                                /FTId=PRO_0000094450.
FT   TOPO_DOM      1     80       Cytoplasmic (By similarity).
FT   TRANSMEM     81    113       By similarity.
FT   TRANSMEM    128    150       By similarity.
FT   TRANSMEM    176    194       By similarity.
FT   TRANSMEM    200    217       By similarity.
FT   TRANSMEM    277    294       By similarity.
FT   TRANSMEM    335    364       By similarity.
FT   TRANSMEM    371    392       By similarity.
FT   TRANSMEM    463    482       By similarity.
FT   TRANSMEM    488    512       By similarity.
FT   TRANSMEM    554    572       By similarity.
FT   TOPO_DOM    573    870       Cytoplasmic (By similarity).
FT   DOMAIN      606    663       CBS 1.
FT   DOMAIN      808    869       CBS 2.
FT   NP_BIND     631    633       ATP (By similarity).
FT   NP_BIND     850    853       ATP (By similarity).
FT   REGION      159    166       In-membrane helix (By similarity).
FT   REGION      241    253       In-membrane helix (By similarity).
FT   REGION      257    265       In-membrane helix (By similarity).
FT   REGION      520    534       In-membrane helix (By similarity).
FT   REGION      535    537       In-membrane loop between two helices (By
FT                                similarity).
FT   REGION      538    549       In-membrane helix (By similarity).
FT   REGION      550    553       In-membrane loop between two helices (By
FT                                similarity).
FT   MOTIF       156    160       Selectivity filter part_1 (By
FT                                similarity).
FT   MOTIF       198    202       Selectivity filter part_2 (By
FT                                similarity).
FT   MOTIF       488    492       Selectivity filter part_3 (By
FT                                similarity).
FT   BINDING     157    157       Chloride (By similarity).
FT   BINDING     490    490       Chloride; via amide nitrogen (By
FT                                similarity).
FT   BINDING     577    577       Chloride (By similarity).
FT   SITE        200    200       Mediates proton transfer from the outer
FT                                aqueous phase to the interior of the
FT                                protein; involved in linking H(+) and
FT                                Cl(-) transport (By similarity).
FT   SITE        267    267       Mediates proton transfer from the protein
FT                                to the inner aqueous phase (By
FT                                similarity).
FT   CARBOHYD    410    410       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    423    423       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    433    433       N-linked (GlcNAc...) (Potential).
SQ   SEQUENCE   870 AA;  96980 MW;  872C090069188749 CRC64;
     MAGCRGSVCC CCRWCCCCGE RESRTPEELT ILGETQEEED EILPRKDYES LDYDRCINDP
     YLEVLETMDN KKGRRYEAVK WMVVFAIGVC TGLVGLFVDF SVRLFTQLKF GVVQTSVEEC
     SQKGCLALSL LELLGFNLTF VFLASLLVLI EPVAAGSGIP EIKCYLNGVK VPGIVRLRTL
     LCKVFGVLFS VSGGLFVGKE GPMIHSGAVV GAGLPQFQSI SLRKIQFNFP YFRSDRDKRD
     FVSAGAAAGV AAAFGAPIGG TLFSLEEGSS FWNQGLTWKV LFCSMSATFT LNFFRSGIQF
     GSWGSFQLPG LLNFGEFKCS DSDKKCHLWT AMDLGFFVVM GVIGGLLGAT FNCLNKRLAK
     YRMRNVHPKP KLVRVLESLL VSLVTTVVVF VASMVLGECR QMSSTSQTGN GSFQLQVTSE
     DVNSTIKAFF CPNDTYNDMA TLFFNSQESA ILQLFHQDGT FSPVTLALFF ILYFLLACWT
     FGTSVPSGLF VPSLLCGAAF GRLVANVLKS YIGLGHLYSG TFALIGAAAF LGGVVRMTIS
     LTVILIESTN EITYGLPIMV TLMVAKWTGD LFNKGIYDVH IGLRGVPLLE WETDVEMDKL
     RASDIMEPNL TYVYPHTRIQ SLVSILRTTV HHAFPVVTEN RGNEKEFMKG NQLISNNIKF
     KKSSILTRAG EQRKRGQSMK SYPSSELRNV CDEHVASEEP AEKEDLLQQM LERRYTPYPN
     LYPDQSPSED WTMEERFRPL TFHGLVLRSQ LVTLLVRGVC YSESQSSASQ PRLSYAEMAE
     DYPRYPDIHD LDLTLLNPRM IVDVTPYMNP SPFTVSPNTH VSQVFNLFRT MGLRHLPVVN
     AVGEIVGIIT RHNLTNEFLQ ARLRQHYQTL
//
ID   CLCN7_HUMAN             Reviewed;         805 AA.
AC   P51798; A6NEJ7; A8K5T9; Q9NYX5;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2001, sequence version 2.
DT   02-MAR-2010, entry version 108.
DE   RecName: Full=H(+)/Cl(-) exchange transporter 7;
DE   AltName: Full=Chloride channel protein 7;
DE            Short=ClC-7;
GN   Name=CLCN7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lens epithelium;
RA   Rae J.L.;
RT   "Ion channels in lens epithelia.";
RL   Submitted (JAN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 17-805.
RC   TISSUE=Brain;
RX   MEDLINE=96130311; PubMed=8543009; DOI=10.1016/0014-5793(95)01298-2;
RA   Brandt S., Jentsch T.J.;
RT   "ClC-6 and ClC-7 are two novel broadly expressed members of the CLC
RT   chloride channel family.";
RL   FEBS Lett. 377:15-20(1995).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 275-432.
RX   MEDLINE=98234303; PubMed=9565675; DOI=10.1016/S0167-4781(98)00014-1;
RA   Eggermont J.;
RT   "The exon-intron architecture of human chloride channel genes is not
RT   conserved.";
RL   Biochim. Biophys. Acta 1397:156-160(1998).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 744-805.
RC   TISSUE=Mammary gland;
RA   Schutte B.C., Malik M.I., Fingert J., Stone E., Lamb F.S.;
RL   Submitted (MAR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-9; SER-60 AND SER-61,
RP   AND MASS SPECTROMETRY.
RC   TISSUE=Epithelium;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [9]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=18449189; DOI=10.1038/nature06907;
RA   Graves A.R., Curran P.K., Smith C.L., Mindell J.A.;
RT   "The Cl-/H+ antiporter ClC-7 is the primary chloride permeation
RT   pathway in lysosomes.";
RL   Nature 453:788-792(2008).
RN   [10]
RP   VARIANT OPTB4 GLN-762.
RX   MEDLINE=21124827; PubMed=11207362; DOI=10.1016/S0092-8674(01)00206-9;
RA   Kornak U., Kasper D., Boesl M.R., Kaiser E., Schweizer M., Schulz A.,
RA   Friedrich W., Delling G., Jentsch T.J.;
RT   "Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and
RT   man.";
RL   Cell 104:205-215(2001).
RN   [11]
RP   VARIANT OPTB4 PRO-766, AND VARIANT OPTA2 TRP-767.
RX   PubMed=11741829; DOI=10.1093/hmg/10.25.2861;
RA   Cleiren E., Benichou O., Van Hul E., Gram J., Bollerslav J.,
RA   Singer F.R., Beaverson K., Aledo A., Whyte M.P., Yoneyama T.,
RA   de Vernejoul M.-C., Van Hul W.;
RT   "Albers-Schonberg disease (autosomal dominant osteopetrosis, type II)
RT   results from mutations in the ClCN7 chloride channel gene.";
RL   Hum. Mol. Genet. 10:2861-2867(2001).
RN   [12]
RP   VARIANTS OPTB4 ARG-240; ARG-249; VAL-332; TRP-526; PRO-614; PHE-744;
RP   GLN-767 AND TRP-767, VARIANTS OPTA2 ARG-215; GLN-286; PHE-490 AND
RP   VAL-677, AND VARIANT MET-418.
RX   PubMed=14584882; DOI=10.1359/jbmr.2003.18.10.1740;
RA   Frattini A., Pangrazio A., Susani L., Sobacchi C., Mirolo M.,
RA   Abinun M., Andolina M., Flanagan A., Horwitz E.M., Mihci E.,
RA   Notarangelo L.D., Ramenghi U., Teti A., Van Hove J., Vujic D.,
RA   Young T., Albertini A., Orchard P.J., Vezzoni P., Villa A.;
RT   "Chloride channel ClCN7 mutations are responsible for severe
RT   recessive, dominant, and intermediate osteopetrosis.";
RL   J. Bone Miner. Res. 18:1740-1747(2003).
RN   [13]
RP   VARIANT OPTB4 PHE-261.
RX   PubMed=17033731; DOI=10.1007/s10038-006-0075-4;
RA   Lam C.-W., Tong S.-F., Wong K., Luo Y.F., Tang H.-Y., Ha S.-Y.,
RA   Chan M.H.-M.;
RT   "DNA-based diagnosis of malignant osteopetrosis by whole-genome scan
RT   using a single-nucleotide polymorphism microarray: standardization of
RT   molecular investigations of genetic diseases due to consanguinity.";
RL   J. Hum. Genet. 52:98-101(2007).
CC   -!- FUNCTION: Mediates the exchange of chloride ions against protons.
CC       Functions as antiporter and contributes to the acidification of
CC       the lysosome lumen.
CC   -!- SUBCELLULAR LOCATION: Lysosome membrane; Multi-pass membrane
CC       protein.
CC   -!- TISSUE SPECIFICITY: Brain, testis, muscle and kidney.
CC   -!- DISEASE: Defects in CLCN7 are the cause of osteopetrosis autosomal
CC       recessive type 4 (OPTB4) [MIM:611490]; also known as infantile
CC       malignant osteopetrosis type 2. Osteopetrosis is a rare genetic
CC       disease characterized by abnormally dense bone, due to defective
CC       resorption of immature bone. The disorder occurs in two forms: a
CC       severe autosomal recessive form occurring in utero, infancy, or
CC       childhood, and a benign autosomal dominant form occurring in
CC       adolescence or adulthood.
CC   -!- DISEASE: Defects in CLCN7 are a cause of osteopetrosis autosomal
CC       dominant type 2 [MIM:166600]; also known as autosomal dominant
CC       Albers-Schonberg disease or marble disease autosomal dominant.
CC       Osteopetrosis is a rare genetic disease characterized by
CC       abnormally dense bone, due to defective resorption of immature
CC       bone. The disorder occurs in two forms: a severe autosomal
CC       recessive form occurring in utero, infancy, or childhood, and a
CC       benign autosomal dominant form occurring in adolescence or
CC       adulthood. OPTA2 is the most common form of osteopetrosis,
CC       occurring in adolescence or adulthood. It is characterized by
CC       sclerosis, predominantly involving the spine, the pelvis and the
CC       skull base.
CC   -!- MISCELLANEOUS: The CLC channel family contains both chloride
CC       channels and proton-coupled anion transporters that exchange
CC       chloride or another anion for protons. The presence of conserved
CC       gating glutamate residues is typical for family members that
CC       function as antiporters (By similarity).
CC   -!- SIMILARITY: Belongs to the chloride channel (TC 2.A.49) family.
CC   -!- SIMILARITY: Contains 2 CBS domains.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/CLCN7";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF224741; AAF34711.1; -; mRNA.
DR   EMBL; AK291404; BAF84093.1; -; mRNA.
DR   EMBL; AL031705; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC012737; AAH12737.1; -; mRNA.
DR   EMBL; Z67743; CAA91556.1; -; mRNA.
DR   EMBL; AJ001910; CAA05083.1; -; Genomic_DNA.
DR   EMBL; U88844; AAB48530.1; -; mRNA.
DR   IPI; IPI00940305; -.
DR   PIR; S68427; S68427.
DR   RefSeq; NP_001107803.1; -.
DR   RefSeq; NP_001278.1; -.
DR   UniGene; Hs.459649; -.
DR   SMR; P51798; 121-606, 614-790.
DR   STRING; P51798; -.
DR   TCDB; 2.A.49.3.3; chloride carrier/channel (ClC) family.
DR   PhosphoSite; P51798; -.
DR   PRIDE; P51798; -.
DR   Ensembl; ENST00000428756; ENSP00000404772; ENSG00000103249; Homo sapiens.
DR   GeneID; 1186; -.
DR   KEGG; hsa:1186; -.
DR   UCSC; uc002clv.2; human.
DR   CTD; 1186; -.
DR   GeneCards; GC16M001435; -.
DR   H-InvDB; HIX0012684; -.
DR   HGNC; HGNC:2025; CLCN7.
DR   MIM; 166600; phenotype.
DR   MIM; 602727; gene.
DR   MIM; 611490; phenotype.
DR   Orphanet; 53; Albers-Schonberg osteopetrosis.
DR   Orphanet; 667; Autosomal recessive malignant osteopetrosis.
DR   Orphanet; 210110; Intermediate osteopetrosis.
DR   PharmGKB; PA26552; -.
DR   eggNOG; prNOG14647; -.
DR   HOVERGEN; HBG050985; -.
DR   OrthoDB; EOG9Z6572; -.
DR   PhylomeDB; P51798; -.
DR   NextBio; 4908; -.
DR   ArrayExpress; P51798; -.
DR   Bgee; P51798; -.
DR   CleanEx; HS_CLCN7; -.
DR   Genevestigator; P51798; -.
DR   GermOnline; ENSG00000103249; Homo sapiens.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005765; C:lysosomal membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0015297; F:antiporter activity; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0031404; F:chloride ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005247; F:voltage-gated chloride channel activity; IEA:InterPro.
DR   GO; GO:0006821; P:chloride transport; IEA:InterPro.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR014743; Cl-channel_core.
DR   InterPro; IPR001807; Cl-channel_volt.
DR   InterPro; IPR002249; Cl_channel7.
DR   InterPro; IPR000644; Cysta_beta_synth_core.
DR   InterPro; IPR006311; TAT_signal.
DR   Gene3D; G3DSA:1.10.3080.10; Cl-channel_core; 1.
DR   PANTHER; PTHR11689; Cl-channel_volt; 1.
DR   Pfam; PF00571; CBS; 2.
DR   Pfam; PF00654; Voltage_CLC; 1.
DR   PRINTS; PR00762; CLCHANNEL.
DR   PRINTS; PR01118; CLCHANNEL7.
DR   SMART; SM00116; CBS; 2.
DR   SUPFAM; SSF81340; Cl-channel_core; 1.
DR   TIGRFAMs; TIGR01409; TAT_signal_seq; 1.
DR   PROSITE; PS51371; CBS; 2.
PE   1: Evidence at protein level;
KW   Antiport; ATP-binding; CBS domain; Chloride; Complete proteome;
KW   Disease mutation; Ion transport; Lysosome; Membrane;
KW   Nucleotide-binding; Osteopetrosis; Phosphoprotein; Polymorphism;
KW   Repeat; Transmembrane; Transport.
FT   CHAIN         1    805       H(+)/Cl(-) exchange transporter 7.
FT                                /FTId=PRO_0000094452.
FT   TOPO_DOM      1    126       Cytoplasmic (By similarity).
FT   TRANSMEM    127    159       By similarity.
FT   TRANSMEM    174    197       By similarity.
FT   TRANSMEM    223    241       By similarity.
FT   TRANSMEM    247    264       By similarity.
FT   TRANSMEM    322    341       By similarity.
FT   TRANSMEM    375    405       By similarity.
FT   TRANSMEM    410    432       By similarity.
FT   TRANSMEM    487    507       By similarity.
FT   TRANSMEM    512    535       By similarity.
FT   TRANSMEM    579    597       By similarity.
FT   TOPO_DOM    598    805       Cytoplasmic (By similarity).
FT   DOMAIN      631    695       CBS 1.
FT   DOMAIN      741    799       CBS 2.
FT   NP_BIND     658    660       ATP (By similarity).
FT   NP_BIND     783    786       ATP (By similarity).
FT   REGION      206    213       In-membrane helix (By similarity).
FT   REGION      288    300       In-membrane helix (By similarity).
FT   REGION      304    312       In-membrane helix (By similarity).
FT   REGION      545    559       In-membrane helix (By similarity).
FT   REGION      560    562       In-membrane loop between two helices (By
FT                                similarity).
FT   REGION      563    574       In-membrane helix (By similarity).
FT   REGION      575    578       In-membrane loop between two helices (By
FT                                similarity).
FT   MOTIF       203    207       Selectivity filter part_1 (By
FT                                similarity).
FT   MOTIF       245    249       Selectivity filter part_2 (By
FT                                similarity).
FT   MOTIF       512    516       Selectivity filter part_3 (By
FT                                similarity).
FT   BINDING     204    204       Chloride (By similarity).
FT   BINDING     514    514       Chloride; via amide nitrogen (By
FT                                similarity).
FT   BINDING     602    602       Chloride (By similarity).
FT   SITE        247    247       Mediates proton transfer from the outer
FT                                aqueous phase to the interior of the
FT                                protein; involved in linking H(+) and
FT                                Cl(-) transport (By similarity).
FT   SITE        314    314       Mediates proton transfer from the protein
FT                                to the inner aqueous phase (By
FT                                similarity).
FT   MOD_RES       9      9       Phosphoserine.
FT   MOD_RES      60     60       Phosphoserine.
FT   MOD_RES      61     61       Phosphoserine.
FT   VARIANT     215    215       G -> R (in OPTA2).
FT                                /FTId=VAR_020997.
FT   VARIANT     240    240       G -> R (in OPTB4).
FT                                /FTId=VAR_020998.
FT   VARIANT     249    249       P -> R (in OPTB4).
FT                                /FTId=VAR_020999.
FT   VARIANT     261    261       I -> F (in OPTB4).
FT                                /FTId=VAR_037427.
FT   VARIANT     286    286       R -> Q (in OPTA2).
FT                                /FTId=VAR_021000.
FT   VARIANT     332    332       M -> V (in OPTB4).
FT                                /FTId=VAR_021001.
FT   VARIANT     418    418       V -> M (in dbSNP:rs12926089).
FT                                /FTId=VAR_021002.
FT   VARIANT     490    490       L -> F (in OPTA2).
FT                                /FTId=VAR_021003.
FT   VARIANT     526    526       R -> W (in OPTB4).
FT                                /FTId=VAR_021004.
FT   VARIANT     614    614       L -> P (in OPTB4).
FT                                /FTId=VAR_021005.
FT   VARIANT     677    677       G -> V (in OPTA2).
FT                                /FTId=VAR_021006.
FT   VARIANT     744    744       S -> F (in OPTB4).
FT                                /FTId=VAR_021007.
FT   VARIANT     762    762       R -> Q (in OPTB4; not detected in the
FT                                fibroblasts from the patient).
FT                                /FTId=VAR_017838.
FT   VARIANT     766    766       L -> P (in OPTB4).
FT                                /FTId=VAR_017839.
FT   VARIANT     767    767       R -> Q (in OPTB4).
FT                                /FTId=VAR_021008.
FT   VARIANT     767    767       R -> W (in OPTA2 and OPTB4).
FT                                /FTId=VAR_017840.
FT   CONFLICT    267    267       T -> S (in Ref. 5; CAA91556).
FT   CONFLICT    279    279       F -> L (in Ref. 5; CAA91556 and 6;
FT                                CAA05083).
SQ   SEQUENCE   805 AA;  88679 MW;  E56BC0B4ADE1C695 CRC64;
     MANVSKKVSW SGRDRDDEEA APLLRRTARP GGGTPLLNGA GPGAARQSPR SALFRVGHMS
     SVELDDELLD PDMDPPHPFP KEIPHNEKLL SLKYESLDYD NSENQLFLEE ERRINHTAFR
     TVEIKRWVIC ALIGILTGLV ACFIDIVVEN LAGLKYRVIK GNIDKFTEKG GLSFSLLLWA
     TLNAAFVLVG SVIVAFIEPV AAGSGIPQIK CFLNGVKIPH VVRLKTLVIK VSGVILSVVG
     GLAVGKEGPM IHSGSVIAAG ISQGRSTSLK RDFKIFEYFR RDTEKRDFVS AGAAAGVSAA
     FGAPVGGVLF SLEEGASFWN QFLTWRIFFA SMISTFTLNF VLSIYHGNMW DLSSPGLINF
     GRFDSEKMAY TIHEIPVFIA MGVVGGVLGA VFNALNYWLT MFRIRYIHRP CLQVIEAVLV
     AAVTATVAFV LIYSSRDCQP LQGGSMSYPL QLFCADGEYN SMAAAFFNTP EKSVVSLFHD
     PPGSYNPLTL GLFTLVYFFL ACWTYGLTVS AGVFIPSLLI GAAWGRLFGI SLSYLTGAAI
     WADPGKYALM GAAAQLGGIV RMTLSLTVIM MEATSNVTYG FPIMLVLMTA KIVGDVFIEG
     LYDMHIQLQS VPFLHWEAPV TSHSLTAREV MSTPVTCLRR REKVGVIVDV LSDTASNHNG
     FPVVEHADDT QPARLQGLIL RSQLIVLLKH KVFVERSNLG LVQRRLRLKD FRDAYPRFPP
     IQSIHVSQDE RECTMDLSEF MNPSPYTVPQ EASLPRVFKL FRALGLRHLV VVDNRNQVVG
     LVTRKDLARY RLGKRGLEEL SLAQT
//
ID   CLCN7_MOUSE             Reviewed;         803 AA.
AC   O70496;
DT   21-FEB-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1998, sequence version 1.
DT   02-MAR-2010, entry version 90.
DE   RecName: Full=H(+)/Cl(-) exchange transporter 7;
DE   AltName: Full=Chloride channel protein 7;
DE            Short=ClC-7;
GN   Name=Clcn7; Synonyms=Clc7;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=21124827; PubMed=11207362; DOI=10.1016/S0092-8674(01)00206-9;
RA   Kornak U., Kasper D., Boesl M.R., Kaiser E., Schweizer M., Schulz A.,
RA   Friedrich W., Delling G., Jentsch T.J.;
RT   "Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and
RT   man.";
RL   Cell 104:205-215(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6; TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-9, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Macrophage;
RX   PubMed=19144319; DOI=10.1016/j.immuni.2008.11.006;
RA   Trost M., English L., Lemieux S., Courcelles M., Desjardins M.,
RA   Thibault P.;
RT   "The phagosomal proteome in interferon-gamma-activated macrophages.";
RL   Immunity 30:143-154(2009).
CC   -!- FUNCTION: Mediates the exchange of chloride ions against protons.
CC       Functions as antiporter and contributes to the acidification of
CC       the lysosome lumen (By similarity).
CC   -!- INTERACTION:
CC       Q8BGT0:Ostm1; NbExp=2; IntAct=EBI-987482, EBI-987431;
CC   -!- SUBCELLULAR LOCATION: Lysosome membrane; Multi-pass membrane
CC       protein (By similarity).
CC   -!- MISCELLANEOUS: The CLC channel family contains both chloride
CC       channels and proton-coupled anion transporters that exchange
CC       chloride or another anion for protons. The presence of conserved
CC       gating glutamate residues is typical for family members that
CC       function as antiporters (By similarity).
CC   -!- SIMILARITY: Belongs to the chloride channel (TC 2.A.49) family.
CC   -!- SIMILARITY: Contains 2 CBS domains.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF063101; AAC18832.1; -; Genomic_DNA.
DR   EMBL; AF063098; AAC18832.1; JOINED; Genomic_DNA.
DR   EMBL; AF063099; AAC18832.1; JOINED; Genomic_DNA.
DR   EMBL; AF063100; AAC18832.1; JOINED; Genomic_DNA.
DR   EMBL; BC050907; AAH50907.1; -; mRNA.
DR   EMBL; BC053049; AAH53049.1; -; mRNA.
DR   EMBL; BC054799; AAH54799.1; -; mRNA.
DR   IPI; IPI00118440; -.
DR   RefSeq; NP_036060.1; -.
DR   UniGene; Mm.270587; -.
DR   SMR; O70496; 119-604, 612-788.
DR   IntAct; O70496; 1.
DR   STRING; O70496; -.
DR   PhosphoSite; O70496; -.
DR   PRIDE; O70496; -.
DR   Ensembl; ENSMUST00000040729; ENSMUSP00000035964; ENSMUSG00000036636; Mus musculus.
DR   GeneID; 26373; -.
DR   KEGG; mmu:26373; -.
DR   UCSC; uc008azv.1; mouse.
DR   CTD; 26373; -.
DR   MGI; MGI:1347048; Clcn7.
DR   eggNOG; roNOG07216; -.
DR   HOGENOM; HBG385491; -.
DR   HOVERGEN; HBG050985; -.
DR   InParanoid; O70496; -.
DR   OMA; RINHTAF; -.
DR   OrthoDB; EOG9Z6572; -.
DR   PhylomeDB; O70496; -.
DR   NextBio; 304273; -.
DR   ArrayExpress; O70496; -.
DR   Bgee; O70496; -.
DR   CleanEx; MM_CLCN7; -.
DR   Genevestigator; O70496; -.
DR   GermOnline; ENSMUSG00000036636; Mus musculus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005765; C:lysosomal membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0015297; F:antiporter activity; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0031404; F:chloride ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0005247; F:voltage-gated chloride channel activity; IEA:InterPro.
DR   GO; GO:0006821; P:chloride transport; IEA:InterPro.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR014743; Cl-channel_core.
DR   InterPro; IPR001807; Cl-channel_volt.
DR   InterPro; IPR002249; Cl_channel7.
DR   InterPro; IPR000644; Cysta_beta_synth_core.
DR   InterPro; IPR006311; TAT_signal.
DR   Gene3D; G3DSA:1.10.3080.10; Cl-channel_core; 1.
DR   PANTHER; PTHR11689; Cl-channel_volt; 1.
DR   Pfam; PF00571; CBS; 2.
DR   Pfam; PF00654; Voltage_CLC; 1.
DR   PRINTS; PR00762; CLCHANNEL.
DR   PRINTS; PR01118; CLCHANNEL7.
DR   SMART; SM00116; CBS; 2.
DR   SUPFAM; SSF81340; Cl-channel_core; 1.
DR   TIGRFAMs; TIGR01409; TAT_signal_seq; 1.
DR   PROSITE; PS51371; CBS; 2.
PE   1: Evidence at protein level;
KW   Antiport; ATP-binding; CBS domain; Chloride; Ion transport; Lysosome;
KW   Membrane; Nucleotide-binding; Phosphoprotein; Repeat; Transmembrane;
KW   Transport.
FT   CHAIN         1    803       H(+)/Cl(-) exchange transporter 7.
FT                                /FTId=PRO_0000094453.
FT   TOPO_DOM      1    124       Cytoplasmic (By similarity).
FT   TRANSMEM    125    157       By similarity.
FT   TRANSMEM    172    195       By similarity.
FT   TRANSMEM    221    239       By similarity.
FT   TRANSMEM    245    262       By similarity.
FT   TRANSMEM    320    339       By similarity.
FT   TRANSMEM    373    403       By similarity.
FT   TRANSMEM    408    430       By similarity.
FT   TRANSMEM    485    505       By similarity.
FT   TRANSMEM    510    533       By similarity.
FT   TRANSMEM    577    595       By similarity.
FT   TOPO_DOM    596    803       Cytoplasmic (By similarity).
FT   DOMAIN      629    693       CBS 1.
FT   DOMAIN      739    797       CBS 2.
FT   NP_BIND     656    658       ATP (By similarity).
FT   NP_BIND     781    784       ATP (By similarity).
FT   REGION      204    211       In-membrane helix (By similarity).
FT   REGION      286    298       In-membrane helix (By similarity).
FT   REGION      302    310       In-membrane helix (By similarity).
FT   REGION      543    557       In-membrane helix (By similarity).
FT   REGION      558    560       In-membrane loop between two helices (By
FT                                similarity).
FT   REGION      561    572       In-membrane helix (By similarity).
FT   REGION      573    576       In-membrane loop between two helices (By
FT                                similarity).
FT   MOTIF       201    205       Selectivity filter part_1 (By
FT                                similarity).
FT   MOTIF       243    247       Selectivity filter part_2 (By
FT                                similarity).
FT   MOTIF       510    514       Selectivity filter part_3 (By
FT                                similarity).
FT   BINDING     202    202       Chloride (By similarity).
FT   BINDING     512    512       Chloride; via amide nitrogen (By
FT                                similarity).
FT   BINDING     600    600       Chloride (By similarity).
FT   SITE        245    245       Mediates proton transfer from the outer
FT                                aqueous phase to the interior of the
FT                                protein; involved in linking H(+) and
FT                                Cl(-) transport (By similarity).
FT   SITE        312    312       Mediates proton transfer from the protein
FT                                to the inner aqueous phase (By
FT                                similarity).
FT   MOD_RES       9      9       Phosphoserine (By similarity).
SQ   SEQUENCE   803 AA;  88713 MW;  A7D6DA5791DAA48C CRC64;
     MANVSKKVSW SGRDRDDEEG APLLRRTGQP DEETPLLNGA GPGARQSHSA LFRIGQMNNV
     ELDDELLDPE VDPPHTFPKE IPHNEKLLSL KYESLDYDNS ENQLFLEEER RINHTAFRTV
     EIKRWVICAL IGILTGLVAC FIDIVVENLA GLKYRVIKDN IDKFTEKGGL SFSLLLWATL
     NSAFVLVGSV IVAFIEPVAA GSGIPQIKCF LNGVKIPHVV RLKTLVIKVS GVILSVVGGL
     AVGKEGPMIH SGSVIAAGIS QGRSTSLKRD FKIFEYFRRD TEKRDFVSAG AAAGVSAAFG
     APVGGVLFSL EEGASFWNQF LTWRIFFASM ISTFTLNFVL SIYHGNMWDL SSPGLINFGR
     FDSEKMAYTI HEIPVFIAMG VVGGILGAVF NALNYWLTMF RIRYIHRPCL QVIEAMLVAA
     VTATVAFVLI YSSRDCQPLQ GSSMSYPLQL FCADGEYNSM AAAFFNTPEK SVVSLFHDPP
     GSYNPMTLGL FTLVYFFLAC WTYGLTVSAG VFIPSLLIGA AWGRLFGISL SYLTGAAIWA
     DPGKYALMGA AAQLGGIVRM TLSLTVIMME ATSNVTYGFP IMLVLMTAKI VGDVFIEGLY
     DMHIQLQSVP FLHWEAPVTS HSLTAREVMS TPVTCLRRRE KVGIIVDVLS DTASNHNGFP
     VVEDVGDTQP ARLQGLILRS QLIVLLKHKV FVERSNMGLV QRRLRLKDFR DAYPRFPPIQ
     SIHVSQDERE CTMDLSEFMN PSPYTVPQEA SLPRVFKLFR ALGLRHLVVV DNHNQVVGLV
     TRKDLARYRL GKGGLEELSL AQT
//
ID   COX6C_HUMAN             Reviewed;          75 AA.
AC   P09669; B2R4D7;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 2.
DT   02-MAR-2010, entry version 93.
DE   RecName: Full=Cytochrome c oxidase subunit 6C;
DE   AltName: Full=Cytochrome c oxidase polypeptide VIc;
GN   Name=COX6C;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=89083509; PubMed=2849755; DOI=10.1093/nar/16.22.10916;
RA   Otsuka M., Mizuno Y., Yoshida M., Kagawa Y., Ohta S.;
RT   "Nucleotide sequence of cDNA encoding human cytochrome c oxidase
RT   subunit VIc.";
RL   Nucleic Acids Res. 16:10916-10916(1988).
RN   [2]
RP   SEQUENCE REVISION TO 52.
RA   Ohta S.;
RL   Submitted (FEB-1996) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=99172094; PubMed=10072584;
RA   Hofmann S., Lichtner P., Schuffenhauer S., Gerbitz K.D., Meitinger T.;
RT   "Assignment of the human genes coding for cytochrome c oxidase
RT   subunits Va (COX5A), VIc (COX6C) and VIIc (COX7C) to chromosome bands
RT   15q25, 8q22-->q23 and 5q14 and of three pseudogenes (COX5AP1, COX6CP1,
RT   COX7CP1) to 14q22, 16p12 and 13q14-->q21 by FISH and radiation hybrid
RT   mapping.";
RL   Cytogenet. Cell Genet. 83:226-227(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE [LARGE SCALE ANALYSIS] OF 2-11.
RX   PubMed=19892738; DOI=10.1073/pnas.0908958106;
RA   Xu G., Shin S.B., Jaffrey S.R.;
RT   "Global profiling of protease cleavage sites by chemoselective
RT   labeling of protein N-termini.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:19310-19315(2009).
RN   [9]
RP   IDENTIFICATION [LARGE SCALE ANALYSIS], AND MASS SPECTROMETRY.
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
CC   -!- FUNCTION: This protein is one of the nuclear-coded polypeptide
CC       chains of cytochrome c oxidase, the terminal oxidase in
CC       mitochondrial electron transport.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane.
CC   -!- SIMILARITY: Belongs to the cytochrome c oxidase subunit 6c family.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/COX6CID251.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X13238; CAA31624.1; -; mRNA.
DR   EMBL; AF067637; AAC73061.1; -; Genomic_DNA.
DR   EMBL; AF067636; AAC73061.1; JOINED; Genomic_DNA.
DR   EMBL; BT007007; AAP35653.1; -; mRNA.
DR   EMBL; AK311791; BAG34734.1; -; mRNA.
DR   EMBL; CH471060; EAW91791.1; -; Genomic_DNA.
DR   EMBL; BC000187; AAH00187.1; -; mRNA.
DR   IPI; IPI00015972; -.
DR   PIR; S01960; OGHU6C.
DR   RefSeq; NP_004365.1; -.
DR   UniGene; Hs.351875; -.
DR   SMR; P09669; 6-75.
DR   IntAct; P09669; 2.
DR   STRING; P09669; -.
DR   PhosphoSite; P09669; -.
DR   PeptideAtlas; P09669; -.
DR   PRIDE; P09669; -.
DR   Ensembl; ENST00000297564; ENSP00000297564; ENSG00000164919; Homo sapiens.
DR   GeneID; 1345; -.
DR   KEGG; hsa:1345; -.
DR   UCSC; uc003yiy.1; human.
DR   CTD; 1345; -.
DR   GeneCards; GC08M100959; -.
DR   H-InvDB; HIX0034326; -.
DR   HGNC; HGNC:2285; COX6C.
DR   HPA; CAB016244; -.
DR   MIM; 124090; gene.
DR   PharmGKB; PA26802; -.
DR   eggNOG; prNOG21405; -.
DR   HOGENOM; HBG505631; -.
DR   HOVERGEN; HBG051091; -.
DR   InParanoid; P09669; -.
DR   OMA; LYKFGVA; -.
DR   OrthoDB; EOG9B8N0F; -.
DR   PhylomeDB; P09669; -.
DR   Reactome; REACT_1505; Integration of energy metabolism.
DR   Reactome; REACT_15380; Diabetes pathways.
DR   NextBio; 5453; -.
DR   ArrayExpress; P09669; -.
DR   Bgee; P09669; -.
DR   CleanEx; HS_COX6C; -.
DR   Genevestigator; P09669; -.
DR   GermOnline; ENSG00000164919; Homo sapiens.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004129; F:cytochrome-c oxidase activity; IEA:InterPro.
DR   GO; GO:0006091; P:generation of precursor metabolites and energy; TAS:ProtInc.
DR   InterPro; IPR004204; Cyt_c_oxidase_su6c.
DR   Gene3D; G3DSA:4.10.93.10; COX6C; 1.
DR   PANTHER; PTHR12916; COX6C; 1.
DR   Pfam; PF02937; COX6C; 1.
DR   ProDom; PD015032; Cyt_c_oxidase_su6c; 1.
DR   SUPFAM; SSF81415; COX6C; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Complete proteome; Direct protein sequencing; Membrane;
KW   Mitochondrion; Mitochondrion inner membrane; Transmembrane.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2     75       Cytochrome c oxidase subunit 6C.
FT                                /FTId=PRO_0000006131.
FT   TOPO_DOM      2     13       Mitochondrial matrix (By similarity).
FT   TRANSMEM     14     54       By similarity.
FT   TOPO_DOM     55     75       Mitochondrial intermembrane (By
FT                                similarity).
FT   MOD_RES      60     60       N6-acetyllysine (By similarity).
SQ   SEQUENCE   75 AA;  8781 MW;  D09FEE0C0AA7A798 CRC64;
     MAPEVLPKPR MRGLLARRLR NHMAVAFVLS LGVAALYKFR VADQRKKAYA DFYRNYDVMK
     DFEEMRKAGI FQSVK
//
ID   COX6C_MOUSE             Reviewed;          76 AA.
AC   Q9CPQ1; Q52KC6;
DT   07-JUN-2004, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 66.
DE   RecName: Full=Cytochrome c oxidase subunit 6C;
DE   AltName: Full=Cytochrome c oxidase polypeptide VIc;
GN   Name=Cox6c;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   PRELIMINARY NUCLEOTIDE SEQUENCE.
RX   MEDLINE=91249818; PubMed=1645653;
RX   DOI=10.1111/j.1432-1033.1991.tb15989.x;
RA   Schneyder B., Mell O., Anthony G., Kadenbach B.;
RT   "Cross reactivity of monoclonal antibodies and cDNA hybridization
RT   suggest evolutionary relationships between cytochrome c oxidase
RT   subunits VIa and VIc and between VIIa and VIIb.";
RL   Eur. J. Biochem. 198:85-92(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Embryo, and Hippocampus;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Liver, and Mammary gland;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PROTEIN SEQUENCE OF 21-38 AND 48-66, AND MASS SPECTROMETRY.
RC   STRAIN=C57BL/6; TISSUE=Brain;
RA   Lubec G., Kang S.U.;
RL   Submitted (APR-2007) to UniProtKB.
RN   [5]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-61, AND MASS SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=16916647; DOI=10.1016/j.molcel.2006.06.026;
RA   Kim S.C., Sprung R., Chen Y., Xu Y., Ball H., Pei J., Cheng T.,
RA   Kho Y., Xiao H., Xiao L., Grishin N.V., White M., Yang X.-J., Zhao Y.;
RT   "Substrate and functional diversity of lysine acetylation revealed by
RT   a proteomics survey.";
RL   Mol. Cell 23:607-618(2006).
CC   -!- FUNCTION: This protein is one of the nuclear-coded polypeptide
CC       chains of cytochrome c oxidase, the terminal oxidase in
CC       mitochondrial electron transport (By similarity).
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane.
CC   -!- PTM: Acetylation of Lys-61 is observed in liver mitochondria from
CC       fasted mice but not from fed mice.
CC   -!- SIMILARITY: Belongs to the cytochrome c oxidase subunit 6c family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK012602; BAB28348.1; -; mRNA.
DR   EMBL; AK013459; BAB28866.1; -; mRNA.
DR   EMBL; BC024666; AAH24666.1; -; mRNA.
DR   EMBL; BC094413; AAH94413.1; -; mRNA.
DR   IPI; IPI00131771; -.
DR   PIR; S16083; S16083.
DR   RefSeq; NP_444301.1; -.
DR   UniGene; Mm.548; -.
DR   SMR; Q9CPQ1; 7-76.
DR   STRING; Q9CPQ1; -.
DR   PhosphoSite; Q9CPQ1; -.
DR   PRIDE; Q9CPQ1; -.
DR   Ensembl; ENSMUST00000014457; ENSMUSP00000014457; ENSMUSG00000014313; Mus musculus.
DR   GeneID; 12864; -.
DR   KEGG; mmu:12864; -.
DR   UCSC; uc007vmi.1; mouse.
DR   CTD; 12864; -.
DR   MGI; MGI:104614; Cox6c.
DR   eggNOG; roNOG17665; -.
DR   HOGENOM; HBG505631; -.
DR   HOVERGEN; HBG051091; -.
DR   InParanoid; Q9CPQ1; -.
DR   OMA; LYKFGVA; -.
DR   OrthoDB; EOG9B8N0F; -.
DR   PhylomeDB; Q9CPQ1; -.
DR   NextBio; 282432; -.
DR   ArrayExpress; Q9CPQ1; -.
DR   Bgee; Q9CPQ1; -.
DR   CleanEx; MM_COX6C; -.
DR   Genevestigator; Q9CPQ1; -.
DR   GermOnline; ENSMUSG00000014313; Mus musculus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IDA:MGI.
DR   GO; GO:0004129; F:cytochrome-c oxidase activity; IEA:InterPro.
DR   InterPro; IPR004204; Cyt_c_oxidase_su6c.
DR   Gene3D; G3DSA:4.10.93.10; COX6C; 1.
DR   PANTHER; PTHR12916; COX6C; 1.
DR   Pfam; PF02937; COX6C; 1.
DR   ProDom; PD015032; Cyt_c_oxidase_su6c; 1.
DR   SUPFAM; SSF81415; COX6C; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Direct protein sequencing; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Transmembrane.
FT   INIT_MET      1      1       Removed (By similarity).
FT   CHAIN         2     76       Cytochrome c oxidase subunit 6C.
FT                                /FTId=PRO_0000191302.
FT   TOPO_DOM      4     14       Mitochondrial matrix (By similarity).
FT   TRANSMEM     15     55       By similarity.
FT   TOPO_DOM     56     76       Mitochondrial intermembrane (By
FT                                similarity).
FT   MOD_RES      61     61       N6-acetyllysine.
SQ   SEQUENCE   76 AA;  8469 MW;  BE02A028CF77D5F4 CRC64;
     MSSGALLPKP QMRGLLAKRL RVHIAGAFIV ALGVAAAYKF GVAEPRKKAY AEFYRNYDSM
     KDFEEMRKAG IFQSAK
//
ID   COX7B_HUMAN             Reviewed;          80 AA.
AC   P24311; B2R4M3; Q6ICR1;
DT   01-MAR-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1994, sequence version 2.
DT   02-MAR-2010, entry version 90.
DE   RecName: Full=Cytochrome c oxidase subunit 7B, mitochondrial;
DE   AltName: Full=Cytochrome c oxidase polypeptide VIIb;
DE   Flags: Precursor;
GN   Name=COX7B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=93176819; PubMed=8382530; DOI=10.1016/0167-4781(93)90301-S;
RA   Sadlock J.E., Lightowlers R.N., Capaldi R.A., Schon E.A.;
RT   "Isolation of a cDNA specifying subunit VIIb of human cytochrome c
RT   oxidase.";
RL   Biochim. Biophys. Acta 1172:223-225(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S.,
RA   Neubert P., Kstrang K., Schatten R., Shen B., Henze S., Mar W.,
RA   Korn B., Zuo D., Hu Y., LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 25-43.
RC   TISSUE=Heart;
RX   MEDLINE=92111565; PubMed=1309697;
RX   DOI=10.1111/j.1432-1033.1992.tb19847.x;
RA   van Kuilenburg A.B.P., van Beeumen J.J., van der Meer N.M.,
RA   Muijsers A.O.;
RT   "Subunits VIIa,b,c of human cytochrome c oxidase. Identification of
RT   both 'heart-type' and 'liver-type' isoforms of subunit VIIa in human
RT   heart.";
RL   Eur. J. Biochem. 203:193-199(1992).
CC   -!- FUNCTION: This protein is one of the nuclear-coded polypeptide
CC       chains of cytochrome c oxidase, the terminal oxidase in
CC       mitochondrial electron transport.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the cytochrome c oxidase VIIb family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z14244; CAA78613.1; -; mRNA.
DR   EMBL; BT009767; AAP88769.1; -; mRNA.
DR   EMBL; CR450332; CAG29328.1; -; mRNA.
DR   EMBL; CR542124; CAG46921.1; -; mRNA.
DR   EMBL; AK311879; BAG34820.1; -; mRNA.
DR   EMBL; AL356235; CAH70525.1; -; Genomic_DNA.
DR   EMBL; CH471104; EAW98607.1; -; Genomic_DNA.
DR   EMBL; BC018386; AAH18386.1; -; mRNA.
DR   IPI; IPI00028003; -.
DR   PIR; S29856; OSHU7B.
DR   RefSeq; NP_001857.1; -.
DR   UniGene; Hs.522699; -.
DR   SMR; P24311; 31-78.
DR   STRING; P24311; -.
DR   PRIDE; P24311; -.
DR   Ensembl; ENST00000481445; ENSP00000417656; ENSG00000131174; Homo sapiens.
DR   GeneID; 1349; -.
DR   KEGG; hsa:1349; -.
DR   UCSC; uc004ecu.1; human.
DR   CTD; 1349; -.
DR   GeneCards; GC0XP077041; -.
DR   H-InvDB; HIX0016887; -.
DR   HGNC; HGNC:2291; COX7B.
DR   MIM; 603792; gene.
DR   PharmGKB; PA26809; -.
DR   eggNOG; prNOG21082; -.
DR   HOGENOM; HBG445322; -.
DR   HOVERGEN; HBG051092; -.
DR   InParanoid; P24311; -.
DR   OMA; WTYTATQ; -.
DR   OrthoDB; EOG9WSZWB; -.
DR   PhylomeDB; P24311; -.
DR   Reactome; REACT_1505; Integration of energy metabolism.
DR   Reactome; REACT_15380; Diabetes pathways.
DR   NextBio; 5467; -.
DR   ArrayExpress; P24311; -.
DR   Bgee; P24311; -.
DR   CleanEx; HS_COX7B; -.
DR   Genevestigator; P24311; -.
DR   GermOnline; ENSG00000131174; Homo sapiens.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005746; C:mitochondrial respiratory chain; IEA:InterPro.
DR   GO; GO:0004129; F:cytochrome-c oxidase activity; TAS:ProtInc.
DR   InterPro; IPR008433; Cyt_c_oxidase_suVIIB.
DR   PANTHER; PTHR16716; COX7B; 1.
DR   Pfam; PF05392; COX7B; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Direct protein sequencing; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Transit peptide; Transmembrane.
FT   TRANSIT       1     24       Mitochondrion.
FT   CHAIN        25     80       Cytochrome c oxidase subunit 7B,
FT                                mitochondrial.
FT                                /FTId=PRO_0000006158.
FT   TOPO_DOM     25     32       Mitochondrial matrix (By similarity).
FT   TRANSMEM     33     59       By similarity.
FT   TOPO_DOM     60     80       Mitochondrial intermembrane (By
FT                                similarity).
FT   CONFLICT     29     29       R -> P (in Ref. 9; AA sequence).
SQ   SEQUENCE   80 AA;  9161 MW;  1EE75BD1AA253E59 CRC64;
     MFPLVKSALN RLQVRSIQQT MARQSHQKRT PDFHDKYGNA VLASGATFCI VTWTYVATQV
     GIEWNLSPVG RVTPKEWRNQ
//
ID   COX7B_RAT               Reviewed;          80 AA.
AC   P80431; Q6AYA9; Q7TPH1;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   28-NOV-2006, sequence version 3.
DT   02-MAR-2010, entry version 65.
DE   RecName: Full=Cytochrome c oxidase subunit 7B, mitochondrial;
DE   AltName: Full=Cytochrome c oxidase polypeptide VIIb;
DE   Flags: Precursor;
GN   Name=Cox7b;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Brain stem;
RA   Zhou L., Guo J., Ma Y.;
RT   "Rattus norvegicus cytochrome c oxidase subunit VIIb.";
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   PROTEIN SEQUENCE OF 25-34.
RC   STRAIN=Wistar; TISSUE=Liver;
RX   MEDLINE=95324529; PubMed=7601105;
RX   DOI=10.1111/j.1432-1033.1995.0235i.x;
RA   Schaegger H., Noack H., Halangk W., Brandt U., von Jagow G.;
RT   "Cytochrome-c oxidase in developing rat heart. Enzymic properties and
RT   amino-terminal sequences suggest identity of the fetal heart and the
RT   adult liver isoform.";
RL   Eur. J. Biochem. 230:235-241(1995).
CC   -!- FUNCTION: This protein is one of the nuclear-coded polypeptide
CC       chains of cytochrome c oxidase, the terminal oxidase in
CC       mitochondrial electron transport.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the cytochrome c oxidase VIIb family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY339885; AAP92332.1; -; mRNA.
DR   EMBL; BC079123; AAH79123.1; -; mRNA.
DR   IPI; IPI00382278; -.
DR   PIR; S65387; S65387.
DR   RefSeq; NP_877971.2; -.
DR   UniGene; Rn.2026; -.
DR   SMR; P80431; 31-78.
DR   STRING; P80431; -.
DR   Ensembl; ENSRNOT00000033847; ENSRNOP00000054370; ENSRNOG00000028451; Rattus norvegicus.
DR   GeneID; 303393; -.
DR   KEGG; rno:303393; -.
DR   UCSC; NM_182819; rat.
DR   CTD; 303393; -.
DR   RGD; 727789; Cox7b.
DR   eggNOG; roNOG17304; -.
DR   HOVERGEN; HBG051092; -.
DR   InParanoid; P80431; -.
DR   OMA; WTYTATQ; -.
DR   OrthoDB; EOG9WSZWB; -.
DR   NextBio; 651270; -.
DR   ArrayExpress; P80431; -.
DR   Genevestigator; P80431; -.
DR   GermOnline; ENSRNOG00000028451; Rattus norvegicus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005746; C:mitochondrial respiratory chain; IEA:InterPro.
DR   GO; GO:0004129; F:cytochrome-c oxidase activity; IEA:InterPro.
DR   InterPro; IPR008433; Cyt_c_oxidase_suVIIB.
DR   PANTHER; PTHR16716; COX7B; 1.
DR   Pfam; PF05392; COX7B; 1.
PE   1: Evidence at protein level;
KW   Direct protein sequencing; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Transit peptide; Transmembrane.
FT   TRANSIT       1     24       Mitochondrion.
FT   CHAIN        25     80       Cytochrome c oxidase subunit 7B,
FT                                mitochondrial.
FT                                /FTId=PRO_0000006160.
FT   TOPO_DOM     25     32       Mitochondrial matrix (By similarity).
FT   TRANSMEM     33     59       By similarity.
FT   TOPO_DOM     60     80       Mitochondrial intermembrane (By
FT                                similarity).
FT   CONFLICT      9      9       L -> I (in Ref. 1; AAP92332).
SQ   SEQUENCE   80 AA;  8995 MW;  A0E9B8E8BD6CCBF7 CRC64;
     MLPLAKNALS RLQVRSIQQV VARQSHQKKT PTFHDKYGNA VLAGGSIFCI SAWTYTATQI
     GIEWNLSPVG RVTPKEWRDQ
//
ID   COX7C_HUMAN             Reviewed;          63 AA.
AC   P15954; Q6NR81;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 1.
DT   02-MAR-2010, entry version 93.
DE   RecName: Full=Cytochrome c oxidase subunit 7C, mitochondrial;
DE   AltName: Full=Cytochrome c oxidase polypeptide VIIc;
DE   Flags: Precursor;
GN   Name=COX7C;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Skeletal muscle;
RX   MEDLINE=90175022; PubMed=2155413; DOI=10.1093/nar/18.3.684;
RA   Koga Y., Fabrizi G.M., Mita S., Arnaudo E., Lomax M.I., Agua M.S.,
RA   Grossman L.I., Schon E.A.;
RT   "Sequence of a cDNA specifying subunit VIIc of human cytochrome c
RT   oxidase.";
RL   Nucleic Acids Res. 18:684-684(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=99172094; PubMed=10072584;
RA   Hofmann S., Lichtner P., Schuffenhauer S., Gerbitz K.D., Meitinger T.;
RT   "Assignment of the human genes coding for cytochrome c oxidase
RT   subunits Va (COX5A), VIc (COX6C) and VIIc (COX7C) to chromosome bands
RT   15q25, 8q22-->q23 and 5q14 and of three pseudogenes (COX5AP1, COX6CP1,
RT   COX7CP1) to 14q22, 16p12 and 13q14-->q21 by FISH and radiation hybrid
RT   mapping.";
RL   Cytogenet. Cell Genet. 83:226-227(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung, and Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PROTEIN SEQUENCE OF 17-40.
RC   TISSUE=Heart, and Skeletal muscle;
RX   MEDLINE=92111565; PubMed=1309697;
RX   DOI=10.1111/j.1432-1033.1992.tb19847.x;
RA   van Kuilenburg A.B.P., van Beeumen J.J., van der Meer N.M.,
RA   Muijsers A.O.;
RT   "Subunits VIIa,b,c of human cytochrome c oxidase. Identification of
RT   both 'heart-type' and 'liver-type' isoforms of subunit VIIa in human
RT   heart.";
RL   Eur. J. Biochem. 203:193-199(1992).
CC   -!- FUNCTION: This protein is one of the nuclear-coded polypeptide
CC       chains of cytochrome c oxidase, the terminal oxidase in
CC       mitochondrial electron transport.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the cytochrome c oxidase VIIc family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X16560; CAA34559.1; -; mRNA.
DR   EMBL; AF067639; AAC73062.1; -; Genomic_DNA.
DR   EMBL; AF067638; AAC73062.1; JOINED; Genomic_DNA.
DR   EMBL; BT007098; AAP35762.1; -; mRNA.
DR   EMBL; BC001005; AAH01005.1; -; mRNA.
DR   EMBL; BC007498; AAH07498.1; -; mRNA.
DR   IPI; IPI00013968; -.
DR   PIR; S15763; OSHU7C.
DR   RefSeq; NP_001858.1; -.
DR   UniGene; Hs.430075; -.
DR   SMR; P15954; 17-62.
DR   STRING; P15954; -.
DR   TCDB; 3.D.4.11.1; proton-translocating cytochrome oxidase (COX) superfamily.
DR   PRIDE; P15954; -.
DR   Ensembl; ENST00000247655; ENSP00000247655; ENSG00000127184; Homo sapiens.
DR   GeneID; 1350; -.
DR   KEGG; hsa:1350; -.
DR   UCSC; uc003kir.1; human.
DR   CTD; 1350; -.
DR   GeneCards; GC05P085949; -.
DR   H-InvDB; HIX0005013; -.
DR   HGNC; HGNC:2292; COX7C.
DR   MIM; 603774; gene.
DR   PharmGKB; PA26812; -.
DR   eggNOG; prNOG21514; -.
DR   HOGENOM; HBG281086; -.
DR   HOVERGEN; HBG051093; -.
DR   InParanoid; P15954; -.
DR   OMA; MLGQAVR; -.
DR   OrthoDB; EOG9MSGJB; -.
DR   PhylomeDB; P15954; -.
DR   Reactome; REACT_1505; Integration of energy metabolism.
DR   Reactome; REACT_15380; Diabetes pathways.
DR   NextBio; 5471; -.
DR   ArrayExpress; P15954; -.
DR   Bgee; P15954; -.
DR   CleanEx; HS_COX7C; -.
DR   Genevestigator; P15954; -.
DR   GermOnline; ENSG00000127184; Homo sapiens.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004129; F:cytochrome-c oxidase activity; IEA:InterPro.
DR   GO; GO:0006091; P:generation of precursor metabolites and energy; TAS:ProtInc.
DR   InterPro; IPR004202; Cyt_c_oxidsae_su7c.
DR   PANTHER; PTHR13313; COX7C; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Direct protein sequencing; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Transit peptide; Transmembrane.
FT   TRANSIT       1     16       Mitochondrion.
FT   CHAIN        17     63       Cytochrome c oxidase subunit 7C,
FT                                mitochondrial.
FT                                /FTId=PRO_0000006164.
FT   TOPO_DOM     17     33       Mitochondrial matrix (By similarity).
FT   TRANSMEM     34     60       By similarity.
FT   TOPO_DOM     61     63       Mitochondrial intermembrane (By
FT                                similarity).
SQ   SEQUENCE   63 AA;  7246 MW;  A7DF0F4BAF39FB28 CRC64;
     MLGQSIRRFT TSVVRRSHYE EGPGKNLPFS VENKWSLLAK MCLYFGSAFA TPFLVVRHQL
     LKT
//
ID   COX7C_MOUSE             Reviewed;          63 AA.
AC   P17665; Q3U5S7;
DT   01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1990, sequence version 1.
DT   02-MAR-2010, entry version 95.
DE   RecName: Full=Cytochrome c oxidase subunit 7C, mitochondrial;
DE   AltName: Full=Cytochrome c oxidase polypeptide VIIc;
DE   Flags: Precursor;
GN   Name=Cox7c; Synonyms=Cox7c1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=BALB/c; TISSUE=Heart;
RX   MEDLINE=90301494; PubMed=2163523; DOI=10.1093/nar/18.12.3645;
RA   Akamatsu M., Grossman L.I.;
RT   "Nucleotide sequence of a cDNA for mouse cytochrome c oxidase subunit
RT   VIIc.";
RL   Nucleic Acids Res. 18:3645-3645(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Bone marrow, Kidney, and Small intestine;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6, and FVB/N; TISSUE=Brain, and Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PROTEIN SEQUENCE OF 37-57, AND MASS SPECTROMETRY.
RC   STRAIN=C57BL/6; TISSUE=Brain;
RA   Lubec G., Kang S.U.;
RL   Submitted (APR-2007) to UniProtKB.
CC   -!- FUNCTION: This protein is one of the nuclear-coded polypeptide
CC       chains of cytochrome c oxidase, the terminal oxidase in
CC       mitochondrial electron transport.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the cytochrome c oxidase VIIc family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X52940; CAA37115.1; -; mRNA.
DR   EMBL; AK002494; BAB22142.1; -; mRNA.
DR   EMBL; AK027989; BAC25693.1; -; mRNA.
DR   EMBL; AK131871; BAE20843.1; -; mRNA.
DR   EMBL; AK153444; BAE31999.1; -; mRNA.
DR   EMBL; AK168077; BAE40050.1; -; mRNA.
DR   EMBL; BC010772; AAH10772.1; -; mRNA.
DR   EMBL; BC086792; AAH86792.1; -; mRNA.
DR   IPI; IPI00111255; -.
DR   PIR; S10303; S10303.
DR   RefSeq; NP_031775.1; -.
DR   RefSeq; XP_001480433.1; -.
DR   UniGene; Mm.378898; -.
DR   SMR; P17665; 17-63.
DR   STRING; P17665; -.
DR   PRIDE; P17665; -.
DR   Ensembl; ENSMUST00000017922; ENSMUSP00000017922; ENSMUSG00000017778; Mus musculus.
DR   GeneID; 100048613; -.
DR   GeneID; 12867; -.
DR   KEGG; mmu:12867; -.
DR   UCSC; uc007riy.1; mouse.
DR   CTD; 12867; -.
DR   MGI; MGI:103226; Cox7c.
DR   eggNOG; roNOG17596; -.
DR   HOGENOM; HBG281086; -.
DR   HOVERGEN; HBG051093; -.
DR   InParanoid; P17665; -.
DR   OMA; MLGQAVR; -.
DR   OrthoDB; EOG9MSGJB; -.
DR   PhylomeDB; P17665; -.
DR   NextBio; 462022; -.
DR   ArrayExpress; P17665; -.
DR   Bgee; P17665; -.
DR   CleanEx; MM_COX7C; -.
DR   Genevestigator; P17665; -.
DR   GermOnline; ENSMUSG00000017778; Mus musculus.
DR   GermOnline; ENSMUSG00000062895; Mus musculus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IDA:MGI.
DR   GO; GO:0004129; F:cytochrome-c oxidase activity; IEA:InterPro.
DR   InterPro; IPR004202; Cyt_c_oxidsae_su7c.
DR   PANTHER; PTHR13313; COX7C; 1.
PE   1: Evidence at protein level;
KW   Direct protein sequencing; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Transit peptide; Transmembrane.
FT   TRANSIT       1     16       Mitochondrion (By similarity).
FT   CHAIN        17     63       Cytochrome c oxidase subunit 7C,
FT                                mitochondrial.
FT                                /FTId=PRO_0000006166.
FT   TOPO_DOM     17     33       Mitochondrial matrix (By similarity).
FT   TRANSMEM     34     60       By similarity.
FT   TOPO_DOM     61     63       Mitochondrial intermembrane (By
FT                                similarity).
SQ   SEQUENCE   63 AA;  7333 MW;  C6A2AD4ABFEB2C7B CRC64;
     MLGQSIRRFT TSVVRRSHYE EGPGKNLPFS VENKWRLLAM MTVYFGSGFA APFFIVRHQL
     LKK
//
ID   COX7C_PIG               Reviewed;          63 AA.
AC   Q1W0Y2; A1XQT3; Q9TRE9;
DT   11-JUL-2006, integrated into UniProtKB/Swiss-Prot.
DT   02-MAY-2006, sequence version 1.
DT   02-MAR-2010, entry version 30.
DE   RecName: Full=Cytochrome c oxidase subunit 7C, mitochondrial;
DE   AltName: Full=Cytochrome c oxidase polypeptide VIIc;
DE   Flags: Precursor;
GN   Name=COX7C; Synonyms=COX7C1;
OS   Sus scrofa (Pig).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Suina; Suidae;
OC   Sus.
OX   NCBI_TaxID=9823;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Huang T., Xiong Y.-Z.;
RT   "Clonging and sequencing the full-length cDNA of pig COX7C gene.";
RL   Submitted (MAR-2006) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Longissimus dorsi muscle;
RA   Cai G., Chen Y., Wang C., Li J., Peng G., Zhang H.;
RT   "Generation and analysis of cDNA sequences derived from a porcine
RT   skeletal muscle library.";
RL   Submitted (MAY-2006) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   PROTEIN SEQUENCE OF 17-63.
RC   TISSUE=Intestine;
RX   MEDLINE=93384597; PubMed=8396926; DOI=10.1006/bbrc.1993.2108;
RA   Sillard R., Joernvall H., Mutt V.;
RT   "Characterization of porcine intestinal cytochrome c oxidase subunit
RT   VIIc, purified by affinity chromatography.";
RL   Biochem. Biophys. Res. Commun. 195:746-750(1993).
CC   -!- FUNCTION: This protein is one of the nuclear-coded polypeptide
CC       chains of cytochrome c oxidase, the terminal oxidase in
CC       mitochondrial electron transport (By similarity).
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the cytochrome c oxidase VIIc family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; DQ456972; ABD98458.1; -; mRNA.
DR   EMBL; DQ456973; ABD98459.1; -; mRNA.
DR   EMBL; DQ629155; ABK55639.1; -; mRNA.
DR   PIR; PN0607; PN0607.
DR   RefSeq; NP_001090943.1; -.
DR   UniGene; Ssc.8993; -.
DR   SMR; Q1W0Y2; 17-63.
DR   Ensembl; ENSSSCT00000015449; ENSSSCP00000015039; ENSSSCG00000014145; Sus scrofa.
DR   GeneID; 100037990; -.
DR   KEGG; ssc:100037990; -.
DR   CTD; 100037990; -.
DR   HOVERGEN; HBG051093; -.
DR   OrthoDB; EOG9MSGJB; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004129; F:cytochrome-c oxidase activity; IEA:InterPro.
DR   InterPro; IPR004202; Cyt_c_oxidsae_su7c.
DR   PANTHER; PTHR13313; COX7C; 1.
PE   1: Evidence at protein level;
KW   Direct protein sequencing; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Transit peptide; Transmembrane.
FT   TRANSIT       1     16       Mitochondrion.
FT   CHAIN        17     63       Cytochrome c oxidase subunit 7C,
FT                                mitochondrial.
FT                                /FTId=PRO_0000245342.
FT   TOPO_DOM     17     33       Mitochondrial matrix (By similarity).
FT   TRANSMEM     34     60       By similarity.
FT   TOPO_DOM     61     63       Mitochondrial intermembrane (By
FT                                similarity).
SQ   SEQUENCE   63 AA;  7347 MW;  C6A2AD4AAF314C7B CRC64;
     MLGQSIRRFT TSVVRRSHYE EGPGKNLPFS VENKWRLLAM MTLYFGSGFA APFFIVRHQL
     LKK
//
ID   COX8A_BOVIN             Reviewed;          69 AA.
AC   P14622; Q32PC5;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 1.
DT   02-MAR-2010, entry version 85.
DE   RecName: Full=Cytochrome c oxidase subunit 8A, mitochondrial;
DE   AltName: Full=Cytochrome c oxidase polypeptide VIII-liver;
DE   AltName: Full=Cytochrome c oxidase subunit 8-2;
DE   AltName: Full=IX;
DE   Flags: Precursor;
GN   Name=COX8A; Synonyms=COX8, COX8L;
OS   Bos taurus (Bovine).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Ruminantia;
OC   Pecora; Bovidae; Bovinae; Bos.
OX   NCBI_TaxID=9913;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   MEDLINE=90153890; PubMed=1689292;
RA   Lightowlers R.N., Ewart G.D., Aggeler R.J., Zhang Y.-Z., Calavetta L.,
RA   Capaldi R.A.;
RT   "Isolation and characterization of the cDNAs encoding two isoforms of
RT   subunit CIX of bovine cytochrome c oxidase.";
RL   J. Biol. Chem. 265:2677-2681(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=Crossbred X Angus; TISSUE=Liver;
RG   NIH - Mammalian Gene Collection (MGC) project;
RL   Submitted (OCT-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   PARTIAL PROTEIN SEQUENCE OF 26-69.
RC   TISSUE=Liver;
RX   MEDLINE=89000697; PubMed=2844245; DOI=10.1021/bi00413a048;
RA   Yanamura W., Zhang Y.-Z., Takamiya S., Capaldi R.A.;
RT   "Tissue-specific differences between heart and liver cytochrome c
RT   oxidase.";
RL   Biochemistry 27:4909-4914(1988).
RN   [4]
RP   PROTEIN SEQUENCE OF 26-31.
RX   MEDLINE=91099535; PubMed=2176624; DOI=10.1016/0014-5793(90)80817-3;
RA   Anthony G., Stroh A., Lottspeich F., Kadenbach B.;
RT   "Different isozymes of cytochrome c oxidase are expressed in bovine
RT   smooth muscle and skeletal or heart muscle.";
RL   FEBS Lett. 277:97-100(1990).
CC   -!- FUNCTION: This protein is one of the nuclear-coded polypeptide
CC       chains of cytochrome c oxidase, the terminal oxidase in
CC       mitochondrial electron transport.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane.
CC   -!- SIMILARITY: Belongs to the cytochrome c oxidase VIII family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J05201; AAA30467.1; -; mRNA.
DR   EMBL; BC108170; AAI08171.1; -; mRNA.
DR   IPI; IPI00692370; -.
DR   PIR; B35537; B35537.
DR   RefSeq; NP_776449.2; -.
DR   UniGene; Bt.4637; -.
DR   SMR; P14622; 26-68.
DR   STRING; P14622; -.
DR   Ensembl; ENSBTAT00000046100; ENSBTAP00000043426; ENSBTAG00000032505; Bos taurus.
DR   GeneID; 281091; -.
DR   KEGG; bta:281091; -.
DR   CTD; 281091; -.
DR   eggNOG; maNOG21543; -.
DR   InParanoid; P14622; -.
DR   OMA; LSHMENY; -.
DR   OrthoDB; EOG98976J; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004129; F:cytochrome-c oxidase activity; IEA:InterPro.
DR   InterPro; IPR003205; Cyt_c_oxidase_su8.
DR   InterPro; IPR016070; Cyt_c_oxidase_su8/PSI_RC_su9.
DR   Gene3D; G3DSA:4.10.81.10; Cyt_c_oxidase_suVIII/PSI_suIX; 1.
DR   PANTHER; PTHR16717; Cyt_c_ox8; 1.
DR   Pfam; PF02285; COX8; 1.
DR   SUPFAM; SSF81431; Cyt_c_oxidase_8; 1.
PE   1: Evidence at protein level;
KW   Direct protein sequencing; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Transit peptide; Transmembrane.
FT   TRANSIT       1     25       Mitochondrion.
FT   CHAIN        26     69       Cytochrome c oxidase subunit 8A,
FT                                mitochondrial.
FT                                /FTId=PRO_0000006182.
FT   TOPO_DOM     26     36       Mitochondrial matrix (By similarity).
FT   TRANSMEM     37     60       By similarity.
FT   TOPO_DOM     61     69       Mitochondrial intermembrane (By
FT                                similarity).
FT   CONFLICT      3      3       V -> E (in Ref. 2; AAI08171).
FT   CONFLICT     39     39       D -> I (in Ref. 3; AA sequence).
FT   CONFLICT     50     50       C -> D (in Ref. 3; AA sequence).
SQ   SEQUENCE   69 AA;  7743 MW;  539BCFE4C945756B CRC64;
     MSVLTPLLLR GLTGPARRLP VPRAQIHSKP PREQLGTMDI AIGLTSCFLC FLLPSGWVLS
     HMENYKKRE
//
ID   COX8A_HUMAN             Reviewed;          69 AA.
AC   P10176; P15955;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1991, sequence version 2.
DT   02-MAR-2010, entry version 99.
DE   RecName: Full=Cytochrome c oxidase subunit 8A, mitochondrial;
DE   AltName: Full=Cytochrome c oxidase polypeptide VIII-liver/heart;
DE   AltName: Full=Cytochrome c oxidase subunit 8-2;
DE   Flags: Precursor;
GN   Name=COX8A; Synonyms=COX8, COX8L;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   MEDLINE=89278125; PubMed=2543673;
RA   Rizzuto R., Nakase H., Darras B., Francke U., Fabrizi G.M., Mengel T.,
RA   Walsh F., Kadenbach B., Dimauro S., Schon E.A.;
RT   "A gene specifying subunit VIII of human cytochrome c oxidase is
RT   localized to chromosome 11 and is expressed in both muscle and non-
RT   muscle tissues.";
RL   J. Biol. Chem. 264:10595-10600(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   PROTEIN SEQUENCE OF 26-69.
RC   TISSUE=Heart;
RX   MEDLINE=89052871; PubMed=2847943; DOI=10.1016/0014-5793(88)80353-3;
RA   van Kuilenburg A.B.P., Muijsers A.O., Demol H., Dekker H.L.,
RA   van Beeumen J.J.;
RT   "Human heart cytochrome c oxidase subunit VIII. Purification and
RT   determination of the complete amino acid sequence.";
RL   FEBS Lett. 240:127-132(1988).
CC   -!- FUNCTION: This protein is one of the nuclear-coded polypeptide
CC       chains of cytochrome c oxidase, the terminal oxidase in
CC       mitochondrial electron transport.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane.
CC   -!- SIMILARITY: Belongs to the cytochrome c oxidase VIII family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J04823; AAA99313.1; -; mRNA.
DR   EMBL; BC063025; AAH63025.1; -; mRNA.
DR   IPI; IPI00019505; -.
DR   PIR; A34103; OSHU8.
DR   RefSeq; NP_004065.1; -.
DR   UniGene; Hs.433901; -.
DR   SMR; P10176; 26-68.
DR   STRING; P10176; -.
DR   TCDB; 3.D.4.11.1; proton-translocating cytochrome oxidase (COX) superfamily.
DR   PRIDE; P10176; -.
DR   Ensembl; ENST00000314133; ENSP00000321260; ENSG00000176340; Homo sapiens.
DR   GeneID; 1351; -.
DR   KEGG; hsa:1351; -.
DR   UCSC; uc001nye.1; human.
DR   CTD; 1351; -.
DR   GeneCards; GC11P063498; -.
DR   H-InvDB; HIX0035986; -.
DR   HGNC; HGNC:2294; COX8A.
DR   MIM; 123870; gene.
DR   PharmGKB; PA26814; -.
DR   eggNOG; prNOG21532; -.
DR   HOGENOM; HBG126814; -.
DR   InParanoid; P10176; -.
DR   OMA; HSRPARE; -.
DR   PhylomeDB; P10176; -.
DR   Reactome; REACT_1505; Integration of energy metabolism.
DR   Reactome; REACT_15380; Diabetes pathways.
DR   NextBio; 5475; -.
DR   ArrayExpress; P10176; -.
DR   Bgee; P10176; -.
DR   CleanEx; HS_COX8A; -.
DR   Genevestigator; P10176; -.
DR   GermOnline; ENSG00000176340; Homo sapiens.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004129; F:cytochrome-c oxidase activity; TAS:ProtInc.
DR   GO; GO:0006091; P:generation of precursor metabolites and energy; TAS:ProtInc.
DR   InterPro; IPR003205; Cyt_c_oxidase_su8.
DR   InterPro; IPR016070; Cyt_c_oxidase_su8/PSI_RC_su9.
DR   Gene3D; G3DSA:4.10.81.10; Cyt_c_oxidase_suVIII/PSI_suIX; 1.
DR   PANTHER; PTHR16717; Cyt_c_ox8; 1.
DR   Pfam; PF02285; COX8; 1.
DR   SUPFAM; SSF81431; Cyt_c_oxidase_8; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Direct protein sequencing; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Transit peptide; Transmembrane.
FT   TRANSIT       1     25       Mitochondrion.
FT   CHAIN        26     69       Cytochrome c oxidase subunit 8A,
FT                                mitochondrial.
FT                                /FTId=PRO_0000006186.
FT   TOPO_DOM     26     36       Mitochondrial matrix (By similarity).
FT   TRANSMEM     37     60       By similarity.
FT   TOPO_DOM     61     69       Mitochondrial intermembrane (By
FT                                similarity).
SQ   SEQUENCE   69 AA;  7579 MW;  E1736E52AD0F76E2 CRC64;
     MSVLTPLLLR GLTGSARRLP VPRAKIHSLP PEGKLGIMEL AVGLTSCFVT FLLPAGWILS
     HLETYRRPE
//
ID   COX8A_RAT               Reviewed;          69 AA.
AC   P80433; A0JMZ9;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   05-MAY-2009, sequence version 3.
DT   02-MAR-2010, entry version 68.
DE   RecName: Full=Cytochrome c oxidase subunit 8A, mitochondrial;
DE   AltName: Full=Cytochrome c oxidase polypeptide VIII-liver;
DE   AltName: Full=Cytochrome c oxidase subunit 8-2;
DE   Flags: Precursor;
GN   Name=Cox8a; Synonyms=Cox8, Cox8l;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Thymus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [2]
RP   PROTEIN SEQUENCE OF 26-39.
RC   STRAIN=Wistar; TISSUE=Heart, and Liver;
RX   MEDLINE=95324529; PubMed=7601105;
RX   DOI=10.1111/j.1432-1033.1995.0235i.x;
RA   Schaegger H., Noack H., Halangk W., Brandt U., von Jagow G.;
RT   "Cytochrome-c oxidase in developing rat heart. Enzymic properties and
RT   amino-terminal sequences suggest identity of the fetal heart and the
RT   adult liver isoform.";
RL   Eur. J. Biochem. 230:235-241(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 35-69.
RC   TISSUE=Hepatoma;
RX   MEDLINE=88029422; PubMed=2822403;
RX   DOI=10.1111/j.1432-1033.1987.tb13410.x;
RA   Suske G., Mengel T., Cordingley M., Kadenbach B.;
RT   "Molecular cloning and further characterization of cDNAs for rat
RT   nuclear-encoded cytochrome c oxidase subunits VIc and VIII.";
RL   Eur. J. Biochem. 168:233-237(1987).
CC   -!- FUNCTION: This protein is one of the nuclear-coded polypeptide
CC       chains of cytochrome c oxidase, the terminal oxidase in
CC       mitochondrial electron transport.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane.
CC   -!- SIMILARITY: Belongs to the cytochrome c oxidase VIII family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; BC126066; AAI26067.1; -; mRNA.
DR   EMBL; M28255; AAA41018.1; -; mRNA.
DR   EMBL; X06146; CAA29505.1; -; mRNA.
DR   IPI; IPI00197445; -.
DR   PIR; S00115; S00115.
DR   PIR; S65392; S65392.
DR   RefSeq; NP_599172.1; -.
DR   UniGene; Rn.2270; -.
DR   SMR; P80433; 26-68.
DR   GeneID; 171335; -.
DR   KEGG; rno:171335; -.
DR   UCSC; NM_134345; rat.
DR   CTD; 171335; -.
DR   RGD; 620638; Cox8a.
DR   BRENDA; 1.9.3.1; 248.
DR   Genevestigator; P80433; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005751; C:mitochondrial respiratory chain complex IV; TAS:RGD.
DR   GO; GO:0004129; F:cytochrome-c oxidase activity; TAS:RGD.
DR   InterPro; IPR003205; Cyt_c_oxidase_su8.
DR   InterPro; IPR016070; Cyt_c_oxidase_su8/PSI_RC_su9.
DR   Gene3D; G3DSA:4.10.81.10; Cyt_c_oxidase_suVIII/PSI_suIX; 1.
DR   PANTHER; PTHR16717; Cyt_c_ox8; 1.
DR   Pfam; PF02285; COX8; 1.
DR   SUPFAM; SSF81431; Cyt_c_oxidase_8; 1.
PE   1: Evidence at protein level;
KW   Direct protein sequencing; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Transit peptide; Transmembrane.
FT   TRANSIT       1     25       Mitochondrion.
FT   CHAIN        26     69       Cytochrome c oxidase subunit 8A,
FT                                mitochondrial.
FT                                /FTId=PRO_0000150129.
FT   TOPO_DOM     26     36       Mitochondrial matrix (By similarity).
FT   TRANSMEM     37     60       By similarity.
FT   TOPO_DOM     61     69       Mitochondrial intermembrane (By
FT                                similarity).
FT   CONFLICT     35     35       L -> G (in Ref. 3; AAA41018/CAA29505).
SQ   SEQUENCE   69 AA;  7672 MW;  BEC3D9935C5E46C1 CRC64;
     MSSLTPLLLR SLTGPARRLM VPRAQVHSKP PREQLGVLDI TIGLTSCFVC CLLPAGWVLS
     HLESYKKRE
//
ID   COX8B_RAT               Reviewed;          70 AA.
AC   P16221;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 3.
DT   02-MAR-2010, entry version 83.
DE   RecName: Full=Cytochrome c oxidase subunit 8B, mitochondrial;
DE   AltName: Full=Cytochrome c oxidase subunit 8H;
DE   AltName: Full=Cytochrome c oxidase polypeptide VIII-heart;
DE   AltName: Full=Cytochrome c oxidase subunit 8-1;
DE   Flags: Precursor;
GN   Name=Cox8b; Synonyms=Cox8h;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Heart;
RX   MEDLINE=92379099; PubMed=1324738; DOI=10.1016/0167-4781(92)90059-9;
RA   Scheja K., Kadenbach B.;
RT   "Nucleotide sequence of cDNA encoding subunit VIII of cytochrome c
RT   oxidase from rat heart.";
RL   Biochim. Biophys. Acta 1132:91-93(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=Fischer;
RX   MEDLINE=97094748; PubMed=8939982; DOI=10.1074/jbc.271.47.30281;
RA   Lenka N., Basu A., Mullick J., Avadhani N.G.;
RT   "The role of an E box binding basic helix loop helix protein in the
RT   cardiac muscle-specific expression of the rat cytochrome oxidase
RT   subunit VIII gene.";
RL   J. Biol. Chem. 271:30281-30289(1996).
RN   [3]
RP   PROTEIN SEQUENCE OF 25-62.
RC   TISSUE=Heart;
RX   MEDLINE=90122894; PubMed=2153407; DOI=10.1016/0005-2728(90)90042-3;
RA   Kadenbach B., Stroh A., Becker A., Eckersorn C., Lottspeich F.;
RT   "Tissue- and species-specific expression of cytochrome c oxidase
RT   isozymes in vertebrates.";
RL   Biochim. Biophys. Acta 1015:368-372(1990).
RN   [4]
RP   PROTEIN SEQUENCE OF 25-39.
RC   TISSUE=Heart;
RX   MEDLINE=95324529; PubMed=7601105;
RX   DOI=10.1111/j.1432-1033.1995.0235i.x;
RA   Schaegger H., Noack H., Halangk W., Brandt U., von Jagow G.;
RT   "Cytochrome-c oxidase in developing rat heart. Enzymic properties and
RT   amino-terminal sequences suggest identity of the fetal heart and the
RT   adult liver isoform.";
RL   Eur. J. Biochem. 230:235-241(1995).
CC   -!- FUNCTION: This protein is one of the nuclear-coded polypeptide
CC       chains of cytochrome c oxidase, the terminal oxidase in
CC       mitochondrial electron transport.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane.
CC   -!- DEVELOPMENTAL STAGE: Increased levels in liver during prenatal
CC       development.
CC   -!- SIMILARITY: Belongs to the cytochrome c oxidase VIII family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X64827; CAA46039.1; -; mRNA.
DR   EMBL; U40836; AAC52906.1; -; Genomic_DNA.
DR   EMBL; U40835; AAC52906.1; JOINED; Genomic_DNA.
DR   IPI; IPI00327473; -.
DR   PIR; S24171; S24171.
DR   RefSeq; NP_036918.2; -.
DR   UniGene; Rn.10325; -.
DR   SMR; P16221; 25-67.
DR   STRING; P16221; -.
DR   Ensembl; ENSRNOT00000019679; ENSRNOP00000019679; ENSRNOG00000014656; Rattus norvegicus.
DR   GeneID; 25250; -.
DR   KEGG; rno:25250; -.
DR   UCSC; NM_012786; rat.
DR   CTD; 25250; -.
DR   RGD; 2386; Cox8h.
DR   eggNOG; maNOG24141; -.
DR   InParanoid; P16221; -.
DR   OMA; FMVPAGW; -.
DR   OrthoDB; EOG98976J; -.
DR   PhylomeDB; P16221; -.
DR   NextBio; 605865; -.
DR   ArrayExpress; P16221; -.
DR   Genevestigator; P16221; -.
DR   GermOnline; ENSRNOG00000014656; Rattus norvegicus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005746; C:mitochondrial respiratory chain; TAS:RGD.
DR   GO; GO:0004129; F:cytochrome-c oxidase activity; TAS:RGD.
DR   GO; GO:0006123; P:mitochondrial electron transport, cytochrom...; TAS:RGD.
DR   GO; GO:0042493; P:response to drug; IEP:RGD.
DR   InterPro; IPR003205; Cyt_c_oxidase_su8.
DR   InterPro; IPR016070; Cyt_c_oxidase_su8/PSI_RC_su9.
DR   Gene3D; G3DSA:4.10.81.10; Cyt_c_oxidase_suVIII/PSI_suIX; 1.
DR   PANTHER; PTHR16717; Cyt_c_ox8; 1.
DR   Pfam; PF02285; COX8; 1.
DR   SUPFAM; SSF81431; Cyt_c_oxidase_8; 1.
PE   1: Evidence at protein level;
KW   Direct protein sequencing; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Transit peptide; Transmembrane.
FT   TRANSIT       1     24       Mitochondrion.
FT   CHAIN        25     70       Cytochrome c oxidase subunit 8B,
FT                                mitochondrial.
FT                                /FTId=PRO_0000006179.
FT   TOPO_DOM     25     35       Mitochondrial matrix (By similarity).
FT   TRANSMEM     36     59       By similarity.
FT   TOPO_DOM     60     70       Mitochondrial intermembrane (By
FT                                similarity).
FT   CONFLICT     47     47       I -> V (in Ref. 1; CAA46039).
SQ   SEQUENCE   70 AA;  7549 MW;  9DF87F37FB7D2D51 CRC64;
     MPRLPPILRL LQAPEKYTVI PKARISSKPA KSPTSAMDQA VGMSVIIAGF MVPAGWVLSH
     LESYKRSSAA
//
ID   CX6C1_RAT               Reviewed;          76 AA.
AC   P11950;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 76.
DE   RecName: Full=Cytochrome c oxidase subunit 6C-1;
DE   AltName: Full=Cytochrome c oxidase polypeptide VIc-1;
GN   Name=Cox6c1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=88224561; PubMed=2836143;
RA   Suske G., Enders C., Schlerf A., Kadenbach B.;
RT   "Organization and nucleotide sequence of two chromosomal genes for rat
RT   cytochrome c oxidase subunit VIc: a structural and a processed gene.";
RL   DNA 7:163-171(1988).
RN   [2]
RP   PROTEIN SEQUENCE OF 2-11.
RC   STRAIN=Wistar; TISSUE=Liver;
RX   MEDLINE=95324529; PubMed=7601105;
RX   DOI=10.1111/j.1432-1033.1995.0235i.x;
RA   Schaegger H., Noack H., Halangk W., Brandt U., von Jagow G.;
RT   "Cytochrome-c oxidase in developing rat heart. Enzymic properties and
RT   amino-terminal sequences suggest identity of the fetal heart and the
RT   adult liver isoform.";
RL   Eur. J. Biochem. 230:235-241(1995).
CC   -!- FUNCTION: This protein is one of the nuclear-coded polypeptide
CC       chains of cytochrome c oxidase, the terminal oxidase in
CC       mitochondrial electron transport.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane.
CC   -!- SIMILARITY: Belongs to the cytochrome c oxidase subunit 6c family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M20183; AAA41012.1; -; mRNA.
DR   IPI; IPI00231122; -.
DR   PIR; B29907; B29907.
DR   RefSeq; NP_775425.1; -.
DR   UniGene; Rn.10885; -.
DR   SMR; P11950; 7-76.
DR   STRING; P11950; -.
DR   PhosphoSite; P11950; -.
DR   PRIDE; P11950; -.
DR   GeneID; 286962; -.
DR   KEGG; rno:286962; -.
DR   UCSC; NM_173303; rat.
DR   CTD; 286962; -.
DR   RGD; 735056; Cox6c1.
DR   eggNOG; maNOG21445; -.
DR   HOVERGEN; HBG051091; -.
DR   InParanoid; P11950; -.
DR   OrthoDB; EOG9B8N0F; -.
DR   PhylomeDB; P11950; -.
DR   NextBio; 625167; -.
DR   ArrayExpress; P11950; -.
DR   Genevestigator; P11950; -.
DR   GermOnline; ENSRNOG00000032602; Rattus norvegicus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004129; F:cytochrome-c oxidase activity; IEA:InterPro.
DR   InterPro; IPR004204; Cyt_c_oxidase_su6c.
DR   Gene3D; G3DSA:4.10.93.10; COX6C; 1.
DR   PANTHER; PTHR12916; COX6C; 1.
DR   Pfam; PF02937; COX6C; 1.
DR   ProDom; PD015032; Cyt_c_oxidase_su6c; 1.
DR   SUPFAM; SSF81415; COX6C; 1.
PE   1: Evidence at protein level;
KW   Direct protein sequencing; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Transmembrane.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2     76       Cytochrome c oxidase subunit 6C-1.
FT                                /FTId=PRO_0000191303.
FT   TOPO_DOM      4     14       Mitochondrial matrix (By similarity).
FT   TRANSMEM     15     55       By similarity.
FT   TOPO_DOM     56     76       Mitochondrial intermembrane (By
FT                                similarity).
SQ   SEQUENCE   76 AA;  8553 MW;  8EEADA4D53EE85E2 CRC64;
     MSSGALLPKP QMHDPLSKRL WVHIVGAFIV DLGVAAAHKF GAAKPRKKAY ADFYRNHDPM
     KDFDEMRKAG VFRSVK
//
ID   CX6C2_RAT               Reviewed;          76 AA.
AC   P11951; Q63703;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 93.
DE   RecName: Full=Cytochrome c oxidase subunit 6C-2;
DE   AltName: Full=Cytochrome c oxidase polypeptide VIc-2;
GN   Name=Cox6c2; Synonyms=Cox6c;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Liver;
RX   MEDLINE=88224561; PubMed=2836143;
RA   Suske G., Enders C., Schlerf A., Kadenbach B.;
RT   "Organization and nucleotide sequence of two chromosomal genes for rat
RT   cytochrome c oxidase subunit VIc: a structural and a processed gene.";
RL   DNA 7:163-171(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=88029422; PubMed=2822403;
RX   DOI=10.1111/j.1432-1033.1987.tb13410.x;
RA   Suske G., Mengel T., Cordingley M., Kadenbach B.;
RT   "Molecular cloning and further characterization of cDNAs for rat
RT   nuclear-encoded cytochrome c oxidase subunits VIc and VIII.";
RL   Eur. J. Biochem. 168:233-237(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Liver;
RX   MEDLINE=89226785; PubMed=2854406;
RX   DOI=10.1111/j.1749-6632.1988.tb35348.x;
RA   Cao X.N., Hengst L., Schlerf A., Droste M., Mengel T., Kadenbach B.;
RT   "Complexity of nucleus-encoded genes of mammalian cytochrome c
RT   oxidase.";
RL   Ann. N. Y. Acad. Sci. 550:337-347(1988).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pituitary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 44-76.
RX   MEDLINE=84153873; PubMed=6200111; DOI=10.1016/0006-291X(84)91480-3;
RA   Parimoo S., Seelan R.S., Desai S., Buse G., Padmanaban G.;
RT   "Construction of a cDNA clone for a nuclear-coded subunit of
RT   cytochrome c oxidase from rat liver.";
RL   Biochem. Biophys. Res. Commun. 118:902-909(1984).
RN   [6]
RP   PROTEIN SEQUENCE OF 2-11.
RC   STRAIN=Wistar; TISSUE=Liver;
RX   MEDLINE=95324529; PubMed=7601105;
RX   DOI=10.1111/j.1432-1033.1995.0235i.x;
RA   Schaegger H., Noack H., Halangk W., Brandt U., von Jagow G.;
RT   "Cytochrome-c oxidase in developing rat heart. Enzymic properties and
RT   amino-terminal sequences suggest identity of the fetal heart and the
RT   adult liver isoform.";
RL   Eur. J. Biochem. 230:235-241(1995).
RN   [7]
RP   PROTEIN SEQUENCE OF 40-46 AND 68-76, AND MASS SPECTROMETRY.
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RA   Lubec G., Kang S.U.;
RL   Submitted (JUL-2007) to UniProtKB.
CC   -!- FUNCTION: This protein is one of the nuclear-coded polypeptide
CC       chains of cytochrome c oxidase, the terminal oxidase in
CC       mitochondrial electron transport.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane.
CC   -!- SIMILARITY: Belongs to the cytochrome c oxidase subunit 6c family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M20153; AAA41011.1; -; Genomic_DNA.
DR   EMBL; M20152; AAA41011.1; JOINED; Genomic_DNA.
DR   EMBL; M27466; AAA79271.1; -; mRNA.
DR   EMBL; M27467; AAA79270.1; ALT_INIT; mRNA.
DR   EMBL; BC058480; AAH58480.1; -; mRNA.
DR   EMBL; K01565; AAA41013.1; -; mRNA.
DR   IPI; IPI00230832; -.
DR   PIR; S00114; S00114.
DR   RefSeq; NP_062233.2; -.
DR   UniGene; Rn.846; -.
DR   SMR; P11951; 7-76.
DR   STRING; P11951; -.
DR   PRIDE; P11951; -.
DR   Ensembl; ENSRNOT00000014407; ENSRNOP00000014407; ENSRNOG00000010807; Rattus norvegicus.
DR   GeneID; 54322; -.
DR   KEGG; rno:54322; -.
DR   UCSC; BC058480; rat.
DR   CTD; 54322; -.
DR   RGD; 620616; Cox6c.
DR   eggNOG; roNOG17665; -.
DR   HOVERGEN; HBG051091; -.
DR   InParanoid; P11951; -.
DR   OMA; LYKFGVA; -.
DR   OrthoDB; EOG9B8N0F; -.
DR   PhylomeDB; P11951; -.
DR   NextBio; 611014; -.
DR   ArrayExpress; P11951; -.
DR   Genevestigator; P11951; -.
DR   GermOnline; ENSRNOG00000010807; Rattus norvegicus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005751; C:mitochondrial respiratory chain complex IV; TAS:RGD.
DR   GO; GO:0004129; F:cytochrome-c oxidase activity; TAS:RGD.
DR   InterPro; IPR004204; Cyt_c_oxidase_su6c.
DR   Gene3D; G3DSA:4.10.93.10; COX6C; 1.
DR   PANTHER; PTHR12916; COX6C; 1.
DR   Pfam; PF02937; COX6C; 1.
DR   ProDom; PD015032; Cyt_c_oxidase_su6c; 1.
DR   SUPFAM; SSF81415; COX6C; 1.
PE   1: Evidence at protein level;
KW   Direct protein sequencing; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Transmembrane.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2     76       Cytochrome c oxidase subunit 6C-2.
FT                                /FTId=PRO_0000191304.
FT   TOPO_DOM      4     14       Mitochondrial matrix (By similarity).
FT   TRANSMEM     15     55       By similarity.
FT   TOPO_DOM     56     76       Mitochondrial intermembrane (By
FT                                similarity).
FT   CONFLICT     29     29       V -> A (in Ref. 3; AAA79270).
SQ   SEQUENCE   76 AA;  8455 MW;  988D10E1F2D387BD CRC64;
     MSSGALLPKP QMRGLLAKRL RVHIVGAFVV ALGVAAAYKF GVAEPRKKAY ADFYRNYDSM
     KDFEEMRQAG VFQSAK
//
ID   CX7A1_HUMAN             Reviewed;          79 AA.
AC   P24310;
DT   01-MAR-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1993, sequence version 2.
DT   02-MAR-2010, entry version 99.
DE   RecName: Full=Cytochrome c oxidase subunit 7A1, mitochondrial;
DE   AltName: Full=Cytochrome c oxidase subunit VIIa-heart;
DE            Short=Cytochrome c oxidase subunit VIIa-H;
DE   AltName: Full=Cytochrome c oxidase subunit VIIa-muscle;
DE            Short=Cytochrome c oxidase subunit VIIa-M;
DE   Flags: Precursor;
GN   Name=COX7A1; Synonyms=COX7AH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=93013002; PubMed=1327965; DOI=10.1016/0378-1119(92)90287-Y;
RA   Arnaudo E., Hirano M., Seelan R.S., Milatovich A., Hsieh C.L.,
RA   Fabrizi G.M., Grossman L.I., Francke U., Schon E.A.;
RT   "Tissue-specific expression and chromosome assignment of genes
RT   specifying two isoforms of subunit VIIa of human cytochrome c
RT   oxidase.";
RL   Gene 119:299-305(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9344674; DOI=10.1006/geno.1997.4937;
RA   Wolz W., Kress W., Mueller C.R.;
RT   "Genomic sequence and organization of the human gene for cytochrome c
RT   oxidase subunit (COX7A1) VIIa-M.";
RL   Genomics 45:438-442(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Heart;
RX   PubMed=11997101; DOI=10.1016/S0167-4781(02)00228-2;
RA   Yu M., Jaradat S.A., Grossman L.I.;
RT   "Genomic organization and promoter regulation of human cytochrome c
RT   oxidase subunit VII heart/muscle isoform (COX7AH).";
RL   Biochim. Biophys. Acta 1574:345-353(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=99268136; PubMed=10335655;
RA   Schmidt T.R., Goodman M., Grossman L.I.;
RT   "Molecular evolution of the COX7A gene family in primates.";
RL   Mol. Biol. Evol. 16:619-626(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 22-51.
RC   TISSUE=Heart, and Skeletal muscle;
RX   MEDLINE=92111565; PubMed=1309697;
RX   DOI=10.1111/j.1432-1033.1992.tb19847.x;
RA   van Kuilenburg A.B.P., van Beeumen J.J., van der Meer N.M.,
RA   Muijsers A.O.;
RT   "Subunits VIIa,b,c of human cytochrome c oxidase. Identification of
RT   both 'heart-type' and 'liver-type' isoforms of subunit VIIa in human
RT   heart.";
RL   Eur. J. Biochem. 203:193-199(1992).
CC   -!- FUNCTION: This protein is one of the nuclear-coded polypeptide
CC       chains of cytochrome c oxidase, the terminal oxidase in
CC       mitochondrial electron transport.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane.
CC   -!- SIMILARITY: Belongs to the cytochrome c oxidase VIIa family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M83186; AAA52166.1; -; mRNA.
DR   EMBL; U81524; AAB82735.1; -; Genomic_DNA.
DR   EMBL; AC002984; AAB81547.1; -; Genomic_DNA.
DR   EMBL; AF037372; AAB92616.1; -; Genomic_DNA.
DR   EMBL; AF127789; AAF72747.1; -; Genomic_DNA.
DR   EMBL; AD001527; AAB51184.1; -; Genomic_DNA.
DR   EMBL; BC002757; AAH02757.1; -; mRNA.
DR   IPI; IPI00306720; -.
DR   PIR; JC1303; OSHU7A.
DR   RefSeq; NP_001855.1; -.
DR   UniGene; Hs.421621; -.
DR   SMR; P24310; 22-77.
DR   STRING; P24310; -.
DR   TCDB; 3.D.4.11.1; proton-translocating cytochrome oxidase (COX) superfamily.
DR   PRIDE; P24310; -.
DR   Ensembl; ENST00000292907; ENSP00000292907; ENSG00000161281; Homo sapiens.
DR   GeneID; 1346; -.
DR   KEGG; hsa:1346; -.
DR   UCSC; uc002odm.1; human.
DR   CTD; 1346; -.
DR   GeneCards; GC19M041333; -.
DR   H-InvDB; HIX0015057; -.
DR   HGNC; HGNC:2287; COX7A1.
DR   MIM; 123995; gene.
DR   PharmGKB; PA26805; -.
DR   eggNOG; prNOG21377; -.
DR   HOVERGEN; HBG051095; -.
DR   InParanoid; P24310; -.
DR   OrthoDB; EOG9TMTM9; -.
DR   PhylomeDB; P24310; -.
DR   NextBio; 5457; -.
DR   ArrayExpress; P24310; -.
DR   Bgee; P24310; -.
DR   CleanEx; HS_COX7A1; -.
DR   Genevestigator; P24310; -.
DR   GermOnline; ENSG00000161281; Homo sapiens.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005746; C:mitochondrial respiratory chain; IEA:InterPro.
DR   GO; GO:0004129; F:cytochrome-c oxidase activity; TAS:ProtInc.
DR   GO; GO:0009055; F:electron carrier activity; IEA:InterPro.
DR   GO; GO:0006091; P:generation of precursor metabolites and energy; TAS:ProtInc.
DR   InterPro; IPR003177; Cyt_c_oxidase_su7a.
DR   Gene3D; G3DSA:4.10.91.10; Cyt_c_oxidase_7a_su; 1.
DR   PANTHER; PTHR10510; COX7a; 1.
DR   Pfam; PF02238; COX7a; 1.
DR   SUPFAM; SSF81419; Cyt_c_oxidase_7a_su; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Direct protein sequencing; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Transit peptide; Transmembrane.
FT   TRANSIT       1     21       Mitochondrion.
FT   CHAIN        22     79       Cytochrome c oxidase subunit 7A1,
FT                                mitochondrial.
FT                                /FTId=PRO_0000006149.
FT   TOPO_DOM     22     46       Mitochondrial matrix (By similarity).
FT   TRANSMEM     47     75       By similarity.
FT   TOPO_DOM     76     79       Mitochondrial intermembrane (By
FT                                similarity).
SQ   SEQUENCE   79 AA;  9118 MW;  AFE9C00C53CE35C2 CRC64;
     MQALRVSQAL IRSFSSTARN RFQNRVREKQ KLFQEDNDIP LYLKGGIVDN ILYRVTMTLC
     LGGTVYSLYS LGWASFPRN
//
ID   DCUB_ECOLI              Reviewed;         446 AA.
AC   P0ABN9; P14409; Q2M6I1;
DT   08-NOV-2005, integrated into UniProtKB/Swiss-Prot.
DT   08-NOV-2005, sequence version 1.
DT   02-MAR-2010, entry version 41.
DE   RecName: Full=Anaerobic C4-dicarboxylate transporter dcuB;
GN   Name=dcuB; Synonyms=genF; OrderedLocusNames=b4123, JW4084;
OS   Escherichia coli (strain K12).
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC   Enterobacteriaceae; Escherichia.
OX   NCBI_TaxID=83333;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=K12;
RX   MEDLINE=94178454; PubMed=8131924;
RA   Six S., Andrews S.C., Roberts R.E., Unden G., Guest J.R.;
RT   "Construction and properties of Escherichia coli mutants defective in
RT   two genes encoding homologous membrane proteins with putative roles in
RT   anaerobic C4-dicarboxylic acid transport.";
RL   Biochem. Soc. Trans. 21:342S-342S(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=K12;
RX   MEDLINE=95050204; PubMed=7961398;
RA   Six S., Andrews S.C., Unden G., Guest J.R.;
RT   "Escherichia coli possesses two homologous anaerobic C4-dicarboxylate
RT   membrane transporters (DcuA and DcuB) distinct from the aerobic
RT   dicarboxylate transport system (Dct).";
RL   J. Bacteriol. 176:6470-6478(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   MEDLINE=95334362; PubMed=7610040; DOI=10.1093/nar/23.12.2105;
RA   Burland V.D., Plunkett G. III, Sofia H.J., Daniels D.L.,
RA   Blattner F.R.;
RT   "Analysis of the Escherichia coli genome VI: DNA sequence of the
RT   region from 92.8 through 100 minutes.";
RL   Nucleic Acids Res. 23:2105-2119(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   MEDLINE=97426617; PubMed=9278503; DOI=10.1126/science.277.5331.1453;
RA   Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,
RA   Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F.,
RA   Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J.,
RA   Mau B., Shao Y.;
RT   "The complete genome sequence of Escherichia coli K-12.";
RL   Science 277:1453-1474(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=16738553; DOI=10.1038/msb4100049;
RA   Hayashi K., Morooka N., Yamamoto Y., Fujita K., Isono K., Choi S.,
RA   Ohtsubo E., Baba T., Wanner B.L., Mori H., Horiuchi T.;
RT   "Highly accurate genome sequences of Escherichia coli K-12 strains
RT   MG1655 and W3110.";
RL   Mol. Syst. Biol. 2:E1-E5(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 67-446.
RC   STRAIN=K12;
RX   MEDLINE=89255123; PubMed=2656658;
RA   Bell P.J., Andrews S.C., Sivak M.N., Guest J.R.;
RT   "Nucleotide sequence of the FNR-regulated fumarase gene (fumB) of
RT   Escherichia coli K-12.";
RL   J. Bacteriol. 171:3494-3503(1989).
RN   [7]
RP   TOPOLOGY [LARGE SCALE ANALYSIS].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=15919996; DOI=10.1126/science.1109730;
RA   Daley D.O., Rapp M., Granseth E., Melen K., Drew D., von Heijne G.;
RT   "Global topology analysis of the Escherichia coli inner membrane
RT   proteome.";
RL   Science 308:1321-1323(2005).
CC   -!- FUNCTION: Responsible for the transport of C4-dicarboxylates from
CC       the periplasm across the inner membrane.
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane; Multi-pass membrane
CC       protein.
CC   -!- SIMILARITY: Belongs to the dcuA/dcuB transporter (TC 2.A.13.1)
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X79886; CAA56258.1; -; Genomic_DNA.
DR   EMBL; U14003; AAA97023.1; -; Genomic_DNA.
DR   EMBL; U00096; AAC77084.1; -; Genomic_DNA.
DR   EMBL; AP009048; BAE78125.1; -; Genomic_DNA.
DR   EMBL; M27058; AAA23826.1; -; Genomic_DNA.
DR   PIR; S56352; S56352.
DR   RefSeq; AP_004624.1; -.
DR   RefSeq; NP_418547.1; -.
DR   STRING; P0ABN9; -.
DR   TCDB; 2.A.13.1.2; C4-dicarboxylate uptake (Dcu) family.
DR   GeneID; 948641; -.
DR   GenomeReviews; AP009048_GR; JW4084.
DR   GenomeReviews; U00096_GR; b4123.
DR   KEGG; ecj:JW4084; -.
DR   KEGG; eco:b4123; -.
DR   EchoBASE; EB0006; -.
DR   EcoGene; EG10006; dcuB.
DR   eggNOG; COG2704; -.
DR   HOGENOM; HBG297083; -.
DR   OMA; MGITASP; -.
DR   ProtClustDB; PRK12489; -.
DR   BioCyc; EcoCyc:DCUB-MONOMER; -.
DR   BioCyc; ECOL168927:B4123-MONOMER; -.
DR   Genevestigator; P0ABN9; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0015556; F:C4-dicarboxylate transmembrane transporter ...; IEA:InterPro.
DR   GO; GO:0015740; P:C4-dicarboxylate transport; IEA:InterPro.
DR   InterPro; IPR004668; Anaer_Dcu_memb_transpt.
DR   Pfam; PF03605; DcuA_DcuB; 1.
DR   PIRSF; PIRSF004539; C4-dicrbxl_trns; 1.
DR   TIGRFAMs; TIGR00770; Dcu; 1.
PE   1: Evidence at protein level;
KW   Cell inner membrane; Cell membrane; Complete proteome; Membrane;
KW   Transmembrane; Transport.
FT   CHAIN         1    446       Anaerobic C4-dicarboxylate transporter
FT                                dcuB.
FT                                /FTId=PRO_0000170355.
FT   TRANSMEM      1     19       By similarity.
FT   TOPO_DOM     20     20       Cytoplasmic (By similarity).
FT   TRANSMEM     21     39       By similarity.
FT   TOPO_DOM     40     55       Periplasmic (By similarity).
FT   TRANSMEM     56     73       By similarity.
FT   TOPO_DOM     74     87       Cytoplasmic (By similarity).
FT   TRANSMEM     88    105       By similarity.
FT   TOPO_DOM    106    134       Periplasmic (By similarity).
FT   TRANSMEM    135    149       By similarity.
FT   TOPO_DOM    150    240       Cytoplasmic (By similarity).
FT   TRANSMEM    241    258       By similarity.
FT   TOPO_DOM    259    275       Periplasmic (By similarity).
FT   TRANSMEM    276    293       By similarity.
FT   TOPO_DOM    294    303       Cytoplasmic (By similarity).
FT   TRANSMEM    304    321       By similarity.
FT   TOPO_DOM    322    343       Periplasmic (By similarity).
FT   TRANSMEM    344    361       By similarity.
FT   TOPO_DOM    362    366       Cytoplasmic (By similarity).
FT   TRANSMEM    367    384       By similarity.
FT   TOPO_DOM    385    446       Periplasmic (By similarity).
SQ   SEQUENCE   446 AA;  47935 MW;  B4AF89BB2E0CCB3B CRC64;
     MLFTIQLIII LICLFYGARK GGIALGLLGG IGLVILVFVF HLQPGKPPVD VMLVIIAVVA
     ASATLQASGG LDVMLQIAEK LLRRNPKYVS IVAPFVTCTL TILCGTGHVV YTILPIIYDV
     AIKNNIRPER PMAASSIGAQ MGIIASPVSV AVVSLVAMLG NVTFDGRHLE FLDLLAITIP
     STLIGILAIG IFSWFRGKDL DKDEEFQKFI SVPENREYVY GDTATLLDKK LPKSNWLAMW
     IFLGAIAVVA LLGADSDLRP SFGGKPLSMV LVIQMFMLLT GALIIILTKT NPASISKNEV
     FRSGMIAIVA VYGIAWMAET MFGAHMSEIQ GVLGEMVKEY PWAYAIVLLL VSKFVNSQAA
     ALAAIVPVAL AIGVDPAYIV ASAPACYGYY ILPTYPSDLA AIQFDRSGTT HIGRFVINHS
     FILPGLIGVS VSCVFGWIFA AMYGFL
//
ID   DHSD_ASCSU              Reviewed;         156 AA.
AC   P92507;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1997, sequence version 2.
DT   02-MAR-2010, entry version 56.
DE   RecName: Full=Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial;
DE            Short=CybS;
DE   AltName: Full=Succinate-ubiquinone reductase membrane anchor subunit;
DE   AltName: Full=Cytochrome b558 small subunit;
DE   Flags: Precursor;
OS   Ascaris suum (Pig roundworm) (Ascaris lumbricoides).
OC   Eukaryota; Metazoa; Nematoda; Chromadorea; Ascaridida; Ascaridoidea;
OC   Ascarididae; Ascaris.
OX   NCBI_TaxID=6253;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Muscle;
RX   MEDLINE=96354363; PubMed=8764887; DOI=10.1016/0005-2728(96)00070-9;
RA   Saruta F., Hirawake H., Takamiya S., Ma Y.-C., Aoki T., Sekimizu K.,
RA   Kojima S., Kita K.;
RT   "Cloning of a cDNA encoding the small subunit of cytochrome b558
RT   (cybS) of mitochondrial fumarate reductase (complex II) from adult
RT   Ascaris suum.";
RL   Biochim. Biophys. Acta 1276:1-5(1996).
RN   [2]
RP   PROTEIN SEQUENCE OF 26-55.
RA   Kita K., Takamiya S., Furushima R., Suzuki H., Ozawa T., Oya H.;
RL   (In) Lenaz G., Barnabei O., Rabbi A., Battino M. (eds.);
RL   Highlights in Ubiquinone Research, pp.174-177, Taylor and Francis,
RL   London (1990).
CC   -!- FUNCTION: Membrane-anchoring subunit of succinate dehydrogenase
CC       (SDH) that is involved in complex II of the mitochondrial electron
CC       transport chain and is responsible for transferring electrons from
CC       succinate to ubiquinone (coenzyme Q) (By similarity).
CC   -!- PATHWAY: Carbohydrate metabolism; tricarboxylic acid cycle.
CC   -!- SUBUNIT: Forms part of complex II containing four subunits: a
CC       flavoprotein (FP), an iron-sulfur protein (IP) and a cytochrome b
CC       composed of a large and a small subunit (By similarity).
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane; Multi-pass
CC       membrane protein (By similarity).
CC   -!- SIMILARITY: Belongs to the CybS family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D78158; BAA11233.1; -; mRNA.
DR   SMR; P92507; 58-156.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005749; C:mitochondrial respiratory chain complex II; ISS:UniProtKB.
DR   GO; GO:0020037; F:heme binding; ISS:UniProtKB.
DR   GO; GO:0048039; F:ubiquinone binding; ISS:UniProtKB.
DR   GO; GO:0022900; P:electron transport chain; IEA:UniProtKB-KW.
DR   GO; GO:0006810; P:transport; IEA:UniProtKB-KW.
DR   GO; GO:0006099; P:tricarboxylic acid cycle; IEA:UniProtKB-KW.
DR   InterPro; IPR007992; Cyt_b_succ_DH_CybS.
DR   PANTHER; PTHR13337; CybS; 1.
DR   Pfam; PF05328; CybS; 1.
PE   1: Evidence at protein level;
KW   Direct protein sequencing; Electron transport; Heme; Iron; Membrane;
KW   Metal-binding; Mitochondrion; Mitochondrion inner membrane;
KW   Transit peptide; Transmembrane; Transport; Tricarboxylic acid cycle.
FT   TRANSIT       1     25       Mitochondrion.
FT   CHAIN        26    156       Succinate dehydrogenase [ubiquinone]
FT                                cytochrome b small subunit,
FT                                mitochondrial.
FT                                /FTId=PRO_0000006490.
FT   TOPO_DOM     26     57       Mitochondrial matrix (By similarity).
FT   TRANSMEM     58     78       By similarity.
FT   TOPO_DOM     79     83       Mitochondrial intermembrane (By
FT                                similarity).
FT   TRANSMEM     84    104       By similarity.
FT   TOPO_DOM    105    117       Mitochondrial matrix (By similarity).
FT   TRANSMEM    118    139       By similarity.
FT   TOPO_DOM    140    156       Mitochondrial intermembrane (By
FT                                similarity).
FT   METAL        95     95       Iron (heme axial ligand); shared with
FT                                large subunit (By similarity).
FT   BINDING     107    107       Ubiquinone; shared with IP (By
FT                                similarity).
SQ   SEQUENCE   156 AA;  16996 MW;  6515299AF6CFA93F CRC64;
     MLSAVRRAIP LSARILRTSL IQRCAGATSA AVTGAAPPQF DPIAAEKGFK PLHSHGTLFK
     IERYFAAAMV PLIPAAYFIH GREMDLCLAL ALTLHVHWGV WGVVNDYGRP FVLGDTLAAA
     VRVGAYIFTA CLLAGLLYFN EHDVGLTRAF EMVWEL
//
ID   DHSD_COXBU              Reviewed;         115 AA.
AC   P51057;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   16-DEC-2008, sequence version 2.
DT   02-MAR-2010, entry version 69.
DE   RecName: Full=Succinate dehydrogenase hydrophobic membrane anchor subunit;
GN   Name=sdhD; OrderedLocusNames=CBU_1402;
OS   Coxiella burnetii.
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Legionellales;
OC   Coxiellaceae; Coxiella.
OX   NCBI_TaxID=777;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND SUBUNIT.
RC   STRAIN=Nine Mile;
RX   MEDLINE=95212926; PubMed=7698664; DOI=10.1016/0378-1119(94)00888-Y;
RA   Heinzen R.A., Mo Y.-Y., Robertson S.J., Mallavia L.P.;
RT   "Characterization of the succinate dehydrogenase-encoding gene cluster
RT   (sdh) from the rickettsia Coxiella burnetii.";
RL   Gene 155:27-34(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Nine Mile phase I / RSA 493;
RX   MEDLINE=22608657; PubMed=12704232; DOI=10.1073/pnas.0931379100;
RA   Seshadri R., Paulsen I.T., Eisen J.A., Read T.D., Nelson K.E.,
RA   Nelson W.C., Ward N.L., Tettelin H., Davidsen T.M., Beanan M.J.,
RA   DeBoy R.T., Daugherty S.C., Brinkac L.M., Madupu R., Dodson R.J.,
RA   Khouri H.M., Lee K.H., Carty H.A., Scanlan D., Heinzen R.A.,
RA   Thompson H.A., Samuel J.E., Fraser C.M., Heidelberg J.F.;
RT   "Complete genome sequence of the Q-fever pathogen, Coxiella
RT   burnetii.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:5455-5460(2003).
CC   -!- FUNCTION: Membrane-anchoring subunit of succinate dehydrogenase
CC       (SDH).
CC   -!- COFACTOR: Heme group. The heme is bound between the two
CC       transmembrane subunits (By similarity).
CC   -!- PATHWAY: Carbohydrate metabolism; tricarboxylic acid cycle.
CC   -!- SUBUNIT: Part of an enzyme complex containing four subunits: a
CC       flavoprotein, an iron-sulfur protein, plus two membrane-anchoring
CC       proteins, sdhC and sdhD.
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane; Multi-pass membrane
CC       protein.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L33409; AAA74132.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AE016828; AAO90901.2; -; Genomic_DNA.
DR   PIR; I40848; I40848.
DR   RefSeq; NP_820387.2; -.
DR   GeneID; 1209308; -.
DR   GenomeReviews; AE016828_GR; CBU_1402.
DR   KEGG; cbu:CBU_1402; -.
DR   NMPDR; fig|227377.1.peg.1331; -.
DR   TIGR; CBU_1402; -.
DR   HOGENOM; HBG730582; -.
DR   ProtClustDB; CLSK914757; -.
DR   BioCyc; CBUR227377:CBU_1402-MONOMER; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005506; F:iron ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0016627; F:oxidoreductase activity, acting on the CH-C...; IEA:InterPro.
DR   GO; GO:0022900; P:electron transport chain; IEA:UniProtKB-KW.
DR   GO; GO:0006810; P:transport; IEA:UniProtKB-KW.
DR   GO; GO:0006099; P:tricarboxylic acid cycle; IEA:UniProtKB-KW.
DR   InterPro; IPR014312; Succ_DH_anchor.
DR   InterPro; IPR000701; Succ_DH_Fumarate_Rdtase_TM-su.
DR   Pfam; PF01127; Sdh_cyt; 1.
DR   TIGRFAMs; TIGR02968; succ_dehyd_anc; 1.
PE   1: Evidence at protein level;
KW   Cell inner membrane; Cell membrane; Complete proteome;
KW   Electron transport; Heme; Iron; Membrane; Metal-binding;
KW   Transmembrane; Transport; Tricarboxylic acid cycle.
FT   CHAIN         1    115       Succinate dehydrogenase hydrophobic
FT                                membrane anchor subunit.
FT                                /FTId=PRO_0000158671.
FT   TOPO_DOM      1     14       Cytoplasmic (By similarity).
FT   TRANSMEM     15     35       By similarity.
FT   TOPO_DOM     36     57       Periplasmic (By similarity).
FT   TRANSMEM     58     79       By similarity.
FT   TOPO_DOM     80     89       Cytoplasmic (By similarity).
FT   TRANSMEM     90    113       By similarity.
FT   METAL        70     70       Iron (heme axial ligand); shared with
FT                                second transmembrane subunit (By
FT                                similarity).
FT   BINDING      82     82       Ubiquinone (By similarity).
SQ   SEQUENCE   115 AA;  13774 MW;  BCBC16AE4DFCC180 CRC64;
     MDMVDRTSRR GYRDWFVQRI TALLSGIYAV FVIVFLLVHH PISYPQWHAL FSHLIMKIFT
     LIVIFSILWH AWIGMWTIFT DYVKNKPIRL ALETLVCLLL VGYFVWAIEF LWIAR
//
ID   DHSD_HUMAN              Reviewed;         159 AA.
AC   O14521; A6ND90; B3KQQ8; Q53XW5; Q6IRW2;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   02-MAR-2010, entry version 111.
DE   RecName: Full=Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial;
DE            Short=CybS;
DE   AltName: Full=Succinate-ubiquinone reductase membrane anchor subunit;
DE   AltName: Full=QPs3;
DE   AltName: Full=CII-4;
DE   AltName: Full=Succinate dehydrogenase complex subunit D;
DE   AltName: Full=Succinate-ubiquinone oxidoreductase cytochrome b small subunit;
DE   Flags: Precursor;
GN   Name=SDHD; Synonyms=SDH4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   MEDLINE=98194224; PubMed=9533030;
RA   Hirawake H., Taniwaki M., Tamura A., Kojima S., Kita K.;
RT   "Cytochrome b in human complex II (succinate-ubiquinone
RT   oxidoreductase): cDNA cloning of the components in liver mitochondria
RT   and chromosome assignment of the genes for the large (SDHC) and small
RT   (SDHD) subunits to 1q21 and 11q23.";
RL   Cytogenet. Cell Genet. 79:132-138(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10482792; DOI=10.1016/S0005-2728(99)00071-7;
RA   Hirawake H., Taniwaki M., Tamura A., Amino H., Tomitsuka E., Kita K.;
RT   "Characterization of the human SDHD gene encoding the small subunit of
RT   cytochrome b (cybS) in mitochondrial succinate-ubiquinone
RT   oxidoreductase.";
RL   Biochim. Biophys. Acta 1412:295-300(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=16303743; DOI=10.1093/dnares/12.2.117;
RA   Otsuki T., Ota T., Nishikawa T., Hayashi K., Suzuki Y., Yamamoto J.,
RA   Wakamatsu A., Kimura K., Sakamoto K., Hatano N., Kawai Y., Ishii S.,
RA   Saito K., Kojima S., Sugiyama T., Ono T., Okano K., Yoshikawa Y.,
RA   Aotsuka S., Sasaki N., Hattori A., Okumura K., Nagai K., Sugano S.,
RA   Isogai T.;
RT   "Signal sequence and keyword trap in silico for selection of full-
RT   length human cDNAs encoding secretion or membrane proteins from oligo-
RT   capped cDNA libraries.";
RL   DNA Res. 12:117-126(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Bone marrow, Brain, Lung, and Skeletal muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   IDENTIFICATION [LARGE SCALE ANALYSIS], AND MASS SPECTROMETRY.
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [10]
RP   VARIANT PHEOCHROMOCYTOMA LEU-81.
RX   MEDLINE=21028068; PubMed=11156372;
RA   Gimm O., Armanios M., Dziema H., Neumann H.P.H., Eng C.;
RT   "Somatic and occult germ-line mutations in SDHD, a mitochondrial
RT   complex II gene, in nonfamilial pheochromocytoma.";
RL   Cancer Res. 60:6822-6825(2000).
RN   [11]
RP   VARIANTS PGL1 LEU-81; TYR-92 AND LEU-102.
RX   MEDLINE=20126372; PubMed=10657297; DOI=10.1126/science.287.5454.848;
RA   Baysal B.E., Ferrell R.E., Willett-Brozick J.E., Lawrence E.C.,
RA   Myssiorek D., Bosch A., van der Mey A., Taschner P.E.M.,
RA   Rubinstein W.S., Myers E.N., Richard C.W. III, Cornelisse C.J.,
RA   Devilee P., Devlin B.;
RT   "Mutations in SDHD, a mitochondrial complex II gene, in hereditary
RT   paraganglioma.";
RL   Science 287:848-851(2000).
RN   [12]
RP   VARIANT PGL1 CYS-114.
RX   MEDLINE=21240027; PubMed=11343322; DOI=10.1002/ajmg.1270;
RA   Milunsky J.M., Maher T.A., Michels V.V., Milunsky A.;
RT   "Novel mutations and the emergence of a common mutation in the SDHD
RT   gene causing familial paraganglioma.";
RL   Am. J. Med. Genet. 100:311-314(2001).
RN   [13]
RP   VARIANT PGL1 TYR-93 DEL.
RX   MEDLINE=21286158; PubMed=11391796; DOI=10.1002/gcc.1142;
RA   Badenhop R.F., Cherian S., Lord R.S.A., Baysal B.E., Taschner P.E.M.,
RA   Schofield P.R.;
RT   "Novel mutations in the SDHD gene in pedigrees with familial carotid
RT   body paraganglioma and sensorineural hearing loss.";
RL   Genes Chromosomes Cancer 31:255-263(2001).
RN   [14]
RP   VARIANTS PGL1 TYR-92 AND PRO-139.
RX   MEDLINE=21286160; PubMed=11391798; DOI=10.1002/gcc.1144;
RA   Taschner P.E.M., Jansen J.C., Baysal B.E., Bosch A., Rosenberg E.H.,
RA   Broecker-Vriends A.H.J.T., van Der Mey A.G.L., van Ommen G.-J.B.,
RA   Cornelisse C.J., Devilee P.;
RT   "Nearly all hereditary paragangliomas in the Netherlands are caused by
RT   two founder mutations in the SDHD gene.";
RL   Genes Chromosomes Cancer 31:274-281(2001).
RN   [15]
RP   VARIANT SER-12.
RX   MEDLINE=21417658; PubMed=11526495; DOI=10.1038/sj.onc.1204579;
RA   Masuoka J., Brandner S., Paulus W., Soffer D., Vital A., Chimelli L.,
RA   Jouvet A., Yonekawa Y., Kleihues P., Ohgaki H.;
RT   "Germline SDHD mutation in paraganglioma of the spinal cord.";
RL   Oncogene 20:5084-5086(2001).
RN   [16]
RP   INVOLVEMENT IN INTESTINAL CARCINOID TUMOR, AND VARIANTS SER-12 AND
RP   ARG-50.
RX   MEDLINE=22021280; PubMed=12007193; DOI=10.1002/gcc.10081;
RA   Kytoelae S., Nord B., Elder E.E., Carling T., Kjellman M.,
RA   Cedermark B., Juhlin C., Hoeoeg A., Isola J., Larsson C.;
RT   "Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell
RT   carcinomas, pheochromocytomas, and abdominal paragangliomas.";
RL   Genes Chromosomes Cancer 34:325-332(2002).
RN   [17]
RP   VARIANTS SER-12 AND ARG-50.
RX   PubMed=14500403;
RA   Gimenez-Roqueplo A.-P., Favier J., Rustin P., Rieubland C.,
RA   Crespin M., Nau V., Khau Van Kien P., Corvol P., Plouin P.-F.,
RA   Jeunemaitre X.;
RT   "Mutations in the SDHB gene are associated with extra-adrenal and/or
RT   malignant phaeochromocytomas.";
RL   Cancer Res. 63:5615-5621(2003).
RN   [18]
RP   VARIANT PHEOCHROMOCYTOMA TYR-92.
RX   PubMed=12000816; DOI=10.1056/NEJMoa020152;
RG   The Freiburg-Warsaw-Columbus pheochromocytoma study group;
RA   Neumann H.P.H., Bausch B., McWhinney S.R., Bender B.U., Gimm O.,
RA   Franke G., Schipper J., Klisch J., Altehoefer C., Zerres K.,
RA   Januszewicz A., Smith W.M., Munk R., Manz T., Glaesker S., Apel T.W.,
RA   Treier M., Reineke M., Walz M.K., Hoang-Vu C., Brauckhoff M.,
RA   Klein-Franke A., Klose P., Schmidt H., Maier-Woelfle M.,
RA   Peczkowska M., Szmigielski C., Eng C.;
RT   "Germ-line mutations in nonsyndromic pheochromocytoma.";
RL   N. Engl. J. Med. 346:1459-1466(2002).
RN   [19]
RP   DISCUSSION OF PATHOGENIC ROLE OF VARIANTS SER-12 AND ARG-50.
RX   MEDLINE=22581370; PubMed=12696072; DOI=10.1002/gcc.10212;
RA   Cascon A., Ruiz-Llorente S., Cebrian A., Leton R., Telleria D.,
RA   Benitez J., Robledo M.;
RT   "G12S and H50R variations are polymorphisms in the SDHD gene.";
RL   Genes Chromosomes Cancer 37:220-221(2003).
RN   [20]
RP   VARIANTS PLG1 LEU-81; CYS-114 AND VAL-148, AND VARIANT
RP   PHEOCHROMOCYTOMA TYR-92.
RX   PubMed=15328326; DOI=10.1001/jama.292.8.943;
RA   Neumann H.P.H., Pawlu C., Peczkowska M., Bausch B., McWhinney S.R.,
RA   Muresan M., Buchta M., Franke G., Klisch J., Bley T.A., Hoegerle S.,
RA   Boedeker C.C., Opocher G., Schipper J., Januszewicz A., Eng C.;
RT   "Distinct clinical features of paraganglioma syndromes associated with
RT   SDHB and SDHD gene mutations.";
RL   JAMA 292:943-951(2004).
RN   [21]
RP   ERRATUM.
RA   Neumann H.P.H., Pawlu C., Peczkowska M., Bausch B., McWhinney S.R.,
RA   Muresan M., Buchta M., Franke G., Klisch J., Bley T.A., Hoegerle S.,
RA   Boedeker C.C., Opocher G., Schipper J., Januszewicz A., Eng C.;
RL   JAMA 292:1686-1686(2004).
RN   [22]
RP   VARIANT SER-12.
RX   PubMed=15032977; DOI=10.1111/j..2004.00174.x;
RA   Leube B., Huber R., Goecke T.O., Sandmann W., Royer-Pokora B.;
RT   "SDHD mutation analysis in seven German patients with sporadic carotid
RT   body paraganglioma: one novel mutation, no Dutch founder mutation and
RT   further evidence that G12S is a polymorphism.";
RL   Clin. Genet. 65:61-63(2004).
RN   [23]
RP   INVOLVEMENT IN PARAGANGLIOMA AND GASTRIC STROMAL SARCOMA.
RX   PubMed=17804857; DOI=10.1056/NEJMc071191;
RA   McWhinney S.R., Pasini B., Stratakis C.A.;
RT   "Familial gastrointestinal stromal tumors and germ-line mutations.";
RL   N. Engl. J. Med. 357:1054-1056(2007).
RN   [24]
RP   VARIANTS SER-12; ARG-50 AND ASN-145, CHARACTERIZATION OF VARIANTS
RP   SER-12; ARG-50 AND ASN-145, AND INVOLVEMENT IN COWDEN-LIKE DISEASE.
RX   PubMed=18678321; DOI=10.1016/j.ajhg.2008.07.011;
RA   Ni Y., Zbuk K.M., Sadler T., Patocs A., Lobo G., Edelman E.,
RA   Platzer P., Orloff M.S., Waite K.A., Eng C.;
RT   "Germline mutations and variants in the succinate dehydrogenase genes
RT   in Cowden and Cowden-like syndromes.";
RL   Am. J. Hum. Genet. 83:261-268(2008).
RN   [25]
RP   VARIANT [LARGE SCALE ANALYSIS] SER-12.
RX   PubMed=18987736; DOI=10.1038/nature07485;
RA   Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K.,
RA   Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., Cook L.,
RA   Abbott R., Larson D.E., Koboldt D.C., Pohl C., Smith S., Hawkins A.,
RA   Abbott S., Locke D., Hillier L.W., Miner T., Fulton L., Magrini V.,
RA   Wylie T., Glasscock J., Conyers J., Sander N., Shi X., Osborne J.R.,
RA   Minx P., Gordon D., Chinwalla A., Zhao Y., Ries R.E., Payton J.E.,
RA   Westervelt P., Tomasson M.H., Watson M., Baty J., Ivanovich J.,
RA   Heath S., Shannon W.D., Nagarajan R., Walter M.J., Link D.C.,
RA   Graubert T.A., DiPersio J.F., Wilson R.K.;
RT   "DNA sequencing of a cytogenetically normal acute myeloid leukaemia
RT   genome.";
RL   Nature 456:66-72(2008).
CC   -!- FUNCTION: Membrane-anchoring subunit of succinate dehydrogenase
CC       (SDH) that is involved in complex II of the mitochondrial electron
CC       transport chain and is responsible for transferring electrons from
CC       succinate to ubiquinone (coenzyme Q) (By similarity).
CC   -!- PATHWAY: Carbohydrate metabolism; tricarboxylic acid cycle.
CC   -!- SUBUNIT: Component of complex II composed of four subunits: the
CC       flavoprotein (FP) SDHA, iron-sulfur protein (IP) SDHB, and a
CC       cytochrome b560 composed of SDHC and SDHD.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane; Multi-pass
CC       membrane protein.
CC   -!- DISEASE: Defects in SDHD are a cause of hereditary paragangliomas
CC       type 1 (PGL1) [MIM:168000]; also known as familial non-chromaffin
CC       paragangliomas type 1. Paragangliomas refer to rare and mostly
CC       benign tumors that arise from any component of the neuroendocrine
CC       system. PGL1 is a rare autosomal dominant disorder which is
CC       characterized by the development of mostly benign, highly
CC       vascular, slowly growing tumors in the head and neck. In the head
CC       and neck region, the carotid body is the largest of all
CC       paraganglia and is also the most common site of the tumors.
CC       Penetrance of PLG1 is incomplete when the disease is transmitted
CC       through fathers. No disease phenotype is transmitted maternally.
CC   -!- DISEASE: Defects in SDHD are a cause of pheochromocytoma
CC       [MIM:171300]. The pheochromocytomas are catecholamine-producing,
CC       chromaffin tumors that arise in the adrenal medulla in 90% of
CC       cases. In the remaining 10% of cases, they develop in extra-
CC       adrenal sympathetic ganglia and may be referred to as
CC       'paraganglioma'. Pheochromocytoma usually presents with
CC       hypertension. Approximately 10% of pheochromocytoma is hereditary.
CC       Although pheochromocytoma susceptibility may be associated with
CC       germline mutations in the tumor-suppressor genes VHL and NF1 and
CC       in the proto-oncogene RET, the genetic basis for most cases of
CC       non-syndromic familial pheochromocytoma is unknown.
CC   -!- DISEASE: Defects in SDHD are involved in intestinal carcinoid
CC       tumor [MIM:114900]. A carcinoid tumor is a yellow circumscribed
CC       tumor arising from enterochromaffin cells, in the small intestine.
CC   -!- DISEASE: Defects in SDHD are a cause of paraganglioma and gastric
CC       stromal sarcoma [MIM:606864]; also called Carney-Stratakis
CC       syndrome. Gastrointestinal stromal tumors may be sporadic or
CC       inherited in an autosomal dominant manner, alone or as a component
CC       of a syndrome associated with other tumors, such as in the context
CC       of neurofibromatosis type 1 (NF1). Patients have both
CC       gastrointestinal stromal tumors and paragangliomas. Susceptibility
CC       to the tumors was inherited in an apparently autosomal dominant
CC       manner, with incomplete penetrance.
CC   -!- DISEASE: Defects in SDHD are a cause of Cowden-like syndrome
CC       [MIM:612359]. Cowden-like syndrome is a cancer predisposition
CC       syndrome associated with elevated risk for tumors of the breast,
CC       thyroid, kidney and uterus.
CC   -!- SIMILARITY: Belongs to the CybS family.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/SDHDID390.html";
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/SDHD";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=SDHD entry;
CC       URL="http://en.wikipedia.org/wiki/SDHD";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB006202; BAA22054.1; -; mRNA.
DR   EMBL; AB026906; BAA81889.1; -; Genomic_DNA.
DR   EMBL; AK075360; BAG52120.1; -; mRNA.
DR   EMBL; BT007238; AAP35902.1; -; mRNA.
DR   EMBL; CR456932; CAG33213.1; -; mRNA.
DR   EMBL; AP002007; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471065; EAW67181.1; -; Genomic_DNA.
DR   EMBL; BC005263; AAH05263.1; -; mRNA.
DR   EMBL; BC009574; AAH09574.1; -; mRNA.
DR   EMBL; BC012603; AAH12603.1; -; mRNA.
DR   EMBL; BC015188; AAH15188.1; -; mRNA.
DR   EMBL; BC015992; AAH15992.1; -; mRNA.
DR   EMBL; BC022350; AAH22350.1; -; mRNA.
DR   EMBL; BC070307; AAH70307.1; -; mRNA.
DR   EMBL; BC071755; AAH71755.1; -; mRNA.
DR   EMBL; BC071756; AAH71756.1; -; mRNA.
DR   IPI; IPI00297325; -.
DR   RefSeq; NP_002993.1; -.
DR   UniGene; Hs.356270; -.
DR   SMR; O14521; 59-159.
DR   STRING; O14521; -.
DR   PRIDE; O14521; -.
DR   Ensembl; ENST00000375549; ENSP00000364699; ENSG00000204370; Homo sapiens.
DR   GeneID; 6392; -.
DR   KEGG; hsa:6392; -.
DR   UCSC; uc001pmz.1; human.
DR   CTD; 6392; -.
DR   GeneCards; GC11P111462; -.
DR   GeneCards; GC11P111463; -.
DR   H-InvDB; HIX0010122; -.
DR   H-InvDB; HIX0029526; -.
DR   H-InvDB; HIX0114505; -.
DR   HGNC; HGNC:10683; SDHD.
DR   MIM; 114900; phenotype.
DR   MIM; 168000; phenotype.
DR   MIM; 171300; phenotype.
DR   MIM; 602690; gene.
DR   MIM; 606864; phenotype.
DR   MIM; 612359; phenotype.
DR   Orphanet; 97286; Carney-Stratakis syndrome.
DR   Orphanet; 201; Cowden syndrome.
DR   Orphanet; 877; Endocrine tumor.
DR   Orphanet; 29072; Hereditary pheochromocytoma-paraganglioma syndrome.
DR   PharmGKB; PA35608; -.
DR   eggNOG; prNOG04089; -.
DR   HOGENOM; HBG714119; -.
DR   HOVERGEN; HBG003003; -.
DR   InParanoid; O14521; -.
DR   OMA; HWGLGQV; -.
DR   OrthoDB; EOG9R52N6; -.
DR   BioCyc; MetaCyc:ENSG00000150781-MONOMER; -.
DR   Reactome; REACT_1046; Pyruvate metabolism and TCA cycle.
DR   Reactome; REACT_1505; Integration of energy metabolism.
DR   Reactome; REACT_15380; Diabetes pathways.
DR   DrugBank; DB00139; Succinic acid.
DR   NextBio; 24838; -.
DR   ArrayExpress; O14521; -.
DR   Bgee; O14521; -.
DR   CleanEx; HS_SDHD; -.
DR   Genevestigator; O14521; -.
DR   GermOnline; ENSG00000204370; Homo sapiens.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005749; C:mitochondrial respiratory chain complex II; ISS:UniProtKB.
DR   GO; GO:0009055; F:electron carrier activity; TAS:UniProtKB.
DR   GO; GO:0020037; F:heme binding; ISS:UniProtKB.
DR   GO; GO:0000104; F:succinate dehydrogenase activity; IDA:UniProtKB.
DR   GO; GO:0048039; F:ubiquinone binding; ISS:UniProtKB.
DR   GO; GO:0022900; P:electron transport chain; IEA:UniProtKB-KW.
DR   GO; GO:0006810; P:transport; IEA:UniProtKB-KW.
DR   GO; GO:0006099; P:tricarboxylic acid cycle; IDA:UniProtKB.
DR   InterPro; IPR007992; Cyt_b_succ_DH_CybS.
DR   PANTHER; PTHR13337; CybS; 1.
DR   Pfam; PF05328; CybS; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Disease mutation; Electron transport; Heme; Iron;
KW   Membrane; Metal-binding; Mitochondrion; Mitochondrion inner membrane;
KW   Polymorphism; Transit peptide; Transmembrane; Transport;
KW   Tricarboxylic acid cycle.
FT   TRANSIT       1     56       Mitochondrion (Potential).
FT   CHAIN        57    159       Succinate dehydrogenase [ubiquinone]
FT                                cytochrome b small subunit,
FT                                mitochondrial.
FT                                /FTId=PRO_0000006487.
FT   TOPO_DOM     57     63       Mitochondrial matrix (By similarity).
FT   TRANSMEM     64     85       By similarity.
FT   TOPO_DOM     86     90       Mitochondrial intermembrane (By
FT                                similarity).
FT   TRANSMEM     91    111       By similarity.
FT   TOPO_DOM    112    120       Mitochondrial matrix (By similarity).
FT   TRANSMEM    121    142       By similarity.
FT   TOPO_DOM    143    159       Mitochondrial intermembrane (By
FT                                similarity).
FT   METAL       102    102       Iron (heme axial ligand); shared with
FT                                SDHC (By similarity).
FT   BINDING     114    114       Ubiquinone; shared with IP/SDHB (By
FT                                similarity).
FT   VARIANT      12     12       G -> S (polymorphism that may increase
FT                                susceptibility for developing
FT                                pheochromocytoma, paraganglioma,
FT                                intestinal carcinoid tumor and breast,
FT                                renal and uterus carcinoma; associated
FT                                with features of Cowden-like syndrome;
FT                                associated with increased manganese
FT                                superoxide dismutase expression;
FT                                associated with increased reactive oxygen
FT                                species; associated with 1.9-fold
FT                                increase in both AKT and MAPK expression;
FT                                dbSNP:rs34677591).
FT                                /FTId=VAR_017870.
FT   VARIANT      50     50       H -> R (polymorphism that may increase
FT                                susceptibility for developing
FT                                paraganglioma, breast and tyroid
FT                                carcinoma; may be involved in somatic
FT                                Merkel cell carcinoma; associated with
FT                                features of Cowden-like syndrome;
FT                                associated with increased manganese
FT                                superoxide dismutase expression;
FT                                associated with increased reactive oxygen
FT                                species; associated with a 2.0-fold
FT                                increase in AKT expression and a 1.7-fold
FT                                increase in MAPK expression;
FT                                dbSNP:rs11214077).
FT                                /FTId=VAR_017871.
FT   VARIANT      81     81       P -> L (in PGL1 and pheochromocytoma).
FT                                /FTId=VAR_010038.
FT   VARIANT      92     92       D -> Y (in PGL1 and pheochromocytoma).
FT                                /FTId=VAR_010039.
FT   VARIANT      93     93       Missing (in PGL1).
FT                                /FTId=VAR_018519.
FT   VARIANT     102    102       H -> L (in PGL1).
FT                                /FTId=VAR_010040.
FT   VARIANT     114    114       Y -> C (in PGL1).
FT                                /FTId=VAR_017872.
FT   VARIANT     139    139       L -> P (in PGL1).
FT                                /FTId=VAR_017873.
FT   VARIANT     145    145       H -> N (found in an individual with
FT                                features of Cowden-like syndrome;
FT                                associated with increased manganese
FT                                superoxide dismutase expression;
FT                                asociated with normal reactive oxygen
FT                                species; associated with no change in AKT
FT                                expression but a 1.2-fold increase of
FT                                MAPK expression).
FT                                /FTId=VAR_054384.
FT   VARIANT     148    148       G -> V (in PLG1).
FT                                /FTId=VAR_054385.
FT   CONFLICT     74     74       V -> F (in Ref. 8; AAH70307).
SQ   SEQUENCE   159 AA;  17043 MW;  6B1AA94831C8C3B6 CRC64;
     MAVLWRLSAV CGALGGRALL LRTPVVRPAH ISAFLQDRPI PEWCGVQHIH LSPSHHSGSK
     AASLHWTSER VVSVLLLGLL PAAYLNPCSA MDYSLAAALT LHGHWGLGQV VTDYVHGDAL
     QKAAKAGLLA LSALTFAGLC YFNYHDVGIC KAVAMLWKL
//
ID   FUS_NDVD                Reviewed;         553 AA.
AC   P35936;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   02-MAR-2010, entry version 71.
DE   RecName: Full=Fusion glycoprotein F0;
DE   Contains:
DE     RecName: Full=Fusion glycoprotein F2;
DE   Contains:
DE     RecName: Full=Fusion glycoprotein F1;
DE   Flags: Precursor;
GN   Name=F;
OS   Newcastle disease virus (strain D26/76) (NDV).
OC   Viruses; ssRNA negative-strand viruses; Mononegavirales;
OC   Paramyxoviridae; Paramyxovirinae; Avulavirus.
OX   NCBI_TaxID=11180;
OH   NCBI_TaxID=9031; Gallus gallus (Chicken).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=89204898; PubMed=2705298; DOI=10.1016/0042-6822(89)90152-9;
RA   Toyoda T., Sakaguchi T., Hirota H., Gotoh B., Kuma K., Miyata T.,
RA   Nagai Y.;
RT   "Newcastle disease virus evolution. II. Lack of gene recombination in
RT   generating virulent and avirulent strains.";
RL   Virology 169:273-282(1989).
RN   [2]
RP   X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF 32-499, GLYCOSYLATION AT
RP   ASN-85 AND ASN-447, AND DISULFIDE BONDS.
RX   MEDLINE=21340790; PubMed=11286892; DOI=10.1016/S0969-2126(01)00581-0;
RA   Chen L., Gorman J.J., McKimm-Breschkin J., Lawrence L.J.,
RA   Tulloch P.A., Smith B.J., Colman P.M., Lawrence M.C.;
RT   "The structure of the fusion glycoprotein of Newcastle disease virus
RT   suggests a novel paradigm for the molecular mechanism of membrane
RT   fusion.";
RL   Structure 9:255-266(2001).
CC   -!- FUNCTION: Class I viral fusion protein. Under the current model,
CC       the protein has at least 3 conformational states: pre-fusion
CC       native state, pre-hairpin intermediate state, and post-fusion
CC       hairpin state. During viral and target cell membrane fusion, the
CC       heptad repeat (HR) regions assume a trimer-of-hairpins structure,
CC       positioning the fusion peptide in close proximity to the C-
CC       terminal region of the ectodomain. The formation of this structure
CC       appears to drive apposition and subsequent fusion of viral and
CC       target cell membranes. Directs fusion of viral and cellular
CC       membranes leading to delivery of the nucleocapsid into the
CC       cytoplasm. This fusion is pH independent and occurs directly at
CC       the outer cell membrane. The trimer of F1-F2 (F protein) probably
CC       interacts with HN at the virion surface. Upon HN binding to its
CC       cellular receptor, the hydrophobic fusion peptide is unmasked and
CC       interacts with the cellular membrane, inducing the fusion between
CC       cell and virion membranes. Later in infection, F proteins
CC       expressed at the plasma membrane of infected cells could mediate
CC       fusion with adjacent cells to form syncytia, a cytopathic effect
CC       that could lead to tissue necrosis (By similarity).
CC   -!- SUBUNIT: Homotrimer of disulfide-linked F1-F2 (By similarity).
CC   -!- SUBCELLULAR LOCATION: Virion membrane; Single-pass type I membrane
CC       protein (By similarity). Host cell membrane; Single-pass membrane
CC       protein (By similarity).
CC   -!- PTM: The inactive precursor F0 is glycosylated and proteolytically
CC       cleaved into F1 and F2 to be functionally active. The cleavage is
CC       mediated by cellular proteases during the transport and maturation
CC       of the polypeptide (By similarity).
CC   -!- SIMILARITY: Belongs to the paramyxoviruses fusion glycoprotein
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M24692; AAA46643.1; -; Genomic_RNA.
DR   PIR; A46329; A46329.
DR   PDB; 1G5G; X-ray; 3.30 A; A/B/C/D/E/F=32-499.
DR   PDBsum; 1G5G; -.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0006948; P:induction by virus of host cell-cell fusion; IEA:InterPro.
DR   InterPro; IPR000776; Fusion_gly.
DR   Pfam; PF00523; Fusion_gly; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Coiled coil; Disulfide bond; Envelope protein;
KW   Fusion protein; Glycoprotein; Host cell membrane; Host membrane;
KW   Lipoprotein; Membrane; Palmitate; Signal; Transmembrane; Virion.
FT   SIGNAL        1     31       Potential.
FT   CHAIN        32    553       Fusion glycoprotein F0.
FT                                /FTId=PRO_0000039297.
FT   CHAIN        32    116       Fusion glycoprotein F2.
FT                                /FTId=PRO_0000039298.
FT   CHAIN       117    553       Fusion glycoprotein F1.
FT                                /FTId=PRO_0000039299.
FT   TOPO_DOM     32    500       Extracellular (By similarity).
FT   TRANSMEM    501    521       By similarity.
FT   TOPO_DOM    522    553       Cytoplasmic (By similarity).
FT   REGION      117    141       Fusion peptide (By similarity).
FT   COILED      142    170       Potential.
FT   COILED      466    491       Potential.
FT   SITE        116    117       Cleavage; by host (By similarity).
FT   LIPID       523    523       S-palmitoyl cysteine; by host
FT                                (Potential).
FT   CARBOHYD     85     85       N-linked (GlcNAc...); by host.
FT   CARBOHYD    191    191       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    366    366       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    447    447       N-linked (GlcNAc...); by host.
FT   CARBOHYD    471    471       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID     76    199       Interchain (between F2 and F1 chains).
FT   DISULFID    338    347
FT   DISULFID    362    370
FT   DISULFID    394    399
FT   DISULFID    401    424
FT   HELIX        36     38
FT   TURN         39     41
FT   STRAND       42     52
FT   STRAND       59     66
FT   HELIX        74    104
FT   HELIX       172    226
FT   HELIX       235    241
FT   TURN        242    244
FT   HELIX       246    253
FT   HELIX       257    259
FT   HELIX       260    266
FT   STRAND      269    271
FT   STRAND      273    277
FT   TURN        278    281
FT   STRAND      282    288
FT   STRAND      293    305
FT   STRAND      321    326
FT   STRAND      331    333
FT   HELIX       335    337
FT   STRAND      338    340
FT   STRAND      342    348
FT   HELIX       357    363
FT   STRAND      382    385
FT   STRAND      387    392
FT   TURN        394    396
FT   STRAND      402    404
FT   TURN        412    414
FT   TURN        421    423
FT   STRAND      441    444
SQ   SEQUENCE   553 AA;  58892 MW;  B90AA98D77CCC470 CRC64;
     MGSRSSTRIP VPLMLTVRIM LALSCVCPTS SLDGRPLAAA GIVVTGDKAV NIYTSSQTGS
     IIIKLLPNMP KDKEACAKAP LEAYNRTLTT LLTPLGDSIR RIQESVTTSG GGKQGRLIGA
     IIGGVALGVA TAAQITAASA LIQANQNAAN ILRLKESIAA TNEAVHEVTD GLSQLAVAVG
     KMQQFVNDQF NKTAQELDCI KITQQVGVEL NLYLTELTTV FGPQITSPAL TQLTIQALYN
     LAGGNMDYLL TKLGVGNNQL SSLIGSGLIT GNPILYDSQT QLLGIQVTLP SVGNLNNMRA
     TYLETLSVST TKGFASALVP KVVTQVGSVI EELDTSYCIE TDLDLYCTRI VTFPMSPGIY
     SCLSGNTSAC MYSKTEGALT TPYMTLKGSV IANCKMTTCR CADPPGIISQ NYGEAVSLID
     RQSCNILSLD GITLRLSGEF DATYQKNISI QDSQVIVTGN LDISTELGNV NNSISNALDK
     LEESNSKLDK VNVKLTSTSA LITYIFLTVI SLVCGILSLV LACYLMYKQK AQQKTLLWLG
     NNTLDQMRAT TKM
//
ID   FUS_PI3H4               Reviewed;         539 AA.
AC   P06828; Q86987;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1989, sequence version 2.
DT   02-MAR-2010, entry version 75.
DE   RecName: Full=Fusion glycoprotein F0;
DE   Contains:
DE     RecName: Full=Fusion glycoprotein F2;
DE   Contains:
DE     RecName: Full=Fusion glycoprotein F1;
DE   Flags: Precursor;
GN   Name=F;
OS   Human parainfluenza 3 virus (strain Wash/47885/57) (HPIV-3) (Human
OS   parainfluenza 3 virus (strain NIH 47885)).
OC   Viruses; ssRNA negative-strand viruses; Mononegavirales;
OC   Paramyxoviridae; Paramyxovirinae; Respirovirus.
OX   NCBI_TaxID=11217;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=86237106; PubMed=3012869; DOI=10.1016/0042-6822(86)90388-0;
RA   Spriggs M.K., Olmsted R.A., Venkatesan S., Coligan J.E., Collins P.L.;
RT   "Fusion glycoprotein of human parainfluenza virus type 3: nucleotide
RT   sequence of the gene, direct identification of the cleavage-activation
RT   site, and comparison with other paramyxoviruses.";
RL   Virology 152:241-251(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=87197191; PubMed=3033123;
RA   Cote M.J., Storey D.G., Kang C.Y., Dimock K.;
RT   "Nucleotide sequence of the coding and flanking regions of the human
RT   parainfluenza virus type 3 fusion glycoprotein gene.";
RL   J. Gen. Virol. 68:1003-1010(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=88072736; PubMed=2825443; DOI=10.1016/0168-1702(87)90016-5;
RA   Galinski M.S., Mink M.A., Pons M.W.;
RT   "Molecular cloning and sequence analysis of the human parainfluenza 3
RT   virus genes encoding the surface glycoproteins, F and HN.";
RL   Virus Res. 8:205-215(1987).
RN   [4]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=92160382; PubMed=1311137; DOI=10.1016/0168-1702(92)90089-R;
RA   Prinoski K., Cote M.J., Kang C.Y., Dimock K.;
RT   "Evolution of the fusion protein gene of human parainfluenza virus
RT   3.";
RL   Virus Res. 22:55-69(1992).
CC   -!- FUNCTION: Class I viral fusion protein. Under the current model,
CC       the protein has at least 3 conformational states: pre-fusion
CC       native state, pre-hairpin intermediate state, and post-fusion
CC       hairpin state. During viral and target cell membrane fusion, the
CC       heptad repeat (HR) regions assume a trimer-of-hairpins structure,
CC       positioning the fusion peptide in close proximity to the C-
CC       terminal region of the ectodomain. The formation of this structure
CC       appears to drive apposition and subsequent fusion of viral and
CC       target cell membranes. Directs fusion of viral and cellular
CC       membranes leading to delivery of the nucleocapsid into the
CC       cytoplasm. This fusion is pH independent and occurs directly at
CC       the outer cell membrane. The trimer of F1-F2 (F protein) probably
CC       interacts with HN at the virion surface. Upon HN binding to its
CC       cellular receptor, the hydrophobic fusion peptide is unmasked and
CC       interacts with the cellular membrane, inducing the fusion between
CC       cell and virion membranes. Later in infection, F proteins
CC       expressed at the plasma membrane of infected cells could mediate
CC       fusion with adjacent cells to form syncytia, a cytopathic effect
CC       that could lead to tissue necrosis (By similarity).
CC   -!- SUBUNIT: Homotrimer of disulfide-linked F1-F2 (By similarity).
CC   -!- SUBCELLULAR LOCATION: Virion membrane; Single-pass type I membrane
CC       protein (By similarity). Host cell membrane; Single-pass membrane
CC       protein (By similarity).
CC   -!- PTM: The inactive precursor F0 is glycosylated and proteolytically
CC       cleaved into F1 and F2 to be functionally active. The cleavage is
CC       mediated by cellular proteases during the transport and maturation
CC       of the polypeptide (By similarity).
CC   -!- SIMILARITY: Belongs to the paramyxoviruses fusion glycoprotein
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X05303; CAA28932.1; -; Genomic_RNA.
DR   EMBL; D00016; BAA00012.1; -; mRNA.
DR   EMBL; M21649; AAA46852.1; -; Genomic_RNA.
DR   EMBL; S82195; AAB21447.1; -; Genomic_RNA.
DR   PIR; A26764; VGNZH3.
DR   PIR; A47610; A47610.
DR   PDB; 1ZTM; X-ray; 3.05 A; A/B/C=19-493.
DR   PDBsum; 1ZTM; -.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0006948; P:induction by virus of host cell-cell fusion; IEA:InterPro.
DR   InterPro; IPR000776; Fusion_gly.
DR   Pfam; PF00523; Fusion_gly; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cleavage on pair of basic residues; Coiled coil;
KW   Disulfide bond; Envelope protein; Fusion protein; Glycoprotein;
KW   Host cell membrane; Host membrane; Membrane; Signal; Transmembrane;
KW   Virion.
FT   SIGNAL        1     18       Potential.
FT   CHAIN        19    539       Fusion glycoprotein F0.
FT                                /FTId=PRO_0000039345.
FT   CHAIN        19    109       Fusion glycoprotein F2.
FT                                /FTId=PRO_0000039346.
FT   CHAIN       110    539       Fusion glycoprotein F1.
FT                                /FTId=PRO_0000039347.
FT   TOPO_DOM     19    493       Extracellular (By similarity).
FT   TRANSMEM    494    514       By similarity.
FT   TOPO_DOM    515    539       Cytoplasmic (By similarity).
FT   REGION      110    134       Fusion peptide (By similarity).
FT   COILED      135    163       Potential.
FT   COILED      459    484       Potential.
FT   COMPBIAS    511    514       Poly-Ile.
FT   SITE        109    110       Cleavage; by host (By similarity).
FT   CARBOHYD    238    238       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    359    359       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    446    446       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID     63    192       Interchain (between F2 and F1 chains) (By
FT                                similarity).
FT   DISULFID    331    340       By similarity.
FT   DISULFID    355    363       By similarity.
FT   DISULFID    387    392       By similarity.
FT   DISULFID    394    417       By similarity.
FT   CONFLICT     35     35       P -> S (in Ref. 1; BAA00012).
FT   CONFLICT    277    277       T -> A (in Ref. 1; BAA00012).
FT   CONFLICT    295    295       R -> K (in Ref. 2 and 4).
FT   CONFLICT    328    328       V -> I (in Ref. 2; CAA28932).
FT   CONFLICT    369    369       K -> T (in Ref. 2 and 4).
FT   CONFLICT    450    450       A -> S (in Ref. 2; CAA28932).
FT   HELIX        26     28
FT   STRAND       30     32
FT   STRAND       36     54
FT   HELIX        65     93
FT   HELIX       144    181
FT   HELIX       183    214
FT   TURN        215    219
FT   HELIX       228    231
FT   TURN        232    234
FT   HELIX       239    242
FT   STRAND      244    246
FT   HELIX       250    259
FT   STRAND      263    270
FT   TURN        271    274
FT   STRAND      275    287
FT   STRAND      291    298
FT   STRAND      301    303
FT   STRAND      306    309
FT   STRAND      314    319
FT   STRAND      322    326
FT   STRAND      335    342
FT   HELIX       350    357
FT   HELIX       360    362
FT   STRAND      375    378
FT   STRAND      380    385
FT   TURN        387    389
FT   STRAND      392    396
FT   STRAND      410    413
FT   TURN        414    416
FT   STRAND      418    422
FT   STRAND      425    427
FT   STRAND      436    438
FT   HELIX       457    480
SQ   SEQUENCE   539 AA;  60060 MW;  E94F4BDB1E658BE5 CRC64;
     MPTSILLIIT TMIMASFCQI DITKLQHVGV LVNSPKGMKI SQNFETRYLI LSLIPKIEDS
     NSCGDQQIKQ YKRLLDRLII PLYDGLRLQK DVIVSNQESN ENTDPRTKRF FGGVIGTIAL
     GVATSAQITA AVALVEAKQA RSDIEKLKEA IRDTNKAVQS VQSSIGNLIV AIKSVQDYVN
     KEIVPSIARL GCEAAGLQLG IALTQHYSEL TNIFGDNIGS LQEKGIKLQG IASLYRTNIT
     EIFTTSTVDK YDIYDLLFTE SIKVRVIDVD LNDYSITLQV RLPLLTRLLN TQIYRVDSIS
     YNIQNREWYI PLPSHIMTKG AFLGGADVKE CIEAFSSYIC PSDPGFVLNH EMESCLSGNI
     SQCPRTVVKS DIVPRYAFVN GGVVANCITT TCTCNGIGNR INQPPDQGVK IITHKECNTI
     GINGMLFNTN KEGTLAFYTP NDITLNNSVA LDPIDISIEL NKAKSDLEES KEWIRRSNQK
     LDSIGNWHQS STTIIIVLIM IIILFIINVT IIIIAVKYYR IQKRNRVDQN DKPYVLTNK
//
ID   FUS_SENDF               Reviewed;         565 AA.
AC   P12575; Q88412;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1989, sequence version 1.
DT   02-MAR-2010, entry version 66.
DE   RecName: Full=Fusion glycoprotein F0;
DE            Short=Protein F;
DE   Contains:
DE     RecName: Full=Fusion glycoprotein F2;
DE   Contains:
DE     RecName: Full=Fusion glycoprotein F1;
DE   Flags: Precursor;
GN   Name=F;
OS   Sendai virus (strain Fushimi) (SeV).
OC   Viruses; ssRNA negative-strand viruses; Mononegavirales;
OC   Paramyxoviridae; Paramyxovirinae; Respirovirus.
OX   NCBI_TaxID=11195;
OH   NCBI_TaxID=10090; Mus musculus (Mouse).
OH   NCBI_TaxID=10116; Rattus norvegicus (Rat).
OH   NCBI_TaxID=10144; Cavia cutleri (Guinea pig).
OH   NCBI_TaxID=36483; Cricetidae sp. (Hamster).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=88061218; PubMed=2824671;
RA   Itoh M., Shibuta H., Homma M.;
RT   "Single amino acid substitution of Sendai virus at the cleavage site
RT   of the fusion protein confers trypsin resistance.";
RL   J. Gen. Virol. 68:2939-2944(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA], AND MUTAGENESIS OF
RP   106-THR--GLN-108; 106-THR--SER-115; 112-VAL--SER-115 AND
RP   114-GLN-SER-115.
RX   MEDLINE=95351040; PubMed=7625124; DOI=10.1016/0168-1702(94)00102-I;
RA   Heminaway B.R., Yang Y., Tanaka Y., Panin M., Huang Y.T.,
RA   Galinski M.S.;
RT   "Role of basic residues in the proteolytic activation of Sendai virus
RT   fusion glycoprotein.";
RL   Virus Res. 36:15-35(1995).
CC   -!- FUNCTION: Class I viral fusion protein. Under the current model,
CC       the protein has at least 3 conformational states: pre-fusion
CC       native state, pre-hairpin intermediate state, and post-fusion
CC       hairpin state. During viral and target cell membrane fusion, the
CC       heptad repeat (HR) regions assume a trimer-of-hairpins structure,
CC       positioning the fusion peptide in close proximity to the C-
CC       terminal region of the ectodomain. The formation of this structure
CC       appears to drive apposition and subsequent fusion of viral and
CC       target cell membranes. Directs fusion of viral and cellular
CC       membranes leading to delivery of the nucleocapsid into the
CC       cytoplasm. This fusion is pH independent and occurs directly at
CC       the outer cell membrane. The trimer of F1-F2 (F protein) interacts
CC       with HN tetramer at the virion surface. Upon HN binding to its
CC       cellular receptor, the hydrophobic fusion peptide is unmasked and
CC       interacts with the cellular membrane, inducing the fusion between
CC       cell and virion membranes. Later in infection, F proteins
CC       expressed at the plasma membrane of infected cells could mediate
CC       fusion with adjacent cells to form syncytia, a cytopathic effect
CC       that could lead to tissue necrosis (By similarity).
CC   -!- SUBUNIT: Homotrimer of disulfide-linked F1-F2. Interacts with HN
CC       and M proteins (By similarity).
CC   -!- SUBCELLULAR LOCATION: Virion membrane; Single-pass type I membrane
CC       protein (By similarity). Host cell membrane; Single-pass membrane
CC       protein (By similarity).
CC   -!- DOMAIN: The cytoplasmic region mediates the interaction with HN
CC       and M proteins (By similarity).
CC   -!- PTM: In natural infection, inactive F0 is matured into F1 and F2
CC       outside the cell by one or more trypsin-like, arginine-specific
CC       endoprotease secreted by the bronchial epithelial cells. One
CC       identified protease that may be involved in this process is
CC       tryptase Clara. Unlike most paramyxoviruses, Sendai F0 processing
CC       occurs on the cell surface and induces a conformational change in
CC       the protein that unmasks the fusion peptide. F0 maturation is a
CC       primary determinant for organ tropism and pathogenicity. F1 and F2
CC       display interchain and intrachain disulfide bonds, that are
CC       necessary for correct folding and intracellular transport (By
CC       similarity).
CC   -!- PTM: N-glycosylated; glycans consist of a mixture of high mannose-
CC       type oligosaccharides and of complex-type oligosaccharides.
CC       Glycosylation at Asn-245 is essential for membrane localization
CC       and F0 cleavage (By similarity).
CC   -!- MISCELLANEOUS: Sendai virus or recombinant F protein are widely
CC       used in cellular biology to fuse cells.
CC   -!- SIMILARITY: Belongs to the paramyxoviruses fusion glycoprotein
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D00152; BAA00107.1; -; Genomic_RNA.
DR   EMBL; U06432; AAC54271.1; -; Genomic_RNA.
DR   PIR; A30037; VGNZFS.
DR   SMR; P12575; 30-483.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0006948; P:induction by virus of host cell-cell fusion; IEA:InterPro.
DR   InterPro; IPR000776; Fusion_gly.
DR   Pfam; PF00523; Fusion_gly; 1.
PE   1: Evidence at protein level;
KW   Coiled coil; Complete proteome; Disulfide bond; Envelope protein;
KW   Fusion protein; Glycoprotein; Host cell membrane; Host membrane;
KW   Membrane; Signal; Transmembrane; Virion.
FT   SIGNAL        1     25       By similarity.
FT   CHAIN        26    565       Fusion glycoprotein F0 (By similarity).
FT                                /FTId=PRO_0000039366.
FT   CHAIN        26    116       Fusion glycoprotein F2 (By similarity).
FT                                /FTId=PRO_0000039367.
FT   CHAIN       117    565       Fusion glycoprotein F1 (By similarity).
FT                                /FTId=PRO_0000039368.
FT   TOPO_DOM     26    500       Extracellular (By similarity).
FT   TRANSMEM    501    521       By similarity.
FT   TOPO_DOM    522    565       Cytoplasmic (By similarity).
FT   DOMAIN      269    307       Leucine-zipper (Potential).
FT   REGION      117    141       Fusion peptide (By similarity).
FT   COILED      142    170       Potential.
FT   COILED      466    491       Potential.
FT   SITE        116    117       Cleavage; by arginine-specific
FT                                endoprotease (By similarity).
FT   CARBOHYD    104    104       N-linked (GlcNAc...); by host (By
FT                                similarity).
FT   CARBOHYD    245    245       N-linked (GlcNAc...); by host (By
FT                                similarity).
FT   CARBOHYD    449    449       N-linked (GlcNAc...); by host (By
FT                                similarity).
FT   DISULFID     70    199       Interchain (between F2 and F1 chains) (By
FT                                similarity).
FT   DISULFID    338    347       By similarity.
FT   DISULFID    362    370       By similarity.
FT   DISULFID    394    399       By similarity.
FT   DISULFID    401    424       By similarity.
FT   VARIANT     461    461       I -> V.
FT   MUTAGEN     106    115       TTQNAGVPQS->DEENAGRRRK: No effect.
FT   MUTAGEN     106    115       TTQNAGVPQS->DEENAGVPRK: Cleaved by
FT                                intracellular CV-1 protease. Displays
FT                                cell fusion activity.
FT   MUTAGEN     106    108       TTQ->DEE: Partially cleaved by
FT                                intracellular CV-1 protease. No cell
FT                                fusion activity.
FT   MUTAGEN     112    115       VPQS->RRRK: Cleaved by intracellular CV-1
FT                                protease. Displays cell fusion activity.
FT   MUTAGEN     114    115       QS->RK: Cleaved by intracellular CV-1
FT                                protease. Partial cell fusion activity.
SQ   SEQUENCE   565 AA;  61552 MW;  16491C66F8E38F84 CRC64;
     MTAYIQRSQC ISTSLLVVLT TLVSCQIPRD RLSNIGVIVD EGKSLKIAGS HESRYIVLSL
     VPGVDLENGC GTAQVIQYKS LLNRLLIPLR DALDLQEALI TVTNDTTQNA GVPQSRFFGA
     VIGTIALGVA TSAQITAGIA LAEAREAKRD IALIKESMTK THKSIELLQN AVGEQILALK
     TLQDFVNDEI KPAISELGCE TAALRLGIKL TQHYSGLLTA FGSNFGTIGE KSLTLQALSS
     LYSANITEIM TTIRTGQSNI YDVIYTEQIK GTVIDVDLER YMVTLSVKIP ILSEVPGVLI
     HKASSISYNI DGEEWYVTVP SHILSRASFL GGADITDCVE SRLTYICPRD PAQLIPDSQQ
     KCILGDTTRC PVTKVVDSLI PKFAFVNGGV VANCIASTCT CGTGRRPISQ DRSKGVVFLT
     HDNCGLIGVN GVELYANRRG HDATWGVQNL TVGPAIAIRP IDISLNLADA TNFLQDSKAE
     LEKARKILSE VGRWYNSRET VITIIVVMVV ILVVIIVIVI VLYRLKRSML MGNPDDRIPR
     DTYTLEPKIR HMYTNGGFDA MAEKR
//
ID   FUS_SV5                 Reviewed;         529 AA.
AC   P04849;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   13-AUG-1987, sequence version 1.
DT   02-MAR-2010, entry version 84.
DE   RecName: Full=Fusion glycoprotein F0;
DE   Contains:
DE     RecName: Full=Fusion glycoprotein F2;
DE   Contains:
DE     RecName: Full=Fusion glycoprotein F1;
DE   Flags: Precursor;
GN   Name=F;
OS   Simian virus 5 (strain W3) (SV5).
OC   Viruses; ssRNA negative-strand viruses; Mononegavirales;
OC   Paramyxoviridae; Paramyxovirinae; Rubulavirus.
OX   NCBI_TaxID=11208;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
OH   NCBI_TaxID=9615; Canis familiaris (Dog).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=85038582; PubMed=6093114; DOI=10.1073/pnas.81.21.6706;
RA   Paterson R.G., Harris T.J.R., Lamb R.A.;
RT   "Fusion protein of the paramyxovirus simian virus 5: nucleotide
RT   sequence of mRNA predicts a highly hydrophobic glycoprotein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:6706-6710(1984).
RN   [2]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 122-185 AND 440-477.
RX   MEDLINE=99214846; PubMed=10198633; DOI=10.1016/S1097-2765(00)80458-X;
RA   Baker K.A., Dutch R.E., Lamb R.A., Jardetzky T.S.;
RT   "Structural basis for paramyxovirus-mediated membrane fusion.";
RL   Mol. Cell 3:309-319(1999).
CC   -!- FUNCTION: Class I viral fusion protein. Under the current model,
CC       the protein has at least 3 conformational states: pre-fusion
CC       native state, pre-hairpin intermediate state, and post-fusion
CC       hairpin state. During viral and target cell membrane fusion, the
CC       heptad repeat (HR) regions assume a trimer-of-hairpins structure,
CC       positioning the fusion peptide in close proximity to the C-
CC       terminal region of the ectodomain. The formation of this structure
CC       appears to drive apposition and subsequent fusion of viral and
CC       target cell membranes. Directs fusion of viral and cellular
CC       membranes leading to delivery of the nucleocapsid into the
CC       cytoplasm. This fusion is pH independent and occurs directly at
CC       the outer cell membrane. The trimer of F1-F2 (F protein) probably
CC       interacts with HN at the virion surface. Upon HN binding to its
CC       cellular receptor, the hydrophobic fusion peptide is unmasked and
CC       interacts with the cellular membrane, inducing the fusion between
CC       cell and virion membranes. Later in infection, F proteins
CC       expressed at the plasma membrane of infected cells could mediate
CC       fusion with adjacent cells to form syncytia, a cytopathic effect
CC       that could lead to tissue necrosis (By similarity).
CC   -!- SUBUNIT: Homotrimer of disulfide-linked F1-F2.
CC   -!- SUBCELLULAR LOCATION: Virion membrane; Single-pass type I membrane
CC       protein (By similarity). Host cell membrane; Single-pass membrane
CC       protein (By similarity).
CC   -!- PTM: The inactive precursor F0 is glycosylated and proteolytically
CC       cleaved into F1 and F2 to be functionally active. The cleavage is
CC       mediated by cellular proteases during the transport and maturation
CC       of the polypeptide.
CC   -!- SIMILARITY: Belongs to the paramyxoviruses fusion glycoprotein
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; K02253; AAA47881.1; -; Genomic_RNA.
DR   EMBL; AF052755; AAC95515.1; -; Genomic_RNA.
DR   PIR; A21688; VGNZSP.
DR   RefSeq; YP_138515.1; -.
DR   PDB; 1SVF; X-ray; 1.40 A; A/C=122-184, B/D=440-477.
DR   PDB; 2B9B; X-ray; 2.85 A; A/B/C=20-475.
DR   PDBsum; 1SVF; -.
DR   PDBsum; 2B9B; -.
DR   GeneID; 3160801; -.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0006948; P:induction by virus of host cell-cell fusion; IEA:InterPro.
DR   InterPro; IPR000776; Fusion_gly.
DR   Pfam; PF00523; Fusion_gly; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cleavage on pair of basic residues; Coiled coil;
KW   Complete proteome; Disulfide bond; Envelope protein; Fusion protein;
KW   Glycoprotein; Host cell membrane; Host membrane; Membrane; Signal;
KW   Transmembrane; Virion.
FT   SIGNAL        1     19       Potential.
FT   CHAIN        20    529       Fusion glycoprotein F0.
FT                                /FTId=PRO_0000039378.
FT   CHAIN        20    102       Fusion glycoprotein F2.
FT                                /FTId=PRO_0000039379.
FT   CHAIN       103    529       Fusion glycoprotein F1.
FT                                /FTId=PRO_0000039380.
FT   TOPO_DOM     20    487       Extracellular (By similarity).
FT   TRANSMEM    488    508       By similarity.
FT   TOPO_DOM    509    529       Cytoplasmic (By similarity).
FT   REGION      103    127       Fusion peptide.
FT   COILED      128    156       Potential.
FT   COILED      452    477       Potential.
FT   COMPBIAS     98    102       Poly-Arg.
FT   SITE        102    103       Cleavage; by host (By similarity).
FT   CARBOHYD     65     65       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD     73     73       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    352    352       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    427    427       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    431    431       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    457    457       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID     64    185       Interchain (between F2 and F1 chains) (By
FT                                similarity).
FT   DISULFID    324    333       By similarity.
FT   DISULFID    348    356       By similarity.
FT   DISULFID    380    385       By similarity.
FT   DISULFID    387    410       By similarity.
FT   HELIX        23     26
FT   TURN         27     29
FT   STRAND       30     52
FT   HELIX        67     94
FT   HELIX       110    113
FT   STRAND      114    117
FT   HELIX       118    129
FT   HELIX       176    182
FT   HELIX       185    204
FT   HELIX       214    216
FT   HELIX       221    228
FT   HELIX       229    231
FT   HELIX       232    239
FT   STRAND      242    244
FT   HELIX       246    251
FT   STRAND      256    263
FT   TURN        264    267
FT   STRAND      268    291
FT   STRAND      294    296
FT   STRAND      299    303
FT   STRAND      307    312
FT   STRAND      315    318
FT   STRAND      324    326
FT   STRAND      328    332
FT   HELIX       343    349
FT   HELIX       353    355
FT   STRAND      358    360
FT   HELIX       365    367
FT   STRAND      368    372
FT   STRAND      375    378
FT   TURN        380    382
FT   STRAND      385    390
FT   STRAND      401    405
FT   TURN        407    409
FT   STRAND      411    415
FT   STRAND      418    421
FT   HELIX       438    440
FT   HELIX       450    475
SQ   SEQUENCE   529 AA;  56597 MW;  3152C37B1AEA2C7E CRC64;
     MGTIIQFLVV SCLLAGAGSL DPAALMQIGV IPTNVRQLMY YTEASSAFIV VKLMPTIDSP
     ISGCNITSIS SYNATVTKLL QPIGENLETI RNQLIPTRRR RRFAGVVIGL AALGVATAAQ
     VTAAVALVKA NENAAAILNL KNAIQKTNAA VADVVQATQS LGTAVQAVQD HINSVVSPAI
     TAANCKAQDA IIGSILNLYL TELTTIFHNQ ITNPALSPIT IQALRILLGS TLPTVVEKSF
     NTQISAAELL SSGLLTGQIV GLDLTYMQMV IKIELPTLTV QPATQIIDLA TISAFINNQE
     VMAQLPTRVM VTGSLIQAYP ASQCTITPNT VYCRYNDAQV LSDDTMACLQ GNLTRCTFSP
     VVGSFLTRFV LFDGIVYANC RSMLCKCMQP AAVILQPSSS PVTVIDMYKC VSLQLDNLRF
     TITQLANVTY NSTIKLESSQ ILSIDPLDIS QNLAAVNKSL SDALQHLAQS DTYLSAITSA
     TTTSVLSIIA ICLGSLGLIL IILLSVVVWK LLTIVVANRN RMENFVYHK
//
ID   GGT2_HUMAN              Reviewed;         569 AA.
AC   P36268;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   20-MAY-2008, sequence version 3.
DT   02-MAR-2010, entry version 79.
DE   RecName: Full=Gamma-glutamyltranspeptidase 2;
DE            Short=GGT 2;
DE            EC=2.3.2.2;
DE   AltName: Full=Gamma-glutamyltransferase 2;
DE   Contains:
DE     RecName: Full=Gamma-glutamyltranspeptidase 2 heavy chain;
DE   Contains:
DE     RecName: Full=Gamma-glutamyltranspeptidase 2 light chain;
DE   Flags: Precursor;
GN   Name=GGT2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   MEDLINE=20057165; PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 362-569 (ISOFORM 2).
RX   MEDLINE=90056497; PubMed=2573352; DOI=10.1016/0006-291X(89)91545-3;
RA   Pawlak A., Wu S.-J., Bulle F., Suzuki A., Chikhi N., Ferry N.,
RA   Baik J.-H., Siegrist S., Guellaen G.;
RT   "Different gamma-glutamyl transpeptidase mRNAs are expressed in human
RT   liver and kidney.";
RL   Biochem. Biophys. Res. Commun. 164:912-918(1989).
RN   [3]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-511, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
CC   -!- FUNCTION: Initiates extracellular glutathione (GSH) breakdown;
CC       catalyzes the transfer of the glutamyl moiety of glutathione to
CC       amino acids and dipeptide acceptors (By similarity).
CC   -!- CATALYTIC ACTIVITY: (5-L-glutamyl)-peptide + an amino acid =
CC       peptide + 5-L-glutamyl amino acid.
CC   -!- PATHWAY: Sulfur metabolism; glutathione metabolism.
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type II membrane
CC       protein (By similarity).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P36268-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P36268-2; Sequence=VSP_033757;
CC   -!- TISSUE SPECIFICITY: Highly expressed in fetal and adult kidney and
CC       liver.
CC   -!- MISCELLANEOUS: Corresponds to the light chain of other gamma-
CC       glutamyltransferase family members.
CC   -!- SIMILARITY: Belongs to the gamma-glutamyltransferase family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AP000550; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BG743316; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AA632626; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; M30479; AAA52765.1; -; Genomic_DNA.
DR   EMBL; M30475; AAA52765.1; JOINED; Genomic_DNA.
DR   EMBL; M30476; AAA52765.1; JOINED; Genomic_DNA.
DR   EMBL; M30477; AAA52765.1; JOINED; Genomic_DNA.
DR   EMBL; M30478; AAA52765.1; JOINED; Genomic_DNA.
DR   EMBL; M30474; AAA52548.1; -; mRNA.
DR   IPI; IPI00879415; -.
DR   IPI; IPI00894564; -.
DR   PIR; A36742; A36742.
DR   UniGene; Hs.568255; -.
DR   SMR; P36268; 37-569.
DR   STRING; P36268; -.
DR   MEROPS; T03.015; -.
DR   Ensembl; ENST00000401924; ENSP00000385721; ENSG00000133475; Homo sapiens.
DR   Ensembl; ENST00000402582; ENSP00000384349; ENSG00000133475; Homo sapiens.
DR   Ensembl; ENST00000424627; ENSP00000402035; ENSG00000133475; Homo sapiens.
DR   GeneCards; GC22M019886; -.
DR   H-InvDB; HIX0037636; -.
DR   H-InvDB; HIX0041197; -.
DR   HGNC; HGNC:4251; GGT2.
DR   MIM; 137181; gene.
DR   PharmGKB; PA28663; -.
DR   HOGENOM; HBG738311; -.
DR   HOVERGEN; HBG005835; -.
DR   InParanoid; P36268; -.
DR   Bgee; P36268; -.
DR   CleanEx; HS_GGT2; -.
DR   Genevestigator; P36268; -.
DR   GermOnline; ENSG00000133475; Homo sapiens.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0008415; F:acyltransferase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003840; F:gamma-glutamyltransferase activity; NAS:UniProtKB.
DR   GO; GO:0006750; P:glutathione biosynthetic process; NAS:UniProtKB.
DR   InterPro; IPR000101; GGT_peptidase.
DR   PANTHER; PTHR11686; GGT_peptidase; 1.
DR   Pfam; PF01019; G_glu_transpept; 1.
DR   PRINTS; PR01210; GGTRANSPTASE.
DR   PROSITE; PS00462; G_GLU_TRANSPEPTIDASE; 1.
PE   1: Evidence at protein level;
KW   Acyltransferase; Alternative splicing; Complete proteome;
KW   Glutathione biosynthesis; Glycoprotein; Membrane; Signal-anchor;
KW   Transferase; Transmembrane; Zymogen.
FT   CHAIN         1    380       Gamma-glutamyltranspeptidase 2 heavy
FT                                chain (By similarity).
FT                                /FTId=PRO_0000205981.
FT   CHAIN       381    569       Gamma-glutamyltranspeptidase 2 light
FT                                chain (By similarity).
FT                                /FTId=PRO_0000334692.
FT   TOPO_DOM      1      4       Cytoplasmic (Potential).
FT   TRANSMEM      5     26       Signal-anchor for type II membrane
FT                                protein (By similarity).
FT   TOPO_DOM     27    569       Extracellular (Potential).
FT   CARBOHYD    230    230       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    511    511       N-linked (GlcNAc...).
FT   VAR_SEQ     404    413       Missing (in isoform 2).
FT                                /FTId=VSP_033757.
SQ   SEQUENCE   569 AA;  61771 MW;  96458403C83B9FFF CRC64;
     MKKKLVVLGL LAVVLVLVIV GLCLWLPSAS KEPDNHVYTR AAMAADAKQC LEIGRDTLRD
     GGSAVDAAIA ALLCVGLMNA HSMGIGVGLF LTIYNSTTGK AEVINAREVA PRLAFASMFN
     SSEQSQKGGL SVAVPGEIRG YELAHQRHGR LPWARLFQPS IQLARQGFPV GKGLAAVLEN
     KRTVIEQQPV LWYVFCRDRK VLREGERLTL PRLADTYEML AIEGAQAFYN GSLMAQIVKD
     IQAAGGIVTA EDLNNYRAEL IEHPLNISLG DAVLYMPSAR LSGPVLALIL NILKGYNFSR
     ESVETPEQKG LTYHRIVEAF RFAYAKRTLL GDPKFVDVTE VVRNMTSEFF AAQLRSQISD
     HTTHPISYYK PEFYTPDDGG TAHLSVVAED GSAVSATSTI NLYFGSKVCS PVSGILFNNE
     WTTSALPAFT NEFGAPPSPA NFIQPGKQPL LSMCLTIMVG QDGQVRMVVG AAGGTQITTD
     TALAIIYNLW FGYDVKRAVE EPRLHNKLLP NVTTVERNID QAVTAALETR HHHTQIASTF
     IAVVQAIVRT AGGWAAALDS RKGGEPAGY
//
ID   HCAT_ECOLI              Reviewed;         379 AA.
AC   Q47142; O05660; P77638;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 2.
DT   02-MAR-2010, entry version 83.
DE   RecName: Full=Probable 3-phenylpropionic acid transporter;
GN   Name=hcaT; Synonyms=yfhS; OrderedLocusNames=b2536, JW2520;
OS   Escherichia coli (strain K12).
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC   Enterobacteriaceae; Escherichia.
OX   NCBI_TaxID=83333;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=K12;
RA   Turlin E., Gasser F., Biville F.;
RL   Submitted (SEP-1994) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND CHARACTERIZATION.
RC   STRAIN=K12 / MC1061 / ATCC 53338 / DSM 7140;
RX   MEDLINE=98269008; PubMed=9603882;
RA   Diaz E., Ferrandez A., Garcia J.L.;
RT   "Characterization of the hca cluster encoding the dioxygenolytic
RT   pathway for initial catabolism of 3-phenylpropionic acid in
RT   Escherichia coli K-12.";
RL   J. Bacteriol. 180:2915-2923(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   MEDLINE=97349980; PubMed=9205837; DOI=10.1093/dnares/4.2.91;
RA   Yamamoto Y., Aiba H., Baba T., Hayashi K., Inada T., Isono K.,
RA   Itoh T., Kimura S., Kitagawa M., Makino K., Miki T., Mitsuhashi N.,
RA   Mizobuchi K., Mori H., Nakade S., Nakamura Y., Nashimoto H.,
RA   Oshima T., Oyama S., Saito N., Sampei G., Satoh Y., Sivasundaram S.,
RA   Tagami H., Takahashi H., Takeda J., Takemoto K., Uehara K., Wada C.,
RA   Yamagata S., Horiuchi T.;
RT   "Construction of a contiguous 874-kb sequence of the Escherichia coli-
RT   K12 genome corresponding to 50.0-68.8 min on the linkage map and
RT   analysis of its sequence features.";
RL   DNA Res. 4:91-113(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   MEDLINE=97426617; PubMed=9278503; DOI=10.1126/science.277.5331.1453;
RA   Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,
RA   Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F.,
RA   Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J.,
RA   Mau B., Shao Y.;
RT   "The complete genome sequence of Escherichia coli K-12.";
RL   Science 277:1453-1474(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=16738553; DOI=10.1038/msb4100049;
RA   Hayashi K., Morooka N., Yamamoto Y., Fujita K., Isono K., Choi S.,
RA   Ohtsubo E., Baba T., Wanner B.L., Mori H., Horiuchi T.;
RT   "Highly accurate genome sequences of Escherichia coli K-12 strains
RT   MG1655 and W3110.";
RL   Mol. Syst. Biol. 2:E1-E5(2006).
CC   -!- FUNCTION: Probable permease involved in the uptake of 3-
CC       phenylpropionic acid.
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane; Multi-pass membrane
CC       protein (Potential).
CC   -!- SIMILARITY: Belongs to the lacY/rafB permease family. HcaT
CC       subfamily.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA86021.1; Type=Frameshift; Positions=208;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z37966; CAA86021.1; ALT_FRAME; Genomic_DNA.
DR   EMBL; Y11071; CAA71954.1; -; Genomic_DNA.
DR   EMBL; U00096; AAC75589.1; -; Genomic_DNA.
DR   EMBL; AP009048; BAA16431.1; -; Genomic_DNA.
DR   PIR; G65030; G65030.
DR   PIR; S49295; S49295.
DR   RefSeq; AP_003122.1; -.
DR   RefSeq; NP_417031.1; -.
DR   SMR; Q47142; 6-367.
DR   STRING; Q47142; -.
DR   TCDB; 2.A.1.27.1; major facilitator superfamily (MFS).
DR   GeneID; 947007; -.
DR   GenomeReviews; AP009048_GR; JW2520.
DR   GenomeReviews; U00096_GR; b2536.
DR   KEGG; ecj:JW2520; -.
DR   KEGG; eco:b2536; -.
DR   EchoBASE; EB3227; -.
DR   EcoGene; EG13454; hcaT.
DR   eggNOG; COG0477; -.
DR   HOGENOM; HBG551193; -.
DR   OMA; HGVTFAM; -.
DR   ProtClustDB; PRK11128; -.
DR   BioCyc; EcoCyc:HCAT-MONOMER; -.
DR   BioCyc; ECOL168927:B2536-MONOMER; -.
DR   Genevestigator; Q47142; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0015293; F:symporter activity; IEA:UniProtKB-KW.
DR   GO; GO:0006810; P:transport; IEA:UniProtKB-KW.
DR   InterPro; IPR020480; LacY_proton/sugar_symporter.
DR   InterPro; IPR016196; MFS_general_subst_transpt.
DR   InterPro; IPR005276; Phenylproprionate_perm.
DR   PRINTS; PR00174; LACYSMPORT.
DR   SUPFAM; SSF103473; MFS_gen_substrate_transporter; 1.
DR   TIGRFAMs; TIGR00902; 2A0127; 1.
PE   1: Evidence at protein level;
KW   Cell inner membrane; Cell membrane; Complete proteome; Membrane;
KW   Symport; Transmembrane; Transport.
FT   CHAIN         1    379       Probable 3-phenylpropionic acid
FT                                transporter.
FT                                /FTId=PRO_0000196189.
FT   TOPO_DOM      1      4       Cytoplasmic (By similarity).
FT   TRANSMEM      5     31       1 (By similarity).
FT   TOPO_DOM     32     37       Periplasmic (By similarity).
FT   TRANSMEM     38     66       2 (By similarity).
FT   TOPO_DOM     67     70       Cytoplasmic (By similarity).
FT   TRANSMEM     71     96       3 (By similarity).
FT   TOPO_DOM     97    100       Periplasmic (By similarity).
FT   TRANSMEM    101    118       4 (By similarity).
FT   TOPO_DOM    119    129       Cytoplasmic (By similarity).
FT   TRANSMEM    130    152       5 (By similarity).
FT   TOPO_DOM    153    155       Periplasmic (By similarity).
FT   TRANSMEM    156    175       6 (By similarity).
FT   TOPO_DOM    176    207       Cytoplasmic (By similarity).
FT   TRANSMEM    208    227       7 (By similarity).
FT   TOPO_DOM    228    231       Periplasmic (By similarity).
FT   TRANSMEM    232    256       8 (By similarity).
FT   TOPO_DOM    257    266       Cytoplasmic (By similarity).
FT   TRANSMEM    267    286       9 (By similarity).
FT   TOPO_DOM    287    289       Periplasmic (By similarity).
FT   TRANSMEM    290    312       10 (By similarity).
FT   TOPO_DOM    313    323       Cytoplasmic (By similarity).
FT   TRANSMEM    324    351       11 (By similarity).
FT   TOPO_DOM    352    354       Periplasmic (By similarity).
FT   TRANSMEM    355    375       12 (By similarity).
FT   TOPO_DOM    376    379       Cytoplasmic (By similarity).
FT   CONFLICT    191    191       S -> N (in Ref. 2; CAA71954).
SQ   SEQUENCE   379 AA;  41593 MW;  76429AD807623482 CRC64;
     MVLQSTRWLA LGYFTYFFSY GIFLPFWSVW LKGIGLTPET IGLLLGAGLV ARFLGSLLIA
     PRVSDPSRLI SALRVLALLT LLFAVAFWAG AHVAWLMLVM IGFNLFFSPL VPLTDALANT
     WQKQFPLDYG KVRLWGSVAF VIGSALTGKL VTMFDYRVIL ALLTLGVASM LLGFLIRPTI
     QPQGASRQQE STGWSAWLAL VRQNWRFLAC VCLLQGAHAA YYGFSAIYWQ AAGYSASAVG
     YLWSLGVVAE VIIFALSNKL FRRCSARDML LISAICGVVR WGIMGATTAL PWLIVVQILH
     CGTFTVCHLA AMRYIAARQG SEVIRLQAVY SAVAMGGSIA IMTVFAGFLY QYLGHGVFWV
     MALVALPAMF LRPKVVPSC
//
ID   HN_SENDF                Reviewed;         575 AA.
AC   P19758; Q88413;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1991, sequence version 1.
DT   02-MAR-2010, entry version 72.
DE   RecName: Full=Hemagglutinin-neuraminidase;
DE            Short=HN protein;
DE            EC=3.2.1.18;
GN   Name=HN;
OS   Sendai virus (strain Fushimi) (SeV).
OC   Viruses; ssRNA negative-strand viruses; Mononegavirales;
OC   Paramyxoviridae; Paramyxovirinae; Respirovirus.
OX   NCBI_TaxID=11195;
OH   NCBI_TaxID=10090; Mus musculus (Mouse).
OH   NCBI_TaxID=10116; Rattus norvegicus (Rat).
OH   NCBI_TaxID=10144; Cavia cutleri (Guinea pig).
OH   NCBI_TaxID=36483; Cricetidae sp. (Hamster).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=91057133; PubMed=2173829; DOI=10.1093/nar/18.21.6427;
RA   Neubert W.J., Willenbrink W.;
RT   "Cloning and sequencing of the HN gene of Sendai virus (strain
RT   Fushimi).";
RL   Nucleic Acids Res. 18:6427-6427(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=95351040; PubMed=7625124; DOI=10.1016/0168-1702(94)00102-I;
RA   Heminaway B.R., Yang Y., Tanaka Y., Panin M., Huang Y.T.,
RA   Galinski M.S.;
RT   "Role of basic residues in the proteolytic activation of Sendai virus
RT   fusion glycoprotein.";
RL   Virus Res. 36:15-35(1995).
RN   [3]
RP   INTERACTION WITH CHAPERONES.
RX   MEDLINE=20047063; PubMed=10578061;
RA   Tomita Y., Yamashita T., Sato H., Taira H.;
RT   "Kinetics of interactions of sendai virus envelope glycoproteins, F
RT   and HN, with endoplasmic reticulum-resident molecular chaperones, BiP,
RT   calnexin, and calreticulin.";
RL   J. Biochem. 126:1090-1100(1999).
CC   -!- FUNCTION: Attaches the virus to sialic acid-containing cell
CC       receptors and thereby initiating infection. Binding of HN protein
CC       to the receptor induces a conformational change that allows the F
CC       protein to trigger virion/cell membranes fusion (By similarity).
CC   -!- FUNCTION: Neuraminidase activity ensures the efficient spread of
CC       the virus by dissociating the mature virions from the neuraminic
CC       acid containing glycoproteins (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of alpha-(2->3)-, alpha-(2->6)-,
CC       alpha-(2->8)- glycosidic linkages of terminal sialic acid residues
CC       in oligosaccharides, glycoproteins, glycolipids, colominic acid
CC       and synthetic substrates.
CC   -!- SUBUNIT: Homotetramer; composed of disulfide-linked homodimers.
CC       Interacts with F protein trimer (By similarity).
CC   -!- SUBCELLULAR LOCATION: Virion membrane; Single-pass type II
CC       membrane protein (Potential). Host cell membrane; Single-pass type
CC       II membrane protein (Potential).
CC   -!- PTM: N-glycosylated; glycans consist of a mixture of high mannose-
CC       type oligosaccharides and of complex-type oligosaccharides (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the paramyxoviruses hemagglutinin-
CC       neuraminidase family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X56131; CAA39596.1; -; Genomic_RNA.
DR   EMBL; U06433; AAC54272.1; -; Genomic_RNA.
DR   PIR; S12135; S12135.
DR   SMR; P19758; 144-572.
DR   CAZy; GH83; Glycoside Hydrolase Family 83.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004308; F:exo-alpha-sialidase activity; IEA:EC.
DR   GO; GO:0046789; F:host cell surface receptor binding; IEA:InterPro.
DR   GO; GO:0019058; P:viral infectious cycle; IEA:InterPro.
DR   InterPro; IPR000665; Hemagglutn-neuramid_glycoprot.
DR   InterPro; IPR016285; Hemagglutn-neuramid_paramyxo.
DR   InterPro; IPR011040; Neuraminidase.
DR   Pfam; PF00423; HN; 1.
DR   PIRSF; PIRSF001072; Hemagglut-neuramid_paramyxoV; 1.
DR   SUPFAM; SSF50939; Sialidase; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Disulfide bond; Envelope protein; Glycoprotein;
KW   Hemagglutinin; Host cell membrane; Host membrane; Hydrolase; Membrane;
KW   Signal-anchor; Transmembrane; Virion.
FT   CHAIN         1    575       Hemagglutinin-neuraminidase.
FT                                /FTId=PRO_0000142637.
FT   TOPO_DOM      1     37       Cytoplasmic (By similarity).
FT   TRANSMEM     38     58       By similarity.
FT   TOPO_DOM     59    575       Extracellular (By similarity).
FT   REGION       10     14       Incorporation in virion (By similarity).
FT   REGION       59    140       Involved in interaction with F protein
FT                                (By similarity).
FT   CARBOHYD     77     77       N-linked (GlcNAc...); by host (By
FT                                similarity).
FT   CARBOHYD    499    499       N-linked (GlcNAc...); by host (By
FT                                similarity).
FT   CARBOHYD    511    511       N-linked (GlcNAc...); by host (By
FT                                similarity).
FT   DISULFID    129    129       Interchain (Potential).
FT   VARIANT      86     86       S -> T.
FT   VARIANT     525    525       Q -> K.
SQ   SEQUENCE   575 AA;  63348 MW;  93FD0532F6147BF6 CRC64;
     MDGDRGKRDS YWSTSPSGST TKLASGWERS SKVDTWLLIL SFTQWALSIA TVIICIIISA
     RQGYSMKEYS MTVEALNMSS REVKESLTSL IRQEVIARAV NIQSSVQTGI PVLLNKNSRD
     VIQMIDKSCS RQELTQLCES TIAVHHAEGI APLEPHSFWR CPVGEPYLSS DPKISLLPGP
     SLLSGSTTIS GCVRLPSLSI GEAIYAYSSN LITQGCADIG KSYQVLQLGY ISLNSDMFPD
     LNPVVSHTYD INDNRKSCSV VATGTRGYQL CSMPTVDERT DYSSDGIEDL VLDVLDLKGS
     TKSHRYRNSE VDLDHPFSAL YPSVGNGIAT EGSLIFLGYG GLTTPLQGDT KCRTQGCQQV
     SQDTCNEALK ITWLGGKQVV SVIIQVNDYL SERPKIRVTT IPITQNYLGA EGRLLKLGDR
     VYIYTRSSGW HSQLQIGVLD VSHPLTINWT PHEALSRPGN EECNWYNTCP KECISGVYTD
     AYPLSPDAAN VATVTLYANT SRVNPTIMYS NTTNIINMLR IKDVQLEAAY TTTSCITHFG
     KGYCFHIIEI NQKSLNTLQP MLFKTSIPKL CKAES
//
ID   HVCN1_HUMAN             Reviewed;         273 AA.
AC   Q96D96; A8MQ37; Q6UW11; Q96IS5;
DT   01-JUL-2008, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   02-MAR-2010, entry version 63.
DE   RecName: Full=Voltage-gated hydrogen channel 1;
DE   AltName: Full=Hydrogen voltage-gated channel 1;
DE            Short=HV1;
DE   AltName: Full=Voltage sensor domain-only protein;
GN   Name=HVCN1; Synonyms=VSOP; ORFNames=UNQ578/PRO1140;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RX   MEDLINE=22887296; PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
RA   Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA   Lewis L., Liao D., Mark M.R., Robbie E., Sanchez C., Schoenfeld J.,
RA   Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA   Vandlen R.L., Watanabe C., Wieand D., Woods K., Xie M.-H.,
RA   Yansura D.G., Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A.D.,
RA   Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale
RT   effort to identify novel human secreted and transmembrane proteins: a
RT   bioinformatics assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Eye, Lung, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, ENZYME REGULATION,
RP   AND MUTAGENESIS OF HIS-140; HIS-193; ARG-205; ARG-208 AND ARG-211.
RX   PubMed=16554753; DOI=10.1038/nature04700;
RA   Ramsey I.S., Moran M.M., Chong J.A., Clapham D.E.;
RT   "A voltage-gated proton-selective channel lacking the pore domain.";
RL   Nature 440:1213-1216(2006).
CC   -!- FUNCTION: Mediates the voltage-dependent proton permeability of
CC       excitable membranes. Forms a proton-selective channel through
CC       which protons may pass in accordance with their electrochemical
CC       gradient. Proton efflux, accompanied by membrane depolarization,
CC       facilitates acute production of reactive oxygen species in
CC       phagocytosis.
CC   -!- ENZYME REGULATION: Sensitive to zinc ions and is inhibited by
CC       them.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q96D96-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q96D96-2; Sequence=VSP_034395;
CC       Name=3;
CC         IsoId=Q96D96-3; Sequence=VSP_034396;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Enriched in immune tissues, such as lymph
CC       nodes, B-lymphocytes, monocytes and spleen.
CC   -!- DOMAIN: The segment S4 is probably the voltage-sensor and is
CC       characterized by a series of positively charged amino acids at
CC       every third position. Unlike other voltage-gated ion channels it
CC       lacks the pore domain.
CC   -!- SIMILARITY: Belongs to the hydrogen channel family.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAQ89413.1; Type=Frameshift; Positions=164, 175;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY359054; AAQ89413.1; ALT_FRAME; mRNA.
DR   EMBL; AC144522; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471054; EAW97935.1; -; Genomic_DNA.
DR   EMBL; CH471054; EAW97936.1; -; Genomic_DNA.
DR   EMBL; BC007277; AAH07277.1; -; mRNA.
DR   EMBL; BC009731; AAH09731.1; -; mRNA.
DR   EMBL; BC032672; AAH32672.1; -; mRNA.
DR   IPI; IPI00153005; -.
DR   IPI; IPI00478137; -.
DR   IPI; IPI00872288; -.
DR   RefSeq; NP_001035196.1; -.
DR   RefSeq; NP_115745.2; -.
DR   UniGene; Hs.211511; -.
DR   UniGene; Hs.334637; -.
DR   DIP; DIP-46112N; -.
DR   STRING; Q96D96; -.
DR   TCDB; 1.A.51.1.2; voltage-gated proton channel (VPC) family.
DR   PhosphoSite; Q96D96; -.
DR   PRIDE; Q96D96; -.
DR   Ensembl; ENST00000356742; ENSP00000349181; ENSG00000122986; Homo sapiens.
DR   GeneID; 84329; -.
DR   KEGG; hsa:84329; -.
DR   UCSC; uc001trq.1; human.
DR   UCSC; uc001trs.1; human.
DR   CTD; 84329; -.
DR   GeneCards; GC12M109570; -.
DR   HGNC; HGNC:28240; HVCN1.
DR   MIM; 611227; gene.
DR   eggNOG; prNOG15301; -.
DR   HOGENOM; HBG714522; -.
DR   HOVERGEN; HBG102207; -.
DR   InParanoid; Q96D96; -.
DR   OrthoDB; EOG966Z67; -.
DR   PhylomeDB; Q96D96; -.
DR   NextBio; 74079; -.
DR   ArrayExpress; Q96D96; -.
DR   Bgee; Q96D96; -.
DR   CleanEx; HS_HVCN1; -.
DR   Genevestigator; Q96D96; -.
DR   GO; GO:0016021; C:integral to membrane; IDA:HGNC.
DR   GO; GO:0030171; F:voltage-gated proton channel activity; IDA:HGNC.
DR   GO; GO:0015992; P:proton transport; ISS:HGNC.
DR   GO; GO:0009268; P:response to pH; ISS:HGNC.
DR   GO; GO:0010043; P:response to zinc ion; IDA:HGNC.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR005821; Ion_trans.
DR   Pfam; PF00520; Ion_trans; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Coiled coil; Complete proteome; Ion transport;
KW   Ionic channel; Membrane; Transmembrane; Transport;
KW   Voltage-gated channel.
FT   CHAIN         1    273       Voltage-gated hydrogen channel 1.
FT                                /FTId=PRO_0000342187.
FT   TOPO_DOM      1    100       Cytoplasmic (Potential).
FT   TRANSMEM    101    121       Segment S1 (By similarity).
FT   TOPO_DOM    122    135       Extracellular (Potential).
FT   TRANSMEM    136    156       Segment S2 (By similarity).
FT   TOPO_DOM    157    169       Cytoplasmic (Potential).
FT   TRANSMEM    170    190       Segment S3 (By similarity).
FT   TOPO_DOM    191    197       Extracellular (Potential).
FT   TRANSMEM    198    218       Segment S4 (By similarity).
FT   TOPO_DOM    219    273       Cytoplasmic (Potential).
FT   COILED      223    266       Potential.
FT   COMPBIAS     46     55       Poly-Glu.
FT   COMPBIAS    176    180       Poly-Val.
FT   VAR_SEQ      66    102       Missing (in isoform 2).
FT                                /FTId=VSP_034395.
FT   VAR_SEQ     253    273       EQEIERLNKLLRQHGLLGEVN -> PLD (in isoform
FT                                3).
FT                                /FTId=VSP_034396.
FT   MUTAGEN     140    140       H->A: Exhibits selectivity to protons but
FT                                sensitivity to zinc ions is abolished;
FT                                when associated with A-193.
FT   MUTAGEN     193    193       H->A: Exhibits selectivity to protons but
FT                                sensitivity to zinc ions is abolished;
FT                                when associated with A-140.
FT   MUTAGEN     205    205       R->A: Faster channel activation and
FT                                deactivation kinetics.
FT   MUTAGEN     208    208       R->A: Faster channel activation and
FT                                deactivation kinetics.
FT   MUTAGEN     211    211       R->A: Faster channel deactivation
FT                                kinetics.
SQ   SEQUENCE   273 AA;  31683 MW;  0F93B428AECBBC4F CRC64;
     MATWDEKAVT RRAKVAPAER MSKFLRHFTV VGDDYHAWNI NYKKWENEEE EEEEEQPPPT
     PVSGEEGRAA APDVAPAPGP APRAPLDFRG MLRKLFSSHR FQVIIICLVV LDALLVLAEL
     ILDLKIIQPD KNNYAAMVFH YMSITILVFF MMEIIFKLFV FRLEFFHHKF EILDAVVVVV
     SFILDIVLLF QEHQFEALGL LILLRLWRVA RIINGIIISV KTRSERQLLR LKQMNVQLAA
     KIQHLEFSCS EKEQEIERLN KLLRQHGLLG EVN
//
ID   HVCN1_MOUSE             Reviewed;         269 AA.
AC   Q3U2S8; Q9DCE4;
DT   01-JUL-2008, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-2008, sequence version 2.
DT   02-MAR-2010, entry version 42.
DE   RecName: Full=Voltage-gated hydrogen channel 1;
DE   AltName: Full=Hydrogen voltage-gated channel 1;
DE            Short=HV1;
DE   AltName: Full=Voltage sensor domain-only protein;
DE            Short=mVSOP;
GN   Name=Hvcn1; Synonyms=Bts, Vsop;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J, and NOD; TISSUE=Kidney;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=FVB/N; TISSUE=Salivary gland;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, DOMAIN, ENZYME
RP   REGULATION, AND MUTAGENESIS OF ARG-201 AND ARG-207.
RX   PubMed=16556803; DOI=10.1126/science.1122352;
RA   Sasaki M., Takagi M., Okamura Y.;
RT   "A voltage sensor-domain protein is a voltage-gated proton channel.";
RL   Science 312:589-592(2006).
CC   -!- FUNCTION: Mediates the voltage-dependent proton permeability of
CC       excitable membranes. Forms a proton-selective channel through
CC       which protons may pass in accordance with their electrochemical
CC       gradient. Proton efflux, accompanied by membrane depolarization,
CC       facilitates acute production of reactive oxygen species in
CC       phagocytosis (By similarity).
CC   -!- ENZYME REGULATION: Sensitive to zinc ions and is inhibited by
CC       them.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Enriched in immune tissues, such as bone
CC       marrow, macrophages and spleen.
CC   -!- DOMAIN: The segment S4 is probably the voltage-sensor and is
CC       characterized by a series of positively charged amino acids at
CC       every third position. Unlike other voltage-gated ion channels it
CC       lacks the pore domain.
CC   -!- SIMILARITY: Belongs to the hydrogen channel family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK002854; BAB22409.1; -; mRNA.
DR   EMBL; AK154880; BAE32899.1; -; mRNA.
DR   EMBL; AK155123; BAE33062.1; -; mRNA.
DR   EMBL; AK170422; BAE41787.1; -; mRNA.
DR   EMBL; BC021548; AAH21548.1; -; mRNA.
DR   IPI; IPI00120788; -.
DR   RefSeq; NP_001035954.1; -.
DR   RefSeq; NP_083028.1; -.
DR   UniGene; Mm.28804; -.
DR   DIP; DIP-46134N; -.
DR   PhosphoSite; Q3U2S8; -.
DR   PRIDE; Q3U2S8; -.
DR   Ensembl; ENSMUST00000072602; ENSMUSP00000072401; ENSMUSG00000064267; Mus musculus.
DR   Ensembl; ENSMUST00000100747; ENSMUSP00000098312; ENSMUSG00000064267; Mus musculus.
DR   GeneID; 74096; -.
DR   KEGG; mmu:74096; -.
DR   CTD; 74096; -.
DR   MGI; MGI:1921346; Hvcn1.
DR   eggNOG; roNOG15859; -.
DR   HOGENOM; HBG714522; -.
DR   HOVERGEN; HBG102207; -.
DR   InParanoid; Q3U2S8; -.
DR   OMA; HHKFEIL; -.
DR   OrthoDB; EOG966Z67; -.
DR   PhylomeDB; Q3U2S8; -.
DR   NextBio; 339755; -.
DR   ArrayExpress; Q3U2S8; -.
DR   Bgee; Q3U2S8; -.
DR   Genevestigator; Q3U2S8; -.
DR   GO; GO:0016021; C:integral to membrane; IC:HGNC.
DR   GO; GO:0030171; F:voltage-gated proton channel activity; IDA:MGI.
DR   GO; GO:0015992; P:proton transport; IDA:MGI.
DR   GO; GO:0009268; P:response to pH; IDA:HGNC.
DR   GO; GO:0010043; P:response to zinc ion; IDA:HGNC.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR005821; Ion_trans.
DR   Pfam; PF00520; Ion_trans; 1.
PE   1: Evidence at protein level;
KW   Coiled coil; Ion transport; Ionic channel; Membrane; Transmembrane;
KW   Transport; Voltage-gated channel.
FT   CHAIN         1    269       Voltage-gated hydrogen channel 1.
FT                                /FTId=PRO_0000342188.
FT   TOPO_DOM      1     96       Cytoplasmic (Potential).
FT   TRANSMEM     97    117       Segment S1 (By similarity).
FT   TOPO_DOM    118    136       Extracellular (Potential).
FT   TRANSMEM    137    157       Segment S2 (By similarity).
FT   TOPO_DOM    158    165       Cytoplasmic (Potential).
FT   TRANSMEM    166    186       Segment S3 (By similarity).
FT   TOPO_DOM    187    193       Extracellular (Potential).
FT   TRANSMEM    194    214       Segment S4 (By similarity).
FT   TOPO_DOM    215    269       Cytoplasmic (Potential).
FT   COILED      221    261       Potential.
FT   COMPBIAS     46     53       Poly-Glu.
FT   COMPBIAS    173    176       Poly-Val.
FT   MUTAGEN     201    201       R->Q: Faster channel activation kinetics.
FT   MUTAGEN     207    207       R->Q: Same activation kinetics as wild-
FT                                type.
FT   CONFLICT     66     66       E -> A (in Ref. 1; BAE33062).
SQ   SEQUENCE   269 AA;  31242 MW;  B549CB553DEB6568 CRC64;
     MTSHDPKAVT RRTKVAPTKR MSRFLKHFTV VGDDYHTWNV NYKKWENEEE EEEPAPTSAE
     GEGNAEGPDA EAGSASTPRQ SLDFRSRLRK LFSSHRFQVI IICLVVLDAL LVLAELLLDL
     KIIEPDEQDY AVTAFHYMSF AILVFFMLEI FFKIFVFRLE FFHHKFEILD AFVVVVSFVL
     DLVLLFKSHH FEALGLLILL RLWRVARIIN GIIISVKTRS ERQILRLKQI NIQLATKIQH
     LEFSCSEKEQ EIERLNKLLK QNGLLGDVN
//
ID   IRK10_HUMAN             Reviewed;         379 AA.
AC   P78508; A3KME7; Q5VUT9; Q8N4I7; Q92808;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1997, sequence version 1.
DT   02-MAR-2010, entry version 95.
DE   RecName: Full=ATP-sensitive inward rectifier potassium channel 10;
DE   AltName: Full=Potassium channel, inwardly rectifying subfamily J member 10;
DE   AltName: Full=Inward rectifier K(+) channel Kir1.2;
DE   AltName: Full=ATP-dependent inwardly rectifying potassium channel Kir4.1;
GN   Name=KCNJ10;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND NUCLEOTIDE SEQUENCE [MRNA] OF
RP   143-379.
RC   TISSUE=Kidney;
RX   MEDLINE=97150765; PubMed=8995301; DOI=10.1074/jbc.272.1.586;
RA   Shuck M.E., Piser T.M., Bock J.H., Slightom J.L., Lee K.S.,
RA   Bienkowski M.J.;
RT   "Cloning and characterization of two K+ inward rectifier (Kir) 1.1
RT   potassium channel homologs from human kidney (Kir1.2 and Kir1.3).";
RL   J. Biol. Chem. 272:586-593(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT CYS-271.
RC   TISSUE=Cerebellum;
RX   MEDLINE=20123391; PubMed=10659995; DOI=10.1016/S0898-6568(99)00059-5;
RA   Schoots O., Wilson J.M., Ethier N., Bigras E., Hebert T.E.,
RA   Van Tol H.H.M.;
RT   "Co-expression of human Kir3 subunits can yield channels with
RT   different functional properties.";
RL   Cell. Signal. 11:871-883(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- FUNCTION: May be responsible for potassium buffering action of
CC       glial cells in the brain. Inward rectifier potassium channels are
CC       characterized by a greater tendency to allow potassium to flow
CC       into the cell rather than out of it. Their voltage dependence is
CC       regulated by the concentration of extracellular potassium; as
CC       external potassium is raised, the voltage range of the channel
CC       opening shifts to more positive voltages. The inward rectification
CC       is mainly due to the blockage of outward current by internal
CC       magnesium. Can be blocked by extracellular barium and cesium (By
CC       similarity).
CC   -!- SUBUNIT: Seems to form heterodimer with Kir5.1/KCNJ16. Interacts
CC       with INADL (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the inward rectifier-type potassium channel
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U73192; AAC50923.1; -; Genomic_DNA.
DR   EMBL; U73193; AAC50924.1; -; mRNA.
DR   EMBL; U52155; AAB07046.1; -; mRNA.
DR   EMBL; AL513302; CAH71493.1; -; Genomic_DNA.
DR   EMBL; CH471121; EAW52749.1; -; Genomic_DNA.
DR   EMBL; BC034036; AAH34036.2; ALT_INIT; mRNA.
DR   EMBL; BC131627; AAI31628.1; -; mRNA.
DR   IPI; IPI00020273; -.
DR   RefSeq; NP_002232.2; -.
DR   UniGene; Hs.408960; -.
DR   SMR; P78508; 27-335, 164-340.
DR   STRING; P78508; -.
DR   PhosphoSite; P78508; -.
DR   PRIDE; P78508; -.
DR   Ensembl; ENST00000368089; ENSP00000357068; ENSG00000177807; Homo sapiens.
DR   GeneID; 3766; -.
DR   KEGG; hsa:3766; -.
DR   UCSC; uc001fuw.1; human.
DR   CTD; 3766; -.
DR   GeneCards; GC01M158273; -.
DR   HGNC; HGNC:6256; KCNJ10.
DR   HPA; CAB022636; -.
DR   HPA; HPA011992; -.
DR   MIM; 602208; gene.
DR   Orphanet; 87884; Nonsyndromic genetic deafness.
DR   Orphanet; 199343; SeSAME syndrome.
DR   PharmGKB; PA30043; -.
DR   HOGENOM; HBG716702; -.
DR   HOVERGEN; HBG006178; -.
DR   InParanoid; P78508; -.
DR   OMA; LGPPANH; -.
DR   OrthoDB; EOG9H48PQ; -.
DR   PhylomeDB; P78508; -.
DR   NextBio; 14767; -.
DR   ArrayExpress; P78508; -.
DR   Bgee; P78508; -.
DR   CleanEx; HS_KCNJ10; -.
DR   Genevestigator; P78508; -.
DR   GermOnline; ENSG00000177807; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0015272; F:ATP-activated inward rectifier potassium ch...; TAS:ProtInc.
DR   GO; GO:0030955; F:potassium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006813; P:potassium ion transport; TAS:ProtInc.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR016449; K_chnl_inward-rec_Kir.
DR   InterPro; IPR001838; K_chnl_inward-rec_Kir-like.
DR   InterPro; IPR003269; K_chnl_inward-rec_Kir1.2.
DR   InterPro; IPR013521; K_chnl_inward-rec_Kir_Cr2.
DR   InterPro; IPR013518; K_chnl_inward-rec_Kir_cyto.
DR   Gene3D; G3DSA:2.60.40.1400; IR_K+channel_cytopl; 1.
DR   PANTHER; PTHR11767; K+channel_IR; 1.
DR   PANTHER; PTHR11767:SF21; KIR12_channel; 1.
DR   Pfam; PF01007; IRK; 1.
DR   PIRSF; PIRSF005465; GIRK_kir; 1.
DR   PRINTS; PR01322; KIR12CHANNEL.
DR   PRINTS; PR01320; KIRCHANNEL.
DR   SUPFAM; SSF81296; Ig_E-set; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Complete proteome; Ion transport; Ionic channel;
KW   Membrane; Nucleotide-binding; Polymorphism; Potassium;
KW   Potassium transport; Transmembrane; Transport; Voltage-gated channel.
FT   CHAIN         1    379       ATP-sensitive inward rectifier potassium
FT                                channel 10.
FT                                /FTId=PRO_0000154953.
FT   TOPO_DOM      1     64       Cytoplasmic (By similarity).
FT   TRANSMEM     65     89       M1 (By similarity).
FT   TOPO_DOM     90    114       Extracellular (By similarity).
FT   TOPO_DOM    134    142       Extracellular (By similarity).
FT   TRANSMEM    143    164       M2 (By similarity).
FT   TOPO_DOM    165    379       Cytoplasmic (By similarity).
FT   NP_BIND     210    217       ATP (Potential).
FT   REGION      115    126       H5 (pore-forming helix) (By similarity).
FT   MOTIF       128    133       Selectivity filter (By similarity).
FT   SITE        158    158       Role in the control of polyamine-mediated
FT                                channel gating and in the blocking by
FT                                intracellular magnesium (By similarity).
FT   VARIANT     271    271       R -> C (in dbSNP:rs1130183).
FT                                /FTId=VAR_034018.
FT   VARIANT     271    271       R -> H (in dbSNP:rs3795339).
FT                                /FTId=VAR_020339.
FT   CONFLICT     50     50       L -> P (in Ref. 2; AAB07046).
FT   CONFLICT     83     83       G -> V (in Ref. 5; AAH34036).
FT   CONFLICT    166    166       L -> Q (in Ref. 2; AAB07046).
SQ   SEQUENCE   379 AA;  42508 MW;  D9DA013FF4003533 CRC64;
     MTSVAKVYYS QTTQTESRPL MGPGIRRRRV LTKDGRSNVR MEHIADKRFL YLKDLWTTFI
     DMQWRYKLLL FSATFAGTWF LFGVVWYLVA VAHGDLLELD PPANHTPCVV QVHTLTGAFL
     FSLESQTTIG YGFRYISEEC PLAIVLLIAQ LVLTTILEIF ITGTFLAKIA RPKKRAETIR
     FSQHAVVASH NGKPCLMIRV ANMRKSLLIG CQVTGKLLQT HQTKEGENIR LNQVNVTFQV
     DTASDSPFLI LPLTFYHVVD ETSPLKDLPL RSGEGDFELV LILSGTVEST SATCQVRTSY
     LPEEILWGYE FTPAISLSAS GKYIADFSLF DQVVKVASPS GLRDSTVRYG DPEKLKLEES
     LREQAEKEGS ALSVRISNV
//
ID   IRK10_MOUSE             Reviewed;         379 AA.
AC   Q9JM63;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   02-MAR-2010, entry version 77.
DE   RecName: Full=ATP-sensitive inward rectifier potassium channel 10;
DE   AltName: Full=Potassium channel, inwardly rectifying subfamily J member 10;
DE   AltName: Full=Inward rectifier K(+) channel Kir4.1;
GN   Name=Kcnj10;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Inanobe A., Takahashi K., Tanemoto M., Fujita A., Kurachi Y.;
RL   Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=CD-1, and ICR; TISSUE=Brain;
RX   MEDLINE=21100968; PubMed=11169792;
RX   DOI=10.1002/1098-1136(20010101)33:1<57::AID-GLIA1006>3.0.CO;2-0;
RA   Li L., Head V., Timpe L.C.;
RT   "Identification of an inward rectifier potassium channel gene
RT   expressed in mouse cortical astrocytes.";
RL   Glia 33:57-71(2001).
RN   [3]
RP   INTERACTION WITH INADL.
RX   MEDLINE=98313406; PubMed=9647694; DOI=10.1006/mcne.1998.0679;
RA   Kurschner C., Mermelstein P.G., Holden W.T., Surmeier D.J.;
RT   "CIPP, a novel multivalent PDZ domain protein, selectively interacts
RT   with Kir4.0 family members, NMDA receptor subunits, neurexins, and
RT   neuroligins.";
RL   Mol. Cell. Neurosci. 11:161-172(1998).
CC   -!- FUNCTION: May be responsible for potassium buffering action of
CC       glial cells in the brain. Inward rectifier potassium channels are
CC       characterized by a greater tendency to allow potassium to flow
CC       into the cell rather than out of it. Their voltage dependence is
CC       regulated by the concentration of extracellular potassium; as
CC       external potassium is raised, the voltage range of the channel
CC       opening shifts to more positive voltages. The inward rectification
CC       is mainly due to the blockage of outward current by internal
CC       magnesium. Can be blocked by extracellular barium and cesium (By
CC       similarity).
CC   -!- SUBUNIT: Seems to form heterodimer with Kir5.1/KCNJ16 (By
CC       similarity). Interacts with INADL.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the inward rectifier-type potassium channel
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB039879; BAA92432.1; -; mRNA.
DR   EMBL; AF322631; AAG42845.1; -; mRNA.
DR   IPI; IPI00124792; -.
DR   RefSeq; NP_001034573.1; -.
DR   UniGene; Mm.254563; -.
DR   SMR; Q9JM63; 27-335, 164-340.
DR   STRING; Q9JM63; -.
DR   PRIDE; Q9JM63; -.
DR   Ensembl; ENSMUST00000056136; ENSMUSP00000054356; ENSMUSG00000044708; Mus musculus.
DR   GeneID; 16513; -.
DR   KEGG; mmu:16513; -.
DR   UCSC; uc007dqj.1; mouse.
DR   CTD; 16513; -.
DR   MGI; MGI:1194504; Kcnj10.
DR   HOVERGEN; HBG006178; -.
DR   InParanoid; Q9JM63; -.
DR   OMA; LGPPANH; -.
DR   OrthoDB; EOG9H48PQ; -.
DR   PhylomeDB; Q9JM63; -.
DR   NextBio; 289861; -.
DR   ArrayExpress; Q9JM63; -.
DR   Bgee; Q9JM63; -.
DR   Genevestigator; Q9JM63; -.
DR   GO; GO:0005887; C:integral to plasma membrane; IC:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005242; F:inward rectifier potassium channel activity; IEA:InterPro.
DR   GO; GO:0030955; F:potassium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:MGI.
DR   GO; GO:0006813; P:potassium ion transport; IDA:MGI.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR016449; K_chnl_inward-rec_Kir.
DR   InterPro; IPR001838; K_chnl_inward-rec_Kir-like.
DR   InterPro; IPR003269; K_chnl_inward-rec_Kir1.2.
DR   InterPro; IPR013521; K_chnl_inward-rec_Kir_Cr2.
DR   InterPro; IPR013518; K_chnl_inward-rec_Kir_cyto.
DR   Gene3D; G3DSA:2.60.40.1400; IR_K+channel_cytopl; 1.
DR   PANTHER; PTHR11767; K+channel_IR; 1.
DR   PANTHER; PTHR11767:SF21; KIR12_channel; 1.
DR   Pfam; PF01007; IRK; 1.
DR   PIRSF; PIRSF005465; GIRK_kir; 1.
DR   PRINTS; PR01322; KIR12CHANNEL.
DR   PRINTS; PR01320; KIRCHANNEL.
DR   SUPFAM; SSF81296; Ig_E-set; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Ion transport; Ionic channel; Membrane;
KW   Nucleotide-binding; Potassium; Potassium transport; Transmembrane;
KW   Transport; Voltage-gated channel.
FT   CHAIN         1    379       ATP-sensitive inward rectifier potassium
FT                                channel 10.
FT                                /FTId=PRO_0000154954.
FT   TOPO_DOM      1     64       Cytoplasmic (By similarity).
FT   TRANSMEM     65     89       M1 (By similarity).
FT   TOPO_DOM     90    114       Extracellular (By similarity).
FT   TOPO_DOM    134    142       Extracellular (By similarity).
FT   TRANSMEM    143    164       M2 (By similarity).
FT   TOPO_DOM    165    379       Cytoplasmic (By similarity).
FT   NP_BIND     210    217       ATP (Potential).
FT   REGION      115    126       H5 (pore-forming helix) (By similarity).
FT   MOTIF       128    133       Selectivity filter (By similarity).
FT   SITE        158    158       Role in the control of polyamine-mediated
FT                                channel gating and in the blocking by
FT                                intracellular magnesium (By similarity).
SQ   SEQUENCE   379 AA;  42432 MW;  7FF08446B7F43453 CRC64;
     MTSVAKVYYS QTTQTESRPL VAPGIRRRRV LTKDGRSNVR MEHIADKRFL YLKDLWTTFI
     DMQWRYKLLL FSATFAGTWF LFGVVWYLVA VAHGDLLELG PPANHTPCVV QVHTLTGAFL
     FSLESQTTIG YGFRYISEEC PLAIVLLIAQ LVLTTILEIF ITGTFLAKIA RPKKRAETIR
     FSQHAVVASH NGKPCLMIRV ANMRKSLLIG CQVTGKLLQT HQTKEGENIR LNQVNVTFQV
     DTASDSPFLI LPLTFYHVVD ETSPLKDLPL RSGEGDFELV LILSGTVEST SATCQVRTSY
     LPEEILWGYE FTPAISLSAS GKYIADFSLF DQVVKVASPS GLRDSTVRYG DPEKLKLEES
     LREQAEKEGS ALSVRISNV
//
ID   IRK10_RAT               Reviewed;         379 AA.
AC   P49655; Q62790;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 1.
DT   02-MAR-2010, entry version 85.
DE   RecName: Full=ATP-sensitive inward rectifier potassium channel 10;
DE   AltName: Full=Potassium channel, inwardly rectifying subfamily J member 10;
DE   AltName: Full=ATP-sensitive inward rectifier potassium channel KAB-2;
DE   AltName: Full=Inward rectifier K(+) channel Kir4.1;
DE   AltName: Full=BIR10;
DE   AltName: Full=Brain-specific inwardly rectifying K(+) channel 1;
DE            Short=BIRK1;
GN   Name=Kcnj10; Synonyms=Kab-2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RX   MEDLINE=95332346; PubMed=7608203; DOI=10.1074/jbc.270.27.16339;
RA   Takumi T., Ishii T., Horio Y., Morishige K., Takahashi N., Yamada M.,
RA   Yamashita T., Kiyama H., Sohmiya K., Nakanishi S., Kurachi Y.;
RT   "A novel ATP-dependent inward rectifier potassium channel expressed
RT   predominantly in glial cells.";
RL   J. Biol. Chem. 270:16339-16346(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RX   MEDLINE=95179470; PubMed=7874445;
RA   Bond C.T., Pessia M., Xia X.-M., Lagrutta A., Kavanaugh M.P.,
RA   Adelman J.P.;
RT   "Cloning and expression of a family of inward rectifier potassium
RT   channels.";
RL   Recept. Channels 2:183-191(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   MEDLINE=95350147; PubMed=7624316; DOI=10.1073/pnas.92.15.6753;
RA   Bredt D.S., Wang T.L., Cohen N.A., Guggino W.B., Snyder S.H.;
RT   "Cloning and expression of two brain-specific inwardly rectifying
RT   potassium channels.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:6753-6757(1995).
CC   -!- FUNCTION: May be responsible for potassium buffering action of
CC       glial cells in the brain. Inward rectifier potassium channels are
CC       characterized by a greater tendency to allow potassium to flow
CC       into the cell rather than out of it. Their voltage dependence is
CC       regulated by the concentration of extracellular potassium; as
CC       external potassium is raised, the voltage range of the channel
CC       opening shifts to more positive voltages. The inward rectification
CC       is mainly due to the blockage of outward current by internal
CC       magnesium. Can be blocked by extracellular barium and cesium.
CC   -!- SUBUNIT: Interacts with INADL (By similarity). Seems to form
CC       heterodimer with Kir5.1/KCNJ16.
CC   -!- INTERACTION:
CC       P11530:Dmd; NbExp=1; IntAct=EBI-706185, EBI-706166;
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Predominantly in glial cells of the cerebellum
CC       and forebrain. Expressed to a lesser extent in the kidney, and
CC       other peripheral tissues.
CC   -!- SIMILARITY: Belongs to the inward rectifier-type potassium channel
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X86818; CAA60501.1; -; mRNA.
DR   EMBL; X83585; CAA58568.1; -; mRNA.
DR   EMBL; U27558; AAA87811.1; -; mRNA.
DR   IPI; IPI00231208; -.
DR   PIR; A57477; A57477.
DR   RefSeq; NP_113790.1; -.
DR   UniGene; Rn.10196; -.
DR   SMR; P49655; 27-335, 164-339.
DR   IntAct; P49655; 1.
DR   STRING; P49655; -.
DR   PhosphoSite; P49655; -.
DR   Ensembl; ENSRNOT00000010146; ENSRNOP00000010146; ENSRNOG00000007705; Rattus norvegicus.
DR   GeneID; 29718; -.
DR   KEGG; rno:29718; -.
DR   UCSC; NM_031602; rat.
DR   CTD; 29718; -.
DR   RGD; 61822; Kcnj10.
DR   eggNOG; maNOG13415; -.
DR   HOVERGEN; HBG006178; -.
DR   InParanoid; P49655; -.
DR   OMA; LGPPANH; -.
DR   OrthoDB; EOG9H48PQ; -.
DR   PhylomeDB; P49655; -.
DR   NextBio; 610177; -.
DR   ArrayExpress; P49655; -.
DR   Genevestigator; P49655; -.
DR   GermOnline; ENSRNOG00000007705; Rattus norvegicus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005242; F:inward rectifier potassium channel activity; IEA:InterPro.
DR   GO; GO:0030955; F:potassium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0006813; P:potassium ion transport; IEA:UniProtKB-KW.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR016449; K_chnl_inward-rec_Kir.
DR   InterPro; IPR001838; K_chnl_inward-rec_Kir-like.
DR   InterPro; IPR003269; K_chnl_inward-rec_Kir1.2.
DR   InterPro; IPR013521; K_chnl_inward-rec_Kir_Cr2.
DR   InterPro; IPR013518; K_chnl_inward-rec_Kir_cyto.
DR   Gene3D; G3DSA:2.60.40.1400; IR_K+channel_cytopl; 1.
DR   PANTHER; PTHR11767; K+channel_IR; 1.
DR   PANTHER; PTHR11767:SF21; KIR12_channel; 1.
DR   Pfam; PF01007; IRK; 1.
DR   PIRSF; PIRSF005465; GIRK_kir; 1.
DR   PRINTS; PR01322; KIR12CHANNEL.
DR   PRINTS; PR01320; KIRCHANNEL.
DR   SUPFAM; SSF81296; Ig_E-set; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Ion transport; Ionic channel; Membrane;
KW   Nucleotide-binding; Potassium; Potassium transport; Transmembrane;
KW   Transport; Voltage-gated channel.
FT   CHAIN         1    379       ATP-sensitive inward rectifier potassium
FT                                channel 10.
FT                                /FTId=PRO_0000154955.
FT   TOPO_DOM      1     64       Cytoplasmic (By similarity).
FT   TRANSMEM     65     89       M1 (By similarity).
FT   TOPO_DOM     90    114       Extracellular (By similarity).
FT   TOPO_DOM    134    142       Extracellular (By similarity).
FT   TRANSMEM    143    164       M2 (By similarity).
FT   TOPO_DOM    165    379       Cytoplasmic (By similarity).
FT   NP_BIND     210    217       ATP (Potential).
FT   REGION      115    126       H5 (pore-forming helix) (By similarity).
FT   MOTIF       128    133       Selectivity filter (By similarity).
FT   SITE        158    158       Role in the control of polyamine-mediated
FT                                channel gating and in the blocking by
FT                                intracellular magnesium (By similarity).
FT   CONFLICT     73     73       A -> P (in Ref. 3; AAA87811).
FT   CONFLICT     76     76       A -> T (in Ref. 3; AAA87811).
FT   CONFLICT    110    112       VQV -> GAGA (in Ref. 3).
FT   CONFLICT    115    116       LT -> YL (in Ref. 3).
FT   CONFLICT    145    145       V -> E (in Ref. 3; AAA87811).
FT   CONFLICT    190    190       H -> L (in Ref. 3; AAA87811).
FT   CONFLICT    228    228       N -> D (in Ref. 3; AAA87811).
FT   CONFLICT    266    266       K -> Q (in Ref. 3; AAA87811).
FT   CONFLICT    304    304       E -> R (in Ref. 2; CAA58568).
SQ   SEQUENCE   379 AA;  42480 MW;  77B3671907B68CB2 CRC64;
     MTSVAKVYYS QTTQTESRPL VAPGIRRRRV LTKDGRSNVR MEHIADKRFL YLKDLWTTFI
     DMQWRYKLLL FSATFAGTWF LFGVVWYLVA VAHGDLLELG PPANHTPCVV QVHTLTGAFL
     FSLESQTTIG YGFRYISEEC PLAIVLLIAQ LVLTTILEIF ITGTFLAKIA RPKKRAETIR
     FSQHAVVAYH NGKLCLMIRV ANMRKSLLIG CQVTGKLLQT HQTKEGENIR LNQVNVTFQV
     DTASDSPFLI LPLTFYHVVD ETSPLKDLPL RSGEGDFELV LILSGTVEST SATCQVRTSY
     LPEEILWGYE FTPAISLSAS GKYVADFSLF DQVVKVASPG GLRDSTVRYG DPEKLKLEES
     LREQAEKEGS ALSVRISNV
//
ID   IRK11_HUMAN             Reviewed;         390 AA.
AC   Q14654; Q2M1H7; Q58EX3;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   27-SEP-2005, sequence version 2.
DT   02-MAR-2010, entry version 112.
DE   RecName: Full=ATP-sensitive inward rectifier potassium channel 11;
DE   AltName: Full=Potassium channel, inwardly rectifying subfamily J member 11;
DE   AltName: Full=Inward rectifier K(+) channel Kir6.2;
DE   AltName: Full=IKATP;
GN   Name=KCNJ11;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT SER-148.
RC   TISSUE=Placenta;
RX   MEDLINE=96072967; PubMed=7502040; DOI=10.1126/science.270.5239.1166;
RA   Inagaki N., Gonoi T., Clement J.P. IV, Namba N., Inazawa J.,
RA   Gonzalez G., Aguilar-Bryan L., Seino S., Bryan J.;
RT   "Reconstitution of IKATP: an inward rectifier subunit plus the
RT   sulfonylurea receptor.";
RL   Science 270:1166-1170(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Spleen;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   MOLECULAR BASIS OF ATP SENSITIVITY.
RX   PubMed=12524280; DOI=10.1016/S0006-3495(03)74847-4;
RA   Ribalet B., John S.A., Weiss J.N.;
RT   "Molecular basis for Kir6.2 channel inhibition by adenine
RT   nucleotides.";
RL   Biophys. J. 84:266-276(2003).
RN   [4]
RP   REVIEW ON VARIANTS.
RX   MEDLINE=99268411; PubMed=10338089;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:5<351::AID-HUMU3>3.3.CO;2-I;
RA   Meissner T., Beinbrech B., Mayatepek E.;
RT   "Congenital hyperinsulinism: molecular basis of a heterogeneous
RT   disease.";
RL   Hum. Mutat. 13:351-361(1999).
RN   [5]
RP   VARIANT HHF2 PRO-147.
RX   MEDLINE=95150032; PubMed=7847376;
RA   Thomas P.M., Cote G.J., Hallman D.M., Mathew P.M.;
RT   "Homozygosity mapping, to chromosome 11p, of the gene for familial
RT   persistent hyperinsulinemic hypoglycemia of infancy.";
RL   Am. J. Hum. Genet. 56:416-421(1995).
RN   [6]
RP   VARIANT HHF2 PRO-147.
RX   PubMed=8923010; DOI=10.1093/hmg/5.11.1809;
RA   Thomas P., Ye Y., Lightner E.;
RT   "Mutation of the pancreatic islet inward rectifier Kir6.2 also leads
RT   to familial persistent hyperinsulinemic hypoglycemia of infancy.";
RL   Hum. Mol. Genet. 5:1809-1812(1996).
RN   [7]
RP   VARIANTS NIDDM PRO-355 AND LYS-PRO-380 INS, AND VARIANTS LYS-23;
RP   VAL-270; VAL-337 AND CYS-385.
RX   MEDLINE=97052379; PubMed=8897013; DOI=10.1007/BF02658512;
RA   Sakura H., Wat N., Horton V., Millns H., Turner R.C., Ashcroft F.M.;
RT   "Sequence variations in the human Kir6.2 gene, a subunit of the beta-
RT   cell ATP-sensitive K-channel: no association with NIDDM in white
RT   Caucasian subjects or evidence of abnormal function when expressed in
RT   vitro.";
RL   Diabetologia 39:1233-1236(1996).
RN   [8]
RP   VARIANTS LYS-10; LYS-23; VAL-270 AND VAL-337.
RX   MEDLINE=97184307; PubMed=9032109;
RA   Inoue H., Ferrer J., Warren-Perry M., Zhang Y., Millns H.,
RA   Turner R.C., Elbein S.C., Hampe C.L., Suarez B.K., Inagaki N.,
RA   Seino S., Permutt M.A.;
RT   "Sequence variants in the pancreatic islet beta-cell inwardly
RT   rectifying K+ channel Kir6.2 (Bir) gene: identification and lack of
RT   role in Caucasian patients with NIDDM.";
RL   Diabetes 46:502-507(1997).
RN   [9]
RP   VARIANT HHF2 ARG-91.
RX   MEDLINE=99220315; PubMed=10204114; DOI=10.1210/er.20.2.101;
RA   Aguilar-Bryan L., Bryan J.;
RT   "Molecular biology of adenosine triphosphate-sensitive potassium
RT   channels.";
RL   Endocr. Rev. 20:101-135(1999).
RN   [10]
RP   VARIANTS LYS-23 AND VAL-337.
RX   MEDLINE=99318094; PubMed=10391210; DOI=10.1038/10297;
RA   Halushka M.K., Fan J.-B., Bentley K., Hsie L., Shen N., Weder A.,
RA   Cooper R., Lipshutz R., Chakravarti A.;
RT   "Patterns of single-nucleotide polymorphisms in candidate genes for
RT   blood-pressure homeostasis.";
RL   Nat. Genet. 22:239-247(1999).
RN   [11]
RP   VARIANT HHF2 ASN-67.
RX   PubMed=12364426; DOI=10.1210/jc.2002-020378;
RA   Huopio H., Jaeaeskelaeinen J., Komulainen J., Miettinen R.,
RA   Kaerkkaeinen P., Laakso M., Tapanainen P., Voutilainen R.,
RA   Otonkoski T.;
RT   "Acute insulin response tests for the differential diagnosis of
RT   congenital hyperinsulinism.";
RL   J. Clin. Endocrinol. Metab. 87:4502-4507(2002).
RN   [12]
RP   VARIANTS PNDM VAL-35; MET-59; HIS-201; CYS-330 AND ILE-333.
RX   PubMed=15448106;
RA   Sagen J.V., Raeder H., Hathout E., Shehadeh N., Gudmundsson K.,
RA   Baevre H., Abuelo D., Phornphutkul C., Molnes J., Bell G.I.,
RA   Gloyn A.L., Hattersley A.T., Molven A., Soevik O., Njoelstad P.R.;
RT   "Permanent neonatal diabetes due to mutations in KCNJ11 encoding
RT   Kir6.2: patient characteristics and initial response to sulfonylurea
RT   therapy.";
RL   Diabetes 53:2713-2718(2004).
RN   [13]
RP   VARIANTS PNDM LEU-35; MET-59; CYS-201; HIS-201; LYS-322 AND CYS-330.
RX   PubMed=15448107;
RA   Vaxillaire M., Populaire C., Busiah K., Cave H., Gloyn A.L.,
RA   Hattersley A.T., Czernichow P., Froguel P., Polak M.;
RT   "Kir6.2 mutations are a common cause of permanent neonatal diabetes in
RT   a large cohort of French patients.";
RL   Diabetes 53:2719-2722(2004).
RN   [14]
RP   VARIANT PNDM CYS-201.
RX   PubMed=15292329; DOI=10.1210/jc.2004-0568;
RA   Gloyn A.L., Cummings E.A., Edghill E.L., Harries L.W., Scott R.,
RA   Costa T., Temple I.K., Hattersley A.T., Ellard S.;
RT   "Permanent neonatal diabetes due to paternal germline mosaicism for an
RT   activating mutation of the KCNJ11 gene encoding the Kir6.2 subunit of
RT   the beta-cell potassium adenosine triphosphate channel.";
RL   J. Clin. Endocrinol. Metab. 89:3932-3935(2004).
RN   [15]
RP   VARIANT HHF2 LEU-254, AND CHARACTERIZATION OF VARIANT HHF2 LEU-254.
RX   PubMed=15579781; DOI=10.1210/jc.2004-1233;
RA   Tornovsky S., Crane A., Cosgrove K.E., Hussain K., Lavie J.,
RA   Heyman M., Nesher Y., Kuchinski N., Ben-Shushan E., Shatz O.,
RA   Nahari E., Potikha T., Zangen D., Tenenbaum-Rakover Y., de Vries L.,
RA   Argente J., Gracia R., Landau H., Eliakim A., Lindley K., Dunne M.J.,
RA   Aguilar-Bryan L., Glaser B.;
RT   "Hyperinsulinism of infancy: novel ABCC8 and KCNJ11 mutations and
RT   evidence for additional locus heterogeneity.";
RL   J. Clin. Endocrinol. Metab. 89:6224-6234(2004).
RN   [16]
RP   VARIANTS PNDM ARG-52; GLY-59; MET-59; HIS-201; CYS-201 AND LEU-296,
RP   AND CHARACTERIZATION OF VARIANT PNDM HIS-201.
RX   PubMed=15115830; DOI=10.1056/NEJMoa032922;
RA   Gloyn A.L., Pearson E.R., Antcliff J.F., Proks P., Bruining G.J.,
RA   Slingerland A.S., Howard N., Srinivasan S., Silva J.M.C.L., Molnes J.,
RA   Edghill E.L., Frayling T.M., Temple I.K., Mackay D., Shield J.P.H.,
RA   Sumnik Z., van Rhijn A., Wales J.K.H., Clark P., Gorman S.,
RA   Aisenberg J., Ellard S., Njoelstad P.R., Ashcroft F.M.,
RA   Hattersley A.T.;
RT   "Activating mutations in the gene encoding the ATP-sensitive
RT   potassium-channel subunit Kir6.2 and permanent neonatal diabetes.";
RL   N. Engl. J. Med. 350:1838-1849(2004).
RN   [17]
RP   ERRATUM.
RA   Gloyn A.L., Pearson E.R., Antcliff J.F., Proks P., Bruining G.J.,
RA   Slingerland A.S., Howard N., Srinivasan S., Silva J.M.C.L., Molnes J.,
RA   Edghill E.L., Frayling T.M., Temple I.K., Mackay D., Shield J.P.H.,
RA   Sumnik Z., van Rhijn A., Wales J.K.H., Clark P., Gorman S.,
RA   Aisenberg J., Ellard S., Njoelstad P.R., Ashcroft F.M.,
RA   Hattersley A.T.;
RL   N. Engl. J. Med. 351:1470-1470(2004).
RN   [18]
RP   CHARACTERIZATION OF VARIANTS PNDM ARG-52; GLY-59 AND CYS-201.
RX   PubMed=15583126; DOI=10.1073/pnas.0404756101;
RA   Proks P., Antcliff J.F., Lippiat J., Gloyn A.L., Hattersley A.T.,
RA   Ashcroft F.M.;
RT   "Molecular basis of Kir6.2 mutations associated with neonatal diabetes
RT   or neonatal diabetes plus neurological features.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:17539-17544(2004).
RN   [19]
RP   VARIANT HHF2 HIS-34, AND VARIANTS LYS-23; SER-148 AND VAL-337.
RX   PubMed=15807877; DOI=10.1111/j.1365-2265.2005.02242.x;
RA   Ohkubo K., Nagashima M., Naito Y., Taguchi T., Suita S., Okamoto N.,
RA   Fujinaga H., Tsumura K., Kikuchi K., Ono J.;
RT   "Genotypes of the pancreatic beta-cell K-ATP channel and clinical
RT   phenotypes of Japanese patients with persistent hyperinsulinaemic
RT   hypoglycaemia of infancy.";
RL   Clin. Endocrinol. (Oxf.) 62:458-465(2005).
RN   [20]
RP   VARIANTS TNDM3 SER-53; ARG-53 AND VAL-182, AND CHARACTERIZATION OF
RP   VARIANTS TNDM3 SER-53; ARG-53 AND VAL-182.
RX   PubMed=15718250; DOI=10.1093/hmg/ddi086;
RA   Gloyn A.L., Reimann F., Girard C., Edghill E.L., Proks P.,
RA   Pearson E.R., Temple I.K., Mackay D.J.G., Shield J.P.H.,
RA   Freedenberg D., Noyes K., Ellard S., Ashcroft F.M., Gribble F.M.,
RA   Hattersley A.T.;
RT   "Relapsing diabetes can result from moderately activating mutations in
RT   KCNJ11.";
RL   Hum. Mol. Genet. 14:925-934(2005).
RN   [21]
RP   VARIANTS PNDM PRO-50; MET-59; ARG-170; ASN-170 AND CYS-201.
RX   PubMed=15580558; DOI=10.1002/humu.20124;
RG   The early onset diabetes study group of the Italian society of
RG   pediatric endocrinology and diabetes;
RA   Massa O., Iafusco D., D'Amato E., Gloyn A.L., Hattersley A.T.,
RA   Pasquino B., Tonini G., Dammacco F., Zanette G., Meschi F., Porzio O.,
RA   Bottazzo G., Crino A., Lorini R., Cerutti F., Vanelli M., Barbetti F.;
RT   "KCNJ11 activating mutations in Italian patients with permanent
RT   neonatal diabetes.";
RL   Hum. Mutat. 25:22-27(2005).
RN   [22]
RP   VARIANTS HHF2 ASP-101; ALA-134; LEU-136; LEU-266 AND HIS-301.
RX   PubMed=15562009; DOI=10.1210/jc.2004-1604;
RA   Henwood M.J., Kelly A., MacMullen C., Bhatia P., Ganguly A.,
RA   Thornton P.S., Stanley C.A.;
RT   "Genotype-phenotype correlations in children with congenital
RT   hyperinsulinism due to recessive mutations of the adenosine
RT   triphosphate-sensitive potassium channel genes.";
RL   J. Clin. Endocrinol. Metab. 90:789-794(2005).
RN   [23]
RP   VARIANT TNDM3 ARG-42, AND CHARACTERIZATION OF VARIANT TNDM3 ARG-42.
RX   PubMed=15784703; DOI=10.1210/jc.2005-0096;
RA   Yorifuji T., Nagashima K., Kurokawa K., Kawai M., Oishi M.,
RA   Akazawa Y., Hosokawa M., Yamada Y., Inagaki N., Nakahata T.;
RT   "The C42R mutation in the Kir6.2 (KCNJ11) gene as a cause of transient
RT   neonatal diabetes, childhood diabetes, or later-onset, apparently type
RT   2 diabetes mellitus.";
RL   J. Clin. Endocrinol. Metab. 90:3174-3178(2005).
RN   [24]
RP   VARIANT HHF2 ARG-259, AND CHARACTERIZATION OF VARIANT HHF2 ARG-259.
RX   PubMed=15998776; DOI=10.1210/jc.2005-0202;
RA   Marthinet E., Bloc A., Oka Y., Tanizawa Y., Wehrle-Haller B.,
RA   Bancila V., Dubuis J.-M., Philippe J., Schwitzgebel V.M.;
RT   "Severe congenital hyperinsulinism caused by a mutation in the Kir6.2
RT   subunit of the adenosine triphosphate-sensitive potassium channel
RT   impairing trafficking and function.";
RL   J. Clin. Endocrinol. Metab. 90:5401-5406(2005).
RN   [25]
RP   VARIANTS PNDM GLN-50 AND PRO-50, AND CHARACTERIZATION OF VARIANTS PNDM
RP   GLN-50 AND PRO-50.
RX   PubMed=16731833; DOI=10.2337/db05-1640;
RA   Shimomura K., Girard C.A.J., Proks P., Nazim J., Lippiat J.D.,
RA   Cerutti F., Lorini R., Ellard S., Hattersely A.T., Barbetti F.,
RA   Ashcroft F.M.;
RT   "Mutations at the same residue (R50) of Kir6.2 (KCNJ11) that cause
RT   neonatal diabetes produce different functional effects.";
RL   Diabetes 55:1705-1712(2006).
RN   [26]
RP   VARIANTS PNDM TYR-46; GLN-50; ARG-52; ASP-53; GLY-59; MET-59; PRO-164;
RP   TYR-166; THR-170; CYS-201; HIS-201; LEU-201; LEU-296 AND SER-330.
RX   PubMed=16609879; DOI=10.1007/s00125-006-0246-z;
RA   Flanagan S.E., Edghill E.L., Gloyn A.L., Ellard S., Hattersley A.T.;
RT   "Mutations in KCNJ11, which encodes Kir6.2, are a common cause of
RT   diabetes diagnosed in the first 6 months of life, with the phenotype
RT   determined by genotype.";
RL   Diabetologia 49:1190-1197(2006).
RN   [27]
RP   VARIANTS LYS-23 AND VAL-337.
RX   PubMed=16429405; DOI=10.1002/humu.9401;
RA   Fernandez-Marmiesse A., Salas A., Vega A., Fernandez-Lorenzo J.R.,
RA   Barreiro J., Carracedo A.;
RT   "Mutation spectra of ABCC8 gene in Spanish patients with
RT   Hyperinsulinism of Infancy (HI).";
RL   Hum. Mutat. 27:214-214(2006).
RN   [28]
RP   VARIANT HHF2 LEU-55, AND CHARACTERIZATION OF VARIANT HHF2 LEU-55.
RX   PubMed=16332676; DOI=10.1074/jbc.M511875200;
RA   Lin Y.-W., MacMullen C., Ganguly A., Stanley C.A., Shyng S.-L.;
RT   "A novel KCNJ11 mutation associated with congenital hyperinsulinism
RT   reduces the intrinsic open probability of beta-cell ATP-sensitive
RT   potassium channels.";
RL   J. Biol. Chem. 281:3006-3012(2006).
RN   [29]
RP   VARIANTS HHF2 ASP-40; ASP-101; PRO-116; LEU-136 AND HIS-301.
RX   PubMed=16357843; DOI=10.1038/modpathol.3800497;
RA   Suchi M., MacMullen C.M., Thornton P.S., Adzick N.S., Ganguly A.,
RA   Ruchelli E.D., Stanley C.A.;
RT   "Molecular and immunohistochemical analyses of the focal form of
RT   congenital hyperinsulinism.";
RL   Mod. Pathol. 19:122-129(2006).
RN   [30]
RP   VARIANTS PNDM TYR-46; PRO-164 AND HIS-201.
RX   PubMed=17213273; DOI=10.1210/jc.2006-2490;
RA   Stanik J., Gasperikova D., Paskova M., Barak L., Javorkova J.,
RA   Jancova E., Ciljakova M., Hlava P., Michalek J., Flanagan S.E.,
RA   Pearson E., Hattersley A.T., Ellard S., Klimes I.;
RT   "Prevalence of permanent neonatal diabetes in Slovakia and successful
RT   replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8
RT   mutation carriers.";
RL   J. Clin. Endocrinol. Metab. 92:1276-1282(2007).
CC   -!- FUNCTION: This receptor is controlled by G proteins. Inward
CC       rectifier potassium channels are characterized by a greater
CC       tendency to allow potassium to flow into the cell rather than out
CC       of it. Their voltage dependence is regulated by the concentration
CC       of extracellular potassium; as external potassium is raised, the
CC       voltage range of the channel opening shifts to more positive
CC       voltages. The inward rectification is mainly due to the blockage
CC       of outward current by internal magnesium. Can be blocked by
CC       extracellular barium (By similarity).
CC   -!- SUBUNIT: Associates with ABCC8/SUR.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- DISEASE: Defects in KCNJ11 are the cause of familial
CC       hyperinsulinemic hypoglycemia type 2 (HHF2) [MIM:601820]; also
CC       known as persistent hyperinsulinemic hypoglycemia of infancy
CC       (PPHI) or congenital hyperinsulinism. HHF is the most common cause
CC       of persistent hypoglycemia in infancy and is due to defective
CC       negative feedback regulation of insulin secretion by low glucose
CC       levels. It causes nesidioblastosis, a diffuse abnormality of the
CC       pancreas in which there is extensive, often disorganized formation
CC       of new islets. Unless early and aggressive intervention is
CC       undertaken, brain damage from recurrent episodes of hypoglycemia
CC       may occur.
CC   -!- DISEASE: Defects in KCNJ11 are a cause of permanent neonatal
CC       diabetes mellitus (PNDM) [MIM:606176]. PNDM is a rare form of
CC       diabetes characterized by insulin-requiring hyperglycemia that is
CC       diagnosed within the first months of life.
CC   -!- DISEASE: Defects in KCNJ11 are the cause of transient neonatal
CC       diabetes mellitus type 3 (TNDM3) [MIM:610582]. Neonatal diabetes
CC       mellitus, defined as insulin-requiring hyperglycemia within the
CC       first month of life, is a rare entity. In about half of the
CC       neonates, diabetes is transient and resolves at a median age of 3
CC       months, whereas the rest have a permanent form of diabetes. In a
CC       significant number of patients with transient neonatal diabetes
CC       mellitus, diabetes type 2 appears later in life. The onset and
CC       severity of TNDM3 is variable with childhood-onset diabetes,
CC       gestational diabetes or adult-onset diabetes described.
CC   -!- DISEASE: Defects in KCNJ11 may contribute to non-insulin-dependent
CC       diabetes mellitus (NIDDM), also known as diabetes mellitus type 2.
CC   -!- SIMILARITY: Belongs to the inward rectifier-type potassium channel
CC       family.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/KCNJ11";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D50582; BAA09131.1; -; Genomic_DNA.
DR   EMBL; BC064497; AAH64497.1; -; mRNA.
DR   EMBL; BC112358; AAI12359.1; -; mRNA.
DR   IPI; IPI00291902; -.
DR   PIR; A57616; A57616.
DR   UniGene; Hs.248141; -.
DR   SMR; Q14654; 32-338, 165-352.
DR   STRING; Q14654; -.
DR   PhosphoSite; Q14654; -.
DR   PRIDE; Q14654; -.
DR   Ensembl; ENST00000339994; ENSP00000345708; ENSG00000187486; Homo sapiens.
DR   GeneCards; GC11M017363; -.
DR   H-InvDB; HIX0035982; -.
DR   HGNC; HGNC:6257; KCNJ11.
DR   MIM; 600937; gene.
DR   MIM; 601820; phenotype.
DR   MIM; 606176; phenotype.
DR   MIM; 610582; phenotype.
DR   Orphanet; 79134; DEND syndrome.
DR   Orphanet; 224; Diabetes mellitus, neonatal.
DR   Orphanet; 99885; Diabetes mellitus, neonatal, permanent.
DR   Orphanet; 99886; Diabetes mellitus, neonatal, transient.
DR   Orphanet; 165988; Diffuse hyperinsulinism, diazoxide-resistant.
DR   Orphanet; 165985; Diffuse hyperinsulinism, diazoxide-sensitive.
DR   Orphanet; 79298; Hyperinsulinism due to focal adenomatous hyperplasia.
DR   Orphanet; 657; Persistent hyperinsulinemic hypoglycemia of infancy.
DR   PharmGKB; PA217; -.
DR   eggNOG; prNOG07403; -.
DR   HOGENOM; HBG716702; -.
DR   HOVERGEN; HBG006178; -.
DR   InParanoid; Q14654; -.
DR   Pathway_Interaction_DB; hnf3bpathway; FOXA2 and FOXA3 transcription factor networks.
DR   Reactome; REACT_1505; Integration of energy metabolism.
DR   Reactome; REACT_15380; Diabetes pathways.
DR   DrugBank; DB01119; Diazoxide.
DR   DrugBank; DB01016; Glibenclamide.
DR   DrugBank; DB00222; Glimepiride.
DR   DrugBank; DB00308; Ibutilide.
DR   DrugBank; DB00922; Levosimendan.
DR   DrugBank; DB01252; Mitiglinide.
DR   DrugBank; DB00731; Nateglinide.
DR   DrugBank; DB00912; Repaglinide.
DR   DrugBank; DB00661; Verapamil.
DR   ArrayExpress; Q14654; -.
DR   Bgee; Q14654; -.
DR   CleanEx; HS_KCNJ11; -.
DR   Genevestigator; Q14654; -.
DR   GermOnline; ENSG00000187486; Homo sapiens.
DR   GO; GO:0008282; C:ATP-sensitive potassium channel complex; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0015272; F:ATP-activated inward rectifier potassium ch...; ISS:UniProtKB.
DR   GO; GO:0030955; F:potassium ion binding; TAS:UniProtKB.
DR   GO; GO:0006006; P:glucose metabolic process; IMP:UniProtKB.
DR   GO; GO:0046676; P:negative regulation of insulin secretion; IMP:UniProtKB.
DR   GO; GO:0050877; P:neurological system process; IMP:UniProtKB.
DR   GO; GO:0010107; P:potassium ion import; ISS:UniProtKB.
DR   GO; GO:0042391; P:regulation of membrane potential; IDA:UniProtKB.
DR   GO; GO:0033198; P:response to ATP; IDA:UniProtKB.
DR   GO; GO:0042493; P:response to drug; IMP:UniProtKB.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR016449; K_chnl_inward-rec_Kir.
DR   InterPro; IPR001838; K_chnl_inward-rec_Kir-like.
DR   InterPro; IPR003279; K_chnl_inward-rec_Kir6.2.
DR   InterPro; IPR013521; K_chnl_inward-rec_Kir_Cr2.
DR   InterPro; IPR013518; K_chnl_inward-rec_Kir_cyto.
DR   Gene3D; G3DSA:2.60.40.1400; IR_K+channel_cytopl; 1.
DR   PANTHER; PTHR11767; K+channel_IR; 1.
DR   Pfam; PF01007; IRK; 1.
DR   PIRSF; PIRSF005465; GIRK_kir; 1.
DR   PRINTS; PR01332; KIR62CHANNEL.
DR   PRINTS; PR01320; KIRCHANNEL.
DR   SUPFAM; SSF81296; Ig_E-set; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Diabetes mellitus; Disease mutation; Ion transport;
KW   Ionic channel; Membrane; Polymorphism; Potassium; Potassium transport;
KW   Transmembrane; Transport; Voltage-gated channel.
FT   CHAIN         1    390       ATP-sensitive inward rectifier potassium
FT                                channel 11.
FT                                /FTId=PRO_0000154957.
FT   TOPO_DOM      1     68       Cytoplasmic (By similarity).
FT   TRANSMEM     69     93       M1 (By similarity).
FT   TOPO_DOM     94    116       Extracellular (By similarity).
FT   TOPO_DOM    136    144       Extracellular (By similarity).
FT   TRANSMEM    145    166       M2 (By similarity).
FT   TOPO_DOM    167    390       Cytoplasmic (By similarity).
FT   REGION      117    128       H5 (pore-forming helix) (By similarity).
FT   MOTIF       130    135       Selectivity filter (By similarity).
FT   SITE        160    160       Role in the control of polyamine-mediated
FT                                channel gating and in the blocking by
FT                                intracellular magnesium (By similarity).
FT   VARIANT      10     10       E -> K (rare polymorphism).
FT                                /FTId=VAR_008659.
FT   VARIANT      18     18       A -> G (in dbSNP:rs41309072).
FT                                /FTId=VAR_055978.
FT   VARIANT      23     23       E -> K (linked to V-337; dbSNP:rs5219).
FT                                /FTId=VAR_008660.
FT   VARIANT      34     34       R -> H (in HHF2).
FT                                /FTId=VAR_031329.
FT   VARIANT      35     35       F -> L (in PNDM).
FT                                /FTId=VAR_026498.
FT   VARIANT      35     35       F -> V (in PNDM).
FT                                /FTId=VAR_026499.
FT   VARIANT      40     40       G -> D (in HHF2).
FT                                /FTId=VAR_031330.
FT   VARIANT      42     42       C -> R (in TNDM3; increased spontaneous
FT                                open probability; reduced ATP
FT                                sensitivity; reduced expression at the
FT                                cell surface of the functional ATP-
FT                                sensitive form).
FT                                /FTId=VAR_031331.
FT   VARIANT      46     46       H -> Y (in PNDM; one patient with mild
FT                                dysmorphic features).
FT                                /FTId=VAR_031332.
FT   VARIANT      50     50       R -> P (in PNDM; decreased inhibition by
FT                                ATP; enhanced activation by Mg(2+);
FT                                increased current; one patient with
FT                                developmental delay).
FT                                /FTId=VAR_026500.
FT   VARIANT      50     50       R -> Q (in PNDM; decreased inhibition by
FT                                ATP; enhanced activation by Mg(2+);
FT                                increased current).
FT                                /FTId=VAR_031333.
FT   VARIANT      52     52       Q -> R (in PNDM; with developmental delay
FT                                and epilepsy; produces larger current and
FT                                more change in ATP sensitivity than
FT                                mutation associated with mild disease C-
FT                                201).
FT                                /FTId=VAR_026501.
FT   VARIANT      53     53       G -> D (in PNDM; with developmental delay
FT                                and epilepsy).
FT                                /FTId=VAR_031334.
FT   VARIANT      53     53       G -> R (in TNDM3; also found in a family
FT                                member with PNDM; reduction in the
FT                                sensitivity to ATP when compared with
FT                                wild-type).
FT                                /FTId=VAR_026502.
FT   VARIANT      53     53       G -> S (in TNDM3; also found in a family
FT                                member with PNDM; reduction in the
FT                                sensitivity to ATP when compared with
FT                                wild-type).
FT                                /FTId=VAR_026503.
FT   VARIANT      55     55       F -> L (in HHF2; does neither affect
FT                                channel expression nor channel response
FT                                to MgADP).
FT                                /FTId=VAR_031335.
FT   VARIANT      59     59       V -> G (in PNDM; with developmental delay
FT                                and epilepsy; with neurologic features;
FT                                produces larger current and more change
FT                                in ATP sensitivity than mutation
FT                                associated with mild disease C-201;
FT                                decreases ATP sensitivity indirectly by
FT                                favoring the open conformation of the
FT                                channel).
FT                                /FTId=VAR_026504.
FT   VARIANT      59     59       V -> M (in PNDM; four patients with
FT                                developmental delay and muscle weakness).
FT                                /FTId=VAR_026505.
FT   VARIANT      67     67       K -> N (in HHF2).
FT                                /FTId=VAR_026506.
FT   VARIANT      91     91       W -> R (in HHF2).
FT                                /FTId=VAR_026507.
FT   VARIANT     101    101       A -> D (in HHF2).
FT                                /FTId=VAR_031336.
FT   VARIANT     116    116       S -> P (in HHF2).
FT                                /FTId=VAR_031337.
FT   VARIANT     134    134       G -> A (in HHF2).
FT                                /FTId=VAR_031338.
FT   VARIANT     136    136       R -> L (in HHF2).
FT                                /FTId=VAR_031339.
FT   VARIANT     147    147       L -> P (in HHF2; dbSNP:rs28936678).
FT                                /FTId=VAR_001557.
FT   VARIANT     148    148       I -> S.
FT                                /FTId=VAR_031340.
FT   VARIANT     164    164       L -> P (in PNDM).
FT                                /FTId=VAR_031341.
FT   VARIANT     166    166       C -> Y (in PNDM; individual also
FT                                diagnosed with West syndrome).
FT                                /FTId=VAR_031342.
FT   VARIANT     170    170       K -> N (in PNDM).
FT                                /FTId=VAR_026508.
FT   VARIANT     170    170       K -> R (in PNDM).
FT                                /FTId=VAR_026509.
FT   VARIANT     170    170       K -> T (in PNDM).
FT                                /FTId=VAR_031343.
FT   VARIANT     182    182       I -> V (in TNDM3; reduction in the
FT                                sensitivity to ATP when compared with
FT                                wild-type).
FT                                /FTId=VAR_026510.
FT   VARIANT     195    195       R -> H (in dbSNP:rs5217).
FT                                /FTId=VAR_014929.
FT   VARIANT     201    201       R -> C (in PNDM; two individuals with
FT                                developmental delay; produces smaller
FT                                current and less change in ATP
FT                                sensitivity than mutations associated
FT                                with severe disease R-52 and G-59).
FT                                /FTId=VAR_026511.
FT   VARIANT     201    201       R -> H (in PNDM; ability of ATP to block
FT                                mutant channels greatly reduced).
FT                                /FTId=VAR_026512.
FT   VARIANT     201    201       R -> L (in PNDM).
FT                                /FTId=VAR_031344.
FT   VARIANT     254    254       P -> L (in HHF2; impairs trafficking of
FT                                the mutant channel).
FT                                /FTId=VAR_026513.
FT   VARIANT     259    259       H -> R (in HHF2; impairs trafficking and
FT                                abolishes channel function).
FT                                /FTId=VAR_031345.
FT   VARIANT     266    266       P -> L (in HHF2).
FT                                /FTId=VAR_031346.
FT   VARIANT     270    270       L -> V (in dbSNP:rs1800467).
FT                                /FTId=VAR_008661.
FT   VARIANT     296    296       I -> L (in PNDM; with developmental delay
FT                                and epilepsy).
FT                                /FTId=VAR_026514.
FT   VARIANT     301    301       R -> H (in HHF2).
FT                                /FTId=VAR_031347.
FT   VARIANT     322    322       E -> K (in PNDM).
FT                                /FTId=VAR_026515.
FT   VARIANT     330    330       Y -> C (in PNDM).
FT                                /FTId=VAR_026516.
FT   VARIANT     330    330       Y -> S (in PNDM).
FT                                /FTId=VAR_031348.
FT   VARIANT     333    333       F -> I (in PNDM).
FT                                /FTId=VAR_026517.
FT   VARIANT     337    337       I -> V (linked to K-23; dbSNP:rs5215).
FT                                /FTId=VAR_008662.
FT   VARIANT     355    355       L -> P (in NIDDM; Afro-Caribbean).
FT                                /FTId=VAR_008663.
FT   VARIANT     380    380       P -> PKP (in NIDDM).
FT                                /FTId=VAR_008664.
FT   VARIANT     385    385       S -> C (in dbSNP:rs41282930).
FT                                /FTId=VAR_008665.
SQ   SEQUENCE   390 AA;  43541 MW;  8345E7DBCE897344 CRC64;
     MLSRKGIIPE EYVLTRLAED PAEPRYRARQ RRARFVSKKG NCNVAHKNIR EQGRFLQDVF
     TTLVDLKWPH TLLIFTMSFL CSWLLFAMAW WLIAFAHGDL APSEGTAEPC VTSIHSFSSA
     FLFSIEVQVT IGFGGRMVTE ECPLAILILI VQNIVGLMIN AIMLGCIFMK TAQAHRRAET
     LIFSKHAVIA LRHGRLCFML RVGDLRKSMI ISATIHMQVV RKTTSPEGEV VPLHQVDIPM
     ENGVGGNSIF LVAPLIIYHV IDANSPLYDL APSDLHHHQD LEIIVILEGV VETTGITTQA
     RTSYLADEIL WGQRFVPIVA EEDGRYSVDY SKFGNTIKVP TPLCTARQLD EDHSLLEALT
     LASARGPLRK RSVPMAKAKP KFSISPDSLS
//
ID   IRK12_HUMAN             Reviewed;         433 AA.
AC   Q14500; O43401; Q15756; Q8NG63;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   11-OCT-2005, sequence version 2.
DT   02-MAR-2010, entry version 102.
DE   RecName: Full=ATP-sensitive inward rectifier potassium channel 12;
DE   AltName: Full=Potassium channel, inwardly rectifying subfamily J member 12;
DE   AltName: Full=Inward rectifier K(+) channel Kir2.2;
DE            Short=IRK-2;
DE   AltName: Full=Inward rectifier K(+) channel Kir2.2v;
GN   Name=KCNJ12; Synonyms=IRK2, KCNJN1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Heart atrium;
RX   MEDLINE=95163209; PubMed=7859381;
RA   Wible B.A., de Biasi M., Majumder K., Taglialatela M., Brown A.M.;
RT   "Cloning and functional expression of an inwardly rectifying K+
RT   channel from human atrium.";
RL   Circ. Res. 76:343-350(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-100.
RX   MEDLINE=96228066; PubMed=8647284; DOI=10.1016/0014-5793(96)00445-0;
RA   Namba N., Inagaki N., Gonoi T., Seino Y., Seino S.;
RT   "Kir2.2v: a possible negative regulator of the inwardly rectifying K+
RT   channel Kir2.2.";
RL   FEBS Lett. 386:211-214(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RX   MEDLINE=22304895; PubMed=12417321; DOI=10.1016/S0014-5793(02)03512-3;
RA   Kaibara M., Ishihara K., Doi Y., Hayashi H., Ehara T., Taniyama K.;
RT   "Identification of human Kir2.2 (KCNJ12) gene encoding functional
RT   inward rectifier potassium channel in both mammalian cells and Xenopus
RT   oocytes.";
RL   FEBS Lett. 531:250-254(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 161-433.
RC   TISSUE=Skeletal muscle;
RX   MEDLINE=98104111; PubMed=9430667; DOI=10.1074/jbc.273.3.1339;
RA   Gallagher P.G., Forget B.G.;
RT   "An alternate promoter directs expression of a truncated, muscle-
RT   specific isoform of the human ankyrin 1 gene.";
RL   J. Biol. Chem. 273:1339-1348(1998).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-405, AND MASS
RP   SPECTROMETRY.
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
CC   -!- FUNCTION: Probably participates in establishing action potential
CC       waveform and excitability of neuronal and muscle tissues. Inward
CC       rectifier potassium channels are characterized by a greater
CC       tendency to allow potassium to flow into the cell rather than out
CC       of it. Their voltage dependence is regulated by the concentration
CC       of extracellular potassium; as external potassium is raised, the
CC       voltage range of the channel opening shifts to more positive
CC       voltages. The inward rectification is mainly due to the blockage
CC       of outward current by internal magnesium. Can be blocked by
CC       extracellular barium and cesium.
CC   -!- SUBUNIT: Association, via its PDZ-recognition domain, with LIN7A,
CC       LIN7B, LIN7C, DLG1, CASK and APBA1 plays a key role in its
CC       localization and trafficking (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the inward rectifier-type potassium channel
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L36069; AAA65122.1; -; mRNA.
DR   EMBL; U53143; AAC50615.1; -; Genomic_DNA.
DR   EMBL; AB074970; BAC02718.1; -; Genomic_DNA.
DR   EMBL; AB182123; BAD23901.1; -; mRNA.
DR   EMBL; BC027982; AAH27982.1; -; mRNA.
DR   EMBL; AF005214; AAC01951.1; -; mRNA.
DR   IPI; IPI00450699; -.
DR   PIR; I52864; I52864.
DR   PIR; S71341; S71341.
DR   RefSeq; NP_066292.2; -.
DR   RefSeq; XP_001718688.2; -.
DR   RefSeq; XP_002347768.1; -.
DR   UniGene; Hs.200629; -.
DR   SMR; Q14500; 43-349, 192-369.
DR   STRING; Q14500; -.
DR   PhosphoSite; Q14500; -.
DR   PRIDE; Q14500; -.
DR   Ensembl; ENST00000331718; ENSP00000328150; ENSG00000184185; Homo sapiens.
DR   GeneID; 100131509; -.
DR   GeneID; 100290070; -.
DR   GeneID; 3768; -.
DR   KEGG; hsa:100131509; -.
DR   KEGG; hsa:100290070; -.
DR   KEGG; hsa:3768; -.
DR   UCSC; uc002gyv.1; human.
DR   CTD; 3768; -.
DR   GeneCards; GC17P021220; -.
DR   GeneCards; GC17P021222; -.
DR   GeneCards; GC17P021223; -.
DR   H-InvDB; HIX0039034; -.
DR   HGNC; HGNC:6258; KCNJ12.
DR   MIM; 602323; gene.
DR   PharmGKB; PA218; -.
DR   eggNOG; prNOG08425; -.
DR   HOGENOM; HBG716702; -.
DR   HOVERGEN; HBG006178; -.
DR   InParanoid; Q14500; -.
DR   OMA; RHDFDRL; -.
DR   OrthoDB; EOG9R26DF; -.
DR   PhylomeDB; Q14500; -.
DR   DrugBank; DB00204; Dofetilide.
DR   NextBio; 14775; -.
DR   ArrayExpress; Q14500; -.
DR   Bgee; Q14500; -.
DR   Genevestigator; Q14500; -.
DR   GermOnline; ENSG00000184185; Homo sapiens.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005242; F:inward rectifier potassium channel activity; TAS:ProtInc.
DR   GO; GO:0008200; F:ion channel inhibitor activity; TAS:ProtInc.
DR   GO; GO:0015459; F:potassium channel regulator activity; TAS:ProtInc.
DR   GO; GO:0030955; F:potassium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008015; P:blood circulation; NAS:ProtInc.
DR   GO; GO:0006936; P:muscle contraction; TAS:ProtInc.
DR   GO; GO:0006813; P:potassium ion transport; TAS:ProtInc.
DR   GO; GO:0008016; P:regulation of heart contraction; TAS:ProtInc.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR016449; K_chnl_inward-rec_Kir.
DR   InterPro; IPR001838; K_chnl_inward-rec_Kir-like.
DR   InterPro; IPR003272; K_chnl_inward-rec_Kir2.2.
DR   InterPro; IPR013521; K_chnl_inward-rec_Kir_Cr2.
DR   InterPro; IPR013518; K_chnl_inward-rec_Kir_cyto.
DR   InterPro; IPR013673; K_chnl_inward-rec_Kir_N.
DR   Gene3D; G3DSA:2.60.40.1400; IR_K+channel_cytopl; 1.
DR   PANTHER; PTHR11767; K+channel_IR; 1.
DR   PANTHER; PTHR11767:SF14; KIR22_channel; 1.
DR   Pfam; PF01007; IRK; 1.
DR   Pfam; PF08466; IRK_N; 1.
DR   PIRSF; PIRSF005465; GIRK_kir; 1.
DR   PRINTS; PR01325; KIR22CHANNEL.
DR   PRINTS; PR01320; KIRCHANNEL.
DR   SUPFAM; SSF81296; Ig_E-set; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Ion transport; Ionic channel; Membrane;
KW   Phosphoprotein; Polymorphism; Potassium; Potassium transport;
KW   Transmembrane; Transport; Voltage-gated channel.
FT   CHAIN         1    433       ATP-sensitive inward rectifier potassium
FT                                channel 12.
FT                                /FTId=PRO_0000154962.
FT   TOPO_DOM      1     80       Cytoplasmic (By similarity).
FT   TRANSMEM     81    105       M1 (By similarity).
FT   TOPO_DOM    106    129       Extracellular (By similarity).
FT   TOPO_DOM    149    157       Extracellular (By similarity).
FT   TRANSMEM    158    179       M2 (By similarity).
FT   TOPO_DOM    180    433       Cytoplasmic (By similarity).
FT   REGION      130    141       H5 (pore-forming helix) (By similarity).
FT   MOTIF       143    148       Selectivity filter (By similarity).
FT   MOTIF       431    433       PDZ-binding (Potential).
FT   SITE        173    173       Role in the control of polyamine-mediated
FT                                channel gating and in the blocking by
FT                                intracellular magnesium (By similarity).
FT   MOD_RES     405    405       Phosphoserine.
FT   VARIANT       6      6       R -> Q (in dbSNP:rs3752032).
FT                                /FTId=VAR_024509.
FT   VARIANT      15     15       S -> L (in dbSNP:rs1657738).
FT                                /FTId=VAR_049671.
FT   VARIANT     100    100       I -> V (in dbSNP:rs8076599).
FT                                /FTId=VAR_059365.
FT   VARIANT     118    118       R -> Q (in dbSNP:rs1657740).
FT                                /FTId=VAR_059366.
FT   VARIANT     156    156       P -> L (in dbSNP:rs1714864).
FT                                /FTId=VAR_049672.
FT   VARIANT     192    192       Q -> H (in dbSNP:rs1657742).
FT                                /FTId=VAR_059367.
FT   VARIANT     249    249       I -> V (in dbSNP:rs4985866).
FT                                /FTId=VAR_049673.
FT   VARIANT     430    430       E -> G (in dbSNP:rs5021699).
FT                                /FTId=VAR_059368.
FT   CONFLICT     43     43       R -> H (in Ref. 2; AAC50615).
FT   CONFLICT     71     71       M -> I (in Ref. 2; AAC50615).
FT   CONFLICT    139    139       E -> K (in Ref. 2; AAC50615).
FT   CONFLICT    142    142       T -> N (in Ref. 2; AAC50615).
FT   CONFLICT    145    145       G -> S (in Ref. 2; AAC50615).
FT   CONFLICT    173    173       D -> N (in Ref. 2; AAC50615).
FT   CONFLICT    184    184       M -> V (in Ref. 5; AAC01951).
FT   CONFLICT    185    185       A -> V (in Ref. 2; AAC50615).
FT   CONFLICT    211    211       L -> F (in Ref. 2; AAC50615).
FT   CONFLICT    239    239       E -> K (in Ref. 2; AAC50615).
FT   CONFLICT    261    262       RI -> HS (in Ref. 2; AAC50615).
FT   CONFLICT    285    285       Missing (in Ref. 1; AAA65122).
FT   CONFLICT    289    290       ET -> QM (in Ref. 2; AAC50615).
FT   CONFLICT    297    297       V -> I (in Ref. 2; AAC50615).
FT   CONFLICT    302    302       M -> I (in Ref. 2; AAC50615).
FT   CONFLICT    334    334       Missing (in Ref. 2; AAC50615 and 5).
FT   CONFLICT    343    343       S -> L (in Ref. 2; AAC50615).
FT   CONFLICT    371    371       S -> R (in Ref. 2; AAC50615).
FT   CONFLICT    378    378       E -> K (in Ref. 2; AAC50615).
FT   CONFLICT    402    402       D -> E (in Ref. 2; AAC50615).
FT   CONFLICT    405    405       S -> I (in Ref. 2; AAC50615).
SQ   SEQUENCE   433 AA;  49001 MW;  082027A1765B6F4E CRC64;
     MTAASRANPY SIVSSEEDGL HLVTMSGANG FGNGKVHTRR RCRNRFVKKN GQCNIEFANM
     DEKSQRYLAD MFTTCVDIRW RYMLLIFSLA FLASWLLFGI IFWVIAVAHG DLEPAEGRGR
     TPCVMQVHGF MAAFLFSIET QTTIGYGLRC VTEECPVAVF MVVAQSIVGC IIDSFMIGAI
     MAKMARPKKR AQTLLFSHNA VVALRDGKLC LMWRVGNLRK SHIVEAHVRA QLIKPRVTEE
     GEYIPLDQID IDVGFDKGLD RIFLVSPITI LHEIDEASPL FGISRQDLET DDFEIVVILE
     GMVEATAMTT QARSSYLANE ILWGHRFEPV LFEEKNQYKI DYSHFHKTYE VPSTPRCSAK
     DLVENKFLLP SANSFCYENE LAFLSRDEED EADGDQDGRS RDGLSPQARH DFDRLQAGGG
     VLEQRPYRRE SEI
//
ID   IRK12_RAT               Reviewed;         427 AA.
AC   P52188;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   02-MAR-2010, entry version 82.
DE   RecName: Full=ATP-sensitive inward rectifier potassium channel 12;
DE   AltName: Full=Potassium channel, inwardly rectifying subfamily J member 12;
DE   AltName: Full=Inward rectifier K(+) channel Kir2.2;
DE            Short=IRK-2;
GN   Name=Kcnj12; Synonyms=Irk2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   MEDLINE=94185816; PubMed=8137958; DOI=10.1016/0014-5793(94)80478-8;
RA   Koyama H., Morishige K., Takahashi N., Zanelli J.S., Fass D.N.,
RA   Kurachi Y.;
RT   "Molecular cloning, functional expression and localization of a novel
RT   inward rectifier potassium channel in the rat brain.";
RL   FEBS Lett. 341:303-307(1994).
RN   [2]
RP   INTERACTION WITH CASK; LIN7A; LIN7B; LIN7C; APBA1 AND DLG1, AND
RP   FUNCTION.
RX   PubMed=14960569; DOI=10.1074/jbc.M400284200;
RA   Leonoudakis D., Conti L.R., Radeke C.M., McGuire L.M.,
RA   Vandenberg C.A.;
RT   "A multiprotein trafficking complex composed of SAP97, CASK, Veli, and
RT   Mint1 is associated with inward rectifier Kir2 potassium channels.";
RL   J. Biol. Chem. 279:19051-19063(2004).
CC   -!- FUNCTION: Probably participates in establishing action potential
CC       waveform and excitability of neuronal and muscle tissues. Inward
CC       rectifier potassium channels are characterized by a greater
CC       tendency to allow potassium to flow into the cell rather than out
CC       of it. Their voltage dependence is regulated by the concentration
CC       of extracellular potassium; as external potassium is raised, the
CC       voltage range of the channel opening shifts to more positive
CC       voltages. The inward rectification is mainly due to the blockage
CC       of outward current by internal magnesium. Can be blocked by
CC       extracellular barium and cesium.
CC   -!- SUBUNIT: Association, via its PDZ-recognition domain, with LIN7A,
CC       LIN7B, LIN7C, DLG1, CASK and APBA1 plays a key role in its
CC       localization and trafficking.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Highest level in cerebellum. Moderately found
CC       in kidney, forebrain and skeletal muscle. Not detected in uterus,
CC       liver and pancreas.
CC   -!- SIMILARITY: Belongs to the inward rectifier-type potassium channel
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X78461; CAA55216.1; -; mRNA.
DR   IPI; IPI00777371; -.
DR   PIR; S43667; S43667.
DR   UniGene; Rn.10406; -.
DR   SMR; P52188; 43-349, 188-369.
DR   STRING; P52188; -.
DR   PhosphoSite; P52188; -.
DR   Ensembl; ENSRNOT00000003138; ENSRNOP00000003138; ENSRNOG00000002303; Rattus norvegicus.
DR   Ensembl; ENSRNOT00000057953; ENSRNOP00000054762; ENSRNOG00000002303; Rattus norvegicus.
DR   UCSC; NM_053981; rat.
DR   RGD; 621660; Kcnj12.
DR   eggNOG; maNOG08081; -.
DR   HOVERGEN; HBG006178; -.
DR   InParanoid; P52188; -.
DR   ArrayExpress; P52188; -.
DR   Genevestigator; P52188; -.
DR   GermOnline; ENSRNOG00000002303; Rattus norvegicus.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030315; C:T-tubule; IDA:RGD.
DR   GO; GO:0005242; F:inward rectifier potassium channel activity; IEA:InterPro.
DR   GO; GO:0030165; F:PDZ domain binding; IPI:RGD.
DR   GO; GO:0030955; F:potassium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006813; P:potassium ion transport; IEA:UniProtKB-KW.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR016449; K_chnl_inward-rec_Kir.
DR   InterPro; IPR001838; K_chnl_inward-rec_Kir-like.
DR   InterPro; IPR003272; K_chnl_inward-rec_Kir2.2.
DR   InterPro; IPR013521; K_chnl_inward-rec_Kir_Cr2.
DR   InterPro; IPR013518; K_chnl_inward-rec_Kir_cyto.
DR   InterPro; IPR013673; K_chnl_inward-rec_Kir_N.
DR   Gene3D; G3DSA:2.60.40.1400; IR_K+channel_cytopl; 1.
DR   PANTHER; PTHR11767; K+channel_IR; 1.
DR   PANTHER; PTHR11767:SF14; KIR22_channel; 1.
DR   Pfam; PF01007; IRK; 1.
DR   Pfam; PF08466; IRK_N; 1.
DR   PIRSF; PIRSF005465; GIRK_kir; 1.
DR   PRINTS; PR01325; KIR22CHANNEL.
DR   PRINTS; PR01320; KIRCHANNEL.
DR   SUPFAM; SSF81296; Ig_E-set; 1.
PE   1: Evidence at protein level;
KW   Ion transport; Ionic channel; Membrane; Phosphoprotein; Potassium;
KW   Potassium transport; Transmembrane; Transport; Voltage-gated channel.
FT   CHAIN         1    427       ATP-sensitive inward rectifier potassium
FT                                channel 12.
FT                                /FTId=PRO_0000154964.
FT   TOPO_DOM      1     80       Cytoplasmic (By similarity).
FT   TRANSMEM     81    105       M1 (By similarity).
FT   TOPO_DOM    106    129       Extracellular (By similarity).
FT   TOPO_DOM    149    157       Extracellular (By similarity).
FT   TRANSMEM    158    179       M2 (By similarity).
FT   TOPO_DOM    180    427       Cytoplasmic (By similarity).
FT   REGION      130    141       H5 (pore-forming helix) (By similarity).
FT   MOTIF       143    148       Selectivity filter (By similarity).
FT   MOTIF       425    427       PDZ-binding (Potential).
FT   SITE        173    173       Role in the control of polyamine-mediated
FT                                channel gating and in the blocking by
FT                                intracellular magnesium (By similarity).
FT   MOD_RES     400    400       Phosphoserine (By similarity).
SQ   SEQUENCE   427 AA;  48399 MW;  6FA100FEB6066677 CRC64;
     MTAASRANPY SIVSSEEDGL HLVTMSGANG FGNGKVHTRR RCRNRFVKKN GQCNIEFANM
     DEKSQRYLAD MFTTCVDIRW RYMLLIFSLA FLASWLLFGI IFWVIAVAHG DLEPAEGRGR
     TPCVLQVHGF MAAFLFSIET QTTIGYGLRC VTEECPVAVF MVVAQSIVGC IIDSFMIGAI
     MAKMGRPKKR AQTLLFSHNA VVALRDGKLC LMWRVGNLRK SHIVEAHVRA QLIKPRVTEE
     GEYIPLDQID IDVGFDKGLD RIFLVSPITI LHEIDEASPL FGISRQDLET DDFEIVVILE
     GMVEATAMTT QARSSYLANE ILWGHRFEPV LFEEKNQYKI DYSHFHKTYE VPSTPRCSAK
     DLVENKFLLP SANSFCYENE LAFLSRDEED EVATDRDGRS PQPEHDFDRL QASSGALERP
     YRRESEI
//
ID   IRK13_HUMAN             Reviewed;         360 AA.
AC   O60928; O76023; Q8N3Y4;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1998, sequence version 1.
DT   02-MAR-2010, entry version 93.
DE   RecName: Full=Inward rectifier potassium channel 13;
DE   AltName: Full=Potassium channel, inwardly rectifying subfamily J member 13;
DE   AltName: Full=Inward rectifier K(+) channel Kir7.1;
GN   Name=KCNJ13;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ILE-175.
RC   TISSUE=Brain;
RX   MEDLINE=98408852; PubMed=9738472; DOI=10.1016/S0014-5793(98)00972-7;
RA   Partiseti M., Collura V., Agnel M., Culouscou J.-M., Graham D.;
RT   "Cloning and characterization of a novel human inwardly rectifying
RT   potassium channel predominantly expressed in small intestine.";
RL   FEBS Lett. 434:171-176(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   MEDLINE=98282025; PubMed=9620703; DOI=10.1016/S0896-6273(00)80480-8;
RA   Krapivinsky G., Medina I., Eng L., Krapivinsky L., Yang Y.,
RA   Clapham D.E.;
RT   "A novel inward rectifier K+ channel with unique pore properties.";
RL   Neuron 20:995-1005(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Small intestine;
RA   Hirose S., Suzuki Y., Nakamura N.;
RL   Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Nakamura N., Matsuki T., Suzuki Y., Sakuta H., Ito T., Hirose S.;
RL   Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Testis;
RA   Doering F., Derst C., Wischmeyer E., Karschin C., Daut J.,
RA   Karschin A.;
RT   "Unique epithelial Kir7.1 subunit defines a new subfamily of inwardly
RT   rectifying potassium channels.";
RL   Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ILE-175; GLN-290
RP   AND CYS-309.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 147-175.
RX   MEDLINE=99097357; PubMed=9878260; DOI=10.1006/geno.1998.5598;
RA   Derst C., Doring F., Preisig-M ueller R., Daut J., Karschin A.,
RA   Jeck N., Weber S., Engel H., Grzeschik K.-H.;
RT   "Partial gene structure and assignment to chromosome 2q37 of the human
RT   inwardly rectifying K+ channel (Kir7.1) gene (KCNJ13).";
RL   Genomics 54:560-563(1998).
RN   [8]
RP   VARIANT SVD TRP-162, AND CHARACTERIZATION OF VARIANT SVD TRP-162.
RX   PubMed=18179896; DOI=10.1016/j.ajhg.2007.08.002;
RA   Hejtmancik J.F., Jiao X., Li A., Sergeev Y.V., Ding X., Sharma A.K.,
RA   Chan C.-C., Medina I., Edwards A.O.;
RT   "Mutations in KCNJ13 cause autosomal-dominant snowflake vitreoretinal
RT   degeneration.";
RL   Am. J. Hum. Genet. 82:174-180(2008).
CC   -!- FUNCTION: Inward rectifier potassium channels are characterized by
CC       a greater tendency to allow potassium to flow into the cell rather
CC       than out of it. Their voltage dependence is regulated by the
CC       concentration of extracellular potassium; as external potassium is
CC       raised, the voltage range of the channel opening shifts to more
CC       positive voltages. The inward rectification is mainly due to the
CC       blockage of outward current by internal magnesium. KCNJ13 has a
CC       very low single channel conductance, low sensitivity to block by
CC       external barium and cesium, and no dependence of its inward
CC       rectification properties on the internal blocking particle
CC       magnesium.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in small intestine.
CC       Expression is also detected in stomach, kidney, and all central
CC       nervous system regions tested with the exception of spinal cord.
CC   -!- DISEASE: Defects in KCNJ13 are the cause of snowflake
CC       vitreoretinal degeneration (SVD) [MIM:193230]. SVD is a
CC       developmental and progressive hereditary eye disorder that affects
CC       multiple tissues within the eye. Diagnostic features of SVD
CC       include fibrillar degeneration of the vitreous humor, early-onset
CC       cataract, minute crystalline deposits in the neurosensory retina,
CC       and retinal detachment.
CC   -!- SIMILARITY: Belongs to the inward rectifier-type potassium channel
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ007557; CAA07552.1; -; mRNA.
DR   EMBL; AF061118; AAC15769.1; -; mRNA.
DR   EMBL; AB013889; BAA28271.1; -; mRNA.
DR   EMBL; AB013891; BAA28273.1; -; mRNA.
DR   EMBL; AJ006128; CAA06878.1; -; mRNA.
DR   EMBL; BC037290; AAH37290.1; -; mRNA.
DR   EMBL; AF082182; AAD08673.1; -; Genomic_DNA.
DR   IPI; IPI00000058; -.
DR   RefSeq; NP_002233.2; -.
DR   UniGene; Hs.467338; -.
DR   SMR; O60928; 39-323.
DR   STRING; O60928; -.
DR   TCDB; 1.A.2.1.8; inward rectifier K+ channel (IRK-C) family.
DR   PhosphoSite; O60928; -.
DR   PRIDE; O60928; -.
DR   Ensembl; ENST00000233826; ENSP00000233826; ENSG00000115474; Homo sapiens.
DR   Ensembl; ENST00000410029; ENSP00000386251; ENSG00000115474; Homo sapiens.
DR   GeneID; 3769; -.
DR   KEGG; hsa:3769; -.
DR   UCSC; uc002vto.2; human.
DR   CTD; 3769; -.
DR   GeneCards; GC02M233339; -.
DR   H-InvDB; HIX0023903; -.
DR   H-InvDB; HIX0030206; -.
DR   HGNC; HGNC:6259; KCNJ13.
DR   MIM; 193230; phenotype.
DR   MIM; 603208; gene.
DR   Orphanet; 91496; Snowflake vitreoretinal degeneration.
DR   PharmGKB; PA30044; -.
DR   eggNOG; prNOG19555; -.
DR   HOGENOM; HBG716702; -.
DR   HOVERGEN; HBG006178; -.
DR   InParanoid; O60928; -.
DR   OMA; AVLYQER; -.
DR   OrthoDB; EOG9XH2K2; -.
DR   PhylomeDB; O60928; -.
DR   NextBio; 14781; -.
DR   ArrayExpress; O60928; -.
DR   Bgee; O60928; -.
DR   CleanEx; HS_KCNJ13; -.
DR   Genevestigator; O60928; -.
DR   GermOnline; ENSG00000115474; Homo sapiens.
DR   GO; GO:0008076; C:voltage-gated potassium channel complex; NAS:UniProtKB.
DR   GO; GO:0005242; F:inward rectifier potassium channel activity; NAS:UniProtKB.
DR   GO; GO:0030955; F:potassium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006813; P:potassium ion transport; NAS:UniProtKB.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR016449; K_chnl_inward-rec_Kir.
DR   InterPro; IPR001838; K_chnl_inward-rec_Kir-like.
DR   InterPro; IPR008062; K_chnl_inward-rec_Kir7.
DR   InterPro; IPR013521; K_chnl_inward-rec_Kir_Cr2.
DR   InterPro; IPR013518; K_chnl_inward-rec_Kir_cyto.
DR   Gene3D; G3DSA:2.60.40.1400; IR_K+channel_cytopl; 1.
DR   PANTHER; PTHR11767; K+channel_IR; 1.
DR   PANTHER; PTHR11767:SF3; KIR7_channel; 1.
DR   Pfam; PF01007; IRK; 1.
DR   PIRSF; PIRSF005465; GIRK_kir; 1.
DR   PRINTS; PR01679; KIR7CHANNEL.
DR   PRINTS; PR01320; KIRCHANNEL.
DR   SUPFAM; SSF81296; Ig_E-set; 1.
PE   1: Evidence at protein level;
KW   Cataract; Complete proteome; Disease mutation; Ion transport;
KW   Ionic channel; Membrane; Phosphoprotein; Polymorphism; Potassium;
KW   Potassium transport; Transmembrane; Transport; Voltage-gated channel.
FT   CHAIN         1    360       Inward rectifier potassium channel 13.
FT                                /FTId=PRO_0000154966.
FT   TOPO_DOM      1     53       Cytoplasmic (By similarity).
FT   TRANSMEM     54     78       M1 (By similarity).
FT   TOPO_DOM     79    105       Extracellular (By similarity).
FT   TOPO_DOM    125    133       Extracellular (By similarity).
FT   TRANSMEM    134    155       M2 (By similarity).
FT   TOPO_DOM    156    360       Cytoplasmic (By similarity).
FT   REGION      106    117       H5 (pore-forming helix) (By similarity).
FT   MOTIF       119    124       Selectivity filter (By similarity).
FT   SITE        149    149       Role in the control of polyamine-mediated
FT                                channel gating and in the blocking by
FT                                intracellular magnesium (By similarity).
FT   MOD_RES     327    327       Phosphothreonine (By similarity).
FT   VARIANT     162    162       R -> W (in SVD; overexpression produces a
FT                                non-selective cation current that
FT                                depolarizes transfected cells and
FT                                increases their fragility).
FT                                /FTId=VAR_043509.
FT   VARIANT     175    175       T -> I (in dbSNP:rs1801251).
FT                                /FTId=VAR_016193.
FT   VARIANT     290    290       P -> Q (in dbSNP:rs17853727).
FT                                /FTId=VAR_043510.
FT   VARIANT     309    309       G -> C (in dbSNP:rs17857137).
FT                                /FTId=VAR_043511.
SQ   SEQUENCE   360 AA;  40530 MW;  0C49D0DBC619BC50 CRC64;
     MDSSNCKVIA PLLSQRYRRM VTKDGHSTLQ MDGAQRGLAY LRDAWGILMD MRWRWMMLVF
     SASFVVHWLV FAVLWYVLAE MNGDLELDHD APPENHTICV KYITSFTAAF SFSLETQLTI
     GYGTMFPSGD CPSAIALLAI QMLLGLMLEA FITGAFVAKI ARPKNRAFSI RFTDTAVVAH
     MDGKPNLIFQ VANTRPSPLT SVRVSAVLYQ ERENGKLYQT SVDFHLDGIS SDECPFFIFP
     LTYYHSITPS SPLATLLQHE NPSHFELVVF LSAMQEGTGE ICQRRTSYLP SEIMLHHCFA
     SLLTRGSKGE YQIKMENFDK TVPEFPTPLV SKSPNRTDLD IHINGQSIDN FQISETGLTE
//
ID   IRK13_MOUSE             Reviewed;         360 AA.
AC   P86046;
DT   25-NOV-2008, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 1.
DT   02-MAR-2010, entry version 16.
DE   RecName: Full=Inward rectifier potassium channel 13;
DE   AltName: Full=Potassium channel, inwardly rectifying subfamily J member 13;
DE   AltName: Full=Inward rectifier K(+) channel Kir7.1;
GN   Name=Kcnj13;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S.,
RA   She X., Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W.,
RA   Kapustin Y., Meric P., Maglott D., Birtle Z., Marques A.C., Graves T.,
RA   Zhou S., Teague B., Potamousis K., Churas C., Place M., Herschleb J.,
RA   Runnheim R., Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z.,
RA   Lindblad-Toh K., Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of
RT   the mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [2]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-327, AND MASS
RP   SPECTROMETRY.
RX   PubMed=18973353; DOI=10.1021/pr800599n;
RA   Zanivan S., Gnad F., Wickstroem S.A., Geiger T., Macek B., Cox J.,
RA   Faessler R., Mann M.;
RT   "Solid tumor proteome and phosphoproteome analysis by high resolution
RT   mass spectrometry.";
RL   J. Proteome Res. 7:5314-5326(2008).
CC   -!- FUNCTION: Inward rectifier potassium channels are characterized by
CC       a greater tendency to allow potassium to flow into the cell rather
CC       than out of it. Their voltage dependence is regulated by the
CC       concentration of extracellular potassium; as external potassium is
CC       raised, the voltage range of the channel opening shifts to more
CC       positive voltages. The inward rectification is mainly due to the
CC       blockage of outward current by internal magnesium. KCNJ13 has a
CC       very low single channel conductance, low sensitivity to block by
CC       external barium and cesium, and no dependence of its inward
CC       rectification properties on the internal blocking particle
CC       magnesium (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the inward rectifier-type potassium channel
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AC157811; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   IPI; IPI00849820; -.
DR   RefSeq; NP_001103697.1; -.
DR   RefSeq; XP_001473790.1; -.
DR   UniGene; Mm.443539; -.
DR   PhosphoSite; P86046; -.
DR   PRIDE; P86046; -.
DR   Ensembl; ENSMUST00000113212; ENSMUSP00000108838; ENSMUSG00000079436; Mus musculus.
DR   GeneID; 100040591; -.
DR   KEGG; mmu:100040591; -.
DR   KEGG; mmu:100045137; -.
DR   CTD; 100040591; -.
DR   MGI; MGI:3781032; Kcnj13.
DR   HOGENOM; HBG716702; -.
DR   HOVERGEN; HBG006178; -.
DR   OMA; AVLYQER; -.
DR   OrthoDB; EOG9XH2K2; -.
DR   PhylomeDB; P86046; -.
DR   ArrayExpress; P86046; -.
DR   Bgee; P86046; -.
DR   Genevestigator; P86046; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005242; F:inward rectifier potassium channel activity; IEA:InterPro.
DR   GO; GO:0030955; F:potassium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006813; P:potassium ion transport; IEA:UniProtKB-KW.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR016449; K_chnl_inward-rec_Kir.
DR   InterPro; IPR001838; K_chnl_inward-rec_Kir-like.
DR   InterPro; IPR008062; K_chnl_inward-rec_Kir7.
DR   InterPro; IPR013521; K_chnl_inward-rec_Kir_Cr2.
DR   InterPro; IPR013518; K_chnl_inward-rec_Kir_cyto.
DR   Gene3D; G3DSA:2.60.40.1400; IR_K+channel_cytopl; 1.
DR   PANTHER; PTHR11767; K+channel_IR; 1.
DR   PANTHER; PTHR11767:SF3; KIR7_channel; 1.
DR   Pfam; PF01007; IRK; 1.
DR   PIRSF; PIRSF005465; GIRK_kir; 1.
DR   PRINTS; PR01679; KIR7CHANNEL.
DR   PRINTS; PR01320; KIRCHANNEL.
DR   SUPFAM; SSF81296; Ig_E-set; 1.
PE   1: Evidence at protein level;
KW   Ion transport; Ionic channel; Membrane; Phosphoprotein; Potassium;
KW   Potassium transport; Transmembrane; Transport; Voltage-gated channel.
FT   CHAIN         1    360       Inward rectifier potassium channel 13.
FT                                /FTId=PRO_0000355142.
FT   TOPO_DOM      1     53       Cytoplasmic (By similarity).
FT   TRANSMEM     54     78       M1 (By similarity).
FT   TOPO_DOM     79    105       Extracellular (By similarity).
FT   TOPO_DOM    125    133       Extracellular (By similarity).
FT   TRANSMEM    134    155       M2 (By similarity).
FT   TOPO_DOM    156    360       Cytoplasmic (By similarity).
FT   REGION      106    117       H5 (pore-forming helix) (By similarity).
FT   MOTIF       119    124       Selectivity filter (By similarity).
FT   SITE        149    149       Role in the control of polyamine-mediated
FT                                channel gating and in the blocking by
FT                                intracellular magnesium (By similarity).
FT   MOD_RES     327    327       Phosphothreonine.
SQ   SEQUENCE   360 AA;  40565 MW;  9D2107FB5C59C11D CRC64;
     MDSSNCKVNA PLLSQRHRRM VTKDGHSTLQ MDGAQRGLVY LRDAWGILMD MRWRWMMLVF
     SASFVVHWLV FAVLWYAVAE MNGDLEIDHD VPPENHTICV KHITSFTAAF SFSLETQLTI
     GYGTMFPSGD CPSAIALLAI QMLLGLMLEA FITGAFVAKI ARPKNRAFSI RFTDLAVVAH
     KDGKPNLIFQ VANTRPSPLT NVRVSAVLYQ ERENGELYQT SVDFHLDGIS SEECPFFIFP
     LTYYHTISPS SPLATLLQHE TPPHFELVVF LSAMQEGTGE ICQRRTSYLP SEIMLHHRFA
     ALMTRGSKGE YQVKMENFDK TVPEHPTPVV SKSPHRTDLD IHINGQSIDN FQIAETGLTE
//
ID   IRK14_HUMAN             Reviewed;         436 AA.
AC   Q9UNX9;
DT   11-OCT-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   02-MAR-2010, entry version 68.
DE   RecName: Full=ATP-sensitive inward rectifier potassium channel 14;
DE   AltName: Full=Potassium channel, inwardly rectifying subfamily J member 14;
DE   AltName: Full=Inward rectifier K(+) channel Kir2.4;
DE            Short=IRK-4;
GN   Name=KCNJ14; Synonyms=IRK4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], CHARACTERIZATION, AND TISSUE SPECIFICITY.
RX   PubMed=10942728;
RA   Hughes B.A., Kumar G., Yuan Y., Swaminathan A., Yan D., Sharma A.,
RA   Plumley L., Yang-Feng T.L., Swaroop A.;
RT   "Cloning and functional expression of human retinal Kir2.4, a pH-
RT   sensitive inwardly rectifying K+ channel.";
RL   Am. J. Physiol. 279:C771-C784(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=20188781; PubMed=10723734; DOI=10.1007/s003350010047;
RA   Toepert C., Doring F., Derst C., Daut J., Grzeschik K.H., Karschin A.;
RT   "Cloning, structure and assignment to chromosome 19q13 of the human
RT   Kir2.4 inwardly rectifying potassium channel gene (KCNJ14).";
RL   Mamm. Genome 11:247-249(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- FUNCTION: Inward rectifier potassium channels are characterized by
CC       a greater tendency to allow potassium to flow into the cell rather
CC       than out of it. Their voltage dependence is regulated by the
CC       concentration of extracellular potassium; as external potassium is
CC       raised, the voltage range of the channel opening shifts to more
CC       positive voltages. The inward rectification is mainly due to the
CC       blockage of outward current by internal magnesium. KCNJ14 gives
CC       rise to low-conductance channels with a low affinity to the
CC       channel blockers Barium and Cesium (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Expressed preferentially in retina.
CC   -!- SIMILARITY: Belongs to the inward rectifier-type potassium channel
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF081466; AAD51376.1; -; mRNA.
DR   EMBL; AF181988; AAF97619.1; -; Genomic_DNA.
DR   EMBL; BC035918; AAH35918.1; -; mRNA.
DR   IPI; IPI00002524; -.
DR   RefSeq; NP_037480.1; -.
DR   RefSeq; NP_733838.1; -.
DR   UniGene; Hs.590945; -.
DR   UniGene; Hs.644912; -.
DR   SMR; Q9UNX9; 49-353, 192-369.
DR   STRING; Q9UNX9; -.
DR   PRIDE; Q9UNX9; -.
DR   Ensembl; ENST00000342291; ENSP00000341479; ENSG00000182324; Homo sapiens.
DR   Ensembl; ENST00000391884; ENSP00000375756; ENSG00000182324; Homo sapiens.
DR   GeneID; 3770; -.
DR   KEGG; hsa:3770; -.
DR   UCSC; uc002pje.1; human.
DR   CTD; 3770; -.
DR   GeneCards; GC19P053650; -.
DR   H-InvDB; HIX0080032; -.
DR   HGNC; HGNC:6260; KCNJ14.
DR   MIM; 603953; gene.
DR   PharmGKB; PA30045; -.
DR   eggNOG; prNOG09749; -.
DR   HOGENOM; HBG716702; -.
DR   HOVERGEN; HBG006178; -.
DR   InParanoid; Q9UNX9; -.
DR   OMA; CNVRFVN; -.
DR   OrthoDB; EOG9NGK73; -.
DR   PhylomeDB; Q9UNX9; -.
DR   NextBio; 14785; -.
DR   ArrayExpress; Q9UNX9; -.
DR   Bgee; Q9UNX9; -.
DR   CleanEx; HS_KCNJ14; -.
DR   Genevestigator; Q9UNX9; -.
DR   GermOnline; ENSG00000182324; Homo sapiens.
DR   GO; GO:0008076; C:voltage-gated potassium channel complex; TAS:ProtInc.
DR   GO; GO:0005242; F:inward rectifier potassium channel activity; TAS:ProtInc.
DR   GO; GO:0030955; F:potassium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006813; P:potassium ion transport; IEA:UniProtKB-KW.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR016449; K_chnl_inward-rec_Kir.
DR   InterPro; IPR001838; K_chnl_inward-rec_Kir-like.
DR   InterPro; IPR013521; K_chnl_inward-rec_Kir_Cr2.
DR   InterPro; IPR013518; K_chnl_inward-rec_Kir_cyto.
DR   Gene3D; G3DSA:2.60.40.1400; IR_K+channel_cytopl; 1.
DR   PANTHER; PTHR11767; K+channel_IR; 1.
DR   Pfam; PF01007; IRK; 1.
DR   PIRSF; PIRSF005465; GIRK_kir; 1.
DR   PRINTS; PR01320; KIRCHANNEL.
DR   SUPFAM; SSF81296; Ig_E-set; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Ion transport; Ionic channel; Membrane;
KW   Polymorphism; Potassium; Potassium transport; Transmembrane;
KW   Transport; Voltage-gated channel.
FT   CHAIN         1    436       ATP-sensitive inward rectifier potassium
FT                                channel 14.
FT                                /FTId=PRO_0000154968.
FT   TOPO_DOM      1     86       Cytoplasmic (By similarity).
FT   TRANSMEM     87    111       M1 (By similarity).
FT   TOPO_DOM    112    133       Extracellular (By similarity).
FT   TOPO_DOM    153    161       Extracellular (By similarity).
FT   TRANSMEM    162    183       M2 (By similarity).
FT   TOPO_DOM    184    436       Cytoplasmic (By similarity).
FT   REGION      134    145       H5 (pore-forming helix) (By similarity).
FT   MOTIF       147    152       Selectivity filter (By similarity).
FT   VARIANT     289    289       R -> C (in dbSNP:rs3745725).
FT                                /FTId=VAR_034019.
SQ   SEQUENCE   436 AA;  47846 MW;  9442E664007D1B7C CRC64;
     MGLARALRRL SGALDSGDSR AGDEEEAGPG LCRNGWAPAP VQSPVGRRRG RFVKKDGHCN
     VRFVNLGGQG ARYLSDLFTT CVDVRWRWMC LLFSCSFLAS WLLFGLAFWL IASLHGDLAA
     PPPPAPCFSH VASFLAAFLF ALETQTSIGY GVRSVTEECP AAVAAVVLQC IAGCVLDAFV
     VGAVMAKMAK PKKRNETLVF SENAVVALRD HRLCLMWRVG NLRRSHLVEA HVRAQLLQPR
     VTPEGEYIPL DHQDVDVGFD GGTDRIFLVS PITIVHEIDS ASPLYELGRA ELARADFELV
     VILEGMVEAT AMTTQCRSSY LPGELLWGHR FEPVLFQRGS QYEVDYRHFH RTYEVPGTPV
     CSAKELDERA EQASHSLKSS FPGSLTAFCY ENELALSCCQ EEDEDDETEE GNGVETEDGA
     ASPRVLTPTL ALTLPP
//
ID   IRK14_RAT               Reviewed;         434 AA.
AC   O70596;
DT   11-OCT-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1998, sequence version 1.
DT   02-MAR-2010, entry version 57.
DE   RecName: Full=ATP-sensitive inward rectifier potassium channel 14;
DE   AltName: Full=Potassium channel, inwardly rectifying subfamily J member 14;
DE   AltName: Full=Inward rectifier K(+) channel Kir2.4;
DE            Short=IRK-4;
GN   Name=Kcnj14; Synonyms=Irk4;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], CHARACTERIZATION, AND TISSUE SPECIFICITY.
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RX   MEDLINE=98256380; PubMed=9592090;
RA   Toepert C., Doering F., Wischmeyer E., Karschin C., Brockhaus J.,
RA   Ballanyi K., Derst C., Karschin A.;
RT   "Kir2.4: a novel K+ inward rectifier channel associated with
RT   motoneurons of cranial nerve nuclei.";
RL   J. Neurosci. 18:4096-4105(1998).
CC   -!- FUNCTION: Inward rectifier potassium channels are characterized by
CC       a greater tendency to allow potassium to flow into the cell rather
CC       than out of it. Their voltage dependence is regulated by the
CC       concentration of extracellular potassium; as external potassium is
CC       raised, the voltage range of the channel opening shifts to more
CC       positive voltages. The inward rectification is mainly due to the
CC       blockage of outward current by internal magnesium. KCNJ14 gives
CC       rise to low-conductance channels with a low affinity to the
CC       channel blockers Barium and Cesium.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Expressed predominantly in motoneurons of
CC       cranial nerve motor nuclei within the general somatic and special
CC       visceral motor cell column.
CC   -!- SIMILARITY: Belongs to the inward rectifier-type potassium channel
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ003065; CAA05839.1; -; mRNA.
DR   IPI; IPI00199587; -.
DR   RefSeq; NP_733836.1; -.
DR   UniGene; Rn.154434; -.
DR   SMR; O70596; 47-351, 190-367.
DR   STRING; O70596; -.
DR   TCDB; 1.A.2.1.5; inward rectifier K+ channel (IRK-C) family.
DR   GeneID; 276720; -.
DR   KEGG; rno:276720; -.
DR   UCSC; NM_170718; rat.
DR   CTD; 276720; -.
DR   RGD; 628872; Kcnj14.
DR   eggNOG; maNOG08316; -.
DR   HOVERGEN; HBG006178; -.
DR   NextBio; 624761; -.
DR   Genevestigator; O70596; -.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005242; F:inward rectifier potassium channel activity; IDA:RGD.
DR   GO; GO:0030955; F:potassium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006813; P:potassium ion transport; IEA:UniProtKB-KW.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR016449; K_chnl_inward-rec_Kir.
DR   InterPro; IPR001838; K_chnl_inward-rec_Kir-like.
DR   InterPro; IPR013521; K_chnl_inward-rec_Kir_Cr2.
DR   InterPro; IPR013518; K_chnl_inward-rec_Kir_cyto.
DR   Gene3D; G3DSA:2.60.40.1400; IR_K+channel_cytopl; 1.
DR   PANTHER; PTHR11767; K+channel_IR; 1.
DR   Pfam; PF01007; IRK; 1.
DR   PIRSF; PIRSF005465; GIRK_kir; 1.
DR   PRINTS; PR01320; KIRCHANNEL.
DR   SUPFAM; SSF81296; Ig_E-set; 1.
PE   1: Evidence at protein level;
KW   Ion transport; Ionic channel; Membrane; Potassium;
KW   Potassium transport; Transmembrane; Transport; Voltage-gated channel.
FT   CHAIN         1    434       ATP-sensitive inward rectifier potassium
FT                                channel 14.
FT                                /FTId=PRO_0000154970.
FT   TOPO_DOM      1     84       Cytoplasmic (By similarity).
FT   TRANSMEM     85    109       M1 (By similarity).
FT   TOPO_DOM    110    131       Extracellular (By similarity).
FT   TOPO_DOM    151    159       Extracellular (By similarity).
FT   TRANSMEM    160    181       M2 (By similarity).
FT   TOPO_DOM    182    434       Cytoplasmic (By similarity).
FT   REGION      132    143       H5 (pore-forming helix) (By similarity).
FT   MOTIF       145    150       Selectivity filter (By similarity).
SQ   SEQUENCE   434 AA;  47609 MW;  AB586F4628AB42EA CRC64;
     MGLARALRRL SGALEPGNSR AGDEEEAGAG LCRNGWAPGP VAGNRRRGRF VKKDGHCNVR
     FVNLGGQGAR YLSDLFTTCV DVRWRWMCLL FSCSFLASWL LFGLTFWLIA SLHGDLAAPP
     PPAPCFSQVA SFLAAFLFAL ETQTSIGYGV RSVTEECPAA VAAVVLQCIA GCVLDAFVVG
     AVMAKMAKPK KRNETLVFSE NAVVALRDRR LCLMWRVGNL RRSHLVEAHV RAQLLQPRVT
     PEGEYIPLDH QDVDVGFDGG TDRIFLVSPI TIVHEIDSAS PLYELGRAEL ARADFELVVI
     LEGMVEATAM TTQCRSSYLP GELLWGHRFE PVLFQRGSQY EVDYRHFHRT YEVPGTPVCS
     AKELDERAEQ ASHSPKSSFP GSLAAFCYEN ELALSCCQEE DEEEDTKEGT SAETPDRAAS
     PQALTPTLAL TLPP
//
ID   IRK15_HUMAN             Reviewed;         375 AA.
AC   Q99712; O00564; Q96L28; Q99446;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   11-OCT-2005, sequence version 2.
DT   02-MAR-2010, entry version 91.
DE   RecName: Full=ATP-sensitive inward rectifier potassium channel 15;
DE   AltName: Full=Potassium channel, inwardly rectifying subfamily J member 15;
DE   AltName: Full=Inward rectifier K(+) channel Kir4.2;
DE   AltName: Full=Inward rectifier K(+) channel Kir1.3;
GN   Name=KCNJ15; Synonyms=KCNJ14;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ASP-98.
RC   TISSUE=Kidney;
RX   MEDLINE=97150765; PubMed=8995301; DOI=10.1074/jbc.272.1.586;
RA   Shuck M.E., Piser T.M., Bock J.H., Slightom J.L., Lee K.S.,
RA   Bienkowski M.J.;
RT   "Cloning and characterization of two K+ inward rectifier (Kir) 1.1
RT   potassium channel homologs from human kidney (Kir1.2 and Kir1.3).";
RL   J. Biol. Chem. 272:586-593(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ASP-98.
RC   TISSUE=Kidney;
RA   Ohira M., Seki N., Nagase T., Suzuki E., Nomura N., Ohara O.,
RA   Hattori M., Sakaki Y., Eki T., Murakami Y., Saito T., Ichikawa H.,
RA   Ohki M.;
RL   Submitted (JAN-1997) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=97446144; PubMed=9299242; DOI=10.1006/geno.1997.4865;
RA   Gosset P., Ghezala G.A., Korn B., Yaspo M.-L., Poutska A., Lehrach H.,
RA   Sinet P.-M., Creau N.;
RT   "A new inward rectifier potassium channel gene (KCNJ15) localized on
RT   chromosome 21 in the Down syndrome chromosome region 1 (DCR1).";
RL   Genomics 44:237-241(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH INADL.
RX   MEDLINE=98313406; PubMed=9647694; DOI=10.1006/mcne.1998.0679;
RA   Kurschner C., Mermelstein P.G., Holden W.T., Surmeier D.J.;
RT   "CIPP, a novel multivalent PDZ domain protein, selectively interacts
RT   with Kir4.0 family members, NMDA receptor subunits, neurexins, and
RT   neuroligins.";
RL   Mol. Cell. Neurosci. 11:161-172(1998).
RN   [6]
RP   VARIANT [LARGE SCALE ANALYSIS] THR-71.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Inward rectifier potassium channels are characterized by
CC       a greater tendency to allow potassium to flow into the cell rather
CC       than out of it. Their voltage dependence is regulated by the
CC       concentration of extracellular potassium; as external potassium is
CC       raised, the voltage range of the channel opening shifts to more
CC       positive voltages. The inward rectification is mainly due to the
CC       blockage of outward current by internal magnesium.
CC   -!- SUBUNIT: Interacts with INADL.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the inward rectifier-type potassium channel
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U73191; AAC50922.1; -; mRNA.
DR   EMBL; D87291; BAA13326.1; -; mRNA.
DR   EMBL; Y10745; CAA71734.1; -; mRNA.
DR   EMBL; BC013327; AAH13327.1; -; mRNA.
DR   IPI; IPI00064771; -.
DR   RefSeq; NP_002234.2; -.
DR   RefSeq; NP_733932.1; -.
DR   RefSeq; NP_733933.1; -.
DR   UniGene; Hs.411299; -.
DR   SMR; Q99712; 26-335, 163-337.
DR   STRING; Q99712; -.
DR   PRIDE; Q99712; -.
DR   Ensembl; ENST00000328656; ENSP00000331698; ENSG00000157551; Homo sapiens.
DR   Ensembl; ENST00000398930; ENSP00000381904; ENSG00000157551; Homo sapiens.
DR   Ensembl; ENST00000398932; ENSP00000381905; ENSG00000157551; Homo sapiens.
DR   Ensembl; ENST00000398934; ENSP00000381907; ENSG00000157551; Homo sapiens.
DR   Ensembl; ENST00000398938; ENSP00000381911; ENSG00000157551; Homo sapiens.
DR   GeneID; 3772; -.
DR   KEGG; hsa:3772; -.
DR   UCSC; uc002ywv.1; human.
DR   CTD; 3772; -.
DR   GeneCards; GC21P038550; -.
DR   H-InvDB; HIX0016107; -.
DR   HGNC; HGNC:6261; KCNJ15.
DR   HPA; HPA016702; -.
DR   MIM; 602106; gene.
DR   PharmGKB; PA30046; -.
DR   eggNOG; prNOG11609; -.
DR   HOGENOM; HBG716702; -.
DR   HOVERGEN; HBG006178; -.
DR   InParanoid; Q99712; -.
DR   OMA; SAPLVKH; -.
DR   PhylomeDB; Q99712; -.
DR   NextBio; 14791; -.
DR   ArrayExpress; Q99712; -.
DR   Bgee; Q99712; -.
DR   CleanEx; HS_KCNJ14; -.
DR   CleanEx; HS_KCNJ15; -.
DR   Genevestigator; Q99712; -.
DR   GermOnline; ENSG00000157551; Homo sapiens.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0005925; C:focal adhesion; IDA:HPA.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0005242; F:inward rectifier potassium channel activity; TAS:ProtInc.
DR   GO; GO:0030955; F:potassium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006813; P:potassium ion transport; TAS:ProtInc.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR016449; K_chnl_inward-rec_Kir.
DR   InterPro; IPR001838; K_chnl_inward-rec_Kir-like.
DR   InterPro; IPR003270; K_chnl_inward-rec_Kir1.3.
DR   InterPro; IPR013521; K_chnl_inward-rec_Kir_Cr2.
DR   InterPro; IPR013518; K_chnl_inward-rec_Kir_cyto.
DR   Gene3D; G3DSA:2.60.40.1400; IR_K+channel_cytopl; 1.
DR   PANTHER; PTHR11767; K+channel_IR; 1.
DR   PANTHER; PTHR11767:SF20; KIR13_channel; 1.
DR   Pfam; PF01007; IRK; 1.
DR   PIRSF; PIRSF005465; GIRK_kir; 1.
DR   PRINTS; PR01323; KIR13CHANNEL.
DR   PRINTS; PR01320; KIRCHANNEL.
DR   SUPFAM; SSF81296; Ig_E-set; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Ion transport; Ionic channel; Membrane;
KW   Polymorphism; Potassium; Potassium transport; Transmembrane;
KW   Transport; Voltage-gated channel.
FT   CHAIN         1    375       ATP-sensitive inward rectifier potassium
FT                                channel 15.
FT                                /FTId=PRO_0000154972.
FT   TOPO_DOM      1     63       Cytoplasmic (By similarity).
FT   TRANSMEM     64     88       M1 (By similarity).
FT   TOPO_DOM     89    113       Extracellular (By similarity).
FT   TOPO_DOM    133    141       Extracellular (By similarity).
FT   TRANSMEM    142    163       M2 (By similarity).
FT   TOPO_DOM    164    375       Cytoplasmic (By similarity).
FT   REGION      114    125       H5 (pore-forming helix) (By similarity).
FT   MOTIF       127    132       Selectivity filter (By similarity).
FT   SITE        157    157       Role in the control of polyamine-mediated
FT                                channel gating and in the blocking by
FT                                intracellular magnesium (By similarity).
FT   VARIANT      30     30       M -> L (in dbSNP:rs3746875).
FT                                /FTId=VAR_025523.
FT   VARIANT      71     71       A -> T (in a breast cancer sample;
FT                                somatic mutation).
FT                                /FTId=VAR_036427.
FT   VARIANT      98     98       G -> D (in dbSNP:rs2230033).
FT                                /FTId=VAR_019728.
FT   CONFLICT    235    235       V -> A (in Ref. 3; CAA71734).
FT   CONFLICT    245    245       S -> G (in Ref. 2; BAA13326).
SQ   SEQUENCE   375 AA;  42577 MW;  CECCB4EDF827B24D CRC64;
     MDAIHIGMSS TPLVKHTAGA GLKANRPRVM SKSGHSNVRI DKVDGIYLLY LQDLWTTVID
     MKWRYKLTLF AATFVMTWFL FGVIYYAIAF IHGDLEPGEP ISNHTPCIMK VDSLTGAFLF
     SLESQTTIGY GVRSITEECP HAIFLLVAQL VITTLIEIFI TGTFLAKIAR PKKRAETIKF
     SHCAVITKQN GKLCLVIQVA NMRKSLLIQC QLSGKLLQTH VTKEGERILL NQATVKFHVD
     SSSESPFLIL PMTFYHVLDE TSPLRDLTPQ NLKEKEFELV VLLNATVEST SAVCQSRTSY
     IPEEIYWGFE FVPVVSLSKN GKYVADFSQF EQIRKSPDCT FYCADSEKQQ LEEKYRQEDQ
     RERELRTLLL QQSNV
//
ID   IRK1_HUMAN              Reviewed;         391 AA.
AC   P48048; B2RMR4; Q6LD67;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 1.
DT   02-MAR-2010, entry version 104.
DE   RecName: Full=ATP-sensitive inward rectifier potassium channel 1;
DE   AltName: Full=Potassium channel, inwardly rectifying subfamily J member 1;
DE   AltName: Full=ATP-regulated potassium channel ROM-K;
DE   AltName: Full=Inward rectifier K(+) channel Kir1.1;
GN   Name=KCNJ1; Synonyms=ROMK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND ALTERNATIVE SPLICING.
RC   TISSUE=Kidney;
RX   MEDLINE=95014165; PubMed=7929082;
RA   Shuck M.E., Bock J.H., Benjamin C.W., Tsai T.-D., Lee K.S.,
RA   Slightom J.L., Bienkowski M.J.;
RT   "Cloning and characterization of multiple forms of the human kidney
RT   ROM-K potassium channel.";
RL   J. Biol. Chem. 269:24261-24270(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND ALTERNATIVE SPLICING.
RC   TISSUE=Kidney;
RX   MEDLINE=94247391; PubMed=8190102;
RA   Yano H., Philipson L.H., Kugler J.L., Tokuyama Y., Davis E.M.,
RA   le Beau M.M., Nelson D.J., Bell G.I., Takeda J.;
RT   "Alternative splicing of human inwardly rectifying K+ channel ROMK1
RT   mRNA.";
RL   Mol. Pharmacol. 45:854-860(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING.
RX   PubMed=9099852; DOI=10.1016/S0378-1119(96)00759-7;
RA   Bock J.H., Shuck M.E., Benjamin C.W., Chee M., Bienkowski M.J.,
RA   Slightom J.L.;
RT   "Nucleotide sequence analysis of the human KCNJ1 potassium channel
RT   locus.";
RL   Gene 188:9-16(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 76-177, AND TISSUE SPECIFICITY.
RC   TISSUE=Brain cortex;
RX   MEDLINE=95362241; PubMed=7635463; DOI=10.1007/BF00207372;
RA   Krishnan S.N., Desai T., Ward D.C., Haddad G.G.;
RT   "Isolation and chromosomal localization of a human ATP-regulated
RT   potassium channel.";
RL   Hum. Genet. 96:155-160(1995).
RN   [7]
RP   VARIANTS BS2 VAL-214; ARG-219 AND THR-357.
RX   PubMed=8841184; DOI=10.1038/ng1096-152;
RA   Simon D.B., Karet F.E., Rodriguez-Soriano J., Hamdan J.H.,
RA   DiPietro A., Trachtman H., Sanjad S.A., Lifton R.P.;
RT   "Genetic heterogeneity of Bartter's syndrome revealed by mutations in
RT   the K+ channel, ROMK.";
RL   Nat. Genet. 14:152-156(1996).
RN   [8]
RP   VARIANTS BS2 GLU-72; TYR-74; CYS-99; HIS-108; LEU-110; GLU-122;
RP   GLU-167; THR-198 AND GLY-315.
RX   MEDLINE=97156205; PubMed=9002665;
RA   Karolyi L., Konrad M., Koeckerling A., Ziegler A., Zimmermann D.K.,
RA   Roth B., Wieg C., Grzeschik K.-H., Koch M.C., Seyberth H.W.,
RA   Vargas R., Forestier L., Jean G., Deschaux M., Rizzoni G.F.,
RA   Niaudet P., Antignac C., Feldmann D., Lorridon F., Cougoureux E.,
RA   Laroze F., Alessandri J.-L., David L., Saunier P., Deschenes G.,
RA   Hildebrandt F., Vollmer M., Proesmans W., Brandis M.,
RA   van den Heuvel L.P.W.J., Lemmink H.H., Nillesen W., Monnens L.A.H.,
RA   Knoers N.V.A.M., Guay-Woodford L.M., Wright C.J., Madrigal G.,
RA   Hebert S.C.;
RT   "Mutations in the gene encoding the inwardly-rectifying renal
RT   potassium channel, ROMK, cause the antenatal variant of Bartter
RT   syndrome: evidence for genetic heterogeneity.";
RL   Hum. Mol. Genet. 6:17-26(1997).
RN   [9]
RP   VARIANT BS2 LYS-124.
RX   PubMed=9727001; DOI=10.1074/jbc.273.37.23884;
RA   Derst C., Wischmeyer E., Preisig-Mueller R., Spauschus A., Konrad M.,
RA   Hensen P., Jeck N., Seyberth H.W., Daut J., Karschin A.;
RT   "A hyperprostaglandin E syndrome mutation in Kir1.1 (renal outer
RT   medullary potassium) channels reveals a crucial residue for channel
RT   function in Kir1.3 channels.";
RL   J. Biol. Chem. 273:23884-23891(1998).
RN   [10]
RP   VARIANT [LARGE SCALE ANALYSIS] PHE-115.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: In the kidney, probably plays a major role in potassium
CC       homeostasis. Inward rectifier potassium channels are characterized
CC       by a greater tendency to allow potassium to flow into the cell
CC       rather than out of it. Their voltage dependence is regulated by
CC       the concentration of extracellular potassium; as external
CC       potassium is raised, the voltage range of the channel opening
CC       shifts to more positive voltages. The inward rectification is
CC       mainly due to the blockage of outward current by internal
CC       magnesium. This channel is activated by internal ATP and can be
CC       blocked by external barium.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=ROM-K1;
CC         IsoId=P48048-1; Sequence=Displayed;
CC       Name=2; Synonyms=2-4-5, ROM-K2, ROM-K4, ROM-K5, ROM-K6;
CC         IsoId=P48048-2; Sequence=VSP_002797;
CC       Name=3; Synonyms=ROM-K3;
CC         IsoId=P48048-3; Sequence=VSP_002798;
CC   -!- TISSUE SPECIFICITY: In the kidney and pancreatic islets. Lower
CC       levels in skeletal muscle, pancreas, spleen, brain, heart and
CC       liver.
CC   -!- DISEASE: Defects in KCNJ1 are the cause of Bartter syndrome type 2
CC       (BS2) [MIM:241200]; also termed hyperprostanglandin E syndrome 2.
CC       BS refers to a group of autosomal recessive disorders
CC       characterized by impaired salt reabsorption in the thick ascending
CC       loop of Henle with pronounced salt wasting, hypokalemic metabolic
CC       alkalosis, and varying degrees of hypercalciuria. BS2 is a life-
CC       threatening condition beginning in utero, with marked fetal
CC       polyuria that leads to polyhydramnios and premature delivery.
CC       Another hallmark of BS2 is a marked hypercalciuria and, as a
CC       secondary consequence, the development of nephrocalcinosis and
CC       osteopenia.
CC   -!- SIMILARITY: Belongs to the inward rectifier-type potassium channel
CC       family.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/KCNJ1";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U12541; AAA61712.1; -; mRNA.
DR   EMBL; U12542; AAA61713.1; -; mRNA.
DR   EMBL; U12543; AAA61714.1; -; mRNA.
DR   EMBL; U12544; AAA61715.1; -; mRNA.
DR   EMBL; U12545; AAA61716.1; -; mRNA.
DR   EMBL; U03884; AAA20594.1; -; mRNA.
DR   EMBL; U65406; AAC51220.1; -; Genomic_DNA.
DR   EMBL; U65406; AAC51221.1; -; Genomic_DNA.
DR   EMBL; U65406; AAC51222.1; -; Genomic_DNA.
DR   EMBL; CH471065; EAW67724.1; -; Genomic_DNA.
DR   EMBL; BC074752; AAH74752.1; -; mRNA.
DR   EMBL; BC136360; AAI36361.1; -; mRNA.
DR   EMBL; BC136361; AAI36362.1; -; mRNA.
DR   EMBL; S78737; AAB35012.1; -; mRNA.
DR   IPI; IPI00007612; -.
DR   IPI; IPI00216258; -.
DR   IPI; IPI00216259; -.
DR   PIR; A55119; A55119.
DR   RefSeq; NP_000211.1; -.
DR   RefSeq; NP_722448.1; -.
DR   RefSeq; NP_722449.2; -.
DR   RefSeq; NP_722450.1; -.
DR   RefSeq; NP_722451.1; -.
DR   UniGene; Hs.527830; -.
DR   SMR; P48048; 39-349, 179-358.
DR   STRING; P48048; -.
DR   TCDB; 1.A.2.1.1; inward rectifier K+ channel (IRK-C) family.
DR   PhosphoSite; P48048; -.
DR   PRIDE; P48048; -.
DR   Ensembl; ENST00000324003; ENSP00000316136; ENSG00000151704; Homo sapiens.
DR   GeneID; 3758; -.
DR   KEGG; hsa:3758; -.
DR   UCSC; uc001qeo.1; human.
DR   UCSC; uc001qep.1; human.
DR   CTD; 3758; -.
DR   GeneCards; GC11M128213; -.
DR   HGNC; HGNC:6255; KCNJ1.
DR   MIM; 241200; phenotype.
DR   MIM; 600359; gene.
DR   Orphanet; 112; Bartter syndrome.
DR   Orphanet; 93604; Bartter syndrome, antenatal form.
DR   PharmGKB; PA213; -.
DR   eggNOG; prNOG17688; -.
DR   HOGENOM; HBG716702; -.
DR   HOVERGEN; HBG006178; -.
DR   InParanoid; P48048; -.
DR   OMA; EEVLWGY; -.
DR   OrthoDB; EOG9JWZ0V; -.
DR   PhylomeDB; P48048; -.
DR   DrugBank; DB00414; Acetohexamide.
DR   DrugBank; DB00672; Chlorpropamide.
DR   DrugBank; DB01016; Glibenclamide.
DR   DrugBank; DB01120; Gliclazide.
DR   DrugBank; DB00222; Glimepiride.
DR   DrugBank; DB01067; Glipizide.
DR   DrugBank; DB01382; Glycodiazine.
DR   DrugBank; DB00350; Minoxidil.
DR   DrugBank; DB00731; Nateglinide.
DR   DrugBank; DB00912; Repaglinide.
DR   DrugBank; DB00839; Tolazamide.
DR   DrugBank; DB01124; Tolbutamide.
DR   NextBio; 14725; -.
DR   ArrayExpress; P48048; -.
DR   Bgee; P48048; -.
DR   CleanEx; HS_KCNJ1; -.
DR   Genevestigator; P48048; -.
DR   GermOnline; ENSG00000151704; Homo sapiens.
DR   GO; GO:0008076; C:voltage-gated potassium channel complex; TAS:ProtInc.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005242; F:inward rectifier potassium channel activity; TAS:ProtInc.
DR   GO; GO:0030955; F:potassium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0007588; P:excretion; TAS:ProtInc.
DR   GO; GO:0006813; P:potassium ion transport; TAS:ProtInc.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR016449; K_chnl_inward-rec_Kir.
DR   InterPro; IPR001838; K_chnl_inward-rec_Kir-like.
DR   InterPro; IPR003268; K_chnl_inward-rec_Kir1.1.
DR   InterPro; IPR013521; K_chnl_inward-rec_Kir_Cr2.
DR   InterPro; IPR013518; K_chnl_inward-rec_Kir_cyto.
DR   Gene3D; G3DSA:2.60.40.1400; IR_K+channel_cytopl; 1.
DR   PANTHER; PTHR11767; K+channel_IR; 1.
DR   PANTHER; PTHR11767:SF6; KIR11_channel; 1.
DR   Pfam; PF01007; IRK; 1.
DR   PIRSF; PIRSF005465; GIRK_kir; 1.
DR   PRINTS; PR01321; KIR11CHANNEL.
DR   PRINTS; PR01320; KIRCHANNEL.
DR   SUPFAM; SSF81296; Ig_E-set; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Bartter syndrome;
KW   Complete proteome; Disease mutation; Ion transport; Ionic channel;
KW   Membrane; Nucleotide-binding; Polymorphism; Potassium;
KW   Potassium transport; Transmembrane; Transport; Voltage-gated channel.
FT   CHAIN         1    391       ATP-sensitive inward rectifier potassium
FT                                channel 1.
FT                                /FTId=PRO_0000154917.
FT   TOPO_DOM      1     77       Cytoplasmic (By similarity).
FT   TRANSMEM     78    102       M1 (By similarity).
FT   TOPO_DOM    103    127       Extracellular (By similarity).
FT   TOPO_DOM    147    155       Extracellular (By similarity).
FT   TRANSMEM    156    177       M2 (By similarity).
FT   TOPO_DOM    178    391       Cytoplasmic (By similarity).
FT   NP_BIND     223    230       ATP (Potential).
FT   REGION      128    139       H5 (pore-forming helix) (By similarity).
FT   MOTIF       141    146       Selectivity filter (By similarity).
FT   SITE        171    171       Role in the control of polyamine-mediated
FT                                channel gating and in the blocking by
FT                                intracellular magnesium (By similarity).
FT   VAR_SEQ       1     19       Missing (in isoform 2).
FT                                /FTId=VSP_002797.
FT   VAR_SEQ       1     12       MNASSRNVFDTL -> MPTVYLCSEQ (in isoform
FT                                3).
FT                                /FTId=VSP_002798.
FT   VARIANT       6      6       R -> W (in dbSNP:rs34191956).
FT                                /FTId=VAR_049668.
FT   VARIANT      72     72       V -> E (in BS2).
FT                                /FTId=VAR_001548.
FT   VARIANT      74     74       D -> Y (in BS2).
FT                                /FTId=VAR_001549.
FT   VARIANT      99     99       W -> C (in BS2).
FT                                /FTId=VAR_001550.
FT   VARIANT     108    108       D -> H (in BS2).
FT                                /FTId=VAR_001551.
FT   VARIANT     110    110       P -> L (in BS2).
FT                                /FTId=VAR_001552.
FT   VARIANT     115    115       S -> F (in a breast cancer sample;
FT                                somatic mutation).
FT                                /FTId=VAR_036426.
FT   VARIANT     122    122       V -> E (in BS2).
FT                                /FTId=VAR_001553.
FT   VARIANT     124    124       N -> K (in BS2).
FT                                /FTId=VAR_019724.
FT   VARIANT     167    167       G -> E (in BS2).
FT                                /FTId=VAR_001554.
FT   VARIANT     198    198       A -> T (in BS2).
FT                                /FTId=VAR_001555.
FT   VARIANT     214    214       A -> V (in BS2).
FT                                /FTId=VAR_019725.
FT   VARIANT     219    219       S -> R (in BS2).
FT                                /FTId=VAR_019726.
FT   VARIANT     315    315       V -> G (in BS2).
FT                                /FTId=VAR_001556.
FT   VARIANT     357    357       M -> T (in BS2; dbSNP:rs59172778).
FT                                /FTId=VAR_019727.
SQ   SEQUENCE   391 AA;  44795 MW;  DF01C89B16BE6205 CRC64;
     MNASSRNVFD TLIRVLTESM FKHLRKWVVT RFFGHSRQRA RLVSKDGRCN IEFGNVEAQS
     RFIFFVDIWT TVLDLKWRYK MTIFITAFLG SWFFFGLLWY AVAYIHKDLP EFHPSANHTP
     CVENINGLTS AFLFSLETQV TIGYGFRCVT EQCATAIFLL IFQSILGVII NSFMCGAILA
     KISRPKKRAK TITFSKNAVI SKRGGKLCLL IRVANLRKSL LIGSHIYGKL LKTTVTPEGE
     TIILDQININ FVVDAGNENL FFISPLTIYH VIDHNSPFFH MAAETLLQQD FELVVFLDGT
     VESTSATCQV RTSYVPEEVL WGYRFAPIVS KTKEGKYRVD FHNFSKTVEV ETPHCAMCLY
     NEKDVRARMK RGYDNPNFIL SEVNETDDTK M
//
ID   IRK1_MOUSE              Reviewed;         372 AA.
AC   O88335;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1998, sequence version 1.
DT   02-MAR-2010, entry version 90.
DE   RecName: Full=ATP-sensitive inward rectifier potassium channel 1;
DE   AltName: Full=Potassium channel, inwardly rectifying subfamily J member 1;
DE   AltName: Full=ATP-regulated potassium channel ROM-K;
DE   AltName: Full=Inward rectifier K(+) channel Kir1.1;
GN   Name=Kcnj1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=CD-1; TISSUE=Kidney;
RA   Xu J.Z., Mount D.B., Hebert S.C.;
RT   "Cloning and characterization of alternatively spliced isoforms of
RT   mouse ROMK.";
RL   Submitted (JUL-1997) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=FVB/N; TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- FUNCTION: In the kidney, probably plays a major role in potassium
CC       homeostasis. Inward rectifier potassium channels are characterized
CC       by a greater tendency to allow potassium to flow into the cell
CC       rather than out of it. Their voltage dependence is regulated by
CC       the concentration of extracellular potassium; as external
CC       potassium is raised, the voltage range of the channel opening
CC       shifts to more positive voltages. The inward rectification is
CC       mainly due to the blockage of outward current by internal
CC       magnesium. This channel is activated by internal ATP and can be
CC       blocked by external barium (By similarity).
CC   -!- INTERACTION:
CC       Q80UE6:Wnk4; NbExp=1; IntAct=EBI-295404, EBI-295378;
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=1;
CC         Comment=A number of isoforms are produced;
CC       Name=1;
CC         IsoId=O88335-1; Sequence=Displayed;
CC   -!- SIMILARITY: Belongs to the inward rectifier-type potassium channel
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF012834; AAC24973.1; -; mRNA.
DR   EMBL; BC020525; AAH20525.1; -; mRNA.
DR   IPI; IPI00129957; -.
DR   RefSeq; NP_062633.1; -.
DR   UniGene; Mm.390168; -.
DR   SMR; O88335; 20-330, 160-339.
DR   IntAct; O88335; 1.
DR   STRING; O88335; -.
DR   PhosphoSite; O88335; -.
DR   PRIDE; O88335; -.
DR   Ensembl; ENSMUST00000047334; ENSMUSP00000046793; ENSMUSG00000041248; Mus musculus.
DR   GeneID; 56379; -.
DR   KEGG; mmu:56379; -.
DR   UCSC; uc009orx.1; mouse.
DR   CTD; 56379; -.
DR   MGI; MGI:1927248; Kcnj1.
DR   eggNOG; roNOG14892; -.
DR   HOGENOM; HBG716702; -.
DR   HOVERGEN; HBG006178; -.
DR   InParanoid; O88335; -.
DR   OMA; EEVLWGY; -.
DR   OrthoDB; EOG9JWZ0V; -.
DR   PhylomeDB; O88335; -.
DR   NextBio; 312456; -.
DR   ArrayExpress; O88335; -.
DR   Bgee; O88335; -.
DR   Genevestigator; O88335; -.
DR   GermOnline; ENSMUSG00000041248; Mus musculus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005242; F:inward rectifier potassium channel activity; IEA:InterPro.
DR   GO; GO:0030955; F:potassium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0006813; P:potassium ion transport; IEA:UniProtKB-KW.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR016449; K_chnl_inward-rec_Kir.
DR   InterPro; IPR001838; K_chnl_inward-rec_Kir-like.
DR   InterPro; IPR003268; K_chnl_inward-rec_Kir1.1.
DR   InterPro; IPR013521; K_chnl_inward-rec_Kir_Cr2.
DR   InterPro; IPR013518; K_chnl_inward-rec_Kir_cyto.
DR   Gene3D; G3DSA:2.60.40.1400; IR_K+channel_cytopl; 1.
DR   PANTHER; PTHR11767; K+channel_IR; 1.
DR   PANTHER; PTHR11767:SF6; KIR11_channel; 1.
DR   Pfam; PF01007; IRK; 1.
DR   PIRSF; PIRSF005465; GIRK_kir; 1.
DR   PRINTS; PR01321; KIR11CHANNEL.
DR   PRINTS; PR01320; KIRCHANNEL.
DR   SUPFAM; SSF81296; Ig_E-set; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Ion transport; Ionic channel;
KW   Membrane; Nucleotide-binding; Potassium; Potassium transport;
KW   Transmembrane; Transport; Voltage-gated channel.
FT   CHAIN         1    372       ATP-sensitive inward rectifier potassium
FT                                channel 1.
FT                                /FTId=PRO_0000154918.
FT   TOPO_DOM      1     58       Cytoplasmic (By similarity).
FT   TRANSMEM     59     83       M1 (By similarity).
FT   TOPO_DOM     84    108       Extracellular (By similarity).
FT   TOPO_DOM    128    136       Extracellular (By similarity).
FT   TRANSMEM    137    158       M2 (By similarity).
FT   TOPO_DOM    159    372       Cytoplasmic (By similarity).
FT   NP_BIND     204    211       ATP (Potential).
FT   REGION      109    120       H5 (pore-forming helix) (By similarity).
FT   MOTIF       122    127       Selectivity filter (By similarity).
FT   SITE        152    152       Role in the control of polyamine-mediated
FT                                channel gating and in the blocking by
FT                                intracellular magnesium (By similarity).
SQ   SEQUENCE   372 AA;  42776 MW;  EA95D896622232D6 CRC64;
     MFKHLRRWFV THIFGRSRQR ARLVSKDGRC NIEFGNVDAQ SRFIFFVDIW TTVLDLKWRY
     KMTVFITAFL GSWFLFGLLW YVVAYVHKDL PEFYPPDNRT PCVENINGMT SAFLFSLETQ
     VTIGYGFRFV TEQCATAIFL LIFQSILGVI INSFMCGAIL AKISRPKKRA KTITFSKNAV
     ISKRGGKLCL LIRVANLRKS LLIGSHIYGK LLKTTITPEG ETIILDQTNI NFVVDAGNEN
     LFFISPLTIY HIIDHNSPFF HMAAETLSQQ DFELVVFLDG TVESTSATCQ VRTSYIPEEV
     LWGYRFVPIV SKTKEGKYRV DFHNFGKTVE VETPHCAMCL YNEKDARARM KRGYDNPNFV
     LSEVDETDDT QM
//
ID   IRK2_HUMAN              Reviewed;         427 AA.
AC   P63252; O15110; P48049;
DT   11-OCT-2004, integrated into UniProtKB/Swiss-Prot.
DT   11-OCT-2004, sequence version 1.
DT   02-MAR-2010, entry version 71.
DE   RecName: Full=Inward rectifier potassium channel 2;
DE   AltName: Full=Potassium channel, inwardly rectifying subfamily J member 2;
DE   AltName: Full=Inward rectifier K(+) channel Kir2.1;
DE            Short=IRK-1;
DE            Short=hIRK1;
DE   AltName: Full=Cardiac inward rectifier potassium channel;
GN   Name=KCNJ2; Synonyms=IRK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Heart;
RX   MEDLINE=95210614; PubMed=7696590;
RA   Raab-Graham K.F., Radeke C.M., Vandenberg C.A.;
RT   "Molecular cloning and expression of a human heart inward rectifier
RT   potassium channel.";
RL   NeuroReport 5:2501-2505(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RA   Tang W., Qin C.L., Yang X.C.;
RL   Submitted (APR-1995) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Heart;
RX   MEDLINE=96011654; PubMed=7590287; DOI=10.1016/0378-1119(95)00244-Z;
RA   Wood L.S., Tsai T.-D., Lee K.S., Vogeli G.;
RT   "Cloning and functional expression of a human gene, hIRK1, encoding
RT   the heart inward rectifier K+-channel.";
RL   Gene 163:313-317(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Blood;
RX   MEDLINE=98154156; PubMed=9490857;
RX   DOI=10.1111/j.1469-7793.1998.303bw.x;
RA   Tare M., Prestwich S.A., Gordienko D.V., Parveen S., Carver J.E.,
RA   Robinson C., Bolton T.B.;
RT   "Inwardly rectifying whole cell potassium current in human blood
RT   eosinophils.";
RL   J. Physiol. (Lond.) 506:303-318(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RX   MEDLINE=21135569; PubMed=11240146; DOI=10.1016/S0014-5793(01)02202-5;
RA   Derst C., Karschin C., Wischmeyer E., Hirsch J.R., Preisig-Muller R.,
RA   Rajan S., Engel H., Grzeschik K., Daut J., Karschin A.;
RT   "Genetic and functional linkage of Kir5.1 and Kir2.1 channel
RT   subunits.";
RL   FEBS Lett. 491:305-311(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-143.
RC   TISSUE=Fetal brain, and Heart;
RX   MEDLINE=95142296; PubMed=7840300;
RA   Ashen M.D., O'Rourke B., Kluge K.A., Johns D.C., Tomaselli G.F.;
RT   "Inward rectifier K+ channel from human heart and brain: cloning and
RT   stable expression in a human cell line.";
RL   Am. J. Physiol. 268:H506-H511(1995).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-337, AND MASS
RP   SPECTROMETRY.
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [8]
RP   CHARACTERIZATION OF VARIANTS LQT7 VAL-71 AND TRP-218, AND VARIANTS
RP   LQT7 VAL-300; 95-SER--PHE-98 DEL AND SER-314-315-TYR DEL.
RX   PubMed=11371347; DOI=10.1016/S0092-8674(01)00342-7;
RA   Plaster N.M., Tawil R., Tristani-Firouzi M., Canun S., Bendahhou S.,
RA   Tsunoda A., Donaldson M.R., Iannaccone S.T., Brunt E., Barohn R.,
RA   Clark J., Deymeer F., George A.L. Jr., Fish F.A., Hahn A., Nitu A.,
RA   Ozdemir C., Serdaroglu P., Subramony S.H., Wolfe G., Fu Y.-H.,
RA   Ptacek L.J.;
RT   "Mutations in Kir2.1 cause the developmental and episodic electrical
RT   phenotypes of Andersen's syndrome.";
RL   Cell 105:511-519(2001).
RN   [9]
RP   VARIANT LQT7 TRP-67.
RX   PubMed=12148092; DOI=10.1086/342360;
RA   Andelfinger G., Tapper A.R., Welch R.C., Vanoye C.G., George A.L. Jr.,
RA   Benson D.W.;
RT   "KCNJ2 mutation results in Andersen syndrome with sex-specific cardiac
RT   and skeletal muscle phenotypes.";
RL   Am. J. Hum. Genet. 71:663-668(2002).
RN   [10]
RP   VARIANTS LQT7 LEU-186; HIS-216 AND MET-302.
RX   PubMed=12163457;
RA   Tristani-Firouzi M., Jensen J.L., Donaldson M.R., Sansone V.,
RA   Meola G., Hahn A., Bendahhou S., Kwiecinski H., Fidzianska A.,
RA   Plaster N., Fu Y.-H., Ptacek L.J., Tawil R.;
RT   "Functional and clinical characterization of KCNJ2 mutations
RT   associated with LQT7 (Andersen syndrome).";
RL   J. Clin. Invest. 110:381-388(2002).
RN   [11]
RP   VARIANT SQT3 ASN-172, AND CHARACTERIZATION OF VARIANT SQT3 ASN-172.
RX   PubMed=15761194; DOI=10.1161/01.RES.0000162101.76263.8c;
RA   Priori S.G., Pandit S.V., Rivolta I., Berenfeld O., Ronchetti E.,
RA   Dhamoon A., Napolitano C., Anumonwo J., di Barletta M.R.,
RA   Gudapakkam S., Bosi G., Stramba-Badiale M., Jalife J.;
RT   "A novel form of short QT syndrome (SQT3) is caused by a mutation in
RT   the KCNJ2 gene.";
RL   Circ. Res. 96:800-807(2005).
CC   -!- FUNCTION: Probably participates in establishing action potential
CC       waveform and excitability of neuronal and muscle tissues. Inward
CC       rectifier potassium channels are characterized by a greater
CC       tendency to allow potassium to flow into the cell rather than out
CC       of it. Their voltage dependence is regulated by the concentration
CC       of extracellular potassium; as external potassium is raised, the
CC       voltage range of the channel opening shifts to more positive
CC       voltages. The inward rectification is mainly due to the blockage
CC       of outward current by internal magnesium. Can be blocked by
CC       extracellular barium or cesium.
CC   -!- SUBUNIT: Homomultimeric and heteromultimeric association with
CC       Kir2.3, resulting in an enhanced G-protein-induced current.
CC       Association, via its PDZ-recognition domain, with LIN7A, LIN7B,
CC       LIN7C, DLG1, CASK and APBA1 plays a key role in its localization
CC       and trafficking (By similarity).
CC   -!- INTERACTION:
CC       P24588:AKAP5; NbExp=1; IntAct=EBI-703457, EBI-703640;
CC       P21333:FLNA; NbExp=1; IntAct=EBI-703457, EBI-350432;
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Heart, brain, placenta, lung, skeletal muscle,
CC       and kidney. Diffusely distributed throughout the brain.
CC   -!- DISEASE: Defects in KCNJ2 are the cause of long QT syndrome type 7
CC       (LQT7) [MIM:170390]; also called Andersen syndrome or Andersen
CC       cardiodysrhythmic periodic paralysis. Long QT syndromes are heart
CC       disorders characterized by a prolonged QT interval on the ECG and
CC       polymorphic ventricular arrhythmias. They cause syncope and sudden
CC       death in response to excercise or emotional stress. LQT7 manifests
CC       itself as a clinical triad consisting of potassium-sensitive
CC       periodic paralysis, ventricular ectopy and dysmorphic features.
CC   -!- DISEASE: Defects in KCNJ2 are the cause of short QT syndrome type
CC       3 (SQT3) [MIM:609622]. Short QT syndromes are heart disorders
CC       characterized by idiopathic persistently and uniformly short QT
CC       interval on ECG in the absence of structural heart disease in
CC       affected individuals. They cause syncope and sudden death. SQT3
CC       has a unique ECG phenotype characterized by asymmetrical T waves.
CC   -!- SIMILARITY: Belongs to the inward rectifier-type potassium channel
CC       family.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/KCNJ2";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U24055; AAB50277.1; -; mRNA.
DR   EMBL; U12507; AAC50072.1; -; mRNA.
DR   EMBL; U16861; AAA91781.1; -; mRNA.
DR   EMBL; AF153819; AAF73242.1; -; Genomic_DNA.
DR   EMBL; AF153820; AAF73241.1; -; mRNA.
DR   EMBL; U22413; AAA64282.1; -; mRNA.
DR   EMBL; AF011904; AAC39555.1; -; mRNA.
DR   EMBL; AF021139; AAB88797.1; -; mRNA.
DR   IPI; IPI00007614; -.
DR   PIR; I38727; I38727.
DR   RefSeq; NP_000882.1; -.
DR   UniGene; Hs.1547; -.
DR   SMR; P63252; 44-348, 190-365.
DR   IntAct; P63252; 2.
DR   STRING; P63252; -.
DR   TCDB; 1.A.2.1.2; inward rectifier K+ channel (IRK-C) family.
DR   PhosphoSite; P63252; -.
DR   PeptideAtlas; P63252; -.
DR   PRIDE; P63252; -.
DR   Ensembl; ENST00000243457; ENSP00000243457; ENSG00000123700; Homo sapiens.
DR   GeneID; 3759; -.
DR   KEGG; hsa:3759; -.
DR   UCSC; uc002jir.1; human.
DR   CTD; 3759; -.
DR   GeneCards; GC17P065677; -.
DR   H-InvDB; HIX0039037; -.
DR   HGNC; HGNC:6263; KCNJ2.
DR   MIM; 170390; phenotype.
DR   MIM; 600681; gene.
DR   MIM; 609622; phenotype.
DR   Orphanet; 334; Atrial fibrillation, familial.
DR   Orphanet; 37553; Cardiodysrythmic potassium-sensitive periodic paralysis.
DR   Orphanet; 768; Long QT syndrome, familial.
DR   Orphanet; 51083; Short QT syndrome, familial.
DR   PharmGKB; PA214; -.
DR   eggNOG; prNOG10748; -.
DR   HOGENOM; HBG716702; -.
DR   HOVERGEN; HBG006178; -.
DR   InParanoid; P63252; -.
DR   OMA; QVSSFTA; -.
DR   PhylomeDB; P63252; -.
DR   NextBio; 14737; -.
DR   ArrayExpress; P63252; -.
DR   Bgee; P63252; -.
DR   CleanEx; HS_KCNJ2; -.
DR   Genevestigator; P63252; -.
DR   GermOnline; ENSG00000123700; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0005242; F:inward rectifier potassium channel activity; TAS:ProtInc.
DR   GO; GO:0030955; F:potassium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0006813; P:potassium ion transport; TAS:ProtInc.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR016449; K_chnl_inward-rec_Kir.
DR   InterPro; IPR001838; K_chnl_inward-rec_Kir-like.
DR   InterPro; IPR003271; K_chnl_inward-rec_Kir2.1.
DR   InterPro; IPR013521; K_chnl_inward-rec_Kir_Cr2.
DR   InterPro; IPR013518; K_chnl_inward-rec_Kir_cyto.
DR   InterPro; IPR013673; K_chnl_inward-rec_Kir_N.
DR   Gene3D; G3DSA:2.60.40.1400; IR_K+channel_cytopl; 1.
DR   PANTHER; PTHR11767; K+channel_IR; 1.
DR   PANTHER; PTHR11767:SF15; KIR21_channel; 1.
DR   Pfam; PF01007; IRK; 1.
DR   Pfam; PF08466; IRK_N; 1.
DR   PIRSF; PIRSF005465; GIRK_kir; 1.
DR   PRINTS; PR01324; KIR21CHANNEL.
DR   PRINTS; PR01320; KIRCHANNEL.
DR   SUPFAM; SSF81296; Ig_E-set; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Disease mutation; Ion transport; Ionic channel;
KW   Long QT syndrome; Membrane; Phosphoprotein; Potassium;
KW   Potassium transport; Short QT syndrome; Transmembrane; Transport;
KW   Voltage-gated channel.
FT   CHAIN         1    427       Inward rectifier potassium channel 2.
FT                                /FTId=PRO_0000154923.
FT   TOPO_DOM      1     81       Cytoplasmic (By similarity).
FT   TRANSMEM     82    106       M1 (By similarity).
FT   TOPO_DOM    107    128       Extracellular (By similarity).
FT   TOPO_DOM    148    156       Extracellular (By similarity).
FT   TRANSMEM    157    178       M2 (By similarity).
FT   TOPO_DOM    179    427       Cytoplasmic (By similarity).
FT   REGION      129    140       H5 (pore-forming helix) (By similarity).
FT   MOTIF       142    147       Selectivity filter (By similarity).
FT   MOTIF       425    427       PDZ-binding (Potential).
FT   SITE        172    172       Role in the control of polyamine-mediated
FT                                channel gating and in the blocking by
FT                                intracellular magnesium (By similarity).
FT   MOD_RES     337    337       Phosphotyrosine.
FT   VARIANT      67     67       R -> W (in LQT7).
FT                                /FTId=VAR_017851.
FT   VARIANT      71     71       D -> V (in LQT7; loss of function and
FT                                dominant-negative effect in current).
FT                                /FTId=VAR_017852.
FT   VARIANT      95     98       Missing (in LQT7).
FT                                /FTId=VAR_017853.
FT   VARIANT     172    172       D -> N (in SQT3; gain of function).
FT                                /FTId=VAR_023842.
FT   VARIANT     186    186       P -> L (in LQT7).
FT                                /FTId=VAR_017854.
FT   VARIANT     216    216       N -> H (in LQT7).
FT                                /FTId=VAR_017855.
FT   VARIANT     218    218       R -> W (in LQT7; loss of function and
FT                                dominant-negative effect in current).
FT                                /FTId=VAR_017856.
FT   VARIANT     300    300       G -> V (in LQT7).
FT                                /FTId=VAR_017857.
FT   VARIANT     302    302       V -> M (in LQT7).
FT                                /FTId=VAR_017858.
FT   VARIANT     314    315       Missing (in LQT7).
FT                                /FTId=VAR_017859.
FT   CONFLICT    330    330       L -> F (in Ref. 4; AAC39555).
FT   CONFLICT    340    340       D -> E (in Ref. 4; AAC39555).
SQ   SEQUENCE   427 AA;  48288 MW;  AB37CAD4B99B4050 CRC64;
     MGSVRTNRYS IVSSEEDGMK LATMAVANGF GNGKSKVHTR QQCRSRFVKK DGHCNVQFIN
     VGEKGQRYLA DIFTTCVDIR WRWMLVIFCL AFVLSWLFFG CVFWLIALLH GDLDASKEGK
     ACVSEVNSFT AAFLFSIETQ TTIGYGFRCV TDECPIAVFM VVFQSIVGCI IDAFIIGAVM
     AKMAKPKKRN ETLVFSHNAV IAMRDGKLCL MWRVGNLRKS HLVEAHVRAQ LLKSRITSEG
     EYIPLDQIDI NVGFDSGIDR IFLVSPITIV HEIDEDSPLY DLSKQDIDNA DFEIVVILEG
     MVEATAMTTQ CRSSYLANEI LWGHRYEPVL FEEKHYYKVD YSRFHKTYEV PNTPLCSARD
     LAEKKYILSN ANSFCYENEV ALTSKEEDDS ENGVPESTST DTPPDIDLHN QASVPLEPRP
     LRRESEI
//
ID   IRK2_MOUSE              Reviewed;         428 AA.
AC   P35561;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   02-MAR-2010, entry version 98.
DE   RecName: Full=Inward rectifier potassium channel 2;
DE   AltName: Full=Potassium channel, inwardly rectifying subfamily J member 2;
DE   AltName: Full=Inward rectifier K(+) channel Kir2.1;
DE            Short=IRK-1;
GN   Name=Kcnj2; Synonyms=Irk1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=BALB/c; TISSUE=Macrophage;
RX   MEDLINE=93196696; PubMed=7680768; DOI=10.1038/362127a0;
RA   Kubo Y., Baldwin T.J., Jan Y.N., Jan L.Y.;
RT   "Primary structure and functional expression of a mouse inward
RT   rectifier potassium channel.";
RL   Nature 362:127-132(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   MEDLINE=94109571; PubMed=8282096; DOI=10.1016/0014-5793(93)80840-Q;
RA   Morishige K., Takahashi N., Findlay I., Koyama H., Zanelli J.S.,
RA   Peterson C., Jenkins N.A., Copeland N.G., Mori N., Kurachi Y.;
RT   "Molecular cloning, functional expression and localization of an
RT   inward rectifier potassium channel in the mouse brain.";
RL   FEBS Lett. 336:375-380(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lens epithelium;
RX   MEDLINE=98288410; PubMed=9533862; DOI=10.1006/exer.1997.0432;
RA   Rae J.L., Shepard A.R.;
RT   "Inwardly rectifying potassium channels in lens epithelium are from
RT   the IRK1 (Kir 2.1) family.";
RL   Exp. Eye Res. 66:347-359(1998).
CC   -!- FUNCTION: Probably participates in establishing action potential
CC       waveform and excitability of neuronal and muscle tissues. Inward
CC       rectifier potassium channels are characterized by a greater
CC       tendency to allow potassium to flow into the cell rather than out
CC       of it. Their voltage dependence is regulated by the concentration
CC       of extracellular potassium; as external potassium is raised, the
CC       voltage range of the channel opening shifts to more positive
CC       voltages. The inward rectification is mainly due to the blockage
CC       of outward current by internal magnesium. Can be blocked by
CC       extracellular barium and cesium.
CC   -!- SUBUNIT: Homomultimeric and heteromultimeric association with
CC       Kir2.3, resulting in an enhanced G-protein-induced current.
CC       Association, via its PDZ-recognition domain, with LIN7A, LIN7B,
CC       LIN7C, DLG1, CASK and APBA1 plays a key role in its localization
CC       and trafficking (By similarity).
CC   -!- INTERACTION:
CC       P24588:AKAP5 (xeno); NbExp=2; IntAct=EBI-703793, EBI-703640;
CC       Q15700-4:DLG2 (xeno); NbExp=2; IntAct=EBI-703793, EBI-663057;
CC       Q2YHQ3:FLNA (xeno); NbExp=3; IntAct=EBI-703793, EBI-779542;
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Prominently expressed in the central nervous
CC       system. Also found in other excitable tissues such as heart and
CC       skeletal muscle.
CC   -!- SIMILARITY: Belongs to the inward rectifier-type potassium channel
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X73052; CAA51526.1; -; mRNA.
DR   EMBL; AF021136; AAB88794.1; -; mRNA.
DR   IPI; IPI00119613; -.
DR   PIR; S32351; S32351.
DR   RefSeq; NP_032451.1; -.
DR   UniGene; Mm.4951; -.
DR   PDB; 1U4F; X-ray; 2.41 A; A/B/C/D=41-428.
DR   PDB; 2GIX; X-ray; 2.02 A; A/B/C/D=44-371.
DR   PDBsum; 1U4F; -.
DR   PDBsum; 2GIX; -.
DR   SMR; P35561; 44-348.
DR   IntAct; P35561; 6.
DR   STRING; P35561; -.
DR   PhosphoSite; P35561; -.
DR   PRIDE; P35561; -.
DR   Ensembl; ENSMUST00000042970; ENSMUSP00000037192; ENSMUSG00000041695; Mus musculus.
DR   GeneID; 16518; -.
DR   KEGG; mmu:16518; -.
DR   UCSC; uc007mdw.1; mouse.
DR   CTD; 16518; -.
DR   MGI; MGI:104744; Kcnj2.
DR   eggNOG; roNOG05227; -.
DR   HOGENOM; HBG716702; -.
DR   HOVERGEN; HBG006178; -.
DR   InParanoid; P35561; -.
DR   OMA; QVSSFTA; -.
DR   OrthoDB; EOG9R26DF; -.
DR   PhylomeDB; P35561; -.
DR   NextBio; 289885; -.
DR   ArrayExpress; P35561; -.
DR   Bgee; P35561; -.
DR   Genevestigator; P35561; -.
DR   GermOnline; ENSMUSG00000041695; Mus musculus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005242; F:inward rectifier potassium channel activity; IEA:InterPro.
DR   GO; GO:0030955; F:potassium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0006813; P:potassium ion transport; IEA:UniProtKB-KW.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR016449; K_chnl_inward-rec_Kir.
DR   InterPro; IPR001838; K_chnl_inward-rec_Kir-like.
DR   InterPro; IPR003271; K_chnl_inward-rec_Kir2.1.
DR   InterPro; IPR013521; K_chnl_inward-rec_Kir_Cr2.
DR   InterPro; IPR013518; K_chnl_inward-rec_Kir_cyto.
DR   InterPro; IPR013673; K_chnl_inward-rec_Kir_N.
DR   Gene3D; G3DSA:2.60.40.1400; IR_K+channel_cytopl; 1.
DR   PANTHER; PTHR11767; K+channel_IR; 1.
DR   PANTHER; PTHR11767:SF15; KIR21_channel; 1.
DR   Pfam; PF01007; IRK; 1.
DR   Pfam; PF08466; IRK_N; 1.
DR   PIRSF; PIRSF005465; GIRK_kir; 1.
DR   PRINTS; PR01324; KIR21CHANNEL.
DR   PRINTS; PR01320; KIRCHANNEL.
DR   SUPFAM; SSF81296; Ig_E-set; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Ion transport; Ionic channel; Membrane; Phosphoprotein;
KW   Potassium; Potassium transport; Transmembrane; Transport;
KW   Voltage-gated channel.
FT   CHAIN         1    428       Inward rectifier potassium channel 2.
FT                                /FTId=PRO_0000154925.
FT   TOPO_DOM      1     81       Cytoplasmic (By similarity).
FT   TRANSMEM     82    106       M1 (By similarity).
FT   TOPO_DOM    107    128       Extracellular (By similarity).
FT   TOPO_DOM    148    156       Extracellular (By similarity).
FT   TRANSMEM    157    178       M2 (By similarity).
FT   TOPO_DOM    179    428       Cytoplasmic (By similarity).
FT   REGION      129    140       H5 (pore-forming helix) (By similarity).
FT   MOTIF       142    147       Selectivity filter (By similarity).
FT   MOTIF       426    428       PDZ-binding (Potential).
FT   SITE        172    172       Role in the control of polyamine-mediated
FT                                channel gating and in the blocking by
FT                                intracellular magnesium (By similarity).
FT   MOD_RES     337    337       Phosphotyrosine (By similarity).
FT   STRAND      180    184
FT   TURN        188    190
FT   STRAND      192    195
FT   STRAND      197    204
FT   STRAND      207    216
FT   STRAND      218    220
FT   STRAND      222    236
FT   STRAND      242    249
FT   TURN        254    259
FT   STRAND      267    272
FT   TURN        278    281
FT   HELIX       284    289
FT   STRAND      293    302
FT   STRAND      308    316
FT   HELIX       317    319
FT   STRAND      320    322
FT   STRAND      324    326
FT   STRAND      330    332
FT   STRAND      334    340
FT   HELIX       341    343
FT   STRAND      347    349
FT   HELIX       358    364
SQ   SEQUENCE   428 AA;  48389 MW;  5B4219F979BBA41C CRC64;
     MGSVRTNRYS IVSSEEDGMK LATMAVANGF GNGKSKVHTR QQCRSRFVKK DGHCNVQFIN
     VGEKGQRYLA DIFTTCVDIR WRWMLVIFCL AFVLSWLFFG CVFWLIALLH GDLDTSKVSK
     ACVSEVNSFT AAFLFSIETQ TTIGYGFRCV TDECPIAVFM VVFQSIVGCI IDAFIIGAVM
     AKMAKPKKRN ETLVFSHNAV IAMRDGKLCL MWRVGNLRKS HLVEAHVRAQ LLKSRITSEG
     EYIPLDQIDI NVGFDSGIDR IFLVSPITIV HEIDEDSPLY DLSKQDIDNA DFEIVVILEG
     MVEATAMTTQ CRSSYLANEI LWGHRYEPVL FEEKHYYKVD YSRFHKTYEV PNTPLCSARD
     LAEKKYILSN ANSFCYENEV ALTSKEEEED SENGVPESTS TDSPPGIDLH NQASVPLEPR
     PLRRESEI
//
ID   IRK2_RAT                Reviewed;         427 AA.
AC   Q64273;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   02-MAR-2010, entry version 89.
DE   RecName: Full=Inward rectifier potassium channel 2;
DE   AltName: Full=Potassium channel, inwardly rectifying subfamily J member 2;
DE   AltName: Full=Inward rectifier K(+) channel Kir2.1;
DE            Short=IRK-1;
DE            Short=RBL-IRK1;
GN   Name=Kcnj2; Synonyms=Irk1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=95327471; PubMed=7603835; DOI=10.1007/BF00374805;
RA   Wischmeyer E., Lentes K.U., Karschin A.;
RT   "Physiological and molecular characterization of an IRK-type inward
RT   rectifier K+ channel in a tumour mast cell line.";
RL   Pflugers Arch. 429:809-819(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Lens epithelium;
RX   MEDLINE=98288410; PubMed=9533862; DOI=10.1006/exer.1997.0432;
RA   Rae J.L., Shepard A.R.;
RT   "Inwardly rectifying potassium channels in lens epithelium are from
RT   the IRK1 (Kir 2.1) family.";
RL   Exp. Eye Res. 66:347-359(1998).
RN   [3]
RP   INTERACTION WITH CASK; LIN7A; LIN7B; LIN7C; APBA1 AND DLG1, AND
RP   FUNCTION.
RX   PubMed=14960569; DOI=10.1074/jbc.M400284200;
RA   Leonoudakis D., Conti L.R., Radeke C.M., McGuire L.M.,
RA   Vandenberg C.A.;
RT   "A multiprotein trafficking complex composed of SAP97, CASK, Veli, and
RT   Mint1 is associated with inward rectifier Kir2 potassium channels.";
RL   J. Biol. Chem. 279:19051-19063(2004).
CC   -!- FUNCTION: Probably participates in establishing action potential
CC       waveform and excitability of neuronal and muscle tissues. Inward
CC       rectifier potassium channels are characterized by a greater
CC       tendency to allow potassium to flow into the cell rather than out
CC       of it. Their voltage dependence is regulated by the concentration
CC       of extracellular potassium; as external potassium is raised, the
CC       voltage range of the channel opening shifts to more positive
CC       voltages. The inward rectification is mainly due to the blockage
CC       of outward current by internal magnesium. Can be blocked by
CC       extracellular barium and cesium (By similarity).
CC   -!- SUBUNIT: Homomultimeric and heteromultimeric association with
CC       Kir2.3, resulting in an enhanced G-protein-induced current.
CC       Association, via its PDZ-recognition domain, with LIN7A, LIN7B,
CC       LIN7C, DLG1, CASK and APBA1 plays a key role in its localization
CC       and trafficking.
CC   -!- INTERACTION:
CC       Q63622-4:Dlg2; NbExp=1; IntAct=EBI-703577, EBI-681971;
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Prominently expressed in the central nervous
CC       system. Also found in other excitable tissues such as heart and
CC       skeletal muscle.
CC   -!- SIMILARITY: Belongs to the inward rectifier-type potassium channel
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L48490; AAB03890.1; -; mRNA.
DR   EMBL; AF021137; AAB88795.1; -; mRNA.
DR   IPI; IPI00210974; -.
DR   RefSeq; NP_058992.1; -.
DR   UniGene; Rn.44415; -.
DR   SMR; Q64273; 44-348, 187-370.
DR   IntAct; Q64273; 1.
DR   STRING; Q64273; -.
DR   Ensembl; ENSRNOT00000006254; ENSRNOP00000006254; ENSRNOG00000004720; Rattus norvegicus.
DR   GeneID; 29712; -.
DR   KEGG; rno:29712; -.
DR   CTD; 29712; -.
DR   RGD; 61968; Kcnj2.
DR   eggNOG; maNOG08267; -.
DR   HOVERGEN; HBG006178; -.
DR   InParanoid; Q64273; -.
DR   OMA; QVSSFTA; -.
DR   OrthoDB; EOG9R26DF; -.
DR   PhylomeDB; Q64273; -.
DR   NextBio; 610149; -.
DR   ArrayExpress; Q64273; -.
DR   Genevestigator; Q64273; -.
DR   GermOnline; ENSRNOG00000004720; Rattus norvegicus.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005242; F:inward rectifier potassium channel activity; IEA:InterPro.
DR   GO; GO:0030955; F:potassium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0006813; P:potassium ion transport; IEA:UniProtKB-KW.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR016449; K_chnl_inward-rec_Kir.
DR   InterPro; IPR001838; K_chnl_inward-rec_Kir-like.
DR   InterPro; IPR003271; K_chnl_inward-rec_Kir2.1.
DR   InterPro; IPR013521; K_chnl_inward-rec_Kir_Cr2.
DR   InterPro; IPR013518; K_chnl_inward-rec_Kir_cyto.
DR   InterPro; IPR013673; K_chnl_inward-rec_Kir_N.
DR   Gene3D; G3DSA:2.60.40.1400; IR_K+channel_cytopl; 1.
DR   PANTHER; PTHR11767; K+channel_IR; 1.
DR   PANTHER; PTHR11767:SF15; KIR21_channel; 1.
DR   Pfam; PF01007; IRK; 1.
DR   Pfam; PF08466; IRK_N; 1.
DR   PIRSF; PIRSF005465; GIRK_kir; 1.
DR   PRINTS; PR01324; KIR21CHANNEL.
DR   PRINTS; PR01320; KIRCHANNEL.
DR   SUPFAM; SSF81296; Ig_E-set; 1.
PE   1: Evidence at protein level;
KW   Ion transport; Ionic channel; Membrane; Phosphoprotein; Potassium;
KW   Potassium transport; Transmembrane; Transport; Voltage-gated channel.
FT   CHAIN         1    427       Inward rectifier potassium channel 2.
FT                                /FTId=PRO_0000154928.
FT   TOPO_DOM      1     81       Cytoplasmic (By similarity).
FT   TRANSMEM     82    106       M1 (By similarity).
FT   TOPO_DOM    107    128       Extracellular (By similarity).
FT   TOPO_DOM    148    156       Extracellular (By similarity).
FT   TRANSMEM    157    178       M2 (By similarity).
FT   TOPO_DOM    179    427       Cytoplasmic (By similarity).
FT   REGION      129    140       H5 (pore-forming helix) (By similarity).
FT   MOTIF       142    147       Selectivity filter (By similarity).
FT   MOTIF       425    427       PDZ-binding (Potential).
FT   SITE        172    172       Role in the control of polyamine-mediated
FT                                channel gating and in the blocking by
FT                                intracellular magnesium (By similarity).
FT   MOD_RES     337    337       Phosphotyrosine (By similarity).
SQ   SEQUENCE   427 AA;  48200 MW;  85538FB1CCEBF8ED CRC64;
     MGSVRTNRYS IVSSEEDGMK LATMAVANGF GNGKSKVHTR QQCRSRFVKK DGHCNVQFIN
     VGEKGQRYLA DIFTTCVDIR WRWMLVIFCL AFVLSWLFFG CVFWLIALLH GDLDASKESK
     ACVSEVNSFT AAFLFSIETQ TTIGYGFRCV TDECPIAVFM VVFQSIVGCI IDAFIIGAVM
     AKMAKPKKRN ETLVFSHNAV IAMRDGKLCL MWRVGNLRKS HLVEAHVRAQ LLKSRITSEG
     EYIPLDQIDI NVGFDSGIDR IFLVSPITIV HEIDEDSPLY DLSKQDIDNA DFEIVVILEG
     MVEATAMTTQ CRSSYLANEI LWGHRYEPVL FEEKHCYKVD YSRFHKTYEV PNTPLCSARD
     LAEKKYILSN ANSFCYENEV ALTSKEEEDS ENGVPESTST DSPPGIDLHN QASVPLEPRP
     LRRESEI
//
ID   IRK3_HUMAN              Reviewed;         501 AA.
AC   P48549; Q8TBI0;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 1.
DT   02-MAR-2010, entry version 90.
DE   RecName: Full=G protein-activated inward rectifier potassium channel 1;
DE            Short=GIRK-1;
DE   AltName: Full=Potassium channel, inwardly rectifying subfamily J member 3;
DE   AltName: Full=Inward rectifier K(+) channel Kir3.1;
GN   Name=KCNJ3; Synonyms=GIRK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   MEDLINE=97021689; PubMed=8868049;
RA   Chan K.W., Langan M.N., Sui J., Kozak A., Pabon A., Ladias J.A.A.,
RA   Logothetis D.E.;
RT   "A recombinant inwardly rectifying potassium channel coupled to GTP-
RT   binding proteins.";
RL   J. Gen. Physiol. 107:381-397(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=96397817; PubMed=8804710; DOI=10.1016/0169-328X(95)00349-W;
RA   Schoots O., Yue K.T., Macdonald J.F., Hampson D.R., Nobrega J.N.,
RA   Dixon L.M., van Tol H.H.M.;
RT   "Cloning of a G protein-activated inwardly rectifying potassium
RT   channel from human cerebellum.";
RL   Brain Res. Mol. Brain Res. 39:23-30(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-69 AND THR-73, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Epithelium;
RX   PubMed=17924679; DOI=10.1021/pr070152u;
RA   Yu L.-R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.;
RT   "Improved titanium dioxide enrichment of phosphopeptides from HeLa
RT   cells and high confident phosphopeptide identification by cross-
RT   validation of MS/MS and MS/MS/MS spectra.";
RL   J. Proteome Res. 6:4150-4162(2007).
CC   -!- FUNCTION: This potassium channel is controlled by G proteins.
CC       Inward rectifier potassium channels are characterized by a greater
CC       tendency to allow potassium to flow into the cell rather than out
CC       of it. Their voltage dependence is regulated by the concentration
CC       of extracellular potassium; as external potassium is raised, the
CC       voltage range of the channel opening shifts to more positive
CC       voltages. The inward rectification is mainly due to the blockage
CC       of outward current by internal magnesium. This receptor plays a
CC       crucial role in regulating the heartbeat.
CC   -!- SUBUNIT: Associates with GIRK2, GIRK3 or GIRK4 to form a G-protein
CC       activated heteromultimer pore-forming unit. The resulting inward
CC       current is much larger (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the inward rectifier-type potassium channel
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U39196; AAB53094.1; -; mRNA.
DR   EMBL; U50964; AAB42176.1; -; mRNA.
DR   EMBL; BC022495; AAH22495.1; -; mRNA.
DR   IPI; IPI00010176; -.
DR   PIR; G02468; G02468.
DR   RefSeq; NP_002230.1; -.
DR   UniGene; Hs.591606; -.
DR   SMR; P48549; 41-364.
DR   STRING; P48549; -.
DR   PhosphoSite; P48549; -.
DR   PRIDE; P48549; -.
DR   Ensembl; ENST00000295101; ENSP00000295101; ENSG00000162989; Homo sapiens.
DR   GeneID; 3760; -.
DR   KEGG; hsa:3760; -.
DR   UCSC; uc002tyv.1; human.
DR   CTD; 3760; -.
DR   GeneCards; GC02P155263; -.
DR   H-InvDB; HIX0002517; -.
DR   HGNC; HGNC:6264; KCNJ3.
DR   HPA; HPA024231; -.
DR   MIM; 601534; gene.
DR   PharmGKB; PA215; -.
DR   eggNOG; prNOG13252; -.
DR   HOGENOM; HBG716702; -.
DR   HOVERGEN; HBG006178; -.
DR   InParanoid; P48549; -.
DR   OMA; FSEHAAI; -.
DR   OrthoDB; EOG9KH5F3; -.
DR   PhylomeDB; P48549; -.
DR   DrugBank; DB01159; Halothane.
DR   NextBio; 14741; -.
DR   ArrayExpress; P48549; -.
DR   Bgee; P48549; -.
DR   CleanEx; HS_KCNJ3; -.
DR   Genevestigator; P48549; -.
DR   GermOnline; ENSG00000162989; Homo sapiens.
DR   GO; GO:0008076; C:voltage-gated potassium channel complex; TAS:ProtInc.
DR   GO; GO:0015467; F:G-protein activated inward rectifier potass...; TAS:ProtInc.
DR   GO; GO:0030955; F:potassium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0006813; P:potassium ion transport; TAS:ProtInc.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR016449; K_chnl_inward-rec_Kir.
DR   InterPro; IPR001838; K_chnl_inward-rec_Kir-like.
DR   InterPro; IPR003274; K_chnl_inward-rec_Kir3.1.
DR   InterPro; IPR013521; K_chnl_inward-rec_Kir_Cr2.
DR   InterPro; IPR013518; K_chnl_inward-rec_Kir_cyto.
DR   Gene3D; G3DSA:2.60.40.1400; IR_K+channel_cytopl; 1.
DR   PANTHER; PTHR11767; K+channel_IR; 1.
DR   Pfam; PF01007; IRK; 1.
DR   PIRSF; PIRSF005465; GIRK_kir; 1.
DR   PRINTS; PR01327; KIR31CHANNEL.
DR   PRINTS; PR01320; KIRCHANNEL.
DR   SUPFAM; SSF81296; Ig_E-set; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Ion transport; Ionic channel; Membrane;
KW   Phosphoprotein; Polymorphism; Potassium; Potassium transport;
KW   Transmembrane; Transport; Voltage-gated channel.
FT   CHAIN         1    501       G protein-activated inward rectifier
FT                                potassium channel 1.
FT                                /FTId=PRO_0000154938.
FT   TOPO_DOM      1     80       Cytoplasmic (By similarity).
FT   TRANSMEM     81    105       M1 (By similarity).
FT   TOPO_DOM    106    129       Extracellular (By similarity).
FT   TOPO_DOM    149    157       Extracellular (By similarity).
FT   TRANSMEM    158    179       M2 (By similarity).
FT   TOPO_DOM    180    501       Cytoplasmic (By similarity).
FT   REGION      130    141       H5 (pore-forming helix) (By similarity).
FT   MOTIF       143    148       Selectivity filter (By similarity).
FT   SITE        173    173       Role in the control of polyamine-mediated
FT                                channel gating and in the blocking by
FT                                intracellular magnesium (By similarity).
FT   MOD_RES      69     69       Phosphoserine.
FT   MOD_RES      73     73       Phosphothreonine.
FT   VARIANT      40     40       K -> R (in dbSNP:rs16838016).
FT                                /FTId=VAR_049669.
FT   CONFLICT    271    271       C -> R (in Ref. 3; AAH22495).
FT   CONFLICT    291    291       E -> K (in Ref. 3; AAH22495).
SQ   SEQUENCE   501 AA;  56603 MW;  825A28ACE2873269 CRC64;
     MSALRRKFGD DYQVVTTSSS GSGLQPQGPG QDPQQQLVPK KKRQRFVDKN GRCNVQHGNL
     GSETSRYLSD LFTTLVDLKW RWNLFIFILT YTVAWLFMAS MWWVIAYTRG DLNKAHVGNY
     TPCVANVYNF PSAFLFFIET EATIGYGYRY ITDKCPEGII LFLFQSILGS IVDAFLIGCM
     FIKMSQPKKR AETLMFSEHA VISMRDGKLT LMFRVGNLRN SHMVSAQIRC KLLKSRQTPE
     GEFLPLDQLE LDVGFSTGAD QLFLVSPLTI CHVIDAKSPF YDLSQRSMQT EQFEIVVILE
     GIVETTGMTC QARTSYTEDE VLWGHRFFPV ISLEEGFFKV DYSQFHATFE VPTPPYSVKE
     QEEMLLMSSP LIAPAITNSK ERHNSVECLD GLDDITTKLP SKLQKITGRE DFPKKLLRMS
     STTSEKAYSL GDLPMKLQRI SSVPGNSEEK LVSKTTKMLS DPMSQSVADL PPKLQKMAGG
     AARMEGNLPA KLRKMNSDRF T
//
ID   IRK3_MOUSE              Reviewed;         501 AA.
AC   P63250; P35562;
DT   11-OCT-2004, integrated into UniProtKB/Swiss-Prot.
DT   11-OCT-2004, sequence version 1.
DT   02-MAR-2010, entry version 62.
DE   RecName: Full=G protein-activated inward rectifier potassium channel 1;
DE            Short=GIRK-1;
DE   AltName: Full=Potassium channel, inwardly rectifying subfamily J member 3;
DE   AltName: Full=Inward rectifier K(+) channel Kir3.1;
GN   Name=Kcnj3; Synonyms=Girk1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=C57BL/6;
RX   MEDLINE=95217202; PubMed=7702616; DOI=10.1006/bbrc.1995.1456;
RA   Kobayashi T., Ikeda K., Ichikawa T., Abe S., Togashi S., Kumanishi T.;
RT   "Molecular cloning of a mouse G-protein-activated K+ channel (mGIRK1)
RT   and distinct distributions of three GIRK (GIRK1, 2 and 3) mRNAs in
RT   mouse brain.";
RL   Biochem. Biophys. Res. Commun. 208:1166-1173(1995).
RN   [2]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 43-63 AND 190-370.
RX   PubMed=12507423; DOI=10.1016/S0092-8674(02)01227-8;
RA   Nishida M., MacKinnon R.;
RT   "Structural basis of inward rectification: cytoplasmic pore of the G
RT   protein-gated inward rectifier GIRK1 at 1.8 A resolution.";
RL   Cell 111:957-965(2002).
CC   -!- FUNCTION: This potassium channel is controlled by G proteins.
CC       Inward rectifier potassium channels are characterized by a greater
CC       tendency to allow potassium to flow into the cell rather than out
CC       of it. Their voltage dependence is regulated by the concentration
CC       of extracellular potassium; as external potassium is raised, the
CC       voltage range of the channel opening shifts to more positive
CC       voltages. The inward rectification is mainly due to the blockage
CC       of outward current by internal magnesium. This receptor plays a
CC       crucial role in regulating the heartbeat.
CC   -!- SUBUNIT: Associates with GIRK2, GIRK3 or GIRK4 to form a G-protein
CC       activated heteromultimer pore-forming unit. The resulting inward
CC       current is much larger (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the inward rectifier-type potassium channel
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D45022; BAA08079.1; -; mRNA.
DR   IPI; IPI00119615; -.
DR   PIR; JC4139; JC4139.
DR   RefSeq; NP_032452.1; -.
DR   UniGene; Mm.5127; -.
DR   PDB; 1N9P; X-ray; 1.80 A; A=41-371.
DR   PDB; 1U4E; X-ray; 2.09 A; A=41-371.
DR   PDB; 2QKS; X-ray; 2.20 A; A/B=41-371.
DR   PDB; 3K6N; X-ray; 2.00 A; A=41-371.
DR   PDBsum; 1N9P; -.
DR   PDBsum; 1U4E; -.
DR   PDBsum; 2QKS; -.
DR   PDBsum; 3K6N; -.
DR   SMR; P63250; 41-364.
DR   STRING; P63250; -.
DR   PRIDE; P63250; -.
DR   Ensembl; ENSMUST00000067101; ENSMUSP00000063329; ENSMUSG00000026824; Mus musculus.
DR   Ensembl; ENSMUST00000112633; ENSMUSP00000108252; ENSMUSG00000026824; Mus musculus.
DR   GeneID; 16519; -.
DR   KEGG; mmu:16519; -.
DR   UCSC; uc008jru.1; mouse.
DR   CTD; 16519; -.
DR   MGI; MGI:104742; Kcnj3.
DR   eggNOG; roNOG12417; -.
DR   HOGENOM; HBG716702; -.
DR   HOVERGEN; HBG006178; -.
DR   InParanoid; P63250; -.
DR   OMA; FSEHAAI; -.
DR   PhylomeDB; P63250; -.
DR   NextBio; 289889; -.
DR   ArrayExpress; P63250; -.
DR   Bgee; P63250; -.
DR   Genevestigator; P63250; -.
DR   GermOnline; ENSMUSG00000026824; Mus musculus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0015467; F:G-protein activated inward rectifier potass...; TAS:MGI.
DR   GO; GO:0030955; F:potassium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006813; P:potassium ion transport; IEA:UniProtKB-KW.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR016449; K_chnl_inward-rec_Kir.
DR   InterPro; IPR001838; K_chnl_inward-rec_Kir-like.
DR   InterPro; IPR003274; K_chnl_inward-rec_Kir3.1.
DR   InterPro; IPR013521; K_chnl_inward-rec_Kir_Cr2.
DR   InterPro; IPR013518; K_chnl_inward-rec_Kir_cyto.
DR   Gene3D; G3DSA:2.60.40.1400; IR_K+channel_cytopl; 1.
DR   PANTHER; PTHR11767; K+channel_IR; 1.
DR   Pfam; PF01007; IRK; 1.
DR   PIRSF; PIRSF005465; GIRK_kir; 1.
DR   PRINTS; PR01327; KIR31CHANNEL.
DR   PRINTS; PR01320; KIRCHANNEL.
DR   SUPFAM; SSF81296; Ig_E-set; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Ion transport; Ionic channel; Membrane; Phosphoprotein;
KW   Potassium; Potassium transport; Transmembrane; Transport;
KW   Voltage-gated channel.
FT   CHAIN         1    501       G protein-activated inward rectifier
FT                                potassium channel 1.
FT                                /FTId=PRO_0000154939.
FT   TOPO_DOM      1     80       Cytoplasmic.
FT   TRANSMEM     81    105       M1 (By similarity).
FT   TOPO_DOM    106    129       Extracellular (By similarity).
FT   TOPO_DOM    149    157       Extracellular (By similarity).
FT   TRANSMEM    158    179       M2 (By similarity).
FT   TOPO_DOM    180    501       Cytoplasmic.
FT   REGION      130    141       H5 (pore-forming helix) (By similarity).
FT   MOTIF       143    148       Selectivity filter (By similarity).
FT   SITE        173    173       Role in the control of polyamine-mediated
FT                                channel gating and in the blocking by
FT                                intracellular magnesium (By similarity).
FT   MOD_RES      69     69       Phosphoserine (By similarity).
FT   MOD_RES      73     73       Phosphothreonine (By similarity).
FT   HELIX        69     77
FT   HELIX        80    108
FT   STRAND      113    115
FT   TURN        123    129
FT   HELIX       130    141
FT   HELIX       159    171
FT   STRAND      180    183
FT   STRAND      194    196
FT   STRAND      200    205
FT   STRAND      208    215
FT   STRAND      219    221
FT   STRAND      223    237
FT   STRAND      243    250
FT   TURN        255    257
FT   STRAND      261    263
FT   STRAND      268    273
FT   TURN        279    282
FT   HELIX       287    289
FT   STRAND      294    303
FT   TURN        304    306
FT   STRAND      312    317
FT   HELIX       318    320
FT   STRAND      321    323
FT   STRAND      325    327
FT   STRAND      331    336
FT   STRAND      338    340
FT   HELIX       342    344
FT   STRAND      348    350
FT   HELIX       358    368
SQ   SEQUENCE   501 AA;  56573 MW;  AB8910E9CC08FFEC CRC64;
     MSALRRKFGD DYQVVTTSSS GSGLQPQGPG QGPQQQLVPK KKRQRFVDKN GRCNVQHGNL
     GSETSRYLSD LFTTLVDLKW RWNLFIFILT YTVAWLFMAS MWWVIAYTRG DLNKAHVGNY
     TPCVANVYNF PSAFLFFIET EATIGYGYRY ITDKCPEGII LFLFQSILGS IVDAFLIGCM
     FIKMSQPKKR AETLMFSEHA VISMRDGKLT LMFRVGNLRN SHMVSAQIRC KLLKSRQTPE
     GEFLPLDQLE LDVGFSTGAD QLFLVSPLTI CHVIDAKSPF YDLSQRSMQT EQFEVVVILE
     GIVETTGMTC QARTSYTEDE VLWGHRFFPV ISLEEGFFKV DYSQFHATFE VPTPPYSVKE
     QEEMLLMSSP LIAPAITNSK ERHNSVECLD GLDDISTKLP SKLQKITGRE DFPKKLLRMS
     STTSEKAYSL GDLPMKLQRI SSVPGNSEEK LVSKTTKMLS DPMSQSVADL PPKLQKMAGG
     PTRMEGNLPA KLRKMNSDRF T
//
ID   IRK4_HUMAN              Reviewed;         445 AA.
AC   P48050; Q14D44;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 1.
DT   02-MAR-2010, entry version 98.
DE   RecName: Full=Inward rectifier potassium channel 4;
DE   AltName: Full=Potassium channel, inwardly rectifying subfamily J member 4;
DE   AltName: Full=Inward rectifier K(+) channel Kir2.3;
DE            Short=IRK-3;
DE   AltName: Full=Hippocampal inward rectifier;
DE            Short=HIR;
DE   AltName: Full=HIRK2;
DE   AltName: Full=HRK1;
GN   Name=KCNJ4; Synonyms=IRK3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Hippocampus;
RX   MEDLINE=94286613; PubMed=8016146; DOI=10.1073/pnas.91.13.6240;
RA   Perier F., Radeke C.M., Vandenberg C.A.;
RT   "Primary structure and characterization of a small-conductance
RT   inwardly rectifying potassium channel from human hippocampus.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:6240-6244(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   MEDLINE=94307432; PubMed=8034048; DOI=10.1016/0014-5793(94)00612-1;
RA   Tang W., Yang X.-C.;
RT   "Cloning a novel human brain inward rectifier potassium channel and
RT   its functional expression in Xenopus oocytes.";
RL   FEBS Lett. 348:239-243(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Hippocampus;
RX   MEDLINE=94327620; PubMed=8051145;
RA   Makhina E.N., Kelly A.J., Lopatin A.N., Mercer R.W., Nichols C.G.;
RT   "Cloning and expression of a novel human brain inward rectifier
RT   potassium channel.";
RL   J. Biol. Chem. 269:20468-20474(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   MEDLINE=20057165; PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- FUNCTION: This receptor is controlled by G proteins. Inward
CC       rectifier potassium channels are characterized by a greater
CC       tendency to allow potassium to flow into the cell rather than out
CC       of it. Their voltage dependence is regulated by the concentration
CC       of extracellular potassium; as external potassium is raised, the
CC       voltage range of the channel opening shifts to more positive
CC       voltages. The inward rectification is mainly due to the blockage
CC       of outward current by internal magnesium. Can be blocked by
CC       extracellular barium and cesium (By similarity).
CC   -!- SUBUNIT: Homomultimeric and heteromultimeric association with
CC       Kir2.1, resulting in an enhanced G-protein-induced current.
CC       Association, via its PDZ-recognition domain, with LIN7A, LIN7B,
CC       LIN7C, DLG1, CASK and APBA1 plays a key role in its localization
CC       and trafficking (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Heart, skeletal muscle, and several different
CC       brain regions including the hippocampus.
CC   -!- DOMAIN: The Val/Gly/Ala/Pro stretch may have a functional role in
CC       the conductance or permeation properties.
CC   -!- SIMILARITY: Belongs to the inward rectifier-type potassium channel
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U07364; AAA19962.1; -; mRNA.
DR   EMBL; U24056; AAA66076.1; -; mRNA.
DR   EMBL; S72503; AAC60632.1; -; mRNA.
DR   EMBL; CR456507; CAG30393.1; -; mRNA.
DR   EMBL; Z97056; CAB09790.1; -; Genomic_DNA.
DR   EMBL; BC113506; AAI13507.1; -; mRNA.
DR   EMBL; BC113508; AAI13509.1; -; mRNA.
DR   IPI; IPI00007626; -.
DR   PIR; A54852; A54852.
DR   PIR; I38521; I38521.
DR   RefSeq; NP_004972.1; -.
DR   RefSeq; NP_690607.1; -.
DR   UniGene; Hs.32505; -.
DR   PDB; 3GJ9; X-ray; 2.80 A; C/D=436-445.
DR   PDBsum; 3GJ9; -.
DR   SMR; P48050; 18-341, 179-357.
DR   STRING; P48050; -.
DR   PhosphoSite; P48050; -.
DR   PRIDE; P48050; -.
DR   Ensembl; ENST00000303592; ENSP00000306497; ENSG00000168135; Homo sapiens.
DR   GeneID; 3761; -.
DR   KEGG; hsa:3761; -.
DR   UCSC; uc003avs.1; human.
DR   CTD; 3761; -.
DR   GeneCards; GC22M037146; -.
DR   H-InvDB; HIX0041164; -.
DR   HGNC; HGNC:6265; KCNJ4.
DR   HPA; HPA003270; -.
DR   MIM; 600504; gene.
DR   PharmGKB; PA30048; -.
DR   eggNOG; maNOG10942; -.
DR   HOGENOM; HBG716702; -.
DR   HOVERGEN; HBG006178; -.
DR   InParanoid; P48050; -.
DR   OMA; QATLPLD; -.
DR   OrthoDB; EOG9K9DZD; -.
DR   PhylomeDB; P48050; -.
DR   NextBio; 14745; -.
DR   ArrayExpress; P48050; -.
DR   Bgee; P48050; -.
DR   CleanEx; HS_KCNJ4; -.
DR   Genevestigator; P48050; -.
DR   GermOnline; ENSG00000168135; Homo sapiens.
DR   GO; GO:0008076; C:voltage-gated potassium channel complex; TAS:ProtInc.
DR   GO; GO:0005242; F:inward rectifier potassium channel activity; TAS:ProtInc.
DR   GO; GO:0030955; F:potassium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006813; P:potassium ion transport; TAS:ProtInc.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR016449; K_chnl_inward-rec_Kir.
DR   InterPro; IPR001838; K_chnl_inward-rec_Kir-like.
DR   InterPro; IPR003273; K_chnl_inward-rec_Kir2.3.
DR   InterPro; IPR013521; K_chnl_inward-rec_Kir_Cr2.
DR   InterPro; IPR013518; K_chnl_inward-rec_Kir_cyto.
DR   Gene3D; G3DSA:2.60.40.1400; IR_K+channel_cytopl; 1.
DR   PANTHER; PTHR11767; K+channel_IR; 1.
DR   PANTHER; PTHR11767:SF13; KIR23_channel; 1.
DR   Pfam; PF01007; IRK; 1.
DR   PIRSF; PIRSF005465; GIRK_kir; 1.
DR   PRINTS; PR01326; KIR23CHANNEL.
DR   PRINTS; PR01320; KIRCHANNEL.
DR   SUPFAM; SSF81296; Ig_E-set; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Ion transport; Ionic channel;
KW   Membrane; Potassium; Potassium transport; Transmembrane; Transport;
KW   Voltage-gated channel.
FT   CHAIN         1    445       Inward rectifier potassium channel 4.
FT                                /FTId=PRO_0000154930.
FT   TOPO_DOM      1     55       Cytoplasmic (By similarity).
FT   TRANSMEM     56     80       M1 (By similarity).
FT   TOPO_DOM     81    120       Extracellular (By similarity).
FT   TOPO_DOM    140    148       Extracellular (By similarity).
FT   TRANSMEM    149    170       M2 (By similarity).
FT   TOPO_DOM    171    445       Cytoplasmic (By similarity).
FT   REGION       91    111       Val/Gly/Ala/Pro stretch.
FT   REGION      121    132       H5 (pore-forming helix) (By similarity).
FT   MOTIF       134    139       Selectivity filter (By similarity).
FT   MOTIF       443    445       PDZ-binding (Potential).
FT   COMPBIAS    102    105       Poly-Gly.
FT   COMPBIAS    362    368       Poly-Pro.
FT   COMPBIAS    383    390       Poly-Glu.
FT   COMPBIAS    391    399       Poly-Ala.
FT   SITE        164    164       Role in the control of polyamine-mediated
FT                                channel gating and in the blocking by
FT                                intracellular magnesium (By similarity).
FT   CONFLICT     16     17       KR -> NG (in Ref. 3; AAC60632).
FT   CONFLICT    107    107       A -> D (in Ref. 2; AAA66076).
FT   CONFLICT    350    350       A -> G (in Ref. 3; AAC60632).
FT   CONFLICT    392    392       A -> S (in Ref. 2; AAA66076).
FT   CONFLICT    395    395       A -> S (in Ref. 2; AAA66076).
FT   CONFLICT    396    396       A -> R (in Ref. 3).
FT   CONFLICT    398    398       A -> G (in Ref. 3).
SQ   SEQUENCE   445 AA;  49500 MW;  893F03365273E8BE CRC64;
     MHGHSRNGQA HVPRRKRRNR FVKKNGQCNV YFANLSNKSQ RYMADIFTTC VDTRWRYMLM
     IFSAAFLVSW LFFGLLFWCI AFFHGDLEAS PGVPAAGGPA AGGGGAAPVA PKPCIMHVNG
     FLGAFLFSVE TQTTIGYGFR CVTEECPLAV IAVVVQSIVG CVIDSFMIGT IMAKMARPKK
     RAQTLLFSHH AVISVRDGKL CLMWRVGNLR KSHIVEAHVR AQLIKPYMTQ EGEYLPLDQR
     DLNVGYDIGL DRIFLVSPII IVHEIDEDSP LYGMGKEELE SEDFEIVVIL EGMVEATAMT
     TQARSSYLAS EILWGHRFEP VVFEEKSHYK VDYSRFHKTY EVAGTPCCSA RELQESKITV
     LPAPPPPPSA FCYENELALM SQEEEEMEEE AAAAAAVAAG LGLEAGSKEE AGIIRMLEFG
     SHLDLERMQA SLPLDNISYR RESAI
//
ID   IRK4_RAT                Reviewed;         446 AA.
AC   P52190; O35752;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   02-MAR-2010, entry version 87.
DE   RecName: Full=Inward rectifier potassium channel 4;
DE   AltName: Full=Potassium channel, inwardly rectifying subfamily J member 4;
DE   AltName: Full=Inward rectifier K(+) channel Kir2.3;
DE            Short=IRK-3;
DE   AltName: Full=BIR11;
DE   AltName: Full=Brain inwardly rectifying K(+) channel 2;
GN   Name=Kcnj4; Synonyms=Irk3;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=GH3/B6;
RX   MEDLINE=95317410; PubMed=7796907; DOI=10.1016/0014-5793(95)00527-G;
RA   Falk T., Meyerhof W., Corrette B.J., Schaefer J., Bauer C.K.,
RA   Schwarz J.R., Richter D.;
RT   "Cloning, functional expression and mRNA distribution of an inwardly
RT   rectifying potassium channel protein.";
RL   FEBS Lett. 367:127-131(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RX   MEDLINE=95179470; PubMed=7874445;
RA   Bond C.T., Pessia M., Xia X.-M., Lagrutta A., Kavanaugh M.P.,
RA   Adelman J.P.;
RT   "Cloning and expression of a family of inward rectifier potassium
RT   channels.";
RL   Recept. Channels 2:183-191(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=95350147; PubMed=7624316; DOI=10.1073/pnas.92.15.6753;
RA   Bredt D.S., Wang T.L., Cohen N.A., Guggino W.B., Snyder S.H.;
RT   "Cloning and expression of two brain-specific inwardly rectifying
RT   potassium channels.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:6753-6757(1995).
RN   [4]
RP   INTERACTION WITH CASK; LIN7A; LIN7B; LIN7C; APBA1 AND DLG1, AND
RP   FUNCTION.
RX   PubMed=14960569; DOI=10.1074/jbc.M400284200;
RA   Leonoudakis D., Conti L.R., Radeke C.M., McGuire L.M.,
RA   Vandenberg C.A.;
RT   "A multiprotein trafficking complex composed of SAP97, CASK, Veli, and
RT   Mint1 is associated with inward rectifier Kir2 potassium channels.";
RL   J. Biol. Chem. 279:19051-19063(2004).
CC   -!- FUNCTION: This receptor is controlled by G proteins. Inward
CC       rectifier potassium channels are characterized by a greater
CC       tendency to allow potassium to flow into the cell rather than out
CC       of it. Their voltage dependence is regulated by the concentration
CC       of extracellular potassium; as external potassium is raised, the
CC       voltage range of the channel opening shifts to more positive
CC       voltages. The inward rectification is mainly due to the blockage
CC       of outward current by internal magnesium. Can be blocked by
CC       extracellular barium and cesium.
CC   -!- SUBUNIT: Homomultimeric and heteromultimeric association with
CC       Kir2.1, resulting in an enhanced G-protein-induced current.
CC       Association, via its PDZ-recognition domain, with LIN7A, LIN7B,
CC       LIN7C, DLG1, CASK and APBA1 plays a key role in its localization
CC       and trafficking.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Widely expressed throughout the brain. Also
CC       found in some peripheral tissues.
CC   -!- SIMILARITY: Belongs to the inward rectifier-type potassium channel
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X87635; CAA60963.1; -; mRNA.
DR   EMBL; X83580; CAA58563.1; -; mRNA.
DR   EMBL; U27582; AAA87812.1; -; mRNA.
DR   IPI; IPI00203244; -.
DR   PIR; S66268; S66268.
DR   RefSeq; NP_446322.2; -.
DR   UniGene; Rn.10197; -.
DR   SMR; P52190; 18-340, 179-357.
DR   STRING; P52190; -.
DR   PhosphoSite; P52190; -.
DR   Ensembl; ENSRNOT00000018564; ENSRNOP00000053014; ENSRNOG00000013869; Rattus norvegicus.
DR   GeneID; 116649; -.
DR   KEGG; rno:116649; -.
DR   UCSC; NM_053870; rat.
DR   CTD; 116649; -.
DR   RGD; 621436; Kcnj4.
DR   eggNOG; maNOG10942; -.
DR   HOVERGEN; HBG006178; -.
DR   InParanoid; P52190; -.
DR   NextBio; 619399; -.
DR   ArrayExpress; P52190; -.
DR   Genevestigator; P52190; -.
DR   GermOnline; ENSRNOG00000013869; Rattus norvegicus.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005242; F:inward rectifier potassium channel activity; IEA:InterPro.
DR   GO; GO:0030955; F:potassium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006813; P:potassium ion transport; IEA:UniProtKB-KW.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR016449; K_chnl_inward-rec_Kir.
DR   InterPro; IPR001838; K_chnl_inward-rec_Kir-like.
DR   InterPro; IPR003273; K_chnl_inward-rec_Kir2.3.
DR   InterPro; IPR013521; K_chnl_inward-rec_Kir_Cr2.
DR   InterPro; IPR013518; K_chnl_inward-rec_Kir_cyto.
DR   Gene3D; G3DSA:2.60.40.1400; IR_K+channel_cytopl; 1.
DR   PANTHER; PTHR11767; K+channel_IR; 1.
DR   PANTHER; PTHR11767:SF13; KIR23_channel; 1.
DR   Pfam; PF01007; IRK; 1.
DR   PIRSF; PIRSF005465; GIRK_kir; 1.
DR   PRINTS; PR01326; KIR23CHANNEL.
DR   PRINTS; PR01320; KIRCHANNEL.
DR   SUPFAM; SSF81296; Ig_E-set; 1.
PE   1: Evidence at protein level;
KW   Ion transport; Ionic channel; Membrane; Potassium;
KW   Potassium transport; Transmembrane; Transport; Voltage-gated channel.
FT   CHAIN         1    446       Inward rectifier potassium channel 4.
FT                                /FTId=PRO_0000154933.
FT   TOPO_DOM      1     55       Cytoplasmic (By similarity).
FT   TRANSMEM     56     80       M1 (By similarity).
FT   TOPO_DOM     81    120       Extracellular (By similarity).
FT   TOPO_DOM    140    148       Extracellular (By similarity).
FT   TRANSMEM    149    170       M2 (By similarity).
FT   TOPO_DOM    171    446       Cytoplasmic (By similarity).
FT   REGION       91    111       Val/Gly/Ala/Pro stretch.
FT   REGION      121    132       H5 (pore-forming helix) (By similarity).
FT   MOTIF       134    139       Selectivity filter (By similarity).
FT   MOTIF       444    446       PDZ-binding (Potential).
FT   COMPBIAS    362    368       Poly-Pro.
FT   COMPBIAS    383    390       Poly-Glu.
FT   COMPBIAS    391    399       Poly-Ala.
FT   SITE        164    164       Role in the control of polyamine-mediated
FT                                channel gating and in the blocking by
FT                                intracellular magnesium (By similarity).
FT   CONFLICT     53     54       Missing (in Ref. 3; AAA87812).
FT   CONFLICT     91     98       PSGPTAGG -> LRAHGGS (in Ref. 3;
FT                                AAA87812).
FT   CONFLICT    109    109       T -> R (in Ref. 3; AAA87812).
FT   CONFLICT    115    122       IMHVNGFL -> YHACKRLFW (in Ref. 3;
FT                                AAA87812).
FT   CONFLICT    130    131       ET -> GA (in Ref. 3; AAA87812).
FT   CONFLICT    135    135       I -> Y (in Ref. 3; AAA87812).
FT   CONFLICT    155    155       Missing (in Ref. 3; AAA87812).
FT   CONFLICT    176    176       P -> A (in Ref. 3; AAA87812).
FT   CONFLICT    176    176       P -> G (in Ref. 2).
FT   CONFLICT    178    178       P -> S (in Ref. 2).
FT   CONFLICT    197    198       DG -> T (in Ref. 3; AAA87812).
FT   CONFLICT    205    207       RVG -> GWV (in Ref. 3; AAA87812).
FT   CONFLICT    294    294       V -> A (in Ref. 3; AAA87812).
FT   CONFLICT    298    298       A -> V (in Ref. 2; CAA60963).
FT   CONFLICT    308    308       L -> Q (in Ref. 3; AAA87812).
SQ   SEQUENCE   446 AA;  49690 MW;  A86073996861D20C CRC64;
     MHGHSRNGQA HVPRRKRRNR FVKKNGQCNV YFANLSNKSQ RYMADIFTTC VDTRWRYMLM
     IFSAAFLVSW LFFGLLFWCI AFFHGDLEPS PSGPTAGGPG GNGGGAAPTA AKPCIMHVNG
     FLGAFLFSVE TQTTIGYGFR CVTEECPLAV IAVVVQSIVG CVIDSFMIGT IMAKMPRPKK
     RAQTLLFSHH AVISVRDGKL CLMWRVGNLR KSHIVEAHVR AQLIKPYMTQ EGEYLPLDQR
     DLNVGYDIGL DRIFLVSPII IVHEIDEDSP LYGMGKEELE SEDFEIVVIL EGMVEATAMT
     TQARSSYLAS EILWGHRFEP VVFEEKSHYK VDYSRFHKTY EVAGTPCCSA RELQESKITV
     LPAPPPPPSA FCYENELALM SQEEEEMEEE AAAAAAVAAG LGLEAGSKEE TGIIRMLEFG
     SHLDLERMQA ATLPLDNISY RRESAI
//
ID   IRK5_HUMAN              Reviewed;         419 AA.
AC   P48544; Q6DK13; Q6DK14; Q92807;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 1.
DT   02-MAR-2010, entry version 99.
DE   RecName: Full=G protein-activated inward rectifier potassium channel 4;
DE            Short=GIRK-4;
DE   AltName: Full=Potassium channel, inwardly rectifying subfamily J member 5;
DE   AltName: Full=Inward rectifier K(+) channel Kir3.4;
DE            Short=IRK-4;
DE   AltName: Full=Heart KATP channel;
DE   AltName: Full=KATP-1;
DE   AltName: Full=Cardiac inward rectifier;
DE            Short=CIR;
GN   Name=KCNJ5; Synonyms=GIRK4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Pancreas;
RA   Chan K.W., Langan M.N., Sui J., Kozak A., Pabon A., Ladias J.A.A.,
RA   Logothetis D.E.;
RL   Submitted (OCT-1995) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=94322936; PubMed=8047164; DOI=10.1038/370456a0;
RA   Ashford M.L.J., Bond C.T., Blair T.A., Adelman J.P.;
RT   "Cloning and functional expression of a rat heart KATP channel.";
RL   Nature 370:456-459(1994).
RN   [3]
RP   ERRATUM, AND RETRACTION.
RX   MEDLINE=96129211; PubMed=8524415; DOI=10.1038/378792a0;
RA   Ashford M.L.J., Bond C.T., Blair T.A., Adelman J.P.;
RL   Nature 378:792-792(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Pituitary;
RX   MEDLINE=20123391; PubMed=10659995; DOI=10.1016/S0898-6568(99)00059-5;
RA   Schoots O., Wilson J.M., Ethier N., Bigras E., Hebert T.E.,
RA   Van Tol H.H.M.;
RT   "Co-expression of human Kir3 subunits can yield channels with
RT   different functional properties.";
RL   Cell. Signal. 11:871-883(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Heart;
RX   MEDLINE=96430921; PubMed=8834003;
RA   Iizuka M., Kubo Y., Tsunenari I., Pan C.X., Akiba I., Kono T.;
RT   "Functional characterization and localization of a cardiac-type
RT   inwardly rectifying K+ channel.";
RL   Recept. Channels 3:299-315(1995).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- FUNCTION: This potassium channel is controlled by G proteins.
CC       Inward rectifier potassium channels are characterized by a greater
CC       tendency to allow potassium to flow into the cell rather than out
CC       of it. Their voltage dependence is regulated by the concentration
CC       of extracellular potassium; as external potassium is raised, the
CC       voltage range of the channel opening shifts to more positive
CC       voltages. The inward rectification is mainly due to the blockage
CC       of outward current by internal magnesium. Can be blocked by
CC       external barium.
CC   -!- SUBUNIT: May associate with GIRK1 and GIRK2 to form a G-protein-
CC       activated heteromultimer pore-forming unit. The resulting inward
CC       current is much larger (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Islets, exocrine pancreas and heart.
CC   -!- SIMILARITY: Belongs to the inward rectifier-type potassium channel
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U39195; AAB53093.1; -; mRNA.
DR   EMBL; L47208; AAB07269.1; -; mRNA.
DR   EMBL; X83582; CAA58565.1; -; mRNA.
DR   EMBL; U52154; AAB07045.1; -; mRNA.
DR   EMBL; D50134; BAA08814.1; -; mRNA.
DR   EMBL; BC069571; AAH69571.1; -; mRNA.
DR   EMBL; BC074838; AAH74838.2; -; mRNA.
DR   EMBL; BC069386; AAH69386.1; -; mRNA.
DR   EMBL; BC069482; AAH69482.1; -; mRNA.
DR   EMBL; BC069499; AAH69499.1; -; mRNA.
DR   EMBL; BC074839; AAH74839.2; -; mRNA.
DR   IPI; IPI00298865; -.
DR   PIR; G02232; G02232.
DR   RefSeq; NP_000881.3; -.
DR   UniGene; Hs.632109; -.
DR   SMR; P48544; 50-356, 197-370.
DR   STRING; P48544; -.
DR   TCDB; 1.A.2.1.3; inward rectifier K+ channel (IRK-C) family.
DR   PhosphoSite; P48544; -.
DR   PRIDE; P48544; -.
DR   Ensembl; ENST00000338350; ENSP00000339960; ENSG00000120457; Homo sapiens.
DR   GeneID; 3762; -.
DR   KEGG; hsa:3762; -.
DR   CTD; 3762; -.
DR   GeneCards; GC11P128266; -.
DR   HGNC; HGNC:6266; KCNJ5.
DR   HPA; CAB022569; -.
DR   HPA; HPA014722; -.
DR   HPA; HPA017353; -.
DR   MIM; 600734; gene.
DR   PharmGKB; PA216; -.
DR   eggNOG; prNOG04147; -.
DR   HOGENOM; HBG716702; -.
DR   HOVERGEN; HBG006178; -.
DR   InParanoid; P48544; -.
DR   DrugBank; DB01016; Glibenclamide.
DR   NextBio; 14751; -.
DR   ArrayExpress; P48544; -.
DR   Bgee; P48544; -.
DR   CleanEx; HS_KCNJ5; -.
DR   Genevestigator; P48544; -.
DR   GermOnline; ENSG00000120457; Homo sapiens.
DR   GO; GO:0008076; C:voltage-gated potassium channel complex; TAS:ProtInc.
DR   GO; GO:0015467; F:G-protein activated inward rectifier potass...; TAS:UniProtKB.
DR   GO; GO:0030955; F:potassium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0006813; P:potassium ion transport; TAS:ProtInc.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR016449; K_chnl_inward-rec_Kir.
DR   InterPro; IPR001838; K_chnl_inward-rec_Kir-like.
DR   InterPro; IPR003277; K_chnl_inward-rec_Kir3.4.
DR   InterPro; IPR013521; K_chnl_inward-rec_Kir_Cr2.
DR   InterPro; IPR013518; K_chnl_inward-rec_Kir_cyto.
DR   Gene3D; G3DSA:2.60.40.1400; IR_K+channel_cytopl; 1.
DR   PANTHER; PTHR11767; K+channel_IR; 1.
DR   Pfam; PF01007; IRK; 1.
DR   PIRSF; PIRSF005465; GIRK_kir; 1.
DR   PRINTS; PR01330; KIR34CHANNEL.
DR   PRINTS; PR01320; KIRCHANNEL.
DR   SUPFAM; SSF81296; Ig_E-set; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Ion transport; Ionic channel; Membrane; Potassium;
KW   Potassium transport; Transmembrane; Transport; Voltage-gated channel.
FT   CHAIN         1    419       G protein-activated inward rectifier
FT                                potassium channel 4.
FT                                /FTId=PRO_0000154934.
FT   TOPO_DOM      1     86       Cytoplasmic (By similarity).
FT   TRANSMEM     87    111       M1 (By similarity).
FT   TOPO_DOM    112    135       Extracellular (By similarity).
FT   TOPO_DOM    155    163       Extracellular (By similarity).
FT   TRANSMEM    164    185       M2 (By similarity).
FT   TOPO_DOM    186    419       Cytoplasmic (By similarity).
FT   REGION      136    147       H5 (pore-forming helix) (By similarity).
FT   MOTIF       149    154       Selectivity filter (By similarity).
FT   SITE        179    179       Role in the control of polyamine-mediated
FT                                channel gating and in the blocking by
FT                                intracellular magnesium (By similarity).
FT   CONFLICT     35     35       I -> T (in Ref. 4; AAB07045).
FT   CONFLICT    388    388       G -> R (in Ref. 2; CAA58565).
SQ   SEQUENCE   419 AA;  47669 MW;  16DF3861F3EA0FC5 CRC64;
     MAGDSRNAMN QDMEIGVTPW DPKKIPKQAR DYVPIATDRT RLLAEGKKPR QRYMEKSGKC
     NVHHGNVQET YRYLSDLFTT LVDLKWRFNL LVFTMVYTVT WLFFGFIWWL IAYIRGDLDH
     VGDQEWIPCV ENLSGFVSAF LFSIETETTI GYGFRVITEK CPEGIILLLV QAILGSIVNA
     FMVGCMFVKI SQPKKRAETL MFSNNAVISM RDEKLCLMFR VGDLRNSHIV EASIRAKLIK
     SRQTKEGEFI PLNQTDINVG FDTGDDRLFL VSPLIISHEI NEKSPFWEMS QAQLHQEEFE
     VVVILEGMVE ATGMTCQARS SYMDTEVLWG HRFTPVLTLE KGFYEVDYNT FHDTYETNTP
     SCCAKELAEM KREGRLLQYL PSPPLLGGCA EAGLDAEAEQ NEEDEPKGLG GSREARGSV
//
ID   IRK5_RAT                Reviewed;         419 AA.
AC   P48548;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 2.
DT   02-MAR-2010, entry version 79.
DE   RecName: Full=G protein-activated inward rectifier potassium channel 4;
DE            Short=GIRK-4;
DE   AltName: Full=Potassium channel, inwardly rectifying subfamily J member 5;
DE   AltName: Full=Inward rectifier K(+) channel Kir3.4;
DE   AltName: Full=Heart KATP channel;
DE   AltName: Full=KATP-1;
DE   AltName: Full=Cardiac inward rectifier;
DE            Short=CIR;
GN   Name=Kcnj5; Synonyms=Girk4;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Heart;
RX   MEDLINE=94322936; PubMed=8047164; DOI=10.1038/370456a0;
RA   Ashford M.L.J., Bond C.T., Blair T.A., Adelman J.P.;
RT   "Cloning and functional expression of a rat heart KATP channel.";
RL   Nature 370:456-459(1994).
RN   [2]
RP   ERRATUM.
RX   MEDLINE=96129211; PubMed=8524415; DOI=10.1038/378792a0;
RA   Ashford M.L.J., Bond C.T., Blair T.A., Adelman J.P.;
RL   Nature 378:792-792(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 31-39 AND 333-341.
RC   STRAIN=Sprague-Dawley; TISSUE=Neonatal heart atrium;
RX   MEDLINE=95183134; PubMed=7877685; DOI=10.1038/374135a0;
RA   Krapivinsky G.B., Gordon E.A., Wickman K., Velimirovic B.,
RA   Krapivinsky L.D., Clapham D.E.;
RT   "The G-protein-gated atrial K+ channel IKACh is a heteromultimer of
RT   two inwardly rectifying K(+)-channel proteins.";
RL   Nature 374:135-141(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Pancreatic islet;
RX   MEDLINE=96064672; PubMed=7592809; DOI=10.1074/jbc.270.44.26086;
RA   Ferrer J., Nichols C.G., Makhina E.N., Salkoff L., Bernstein J.,
RA   Gerhard D., Wasson J., Ramanadham S., Permutt A.;
RT   "Pancreatic islet cells express a family of inwardly rectifying K+
RT   channel subunits which interact to form G-protein-activated
RT   channels.";
RL   J. Biol. Chem. 270:26086-26091(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Heart;
RX   MEDLINE=96430921; PubMed=8834003;
RA   Iizuka M., Kubo Y., Tsunenari I., Pan C.X., Akiba I., Kono T.;
RT   "Functional characterization and localization of a cardiac-type
RT   inwardly rectifying K+ channel.";
RL   Recept. Channels 3:299-315(1995).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Heart;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- FUNCTION: This potassium channel is controlled by G proteins.
CC       Inward rectifier potassium channels are characterized by a greater
CC       tendency to allow potassium to flow into the cell rather than out
CC       of it. Their voltage dependence is regulated by the concentration
CC       of extracellular potassium; as external potassium is raised, the
CC       voltage range of the channel opening shifts to more positive
CC       voltages. The inward rectification is mainly due to the blockage
CC       of outward current by internal magnesium. Can be blocked by
CC       external barium.
CC   -!- SUBUNIT: Associates with GIRK1 or GIRK2 to form a G-protein-
CC       activated heteromultimer pore-forming unit. The resulting inward
CC       current is much larger.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Most abundant in heart tissue where it is
CC       found predominantly in atria. Also found in brain, kidney, liver,
CC       spleen, lung and thymus.
CC   -!- SIMILARITY: Belongs to the inward rectifier-type potassium channel
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X83584; CAA58567.1; -; mRNA.
DR   EMBL; L35771; AAC42048.1; -; mRNA.
DR   EMBL; D50135; BAA08815.1; -; mRNA.
DR   EMBL; BC087022; AAH87022.1; -; mRNA.
DR   IPI; IPI00191858; -.
DR   PIR; S48077; S48077.
DR   RefSeq; NP_058993.1; -.
DR   UniGene; Rn.10047; -.
DR   SMR; P48548; 50-356, 197-375.
DR   STRING; P48548; -.
DR   PhosphoSite; P48548; -.
DR   Ensembl; ENSRNOT00000041038; ENSRNOP00000048134; ENSRNOG00000033796; Rattus norvegicus.
DR   GeneID; 29713; -.
DR   KEGG; rno:29713; -.
DR   CTD; 29713; -.
DR   RGD; 61971; Kcnj5.
DR   eggNOG; maNOG16003; -.
DR   HOVERGEN; HBG006178; -.
DR   InParanoid; P48548; -.
DR   NextBio; 610153; -.
DR   Genevestigator; P48548; -.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:RGD.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030315; C:T-tubule; IDA:RGD.
DR   GO; GO:0015467; F:G-protein activated inward rectifier potass...; IEA:InterPro.
DR   GO; GO:0030955; F:potassium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006813; P:potassium ion transport; IEA:UniProtKB-KW.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR016449; K_chnl_inward-rec_Kir.
DR   InterPro; IPR001838; K_chnl_inward-rec_Kir-like.
DR   InterPro; IPR003277; K_chnl_inward-rec_Kir3.4.
DR   InterPro; IPR013521; K_chnl_inward-rec_Kir_Cr2.
DR   InterPro; IPR013518; K_chnl_inward-rec_Kir_cyto.
DR   Gene3D; G3DSA:2.60.40.1400; IR_K+channel_cytopl; 1.
DR   PANTHER; PTHR11767; K+channel_IR; 1.
DR   Pfam; PF01007; IRK; 1.
DR   PIRSF; PIRSF005465; GIRK_kir; 1.
DR   PRINTS; PR01330; KIR34CHANNEL.
DR   PRINTS; PR01320; KIRCHANNEL.
DR   SUPFAM; SSF81296; Ig_E-set; 1.
PE   1: Evidence at protein level;
KW   Direct protein sequencing; Ion transport; Ionic channel; Membrane;
KW   Potassium; Potassium transport; Transmembrane; Transport;
KW   Voltage-gated channel.
FT   CHAIN         1    419       G protein-activated inward rectifier
FT                                potassium channel 4.
FT                                /FTId=PRO_0000154937.
FT   TOPO_DOM      1     86       Cytoplasmic (By similarity).
FT   TRANSMEM     87    111       M1 (By similarity).
FT   TOPO_DOM    112    135       Extracellular (By similarity).
FT   TOPO_DOM    155    163       Extracellular (By similarity).
FT   TRANSMEM    164    185       M2 (By similarity).
FT   TOPO_DOM    186    419       Cytoplasmic (By similarity).
FT   REGION      136    147       H5 (pore-forming helix) (By similarity).
FT   MOTIF       149    154       Selectivity filter (By similarity).
FT   COMPBIAS    402    405       Poly-Glu.
FT   SITE        179    179       Role in the control of polyamine-mediated
FT                                channel gating and in the blocking by
FT                                intracellular magnesium (By similarity).
FT   CONFLICT    188    188       V -> I (in Ref. 1; CAA58567).
FT   CONFLICT    375    375       Q -> E (in Ref. 1; CAA58567).
SQ   SEQUENCE   419 AA;  47783 MW;  DFF537CD79A7370D CRC64;
     MAGDSRNAMN QDMEIGVTSQ DHKKIPKQAR DYIPIATDRT RLLPEGKKPR QRYMEKTGKC
     NVHHGNVQET YRYLSDLFTT LVDLKWRFNL LVFTMVYTIT WLFFGFIWWL IAYVRGDLDH
     VGDQEWIPCV ENLSGFVSAF LFSIETETTI GYGFRVITEK CPEGIILLLV QAILGSIVNA
     FMVGCMFVKI SQPKKRAETL MFSNNAVISM RDEKLCLMFR VGDLRNSHIV EASIRAKLIK
     SRQTKEGEFI PLNQTDINVG FDTGDDRLFL VSPLIISHEI NEKSPFWEMS RAQLEQEEFE
     VVVILEGMVE ATGMTCQARS SYMDTEVLWG HRFTPVLTLE KGFYEVDYNT FHDTYETNTP
     SCCAKELAEM KRNGQLLQSL PSPPLLGGCA EAEKEAEAEH DEEEEPNGLS VSRATRGSM
//
ID   IRK6_HUMAN              Reviewed;         423 AA.
AC   P48051; Q3MJ74; Q53WW6;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 1.
DT   02-MAR-2010, entry version 91.
DE   RecName: Full=G protein-activated inward rectifier potassium channel 2;
DE            Short=GIRK-2;
DE   AltName: Full=Potassium channel, inwardly rectifying subfamily J member 6;
DE   AltName: Full=Inward rectifier K(+) channel Kir3.2;
DE   AltName: Full=KATP-2;
DE   AltName: Full=BIR1;
GN   Name=KCNJ6; Synonyms=GIRK2, KATP2, KCNJ7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Insulinoma;
RX   MEDLINE=96064672; PubMed=7592809; DOI=10.1074/jbc.270.44.26086;
RA   Ferrer J., Nichols C.G., Makhina E.N., Salkoff L., Bernstein J.,
RA   Gerhard D., Wasson J., Ramanadham S., Permutt A.;
RT   "Pancreatic islet cells express a family of inwardly rectifying K+
RT   channel subunits which interact to form G-protein-activated
RT   channels.";
RL   J. Biol. Chem. 270:26086-26091(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Hippocampus;
RA   Dissmann E., Karschin A.;
RT   "Subunit interactions in the assembly of neuronal G protein-activated
RT   inwardly rectifying K+ channels.";
RL   Submitted (JUN-1996) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RA   Ohira M., Seki N., Nagase T., Suzuki E., Nomura N., Ohara O.,
RA   Saito T., Ichikawa H., Ohki M.;
RT   "Gene identification in the 1.6 Mb of the Down syndrome region on
RT   chromosome 21.";
RL   Submitted (JAN-1997) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Cerebellum;
RX   MEDLINE=20123391; PubMed=10659995; DOI=10.1016/S0898-6568(99)00059-5;
RA   Schoots O., Wilson J.M., Ethier N., Bigras E., Hebert T.E.,
RA   Van Tol H.H.M.;
RT   "Co-expression of human Kir3 subunits can yield channels with
RT   different functional properties.";
RL   Cell. Signal. 11:871-883(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 17-423.
RX   MEDLINE=95317425; PubMed=7796919; DOI=10.1016/0014-5793(95)00498-X;
RA   Sakura H., Bond C., Warren-Perry M., Horsley S., Kearney L.,
RA   Tucker S., Adelman J., Turner R., Ashcroft F.M.;
RT   "Characterization and variation of a human inwardly-rectifying-K-
RT   channel gene (KCNJ6): a putative ATP-sensitive K-channel subunit.";
RL   FEBS Lett. 367:193-197(1995).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 116-211.
RX   MEDLINE=95246962; PubMed=7729621;
RA   Tsaur M.-L., Menzel S., Lai F.-P., Espinosa R. III, Concannon P.,
RA   Spielman R.S., Hanis C.L., Cox N.J., le Beau M.M., German M.S.,
RA   Jan L.Y., Bell G.I., Stoffel M.;
RT   "Isolation of a cDNA clone encoding a KATP channel-like protein
RT   expressed in insulin-secreting cells, localization of the human gene
RT   to chromosome band 21q22.1, and linkage studies with NIDDM.";
RL   Diabetes 44:592-596(1995).
CC   -!- FUNCTION: This potassium channel may be involved in the regulation
CC       of insulin secretion by glucose and/or neurotransmitters acting
CC       through G-protein-coupled receptors. Inward rectifier potassium
CC       channels are characterized by a greater tendency to allow
CC       potassium to flow into the cell rather than out of it. Their
CC       voltage dependence is regulated by the concentration of
CC       extracellular potassium; as external potassium is raised, the
CC       voltage range of the channel opening shifts to more positive
CC       voltages. The inward rectification is mainly due to the blockage
CC       of outward current by internal magnesium.
CC   -!- SUBUNIT: Associates with GIRK1 or GIRK4 to form a G-protein-
CC       activated heteromultimer pore-forming unit. The resulting inward
CC       current is much larger (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Most abundant in cerebellum, and to a lesser
CC       degree in islets and exocrine pancreas.
CC   -!- SIMILARITY: Belongs to the inward rectifier-type potassium channel
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U24660; AAC50258.1; -; mRNA.
DR   EMBL; L78480; AAB02277.1; -; mRNA.
DR   EMBL; D87327; BAA13331.1; -; mRNA.
DR   EMBL; U52153; AAB07044.1; -; mRNA.
DR   EMBL; BC101547; AAI01548.1; -; mRNA.
DR   EMBL; S78685; AAB34738.2; -; Genomic_DNA.
DR   EMBL; S78684; AAB34738.2; JOINED; Genomic_DNA.
DR   EMBL; G02354; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   IPI; IPI00007627; -.
DR   PIR; I38979; I38979.
DR   RefSeq; NP_002231.1; -.
DR   UniGene; Hs.658533; -.
DR   SMR; P48051; 54-359, 200-378.
DR   STRING; P48051; -.
DR   PhosphoSite; P48051; -.
DR   PRIDE; P48051; -.
DR   Ensembl; ENST00000400482; ENSP00000383330; ENSG00000157542; Homo sapiens.
DR   GeneID; 3763; -.
DR   KEGG; hsa:3763; -.
DR   UCSC; uc002ywo.1; human.
DR   CTD; 3763; -.
DR   GeneCards; GC21M037918; -.
DR   H-InvDB; HIX0040889; -.
DR   HGNC; HGNC:6267; KCNJ6.
DR   HPA; CAB012452; -.
DR   MIM; 600877; gene.
DR   PharmGKB; PA30049; -.
DR   eggNOG; prNOG19724; -.
DR   HOGENOM; HBG716702; -.
DR   HOVERGEN; HBG006178; -.
DR   OMA; TNAVISM; -.
DR   OrthoDB; EOG9XWJH5; -.
DR   DrugBank; DB01159; Halothane.
DR   NextBio; 14755; -.
DR   ArrayExpress; P48051; -.
DR   Bgee; P48051; -.
DR   CleanEx; HS_KCNJ6; -.
DR   Genevestigator; P48051; -.
DR   GermOnline; ENSG00000157542; Homo sapiens.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0008076; C:voltage-gated potassium channel complex; TAS:ProtInc.
DR   GO; GO:0015467; F:G-protein activated inward rectifier potass...; TAS:ProtInc.
DR   GO; GO:0030955; F:potassium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0006813; P:potassium ion transport; TAS:ProtInc.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR016449; K_chnl_inward-rec_Kir.
DR   InterPro; IPR001838; K_chnl_inward-rec_Kir-like.
DR   InterPro; IPR003275; K_chnl_inward-rec_Kir3.2.
DR   InterPro; IPR013521; K_chnl_inward-rec_Kir_Cr2.
DR   InterPro; IPR013518; K_chnl_inward-rec_Kir_cyto.
DR   Gene3D; G3DSA:2.60.40.1400; IR_K+channel_cytopl; 1.
DR   PANTHER; PTHR11767; K+channel_IR; 1.
DR   PANTHER; PTHR11767:SF19; KIR32_channel; 1.
DR   Pfam; PF01007; IRK; 1.
DR   PIRSF; PIRSF005465; GIRK_kir; 1.
DR   PRINTS; PR01328; KIR32CHANNEL.
DR   PRINTS; PR01320; KIRCHANNEL.
DR   SUPFAM; SSF81296; Ig_E-set; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Ion transport; Ionic channel; Membrane; Potassium;
KW   Potassium transport; Transmembrane; Transport; Voltage-gated channel.
FT   CHAIN         1    423       G protein-activated inward rectifier
FT                                potassium channel 2.
FT                                /FTId=PRO_0000154942.
FT   TOPO_DOM      1     89       Cytoplasmic (By similarity).
FT   TRANSMEM     90    114       M1 (By similarity).
FT   TOPO_DOM    115    138       Extracellular (By similarity).
FT   TOPO_DOM    158    166       Extracellular (By similarity).
FT   TRANSMEM    167    188       M2 (By similarity).
FT   TOPO_DOM    189    423       Cytoplasmic (By similarity).
FT   REGION      139    150       H5 (pore-forming helix) (By similarity).
FT   MOTIF       152    157       Selectivity filter (By similarity).
FT   SITE        182    182       Role in the control of polyamine-mediated
FT                                channel gating and in the blocking by
FT                                intracellular magnesium (By similarity).
SQ   SEQUENCE   423 AA;  48451 MW;  7A02F6B0FBF8B7D4 CRC64;
     MAKLTESMTN VLEGDSMDQD VESPVAIHQP KLPKQARDDL PRHISRDRTK RKIQRYVRKD
     GKCNVHHGNV RETYRYLTDI FTTLVDLKWR FNLLIFVMVY TVTWLFFGMI WWLIAYIRGD
     MDHIEDPSWT PCVTNLNGFV SAFLFSIETE TTIGYGYRVI TDKCPEGIIL LLIQSVLGSI
     VNAFMVGCMF VKISQPKKRA ETLVFSTHAV ISMRDGKLCL MFRVGDLRNS HIVEASIRAK
     LIKSKQTSEG EFIPLNQTDI NVGYYTGDDR LFLVSPLIIS HEINQQSPFW EISKAQLPKE
     ELEIVVILEG MVEATGMTCQ ARSSYITSEI LWGYRFTPVL TLEDGFYEVD YNSFHETYET
     STPSLSAKEL AELASRAELP LSWSVSSKLN QHAELETEEE EKNLEEQTER NGDVANLENE
     SKV
//
ID   IRK6_MOUSE              Reviewed;         425 AA.
AC   P48542; O70290; P70216; P70306; P70307; P70308; P70309; P70454;
AC   Q9QYH5;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 1.
DT   02-MAR-2010, entry version 91.
DE   RecName: Full=G protein-activated inward rectifier potassium channel 2;
DE            Short=GIRK-2;
DE   AltName: Full=Potassium channel, inwardly rectifying subfamily J member 6;
DE   AltName: Full=Inward rectifier K(+) channel Kir3.2;
GN   Name=Kcnj6; Synonyms=Girk2, Kcnj7, W;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM GIRK2-1).
RC   TISSUE=Brain;
RX   MEDLINE=95010760; PubMed=7926018; DOI=10.1016/0014-5793(94)01007-2;
RA   Lesage F., Duprat F., Fink M., Guillemare E., Coppola T.,
RA   Lazdunski M., Hugnot J.-P.;
RT   "Cloning provides evidence for a family of inward rectifier and G-
RT   protein coupled K+ channels in the brain.";
RL   FEBS Lett. 353:37-42(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM GIRK2A).
RC   TISSUE=Brain;
RX   MEDLINE=96081927; PubMed=7499385; DOI=10.1074/jbc.270.48.28660;
RA   Lesage F., Guillemare E., Fink M., Duprat F., Heurteaux C., Fosset M.,
RA   Romey G., Barhanin J., Lazdunski M.;
RT   "Molecular properties of neuronal G-protein-activated inwardly
RT   rectifying K+ channels.";
RL   J. Biol. Chem. 270:28660-28667(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM GIRK2B).
RC   TISSUE=Brain;
RX   MEDLINE=96136315; PubMed=8573147; DOI=10.1006/bbrc.1996.0050;
RA   Isomoto S., Kondo C., Takahashi N., Matsumoto S., Yamada M.,
RA   Takumi T., Horio Y., Kurachi Y.;
RT   "A novel ubiquitously distributed isoform of GIRK2 (GIRK2B) enhances
RT   GIRK1 expression of the G-protein-gated K+ current in Xenopus
RT   oocytes.";
RL   Biochem. Biophys. Res. Commun. 218:286-291(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND ALTERNATIVE SPLICING.
RC   STRAIN=129/SvJ;
RX   MEDLINE=98389623; PubMed=9721208; DOI=10.1006/geno.1998.5369;
RA   Wei J., Hodes M.E., Piva R., Feng Y., Wang Y., Ghetti B., Dlouhy S.R.;
RT   "Characterization of murine Girk2 transcript isoforms: structure and
RT   differential expression.";
RL   Genomics 51:379-390(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM GIRK2D).
RA   Inanobe A., Horio Y., Fujita A., Tanemoto M., Kurachi Y.;
RT   "Molecular cloning and characterization of a novel splicing variant of
RT   Kir3.2/GIRK2 predominantly expressed in mouse testis.";
RL   Submitted (JUL-1999) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   PROTEIN SEQUENCE OF 379-390, AND MASS SPECTROMETRY.
RC   STRAIN=OF1; TISSUE=Hippocampus;
RA   Lubec G., Sunyer B., Chen W.-Q.;
RL   Submitted (JAN-2009) to UniProtKB.
RN   [7]
RP   VARIANT WV SER-156.
RX   MEDLINE=96024646; PubMed=7550338; DOI=10.1038/ng1095-126;
RA   Patil N., Cox D.R., Bhat D., Faham M., Myers R.M., Peterson A.S.;
RT   "A potassium channel mutation in weaver mice implicates membrane
RT   excitability in granule cell differentiation.";
RL   Nat. Genet. 11:126-129(1995).
CC   -!- FUNCTION: This potassium channel is controlled by G proteins. It
CC       plays a role in granule cell differentiation, possibly via
CC       membrane hyperpolarization. Inward rectifier potassium channels
CC       are characterized by a greater tendency to allow potassium to flow
CC       into the cell rather than out of it. Their voltage dependence is
CC       regulated by the concentration of extracellular potassium; as
CC       external potassium is raised, the voltage range of the channel
CC       opening shifts to more positive voltages. The inward rectification
CC       is mainly due to the blockage of outward current by internal
CC       magnesium.
CC   -!- SUBUNIT: May associate with GIRK1 or GIRK4 to form a G-protein-
CC       activated heteromultimer pore-forming unit. The resulting inward
CC       current is much larger (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC         Comment=Additional isoforms seem to exist;
CC       Name=GIRK2A;
CC         IsoId=P48542-1; Sequence=Displayed;
CC       Name=GIRK2-1;
CC         IsoId=P48542-2; Sequence=VSP_002803;
CC       Name=GIRK2B;
CC         IsoId=P48542-3; Sequence=VSP_002804, VSP_002805;
CC       Name=GIRK2C;
CC         IsoId=P48542-4; Sequence=VSP_002806, VSP_002807, VSP_002808;
CC       Name=GIRK2D; Synonyms=KIR3.2D;
CC         IsoId=P48542-5; Sequence=Not described;
CC   -!- TISSUE SPECIFICITY: Cerebellum, testes, cortex and substentia
CC       nigra.
CC   -!- DISEASE: Defects in Kcnj6 are the cause of the weaver (wv)
CC       phenotype. Homozygous animals suffer from severe ataxia that is
CC       obvious by about the second postnatal week. The cerebellum of
CC       these animals is drastically reduced in size due to depletion of
CC       the major cell type of cerebellum, the granule cell neuron.
CC       Heterozygous animals are not ataxic but have an intermediate
CC       number of surviving granule cells. Male homozygotes are sterile,
CC       because of complete failure of sperm production. Both hetero- and
CC       homozygous animals undergo sporadic tonic-clonic seizures.
CC   -!- SIMILARITY: Belongs to the inward rectifier-type potassium channel
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U37253; AAA91457.1; -; mRNA.
DR   EMBL; U11859; AAA53245.1; -; mRNA.
DR   EMBL; U51122; AAC34141.1; -; mRNA.
DR   EMBL; U51123; AAC34142.1; -; mRNA.
DR   EMBL; U51124; AAC34143.1; -; mRNA.
DR   EMBL; U51125; AAC34144.1; -; mRNA.
DR   EMBL; U51126; AAC34145.1; -; mRNA.
DR   EMBL; AF040049; AAC34286.1; -; Genomic_DNA.
DR   EMBL; AF040047; AAC34286.1; JOINED; Genomic_DNA.
DR   EMBL; AF040050; AAC34287.1; -; Genomic_DNA.
DR   EMBL; AF040049; AAC34287.1; JOINED; Genomic_DNA.
DR   EMBL; AF040051; AAC34285.1; -; Genomic_DNA.
DR   EMBL; AF040047; AAC34285.1; JOINED; Genomic_DNA.
DR   EMBL; AF040049; AAC34285.1; JOINED; Genomic_DNA.
DR   EMBL; AF040052; AAC34284.1; -; Genomic_DNA.
DR   EMBL; AF040047; AAC34284.1; JOINED; Genomic_DNA.
DR   EMBL; AF040049; AAC34284.1; JOINED; Genomic_DNA.
DR   EMBL; AF040051; AAC34284.1; JOINED; Genomic_DNA.
DR   EMBL; D86040; BAA12972.1; -; mRNA.
DR   EMBL; AB029502; BAA88430.1; -; mRNA.
DR   IPI; IPI00227085; -.
DR   IPI; IPI00227086; -.
DR   IPI; IPI00227087; -.
DR   IPI; IPI00313365; -.
DR   PIR; JC4586; JC4586.
DR   PIR; S48738; S48738.
DR   RefSeq; NP_001020756.1; -.
DR   RefSeq; NP_001020761.1; -.
DR   RefSeq; NP_034736.2; -.
DR   UniGene; Mm.328720; -.
DR   PDB; 2E4F; X-ray; 2.30 A; A=53-381.
DR   PDBsum; 2E4F; -.
DR   SMR; P48542; 56-361.
DR   STRING; P48542; -.
DR   PhosphoSite; P48542; -.
DR   PRIDE; P48542; -.
DR   Ensembl; ENSMUST00000056268; ENSMUSP00000052888; ENSMUSG00000043301; Mus musculus.
DR   Ensembl; ENSMUST00000095873; ENSMUSP00000093558; ENSMUSG00000043301; Mus musculus.
DR   Ensembl; ENSMUST00000099508; ENSMUSP00000097108; ENSMUSG00000043301; Mus musculus.
DR   GeneID; 16522; -.
DR   CTD; 16522; -.
DR   MGI; MGI:104781; Kcnj6.
DR   eggNOG; roNOG05377; -.
DR   HOVERGEN; HBG006178; -.
DR   NextBio; 289901; -.
DR   ArrayExpress; P48542; -.
DR   Bgee; P48542; -.
DR   Genevestigator; P48542; -.
DR   GermOnline; ENSMUSG00000043301; Mus musculus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0015467; F:G-protein activated inward rectifier potass...; IDA:MGI.
DR   GO; GO:0030955; F:potassium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006813; P:potassium ion transport; IEA:UniProtKB-KW.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR016449; K_chnl_inward-rec_Kir.
DR   InterPro; IPR001838; K_chnl_inward-rec_Kir-like.
DR   InterPro; IPR003275; K_chnl_inward-rec_Kir3.2.
DR   InterPro; IPR013521; K_chnl_inward-rec_Kir_Cr2.
DR   InterPro; IPR013518; K_chnl_inward-rec_Kir_cyto.
DR   Gene3D; G3DSA:2.60.40.1400; IR_K+channel_cytopl; 1.
DR   PANTHER; PTHR11767; K+channel_IR; 1.
DR   PANTHER; PTHR11767:SF19; KIR32_channel; 1.
DR   Pfam; PF01007; IRK; 1.
DR   PIRSF; PIRSF005465; GIRK_kir; 1.
DR   PRINTS; PR01328; KIR32CHANNEL.
DR   PRINTS; PR01320; KIRCHANNEL.
DR   SUPFAM; SSF81296; Ig_E-set; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Direct protein sequencing;
KW   Disease mutation; Ion transport; Ionic channel; Membrane; Potassium;
KW   Potassium transport; Transmembrane; Transport; Voltage-gated channel.
FT   CHAIN         1    425       G protein-activated inward rectifier
FT                                potassium channel 2.
FT                                /FTId=PRO_0000154944.
FT   TOPO_DOM      1     91       Cytoplasmic (By similarity).
FT   TRANSMEM     92    116       M1 (By similarity).
FT   TOPO_DOM    117    140       Extracellular (By similarity).
FT   TOPO_DOM    160    168       Extracellular (By similarity).
FT   TRANSMEM    169    190       M2 (By similarity).
FT   TOPO_DOM    191    425       Cytoplasmic (By similarity).
FT   REGION      141    152       H5 (pore-forming helix) (By similarity).
FT   MOTIF       154    159       Selectivity filter (By similarity).
FT   SITE        184    184       Role in the control of polyamine-mediated
FT                                channel gating and in the blocking by
FT                                intracellular magnesium (By similarity).
FT   VAR_SEQ       1     18       Missing (in isoform GIRK2C).
FT                                /FTId=VSP_002806.
FT   VAR_SEQ     319    327       MTCQARSSY -> KMGFALGFL (in isoform
FT                                GIRK2B).
FT                                /FTId=VSP_002804.
FT   VAR_SEQ     319    320       MT -> QF (in isoform GIRK2C).
FT                                /FTId=VSP_002807.
FT   VAR_SEQ     321    425       Missing (in isoform GIRK2C).
FT                                /FTId=VSP_002808.
FT   VAR_SEQ     328    425       Missing (in isoform GIRK2B).
FT                                /FTId=VSP_002805.
FT   VAR_SEQ     415    425       Missing (in isoform GIRK2-1).
FT                                /FTId=VSP_002803.
FT   VARIANT     156    156       G -> S (in wv).
FT   VARIANT     313    313       I -> M.
FT   VARIANT     344    344       M -> L.
FT   CONFLICT     67     67       V -> C (in Ref. 3 and 4).
FT   CONFLICT    260    260       S -> T (in Ref. 3; BAA12972, 4; AAC34145
FT                                and 5; BAA88430).
FT   CONFLICT    381    381       V -> L (in Ref. 5; BAA88430).
FT   STRAND      205    207
FT   STRAND      211    215
FT   STRAND      220    226
FT   STRAND      238    248
FT   STRAND      254    262
FT   STRAND      279    284
FT   TURN        290    293
FT   TURN        296    301
FT   STRAND      305    311
FT   STRAND      323    328
FT   HELIX       329    331
FT   STRAND      349    351
FT   HELIX       353    355
FT   HELIX       369    378
SQ   SEQUENCE   425 AA;  48652 MW;  2E5153DCB1B60331 CRC64;
     MTMAKLTESM TNVLEGDSMD QDVESPVAIH QPKLPKQARD DLPRHISRDR TKRKIQRYVR
     KDGKCNVHHG NVRETYRYLT DIFTTLVDLK WRFNLLIFVM VYTVTWLFFG MIWWLIAYIR
     GDMDHIEDPS WTPCVTNLNG FVSAFLFSIE TETTIGYGYR VITDKCPEGI ILLLIQSVLG
     SIVNAFMVGC MFVKISQPKK RAETLVFSTH AVISMRDGKL CLMFRVGDLR NSHIVEASIR
     AKLIKSKQTS EGEFIPLNQS DINVGYYTGD DRLFLVSPLI ISHEINQQSP FWEISKAQLP
     KEELEIVVIL EGIVEATGMT CQARSSYITS EILWGYRFTP VLTMEDGFYE VDYNSFHETY
     ETSTPSLSAK ELAELANRAE VPLSWSVSSK LNQHAELETE EEEKNPEELT ERNGDVANLE
     NESKV
//
ID   IRK8_HUMAN              Reviewed;         424 AA.
AC   Q15842; O00657;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   02-MAR-2010, entry version 95.
DE   RecName: Full=ATP-sensitive inward rectifier potassium channel 8;
DE   AltName: Full=Potassium channel, inwardly rectifying subfamily J member 8;
DE   AltName: Full=Inward rectifier K(+) channel Kir6.1;
DE   AltName: Full=uKATP-1;
GN   Name=KCNJ8;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RC   TISSUE=Lung, and Placenta;
RX   MEDLINE=96129311; PubMed=8595887; DOI=10.1006/geno.1995.0018;
RA   Inagaki N., Inazawa J., Seino S.;
RT   "cDNA sequence, gene structure, and chromosomal localization of the
RT   human ATP-sensitive potassium channel, uKATP-1, gene (KCNJ8).";
RL   Genomics 30:102-104(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-397, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Epithelium;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-62, AND MASS
RP   SPECTROMETRY.
RX   PubMed=18187866; DOI=10.2116/analsci.24.161;
RA   Imami K., Sugiyama N., Kyono Y., Tomita M., Ishihama Y.;
RT   "Automated phosphoproteome analysis for cultured cancer cells by two-
RT   dimensional nanoLC-MS using a calcined titania/C18 biphasic column.";
RL   Anal. Sci. 24:161-166(2008).
CC   -!- FUNCTION: This potassium channel is controlled by G proteins.
CC       Inward rectifier potassium channels are characterized by a greater
CC       tendency to allow potassium to flow into the cell rather than out
CC       of it. Their voltage dependence is regulated by the concentration
CC       of extracellular potassium; as external potassium is raised, the
CC       voltage range of the channel opening shifts to more positive
CC       voltages. The inward rectification is mainly due to the blockage
CC       of outward current by internal magnesium. Can be blocked by
CC       external barium (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the inward rectifier-type potassium channel
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D50312; BAA08851.1; -; mRNA.
DR   EMBL; D50315; BAA08852.1; -; Genomic_DNA.
DR   EMBL; BC000544; AAH00544.1; -; mRNA.
DR   IPI; IPI00020003; -.
DR   RefSeq; NP_004973.1; -.
DR   UniGene; Hs.102308; -.
DR   UniGene; Hs.619408; -.
DR   SMR; Q15842; 33-347, 184-361.
DR   STRING; Q15842; -.
DR   PhosphoSite; Q15842; -.
DR   PRIDE; Q15842; -.
DR   Ensembl; ENST00000240662; ENSP00000240662; ENSG00000121361; Homo sapiens.
DR   GeneID; 3764; -.
DR   KEGG; hsa:3764; -.
DR   NMPDR; fig|9606.3.peg.7291; -.
DR   UCSC; uc001rff.1; human.
DR   CTD; 3764; -.
DR   GeneCards; GC12M021809; -.
DR   H-InvDB; HIX0010482; -.
DR   HGNC; HGNC:6269; KCNJ8.
DR   HPA; CAB009504; -.
DR   MIM; 600935; gene.
DR   PharmGKB; PA30050; -.
DR   eggNOG; prNOG11516; -.
DR   HOGENOM; HBG716702; -.
DR   HOVERGEN; HBG006178; -.
DR   InParanoid; Q15842; -.
DR   OMA; EVIPIHQ; -.
DR   OrthoDB; EOG9C2KW6; -.
DR   PhylomeDB; Q15842; -.
DR   DrugBank; DB00922; Levosimendan.
DR   NextBio; 14759; -.
DR   ArrayExpress; Q15842; -.
DR   Bgee; Q15842; -.
DR   CleanEx; HS_KCNJ8; -.
DR   Genevestigator; Q15842; -.
DR   GermOnline; ENSG00000121361; Homo sapiens.
DR   GO; GO:0008076; C:voltage-gated potassium channel complex; TAS:ProtInc.
DR   GO; GO:0015272; F:ATP-activated inward rectifier potassium ch...; IEA:InterPro.
DR   GO; GO:0030955; F:potassium ion binding; IEA:UniProtKB-KW.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR016449; K_chnl_inward-rec_Kir.
DR   InterPro; IPR001838; K_chnl_inward-rec_Kir-like.
DR   InterPro; IPR003278; K_chnl_inward-rec_Kir6.1.
DR   InterPro; IPR013521; K_chnl_inward-rec_Kir_Cr2.
DR   InterPro; IPR013518; K_chnl_inward-rec_Kir_cyto.
DR   Gene3D; G3DSA:2.60.40.1400; IR_K+channel_cytopl; 1.
DR   PANTHER; PTHR11767; K+channel_IR; 1.
DR   Pfam; PF01007; IRK; 1.
DR   PIRSF; PIRSF005465; GIRK_kir; 1.
DR   PRINTS; PR01331; KIR61CHANNEL.
DR   PRINTS; PR01320; KIRCHANNEL.
DR   SUPFAM; SSF81296; Ig_E-set; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Ion transport; Ionic channel; Membrane;
KW   Phosphoprotein; Polymorphism; Potassium; Potassium transport;
KW   Transmembrane; Transport; Voltage-gated channel.
FT   CHAIN         1    424       ATP-sensitive inward rectifier potassium
FT                                channel 8.
FT                                /FTId=PRO_0000154947.
FT   TOPO_DOM      1     69       Cytoplasmic (By similarity).
FT   TRANSMEM     70     94       M1 (By similarity).
FT   TOPO_DOM     95    126       Extracellular (By similarity).
FT   TOPO_DOM    146    154       Extracellular (By similarity).
FT   TRANSMEM    155    176       M2 (By similarity).
FT   TOPO_DOM    177    424       Cytoplasmic (By similarity).
FT   REGION      127    138       H5 (pore-forming helix) (By similarity).
FT   MOTIF       140    145       Selectivity filter (By similarity).
FT   SITE        170    170       Role in the control of polyamine-mediated
FT                                channel gating and in the blocking by
FT                                intracellular magnesium (By similarity).
FT   MOD_RES      62     62       Phosphothreonine.
FT   MOD_RES     397    397       Phosphoserine.
FT   VARIANT     334    334       V -> A (in dbSNP:rs34811413).
FT                                /FTId=VAR_049670.
SQ   SEQUENCE   424 AA;  47968 MW;  973EAA5900C6447C CRC64;
     MLARKSIIPE EYVLARIAAE NLRKPRIRDR LPKARFIAKS GACNLAHKNI REQGRFLQDI
     FTTLVDLKWR HTLVIFTMSF LCSWLLFAIM WWLVAFAHGD IYAYMEKSGM EKSGLESTVC
     VTNVRSFTSA FLFSIEVQVT IGFGGRMMTE ECPLAITVLI LQNIVGLIIN AVMLGCIFMK
     TAQAHRRAET LIFSRHAVIA VRNGKLCFMF RVGDLRKSMI ISASVRIQVV KKTTTPEGEV
     VPIHQLDIPV DNPIESNNIF LVAPLIICHV IDKRSPLYDI SATDLANQDL EVIVILEGVV
     ETTGITTQAR TSYIAEEIQW GHRFVSIVTE EEGVYSVDYS KFGNTVKVAA PRCSARELDE
     KPSILIQTLQ KSELSHQNSL RKRNSMRRNN SMRRNNSIRR NNSSLMVPKV QFMTPEGNQN
     TSES
//
ID   KCSA_STRCO              Reviewed;         160 AA.
AC   P0A333; Q54397;
DT   15-MAR-2005, integrated into UniProtKB/Swiss-Prot.
DT   15-MAR-2005, sequence version 1.
DT   02-MAR-2010, entry version 37.
DE   RecName: Full=Voltage-gated potassium channel;
GN   Name=kcsA; Synonyms=skc1; OrderedLocusNames=SCO7660;
GN   ORFNames=SC10F4.33;
OS   Streptomyces coelicolor.
OC   Bacteria; Actinobacteria; Actinobacteridae; Actinomycetales;
OC   Streptomycineae; Streptomycetaceae; Streptomyces.
OX   NCBI_TaxID=1902;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC BAA-471 / A3(2) / M145;
RX   MEDLINE=21996410; PubMed=12000953; DOI=10.1038/417141a;
RA   Bentley S.D., Chater K.F., Cerdeno-Tarraga A.-M., Challis G.L.,
RA   Thomson N.R., James K.D., Harris D.E., Quail M.A., Kieser H.,
RA   Harper D., Bateman A., Brown S., Chandra G., Chen C.W., Collins M.,
RA   Cronin A., Fraser A., Goble A., Hidalgo J., Hornsby T., Howarth S.,
RA   Huang C.-H., Kieser T., Larke L., Murphy L.D., Oliver K., O'Neil S.,
RA   Rabbinowitsch E., Rajandream M.A., Rutherford K.M., Rutter S.,
RA   Seeger K., Saunders D., Sharp S., Squares R., Squares S., Taylor K.,
RA   Warren T., Wietzorrek A., Woodward J.R., Barrell B.G., Parkhill J.,
RA   Hopwood D.A.;
RT   "Complete genome sequence of the model actinomycete Streptomyces
RT   coelicolor A3(2).";
RL   Nature 417:141-147(2002).
CC   -!- FUNCTION: Acts as a potassium ion channel (By similarity).
CC   -!- SUBUNIT: Homotetramer (By similarity).
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein
CC       (By similarity).
CC   -!- MISCELLANEOUS: The amino acids 62-79 are situated in the membrane
CC       and are important for channel structure and properties (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the potassium channel family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AL939132; CAC16993.1; -; Genomic_DNA.
DR   RefSeq; NP_631700.1; -.
DR   PDB; 1S5H; X-ray; 2.20 A; C=3-124.
DR   PDB; 2HFE; X-ray; 2.25 A; C=22-78, D=80-122.
DR   PDBsum; 1S5H; -.
DR   PDBsum; 2HFE; -.
DR   GeneID; 1103098; -.
DR   GenomeReviews; AL645882_GR; SCO7660.
DR   KEGG; sco:SCO7660; -.
DR   NMPDR; fig|100226.1.peg.7591; -.
DR   BioCyc; SCOE100226:SCO7660-MONOMER; -.
DR   GO; GO:0008076; C:voltage-gated potassium channel complex; IEA:InterPro.
DR   GO; GO:0005249; F:voltage-gated potassium channel activity; IEA:InterPro.
DR   GO; GO:0006813; P:potassium ion transport; IEA:InterPro.
DR   InterPro; IPR013099; Ion_trans_2.
DR   InterPro; IPR003091; K_chnl.
DR   Pfam; PF07885; Ion_trans_2; 1.
DR   PRINTS; PR00169; KCHANNEL.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Complete proteome; Ion transport;
KW   Ionic channel; Membrane; Transmembrane; Transport;
KW   Voltage-gated channel.
FT   CHAIN         1    160       Voltage-gated potassium channel.
FT                                /FTId=PRO_0000054101.
FT   TOPO_DOM      1     27       Cytoplasmic (By similarity).
FT   TRANSMEM     28     50       By similarity.
FT   TOPO_DOM     51     61       Extracellular (By similarity).
FT   TOPO_DOM     81     87       Extracellular (By similarity).
FT   TRANSMEM     88    111       By similarity.
FT   TOPO_DOM    112    160       Cytoplasmic (By similarity).
FT   REGION       62     72       Pore-forming helix (By similarity).
FT   MOTIF        75     80       Selectivity filter.
FT   HELIX        24     51
FT   HELIX        62     73
FT   STRAND       79     81
FT   HELIX        86    121
SQ   SEQUENCE   160 AA;  17694 MW;  DEBD9E64384BF40C CRC64;
     MPPMLSGLLA RLVKLLLGRH GSALHWRAAG AATVLLVIVL LAGSYLAVLA ERGAPGAQLI
     TYPRALWWSV ETATTVGYGD LYPVTLWGRL VAVVVMVAGI TSFGLVTAAL ATWFVGREQE
     RRGHFVRHSE KAAEEAYTRT TRALHERFDR LERMLDDNRR
//
ID   LAMB_ECOL6              Reviewed;         446 AA.
AC   Q8CVI4;
DT   25-MAR-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2003, sequence version 1.
DT   02-MAR-2010, entry version 50.
DE   RecName: Full=Maltoporin;
DE   AltName: Full=Maltose-inducible porin;
DE   Flags: Precursor;
GN   Name=lamB; OrderedLocusNames=c5006;
OS   Escherichia coli O6.
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC   Enterobacteriaceae; Escherichia.
OX   NCBI_TaxID=217992;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=O6:H1 / CFT073 / ATCC 700928 / UPEC;
RX   MEDLINE=22388234; PubMed=12471157; DOI=10.1073/pnas.252529799;
RA   Welch R.A., Burland V., Plunkett G. III, Redford P., Roesch P.,
RA   Rasko D., Buckles E.L., Liou S.-R., Boutin A., Hackett J., Stroud D.,
RA   Mayhew G.F., Rose D.J., Zhou S., Schwartz D.C., Perna N.T.,
RA   Mobley H.L.T., Donnenberg M.S., Blattner F.R.;
RT   "Extensive mosaic structure revealed by the complete genome sequence
RT   of uropathogenic Escherichia coli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:17020-17024(2002).
CC   -!- FUNCTION: Involved in the transport of maltose and maltodextrins
CC       (By similarity).
CC   -!- SUBUNIT: Homotrimer formed of three 18-stranded antiparallel beta-
CC       barrels, containing three independent channels (By similarity).
CC   -!- SUBCELLULAR LOCATION: Cell outer membrane; Multi-pass membrane
CC       protein (By similarity).
CC   -!- INDUCTION: By maltose (Probable).
CC   -!- SIMILARITY: Belongs to the porin lamB (TC 1.B.3) family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AE014075; AAN83432.1; -; Genomic_DNA.
DR   RefSeq; NP_756858.1; -.
DR   PDB; 2VDA; NMR; -; B=1-25.
DR   PDBsum; 2VDA; -.
DR   SMR; Q8CVI4; 26-446.
DR   GeneID; 1039561; -.
DR   GenomeReviews; AE014075_GR; c5006.
DR   KEGG; ecc:c5006; -.
DR   HOGENOM; HBG309714; -.
DR   OMA; NVKSQRT; -.
DR   ProtClustDB; PRK09360; -.
DR   GO; GO:0009279; C:cell outer membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-KW.
DR   GO; GO:0046930; C:pore complex; IEA:UniProtKB-KW.
DR   GO; GO:0015288; F:porin activity; IEA:HAMAP.
DR   GO; GO:0005351; F:sugar:hydrogen symporter activity; IEA:InterPro.
DR   GO; GO:0006811; P:ion transport; IEA:UniProtKB-KW.
DR   GO; GO:0015768; P:maltose transport; IEA:HAMAP.
DR   HAMAP; MF_01301; LamB; 1; -.
DR   InterPro; IPR003192; Porin_LamB.
DR   Gene3D; G3DSA:2.40.170.10; Porin_LamB; 1.
DR   Pfam; PF02264; LamB; 1.
DR   ProDom; PD008788; Porin_LamB; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Cell outer membrane; Complete proteome;
KW   Disulfide bond; Ion transport; Membrane; Porin; Signal;
KW   Sugar transport; Transmembrane; Transport.
FT   SIGNAL        1     25       Potential.
FT   CHAIN        26    446       Maltoporin.
FT                                /FTId=PRO_0000025176.
FT   TOPO_DOM     26     26       Periplasmic (By similarity).
FT   TRANSMEM     27     35       By similarity.
FT   TOPO_DOM     36     64       Extracellular (By similarity).
FT   TRANSMEM     65     78       By similarity.
FT   TOPO_DOM     79     80       Periplasmic (By similarity).
FT   TRANSMEM     81     93       By similarity.
FT   TOPO_DOM     94    104       Extracellular (By similarity).
FT   TRANSMEM    105    115       By similarity.
FT   TOPO_DOM    116    122       Periplasmic (By similarity).
FT   TRANSMEM    123    130       By similarity.
FT   TOPO_DOM    131    148       Extracellular (By similarity).
FT   TRANSMEM    149    159       By similarity.
FT   TOPO_DOM    160    161       Periplasmic (By similarity).
FT   TRANSMEM    162    173       By similarity.
FT   TOPO_DOM    174    191       Extracellular (By similarity).
FT   TRANSMEM    192    205       By similarity.
FT   TOPO_DOM    206    209       Periplasmic (By similarity).
FT   TRANSMEM    210    222       By similarity.
FT   TOPO_DOM    223    234       Extracellular (By similarity).
FT   TRANSMEM    235    248       By similarity.
FT   TOPO_DOM    249    250       Periplasmic (By similarity).
FT   TRANSMEM    251    263       By similarity.
FT   TOPO_DOM    264    290       Extracellular (By similarity).
FT   TRANSMEM    291    305       By similarity.
FT   TOPO_DOM    306    307       Periplasmic (By similarity).
FT   TRANSMEM    308    323       By similarity.
FT   TOPO_DOM    324    326       Extracellular (By similarity).
FT   TRANSMEM    327    341       By similarity.
FT   TOPO_DOM    342    343       Periplasmic (By similarity).
FT   TRANSMEM    344    359       By similarity.
FT   TOPO_DOM    360    362       Extracellular (By similarity).
FT   TRANSMEM    363    378       By similarity.
FT   TOPO_DOM    379    385       Periplasmic (By similarity).
FT   TRANSMEM    386    400       By similarity.
FT   TOPO_DOM    401    430       Extracellular (By similarity).
FT   TRANSMEM    431    445       By similarity.
FT   TOPO_DOM    446    446       Periplasmic (By similarity).
FT   SITE         31     31       Greasy slide, important in sugar
FT                                transport (By similarity).
FT   SITE         66     66       Greasy slide, important in sugar
FT                                transport (By similarity).
FT   SITE         99     99       Greasy slide, important in sugar
FT                                transport (By similarity).
FT   SITE        143    143       Important in sugar transport (By
FT                                similarity).
FT   SITE        252    252       Greasy slide, important in sugar
FT                                transport (By similarity).
FT   SITE        383    383       Greasy slide, important in sugar
FT                                transport (By similarity).
FT   SITE        445    445       Greasy slide, important in sugar
FT                                transport (By similarity).
FT   DISULFID     47     63       By similarity.
FT   HELIX        10     17
SQ   SEQUENCE   446 AA;  49941 MW;  66AD83740268B030 CRC64;
     MMITLRKLPL AVAVAAGVMS AQAMAVDFHG YARSGIGWTG SGGEQQCFQT TGAQSKYRLG
     NECETYAELK LGQEVWKEGD KSFYFDTNVA YSVAQQNDWE ATDPAFREAN VQGKNLIEWL
     PGSTIWAGKR FYQRHDVHMI DFYYWDISGP GAGLENIDVG FGKLSLAATR SSEAGGSSSF
     ASNNIYDYTN ETANDVFDVR LAQMEINPGG TLELGVDYGR ANLRDNYRLV DGASKDGWLF
     TAEHTQSVLK GFNKFVVQYA TDSMTSQGKG LSQGSGVAFD NEKFAYNINN NGHMLRILDH
     GAISMGDNWD MMYVGMYQDI NWDNDNGTKW WTVGIRPMYK WTPIMSTVME IGYDNVESQR
     TGDKNNQYKI TLAQQWQAGD SIWSRPAIRV FATYAKWDEK WGYDYTGSSS TNPYYGKAVS
     ADFNGGSFGR GDSDEWTFGA QMEIWW
//
ID   LTC4S_MOUSE             Reviewed;         150 AA.
AC   Q60860; Q5SVR7; Q9QVS1;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   02-MAR-2010, entry version 67.
DE   RecName: Full=Leukotriene C4 synthase;
DE            Short=LTC4 synthase;
DE            EC=4.4.1.20;
DE   AltName: Full=Leukotriene-C(4) synthase;
GN   Name=Ltc4s;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=98000279; PubMed=9342232;
RX   DOI=10.1111/j.1432-1033.1997.00807.x;
RA   Penrose J.F., Baldasaro M.H., Webster M., Xu K., Austen K.F.,
RA   Lam B.K.;
RT   "Molecular cloning of the gene for mouse leukotriene-C4 synthase.";
RL   Eur. J. Biochem. 248:807-813(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S.,
RA   She X., Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W.,
RA   Kapustin Y., Meric P., Maglott D., Birtle Z., Marques A.C., Graves T.,
RA   Zhou S., Teague B., Potamousis K., Churas C., Place M., Herschleb J.,
RA   Runnheim R., Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z.,
RA   Lindblad-Toh K., Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of
RT   the mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [3]
RP   PROTEIN SEQUENCE OF 1-27.
RC   TISSUE=Mast cell;
RX   MEDLINE=95284134; PubMed=7766706; DOI=10.1016/0005-2760(95)00031-7;
RA   Goppelt-Struebe M.;
RT   "Two step purification of human and murine leukotriene C4 synthase.";
RL   Biochim. Biophys. Acta 1256:257-261(1995).
RN   [4]
RP   IDENTIFICATION, AND TISSUE SPECIFICITY.
RX   PubMed=8706658; DOI=10.1111/j.1432-1033.1996.0606w.x;
RA   Lam B.K., Penrose J.F., Rokach J., Xu K., Baldasaro M.H., Austen K.F.;
RT   "Molecular cloning, expression and characterization of mouse
RT   leukotriene C4 synthase.";
RL   Eur. J. Biochem. 238:606-612(1996).
CC   -!- FUNCTION: Catalyzes the conjugation of leukotriene A4 with reduced
CC       glutathione to form leukotriene C4.
CC   -!- CATALYTIC ACTIVITY: Leukotriene C(4) = leukotriene A(4) +
CC       glutathione.
CC   -!- SUBUNIT: Homotrimer. Interacts with ALOX5AP and ALOX5 (By
CC       similarity).
CC   -!- SUBCELLULAR LOCATION: Nucleus outer membrane; Multi-pass membrane
CC       protein (By similarity). Endoplasmic reticulum membrane; Multi-
CC       pass membrane protein (By similarity).
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC   -!- SIMILARITY: Belongs to the MAPEG family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U27195; AAA75042.1; -; mRNA.
DR   EMBL; AL627187; CAI25121.1; -; Genomic_DNA.
DR   IPI; IPI00121507; -.
DR   PIR; S68961; S68961.
DR   RefSeq; NP_032547.1; -.
DR   UniGene; Mm.245151; -.
DR   SMR; Q60860; 2-111.
DR   STRING; Q60860; -.
DR   PhosphoSite; Q60860; -.
DR   PRIDE; Q60860; -.
DR   Ensembl; ENSMUST00000102772; ENSMUSP00000099833; ENSMUSG00000020377; Mus musculus.
DR   GeneID; 17001; -.
DR   KEGG; mmu:17001; -.
DR   UCSC; uc007isa.1; mouse.
DR   CTD; 17001; -.
DR   MGI; MGI:107498; Ltc4s.
DR   HOGENOM; HBG594959; -.
DR   HOVERGEN; HBG105513; -.
DR   InParanoid; Q60860; -.
DR   OMA; QVNCSEY; -.
DR   PhylomeDB; Q60860; -.
DR   BRENDA; 4.4.1.20; 244.
DR   NextBio; 291112; -.
DR   ArrayExpress; Q60860; -.
DR   Bgee; Q60860; -.
DR   CleanEx; MM_LTC4S; -.
DR   Genevestigator; Q60860; -.
DR   GermOnline; ENSMUSG00000020377; Mus musculus.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005640; C:nuclear outer membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0008047; F:enzyme activator activity; IEA:InterPro.
DR   GO; GO:0004464; F:leukotriene-C4 synthase activity; IDA:MGI.
DR   GO; GO:0008289; F:lipid binding; IDA:MGI.
DR   GO; GO:0019370; P:leukotriene biosynthetic process; IEA:UniProtKB-KW.
DR   InterPro; IPR001446; 5_LipOase_AP.
DR   InterPro; IPR018295; FLAP/GST2/LTC4S_CS.
DR   InterPro; IPR001129; Membr-assoc_MAPEG.
DR   Pfam; PF01124; MAPEG; 1.
DR   PRINTS; PR00488; 5LPOXGNASEAP.
DR   PROSITE; PS01297; FLAP_GST2_LTC4S; 1.
PE   1: Evidence at protein level;
KW   Direct protein sequencing; Endoplasmic reticulum;
KW   Leukotriene biosynthesis; Lyase; Membrane; Nucleus; Transmembrane.
FT   CHAIN         1    150       Leukotriene C4 synthase.
FT                                /FTId=PRO_0000217749.
FT   TOPO_DOM      1      6       Cytoplasmic (By similarity).
FT   TRANSMEM      7     27       By similarity.
FT   TOPO_DOM     28     48       Lumenal (By similarity).
FT   TRANSMEM     49     69       By similarity.
FT   TOPO_DOM     70     73       Cytoplasmic (By similarity).
FT   TRANSMEM     74     94       By similarity.
FT   TOPO_DOM     95    104       Lumenal (By similarity).
FT   TRANSMEM    105    124       By similarity.
FT   TOPO_DOM    125    150       Cytoplasmic (By similarity).
FT   REGION       51     55       Glutathione binding (By similarity).
FT   REGION       58     59       Glutathione binding (By similarity).
FT   REGION       93     97       Glutathione binding (By similarity).
FT   ACT_SITE     31     31       Proton donor (By similarity).
FT   ACT_SITE    104    104       Proton acceptor (By similarity).
FT   BINDING      30     30       Glutathione (By similarity).
SQ   SEQUENCE   150 AA;  16814 MW;  120ABC53892189C0 CRC64;
     MKDEVALLAT VTLVGVLLQA YFSLQVISAR RAFHVSPPLT SGPPEFERVF RAQVNCSEYF
     PLFLATLWVA GIFFHEGAAA LCGLFYLFAR LRYFQGYARS AQLRLTPLYA SARALWLLVA
     MAALGLLVHF LPGTLRTALF RWLQMLLPMA
//
ID   MDR3_HUMAN              Reviewed;        1286 AA.
AC   P21439; A0A2V7; A4D1D3; A4D1D4; Q14813;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   20-FEB-2007, sequence version 2.
DT   02-MAR-2010, entry version 111.
DE   RecName: Full=Multidrug resistance protein 3;
DE            EC=3.6.3.44;
DE   AltName: Full=ATP-binding cassette sub-family B member 4;
DE   AltName: Full=P-glycoprotein 3;
GN   Name=ABCB4; Synonyms=MDR3, PGY3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   MEDLINE=89138016; PubMed=2906314; DOI=10.1016/0378-1119(88)90057-1;
RA   van der Bliek A.M., Kooiman P.M., Schneider C., Borst P.;
RT   "Sequence of mdr3 cDNA encoding a human P-glycoprotein.";
RL   Gene 71:401-411(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-238; VAL-263;
RP   ASP-528; GLN-590; ASN-651; GLY-652 AND GLN-788.
RG   NIEHS SNPs program;
RL   Submitted (OCT-2006) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   MEDLINE=22616434; PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S.,
RA   Kwasnicka D., Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z.,
RA   Lu F., Zeesman S., Nowaczyk M.J., Teshima I., Chitayat D., Shuman C.,
RA   Weksberg R., Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J.,
RA   Rahman N., Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F.,
RA   Belloni E., Shaffer L.G., Pober B., Morton C.C., Gusella J.F.,
RA   Bruns G.A.P., Korf B.R., Quade B.J., Ligon A.H., Ferguson H.,
RA   Higgins A.W., Leach N.T., Herrick S.R., Lemyre E., Farra C.G.,
RA   Kim H.-G., Summers A.M., Gripp K.W., Roberts W., Szatmari P.,
RA   Winsor E.J.T., Grzeschik K.-H., Teebi A., Minassian B.A., Kere J.,
RA   Armengol L., Pujana M.A., Estivill X., Wilson M.D., Koop B.F.,
RA   Tosi S., Moore G.E., Boright A.P., Zlotorynski E., Kerem B.,
RA   Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W.,
RA   Mural R.J., Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-72.
RC   TISSUE=Liver;
RX   MEDLINE=95200972; PubMed=7893760; DOI=10.1016/0167-4781(94)00214-N;
RA   Smit J.J., Mol C.A., van Deemter L., Wagenaar E., Schinkel A.H.,
RA   Borst P.;
RT   "Characterization of the promoter region of the human MDR3 P-
RT   glycoprotein gene.";
RL   Biochim. Biophys. Acta 1261:44-56(1995).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 856-1286 (ISOFORM 1), AND ALTERNATIVE
RP   SPLICING.
RX   MEDLINE=88111519; PubMed=2892668;
RA   van der Bliek A.M., Baas F., ten Houte de Lange T., Kooiman P.M.,
RA   van der Velde-Koerts T., Borst P.;
RT   "The human mdr3 gene encodes a novel P-glycoprotein homologue and
RT   gives rise to alternatively spliced mRNAs in liver.";
RL   EMBO J. 6:3325-3331(1987).
RN   [7]
RP   GENE STRUCTURE.
RX   MEDLINE=91161629; PubMed=2002063;
RA   Lincke C.R., Smit J.J.M., van der Velde-Koerts T., Borst P.;
RT   "Structure of the human MDR3 gene and physical mapping of the human
RT   MDR locus.";
RL   J. Biol. Chem. 266:5303-5310(1991).
RN   [8]
RP   INVOLVEMENT IN PFIC3.
RX   PubMed=9419367; DOI=10.1073/pnas.95.1.282;
RA   de Vree J.M.L., Jacquemin E., Sturm E., Cresteil D., Bosma P.J.,
RA   Aten J., Deleuze J.-F., Desrochers M., Burdelski M., Bernard O.,
RA   Oude Elferink R.P.J., Hadchouel M.;
RT   "Mutations in the MDR3 gene cause progressive familial intrahepatic
RT   cholestasis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:282-287(1998).
RN   [9]
RP   VARIANT ICP ASP-546, AND CHARACTERIZATION OF VARIANT ICP ASP-546.
RX   PubMed=10767346; DOI=10.1093/hmg/9.8.1209;
RA   Dixon P.H., Weerasekera N., Linton K.J., Donaldson O., Chambers J.,
RA   Egginton E., Weaver J., Nelson-Piercy C., de Swiet M., Warnes G.,
RA   Elias E., Higgins C.F., Johnston D.G., McCarthy M.I., Williamson C.;
RT   "Heterozygous MDR3 missense mutation associated with intrahepatic
RT   cholestasis of pregnancy: evidence for a defect in protein
RT   trafficking.";
RL   Hum. Mol. Genet. 9:1209-1217(2000).
RN   [10]
RP   VARIANTS PFIC3 ARG-138; ILE-346; GLY-395; ALA-424; MET-425; PHE-541;
RP   ARG-556; GLY-564; SER-711 AND SER-983, AND VARIANT GLY-652.
RX   PubMed=11313315;
RA   Jacquemin E., De Vree J.M.L., Cresteil D., Sokal E.M., Sturm E.,
RA   Dumont M., Scheffer G.L., Paul M., Burdelski M., Bosma P.J.,
RA   Bernard O., Hadchouel M., Elferink R.P.;
RT   "The wide spectrum of multidrug resistance 3 deficiency: from neonatal
RT   cholestasis to cirrhosis of adulthood.";
RL   Gastroenterology 120:1448-1458(2001).
RN   [11]
RP   VARIANTS CHOLELITHIASIS PHE-320 AND SER-1168, AND VARIANT ALA-175.
RX   PubMed=11313316;
RA   Rosmorduc O., Hermelin B., Poupon R.;
RT   "MDR3 gene defect in adults with symptomatic intrahepatic and
RT   gallbladder cholesterol cholelithiasis.";
RL   Gastroenterology 120:1459-1467(2001).
RN   [12]
RP   VARIANT PFIC3 ASP-535.
RX   PubMed=12671900; DOI=10.1053/gast.2003.50144;
RA   Lucena J.-F., Herrero J.I., Quiroga J., Sangro B.,
RA   Garcia-Foncillas J., Zabalegui N., Sola J., Herraiz M., Medina J.F.,
RA   Prieto J.;
RT   "A multidrug resistance 3 gene mutation causing cholelithiasis,
RT   cholestasis of pregnancy, and adulthood biliary cirrhosis.";
RL   Gastroenterology 124:1037-1042(2003).
RN   [13]
RP   VARIANTS CHOLELITHIASIS ILE-165; THR-301; PHE-320; GLN-591; THR-934
RP   AND SER-1168, AND VARIANTS ALA-175; ASP-528; GLN-590; GLY-652; SER-742
RP   AND GLN-788.
RX   PubMed=12891548; DOI=10.1016/S0016-5085(03)00898-9;
RA   Rosmorduc O., Hermelin B., Boelle P.Y., Parc R., Taboury J.,
RA   Poupon R.;
RT   "ABCB4 gene mutation-associated cholelithiasis in adults.";
RL   Gastroenterology 125:452-459(2003).
RN   [14]
RP   VARIANT ICP LYS-150, AND VARIANT GLY-652.
RX   PubMed=12746424; DOI=10.1136/jmg.40.5.e70;
RA   Muellenbach R., Linton K.J., Wiltshire S., Weerasekera N.,
RA   Chambers J., Elias E., Higgins C.F., Johnston D.G., McCarthy M.I.,
RA   Williamson C.;
RT   "ABCB4 gene sequence variation in women with intrahepatic cholestasis
RT   of pregnancy.";
RL   J. Med. Genet. 40:E70-E70(2003).
RN   [15]
RP   VARIANTS ALA-175; ASP-528; GLY-652 AND MET-775, AND VARIANTS ICP
RP   PHE-320 AND GLU-762.
RX   PubMed=15077010; DOI=10.1097/00008571-200402000-00003;
RA   Pauli-Magnus C., Lang T., Meier Y., Zodan-Marin T., Jung D.,
RA   Breymann C., Zimmermann R., Kenngott S., Beuers U., Reichel C.,
RA   Kerb R., Penger A., Meier P.J., Kullak-Ublick G.A.;
RT   "Sequence analysis of bile salt export pump (ABCB11) and multidrug
RT   resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with
RT   intrahepatic cholestasis of pregnancy.";
RL   Pharmacogenetics 14:91-102(2004).
RN   [16]
RP   VARIANTS GLU-87; SER-95; ALA-175; VAL-367; GLY-450; GLN-590 AND
RP   GLY-652.
RX   PubMed=16763017; DOI=10.1124/dmd.105.008854;
RA   Lang T., Haberl M., Jung D., Drescher A., Schlagenhaufer R., Keil A.,
RA   Mornhinweg E., Stieger B., Kullak-Ublick G.A., Kerb R.;
RT   "Genetic variability, haplotype structures, and ethnic diversity of
RT   hepatic transporters MDR3 (ABCB4) and bile salt export pump
RT   (ABCB11).";
RL   Drug Metab. Dispos. 34:1582-1599(2006).
RN   [17]
RP   VARIANTS ALA-175; GLN-590; GLY-652; LEU-764 AND GLN-1082.
RX   PubMed=17264802; DOI=10.1097/01.fpc.0000230418.28091.76;
RA   Lang C., Meier Y., Stieger B., Beuers U., Lang T., Kerb R.,
RA   Kullak-Ublick G.A., Meier P.J., Pauli-Magnus C.;
RT   "Mutations and polymorphisms in the bile salt export pump and the
RT   multidrug resistance protein 3 associated with drug-induced liver
RT   injury.";
RL   Pharmacogenet. Genomics 17:47-60(2007).
CC   -!- FUNCTION: Mediates ATP-dependent export of organic anions and
CC       drugs from the cytoplasm. Hydrolyzes ATP with low efficiency.
CC       Human MDR3 is not capable of conferring drug resistance. Mediates
CC       the translocation of phosphatidylcholine across the canalicular
CC       membrane of the hepatocyte.
CC   -!- CATALYTIC ACTIVITY: ATP + H(2)O + xenobiotic(In) = ADP + phosphate
CC       + xenobiotic(Out).
CC   -!- SUBUNIT: Interacts with HAX1 (By similarity).
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P21439-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P21439-2; Sequence=VSP_023263;
CC   -!- DISEASE: Defects in ABCB4 are the cause of progressive familial
CC       intrahepatic cholestasis type 3 (PFIC3) [MIM:602347]. PFIC3 is an
CC       autosomal recessive liver disorder presenting with early onset
CC       cholestasis that progresses to cirrhosis and liver failure before
CC       adulthood. It is characterized by elevated serum gamma-
CC       glutamyltransferase levels.
CC   -!- DISEASE: Defects in ABCB4 are a cause of intrahepatic cholestasis
CC       of pregnancy (ICP) [MIM:147480]; also known as obstetric
CC       cholestasis. ICP is a multifactorial liver disorder of pregnancy.
CC       It presents during the second or, more commonly, the third
CC       trimestre of pregnancy with intense pruritus which becomes more
CC       severe with advancing gestation and cholestasis. Cholestasis
CC       results from abnormal biliary transport from the liver into the
CC       small intestine. ICP causes fetal distress, spontaneous premature
CC       delivery and intrauterine death. ICP patients have spontaneous and
CC       progressive disappearance of cholestasis after delivery.
CC   -!- DISEASE: Defects in ABCB4 are a cause of cholelithiasis
CC       [MIM:600803]; also known as gallstones.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCB
CC       family. Multidrug resistance exporter (TC 3.A.1.201) subfamily.
CC   -!- SIMILARITY: Contains 2 ABC transmembrane type-1 domains.
CC   -!- SIMILARITY: Contains 2 ABC transporter domains.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/ABCB4";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/abcb4/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M23234; AAA36207.1; -; mRNA.
DR   EMBL; EF034088; ABJ53424.1; -; Genomic_DNA.
DR   EMBL; CH236949; EAL24174.1; -; Genomic_DNA.
DR   EMBL; CH236949; EAL24175.1; -; Genomic_DNA.
DR   EMBL; CH471091; EAW76946.1; -; Genomic_DNA.
DR   EMBL; CH471091; EAW76947.1; -; Genomic_DNA.
DR   EMBL; Z35284; CAA84542.1; -; mRNA.
DR   EMBL; X06181; CAA29547.1; -; mRNA.
DR   IPI; IPI00042932; -.
DR   IPI; IPI00218731; -.
DR   PIR; JS0051; DVHU3.
DR   RefSeq; NP_000434.1; -.
DR   RefSeq; NP_061337.1; -.
DR   UniGene; Hs.654403; -.
DR   SMR; P21439; 132-632, 699-1280, 1028-1282.
DR   STRING; P21439; -.
DR   TCDB; 3.A.1.201.3; ATP-binding cassette (ABC) superfamily.
DR   PRIDE; P21439; -.
DR   Ensembl; ENST00000265723; ENSP00000265723; ENSG00000005471; Homo sapiens.
DR   GeneID; 5244; -.
DR   KEGG; hsa:5244; -.
DR   UCSC; uc003uiv.1; human.
DR   UCSC; uc003uiw.1; human.
DR   CTD; 5244; -.
DR   GeneCards; GC07M086869; -.
DR   HGNC; HGNC:45; ABCB4.
DR   HPA; CAB004498; -.
DR   MIM; 147480; phenotype.
DR   MIM; 171060; gene.
DR   MIM; 600803; phenotype.
DR   MIM; 602347; phenotype.
DR   Orphanet; 79305; Cholestasis, progressive familial intrahepatic 3.
DR   Orphanet; 69665; Intrahepatic cholestasis of pregnancy.
DR   Orphanet; 69663; Low phospholipid associated cholelithiasis.
DR   Orphanet; 172; Progressive familial intrahepatic cholestasis.
DR   PharmGKB; PA268; -.
DR   eggNOG; prNOG19542; -.
DR   HOGENOM; HBG758042; -.
DR   HOVERGEN; HBG080809; -.
DR   InParanoid; P21439; -.
DR   OMA; RKAHIYG; -.
DR   OrthoDB; EOG98KTX2; -.
DR   PhylomeDB; P21439; -.
DR   BRENDA; 3.6.3.44; 247.
DR   Reactome; REACT_602; Metabolism of lipids and lipoproteins.
DR   NextBio; 20258; -.
DR   ArrayExpress; P21439; -.
DR   Bgee; P21439; -.
DR   CleanEx; HS_ABCB4; -.
DR   Genevestigator; P21439; -.
DR   GermOnline; ENSG00000005471; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0005624; C:membrane fraction; TAS:ProtInc.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008559; F:xenobiotic-transporting ATPase activity; IEA:EC.
DR   GO; GO:0006629; P:lipid metabolic process; TAS:ProtInc.
DR   GO; GO:0042493; P:response to drug; TAS:ProtInc.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR017940; ABC_transporter_type1.
DR   InterPro; IPR001140; ABC_transptr_TM_dom.
DR   InterPro; IPR011527; ABC_transptrTM_dom_typ1.
DR   InterPro; IPR003593; ATPase_AAA+_core.
DR   Pfam; PF00664; ABC_membrane; 2.
DR   Pfam; PF00005; ABC_tran; 2.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF90123; ABC_TM_1; 2.
DR   PROSITE; PS50929; ABC_TM1F; 2.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 2.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cell membrane; Complete proteome;
KW   Disease mutation; Glycoprotein; Hydrolase; Intrahepatic cholestasis;
KW   Membrane; Nucleotide-binding; Polymorphism; Repeat; Transmembrane;
KW   Transport.
FT   CHAIN         1   1286       Multidrug resistance protein 3.
FT                                /FTId=PRO_0000093333.
FT   TOPO_DOM      1     50       Cytoplasmic (By similarity).
FT   TRANSMEM     51     73       By similarity.
FT   TOPO_DOM     74    118       Extracellular (By similarity).
FT   TRANSMEM    119    139       By similarity.
FT   TOPO_DOM    140    188       Cytoplasmic (By similarity).
FT   TRANSMEM    189    210       By similarity.
FT   TOPO_DOM    211    217       Extracellular (By similarity).
FT   TRANSMEM    218    238       By similarity.
FT   TOPO_DOM    239    296       Cytoplasmic (By similarity).
FT   TRANSMEM    297    318       By similarity.
FT   TOPO_DOM    319    332       Extracellular (By similarity).
FT   TRANSMEM    333    354       By similarity.
FT   TOPO_DOM    355    711       Cytoplasmic (By similarity).
FT   TRANSMEM    712    732       By similarity.
FT   TOPO_DOM    733    755       Extracellular (By similarity).
FT   TRANSMEM    756    776       By similarity.
FT   TOPO_DOM    777    831       Cytoplasmic (By similarity).
FT   TRANSMEM    832    852       By similarity.
FT   TOPO_DOM    853    853       Extracellular (By similarity).
FT   TRANSMEM    854    873       By similarity.
FT   TOPO_DOM    874    933       Cytoplasmic (By similarity).
FT   TRANSMEM    934    956       By similarity.
FT   TOPO_DOM    957    972       Extracellular (By similarity).
FT   TRANSMEM    973    994       By similarity.
FT   TOPO_DOM    995   1286       Cytoplasmic (By similarity).
FT   DOMAIN       57    359       ABC transmembrane type-1 1.
FT   DOMAIN      394    630       ABC transporter 1.
FT   DOMAIN      711    999       ABC transmembrane type-1 2.
FT   DOMAIN     1034   1279       ABC transporter 2.
FT   NP_BIND     429    436       ATP 1 (By similarity).
FT   NP_BIND    1069   1076       ATP 2 (By similarity).
FT   REGION      625    647       Interaction with HAX1 (By similarity).
FT   CARBOHYD     91     91       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     97     97       N-linked (GlcNAc...) (Potential).
FT   VAR_SEQ    1094   1100       Missing (in isoform 2).
FT                                /FTId=VSP_023263.
FT   VARIANT      87     87       D -> E.
FT                                /FTId=VAR_043078.
FT   VARIANT      95     95       P -> S.
FT                                /FTId=VAR_043079.
FT   VARIANT     138    138       W -> R (in PFIC3).
FT                                /FTId=VAR_043080.
FT   VARIANT     150    150       R -> K (in ICP).
FT                                /FTId=VAR_043081.
FT   VARIANT     165    165       F -> I (in cholelithiasis).
FT                                /FTId=VAR_043082.
FT   VARIANT     175    175       T -> A (in dbSNP:rs58238559).
FT                                /FTId=VAR_023501.
FT   VARIANT     238    238       L -> V (in dbSNP:rs45596335).
FT                                /FTId=VAR_020223.
FT   VARIANT     263    263       I -> V (in dbSNP:rs45547936).
FT                                /FTId=VAR_030763.
FT   VARIANT     301    301       M -> T (in cholelithiasis).
FT                                /FTId=VAR_043083.
FT   VARIANT     320    320       S -> F (in ICP and cholelithiasis).
FT                                /FTId=VAR_023502.
FT   VARIANT     346    346       S -> I (in PFIC3).
FT                                /FTId=VAR_043084.
FT   VARIANT     367    367       I -> V.
FT                                /FTId=VAR_043085.
FT   VARIANT     395    395       E -> G (in PFIC3).
FT                                /FTId=VAR_043086.
FT   VARIANT     424    424       T -> A (in PFIC3).
FT                                /FTId=VAR_043087.
FT   VARIANT     425    425       V -> M (in PFIC3).
FT                                /FTId=VAR_043088.
FT   VARIANT     450    450       E -> G.
FT                                /FTId=VAR_043089.
FT   VARIANT     528    528       E -> D (in dbSNP:rs8187797).
FT                                /FTId=VAR_043090.
FT   VARIANT     535    535       G -> D (in PFIC3).
FT                                /FTId=VAR_043091.
FT   VARIANT     541    541       I -> F (in PFIC3).
FT                                /FTId=VAR_043092.
FT   VARIANT     546    546       A -> D (in ICP; disruption of protein
FT                                trafficking with subsequent lack of
FT                                functional protein at the cell surface).
FT                                /FTId=VAR_023503.
FT   VARIANT     556    556       L -> R (in PFIC3).
FT                                /FTId=VAR_043093.
FT   VARIANT     564    564       D -> G (in PFIC3).
FT                                /FTId=VAR_043094.
FT   VARIANT     590    590       R -> Q (in dbSNP:rs45575636).
FT                                /FTId=VAR_043095.
FT   VARIANT     591    591       L -> Q (in cholelithiasis).
FT                                /FTId=VAR_043096.
FT   VARIANT     651    651       T -> N (in dbSNP:rs45476795).
FT                                /FTId=VAR_030765.
FT   VARIANT     652    652       R -> G (in dbSNP:rs2230028).
FT                                /FTId=VAR_020225.
FT   VARIANT     711    711       F -> S (in PFIC3).
FT                                /FTId=VAR_043097.
FT   VARIANT     742    742       G -> S.
FT                                /FTId=VAR_043098.
FT   VARIANT     762    762       G -> E (in ICP).
FT                                /FTId=VAR_043099.
FT   VARIANT     764    764       I -> L (in a heterozygous patient with
FT                                risperidone-induced cholestasis).
FT                                /FTId=VAR_043100.
FT   VARIANT     775    775       T -> M.
FT                                /FTId=VAR_043101.
FT   VARIANT     788    788       R -> Q.
FT                                /FTId=VAR_024359.
FT   VARIANT     934    934       A -> T (in cholelithiasis).
FT                                /FTId=VAR_043102.
FT   VARIANT     983    983       G -> S (in PFIC3; dbSNP:rs56187107).
FT                                /FTId=VAR_043103.
FT   VARIANT    1082   1082       L -> Q (in a heterozygous patient with
FT                                amoxicillin/clavulanic acid-induced
FT                                cholestasis).
FT                                /FTId=VAR_043104.
FT   VARIANT    1161   1161       Missing (in cholelithiasis).
FT                                /FTId=VAR_043105.
FT   VARIANT    1168   1168       P -> S (in cholelithiasis).
FT                                /FTId=VAR_023504.
FT   CONFLICT     62     72       IMAIAHGSGLP -> RGSSRVDLQAC (in Ref. 5;
FT                                CAA84542).
SQ   SEQUENCE   1286 AA;  141523 MW;  9A9066F2292F2CCF CRC64;
     MDLEAAKNGT AWRPTSAEGD FELGISSKQK RKKTKTVKMI GVLTLFRYSD WQDKLFMSLG
     TIMAIAHGSG LPLMMIVFGE MTDKFVDTAG NFSFPVNFSL SLLNPGKILE EEMTRYAYYY
     SGLGAGVLVA AYIQVSFWTL AAGRQIRKIR QKFFHAILRQ EIGWFDINDT TELNTRLTDD
     ISKISEGIGD KVGMFFQAVA TFFAGFIVGF IRGWKLTLVI MAISPILGLS AAVWAKILSA
     FSDKELAAYA KAGAVAEEAL GAIRTVIAFG GQNKELERYQ KHLENAKEIG IKKAISANIS
     MGIAFLLIYA SYALAFWYGS TLVISKEYTI GNAMTVFFSI LIGAFSVGQA APCIDAFANA
     RGAAYVIFDI IDNNPKIDSF SERGHKPDSI KGNLEFNDVH FSYPSRANVK ILKGLNLKVQ
     SGQTVALVGS SGCGKSTTVQ LIQRLYDPDE GTINIDGQDI RNFNVNYLRE IIGVVSQEPV
     LFSTTIAENI CYGRGNVTMD EIKKAVKEAN AYEFIMKLPQ KFDTLVGERG AQLSGGQKQR
     IAIARALVRN PKILLLDEAT SALDTESEAE VQAALDKARE GRTTIVIAHR LSTVRNADVI
     AGFEDGVIVE QGSHSELMKK EGVYFKLVNM QTSGSQIQSE EFELNDEKAA TRMAPNGWKS
     RLFRHSTQKN LKNSQMCQKS LDVETDGLEA NVPPVSFLKV LKLNKTEWPY FVVGTVCAIA
     NGGLQPAFSV IFSEIIAIFG PGDDAVKQQK CNIFSLIFLF LGIISFFTFF LQGFTFGKAG
     EILTRRLRSM AFKAMLRQDM SWFDDHKNST GALSTRLATD AAQVQGATGT RLALIAQNIA
     NLGTGIIISF IYGWQLTLLL LAVVPIIAVS GIVEMKLLAG NAKRDKKELE AAGKIATEAI
     ENIRTVVSLT QERKFESMYV EKLYGPYRNS VQKAHIYGIT FSISQAFMYF SYAGCFRFGA
     YLIVNGHMRF RDVILVFSAI VFGAVALGHA SSFAPDYAKA KLSAAHLFML FERQPLIDSY
     SEEGLKPDKF EGNITFNEVV FNYPTRANVP VLQGLSLEVK KGQTLALVGS SGCGKSTVVQ
     LLERFYDPLA GTVFVDFGFQ LLDGQEAKKL NVQWLRAQLG IVSQEPILFD CSIAENIAYG
     DNSRVVSQDE IVSAAKAANI HPFIETLPHK YETRVGDKGT QLSGGQKQRI AIARALIRQP
     QILLLDEATS ALDTESEKVV QEALDKAREG RTCIVIAHRL STIQNADLIV VFQNGRVKEH
     GTHQQLLAQK GIYFSMVSVQ AGTQNL
//
ID   MDTF_ECOLI              Reviewed;        1037 AA.
AC   P37637; Q2M7H6;
DT   01-OCT-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1994, sequence version 1.
DT   02-MAR-2010, entry version 78.
DE   RecName: Full=Multidrug resistance protein mdtF;
GN   Name=mdtF; Synonyms=yhiV; OrderedLocusNames=b3514, JW3482;
OS   Escherichia coli (strain K12).
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC   Enterobacteriaceae; Escherichia.
OX   NCBI_TaxID=83333;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   MEDLINE=94316500; PubMed=8041620; DOI=10.1093/nar/22.13.2576;
RA   Sofia H.J., Burland V., Daniels D.L., Plunkett G. III, Blattner F.R.;
RT   "Analysis of the Escherichia coli genome. V. DNA sequence of the
RT   region from 76.0 to 81.5 minutes.";
RL   Nucleic Acids Res. 22:2576-2586(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   MEDLINE=97426617; PubMed=9278503; DOI=10.1126/science.277.5331.1453;
RA   Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,
RA   Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F.,
RA   Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J.,
RA   Mau B., Shao Y.;
RT   "The complete genome sequence of Escherichia coli K-12.";
RL   Science 277:1453-1474(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=16738553; DOI=10.1038/msb4100049;
RA   Hayashi K., Morooka N., Yamamoto Y., Fujita K., Isono K., Choi S.,
RA   Ohtsubo E., Baba T., Wanner B.L., Mori H., Horiuchi T.;
RT   "Highly accurate genome sequences of Escherichia coli K-12 strains
RT   MG1655 and W3110.";
RL   Mol. Syst. Biol. 2:E1-E5(2006).
RN   [4]
RP   MULTIDRUG RESISTANCE.
RX   PubMed=11566977; DOI=10.1128/JB.183.20.5803-5812.2001;
RA   Nishino K., Yamaguchi A.;
RT   "Analysis of a complete library of putative drug transporter genes in
RT   Escherichia coli.";
RL   J. Bacteriol. 183:5803-5812(2001).
RN   [5]
RP   INDUCTION, AND INTERACTION WITH TOLC.
RX   PubMed=11914367; DOI=10.1128/JB.184.8.2319-2323.2002;
RA   Nishino K., Yamaguchi A.;
RT   "EvgA of the two-component signal transduction system modulates
RT   production of the yhiUV multidrug transporter in Escherichia coli.";
RL   J. Bacteriol. 184:2319-2323(2002).
RN   [6]
RP   INDUCTION.
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=12399493; DOI=10.1128/JB.184.22.6225-6234.2002;
RA   Masuda N., Church G.M.;
RT   "Escherichia coli gene expression responsive to levels of the response
RT   regulator EvgA.";
RL   J. Bacteriol. 184:6225-6234(2002).
RN   [7]
RP   INDUCTION.
RX   PubMed=14523115; DOI=10.1099/mic.0.26460-0;
RA   Eguchi Y., Oshima T., Mori H., Aono R., Yamamoto K., Ishihama A.,
RA   Utsumi R.;
RT   "Transcriptional regulation of drug efflux genes by EvgAS, a two-
RT   component system in Escherichia coli.";
RL   Microbiology 149:2819-2828(2003).
RN   [8]
RP   INDUCTION.
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=12694615; DOI=10.1046/j.1365-2958.2003.03477.x;
RA   Masuda N., Church G.M.;
RT   "Regulatory network of acid resistance genes in Escherichia coli.";
RL   Mol. Microbiol. 48:699-712(2003).
RN   [9]
RP   HOMOTRIMERIZATION, AND SUBCELLULAR LOCATION.
RC   STRAIN=BL21-DE3;
RX   PubMed=16079137; DOI=10.1074/jbc.M506479200;
RA   Stenberg F., Chovanec P., Maslen S.L., Robinson C.V., Ilag L.,
RA   von Heijne G., Daley D.O.;
RT   "Protein complexes of the Escherichia coli cell envelope.";
RL   J. Biol. Chem. 280:34409-34419(2005).
RN   [10]
RP   TOPOLOGY [LARGE SCALE ANALYSIS].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=15919996; DOI=10.1126/science.1109730;
RA   Daley D.O., Rapp M., Granseth E., Melen K., Drew D., von Heijne G.;
RT   "Global topology analysis of the Escherichia coli inner membrane
RT   proteome.";
RL   Science 308:1321-1323(2005).
CC   -!- FUNCTION: Part of a multidrug resistance efflux system that
CC       confers resistance to compounds such as rhodamine 6G,
CC       erythromycin, doxorubicin, ethidium bromide, TPP, SDS,
CC       deoxycholate, crystal violet and benzalkonium.
CC   -!- SUBUNIT: Homotrimer. Part of a tripartite efflux system composed
CC       of mdtE, mdtF and tolC.
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane; Multi-pass membrane
CC       protein.
CC   -!- INDUCTION: Induced by evgA, probably via ydeO.
CC   -!- SIMILARITY: Belongs to the acrB/acrD/acrF (TC 2.A.6) family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U00039; AAB18490.1; -; Genomic_DNA.
DR   EMBL; U00096; AAC76539.1; -; Genomic_DNA.
DR   EMBL; AP009048; BAE77780.1; -; Genomic_DNA.
DR   PIR; S47734; S47734.
DR   RefSeq; AP_004279.1; -.
DR   RefSeq; NP_417971.1; -.
DR   SMR; P37637; 3-1017.
DR   IntAct; P37637; 2.
DR   STRING; P37637; -.
DR   TCDB; 2.A.6.2.13; resistance-nodulation-cell division (RND) superfamily.
DR   GeneID; 948030; -.
DR   GenomeReviews; AP009048_GR; JW3482.
DR   GenomeReviews; U00096_GR; b3514.
DR   KEGG; ecj:JW3482; -.
DR   KEGG; eco:b3514; -.
DR   EchoBASE; EB2152; -.
DR   EcoGene; EG12241; mdtF.
DR   eggNOG; COG0841; -.
DR   HOGENOM; HBG293864; -.
DR   OMA; VIYLLIC; -.
DR   ProtClustDB; CLSK880698; -.
DR   BioCyc; EcoCyc:YHIV-MONOMER; -.
DR   BioCyc; ECOL168927:B3514-MONOMER; -.
DR   Genevestigator; P37637; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005215; F:transporter activity; IEA:InterPro.
DR   GO; GO:0046677; P:response to antibiotic; IEA:UniProtKB-KW.
DR   GO; GO:0006810; P:transport; IEA:UniProtKB-KW.
DR   InterPro; IPR001036; Acrflvin-R.
DR   InterPro; IPR004764; HAE1.
DR   Pfam; PF00873; ACR_tran; 1.
DR   PRINTS; PR00702; ACRIFLAVINRP.
DR   TIGRFAMs; TIGR00915; 2A0602; 1.
PE   1: Evidence at protein level;
KW   Antibiotic resistance; Cell inner membrane; Cell membrane;
KW   Complete proteome; Membrane; Transmembrane; Transport.
FT   CHAIN         1   1037       Multidrug resistance protein mdtF.
FT                                /FTId=PRO_0000161841.
FT   TOPO_DOM      1      9       Cytoplasmic (By similarity).
FT   TRANSMEM     10     28       1 (By similarity).
FT   TOPO_DOM     29    339       Periplasmic (By similarity).
FT   TRANSMEM    340    359       2 (By similarity).
FT   TOPO_DOM    360    365       Cytoplasmic (By similarity).
FT   TRANSMEM    366    385       3 (By similarity).
FT   TOPO_DOM    386    391       Periplasmic (By similarity).
FT   TRANSMEM    392    413       4 (By similarity).
FT   TOPO_DOM    414    441       Cytoplasmic (By similarity).
FT   TRANSMEM    442    460       5 (By similarity).
FT   TOPO_DOM    461    473       Periplasmic (By similarity).
FT   TRANSMEM    474    496       6 (By similarity).
FT   TOPO_DOM    497    536       Cytoplasmic (By similarity).
FT   TRANSMEM    537    555       7 (By similarity).
FT   TOPO_DOM    556    870       Periplasmic (By similarity).
FT   TRANSMEM    871    890       8 (By similarity).
FT   TOPO_DOM    891    896       Cytoplasmic (By similarity).
FT   TRANSMEM    897    916       9 (By similarity).
FT   TOPO_DOM    917    922       Periplasmic (By similarity).
FT   TRANSMEM    923    944       10 (By similarity).
FT   TOPO_DOM    945    972       Cytoplasmic (By similarity).
FT   TRANSMEM    973    991       11 (By similarity).
FT   TOPO_DOM    992   1004       Periplasmic (By similarity).
FT   TRANSMEM   1005   1027       12 (By similarity).
FT   TOPO_DOM   1028   1037       Cytoplasmic (By similarity).
SQ   SEQUENCE   1037 AA;  111517 MW;  3B67502160F51724 CRC64;
     MANYFIDRPV FAWVLAIIMM LAGGLAIMNL PVAQYPQIAP PTITVSATYP GADAQTVEDS
     VTQVIEQNMN GLDGLMYMSS TSDAAGNASI TLTFETGTSP DIAQVQVQNK LQLAMPSLPE
     AVQQQGISVD KSSSNILMVA AFISDNGSLN QYDIADYVAS NIKDPLSRTA GVGSVQLFGS
     EYAMRIWLDP QKLNKYNLVP SDVISQIKVQ NNQISGGQLG GMPQAADQQL NASIIVQTRL
     QTPEEFGKIL LKVQQDGSQV LLRDVARVEL GAEDYSTVAR YNGKPAAGIA IKLAAGANAL
     DTSRAVKEEL NRLSAYFPAS LKTVYPYDTT PFIEISIQEV FKTLVEAIIL VFLVMYLFLQ
     NFRATIIPTI AVPVVILGTF AILSAVGFTI NTLTMFGMVL AIGLLVDDAI VVVENVERVI
     AEDKLPPKEA THKSMGQIQR ALVGIAVVLS AVFMPMAFMS GATGEIYRQF SITLISSMLL
     SVFVAMSLTP ALCATILKAA PEGGHKPNAL FARFNTLFEK STQHYTDSTR SLLRCTGRYM
     VVYLLICAGM AVLFLRTPTS FLPEEDQGVF MTTAQLPSGA TMVNTTKVLQ QVTDYYLTKE
     KDNVQSVFTV GGFGFSGQGQ NNGLAFISLK PWSERVGEEN SVTAIIQRAM IALSSINKAV
     VFPFNLPAVA ELGTASGFDM ELLDNGNLGH EKLTQARNEL LSLAAQSPNQ VTGVRPNGLE
     DTPMFKVNVN AAKAEAMGVA LSDINQTIST AFGSSYVNDF LNQGRVKKVY VQAGTPFRML
     PDNINQWYVR NASGTMAPLS AYSSTEWTYG SPRLERYNGI PSMEILGEAA AGKSTGDAMK
     FMADLVAKLP AGVGYSWTGL SYQEALSSNQ APALYAISLV VVFLALAALY ESWSIPFSVM
     LVVPLGVVGA LLATDLRGLS NDVYFQVGLL TTIGLSAKNA ILIVEFAVEM MQKEGKTPIE
     AIIEAARMRL RPILMTSLAF ILGVLPLVIS HGAGSGAQNA VGTGVMGGMF AATVLAIYFV
     PVFFVVVEHL FARFKKA
//
ID   MGTE_ENTFA              Reviewed;         453 AA.
AC   Q830V1;
DT   10-FEB-2009, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2003, sequence version 1.
DT   02-MAR-2010, entry version 44.
DE   RecName: Full=Magnesium transporter mgtE;
GN   Name=mgtE; OrderedLocusNames=EF_2668;
OS   Enterococcus faecalis (Streptococcus faecalis).
OC   Bacteria; Firmicutes; Lactobacillales; Enterococcaceae; Enterococcus.
OX   NCBI_TaxID=1351;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=V583 / ATCC 700802;
RX   MEDLINE=22550857; PubMed=12663927; DOI=10.1126/science.1080613;
RA   Paulsen I.T., Banerjei L., Myers G.S.A., Nelson K.E., Seshadri R.,
RA   Read T.D., Fouts D.E., Eisen J.A., Gill S.R., Heidelberg J.F.,
RA   Tettelin H., Dodson R.J., Umayam L.A., Brinkac L.M., Beanan M.J.,
RA   Daugherty S.C., DeBoy R.T., Durkin S.A., Kolonay J.F., Madupu R.,
RA   Nelson W.C., Vamathevan J.J., Tran B., Upton J., Hansen T., Shetty J.,
RA   Khouri H.M., Utterback T.R., Radune D., Ketchum K.A., Dougherty B.A.,
RA   Fraser C.M.;
RT   "Role of mobile DNA in the evolution of vancomycin-resistant
RT   Enterococcus faecalis.";
RL   Science 299:2071-2074(2003).
RN   [2]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 2-285.
RG   New York structural genomics research consortium (NYSGRC);
RT   "Crystal structure of the soluble part of a magnesium transporter.";
RL   Submitted (FEB-2007) to the PDB data bank.
CC   -!- FUNCTION: Acts as a magnesium transporter (By similarity).
CC   -!- SUBUNIT: Homodimer (By similarity).
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein
CC       (Potential).
CC   -!- SIMILARITY: Belongs to the SLC41A transporter family.
CC   -!- SIMILARITY: Contains 2 CBS domains.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AE016830; AAO82375.1; -; Genomic_DNA.
DR   RefSeq; NP_816305.1; -.
DR   PDB; 2OUX; X-ray; 2.16 A; A/B=2-285.
DR   PDBsum; 2OUX; -.
DR   SMR; Q830V1; 15-450.
DR   GeneID; 1201525; -.
DR   GenomeReviews; AE016830_GR; EF_2668.
DR   KEGG; efa:EF2668; -.
DR   NMPDR; fig|226185.1.peg.2490; -.
DR   TIGR; EF_2668; -.
DR   HOGENOM; HBG680933; -.
DR   OMA; ETLNVIY; -.
DR   ProtClustDB; CLSK583150; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0008324; F:cation transmembrane transporter activity; IEA:InterPro.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006812; P:cation transport; IEA:InterPro.
DR   InterPro; IPR000644; Cysta_beta_synth_core.
DR   InterPro; IPR006668; Mg_transptr_MgtE_intracell_dom.
DR   InterPro; IPR006667; MgtE_Mg_transptr_membr_reg.
DR   InterPro; IPR006669; MgtE_transporter.
DR   Pfam; PF00571; CBS; 2.
DR   Pfam; PF01769; MgtE; 1.
DR   Pfam; PF03448; MgtE_N; 1.
DR   SMART; SM00116; CBS; 2.
DR   TIGRFAMs; TIGR00400; mgtE; 1.
DR   PROSITE; PS51371; CBS; 2.
PE   1: Evidence at protein level;
KW   3D-structure; CBS domain; Cell membrane; Complete proteome; Magnesium;
KW   Membrane; Metal-binding; Repeat; Transmembrane; Transport.
FT   CHAIN         1    453       Magnesium transporter mgtE.
FT                                /FTId=PRO_0000363888.
FT   TOPO_DOM      1    278       Cytoplasmic (By similarity).
FT   TRANSMEM    279    306       1 (By similarity).
FT   TOPO_DOM    307    321       In membrane (By similarity).
FT   TRANSMEM    322    345       2 (By similarity).
FT   TOPO_DOM    346    352       Cytoplasmic (By similarity).
FT   TRANSMEM    353    383       3 (By similarity).
FT   TOPO_DOM    384    387       In membrane (By similarity).
FT   TRANSMEM    388    416       4 (By similarity).
FT   TOPO_DOM    417    426       In membrane (By similarity).
FT   TRANSMEM    427    449       5 (By similarity).
FT   TOPO_DOM    450    452       Periplasmic (By similarity).
FT   DOMAIN      142    205       CBS 1.
FT   DOMAIN      206    262       CBS 2.
FT   METAL        98     98       Magnesium 1 (By similarity).
FT   METAL       102    102       Magnesium 2 (By similarity).
FT   METAL       218    218       Magnesium 3 (By similarity).
FT   METAL       220    220       Magnesium 4 (By similarity).
FT   METAL       230    230       Magnesium 5 (By similarity).
FT   METAL       251    251       Magnesium 1 (By similarity).
FT   METAL       259    259       Magnesium 3 (By similarity).
FT   METAL       263    263       Magnesium 4 (By similarity).
FT   METAL       420    420       Magnesium 4 (By similarity).
FT   METAL       434    434       Magnesium 6 (By similarity).
FT   HELIX         7     20
FT   HELIX        23     30
FT   TURN         35     37
FT   TURN         42     44
FT   HELIX        47     56
FT   HELIX        59     66
FT   STRAND       73     75
FT   HELIX        78     82
FT   HELIX        85     92
FT   HELIX        97    106
FT   HELIX       109    117
FT   TURN        121    123
FT   HELIX       127    130
FT   STRAND      151    154
FT   HELIX       155    165
FT   STRAND      173    178
FT   HELIX       190    193
FT   HELIX       202    205
FT   HELIX       219    229
FT   STRAND      232    234
FT   HELIX       249    261
SQ   SEQUENCE   453 AA;  50320 MW;  CDB202115B7BD54F CRC64;
     MNEGQEMEEQ FALLLETLKN QQMNEFRELF LALHIYEQGQ FYQSLDEKDR QHLYNYLSPK
     ELADMFDVIE EDNENMKDYL AEMRPSYAAD MLAEMYTDNA VDLLNMLDKS QKAKYLSLLS
     SEEAGEIKEL LHYEDETAGA IMTTEFVSIV ANQTVRSAMY VLKNQADMAE TIYYVYVVDQ
     ENHLVGVISL RDLIVNDDDT LIADILNERV ISVHVGDDQE DVAQTIRDYD FLAVPVTDYD
     DHLLGIVTVD DIIDVIDDEA ASDYSGLAGV DVEEVSENPL KAASKRLPWL ITLLFLGMST
     ASLISNYESL VSEASILAVF ISLITGTAGN AGTQSLAVAV RRLAMKDEKD SNFGRLILSE
     VLTGLVTGAV TGLTIMIVVG VWQHNLPLGF VIGMAMLCAI TVANLAGSLI PMLMDKLGFD
     PAVASGPFIT TLSDLTSVLI YFNIASMFMR YFV
//
ID   MRP1_MOUSE              Reviewed;        1528 AA.
AC   O35379;
DT   27-SEP-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   02-MAR-2010, entry version 73.
DE   RecName: Full=Multidrug resistance-associated protein 1;
DE   AltName: Full=ATP-binding cassette sub-family C member 1;
DE   AltName: Full=Leukotriene C(4) transporter;
DE            Short=LTC4 transporter;
GN   Name=Abcc1; Synonyms=Abcc1a, Abcc1b, Mdrap, Mrp;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Muscle;
RX   MEDLINE=96251691; PubMed=8649356;
RA   Stride B.D., Valdimarsson G., Gerlach J.H., Wilson G.M., Cole S.P.C.,
RA   Deeley R.G.;
RT   "Structure and expression of the messenger RNA encoding the murine
RT   multidrug resistance protein, an ATP-binding cassette transporter.";
RL   Mol. Pharmacol. 49:962-971(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Testis;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [3]
RP   FUNCTION.
RX   PubMed=9281595;
RA   Stride B.D., Grant C.E., Loe D.W., Hipfner D.R., Cole S.P.C.,
RA   Deeley R.G.;
RT   "Pharmacological characterization of the murine and human orthologs of
RT   multidrug-resistance protein in transfected human embryonic kidney
RT   cells.";
RL   Mol. Pharmacol. 52:344-353(1997).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-878 AND SER-882, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Macrophage;
RX   PubMed=19144319; DOI=10.1016/j.immuni.2008.11.006;
RA   Trost M., English L., Lemieux S., Courcelles M., Desjardins M.,
RA   Thibault P.;
RT   "The phagosomal proteome in interferon-gamma-activated macrophages.";
RL   Immunity 30:143-154(2009).
CC   -!- FUNCTION: Mediates export of organic anions and drugs from the
CC       cytoplasm. Mediates ATP-dependent transport of glutathione and
CC       glutathione conjugates, leukotriene C4, estradiol-17-beta-o-
CC       glucuronide, methotrexate, antiviral drugs and other xenobiotics.
CC       Confers resistance to anticancer drugs. Hydrolyzes ATP with low
CC       efficiency.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein
CC       (By similarity).
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCC
CC       family. Conjugate transporter (TC 3.A.1.208) subfamily.
CC   -!- SIMILARITY: Contains 2 ABC transmembrane type-1 domains.
CC   -!- SIMILARITY: Contains 2 ABC transporter domains.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF022908; AAB80938.1; -; mRNA.
DR   EMBL; AK029876; BAC26654.1; -; mRNA.
DR   IPI; IPI00129915; -.
DR   RefSeq; NP_032602.1; -.
DR   UniGene; Mm.196634; -.
DR   SMR; O35379; 642-871, 1035-1526.
DR   STRING; O35379; -.
DR   PhosphoSite; O35379; -.
DR   PRIDE; O35379; -.
DR   Ensembl; ENSMUST00000100167; ENSMUSP00000097743; ENSMUSG00000023088; Mus musculus.
DR   GeneID; 17250; -.
DR   KEGG; mmu:17250; -.
DR   UCSC; uc007yhj.1; mouse.
DR   CTD; 17250; -.
DR   MGI; MGI:102676; Abcc1.
DR   HOGENOM; HBG758042; -.
DR   HOVERGEN; HBG108314; -.
DR   InParanoid; O35379; -.
DR   OMA; SNADIYL; -.
DR   OrthoDB; EOG9SJ80K; -.
DR   PhylomeDB; O35379; -.
DR   NextBio; 291714; -.
DR   ArrayExpress; O35379; -.
DR   Bgee; O35379; -.
DR   Genevestigator; O35379; -.
DR   GermOnline; ENSMUSG00000023088; Mus musculus.
DR   GO; GO:0005887; C:integral to plasma membrane; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR017940; ABC_transporter_type1.
DR   InterPro; IPR001140; ABC_transptr_TM_dom.
DR   InterPro; IPR011527; ABC_transptrTM_dom_typ1.
DR   InterPro; IPR003593; ATPase_AAA+_core.
DR   InterPro; IPR005292; Multidrug-R_assoc.
DR   Pfam; PF00664; ABC_membrane; 2.
DR   Pfam; PF00005; ABC_tran; 2.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF90123; ABC_TM_1; 2.
DR   TIGRFAMs; TIGR00957; MRP_assoc_pro; 1.
DR   PROSITE; PS50929; ABC_TM1F; 2.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 2.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
PE   1: Evidence at protein level;
KW   ATP-binding; Cell membrane; Glycoprotein; Hydrolase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Repeat; Transmembrane; Transport.
FT   CHAIN         1   1528       Multidrug resistance-associated protein
FT                                1.
FT                                /FTId=PRO_0000093353.
FT   TOPO_DOM      1     33       Extracellular (By similarity).
FT   TRANSMEM     34     54       1 (By similarity).
FT   TOPO_DOM     55     74       Cytoplasmic (By similarity).
FT   TRANSMEM     75     95       2 (By similarity).
FT   TOPO_DOM     96    100       Extracellular (By similarity).
FT   TRANSMEM    101    121       3 (By similarity).
FT   TOPO_DOM    122    133       Cytoplasmic (By similarity).
FT   TRANSMEM    134    154       4 (By similarity).
FT   TOPO_DOM    155    172       Extracellular (By similarity).
FT   TRANSMEM    173    193       5 (By similarity).
FT   TOPO_DOM    194    317       Cytoplasmic (By similarity).
FT   TRANSMEM    318    338       6 (By similarity).
FT   TOPO_DOM    339    364       Extracellular (By similarity).
FT   TRANSMEM    365    385       7 (By similarity).
FT   TOPO_DOM    386    441       Cytoplasmic (By similarity).
FT   TRANSMEM    442    462       8 (By similarity).
FT   TOPO_DOM    463    465       Extracellular (By similarity).
FT   TRANSMEM    466    486       9 (By similarity).
FT   TOPO_DOM    487    548       Cytoplasmic (By similarity).
FT   TRANSMEM    549    569       10 (By similarity).
FT   TOPO_DOM    570    591       Extracellular (By similarity).
FT   TRANSMEM    592    612       11 (By similarity).
FT   TOPO_DOM    613    963       Cytoplasmic (By similarity).
FT   TRANSMEM    964    984       12 (By similarity).
FT   TOPO_DOM    985   1022       Extracellular (By similarity).
FT   TRANSMEM   1023   1043       13 (By similarity).
FT   TOPO_DOM   1044   1086       Cytoplasmic (By similarity).
FT   TRANSMEM   1087   1107       14 (By similarity).
FT   TOPO_DOM   1108   1108       Extracellular (By similarity).
FT   TRANSMEM   1109   1129       15 (By similarity).
FT   TOPO_DOM   1130   1200       Cytoplasmic (By similarity).
FT   TRANSMEM   1201   1221       16 (By similarity).
FT   TOPO_DOM   1222   1223       Extracellular (By similarity).
FT   TRANSMEM   1224   1244       17 (By similarity).
FT   TOPO_DOM   1245   1528       Cytoplasmic (By similarity).
FT   DOMAIN      326    609       ABC transmembrane type-1 1.
FT   DOMAIN      644    868       ABC transporter 1.
FT   DOMAIN      971   1253       ABC transmembrane type-1 2.
FT   DOMAIN     1290   1524       ABC transporter 2.
FT   NP_BIND     678    685       ATP 1 (Potential).
FT   NP_BIND    1324   1331       ATP 2 (Potential).
FT   MOD_RES     878    878       Phosphoserine.
FT   MOD_RES     882    882       Phosphoserine.
FT   MOD_RES     912    912       Phosphoserine (By similarity).
FT   MOD_RES     914    914       Phosphoserine (By similarity).
FT   MOD_RES     927    927       Phosphoserine (By similarity).
FT   CARBOHYD     19     19       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1003   1003       N-linked (GlcNAc...) (Potential).
SQ   SEQUENCE   1528 AA;  171185 MW;  68FD13667D61DBBB CRC64;
     MALRSFCSAD GSDPLWDWNV TWHTSNPDFT KCFQNTVLTW VPCFYLWSCF PLYFFYLSRH
     DRGYIQMTHL NKTKTALGFF LWIICWADLF YSFWERSQGV LRAPVLLVSP TLLGITMLLA
     TFLIQLERRK GVQSSGIMLT FWLVALLCAL AILRSKIISA LKKDAHVDVF RDSTFYLYFT
     LVLVQLVLSC FSDCSPLFSE TVHDRNPCPE SSASFLSRIT FWWITGMMVH GYRQPLESSD
     LWSLNKEDTS EEVVPVLVNN WKKECDKSRK QPVRIVYAPP KDPSKPKGSS QLDVNEEVEA
     LIVKSPHKDR EPSLFKVLYK TFGPYFLMSF LYKALHDLMM FAGPKILELI INFVNDREAP
     DWQGYFYTAL LFVSACLQTL ALHQYFHICF VSGMRIKTAV VGAVYRKALL ITNAARKSST
     VGEIVNLMSV DAQRFMDLAT YINMIWSAPL QVILALYFLW LSLGPSVLAG VAVMILMVPL
     NAVMAMKTKT YQVAHMKSKD NRIKLMNEIL NGIKVLKLYA WELAFQDKVM SIRQEELKVL
     KKSAYLAAVG TFTWVCTPFL VALSTFAVFV TVDERNILDA KKAFVSLALF NILRFPLNIL
     PMVISSIVQA SVSLKRLRIF LSHEELEPDS IERRSIKSGE GNSITVKNAT FTWARGEPPT
     LNGITFSIPE GALVAVVGQV GCGKSSLLSA LLAEMDKVEG HVTLKGSVAY VPQQAWIQND
     SLRENILFGH PLQENYYKAV MEACALLPDL EILPSGDRTE IGEKGVNLSG GQKQRVSLAR
     AVYSNSDIYL FDDPLSAVDA HVGKHIFEKV VGPMGLLKNK TRILVTHGIS YLPQVDVIIV
     MSGGKISEMG SYQELLDRDG AFAEFLRTYA NAEQDLASED DSVSGSGKES KPVENGMLVT
     DTVGKHLQRH LSNSSSHSGD TSQQHSSIAE LQKAGAKEET WKLMEADKAQ TGQVQLSVYW
     NYMKAIGLFI TFLSIFLFLC NHVSALASNY WLSLWTDDPP VVNGTQANRN FRLSVYGALG
     ILQGAAIFGY SMAVSIGGIF ASRRLHLDLL YNVLRSPMSF FERTPSGNLV NRFSKELDTV
     DSMIPQVIKM FMGSLFSVIG AVIIILLATP IAAVIIPPLG LVYFFVQRFY VASSRQLKRL
     ESVSRSPVYS HFNETLLGVS VIRAFEEQER FIHQSDLKVD ENQKAYYPSI VANRWLAVRL
     ECVGNCIVLF AALFAVISRH SLSAGLVGLS VSYSLQITAY LNWLVRMSSE METNIVAVER
     LKEYSETEKE APWQIQETAP PSTWPHSGRV EFRDYCLRYR EDLDLVLKHI NVTIEGGEKV
     GIVGRTGAGK SSLTLGLFRI NESAEGEIII DGVNIAKIGL HNLRFKITII PQDPVLFSGS
     LRMNLDPFSQ YSDEEVWMAL ELAHLKGFVS ALPDKLNHEC AEGGENLSVG QRQLVCLARA
     LLRKTKILVL DEATAAVDLE TDNLIQSTIR TQFEDCTVLT IAHRLNTIMD YTRVIVLDKG
     EVRECGAPSE LLQQRGIFYS MAKDAGLV
//
ID   MRP1_RAT                Reviewed;        1532 AA.
AC   Q8CG09; Q63346; Q810E4; Q810G9; Q9JHS0;
DT   24-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   24-JAN-2006, sequence version 2.
DT   02-MAR-2010, entry version 63.
DE   RecName: Full=Multidrug resistance-associated protein 1;
DE   AltName: Full=ATP-binding cassette sub-family C member 1;
DE   AltName: Full=Leukotriene C(4) transporter;
DE            Short=LTC4 transporter;
GN   Name=Abcc1; Synonyms=Mrp1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RX   PubMed=12423064; DOI=10.1208/ps040315;
RA   Yang Z., Li C.S.W., Shen D.D., Ho R.J.Y.;
RT   "Cloning and characterization of the rat multidrug resistance-
RT   associated protein 1.";
RL   AAPS PharmSci 4:E15-E15(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   MUTAGENESIS OF LEU-983; GLN-1090; SER-1101; VAL-1106 AND ALA-1243.
RC   STRAIN=Sprague-Dawley; TISSUE=Skeletal muscle;
RX   PubMed=12867490; DOI=10.1124/dmd.31.8.1016;
RA   Nunoya K., Grant C.E., Zhang D.-W., Cole S.P.C., Deeley R.G.;
RT   "Molecular cloning and pharmacological characterization of rat
RT   multidrug resistance protein 1 (mrp1).";
RL   Drug Metab. Dispos. 31:1016-1026(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   STRAIN=Sprague-Dawley; TISSUE=Spleen;
RA   Yabuuchi H., Takayanagi S., Ishikawa T.;
RL   Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   STRAIN=Sprague-Dawley; TISSUE=Spleen;
RA   Takayanagi S., Ishikawa T.;
RL   Submitted (NOV-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 711-1532 (ISOFORM 1).
RX   MEDLINE=22130255; PubMed=11208926;
RX   DOI=10.1046/j.1471-4159.2001.00101.x;
RA   Hirrlinger J., Koenig J., Keppler D., Lindenau J., Schulz J.B.,
RA   Dringen R.;
RT   "The multidrug resistance protein MRP1 mediates the release of
RT   glutathione disulfide from rat astrocytes during oxidative stress.";
RL   J. Neurochem. 76:627-636(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1426-1532 (ISOFORMS 1/2).
RX   MEDLINE=96279006; PubMed=8662992; DOI=10.1074/jbc.271.25.15091;
RA   Buechler M., Koenig J., Brom M., Kartenbeck J., Spring H., Horie T.,
RA   Keppler D.;
RT   "cDNA cloning of the hepatocyte canalicular isoform of the multidrug
RT   resistance protein, cMrp, reveals a novel conjugate export pump
RT   deficient in hyperbilirubinemic mutant rats.";
RL   J. Biol. Chem. 271:15091-15098(1996).
RN   [7]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15129170; DOI=10.1097/00001756-200405190-00020;
RA   Dallas S., Ronaldson P.T., Bendayan M., Bendayan R.;
RT   "Multidrug resistance protein 1-mediated transport of saquinavir by
RT   microglia.";
RL   NeuroReport 15:1183-1186(2004).
CC   -!- FUNCTION: Mediates export of organic anions and drugs from the
CC       cytoplasm. Mediates ATP-dependent transport of glutathione and
CC       glutathione conjugates, leukotriene C4, estradiol-17-beta-o-
CC       glucuronide, methotrexate, antiviral drugs and other xenobiotics.
CC       Confers resistance to anticancer drugs. Hydrolyzes ATP with low
CC       efficiency.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q8CG09-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8CG09-2; Sequence=VSP_017015;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Skeletal muscle, brain, heart, spleen, lung
CC       and kidney.
CC   -!- PTM: Glycosylated.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCC
CC       family. Conjugate transporter (TC 3.A.1.208) subfamily.
CC   -!- SIMILARITY: Contains 2 ABC transmembrane type-1 domains.
CC   -!- SIMILARITY: Contains 2 ABC transporter domains.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY170916; AAN86532.1; -; mRNA.
DR   EMBL; AF487549; AAO85437.1; -; mRNA.
DR   EMBL; AY174892; AAO44983.1; -; mRNA.
DR   EMBL; AJ277881; CAB97204.1; -; mRNA.
DR   EMBL; X96394; CAA65258.1; -; mRNA.
DR   IPI; IPI00331756; -.
DR   IPI; IPI00734748; -.
DR   RefSeq; NP_071617.2; -.
DR   UniGene; Rn.10495; -.
DR   SMR; Q8CG09; 643-872, 1039-1530.
DR   STRING; Q8CG09; -.
DR   PhosphoSite; Q8CG09; -.
DR   Ensembl; ENSRNOT00000046607; ENSRNOP00000045518; ENSRNOG00000032748; Rattus norvegicus.
DR   GeneID; 24565; -.
DR   KEGG; rno:24565; -.
DR   CTD; 24565; -.
DR   RGD; 3112; Abcc1.
DR   eggNOG; maNOG06639; -.
DR   HOVERGEN; HBG108314; -.
DR   PhylomeDB; Q8CG09; -.
DR   NextBio; 603696; -.
DR   ArrayExpress; Q8CG09; -.
DR   Genevestigator; Q8CG09; -.
DR   GermOnline; ENSRNOG00000032748; Rattus norvegicus.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:RGD.
DR   GO; GO:0005737; C:cytoplasm; IDA:RGD.
DR   GO; GO:0005887; C:integral to plasma membrane; IDA:RGD.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0015562; F:efflux transmembrane transporter activity; IDA:RGD.
DR   GO; GO:0015431; F:glutathione S-conjugate-exporting ATPase ac...; IMP:RGD.
DR   GO; GO:0034634; F:glutathione transmembrane transporter activity; IMP:RGD.
DR   GO; GO:0034040; F:lipid-transporting ATPase activity; IDA:RGD.
DR   GO; GO:0005324; F:long-chain fatty acid transporter activity; IDA:RGD.
DR   GO; GO:0015559; F:multidrug efflux pump activity; IDA:RGD.
DR   GO; GO:0016491; F:oxidoreductase activity; IEA:InterPro.
DR   GO; GO:0046624; F:sphingolipid transporter activity; IMP:RGD.
DR   GO; GO:0008559; F:xenobiotic-transporting ATPase activity; IDA:RGD.
DR   GO; GO:0060326; P:cell chemotaxis; IMP:RGD.
DR   GO; GO:0043215; P:daunorubicin transport; IMP:RGD.
DR   GO; GO:0046618; P:drug export; IDA:RGD.
DR   GO; GO:0034775; P:glutathione transmembrane transport; IMP:RGD.
DR   GO; GO:0006855; P:multidrug transport; IDA:RGD.
DR   GO; GO:0043526; P:neuroprotection; IMP:RGD.
DR   GO; GO:0055114; P:oxidation reduction; IEA:InterPro.
DR   GO; GO:0033700; P:phospholipid efflux; IMP:RGD.
DR   GO; GO:0015911; P:plasma membrane long-chain fatty acid trans...; IDA:RGD.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:RGD.
DR   GO; GO:0006979; P:response to oxidative stress; IMP:RGD.
DR   GO; GO:0042908; P:xenobiotic transport; IMP:RGD.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR017940; ABC_transporter_type1.
DR   InterPro; IPR001140; ABC_transptr_TM_dom.
DR   InterPro; IPR011527; ABC_transptrTM_dom_typ1.
DR   InterPro; IPR018170; Aldo/ket_reductase_CS.
DR   InterPro; IPR003593; ATPase_AAA+_core.
DR   InterPro; IPR005292; Multidrug-R_assoc.
DR   Pfam; PF00664; ABC_membrane; 2.
DR   Pfam; PF00005; ABC_tran; 2.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF90123; ABC_TM_1; 2.
DR   TIGRFAMs; TIGR00957; MRP_assoc_pro; 1.
DR   PROSITE; PS50929; ABC_TM1F; 2.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 2.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
DR   PROSITE; PS00063; ALDOKETO_REDUCTASE_3; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cell membrane; Glycoprotein;
KW   Hydrolase; Membrane; Nucleotide-binding; Phosphoprotein; Repeat;
KW   Transmembrane; Transport.
FT   CHAIN         1   1532       Multidrug resistance-associated protein
FT                                1.
FT                                /FTId=PRO_0000093354.
FT   TOPO_DOM      1     33       Extracellular (By similarity).
FT   TRANSMEM     34     54       1 (By similarity).
FT   TOPO_DOM     55     74       Cytoplasmic (By similarity).
FT   TRANSMEM     75     95       2 (By similarity).
FT   TOPO_DOM     96    100       Extracellular (By similarity).
FT   TRANSMEM    101    121       3 (By similarity).
FT   TOPO_DOM    122    133       Cytoplasmic (By similarity).
FT   TRANSMEM    134    154       4 (By similarity).
FT   TOPO_DOM    155    172       Extracellular (By similarity).
FT   TRANSMEM    173    193       5 (By similarity).
FT   TOPO_DOM    194    317       Cytoplasmic (By similarity).
FT   TRANSMEM    318    338       6 (By similarity).
FT   TOPO_DOM    339    364       Extracellular (By similarity).
FT   TRANSMEM    365    385       7 (By similarity).
FT   TOPO_DOM    386    441       Cytoplasmic (By similarity).
FT   TRANSMEM    442    462       8 (By similarity).
FT   TOPO_DOM    463    465       Extracellular (By similarity).
FT   TRANSMEM    466    486       9 (By similarity).
FT   TOPO_DOM    487    548       Cytoplasmic (By similarity).
FT   TRANSMEM    549    569       10 (By similarity).
FT   TOPO_DOM    570    591       Extracellular (By similarity).
FT   TRANSMEM    592    612       11 (By similarity).
FT   TOPO_DOM    613    967       Cytoplasmic (By similarity).
FT   TRANSMEM    968    988       12 (By similarity).
FT   TOPO_DOM    989   1026       Extracellular (By similarity).
FT   TRANSMEM   1027   1047       13 (By similarity).
FT   TOPO_DOM   1048   1090       Cytoplasmic (By similarity).
FT   TRANSMEM   1091   1111       14 (By similarity).
FT   TOPO_DOM   1112   1112       Extracellular (By similarity).
FT   TRANSMEM   1113   1133       15 (By similarity).
FT   TOPO_DOM   1134   1204       Cytoplasmic (By similarity).
FT   TRANSMEM   1205   1225       16 (By similarity).
FT   TOPO_DOM   1226   1227       Extracellular (By similarity).
FT   TRANSMEM   1228   1248       17 (By similarity).
FT   TOPO_DOM   1249   1532       Cytoplasmic (By similarity).
FT   DOMAIN      326    609       ABC transmembrane type-1 1.
FT   DOMAIN      645    869       ABC transporter 1.
FT   DOMAIN      975   1257       ABC transmembrane type-1 2.
FT   DOMAIN     1294   1528       ABC transporter 2.
FT   NP_BIND     679    686       ATP 1 (Potential).
FT   NP_BIND    1328   1335       ATP 2 (Potential).
FT   MOD_RES     879    879       Phosphoserine (By similarity).
FT   MOD_RES     883    883       Phosphoserine (By similarity).
FT   MOD_RES     916    916       Phosphoserine (By similarity).
FT   MOD_RES     918    918       Phosphoserine (By similarity).
FT   MOD_RES     931    931       Phosphoserine (By similarity).
FT   CARBOHYD     19     19       N-linked (GlcNAc...) (Potential).
FT   VAR_SEQ     912    920       Missing (in isoform 2).
FT                                /FTId=VSP_017015.
FT   MUTAGEN     983    983       L->M: No effect on estradiol glucuronide
FT                                transport.
FT   MUTAGEN    1090   1090       Q->E: 7.6-fold increase of the estradiol
FT                                glucuronide transport; when associated
FT                                with T-1243. Increases doxorubicin
FT                                inhibition.
FT   MUTAGEN    1101   1101       S->N: 50% increase of estradiol
FT                                glucuronide transport.
FT   MUTAGEN    1106   1106       V->C: No effect on estradiol glucuronide
FT                                transport.
FT   MUTAGEN    1243   1243       A->T: 7.6-fold increase of the estradiol
FT                                glucuronide transport; when associated
FT                                with E-1090.
FT   CONFLICT      4      4       S -> R (in Ref. 1 and 4).
FT   CONFLICT    480    480       F -> S (in Ref. 4; AAO44983).
FT   CONFLICT    820    820       N -> S (in Ref. 5; CAB97204).
FT   CONFLICT    868    868       R -> P (in Ref. 5; CAB97204).
FT   CONFLICT    916    916       S -> G (in Ref. 5; CAB97204).
FT   CONFLICT   1122   1122       P -> T (in Ref. 5; CAB97204).
FT   CONFLICT   1382   1382       S -> P (in Ref. 1; AAN86532).
FT   CONFLICT   1473   1473       I -> V (in Ref. 1; AAN86532).
SQ   SEQUENCE   1532 AA;  171493 MW;  2E6939F63F5A3F68 CRC64;
     MALSSFCSSD GSDPLWDWNV TWHTSNPDFT KCFQNTVLTW VPCFYLWSCF PLYFLYLSRH
     DRGYIQMTHL NKAKTALGFF LWIICWADLF YSFWERSQGM LLAPVLLVSP TLLGITMLLA
     TFLIQFERRK GVQSSGIMLT FWLVALLCAL AILRSKIISA LKKDAQVDMF RDSAFYLYFT
     LVFIQLVLSC FSDSSPLFSE TVRDPNPCPE SSASFLSRIT FWWITGMMVQ GYRQPLKSSD
     LWSLNKEDTS EEVVPVLVNN WKKECVKSRK QPVRIVYAPP KDPTKPKGSS QLDVNEEVEA
     LIVKSSHKDR DPSLFKVLYK TFGPYFLMSF LYKALHDLMM FAGPEILELI INFVNDREAP
     DWQGYLYTAL LFVSACLQTL ALHQYFHICF VTGMRIKTAV VGAVYRKALV ITNSARKSST
     VGEIVNLMSV DAQRFMDLAT YINMIWSAPL QVTLALYFLW LNLGPSVLAG VAVMILMVPF
     NAVMAMKTKT YQVAHMKSKD NRIKLMNEIL NGIKVLKLYA WELAFQDKVM NIRQEELKVL
     KKSAYLAAVG TFTWVCTPFL VALSTFAVFV TVDEKNILDA KKAFVSLALF NILRFPLNIL
     PMVISSIVQA SVSLKRLRIF LSHEELEPDS IERWSIKDGG GMNSITVKNA TFTWARDEPP
     TLNGITFAIP DGALVAVVGQ VGCGKSSLLS ALLAEMDKVE GHVTLKGSVA YVPQQAWIQN
     DSLRENILFG RPLQEHCYKA VMEACALLPD LEILPSGDLT EIGEKGVNLS GGQKQRVSLA
     RAVYCNSDIY LLDDPLSAVD AHVGKHIFEK VVGPMGLLKN KTRILVTHGI SYLPQVDVII
     VMSGGKISEM GSYQELLDRD GAFAEFVRTY ANTEQDLASE DDSKNGVSGL GKESKPVENG
     ILVTDAVGKP LQRHLSNSSS HSVVTNQQHS STAELQKSGV KEETWKLMEA DKAQTGQVKL
     SVYWNYMKAI GLCISFLSIF LFLCNHVSAL ASNYWLSLWT DDRPAVNGTQ ENRNFRLSVY
     GALGILQGVA VFGYSMAVSI GGIFASRRLH LDLLQNVLRS PMSFFERTPS GNLVNRFSKE
     LDTVDSMIPQ VIKMFMGSLF SVIGAVIIIL LATPIAAVII PPLGLVYFFV QRFYVASSRQ
     LKRLESVSRS PVYSHFNETL LGVSVIRAFE EQERFIRQSD LKVDENQKAY YPSIVANRWL
     AVRLECVGNC IVLFAALFAV ISRHSLSAGL VGLSVSYSLQ ITAYLNWLVR MSSEMETNIV
     AVERLKEYSE TEKEASWQIQ ETAPPSTWPH SGRVEFRDYC LRYREDLDLV LKHINVTIEG
     GEKVGIVGRT GAGKSSLTLG LFRINESAEG EIIIDGINIA KIGLHNLRFK ITIIPQDPVL
     FSGSLRMNLD PFSQYSDEEV WMALELAHLK GFVSALPDKL NHECAEGGEN LSVGQRQLVC
     LARALLRKTK ILVLDEATAA VDLETDDLIQ STIRTQFEDS TVLTIAHRLN TIMDYTRVIV
     LDKGEIRECG APSELLQQRG VFYSMAKDAG LV
//
ID   MRP2_HUMAN              Reviewed;        1545 AA.
AC   Q92887; B2RMT8; Q14022; Q5T2B1; Q92500; Q92798; Q99663; Q9UMS2;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1997, sequence version 2.
DT   02-MAR-2010, entry version 106.
DE   RecName: Full=Canalicular multispecific organic anion transporter 1;
DE   AltName: Full=ATP-binding cassette sub-family C member 2;
DE   AltName: Full=Multidrug resistance-associated protein 2;
DE   AltName: Full=Canalicular multidrug resistance protein;
GN   Name=ABCC2; Synonyms=CMOAT, CMOAT1, CMRP, MRP2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=96390592; PubMed=8797578;
RA   Taniguchi K., Wada M., Kohno K., Nakamura T., Kawabe T., Kawakami M.,
RA   Kagotani K., Okumura K., Akiyama S., Kuwano M.;
RT   "A human canalicular multispecific organic anion transporter (cMOAT)
RT   gene is overexpressed in cisplatin-resistant human cancer cell lines
RT   with decreased drug accumulation.";
RL   Cancer Res. 56:4124-4129(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS GLU-1188 AND TYR-1515.
RA   Kool M., de Haas M., Ponne N.J., Paulusma C.C., Oude-Elferink R.P.J.,
RA   Baas F., Borst P.;
RL   Submitted (FEB-1996) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=96279006; PubMed=8662992; DOI=10.1074/jbc.271.25.15091;
RA   Buechler M., Koenig J., Brom M., Kartenbeck J., Spring H., Horie T.,
RA   Keppler D.;
RT   "cDNA cloning of the hepatocyte canalicular isoform of the multidrug
RT   resistance protein, cMrp, reveals a novel conjugate export pump
RT   deficient in hyperbilirubinemic mutant rats.";
RL   J. Biol. Chem. 271:15091-15098(1996).
RN   [4]
RP   SEQUENCE REVISION.
RA   Keppler D.;
RL   Submitted (AUG-1996) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT DJS 1392-ARG-MET-1393
RP   DEL.
RX   MEDLINE=99395001; PubMed=10464142;
RA   Tsujii H., Koenig J., Rost D., Stoeckel B., Leuschner U., Keppler D.;
RT   "Exon-intron organization of the human multidrug-resistance protein 2
RT   (MRP2) gene mutated in Dubin-Johnson syndrome.";
RL   Gastroenterology 117:653-660(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT TYR-39.
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   REVIEW.
RX   MEDLINE=20527024; PubMed=11076395; DOI=10.1055/s-2000-9391;
RA   Keppler D., Koenig J.;
RT   "Hepatic secretion of conjugated drugs and endogenous substances.";
RL   Semin. Liver Dis. 20:265-272(2000).
RN   [10]
RP   MUTAGENESIS OF TRP-1254.
RX   MEDLINE=21474353; PubMed=11500505; DOI=10.1074/jbc.M105160200;
RA   Ito K., Oleschuk C.J., Westlake C., Vasa M.Z., Deeley R.G.,
RA   Cole S.P.C.;
RT   "Mutation of Trp1254 in the multispecific organic anion transporter,
RT   multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate
RT   specificity and results in loss of methotrexate transport activity.";
RL   J. Biol. Chem. 276:38108-38114(2001).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-283, AND MASS
RP   SPECTROMETRY.
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-283 AND SER-878, AND
RP   MASS SPECTROMETRY.
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   VARIANT DJS TRP-768.
RX   MEDLINE=98087571; PubMed=9425227; DOI=10.1093/hmg/7.2.203;
RA   Wada M., Toh S., Taniguchi K., Nakamura T., Uchiumi T., Kohno K.,
RA   Yoshida I., Kimura A., Sakisaka S., Adachi Y., Kuwano M.;
RT   "Mutations in the canilicular multispecific organic anion transporter
RT   (cMOAT) gene, a novel ABC transporter, in patients with
RT   hyperbilirubinemia II/Dubin-Johnson syndrome.";
RL   Hum. Mol. Genet. 7:203-207(1998).
RN   [14]
RP   VARIANTS DJS TRP-768 AND ARG-1382.
RX   MEDLINE=99162196; PubMed=10053008; DOI=10.1086/302292;
RA   Toh S., Wada M., Uchiumi T., Inokuchi A., Makino Y., Horie Y.,
RA   Adachi Y., Sakisaka S., Kuwano M.;
RT   "Genomic structure of the canalicular multispecific organic anion-
RT   transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-
RT   cassette region in Dubin-Johnson syndrome.";
RL   Am. J. Hum. Genet. 64:739-746(1999).
RN   [15]
RP   CHARACTERIZATION OF VARIANT DJS 1392-ARG-MET-1393 DEL.
RX   MEDLINE=20545299; PubMed=11093739; DOI=10.1053/jhep.2000.19791;
RA   Keitel V., Kartenbeck J., Nies A.T., Spring H., Brom M., Keppler D.;
RT   "Impaired protein maturation of the conjugate export pump multidrug
RT   resistance protein 2 as a consequence of a deletion mutation in Dubin-
RT   Johnson syndrome.";
RL   Hepatology 32:1317-1328(2000).
RN   [16]
RP   VARIANTS DJS HIS-1150 AND PHE-1173, AND VARIANTS ASN-281 AND ILE-417.
RX   MEDLINE=21463061; PubMed=11477083; DOI=10.1074/jbc.M105047200;
RA   Mor-Cohen R., Zivelin A., Rosenberg N., Shani M., Muallem S.,
RA   Seligsohn U.;
RT   "Identification and functional analysis of two novel mutations in the
RT   multidrug resistance protein 2 gene in Israeli patients with Dubin-
RT   Johnson syndrome.";
RL   J. Biol. Chem. 276:36923-36930(2001).
RN   [17]
RP   VARIANT DJS TRP-768, AND VARIANTS ILE-417; PHE-789 AND THR-1450.
RX   MEDLINE=21163848; PubMed=11266082;
RX   DOI=10.1097/00008571-200103000-00008;
RA   Ito S., Ieiri I., Tanabe M., Suzuki A., Higuchi S., Otsubo K.;
RT   "Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT,
RT   in healthy Japanese subjects.";
RL   Pharmacogenetics 11:175-184(2001).
CC   -!- FUNCTION: Mediates hepatobiliary excretion of numerous organic
CC       anions. May function as a cellular cisplatin transporter.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Found on the apical membrane of polarized
CC       cells in liver, kidney and intestine. The highest expression is
CC       found in liver.
CC   -!- DISEASE: Defects in ABCC2 are the cause of Dubin-Johnson syndrome
CC       (DJS) [MIM:237500]. DJS is an autosomal recessive disorder
CC       characterized by conjugated hyperbilirubinemia, an increase in the
CC       urinary excretion of coproporphyrin isomer I, deposition of
CC       melanin-like pigment in hepatocytes, and prolonged retention of
CC       sulfobromophthalein, but otherwise normal liver function.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCC
CC       family. Conjugate transporter (TC 3.A.1.208) subfamily.
CC   -!- SIMILARITY: Contains 2 ABC transmembrane type-1 domains.
CC   -!- SIMILARITY: Contains 2 ABC transporter domains.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/ABCC2";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U63970; AAB39892.1; -; mRNA.
DR   EMBL; U49248; AAB09422.1; -; mRNA.
DR   EMBL; X96395; CAA65259.2; -; mRNA.
DR   EMBL; AJ132244; CAB45309.1; -; Genomic_DNA.
DR   EMBL; AJ132287; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ245625; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132288; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132289; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132290; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132291; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132292; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132293; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132294; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132295; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132296; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132297; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132298; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132299; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132300; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132301; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132302; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132303; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ245626; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132304; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132305; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132306; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132307; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132308; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ245627; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132309; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132310; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132311; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132312; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132313; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132314; CAB45309.1; JOINED; Genomic_DNA.
DR   EMBL; AL392107; CAI11010.1; -; Genomic_DNA.
DR   EMBL; AL133353; CAI11010.1; JOINED; Genomic_DNA.
DR   EMBL; AL133353; CAI14502.1; -; Genomic_DNA.
DR   EMBL; AL392107; CAI14502.1; JOINED; Genomic_DNA.
DR   EMBL; CH471066; EAW49853.1; -; Genomic_DNA.
DR   EMBL; BC136419; AAI36420.1; -; mRNA.
DR   IPI; IPI00023868; -.
DR   PIR; S71841; S71841.
DR   RefSeq; NP_000383.1; -.
DR   UniGene; Hs.368243; -.
DR   SMR; Q92887; 642-862, 1028-1534.
DR   STRING; Q92887; -.
DR   TCDB; 3.A.1.208.2; ATP-binding cassette (ABC) superfamily.
DR   PhosphoSite; Q92887; -.
DR   PRIDE; Q92887; -.
DR   Ensembl; ENST00000370449; ENSP00000359478; ENSG00000023839; Homo sapiens.
DR   GeneID; 1244; -.
DR   KEGG; hsa:1244; -.
DR   UCSC; uc001kqf.2; human.
DR   CTD; 1244; -.
DR   GeneCards; GC10P101532; -.
DR   H-InvDB; HIX0035426; -.
DR   HGNC; HGNC:53; ABCC2.
DR   HPA; HPA004860; -.
DR   MIM; 237500; phenotype.
DR   MIM; 601107; gene.
DR   Orphanet; 234; Dubin-Johnson syndrome.
DR   PharmGKB; PA116; -.
DR   eggNOG; prNOG14927; -.
DR   HOVERGEN; HBG108314; -.
DR   InParanoid; Q92887; -.
DR   PhylomeDB; Q92887; -.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   DrugBank; DB00957; Norgestimate.
DR   DrugBank; DB00175; Pravastatin.
DR   DrugBank; DB01232; Saquinavir.
DR   DrugBank; DB01138; Sulfinpyrazone.
DR   NextBio; 5071; -.
DR   ArrayExpress; Q92887; -.
DR   Bgee; Q92887; -.
DR   CleanEx; HS_ABCC2; -.
DR   Genevestigator; Q92887; -.
DR   GermOnline; ENSG00000023839; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042626; F:ATPase activity, coupled to transmembrane m...; TAS:ProtInc.
DR   GO; GO:0008514; F:organic anion transmembrane transporter act...; TAS:ProtInc.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR017940; ABC_transporter_type1.
DR   InterPro; IPR001140; ABC_transptr_TM_dom.
DR   InterPro; IPR011527; ABC_transptrTM_dom_typ1.
DR   InterPro; IPR003593; ATPase_AAA+_core.
DR   InterPro; IPR005292; Multidrug-R_assoc.
DR   Pfam; PF00664; ABC_membrane; 2.
DR   Pfam; PF00005; ABC_tran; 2.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF90123; ABC_TM_1; 2.
DR   TIGRFAMs; TIGR00957; MRP_assoc_pro; 1.
DR   PROSITE; PS50929; ABC_TM1F; 2.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
PE   1: Evidence at protein level;
KW   ATP-binding; Complete proteome; Disease mutation; Glycoprotein;
KW   Membrane; Nucleotide-binding; Phosphoprotein; Polymorphism; Repeat;
KW   Transmembrane; Transport.
FT   CHAIN         1   1545       Canalicular multispecific organic anion
FT                                transporter 1.
FT                                /FTId=PRO_0000093356.
FT   TOPO_DOM      1     27       Extracellular (By similarity).
FT   TRANSMEM     28     48       1 (By similarity).
FT   TOPO_DOM     49     68       Cytoplasmic (By similarity).
FT   TRANSMEM     69     89       2 (By similarity).
FT   TOPO_DOM     90     93       Extracellular (By similarity).
FT   TRANSMEM     94    114       3 (By similarity).
FT   TOPO_DOM    115    126       Cytoplasmic (By similarity).
FT   TRANSMEM    127    147       4 (By similarity).
FT   TOPO_DOM    148    165       Extracellular (By similarity).
FT   TRANSMEM    166    186       5 (By similarity).
FT   TOPO_DOM    187    313       Cytoplasmic (By similarity).
FT   TRANSMEM    314    334       6 (By similarity).
FT   TOPO_DOM    335    360       Extracellular (By similarity).
FT   TRANSMEM    361    381       7 (By similarity).
FT   TOPO_DOM    382    437       Cytoplasmic (By similarity).
FT   TRANSMEM    438    458       8 (By similarity).
FT   TOPO_DOM    459    461       Extracellular (By similarity).
FT   TRANSMEM    462    482       9 (By similarity).
FT   TOPO_DOM    483    544       Cytoplasmic (By similarity).
FT   TRANSMEM    545    565       10 (By similarity).
FT   TOPO_DOM    566    587       Extracellular (By similarity).
FT   TRANSMEM    588    608       11 (By similarity).
FT   TOPO_DOM    609    971       Cytoplasmic (By similarity).
FT   TRANSMEM    972    992       12 (By similarity).
FT   TOPO_DOM    993   1033       Extracellular (By similarity).
FT   TRANSMEM   1034   1054       13 (By similarity).
FT   TOPO_DOM   1055   1097       Cytoplasmic (By similarity).
FT   TRANSMEM   1098   1118       14 (By similarity).
FT   TOPO_DOM   1119   1119       Extracellular (By similarity).
FT   TRANSMEM   1120   1140       15 (By similarity).
FT   TOPO_DOM   1141   1211       Cytoplasmic (By similarity).
FT   TRANSMEM   1212   1232       16 (By similarity).
FT   TOPO_DOM   1233   1234       Extracellular (By similarity).
FT   TRANSMEM   1235   1255       17 (By similarity).
FT   TOPO_DOM   1256   1545       Cytoplasmic (By similarity).
FT   DOMAIN      322    605       ABC transmembrane type-1 1.
FT   DOMAIN      637    861       ABC transporter 1.
FT   DOMAIN      979   1264       ABC transmembrane type-1 2.
FT   DOMAIN     1300   1534       ABC transporter 2.
FT   NP_BIND     671    678       ATP 1 (Potential).
FT   NP_BIND    1334   1341       ATP 2 (Potential).
FT   MOD_RES     283    283       Phosphoserine.
FT   MOD_RES     878    878       Phosphoserine.
FT   CARBOHYD      7      7       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     12     12       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1011   1011       N-linked (GlcNAc...) (Potential).
FT   VARIANT      39     39       F -> Y (in dbSNP:rs927344).
FT                                /FTId=VAR_047152.
FT   VARIANT     246    246       M -> L (in dbSNP:rs45462493).
FT                                /FTId=VAR_029113.
FT   VARIANT     281    281       S -> N (in dbSNP:rs56131651).
FT                                /FTId=VAR_013324.
FT   VARIANT     333    333       D -> G (in dbSNP:rs17222674).
FT                                /FTId=VAR_020226.
FT   VARIANT     353    353       R -> H (in dbSNP:rs7080681).
FT                                /FTId=VAR_020227.
FT   VARIANT     417    417       V -> I (in dbSNP:rs2273697).
FT                                /FTId=VAR_013325.
FT   VARIANT     495    495       K -> E (in dbSNP:rs17222561).
FT                                /FTId=VAR_029115.
FT   VARIANT     562    562       F -> L (in dbSNP:rs17216233).
FT                                /FTId=VAR_029116.
FT   VARIANT     670    670       I -> T (in dbSNP:rs17222632).
FT                                /FTId=VAR_020228.
FT   VARIANT     768    768       R -> W (in DJS; dbSNP:rs56199535).
FT                                /FTId=VAR_000099.
FT   VARIANT     789    789       S -> F (in dbSNP:rs56220353).
FT                                /FTId=VAR_013326.
FT   VARIANT     849    849       L -> R (in dbSNP:rs17222617).
FT                                /FTId=VAR_020229.
FT   VARIANT     982    982       I -> V (in dbSNP:rs17222554).
FT                                /FTId=VAR_029117.
FT   VARIANT    1036   1036       I -> T (in dbSNP:rs45441199).
FT                                /FTId=VAR_020230.
FT   VARIANT    1063   1063       N -> S (in dbSNP:rs17222540).
FT                                /FTId=VAR_029118.
FT   VARIANT    1150   1150       R -> H (in DJS; protein is properly
FT                                localized at the plasma membrane, but
FT                                transport activity is impaired).
FT                                /FTId=VAR_013327.
FT   VARIANT    1173   1173       I -> F (in DJS; low expression and
FT                                mislocation to the endoplasmic
FT                                reticulum).
FT                                /FTId=VAR_013328.
FT   VARIANT    1181   1181       R -> L (in dbSNP:rs8187692).
FT                                /FTId=VAR_020231.
FT   VARIANT    1188   1188       V -> E (in dbSNP:rs17222723).
FT                                /FTId=VAR_020232.
FT   VARIANT    1273   1273       T -> A (in dbSNP:rs8187699).
FT                                /FTId=VAR_024360.
FT   VARIANT    1291   1291       P -> L (in dbSNP:rs17216317).
FT                                /FTId=VAR_020233.
FT   VARIANT    1382   1382       Q -> R (in DJS).
FT                                /FTId=VAR_010756.
FT   VARIANT    1392   1393       Missing (in DJS; impaired maturation and
FT                                intercompartmental trafficking).
FT                                /FTId=VAR_013329.
FT   VARIANT    1450   1450       A -> T (in dbSNP:rs56296335).
FT                                /FTId=VAR_013330.
FT   VARIANT    1515   1515       C -> Y (in dbSNP:rs8187710).
FT                                /FTId=VAR_020234.
FT   MUTAGEN    1254   1254       W->A,C: Fails to transport methotrexate,
FT                                leukotriene C4 and estradiol glucuronide.
FT   MUTAGEN    1254   1254       W->F: Fails to transport methotrexate and
FT                                leukotriene C4. Does not affect estradiol
FT                                glucuronide transport.
FT   MUTAGEN    1254   1254       W->Y: Fails to transport methotrexate;
FT                                reduces leukotriene C4 transport. Does
FT                                not affect estradiol glucuronide
FT                                transport.
FT   CONFLICT   1430   1430       V -> G (in Ref. 5; CAB45309).
SQ   SEQUENCE   1545 AA;  174191 MW;  EA12668A4DD0F391 CRC64;
     MLEKFCNSTF WNSSFLDSPE ADLPLCFEQT VLVWIPLGFL WLLAPWQLLH VYKSRTKRSS
     TTKLYLAKQV FVGFLLILAA IELALVLTED SGQATVPAVR YTNPSLYLGT WLLVLLIQYS
     RQWCVQKNSW FLSLFWILSI LCGTFQFQTL IRTLLQGDNS NLAYSCLFFI SYGFQILILI
     FSAFSENNES SNNPSSIASF LSSITYSWYD SIILKGYKRP LTLEDVWEVD EEMKTKTLVS
     KFETHMKREL QKARRALQRR QEKSSQQNSG ARLPGLNKNQ SQSQDALVLE DVEKKKKKSG
     TKKDVPKSWL MKALFKTFYM VLLKSFLLKL VNDIFTFVSP QLLKLLISFA SDRDTYLWIG
     YLCAILLFTA ALIQSFCLQC YFQLCFKLGV KVRTAIMASV YKKALTLSNL ARKEYTVGET
     VNLMSVDAQK LMDVTNFMHM LWSSVLQIVL SIFFLWRELG PSVLAGVGVM VLVIPINAIL
     STKSKTIQVK NMKNKDKRLK IMNEILSGIK ILKYFAWEPS FRDQVQNLRK KELKNLLAFS
     QLQCVVIFVF QLTPVLVSVV TFSVYVLVDS NNILDAQKAF TSITLFNILR FPLSMLPMMI
     SSMLQASVST ERLEKYLGGD DLDTSAIRHD CNFDKAMQFS EASFTWEHDS EATVRDVNLD
     IMAGQLVAVI GPVGSGKSSL ISAMLGEMEN VHGHITIKGT TAYVPQQSWI QNGTIKDNIL
     FGTEFNEKRY QQVLEACALL PDLEMLPGGD LAEIGEKGIN LSGGQKQRIS LARATYQNLD
     IYLLDDPLSA VDAHVGKHIF NKVLGPNGLL KGKTRLLVTH SMHFLPQVDE IVVLGNGTIV
     EKGSYSALLA KKGEFAKNLK TFLRHTGPEE EATVHDGSEE EDDDYGLISS VEEIPEDAAS
     ITMRRENSFR RTLSRSSRSN GRHLKSLRNS LKTRNVNSLK EDEELVKGQK LIKKEFIETG
     KVKFSIYLEY LQAIGLFSIF FIILAFVMNS VAFIGSNLWL SAWTSDSKIF NSTDYPASQR
     DMRVGVYGAL GLAQGIFVFI AHFWSAFGFV HASNILHKQL LNNILRAPMR FFDTTPTGRI
     VNRFAGDIST VDDTLPQSLR SWITCFLGII STLVMICMAT PVFTIIVIPL GIIYVSVQMF
     YVSTSRQLRR LDSVTRSPIY SHFSETVSGL PVIRAFEHQQ RFLKHNEVRI DTNQKCVFSW
     ITSNRWLAIR LELVGNLTVF FSALMMVIYR DTLSGDTVGF VLSNALNITQ TLNWLVRMTS
     EIETNIVAVE RITEYTKVEN EAPWVTDKRP PPDWPSKGKI QFNNYQVRYR PELDLVLRGI
     TCDIGSMEKI GVVGRTGAGK SSLTNCLFRI LEAAGGQIII DGVDIASIGL HDLREKLTII
     PQDPILFSGS LRMNLDPFNN YSDEEIWKAL ELAHLKSFVA SLQLGLSHEV TEAGGNLSIG
     QRQLLCLGRA LLRKSKILVL DEATAAVDLE TDNLIQTTIQ NEFAHCTVIT IAHRLHTIMD
     SDKVMVLDNG KIIECGSPEE LLQIPGPFYF MAKEAGIENV NSTKF
//
ID   MRP6_HUMAN              Reviewed;        1503 AA.
AC   O95255; P78420; Q9UMZ7;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   24-NOV-2009, sequence version 2.
DT   02-MAR-2010, entry version 114.
DE   RecName: Full=Multidrug resistance-associated protein 6;
DE   AltName: Full=ATP-binding cassette sub-family C member 6;
DE   AltName: Full=Anthracycline resistance-associated protein;
DE   AltName: Full=Multi-specific organic anion transporter E;
DE            Short=MOAT-E;
GN   Name=ABCC6; Synonyms=ARA, MRP6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS TRP-64 AND VAL-848.
RX   MEDLINE=99107222; PubMed=9892204;
RA   Kool M., van der Linden M., de Haas M., Baas F., Borst P.;
RT   "Expression of human MRP6, a homologue of the multidrug resistance
RT   protein gene MRP1, in tissues and cancer cells.";
RL   Cancer Res. 59:175-182(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANTS TRP-64 AND
RP   VAL-848.
RX   MEDLINE=99425270; PubMed=10493829; DOI=10.1006/geno.1999.5927;
RA   Loftus B.J., Kim U.-J., Sneddon V.P., Kalush F., Brandon R.,
RA   Fuhrmann J., Mason T., Crosby M.L., Barnstead M., Cronin L.,
RA   Mays A.D., Cao Y., Xu R.X., Kang H.-L., Mitchell S., Eichler E.E.,
RA   Harris P.C., Venter J.C., Adams M.D.;
RT   "Genome duplications and other features in 12 Mb of DNA sequence from
RT   human chromosome 16p and 16q.";
RL   Genomics 60:295-308(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT VAL-848.
RX   MEDLINE=99352020; PubMed=10424734; DOI=10.1038/sj.bjc.6690527;
RA   Belinsky M.G., Kruh G.D.;
RT   "MOAT-E (ARA) is a full-length MRP/cMOAT subfamily transporter
RT   expressed in kidney and liver.";
RL   Br. J. Cancer 80:1342-1349(1999).
RN   [5]
RP   FUNCTION, AND CHARACTERIZATION OF VARIANTS PXE PHE-1298; ARG-1302 AND
RP   SER-1321.
RX   MEDLINE=21988190; PubMed=11880368; DOI=10.1074/jbc.M110918200;
RA   Ilias A., Urban Z., Seidl T.L., Le Saux O., Sinko E., Boyd C.D.,
RA   Sarkadi B., Varadi A.;
RT   "Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-
RT   associated mutants of human ABCC6 (MRP6).";
RL   J. Biol. Chem. 277:16860-16867(2002).
RN   [6]
RP   REVIEW, AND VARIANT PXE PRO-455.
RX   MEDLINE=21321623; PubMed=11427982; DOI=10.1016/S1471-4914(00)01869-4;
RA   Uitto J., Pulkkinen L., Ringpfeil F.;
RT   "Molecular genetics of pseudoxanthoma elasticum: a metabolic disorder
RT   at the environment-genome interface?";
RL   Trends Mol. Med. 7:13-17(2001).
RN   [7]
RP   SUBCELLULAR LOCATION, TOPOLOGY, AND GLYCOSYLATION AT ASN-15.
RX   PubMed=12901863; DOI=10.1016/S0006-291X(03)01349-4;
RA   Sinko E., Ilias A., Ujhelly O., Homolya L., Scheffer G.L.,
RA   Bergen A.A., Sarkadi B., Varadi A.;
RT   "Subcellular localization and N-glycosylation of human ABCC6,
RT   expressed in MDCKII cells.";
RL   Biochem. Biophys. Res. Commun. 308:263-269(2003).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-902, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Epithelium;
RX   PubMed=17924679; DOI=10.1021/pr070152u;
RA   Yu L.-R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.;
RT   "Improved titanium dioxide enrichment of phosphopeptides from HeLa
RT   cells and high confident phosphopeptide identification by cross-
RT   validation of MS/MS and MS/MS/MS spectra.";
RL   J. Proteome Res. 6:4150-4162(2007).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-681 AND SER-1310, AND
RP   MASS SPECTROMETRY.
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [10]
RP   VARIANT GLN-1268.
RX   MEDLINE=20374463; PubMed=10913334; DOI=10.1006/bbrc.2000.3101;
RA   Germain D.P., Perdu J., Remones V., Jeunemaitre X.;
RT   "Homozygosity for the R1268Q mutation in MRP6, the pseudoxanthoma
RT   elasticum gene, is not disease-causing.";
RL   Biochem. Biophys. Res. Commun. 274:297-301(2000).
RN   [11]
RP   VARIANT TRP-64.
RX   MEDLINE=20514578; PubMed=11058917;
RX   DOI=10.1002/1098-1004(200011)16:5<449::AID-HUMU24>3.0.CO;2-O;
RA   Germain D.P., Perdu J., Remones V., Manzoni K., Jeunemaitre X.;
RT   "Identification of two polymorphisms (c189G>C; c190T>C) in exon 2 of
RT   the human MRP6 gene (ABCC6) by screening of Pseudoxanthoma elasticum
RT   patients: possible sequence correction?";
RL   Hum. Mutat. 16:449-449(2000).
RN   [12]
RP   VARIANT PXE CYS-1339, AND VARIANT GLN-632.
RX   MEDLINE=20408303; PubMed=10954200; DOI=10.1007/s001090000114;
RA   Struk B., Cai L., Zaech S., Ji W., Chung J., Lumsden A., Stumm M.,
RA   Huber M., Schaen L., Kim C.-A., Goldsmith L.A., Viljoen D.,
RA   Figuera L.E., Fuchs W., Munier F., Ramesar R., Hohl D., Richards R.,
RA   Neldner K.H., Lindpaintner K.;
RT   "Mutations of the gene encoding the transmembrane transporter protein
RT   ABC-C6 cause pseudoxanthoma elasticum.";
RL   J. Mol. Med. 78:282-286(2000).
RN   [13]
RP   VARIANTS PXE PRO-1114; GLN-1138 AND TRP-1314, AND VARIANT ALA-614.
RX   MEDLINE=20296630; PubMed=10835642; DOI=10.1038/76102;
RA   Le Saux O., Urban Z., Tschuch C., Csiszar K., Bacchelli B.,
RA   Quaglino D., Pasquali-Ronchetti I., Pope F.M., Richards A., Terry S.,
RA   Bercovitch L., de Paepe A., Boyd C.D.;
RT   "Mutations in a gene encoding an ABC transporter cause pseudoxanthoma
RT   elasticum.";
RL   Nat. Genet. 25:223-227(2000).
RN   [14]
RP   VARIANT PXE TRP-1138, AND VARIANT GLN-1268.
RX   MEDLINE=20283940; PubMed=10811882; DOI=10.1073/pnas.100041297;
RA   Ringpfeil F., Lebwohl M.G., Christiano A.M., Uitto J.;
RT   "Pseudoxanthoma elasticum: mutations in the MRP6 gene encoding a
RT   transmembrane ATP-binding cassette (ABC) transporter.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:6001-6006(2000).
RN   [15]
RP   VARIANTS PXE LYS-411; GLN-518; SER-568; PRO-673; GLN-765; PRO-1114;
RP   TRP-1121; PRO-1138; GLN-1138; ASP-1203; PHE-1298; ILE-1301; ARG-1302;
RP   PRO-1303; GLN-1314; TRP-1314; SER-1321; CYS-1339; HIS-1347; ASN-1361
RP   AND THR-1424, AND VARIANTS ASP-61; ARG-207; GLY-265; GLU-281; VAL-319;
RP   LYS-497; ALA-614; GLN-632; HIS-953; CYS-1241 AND GLN-1268.
RX   MEDLINE=21426347; PubMed=11536079; DOI=10.1086/323704;
RA   Le Saux O., Beck K., Sachsinger C., Silvestri C., Treiber C.,
RA   Goering H.H.H., Johnson E.W., De Paepe A., Pope F.M.,
RA   Pasquali-Ronchetti I., Bercovitch L., Terry S., Boyd C.D.;
RT   "A spectrum of ABCC6 mutations is responsible for pseudoxanthoma
RT   elasticum.";
RL   Am. J. Hum. Genet. 69:749-764(2001).
RN   [16]
RP   VARIANTS PXE 60-ARG--TYR-62 DEL; ARG-364 AND ARG-1354, AND VARIANT
RP   GLY-265.
RX   MEDLINE=21558431; PubMed=11702217; DOI=10.1007/s004390100582;
RA   Pulkkinen L., Nakano A., Ringpfeil F., Uitto J.;
RT   "Identification of ABCC6 pseudogenes on human chromosome 16p:
RT   implications for mutation detection in pseudoxanthoma elasticum.";
RL   Hum. Genet. 109:356-365(2001).
RN   [17]
RP   VARIANTS ALA-614; GLN-632 AND GLN-1268.
RX   MEDLINE=21632106; PubMed=11776382; DOI=10.1007/s100380170003;
RA   Wang J., Near S., Young K., Connelly P.W., Hegele R.A.;
RT   "ABCC6 gene polymorphism associated with variation in plasma
RT   lipoproteins.";
RL   J. Hum. Genet. 46:699-705(2001).
RN   [18]
RP   VARIANT [LARGE SCALE ANALYSIS] GLN-1268.
RX   PubMed=18987736; DOI=10.1038/nature07485;
RA   Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K.,
RA   Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., Cook L.,
RA   Abbott R., Larson D.E., Koboldt D.C., Pohl C., Smith S., Hawkins A.,
RA   Abbott S., Locke D., Hillier L.W., Miner T., Fulton L., Magrini V.,
RA   Wylie T., Glasscock J., Conyers J., Sander N., Shi X., Osborne J.R.,
RA   Minx P., Gordon D., Chinwalla A., Zhao Y., Ries R.E., Payton J.E.,
RA   Westervelt P., Tomasson M.H., Watson M., Baty J., Ivanovich J.,
RA   Heath S., Shannon W.D., Nagarajan R., Walter M.J., Link D.C.,
RA   Graubert T.A., DiPersio J.F., Wilson R.K.;
RT   "DNA sequencing of a cytogenetically normal acute myeloid leukaemia
RT   genome.";
RL   Nature 456:66-72(2008).
CC   -!- FUNCTION: May participate directly in the active transport of
CC       drugs into subcellular organelles or influence drug distribution
CC       indirectly. Transports glutathione conjugates as leukotriene-c4
CC       (LTC4) and N-ethylmaleimide S-glutathione (NEM-GS).
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein (By
CC       similarity). Note=Localized to the basolateral membrane.
CC   -!- TISSUE SPECIFICITY: Expressed in kidney and liver. Very low
CC       expression in other tissues.
CC   -!- DISEASE: Defects in ABCC6 are the cause of pseudoxanthoma
CC       elasticum (PXE) [MIM:264800]. PXE is a disorder characterized by
CC       calcification of elastic fibers in skin, arteries and retina that
CC       results in dermal lesions with associated laxity and loss of
CC       elasticity, arterial insufficiency and retinal hemorrhages leading
CC       to macular degeneration. PXE is caused in the overwhelming
CC       majority of cases by homozygous or compound heterozygous mutations
CC       in the ABCC6 gene (autosomal recessive PXE). Individuals carrying
CC       heterozygous mutations express limited manifestations of the
CC       pseudoxanthoma elasticum phenotype (autosomal dominant PXE).
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCC
CC       family. Conjugate transporter (TC 3.A.1.208) subfamily.
CC   -!- SIMILARITY: Contains 2 ABC transmembrane type-1 domains.
CC   -!- SIMILARITY: Contains 2 ABC transporter domains.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC15785.1; Type=Erroneous gene model prediction;
CC   -!- WEB RESOURCE: Name=Mutations of the ABCC6 gene; Note=Retina
CC       International's Scientific Newsletter;
CC       URL="http://www.retina-international.com/sci-news/abcc6mut.htm";
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/ABCC6";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF076622; AAC79696.1; -; mRNA.
DR   EMBL; AC136624; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; U91318; AAC15785.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AF168791; AAD51293.1; -; mRNA.
DR   IPI; IPI00029455; -.
DR   RefSeq; NP_001162.4; -.
DR   UniGene; Hs.442182; -.
DR   SMR; O95255; 310-852, 1012-1498, 1265-1499.
DR   STRING; O95255; -.
DR   TCDB; 3.A.1.208.10; ATP-binding cassette (ABC) superfamily.
DR   Ensembl; ENST00000205557; ENSP00000205557; ENSG00000091262; Homo sapiens.
DR   GeneID; 368; -.
DR   CTD; 368; -.
DR   GeneCards; GC16M016151; -.
DR   H-InvDB; HIX0026937; -.
DR   H-InvDB; HIX0038600; -.
DR   HGNC; HGNC:57; ABCC6.
DR   MIM; 177850; phenotype.
DR   MIM; 264800; phenotype.
DR   MIM; 603234; gene.
DR   Orphanet; 758; Pseudoxanthoma elasticum.
DR   PharmGKB; PA58; -.
DR   HOGENOM; HBG758042; -.
DR   HOVERGEN; HBG108314; -.
DR   InParanoid; O95255; -.
DR   OMA; HQEEQMR; -.
DR   PhylomeDB; O95255; -.
DR   ArrayExpress; O95255; -.
DR   Bgee; O95255; -.
DR   CleanEx; HS_ABCC6; -.
DR   Genevestigator; O95255; -.
DR   GermOnline; ENSG00000091262; Homo sapiens.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; TAS:ProtInc.
DR   GO; GO:0042626; F:ATPase activity, coupled to transmembrane m...; TAS:ProtInc.
DR   GO; GO:0042493; P:response to drug; TAS:ProtInc.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   GO; GO:0007601; P:visual perception; IEA:UniProtKB-KW.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR017940; ABC_transporter_type1.
DR   InterPro; IPR001140; ABC_transptr_TM_dom.
DR   InterPro; IPR011527; ABC_transptrTM_dom_typ1.
DR   InterPro; IPR003593; ATPase_AAA+_core.
DR   InterPro; IPR005292; Multidrug-R_assoc.
DR   Pfam; PF00664; ABC_membrane; 2.
DR   Pfam; PF00005; ABC_tran; 2.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF90123; ABC_TM_1; 2.
DR   TIGRFAMs; TIGR00957; MRP_assoc_pro; 1.
DR   PROSITE; PS50929; ABC_TM1F; 2.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 2.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
PE   1: Evidence at protein level;
KW   ATP-binding; Complete proteome; Disease mutation; Glycoprotein;
KW   Membrane; Nucleotide-binding; Phosphoprotein; Polymorphism; Repeat;
KW   Sensory transduction; Transmembrane; Transport; Vision.
FT   CHAIN         1   1503       Multidrug resistance-associated protein
FT                                6.
FT                                /FTId=PRO_0000093366.
FT   TOPO_DOM      1     31       Extracellular (By similarity).
FT   TRANSMEM     32     52       1 (By similarity).
FT   TOPO_DOM     53     72       Cytoplasmic (By similarity).
FT   TRANSMEM     73     93       2 (By similarity).
FT   TOPO_DOM     94     98       Extracellular (By similarity).
FT   TRANSMEM     99    119       3 (By similarity).
FT   TOPO_DOM    120    131       Cytoplasmic (By similarity).
FT   TRANSMEM    132    149       4 (By similarity).
FT   TOPO_DOM    150    167       Extracellular (By similarity).
FT   TRANSMEM    168    188       5 (By similarity).
FT   TOPO_DOM    189    302       Cytoplasmic (By similarity).
FT   TRANSMEM    303    323       6 (By similarity).
FT   TOPO_DOM    324    349       Extracellular (By similarity).
FT   TRANSMEM    350    370       7 (By similarity).
FT   TOPO_DOM    371    426       Cytoplasmic (By similarity).
FT   TRANSMEM    427    447       8 (By similarity).
FT   TOPO_DOM    448    450       Extracellular (By similarity).
FT   TRANSMEM    451    471       9 (By similarity).
FT   TOPO_DOM    472    533       Cytoplasmic (By similarity).
FT   TRANSMEM    534    554       10 (By similarity).
FT   TOPO_DOM    555    575       Extracellular (By similarity).
FT   TRANSMEM    576    596       11 (By similarity).
FT   TOPO_DOM    597    939       Cytoplasmic (By similarity).
FT   TRANSMEM    940    960       12 (By similarity).
FT   TOPO_DOM    961    997       Extracellular (By similarity).
FT   TRANSMEM    998   1018       13 (By similarity).
FT   TOPO_DOM   1019   1061       Cytoplasmic (By similarity).
FT   TRANSMEM   1062   1082       14 (By similarity).
FT   TOPO_DOM   1083   1083       Extracellular (By similarity).
FT   TRANSMEM   1084   1104       15 (By similarity).
FT   TOPO_DOM   1105   1175       Cytoplasmic (By similarity).
FT   TRANSMEM   1176   1196       16 (By similarity).
FT   TOPO_DOM   1197   1198       Extracellular (By similarity).
FT   TRANSMEM   1199   1219       17 (By similarity).
FT   TOPO_DOM   1220   1503       Cytoplasmic (By similarity).
FT   DOMAIN      311    593       ABC transmembrane type-1 1.
FT   DOMAIN      629    853       ABC transporter 1.
FT   DOMAIN      947   1228       ABC transmembrane type-1 2.
FT   DOMAIN     1265   1499       ABC transporter 2.
FT   NP_BIND     663    670       ATP 1 (Potential).
FT   NP_BIND    1299   1306       ATP 2 (Potential).
FT   MOD_RES     244    244       Phosphoserine (By similarity).
FT   MOD_RES     681    681       Phosphoserine.
FT   MOD_RES     902    902       Phosphoserine.
FT   MOD_RES    1310   1310       Phosphoserine.
FT   CARBOHYD     15     15       N-linked (GlcNAc...) (Probable).
FT   VARIANT      60     62       Missing (in PXE; autosomal recessive).
FT                                /FTId=VAR_013363.
FT   VARIANT      61     61       G -> D.
FT                                /FTId=VAR_013364.
FT   VARIANT      64     64       R -> W.
FT                                /FTId=VAR_013365.
FT   VARIANT     207    207       G -> R.
FT                                /FTId=VAR_013366.
FT   VARIANT     265    265       R -> G.
FT                                /FTId=VAR_013367.
FT   VARIANT     281    281       K -> E (in dbSNP:rs4780606).
FT                                /FTId=VAR_013368.
FT   VARIANT     319    319       I -> V.
FT                                /FTId=VAR_013369.
FT   VARIANT     364    364       T -> R (in PXE; autosomal recessive).
FT                                /FTId=VAR_013370.
FT   VARIANT     411    411       N -> K (in PXE; autosomal dominant).
FT                                /FTId=VAR_013371.
FT   VARIANT     455    455       A -> P (in PXE; autosomal dominant).
FT                                /FTId=VAR_013372.
FT   VARIANT     497    497       N -> K.
FT                                /FTId=VAR_013373.
FT   VARIANT     518    518       R -> Q (in PXE).
FT                                /FTId=VAR_013374.
FT   VARIANT     568    568       F -> S (in PXE; autosomal dominant).
FT                                /FTId=VAR_013375.
FT   VARIANT     614    614       V -> A (in dbSNP:rs12931472).
FT                                /FTId=VAR_011490.
FT   VARIANT     632    632       H -> Q (in dbSNP:rs8058694).
FT                                /FTId=VAR_013376.
FT   VARIANT     665    665       V -> A (in dbSNP:rs4341770).
FT                                /FTId=VAR_055477.
FT   VARIANT     673    673       L -> P (in PXE; autosomal dominant).
FT                                /FTId=VAR_013377.
FT   VARIANT     765    765       R -> Q (in PXE; autosomal dominant).
FT                                /FTId=VAR_013378.
FT   VARIANT     848    848       M -> V (in dbSNP:rs6416668).
FT                                /FTId=VAR_059108.
FT   VARIANT     953    953       L -> H.
FT                                /FTId=VAR_013379.
FT   VARIANT    1097   1097       L -> I (in dbSNP:rs60707953).
FT                                /FTId=VAR_060988.
FT   VARIANT    1114   1114       R -> P (in PXE; autosomal recessive).
FT                                /FTId=VAR_011491.
FT   VARIANT    1121   1121       S -> W (in PXE; autosomal dominant).
FT                                /FTId=VAR_013380.
FT   VARIANT    1138   1138       R -> P (in PXE; autosomal dominant).
FT                                /FTId=VAR_013381.
FT   VARIANT    1138   1138       R -> Q (in PXE; autosomal recessive;
FT                                dbSNP:rs60791294).
FT                                /FTId=VAR_011492.
FT   VARIANT    1138   1138       R -> W (in PXE; autosomal recessive;
FT                                dbSNP:rs28939701).
FT                                /FTId=VAR_011493.
FT   VARIANT    1203   1203       G -> D (in PXE; autosomal dominant).
FT                                /FTId=VAR_013382.
FT   VARIANT    1241   1241       W -> C.
FT                                /FTId=VAR_013383.
FT   VARIANT    1268   1268       R -> Q (associated with lower plasma
FT                                triglycerides and higher plasma HDL
FT                                cholesterol; dbSNP:rs2238472).
FT                                /FTId=VAR_011494.
FT   VARIANT    1298   1298       V -> F (in PXE; autosomal dominant;
FT                                abolishes LTC4 and NEM-GS transport).
FT                                /FTId=VAR_013384.
FT   VARIANT    1301   1301       T -> I (in PXE; autosomal dominant).
FT                                /FTId=VAR_013385.
FT   VARIANT    1302   1302       G -> R (in PXE; autosomal dominant;
FT                                abolishes LTC4 and NEM-GS transport).
FT                                /FTId=VAR_013386.
FT   VARIANT    1303   1303       A -> P (in PXE; autosomal dominant).
FT                                /FTId=VAR_013387.
FT   VARIANT    1314   1314       R -> Q (in PXE; autosomal dominant).
FT                                /FTId=VAR_013388.
FT   VARIANT    1314   1314       R -> W (in PXE; autosomal recessive).
FT                                /FTId=VAR_011495.
FT   VARIANT    1321   1321       G -> S (in PXE; autosomal dominant;
FT                                abolishes LTC4 and NEM-GS transport).
FT                                /FTId=VAR_013389.
FT   VARIANT    1339   1339       R -> C (in PXE; autosomal recessive;
FT                                dbSNP:rs28939702).
FT                                /FTId=VAR_013390.
FT   VARIANT    1347   1347       Q -> H (in PXE; autosomal dominant).
FT                                /FTId=VAR_013391.
FT   VARIANT    1354   1354       G -> R (in PXE; autosomal recessive).
FT                                /FTId=VAR_013392.
FT   VARIANT    1361   1361       D -> N (in PXE; autosomal dominant;
FT                                dbSNP:rs58695352).
FT                                /FTId=VAR_013393.
FT   VARIANT    1424   1424       I -> T (in PXE; autosomal dominant).
FT                                /FTId=VAR_013394.
FT   CONFLICT    377    377       L -> P (in Ref. 4; AAD51293).
FT   CONFLICT   1274   1274       Y -> C (in Ref. 4; AAD51293).
FT   CONFLICT   1455   1455       L -> P (in Ref. 4; AAD51293).
SQ   SEQUENCE   1503 AA;  164906 MW;  2107BE13B1547B39 CRC64;
     MAAPAEPCAG QGVWNQTEPE PAATSLLSLC FLRTAGVWVP PMYLWVLGPI YLLFIHHHGR
     GYLRMSPLFK AKMVLGFALI VLCTSSVAVA LWKIQQGTPE APEFLIHPTV WLTTMSFAVF
     LIHTERKKGV QSSGVLFGYW LLCFVLPATN AAQQASGAGF QSDPVRHLST YLCLSLVVAQ
     FVLSCLADQP PFFPEDPQQS NPCPETGAAF PSKATFWWVS GLVWRGYRRP LRPKDLWSLG
     RENSSEELVS RLEKEWMRNR SAARRHNKAI AFKRKGGSGM KAPETEPFLR QEGSQWRPLL
     KAIWQVFHST FLLGTLSLII SDVFRFTVPK LLSLFLEFIG DPKPPAWKGY LLAVLMFLSA
     CLQTLFEQQN MYRLKVLQMR LRSAITGLVY RKVLALSSGS RKASAVGDVV NLVSVDVQRL
     TESVLYLNGL WLPLVWIVVC FVYLWQLLGP SALTAIAVFL SLLPLNFFIS KKRNHHQEEQ
     MRQKDSRARL TSSILRNSKT IKFHGWEGAF LDRVLGIRGQ ELGALRTSGL LFSVSLVSFQ
     VSTFLVALVV FAVHTLVAEN AMNAEKAFVT LTVLNILNKA QAFLPFSIHS LVQARVSFDR
     LVTFLCLEEV DPGVVDSSSS GSAAGKDCIT IHSATFAWSQ ESPPCLHRIN LTVPQGCLLA
     VVGPVGAGKS SLLSALLGEL SKVEGFVSIE GAVAYVPQEA WVQNTSVVEN VCFGQELDPP
     WLERVLEACA LQPDVDSFPE GIHTSIGEQG MNLSGGQKQR LSLARAVYRK AAVYLLDDPL
     AALDAHVGQH VFNQVIGPGG LLQGTTRILV THALHILPQA DWIIVLANGA IAEMGSYQEL
     LQRKGALMCL LDQARQPGDR GEGETEPGTS TKDPRGTSAG RRPELRRERS IKSVPEKDRT
     TSEAQTEVPL DDPDRAGWPA GKDSIQYGRV KATVHLAYLR AVGTPLCLYA LFLFLCQQVA
     SFCRGYWLSL WADDPAVGGQ QTQAALRGGI FGLLGCLQAI GLFASMAAVL LGGARASRLL
     FQRLLWDVVR SPISFFERTP IGHLLNRFSK ETDTVDVDIP DKLRSLLMYA FGLLEVSLVV
     AVATPLATVA ILPLFLLYAG FQSLYVVSSC QLRRLESASY SSVCSHMAET FQGSTVVRAF
     RTQAPFVAQN NARVDESQRI SFPRLVADRW LAANVELLGN GLVFAAATCA VLSKAHLSAG
     LVGFSVSAAL QVTQTLQWVV RNWTDLENSI VSVERMQDYA WTPKEAPWRL PTCAAQPPWP
     QGGQIEFRDF GLRYRPELPL AVQGVSFKIH AGEKVGIVGR TGAGKSSLAS GLLRLQEAAE
     GGIWIDGVPI AHVGLHTLRS RISIIPQDPI LFPGSLRMNL DLLQEHSDEA IWAALETVQL
     KALVASLPGQ LQYKCADRGE DLSVGQKQLL CLARALLRKT QILILDEATA AVDPGTELQM
     QAMLGSWFAQ CTVLLIAHRL RSVMDCARVL VMDKGQVAES GSPAQLLAQK GLFYRLAQES
     GLV
//
ID   MRP6_MOUSE              Reviewed;        1498 AA.
AC   Q9R1S7; Q80YB6;
DT   19-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   02-MAR-2010, entry version 71.
DE   RecName: Full=Multidrug resistance-associated protein 6;
DE   AltName: Full=ATP-binding cassette sub-family C member 6;
GN   Name=Abcc6; Synonyms=Mrp6;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=ddY; TISSUE=Liver;
RA   Morikawa A., Suzuki H., Hirohashi T., Sugiyama Y.;
RT   "Mus musculus mRNA for multidrug resistance-associated protein 6
RT   (MRP6), complete cds.";
RL   Submitted (JUN-1999) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 685-1498.
RC   STRAIN=FVB/N; TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-250 AND SER-897, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=17242355; DOI=10.1073/pnas.0609836104;
RA   Villen J., Beausoleil S.A., Gerber S.A., Gygi S.P.;
RT   "Large-scale phosphorylation analysis of mouse liver.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:1488-1493(2007).
CC   -!- FUNCTION: May participate directly in the active transport of
CC       drugs into subcellular organelles or influence drug distribution
CC       indirectly (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCC
CC       family. Conjugate transporter (TC 3.A.1.208) subfamily.
CC   -!- SIMILARITY: Contains 2 ABC transmembrane type-1 domains.
CC   -!- SIMILARITY: Contains 2 ABC transporter domains.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB028737; BAA83820.1; -; mRNA.
DR   EMBL; BC049980; AAH49980.1; -; mRNA.
DR   IPI; IPI00129079; -.
DR   UniGene; Mm.63514; -.
DR   SMR; Q9R1S7; 298-850, 1015-1494.
DR   STRING; Q9R1S7; -.
DR   PRIDE; Q9R1S7; -.
DR   Ensembl; ENSMUST00000002850; ENSMUSP00000002850; ENSMUSG00000030834; Mus musculus.
DR   UCSC; uc009gya.1; mouse.
DR   MGI; MGI:1351634; Abcc6.
DR   HOGENOM; HBG758042; -.
DR   HOVERGEN; HBG108314; -.
DR   InParanoid; Q9R1S7; -.
DR   PhylomeDB; Q9R1S7; -.
DR   ArrayExpress; Q9R1S7; -.
DR   Bgee; Q9R1S7; -.
DR   Genevestigator; Q9R1S7; -.
DR   GermOnline; ENSMUSG00000030834; Mus musculus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042626; F:ATPase activity, coupled to transmembrane m...; IEA:InterPro.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR017940; ABC_transporter_type1.
DR   InterPro; IPR001140; ABC_transptr_TM_dom.
DR   InterPro; IPR011527; ABC_transptrTM_dom_typ1.
DR   InterPro; IPR003593; ATPase_AAA+_core.
DR   InterPro; IPR005292; Multidrug-R_assoc.
DR   Pfam; PF00664; ABC_membrane; 2.
DR   Pfam; PF00005; ABC_tran; 2.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF90123; ABC_TM_1; 2.
DR   TIGRFAMs; TIGR00957; MRP_assoc_pro; 1.
DR   PROSITE; PS50929; ABC_TM1F; 2.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
PE   1: Evidence at protein level;
KW   ATP-binding; Glycoprotein; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Repeat; Transmembrane; Transport.
FT   CHAIN         1   1498       Multidrug resistance-associated protein
FT                                6.
FT                                /FTId=PRO_0000093367.
FT   TOPO_DOM      1     37       Extracellular (By similarity).
FT   TRANSMEM     38     58       1 (By similarity).
FT   TOPO_DOM     59     78       Cytoplasmic (By similarity).
FT   TRANSMEM     79     99       2 (By similarity).
FT   TOPO_DOM    100    104       Extracellular (By similarity).
FT   TRANSMEM    105    125       3 (By similarity).
FT   TOPO_DOM    126    137       Cytoplasmic (By similarity).
FT   TRANSMEM    138    155       4 (By similarity).
FT   TOPO_DOM    156    173       Extracellular (By similarity).
FT   TRANSMEM    174    194       5 (By similarity).
FT   TOPO_DOM    195    300       Cytoplasmic (By similarity).
FT   TRANSMEM    301    321       6 (By similarity).
FT   TOPO_DOM    322    347       Extracellular (By similarity).
FT   TRANSMEM    348    368       7 (By similarity).
FT   TOPO_DOM    369    424       Cytoplasmic (By similarity).
FT   TRANSMEM    425    445       8 (By similarity).
FT   TOPO_DOM    446    448       Extracellular (By similarity).
FT   TRANSMEM    449    469       9 (By similarity).
FT   TOPO_DOM    470    531       Cytoplasmic (By similarity).
FT   TRANSMEM    532    552       10 (By similarity).
FT   TOPO_DOM    553    574       Extracellular (By similarity).
FT   TRANSMEM    575    595       11 (By similarity).
FT   TOPO_DOM    596    934       Cytoplasmic (By similarity).
FT   TRANSMEM    935    955       12 (By similarity).
FT   TOPO_DOM    956    992       Extracellular (By similarity).
FT   TRANSMEM    993   1013       13 (By similarity).
FT   TOPO_DOM   1014   1056       Cytoplasmic (By similarity).
FT   TRANSMEM   1057   1077       14 (By similarity).
FT   TOPO_DOM   1078   1078       Extracellular (By similarity).
FT   TRANSMEM   1079   1099       15 (By similarity).
FT   TOPO_DOM   1100   1170       Cytoplasmic (By similarity).
FT   TRANSMEM   1171   1191       16 (By similarity).
FT   TOPO_DOM   1192   1193       Extracellular (By similarity).
FT   TRANSMEM   1194   1214       17 (By similarity).
FT   TOPO_DOM   1215   1498       Cytoplasmic (By similarity).
FT   DOMAIN      309    592       ABC transmembrane type-1 1.
FT   DOMAIN      627    851       ABC transporter 1.
FT   DOMAIN      942   1223       ABC transmembrane type-1 2.
FT   DOMAIN     1260   1494       ABC transporter 2.
FT   NP_BIND     661    668       ATP 1 (Potential).
FT   NP_BIND    1294   1301       ATP 2 (Potential).
FT   MOD_RES     250    250       Phosphoserine.
FT   MOD_RES     897    897       Phosphoserine.
FT   CARBOHYD     21     21       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    341    341       N-linked (GlcNAc...) (Potential).
FT   CONFLICT    706    706       A -> V (in Ref. 2; AAH49980).
FT   CONFLICT    927    927       I -> T (in Ref. 2; AAH49980).
FT   CONFLICT   1401   1401       H -> Q (in Ref. 2; AAH49980).
FT   CONFLICT   1448   1448       L -> V (in Ref. 2; AAH49980).
FT   CONFLICT   1477   1477       N -> S (in Ref. 2; AAH49980).
SQ   SEQUENCE   1498 AA;  164788 MW;  EFCFF33F0EEC813C CRC64;
     MNSGRSMATP GEQCAGLRVW NQTEQEPAAY HLLSLCFVRA ASSWVPPMYL WVLGPIYLLY
     IHRHGRCYLR MSHLFKTKMV LGLALILLYT FNVAVPLWRI HQGVPQAPEL LIHPTVWLTT
     MSFATFLIHM ERRKGVRSSG VLFGYWLLCC ILPGINTVQQ ASAGNLRQEP LHHLATYLCL
     SLVVAELVLS CLVDQPPFFS EDSQPLNPCP EAEASFPSKA MFWWASGLLW RGYKKLLGPK
     DLWSLGRENS SEELVSQLER EWRRSCNGLP GHKGHSSVGA PETEAFLQPE RSQRGPLLRA
     IWRVFRSTFL LGTLSLVISD AFRFAVPKLL SLFLEFMGDR NSSAWTGWLL AVLMFAAACL
     QTLFEQQHMY RAKVLQMRLR TAITGLVYRK VLVLSSGSRK SSAAGDVVNL VSVDIQRLAE
     SIIYLNGLWL LFLWIFVCFV YLWQLLGPSA LTAVAVFLSL LPLNFFITKK RGFHQEEQMR
     QKASRARLTS SMLRTVRTIK SHGWEHAFLE RLLHIRGQEL SALKTSTLLF SVSLVSFQVS
     TFLVALVVFA VHTLVAEDNA MDAEKAFVTL TVLSILNKAQ AFLPFSVHCI VQARVSFDRL
     AAFLCLEEVD PNGMIASNSR RSSKDRISVH NGTFAWSQES PPCLHGINLT VPQGCLLAVV
     GPVGAGKSSL LSALLGELLK VEGSVSIEGS VAYVPQEAWV QNTSVAENVC FRQELDLPWL
     QKVLDACALG SDVASFPAGV HTPIGEQGMN LSGGQKQRLS LARAVYKKAA IYLLDDPLAA
     LDAHVSQQVF KQVIGPSGLL QGTTRILVTH TLHVLPQADR ILVLANGTIA EMGSYQDLLQ
     RNGALVGLLD GARQPAGTHD AATSDDLGGF PGGGRPTCRP DRPRPTEAAP VKGRSTSEVQ
     MEASLDDPEA TGLTAEEDSV RYGRVKITIY LSYLRAVGTP LCTYTLFLFL CQQVASFSQG
     YWLSLWADDP VVDGRQMHAA LRGWVFGLLG CLQAIGLFAS MAAVFLGGAR ASGLLFRSLL
     WDVARSPIGF FERTPVGNLL NRFSKETDTV DVDIPDKLRS LLTYAFGLLE VGLAVTMATP
     LAIVAILPLM VLYAGFQSLY VATSCQLRRL ESARYSSVCS HMAETFQGSL VVRAFRAQAS
     FTAQHDALMD ENQRVSFPKL VADRWLATNL ELLGNGLVFV AATCAVLSKA HLSAGLVGFS
     VSAALQVTQT LQWVVRSWTD LENSMVAVER VQDYARIPKE APWRLPTCAA QPLWPCGGQI
     EFRDFGLRHR PELPLAVQGV SLKIHAGEKV GIVGRTGAGK SSLAWGLLRL QEAAEGNIWI
     DGVPITHVGL HTLRSRITII PQDPVLFPGS LRMNLDLLQE HTDEGIWAAL ETVQLKAFVT
     SLPGQLQYEC AGQGDDLSVG HKQLLCLARA LLRKTQILIL DEATASVDPG TEMQMQAALE
     RWFTQCTLLL IAHRLRSVMD CARVLVMDEG QVAESGNPAQ LLAQKGLFYR LAHESGLA
//
ID   MSCL_STAAW              Reviewed;         120 AA.
AC   P68806; O68285;
DT   21-DEC-2004, integrated into UniProtKB/Swiss-Prot.
DT   21-DEC-2004, sequence version 1.
DT   02-MAR-2010, entry version 37.
DE   RecName: Full=Large-conductance mechanosensitive channel;
GN   Name=mscL; OrderedLocusNames=MW1235;
OS   Staphylococcus aureus (strain MW2).
OC   Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX   NCBI_TaxID=196620;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   MEDLINE=22040717; PubMed=12044378; DOI=10.1016/S0140-6736(02)08713-5;
RA   Baba T., Takeuchi F., Kuroda M., Yuzawa H., Aoki K., Oguchi A.,
RA   Nagai Y., Iwama N., Asano K., Naimi T., Kuroda H., Cui L.,
RA   Yamamoto K., Hiramatsu K.;
RT   "Genome and virulence determinants of high virulence community-
RT   acquired MRSA.";
RL   Lancet 359:1819-1827(2002).
CC   -!- FUNCTION: Channel that opens in response to stretch forces in the
CC       membrane lipid bilayer. May participate in the regulation of
CC       osmotic pressure changes within the cell.
CC   -!- SUBUNIT: Homopentamer (By similarity).
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein
CC       (By similarity).
CC   -!- SIMILARITY: Belongs to the mscL family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; BA000033; BAB95100.1; -; Genomic_DNA.
DR   RefSeq; NP_646052.1; -.
DR   PDB; 3HZQ; X-ray; 3.82 A; A=1-94.
DR   PDBsum; 3HZQ; -.
DR   SMR; P68806; 1-119.
DR   STRING; P68806; -.
DR   GeneID; 1003347; -.
DR   GenomeReviews; BA000033_GR; MW1235.
DR   KEGG; sam:MW1235; -.
DR   eggNOG; COG1970; -.
DR   HOGENOM; HBG727604; -.
DR   ProtClustDB; PRK13954; -.
DR   BioCyc; SAUR196620:MW1235-MONOMER; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005216; F:ion channel activity; IEA:UniProtKB-KW.
DR   GO; GO:0006811; P:ion transport; IEA:UniProtKB-KW.
DR   HAMAP; MF_00115; MscL; 1; -.
DR   InterPro; IPR019823; Mechanosensitive_channel_CS.
DR   InterPro; IPR001185; MS_channel.
DR   Pfam; PF01741; MscL; 1.
DR   PRINTS; PR01264; MECHCHANNEL.
DR   SUPFAM; SSF81330; MS_channel; 1.
DR   TIGRFAMs; TIGR00220; mscL; 1.
DR   PROSITE; PS01327; MSCL; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Complete proteome; Ion transport;
KW   Ionic channel; Membrane; Transmembrane; Transport.
FT   CHAIN         1    120       Large-conductance mechanosensitive
FT                                channel.
FT                                /FTId=PRO_0000192466.
FT   TOPO_DOM      1     13       Cytoplasmic (Potential).
FT   TRANSMEM     14     40       By similarity.
FT   TOPO_DOM     41     62       Extracellular (Potential).
FT   TRANSMEM     63     84       By similarity.
FT   TOPO_DOM     85    120       Cytoplasmic (Potential).
SQ   SEQUENCE   120 AA;  13616 MW;  A4D1E6B2A7B7D2E5 CRC64;
     MLKEFKEFAL KGNVLDLAIA VVMGAAFNKI ISSLVENIIM PLIGKIFGSV DFAKEWSFWG
     IKYGLFIQSV IDFIIIAFAL FIFVKIANTL MKKEEAEEEA VVEENVVLLT EIRDLLREKK
//
ID   MYP0_MOUSE              Reviewed;         248 AA.
AC   P27573; Q542C9;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1992, sequence version 1.
DT   02-MAR-2010, entry version 85.
DE   RecName: Full=Myelin protein P0;
DE   AltName: Full=Myelin protein zero;
DE   AltName: Full=Myelin peripheral protein;
DE            Short=MPP;
DE   Flags: Precursor;
GN   Name=Mpz; Synonyms=P0;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=91244320; PubMed=1709914; DOI=10.1016/0888-7543(91)90370-T;
RA   You K.H., Hsieh C.L., Hayes C., Stahl N., Francke U., Popko B.;
RT   "DNA sequence, genomic organization, and chromosomal localization of
RT   the mouse peripheral myelin protein zero gene: identification of
RT   polymorphic alleles.";
RL   Genomics 9:751-757(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J, and NOD; TISSUE=Inner ear;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PHOSPHORYLATION AT SER-226; SER-228; SER-233; SER-237 AND SER-243.
RX   PubMed=7530295;
RA   Hilmi S., Fournier M., Valeins H., Gandar J.C., Bonnet J.;
RT   "Myelin P0 glycoprotein: identification of the site phosphorylated in
RT   vitro and in vivo by endogenous protein kinases.";
RL   J. Neurochem. 64:902-907(1995).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-216 AND SER-243, AND
RP   MASS SPECTROMETRY.
RX   PubMed=18973353; DOI=10.1021/pr800599n;
RA   Zanivan S., Gnad F., Wickstroem S.A., Geiger T., Macek B., Cox J.,
RA   Faessler R., Mann M.;
RT   "Solid tumor proteome and phosphoproteome analysis by high resolution
RT   mass spectrometry.";
RL   J. Proteome Res. 7:5314-5326(2008).
CC   -!- FUNCTION: Creation of an extracellular membrane face which guides
CC       the wrapping process and ultimately compacts adjacent lamellae.
CC   -!- INTERACTION:
CC       Q08460:Kcnma1; NbExp=1; IntAct=EBI-1634589, EBI-1633915;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- TISSUE SPECIFICITY: Found only in peripheral nervous system
CC       Schwann cells.
CC   -!- PTM: N-glycosylated; contains sulfate-substituted glycan (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the myelin P0 protein family.
CC   -!- SIMILARITY: Contains 1 Ig-like V-type (immunoglobulin-like)
CC       domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M62860; AAA39867.1; -; Genomic_DNA.
DR   EMBL; M62857; AAA39867.1; JOINED; Genomic_DNA.
DR   EMBL; M62858; AAA39867.1; JOINED; Genomic_DNA.
DR   EMBL; M62859; AAA39867.1; JOINED; Genomic_DNA.
DR   EMBL; AK089180; BAC40781.1; -; mRNA.
DR   EMBL; AK157960; BAE34285.1; -; mRNA.
DR   EMBL; CH466520; EDL39129.1; -; Genomic_DNA.
DR   EMBL; CH466520; EDL39131.1; -; Genomic_DNA.
DR   EMBL; BC139139; AAI39140.1; -; mRNA.
DR   EMBL; BC141226; AAI41227.1; -; mRNA.
DR   IPI; IPI00117735; -.
DR   PIR; A54662; A54662.
DR   RefSeq; NP_032649.2; -.
DR   UniGene; Mm.9986; -.
DR   SMR; P27573; 30-148.
DR   IntAct; P27573; 1.
DR   STRING; P27573; -.
DR   PhosphoSite; P27573; -.
DR   PRIDE; P27573; -.
DR   Ensembl; ENSMUST00000070758; ENSMUSP00000066701; ENSMUSG00000056569; Mus musculus.
DR   Ensembl; ENSMUST00000111334; ENSMUSP00000106966; ENSMUSG00000056569; Mus musculus.
DR   GeneID; 17528; -.
DR   KEGG; mmu:17528; -.
DR   UCSC; uc007dnc.1; mouse.
DR   CTD; 17528; -.
DR   MGI; MGI:103177; Mpz.
DR   eggNOG; maNOG17506; -.
DR   HOGENOM; HBG125865; -.
DR   HOVERGEN; HBG096384; -.
DR   InParanoid; P27573; -.
DR   ArrayExpress; P27573; -.
DR   Bgee; P27573; -.
DR   CleanEx; MM_MPZ; -.
DR   Genevestigator; P27573; -.
DR   GermOnline; ENSMUSG00000056569; Mus musculus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0045217; P:cell-cell junction maintenance; IMP:MGI.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013106; Ig_V-set.
DR   InterPro; IPR003596; Ig_V-set_sub.
DR   InterPro; IPR019566; Myelin-PO_C.
DR   InterPro; IPR000920; Myelin_P0.
DR   InterPro; IPR019738; Myelin_P0_CS.
DR   Gene3D; G3DSA:2.60.40.10; Ig-like_fold; 1.
DR   Pfam; PF10570; Myelin-PO_N; 1.
DR   Pfam; PF07686; V-set; 1.
DR   PRINTS; PR00213; MYELINP0.
DR   SMART; SM00406; IGv; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00568; MYELIN_P0; 1.
PE   1: Evidence at protein level;
KW   Disulfide bond; Glycoprotein; Immunoglobulin domain; Membrane;
KW   Phosphoprotein; Signal; Transmembrane.
FT   SIGNAL        1     29       By similarity.
FT   CHAIN        30    248       Myelin protein P0.
FT                                /FTId=PRO_0000019301.
FT   TOPO_DOM     30    153       Extracellular (By similarity).
FT   TRANSMEM    154    179       By similarity.
FT   TOPO_DOM    180    248       Cytoplasmic (By similarity).
FT   DOMAIN       30    143       Ig-like V-type.
FT   MOD_RES     210    210       Phosphoserine; by PKC (By similarity).
FT   MOD_RES     216    216       Phosphothreonine.
FT   MOD_RES     226    226       Phosphoserine.
FT   MOD_RES     228    228       Phosphoserine.
FT   MOD_RES     233    233       Phosphoserine; by PKC (By similarity).
FT   MOD_RES     237    237       Phosphoserine.
FT   MOD_RES     243    243       Phosphoserine.
FT   CARBOHYD    122    122       N-linked (GlcNAc...) (complex)
FT                                (Potential).
FT   DISULFID     50    127       Potential.
SQ   SEQUENCE   248 AA;  27622 MW;  936D66684300CAC9 CRC64;
     MAPGAPSSSP SPILAALLFS SLVLSPALAI VVYTDREIYG AVGSQVTLHC SFWSSEWVSD
     DISFTWRYQP EGGRDAISIF HYAKGQPYID EVGAFKERIQ WVGDPRWKDG SIVIHNLDYS
     DNGTFTCDVK NPPDIVGKTS QVTLYVFEKV PTRYGVVLGA VIGGILGVVL LLLLLFYLIR
     YCWLRRQAAL QRRLSAMEKG RFHKSSKDSS KRGRQTPVLY AMLDHSRSTK AASEKKSKGL
     GESRKDKK
//
ID   NARV_ECOLI              Reviewed;         226 AA.
AC   P0AF32; P19316;
DT   20-DEC-2005, integrated into UniProtKB/Swiss-Prot.
DT   20-DEC-2005, sequence version 1.
DT   02-MAR-2010, entry version 42.
DE   RecName: Full=Respiratory nitrate reductase 2 gamma chain;
DE            EC=1.7.99.4;
GN   Name=narV; OrderedLocusNames=b1465, JW1460;
OS   Escherichia coli (strain K12).
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC   Enterobacteriaceae; Escherichia.
OX   NCBI_TaxID=83333;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=91042410; PubMed=2233673;
RA   Blasco F., Iobbi C., Ratouchniak J., Bonnefoy V., Chippaux M.;
RT   "Nitrate reductases of Escherichia coli: sequence of the second
RT   nitrate reductase and comparison with that encoded by the narGHJI
RT   operon.";
RL   Mol. Gen. Genet. 222:104-111(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   MEDLINE=97251357; PubMed=9097039; DOI=10.1093/dnares/3.6.363;
RA   Aiba H., Baba T., Fujita K., Hayashi K., Inada T., Isono K., Itoh T.,
RA   Kasai H., Kashimoto K., Kimura S., Kitakawa M., Kitagawa M.,
RA   Makino K., Miki T., Mizobuchi K., Mori H., Mori T., Motomura K.,
RA   Nakade S., Nakamura Y., Nashimoto H., Nishio Y., Oshima T., Saito N.,
RA   Sampei G., Seki Y., Sivasundaram S., Tagami H., Takeda J.,
RA   Takemoto K., Takeuchi Y., Wada C., Yamamoto Y., Horiuchi T.;
RT   "A 570-kb DNA sequence of the Escherichia coli K-12 genome
RT   corresponding to the 28.0-40.1 min region on the linkage map.";
RL   DNA Res. 3:363-377(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   MEDLINE=97426617; PubMed=9278503; DOI=10.1126/science.277.5331.1453;
RA   Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,
RA   Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F.,
RA   Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J.,
RA   Mau B., Shao Y.;
RT   "The complete genome sequence of Escherichia coli K-12.";
RL   Science 277:1453-1474(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=16738553; DOI=10.1038/msb4100049;
RA   Hayashi K., Morooka N., Yamamoto Y., Fujita K., Isono K., Choi S.,
RA   Ohtsubo E., Baba T., Wanner B.L., Mori H., Horiuchi T.;
RT   "Highly accurate genome sequences of Escherichia coli K-12 strains
RT   MG1655 and W3110.";
RL   Mol. Syst. Biol. 2:E1-E5(2006).
RN   [5]
RP   TOPOLOGY [LARGE SCALE ANALYSIS].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=15919996; DOI=10.1126/science.1109730;
RA   Daley D.O., Rapp M., Granseth E., Melen K., Drew D., von Heijne G.;
RT   "Global topology analysis of the Escherichia coli inner membrane
RT   proteome.";
RL   Science 308:1321-1323(2005).
CC   -!- FUNCTION: This is a second nitrate reductase enzyme which can
CC       substitute for the NRA enzyme and allows E.coli to use nitrate as
CC       an electron acceptor during anaerobic growth. The gamma chain is a
CC       membrane-embedded heme-iron unit resembling cytochrome b, which
CC       transfers electrons from quinones to the beta subunit.
CC   -!- CATALYTIC ACTIVITY: Nitrite + acceptor = nitrate + reduced
CC       acceptor.
CC   -!- COFACTOR: Binds 2 heme groups per subunit. Heme 1 is located at
CC       the cytoplasmic interface, heme 2 is located at the periplasmic
CC       interface. Electrons are transferred from the periplasmic to the
CC       cytoplasmic heme (By similarity).
CC   -!- SUBUNIT: Dimer of heterotrimers each composed of an alpha, a beta
CC       and a gamma chain. Alpha and beta are catalytic chains; gamma
CC       chains are involved in binding the enzyme complex to the
CC       cytoplasmic membrane.
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane; Multi-pass membrane
CC       protein.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X17110; CAA34967.1; -; Genomic_DNA.
DR   EMBL; U00096; AAC74547.1; -; Genomic_DNA.
DR   EMBL; AP009048; BAA15102.1; -; Genomic_DNA.
DR   PIR; S11430; S11430.
DR   RefSeq; AP_002088.1; -.
DR   RefSeq; NP_415982.1; -.
DR   SMR; P0AF32; 3-225.
DR   STRING; P0AF32; -.
DR   TCDB; 5.A.3.1.2; prokaryotic molybdopterin-containing oxidoreductase (PMO) family.
DR   GeneID; 946029; -.
DR   GenomeReviews; AP009048_GR; JW1460.
DR   GenomeReviews; U00096_GR; b1465.
DR   KEGG; ecj:JW1460; -.
DR   KEGG; eco:b1465; -.
DR   EchoBASE; EB0638; -.
DR   EcoGene; EG10644; narV.
DR   eggNOG; COG2181; -.
DR   HOGENOM; HBG308661; -.
DR   OMA; DILILCI; -.
DR   ProtClustDB; CLSK880007; -.
DR   BioCyc; EcoCyc:NARV-MONOMER; -.
DR   BioCyc; ECOL168927:B1465-MONOMER; -.
DR   BioCyc; MetaCyc:NARV-MONOMER; -.
DR   Genevestigator; P0AF32; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0009325; C:nitrate reductase complex; IEA:InterPro.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0009055; F:electron carrier activity; IDA:UniProtKB.
DR   GO; GO:0005506; F:iron ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008940; F:nitrate reductase activity; IEA:EC.
DR   GO; GO:0009061; P:anaerobic respiration; IDA:UniProtKB.
DR   GO; GO:0022900; P:electron transport chain; IEA:UniProtKB-KW.
DR   GO; GO:0042128; P:nitrate assimilation; IEA:UniProtKB-KW.
DR   GO; GO:0006810; P:transport; IEA:UniProtKB-KW.
DR   InterPro; IPR003816; Nitrate_red_gam.
DR   Pfam; PF02665; Nitrate_red_gam; 1.
DR   TIGRFAMs; TIGR00351; narI; 1.
PE   1: Evidence at protein level;
KW   Cell inner membrane; Cell membrane; Complete proteome;
KW   Electron transport; Heme; Iron; Membrane; Metal-binding;
KW   Nitrate assimilation; Oxidoreductase; Transmembrane; Transport.
FT   CHAIN         1    226       Respiratory nitrate reductase 2 gamma
FT                                chain.
FT                                /FTId=PRO_0000096731.
FT   TOPO_DOM      2      4       Periplasmic (By similarity).
FT   TRANSMEM      5     30       1 (By similarity).
FT   TOPO_DOM     31     48       Cytoplasmic (By similarity).
FT   TRANSMEM     49     71       2 (By similarity).
FT   TOPO_DOM     72     83       Periplasmic (By similarity).
FT   TRANSMEM     84    113       3 (By similarity).
FT   TOPO_DOM    114    125       Cytoplasmic (By similarity).
FT   TRANSMEM    126    149       4 (By similarity).
FT   TOPO_DOM    150    183       Periplasmic (By similarity).
FT   TRANSMEM    184    199       5 (By similarity).
FT   TOPO_DOM    200    226       Cytoplasmic (By similarity).
FT   METAL        57     57       Iron (heme B 1 axial ligand) (By
FT                                similarity).
FT   METAL        67     67       Iron (heme B 2 axial ligand) (By
FT                                similarity).
FT   METAL       188    188       Iron (heme B 2 axial ligand) (By
FT                                similarity).
FT   METAL       206    206       Iron (heme B 1 axial ligand) (By
FT                                similarity).
SQ   SEQUENCE   226 AA;  26018 MW;  1D5FAC307F3D5B84 CRC64;
     MIQYLNVFFY DIYPYICATV FFLGSWLRYD YGQYTWRASS SQMLDKRGMV IWSNLFHIGI
     LGIFFGHLFG MLTPHWMYAW FLPVAAKQLM AMVLGGICGV LTLIGGAGLL WRRLTNQRVR
     ATSTTPDIII MSILLIQCLL GLSTIPFSAQ YPDGSEMMKL VGWAQSIVTF RGGSSEMLNG
     VAFVFRLHLV LGMTIFLLFP FTRLVHVWSA PFEYFTRRYQ IVRSRR
//
ID   OMPA_YERPS              Reviewed;         353 AA.
AC   P38399; Q66CF0;
DT   01-OCT-1994, integrated into UniProtKB/Swiss-Prot.
DT   23-NOV-2004, sequence version 2.
DT   02-MAR-2010, entry version 68.
DE   RecName: Full=Outer membrane protein A;
DE   AltName: Full=Outer membrane protein II;
DE   Flags: Precursor;
GN   Name=ompA; OrderedLocusNames=YPTB1453;
OS   Yersinia pseudotuberculosis.
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC   Enterobacteriaceae; Yersinia.
OX   NCBI_TaxID=633;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=IP32953 / Serotype I;
RX   PubMed=15358858; DOI=10.1073/pnas.0404012101;
RA   Chain P.S.G., Carniel E., Larimer F.W., Lamerdin J., Stoutland P.O.,
RA   Regala W.M., Georgescu A.M., Vergez L.M., Land M.L., Motin V.L.,
RA   Brubaker R.R., Fowler J., Hinnebusch J., Marceau M., Medigue C.,
RA   Simonet M., Chenal-Francisque V., Souza B., Dacheux D., Elliott J.M.,
RA   Derbise A., Hauser L.J., Garcia E.;
RT   "Insights into the evolution of Yersinia pestis through whole-genome
RT   comparison with Yersinia pseudotuberculosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:13826-13831(2004).
RN   [2]
RP   PROTEIN SEQUENCE OF 22-50.
RX   MEDLINE=90038529; PubMed=2478630;
RA   Zhang J.J., Hamachi M., Hamachi T., Zhao Y.P., Yu D.T.Y.;
RT   "The bacterial outer membrane protein that reacts with anti-HLA-B27
RT   antibodies is the OmpA protein.";
RL   J. Immunol. 143:2955-2960(1989).
CC   -!- FUNCTION: Required for the action of colicins K and L and for the
CC       stabilization of mating aggregates in conjugation. Serves as a
CC       receptor for a number of T-even like phages. Also acts as a porin
CC       with low permeability that allows slow penetration of small
CC       solutes (By similarity).
CC   -!- SUBUNIT: Monomer (Probable).
CC   -!- SUBCELLULAR LOCATION: Cell outer membrane; Multi-pass membrane
CC       protein.
CC   -!- SIMILARITY: Belongs to the ompA family.
CC   -!- SIMILARITY: Contains 1 OmpA-like domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; BX936398; CAH20693.1; -; Genomic_DNA.
DR   PIR; A60752; A60752.
DR   RefSeq; YP_069984.1; -.
DR   SMR; P38399; 22-198, 215-343.
DR   GeneID; 2956188; -.
DR   GenomeReviews; BX936398_GR; YPTB1453.
DR   KEGG; yps:YPTB1453; -.
DR   HOGENOM; HBG741096; -.
DR   OMA; DDNEAQK; -.
DR   ProtClustDB; PRK10808; -.
DR   BioCyc; YPSE273123:YPTB1453-MONOMER; -.
DR   GO; GO:0009279; C:cell outer membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-KW.
DR   GO; GO:0046930; C:pore complex; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0000746; P:conjugation; IEA:UniProtKB-KW.
DR   GO; GO:0009597; P:detection of virus; IEA:UniProtKB-KW.
DR   GO; GO:0046718; P:entry of virus into host cell; IEA:UniProtKB-KW.
DR   GO; GO:0006811; P:ion transport; IEA:UniProtKB-KW.
DR   InterPro; IPR011250; OMP_b-brl.
DR   InterPro; IPR006664; OMP_bac.
DR   InterPro; IPR002368; OmpA.
DR   InterPro; IPR006690; OMPA-like_CS.
DR   InterPro; IPR006665; OmpA/MotB_C.
DR   Gene3D; G3DSA:2.40.160.20; OMP_b-brl; 1.
DR   Gene3D; G3DSA:3.30.1330.60; OmpA/MotB_C; 1.
DR   Pfam; PF00691; OmpA; 1.
DR   PRINTS; PR01021; OMPADOMAIN.
DR   PRINTS; PR01022; OUTRMMBRANEA.
DR   SUPFAM; SSF103088; OmpA/MotB_C; 1.
DR   PROSITE; PS01068; OMPA_1; 1.
DR   PROSITE; PS51123; OMPA_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Cell outer membrane; Complete proteome; Conjugation;
KW   Direct protein sequencing; Disulfide bond; Ion transport; Membrane;
KW   Phage recognition; Porin; Repeat; Signal; Transmembrane; Transport.
FT   SIGNAL        1     21
FT   CHAIN        22    353       Outer membrane protein A.
FT                                /FTId=PRO_0000020103.
FT   TRANSMEM     27     37       By similarity.
FT   TRANSMEM     56     67       By similarity.
FT   TRANSMEM     71     82       By similarity.
FT   TRANSMEM     94    108       By similarity.
FT   TRANSMEM    113    128       By similarity.
FT   TRANSMEM    141    157       By similarity.
FT   TRANSMEM    162    170       By similarity.
FT   TRANSMEM    188    197       By similarity.
FT   REPEAT      208    209       1.
FT   REPEAT      210    211       2.
FT   REPEAT      212    213       3.
FT   REPEAT      214    215       4.
FT   DOMAIN      217    345       OmpA-like.
FT   REGION      208    215       4 X 2 AA approximate tandem repeats of A-
FT                                P.
FT   DISULFID    318    330       By similarity.
FT   CONFLICT     35     35       G -> P (in Ref. 2; AA sequence).
FT   CONFLICT     42     45       TGSI -> DPW (in Ref. 2; AA sequence).
FT   CONFLICT     49     49       D -> K (in Ref. 2; AA sequence).
SQ   SEQUENCE   353 AA;  37930 MW;  38D23EFDD5466CBF CRC64;
     MKKTAIALAV ALVGFATVAQ AAPKDNTWYT GGKLGWSQYQ DTGSIINNDG PTHKDQLGAG
     AFFGYQANQY LGFEMGYDWL GRMPYKGDIN NGAFKAQGVQ LAAKLSYPVA QDLDVYTRLG
     GLVWRADAKG SFDGGLDRAS GHDTGVSPLV ALGAEYAWTK NWATRMEYQW VNNIGDRETV
     GARPDNGLLS VGVSYRFGQE DAAAPIVAPT PAPAPIVDTK RFTLKSDVLF GFNKANLKPE
     GQQALDQLYA QLSSIDPKDG SVVVLGFADR IGQPAPNLAL SQRRADSVRD YLVSKGIPAD
     KITARGEGQA NPVTGNTCDN VKPRAALIEC LAPDRRVEIE VKGYKEVVTQ PQA
//
ID   OMPX_ENTCL              Reviewed;         172 AA.
AC   P25253;
DT   01-MAY-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1992, sequence version 1.
DT   02-MAR-2010, entry version 55.
DE   RecName: Full=Outer membrane protein X;
DE   Flags: Precursor;
GN   Name=ompX;
OS   Enterobacter cloacae.
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC   Enterobacteriaceae; Enterobacter; Enterobacter cloacae complex.
OX   NCBI_TaxID=550;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 24-38.
RX   MEDLINE=91100276; PubMed=1987115;
RA   Stoorvogel J., van Bussel M.J.A.W.M., Tommassen J.,
RA   van de Klundert J.A.M.;
RT   "Molecular characterization of an Enterobacter cloacae outer membrane
RT   protein (OmpX).";
RL   J. Bacteriol. 173:156-160(1991).
RN   [2]
RP   CHARACTERIZATION.
RX   MEDLINE=91100278; PubMed=1702778;
RA   Stoorvogel J., van Bussel M.J.A.W.M., van de Klundert J.A.M.;
RT   "Biological characterization of an Enterobacter cloacae outer membrane
RT   protein (OmpX).";
RL   J. Bacteriol. 173:161-167(1991).
CC   -!- SUBCELLULAR LOCATION: Cell outer membrane; Multi-pass membrane
CC       protein.
CC   -!- SIMILARITY: Belongs to the ail/ompX/pagC/lom family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M33878; AAA24808.1; -; Genomic_DNA.
DR   PIR; A39189; A39189.
DR   SMR; P25253; 24-172.
DR   GO; GO:0009279; C:cell outer membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-KW.
DR   InterPro; IPR000758; Enterovir_OMP.
DR   InterPro; IPR011250; OMP_b-brl.
DR   Gene3D; G3DSA:2.40.160.20; OMP_b-brl; 1.
DR   Pfam; PF06316; Ail_Lom; 1.
DR   PRINTS; PR00316; ENTEROVIROMP.
DR   PROSITE; PS00694; ENT_VIR_OMP_1; 1.
DR   PROSITE; PS00695; ENT_VIR_OMP_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Cell outer membrane; Direct protein sequencing;
KW   Membrane; Signal; Transmembrane.
FT   SIGNAL        1     23
FT   CHAIN        24    172       Outer membrane protein X.
FT                                /FTId=PRO_0000020203.
FT   TOPO_DOM     24     25       Periplasmic (By similarity).
FT   TRANSMEM     26     35       By similarity.
FT   TOPO_DOM     36     44       Extracellular (By similarity).
FT   TRANSMEM     45     55       By similarity.
FT   TOPO_DOM     56     59       Periplasmic (By similarity).
FT   TRANSMEM     60     69       By similarity.
FT   TOPO_DOM     70     83       Extracellular (By similarity).
FT   TRANSMEM     84     94       By similarity.
FT   TOPO_DOM     95     98       Periplasmic (By similarity).
FT   TRANSMEM     99    108       By similarity.
FT   TOPO_DOM    109    130       Extracellular (By similarity).
FT   TRANSMEM    131    140       By similarity.
FT   TOPO_DOM    141    144       Periplasmic (By similarity).
FT   TRANSMEM    145    154       By similarity.
FT   TOPO_DOM    155    161       Extracellular (By similarity).
FT   TRANSMEM    162    171       By similarity.
FT   TOPO_DOM    172    172       Periplasmic (By similarity).
SQ   SEQUENCE   172 AA;  18654 MW;  15DA91BBB36ACF16 CRC64;
     MKKIACLSAL AAVLAVSAGT AVAATSTVTG GYAQSDMQGV MNKTNGFNLK YRYEQDNNPL
     GVIGSFTYTE KDRTENGSYN KGQYYGITAG PAYRLNDWAS IYGVVGVGYG KFQQTENQGL
     NRTASNSDYG FSYGAGMQFN PIENVALDFS YEQSRIRNVD VGTWIAGVGY RF
//
ID   PEX2_CRIGR              Reviewed;         304 AA.
AC   Q06438;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   02-MAR-2010, entry version 57.
DE   RecName: Full=Peroxisome assembly factor 1;
DE            Short=PAF-1;
DE   AltName: Full=Peroxin-2;
DE   AltName: Full=Peroxisomal membrane protein 3;
GN   Name=PXMP3; Synonyms=PAF1, PEX2, PMP35;
OS   Cricetulus griseus (Chinese hamster).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Cricetidae; Cricetinae; Cricetulus.
OX   NCBI_TaxID=10029;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Ovary;
RX   MEDLINE=93286102; PubMed=7685346;
RA   Thieringer R., Raetz C.R.H.;
RT   "Peroxisome-deficient Chinese hamster ovary cells with point mutations
RT   in peroxisome assembly factor-1.";
RL   J. Biol. Chem. 268:12631-12636(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=94309666; PubMed=8035823;
RA   Tsukamoto T., Shimozawa N., Fujiki Y.;
RT   "Peroxisome assembly factor 1: nonsense mutation in a peroxisome-
RT   deficient Chinese hamster ovary cell mutant and deletion analysis.";
RL   Mol. Cell. Biol. 14:5458-5465(1994).
CC   -!- FUNCTION: Somewhat implicated in the biogenesis of peroxisomes.
CC   -!- SUBCELLULAR LOCATION: Peroxisome membrane; Multi-pass membrane
CC       protein.
CC   -!- SIMILARITY: Belongs to the pex2/pex10/pex12 family.
CC   -!- SIMILARITY: Contains 1 RING-type zinc finger.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z17220; CAA78929.1; -; mRNA.
DR   EMBL; D30618; BAA06308.1; -; mRNA.
DR   PIR; A45989; A45989.
DR   SMR; Q06438; 241-293.
DR   HOVERGEN; HBG000416; -.
DR   GO; GO:0005779; C:integral to peroxisomal membrane; ISS:UniProtKB.
DR   GO; GO:0005515; F:protein binding; ISS:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0007031; P:peroxisome organization; ISS:UniProtKB.
DR   InterPro; IPR006845; Pex_N.
DR   InterPro; IPR018957; Znf_C3HC4_RING-type.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   Pfam; PF04757; Pex2_Pex12; 1.
DR   Pfam; PF00097; zf-C3HC4; 1.
DR   SMART; SM00184; RING; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   Membrane; Metal-binding; Peroxisome; Transmembrane; Zinc; Zinc-finger.
FT   CHAIN         1    304       Peroxisome assembly factor 1.
FT                                /FTId=PRO_0000056368.
FT   TRANSMEM    139    158       By similarity.
FT   TRANSMEM    194    212       By similarity.
FT   ZN_FING     243    283       RING-type.
FT   MUTAGEN     246    246       C->Y: Loss of function.
SQ   SEQUENCE   304 AA;  34795 MW;  84EC5FA613C148BF CRC64;
     MAGREKTKSA NRVLRISQLD ALELNKALEQ LVWSQFTQCF HGFKPGLLAR FEPEVKACLW
     LFLWRFTIYS KNATVGQSVL NIQYKNDFSS NSRYQPPSKN QKLWYAVCTI GGRWLEERCY
     DLFRNRHLAS FGKVKQCMNV MVGLLKLGEL INFLIFLQKG KFATLTERLL GIHSVFCKPQ
     NIREVGFDYM NRELLWHGFA EFLIFLLPLI NIQKFKAKLS SWCIPLTGAA SSDSALASSG
     KECALCGEWP TMPHTIGCEH VFCYYCVKSS FLFDMYFTCP KCGIEVHSVQ PLKSGIEMSE
     VNAL
//
ID   PLS3_HUMAN              Reviewed;         295 AA.
AC   Q9NRY6; A8K252; Q567U0; Q8NBW6; Q96F13;
DT   20-JUN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   02-MAR-2010, entry version 79.
DE   RecName: Full=Phospholipid scramblase 3;
DE            Short=PL scramblase 3;
DE   AltName: Full=Ca(2+)-dependent phospholipid scramblase 3;
GN   Name=PLSCR3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=20439549; PubMed=10930526; DOI=10.1016/S0005-2736(00)00236-4;
RA   Wiedmer T., Zhou Q., Kwoh D.Y., Sims P.J.;
RT   "Identification of three new members of the phospholipid scramblase
RT   gene family.";
RL   Biochim. Biophys. Acta 1467:244-253(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT VAL-293.
RC   TISSUE=Placenta, and Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT VAL-293.
RC   TISSUE=B-cell, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH PDCD6, AND MUTAGENESIS OF PHE-49 AND PHE-52.
RX   PubMed=18256029; DOI=10.1074/jbc.M800717200;
RA   Shibata H., Suzuki H., Kakiuchi T., Inuzuka T., Yoshida H., Mizuno T.,
RA   Maki M.;
RT   "Identification of Alix-type and non-Alix-type ALG-2-binding sites in
RT   human phospholipid scramblase 3: differential binding to an
RT   alternatively spliced isoform and amino acid-substituted mutants.";
RL   J. Biol. Chem. 283:9623-9632(2008).
CC   -!- FUNCTION: May mediate accelerated ATP-independent bidirectional
CC       transbilayer migration of phospholipids upon binding calcium ions
CC       that results in a loss of phospholipid asymmetry in the plasma
CC       membrane. May play a central role in the initiation of fibrin clot
CC       formation, in the activation of mast cells and in the recognition
CC       of apoptotic and injured cells by the reticuloendothelial system.
CC   -!- COFACTOR: Calcium (By similarity).
CC   -!- SUBUNIT: Interacts with PDCD6 in a calcium-dependent manner.
CC   -!- INTERACTION:
CC       O75340:PDCD6; NbExp=7; IntAct=EBI-750734, EBI-352915;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type II membrane
CC       protein (By similarity).
CC   -!- TISSUE SPECIFICITY: Expressed in heart, placenta, lung, liver,
CC       skeletal muscle, kidney, pancreas, spleen, thymus, prostate,
CC       uterus, small intestine and peripheral blood lymphocytes. Not
CC       detected in testis, brain and liver.
CC   -!- SIMILARITY: Belongs to the phospholipid scramblase family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF159442; AAF91083.1; -; mRNA.
DR   EMBL; AK075188; BAC11458.1; -; mRNA.
DR   EMBL; AK290117; BAF82806.1; -; mRNA.
DR   EMBL; CH471108; EAW90200.1; -; Genomic_DNA.
DR   EMBL; BC011735; AAH11735.1; -; mRNA.
DR   EMBL; BC093026; AAH93026.1; -; mRNA.
DR   IPI; IPI00216127; -.
DR   RefSeq; NP_065093.2; -.
DR   UniGene; Hs.655161; -.
DR   IntAct; Q9NRY6; 3.
DR   STRING; Q9NRY6; -.
DR   PhosphoSite; Q9NRY6; -.
DR   PRIDE; Q9NRY6; -.
DR   Ensembl; ENST00000324822; ENSP00000316021; ENSG00000187838; Homo sapiens.
DR   GeneID; 57048; -.
DR   KEGG; hsa:57048; -.
DR   CTD; 57048; -.
DR   GeneCards; GC17M007233; -.
DR   H-InvDB; HIX0013495; -.
DR   H-InvDB; HIX0079952; -.
DR   HGNC; HGNC:16495; PLSCR3.
DR   MIM; 607611; gene.
DR   PharmGKB; PA33421; -.
DR   eggNOG; prNOG15409; -.
DR   HOGENOM; HBG452824; -.
DR   HOVERGEN; HBG019157; -.
DR   InParanoid; Q9NRY6; -.
DR   NextBio; 62812; -.
DR   ArrayExpress; Q9NRY6; -.
DR   Bgee; Q9NRY6; -.
DR   CleanEx; HS_PLSCR3; -.
DR   Genevestigator; Q9NRY6; -.
DR   GermOnline; ENSG00000187838; Homo sapiens.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; NAS:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; NAS:UniProtKB.
DR   GO; GO:0048306; F:calcium-dependent protein binding; IPI:UniProtKB.
DR   GO; GO:0017128; F:phospholipid scramblase activity; NAS:UniProtKB.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0017121; P:phospholipid scrambling; NAS:UniProtKB.
DR   InterPro; IPR005552; Scramblase.
DR   PANTHER; PTHR23248; Scramblase; 1.
DR   Pfam; PF03803; Scramblase; 1.
PE   1: Evidence at protein level;
KW   Calcium; Complete proteome; Lipoprotein; Membrane; Palmitate;
KW   Phosphoprotein; Polymorphism; Repeat; SH3-binding; Transmembrane.
FT   CHAIN         1    295       Phospholipid scramblase 3.
FT                                /FTId=PRO_0000100789.
FT   TOPO_DOM      1    265       Cytoplasmic (By similarity).
FT   TRANSMEM    266    282       By similarity.
FT   TOPO_DOM    283    295       Extracellular (By similarity).
FT   MOTIF         7     15       SH3-binding 1 (Potential).
FT   MOTIF        15     18       WW-binding (Potential).
FT   MOTIF        21     27       SH3-binding 2 (Potential).
FT   MOTIF        65     70       SH3-binding 3 (Potential).
FT   COMPBIAS     12     19       Poly-Pro.
FT   COMPBIAS    158    165       Cys-rich.
FT   LIPID       211    211       S-palmitoyl cysteine (Probable).
FT   LIPID       214    214       S-palmitoyl cysteine (Probable).
FT   LIPID       216    216       S-palmitoyl cysteine (Probable).
FT   VARIANT     293    293       I -> V (in dbSNP:rs3744549).
FT                                /FTId=VAR_015568.
FT   MUTAGEN      49     49       F->A: Reduces interaction with PDCD6.
FT                                Abolishes interaction with PDCD6; when
FT                                associated with A-52.
FT   MUTAGEN      49     49       F->W: No effect on the interaction with
FT                                PDCD6.
FT   MUTAGEN      49     49       F->Y,L: Reduces interaction with PDCD6.
FT   MUTAGEN      52     52       F->A: Abolishes interaction with PDCD6;
FT                                when associated with A-49.
FT   CONFLICT    149    149       V -> L (in Ref. 4; AAH11735).
SQ   SEQUENCE   295 AA;  31662 MW;  B53AB81166E6D99E CRC64;
     MAGYLPPKGY APSPPPPYPV TPGYPEPALH PGPGQAPVPA QVPAPAPGFA LFPSPGPVAL
     GSAAPFLPLP GVPSGLEFLV QIDQILIHQK AERVETFLGW ETCNRYELRS GAGQPLGQAA
     EESNCCARLC CGARRPLRVR LADPGDREVL RLLRPLHCGC SCCPCGLQEM EVQAPPGTTI
     GHVLQTWHPF LPKFSIQDAD RQTVLRVVGP CWTCGCGTDT NFEVKTRDES RSVGRISKQW
     GGLVREALTD ADDFGLQFPL DLDVRVKAVL LGATFLIDYM FFEKRGGAGP SAITS
//
ID   PMP22_BOVIN             Reviewed;         160 AA.
AC   Q9TQZ3; A6QLT1;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   10-FEB-2009, sequence version 2.
DT   02-MAR-2010, entry version 57.
DE   RecName: Full=Peripheral myelin protein 22;
DE            Short=PMP-22;
DE   AltName: Full=PAS positive glycoprotein;
DE            Short=PASII;
GN   Name=PMP22;
OS   Bos taurus (Bovine).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Ruminantia;
OC   Pecora; Bovidae; Bovinae; Bos.
OX   NCBI_TaxID=9913;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=Hereford; TISSUE=Fetal muscle;
RG   NIH - Mammalian Gene Collection (MGC) project;
RL   Submitted (JUN-2007) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   PROTEIN SEQUENCE OF 1-44 AND 93-123.
RC   TISSUE=Peripheral nerve;
RX   MEDLINE=96040843; PubMed=7568893;
RA   Uyemura K., Asou H., Takeda Y.;
RT   "Structure and function of peripheral nerve myelin proteins.";
RL   Prog. Brain Res. 105:311-318(1995).
RN   [3]
RP   GLYCOSYLATION AT ASN-41, AND STRUCTURE OF CARBOHYDRATES.
RX   MEDLINE=20359526; PubMed=10899964;
RX   DOI=10.1046/j.1471-4159.2000.0750853.x;
RA   Kitamura K., Uyemura K., Shibuya K., Sakamoto Y., Yoshimura K.,
RA   Nomura M.;
RT   "Structure of a major oligosaccharide of PASII/PMP22 glycoprotein in
RT   bovine peripheral nerve myelin.";
RL   J. Neurochem. 75:853-860(2000).
CC   -!- FUNCTION: Might be involved in growth regulation, and in
CC       myelinization in the peripheral nervous system.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein (By
CC       similarity).
CC   -!- PTM: The N-terminus is blocked.
CC   -!- SIMILARITY: Belongs to the PMP-22/EMP/MP20 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; BC148075; AAI48076.1; -; mRNA.
DR   IPI; IPI00714318; -.
DR   RefSeq; NP_001094626.1; -.
DR   UniGene; Bt.22534; -.
DR   STRING; Q9TQZ3; -.
DR   GlycoSuiteDB; Q9TQZ3; -.
DR   GeneID; 534497; -.
DR   KEGG; bta:534497; -.
DR   CTD; 534497; -.
DR   eggNOG; maNOG19866; -.
DR   HOVERGEN; HBG001690; -.
DR   OMA; STIVSAW; -.
DR   OrthoDB; EOG979HSQ; -.
DR   PhylomeDB; Q9TQZ3; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0007050; P:cell cycle arrest; IEA:UniProtKB-KW.
DR   InterPro; IPR003936; PMP22.
DR   InterPro; IPR004031; PMP22/EMP/MP20/Claudin.
DR   InterPro; IPR004032; PMP22_EMP_MP20.
DR   Pfam; PF00822; PMP22_Claudin; 1.
DR   PRINTS; PR01453; EPMEMFAMILY.
DR   PRINTS; PR01458; PMYELIN22.
DR   PROSITE; PS01221; PMP22_1; 1.
DR   PROSITE; PS01222; PMP22_2; 1.
PE   1: Evidence at protein level;
KW   Cell cycle; Direct protein sequencing; Glycoprotein; Growth arrest;
KW   Membrane; Transmembrane.
FT   CHAIN         1    160       Peripheral myelin protein 22.
FT                                /FTId=PRO_0000164648.
FT   TRANSMEM      2     31       By similarity.
FT   TRANSMEM     65     91       By similarity.
FT   TRANSMEM     96    119       By similarity.
FT   TRANSMEM    134    156       By similarity.
FT   CARBOHYD     41     41       N-linked (GlcNAc...) (complex).
FT                                /FTId=CAR_000191.
FT   CONFLICT    122    122       P -> L (in Ref. 2; AA sequence).
SQ   SEQUENCE   160 AA;  17803 MW;  428B538661AD4AC3 CRC64;
     MLLLLLGIIV LHVAVLVLLF VSTIVSQWMV GNGHATDLWQ NCSTSLMGSV QHCFSSSANE
     WLQSVQATMI LSIIFSVLSL FLFFCQLFTL TKGGRFYITG VFQILAGLCV MSAASIYTVR
     HPEWHFNSDG SYGFAYILAW VAFPLALLSG VIYVILRKRE
//
ID   PMP22_HUMAN             Reviewed;         160 AA.
AC   Q01453; Q8WV01;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1993, sequence version 1.
DT   02-MAR-2010, entry version 111.
DE   RecName: Full=Peripheral myelin protein 22;
DE            Short=PMP-22;
DE   AltName: Full=Growth arrest-specific protein 3;
DE            Short=GAS-3;
GN   Name=PMP22; Synonyms=GAS3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=93265095; PubMed=1303228; DOI=10.1038/ng0692-159;
RA   Patel P.I., Roa B.B., Welcher A.A., Schoener-Scott R., Trask B.,
RA   Pentao L., Snipes G.J., Garcia C.A., Francke U., Shooter E.M.,
RA   Lupski J.R., Suter U.;
RT   "The gene for the peripheral myelin protein PMP-22 is a candidate for
RT   Charcot-Marie-Tooth disease type 1A.";
RL   Nat. Genet. 1:159-165(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Spinal cord;
RX   MEDLINE=92360032; PubMed=1497668; DOI=10.1016/0006-291X(92)90820-B;
RA   Hayasaka K., Himoro M., Nanao K., Sato W., Miura M., Uyemura K.,
RA   Takahashi E., Takada G.;
RT   "Isolation and sequence determination of cDNA encoding PMP-22 (PAS-
RT   II/SR13/Gas-3) of human peripheral myelin.";
RL   Biochem. Biophys. Res. Commun. 186:827-831(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT CMT1A PRO-16.
RX   MEDLINE=93265161; PubMed=1303281; DOI=10.1038/ng1292-288;
RA   Valentijn L.J., Baas F., Wolterman R.A., Hoogendijk J.E.,
RA   van den Bosch N.H.A., Zorn I., Gabreeels-Festen A.A.W.M.,
RA   de Visser M., Bolhuis P.A.;
RT   "Identical point mutations of PMP-22 in Trembler-J mouse and Charcot-
RT   Marie-Tooth disease type 1A.";
RL   Nat. Genet. 2:288-291(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=93246261; PubMed=8482547; DOI=10.1016/0378-1119(93)90384-F;
RA   Edomi P., Martinotti A., Colombo M.P., Schneider C.;
RT   "Sequence of human GAS3/PMP22 full-length cDNA.";
RL   Gene 126:289-290(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 61-160.
RC   TISSUE=Fetal fibroblast;
RX   MEDLINE=93265058; PubMed=1303210; DOI=10.1093/hmg/1.5.331;
RA   Martinotti A., Cariani C.T., Melani C., Sozzi G., Spurr N.K.,
RA   Pierotti M.A., Colombo M.P.;
RT   "Isolation and mapping to 17p12-13 of the human homologous of the
RT   murine growth arrest specific Gas-3 gene.";
RL   Hum. Mol. Genet. 1:331-334(1992).
RN   [7]
RP   REVIEW ON CMT1A VARIANTS.
RX   MEDLINE=95282670; PubMed=7762451;
RA   Roa B.B., Lupski J.R.;
RT   "Molecular genetics of Charcot-Marie-Tooth neuropathy.";
RL   Adv. Hum. Genet. 22:117-152(1994).
RN   [8]
RP   REVIEW ON CMT1A VARIANTS.
RX   MEDLINE=94302675; PubMed=7518101; DOI=10.1016/0168-9525(94)90214-3;
RA   Patel P.I., Lupski J.R.;
RT   "Charcot-Marie-Tooth disease: a new paradigm for the mechanism of
RT   inherited disease.";
RL   Trends Genet. 10:128-133(1994).
RN   [9]
RP   REVIEW ON CMT1A AND DSS VARIANTS.
RX   MEDLINE=99103460; PubMed=9888385;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:1<11::AID-HUMU2>3.3.CO;2-1;
RA   Nelis E., Haites N., van Broeckhoven C.;
RT   "Mutations in the peripheral myelin genes and associated genes in
RT   inherited peripheral neuropathies.";
RL   Hum. Mutat. 13:11-28(1999).
RN   [10]
RP   VARIANTS DSS LYS-69 AND LEU-72, AND VARIANTS CMT1A CYS-79 AND MET-118.
RX   MEDLINE=94073197; PubMed=8252046; DOI=10.1038/ng1093-189;
RA   Roa B.B., Garcia C.A., Pentao L., Killian J.M., Trask B.J., Suter U.,
RA   Snipes G.J., Ortiz-Lopez R., Shooter E.M., Patel P.I., Lupski J.R.;
RT   "Evidence for a recessive PMP22 point mutation in Charcot-Marie-Tooth
RT   disease type 1A.";
RL   Nat. Genet. 5:189-194(1993).
RN   [11]
RP   VARIANTS DSS LYS-69 AND LEU-72.
RX   MEDLINE=94100982; PubMed=8275092; DOI=10.1038/ng1193-269;
RA   Roa B.B., Dyck P.J., Marks H.G., Chance P.F., Lupski J.R.;
RT   "Dejerine-Sottas syndrome associated with point mutation in the
RT   peripheral myelin protein 22 (PMP22) gene.";
RL   Nat. Genet. 5:269-273(1993).
RN   [12]
RP   VARIANT CMT1A CYS-79.
RX   MEDLINE=93288088; PubMed=8510709; DOI=10.1056/NEJM199307083290205;
RA   Roa B.B., Garcia C.A., Suter U., Kulpa D.A., Wise C.A., Mueller J.,
RA   Welcher A.A., Snipes G.J., Shooter E.M., Patel P.I., Lupski J.R.;
RT   "Charcot-Marie-Tooth disease type 1A. Association with a spontaneous
RT   point mutation in the PMP22 gene.";
RL   N. Engl. J. Med. 329:96-101(1993).
RN   [13]
RP   VARIANT CMT1A ARG-105.
RX   MEDLINE=96191764; PubMed=8615087; DOI=10.1007/BF00318579;
RA   Gabreeels-Festen A.A.W.M., Bolhuis P.A., Hoogendijk J.E.,
RA   Valentijn L.J., Eshuis E.J., Gabreeels F.J.M.;
RT   "Charcot-Marie-Tooth disease type 1A: morphological phenotype of the
RT   17p duplication versus PMP22 point mutations.";
RL   Acta Neuropathol. 90:645-649(1995).
RN   [14]
RP   VARIANT DSS GLN-12.
RX   MEDLINE=95245343; PubMed=7728152; DOI=10.1002/humu.1380050110;
RA   Valentijn L.J., Ouvrier R.A., van den Bosch N.H.A., Bolhuis P.A.,
RA   Baas F., Nicholson G.A.;
RT   "Dejerine-Sottas neuropathy is associated with a de novo PMP22
RT   mutation.";
RL   Hum. Mutat. 5:76-80(1995).
RN   [15]
RP   VARIANT DSS LEU-72.
RX   MEDLINE=95405644; PubMed=7675244;
RA   Ionasescu V.V., Ionasescu R., Searby C.C., Neahring R.;
RT   "Dejerine-Sottas disease with de novo dominant point mutation of the
RT   PMP22 gene.";
RL   Neurology 45:1766-1767(1995).
RN   [16]
RP   VARIANT CMT1A ARG-93.
RX   MEDLINE=96241146; PubMed=8777804;
RA   Ohnishi A., Yoshimura T., Kanehisa Y., Fukushima Y.;
RT   "A case of hereditary motor and sensory neuropathy type I with a new
RT   type of peripheral myelin protein (PMP)-22 mutation.";
RL   Rinsho Shinkeigaku 35:788-792(1995).
RN   [17]
RP   VARIANT CMT1A ARG-147.
RX   MEDLINE=96209919; PubMed=8655153; DOI=10.1007/s004390050116;
RA   Navon R., Seifried B., Gal-On N.S., Sadeh M.;
RT   "A new point mutation affecting the fourth transmembrane domain of
RT   PMP22 results in severe de novo Charcot-Marie-Tooth disease.";
RL   Hum. Genet. 97:685-687(1996).
RN   [18]
RP   VARIANT DSS LEU-72.
RX   PubMed=9004143;
RA   Ionasescu V.V., Searby C., Greenberg S.A.;
RT   "Dejerine-Sottas disease with sensorineural hearing loss, nystagmus,
RT   and peripheral facial nerve weakness: de novo dominant point mutation
RT   of the PMP22 gene.";
RL   J. Med. Genet. 33:1048-1049(1996).
RN   [19]
RP   VARIANTS DSS TRP-72; ILE-76 AND PRO-80.
RX   MEDLINE=97208855; PubMed=9055797; DOI=10.1093/brain/120.1.47;
RA   Tyson J., Ellis D., Fairbrother U., King R.H., Muntoni F., Jacobs J.,
RA   Malcolm S., Harding A.E., Thomas P.K.;
RT   "Hereditary demyelinating neuropathy of infancy. A genetically complex
RT   syndrome.";
RL   Brain 120:47-63(1997).
RN   [20]
RP   VARIANT DSS ARG-100.
RX   MEDLINE=97331335; PubMed=9187667; DOI=10.1007/s004390050442;
RA   Bort S., Nelis E., Timmerman V., Sevilla T., Cruz-Martinez A.,
RA   Martinez F., Millan J.M., Arpa J., Vilchez J.J., Prieto F.,
RA   van Broeckhoven C., Palau F.;
RT   "Mutational analysis of the MPZ, PMP22 and Cx32 genes in patients of
RT   Spanish ancestry with Charcot-Marie-Tooth disease and hereditary
RT   neuropathy with liability to pressure palsies.";
RL   Hum. Genet. 99:746-754(1997).
RN   [21]
RP   VARIANT DSS ASP-150.
RX   MEDLINE=97151053; PubMed=8995589;
RX   DOI=10.1002/(SICI)1097-4598(199701)20:1<97::AID-MUS13>3.0.CO;2-Z;
RA   Ionasescu V.V., Searby C.C., Ionasescu R., Chatkupt S., Patel N.,
RA   Koenigsberger R.;
RT   "Dejerine-Sottas neuropathy in mother and son with same point mutation
RT   of PMP22 gene.";
RL   Muscle Nerve 20:97-99(1997).
RN   [22]
RP   VARIANT MET-118.
RX   MEDLINE=97141911; PubMed=8988161; DOI=10.1038/ng0197-13;
RA   Nelis E., Holmberg B., Adolfsson R., Holmgren G., van Broeckhoven C.;
RT   "PMP22 Thr(118)Met: recessive CMT1 mutation or polymorphism?";
RL   Nat. Genet. 15:13-14(1997).
RN   [23]
RP   VARIANT CMT1A VAL-107.
RX   MEDLINE=97193152; PubMed=9040744;
RA   Marrosu M.G., Vaccargiu S., Marrosu G., Vannelli A., Cianchetti C.,
RA   Muntoni F.;
RT   "A novel point mutation in the peripheral myelin protein 22 (PMP22)
RT   gene associated with Charcot-Marie-Tooth disease type 1A.";
RL   Neurology 48:489-493(1997).
RN   [24]
RP   VARIANTS DSS LEU-72 AND GLU-100.
RX   MEDLINE=98244766; PubMed=9585367; DOI=10.1002/ana.410430521;
RA   Marques W. Jr., Thomas P.K., Sweeney M.G., Carr L., Wood N.W.;
RT   "Dejerine-Sottas neuropathy and PMP22 point mutations: a new base pair
RT   substitution and a possible 'hot spot' on Ser72.";
RL   Ann. Neurol. 43:680-683(1998).
RN   [25]
RP   VARIANT DSS CYS-150.
RX   MEDLINE=98204401; PubMed=9544841; DOI=10.1007/s004390050694;
RA   Ikegami T., Ikeda H., Aoyama M., Matsuki T., Imota T., Fukuuchi Y.,
RA   Amano T., Toyoshima I., Ishihara Y., Endoh H., Hayasaka K.;
RT   "Novel mutations of the peripheral myelin protein 22 gene in two
RT   pedigrees with Dejerine-Sottas disease.";
RL   Hum. Genet. 102:294-298(1998).
RN   [26]
RP   VARIANT DSS PRO-79.
RX   MEDLINE=98112432; PubMed=9452053;
RA   Bort S., Sevilla T., Garcia-Planells J., Blesa D., Paricio N.,
RA   Vilchez J.J., Prieto F., Palau F.;
RT   "Dejerine-Sottas neuropathy associated with de novo S79P mutation of
RT   the peripheral myelin protein 22 (PMP22) gene.";
RL   Hum. Mutat. Suppl. 1:S95-S98(1998).
RN   [27]
RP   VARIANT MET-118.
RX   MEDLINE=98112478; PubMed=9452099;
RA   Sorour E., Upadhyaya M.;
RT   "Mutation analysis in Charcot-Marie-Tooth disease type 1 (CMT1).";
RL   Hum. Mutat. Suppl. 1:S242-S247(1998).
RN   [28]
RP   VARIANT DSS PHE-84 DEL.
RX   MEDLINE=98295578; PubMed=9633821;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:1<59::AID-HUMU9>3.3.CO;2-1;
RA   Silander K., Meretoja P., Juvonen V., Ignatius J., Pihko H.,
RA   Saarinen A., Wallden T., Herrgaard E., Aula P., Savontaus M.-L.;
RT   "Spectrum of mutations in Finnish patients with Charcot-Marie-Tooth
RT   disease and related neuropathies.";
RL   Hum. Mutat. 12:59-68(1998).
RN   [29]
RP   VARIANT HNPP MET-30.
RX   MEDLINE=98418809; PubMed=9748013;
RA   Sahenk Z., Chen L., Freimer M.;
RT   "A novel PMP22 point mutation causing HNPP phenotype: studies on nerve
RT   xenografts.";
RL   Neurology 51:702-707(1998).
RN   [30]
RP   VARIANT CMT1E PRO-67.
RX   MEDLINE=99264239; PubMed=10330345; DOI=10.1086/302420;
RA   Kovach M.J., Lin J.-P., Boyadjiev S., Campbell K., Mazzeo L.,
RA   Herman K., Rimer L.A., Frank W., Llewellyn B., Wang Jabs E.,
RA   Gelber D., Kimonis V.E.;
RT   "A unique point mutation in the PMP22 gene is associated with Charcot-
RT   Marie-Tooth disease and deafness.";
RL   Am. J. Hum. Genet. 64:1580-1593(1999).
RN   [31]
RP   VARIANT DSS TRP-157.
RC   TISSUE=Peripheral blood;
RX   MEDLINE=99226460; PubMed=10211478;
RX   DOI=10.1002/1531-8249(199904)45:4<518::AID-ANA15>3.0.CO;2-U;
RA   Parman Y., Plante-Bordeneuve V., Guiochon-Mantel A., Eraksoy M.,
RA   Said G.;
RT   "Recessive inheritance of a new point mutation of the PMP22 gene in
RT   Dejerine-Sottas disease.";
RL   Ann. Neurol. 45:518-522(1999).
RN   [32]
RP   VARIANT CMT1A VAL-37.
RX   MEDLINE=99417177; PubMed=10489052;
RA   Fabrizi G.M., Cavallaro T., Taioli F., Orrico D., Morbin M.,
RA   Simonati A., Rizzuto N.;
RT   "Myelin uncompaction in Charcot-Marie-Tooth neuropathy type 1A with a
RT   point mutation of peripheral myelin protein-22.";
RL   Neurology 53:846-851(1999).
RN   [33]
RP   VARIANT DSS ARG-149.
RX   PubMed=10663978; DOI=10.1007/PL00007446;
RA   Ohnishi A., Yamamoto T., Izawa K., Yamamori S., Takahashi K., Mega H.,
RA   Jinnai K.;
RT   "Dejerine-Sottas disease with a novel de novo dominant mutation, Ser
RT   149 Arg, of the peripheral myelin protein 22.";
RL   Acta Neuropathol. 99:327-330(2000).
RN   [34]
RP   VARIANT GLY-157.
RC   TISSUE=Peripheral blood leukocyte;
RX   MEDLINE=20095968; PubMed=10632107;
RX   DOI=10.1002/1531-8249(200001)47:1<101::AID-ANA16>3.3.CO;2-U;
RA   Numakura C., Lin C., Oka N., Akiguchi I., Hayasaka K.;
RT   "Hemizygous mutation of the peripheral myelin protein 22 gene
RT   associated with Charcot-Marie-Tooth disease type 1.";
RL   Ann. Neurol. 47:101-103(2000).
RN   [35]
RP   VARIANT CMT1A LEU-72.
RX   PubMed=11140841; DOI=10.1034/j.1399-0004.2000.580511.x;
RA   Bissar-Tadmouri N., Parman Y., Boutrand L., Deymeer F., Serdaroglu P.,
RA   Vandenberghe A., Battaloglu E.;
RT   "Mutational analysis and genotype/phenotype correlation in Turkish
RT   Charcot-Marie-Tooth type 1 and HNPP patients.";
RL   Clin. Genet. 58:396-402(2000).
RN   [36]
RP   VARIANTS CMT1A 25-VAL-SER-26 DEL AND ARG-147, AND VARIANT MET-118.
RX   PubMed=10737979;
RX   DOI=10.1002/(SICI)1098-1004(200004)15:4<340::AID-HUMU6>3.3.CO;2-P;
RA   Mersiyanova I.V., Ismailov S.M., Polyakov A.V., Dadali E.L.,
RA   Fedotov V.P., Nelis E., Loefgren A., Timmerman V., Van Broeckhoven C.,
RA   Evgrafov O.V.;
RT   "Screening for mutations in the peripheral myelin genes PMP22, MPZ and
RT   Cx32 (GJB1) in Russian Charcot-Marie-Tooth neuropathy patients.";
RL   Hum. Mutat. 15:340-347(2000).
RN   [37]
RP   VARIANTS DSS LEU-72 AND ARG-109.
RX   PubMed=11438991; DOI=10.1002/humu.1147;
RA   Mostacciuolo M.L., Righetti E., Zortea M., Bosello V., Schiavon F.,
RA   Vallo L., Merlini L., Siciliano G., Fabrizi G.M., Rizzuto N.,
RA   Milani M., Baratta S., Taroni F.;
RT   "Charcot-Marie-Tooth disease type I and related demyelinating
RT   neuropathies: mutation analysis in a large cohort of Italian
RT   families.";
RL   Hum. Mutat. 18:32-41(2001).
RN   [38]
RP   INVOLVEMENT IN IDP.
RX   PubMed=12439896; DOI=10.1002/ajmg.10725;
RA   Korn-Lubetzki I., Argov Z., Raas-Rothschild A., Wirguin I.,
RA   Steiner I.;
RT   "Family with inflammatory demyelinating polyneuropathy and the HNPP
RT   17p12 deletion.";
RL   Am. J. Med. Genet. 113:275-278(2002).
RN   [39]
RP   VARIANT CMT1E ARG-28, AND VARIANT CMT1A/DSS PRO-71.
RX   MEDLINE=21823270; PubMed=11835375; DOI=10.1002/ana.10089;
RA   Boerkoel C.F., Takashima H., Garcia C.A., Olney R.K., Johnson J.,
RA   Berry K., Russo P., Kennedy S., Teebi A.S., Scavina M., Williams L.L.,
RA   Mancias P., Butler I.J., Krajewski K., Shy M., Lupski J.R.;
RT   "Charcot-Marie-Tooth disease and related neuropathies: mutation
RT   distribution and genotype-phenotype correlation.";
RL   Ann. Neurol. 51:190-201(2002).
RN   [40]
RP   VARIANT CMT1A LEU-72.
RX   PubMed=12402337; DOI=10.1002/humu.10134;
RA   Numakura C., Lin C., Ikegami T., Guldberg P., Hayasaka K.;
RT   "Molecular analysis in Japanese patients with Charcot-Marie-Tooth
RT   disease: DGGE analysis for PMP22, MPZ, and Cx32/GJB1 mutations.";
RL   Hum. Mutat. 20:392-398(2002).
RN   [41]
RP   VARIANTS DSS PRO-16; ARG-80 AND ARG-105.
RX   PubMed=12090401; DOI=10.1046/j.1469-7580.2002.00043.x;
RA   Gabreeels-Festen A.A.W.M.;
RT   "Dejerine-Sottas syndrome grown to maturity: overview of genetic and
RT   morphological heterogeneity and follow-up of 25 patients.";
RL   J. Anat. 200:341-356(2002).
RN   [42]
RP   VARIANT CMT1A PHE-65.
RX   PubMed=12497641; DOI=10.1002/humu.9101;
RA   Huehne K., Benes V., Thiel C., Kraus C., Kress W., Hoeltzenbein M.,
RA   Ploner C.J., Kotzian J., Reis A., Rott H.D., Rautenstrauss B.W.;
RT   "Novel mutations in the Charcot-Marie-Tooth disease genes PMP22, MPZ,
RT   and GJB1.";
RL   Hum. Mutat. 21:100-100(2003).
RN   [43]
RP   VARIANT CMT1E 115-ALA--THR-118 DEL.
RX   PubMed=12578939;
RA   Sambuughin N., de Bantel A., McWilliams S., Sivakumar K.;
RT   "Deafness and CMT disease associated with a novel four amino acid
RT   deletion in the PMP22 gene.";
RL   Neurology 60:506-508(2003).
RN   [44]
RP   VARIANT HNPP THR-67.
RX   PubMed=12796555;
RA   Nodera H., Nishimura M., Logigian E.L., Herrmann D.N., Kaji R.;
RT   "HNPP due to a novel missense mutation of the PMP22 gene.";
RL   Neurology 60:1863-1864(2003).
RN   [45]
RP   VARIANT HNPP/CMT1A PHE-22.
RX   PubMed=15205993; DOI=10.1007/s10048-004-0184-1;
RA   Kleopa K.A., Georgiou D.-M., Nicolaou P., Koutsou P.,
RA   Papathanasiou E., Kyriakides T., Christodoulou K.;
RT   "A novel PMP22 mutation Ser22Phe in a family with hereditary
RT   neuropathy with liability to pressure palsies and CMT1A phenotypes.";
RL   Neurogenetics 5:171-175(2004).
RN   [46]
RP   VARIANT CMT1E ARG-23.
RX   PubMed=15099592; DOI=10.1016/j.nmd.2004.02.009;
RA   Joo I.S., Ki C.S., Joo S.Y., Huh K., Kim J.W.;
RT   "A novel point mutation in PMP22 gene associated with a familial case
RT   of Charcot-Marie-Tooth disease type 1A with sensorineural deafness.";
RL   Neuromuscul. Disord. 14:325-328(2004).
RN   [47]
RP   VARIANT CNT1A MET-118.
RX   PubMed=16437560; DOI=10.1002/ana.20777;
RA   Shy M.E., Scavina M.T., Clark A., Krajewski K.M., Li J., Kamholz J.,
RA   Kolodny E., Szigeti K., Fischer R.A., Saifi G.M., Scherer S.S.,
RA   Lupski J.R.;
RT   "T118M PMP22 mutation causes partial loss of function and HNPP-like
RT   neuropathy.";
RL   Ann. Neurol. 59:358-364(2006).
CC   -!- FUNCTION: Might be involved in growth regulation, and in
CC       myelinization in the peripheral nervous system.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- DISEASE: Defects in PMP22 are the cause of Charcot-Marie-Tooth
CC       disease type 1A (CMT1A) [MIM:118220]; also known as hereditary
CC       motor and sensory neuropathy IA. CMT1A is a form of Charcot-Marie-
CC       Tooth disease, the most common inherited disorder of the
CC       peripheral nervous system. Charcot-Marie-Tooth disease is
CC       classified in two main groups on the basis of electrophysiologic
CC       properties and histopathology: primary peripheral demyelinating
CC       neuropathy or CMT1, and primary peripheral axonal neuropathy or
CC       CMT2. Neuropathies of the CMT1 group are characterized by severely
CC       reduced nerve conduction velocities (less than 38 m/sec),
CC       segmental demyelination and remyelination with onion bulb
CC       formations on nerve biopsy, slowly progressive distal muscle
CC       atrophy and weakness, absent deep tendon reflexes, and hollow
CC       feet. CMT1A inheritance is autosomal dominant.
CC   -!- DISEASE: Defects in PMP22 are a cause of Dejerine-Sottas syndrome
CC       (DSS) [MIM:145900]; also known as Dejerine-Sottas neuropathy (DSN)
CC       or hereditary motor and sensory neuropathy III (HMSN3). DSS is a
CC       severe degenerating neuropathy of the demyelinating Charcot-Marie-
CC       Tooth disease category, with onset by age 2 years. DSS is
CC       characterized by motor and sensory neuropathy with very slow nerve
CC       conduction velocities, increased cerebrospinal fluid protein
CC       concentrations, hypertrophic nerve changes, delayed age of walking
CC       as well as areflexia. There are both autosomal dominant and
CC       autosomal recessive forms of Dejerine-Sottas syndrome.
CC   -!- DISEASE: Defects in PMP22 are a cause of hereditary neuropathy
CC       with liability to pressure palsies (HNPP) [MIM:162500]; an
CC       autosomal dominant disorder characterized by transient episodes of
CC       decreased perception or peripheral nerve palsies after slight
CC       traction, compression or minor traumas.
CC   -!- DISEASE: Defects in PMP22 are the cause of Charcot-Marie-Tooth
CC       disease type 1E (CMT1E) [MIM:118300]; also known as Charcot-Marie-
CC       Tooth disease and deafness autosomal dominant. CMT1E is an
CC       autosomal dominant form of Charcot-Marie-Tooth disease
CC       characterized by the association of sensorineural hearing loss
CC       with peripheral demyelinating neuropathy.
CC   -!- DISEASE: Defects in PMP22 may be a cause of inflammatory
CC       demyelinating polyneuropathy (IDP) [MIM:139393]. IDP is a putative
CC       autoimmune disorder presenting in an acute (AIDP) or chronic form
CC       (CIDP). The acute form is also known as Guillain-Barre syndrome.
CC   -!- SIMILARITY: Belongs to the PMP-22/EMP/MP20 family.
CC   -!- WEB RESOURCE: Name=Inherited peripheral neuropathies mutation db;
CC       URL="http://www.molgen.ua.ac.be/CMTMutations/";
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/PMP22";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M94048; AAA36457.1; -; mRNA.
DR   EMBL; D11428; BAA01995.1; -; mRNA.
DR   EMBL; S61788; AAB26811.1; -; mRNA.
DR   EMBL; L03203; AAA58495.1; -; mRNA.
DR   EMBL; BC019040; AAH19040.2; -; mRNA.
DR   EMBL; X65968; CAA46781.1; -; mRNA.
DR   IPI; IPI00007769; -.
DR   PIR; JN0503; JN0503.
DR   RefSeq; NP_000295.1; -.
DR   RefSeq; NP_696996.1; -.
DR   RefSeq; NP_696997.1; -.
DR   UniGene; Hs.372031; -.
DR   STRING; Q01453; -.
DR   Ensembl; ENST00000312280; ENSP00000308937; ENSG00000109099; Homo sapiens.
DR   Ensembl; ENST00000395938; ENSP00000379269; ENSG00000109099; Homo sapiens.
DR   Ensembl; ENST00000426385; ENSP00000409824; ENSG00000109099; Homo sapiens.
DR   GeneID; 5376; -.
DR   KEGG; hsa:5376; -.
DR   UCSC; uc002goj.1; human.
DR   CTD; 5376; -.
DR   GeneCards; GC17M015073; -.
DR   H-InvDB; HIX0013554; -.
DR   HGNC; HGNC:9118; PMP22.
DR   MIM; 118220; phenotype.
DR   MIM; 118300; phenotype.
DR   MIM; 139393; phenotype.
DR   MIM; 145900; phenotype.
DR   MIM; 162500; phenotype.
DR   MIM; 601097; gene.
DR   Orphanet; 98916; Acute inflammatory demyelinating polyradiculoneuropathy.
DR   Orphanet; 65753; Charcot-Marie-Tooth disease, type 1.
DR   Orphanet; 101081; Charcot-Marie-Tooth disease, type 1A.
DR   Orphanet; 90658; Charcot-Marie-Tooth disease, type 1E.
DR   Orphanet; 99951; Charcot-Marie-Tooth disease, type 4E.
DR   Orphanet; 2932; Chronic inflammatory demyelinating polyneuropathy.
DR   Orphanet; 64748; Dejerine-Sottas syndrome.
DR   Orphanet; 2103; Guillain-Barre syndrome.
DR   Orphanet; 640; Hereditary neuropathy with liability to pressure palsies.
DR   PharmGKB; PA33444; -.
DR   eggNOG; prNOG20364; -.
DR   HOGENOM; HBG443769; -.
DR   HOVERGEN; HBG001690; -.
DR   InParanoid; Q01453; -.
DR   OMA; STIVSAW; -.
DR   PhylomeDB; Q01453; -.
DR   Pathway_Interaction_DB; a6b1_a6b4_integrin_pathway; a6b1 and a6b4 Integrin signaling.
DR   NextBio; 20856; -.
DR   ArrayExpress; Q01453; -.
DR   Bgee; Q01453; -.
DR   CleanEx; HS_PMP22; -.
DR   Genevestigator; Q01453; -.
DR   GermOnline; ENSG00000109099; Homo sapiens.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0007422; P:peripheral nervous system development; TAS:ProtInc.
DR   GO; GO:0007268; P:synaptic transmission; TAS:ProtInc.
DR   InterPro; IPR003936; PMP22.
DR   InterPro; IPR004031; PMP22/EMP/MP20/Claudin.
DR   InterPro; IPR004032; PMP22_EMP_MP20.
DR   PANTHER; PTHR10671; PMP22_EMP_MP20; 1.
DR   Pfam; PF00822; PMP22_Claudin; 1.
DR   PRINTS; PR01453; EPMEMFAMILY.
DR   PRINTS; PR01458; PMYELIN22.
DR   PROSITE; PS01221; PMP22_1; 1.
DR   PROSITE; PS01222; PMP22_2; 1.
PE   1: Evidence at protein level;
KW   Charcot-Marie-Tooth disease; Complete proteome; Deafness;
KW   Dejerine-Sottas syndrome; Disease mutation; Glycoprotein; Membrane;
KW   Neuropathy; Polymorphism; Transmembrane.
FT   CHAIN         1    160       Peripheral myelin protein 22.
FT                                /FTId=PRO_0000164650.
FT   TRANSMEM      2     31       By similarity.
FT   TRANSMEM     65     91       By similarity.
FT   TRANSMEM     96    119       By similarity.
FT   TRANSMEM    134    156       By similarity.
FT   CARBOHYD     41     41       N-linked (GlcNAc...) (Potential).
FT   VARIANT      12     12       H -> Q (in DSS).
FT                                /FTId=VAR_006359.
FT   VARIANT      16     16       L -> P (in CMT1A and DSS).
FT                                /FTId=VAR_006360.
FT   VARIANT      19     19       L -> P (in DSS).
FT                                /FTId=VAR_006361.
FT   VARIANT      22     22       S -> F (in HNPP and CMT1A).
FT                                /FTId=VAR_029960.
FT   VARIANT      23     23       T -> R (in CMT1E).
FT                                /FTId=VAR_029961.
FT   VARIANT      25     26       Missing (in CMT1A).
FT                                /FTId=VAR_029962.
FT   VARIANT      28     28       W -> R (in CMT1E).
FT                                /FTId=VAR_029963.
FT   VARIANT      30     30       V -> M (in HNPP).
FT                                /FTId=VAR_009659.
FT   VARIANT      37     37       D -> V (in CMT1A; with focally folded
FT                                myelin sheaths).
FT                                /FTId=VAR_009660.
FT   VARIANT      65     65       V -> F (in CMT1A).
FT                                /FTId=VAR_029964.
FT   VARIANT      67     67       A -> P (in CMT1E).
FT                                /FTId=VAR_009661.
FT   VARIANT      67     67       A -> T (in HNPP).
FT                                /FTId=VAR_029965.
FT   VARIANT      69     69       M -> K (in DSS).
FT                                /FTId=VAR_006362.
FT   VARIANT      71     71       L -> P (in DSS).
FT                                /FTId=VAR_029966.
FT   VARIANT      72     72       S -> L (in DSS and CMT1A).
FT                                /FTId=VAR_006363.
FT   VARIANT      72     72       S -> P (in DSS).
FT                                /FTId=VAR_006364.
FT   VARIANT      72     72       S -> W (in DSS).
FT                                /FTId=VAR_006365.
FT   VARIANT      76     76       S -> I (in DSS).
FT                                /FTId=VAR_006366.
FT   VARIANT      79     79       S -> C (in CMT1A).
FT                                /FTId=VAR_006367.
FT   VARIANT      79     79       S -> P (in DSS).
FT                                /FTId=VAR_006368.
FT   VARIANT      80     80       L -> P (in DSS).
FT                                /FTId=VAR_006369.
FT   VARIANT      80     80       L -> R (in DSS).
FT                                /FTId=VAR_029967.
FT   VARIANT      84     84       Missing (in DSS).
FT                                /FTId=VAR_006370.
FT   VARIANT      93     93       G -> R (in CMT1A).
FT                                /FTId=VAR_009662.
FT   VARIANT     100    100       G -> E (in DSS).
FT                                /FTId=VAR_006371.
FT   VARIANT     100    100       G -> R (in DSS).
FT                                /FTId=VAR_006372.
FT   VARIANT     105    105       L -> R (in CMT1A and DSS).
FT                                /FTId=VAR_006373.
FT   VARIANT     107    107       G -> V (in CMT1A).
FT                                /FTId=VAR_006374.
FT   VARIANT     109    109       C -> R (in DSS).
FT                                /FTId=VAR_029968.
FT   VARIANT     115    118       Missing (in CMT1E).
FT                                /FTId=VAR_029969.
FT   VARIANT     118    118       T -> M (in CMT1A).
FT                                /FTId=VAR_006375.
FT   VARIANT     137    137       I -> V.
FT                                /FTId=VAR_006376.
FT   VARIANT     147    147       L -> R (in CMT1A).
FT                                /FTId=VAR_006377.
FT   VARIANT     149    149       S -> R (in DSS).
FT                                /FTId=VAR_029970.
FT   VARIANT     150    150       G -> C (in DSS).
FT                                /FTId=VAR_006378.
FT   VARIANT     150    150       G -> D (in DSS).
FT                                /FTId=VAR_006379.
FT   VARIANT     157    157       R -> G (in dbSNP:rs28936682).
FT                                /FTId=VAR_009663.
FT   VARIANT     157    157       R -> W (in DSS; dbSNP:rs28936682).
FT                                /FTId=VAR_009664.
SQ   SEQUENCE   160 AA;  17891 MW;  7ECF7F91BED0CF9D CRC64;
     MLLLLLSIIV LHVAVLVLLF VSTIVSQWIV GNGHATDLWQ NCSTSSSGNV HHCFSSSPNE
     WLQSVQATMI LSIIFSILSL FLFFCQLFTL TKGGRFYITG IFQILAGLCV MSAAAIYTVR
     HPEWHLNSDY SYGFAYILAW VAFPLALLSG VIYVILRKRE
//
ID   POLG_HCV1               Reviewed;        3011 AA.
AC   P26664; Q9IFE5;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 113.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 1a (isolate 1) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=11104;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=91172826; PubMed=1848704; DOI=10.1073/pnas.88.6.2451;
RA   Choo Q.-L., Richman K.H., Han J.H., Berger K., Lee C., Dong C.,
RA   Gallegos C., Coit D., Medina-Selby A., Barr P.J., Weiner A.J.,
RA   Bradley D.W., Kuo G., Houghton M.;
RT   "Genetic organization and diversity of the hepatitis C virus.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:2451-2455(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Infectious clone pHCV-1/SF;
RX   MEDLINE=21262212; PubMed=11369872;
RA   Lanford R.E., Lee H., Chavez D., Guerra B., Brasky K.M.;
RT   "Infectious cDNA clone of the hepatitis C virus genotype 1 prototype
RT   sequence.";
RL   J. Gen. Virol. 82:1291-1297(2001).
RN   [3]
RP   PROTEIN SEQUENCE OF 2-16, AND SUBCELLULAR LOCATION OF CORE PROTEIN.
RX   MEDLINE=96074521; PubMed=7491770; DOI=10.1006/viro.1995.0018;
RA   Lo S.-Y., Masiarz F., Hwang S.B., Lai M.M.C., Ou J.-H.;
RT   "Differential subcellular localization of hepatitis C virus core gene
RT   products.";
RL   Virology 213:455-461(1995).
RN   [4]
RP   FUNCTION OF CORE PROTEIN.
RX   MEDLINE=96136654; PubMed=8533458; DOI=10.1016/0168-1702(95)00034-N;
RA   Ray R.B., Lagging L.M., Meyer K., Steele R., Ray R.;
RT   "Transcriptional regulation of cellular and viral promoters by the
RT   hepatitis C virus core protein.";
RL   Virus Res. 37:209-220(1995).
RN   [5]
RP   INTERACTION OF CORE PROTEIN WITH E1 PROTEIN.
RX   PubMed=8764026;
RA   Lo S.-Y., Selby M.J., Ou J.-H.;
RT   "Interaction between hepatitis C virus core protein and E1 envelope
RT   protein.";
RL   J. Virol. 70:5177-5182(1996).
RN   [6]
RP   FUNCTION OF CORE PROTEIN.
RX   MEDLINE=97124641; PubMed=8955036; DOI=10.1006/viro.1996.0644;
RA   Ray R.B., Meyer K., Ray R.;
RT   "Suppression of apoptotic cell death by hepatitis C virus core
RT   protein.";
RL   Virology 226:176-182(1996).
RN   [7]
RP   FUNCTION OF CORE PROTEIN.
RX   MEDLINE=97268985; PubMed=9110985; DOI=10.1074/jbc.272.17.10983;
RA   Ray R.B., Steele R., Meyer K., Ray R.;
RT   "Transcriptional repression of p53 promoter by hepatitis C virus core
RT   protein.";
RL   J. Biol. Chem. 272:10983-10986(1997).
RN   [8]
RP   INTERACTION OF NS5A WITH HUMAN EIF2AK2/PKR.
RX   MEDLINE=97288299; PubMed=9143277; DOI=10.1006/viro.1997.8493;
RA   Gale M.J. Jr., Korth M.J., Tang N.M., Tan S.-L., Hopkins D.A.,
RA   Dever T.E., Polyak S.J., Gretch D.R., Katze M.G.;
RT   "Evidence that hepatitis C virus resistance to interferon is mediated
RT   through repression of the PKR protein kinase by the nonstructural 5A
RT   protein.";
RL   Virology 230:217-227(1997).
RN   [9]
RP   FUNCTION OF CORE PROTEIN.
RX   MEDLINE=98201630; PubMed=9524287; DOI=10.1016/S0378-1119(98)00030-4;
RA   Ray R.B., Steele R., Meyer K., Ray R.;
RT   "Hepatitis C virus core protein represses p21WAF1/Cip1/Sid1 promoter
RT   activity.";
RL   Gene 208:331-336(1998).
RN   [10]
RP   FUNCTION OF CORE PROTEIN.
RX   PubMed=9811706;
RA   Shrivastava A., Manna S.K., Ray R., Aggarwal B.B.;
RT   "Ectopic expression of hepatitis C virus core protein differentially
RT   regulates nuclear transcription factors.";
RL   J. Virol. 72:9722-9728(1998).
RN   [11]
RP   INTERACTION OF E2 WITH HUMAN EIF2AK2/PKR.
RX   MEDLINE=99322192; PubMed=10390359; DOI=10.1126/science.285.5424.107;
RA   Taylor D.R., Shi S.T., Romano P.R., Barber G.N., Lai M.M.C.;
RT   "Inhibition of the interferon-inducible protein kinase PKR by HCV E2
RT   protein.";
RL   Science 285:107-110(1999).
RN   [12]
RP   FUNCTION OF E2.
RX   MEDLINE=20583813; PubMed=11152499;
RX   DOI=10.1128/JVI.75.3.1265-1273.2001;
RA   Taylor D.R., Tian B., Romano P.R., Hinnebusch A.G., Lai M.M.C.,
RA   Mathews M.B.;
RT   "Hepatitis C virus envelope protein E2 does not inhibit PKR by simple
RT   competition with autophosphorylation sites in the RNA-binding
RT   domain.";
RL   J. Virol. 75:1265-1273(2001).
RN   [13]
RP   TOPOLOGY OF NS2 PROTEIN.
RX   MEDLINE=22194337; PubMed=12082096; DOI=10.1074/jbc.M202304200;
RA   Yamaga A.K., Ou J.-H.;
RT   "Membrane topology of the hepatitis C virus NS2 protein.";
RL   J. Biol. Chem. 277:33228-33234(2002).
RN   [14]
RP   INTERACTION OF NS5A WITH HUMAN SRC-FAMILY KINASES, AND MUTAGENESIS OF
RP   2001-PRO--PRO-2004; 2315-PRO--PRO-2318 AND 2322-PRO--PRO-2326.
RX   PubMed=14993658; DOI=10.1099/vir.0.19691-0;
RA   Macdonald A., Crowder K., Street A., McCormick C., Harris M.;
RT   "The hepatitis C virus NS5A protein binds to members of the Src family
RT   of tyrosine kinases and regulates kinase activity.";
RL   J. Gen. Virol. 85:721-729(2004).
RN   [15]
RP   SUBCELLULAR LOCATION OF CORE PROTEIN.
RX   PubMed=15254168; DOI=10.1128/JVI.78.15.7958-7968.2004;
RA   Schwer B., Ren S., Pietschmann T., Kartenbeck J., Kaehlcke K.,
RA   Bartenschlager R., Yen T.S.B., Ott M.;
RT   "Targeting of hepatitis C virus core protein to mitochondria through a
RT   novel C-terminal localization motif.";
RL   J. Virol. 78:7958-7968(2004).
RN   [16]
RP   FUNCTION OF NS5A.
RX   PubMed=15784895; DOI=10.1099/vir.0.80728-0;
RA   Kalliampakou K.I., Kalamvoki M., Mavromara P.;
RT   "Hepatitis C virus (HCV) NS5A protein downregulates HCV IRES-dependent
RT   translation.";
RL   J. Gen. Virol. 86:1015-1025(2005).
RN   [17]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [18]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [19]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection.
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation.
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein. Host mitochondrion
CC       membrane; Single-pass type I membrane protein. Host lipid droplet.
CC       Note=The C-terminal transmembrane domain of core protein p21
CC       contains an ER signal leading the nascent polyprotein to the ER
CC       membrane. Only a minor proportion of core protein is present in
CC       the nucleus and an unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion. Host cytoplasm.
CC       Host nucleus. Secreted.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Ribosomal frameshifting; Named isoforms=2;
CC         Comment=The exact location of the ribosomal frameshift is
CC         unknown. The F protein seems to be generated by a -2 ribosomal
CC         frameshift located in the vicinity of codon 11 of the core
CC         protein coding sequence. However, some F proteins may also be
CC         generated by +1 ribosomal frameshift. Since the core gene
CC         encodes alternative reading frame proteins (ARFPs), many
CC         functions depicted for the core protein might belong to the
CC         ARFPs;
CC       Name=Genome polyprotein;
CC         IsoId=P26664-1; Sequence=Displayed;
CC         Note=Produced by conventional translation;
CC       Name=F protein; Synonyms=Frameshifted protein;
CC         IsoId=P0C044-1; Sequence=External;
CC         Note=Produced by ribosomal frameshifting;
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain two highly variable regions called
CC       hypervariable region 1 and 2 (HVR1 and HVR2). E2 also contain two
CC       segments involved in CD81-binding. HVR1 is implicated in the
CC       SCARB1-mediated cell entry. HVR2 and CD81-binding regions may be
CC       involved in sensitivity and/or resistance to IFN-alpha therapy (By
CC       similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A seems to be intrinsically disordered and
CC       interacts with NS5B and host PKR. The C-terminus of NS5A contains
CC       a variable region called variable region 3 (V3) (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases.
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M62321; AAA45676.1; -; Genomic_RNA.
DR   EMBL; AF271632; AAF81759.1; -; Genomic_RNA.
DR   PIR; A39166; GNWVC3.
DR   PDB; 1RTL; X-ray; 2.75 A; A/B=1022-1207.
DR   PDB; 2A4G; X-ray; 2.50 A; A/C=1027-1207.
DR   PDB; 2GVF; X-ray; 2.50 A; A/C=1027-1207, B/D=1680-1696.
DR   PDB; 3EYD; X-ray; 2.30 A; A/C=1027-1207, B/D=1680-1696.
DR   PDBsum; 1RTL; -.
DR   PDBsum; 2A4G; -.
DR   PDBsum; 2GVF; -.
DR   PDBsum; 3EYD; -.
DR   MEROPS; C18.001; -.
DR   MEROPS; S29.001; -.
DR   euHCVdb; AF271632; -.
DR   euHCVdb; M62321; -.
DR   PMAP-CutDB; P26664; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; FALSE_NEG.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Direct protein sequencing; Disulfide bond;
KW   Envelope protein; Fusion protein; Glycoprotein; Helicase;
KW   Host cell membrane; Host cytoplasm; Host endoplasmic reticulum;
KW   Host lipid droplet; Host membrane; Host mitochondrion; Host nucleus;
KW   Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; Ribosomal frameshifting; RNA replication;
KW   RNA-binding; RNA-directed RNA polymerase; Secreted; Serine protease;
KW   SH3-binding; Thiol protease; Transcription; Transcription regulation;
KW   Transferase; Transmembrane; Ubl conjugation; Viral nucleoprotein;
KW   Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host.
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000037517.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000037518.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000037519.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000037520.
FT   CHAIN       384    746       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000037521.
FT   CHAIN       747    809       p7 (By similarity).
FT                                /FTId=PRO_0000037522.
FT   CHAIN       810   1026       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000037523.
FT   CHAIN      1027   1657       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000037524.
FT   CHAIN      1658   1711       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000037525.
FT   CHAIN      1712   1972       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000037526.
FT   CHAIN      1973   2420       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000037527.
FT   CHAIN      2421   3011       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000037528.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    725       Lumenal (Potential).
FT   TRANSMEM    726    746       Potential.
FT   TOPO_DOM    747    757       Lumenal (Potential).
FT   TRANSMEM    758    778       Potential.
FT   TOPO_DOM    779    782       Cytoplasmic (Potential).
FT   TRANSMEM    783    803       Potential.
FT   TOPO_DOM    804    813       Lumenal (Potential).
FT   TRANSMEM    814    834       Potential.
FT   TOPO_DOM    835    881       Cytoplasmic (Potential).
FT   TRANSMEM    882    902       Potential.
FT   TOPO_DOM    903    928       Lumenal (Potential).
FT   TRANSMEM    929    949       Potential.
FT   TOPO_DOM    950   1657       Cytoplasmic (Potential).
FT   TRANSMEM   1658   1678       Potential.
FT   TOPO_DOM   1679   1805       Cytoplasmic (Potential).
FT   TRANSMEM   1806   1826       Potential.
FT   TOPO_DOM   1827   1828       Lumenal (Potential).
FT   TRANSMEM   1829   1849       Potential.
FT   TOPO_DOM   1850   1850       Cytoplasmic (Potential).
FT   TRANSMEM   1851   1871       Potential.
FT   TOPO_DOM   1872   1881       Lumenal (Potential).
FT   TRANSMEM   1882   1902       Potential.
FT   TOPO_DOM   1903   1972       Cytoplasmic (Potential).
FT   TOPO_DOM   1973   2002       In membrane.
FT   TOPO_DOM   2003   2990       Cytoplasmic (Potential).
FT   TRANSMEM   2991   3011       By similarity.
FT   DOMAIN     1217   1369       Helicase ATP-binding.
FT   DOMAIN     2634   2752       RdRp catalytic.
FT   NP_BIND    1230   1237       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal
FT                                (Probable).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      385    411       HVR1 (By similarity).
FT   REGION      475    481       HVR2 (By similarity).
FT   REGION      482    494       CD81-binding 1 (Potential).
FT   REGION      522    553       CD81-binding 2 (Potential).
FT   REGION      660    671       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD).
FT   REGION     1679   1690       NS3-binding (by NS4A) (Potential).
FT   REGION     2120   2332       Transcriptional activation (Potential).
FT   REGION     2120   2208       FKBP8-binding (Potential).
FT   REGION     2200   2250       Basal phosphorylation (By similarity).
FT   REGION     2210   2275       PKR-binding (Potential).
FT   REGION     2249   2306       NS4B-binding (Potential).
FT   REGION     2351   2420       Basal phosphorylation (By similarity).
FT   REGION     2354   2377       V3 (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1316   1319       DECH box.
FT   MOTIF      2322   2325       SH3-binding (Potential).
FT   MOTIF      2327   2335       Nuclear localization signal (Potential).
FT   COMPBIAS    796    803       Poly-Leu.
FT   COMPBIAS   1432   1435       Poly-Val.
FT   COMPBIAS   2286   2327       Pro-rich.
FT   COMPBIAS   2996   2999       Poly-Leu.
FT   ACT_SITE    952    952       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    972    972       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    993    993       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1083   1083       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1107   1107       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1165   1165       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1123   1123       Zinc (By similarity).
FT   METAL      1125   1125       Zinc (By similarity).
FT   METAL      1171   1171       Zinc (By similarity).
FT   METAL      1175   1175       Zinc (By similarity).
FT   METAL      2011   2011       Zinc (By similarity).
FT   METAL      2029   2029       Zinc (By similarity).
FT   METAL      2031   2031       Zinc (By similarity).
FT   METAL      2052   2052       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        191    192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        746    747       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        809    810       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1026   1027       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1657   1658       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1711   1712       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1972   1973       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2420   2421       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2194   2194       Phosphoserine; by host; in p56 (By
FT                                similarity).
FT   MOD_RES    2197   2197       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2201   2201       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2204   2204       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2321   2321       Phosphoserine; by host (By similarity).
FT   LIPID      1968   1968       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   LIPID      1972   1972       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    417    417       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    423    423       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    430    430       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    448    448       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    476    476       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    532    532       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    540    540       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    556    556       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    576    576       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    623    623       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    645    645       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2114   2162       By similarity.
FT   VARIANT       9     11       KKN -> RKT (in infectious clone pHCV-1/
FT                                SF).
FT   VARIANT     399    399       F -> S (in strain: Isolate infectious
FT                                clone pHCV-1/SF).
FT   VARIANT     402    402       L -> F (in strain: Isolate infectious
FT                                clone pHCV-1/SF).
FT   VARIANT     929    929       I -> A (in strain: Isolate infectious
FT                                clone pHCV-1/SF).
FT   VARIANT    1703   1703       R -> Q (in strain: Isolate infectious
FT                                clone pHCV-1/SF).
FT   VARIANT    2021   2021       V -> G (in strain: Isolate infectious
FT                                clone pHCV-1/SF).
FT   VARIANT    2349   2350       TR -> IK (in strain: Isolate infectious
FT                                clone pHCV-1/SF).
FT   VARIANT    2378   2378       P -> R (in strain: Isolate infectious
FT                                clone pHCV-1/SF).
FT   VARIANT    2413   2413       N -> S (in strain: Isolate infectious
FT                                clone pHCV-1/SF).
FT   VARIANT    2992   2992       I -> F (in strain: Isolate infectious
FT                                clone pHCV-1/SF).
FT   MUTAGEN    2001   2004       PQLP->AQLA: No effect on binding to Src-
FT                                family kinases.
FT   MUTAGEN    2315   2318       PLPP->ALAA: No effect on binding to Src-
FT                                family kinases.
FT   MUTAGEN    2322   2326       PPVPP->APVAA: Complete loss of binding to
FT                                GRB2 and Src-family kinases.
FT   HELIX      1043   1047
FT   STRAND     1059   1063
FT   STRAND     1068   1074
FT   STRAND     1078   1081
FT   TURN       1104   1107
FT   STRAND     1129   1133
FT   STRAND     1139   1143
FT   STRAND     1152   1154
FT   HELIX      1158   1161
FT   STRAND     1180   1186
FT   STRAND     1190   1195
FT   HELIX      1199   1205
SQ   SEQUENCE   3011 AA;  327202 MW;  65F8C9447FCE5AF9 CRC64;
     MSTNPKPQKK NKRNTNRRPQ DVKFPGGGQI VGGVYLLPRR GPRLGVRATR KTSERSQPRG
     RRQPIPKARR PEGRTWAQPG YPWPLYGNEG CGWAGWLLSP RGSRPSWGPT DPRRRSRNLG
     KVIDTLTCGF ADLMGYIPLV GAPLGGAARA LAHGVRVLED GVNYATGNLP GCSFSIFLLA
     LLSCLTVPAS AYQVRNSTGL YHVTNDCPNS SIVYEAADAI LHTPGCVPCV REGNASRCWV
     AMTPTVATRD GKLPATQLRR HIDLLVGSAT LCSALYVGDL CGSVFLVGQL FTFSPRRHWT
     TQGCNCSIYP GHITGHRMAW DMMMNWSPTT ALVMAQLLRI PQAILDMIAG AHWGVLAGIA
     YFSMVGNWAK VLVVLLLFAG VDAETHVTGG SAGHTVSGFV SLLAPGAKQN VQLINTNGSW
     HLNSTALNCN DSLNTGWLAG LFYHHKFNSS GCPERLASCR PLTDFDQGWG PISYANGSGP
     DQRPYCWHYP PKPCGIVPAK SVCGPVYCFT PSPVVVGTTD RSGAPTYSWG ENDTDVFVLN
     NTRPPLGNWF GCTWMNSTGF TKVCGAPPCV IGGAGNNTLH CPTDCFRKHP DATYSRCGSG
     PWITPRCLVD YPYRLWHYPC TINYTIFKIR MYVGGVEHRL EAACNWTRGE RCDLEDRDRS
     ELSPLLLTTT QWQVLPCSFT TLPALSTGLI HLHQNIVDVQ YLYGVGSSIA SWAIKWEYVV
     LLFLLLADAR VCSCLWMMLL ISQAEAALEN LVILNAASLA GTHGLVSFLV FFCFAWYLKG
     KWVPGAVYTF YGMWPLLLLL LALPQRAYAL DTEVAASCGG VVLVGLMALT LSPYYKRYIS
     WCLWWLQYFL TRVEAQLHVW IPPLNVRGGR DAVILLMCAV HPTLVFDITK LLLAVFGPLW
     ILQASLLKVP YFVRVQGLLR FCALARKMIG GHYVQMVIIK LGALTGTYVY NHLTPLRDWA
     HNGLRDLAVA VEPVVFSQME TKLITWGADT AACGDIINGL PVSARRGREI LLGPADGMVS
     KGWRLLAPIT AYAQQTRGLL GCIITSLTGR DKNQVEGEVQ IVSTAAQTFL ATCINGVCWT
     VYHGAGTRTI ASPKGPVIQM YTNVDQDLVG WPAPQGSRSL TPCTCGSSDL YLVTRHADVI
     PVRRRGDSRG SLLSPRPISY LKGSSGGPLL CPAGHAVGIF RAAVCTRGVA KAVDFIPVEN
     LETTMRSPVF TDNSSPPVVP QSFQVAHLHA PTGSGKSTKV PAAYAAQGYK VLVLNPSVAA
     TLGFGAYMSK AHGIDPNIRT GVRTITTGSP ITYSTYGKFL ADGGCSGGAY DIIICDECHS
     TDATSILGIG TVLDQAETAG ARLVVLATAT PPGSVTVPHP NIEEVALSTT GEIPFYGKAI
     PLEVIKGGRH LIFCHSKKKC DELAAKLVAL GINAVAYYRG LDVSVIPTSG DVVVVATDAL
     MTGYTGDFDS VIDCNTCVTQ TVDFSLDPTF TIETITLPQD AVSRTQRRGR TGRGKPGIYR
     FVAPGERPSG MFDSSVLCEC YDAGCAWYEL TPAETTVRLR AYMNTPGLPV CQDHLEFWEG
     VFTGLTHIDA HFLSQTKQSG ENLPYLVAYQ ATVCARAQAP PPSWDQMWKC LIRLKPTLHG
     PTPLLYRLGA VQNEITLTHP VTKYIMTCMS ADLEVVTSTW VLVGGVLAAL AAYCLSTGCV
     VIVGRVVLSG KPAIIPDREV LYREFDEMEE CSQHLPYIEQ GMMLAEQFKQ KALGLLQTAS
     RQAEVIAPAV QTNWQKLETF WAKHMWNFIS GIQYLAGLST LPGNPAIASL MAFTAAVTSP
     LTTSQTLLFN ILGGWVAAQL AAPGAATAFV GAGLAGAAIG SVGLGKVLID ILAGYGAGVA
     GALVAFKIMS GEVPSTEDLV NLLPAILSPG ALVVGVVCAA ILRRHVGPGE GAVQWMNRLI
     AFASRGNHVS PTHYVPESDA AARVTAILSS LTVTQLLRRL HQWISSECTT PCSGSWLRDI
     WDWICEVLSD FKTWLKAKLM PQLPGIPFVS CQRGYKGVWR VDGIMHTRCH CGAEITGHVK
     NGTMRIVGPR TCRNMWSGTF PINAYTTGPC TPLPAPNYTF ALWRVSAEEY VEIRQVGDFH
     YVTGMTTDNL KCPCQVPSPE FFTELDGVRL HRFAPPCKPL LREEVSFRVG LHEYPVGSQL
     PCEPEPDVAV LTSMLTDPSH ITAEAAGRRL ARGSPPSVAS SSASQLSAPS LKATCTANHD
     SPDAELIEAN LLWRQEMGGN ITRVESENKV VILDSFDPLV AEEDEREISV PAEILRKSRR
     FAQALPVWAR PDYNPPLVET WKKPDYEPPV VHGCPLPPPK SPPVPPPRKK RTVVLTESTL
     STALAELATR SFGSSSTSGI TGDNTTTSSE PAPSGCPPDS DAESYSSMPP LEGEPGDPDL
     SDGSWSTVSS EANAEDVVCC SMSYSWTGAL VTPCAAEEQK LPINALSNSL LRHHNLVYST
     TSRSACQRQK KVTFDRLQVL DSHYQDVLKE VKAAASKVKA NLLSVEEACS LTPPHSAKSK
     FGYGAKDVRC HARKAVTHIN SVWKDLLEDN VTPIDTTIMA KNEVFCVQPE KGGRKPARLI
     VFPDLGVRVC EKMALYDVVT KLPLAVMGSS YGFQYSPGQR VEFLVQAWKS KKTPMGFSYD
     TRCFDSTVTE SDIRTEEAIY QCCDLDPQAR VAIKSLTERL YVGGPLTNSR GENCGYRRCR
     ASGVLTTSCG NTLTCYIKAR AACRAAGLQD CTMLVCGDDL VVICESAGVQ EDAASLRAFT
     EAMTRYSAPP GDPPQPEYDL ELITSCSSNV SVAHDGAGKR VYYLTRDPTT PLARAAWETA
     RHTPVNSWLG NIIMFAPTLW ARMILMTHFF SVLIARDQLE QALDCEIYGA CYSIEPLDLP
     PIIQRLHGLS AFSLHSYSPG EINRVAACLR KLGVPPLRAW RHRARSVRAR LLARGGRAAI
     CGKYLFNWAV RTKLKLTPIA AAGQLDLSGW FTAGYSGGDI YHSVSHARPR WIWFCLLLLA
     AGVGIYLLPN R
//
ID   POLG_HCV6A              Reviewed;        3019 AA.
AC   Q5I2N3;
DT   10-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 54.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 6a (isolate 6a33) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=356391;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RA   Zhou X.M., Chan P.K.S., Tam J.S.L.;
RT   "Full genome sequence of HCV 6a virus strains isolated in Hong Kong.";
RL   Submitted (DEC-2004) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [3]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [4]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain a highly variable region called hypervariable
CC       region 1 (HVR1). E2 also contains two segments involved in CD81-
CC       binding. HVR1 is implicated in the SCARB1-mediated cell entry.
CC       CD81-binding regions may be involved in sensitivity and/or
CC       resistance to IFN-alpha therapy (By similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A seems to be intrinsically disordered and
CC       interacts with NS5B and host PKR (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY859526; AAW56714.1; -; Genomic_RNA.
DR   euHCVdb; AY859526; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; FALSE_NEG.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Disulfide bond; Envelope protein; Fusion protein;
KW   Glycoprotein; Helicase; Host cell membrane; Host cytoplasm;
KW   Host endoplasmic reticulum; Host lipid droplet; Host membrane;
KW   Host mitochondrion; Host nucleus; Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000045508.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000045509.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000045510.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000045511.
FT   CHAIN       384    751       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000045512.
FT   CHAIN       752    814       p7 (By similarity).
FT                                /FTId=PRO_0000045513.
FT   CHAIN       815   1031       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000045514.
FT   CHAIN      1032   1662       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000045515.
FT   CHAIN      1663   1716       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000045516.
FT   CHAIN      1717   1977       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000045517.
FT   CHAIN      1978   2428       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000045518.
FT   CHAIN      2429   3019       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000045519.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    730       Lumenal (Potential).
FT   TRANSMEM    731    751       Potential.
FT   TOPO_DOM    752    762       Lumenal (Potential).
FT   TRANSMEM    763    783       Potential.
FT   TOPO_DOM    784    787       Cytoplasmic (Potential).
FT   TRANSMEM    788    808       Potential.
FT   TOPO_DOM    809    818       Lumenal (Potential).
FT   TRANSMEM    819    839       Potential.
FT   TOPO_DOM    840    886       Cytoplasmic (Potential).
FT   TRANSMEM    887    907       Potential.
FT   TOPO_DOM    908    933       Lumenal (Potential).
FT   TRANSMEM    934    954       Potential.
FT   TOPO_DOM    955   1662       Cytoplasmic (Potential).
FT   TRANSMEM   1663   1683       Potential.
FT   TOPO_DOM   1684   1810       Cytoplasmic (Potential).
FT   TRANSMEM   1811   1831       Potential.
FT   TOPO_DOM   1832   1833       Lumenal (Potential).
FT   TRANSMEM   1834   1854       Potential.
FT   TOPO_DOM   1855   1855       Cytoplasmic (Potential).
FT   TRANSMEM   1856   1876       Potential.
FT   TOPO_DOM   1877   1886       Lumenal (Potential).
FT   TRANSMEM   1887   1907       Potential.
FT   TOPO_DOM   1908   1977       Cytoplasmic (Potential).
FT   TOPO_DOM   1978   2007       In membrane (By similarity).
FT   TOPO_DOM   2008   2998       Cytoplasmic (Potential).
FT   TRANSMEM   2999   3019       By similarity.
FT   DOMAIN     1222   1374       Helicase ATP-binding.
FT   DOMAIN     2642   2760       RdRp catalytic.
FT   NP_BIND    1235   1242       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      384    410       HVR1 (By similarity).
FT   REGION      483    495       CD81-binding 1 (Potential).
FT   REGION      523    554       CD81-binding 2 (Potential).
FT   REGION      665    676       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1684   1695       NS3-binding (by NS4A) (Potential).
FT   REGION     2125   2338       Transcriptional activation (Potential).
FT   REGION     2125   2213       FKBP8-binding (Potential).
FT   REGION     2205   2255       Basal phosphorylation (By similarity).
FT   REGION     2215   2280       PKR-binding (Potential).
FT   REGION     2254   2312       NS4B-binding (Potential).
FT   REGION     2357   2428       Basal phosphorylation (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1321   1324       DECH box (By similarity).
FT   MOTIF      2328   2331       SH3-binding (Potential).
FT   MOTIF      2333   2341       Nuclear localization signal (Potential).
FT   COMPBIAS   2282   2333       Pro-rich.
FT   COMPBIAS   2999   3007       Poly-Leu.
FT   ACT_SITE    957    957       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    977    977       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    998    998       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1088   1088       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1112   1112       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1170   1170       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1128   1128       Zinc (By similarity).
FT   METAL      1130   1130       Zinc (By similarity).
FT   METAL      1176   1176       Zinc (By similarity).
FT   METAL      1180   1180       Zinc (By similarity).
FT   METAL      2016   2016       Zinc (By similarity).
FT   METAL      2034   2034       Zinc (By similarity).
FT   METAL      2036   2036       Zinc (By similarity).
FT   METAL      2057   2057       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        191    192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        751    752       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        814    815       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1031   1032       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1662   1663       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1716   1717       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1977   1978       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2428   2429       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2199   2199       Phosphoserine; by host; in p56 (By
FT                                similarity).
FT   MOD_RES    2202   2202       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2206   2206       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2209   2209       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1977   1977       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    250    250       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    415    415       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    422    422       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    429    429       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    447    447       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    476    476       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    533    533       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    557    557       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    578    578       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    628    628       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    650    650       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2119   2167       By similarity.
SQ   SEQUENCE   3019 AA;  328857 MW;  FF1161164B164DF3 CRC64;
     MSTLPKPQRK TKRNTNRRPM DVKFPGGGQI VGGVYLLPRR GPRLGVRATR KTSERSQPRG
     RRQPIPKARQ PQGRHWAQPG YPWPLYGNEG CGWAGWLLSP RGSRPHWGPN DPRRRSRNLG
     KVIDTLTCGF ADLMGYIPVV GAPLGGVAAA LAHGVRAIED GINYATGNLP GCSFSIFLLA
     LLSCLTTPAS ALTYGNSSGL YHLTNDCPNS SIVLEADAMI LHLPGCLPCV KVGNQSTCWH
     AVSPTLAIPN ASTPATGFRR HVDLLAGAAV VCSSLYIGDL CGSLFLAGQL FTFQPRRHWT
     VQECNCSIYT GHVTGHRMAW DMMMSWSPTT TLVLSSILRV PEICASVIFG GHWGILLAVA
     YFGMAGNWLK VLAVLFLFAG VEATTTVGHG VARTTAGITG LFSPGASQNL QLIKNGSSWH
     INRTALNCND SLQTGFLASL FYVRKFNSSG CPERMAVCKS LADFRQGWGQ ITYKVNISGP
     SDDRPYCWHY APRPCDVVPA STVCGPVYCF TPSPVVIGTT DRRGNPTYTW GENETDVFML
     ESLRPPTGGW FGCTWMNSTG FTKTCGAPPC QIIPGDYNSS ANELLCPTDC FRKHPEATYQ
     RCGSGPWVTP RCLVDYPYRL WHYPCTVNFT VHKVRMFVGG IEHRFDAACN WTRGERCELH
     DRDRIEMSPL LFSTTQLAIL PCSFSTMPAL STGLIHLHQN IVDVQYLYGV SSSVTSWVVK
     WEYIVLMFLV LADARICTCL WLMLLISNVE AAVERLVVLN AASAAGTAGW WWAVLFLCCV
     WYVKGRLVPA CTYMALGMWP LLLTILALPH RAYAMDNEQA ASLGAVGLLA ITIFTITPTY
     KKLLTCFIWW NQYFLARAEA MVHEWVPDLR VRGGRDSIIL LTCLLHPQLG FEVTKILLAI
     LAPLYILQYS LLKVPYFVRA HILLRACLLV RRLAGGRYVQ ACLLRLGAWT GTFIYDHLAP
     LSDWASDGLR DLAVAVEPVI FSPMEKKIIT WGADTAACGD ILSGLPVSAR LGNLVLLGPA
     DDMQRGGWKL LAPITAYAQQ TRGLVGTIVT SLTGRDKNEV EGEVQVVSTA TQSFLATSIN
     GVMWTVYHGA GSKTLAGPKG PVCQMYTNVD KDLVGWPSPP GARSLTPCTC GSSDLYLVTR
     EADVIPARRR GDNRAALLSP RPISTLKGSS GGPVMCPSGH VVGLFRAAVC TRGVAKSLDF
     IPVENMETTM RSPSFTDNST PPAVPQTYQV GYLHAPTGSG KSTRVPAAYA SQGYKVLVLN
     PSVAATLSFG SYMRQAYGVE PNVRTGVRTV TTGGAITYST YGKFLADGGC SGGAYDIIIC
     DECHSTDPTT VLGIGTVLDQ AETAGARLTV LATATPPGSI TVPHPNITET ALPTTGEIPF
     YGKAIPLEYI KGGRHLIFCH SKKKCDELAG KLKSLGLNAV AFYRGVDVSV IPTSGDVVIC
     ATDALMTGYT GDFDSVIDCN VAVTQVVDFS LDPTFSIETT TVPQDAVSRS QRRGRTGRGK
     PGVYRFVSQG ERPSGMFDTV VLCEAYDTGC AWYELTPSET TVRLRAYMNT PGLPVCQDHL
     EFWEGVFTGL THIDAHFLSQ TKQGGENFAY LVAYQATVCA RAKAPPPSWD TMWKCLIRLK
     PTLTGPTPLL YRLGAVQNEI ITTHPITKYI MTCMSADLEV ITSTWVLVGG VLAALAAYCL
     SVGCVVICGR ITLTGKPAVV PDREILYQQF DEMEECSRHI PYLAEGQQIA EQFRQKVLGL
     LQASAKQAEE LKPAVHSAWP RMEEFWRKHM WNFVSGIQYL AGLSTLPGNP AVASLMSFTA
     SLTSPLRTSQ TLLLNILGGW IAAQVAPPPA STAFVVSGLA GAAVGSIRLG RVLVDVLAGY
     GAGVSGALVA FKIMSGDCPT TEDMVNLLPA LLSPGALVVG VVCAAILRRH VGPAEGANQW
     MNRLIAFASR GNHVSPTHYV PETDASKNVT QILTSLTITS LLRRLHQWVN EDTATPCATS
     WLRDVWDWVC TVLSDFKVWL QAKLFPRLPG IPFLSCQTGY RGVWAGDGVC HTTCTCGAVI
     AGHVKNGTMK ITGPKTCSNT WHGTFPINAT TTGPSTPRPA PNYQRALWRV SAEDYVEVRR
     LGDCHYVVGV TAEGLKCPCQ VPAPEFFTEV DGVRIHRYAP PCKPLLRDEV TFSVGLSNYA
     IGSQLPCEPE PDVTVVTSML TDPTHITAET ASRRLKRGSP PSLASSSASQ LSAPSLKATC
     TTSKDHPDME LIEANLLWRQ EMGGNITRVE SENKVVVLDS FEPLTAEYDE REISVSAECH
     RPPRHKFPPA LPIWARPDYN PPLLQAWQMP GYEPPVVSGC AVAPPKPAPI PPPRRKRLVH
     LDESTVSRAL AQLADKVFVE GSSDPGPSSD SGLSITSPDP PAPTTPDDAC SEAESYSSMP
     PLEGEPGDPD LSSGSWSTVS DQDDVVCCSM SYSWTGALIT PCAAEEEKLP INPLSNSLIR
     HHNMVYSTTS RSASLRQKKV TFDRLQVFDQ HYQDVLKEIK LRASTVQARL LSIEEACDLT
     PSHSARSKYG YGAQDVRSHA SKAINHIRSV WEDLLEDSDT PIPTTIMAKN EVFCVDPSKG
     GRKPARLIVY PDLGVRVCEK MALYDVTRKL PQAVMGSAYG FQYSPNQRVE YLLKMWRSKK
     VPMGFSYDTR CFDSTVTERD IRTENDIYQS CQLDPVARRA VSSLTERLYV GGPMVNSKGQ
     SCGYRRCRAS GVLPTSMGNT LTCYLKAQAA CRAANIKDCD MLVCGDDLVV ICESAGVQED
     TASLRAFTDA MTRYSAPPGD VPQPTYDLEL ITSCSSNVSV AHDGNGKRYY YLTRDCTTPL
     ARAAWETARH TPVNSWLGNI IMFAPTIWVR MVLMTHFFSI LQSQEQLEKA LDFDIYGVTY
     SVSPLDLPAI IQRLHGMAAF SLHGYSPTEL NRVGACLRKL GVPPLRAWRH RARAVRAKLI
     AQGGKAAICG KYLFNWAVKT KLKLTPLVSA SKLDLSGWFV AGYDGGDIYH SVSQARPRLL
     LLGLLLLTVG VGIFLVPAR
//
ID   POLG_HCVBB              Reviewed;        3037 AA.
AC   Q68749;
DT   10-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 79.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 2c (isolate BEBE1) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=356413;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=96215652; PubMed=8645105; DOI=10.1007/BF01718327;
RA   Nakao H., Okamoto H., Tokita H., Inoue T., Iizuka H., Pozzato G.,
RA   Mishiro S.;
RT   "Full-length genomic sequence of a hepatitis C virus genotype 2c
RT   isolate (BEBE1) and the 2c-specific PCR primers.";
RL   Arch. Virol. 141:701-704(1996).
RN   [2]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [3]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [4]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain a highly variable region called hypervariable
CC       region 1 (HVR1). E2 also contains two segments involved in CD81-
CC       binding. HVR1 is implicated in the SCARB1-mediated cell entry.
CC       CD81-binding regions may be involved in sensitivity and/or
CC       resistance to IFN-alpha therapy (By similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A seems to be intrinsically disordered and
CC       interacts with NS5B and host PKR (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D50409; BAA08911.1; -; Genomic_RNA.
DR   euHCVdb; D50409; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; FALSE_NEG.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Disulfide bond; Envelope protein; Fusion protein;
KW   Glycoprotein; Helicase; Host cell membrane; Host cytoplasm;
KW   Host endoplasmic reticulum; Host lipid droplet; Host membrane;
KW   Host mitochondrion; Host nucleus; Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000045520.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000045521.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000045522.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000045523.
FT   CHAIN       384    750       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000045524.
FT   CHAIN       751    813       p7 (By similarity).
FT                                /FTId=PRO_0000045525.
FT   CHAIN       814   1030       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000045526.
FT   CHAIN      1031   1661       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000045527.
FT   CHAIN      1662   1715       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000045528.
FT   CHAIN      1716   1976       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000045529.
FT   CHAIN      1977   2446       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000045530.
FT   CHAIN      2447   3037       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000045531.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    729       Lumenal (Potential).
FT   TRANSMEM    730    750       Potential.
FT   TOPO_DOM    751    761       Lumenal (Potential).
FT   TRANSMEM    762    782       Potential.
FT   TOPO_DOM    783    786       Cytoplasmic (Potential).
FT   TRANSMEM    787    807       Potential.
FT   TOPO_DOM    808    817       Lumenal (Potential).
FT   TRANSMEM    818    838       Potential.
FT   TOPO_DOM    839    885       Cytoplasmic (Potential).
FT   TRANSMEM    886    906       Potential.
FT   TOPO_DOM    907    932       Lumenal (Potential).
FT   TRANSMEM    933    953       Potential.
FT   TOPO_DOM    954   1661       Cytoplasmic (Potential).
FT   TRANSMEM   1662   1682       Potential.
FT   TOPO_DOM   1683   1809       Cytoplasmic (Potential).
FT   TRANSMEM   1810   1830       Potential.
FT   TOPO_DOM   1831   1832       Lumenal (Potential).
FT   TRANSMEM   1833   1853       Potential.
FT   TOPO_DOM   1854   1854       Cytoplasmic (Potential).
FT   TRANSMEM   1855   1875       Potential.
FT   TOPO_DOM   1876   1885       Lumenal (Potential).
FT   TRANSMEM   1886   1906       Potential.
FT   TOPO_DOM   1907   1976       Cytoplasmic (Potential).
FT   TOPO_DOM   1977   2006       In membrane (By similarity).
FT   TOPO_DOM   2007   3016       Cytoplasmic (Potential).
FT   TRANSMEM   3017   3037       By similarity.
FT   DOMAIN     1221   1373       Helicase ATP-binding.
FT   DOMAIN     2660   2778       RdRp catalytic.
FT   NP_BIND    1234   1241       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      385    411       HVR1 (By similarity).
FT   REGION      484    496       CD81-binding 1 (Potential).
FT   REGION      524    555       CD81-binding 2 (Potential).
FT   REGION      664    675       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1683   1694       NS3-binding (by NS4A) (Potential).
FT   REGION     2124   2336       Transcriptional activation (Potential).
FT   REGION     2124   2212       FKBP8-binding (Potential).
FT   REGION     2204   2254       Basal phosphorylation (By similarity).
FT   REGION     2214   2279       PKR-binding (Potential).
FT   REGION     2253   2310       NS4B-binding (Potential).
FT   REGION     2355   2446       Basal phosphorylation (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1320   1323       DECH box (By similarity).
FT   MOTIF      2326   2329       SH3-binding (Potential).
FT   MOTIF      2331   2339       Nuclear localization signal (Potential).
FT   COMPBIAS    290    293       Poly-Val.
FT   COMPBIAS    742    745       Poly-Leu.
FT   COMPBIAS   1436   1439       Poly-Val.
FT   COMPBIAS   2281   2331       Pro-rich.
FT   COMPBIAS   2332   2335       Poly-Arg.
FT   COMPBIAS   3017   3025       Poly-Leu.
FT   ACT_SITE    956    956       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    976    976       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    997    997       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1087   1087       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1111   1111       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1169   1169       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1127   1127       Zinc (By similarity).
FT   METAL      1129   1129       Zinc (By similarity).
FT   METAL      1175   1175       Zinc (By similarity).
FT   METAL      1179   1179       Zinc (By similarity).
FT   METAL      2015   2015       Zinc (By similarity).
FT   METAL      2033   2033       Zinc (By similarity).
FT   METAL      2035   2035       Zinc (By similarity).
FT   METAL      2056   2056       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        191    192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        750    751       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        813    814       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1030   1031       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1661   1662       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1715   1716       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1976   1977       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2446   2447       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2198   2198       Phosphoserine; by host; in p56 (By
FT                                similarity).
FT   MOD_RES    2201   2201       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2205   2205       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2208   2208       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1972   1972       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   LIPID      1976   1976       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    417    417       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    423    423       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    430    430       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    448    448       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    534    534       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    542    542       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    558    558       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    578    578       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    627    627       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    649    649       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2118   2166       By similarity.
SQ   SEQUENCE   3037 AA;  329405 MW;  024337215F0B3CAD CRC64;
     MSTNPKPQRK TKRNTNRRPQ DVKFPGGGQI VGGVYLLPRR GPRLGVRAAR KTSERSQPRG
     RRQPIPKDRR STGKSWGRPG YPWPLYRNEG LGWAGWLLSP RGSRPSWGPS DPRHKSRNLG
     KVIDTLTCGF ADLMGYIPVV GAPVGGVARA LAHGVRVLED GINYATGNLP GCSFSIFLLA
     LLSCISVPVS AVEVRNTSSS YMATNDCSNS SIVWQLEGAV LHTPGCVPCE KTGNKSRCWV
     PVTPNIAINQ PGALTKGLRA HIDVIVMSAT LCSALYVGDV CGALMIAAQV VVVSPQHHHF
     VQECNCSIYP GKITGHRMAW DMMMNWSPTT TMLLAYLVRI PEVVLDIITG GHWGVMFGLA
     YFSMQGAWAK VVVILLLTAG VEASTYTTGA VVGRSTHLFT SMFSLGSQQR VQLIHTNGSW
     HINRTALNCN DSLETGFLAA LFYTSSFNSS GCPERLAACR SIESFRIGWG SLEYEESVTN
     DADMRPYCWH YPPRPCGIVP ARTVCGPVYC FTPSPVVVGT TDRAGAPTYN WGENETDVFL
     LNSTRPPKGA WFGCTWMNGT GFTKTCGAPP CRIRKDFNAS EDLLCPTDCF RKHPGATYIK
     CGAGPWLTPR CLVDYPYRLW HYPCTVNYTI YKVRMFVGGI EHRLQAACNF TRGDRCNLED
     RDRSQLSPLL HSTTEWAILP CSYTDLPALS TGLLHLHQNI VDVQYLYGLS PAITKYVVKW
     EWVVLLFLLL ADARVCACLW MLLLLGQAEA ALEKLVILHA ASAASSNGLL YFILFFVAAW
     CIKGRAVPMV TYTLLGCWSF VLLLMALPHQ AYALDAAEQG QIGMALLIAI TAFTITPAYK
     ILLSRCLWWT CYMLVLAEAL IQDWIPPLQA RGGRDGVIWA MTMFYPGVVF DITKWLLAIL
     GPGYLFRAAV MRTPYFVRAN ALLRMCALVK QLAGGKYVQV ALITLGKWTG TYIYDHLSPM
     SDWAADGLRD LAVAVEPIVF SPMERKVIVW GAETTACGDI IHGLPVSARL GQEVLLGPAD
     GYTSKGWRLL APITAYAQQT RGLLSAIVVS MTGRDKTDQA GEIQVLSTVT QSFLGTSISG
     VLWTVFHGAG NKTLAGSRGP VTQMYSSAEG DLVGWPSPPG TRSLEPCTCG AVDLYLVTRN
     ADVIPARRRG DRRGALLSPR PLSSLKGSSG GPVLCPRGHA VGIFRAAVCS RGVAKSIDFI
     PVESLDVVTR SPNFTDNSTP PAVPQTYQVG YLHAPTGSGK STKVPAAYAA QGYKVLVLNP
     SVAATLGFGA YMSKAYGINP NIRTGVRTVT TGDAITYSTY GKFLADGGCS GGAYDVIICD
     ECHSVDSTTI LGIGTVLDQA ETAGVRLTVL ATATPPGSVT TPHPNIEEVA LGHEGEIPFY
     GKAIPLSAIK GGRHLIFCHS KKKCDELAVA LRGMGLNAVA YYRGLDVSII PTQGDVVVVA
     TDALMTGYTG DFDSVIDCNV AVTQVVDFSL DPTFTITTQT VPQDSVSRSQ RRGRTGRGRL
     GIYRYVSSGE RASGMFDTVV LCECYDAGAA WYELTPAETT VRLRAYFNTP GLPVCQDHLE
     FWEAVFTGLT HIDAHFLSQT KQAGEGFPYL VAYQATVCAR AKAPPPSWDV MWKCLIRLKP
     TLVGPTPLLY RLGSVTNEVT LTHPVTKYIA TCMQADLEIM TSTWVLAGGV LAAVAAYCLA
     TGCVSIIGRI HVNQKTIIAP DKEVLYEAFD EMEECASRTA LIEEGHRIAE MLKSKIQGLM
     QQASKQAQGV QPAVQATWPK LEQFWAKHMW NFISGIQYLA GLSTLPGNPA VASMMSFSAA
     LTSPLSTSTT ILLNIMGGWL ASQIAPPAGA TGFVVSGLVG AAVGSIGLGK ILVDVLAGYG
     AGISGALVAF KIMSGEKPSV EDVVNLLPAI LSPGALVVGV ICAAILRRHV GQGEGAVQWM
     NRLIAFASRG NHVAPTHYVA ESDASQRVTQ LLGSLTITSL LRRLHQWITE DCPVPCSGSW
     LRDVWDWVCS ILIDFKNWLS AKLFPRLPGI PFISCQKGYR GTWAGTGIMT TRCPCGANIT
     GNVRLGTMRI SGPKTCLNTW QGTFPINCYT EGSCVPKPAP NFKTAIWRVA ASEYAEVTQH
     DSHAYVTGLT ADNLKVPCQL PCPEFFSWVD GVQIHRFAPT PKAFMRDEVS FSVGLNSYVV
     GSQLPCEPEP DTEVLASMLT DPSHITAEAA ARRLARGSPP SAASSSASQL SAPSLRATCT
     THAKCPDIDM VDANLFCWCT MGGNMTRIES ESKVLMVDSF DPVVDKEDER EPSIPSEYLL
     PKSRFPPALP PWARPDYNPP LLETWKRPDY QPPVVAGCAL PPPGTTPVPP PRRRRAVVLD
     QSNVGEALKE LAIKSFGCPP PSGDPGHSTG GGTTGETSKS PPDEPDDSEA GSVSSMPPLE
     GEPGDPDLEP EQVEHPAPPQ EGGAAPGSDS GSWSTCSDVD DSVVCCSMSY SWTGALITPC
     SPEEEKLPIN PLSNSLLRYH NKVYCTTSRS ASQRAKKVTF DRVQLLDSHY ESVLKDVKQA
     ATKVSAKLLS IEEACALTPP HSARSKYGFG AKEVRSLSRR AVDHIKSVWE DLLEDHCSPI
     DTTIMAKNEV FCVDPTKGGK KPARLIVYPD LGVRVCEKMA LYDITQKLPV AVMGQSYGFQ
     YSPAQRVDFL LQAWKEKKTP MGFSYDTRCF DSTVTERDIR TEESIYLSCS LPEEARTAIH
     SLTERLYVGG PMTNSKGQSC GYRRCRASGV LTTSMGNTLT CYVKAKAACN AAGIVAPTML
     VCGDDLVVIS ESQGVEEDER NLRVFTEAMT RYSAPPGDPP KAEYDLELIT SCSSNVSVAL
     DPRGRRRYYL TRDPTTPLAR AAWETARHSP VNSWLGNIIQ YAPTVWVRMV LMTHFFSVLM
     AQDTLDQDLN FEMYGAVYSV SPLDLPAIIE RLHGLEAFSL HSYSPHELTR VAAALRKLGA
     PPLRAWKSRA RAVRASLISR GGSAATCGRY LFNWAVRTKL KLTPLPAARL LDLSSWFTVS
     AGGGDIYHSV SRARPRLLLL GLLLLCVGVG IFLLPAR
//
ID   POLG_HCVBK              Reviewed;        3010 AA.
AC   P26663;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 120.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 1b (isolate BK) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=11105;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=91140698; PubMed=1847440;
RA   Takamizawa A., Mori C., Fuke I., Manabe S., Murakami S., Fujita J.,
RA   Onishi E., Andoh T., Yoshida I., Okayama H.;
RT   "Structure and organization of the hepatitis C virus genome isolated
RT   from human carriers.";
RL   J. Virol. 65:1105-1113(1991).
RN   [2]
RP   PROTEIN SEQUENCE OF 1487-1500.
RX   MEDLINE=96235224; PubMed=8647104;
RX   DOI=10.1111/j.1432-1033.1996.0611p.x;
RA   Borowski P., Heiland M., Oehlmann K., Becker B., Korneteky L.;
RT   "Non-structural protein 3 of hepatitis C virus inhibits
RT   phosphorylation mediated by cAMP-dependent protein kinase.";
RL   Eur. J. Biochem. 237:611-618(1996).
RN   [3]
RP   SUBCELLULAR LOCATION, AND RNA BINDING ACTIVITY OF CORE PROTEIN.
RX   PubMed=8189501;
RA   Santolini E., Migliaccio G., La Monica N.;
RT   "Biosynthesis and biochemical properties of the hepatitis C virus core
RT   protein.";
RL   J. Virol. 68:3631-3641(1994).
RN   [4]
RP   CHARACTERIZATION OF PROTEASE NS2-3.
RX   PubMed=9261354;
RA   Pieroni L., Santolini E., Fipaldini C., Pacini L., Migliaccio G.,
RA   La Monica N.;
RT   "In vitro study of the NS2-3 protease of hepatitis C virus.";
RL   J. Virol. 71:6373-6380(1997).
RN   [5]
RP   FUNCTION OF NS5A.
RX   PubMed=9710605;
RA   Gale M.J. Jr., Blakely C.M., Kwieciszewski B., Tan S.-L., Dossett M.,
RA   Tang N.M., Korth M.J., Polyak S.J., Gretch D.R., Katze M.G.;
RT   "Control of PKR protein kinase by hepatitis C virus nonstructural 5A
RT   protein: molecular mechanisms of kinase regulation.";
RL   Mol. Cell. Biol. 18:5208-5218(1998).
RN   [6]
RP   INTERACTION OF NS5A WITH HUMAN GRB2, AND MUTAGENESIS OF PRO-2322;
RP   PRO-2323 AND PRO-2326.
RX   MEDLINE=99254075; PubMed=10318918; DOI=10.1073/pnas.96.10.5533;
RA   Tan S.-L., Nakao H., He Y., Vijaysri S., Neddermann P., Jacobs B.L.,
RA   Mayer B.J., Katze M.G.;
RT   "NS5A, a nonstructural protein of hepatitis C virus, binds growth
RT   factor receptor-bound protein 2 adaptor protein in a Src homology 3
RT   domain/ligand-dependent manner and perturbs mitogenic signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:5533-5538(1999).
RN   [7]
RP   MUTAGENESIS OF SER-2194.
RX   PubMed=11118372; DOI=10.1006/viro.2000.0662;
RA   Katze M.G., Kwieciszewski B., Goodlett D.R., Blakely C.M.,
RA   Neddermann P., Tan S.-L., Aebersold R.;
RT   "Ser(2194) is a highly conserved major phosphorylation site of the
RT   hepatitis C virus nonstructural protein NS5A.";
RL   Virology 278:501-513(2000).
RN   [8]
RP   CHARACTERIZATION OF PROTEASE NS2-3.
RX   MEDLINE=21588263; PubMed=11591719; DOI=10.1074/jbc.M108266200;
RA   Thibeault D., Maurice R., Pilote L., Lamarre D., Pause A.;
RT   "In vitro characterization of a purified NS2/3 protease variant of
RT   hepatitis C virus.";
RL   J. Biol. Chem. 276:46678-46684(2001).
RN   [9]
RP   INTERACTION OF NS5A WITH HUMAN PIK3R1.
RX   PubMed=12186904; DOI=10.1128/JVI.76.18.9207-9217.2002;
RA   He Y., Nakao H., Tan S.-L., Polyak S.J., Neddermann P., Vijaysri S.,
RA   Jacobs B.L., Katze M.G.;
RT   "Subversion of cell signaling pathways by hepatitis C virus
RT   nonstructural 5A protein via interaction with Grb2 and P85
RT   phosphatidylinositol 3-kinase.";
RL   J. Virol. 76:9207-9217(2002).
RN   [10]
RP   DOMAINS CD81-BINDING AND HVR2.
RX   MEDLINE=22547000; PubMed=12660945; DOI=10.1086/368221;
RA   Hofmann W.P., Sarrazin C., Kronenberger B., Schonberger B., Bruch K.,
RA   Zeuzem S.;
RT   "Mutations within the CD81-binding sites and hypervariable region 2 of
RT   the envelope 2 protein: correlation with treatment response in
RT   hepatitis C virus-infected patients.";
RL   J. Infect. Dis. 187:982-987(2003).
RN   [11]
RP   PHOSPHORYLATION OF NS5A.
RX   PubMed=15016873; DOI=10.1128/JVI.78.7.3502-3513.2004;
RA   Coito C., Diamond D.L., Neddermann P., Korth M.J., Katze M.G.;
RT   "High-throughput screening of the yeast kinome: identification of
RT   human serine/threonine protein kinases that phosphorylate the
RT   hepatitis C virus NS5A protein.";
RL   J. Virol. 78:3502-3513(2004).
RN   [12]
RP   DOMAINS ISDR AND V3 REGIONS.
RX   PubMed=15258967; DOI=10.1002/jmv.20144;
RA   Vuillermoz I., Khattab E., Sablon E., Ottevaere I., Durantel D.,
RA   Vieux C., Trepo C., Zoulim F.;
RT   "Genetic variability of hepatitis C virus in chronically infected
RT   patients with viral breakthrough during interferon-ribavirin
RT   therapy.";
RL   J. Med. Virol. 74:41-53(2004).
RN   [13]
RP   INTERACTION OF NS5A WITH CELLULAR PROTEINS.
RX   PubMed=15607035;
RA   Ahn J., Chung K.-S., Kim D.-U., Won M., Kim L., Kim K.-S., Nam M.,
RA   Choi S.-J., Kim H.-C., Yoon M., Chae S.-K., Hoe K.-L.;
RT   "Systematic identification of hepatocellular proteins interacting with
RT   NS5A of the hepatitis C virus.";
RL   J. Biochem. Mol. Biol. 37:741-748(2004).
RN   [14]
RP   INTERACTION OF NS5A WITH HUMAN BIN1, AND FUNCTION OF NS5A.
RX   PubMed=16530520; DOI=10.1053/j.gastro.2005.12.030;
RA   Nanda S.K., Herion D., Liang T.J.;
RT   "The SH3 binding motif of HCV NS5A protein interacts with Bin1 and is
RT   important for apoptosis and infectivity.";
RL   Gastroenterology 130:794-809(2006).
RN   [15]
RP   SUBCELLULAR LOCATION OF CORE PROTEIN, AND FUNCTION OF CORE PROTEIN.
RX   PubMed=17188392; DOI=10.1016/j.jhep.2006.10.019;
RA   Jackel-Cram C., Babiuk L.A., Liu Q.;
RT   "Up-regulation of fatty acid synthase promoter by hepatitis C virus
RT   core protein: genotype-3a core has a stronger effect than genotype-1b
RT   core.";
RL   J. Hepatol. 46:999-1008(2007).
RN   [16]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [17]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [18]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 1027-1215.
RX   MEDLINE=97015088; PubMed=8861916; DOI=10.1016/S0092-8674(00)81350-1;
RA   Love R.A., Parge H.E., Wickersham J.A., Hostomsky Z., Habuka N.,
RA   Moomaw E.W., Adachi T., Hostomska Z.;
RT   "The crystal structure of hepatitis C virus NS3 proteinase reveals a
RT   trypsin-like fold and a structural zinc binding site.";
RL   Cell 87:331-342(1996).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1027-1206 AND 1678-1691.
RX   MEDLINE=98227846; PubMed=9568891;
RA   Yan Y., Li Y., Munshi S., Sardana V., Cole J.L., Sardana M.,
RA   Steinkuehler C., Tomei L., de Francesco R., Kuo L.C., Chen Z.;
RT   "Complex of NS3 protease and NS4A peptide of BK strain hepatitis C
RT   virus: a 2.2-A resolution structure in a hexagonal crystal form.";
RL   Protein Sci. 7:837-847(1998).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1216-1650.
RX   MEDLINE=98279021; PubMed=9614113; DOI=10.1074/jbc.273.24.15045;
RA   Cho H.-S., Ha N.-C., Kang L.-W., Chung K.M., Back S.H., Jang S.K.,
RA   Oh B.-H.;
RT   "Crystal structure of RNA helicase from genotype 1b hepatitis C virus.
RT   A feasible mechanism of unwinding duplex RNA.";
RL   J. Biol. Chem. 273:15045-15052(1998).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1013-1657.
RX   MEDLINE=20045185; PubMed=10574797; DOI=10.1016/S0969-2126(00)80025-8;
RA   Yao N., Reichert P., Taremi S.S., Prosise W.W., Weber P.C.;
RT   "Molecular views of viral polyprotein processing revealed by the
RT   crystal structure of the hepatitis C virus bifunctional protease-
RT   helicase.";
RL   Structure 7:1353-1363(1999).
RN   [23]
RP   STRUCTURE BY NMR OF 1027-1206.
RX   PubMed=10366511; DOI=10.1006/jmbi.1999.2745;
RA   Barbato G., Cicero D.O., Nardi M.C., Steinkuehler C., Cortese R.,
RA   De Francesco R., Bazzo R.;
RT   "The solution structure of the N-terminal proteinase domain of the
RT   hepatitis C virus (HCV) NS3 protein provides new insights into its
RT   activation and catalytic mechanism.";
RL   J. Mol. Biol. 289:371-384(1999).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 2420-2950.
RX   MEDLINE=20027495; PubMed=10557268; DOI=10.1073/pnas.96.23.13034;
RA   Bressanelli S., Tomei L., Roussel A., Incitti I., Vitale R.L.,
RA   Mathieu M., De Francesco R., Rey F.A.;
RT   "Crystal structure of the RNA-dependent RNA polymerase of hepatitis C
RT   virus.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:13034-13039(1999).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 2414-2989.
RX   PubMed=10504728; DOI=10.1038/13305;
RA   Lesburg C.A., Cable M.B., Ferrari E., Hong Z., Mannarino A.F.,
RA   Weber P.C.;
RT   "Crystal structure of the RNA-dependent RNA polymerase from hepatitis
RT   C virus reveals a fully encircled active site.";
RL   Nat. Struct. Biol. 6:937-943(1999).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 2420-2999.
RX   MEDLINE=20045191; PubMed=10574802; DOI=10.1016/S0969-2126(00)80031-3;
RA   Ago H., Adachi T., Yoshida A., Yamamoto M., Habuka N., Yatsunami K.,
RA   Miyano M.;
RT   "Crystal structure of the RNA-dependent RNA polymerase of hepatitis C
RT   virus.";
RL   Structure 7:1417-1426(1999).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 2420-2955.
RX   PubMed=11884572; DOI=10.1128/JVI.76.7.3482-3492.2002;
RA   Bressanelli S., Tomei L., Rey F.A., De Francesco R.;
RT   "Structural analysis of the hepatitis C virus RNA polymerase in
RT   complex with ribonucleotides.";
RL   J. Virol. 76:3482-3492(2002).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 2420-2989 IN COMPLEX WITH A
RP   NON-NUCLEOSIDE INHIBITOR.
RX   PubMed=12509436; DOI=10.1074/jbc.M209397200;
RA   Wang M., Ng K.K.-S., Cherney M.M., Chan L., Yannopoulos C.G.,
RA   Bedard J., Morin N., Nguyen-Ba N., Alaoui-Ismaili M.H., Bethell R.C.,
RA   James M.N.G.;
RT   "Non-nucleoside analogue inhibitors bind to an allosteric site on HCV
RT   NS5B polymerase. Crystal structures and mechanism of inhibition.";
RL   J. Biol. Chem. 278:9489-9495(2003).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 2420-2995 IN COMPLEX WITH AN
RP   INHIBITOR.
RX   PubMed=12805457; DOI=10.1128/JVI.77.13.7575-7581.2003;
RA   Love R.A., Parge H.E., Yu X., Hickey M.J., Diehl W., Gao J.,
RA   Wriggers H., Ekker A., Wang L., Thomson J.A., Dragovich P.S.,
RA   Fuhrman S.A.;
RT   "Crystallographic identification of a noncompetitive inhibitor binding
RT   site on the hepatitis C virus NS5B RNA polymerase enzyme.";
RL   J. Virol. 77:7575-7581(2003).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA, 1,10-phenanthroline,
CC       iodocetamide and N-ethylmaleimide. According to PubMed:9261354,
CC       completely inhibited by the serine protease inhibitors TLCK and
CC       TPCK. According to PubMed:8189501, almost completely inhibited by
CC       TPCK and slightly inhibited by TLCK. Not inhibited by antipain,
CC       aprotinin, E64, PMSF and pepstatin. Also inhibited by NS2-3 and
CC       NS4A derived peptides. Serine protease NS3 is also activated by
CC       zinc ions.
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein. Host mitochondrion
CC       membrane; Single-pass type I membrane protein. Host lipid droplet.
CC       Note=The C-terminal transmembrane domain of core protein p21
CC       contains an ER signal leading the nascent polyprotein to the ER
CC       membrane. Only a minor proportion of core protein is present in
CC       the nucleus and an unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain two highly variable regions called
CC       hypervariable region 1 and 2 (HVR1 and HVR2). E2 also contain two
CC       segments involved in CD81-binding. HVR1 is implicated in the
CC       SCARB1-mediated cell entry. HVR2 and CD81-binding regions may be
CC       involved in sensitivity and/or resistance to IFN-alpha therapy (By
CC       similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A contains a variable region called interferon
CC       sensitivity determining region (ISDR) and seems to be
CC       intrinsically disordered and interacts with NS5B and host PKR (By
CC       similarity). The C-terminus of NS5A contains a variable region
CC       called variable region 3 (V3). ISDR and V3 may be involved in
CC       sensitivity and/or resistance to IFN-alpha therapy.
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases.
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3.
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation.
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M58335; AAA72945.1; -; Genomic_RNA.
DR   PIR; A38465; GNWVTC.
DR   PDB; 1A1Q; X-ray; 2.40 A; A/B/C=1027-1215.
DR   PDB; 1BT7; NMR; -; A=1027-1206.
DR   PDB; 1C2P; X-ray; 1.90 A; A/B=2422-2989.
DR   PDB; 1CSJ; X-ray; 2.80 A; A/B=2420-2950.
DR   PDB; 1CU1; X-ray; 2.50 A; A/B=1029-1657.
DR   PDB; 1GX5; X-ray; 1.70 A; A=2420-2955.
DR   PDB; 1GX6; X-ray; 1.85 A; A=2420-2950.
DR   PDB; 1JXP; X-ray; 2.20 A; A/B=1027-1206, C/D=1678-1691.
DR   PDB; 1NHU; X-ray; 2.00 A; A/B=2420-2989.
DR   PDB; 1NHV; X-ray; 2.90 A; A/B=2420-2989.
DR   PDB; 1NS3; X-ray; 2.80 A; A/B=1029-1206, C/D=1678-1689.
DR   PDB; 1OS5; X-ray; 2.20 A; A=2420-2989.
DR   PDB; 1QUV; X-ray; 2.50 A; A=2420-2989.
DR   PDB; 2AWZ; X-ray; 2.15 A; A/B=2420-2988.
DR   PDB; 2AX0; X-ray; 2.00 A; A/B=2420-2988.
DR   PDB; 2AX1; X-ray; 2.10 A; A/B=2420-2988.
DR   PDB; 2BRK; X-ray; 2.30 A; A=2420-2955.
DR   PDB; 2BRL; X-ray; 2.40 A; A=2420-2955.
DR   PDB; 2DXS; X-ray; 2.20 A; A/B=2420-2962.
DR   PDB; 2GIQ; X-ray; 1.65 A; A/B=2421-2980.
DR   PDB; 2GIR; X-ray; 1.90 A; A/B=2421-2980.
DR   PDB; 2HAI; X-ray; 1.58 A; A=2420-2988.
DR   PDB; 2HWH; X-ray; 2.30 A; A/B=2422-2988.
DR   PDB; 2HWI; X-ray; 2.00 A; A/B=2422-2988.
DR   PDB; 2I1R; X-ray; 2.20 A; A/B=2422-2988.
DR   PDB; 2JC0; X-ray; 2.20 A; A/B=2420-2989.
DR   PDB; 2JC1; X-ray; 2.00 A; A/B=2420-2989.
DR   PDB; 2O5D; X-ray; 2.20 A; A/B=2422-2989.
DR   PDB; 2WCX; X-ray; 2.00 A; A=2420-2955.
DR   PDB; 2WHO; X-ray; 2.00 A; A/B=2420-2955.
DR   PDB; 2ZKU; X-ray; 1.95 A; A/B/C/D=2420-2989.
DR   PDB; 3BR9; X-ray; 2.30 A; A/B=2420-2989.
DR   PDB; 3BSA; X-ray; 2.30 A; A/B=2420-2989.
DR   PDB; 3BSC; X-ray; 2.65 A; A/B=2420-2989.
DR   PDB; 3CDE; X-ray; 2.10 A; A/B=2420-2989.
DR   PDB; 3CIZ; X-ray; 1.87 A; A/B=2421-2989.
DR   PDB; 3CJ0; X-ray; 1.90 A; A/B=2421-2989.
DR   PDB; 3CJ2; X-ray; 1.75 A; A/B=2421-2989.
DR   PDB; 3CJ3; X-ray; 1.87 A; A/B=2421-2989.
DR   PDB; 3CJ4; X-ray; 2.07 A; A/B=2421-2989.
DR   PDB; 3CJ5; X-ray; 1.92 A; A/B=2421-2989.
DR   PDB; 3CO9; X-ray; 2.10 A; A/B=2420-2989.
DR   PDB; 3CVK; X-ray; 2.31 A; A/B=2420-2989.
DR   PDB; 3CWJ; X-ray; 2.40 A; A/B=2420-2989.
DR   PDB; 3D28; X-ray; 2.30 A; A/B=2420-2989.
DR   PDB; 3D5M; X-ray; 2.20 A; A/B=2420-2989.
DR   PDB; 3E51; X-ray; 1.90 A; A/B=2420-2989.
DR   PDB; 3FQK; X-ray; 2.20 A; A/B=2421-2989.
DR   PDB; 3FRZ; X-ray; 1.86 A; A=2420-2989.
DR   PDB; 3G86; X-ray; 2.20 A; A/B=2421-2989.
DR   PDB; 3GYN; X-ray; 2.15 A; A/B=2420-2989.
DR   PDB; 3H2L; X-ray; 1.90 A; A/B=2420-2989.
DR   PDB; 3H59; X-ray; 2.10 A; A/B=2421-2989.
DR   PDB; 3H5S; X-ray; 2.00 A; A/B=2421-2989.
DR   PDB; 3H5U; X-ray; 1.95 A; A/B=2421-2989.
DR   PDB; 3H98; X-ray; 1.90 A; A/B=2421-2989.
DR   PDB; 3IGV; X-ray; 2.60 A; A/B=2420-2989.
DR   PDB; 8OHM; X-ray; 2.30 A; A=1216-1650.
DR   PDBsum; 1A1Q; -.
DR   PDBsum; 1BT7; -.
DR   PDBsum; 1C2P; -.
DR   PDBsum; 1CSJ; -.
DR   PDBsum; 1CU1; -.
DR   PDBsum; 1GX5; -.
DR   PDBsum; 1GX6; -.
DR   PDBsum; 1JXP; -.
DR   PDBsum; 1NHU; -.
DR   PDBsum; 1NHV; -.
DR   PDBsum; 1NS3; -.
DR   PDBsum; 1OS5; -.
DR   PDBsum; 1QUV; -.
DR   PDBsum; 2AWZ; -.
DR   PDBsum; 2AX0; -.
DR   PDBsum; 2AX1; -.
DR   PDBsum; 2BRK; -.
DR   PDBsum; 2BRL; -.
DR   PDBsum; 2DXS; -.
DR   PDBsum; 2GIQ; -.
DR   PDBsum; 2GIR; -.
DR   PDBsum; 2HAI; -.
DR   PDBsum; 2HWH; -.
DR   PDBsum; 2HWI; -.
DR   PDBsum; 2I1R; -.
DR   PDBsum; 2JC0; -.
DR   PDBsum; 2JC1; -.
DR   PDBsum; 2O5D; -.
DR   PDBsum; 2WCX; -.
DR   PDBsum; 2WHO; -.
DR   PDBsum; 2ZKU; -.
DR   PDBsum; 3BR9; -.
DR   PDBsum; 3BSA; -.
DR   PDBsum; 3BSC; -.
DR   PDBsum; 3CDE; -.
DR   PDBsum; 3CIZ; -.
DR   PDBsum; 3CJ0; -.
DR   PDBsum; 3CJ2; -.
DR   PDBsum; 3CJ3; -.
DR   PDBsum; 3CJ4; -.
DR   PDBsum; 3CJ5; -.
DR   PDBsum; 3CO9; -.
DR   PDBsum; 3CVK; -.
DR   PDBsum; 3CWJ; -.
DR   PDBsum; 3D28; -.
DR   PDBsum; 3D5M; -.
DR   PDBsum; 3E51; -.
DR   PDBsum; 3FQK; -.
DR   PDBsum; 3FRZ; -.
DR   PDBsum; 3G86; -.
DR   PDBsum; 3GYN; -.
DR   PDBsum; 3H2L; -.
DR   PDBsum; 3H59; -.
DR   PDBsum; 3H5S; -.
DR   PDBsum; 3H5U; -.
DR   PDBsum; 3H98; -.
DR   PDBsum; 3IGV; -.
DR   PDBsum; 8OHM; -.
DR   SMR; P26663; 2-45, 902-1026, 1029-1657, 1973-2003, 2008-2170.
DR   euHCVdb; M58335; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; FALSE_NEG.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Direct protein sequencing; Disulfide bond;
KW   Envelope protein; Fusion protein; Glycoprotein; Helicase;
KW   Host cell membrane; Host cytoplasm; Host endoplasmic reticulum;
KW   Host lipid droplet; Host membrane; Host mitochondrion; Host nucleus;
KW   Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000037529.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000037530.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000037531.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000037532.
FT   CHAIN       384    746       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000037533.
FT   CHAIN       747    809       p7 (By similarity).
FT                                /FTId=PRO_0000037534.
FT   CHAIN       810   1026       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000037535.
FT   CHAIN      1027   1657       Serine protease/NTPase/helicase NS3.
FT                                /FTId=PRO_0000037536.
FT   CHAIN      1658   1711       Non-structural protein 4A.
FT                                /FTId=PRO_0000037537.
FT   CHAIN      1712   1972       Non-structural protein 4B.
FT                                /FTId=PRO_0000037538.
FT   CHAIN      1973   2419       Non-structural protein 5A.
FT                                /FTId=PRO_0000037539.
FT   CHAIN      2420   3010       RNA-directed RNA polymerase.
FT                                /FTId=PRO_0000037540.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    725       Lumenal (Potential).
FT   TRANSMEM    726    746       Potential.
FT   TOPO_DOM    747    757       Lumenal (Potential).
FT   TRANSMEM    758    778       Potential.
FT   TOPO_DOM    779    782       Cytoplasmic (Potential).
FT   TRANSMEM    783    803       Potential.
FT   TOPO_DOM    804    813       Lumenal (Potential).
FT   TRANSMEM    814    834       Potential.
FT   TOPO_DOM    835    881       Cytoplasmic (Potential).
FT   TRANSMEM    882    902       Potential.
FT   TOPO_DOM    903    928       Lumenal (Potential).
FT   TRANSMEM    929    949       Potential.
FT   TOPO_DOM    950   1657       Cytoplasmic (Potential).
FT   TRANSMEM   1658   1678       Potential.
FT   TOPO_DOM   1679   1805       Cytoplasmic (Potential).
FT   TRANSMEM   1806   1826       Potential.
FT   TOPO_DOM   1827   1828       Lumenal (Potential).
FT   TRANSMEM   1829   1849       Potential.
FT   TOPO_DOM   1850   1850       Cytoplasmic (Potential).
FT   TRANSMEM   1851   1871       Potential.
FT   TOPO_DOM   1872   1881       Lumenal (Potential).
FT   TRANSMEM   1882   1902       Potential.
FT   TOPO_DOM   1903   1972       Cytoplasmic (Potential).
FT   TOPO_DOM   1973   2002       In membrane (By similarity).
FT   TOPO_DOM   2003   2989       Cytoplasmic (Potential).
FT   TRANSMEM   2990   3010       By similarity.
FT   DOMAIN     1217   1369       Helicase ATP-binding.
FT   DOMAIN     2633   2751       RdRp catalytic.
FT   NP_BIND    1230   1237       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      148    236       Interaction with FKBP8.
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      385    411       HVR1.
FT   REGION      475    481       HVR2.
FT   REGION      482    494       CD81-binding 1 (Potential).
FT   REGION      522    553       CD81-binding 2 (Potential).
FT   REGION      660    671       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD).
FT   REGION     1679   1690       NS3-binding (by NS4A) (Potential).
FT   REGION     2120   2332       Transcriptional activation (Potential).
FT   REGION     2120   2208       FKBP8-binding (Potential).
FT   REGION     2200   2250       Basal phosphorylation (By similarity).
FT   REGION     2210   2275       PKR-binding (Potential).
FT   REGION     2210   2249       ISDR.
FT   REGION     2249   2306       NS4B-binding (Potential).
FT   REGION     2351   2419       Basal phosphorylation (By similarity).
FT   REGION     2354   2377       V3.
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1316   1319       DECH box.
FT   MOTIF      2322   2325       SH3-binding (Potential).
FT   MOTIF      2327   2335       Nuclear localization signal (Potential).
FT   COMPBIAS    796    803       Poly-Leu.
FT   COMPBIAS   1432   1435       Poly-Val.
FT   COMPBIAS   2282   2327       Pro-rich.
FT   COMPBIAS   2995   2998       Poly-Leu.
FT   ACT_SITE    952    952       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    972    972       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    993    993       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1083   1083       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1107   1107       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1165   1165       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1123   1123       Zinc.
FT   METAL      1125   1125       Zinc.
FT   METAL      1171   1171       Zinc.
FT   METAL      1175   1175       Zinc.
FT   METAL      2011   2011       Zinc (By similarity).
FT   METAL      2029   2029       Zinc (By similarity).
FT   METAL      2031   2031       Zinc (By similarity).
FT   METAL      2052   2052       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        191    192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        746    747       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        809    810       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1026   1027       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1657   1658       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1711   1712       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1972   1973       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2419   2420       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2194   2194       Phosphoserine; by host; in p56
FT                                (Probable).
FT   MOD_RES    2197   2197       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2201   2201       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2204   2204       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1968   1968       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   LIPID      1972   1972       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    250    250       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    417    417       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    423    423       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    430    430       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    448    448       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    532    532       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    540    540       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    556    556       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    576    576       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    623    623       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    645    645       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2114   2162       By similarity.
FT   MUTAGEN    2194   2194       S->A: Loss of phosphorylation.
FT   MUTAGEN    2322   2322       P->A: Complete loss of binding to GRB2.
FT   MUTAGEN    2323   2323       P->A: Complete loss of binding to GRB2.
FT   MUTAGEN    2326   2326       P->A: Complete loss of binding to GRB2.
FT   STRAND     1031   1035
FT   HELIX      1039   1047
FT   STRAND     1057   1063
FT   STRAND     1068   1074
FT   STRAND     1077   1081
FT   HELIX      1082   1085
FT   STRAND     1090   1092
FT   STRAND     1095   1097
FT   STRAND     1100   1103
FT   TURN       1104   1107
FT   STRAND     1108   1112
FT   STRAND     1129   1133
FT   STRAND     1139   1144
FT   STRAND     1146   1157
FT   HELIX      1158   1161
FT   STRAND     1168   1171
FT   TURN       1172   1174
FT   STRAND     1175   1186
FT   STRAND     1189   1197
FT   HELIX      1198   1202
FT   STRAND     1224   1229
FT   STRAND     1232   1235
FT   TURN       1236   1238
FT   HELIX      1239   1245
FT   TURN       1246   1248
FT   STRAND     1251   1256
FT   HELIX      1258   1271
FT   STRAND     1277   1279
FT   STRAND     1290   1295
FT   HELIX      1296   1302
FT   STRAND     1311   1316
FT   TURN       1317   1319
FT   HELIX      1323   1335
FT   TURN       1336   1340
FT   STRAND     1342   1350
FT   STRAND     1362   1366
FT   STRAND     1371   1375
FT   STRAND     1378   1380
FT   HELIX      1382   1384
FT   STRAND     1386   1393
FT   STRAND     1395   1397
FT   HELIX      1398   1409
FT   STRAND     1414   1417
FT   STRAND     1431   1436
FT   HELIX      1440   1443
FT   STRAND     1448   1453
FT   STRAND     1456   1463
FT   STRAND     1467   1469
FT   STRAND     1471   1478
FT   HELIX      1481   1488
FT   STRAND     1493   1495
FT   STRAND     1497   1502
FT   STRAND     1509   1511
FT   HELIX      1514   1526
FT   HELIX      1532   1544
FT   HELIX      1555   1563
FT   HELIX      1570   1579
FT   HELIX      1584   1596
FT   HELIX      1606   1617
FT   STRAND     1627   1629
FT   HELIX      1640   1648
FT   STRAND     1653   1656
FT   STRAND     1680   1688
FT   STRAND     2422   2425
FT   HELIX      2446   2449
FT   HELIX      2453   2455
FT   STRAND     2456   2458
FT   HELIX      2461   2463
FT   HELIX      2464   2471
FT   HELIX      2481   2494
FT   HELIX      2504   2509
FT   HELIX      2524   2528
FT   HELIX      2532   2547
FT   STRAND     2549   2551
FT   STRAND     2555   2559
FT   STRAND     2563   2565
FT   STRAND     2578   2581
FT   HELIX      2584   2606
FT   HELIX      2607   2609
FT   HELIX      2611   2613
FT   HELIX      2616   2629
FT   STRAND     2630   2638
FT   HELIX      2643   2646
FT   HELIX      2649   2661
FT   HELIX      2666   2678
FT   STRAND     2683   2686
FT   STRAND     2692   2696
FT   HELIX      2706   2725
FT   STRAND     2728   2735
FT   STRAND     2738   2744
FT   HELIX      2748   2764
FT   STRAND     2769   2771
FT   HELIX      2779   2781
FT   STRAND     2787   2793
FT   STRAND     2799   2804
FT   HELIX      2808   2819
FT   HELIX      2826   2834
FT   HELIX      2838   2842
FT   HELIX      2844   2854
FT   STRAND     2862   2866
FT   STRAND     2869   2873
FT   HELIX      2875   2877
FT   HELIX      2878   2886
FT   HELIX      2888   2891
FT   HELIX      2898   2911
FT   HELIX      2916   2933
FT   HELIX      2935   2944
FT   HELIX      2946   2948
FT   STRAND     2949   2951
FT   HELIX      2959   2963
FT   TURN       2967   2970
SQ   SEQUENCE   3010 AA;  327194 MW;  F8422D5ECCFDFD9C CRC64;
     MSTNPKPQRK TKRNTNRRPQ DVKFPGGGQI VGGVYLLPRR GPRLGVRAPR KTSERSQPRG
     RRQPIPKARR PEGRTWAQPG YPWPLYGNEG LGWAGWLLSP RGSRPSWGPT DPRRRSRNLG
     KVIDTLTCGF ADLMGYIPLV GAPLGGAARA LAHGVRVLED GVNYATGNLP GCSFSIFLLA
     LLSCLTTPAS AYEVHNVSGI YHVTNDCSNA SIVYEAADLI MHTPGCVPCV REGNSSRCWV
     ALTPTLAARN VTIPTTTIRR HVDLLVGAAA FCSAMYVGDL CGSVFLVSQL FTFSPRRHVT
     LQDCNCSIYP GHVSGHRMAW DMMMNWSPTT ALVVSQLLRI PQAVVDMVAG AHWGVLAGLA
     YYSMAGNWAK VLIVMLLFAG VDGDTHVTGG AQAKTTNRLV SMFASGPSQK IQLINTNGSW
     HINRTALNCN DSLQTGFLAA LFYTHSFNSS GCPERMAQCR TIDKFDQGWG PITYAESSRS
     DQRPYCWHYP PPQCTIVPAS EVCGPVYCFT PSPVVVGTTD RFGVPTYRWG ENETDVLLLN
     NTRPPQGNWF GCTWMNSTGF TKTCGGPPCN IGGVGNNTLT CPTDCFRKHP EATYTKCGSG
     PWLTPRCMVD YPYRLWHYPC TVNFTIFKVR MYVGGVEHRL NAACNWTRGE RCDLEDRDRP
     ELSPLLLSTT EWQVLPCSFT TLPALSTGLI HLHQNIVDVQ YLYGIGSAVV SFAIKWEYVL
     LLFLLLADAR VCACLWMMLL IAQAEAALEN LVVLNSASVA GAHGILSFLV FFCAAWYIKG
     RLVPGATYAL YGVWPLLLLL LALPPRAYAM DREMAASCGG AVFVGLVLLT LSPYYKVFLA
     RLIWWLQYFT TRAEADLHVW IPPLNARGGR DAIILLMCAV HPELIFDITK LLIAILGPLM
     VLQAGITRVP YFVRAQGLIH ACMLVRKVAG GHYVQMAFMK LGALTGTYIY NHLTPLRDWP
     RAGLRDLAVA VEPVVFSDME TKIITWGADT AACGDIILGL PVSARRGKEI LLGPADSLEG
     RGLRLLAPIT AYSQQTRGLL GCIITSLTGR DKNQVEGEVQ VVSTATQSFL ATCVNGVCWT
     VYHGAGSKTL AAPKGPITQM YTNVDQDLVG WPKPPGARSL TPCTCGSSDL YLVTRHADVI
     PVRRRGDSRG SLLSPRPVSY LKGSSGGPLL CPFGHAVGIF RAAVCTRGVA KAVDFVPVES
     METTMRSPVF TDNSSPPAVP QSFQVAHLHA PTGSGKSTKV PAAYAAQGYK VLVLNPSVAA
     TLGFGAYMSK AHGIDPNIRT GVRTITTGAP VTYSTYGKFL ADGGCSGGAY DIIICDECHS
     TDSTTILGIG TVLDQAETAG ARLVVLATAT PPGSVTVPHP NIEEVALSNT GEIPFYGKAI
     PIEAIRGGRH LIFCHSKKKC DELAAKLSGL GINAVAYYRG LDVSVIPTIG DVVVVATDAL
     MTGYTGDFDS VIDCNTCVTQ TVDFSLDPTF TIETTTVPQD AVSRSQRRGR TGRGRRGIYR
     FVTPGERPSG MFDSSVLCEC YDAGCAWYEL TPAETSVRLR AYLNTPGLPV CQDHLEFWES
     VFTGLTHIDA HFLSQTKQAG DNFPYLVAYQ ATVCARAQAP PPSWDQMWKC LIRLKPTLHG
     PTPLLYRLGA VQNEVTLTHP ITKYIMACMS ADLEVVTSTW VLVGGVLAAL AAYCLTTGSV
     VIVGRIILSG RPAIVPDREL LYQEFDEMEE CASHLPYIEQ GMQLAEQFKQ KALGLLQTAT
     KQAEAAAPVV ESKWRALETF WAKHMWNFIS GIQYLAGLST LPGNPAIASL MAFTASITSP
     LTTQSTLLFN ILGGWVAAQL APPSAASAFV GAGIAGAAVG SIGLGKVLVD ILAGYGAGVA
     GALVAFKVMS GEMPSTEDLV NLLPAILSPG ALVVGVVCAA ILRRHVGPGE GAVQWMNRLI
     AFASRGNHVS PTHYVPESDA AARVTQILSS LTITQLLKRL HQWINEDCST PCSGSWLRDV
     WDWICTVLTD FKTWLQSKLL PQLPGVPFFS CQRGYKGVWR GDGIMQTTCP CGAQITGHVK
     NGSMRIVGPK TCSNTWHGTF PINAYTTGPC TPSPAPNYSR ALWRVAAEEY VEVTRVGDFH
     YVTGMTTDNV KCPCQVPAPE FFSEVDGVRL HRYAPACRPL LREEVTFQVG LNQYLVGSQL
     PCEPEPDVAV LTSMLTDPSH ITAETAKRRL ARGSPPSLAS SSASQLSAPS LKATCTTHHV
     SPDADLIEAN LLWRQEMGGN ITRVESENKV VVLDSFDPLR AEEDEREVSV PAEILRKSKK
     FPAAMPIWAR PDYNPPLLES WKDPDYVPPV VHGCPLPPIK APPIPPPRRK RTVVLTESSV
     SSALAELATK TFGSSESSAV DSGTATALPD QASDDGDKGS DVESYSSMPP LEGEPGDPDL
     SDGSWSTVSE EASEDVVCCS MSYTWTGALI TPCAAEESKL PINALSNSLL RHHNMVYATT
     SRSAGLRQKK VTFDRLQVLD DHYRDVLKEM KAKASTVKAK LLSVEEACKL TPPHSAKSKF
     GYGAKDVRNL SSKAVNHIHS VWKDLLEDTV TPIDTTIMAK NEVFCVQPEK GGRKPARLIV
     FPDLGVRVCE KMALYDVVST LPQVVMGSSY GFQYSPGQRV EFLVNTWKSK KNPMGFSYDT
     RCFDSTVTEN DIRVEESIYQ CCDLAPEARQ AIKSLTERLY IGGPLTNSKG QNCGYRRCRA
     SGVLTTSCGN TLTCYLKASA ACRAAKLQDC TMLVNGDDLV VICESAGTQE DAASLRVFTE
     AMTRYSAPPG DPPQPEYDLE LITSCSSNVS VAHDASGKRV YYLTRDPTTP LARAAWETAR
     HTPVNSWLGN IIMYAPTLWA RMILMTHFFS ILLAQEQLEK ALDCQIYGAC YSIEPLDLPQ
     IIERLHGLSA FSLHSYSPGE INRVASCLRK LGVPPLRVWR HRARSVRARL LSQGGRAATC
     GKYLFNWAVK TKLKLTPIPA ASRLDLSGWF VAGYSGGDIY HSLSRARPRW FMLCLLLLSV
     GVGIYLLPNR
//
ID   POLG_HCVCO              Reviewed;        3010 AA.
AC   Q9WMX2;
DT   05-JUL-2005, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 84.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 1b (isolate Con1) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=333284;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=99322193; PubMed=10390360; DOI=10.1126/science.285.5424.110;
RA   Lohmann V., Koerner F., Koch J.O., Herian U., Theilmann L.,
RA   Bartenschlager R.;
RT   "Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell
RT   line.";
RL   Science 285:110-113(1999).
RN   [2]
RP   FUNCTION OF NS3 AND NS4A.
RX   PubMed=12702807; DOI=10.1126/science.1082604;
RA   Foy E., Li K., Wang C., Sumpter R. Jr., Ikeda M., Lemon S.M.,
RA   Gale M. Jr.;
RT   "Regulation of interferon regulatory factor-3 by the hepatitis C virus
RT   serine protease.";
RL   Science 300:1145-1148(2003).
RN   [3]
RP   FUNCTION OF NS5A.
RX   PubMed=15542681; DOI=10.1128/JVI.78.23.13306-13314.2004;
RA   Neddermann P., Quintavalle M., Di Pietro C., Clementi A.,
RA   Cerretani M., Altamura S., Bartholomew L., De Francesco R.;
RT   "Reduction of hepatitis C virus NS5A hyperphosphorylation by selective
RT   inhibition of cellular kinases activates viral RNA replication in cell
RT   culture.";
RL   J. Virol. 78:13306-13314(2004).
RN   [4]
RP   PHOSPHORYLATION AT SER-2194; SER-2197; SER-2201 AND SER-2204, AND
RP   MUTAGENESIS OF SER-2158; SER-2173; SER-2179; SER-2194; SER-2197;
RP   SER-2200; SER-2201; SER-2202; SER-2204; SER-2207; SER-2210; SER-2246;
RP   SER-2255 AND SER-2269.
RX   PubMed=15709040; DOI=10.1128/JVI.79.5.3187-3194.2005;
RA   Appel N., Pietschmann T., Bartenschlager R.;
RT   "Mutational analysis of hepatitis C virus nonstructural protein 5A:
RT   potential role of differential phosphorylation in RNA replication and
RT   identification of a genetically flexible domain.";
RL   J. Virol. 79:3187-3194(2005).
RN   [5]
RP   INTERACTION WITH HUMAN TBK1.
RX   PubMed=15841462; DOI=10.1002/hep.20666;
RA   Otsuka M., Kato N., Moriyama M., Taniguchi H., Wang Y., Dharel N.,
RA   Kawabe T., Omata M.;
RT   "Interaction between the HCV NS3 protein and the host TBK1 protein
RT   leads to inhibition of cellular antiviral responses.";
RL   Hepatology 41:1004-1012(2005).
RN   [6]
RP   PHOSPHORYLATION BY HOST CSNK1A1.
RC   STRAIN=Isolate HCV-AT;
RX   PubMed=16943283; DOI=10.1128/JVI.01465-06;
RA   Quintavalle M., Sambucini S., Di Pietro C., De Francesco R.,
RA   Neddermann P.;
RT   "The alpha isoform of protein kinase CKI is responsible for hepatitis
RT   C virus NS5A hyperphosphorylation.";
RL   J. Virol. 80:11305-11312(2006).
RN   [7]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [8]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [9]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 2008-2170, AND DISULFIDE
RP   BOND.
RX   PubMed=15902263; DOI=10.1038/nature03580;
RA   Tellinghuisen T.L., Marcotrigiano J., Rice C.M.;
RT   "Structure of the zinc-binding domain of an essential component of the
RT   hepatitis C virus replicase.";
RL   Nature 435:374-379(2005).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3 RNA helicase binds
CC       to RNA and unwinds dsRNA in the 3' to 5' direction, and likely RNA
CC       stable secondary structure in the template strand. Cleaves the
CC       host antiviral protein MAVS (By similarity). NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state.
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- INTERACTION:
CC       P06241:FYN (xeno); NbExp=2; IntAct=EBI-710918, EBI-515315;
CC       P62993:GRB2 (xeno); NbExp=1; IntAct=EBI-710918, EBI-401755;
CC       P08631:HCK (xeno); NbExp=1; IntAct=EBI-710918, EBI-346340;
CC       P06239:LCK (xeno); NbExp=1; IntAct=EBI-710918, EBI-1348;
CC       P07948:LYN (xeno); NbExp=2; IntAct=EBI-710918, EBI-79452;
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain two highly variable regions called
CC       hypervariable region 1 and 2 (HVR1 and HVR2). E2 also contain two
CC       segments involved in CD81-binding. HVR1 is implicated in the
CC       SCARB1-mediated cell entry. HVR2 and CD81-binding regions may be
CC       involved in sensitivity and/or resistance to IFN-alpha therapy (By
CC       similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A contains a variable region called interferon
CC       sensitivity determining region (ISDR) and seems to be
CC       intrinsically disordered and interacts with NS5B and host PKR. The
CC       C-terminus of NS5A contains a variable region called variable
CC       region 3 (V3). ISDR and V3 may be involved in sensitivity and/or
CC       resistance to IFN-alpha therapy (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ238799; CAB46677.1; -; Genomic_RNA.
DR   PIR; A61196; A61196.
DR   PIR; PQ0246; PQ0246.
DR   PIR; PS0329; PS0329.
DR   PDB; 1ZH1; X-ray; 2.50 A; A/B=2008-2170.
DR   PDB; 3FQL; X-ray; 1.80 A; A=2421-2989.
DR   PDB; 3FQM; X-ray; 1.90 A; A/B=2005-2174.
DR   PDB; 3FQQ; X-ray; 2.20 A; A/B=2005-2174.
DR   PDB; 3KQH; X-ray; 2.40 A; A/B=1215-1650.
DR   PDB; 3KQK; X-ray; 2.80 A; A/B=1215-1650.
DR   PDB; 3KQL; X-ray; 2.50 A; A/B=1215-1650.
DR   PDB; 3KQN; X-ray; 2.05 A; A=1215-1650.
DR   PDB; 3KQU; X-ray; 2.40 A; A/B/C/D/E/F=1215-1650.
DR   PDBsum; 1ZH1; -.
DR   PDBsum; 3FQL; -.
DR   PDBsum; 3FQM; -.
DR   PDBsum; 3FQQ; -.
DR   PDBsum; 3KQH; -.
DR   PDBsum; 3KQK; -.
DR   PDBsum; 3KQL; -.
DR   PDBsum; 3KQN; -.
DR   PDBsum; 3KQU; -.
DR   SMR; Q9WMX2; 2-45, 902-1026, 1029-1657, 1973-2003.
DR   IntAct; Q9WMX2; 5.
DR   euHCVdb; AJ238799; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; FALSE_NEG.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Disulfide bond; Envelope protein; Fusion protein;
KW   Glycoprotein; Helicase; Host cell membrane; Host cytoplasm;
KW   Host endoplasmic reticulum; Host lipid droplet; Host membrane;
KW   Host mitochondrion; Host nucleus; Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000037541.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000037542.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000037543.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000037544.
FT   CHAIN       384    746       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000037545.
FT   CHAIN       747    809       p7 (By similarity).
FT                                /FTId=PRO_0000037546.
FT   CHAIN       810   1026       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000037547.
FT   CHAIN      1027   1657       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000037548.
FT   CHAIN      1658   1711       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000037549.
FT   CHAIN      1712   1972       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000037550.
FT   CHAIN      1973   2419       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000037551.
FT   CHAIN      2420   3010       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000037552.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    725       Lumenal (Potential).
FT   TRANSMEM    726    746       Potential.
FT   TOPO_DOM    747    757       Lumenal (Potential).
FT   TRANSMEM    758    778       Potential.
FT   TOPO_DOM    779    782       Cytoplasmic (Potential).
FT   TRANSMEM    783    803       Potential.
FT   TOPO_DOM    804    813       Lumenal (Potential).
FT   TRANSMEM    814    834       Potential.
FT   TOPO_DOM    835    881       Cytoplasmic (Potential).
FT   TRANSMEM    882    902       Potential.
FT   TOPO_DOM    903    928       Lumenal (Potential).
FT   TRANSMEM    929    949       Potential.
FT   TOPO_DOM    950   1657       Cytoplasmic (Potential).
FT   TRANSMEM   1658   1678       Potential.
FT   TOPO_DOM   1679   1805       Cytoplasmic (Potential).
FT   TRANSMEM   1806   1826       Potential.
FT   TOPO_DOM   1827   1828       Lumenal (Potential).
FT   TRANSMEM   1829   1849       Potential.
FT   TOPO_DOM   1850   1850       Cytoplasmic (Potential).
FT   TRANSMEM   1851   1871       Potential.
FT   TOPO_DOM   1872   1881       Lumenal (Potential).
FT   TRANSMEM   1882   1902       Potential.
FT   TOPO_DOM   1903   1972       Cytoplasmic (Potential).
FT   TOPO_DOM   1973   2002       In membrane (By similarity).
FT   TOPO_DOM   2003   2989       Cytoplasmic (Potential).
FT   TRANSMEM   2990   3010       By similarity.
FT   DOMAIN     1217   1369       Helicase ATP-binding.
FT   DOMAIN     2633   2751       RdRp catalytic.
FT   NP_BIND    1230   1237       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      385    411       HVR1 (By similarity).
FT   REGION      475    481       HVR2 (By similarity).
FT   REGION      482    494       CD81-binding 1 (Potential).
FT   REGION      522    553       CD81-binding 2 (Potential).
FT   REGION      660    671       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1679   1690       NS3-binding (by NS4A) (Potential).
FT   REGION     2120   2332       Transcriptional activation (Potential).
FT   REGION     2120   2208       FKBP8-binding (Potential).
FT   REGION     2200   2250       Basal phosphorylation (By similarity).
FT   REGION     2210   2275       PKR-binding (Potential).
FT   REGION     2210   2249       ISDR (By similarity).
FT   REGION     2249   2306       NS4B-binding (Potential).
FT   REGION     2351   2419       Basal phosphorylation (By similarity).
FT   REGION     2354   2377       V3 (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1316   1319       DECH box.
FT   MOTIF      2322   2325       SH3-binding (Potential).
FT   MOTIF      2327   2335       Nuclear localization signal (Potential).
FT   COMPBIAS    796    803       Poly-Leu.
FT   COMPBIAS   2282   2327       Pro-rich.
FT   COMPBIAS   2718   2721       Poly-Ala.
FT   COMPBIAS   2995   2998       Poly-Leu.
FT   ACT_SITE    952    952       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    972    972       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    993    993       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1083   1083       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1107   1107       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1165   1165       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1123   1123       Zinc (By similarity).
FT   METAL      1125   1125       Zinc (By similarity).
FT   METAL      1171   1171       Zinc (By similarity).
FT   METAL      1175   1175       Zinc (By similarity).
FT   METAL      2011   2011       Zinc (Probable).
FT   METAL      2029   2029       Zinc (Probable).
FT   METAL      2031   2031       Zinc (Probable).
FT   METAL      2052   2052       Zinc (Probable).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        191    192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        746    747       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        809    810       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1026   1027       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1657   1658       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1711   1712       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1972   1973       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2419   2420       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2194   2194       Phosphoserine; by host; in p56.
FT   MOD_RES    2197   2197       Phosphoserine; by host; in p58.
FT   MOD_RES    2201   2201       Phosphoserine; by host; in p58.
FT   MOD_RES    2204   2204       Phosphoserine; by host; in p58.
FT   LIPID      1968   1968       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   LIPID      1972   1972       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    250    250       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    417    417       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    423    423       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    430    430       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    448    448       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    532    532       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    556    556       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    576    576       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    623    623       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    645    645       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2114   2162       Probable.
FT   VARIANT    2204   2204       S -> I.
FT   MUTAGEN    2158   2158       S->A: No effect on replication.
FT   MUTAGEN    2173   2173       S->A: No effect on replication.
FT   MUTAGEN    2179   2179       S->A: No effect on replication.
FT   MUTAGEN    2194   2194       S->A: No effect on replication. No effect
FT                                on NS5A hyperphosphorylation.
FT   MUTAGEN    2194   2194       S->E: No effect on replication. No effect
FT                                on NS5A hyperphosphorylation.
FT   MUTAGEN    2197   2197       S->A: Enhanced replication. Decreased
FT                                NS5A hyperphosphorylation.
FT   MUTAGEN    2197   2197       S->E: No effect on replication. Decreased
FT                                NS5A hyperphosphorylation.
FT   MUTAGEN    2200   2200       S->A: No effect on replication. Decreased
FT                                NS5A hyperphosphorylation.
FT   MUTAGEN    2200   2200       S->E: No effect on replication. Decreased
FT                                NS5A hyperphosphorylation.
FT   MUTAGEN    2201   2201       S->A: Enhanced replication. Decreased
FT                                NS5A hyperphosphorylation.
FT   MUTAGEN    2201   2201       S->E: Enhanced replication. Decreased
FT                                NS5A hyperphosphorylation.
FT   MUTAGEN    2202   2202       S->A: Enhanced replication.No effect on
FT                                NS5A hyperphosphorylation.
FT   MUTAGEN    2202   2202       S->E: No effect on replication. Decreased
FT                                NS5A hyperphosphorylation.
FT   MUTAGEN    2204   2204       S->A: Enhanced replication. Decreased
FT                                NS5A hyperphosphorylation.
FT   MUTAGEN    2204   2204       S->E: No effect on replication. No effect
FT                                on NS5A hyperphosphorylation.
FT   MUTAGEN    2207   2207       S->A: Enhanced replication. No effect on
FT                                hyperphosphorylation.
FT   MUTAGEN    2207   2207       S->E: No effect on replication.
FT   MUTAGEN    2210   2210       S->A: No effect on replication. No effect
FT                                on hyperphosphorylation.
FT   MUTAGEN    2210   2210       S->E: No effect on replication. No effect
FT                                on hyperphosphorylation.
FT   MUTAGEN    2221   2221       S->A: No effect on hyperphosphorylation.
FT   MUTAGEN    2246   2246       S->A: No effect on replication.
FT   MUTAGEN    2255   2255       S->A: No effect on replication.
FT   MUTAGEN    2269   2269       S->A: No effect on replication.
FT   STRAND     2019   2021
FT   STRAND     2023   2028
FT   STRAND     2034   2040
FT   STRAND     2043   2047
FT   HELIX      2053   2057
FT   STRAND     2079   2084
FT   STRAND     2086   2088
FT   STRAND     2090   2096
FT   STRAND     2099   2107
FT   HELIX      2119   2121
FT   STRAND     2122   2125
FT   STRAND     2146   2149
FT   STRAND     2152   2155
SQ   SEQUENCE   3010 AA;  326906 MW;  37B3448DAFA9A10B CRC64;
     MSTNPKPQRK TKRNTNRRPQ DVKFPGGGQI VGGVYLLPRR GPRLGVRATR KTSERSQPRG
     RRQPIPKARQ PEGRAWAQPG YPWPLYGNEG LGWAGWLLSP RGSRPSWGPT DPRRRSRNLG
     KVIDTLTCGF ADLMGYIPLV GAPLGGAARA LAHGVRVLED GVNYATGNLP GCSFSIFLLA
     LLSCLTIPAS AYEVRNVSGV YHVTNDCSNA SIVYEAADMI MHTPGCVPCV RENNSSRCWV
     ALTPTLAARN ASVPTTTIRR HVDLLVGAAA LCSAMYVGDL CGSVFLVAQL FTFSPRRHET
     VQDCNCSIYP GHVTGHRMAW DMMMNWSPTA ALVVSQLLRI PQAVVDMVAG AHWGVLAGLA
     YYSMVGNWAK VLIVMLLFAG VDGGTYVTGG TMAKNTLGIT SLFSPGSSQK IQLVNTNGSW
     HINRTALNCN DSLNTGFLAA LFYVHKFNSS GCPERMASCS PIDAFAQGWG PITYNESHSS
     DQRPYCWHYA PRPCGIVPAA QVCGPVYCFT PSPVVVGTTD RFGVPTYSWG ENETDVLLLN
     NTRPPQGNWF GCTWMNSTGF TKTCGGPPCN IGGIGNKTLT CPTDCFRKHP EATYTKCGSG
     PWLTPRCLVH YPYRLWHYPC TVNFTIFKVR MYVGGVEHRL EAACNWTRGE RCNLEDRDRS
     ELSPLLLSTT EWQVLPCSFT TLPALSTGLI HLHQNVVDVQ YLYGIGSAVV SFAIKWEYVL
     LLFLLLADAR VCACLWMMLL IAQAEAALEN LVVLNAASVA GAHGILSFLV FFCAAWYIKG
     RLVPGAAYAL YGVWPLLLLL LALPPRAYAM DREMAASCGG AVFVGLILLT LSPHYKLFLA
     RLIWWLQYFI TRAEAHLQVW IPPLNVRGGR DAVILLTCAI HPELIFTITK ILLAILGPLM
     VLQAGITKVP YFVRAHGLIR ACMLVRKVAG GHYVQMALMK LAALTGTYVY DHLTPLRDWA
     HAGLRDLAVA VEPVVFSDME TKVITWGADT AACGDIILGL PVSARRGREI HLGPADSLEG
     QGWRLLAPIT AYSQQTRGLL GCIITSLTGR DRNQVEGEVQ VVSTATQSFL ATCVNGVCWT
     VYHGAGSKTL AGPKGPITQM YTNVDQDLVG WQAPPGARSL TPCTCGSSDL YLVTRHADVI
     PVRRRGDSRG SLLSPRPVSY LKGSSGGPLL CPSGHAVGIF RAAVCTRGVA KAVDFVPVES
     METTMRSPVF TDNSSPPAVP QTFQVAHLHA PTGSGKSTKV PAAYAAQGYK VLVLNPSVAA
     TLGFGAYMSK AHGIDPNIRT GVRTITTGAP ITYSTYGKFL ADGGCSGGAY DIIICDECHS
     TDSTTILGIG TVLDQAETAG ARLVVLATAT PPGSVTVPHP NIEEVALSST GEIPFYGKAI
     PIETIKGGRH LIFCHSKKKC DELAAKLSGL GLNAVAYYRG LDVSVIPTSG DVIVVATDAL
     MTGFTGDFDS VIDCNTCVTQ TVDFSLDPTF TIETTTVPQD AVSRSQRRGR TGRGRMGIYR
     FVTPGERPSG MFDSSVLCEC YDAGCAWYEL TPAETSVRLR AYLNTPGLPV CQDHLEFWES
     VFTGLTHIDA HFLSQTKQAG DNFPYLVAYQ ATVCARAQAP PPSWDQMWKC LIRLKPTLHG
     PTPLLYRLGA VQNEVTTTHP ITKYIMACMS ADLEVVTSTW VLVGGVLAAL AAYCLTTGSV
     VIVGRIILSG KPAIIPDREV LYREFDEMEE CASHLPYIEQ GMQLAEQFKQ KAIGLLQTAT
     KQAEAAAPVV ESKWRTLEAF WAKHMWNFIS GIQYLAGLST LPGNPAIASL MAFTASITSP
     LTTQHTLLFN ILGGWVAAQL APPSAASAFV GAGIAGAAVG SIGLGKVLVD ILAGYGAGVA
     GALVAFKVMS GEMPSTEDLV NLLPAILSPG ALVVGVVCAA ILRRHVGPGE GAVQWMNRLI
     AFASRGNHVS PTHYVPESDA AARVTQILSS LTITQLLKRL HQWINEDCST PCSGSWLRDV
     WDWICTVLTD FKTWLQSKLL PRLPGVPFFS CQRGYKGVWR GDGIMQTTCP CGAQITGHVK
     NGSMRIVGPR TCSNTWHGTF PINAYTTGPC TPSPAPNYSR ALWRVAAEEY VEVTRVGDFH
     YVTGMTTDNV KCPCQVPAPE FFTEVDGVRL HRYAPACKPL LREEVTFLVG LNQYLVGSQL
     PCEPEPDVAV LTSMLTDPSH ITAETAKRRL ARGSPPSLAS SSASQLSAPS LKATCTTRHD
     SPDADLIEAN LLWRQEMGGN ITRVESENKV VILDSFEPLQ AEEDEREVSV PAEILRRSRK
     FPRAMPIWAR PDYNPPLLES WKDPDYVPPV VHGCPLPPAK APPIPPPRRK RTVVLSESTV
     SSALAELATK TFGSSESSAV DSGTATASPD QPSDDGDAGS DVESYSSMPP LEGEPGDPDL
     SDGSWSTVSE EASEDVVCCS MSYTWTGALI TPCAAEETKL PINALSNSLL RHHNLVYATT
     SRSASLRQKK VTFDRLQVLD DHYRDVLKEM KAKASTVKAK LLSVEEACKL TPPHSARSKF
     GYGAKDVRNL SSKAVNHIRS VWKDLLEDTE TPIDTTIMAK NEVFCVQPEK GGRKPARLIV
     FPDLGVRVCE KMALYDVVST LPQAVMGSSY GFQYSPGQRV EFLVNAWKAK KCPMGFAYDT
     RCFDSTVTEN DIRVEESIYQ CCDLAPEARQ AIRSLTERLY IGGPLTNSKG QNCGYRRCRA
     SGVLTTSCGN TLTCYLKAAA ACRAAKLQDC TMLVCGDDLV VICESAGTQE DEASLRAFTE
     AMTRYSAPPG DPPKPEYDLE LITSCSSNVS VAHDASGKRV YYLTRDPTTP LARAAWETAR
     HTPVNSWLGN IIMYAPTLWA RMILMTHFFS ILLAQEQLEK ALDCQIYGAC YSIEPLDLPQ
     IIQRLHGLSA FSLHSYSPGE INRVASCLRK LGVPPLRVWR HRARSVRARL LSQGGRAATC
     GKYLFNWAVR TKLKLTPIPA ASQLDLSSWF VAGYSGGDIY HSLSRARPRW FMWCLLLLSV
     GVGIYLLPNR
//
ID   POLG_HCVED              Reviewed;        3008 AA.
AC   O39929;
DT   10-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 78.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 4a (isolate ED43) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=356418;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=97335261; PubMed=9191927;
RA   Chamberlain R.W., Adams N., Saeed A.A., Simmonds P., Elliott R.M.;
RT   "Complete nucleotide sequence of a type 4 hepatitis C virus variant,
RT   the predominant genotype in the Middle East.";
RL   J. Gen. Virol. 78:1341-1347(1997).
RN   [2]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [3]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [4]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain a highly variable region called hypervariable
CC       region 1 (HVR1). E2 also contains two segments involved in CD81-
CC       binding. HVR1 is implicated in the SCARB1-mediated cell entry.
CC       CD81-binding regions may be involved in sensitivity and/or
CC       resistance to IFN-alpha therapy (By similarity).
CC   -!- DOMAIN: The N-terminus of NS5A act as membrane anchor. The central
CC       part of NS5A seems to be intrinsically disordered and interacts
CC       with NS5B and host PKR (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y11604; CAA72338.1; -; Genomic_RNA.
DR   PIR; PQ0804; PQ0804.
DR   RefSeq; YP_001469632.1; -.
DR   MEROPS; S29.001; -.
DR   euHCVdb; Y11604; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; FALSE_NEG.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Disulfide bond; Envelope protein; Fusion protein;
KW   Glycoprotein; Helicase; Host cell membrane; Host cytoplasm;
KW   Host endoplasmic reticulum; Host lipid droplet; Host membrane;
KW   Host mitochondrion; Host nucleus; Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000045532.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000045533.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000045534.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000045535.
FT   CHAIN       384    746       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000045536.
FT   CHAIN       747    809       p7 (By similarity).
FT                                /FTId=PRO_0000045537.
FT   CHAIN       810   1026       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000045538.
FT   CHAIN      1027   1657       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000045539.
FT   CHAIN      1658   1711       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000045540.
FT   CHAIN      1712   1972       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000045541.
FT   CHAIN      1973   2417       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000045542.
FT   CHAIN      2418   3008       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000045543.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    725       Lumenal (Potential).
FT   TRANSMEM    726    746       Potential.
FT   TOPO_DOM    747    757       Lumenal (Potential).
FT   TRANSMEM    758    778       Potential.
FT   TOPO_DOM    779    782       Cytoplasmic (Potential).
FT   TRANSMEM    783    803       Potential.
FT   TOPO_DOM    804    813       Lumenal (Potential).
FT   TRANSMEM    814    834       Potential.
FT   TOPO_DOM    835    881       Cytoplasmic (Potential).
FT   TRANSMEM    882    902       Potential.
FT   TOPO_DOM    903    928       Lumenal (Potential).
FT   TRANSMEM    929    949       Potential.
FT   TOPO_DOM    950   1657       Cytoplasmic (Potential).
FT   TRANSMEM   1658   1678       Potential.
FT   TOPO_DOM   1679   1805       Cytoplasmic (Potential).
FT   TRANSMEM   1806   1826       Potential.
FT   TOPO_DOM   1827   1828       Lumenal (Potential).
FT   TRANSMEM   1829   1849       Potential.
FT   TOPO_DOM   1850   1850       Cytoplasmic (Potential).
FT   TRANSMEM   1851   1871       Potential.
FT   TOPO_DOM   1872   1881       Lumenal (Potential).
FT   TRANSMEM   1882   1902       Potential.
FT   TOPO_DOM   1903   1972       Cytoplasmic (Potential).
FT   TOPO_DOM   1973   2002       In membrane (By similarity).
FT   TOPO_DOM   2003   2987       Cytoplasmic (Potential).
FT   TRANSMEM   2988   3008       By similarity.
FT   DOMAIN     1217   1369       Helicase ATP-binding.
FT   DOMAIN     2631   2749       RdRp catalytic.
FT   NP_BIND    1230   1237       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      385    411       HVR1 (By similarity).
FT   REGION      483    495       CD81-binding 1 (Potential).
FT   REGION      523    554       CD81-binding 2 (Potential).
FT   REGION      660    671       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1679   1690       NS3-binding (by NS4A) (Potential).
FT   REGION     2120   2329       Transcriptional activation (Potential).
FT   REGION     2120   2208       FKBP8-binding (Potential).
FT   REGION     2200   2246       Basal phosphorylation (By similarity).
FT   REGION     2210   2272       PKR-binding (Potential).
FT   REGION     2245   2303       NS4B-binding (Potential).
FT   REGION     2348   2417       Basal phosphorylation (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1316   1319       DECH box; atypical (By similarity).
FT   MOTIF      2319   2322       SH3-binding (Potential).
FT   MOTIF      2325   2333       Nuclear localization signal (Potential).
FT   COMPBIAS    784    790       Poly-Ala.
FT   COMPBIAS    798    803       Poly-Leu.
FT   COMPBIAS   2274   2324       Pro-rich.
FT   ACT_SITE    952    952       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    972    972       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    993    993       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1083   1083       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1107   1107       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1165   1165       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1123   1123       Zinc (By similarity).
FT   METAL      1125   1125       Zinc (By similarity).
FT   METAL      1171   1171       Zinc (By similarity).
FT   METAL      1175   1175       Zinc (By similarity).
FT   METAL      2029   2029       Zinc (By similarity).
FT   METAL      2031   2031       Zinc (By similarity).
FT   METAL      2052   2052       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        191    192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        746    747       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        809    810       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1026   1027       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1657   1658       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1711   1712       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1972   1973       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2417   2418       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2194   2194       Phosphoserine; by host; in p56 (By
FT                                similarity).
FT   MOD_RES    2197   2197       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2201   2201       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2204   2204       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1968   1968       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   LIPID      1972   1972       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    417    417       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    423    423       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    430    430       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    448    448       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    476    476       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    533    533       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    541    541       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    557    557       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    576    576       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    623    623       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    645    645       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2114   2162       By similarity.
SQ   SEQUENCE   3008 AA;  327599 MW;  8E7FC932E27C406F CRC64;
     MSTNPKPQRK TKRNTNRRPM DVKFPGGGQI VGGVYLLPRR GPRLGVRATR KTSERSQPRG
     RRQPIPKARR PEGRSWAQPG YPWPLYGNEG CGWAGWLLSP RGSRPSWGPN DPRGRSRNLG
     KVIDTLTCGF ADLMGYIPLV GAPVGSVARA LAHGVRALED GINYATGNLP GCSFSIFLLA
     LLSCLTVPAS AVNYRNVSGI YHVTNDCPNS SIVYEADHHI MHLPGCVPCV REGNQSRCWV
     ALTPTVAAPY IGAPLESLRS HVDLMVGAAT VCSGLYIGDL CGGLFLVGQM FSFRPRRHWT
     TQDCNCSIYT GHITGHRMAW DMMMNWSPTT TLVLAQVMRI PTTLVDLLSG GHWGVLVGVA
     YFSMQANWAK VILVLFLFAG VDAETHVSGA AVGRSTAGLA NLFSSGSKQN LQLINSNGSW
     HINRTALNCN DSLNTGFLAS LFYTHKFNSS GCSERLACCK SLDSYGQGWG PLGVANISGS
     SDDRPYCWHY APRPCGIVPA SSVCGPVYCF TPSPVVVGTT DHVGVPTYTW GENETDVFLL
     NSTRPPHGAW FGCVWMNSTG FTKTCGAPPC EVNTNNGTWH CPTDCFRKHP ETTYAKCGSG
     PWITPRCLID YPYRLWHFPC TANFSVFNIR TFVGGIEHRM QAACNWTRGE VCGLEHRDRV
     ELSPLLLTTT AWQILPCSFT TLPALSTGLI HLHQNIVDVQ YLYGVGSAVV SWALKWEYVV
     LAFLLLADAR VSAYLWMMFM VSQVEAALSN LININAASAA GAQGFWYAIL FICIVWHVKG
     RFPAAAAYAA CGLWPCFLLL LMLPERAYAY DQEVAGSLGG AIVVMLTILT LSPHYKLWLA
     RGLWWIQYFI ARTEAVLHVY IPSFNVRGPR DSVIVLAVLV CPDLVFDITK YLLAILGPLH
     ILQASLLRIP YFVRAQALVK ICSLLRGVVY GKYFQMVVLK SRGLTGTYIY DHLTPMSDWP
     PYGLRDLAVA LEPVVFTPME KKVIVWGADT AACGDIIRGL PVSARLGNEI LLGPADTETS
     KGWRLLAPIT AYAQQTRGLF STIVTSLTGR DTNENCGEVQ VLSTATQSFL GTAVNGVMWT
     VYHGAGAKTI SGPKGPVNQM YTNVDQDLVG WPAPPGVRSL APCTCGSADL YLVTRHADVI
     PVRRRGDTRG ALLSPRPISI LKGSSGGPLL CPMGHRAGIF RAAVCTRGVA KAVDFVPVES
     LETTMRSPVF TDNSTPPAVP QTYQVAHLHA PTGSGKSTKV PAAHAAQGYK VLVLNPSVAA
     TLGFGVYMSK AYGIDPNIRS GVRTITTGAP ITYSTYGKFL ADGGCSGGAY DIIICDECYS
     TDSTTILGIG TVLDQAETAG VRLTVLATAT PPGSVTTPHS NIEEVALPTT GEIPFYGKAI
     PLELIKGGRH LIFCHSKKKC DELARQLTSL GLNAVAYYRG LDVSVIPTSG DVVVCATDAL
     MTGFTGDFDS VIDCNTSVIQ TVDFSLDPTF SIEITTVPQD AVSRSQRRGR TGRGRLGTYR
     YVTPGERPSG MFDTAELCEC YDAGCAWYEL TPAETTTRLK AYFDTPGLPV CQDHLEFWES
     VFTGLTHIDG HFLSQTKQSG ENFPYLVAYQ ATVSAKVWLA PPSWDTMWKC LIRLKPTLHG
     PTPLLYRLGS VQNEVVLTHP ITKYIMACMS ADLEVVTSTW VLVGGVLAAL AAYCLSVGSV
     VIVGRVVLSG QPAVIPDREV LYQQFDEMEE CSKHLPLVEH GLQLAEQFKQ KALGLLNFAG
     KQAQEATPVI QSNFAKLEQF WANDMWNFIS GIQYLAGLST LPGNPAIASL MSFTAAVTSP
     LTTQQTLLFN ILGGWVASQI RDSDASTAFV VSGLAGAAVG SVGLGKILVD ILPGYGAGVR
     GAVVTFKIMS GEMPSTEDLV NLLPAILSPG ALVVEVVCPA ILRRHVGPGE GAVQWMNRLI
     AFASRGNHVS PTHYVPESDA ARRVTTILSS LTVTSLLRRL HKWINEDCST PCAESWLWEV
     WDWVLHVLSD FKTCLKAKFV PLMPGIPLLS WPRGYKGEWR GDGVMHTTCP CGADLAGHIK
     NGSMRITGPK TCSNTWHGTF PINAYTTGPG VPIPAPNYKF ALWRVSAEDY VEVRRVGDFH
     YVTGVTQDNI KFPCQVPAPE LFTEVDGIRI HRHAPKCKPL LRDEVSFSVG LNSFVVGSQL
     PCEPEPDVAV LTSMLTDPSH ITAESARRRL ARGSRPSLAS SSASQLSPRL LQATCTAPHD
     SPGTDLLEAN LLWGSTATRV ETDEKVIILD SFESCVAEQN DDREVSVAAE ILRPTKKFPP
     ALPIWARPDY NPPLTETWKQ QDYQAPTVHG CALPPAKQPP VPSPRRKRTV QLTESVVSTA
     LAELAAKTFG QSEPSSDRDT DLTTPTETTD SGPIVVDDAS DDGSYSSMPP LEGEPGDPDL
     TSDSWSTVSG SEDVVCCSMS YSWTGALVTP CAAEESKLPI SPLSNSLLRH HNMVYATTTR
     SAVTRQKKVT FDRLQVVDST YNEVLKEIKA RASRVKPRLL TTEEACDLTP PHSARSKFGY
     GKKDVRSHSR KAINHISSVW KDLLDDNNTP IPTTIMAKNE VFAVNPAKGG RKPARLIVYP
     DLGSRVCEKR ALHDVIKKTA LAVMGAAYGF QYSPAQRVEF LLTAWKSKND PMGFSYDTRC
     FDSTVTEKDI RVEEEVYQCC DLEPEARKVI TALTDRLYVG GPMHNSKGDL CGYRRCRATG
     VYTTSFGNTL TCYLKATAAI RAAALRDCTM LVCGDDLVVI AESDGVEEDN RALRAFTEAM
     TRYSAPPGDA PQPAYDLELI TSCSSNVSVA HDVTGKKVYY LTRDPETPLA RAVWETVRHT
     PVNSWLGNII VYAPTIWVRM ILMTHFFSIL QSQEALEKAL DFDMYGVTYS ITPLDLPAII
     QRLHGLSAFT LHGYSPHELN RVAGALRKLG VPPLRAWRHR ARAVRAKLIA QGGRAKICGI
     YLFNWAVKTK LKLTPLPAAA KLDLSGWFTV GAGGGDIYHS MSHARPRYLL LCLLILTVGV
     GIFLLPAR
//
ID   POLG_HCVEU              Reviewed;        3018 AA.
AC   O39927;
DT   10-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 77.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 6a (isolate EUHK2) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=356420;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=97320431; PubMed=9177282; DOI=10.1006/bbrc.1997.6627;
RA   Adams A., Chamberlain R.W., Taylor L.A., Davidson F., Lin C.K.,
RA   Simmonds P., Elliot R.M.;
RT   "Complete coding sequence of hepatitis C virus genotype 6a.";
RL   Biochem. Biophys. Res. Commun. 234:393-396(1997).
RN   [2]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [3]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [4]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain a highly variable region called hypervariable
CC       region 1 (HVR1). E2 also contains two segments involved in CD81-
CC       binding. HVR1 is implicated in the SCARB1-mediated cell entry.
CC       CD81-binding regions may be involved in sensitivity and/or
CC       resistance to IFN-alpha therapy (By similarity).
CC   -!- DOMAIN: The N-terminus of NS5A act as membrane anchor. The central
CC       part of NS5A seems to be intrinsically disordered and interacts
CC       with NS5B and host PKR (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y12083; CAA72801.1; -; Genomic_RNA.
DR   euHCVdb; Y12083; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; FALSE_NEG.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Disulfide bond; Envelope protein; Fusion protein;
KW   Glycoprotein; Helicase; Host cell membrane; Host cytoplasm;
KW   Host endoplasmic reticulum; Host lipid droplet; Host membrane;
KW   Host mitochondrion; Host nucleus; Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000045544.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000045545.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000045546.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000045547.
FT   CHAIN       384    750       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000045548.
FT   CHAIN       751    813       p7 (By similarity).
FT                                /FTId=PRO_0000045549.
FT   CHAIN       814   1030       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000045550.
FT   CHAIN      1031   1661       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000045551.
FT   CHAIN      1662   1715       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000045552.
FT   CHAIN      1716   1976       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000045553.
FT   CHAIN      1977   2427       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000045554.
FT   CHAIN      2428   3018       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000045555.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    729       Lumenal (Potential).
FT   TRANSMEM    730    750       Potential.
FT   TOPO_DOM    751    761       Lumenal (Potential).
FT   TRANSMEM    762    782       Potential.
FT   TOPO_DOM    783    786       Cytoplasmic (Potential).
FT   TRANSMEM    787    807       Potential.
FT   TOPO_DOM    808    817       Lumenal (Potential).
FT   TRANSMEM    818    838       Potential.
FT   TOPO_DOM    839    885       Cytoplasmic (Potential).
FT   TRANSMEM    886    906       Potential.
FT   TOPO_DOM    907    932       Lumenal (Potential).
FT   TRANSMEM    933    953       Potential.
FT   TOPO_DOM    954   1661       Cytoplasmic (Potential).
FT   TRANSMEM   1662   1682       Potential.
FT   TOPO_DOM   1683   1809       Cytoplasmic (Potential).
FT   TRANSMEM   1810   1830       Potential.
FT   TOPO_DOM   1831   1832       Lumenal (Potential).
FT   TRANSMEM   1833   1853       Potential.
FT   TOPO_DOM   1854   1854       Cytoplasmic (Potential).
FT   TRANSMEM   1855   1875       Potential.
FT   TOPO_DOM   1876   1885       Lumenal (Potential).
FT   TRANSMEM   1886   1906       Potential.
FT   TOPO_DOM   1907   1976       Cytoplasmic (Potential).
FT   TOPO_DOM   1977   2006       In membrane (By similarity).
FT   TOPO_DOM   2007   2997       Cytoplasmic (Potential).
FT   TRANSMEM   2998   3018       By similarity.
FT   DOMAIN     2641   2759       RdRp catalytic.
FT   NP_BIND    1234   1241       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      384    410       HVR1 (By similarity).
FT   REGION      482    494       CD81-binding 1 (Potential).
FT   REGION      522    553       CD81-binding 2 (Potential).
FT   REGION      664    675       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1683   1694       NS3-binding (by NS4A) (Potential).
FT   REGION     2124   2337       Transcriptional activation (Potential).
FT   REGION     2124   2212       FKBP8-binding (Potential).
FT   REGION     2204   2254       Basal phosphorylation (By similarity).
FT   REGION     2214   2279       PKR-binding (Potential).
FT   REGION     2253   2311       NS4B-binding (Potential).
FT   REGION     2356   2427       Basal phosphorylation (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1320   1323       DECH box (By similarity).
FT   MOTIF      2327   2330       SH3-binding (Potential).
FT   MOTIF      2332   2340       Nuclear localization signal (Potential).
FT   COMPBIAS   2282   2332       Pro-rich.
FT   COMPBIAS   2999   3006       Poly-Leu.
FT   ACT_SITE    956    956       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    976    976       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    997    997       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1087   1087       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1111   1111       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1169   1169       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1127   1127       Zinc (By similarity).
FT   METAL      1129   1129       Zinc (By similarity).
FT   METAL      1175   1175       Zinc (By similarity).
FT   METAL      1179   1179       Zinc (By similarity).
FT   METAL      2015   2015       Zinc (By similarity).
FT   METAL      2033   2033       Zinc (By similarity).
FT   METAL      2035   2035       Zinc (By similarity).
FT   METAL      2056   2056       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        191    192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        750    751       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        813    814       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1030   1031       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1661   1662       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1715   1716       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1976   1977       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2427   2428       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2198   2198       Phosphoserine; by host; in p56 (By
FT                                similarity).
FT   MOD_RES    2201   2201       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2205   2205       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1976   1976       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    250    250       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    416    416       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    422    422       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    429    429       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    447    447       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    475    475       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    532    532       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    556    556       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    577    577       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    627    627       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    649    649       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    712    712       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2118   2166       By similarity.
SQ   SEQUENCE   3018 AA;  329020 MW;  6E67FB3CF6A61AE3 CRC64;
     MSTLPKPQRK TKRNTNRRPM DVKFPGGGQI VGGVYLLPRK GPRLGVRATR KTSERSQPRG
     RRQPIPKARQ PQGRHWAQPG YPWPLYGSEG CGWAGWLLSP RGSRPHWGPN DPRRRSRNLG
     KVIDTLTCGF ADLMWYIPVV GAPLGGVAAA LAHGVRAIED GINYATGNLP GCSFSIFLLA
     LLSCLTTPAS ALTYGNSSGL YHLTNDCSNS SIVLEADAMI LHLPGCLPCV RVGNQSTCWH
     AVSPTLATPN ASTPATGFRR HVDLLAGAAV VCSSLYIGDL CGSLFLAGQL FAFQPRRHWT
     VQDCNCSIYT GHVTGHKMAW DMMMNWSPTT TLVLSSILRV PEICASVIFG GHWGILLAVA
     YFGMAGNWLK VLAVLFLFAG VEAQTMIAHG VSQTTSGFAS LLTPGAKQNI QLINTNGSWH
     INRTALNCND SLQTGFLASL FYTHKFNSSG CPERMAACKP LAEFRQGWGQ ITHKNVSGPS
     DDRPYCWHYA PRPCEVVPAR SVCGPVYCFT PSPVVVGTTD KRGNPTYTWG ENETDVFMLE
     SLRPPTGGWF GCTWMNSTGF TKTCGAPPCQ IVPGNYNSSA NELLCPTDCF RKHPEATYQR
     CGSGPWVTPR CLVDYAYRLW HYPCTVNFTL HKVRMFVGGT EHRFDVACNW TRGERCELHD
     RNRIEMSPLL FSTTQLSILP CSFSTMPALS TGLIHLHQNI VDVQYLYGVS TNVTSWVVKW
     EYIVLMFLVL ADARICTCLW LMLLISTVEA AVERLVVLNA ASAAGTAGWW WAVLFLCCVW
     YVKGRLVPAC TYMALGMWPL LLTILALPPR AYAMDNEQAA SLGAVGLLVI TIFSITPMYK
     KLLNCFIWWN QYFLARAEAM VHEWVPDLRV RGGRDSIILL TCLLHPQLGF EVTKILLAVL
     APLYILQYSL LKVPYFVRAH ILLRACLLVR RLAGGKYVQA CLLRLGAWTG TFVYDHLAPL
     SDWASDGLRD LAVAVEPVIF SPMEKKIITW GADTAACGDI LSGLPVSARL GNLVLLGPAD
     DMQRGGWKLL APITAYAQQT RGLVGTIVTS LTGRDKNEVE GEVQVVSTDT QSFVATSING
     VMWTVYHGPG FKTLAGPKGP VCQMYTNVDL DLVGWPSPPG ARSLTPCNCG SSDLYLVTRE
     ADVIPARRRG DSRAALLSPR PISTLKGSSG GPIMCPSGHV VGLFRAAVCT RGVAKSLDFI
     PVENMETTMR SPSFTDNSTP PAVPQTYQVG YLHAPTGSGK STRVPAAYAS QGYKVLVLNP
     SVAATLSFGS YMRQAYGVEP NIRTGVRTVT TGGAITYSTY GEFLADGGCS GGAYDIIICD
     ECHSTDPTTV LGVGTVLDQA ETAGVRLTVL PTATPPGSVT VPHPNITETA LPTTGEIPFY
     GKAIPLEYIK GGRHLIFCHS KKKCDELAGK LKSLGLNAVA FYRGVDVSVI PTSGDVVVCA
     TDALMTGYTG DFDSVIDCNV AVTQVVDFSL DPTFSIETTT VPQDAVSRSQ RRGRTGRGKP
     GVYRFVSQGE RPSGMFDTVV LCEAYDTGCA WYELTPSETT VRLRAYMNTP GLPVCQDHLE
     FWEGVFTGLT HIDAHFLSHT KQAGENFAYL VAYQATVCAR AKAPPPSWDM MWKCLIRLKP
     TLTGPTPLLY RLGAVQNGVI TTHPITKYIM TCMSADLEVI TSTWVLVGGV LAALAAYCLS
     VGCVVICGRI TLTGKPAVVP DREILYQQFD EMEECSRHIP YLAEGQQIAE QFRQKVLGLL
     QASAKQAEEL KPAVHSAWPR VEDFWRKHMW NFVSGIQYLA GLSTLPGNPA VASLMSFTAS
     LTSPLRTSQT LLLNILGGWI AAQVAPPPAS TAFVVSGLAG AAVGSIRLGR VLVDVLAGYG
     AGVSGALVAF KIMSGECPST EDMVNLLPAL LSPGVALVGV VCAAILRRHV GPAEGANQWM
     NRLIAFASRG NHVSPTHYVP ETDASKNVTQ ILTSLTITSL LRRLHQWVNE DTATPCATSW
     LRDVWDWVCT VLSDFKVWLQ AKLFPRLPGI PFLSCQAGYR GVWAGDGVCH TTCTCGAVIA
     GHVKNGTMKI TGPKTCSNTW HGTFPINATT TGPSTPRPAP NYQRALWRVS AEDYVEVRRL
     GDCHYVVGVT AEGLKCPCQV PAPEFFTEVD GVRIHRYAPP CKPLLRDEVT FSVGLSNYAV
     GSQLPCEPEP DVTVVTSMLT DPTHITAETA ARRLKKGSPP SLASSSANQL SAPSLRATCT
     TSQKHPEMEL LQANLLWKHE MGSHIPRVQS ENKVVVLDSF ELYPLEYEER EISVSVECHR
     QPRCKFPPVF PVWARPDNNP PFIQAWQMPG YEPPVVSGCA VAPPKPAPVP PPRRKRLVHL
     DESTVSHALA QLADKVFVES SNDPGPSSDS GLSITSPVPP DPTTPEDAGS EAESYSSMPP
     LEGEPGDPDL SSGSWSTVSD EDDVVCCSMS YSWTGALITP CAAEEEKLPI NPLSNSLVRH
     HNMVYSTTSR SASLRQKKVT FDRVQVFDQH YQDVLKEIKL RASTVQAKLL SIEEACDLTP
     SHSARSKYGY GAQDVRSRAS KAVDHIPSVW EGLLEDSDTP IPTTIMAKNE VFCVDPSKGG
     RKPARLIVYP DLGVRVCEKM ALYDVTQKLP QAVMGPAYGF QYSPNQRVEY LLKMWRSKKV
     PMGFSYDTRC FDSTVTERDI RTENDIYQSC QLDPVARRVV SSLTERLYVG GPMANSKGQS
     CGYRRCRASG VLPTSMGNTL TCYLKAQAAC RAANIKDCDM LVCGDDLVVI CESAGVQEDT
     ASLRAFTDAM TRYSAPPGDA PQPTYDLELI TSCSSNVSVA HEGNGKKYYY LTRDCTTPLA
     RAAWETARHT PVNSWLGNII MFAPTIWVRM VLMNHFFSIL QSQEQLEKAF DFDIYGVTYS
     VSPLDLPAII QRLHGMAAFS LHGYSPVELN RVGACLRKLG VLPSRAWRHR ARAVRAKLIA
     QGGKAAICGK YLFNWAVKTK LKLTPLVSAS KLDLSGWFVA GYDGGDIYHS VSQARPRFLL
     LGLLLLTVGV GIFLLPAR
//
ID   POLG_HCVEV              Reviewed;        3014 AA.
AC   O39928;
DT   10-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 76.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 5a (isolate EUH1480) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=356419;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=97366593; PubMed=9223423; DOI=10.1006/bbrc.1997.6902;
RA   Chamberlain R.W., Adams N.J., Taylor L.A., Simmonds P., Elliot R.M.;
RT   "The complete coding sequence of hepatitis C virus genotype 5a, the
RT   predominant genotype in South Africa.";
RL   Biochem. Biophys. Res. Commun. 236:44-49(1997).
RN   [2]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [3]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [4]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain a highly variable region called hypervariable
CC       region 1 (HVR1). E2 also contains two segments involved in CD81-
CC       binding. HVR1 is implicated in the SCARB1-mediated cell entry.
CC       CD81-binding regions may be involved in sensitivity and/or
CC       resistance to IFN-alpha therapy (By similarity).
CC   -!- DOMAIN: The N-terminus of NS5A act as membrane anchor. The central
CC       part of NS5A seems to be intrinsically disordered and interacts
CC       with NS5B and host PKR (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 helicase C-terminal domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y13184; CAA73640.1; -; Genomic_RNA.
DR   PIR; JC5620; JC5620.
DR   RefSeq; YP_001469633.1; -.
DR   MEROPS; S29.001; -.
DR   euHCVdb; Y13184; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; 1.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Disulfide bond; Envelope protein; Fusion protein;
KW   Glycoprotein; Helicase; Host cell membrane; Host cytoplasm;
KW   Host endoplasmic reticulum; Host lipid droplet; Host membrane;
KW   Host mitochondrion; Host nucleus; Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000045556.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000045557.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000045558.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000045559.
FT   CHAIN       384    747       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000045560.
FT   CHAIN       748    810       p7 (By similarity).
FT                                /FTId=PRO_0000045561.
FT   CHAIN       811   1027       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000045562.
FT   CHAIN      1028   1658       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000045563.
FT   CHAIN      1659   1712       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000045564.
FT   CHAIN      1713   1973       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000045565.
FT   CHAIN      1974   2423       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000045566.
FT   CHAIN      2424   3014       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000045567.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    726       Lumenal (Potential).
FT   TRANSMEM    727    747       Potential.
FT   TOPO_DOM    748    758       Lumenal (Potential).
FT   TRANSMEM    759    779       Potential.
FT   TOPO_DOM    780    783       Cytoplasmic (Potential).
FT   TRANSMEM    784    804       Potential.
FT   TOPO_DOM    805    814       Lumenal (Potential).
FT   TRANSMEM    815    835       Potential.
FT   TOPO_DOM    836    882       Cytoplasmic (Potential).
FT   TRANSMEM    883    903       Potential.
FT   TOPO_DOM    904    929       Lumenal (Potential).
FT   TRANSMEM    930    950       Potential.
FT   TOPO_DOM    951   1658       Cytoplasmic (Potential).
FT   TRANSMEM   1659   1679       Potential.
FT   TOPO_DOM   1680   1806       Cytoplasmic (Potential).
FT   TRANSMEM   1807   1827       Potential.
FT   TOPO_DOM   1828   1829       Lumenal (Potential).
FT   TRANSMEM   1830   1850       Potential.
FT   TOPO_DOM   1851   1851       Cytoplasmic (Potential).
FT   TRANSMEM   1852   1872       Potential.
FT   TOPO_DOM   1873   1882       Lumenal (Potential).
FT   TRANSMEM   1883   1903       Potential.
FT   TOPO_DOM   1904   1973       Cytoplasmic (Potential).
FT   TOPO_DOM   1974   2003       In membrane (By similarity).
FT   TOPO_DOM   2004   2993       Cytoplasmic (Potential).
FT   TRANSMEM   2994   3014       By similarity.
FT   DOMAIN     1218   1351       Helicase ATP-binding.
FT   DOMAIN     1362   1539       Helicase C-terminal.
FT   DOMAIN     2637   2755       RdRp catalytic.
FT   NP_BIND    1231   1238       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      385    411       HVR1 (By similarity).
FT   REGION      483    495       CD81-binding 1 (Potential).
FT   REGION      523    554       CD81-binding 2 (Potential).
FT   REGION      661    672       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1680   1691       NS3-binding (by NS4A) (Potential).
FT   REGION     2121   2334       Transcriptional activation (Potential).
FT   REGION     2121   2209       FKBP8-binding (Potential).
FT   REGION     2201   2251       Basal phosphorylation (By similarity).
FT   REGION     2211   2276       PKR-binding (Potential).
FT   REGION     2250   2307       NS4B-binding (Potential).
FT   REGION     2353   2423       Basal phosphorylation (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1317   1320       DECH box (By similarity).
FT   MOTIF      2323   2326       SH3-binding (Potential).
FT   MOTIF      2328   2337       Nuclear localization signal (Potential).
FT   COMPBIAS    757    761       Poly-Ala.
FT   COMPBIAS   2280   2328       Pro-rich.
FT   COMPBIAS   2995   3002       Poly-Leu.
FT   ACT_SITE    953    953       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    973    973       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    994    994       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1084   1084       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1108   1108       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1166   1166       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1124   1124       Zinc (By similarity).
FT   METAL      1126   1126       Zinc (By similarity).
FT   METAL      1172   1172       Zinc (By similarity).
FT   METAL      1176   1176       Zinc (By similarity).
FT   METAL      2012   2012       Zinc (By similarity).
FT   METAL      2030   2030       Zinc (By similarity).
FT   METAL      2032   2032       Zinc (By similarity).
FT   METAL      2053   2053       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        191    192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        747    748       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        810    811       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1027   1028       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1658   1659       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1712   1713       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1973   1974       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2423   2424       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2195   2195       Phosphoserine; by host; in p56 (By
FT                                similarity).
FT   MOD_RES    2198   2198       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2202   2202       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2205   2205       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1973   1973       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    417    417       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    423    423       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    430    430       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    448    448       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    533    533       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    557    557       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    577    577       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    624    624       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    646    646       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2115   2163       By similarity.
SQ   SEQUENCE   3014 AA;  327671 MW;  84934E2B77A1964B CRC64;
     MSTNPKPQRK TKRNTNRRPQ DVKFPGGGQI VGGVYLLPRR GPKLGVRATR KNSERSQPRG
     RRQPIPKARR PTGRSWGQPG YPWPLYANEG LGWAGWLLSP RSSRPNWGPN DPRRKSPNLG
     RVIHTLTCGF PHLMGYIPLV GGPVGGVSRA LAHGVKVLED GINYATGNLP GCPFSIFVLA
     LLWCLTVPAS AVPYRNASGV YHVTNDCPNS SIVYEADNLI LHAPGCVPCV LEDNVSRCWV
     QITPTLSAPS FGAVTALLRR AVDYLAGGAA FCSALYVGDA CGALSLVGQM FTYKPRQHTT
     VQDCNCSIYS GHITGHRMAW DMMMKWSPTT ALLMAQLLRI PQVVIDIIAG GHWGVLLAAA
     YFASTANWAK VILVLFLFAG VDGRTHTVGG TVGQGLKSLT SFFNPGPQRQ LQFVNTNGSW
     HINSTALNCN DSLQTGFIAG LMYAHKFNSS GCPERMSSCR PLAAFDQGWG TISYATISGP
     SDDKPYCWHY PPRPCGVVPA RDVCGPVYCF TPSPVVVGTT DRRGCPTYNW GSNETDILLL
     NNIRPPAGNW FGCTWMNSTG FVKNCGAPPC NLGPTGNNSL KCPTDCFRKH PDATYTRCGS
     GPWLTPRCLV HYPYRLWHYP CTVNYTIFKV RMFIGGLEHR LEAACNWTYG ERCDLEDRDR
     AELSPLLHTT TQWAILPCSF TPTPALSTGL IHLHQNIVDT QYLYGLSSSI VSWAVKWEYI
     MLVFLLLADA RICTCLLILL LICQAEATCK NVIVLNAAAA AGNHGFFWGL LVVCLAWHVK
     GRLVPGATYL CLGVWPLLLV RLLRPHRALA LDSSDGGTVG CLVLIVLTIF TLTPGYKKKV
     VLVMWWLQYF IARVEAIIHV WVPPLQVKGG RDAVIMLTCL FHPALGFEIT KILFGILGPL
     YLLQHSLTKV PYFLRARALL RLCLLAKHLV YGKYVQAALL HLGRLTGTYI YDHLAPMKDW
     AASGLRELTV ATEPIVFSAM ETKVITWGAD TAACGNILAV LPVSARRGRE IFLGPADDIK
     TSGWRLLAPI TAYAQQTRGV LGAIVLSLTG RDKNEAEGEV QFLSTATQTF LGICINGVMW
     TLFHGAGSKT LAGPKGPVVQ MYTNVDKDLV GWPSPPGKGS LTRCTCGSAD LYLVTRHADV
     IPARRRGDTR ASLLSPRPIS YLKGSSGGPI MCPSGHVVGV FRAAVCTRGV AKALEFVPVE
     NLETTMRSPV FTDNSTPPAV PHEFQVGHLH APTGSGKSTK VPAAYAAQGY KVLVLNPSVA
     ATFGFGAYMS RAYGVDPNIR TGVRTVTTGA GITYSTYGKF FADGGCSGGA YDVIICDECH
     SQDATTILGI GTVLDQAETA GARLVVLATA IPPGSVTTPH PNIEEVALPS EGEIPFYGRA
     IPLVLIKGGR HLIFCHSKKK CDELAKQLTS LGVNAVAYYR GLDVAVIPAT GDVVVCSTDA
     LMTGFTGDFD SVIDCNSAVT QTVDFSLDPT FTIETTTVPQ DAVSRSQRRG RTGRGRHGIY
     RYVSSGERPS GIFDSVVLCE CYDAGCAWYD LTPAETTVRL RAYLNTPGLP VCQEHLEFWE
     GVFTGLTNID AHMLSQAKQG GENFPYLVAY QATVCVRAKA PPPSWDTMWK CMICLKPTLT
     GPTPLLYRLG AVQNEITLTH PITKYIMACM SADLEVITST WVLVGGVVAA LAAYCLTVGS
     VAIVGRIILS GRPAITPDRE VLYQQFDEME ECSASLPYVD EARAIAGQFK EKVLGLIGTA
     GQKAETLKPA ATSMWSKAEQ FWAKHMWNFV SGIQYLAGLS TLPGNPAVAT LMSFTAAVTS
     PLTTHQTLLF NILGGWVASQ IAPPTAATAF VVSGMAGAAV GNIGLGRVLI DILAGYGTGV
     AGALVAFKIM CGERPTAEEL VNLLPSILCP GALVVGVICA AVLRRHIGPG EGAVQWMNRL
     IAFASRGNHG SPTHYVPETD ASAKVTQLLS SLTVTSLLKR LHTWIGEDYS TPCDGTWLRA
     IWDWVCTALT DFKAWLQAKL LPQLPGVPFF SCQKGYKGVW RGDGVNSTKC PCGATISGHV
     KNGTMRIVGP KLCSNTWQGT FPINATTTGP SVPAPAPNYK FALWRVGAAD YAEVRRVGDY
     HYITGVTQDN LKCPCQVPSP EFFTELDGVR IHRFAPPCNP LLREEVTFSV GLHSYVVGSQ
     LPCEPEPDVT VLTSMLSDPA HITAETAKRR LNRGSPPSLA NSSASQLSAP SLKATCTIQG
     HHPDADLIKA NLLWRQCMGG NITRVEAENK VEILDCFKPL KEEEDDREIS VSADCFKKGP
     AFPPALPVWA RPGYDPPLLE TWKRPDYDPP QVWGCPIPPA GPPPVPLPRR KRKPMELSDS
     TVSQVMADLA DARFKVDTPS IEGQDSALGT SSQHDSGPEE KRDDNSDAAS YSSMPPLEGE
     PGDPDLSSGS WSTVSGEDNV VCCSMSYTWT GALITPCSAE EEKLPINPLS NTLLRHHNLV
     YSTSSRSAGL RQKKVTFDRL QVLDDHYREV VDEMKRLASK VKARLLPLEE ACGLTPPHSA
     RSKYGYGAKE VRSLDKKALK HIEGVWQDLL DDSDTPLPTT IMAKNEVFAV EPSKGGKKPA
     RLIVYPDLGV RVCEKRALYD VAQKLPTALM GPSYGFQYSP AQRVDFLLKA WKSKKIPMAF
     SYDTRCFDST ITEHDIMTEE SIYQSCDLQP EARVAIRSLT QRLYCGGPMY NSKGQQCGYR
     RCRASGVFTT SMGNTMTCYI KALASCRAAK LRDCTLLVCG DDLVAICESQ GTHEDEASLR
     AFTEAMTRYS APPGDPPVPA YDLELVTSCS SNVSVARDAS GNRIYYLTRD PQVPLAKAAW
     ETAKHSPVNS WLGNIIMYAP TLWARIVLMT HFFSVLQSQE QLEKTLAFEM YGSVYSVTPL
     DLPAIIQRLH GLSAFSLHSY SPSEINRVAS CLRKLGVPPL RAWRHRARAV RAKLIAQGGR
     AAICGIYLFN WAVKTKRKLT PLADADRLDL SSWFTVGAGG GDIYHSMSRA RPRNLLLCLL
     LLSVGVGIFL LPAR
//
ID   POLG_HCVH               Reviewed;        3011 AA.
AC   P27958; O36579; O36608; O36609; O36610;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 120.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 1a (isolate H) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=11108;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA], AND DOMAIN V3 REGION.
RX   MEDLINE=92052256; PubMed=1658800; DOI=10.1073/pnas.88.22.10292;
RA   Inchauspe G., Zebedee S., Lee D.H.H., Sugitani M., Nasoff M.,
RA   Prince A.M.;
RT   "Genomic structure of the human prototype strain H of hepatitis C
RT   virus: comparison with American and Japanese isolates.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:10292-10296(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate H77;
RX   MEDLINE=97373636; PubMed=9228008; DOI=10.1126/science.277.5325.570;
RA   Kolykhalov A.A., Agapov E.V., Blight K.J., Mihalik K., Feinstone S.M.,
RA   Rice C.M.;
RT   "Transmission of hepatitis C by intrahepatic inoculation with
RT   transcribed RNA.";
RL   Science 277:570-574(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate H77;
RX   MEDLINE=97385173; PubMed=9238047; DOI=10.1073/pnas.94.16.8738;
RA   Yanagi M., Purcell R.H., Emerson S.U., Bukh J.;
RT   "Transcripts from a single full-length cDNA clone of hepatitis C virus
RT   are infectious when directly transfected into the liver of a
RT   chimpanzee.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:8738-8743(1997).
RN   [4]
RP   IDENTIFICATION OF THE CYSTEINE PROTEASE, AND MUTAGENESIS OF HIS-952;
RP   CYS-993 AND SER-1165.
RX   PubMed=8248148; DOI=10.1073/pnas.90.22.10583;
RA   Grakoui A., McCourt D.W., Wychowski C., Feinstone S.M., Rice C.M.;
RT   "A second hepatitis C virus-encoded proteinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:10583-10587(1993).
RN   [5]
RP   PROTEOLYTIC PROCESSING OF POLYPROTEIN.
RX   PubMed=7679746;
RA   Grakoui A., Wychowski C., Lin C., Feinstone S.M., Rice C.M.;
RT   "Expression and identification of hepatitis C virus polyprotein
RT   cleavage products.";
RL   J. Virol. 67:1385-1395(1993).
RN   [6]
RP   SUBCELLULAR LOCATION OF NS5A, AND NUCLEAR LOCALIZATION SIGNAL.
RX   MEDLINE=97136712; PubMed=8982089; DOI=10.1016/S0378-1119(96)00555-0;
RA   Ide Y., Zhang L., Chen M., Inchauspe G., Bahl C., Sasaguri Y.,
RA   Padmanabhan R.;
RT   "Characterization of the nuclear localization signal and subcellular
RT   distribution of hepatitis C virus nonstructural protein NS5A.";
RL   Gene 182:203-211(1996).
RN   [7]
RP   PHOSPHORYLATION AT SER-2321, AND MUTAGENESIS OF SER-2321.
RX   MEDLINE=99419094; PubMed=10488152; DOI=10.1074/jbc.274.39.28011;
RA   Reed K.E., Rice C.M.;
RT   "Identification of the major phosphorylation site of the hepatitis C
RT   virus H strain NS5A protein as serine 2321.";
RL   J. Biol. Chem. 274:28011-28018(1999).
RN   [8]
RP   INTERACTION OF NS5A WITH SRCAP, AND SUBCELLULAR LOCATION OF NS5A.
RX   PubMed=10702287; DOI=10.1074/jbc.275.10.7184;
RA   Ghosh A.K., Majumder M., Steele R., Yaciuk P., Chrivia J., Ray R.,
RA   Ray R.B.;
RT   "Hepatitis C virus NS5A protein modulates transcription through a
RT   novel cellular transcription factor SRCAP.";
RL   J. Biol. Chem. 275:7184-7188(2000).
RN   [9]
RP   SUBCELLULAR LOCATION OF E1 AND E2, AND ROLE OF TRANSMEMBRANE DOMAINS.
RX   PubMed=10729138; DOI=10.1128/JVI.74.8.3623-3633.2000;
RA   Cocquerel L., Wychowski C., Minner F., Penin F., Dubuisson J.;
RT   "Charged residues in the transmembrane domains of hepatitis C virus
RT   glycoproteins play a major role in the processing, subcellular
RT   localization, and assembly of these envelope proteins.";
RL   J. Virol. 74:3623-3633(2000).
RN   [10]
RP   INTERACTION OF CORE PROTEIN WITH HUMAN C1QR1.
RX   PubMed=11086025; DOI=10.1172/JCI10323;
RA   Kittlesen D.J., Chianese-Bullock K.A., Yao Z.Q., Braciale T.J.,
RA   Hahn Y.S.;
RT   "Interaction between complement receptor gC1qR and hepatitis C virus
RT   core protein inhibits T-lymphocyte proliferation.";
RL   J. Clin. Invest. 106:1239-1249(2000).
RN   [11]
RP   CHARACTERIZATION OF HVR1 REGION.
RX   PubMed=11356980; DOI=10.1128/JVI.75.12.5703-5710.2001;
RA   Penin F., Combet C., Germanidis G., Frainais P.-O., Deleage G.,
RA   Pawlotsky J.-M.;
RT   "Conservation of the conformation and positive charges of hepatitis C
RT   virus E2 envelope glycoprotein hypervariable region 1 points to a role
RT   in cell attachment.";
RL   J. Virol. 75:5703-5710(2001).
RN   [12]
RP   TOPOLOGY OF NS5B.
RX   MEDLINE=21570199; PubMed=11557752; DOI=10.1074/jbc.M103358200;
RA   Schmidt-Mende J., Bieck E., Huegle T., Penin F., Rice C.M., Blum H.E.,
RA   Moradpour D.;
RT   "Determinants for membrane association of the hepatitis C virus RNA-
RT   dependent RNA polymerase.";
RL   J. Biol. Chem. 276:44052-44063(2001).
RN   [13]
RP   TOPOLOGY OF ENVELOPE GLYCOPROTEINS E1 AND E2.
RX   MEDLINE=22060489; PubMed=12065403; DOI=10.1093/emboj/cdf295;
RA   Cocquerel L., Op de Beeck A., Lambot M., Roussel J., Delgrange D.,
RA   Pillez A., Wychowski C., Penin F., Dubuisson J.;
RT   "Topological changes in the transmembrane domains of hepatitis C virus
RT   envelope glycoproteins.";
RL   EMBO J. 21:2893-2902(2002).
RN   [14]
RP   TOPOLOGY, AND SUBCELLULAR LOCATION OF P7.
RX   PubMed=11907211; DOI=10.1128/JVI.76.8.3720-3730.2002;
RA   Carrere-Kremer S., Montpellier-Pala C., Cocquerel L., Wychowski C.,
RA   Penin F., Dubuisson J.;
RT   "Subcellular localization and topology of the p7 polypeptide of
RT   hepatitis C virus.";
RL   J. Virol. 76:3720-3730(2002).
RN   [15]
RP   TOPOLOGY OF NS5A.
RX   MEDLINE=21864171; PubMed=11744739; DOI=10.1074/jbc.M111289200;
RA   Brass V., Bieck E., Montserret R., Woelk B., Hellings J.A., Blum H.E.,
RA   Penin F., Moradpour D.;
RT   "An amino-terminal amphipathic alpha-helix mediates membrane
RT   association of the hepatitis C virus nonstructural protein 5A.";
RL   J. Biol. Chem. 277:8130-8139(2002).
RN   [16]
RP   REPLICATION COMPLEX.
RX   PubMed=12021330; DOI=10.1128/JVI.76.12.5974-5984.2002;
RA   Egger D., Woelk B., Gosert R., Bianchi L., Blum H.E., Moradpour D.,
RA   Bienz K.;
RT   "Expression of hepatitis C virus proteins induces distinct membrane
RT   alterations including a candidate viral replication complex.";
RL   J. Virol. 76:5974-5984(2002).
RN   [17]
RP   REPLICATION COMPLEX.
RX   PubMed=12692249; DOI=10.1128/JVI.77.9.5487-5492.2003;
RA   Gosert R., Egger D., Lohmann V., Bartenschlager R., Blum H.E.,
RA   Bienz K., Moradpour D.;
RT   "Identification of the hepatitis C virus RNA replication complex in
RT   Huh-7 cells harboring subgenomic replicons.";
RL   J. Virol. 77:5487-5492(2003).
RN   [18]
RP   INHIBITION OF P7 BY LONG-ALKYL-CHAIN IMINOSUGAR DERIVATIVES.
RX   MEDLINE=22631661; PubMed=12719519; DOI=10.1073/pnas.1031527100;
RA   Pavlovic D., Neville D.C., Argaud O., Blumberg B., Dwek R.A.,
RA   Fischer W.B., Zitzmann N.;
RT   "The hepatitis C virus p7 protein forms an ion channel that is
RT   inhibited by long-alkyl-chain iminosugar derivatives.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:6104-6108(2003).
RN   [19]
RP   MUTAGENESIS OF LYS-779 AND ARG-781.
RC   STRAIN=Isolate H77;
RX   PubMed=14504405; DOI=10.1073/pnas.1834545100;
RA   Sakai A., Claire M.S., Faulk K., Govindarajan S., Emerson S.U.,
RA   Purcell R.H., Bukh J.;
RT   "The p7 polypeptide of hepatitis C virus is critical for infectivity
RT   and contains functionally important genotype-specific sequences.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:11646-11651(2003).
RN   [20]
RP   INTERACTION BETWEEN NON-STRUCTURAL PROTEINS.
RX   PubMed=12692242; DOI=10.1128/JVI.77.9.5401-5414.2003;
RA   Dimitrova M., Imbert I., Kieny M.P., Schuster C.;
RT   "Protein-protein interactions between hepatitis C virus nonstructural
RT   proteins.";
RL   J. Virol. 77:5401-5414(2003).
RN   [21]
RP   TOPOLOGY, AND SUBCELLULAR LOCATION OF NS4B.
RC   STRAIN=Isolate H77;
RX   PubMed=12692244; DOI=10.1128/JVI.77.9.5428-5438.2003;
RA   Lundin M., Monne M., Widell A., Von Heijne G., Persson M.A.A.;
RT   "Topology of the membrane-associated hepatitis C virus protein NS4B.";
RL   J. Virol. 77:5428-5438(2003).
RN   [22]
RP   INTERACTION OF E1/E2 HETERODIMER WITH HUMAN CD81.
RX   PubMed=12970454; DOI=10.1128/JVI.77.19.10677-10683.2003;
RA   Cocquerel L., Kuo C.-C., Dubuisson J., Levy S.;
RT   "CD81-dependent binding of hepatitis C virus E1E2 heterodimers.";
RL   J. Virol. 77:10677-10683(2003).
RN   [23]
RP   INTERACTION OF E1/E2 HETERODIMER WITH HUMAN CD81; LDLR AND SCARB1.
RX   MEDLINE=22503048; PubMed=12615904; DOI=10.1084/jem.20021756;
RA   Bartosch B., Dubuisson J., Cosset F.-L.;
RT   "Infectious hepatitis C virus pseudo-particles containing functional
RT   E1-E2 envelope protein complexes.";
RL   J. Exp. Med. 197:633-642(2003).
RN   [24]
RP   INTERACTION OF E1/E2 HETERODIMER WITH HUMAN CD81.
RX   MEDLINE=22928135; PubMed=12913001; DOI=10.1074/jbc.M305289200;
RA   Bartosch B., Vitelli A., Granier C., Goujon C., Dubuisson J.,
RA   Pascale S., Scarselli E., Cortese R., Nicosia A., Cosset F.-L.;
RT   "Cell entry of hepatitis C virus requires a set of co-receptors that
RT   include the CD81 tetraspanin and the SR-B1 scavenger receptor.";
RL   J. Biol. Chem. 278:41624-41630(2003).
RN   [25]
RP   CHARACTERIZATION OF E1 AND E2.
RX   PubMed=14990718; DOI=10.1128/JVI.78.6.2994-3002.2004;
RA   Op De Beeck A., Voisset C., Bartosch B., Ciczora Y., Cocquerel L.,
RA   Keck Z., Foung S., Cosset F.-L., Dubuisson J.;
RT   "Characterization of functional hepatitis C virus envelope
RT   glycoproteins.";
RL   J. Virol. 78:2994-3002(2004).
RN   [26]
RP   PROTEOLYTIC PROCESSING OF POLYPROTEIN.
RX   PubMed=15247249; DOI=10.1074/jbc.M406315200;
RA   Carrere-Kremer S., Montpellier C., Lorenzo L., Brulin B.,
RA   Cocquerel L., Belouzard S., Penin F., Dubuisson J.;
RT   "Regulation of hepatitis C virus polyprotein processing by signal
RT   peptidase involves structural determinants at the p7 sequence
RT   junctions.";
RL   J. Biol. Chem. 279:41384-41392(2004).
RN   [27]
RP   INTERACTION WITH HUMAN CD209/DC-SIGN AND CLEC4M/DC-SIGNR.
RC   STRAIN=Isolate H77;
RX   PubMed=15371595; DOI=10.1073/pnas.0405695101;
RA   Cormier E.G., Durso R.J., Tsamis F., Boussemart L., Manix C.,
RA   Olson W.C., Gardner J.P., Dragic T.;
RT   "L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver
RT   cells by hepatitis C virus.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:14067-14072(2004).
RN   [28]
RP   CLEAVAGE BETWEEN E2 AND P7, TOPOLOGY OF P7, AND MUTAGENESIS OF
RP   VAL-720.
RX   PubMed=15722527; DOI=10.1099/vir.0.80737-0;
RA   Isherwood B.J., Patel A.H.;
RT   "Analysis of the processing and transmembrane topology of the E2p7
RT   protein of hepatitis C virus.";
RL   J. Gen. Virol. 86:667-676(2005).
RN   [29]
RP   INTERACTION OF NS3 PROTEASE WITH HUMAN MAVS.
RX   PubMed=16301520; DOI=10.1073/pnas.0508531102;
RA   Li X.D., Sun L., Seth R.B., Pineda G., Chen Z.J.;
RT   "Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral
RT   signaling protein off the mitochondria to evade innate immunity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:17717-17722(2005).
RN   [30]
RP   PALMITOYLATION AT CYS-1968 AND CYS-1972 (NS4B) BY HOST, AND
RP   MUTAGENESIS OF CYS-1968 AND CYS-1972.
RC   STRAIN=Isolate H77;
RX   PubMed=16731940; DOI=10.1128/JVI.00053-06;
RA   Yu G.-Y., Lee K.-J., Gao L., Lai M.M.C.;
RT   "Palmitoylation and polymerization or in protein-protein interactions
RT   of hepatitis C virus NS4B protein.";
RL   J. Virol. 80:6013-6023(2006).
RN   [31]
RP   FUNCTION OF E1 AND E2.
RC   STRAIN=Isolate H77;
RX   PubMed=16894197; DOI=10.1099/vir.0.81710-0;
RA   Codran A., Royer C., Jaeck D., Bastien-Valle M., Baumert T.F.,
RA   Kieny M.P., Pereira C.A., Martin J.P.;
RT   "Entry of hepatitis C virus pseudotypes into primary human hepatocytes
RT   by clathrin-dependent endocytosis.";
RL   J. Gen. Virol. 87:2583-2593(2006).
RN   [32]
RP   CHARACTERIZATION OF THE FUSION PEPTIDE.
RC   STRAIN=Isolate H77;
RX   PubMed=16533059; DOI=10.1021/bi0523963;
RA   Perez-Berna A.J., Moreno M.R., Guillen J., Bernabeu A., Villalain J.;
RT   "The membrane-active regions of the hepatitis C virus E1 and E2
RT   envelope glycoproteins.";
RL   Biochemistry 45:3755-3768(2006).
RN   [33]
RP   TOPOLOGY OF NS4B.
RC   STRAIN=Isolate H77;
RX   PubMed=17030859; DOI=10.1099/vir.0.82211-0;
RA   Lundin M., Lindstrom H., Groenwall C., Persson M.A.;
RT   "Dual topology of the processed hepatitis C virus protein NS4B is
RT   influenced by the NS5A protein.";
RL   J. Gen. Virol. 87:3263-3272(2006).
RN   [34]
RP   INTERACTION OF NS5A WITH NS5B AND HOST PKR.
RX   PubMed=16951545;
RA   Liang Y., Kang C.B., Yoon H.S.;
RT   "Molecular and structural characterization of the domain 2 of
RT   hepatitis C virus non-structural protein 5A.";
RL   Mol. Cells 22:13-20(2006).
RN   [35]
RP   SUBCELLULAR LOCATION OF NS5A.
RX   PubMed=17192310; DOI=10.1128/JVI.01279-06;
RA   Brass V., Pal Z., Sapay N., Deleage G., Blum H.E., Penin F.,
RA   Moradpour D.;
RT   "Conserved determinants for membrane association of nonstructural
RT   protein 5A from hepatitis C virus and related viruses.";
RL   J. Virol. 81:2745-2757(2007).
RN   [36]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
RN   [37]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [38]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [39]
RP   INTERACTION WITH ACY3.
RX   PubMed=19486448; DOI=10.1111/j.1440-1746.2009.05846.x;
RA   Chen Y.R., Chen T.Y., Zhang S.L., Lin S.M., Zhao Y.R., Ye F.,
RA   Zhang X., Shi L., Dang S.S., Liu M.;
RT   "Identification of a novel protein binding to hepatitis C virus core
RT   protein.";
RL   J. Gastroenterol. Hepatol. 24:1300-1304(2009).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1206-1656.
RX   MEDLINE=97331322; PubMed=9187654; DOI=10.1038/nsb0697-463;
RA   Yao N., Hesson T., Cable M.B., Hong Z., Kwong A.D., Le H.V.,
RA   Weber P.C.;
RT   "Structure of the hepatitis C virus RNA helicase domain.";
RL   Nat. Struct. Biol. 4:463-467(1997).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1027-1206 IN COMPLEX WITH
RP   NS4A.
RX   MEDLINE=97015089; PubMed=8861917; DOI=10.1016/S0092-8674(00)81351-3;
RA   Kim J.L., Morgenstern K.A., Lin C., Fox T., Dwyer M.D., Landro J.A.,
RA   Chambers S.P., Markland W., Lepre C.A., O'Malley E.T., Harbeson S.L.,
RA   Rice C.M., Murcko M.A., Caron P.R., Thomson J.A.;
RT   "Crystal structure of the hepatitis C virus NS3 protease domain
RT   complexed with a synthetic NS4A cofactor peptide.";
RL   Cell 87:343-355(1996).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1192-1657.
RX   MEDLINE=98154321; PubMed=9493270; DOI=10.1016/S0969-2126(98)00010-0;
RA   Kim J.L., Morgenstern K.A., Griffith J.P., Dwyer M.D., Thomson J.A.,
RA   Murcko M.A., Lin C., Caron P.R.;
RT   "Hepatitis C virus NS3 RNA helicase domain with a bound
RT   oligonucleotide: the crystal structure provides insights into the mode
RT   of unwinding.";
RL   Structure 6:89-100(1998).
RN   [43]
RP   STRUCTURE BY NMR OF 1353-1507.
RX   PubMed=11846566; DOI=10.1006/jmbi.2001.5146;
RA   Liu D., Wang Y.-S., Gesell J.J., Wyss D.F.;
RT   "Solution structure and backbone dynamics of an engineered arginine-
RT   rich subdomain 2 of the hepatitis C virus NS3 RNA helicase.";
RL   J. Mol. Biol. 314:543-561(2001).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 1027-1207.
RX   PubMed=12465917; DOI=10.1021/ol027014p;
RA   Andrews D.M., Chaignot H., Coomber B.A., Good A.C., Hind S.L.,
RA   Johnson M.R., Jones P.S., Mills G., Robinson J.E., Skarzynski T.,
RA   Slater M.J., Somers D.O.;
RT   "Pyrrolidine-5,5-trans-lactams. 2. The use of X-ray crystal structure
RT   data in the optimization of P3 and P4 substituents.";
RL   Org. Lett. 4:4479-4482(2002).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.28 ANGSTROMS) OF 903-1026, AND MUTAGENESIS OF
RP   HIS-952 AND CYS-993.
RX   PubMed=16862121; DOI=10.1038/nature04975;
RA   Lorenz I.C., Marcotrigiano J., Dentzer T.G., Rice C.M.;
RT   "Structure of the catalytic domain of the hepatitis C virus NS2-3
RT   protease.";
RL   Nature 442:831-835(2006).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine (By
CC       similarity). Also inhibited by long-alkyl-chain iminosugar
CC       derivatives. Essential for infectivity.
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand (By
CC       similarity). Cleaves and inhibits the host antiviral protein MAVS.
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex. NS4B polymerization or in
CC       protein-protein interactions activity may contribute to its
CC       function in membranous web formation.
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication.
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin).
CC       Interact with human ACY3. E1 and E2 glycoproteins form a
CC       heterodimer that binds to human LDLR, CLDN1, CD81 and SCARB1
CC       receptors. E2 binds and inhibits human EIF2AK2/PKR. Also binds
CC       human CD209/DC-SIGN and CLEC4M/DC-SIGNR. p7 forms a homoheptamer
CC       in vitro. NS2 forms a homodimer containing a pair of composite
CC       active sites at the dimerization interface. NS2 seems to interact
CC       with all other non-structural (NS) proteins. NS4A interacts with
CC       NS3 serine protease and stabilizes its folding. NS3-NS4A complex
CC       is essential for the activation of the latter and allows membrane
CC       anchorage of NS3. NS3 interacts with human TANK-binding kinase
CC       TBK1 and MAVS. NS4B and NS5A form homodimers and seem to interact
CC       with all other non-structural (NS) proteins. NS5A also interacts
CC       with human EIF2AK2/PKR, FKBP8, GRB2, BIN1, PIK3R1, SRCAP, VAPB and
CC       with most Src-family kinases. NS5B is a homooligomer and interacts
CC       with human VAPB, HNRNPA1 and SEPT6 (By similarity).
CC   -!- INTERACTION:
CC       P06241:FYN (xeno); NbExp=4; IntAct=EBI-706378, EBI-515315;
CC       P62993:GRB2 (xeno); NbExp=3; IntAct=EBI-706378, EBI-401755;
CC       P08631:HCK (xeno); NbExp=5; IntAct=EBI-706378, EBI-346340;
CC       P06239:LCK (xeno); NbExp=1; IntAct=EBI-706378, EBI-1348;
CC       P06240:Lck (xeno); NbExp=3; IntAct=EBI-706378, EBI-1401;
CC       P07948:LYN (xeno); NbExp=5; IntAct=EBI-706378, EBI-79452;
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein. Note=The
CC       C-terminal transmembrane domain acts as a signal sequence and
CC       forms a hairpin structure before cleavage by host signal
CC       peptidase. After cleavage, the membrane sequence is retained at
CC       the C-terminus of the protein, serving as ER membrane anchor. A
CC       reorientation of the second hydrophobic stretch occurs after
CC       cleavage producing a single reoriented transmembrane domain. These
CC       events explain the final topology of the protein. ER retention of
CC       E1 is leaky and, in overexpression conditions, only a small
CC       fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein. Note=The
CC       C-terminal transmembrane domain acts as a signal sequence and
CC       forms a hairpin structure before cleavage by host signal
CC       peptidase. After cleavage, the membrane sequence is retained at
CC       the C-terminus of the protein, serving as ER membrane anchor. A
CC       reorientation of the second hydrophobic stretch occurs after
CC       cleavage producing a single reoriented transmembrane domain. These
CC       events explain the final topology of the protein. ER retention of
CC       E2 is leaky and, in overexpression conditions, only a small
CC       fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein. Host cell membrane. Note=The C-
CC       terminus of p7 membrane domain acts as a signal sequence. After
CC       cleavage by host signal peptidase, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. Only a fraction localizes to the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein. Host cytoplasm,
CC       host perinuclear region. Host mitochondrion. Note=Host membrane
CC       insertion occurs after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Ribosomal frameshifting; Named isoforms=2;
CC         Comment=The exact location of the ribosomal frameshift is
CC         unknown. The F protein seems to be generated by a -2 ribosomal
CC         frameshift located in the vicinity of codon 11 of the core
CC         protein coding sequence. However, some F proteins may also be
CC         generated by +1 ribosomal frameshift. Since the core gene
CC         encodes alternative reading frame proteins (ARFPs), many
CC         functions depicted for the core protein might belong to the
CC         ARFPs;
CC       Name=Genome polyprotein;
CC         IsoId=P27958-1; Sequence=Displayed;
CC         Note=Produced by conventional translation;
CC       Name=F protein; Synonyms=Frameshifted protein;
CC         IsoId=P0C045-1; Sequence=External;
CC         Note=Produced by ribosomal frameshifting;
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain two highly variable regions called
CC       hypervariable region 1 and 2 (HVR1 and HVR2). E2 also contain two
CC       segments involved in CD81-binding. HVR1 is implicated in the
CC       SCARB1-mediated cell entry. HVR2 and CD81-binding regions may be
CC       involved in sensitivity and/or resistance to IFN-alpha therapy (By
CC       similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A seems to be intrinsically disordered and
CC       interacts with NS5B and host PKR. The C-terminus of NS5A contains
CC       a variable region called variable region 3 (V3) (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3.
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated.
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions.
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M67463; AAA45534.1; -; Genomic_RNA.
DR   EMBL; AF009606; AAB66324.1; -; Genomic_RNA.
DR   EMBL; AF011751; AAB67036.1; -; Genomic_RNA.
DR   EMBL; AF011752; AAB67037.1; -; Genomic_RNA.
DR   EMBL; AF011753; AAB67038.1; -; Genomic_RNA.
DR   PIR; A36814; GNWVCH.
DR   PDB; 1A1R; X-ray; 2.50 A; A/B=1027-1206.
DR   PDB; 1A1V; X-ray; 2.20 A; A=1193-1657.
DR   PDB; 1CWX; NMR; -; A=2-45.
DR   PDB; 1HEI; X-ray; 2.10 A; A/B=1206-1656.
DR   PDB; 1JR6; NMR; -; A=1353-1507.
DR   PDB; 1N1L; X-ray; 2.60 A; A/B=1027-1206.
DR   PDB; 1ONB; NMR; -; A=1353-1507.
DR   PDB; 1R7C; NMR; -; A=1973-2003.
DR   PDB; 1R7D; NMR; -; A=1973-2003.
DR   PDB; 1R7E; NMR; -; A=1973-2003.
DR   PDB; 1R7F; NMR; -; A=1973-2003.
DR   PDB; 1R7G; NMR; -; A=1973-2003.
DR   PDB; 1RGQ; X-ray; 2.90 A; A/B=1027-1206.
DR   PDB; 2F9V; X-ray; 2.60 A; A/C=1027-1207, B/D=1680-1696.
DR   PDB; 2HD0; X-ray; 2.28 A; A/B/C/D/E/F/G/H/I/J/K/L=903-1026.
DR   PDB; 2JXF; NMR; -; A=1751-1780.
DR   PDB; 2KDR; NMR; -; X=1938-1965.
DR   PDB; 2O8M; X-ray; 2.00 A; A/B=1022-1207, C/D=1678-1695.
DR   PDB; 2OBO; X-ray; 2.60 A; A/C=1022-1207, B/D=1677-1695.
DR   PDB; 2OBQ; X-ray; 2.50 A; A/C=1022-1207, B/D=1678-1695.
DR   PDB; 2OC0; X-ray; 2.30 A; A/C=1022-1207, B/D=1677-1695.
DR   PDB; 2OC1; X-ray; 2.70 A; A/C=1022-1207, B/D=1677-1695.
DR   PDB; 2OC7; X-ray; 2.70 A; A/C=1022-1207, B/D=1677-1695.
DR   PDB; 2OC8; X-ray; 2.66 A; A/C=1022-1207, B/D=1677-1695.
DR   PDB; 2OIN; X-ray; 2.50 A; A/B=1027-1207.
DR   PDB; 2P59; X-ray; 2.90 A; A/B=1027-1207, C/D=1678-1696.
DR   PDBsum; 1A1R; -.
DR   PDBsum; 1A1V; -.
DR   PDBsum; 1CWX; -.
DR   PDBsum; 1HEI; -.
DR   PDBsum; 1JR6; -.
DR   PDBsum; 1N1L; -.
DR   PDBsum; 1ONB; -.
DR   PDBsum; 1R7C; -.
DR   PDBsum; 1R7D; -.
DR   PDBsum; 1R7E; -.
DR   PDBsum; 1R7F; -.
DR   PDBsum; 1R7G; -.
DR   PDBsum; 1RGQ; -.
DR   PDBsum; 2F9V; -.
DR   PDBsum; 2HD0; -.
DR   PDBsum; 2JXF; -.
DR   PDBsum; 2KDR; -.
DR   PDBsum; 2O8M; -.
DR   PDBsum; 2OBO; -.
DR   PDBsum; 2OBQ; -.
DR   PDBsum; 2OC0; -.
DR   PDBsum; 2OC1; -.
DR   PDBsum; 2OC7; -.
DR   PDBsum; 2OC8; -.
DR   PDBsum; 2OIN; -.
DR   PDBsum; 2P59; -.
DR   SMR; P27958; 1029-1657, 2008-2170, 2421-2982.
DR   IntAct; P27958; 6.
DR   euHCVdb; AF009606; -.
DR   euHCVdb; AF011751; -.
DR   euHCVdb; AF011752; -.
DR   euHCVdb; AF011753; -.
DR   euHCVdb; M67463; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; FALSE_NEG.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Disulfide bond; Envelope protein; Fusion protein;
KW   Glycoprotein; Helicase; Host cell membrane; Host cytoplasm;
KW   Host endoplasmic reticulum; Host lipid droplet; Host membrane;
KW   Host mitochondrion; Host nucleus; Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; Ribosomal frameshifting; RNA replication;
KW   RNA-binding; RNA-directed RNA polymerase; Secreted; Serine protease;
KW   SH3-binding; Thiol protease; Transcription; Transcription regulation;
KW   Transferase; Transmembrane; Ubl conjugation; Viral nucleoprotein;
KW   Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000037566.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000037567.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000037568.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000037569.
FT   CHAIN       384    746       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000037570.
FT   CHAIN       747    809       p7.
FT                                /FTId=PRO_0000037571.
FT   CHAIN       810   1026       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000037572.
FT   CHAIN      1027   1657       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000037573.
FT   CHAIN      1658   1711       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000037574.
FT   CHAIN      1712   1972       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000037575.
FT   CHAIN      1973   2420       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000037576.
FT   CHAIN      2421   3011       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000037577.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    725       Lumenal (Potential).
FT   TRANSMEM    726    746       Potential.
FT   TOPO_DOM    747    757       Lumenal (Potential).
FT   TRANSMEM    758    778       Potential.
FT   TOPO_DOM    779    782       Cytoplasmic (Potential).
FT   TRANSMEM    783    803       Potential.
FT   TOPO_DOM    804    813       Lumenal (Potential).
FT   TRANSMEM    814    834       Potential.
FT   TOPO_DOM    835    881       Cytoplasmic (Potential).
FT   TRANSMEM    882    902       Potential.
FT   TOPO_DOM    903    928       Lumenal (Potential).
FT   TRANSMEM    929    949       Potential.
FT   TOPO_DOM    950   1657       Cytoplasmic (Potential).
FT   TRANSMEM   1658   1678       Potential.
FT   TOPO_DOM   1679   1805       Cytoplasmic (Potential).
FT   TRANSMEM   1806   1826       Potential.
FT   TOPO_DOM   1827   1828       Lumenal (Potential).
FT   TRANSMEM   1829   1849       Potential.
FT   TOPO_DOM   1850   1850       Cytoplasmic (Potential).
FT   TRANSMEM   1851   1871       Potential.
FT   TOPO_DOM   1872   1881       Lumenal (Potential).
FT   TRANSMEM   1882   1902       Potential.
FT   TOPO_DOM   1903   1972       Cytoplasmic (Potential).
FT   TOPO_DOM   1973   2002       In membrane (By similarity).
FT   TOPO_DOM   2003   2990       Cytoplasmic (Potential).
FT   TRANSMEM   2991   3011       By similarity.
FT   DOMAIN     1217   1369       Helicase ATP-binding.
FT   DOMAIN     2634   2752       RdRp catalytic.
FT   NP_BIND    1230   1237       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      385    411       HVR1 (By similarity).
FT   REGION      475    481       HVR2 (By similarity).
FT   REGION      482    494       CD81-binding 1 (Potential).
FT   REGION      522    553       CD81-binding 2 (Potential).
FT   REGION      660    671       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD).
FT   REGION     1679   1690       NS3-binding (by NS4A) (Potential).
FT   REGION     2120   2332       Transcriptional activation (Potential).
FT   REGION     2120   2208       FKBP8-binding (Potential).
FT   REGION     2200   2250       Basal phosphorylation (By similarity).
FT   REGION     2210   2275       PKR-binding (Potential).
FT   REGION     2249   2306       NS4B-binding (Potential).
FT   REGION     2351   2420       Basal phosphorylation (By similarity).
FT   REGION     2354   2377       V3.
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1316   1319       DECH box.
FT   MOTIF      2322   2325       SH3-binding (Potential).
FT   MOTIF      2327   2335       Nuclear localization signal (Potential).
FT   COMPBIAS    796    803       Poly-Leu.
FT   COMPBIAS   1432   1435       Poly-Val.
FT   COMPBIAS   2286   2327       Pro-rich.
FT   COMPBIAS   2996   2999       Poly-Leu.
FT   ACT_SITE    952    952       For protease NS2-3 activity; shared with
FT                                dimeric partner.
FT   ACT_SITE    972    972       For protease NS2-3 activity; shared with
FT                                dimeric partner.
FT   ACT_SITE    993    993       For protease NS2-3 activity; shared with
FT                                dimeric partner.
FT   ACT_SITE   1083   1083       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1107   1107       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1165   1165       Charge relay system; for serine protease
FT                                NS3 activity.
FT   METAL      1123   1123       Zinc.
FT   METAL      1125   1125       Zinc.
FT   METAL      1171   1171       Zinc.
FT   METAL      1175   1175       Zinc.
FT   METAL      2011   2011       Zinc (By similarity).
FT   METAL      2029   2029       Zinc (By similarity).
FT   METAL      2031   2031       Zinc (By similarity).
FT   METAL      2052   2052       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        191    192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        746    747       Cleavage; by host signal peptidase.
FT   SITE        809    810       Cleavage; by host signal peptidase.
FT   SITE       1026   1027       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1657   1658       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1711   1712       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1972   1973       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2420   2421       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2194   2194       Phosphoserine; by host; in p56 (By
FT                                similarity).
FT   MOD_RES    2197   2197       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2201   2201       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2204   2204       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2321   2321       Phosphoserine; by host.
FT   LIPID      1968   1968       S-palmitoyl cysteine; by host.
FT   LIPID      1972   1972       S-palmitoyl cysteine; by host; partial.
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    417    417       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    423    423       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    430    430       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    448    448       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    476    476       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    532    532       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    540    540       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    556    556       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    576    576       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    623    623       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    645    645       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2114   2162       By similarity.
FT   VARIANT     212    212       V -> I (in strain: Isolate H77).
FT   VARIANT     297    297       H -> R (in strain: Isolate H77).
FT   VARIANT     303    303       D -> S (in strain: Isolate H77).
FT   VARIANT     321    321       N -> D (in strain: Isolate H77).
FT   VARIANT     360    360       K -> A (in strain: Isolate H77).
FT   VARIANT     391    391       N -> S (in strain: Isolate H77).
FT   VARIANT     394    394       R -> H (in strain: Isolate H77).
FT   VARIANT     431    431       E -> D (in strain: Isolate H77).
FT   VARIANT     434    434       N -> T (in strain: Isolate H77).
FT   VARIANT     444    444       Q -> R (in strain: Isolate H77).
FT   VARIANT     457    457       A -> T (in strain: Isolate H77).
FT   VARIANT     564    566       CGA -> RGV (in strain: Isolate H77).
FT   VARIANT     589    589       Y -> H (in strain: Isolate H77).
FT   VARIANT     602    602       R -> W (in strain: Isolate H77).
FT   VARIANT     650    650       E -> G (in strain: Isolate H77).
FT   VARIANT     773    773       C -> R (in strain: Isolate H77).
FT   VARIANT     787    787       V -> A (in strain: Isolate H77).
FT   VARIANT     790    790       L -> F (in strain: Isolate H77).
FT   VARIANT     877    877       T -> M (in strain: Isolate H77).
FT   VARIANT     883    883       A -> T (in strain: Isolate H77).
FT   VARIANT     948    948       C -> Y (in strain: Isolate H77).
FT   VARIANT     954    954       A -> T (in strain: Isolate H77).
FT   VARIANT    1026   1026       L -> Q (in strain: Isolate H77).
FT   VARIANT    1033   1033       A -> T (in strain: Isolate H77).
FT   VARIANT    1049   1049       G -> S (in strain: Isolate H77).
FT   VARIANT    1100   1100       T -> M (in strain: Isolate H77).
FT   VARIANT    1121   1121       T -> A (in strain: Isolate H77).
FT   VARIANT    1173   1173       T -> A (in strain: Isolate H77).
FT   VARIANT    1202   1202       E -> G (in strain: Isolate H77).
FT   VARIANT    1214   1214       S -> P (in strain: Isolate H77).
FT   VARIANT    1247   1247       K -> Q (in strain: Isolate H77).
FT   VARIANT    1303   1303       A -> G (in strain: Isolate H77).
FT   VARIANT    1327   1327       S -> L (in strain: Isolate H77).
FT   VARIANT    1556   1556       G -> E (in strain: Isolate H77).
FT   VARIANT    1608   1608       R -> W (in strain: Isolate H77).
FT   VARIANT    1742   1742       H -> Q (in strain: Isolate H77).
FT   VARIANT    1839   1840       LD -> IG (in strain: Isolate H77).
FT   VARIANT    1893   1893       A -> V (in strain: Isolate H77).
FT   VARIANT    1898   1900       FAS -> CAA (in strain: Isolate H77).
FT   VARIANT    1905   1905       R -> H (in strain: Isolate H77).
FT   VARIANT    1940   1940       A -> V (in strain: Isolate H77).
FT   VARIANT    2043   2043       T -> A (in strain: Isolate H77).
FT   VARIANT    2053   2053       K -> R (in strain: Isolate H77).
FT   VARIANT    2061   2061       F -> L (in strain: Isolate H77).
FT   VARIANT    2102   2102       V -> I (in strain: Isolate H77).
FT   VARIANT    2185   2185       A -> E (in strain: Isolate H77).
FT   VARIANT    2283   2283       P -> R (in strain: Isolate H77).
FT   VARIANT    2296   2296       L -> P (in strain: Isolate H77).
FT   VARIANT    2341   2341       P -> S (in strain: Isolate H77).
FT   VARIANT    2355   2355       S -> P (in strain: Isolate H77).
FT   VARIANT    2400   2400       L -> F (in strain: Isolate H77).
FT   VARIANT    2425   2425       S -> T (in strain: Isolate H77).
FT   VARIANT    2469   2469       K -> Q (in strain: Isolate H77).
FT   VARIANT    2512   2512       A -> T (in strain: Isolate H77).
FT   VARIANT    2637   2637       L -> F (in strain: Isolate H77).
FT   VARIANT    2703   2703       R -> G (in strain: Isolate H77).
FT   VARIANT    2715   2715       R -> C (in strain: Isolate H77).
FT   VARIANT    2755   2755       S -> N (in strain: Isolate H77).
FT   VARIANT    2925   2925       W -> R (in strain: Isolate H77).
FT   VARIANT    2933   2933       A -> S (in strain: Isolate H77).
FT   VARIANT    2937   2937       K -> R (in strain: Isolate H77).
FT   VARIANT    2960   2960       T -> A (in strain: Isolate H77).
FT   MUTAGEN     720    720       V->L: Increases processing between E2 and
FT                                p7.
FT   MUTAGEN     779    779       K->I: Virus can no longer infect
FT                                chimpanzee.
FT   MUTAGEN     781    781       R->S: Virus can no longer infect
FT                                chimpanzee.
FT   MUTAGEN     952    952       H->A: Complete loss of NS2-NS3 cleavage.
FT   MUTAGEN     993    993       C->A: Complete loss of NS2-NS3 cleavage.
FT   MUTAGEN    1165   1165       S->A: Complete loss of NS3-NS4A, NS4A-
FT                                NS4B, NS4B-NS5A and NS5A-NS5B cleavages.
FT   MUTAGEN    1968   1968       C->A: Strong decrease in NS4B
FT                                palmitoylation.
FT   MUTAGEN    1972   1972       C->A: Slight decrease in NS4B
FT                                palmitoylation.
FT   MUTAGEN    2321   2321       S->A: Loss of phosphorylation.
FT   STRAND       10     12
FT   STRAND       16     18
FT   TURN         19     23
FT   STRAND       30     35
FT   TURN         36     38
FT   STRAND       39     41
FT   STRAND     1032   1035
FT   HELIX      1039   1048
FT   STRAND     1057   1063
FT   STRAND     1068   1074
FT   STRAND     1077   1081
FT   HELIX      1082   1085
FT   STRAND     1100   1103
FT   TURN       1104   1107
FT   STRAND     1108   1112
FT   STRAND     1128   1133
FT   STRAND     1139   1144
FT   STRAND     1146   1157
FT   HELIX      1158   1160
FT   TURN       1161   1163
FT   STRAND     1168   1170
FT   STRAND     1176   1186
FT   STRAND     1189   1197
FT   HELIX      1198   1206
FT   STRAND     1224   1229
FT   TURN       1236   1238
FT   HELIX      1239   1245
FT   TURN       1246   1248
FT   STRAND     1251   1256
FT   HELIX      1258   1272
FT   STRAND     1277   1279
FT   STRAND     1290   1295
FT   HELIX      1296   1301
FT   HELIX      1304   1307
FT   STRAND     1311   1316
FT   TURN       1317   1319
FT   HELIX      1323   1335
FT   TURN       1336   1340
FT   STRAND     1342   1350
FT   STRAND     1362   1366
FT   STRAND     1371   1375
FT   STRAND     1378   1380
FT   HELIX      1383   1386
FT   STRAND     1387   1393
FT   HELIX      1397   1409
FT   STRAND     1414   1417
FT   HELIX      1423   1425
FT   STRAND     1428   1436
FT   STRAND     1448   1453
FT   STRAND     1456   1463
FT   STRAND     1467   1469
FT   STRAND     1471   1478
FT   HELIX      1481   1488
FT   STRAND     1493   1495
FT   STRAND     1497   1502
FT   HELIX      1514   1526
FT   HELIX      1532   1544
FT   HELIX      1555   1564
FT   HELIX      1570   1578
FT   HELIX      1584   1597
FT   HELIX      1606   1611
FT   TURN       1612   1614
FT   HELIX      1615   1617
FT   STRAND     1626   1629
FT   HELIX      1640   1649
FT   STRAND     1680   1687
FT   HELIX      1976   1999
SQ   SEQUENCE   3011 AA;  327146 MW;  772CBB29CCD94753 CRC64;
     MSTNPKPQRK TKRNTNRRPQ DVKFPGGGQI VGGVYLLPRR GPRLGVRATR KTSERSQPRG
     RRQPIPKARR PEGRTWAQPG YPWPLYGNEG CGWAGWLLSP RGSRPSWGPT DPRRRSRNLG
     KVIDTLTCGF ADLMGYIPLV GAPLGGAARA LAHGVRVLED GVNYATGNLP GCSFSIFLLA
     LLSCLTVPAS AYQVRNSSGL YHVTNDCPNS SVVYEAADAI LHTPGCVPCV REGNASRCWV
     AVTPTVATRD GKLPTTQLRR HIDLLVGSAT LCSALYVGDL CGSVFLVGQL FTFSPRHHWT
     TQDCNCSIYP GHITGHRMAW NMMMNWSPTA ALVVAQLLRI PQAIMDMIAG AHWGVLAGIK
     YFSMVGNWAK VLVVLLLFAG VDAETHVTGG NAGRTTAGLV GLLTPGAKQN IQLINTNGSW
     HINSTALNCN ESLNTGWLAG LFYQHKFNSS GCPERLASCR RLTDFAQGWG PISYANGSGL
     DERPYCWHYP PRPCGIVPAK SVCGPVYCFT PSPVVVGTTD RSGAPTYSWG ANDTDVFVLN
     NTRPPLGNWF GCTWMNSTGF TKVCGAPPCV IGGVGNNTLL CPTDCFRKYP EATYSRCGSG
     PRITPRCMVD YPYRLWHYPC TINYTIFKVR MYVGGVEHRL EAACNWTRGE RCDLEDRDRS
     ELSPLLLSTT QWQVLPCSFT TLPALSTGLI HLHQNIVDVQ YLYGVGSSIA SWAIKWEYVV
     LLFLLLADAR VCSCLWMMLL ISQAEAALEN LVILNAASLA GTHGLVSFLV FFCFAWYLKG
     RWVPGAVYAL YGMWPLLLLL LALPQRAYAL DTEVAASCGG VVLVGLMALT LSPYYKRYIS
     WCMWWLQYFL TRVEAQLHVW VPPLNVRGGR DAVILLTCVV HPALVFDITK LLLAIFGPLW
     ILQASLLKVP YFVRVQGLLR ICALARKIAG GHYVQMAIIK LGALTGTCVY NHLAPLRDWA
     HNGLRDLAVA VEPVVFSRME TKLITWGADT AACGDIINGL PVSARRGQEI LLGPADGMVS
     KGWRLLAPIT AYAQQTRGLL GCIITSLTGR DKNQVEGEVQ IVSTATQTFL ATCINGVCWT
     VYHGAGTRTI ASPKGPVIQT YTNVDQDLVG WPAPQGSRSL TPCTCGSSDL YLVTRHADVI
     PVRRRGDSRG SLLSPRPISY LKGSSGGPLL CPTGHAVGLF RAAVCTRGVA KAVDFIPVEN
     LETTMRSPVF TDNSSPPAVP QSFQVAHLHA PTGSGKSTKV PAAYAAKGYK VLVLNPSVAA
     TLGFGAYMSK AHGVDPNIRT GVRTITTGSP ITYSTYGKFL ADAGCSGGAY DIIICDECHS
     TDATSISGIG TVLDQAETAG ARLVVLATAT PPGSVTVSHP NIEEVALSTT GEIPFYGKAI
     PLEVIKGGRH LIFCHSKKKC DELAAKLVAL GINAVAYYRG LDVSVIPTSG DVVVVSTDAL
     MTGFTGDFDS VIDCNTCVTQ TVDFSLDPTF TIETTTLPQD AVSRTQRRGR TGRGKPGIYR
     FVAPGERPSG MFDSSVLCEC YDAGCAWYEL TPAETTVRLR AYMNTPGLPV CQDHLGFWEG
     VFTGLTHIDA HFLSQTKQSG ENFPYLVAYQ ATVCARAQAP PPSWDQMRKC LIRLKPTLHG
     PTPLLYRLGA VQNEVTLTHP ITKYIMTCMS ADLEVVTSTW VLVGGVLAAL AAYCLSTGCV
     VIVGRIVLSG KPAIIPDREV LYQEFDEMEE CSQHLPYIEQ GMMLAEQFKQ KALGLLQTAS
     RHAEVITPAV QTNWQKLEVF WAKHMWNFIS GIQYLAGLST LPGNPAIASL MAFTAAVTSP
     LTTGQTLLFN ILGGWVAAQL AAPGAATAFV GAGLAGAALD SVGLGKVLVD ILAGYGAGVA
     GALVAFKIMS GEVPSTEDLV NLLPAILSPG ALAVGVVFAS ILRRRVGPGE GAVQWMNRLI
     AFASRGNHVS PTHYVPESDA AARVTAILSS LTVTQLLRRL HQWISSECTT PCSGSWLRDI
     WDWICEVLSD FKTWLKAKLM PQLPGIPFVS CQRGYRGVWR GDGIMHTRCH CGAEITGHVK
     NGTMRIVGPR TCKNMWSGTF FINAYTTGPC TPLPAPNYKF ALWRVSAEEY VEIRRVGDFH
     YVSGMTTDNL KCPCQIPSPE FFTELDGVRL HRFAPPCKPL LREEVSFRVG LHEYPVGSQL
     PCEPEPDVAV LTSMLTDPSH ITAEAAGRRL ARGSPPSMAS SSASQLSAPS LKATCTANHD
     SPDAELIEAN LLWRQEMGGN ITRVESENKV VILDSFDPLV AEEDEREVSV PAEILRKSRR
     FAPALPVWAR PDYNPLLVET WKKPDYEPPV VHGCPLPPPR SPPVPPPRKK RTVVLTESTL
     PTALAELATK SFGSSSTSGI TGDNTTTSSE PAPSGCPPDS DVESYSSMPP LEGEPGDPDL
     SDGSWSTVSS GADTEDVVCC SMSYSWTGAL VTPCAAEEQK LPINALSNSL LRHHNLVYST
     TSRSACQRKK KVTFDRLQVL DSHYQDVLKE VKAAASKVKA NLLSVEEACS LAPPHSAKSK
     FGYGAKDVRC HARKAVAHIN SVWKDLLEDS VTPIDTTIMA KNEVFCVQPE KGGRKPARLI
     VFPDLGVRVC EKMALYDVVS KLPLAVMGSS YGFQYSPGQR VEFLVQAWKS KKTPMGLSYD
     TRCFDSTVTE SDIRTEEAIY QCCDLDPQAR VAIKSLTERL YVGGPLTNSR GENCGYRRCR
     ASRVLTTSCG NTLTRYIKAR AACRAAGLQD CTMLVCGDDL VVICESAGVQ EDAASLRAFT
     EAMTRYSAPP GDPPQPEYDL ELITSCSSNV SVAHDGAGKR VYYLTRDPTT PLARAAWETA
     RHTPVNSWLG NIIMFAPTLW ARMILMTHFF SVLIARDQLE QALNCEIYGA CYSIEPLDLP
     PIIQRLHGLS AFSLHSYSPG EINRVAACLR KLGVPPLRAW RHRAWSVRAR LLARGGKAAI
     CGKYLFNWAV RTKLKLTPIT AAGRLDLSGW FTAGYSGGDI YHSVSHARPR WFWFCLLLLA
     AGVGIYLLPN R
//
ID   POLG_HCVH9              Reviewed;        3011 AA.
AC   Q81754;
DT   10-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 80.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 1c (isolate HC-G9) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=356410;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=94172337; PubMed=8126459;
RA   Okamoto H., Kojima M., Sakamoto M., Iizuka H., Hadiwandowo S.,
RA   Suwignyo S., Miyakawa Y., Mayumi M.;
RT   "The entire nucleotide sequence and classification of a hepatitis C
RT   virus isolate of a novel genotype from an Indonesian patient with
RT   chronic liver disease.";
RL   J. Gen. Virol. 75:629-635(1994).
RN   [2]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [3]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [4]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain two highly variable regions called
CC       hypervariable region 1 and 2 (HVR1 and HVR2). E2 also contain two
CC       segments involved in CD81-binding. HVR1 is implicated in the
CC       SCARB1-mediated cell entry. HVR2 and CD81-binding regions may be
CC       involved in sensitivity and/or resistance to IFN-alpha therapy (By
CC       similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A seems to be intrinsically disordered and
CC       interacts with NS5B and host PKR. The C-terminus of NS5A contains
CC       a variable region called variable region 3 (V3) (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D14853; BAA03581.1; -; Genomic_RNA.
DR   PIR; PQ0804; PQ0804.
DR   euHCVdb; D14853; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; FALSE_NEG.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Disulfide bond; Envelope protein; Fusion protein;
KW   Glycoprotein; Helicase; Host cell membrane; Host cytoplasm;
KW   Host endoplasmic reticulum; Host lipid droplet; Host membrane;
KW   Host mitochondrion; Host nucleus; Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000045568.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000045569.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000045570.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000045571.
FT   CHAIN       384    746       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000045572.
FT   CHAIN       747    809       p7 (By similarity).
FT                                /FTId=PRO_0000045573.
FT   CHAIN       810   1026       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000045574.
FT   CHAIN      1027   1657       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000045575.
FT   CHAIN      1658   1711       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000045576.
FT   CHAIN      1712   1972       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000045577.
FT   CHAIN      1973   2420       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000045578.
FT   CHAIN      2421   3011       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000045579.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    725       Lumenal (Potential).
FT   TRANSMEM    726    746       Potential.
FT   TOPO_DOM    747    757       Lumenal (Potential).
FT   TRANSMEM    758    778       Potential.
FT   TOPO_DOM    779    782       Cytoplasmic (Potential).
FT   TRANSMEM    783    803       Potential.
FT   TOPO_DOM    804    813       Lumenal (Potential).
FT   TRANSMEM    814    834       Potential.
FT   TOPO_DOM    835    881       Cytoplasmic (Potential).
FT   TRANSMEM    882    902       Potential.
FT   TOPO_DOM    903    928       Lumenal (Potential).
FT   TRANSMEM    929    949       Potential.
FT   TOPO_DOM    950   1657       Cytoplasmic (Potential).
FT   TRANSMEM   1658   1678       Potential.
FT   TOPO_DOM   1679   1805       Cytoplasmic (Potential).
FT   TRANSMEM   1806   1826       Potential.
FT   TOPO_DOM   1827   1828       Lumenal (Potential).
FT   TRANSMEM   1829   1849       Potential.
FT   TOPO_DOM   1850   1850       Cytoplasmic (Potential).
FT   TRANSMEM   1851   1871       Potential.
FT   TOPO_DOM   1872   1881       Lumenal (Potential).
FT   TRANSMEM   1882   1902       Potential.
FT   TOPO_DOM   1903   1972       Cytoplasmic (Potential).
FT   TOPO_DOM   1973   2002       In membrane (By similarity).
FT   TOPO_DOM   2003   2990       Cytoplasmic (Potential).
FT   TRANSMEM   2991   3011       By similarity.
FT   DOMAIN     1217   1369       Helicase ATP-binding.
FT   DOMAIN     2634   2752       RdRp catalytic.
FT   NP_BIND    1230   1237       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      385    411       HVR1 (By similarity).
FT   REGION      475    481       HVR2 (By similarity).
FT   REGION      482    494       CD81-binding 1 (Potential).
FT   REGION      522    553       CD81-binding 2 (Potential).
FT   REGION      660    671       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1679   1690       NS3-binding (by NS4A) (Potential).
FT   REGION     2120   2332       Transcriptional activation (Potential).
FT   REGION     2120   2208       FKBP8-binding (Potential).
FT   REGION     2200   2250       Basal phosphorylation (By similarity).
FT   REGION     2210   2275       PKR-binding (Potential).
FT   REGION     2249   2306       NS4B-binding (Potential).
FT   REGION     2351   2420       Basal phosphorylation (By similarity).
FT   REGION     2354   2377       V3 (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1316   1319       DECH box (By similarity).
FT   MOTIF      2322   2325       SH3-binding (Potential).
FT   MOTIF      2327   2335       Nuclear localization signal (Potential).
FT   COMPBIAS    371    374       Poly-Val.
FT   COMPBIAS    796    803       Poly-Leu.
FT   COMPBIAS   1432   1435       Poly-Val.
FT   COMPBIAS   2282   2327       Pro-rich.
FT   COMPBIAS   2996   2999       Poly-Leu.
FT   ACT_SITE    952    952       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    972    972       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    993    993       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1083   1083       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1107   1107       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1165   1165       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1123   1123       Zinc (By similarity).
FT   METAL      1125   1125       Zinc (By similarity).
FT   METAL      1171   1171       Zinc (By similarity).
FT   METAL      1175   1175       Zinc (By similarity).
FT   METAL      2011   2011       Zinc (By similarity).
FT   METAL      2029   2029       Zinc (By similarity).
FT   METAL      2031   2031       Zinc (By similarity).
FT   METAL      2052   2052       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        191    192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        746    747       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        809    810       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1026   1027       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1657   1658       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1711   1712       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1972   1973       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2420   2421       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2194   2194       Phosphoserine; by host; in p56 (By
FT                                similarity).
FT   MOD_RES    2197   2197       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2201   2201       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2204   2204       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1968   1968       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   LIPID      1972   1972       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    417    417       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    423    423       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    430    430       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    448    448       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    477    477       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    532    532       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    540    540       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    556    556       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    576    576       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    623    623       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    645    645       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2114   2162       By similarity.
SQ   SEQUENCE   3011 AA;  327216 MW;  9C16C120F4E79268 CRC64;
     MSTNPKPQRK TKRNTNRRPQ DVKFPGGGQI VGGVYLLPRR GPRVGVRATR KTSERSQPRG
     RRQPIPKARR PEGRSWAQPG YPWPLYGNEG CGWAGWLLSP RGSRPSWGPS DPRRRSRNLG
     KVIDTLTCGF ADLMGYIPLV GAPLGGAARA LAHGVRVLED GVNYATGNLP GCSFSIFLLA
     LLSCLTVPAS AVGVRNSSGV YHVTNDCPNA SVVYETENLI MHLPGCVPYV REGNASRCWV
     SLSPTVAARD SRVPVSEVRR RVDSIVGAAA FCSAMYVGDL CGSIFLVGQI FTFSPRHHWT
     TQDCNCSIYP GHVTGHRMAW DMMMNWSPTG ALVVAQLLRI PQAIVDMIAG AHWGVLAGLA
     YYSMVGNWAK VVVVLLLFAG VDAETRVTGG AAGHTAFGFA SFLAPGAKQK IQLINTNGSW
     HINRTALNCN ESLDTGWLAG LLYYHKFNSS GCPERMASCQ PLTAFDQGWG PITHEGNASD
     DQRPYCWHYA LRPCGIVPAK KVCGPVYCFT PSPVVVGTTD RAGVPTYRWG ANETDVLLLN
     NSRPPMGNWF GCTWMNSSGF TKTCGAPACN IGGSGNNTLL CPTDCFRKHP DATYSRCGSG
     PWLTPRCLVD YPYRLWHYPC TVNYTIFKIR MFVGGVEHRL DAACNWTRGE RCDLDDRDRA
     ELSPLLLSTT QWQVLPCSFT TLPALSTGLI HLHQNIVDVQ YLYGLSSAVT SWVIKWEYVV
     LLFLLLADAR ICACLWMMLL ISQVEAALEN LIVLNAASLV GTHGIVPFFI FFCAAWYLKG
     KWAPGLAYSV YGMWPLLLLL LALPQRAYAL DQELAASCGA TVFICLAVLT LSPYYKQYMA
     RGIWWLQYML TRAEALLQVW VPPLNARGGR DGVVLLTCVL HPHLLFEITK IMLAILGPLW
     ILQASLLKVP YFVRAHGLIR LCMLVRKTAG GQYVQMALLK LGAFAGTYIY NHLSPLQDWA
     HSGLRDLAVA TEPVIFSRME IKTITWGADT AACGDIINGL PVSARRGREV LLGPADALTD
     KGWRLLAPIT AYAQQTRGLL GCIITSLTGR DKNQVEGEVQ IVSTATQTFL ATCVNGVCWT
     VYHGAGSRTI ASASGPVIQM YTNVDQDLVG WPAPQGARSL TPCTCGASDL YLVTRHADVI
     PVRRRGDNRG SLLSPRPISY LKGSSGGPLL CPMGHAVGIF RAAVCTRGVA KAVDFVPVES
     LETTMRSPVF TDNSSPPTVP QSYQVAHLHA PTGSGKSTKV PAAYAAQGYK VLVLNPSVAA
     TLGFGAYMSK AHGIDPNVRT GVRTITTGSP ITHSTYGKFL ADGGCSGGAY DIIICDECHS
     VDATSILGIG TVLDQAETAG VRLTILATAT PPGSVTVPHS NIEEVALSTE GEIPFYGKAI
     PLNYIKGGRH LIFCHSKKKC DELAAKLVGL GVNAVAFYRG LDVSVIPTTG DVVVVATDAL
     MTGYTGDFDS VIDCNTCVVQ TVDFSLDPTF SIETSTVPQD AVSRSQRRGR TGRGKHGIYR
     YVSPGERPSG MFDSVVLCEC YDAGCAWYEL TPAETTVRLR AYLNTPGLPV CQDHLEFWES
     VFTGLTHIDA HFLSQTKQSG ENFPYLVAYQ ATVCARAKAP PPSWDQMWKC LIRLKPTLTG
     ATPLLYRLGG VQNEITLTHP ITKYIMACMS ADLEVVTSTW VLVGGVLAAL AAYCLSTGSV
     VIVGRIILSG KPAVIPDREV LYREFDEMEE CAAHIPYLEQ GMHLAEQFKQ KALGLLQTAS
     KQAETITPAV HTNWQKLESF WAKHMWNFVS GIQYLAGLST LPGNPAIASL MSFTAAVTSP
     LTTQQTLLFN ILGGWVAAQL AAPAAATAFV GAGITGAVIG SVGLGKVLVD ILAGYGAGVA
     GALVAFKIMS GEAPTAEDLV NLLPAILSPG ALVVGVVCAA ILRRHVGPGE GAVQWMNRLI
     AFASRGNHVS PTHYVPESDA SVRVTHILTS LTVTQLLKRL HVWISSDCTA PCAGSWLKDV
     WDWICEVLSD FKSWLKAKLM PQLPGIPFVS CQRGYRGVWR GEGIMHARCP CGADITGHVK
     NGSMRIVGPK TCSNTWRGSF PINAHTTGPC TPSPAPNYTF ALWRVSAEEY VEVRRLGDFH
     YITGVTTDKI KCPCQVPSPE FFTEVDGVRL HRYAPPCKPL LRDEVTFSIG LNEYLVGSQL
     PCEPEPDVAV LTSMLTDPSH ITAETAARRL NRGSPPSLAS SSASQLSAPS LKATCTTHHD
     SPDADLITAN LLWRQEMGGN ITRVESENKI VILDSFDPLV AEEDDREISV PAEILLKSKK
     FPPAMPIWAR PDYNPPLVEP WKRPDYEPPL VHGCPLPPPK PTPVPPPRRK RTVVLDESTV
     SSALAELATK TFGSSTTSGV TSGEAAESSP APSCDGELDS EAESYSSMPP LEGEPGDPDL
     SDGSWSTVSS DGGTEDVVCC SMSYSWTGAL ITPCAAEETK LPINALSNSL LRHHNLVYST
     TSRSAGQRQK KVTFDRLQVL DDHYRDVLKE AKAKASTVKA KLLSVEEACS LTPPHSARSK
     FGYGAKDVRS HSSKAIRHIN SVWQDLLEDN TTPIDTTIMA KNEVFCVKPE KGGRKPARLI
     VYPDLGVRVC EKRALYDVVK QLPIAVMGTS YGFQYSPAQR VDFLLNAWKS KKNPMGFSYD
     TRCFDSTVTE ADIRTEEDLY QSCDLVPEAR AAIRSLTERL YIGGPLTNSK GQNCGYRRCR
     ASGVLTTSCG NTITCYLKAS AACRAAKLRD CTMLVCGDDL VVICESAGVQ EDAANLRAFT
     EAMTRYSAPP GDPPQPEYDL ELITSCSSNV SVAHDGAGKR VYYLTRDPET PLARAAWETA
     RHTPVNSWLG NIIMFAPTLW VRMVLMTHFF SILIAQEHLE KALDCEIYGA VHSVQPLDLP
     EIIQRLHGLS AFSLHSYSPG EINRVAACLR KLGVPPLRAW RHRARSVRAT LLSQGGRAAI
     CGKYLFNWAV KTKLKLTPLP SASQLDLSNW FTGGYSGGDI YHSVSHVRPR WFFWCLLLLS
     VGVGIYLLPN R
//
ID   POLG_HCVIN              Reviewed;        3011 AA.
AC   Q913D4;
DT   10-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 67.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 1c (isolate India) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=356386;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RA   Guntaka R.V., Munpally S.K., Khaja M.N., Kota K.K., Ramana V.K.,
RA   Swamynathan S.K., Sakata Y., Habibullah C.M.;
RT   "Nucleotide Sequence of Indian strain of Hepatitis C Virus.";
RL   Submitted (AUG-2001) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain two highly variable regions called
CC       hypervariable region 1 and 2 (HVR1 and HVR2). E2 also contain two
CC       segments involved in CD81-binding. HVR1 is implicated in the
CC       SCARB1-mediated cell entry. HVR2 and CD81-binding regions may be
CC       involved in sensitivity and/or resistance to IFN-alpha therapy (By
CC       similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A seems to be intrinsically disordered and
CC       interacts with NS5B and host PKR. The C-terminus of NS5A contains
CC       a variable region called variable region 3 (V3) (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY051292; AAK95832.1; -; Genomic_RNA.
DR   euHCVdb; AY051292; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; FALSE_NEG.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Disulfide bond; Envelope protein; Fusion protein;
KW   Glycoprotein; Helicase; Host cell membrane; Host cytoplasm;
KW   Host endoplasmic reticulum; Host lipid droplet; Host membrane;
KW   Host mitochondrion; Host nucleus; Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000045580.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000045581.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000045582.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000045583.
FT   CHAIN       384    746       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000045584.
FT   CHAIN       747    809       p7 (By similarity).
FT                                /FTId=PRO_0000045585.
FT   CHAIN       810   1026       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000045586.
FT   CHAIN      1027   1657       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000045587.
FT   CHAIN      1658   1711       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000045588.
FT   CHAIN      1712   1972       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000045589.
FT   CHAIN      1973   2420       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000045590.
FT   CHAIN      2421   3011       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000045591.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    725       Lumenal (Potential).
FT   TRANSMEM    726    746       Potential.
FT   TOPO_DOM    747    757       Lumenal (Potential).
FT   TRANSMEM    758    778       Potential.
FT   TOPO_DOM    779    782       Cytoplasmic (Potential).
FT   TRANSMEM    783    803       Potential.
FT   TOPO_DOM    804    813       Lumenal (Potential).
FT   TRANSMEM    814    834       Potential.
FT   TOPO_DOM    835    881       Cytoplasmic (Potential).
FT   TRANSMEM    882    902       Potential.
FT   TOPO_DOM    903    928       Lumenal (Potential).
FT   TRANSMEM    929    949       Potential.
FT   TOPO_DOM    950   1657       Cytoplasmic (Potential).
FT   TRANSMEM   1658   1678       Potential.
FT   TOPO_DOM   1679   1805       Cytoplasmic (Potential).
FT   TRANSMEM   1806   1826       Potential.
FT   TOPO_DOM   1827   1828       Lumenal (Potential).
FT   TRANSMEM   1829   1849       Potential.
FT   TOPO_DOM   1850   1850       Cytoplasmic (Potential).
FT   TRANSMEM   1851   1871       Potential.
FT   TOPO_DOM   1872   1881       Lumenal (Potential).
FT   TRANSMEM   1882   1902       Potential.
FT   TOPO_DOM   1903   1972       Cytoplasmic (Potential).
FT   TOPO_DOM   1973   2002       In membrane (By similarity).
FT   TOPO_DOM   2003   2990       Cytoplasmic (Potential).
FT   TRANSMEM   2991   3011       By similarity.
FT   DOMAIN     1217   1369       Helicase ATP-binding.
FT   DOMAIN     2634   2752       RdRp catalytic.
FT   NP_BIND    1230   1237       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      385    411       HVR1 (By similarity).
FT   REGION      475    481       HVR2 (By similarity).
FT   REGION      482    494       CD81-binding 1 (Potential).
FT   REGION      522    553       CD81-binding 2 (Potential).
FT   REGION      660    671       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1679   1690       NS3-binding (by NS4A) (Potential).
FT   REGION     2120   2332       Transcriptional activation (Potential).
FT   REGION     2120   2208       FKBP8-binding (Potential).
FT   REGION     2200   2250       Basal phosphorylation (By similarity).
FT   REGION     2210   2275       PKR-binding (Potential).
FT   REGION     2249   2306       NS4B-binding (Potential).
FT   REGION     2351   2420       Basal phosphorylation (By similarity).
FT   REGION     2354   2377       V3 (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1316   1319       DECH box (By similarity).
FT   MOTIF      2322   2325       SH3-binding (Potential).
FT   MOTIF      2327   2335       Nuclear localization signal (Potential).
FT   COMPBIAS    796    803       Poly-Leu.
FT   COMPBIAS   1432   1435       Poly-Val.
FT   COMPBIAS   2282   2327       Pro-rich.
FT   COMPBIAS   2996   2999       Poly-Leu.
FT   ACT_SITE    952    952       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    972    972       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    993    993       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1083   1083       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1107   1107       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1165   1165       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1123   1123       Zinc (By similarity).
FT   METAL      1125   1125       Zinc (By similarity).
FT   METAL      1171   1171       Zinc (By similarity).
FT   METAL      1175   1175       Zinc (By similarity).
FT   METAL      2011   2011       Zinc (By similarity).
FT   METAL      2029   2029       Zinc (By similarity).
FT   METAL      2031   2031       Zinc (By similarity).
FT   METAL      2052   2052       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        191    192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        746    747       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        809    810       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1026   1027       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1657   1658       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1711   1712       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1972   1973       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2420   2421       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2194   2194       Phosphoserine; by host; in p56 (By
FT                                similarity).
FT   MOD_RES    2197   2197       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2201   2201       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2204   2204       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1968   1968       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   LIPID      1972   1972       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    417    417       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    423    423       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    430    430       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    448    448       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    532    532       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    540    540       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    556    556       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    623    623       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    645    645       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2114   2162       By similarity.
SQ   SEQUENCE   3011 AA;  327239 MW;  57A21964B4227B60 CRC64;
     MSTNPKPQRK TKRNTNRRPQ NVKFPGGGQI VGGVCLLPRR GPRVGVRATR KTSERSQPRG
     RRQPIPKARR PEGRSWAQPG YPWPLYGNEG CGWAGWLLSP RGSRPSRGPS DPRRRSRNLG
     KVIDTLTCGF ADLMGYIPLV GAPLGGAARA LAHGVRVLED GVNYATGNLP GCSFSIFLLA
     LLSCLTVPAS AVEVRNSSGI YHVTNDCPNA SVVYETDSLI IHLPGCVPCV REGNASRCWV
     SLSPTVAAKD PGVPVNEIRR HVDLIVGAAA FCSAMYVGDL CGSIFLVGQL FTLSPRRHWT
     TQDCNCSIYP GHVTGHRMAW DMMMNWSPTG ALVVAQLLRI PQAVLDMIAG AHWGVLAGPA
     YYSMVGNWAK VLVVLLLFAG VDATTQVTGG TAGRNAYRLA SLFSTGPSQN IQLINSNGSW
     HINRTALNCN DSLHTGWVAA LFYSHKFNSS GRPERMASCR PLTAFDQGWG PITYGGKASN
     DQRPYCWHYA PRPCGIVPAK EVCGPVYCFT PSPVVVGTTD KYGVPTYTWG ENETDVLLLN
     NSRPPIGNWF GCTWMNSTGF TKTCGAPACN VGGSETNTLS CPTDCFRRHP DATYAKCGSG
     PWLNPRCMVD YPYRLWHYPC TVNYTIFKIR MFVGGIEHRL TAACNWTRGE RCDLDDRDRA
     ELSPLLLSTT QWQVLPCSFT TLPALSTGLI HLHQNIVDVQ YLYGLSSVVT SWAIRWEYVV
     LLFLLLADAR ICACLWMMLL ISQVEAALEN LIVLNAASLA GTHGIVPFFI FFCAAWYLKG
     KWAPGLVYSV YGMWPLLLLL LALPQRAYAL DQELAASCGA VVFISLAVLT LSPYYKQYMA
     RGIWWLQYML TRAEALLHVW VPSLNARGGR DGAILLMCVL HPHLLFDITK IMLAILGPLW
     ILQASLLRVP YFVRAHGLIR LCMLVRKTAG GHYVQMALLK LGALTGTYIY NHLSPLQDWA
     HGSLRDLAVA TEPVIFSRME IKTITWGADT AACGDIINGL PVSARRGREV LLGPADALTD
     KGWRLLAPIT AYAQQTRGLL GCIVTSLTGR DKNQVEGEIQ IVSTATQTFL ATCINGACWT
     VYHGAGSRTI ASASGPVVRM YTNVDQDLVG WPAPQGARSL TPCTCGASDL YLVTRHADVI
     PVRRRGDNRG SLLSPRPISY LKGSSGGPLL CPMGHVAGIF RAAVCTRGVA KAVDFVPVES
     LETTMRSPVF TDNSSPPTVP QSYQVAHLHA PTGSGKSTKV PAAYAAQGYK VLVLNPSVAA
     TLGFGAYMSK AHGIDPNVRT GVRTITTGSP ITYSTYGKFL ADGGCPGGAY DIIICDECHS
     VDATSILGIG TVLDQAETAG VRLTVLATAT PPGLVTVPHS NIEEVALSAD GEKPFYGKAI
     PLNYIKGGRH LIFCHSKKKC DELAAKLVGL GVNAVAFYRG LDVSVIPTTG DVVVVATDAL
     MTGFTGDFDS VIDCNTCVVQ TVDFSLDPIF SIETSTVPQD AVSRSQRRGR TGRGKHGIYR
     YVSPGERPSG MFDSVVLCEC YDAGCAWYEL TPAETTVRLR AYLNTPGLPV CQDHLEFWES
     VFTGLTHIDA HFLSQTKQSG ENFPYLVAYQ ATVCARARAP PPSWDQMWKC LIRLKPTLTG
     ATPLLYRLGS VQNEITLTHP ITQYIMACMS ADLEVVTSTW VLVGGVLAAL AAYCLSTGSV
     VIVGRIILGG KPAVIPDREV LYREFDEMEE CAAHVPYLEQ GMHLAGQFKQ KALGLLQTAS
     KQAETITPTV RTNWQKLESF WAKHMWNFVS GIQYLAGLST LPGNPAIASL MSFTAAVTSP
     LTTQQTLFFN ILGGWVAAQL ASPAAATAFV GAGITGAVVG SVGLGKVLVD IIAGYGAGVA
     GALVAFKIMS GETPTTEDLV NLLPAILSPG ALVVGVVCAA ILRRHVGPGE GAVQWMNRLI
     AFASRGNHVS PTHYVPESDA SARVTQILTS LTVTQLLKRL HVWISSDCIA PCASSWLKDV
     WDWICEVLSD FKNWLKAKLV PQLPGIPFVS CQRGYRGVWR GEGIVHTRCP CGANITGHVK
     NGSMRIVGPK TCSNTWRGSF PINAYTTGPC TPSPAPNYTF ALWRVSAEEY VEVRRLGDFH
     YVTGVTTDKL KCPCQVPSPE FFTEVDGVRL HRYAPPCKPL LREEVTFSIG LNEYLVGSQL
     PCEPEPDVAV LTSMLTDPSH ITAETAARRL KRGSPPSLAS SSASQLSAPS LKATCTTHHD
     SPDADLIEAN LLWRQEMGGN ITRVESENKI VVLDSFDPLV AEEDDREISI PAEILRKFKQ
     FPPAMPIWAR PDYNPPLVEP WKRPDYEPPL VHGCPLPPPK PTPVPPPRRK RTVVLDESTV
     SSALAELATK TFGSSTTSGV TSGEATESSP APSCGGELDS EAESYSSMPP LEGEPGDPDL
     SDGSWSTVSS DGGTEDVVCC SMSYSWTGAL ITPCASEEAK LPINALSNSL LRHHNLVYST
     TSRSAGQRQK KVTFDRVQVL DDHYRDVLKE AKAKASTVKA RLLSVEEACS LTPPHSARSK
     FGYGAKDVRS HSSKAIRHIN SVWQDLLEDN TTPIDTTIMA KNEVFCVKPE KGGRKPARLI
     VYPDLGVRVC EKRALYDVVK QLPIAVMGAS YGFQYSPAQR VDFLLKAWKS KKVPMGFSYD
     TRCFDSTVTE ADIRTEEDLY QSCDLAPEAR IAIRSLTERL YIGGPLTNSK GQNCGYRRCR
     ASGVLTTSCG NTITCFLKAS AACRAAKLQD CTMLVCGDDL VVICESAGVQ EDAASLRAFT
     EAMTRYSAPP GDPPQPEYDL ELITSCSSNV SVARDGAGKR VYYLTRDPET PLARAAWETA
     RHTPVNSWLG NIIMFAPTLW VRMVLMTHFF SILIAQEHLG KALDCEIYGA VHSVQPLDLP
     EIIQRLHSLS AFSLHSYSPG EINRVAACLR KLGVPPLRAW RHRARSVRAT LLSQGGKAAI
     CGKYLFNWAV KTKLKLTPLP SMSQLDLSNW FTGGYSGGDI YHSVSHARPR LFLWCLLLLS
     VGVGIYLLPN R
//
ID   POLG_HCVJ1              Reviewed;        3011 AA.
AC   Q03463;
DT   20-FEB-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   02-MAR-2010, entry version 75.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 1b (isolate HC-J1) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=421877;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=93117120; PubMed=1335573; DOI=10.1093/nar/20.23.6410;
RA   Okamoto H., Kanai N., Mishiro S.;
RT   "Full-length nucleotide sequence of a Japanese hepatitis C virus
RT   isolate (HC-J1) with high homology to USA isolates.";
RL   Nucleic Acids Res. 20:6410-6410(1992).
RN   [2]
RP   DEGRADATION, AND INTERACTION OF CORE PROTEIN WITH HUMAN UBE3A.
RX   PubMed=17108031; DOI=10.1128/JVI.01684-06;
RA   Shirakura M., Murakami K., Ichimura T., Suzuki R., Shimoji T.,
RA   Fukuda K., Abe K., Sato S., Fukasawa M., Yamakawa Y., Nishijima M.,
RA   Moriishi K., Matsuura Y., Wakita T., Suzuki T., Howley P.M.,
RA   Miyamura T., Shoji I.;
RT   "E6AP ubiquitin ligase mediates ubiquitylation and degradation of
RT   hepatitis C virus core protein.";
RL   J. Virol. 81:1174-1185(2007).
RN   [3]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain two highly variable regions called
CC       hypervariable region 1 and 2 (HVR1 and HVR2). E2 also contain two
CC       segments involved in CD81-binding. HVR1 is implicated in the
CC       SCARB1-mediated cell entry. HVR2 and CD81-binding regions may be
CC       involved in sensitivity and/or resistance to IFN-alpha therapy (By
CC       similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A seems to be intrinsically disordered and
CC       interacts with NS5B and host PKR. The C-terminus of NS5A contains
CC       a variable region called variable region 3 (V3) (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation.
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D10749; BAA01582.1; -; Genomic_RNA.
DR   PIR; PS0326; PS0326.
DR   PIR; PS0327; PS0327.
DR   PIR; PS0328; PS0328.
DR   PIR; S40770; S40770.
DR   PDB; 2KNU; NMR; -; A=314-342.
DR   PDBsum; 2KNU; -.
DR   IntAct; Q03463; 6.
DR   euHCVdb; D10749; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; FALSE_NEG.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Envelope protein; Fusion protein; Glycoprotein;
KW   Helicase; Host cell membrane; Host cytoplasm;
KW   Host endoplasmic reticulum; Host lipid droplet; Host membrane;
KW   Host mitochondrion; Host nucleus; Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000278730.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000278731.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000278732.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000278733.
FT   CHAIN       384    746       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000278734.
FT   CHAIN       747    809       p7 (By similarity).
FT                                /FTId=PRO_0000278735.
FT   CHAIN       810   1026       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000278736.
FT   CHAIN      1027   1657       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000278737.
FT   CHAIN      1658   1711       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000278738.
FT   CHAIN      1712   1972       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000278739.
FT   CHAIN      1973   2420       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000278740.
FT   CHAIN      2421   3011       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000278741.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    725       Lumenal (Potential).
FT   TRANSMEM    726    746       Potential.
FT   TOPO_DOM    747    757       Lumenal (Potential).
FT   TRANSMEM    758    778       Potential.
FT   TOPO_DOM    779    782       Cytoplasmic (Potential).
FT   TRANSMEM    783    803       Potential.
FT   TOPO_DOM    804    813       Lumenal (Potential).
FT   TRANSMEM    814    834       Potential.
FT   TOPO_DOM    835    881       Cytoplasmic (Potential).
FT   TRANSMEM    882    902       Potential.
FT   TOPO_DOM    903    928       Lumenal (Potential).
FT   TRANSMEM    929    949       Potential.
FT   TOPO_DOM    950   1657       Cytoplasmic (Potential).
FT   TRANSMEM   1658   1678       Potential.
FT   TOPO_DOM   1679   1805       Cytoplasmic (Potential).
FT   TRANSMEM   1806   1826       Potential.
FT   TOPO_DOM   1827   1828       Lumenal (Potential).
FT   TRANSMEM   1829   1849       Potential.
FT   TOPO_DOM   1850   1850       Cytoplasmic (Potential).
FT   TRANSMEM   1851   1871       Potential.
FT   TOPO_DOM   1872   1881       Lumenal (Potential).
FT   TRANSMEM   1882   1902       Potential.
FT   TOPO_DOM   1903   1972       Cytoplasmic (Potential).
FT   TOPO_DOM   1973   2002       In membrane (By similarity).
FT   TOPO_DOM   2003   2990       Cytoplasmic (Potential).
FT   TRANSMEM   2991   3011       By similarity.
FT   DOMAIN     1217   1369       Helicase ATP-binding.
FT   DOMAIN     2634   2752       RdRp catalytic.
FT   NP_BIND    1230   1237       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      385    411       HVR1 (By similarity).
FT   REGION      475    481       HVR2 (By similarity).
FT   REGION      482    494       CD81-binding 1 (Potential).
FT   REGION      522    553       CD81-binding 2 (Potential).
FT   REGION      660    671       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1679   1690       NS3-binding (by NS4A) (Potential).
FT   REGION     2120   2332       Transcriptional activation (Potential).
FT   REGION     2120   2208       FKBP8-binding (Potential).
FT   REGION     2200   2250       Basal phosphorylation (By similarity).
FT   REGION     2210   2275       PKR-binding (Potential).
FT   REGION     2210   2249       ISDR (By similarity).
FT   REGION     2249   2306       NS4B-binding (Potential).
FT   REGION     2351   2420       Basal phosphorylation (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1316   1319       DECH box (By similarity).
FT   MOTIF      2322   2325       SH3-binding (Potential).
FT   MOTIF      2327   2335       Nuclear localization signal (Potential).
FT   COMPBIAS    572    575       Poly-Gly.
FT   COMPBIAS    796    803       Poly-Leu.
FT   COMPBIAS   1432   1435       Poly-Val.
FT   COMPBIAS   2183   2186       Poly-Ala.
FT   COMPBIAS   2282   2327       Pro-rich.
FT   COMPBIAS   2996   2999       Poly-Leu.
FT   ACT_SITE    952    952       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    972    972       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    993    993       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1083   1083       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1107   1107       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1165   1165       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1123   1123       Zinc (By similarity).
FT   METAL      1125   1125       Zinc (By similarity).
FT   METAL      1171   1171       Zinc (By similarity).
FT   METAL      1175   1175       Zinc (By similarity).
FT   METAL      2011   2011       Zinc (By similarity).
FT   METAL      2029   2029       Zinc (By similarity).
FT   METAL      2031   2031       Zinc (By similarity).
FT   METAL      2052   2052       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        191    192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        746    747       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        809    810       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1026   1027       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1657   1658       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1711   1712       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1972   1973       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2420   2421       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2194   2194       Phosphoserine; by host; in p56 (By
FT                                similarity).
FT   MOD_RES    2197   2197       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2201   2201       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2204   2204       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1972   1972       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    417    417       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    423    423       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    430    430       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    448    448       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    476    476       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    532    532       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    540    540       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    556    556       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    576    576       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    623    623       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    645    645       N-linked (GlcNAc...); by host
FT                                (Potential).
SQ   SEQUENCE   3011 AA;  327117 MW;  97E9052C0250463B CRC64;
     MSTIPKPQRK TKRNTNRRPQ DVKFPGGGQI VGGVYLLPRR GPRLGVRATR KTSERSQPRG
     RRQPIPKVRR PEGRTWAQPG YPWPLYGNEG CGWAGWLLSP RGSRPSWGPT DPRRRSRNLG
     KVIDTLTCGF ADLMGYIPLV GAPLGGAARA LAHGVRVLED GVNYATGNLP GCSFSIFLLA
     LLSCLTVPAS AYQVRNSTGL YHVTNDCPNS SIVYEAHDAI LHTPGCVPCV REGNVSRCWV
     AMTPTVATRD GKLPATQLRR HIDLLVGSAT LCSALYVGDL CGSVFLIGQL FTFSPRRHWT
     TQGCNCSIYP GHITGHRMAW DMMMNWSPTA ALVMAQLLRI PQAILDMIAG AHWGVLAGIA
     YFSMVGNWAK VLVVLLLFAG VDAETIVSGG QAARAMSGLV SLFTPGAKQN IQLINTNGSW
     HINSTALNCN ESLNTGWLAG LIYQHKFNSS GCPERLASCR RLTDFDQGWG PISHANGSGP
     DQRPYCWHYP PKPCGIVPAK SVCGPVYCFT PSPVVVGTTD RSGAPTYNWG ANDTDVFVLN
     NTRPPLGNWF GCTWMNSTGF TKVCGAPPCV IGGGGNNTLH CPTDCFRKHP EATYSRCGSG
     PWITPRCLVD YPYRLWHYPC TINYTIFKVR MYVGGVEHRL DAACNWTRGE RCDLEDRDRS
     ELSPLLLSTT QWQVLPCSFT TLPALSTGLI HLHQNIVDVQ YLYGVGSSIA SWAIKWEYVV
     LLFLLLADAR VCSCLWMMLL ISQAEAALEN LVILNAASLA GTRGLVSFLV FFCFAWYLKG
     RWVPGAAYAL YGMWPLLLLL LALPQRAYAL DTEVAASCGG VVLVGLMALT LSPYYKRCIS
     WCLWWLQYFL TRVEAQLHVW VPPLNVRGGR DAVILLMCVV HPTLVFDITK LLLAVLGPLW
     ILQASLLKVP YFVRVQGLLR ICALARKMVG GHYVQMAIIK LGALTGTYVY NHLTPLRDWA
     HNGLRDLAVA VEPVVFSQME TKLITWGADT AACGDIINGL PVSARKGREI LLGPADGMVS
     KGWRLLAPIT AYAQQTRGLL GCIITSLTGR DKNQVEGEVQ IVSTAAQTFL ATCINGVCWT
     VYHGAGTRTI ASPKGPVIQM YTNVDQDLVG WPAPQGARSL TPCTCGSSDL YLVTRHADVI
     PVRRRGDSRG SLLSPRPISY LKGSSGGPLL CPAGHVVGIF RAAVCTRGVA KAVDFIPVES
     LETTMRSPVF TDNSSPPAVP QSFQVAHLHA PTGSGKSTKV PAAYAAQGYK VLVLNPSVAA
     TLGFGAYMSK AHGIDPNIRT GVRTITTGSP ITYSTYGKFL ADGGCSGGAY DIIICDECHS
     TDATSVLGIG TVLDQAETAG ARLVVLATAT PPGSITVPHA NIEEVALSTT GEIPFYGKAI
     PLEAIKGGRH LIFCHSKKKC DELAAKLVAL GVNAVAYYRG LDVSVIPTSG DVVVVATDAL
     MTGYTGDFDS VIDCNTCVTQ TVDFSLDPTF TIETTTLPQD AVSRTQRRGR TGRGKPGIYR
     FVAPGERPSG MFDSSILCEC YDTGCAWYEL TPAETTVRLR AYMNTPGLPV CQDHLEFWEG
     VFTGLTHIDA HFLSQTKQGG ENFPYLVAYQ ATVCARAQAP PPSWDQMWKC LIRLKPTLHG
     PTPLLYRLGA VQGEVTLTHP VTKYIMTCMS ADLEVVTSTW VLVGGVLAAL AAYCLSTGCV
     VIVGRIVLSG RPAIIPDREV LYREFDEMEE CSQHLPYIEQ GMMLAEQFKQ KALGLLQTAS
     RQAEVIAPTV QTNWQKLEAF WAKHMWNFIS GIQYLAGLST LPGNPAIASL MAFTAAVTSP
     LTTSQTLLFN ILGGWVAAQL AAPGAATAFV GSGLAGAAVG SVGLGRVLVD ILAGYGAGVA
     GALVAFKIMS GELPSTEDLV NLLPAILSPG ALVVGVVCAA ILRRHVGPGE GAVQWMNRLI
     AFASRGNHVS PTHYVPESDA AARVTAILSS LTVTQLLRRL HQWLSSESTT PCSGSWLRDI
     WDWICEVLSD FKTWLKTKLM PHLPGIPFVS CQHGYKGVWR GDGIMHTRCH CGAEITGHVK
     NGTMRIVGPK TCRNMWSGTF PINAYTTGPC TPLPAPNYTF ALWRVSAEEY VEIRRVGDFH
     YVTGMTTDNL KCPCQVPSPE FFTELDGVRL HRFAPPCKPL LREEVSFRVG LHDYPVGSQL
     PCEPEPDVAV LTSMLTDPSH ITAAAAGRRL ARGSPPSEAS SSASQLSAPS LKATCTINHD
     SPDAELIEAN LLWRQEMGGN ITRVESENKV VILDSFDPLV AEEDEREISV PAEILRKSRR
     FTQALPIWAR PDYNPPLIET WKKPNYEPPV VHGCPLPPPQ SPPVPPPRKK RTVVLTESTL
     STALAELAAK SFGSSSTSGI TGDNTTTSSE PAPSGCSPDS DAESYSSMPP LEGEPGDPDL
     SDGSWSTVSS EAGTEDVVCC SMSYTWTGAL ITPCAAEEQK LPINALSNSL LRHHNLVYST
     TSRSACQRQK KVTFDRLQVL DSHYQDVLKE VKAAASKVKA NLLSVEEACS LTPPHSAKSK
     FGYGAKDVRC HARKAVNHIN SVWKDLLEDS VTPIQTTIMA KNEVFCVQPE KGGRKPARLI
     VFPDLGVRVC EKMALYDVVS KLPPAVMGSS YGFQYSPGQR VEFLVQAWKS KRTPMGFSYD
     TRCFDSTVTE SDIRTEEAIY QCCDLDPQAR VAIRSLTERL YVGGPLTNSR GENCGYRRCR
     ASGVLTTSCG NTLTCYIKAR AACRAAGLQD CTMLVCGDDL VVICESAGVQ EDAASLRAFT
     EAMTRYSAPP GDPPQPEYDL ELITSCSSNV SVAHDGTGKR VYYLTRDPTT PLARAAWETA
     RHTPVNSWLG NIIMFAPTLW ARMILMTHFF SVLIARDQLE QALDCEIYGA CYSIEPLDLP
     PIIQRLHGLS AFSLHSYSPG EINRVAACLR KLGVPPLRAW RHRARSVRAR LLSRGGRAAI
     CGKYLFNWAV RTKLKLTPIA AAGRLDLSGW FTAGYSGGDI YHSVSHARPR WFWFCLLLLA
     AGVGIYLLPN R
//
ID   POLG_HCVJ4              Reviewed;        3010 AA.
AC   O92972; O92969; O92970; O92971; Q02828;
DT   20-FEB-2007, integrated into UniProtKB/Swiss-Prot.
DT   20-FEB-2007, sequence version 2.
DT   02-MAR-2010, entry version 74.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 1b (strain HC-J4) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=420174;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HC-J4/91;
RX   MEDLINE=92391112; PubMed=1325713; DOI=10.1016/0042-6822(92)90933-G;
RA   Okamoto H., Kojima M., Okada S., Yoshizawa H., Iizuka H., Tanaka T.,
RA   Muchmore E.E., Peterson D.A., Ito Y., Mishiro S.;
RT   "Genetic drift of hepatitis C virus during an 8.2-year infection in a
RT   chimpanzee: variability and stability.";
RL   Virology 190:894-899(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=HC-J4, Isolate pCV-J4L2S, Isolate pCV-J4L4S, and
RC   Isolate pCV-J4L6S;
RX   MEDLINE=98240944; PubMed=9581788; DOI=10.1006/viro.1998.9092;
RA   Yanagi M., St Claire M., Shapiro M., Emerson S.U., Purcell R.H.,
RA   Bukh J.;
RT   "Transcripts of a chimeric cDNA clone of hepatitis C virus genotype 1b
RT   are infectious in vivo.";
RL   Virology 244:161-172(1998).
RN   [3]
RP   SUBUNIT.
RX   PubMed=17032656; DOI=10.1074/jbc.M602434200;
RA   Clarke D., Griffin S., Beales L., Gelais C.S., Burgess S., Harris M.,
RA   Rowlands D.;
RT   "Evidence for the formation of a heptameric ion channel complex by the
RT   hepatitis C virus p7 protein in vitro.";
RL   J. Biol. Chem. 281:37057-37068(2006).
RN   [4]
RP   CHARACTERIZATION OF NS5B, AND SUBUNIT.
RC   STRAIN=Isolate pCV-J4L6S;
RX   PubMed=16533043; DOI=10.1021/bi051483s;
RA   Cramer J., Jaeger J., Restle T.;
RT   "Biochemical and pre-steady-state kinetic characterization of the
RT   hepatitis C virus RNA polymerase (NS5BDelta21, HC-J4).";
RL   Biochemistry 45:3610-3619(2006).
RN   [5]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 2420-2989.
RX   MEDLINE=22478154; PubMed=12589751; DOI=10.1016/S0022-2836(02)01439-0;
RA   O'Farrell D., Trowbridge R., Rowlands D., Jager J.;
RT   "Substrate complexes of hepatitis C virus RNA polymerase (HC-J4):
RT   structural evidence for nucleotide import and de-novo initiation.";
RL   J. Mol. Biol. 326:1025-1035(2003).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- INTERACTION:
CC       P06241:FYN (xeno); NbExp=2; IntAct=EBI-710506, EBI-515315;
CC       P62993:GRB2 (xeno); NbExp=2; IntAct=EBI-710506, EBI-401755;
CC       P08631:HCK (xeno); NbExp=2; IntAct=EBI-710506, EBI-346340;
CC       P06240:Lck (xeno); NbExp=2; IntAct=EBI-710506, EBI-1401;
CC       P07948:LYN (xeno); NbExp=2; IntAct=EBI-710506, EBI-79452;
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain two highly variable regions called
CC       hypervariable region 1 and 2 (HVR1 and HVR2). E2 also contain two
CC       segments involved in CD81-binding. HVR1 is implicated in the
CC       SCARB1-mediated cell entry. HVR2 and CD81-binding regions may be
CC       involved in sensitivity and/or resistance to IFN-alpha therapy (By
CC       similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A seems to be intrinsically disordered and
CC       interacts with NS5B and host PKR. The C-terminus of NS5A contains
CC       a variable region called variable region 3 (V3) (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D10750; BAA01583.1; -; Genomic_RNA.
DR   EMBL; AF054247; AAC15722.1; -; Genomic_RNA.
DR   EMBL; AF054248; AAC15723.1; -; Genomic_RNA.
DR   EMBL; AF054249; AAC15724.1; -; Genomic_RNA.
DR   EMBL; AF054250; AAC15725.1; -; Genomic_RNA.
DR   PIR; A61196; A61196.
DR   PIR; PQ0246; PQ0246.
DR   PIR; PQ0804; PQ0804.
DR   PIR; PS0329; PS0329.
DR   PDB; 1NB4; X-ray; 2.00 A; A/B=2420-2989.
DR   PDB; 1NB6; X-ray; 2.60 A; A/B=2420-2989.
DR   PDB; 1NB7; X-ray; 2.90 A; A/B=2420-2989.
DR   PDB; 2F55; X-ray; 3.30 A; A/B/C=1216-1650.
DR   PDB; 3CSO; X-ray; 2.71 A; A/B=2420-2989.
DR   PDB; 3GNV; X-ray; 2.75 A; A/B=2420-2989.
DR   PDB; 3GNW; X-ray; 2.39 A; A/B=2420-2989.
DR   PDB; 3GOL; X-ray; 2.85 A; A/B=2420-2989.
DR   PDBsum; 1NB4; -.
DR   PDBsum; 1NB6; -.
DR   PDBsum; 1NB7; -.
DR   PDBsum; 2F55; -.
DR   PDBsum; 3CSO; -.
DR   PDBsum; 3GNV; -.
DR   PDBsum; 3GNW; -.
DR   PDBsum; 3GOL; -.
DR   SMR; O92972; 2-45, 902-1026, 1029-1657, 1973-2003, 2008-2170.
DR   IntAct; O92972; 5.
DR   euHCVdb; AF054247; -.
DR   euHCVdb; AF054248; -.
DR   euHCVdb; AF054249; -.
DR   euHCVdb; AF054250; -.
DR   euHCVdb; D10750; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; FALSE_NEG.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Envelope protein; Fusion protein; Glycoprotein;
KW   Helicase; Host cell membrane; Host cytoplasm;
KW   Host endoplasmic reticulum; Host lipid droplet; Host membrane;
KW   Host mitochondrion; Host nucleus; Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000278742.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000278743.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000278744.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000278745.
FT   CHAIN       384    746       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000278746.
FT   CHAIN       747    809       p7 (By similarity).
FT                                /FTId=PRO_0000278747.
FT   CHAIN       810   1026       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000278748.
FT   CHAIN      1027   1657       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000278749.
FT   CHAIN      1658   1711       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000278750.
FT   CHAIN      1712   1972       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000278751.
FT   CHAIN      1973   2419       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000278752.
FT   CHAIN      2420   3010       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000278753.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    725       Lumenal (Potential).
FT   TRANSMEM    726    746       Potential.
FT   TOPO_DOM    747    757       Lumenal (Potential).
FT   TRANSMEM    758    778       Potential.
FT   TOPO_DOM    779    782       Cytoplasmic (Potential).
FT   TRANSMEM    783    803       Potential.
FT   TOPO_DOM    804    813       Lumenal (Potential).
FT   TRANSMEM    814    834       Potential.
FT   TOPO_DOM    835    881       Cytoplasmic (Potential).
FT   TRANSMEM    882    902       Potential.
FT   TOPO_DOM    903    928       Lumenal (Potential).
FT   TRANSMEM    929    949       Potential.
FT   TOPO_DOM    950   1657       Cytoplasmic (Potential).
FT   TRANSMEM   1658   1678       Potential.
FT   TOPO_DOM   1679   1805       Cytoplasmic (Potential).
FT   TRANSMEM   1806   1826       Potential.
FT   TOPO_DOM   1827   1828       Lumenal (Potential).
FT   TRANSMEM   1829   1849       Potential.
FT   TOPO_DOM   1850   1850       Cytoplasmic (Potential).
FT   TRANSMEM   1851   1871       Potential.
FT   TOPO_DOM   1872   1881       Lumenal (Potential).
FT   TRANSMEM   1882   1902       Potential.
FT   TOPO_DOM   1903   1972       Cytoplasmic (Potential).
FT   TOPO_DOM   1973   2002       In membrane (By similarity).
FT   TOPO_DOM   2003   2989       Cytoplasmic (Potential).
FT   TRANSMEM   2990   3010       By similarity.
FT   DOMAIN     1217   1369       Helicase ATP-binding.
FT   DOMAIN     2633   2751       RdRp catalytic.
FT   NP_BIND    1230   1237       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      385    411       HVR1 (By similarity).
FT   REGION      475    481       HVR2 (By similarity).
FT   REGION      482    494       CD81-binding 1 (Potential).
FT   REGION      522    553       CD81-binding 2 (Potential).
FT   REGION      660    671       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1679   1690       NS3-binding (by NS4A) (Potential).
FT   REGION     2120   2332       Transcriptional activation (Potential).
FT   REGION     2120   2208       FKBP8-binding (Potential).
FT   REGION     2200   2250       Basal phosphorylation (By similarity).
FT   REGION     2210   2275       PKR-binding (Potential).
FT   REGION     2210   2249       ISDR (By similarity).
FT   REGION     2249   2306       NS4B-binding (Potential).
FT   REGION     2351   2419       Basal phosphorylation (By similarity).
FT   REGION     2354   2377       V3 (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1316   1319       DECH box.
FT   MOTIF      2322   2325       SH3-binding (Potential).
FT   MOTIF      2327   2335       Nuclear localization signal (Potential).
FT   COMPBIAS    796    803       Poly-Leu.
FT   COMPBIAS   1432   1435       Poly-Val.
FT   COMPBIAS   2282   2327       Pro-rich.
FT   COMPBIAS   2993   2998       Poly-Leu.
FT   ACT_SITE    952    952       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    972    972       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    993    993       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1083   1083       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1107   1107       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1165   1165       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1123   1123       Zinc (By similarity).
FT   METAL      1125   1125       Zinc (By similarity).
FT   METAL      1171   1171       Zinc (By similarity).
FT   METAL      1175   1175       Zinc (By similarity).
FT   METAL      2011   2011       Zinc (By similarity).
FT   METAL      2029   2029       Zinc (By similarity).
FT   METAL      2031   2031       Zinc (By similarity).
FT   METAL      2052   2052       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        191    192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        746    747       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        809    810       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1026   1027       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1657   1658       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1711   1712       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1972   1973       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2419   2420       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2194   2194       Phosphoserine; by host; in p56
FT                                (Probable).
FT   MOD_RES    2197   2197       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2201   2201       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2204   2204       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1968   1968       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   LIPID      1972   1972       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    250    250       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    417    417       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    423    423       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    430    430       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    448    448       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    478    478       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    532    532       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    540    540       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    556    556       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    576    576       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    623    623       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    645    645       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   VARIANT      52     52       A -> T (in strain: Isolate pCV-J4L4S and
FT                                Isolate HC-J4/91).
FT   VARIANT      70     70       R -> Q (in strain: Isolate HC-J4/91).
FT   VARIANT     231    231       R -> Q (in strain: Isolate pCV-J4L2S and
FT                                Isolate pCV-J4L6S).
FT   VARIANT     250    250       N -> D (in strain: Isolate HC-J4/91 and
FT                                Isolate pCV-J4L4S).
FT   VARIANT     304    304       C -> Y (in strain: Isolate pCV-J4L2S).
FT   VARIANT     384    390       ETHTTGR -> ATYTSGG (in strain: Isolate
FT                                HC-J4/91).
FT   VARIANT     394    394       H -> R (in strain: Isolate HC-J4/91 and
FT                                Isolate pCV-J4L4S).
FT   VARIANT     434    434       Q -> H (in strain: Isolate HC-J4/91).
FT   VARIANT     438    438       F -> L (in strain: Isolate pCV-J4L4S).
FT   VARIANT     444    444       A -> T (in strain: Isolate pCV-J4L4S and
FT                                Isolate HC-J4/91).
FT   VARIANT     450    450       S -> P (in strain: Isolate pCV-J4L4S).
FT   VARIANT     464    464       W -> G (in strain: Isolate HC-J4/91).
FT   VARIANT     476    476       K -> E (in strain: Isolate pCV-J4L4S and
FT                                Isolate HC-J4/91).
FT   VARIANT     480    480       S -> P (in strain: Isolate HC-J4/91).
FT   VARIANT     496    496       V -> I (in strain: Isolate pCV-J4L4S and
FT                                Isolate HC-J4/91).
FT   VARIANT     536    536       V -> M (in strain: Isolate pCV-J4L2S).
FT   VARIANT     934    934       V -> I (in strain: Isolate pCV-J4L2S).
FT   VARIANT     937    937       A -> V (in strain: Isolate pCV-J4L6S).
FT   VARIANT    1043   1043       I -> V (in strain: Isolate pCV-J4L2S and
FT                                Isolate pCV-J4L4S).
FT   VARIANT    1215   1215       S -> T (in strain: Isolate pCV-J4L6S).
FT   VARIANT    1223   1223       F -> S (in strain: Isolate pCV-J4L2S).
FT   VARIANT    1528   1528       Y -> H (in strain: Isolate pCV-J4L4S).
FT   VARIANT    1662   1662       L -> P (in strain: Isolate pCV-J4L2S).
FT   VARIANT    1753   1753       K -> R (in strain: Isolate pCV-J4L2S).
FT   VARIANT    1805   1805       N -> H (in strain: Isolate pCV-J4L2S).
FT   VARIANT    1949   1949       S -> P (in strain: Isolate pCV-J4L4S).
FT   VARIANT    2138   2138       K -> R (in strain: Isolate pCV-J4L4S).
FT   VARIANT    2385   2385       Y -> H (in strain: Isolate pCV-J4L4S).
FT   VARIANT    2785   2785       C -> R (in strain: Isolate pCV-J4L2S).
FT   VARIANT    2824   2824       I -> V (in strain: Isolate pCV-J4L2S).
FT   VARIANT    2999   2999       S -> F (in strain: Isolate HC-J4/91).
FT   STRAND     2421   2423
FT   HELIX      2446   2449
FT   HELIX      2453   2455
FT   STRAND     2456   2458
FT   HELIX      2461   2463
FT   HELIX      2464   2471
FT   HELIX      2481   2494
FT   HELIX      2504   2509
FT   HELIX      2525   2528
FT   HELIX      2532   2547
FT   STRAND     2549   2551
FT   STRAND     2555   2559
FT   STRAND     2563   2565
FT   STRAND     2578   2581
FT   HELIX      2587   2605
FT   HELIX      2616   2629
FT   STRAND     2630   2634
FT   STRAND     2636   2638
FT   HELIX      2643   2646
FT   HELIX      2649   2659
FT   HELIX      2666   2678
FT   HELIX      2711   2725
FT   STRAND     2731   2734
FT   STRAND     2739   2744
FT   HELIX      2749   2764
FT   HELIX      2779   2781
FT   STRAND     2787   2792
FT   STRAND     2800   2804
FT   HELIX      2808   2819
FT   HELIX      2831   2834
FT   HELIX      2838   2842
FT   HELIX      2844   2855
FT   STRAND     2858   2860
FT   STRAND     2862   2865
FT   STRAND     2870   2873
FT   HELIX      2875   2877
FT   HELIX      2878   2885
FT   HELIX      2889   2891
FT   HELIX      2901   2910
FT   HELIX      2916   2931
FT   TURN       2937   2939
FT   HELIX      2946   2948
FT   TURN       2959   2964
SQ   SEQUENCE   3010 AA;  326767 MW;  0480D428ABDE9847 CRC64;
     MSTNPKPQRK TKRNTNRRPQ DVKFPGGGQI VGGVYLLPRR GPRLGVRATR KASERSQPRG
     RRQPIPKARR PEGRAWAQPG YPWPLYGNEG LGWAGWLLSP RGSRPSWGPT DPRRRSRNLG
     KVIDTLTCGF ADLMGYIPLV GAPLGGAARA LAHGVRVLED GVNYATGNLP GCSFSIFLLA
     LLSCLTIPAS AYEVRNVSGI YHVTNDCSNS SIVYEAADVI MHTPGCVPCV REGNSSRCWV
     ALTPTLAARN ASVPTTTIRR HVDLLVGTAA FCSAMYVGDL CGSIFLVSQL FTFSPRRHET
     VQDCNCSIYP GHVSGHRMAW DMMMNWSPTT ALVVSQLLRI PQAVVDMVAG AHWGVLAGLA
     YYSMVGNWAK VLIVALLFAG VDGETHTTGR VAGHTTSGFT SLFSSGASQK IQLVNTNGSW
     HINRTALNCN DSLQTGFFAA LFYAHKFNSS GCPERMASCR PIDWFAQGWG PITYTKPNSS
     DQRPYCWHYA PRPCGVVPAS QVCGPVYCFT PSPVVVGTTD RSGVPTYSWG ENETDVMLLN
     NTRPPQGNWF GCTWMNSTGF TKTCGGPPCN IGGVGNRTLI CPTDCFRKHP EATYTKCGSG
     PWLTPRCLVD YPYRLWHYPC TLNFSIFKVR MYVGGVEHRL NAACNWTRGE RCNLEDRDRS
     ELSPLLLSTT EWQILPCAFT TLPALSTGLI HLHQNIVDVQ YLYGVGSAFV SFAIKWEYIL
     LLFLLLADAR VCACLWMMLL IAQAEAALEN LVVLNAASVA GAHGILSFLV FFCAAWYIKG
     RLAPGAAYAF YGVWPLLLLL LALPPRAYAL DREMAASCGG AVLVGLVFLT LSPYYKVFLT
     RLIWWLQYFI TRAEAHMQVW VPPLNVRGGR DAIILLTCAV HPELIFDITK LLLAILGPLM
     VLQAGITRVP YFVRAQGLIR ACMLVRKVAG GHYVQMAFMK LGALTGTYVY NHLTPLRDWA
     HAGLRDLAVA VEPVVFSAME TKVITWGADT AACGDIILGL PVSARRGKEI FLGPADSLEG
     QGWRLLAPIT AYSQQTRGVL GCIITSLTGR DKNQVEGEVQ VVSTATQSFL ATCINGVCWT
     VYHGAGSKTL AGPKGPITQM YTNVDLDLVG WQAPPGARSM TPCSCGSSDL YLVTRHADVI
     PVRRRGDSRG SLLSPRPVSY LKGSSGGPLL CPSGHVVGVF RAAVCTRGVA KAVDFIPVES
     METTMRSPVF TDNSSPPAVP QTFQVAHLHA PTGSGKSTKV PAAYAAQGYK VLVLNPSVAA
     TLGFGAYMSK AHGIDPNIRT GVRTITTGGS ITYSTYGKFL ADGGCSGGAY DIIICDECHS
     TDSTTILGIG TVLDQAETAG ARLVVLATAT PPGSVTVPHP NIEEIGLSNN GEIPFYGKAI
     PIEAIKGGRH LIFCHSKKKC DELAAKLTGL GLNAVAYYRG LDVSVIPPIG DVVVVATDAL
     MTGFTGDFDS VIDCNTCVTQ TVDFSLDPTF TIETTTVPQD AVSRSQRRGR TGRGRSGIYR
     FVTPGERPSG MFDSSVLCEC YDAGCAWYEL TPAETSVRLR AYLNTPGLPV CQDHLEFWES
     VFTGLTHIDA HFLSQTKQAG DNFPYLVAYQ ATVCARAQAP PPSWDQMWKC LIRLKPTLHG
     PTPLLYRLGA VQNEVILTHP ITKYIMACMS ADLEVVTSTW VLVGGVLAAL AAYCLTTGSV
     VIVGRIILSG KPAVVPDREV LYQEFDEMEE CASQLPYIEQ GMQLAEQFKQ KALGLLQTAT
     KQAEAAAPVV ESKWRALETF WAKHMWNFIS GIQYLAGLST LPGNPAIASL MAFTASITSP
     LTTQNTLLFN ILGGWVAAQL APPSAASAFV GAGIAGAAVG SIGLGKVLVD ILAGYGAGVA
     GALVAFKVMS GEVPSTEDLV NLLPAILSPG ALVVGVVCAA ILRRHVGPGE GAVQWMNRLI
     AFASRGNHVS PTHYVPESDA AARVTQILSS LTITQLLKRL HQWINEDCST PCSGSWLRDV
     WDWICTVLTD FKTWLQSKLL PRLPGVPFLS CQRGYKGVWR GDGIMQTTCP CGAQIAGHVK
     NGSMRIVGPR TCSNTWHGTF PINAYTTGPC TPSPAPNYSR ALWRVAAEEY VEVTRVGDFH
     YVTGMTTDNV KCPCQVPAPE FFTEVDGVRL HRYAPACKPL LREDVTFQVG LNQYLVGSQL
     PCEPEPDVTV LTSMLTDPSH ITAETAKRRL ARGSPPSLAS SSASQLSAPS LKATCTTHHD
     SPDADLIEAN LLWRQEMGGN ITRVESENKV VILDSFEPLH AEGDEREISV AAEILRKSRK
     FPSALPIWAR PDYNPPLLES WKDPDYVPPV VHGCPLPPTK APPIPPPRRK RTVVLTESNV
     SSALAELATK TFGSSGSSAV DSGTATALPD LASDDGDKGS DVESYSSMPP LEGEPGDPDL
     SDGSWSTVSE EASEDVVCCS MSYTWTGALI TPCAAEESKL PINPLSNSLL RHHNMVYATT
     SRSASLRQKK VTFDRLQVLD DHYRDVLKEM KAKASTVKAK LLSIEEACKL TPPHSAKSKF
     GYGAKDVRNL SSRAVNHIRS VWEDLLEDTE TPIDTTIMAK SEVFCVQPEK GGRKPARLIV
     FPDLGVRVCE KMALYDVVST LPQAVMGSSY GFQYSPKQRV EFLVNTWKSK KCPMGFSYDT
     RCFDSTVTES DIRVEESIYQ CCDLAPEARQ AIRSLTERLY IGGPLTNSKG QNCGYRRCRA
     SGVLTTSCGN TLTCYLKATA ACRAAKLQDC TMLVNGDDLV VICESAGTQE DAAALRAFTE
     AMTRYSAPPG DPPQPEYDLE LITSCSSNVS VAHDASGKRV YYLTRDPTTP LARAAWETAR
     HTPINSWLGN IIMYAPTLWA RMILMTHFFS ILLAQEQLEK ALDCQIYGAC YSIEPLDLPQ
     IIERLHGLSA FTLHSYSPGE INRVASCLRK LGVPPLRTWR HRARSVRAKL LSQGGRAATC
     GRYLFNWAVR TKLKLTPIPA ASQLDLSGWF VAGYSGGDIY HSLSRARPRW FPLCLLLLSV
     GVGIYLLPNR
//
ID   POLG_HCVJ6              Reviewed;        3033 AA.
AC   P26660;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 103.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 2a (isolate HC-J6) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=11113;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=92044440; PubMed=1658196;
RA   Okamoto H., Okada S., Sugiyama Y., Kurai K., Lizuka H., Machida A.,
RA   Miyakawa Y., Mayumi M.;
RT   "Nucleotide sequence of the genomic RNA of hepatitis C virus isolated
RT   from a human carrier: comparison with reported isolates for conserved
RT   and divergent regions.";
RL   J. Gen. Virol. 72:2697-2704(1991).
RN   [2]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
RN   [3]
RP   INTERACTION WITH HUMAN CLDN1.
RX   PubMed=17325668; DOI=10.1038/nature05654;
RA   Evans M.J., von Hahn T., Tscherne D.M., Syder A.J., Panis M., Wolk B.,
RA   Hatziioannou T., McKeating J.A., Bieniasz P.D., Rice C.M.;
RT   "Claudin-1 is a hepatitis C virus co-receptor required for a late step
RT   in entry.";
RL   Nature 446:801-805(2007).
RN   [4]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [5]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 2443-3012.
RX   PubMed=15746101; DOI=10.1074/jbc.M413410200;
RA   Biswal B.K., Cherney M.M., Wang M., Chan L., Yannopoulos C.G.,
RA   Bilimoria D., Nicolas O., Bedard J., James M.N.G.;
RT   "Crystal structures of the RNA-dependent RNA polymerase genotype 2a of
RT   hepatitis C virus reveal two conformations and suggest mechanisms of
RT   inhibition by non-nucleoside inhibitors.";
RL   J. Biol. Chem. 280:18202-18210(2005).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3 RNA helicase binds
CC       to RNA and unwinds dsRNA in the 3' to 5' direction, and likely RNA
CC       stable secondary structure in the template strand. Cleaves the
CC       host antiviral protein MAVS (By similarity). NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state.
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- INTERACTION:
CC       P06241:FYN (xeno); NbExp=1; IntAct=EBI-706322, EBI-515315;
CC       P62993:GRB2 (xeno); NbExp=1; IntAct=EBI-706322, EBI-401755;
CC       P08631:HCK (xeno); NbExp=1; IntAct=EBI-706322, EBI-346340;
CC       P06240:Lck (xeno); NbExp=1; IntAct=EBI-706322, EBI-1401;
CC       P07948:LYN (xeno); NbExp=1; IntAct=EBI-706322, EBI-79452;
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain a highly variable region called hypervariable
CC       region 1 (HVR1). E2 also contains two segments involved in CD81-
CC       binding. HVR1 is implicated in the SCARB1-mediated cell entry.
CC       CD81-binding regions may be involved in sensitivity and/or
CC       resistance to IFN-alpha therapy (By similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A seems to be intrinsically disordered and
CC       interacts with NS5B and host PKR (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D00944; BAA00792.1; -; Genomic_RNA.
DR   PIR; JQ1303; JQ1303.
DR   PDB; 1YUY; X-ray; 1.90 A; A=2443-3012.
DR   PDB; 1YV2; X-ray; 2.50 A; A=2443-3012.
DR   PDB; 1YVX; X-ray; 2.00 A; A=2443-3012.
DR   PDB; 1YVZ; X-ray; 2.20 A; A=2443-3012.
DR   PDBsum; 1YUY; -.
DR   PDBsum; 1YV2; -.
DR   PDBsum; 1YVX; -.
DR   PDBsum; 1YVZ; -.
DR   SMR; P26660; 2-45, 906-1030, 1033-1661, 1977-2007, 2012-2174.
DR   IntAct; P26660; 5.
DR   euHCVdb; D00944; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; FALSE_NEG.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Disulfide bond; Envelope protein; Fusion protein;
KW   Glycoprotein; Helicase; Host cell membrane; Host cytoplasm;
KW   Host endoplasmic reticulum; Host lipid droplet; Host membrane;
KW   Host mitochondrion; Host nucleus; Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000037608.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000037609.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000037610.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000037611.
FT   CHAIN       384    750       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000037612.
FT   CHAIN       751    813       p7 (By similarity).
FT                                /FTId=PRO_0000037613.
FT   CHAIN       814   1030       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000037614.
FT   CHAIN      1031   1661       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000037615.
FT   CHAIN      1662   1715       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000037616.
FT   CHAIN      1716   1976       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000037617.
FT   CHAIN      1977   2442       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000037618.
FT   CHAIN      2443   3033       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000037619.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    729       Lumenal (Potential).
FT   TRANSMEM    730    750       Potential.
FT   TOPO_DOM    751    761       Lumenal (Potential).
FT   TRANSMEM    762    782       Potential.
FT   TOPO_DOM    783    786       Cytoplasmic (Potential).
FT   TRANSMEM    787    807       Potential.
FT   TOPO_DOM    808    817       Lumenal (Potential).
FT   TRANSMEM    818    838       Potential.
FT   TOPO_DOM    839    885       Cytoplasmic (Potential).
FT   TRANSMEM    886    906       Potential.
FT   TOPO_DOM    907    932       Lumenal (Potential).
FT   TRANSMEM    933    953       Potential.
FT   TOPO_DOM    954   1661       Cytoplasmic (Potential).
FT   TRANSMEM   1662   1682       Potential.
FT   TOPO_DOM   1683   1809       Cytoplasmic (Potential).
FT   TRANSMEM   1810   1830       Potential.
FT   TOPO_DOM   1831   1832       Lumenal (Potential).
FT   TRANSMEM   1833   1853       Potential.
FT   TOPO_DOM   1854   1854       Cytoplasmic (Potential).
FT   TRANSMEM   1855   1875       Potential.
FT   TOPO_DOM   1876   1885       Lumenal (Potential).
FT   TRANSMEM   1886   1906       Potential.
FT   TOPO_DOM   1907   1976       Cytoplasmic (Potential).
FT   TOPO_DOM   1977   2006       In membrane (By similarity).
FT   TOPO_DOM   2007   3012       Cytoplasmic (Potential).
FT   TRANSMEM   3013   3033       By similarity.
FT   DOMAIN     1221   1373       Helicase ATP-binding.
FT   DOMAIN     2656   2774       RdRp catalytic.
FT   NP_BIND    1234   1241       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      385    411       HVR1 (By similarity).
FT   REGION      484    496       CD81-binding 1 (Potential).
FT   REGION      524    555       CD81-binding 2 (Potential).
FT   REGION      664    675       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1683   1694       NS3-binding (by NS4A) (Potential).
FT   REGION     2124   2332       Transcriptional activation (Potential).
FT   REGION     2124   2212       FKBP8-binding (Potential).
FT   REGION     2204   2250       Basal phosphorylation (By similarity).
FT   REGION     2214   2275       PKR-binding (Potential).
FT   REGION     2249   2306       NS4B-binding (Potential).
FT   REGION     2351   2442       Basal phosphorylation (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1320   1323       DECH box (By similarity).
FT   MOTIF      2322   2325       SH3-binding (Potential).
FT   MOTIF      2327   2335       Nuclear localization signal (Potential).
FT   COMPBIAS    802    807       Poly-Leu.
FT   COMPBIAS   1436   1439       Poly-Val.
FT   COMPBIAS   2282   2327       Pro-rich.
FT   COMPBIAS   2328   2331       Poly-Arg.
FT   COMPBIAS   3013   3021       Poly-Leu.
FT   ACT_SITE    956    956       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    976    976       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    997    997       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1087   1087       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1111   1111       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1169   1169       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1127   1127       Zinc (By similarity).
FT   METAL      1129   1129       Zinc (By similarity).
FT   METAL      1175   1175       Zinc (By similarity).
FT   METAL      1179   1179       Zinc (By similarity).
FT   METAL      2015   2015       Zinc (By similarity).
FT   METAL      2033   2033       Zinc (By similarity).
FT   METAL      2035   2035       Zinc (By similarity).
FT   METAL      2056   2056       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        191    192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        750    751       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        813    814       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1030   1031       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1661   1662       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1715   1716       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1976   1977       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2442   2443       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2198   2198       Phosphoserine; by host; in p56 (By
FT                                similarity).
FT   MOD_RES    2201   2201       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2205   2205       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2208   2208       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1972   1972       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   LIPID      1976   1976       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    417    417       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    423    423       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    430    430       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    448    448       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    477    477       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    534    534       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    542    542       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    558    558       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    578    578       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    627    627       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    649    649       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2118   2166       By similarity.
FT   STRAND     2444   2448
FT   HELIX      2467   2470
FT   HELIX      2476   2478
FT   STRAND     2479   2481
FT   HELIX      2484   2486
FT   HELIX      2487   2494
FT   HELIX      2504   2517
FT   HELIX      2527   2532
FT   STRAND     2542   2544
FT   HELIX      2547   2551
FT   HELIX      2555   2570
FT   STRAND     2572   2574
FT   STRAND     2578   2582
FT   STRAND     2586   2588
FT   STRAND     2601   2605
FT   HELIX      2607   2629
FT   HELIX      2630   2632
FT   HELIX      2634   2636
FT   HELIX      2639   2651
FT   STRAND     2653   2661
FT   HELIX      2666   2669
FT   HELIX      2672   2683
FT   HELIX      2689   2701
FT   TURN       2702   2704
FT   STRAND     2706   2709
FT   STRAND     2715   2719
FT   HELIX      2729   2748
FT   STRAND     2751   2758
FT   STRAND     2761   2767
FT   HELIX      2771   2787
FT   STRAND     2792   2794
FT   HELIX      2802   2804
FT   STRAND     2810   2816
FT   STRAND     2822   2827
FT   HELIX      2831   2842
FT   STRAND     2846   2849
FT   HELIX      2850   2856
FT   TURN       2857   2859
FT   HELIX      2861   2865
FT   HELIX      2867   2878
FT   STRAND     2885   2889
FT   STRAND     2892   2896
FT   HELIX      2898   2900
FT   HELIX      2901   2909
FT   HELIX      2911   2914
FT   HELIX      2921   2934
FT   HELIX      2939   2956
FT   HELIX      2958   2967
FT   HELIX      2969   2971
FT   STRAND     2972   2974
FT   HELIX      2982   2985
FT   HELIX      2994   2996
SQ   SEQUENCE   3033 AA;  329169 MW;  F957F5C1A273BE9E CRC64;
     MSTNPKPQRK TKRNTNRRPQ DVKFPGGGQI VGGVYLLPRR GPRLGVRATR KTSERSQPRG
     RRQPIPKDRR STGKSWGKPG YPWPLYGNEG LGWAGWLLSP RGSRPSWGPN DPRHRSRNVG
     KVIDTLTCGF ADLMGYIPVV GAPLGGVARA LAHGVRVLED GVNFATGNLP GCSFSIFLLA
     LLSCITTPVS AAEVKNISTG YMVTNDCTND SITWQLQAAV LHVPGCVPCE KVGNTSRCWI
     PVSPNVAVQQ PGALTQGLRT HIDMVVMSAT LCSALYVGDL CGGVMLAAQM FIVSPQHHWF
     VQDCNCSIYP GTITGHRMAW DMMMNWSPTA TMILAYAMRV PEVIIDIIGG AHWGVMFGLA
     YFSMQGAWAK VVVILLLAAG VDAQTHTVGG STAHNARTLT GMFSLGARQK IQLINTNGSW
     HINRTALNCN DSLHTGFLAS LFYTHSFNSS GCPERMSACR SIEAFRVGWG ALQYEDNVTN
     PEDMRPYCWH YPPRQCGVVS ASSVCGPVYC FTPSPVVVGT TDRLGAPTYT WGENETDVFL
     LNSTRPPQGS WFGCTWMNST GYTKTCGAPP CRIRADFNAS MDLLCPTDCF RKHPDTTYIK
     CGSGPWLTPR CLIDYPYRLW HYPCTVNYTI FKIRMYVGGV EHRLTAACNF TRGDRCNLED
     RDRSQLSPLL HSTTEWAILP CTYSDLPALS TGLLHLHQNI VDVQFMYGLS PALTKYIVRW
     EWVVLLFLLL ADARVCACLW MLILLGQAEA ALEKLVVLHA ASAASCNGFL YFVIFFVAAW
     YIKGRVVPLA TYSLTGLWSF GLLLLALPQQ AYAYDASVHG QIGAALLVLI TLFTLTPGYK
     TLLSRFLWWL CYLLTLAEAM VQEWAPPMQV RGGRDGIIWA VAIFCPGVVF DITKWLLAVL
     GPAYLLKGAL TRVPYFVRAH ALLRMCTMVR HLAGGRYVQM VLLALGRWTG TYIYDHLTPM
     SDWAANGLRD LAVAVEPIIF SPMEKKVIVW GAETAACGDI LHGLPVSARL GREVLLGPAD
     GYTSKGWSLL APITAYAQQT RGLLGTIVVS MTGRDKTEQA GEIQVLSTVT QSFLGTTISG
     VLWTVYHGAG NKTLAGSRGP VTQMYSSAEG DLVGWPSPPG TKSLEPCTCG AVDLYLVTRN
     ADVIPARRRG DKRGALLSPR PLSTLKGSSG GPVLCPRGHA VGVFRAAVCS RGVAKSIDFI
     PVETLDIVTR SPTFSDNSTP PAVPQTYQVG YLHAPTGSGK STKVPVAYAA QGYKVLVLNP
     SVAATLGFGA YLSKAHGINP NIRTGVRTVT TGAPITYSTY GKFLADGGCA GGAYDIIICD
     ECHAVDSTTI LGIGTVLDQA ETAGVRLTVL ATATPPGSVT TPHPNIEEVA LGQEGEIPFY
     GRAIPLSYIK GGRHLIFCHS KKKCDELAAA LRGMGLNAVA YYRGLDVSVI PTQGDVVVVA
     TDALMTGFTG DFDSVIDCNV AVTQVVDFSL DPTFTITTQT VPQDAVSRSQ RRGRTGRGRL
     GIYRYVSTGE RASGMFDSVV LCECYDAGAA WYELTPAETT VRLRAYFNTP GLPVCQDHLE
     FWEAVFTGLT HIDAHFLSQT KQSGENFAYL TAYQATVCAR AKAPPPSWDV MWKCLTRLKP
     TLVGPTPLLY RLGSVTNEVT LTHPVTKYIA TCMQADLEVM TSTWVLAGGV LAAVAAYCLA
     TGCVCIIGRL HVNQRAVVAP DKEVLYEAFD EMEECASRAA LIEEGQRIAE MLKSKIQGLL
     QQASKQAQDI QPAVQASWPK VEQFWAKHMW NFISGIQYLA GLSTLPGNPA VASMMAFSAA
     LTSPLSTSTT ILLNILGGWL ASQIAPPAGA TGFVVSGLVG AAVGSIGLGK VLVDILAGYG
     AGISGALVAF KIMSGEKPSM EDVVNLLPGI LSPGALVVGV ICAAILRRHV GPGEGAVQWM
     NRLIAFASRG NHVAPTHYVT ESDASQRVTQ LLGSLTITSL LRRLHNWITE DCPIPCSGSW
     LRDVWDWVCT ILTDFKNWLT SKLFPKMPGL PFISCQKGYK GVWAGTGIMT TRCPCGANIS
     GNVRLGSMRI TGPKTCMNIW QGTFPINCYT EGQCVPKPAP NFKIAIWRVA ASEYAEVTQH
     GSYHYITGLT TDNLKVPCQL PSPEFFSWVD GVQIHRFAPI PKPFFRDEVS FCVGLNSFVV
     GSQLPCDPEP DTDVLTSMLT DPSHITAETA ARRLARGSPP SEASSSASQL SAPSLRATCT
     THGKAYDVDM VDANLFMGGD VTRIESESKV VVLDSLDPMV EERSDLEPSI PSEYMLPKKR
     FPPALPAWAR PDYNPPLVES WKRPDYQPAT VAGCALPPPK KTPTPPPRRR RTVGLSESSI
     ADALQQLAIK SFGQPPPSGD SGLSTGADAA DSGSRTPPDE LALSETGSIS SMPPLEGEPG
     DPDLEPEQVE LQPPPQGGVV TPGSGSGSWS TCSEEDDSVV CCSMSYSWTG ALITPCSPEE
     EKLPINPLSN SLLRYHNKVY CTTSKSASLR AKKVTFDRMQ ALDAHYDSVL KDIKLAASKV
     TARLLTLEEA CQLTPPHSAR SKYGFGAKEV RSLSGRAVNH IKSVWKDLLE DTQTPIPTTI
     MAKNEVFCVD PTKGGKKAAR LIVYPDLGVR VCEKMALYDI TQKLPQAVMG ASYGFQYSPA
     QRVEFLLKAW AEKKDPMGFS YDTRCFDSTV TERDIRTEES IYRACSLPEE AHTAIHSLTE
     RLYVGGPMFN SKGQTCGYRR CRASGVLTTS MGNTITCYVK ALAACKAAGI IAPTMLVCGD
     DLVVISESQG TEEDERNLRA FTEAMTRYSA PPGDPPRPEY DLELITSCSS NVSVALGPQG
     RRRYYLTRDP TTPIARAAWE TVRHSPVNSW LGNIIQYAPT IWARMVLMTH FFSILMAQDT
     LDQNLNFEMY GAVYSVSPLD LPAIIERLHG LDAFSLHTYT PHELTRVASA LRKLGAPPLR
     AWKSRARAVR ASLISRGGRA AVCGRYLFNW AVKTKLKLTP LPEARLLDLS SWFTVGAGGG
     DIYHSVSRAR PRLLLLGLLL LFVGVGLFLL PAR
//
ID   POLG_HCVJ8              Reviewed;        3033 AA.
AC   P26661;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 106.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 2b (isolate HC-J8) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=11115;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=92230232; PubMed=1314459; DOI=10.1016/0042-6822(92)90762-E;
RA   Okamoto H., Kurai K., Okada S., Yamamoto K., Lizuka H., Tanaka T.,
RA   Fukuda S., Tsuda F., Mishiro S.;
RT   "Full-length sequence of a hepatitis C virus genome having poor
RT   homology to reported isolates: comparative study of four distinct
RT   genotypes.";
RL   Virology 188:331-341(1992).
RN   [2]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [3]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [4]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain a highly variable region called hypervariable
CC       region 1 (HVR1). E2 also contains two segments involved in CD81-
CC       binding. HVR1 is implicated in the SCARB1-mediated cell entry.
CC       CD81-binding regions may be involved in sensitivity and/or
CC       resistance to IFN-alpha therapy (By similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A seems to be intrinsically disordered and
CC       interacts with NS5B and host PKR (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D10988; BAA01761.1; -; Genomic_RNA.
DR   PIR; A40250; GNWVJ8.
DR   PDB; 1XCQ; X-ray; 3.50 A; P/Q/S=2-44.
DR   PDB; 1XCT; X-ray; 3.05 A; P/Q=2-44.
DR   PDB; 1XF5; X-ray; 2.60 A; P/Q=2-44.
DR   PDB; 3GSZ; X-ray; 1.90 A; A/B=2443-3005.
DR   PDB; 3HVO; X-ray; 2.00 A; A/B=2443-3005.
DR   PDBsum; 1XCQ; -.
DR   PDBsum; 1XCT; -.
DR   PDBsum; 1XF5; -.
DR   PDBsum; 3GSZ; -.
DR   PDBsum; 3HVO; -.
DR   SMR; P26661; 906-1030, 1033-1661, 1977-2007, 2012-2174.
DR   euHCVdb; D10988; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; FALSE_NEG.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Disulfide bond; Envelope protein; Fusion protein;
KW   Glycoprotein; Helicase; Host cell membrane; Host cytoplasm;
KW   Host endoplasmic reticulum; Host lipid droplet; Host membrane;
KW   Host mitochondrion; Host nucleus; Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000037625.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000037626.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000037627.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000037628.
FT   CHAIN       384    750       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000037629.
FT   CHAIN       751    813       p7 (By similarity).
FT                                /FTId=PRO_0000037630.
FT   CHAIN       814   1030       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000037631.
FT   CHAIN      1031   1661       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000037632.
FT   CHAIN      1662   1715       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000037633.
FT   CHAIN      1716   1976       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000037634.
FT   CHAIN      1977   2442       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000037635.
FT   CHAIN      2443   3033       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000037636.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    729       Lumenal (Potential).
FT   TRANSMEM    730    750       Potential.
FT   TOPO_DOM    751    761       Lumenal (Potential).
FT   TRANSMEM    762    782       Potential.
FT   TOPO_DOM    783    786       Cytoplasmic (Potential).
FT   TRANSMEM    787    807       Potential.
FT   TOPO_DOM    808    817       Lumenal (Potential).
FT   TRANSMEM    818    838       Potential.
FT   TOPO_DOM    839    885       Cytoplasmic (Potential).
FT   TRANSMEM    886    906       Potential.
FT   TOPO_DOM    907    932       Lumenal (Potential).
FT   TRANSMEM    933    953       Potential.
FT   TOPO_DOM    954   1661       Cytoplasmic (Potential).
FT   TRANSMEM   1662   1682       Potential.
FT   TOPO_DOM   1683   1809       Cytoplasmic (Potential).
FT   TRANSMEM   1810   1830       Potential.
FT   TOPO_DOM   1831   1832       Lumenal (Potential).
FT   TRANSMEM   1833   1853       Potential.
FT   TOPO_DOM   1854   1854       Cytoplasmic (Potential).
FT   TRANSMEM   1855   1875       Potential.
FT   TOPO_DOM   1876   1885       Lumenal (Potential).
FT   TRANSMEM   1886   1906       Potential.
FT   TOPO_DOM   1907   1976       Cytoplasmic (Potential).
FT   TOPO_DOM   1977   2006       In membrane (By similarity).
FT   TOPO_DOM   2007   3012       Cytoplasmic (Potential).
FT   TRANSMEM   3013   3033       By similarity.
FT   DOMAIN     1221   1373       Helicase ATP-binding.
FT   DOMAIN     2656   2774       RdRp catalytic.
FT   NP_BIND    1234   1241       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      385    411       HVR1 (By similarity).
FT   REGION      484    496       CD81-binding 1 (Potential).
FT   REGION      524    555       CD81-binding 2 (Potential).
FT   REGION      664    675       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1683   1694       NS3-binding (by NS4A) (Potential).
FT   REGION     2124   2332       Transcriptional activation (Potential).
FT   REGION     2124   2212       FKBP8-binding (Potential).
FT   REGION     2204   2250       Basal phosphorylation (By similarity).
FT   REGION     2214   2275       PKR-binding (Potential).
FT   REGION     2249   2306       NS4B-binding (Potential).
FT   REGION     2351   2442       Basal phosphorylation (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1320   1323       DECH box (By similarity).
FT   MOTIF      2322   2325       SH3-binding (Potential).
FT   MOTIF      2327   2335       Nuclear localization signal (Potential).
FT   COMPBIAS   1436   1439       Poly-Val.
FT   COMPBIAS   2282   2327       Pro-rich.
FT   COMPBIAS   2328   2331       Poly-Arg.
FT   COMPBIAS   3013   3021       Poly-Leu.
FT   ACT_SITE    956    956       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    976    976       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    997    997       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1087   1087       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1111   1111       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1169   1169       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1127   1127       Zinc (By similarity).
FT   METAL      1129   1129       Zinc (By similarity).
FT   METAL      1175   1175       Zinc (By similarity).
FT   METAL      1179   1179       Zinc (By similarity).
FT   METAL      2015   2015       Zinc (By similarity).
FT   METAL      2033   2033       Zinc (By similarity).
FT   METAL      2035   2035       Zinc (By similarity).
FT   METAL      2056   2056       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        191    192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        750    751       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        813    814       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1030   1031       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1661   1662       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1715   1716       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1976   1977       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2442   2443       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2198   2198       Phosphoserine; by host; in p56 (By
FT                                similarity).
FT   MOD_RES    2201   2201       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2205   2205       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2208   2208       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1972   1972       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   LIPID      1976   1976       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    233    233       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    299    299       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    417    417       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    423    423       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    430    430       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    448    448       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    477    477       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    534    534       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    542    542       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    558    558       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    578    578       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    627    627       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    649    649       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2118   2166       By similarity.
FT   STRAND       18     20
FT   STRAND       23     25
FT   HELIX        33     35
SQ   SEQUENCE   3033 AA;  330182 MW;  1A173E7E3381FD1A CRC64;
     MSTNPKPQRK TKRNTNRRPQ DVKFPGGGQI VGGVYLLPRR GPRLGVRATR KTSERSQPRG
     RRQPIPKDRR STGKSWGKPG YPWPLYGNEG CGWAGWLLSP RGSRPTWGPT DPRHRSRNLG
     RVIDTITCGF ADLMGYIPVV GAPVGGVARA LAHGVRVLED GINYATGNLP GCSFSIFLLA
     LLSCVTVPVS AVEVRNISSS YYATNDCSNN SITWQLTDAV LHLPGCVPCE NDNGTLHCWI
     QVTPNVAVKH RGALTRSLRT HVDMIVMAAT ACSALYVGDV CGAVMILSQA FMVSPQRHNF
     TQECNCSIYQ GHITGHRMAW DMMLSWSPTL TMILAYAARV PELVLEIIFG GHWGVVFGLA
     YFSMQGAWAK VIAILLLVAG VDATTYSSGQ EAGRTVAGFA GLFTTGAKQN LYLINTNGSW
     HINRTALNCN DSLQTGFLAS LFYTHKFNSS GCPERLSSCR GLDDFRIGWG TLEYETNVTN
     DGDMRPYCWH YPPRPCGIVP ARTVCGPVYC FTPSPVVVGT TDKQGVPTYT WGENETDVFL
     LNSTRPPRGA WFGCTWMNGT GFTKTCGAPP CRIRKDYNST IDLLCPTDCF RKHPDATYLK
     CGAGPWLTPR CLVDYPYRLW HYPCTVNFTI FKARMYVGGV EHRFSAACNF TRGDRCRLED
     RDRGQQSPLL HSTTEWAVLP CSFSDLPALS TGLLHLHQNI VDVQYLYGLS PALTRYIVKW
     EWVILLFLLL ADARICACLW MLIILGQAEA ALEKLIILHS ASAASANGPL WFFIFFTAAW
     YLKGRVVPVA TYSVLGLWSF LLLVLALPQQ AYALDAAEQG ELGLAILVII SIFTLTPAYK
     ILLSRSVWWL SYMLVLAEAQ IQQWVPPLEV RGGRDGIIWV AVILHPRLVF EVTKWLLAIL
     GPAYLLKASL LRIPYFVRAH ALLRVCTLVK HLAGARYIQM LLITIGRWTG TYIYDHLSPL
     STWAAQGLRD LAIAVEPVVF SPMEKKVIVW GAETVACGDI LHGLPVSARL GREVLLGPAD
     GYTSKGWKLL APITAYTQQT RGLLGAIVVS LTGRDKNEQA GQVQVLSSVT QTFLGTSISG
     VLWTVYHGAG NKTLAGPKGP VTQMYTSAEG DLVGWPSPPG TKSLDPCTCG AVDLYLVTRN
     ADVIPVRRKD DRRGALLSPR PLSTLKGSSG GPVLCSRGHA VGLFRAAVCA RGVAKSIDFI
     PVESLDVATR TPSFSDNSTP PAVPQSYQVG YLHAPTGSGK STKVPAAYAS QGYKVLVLNP
     SVAATLGFGA YMSKAHGINP NIRTGVRTVT TGDSITYSTY GKFIADGGCA AGAYDIIICD
     ECHSVDATTI LGIGTVLDQA ETAGVRLVVL ATATPPGTVT TPHSNIEEVA LGHEGEIPFY
     GKAIPLAFIK GGRHLIFCHS KKKCDELAAA LRGMGVNAVA YYRGLDVSVI PTQGDVVVVA
     TDALMTGYTG DFDSVIDCNV AVSQIVDFSL DPTFTITTQT VPQDAVSRSQ RRGRTGRGRL
     GVYRYVSSGE RPSGMFDSVV LCECYDAGAA WYELTPAETT VRLRAYFNTP GLPVCQDHLE
     FWEAVFTGLT HIDAHFLSQT KQGGENFAYL TAYQATVCAR AKAPPPSWDV MWKCLTRLKP
     TLTGPTPLLY RLGAVTNEVT LTHPVTKYIA TCMQADLEIM TSSWVLAGGV LAAVAAYCLA
     TGCISIIGRL HLNDRVVVAP DKEILYEAFD EMEECASKAA LIEEGQRMAE MLKSKIQGLL
     QQATRQAQDI QPAIQSSWPK LEQFWAKHMW NFISGIQYLA GLSTLPGNPA VASMMAFSAA
     LTSPLPTSTT ILLNIMGGWL ASQIAPPAGA TGFVVSGLVG AAVGSIGLGK ILVDVLAGYG
     AGISGALVAF KIMSGEKPTV EDVVNLLPAI LSPGALVVGV ICAAILRRHV GQGEGAVQWM
     NRLIAFASRG NHVAPTHYVV ESDASQRVTQ VLSSLTITSL LRRLHAWITE DCPVPCSGSW
     LQDIWDWVCS ILTDFKNWLS SKLLPKMPGI PFISCQKGYK GVWAGTGVMT TRCPCGANIS
     GHVRMGTMKI TGPKTCLNLW QGTFPINCYT EGPCVPKPPP NYKTAIWRVA ASEYVEVTQH
     GSFSYVTGLT SDNLKVPCQV PAPEFFSWVD GVQIHRFAPV PGPFFRDEVT FTVGLNSFVV
     GSQLPCDPEP DTEVLASMLT DPSHITAEAA ARRLARGSPP SQASSSASQL SAPSLKATCT
     THKTAYDCDM VDANLFMGGD VTRIESDSKV IVLDSLDSMT EVEDDREPSV PSEYLIKRRK
     FPPALPPWAR PDYNPVLIET WKRPGYEPPT VLGCALPPTP QTPVPPPRRR RAKVLTQDNV
     EGVLREMADK VLSPLQDNND SGHSTGADTG GDIVQQPSDE TAASEAGSLS SMPPLEGEPG
     DPDLEFEPVG SAPPSEGECE VIDSDSKSWS TVSDQEDSVI CCSMSYSWTG ALITPCGPEE
     EKLPINPLSN SLMRFHNKVY STTSRSASLR AKKVTFDRVQ VLDAHYDSVL QDVKRAASKV
     SARLLTVEEA CALTPPHSAK SRYGFGAKEV RSLSRRAVNH IRSVWEDLLE DQHTPIDTTI
     MAKNEVFCID PTKGGKKPAR LIVYPDLGVR VCEKMALYDI AQKLPKAIMG PSYGFQYSPA
     ERVDFLLKAW GSKKDPMGFS YDTRCFDSTV TERDIRTEES IYQACSLPQE ARTVIHSLTE
     RLYVGGPMTN SKGQSCGYRR CRASGVFTTS MGNTMTCYIK ALAACKAAGI VDPVMLVCGD
     DLVVISESQG NEEDERNLRA FTEAMTRYSA PPGDLPRPEY DLELITSCSS NVSVALDSRG
     RRRYFLTRDP TTPITRAAWE TVRHSPVNSW LGNIIQYAPT IWVRMVIMTH FFSILLAQDT
     LNQNLNFEMY GAVYSVNPLD LPAIIERLHG LEAFSLHTYS PHELSRVAAT LRKLGAPPLR
     AWKSRARAVR ASLIAQGARA AICGRYLFNW AVKTKLKLTP LPEASRLDLS GWFTVGAGGG
     DIYHSVSHAR PRLLLLCLLL LSVGVGIFLL PAR
//
ID   POLG_HCVJA              Reviewed;        3010 AA.
AC   P26662; P89966; Q81755;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 112.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 1b (isolate Japanese) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=11116;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=91088550; PubMed=2175903; DOI=10.1073/pnas.87.24.9524;
RA   Kato N., Hijikata M., Ootsuyama Y., Nakagawa M., Ohkoshi S.,
RA   Sugimura T., Shimotohno K.;
RT   "Molecular cloning of the human hepatitis C virus genome from Japanese
RT   patients with non-A, non-B hepatitis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:9524-9528(1990).
RN   [2]
RP   DISCUSSION OF SEQUENCE.
RX   MEDLINE=91192160; PubMed=1849488; DOI=10.1016/0014-5793(91)80322-T;
RA   Kato N., Hijikata M., Nakagawa M., Ootsuyama Y., Muraiso K.,
RA   Ohkoshi S., Shimotohno K.;
RT   "Molecular structure of the Japanese hepatitis C viral genome.";
RL   FEBS Lett. 280:325-328(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RA   Tanaka T.;
RL   Submitted (JAN-1997) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA] OF 723-1908, IDENTIFICATION OF BOTH
RP   PROTEASES, AND MUTAGENESIS OF CYS-922; HIS-932; HIS-952; GLU-972;
RP   GLU-980; CYS-993; GLU-1009; GLU-1058; HIS-1083; ASP-1107; CYS-1123;
RP   CYS-1125; HIS-1136; SER-1165; CYS-1171; HIS-1175; CYS-1185; GLU-1199;
RP   GLU-1202; HIS-1227 AND HIS-1229.
RX   MEDLINE=93323208; PubMed=8392606;
RA   Hijikata M., Mizushima H., Akagi T., Mori S., Kakiuchi N., Kato N.,
RA   Tanaka T., Kimura K., Shimotohno K.;
RT   "Two distinct proteinase activities required for the processing of a
RT   putative nonstructural precursor protein of hepatitis C virus.";
RL   J. Virol. 67:4665-4675(1993).
RN   [5]
RP   INHIBITION OF HEPATITIS B VIRUS GENE EXPRESSION.
RX   PubMed=8396658;
RA   Shih C.-M., Lo S.J., Miyamura T., Chen S.-Y., Lee Y.-H.W.;
RT   "Suppression of hepatitis B virus expression and replication by
RT   hepatitis C virus core protein in HuH-7 cells.";
RL   J. Virol. 67:5823-5832(1993).
RN   [6]
RP   PROTEOLYTIC PROCESSING OF POLYPROTEIN, MUTAGENESIS OF HIS-1083;
RP   ASP-1107 AND SER-1165, AND IDENTIFICATION OF THE SERINE PROTEASE.
RX   PubMed=8389908;
RA   Bartenschlager R., Ahlborn-Laake L., Mous J., Jacobsen H.;
RT   "Nonstructural protein 3 of the hepatitis C virus encodes a serine-
RT   type proteinase required for cleavage at the NS3/4 and NS4/5
RT   junctions.";
RL   J. Virol. 67:3835-3844(1993).
RN   [7]
RP   PHOSPHORYLATION OF NS5A.
RX   MEDLINE=95091744; PubMed=7999043; DOI=10.1006/bbrc.1994.2667;
RA   Kaneko T., Tanji Y., Satoh S., Hijikata M., Asabe S., Kimura K.,
RA   Shimotohno K.;
RT   "Production of two phosphoproteins from the NS5A region of the
RT   hepatitis C viral genome.";
RL   Biochem. Biophys. Res. Commun. 205:320-326(1994).
RN   [8]
RP   MUTAGENESIS OF SER-2194; SER-2197; SER-2200; SER-2201; SER-2202;
RP   SER-2204; SER-2207; SER-2210 AND SER-2221.
RX   PubMed=7769656;
RA   Tanji Y., Kaneko T., Satoh S., Shimotohno K.;
RT   "Phosphorylation of hepatitis C virus-encoded nonstructural protein
RT   NS5A.";
RL   J. Virol. 69:3980-3986(1995).
RN   [9]
RP   FUNCTION OF NS5A.
RX   MEDLINE=96127954; PubMed=8531962; DOI=10.1056/NEJM199601113340203;
RA   Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T.,
RA   Yamamoto C., Ogura Y., Izumi N., Marumo F., Sato C.;
RT   "Mutations in the nonstructural protein 5A gene and response to
RT   interferon in patients with chronic hepatitis C virus 1b infection.";
RL   N. Engl. J. Med. 334:77-81(1996).
RN   [10]
RP   FUNCTION OF NS5A.
RX   PubMed=9343247;
RA   Kato N., Lan K.H., Ono-Nita S.K., Shiratori Y., Omata M.;
RT   "Hepatitis C virus nonstructural region 5A protein is a potent
RT   transcriptional activator.";
RL   J. Virol. 71:8856-8859(1997).
RN   [11]
RP   ZINC-BINDING REGION OF SERINE PROTEASE NS3, COFACTOR, AND MUTAGENESIS
RP   OF CYS-1042; CYS-1073; CYS-1078; HIS-1083; HIS-1136; SER-1165;
RP   HIS-1175; CYS-1185; HIS-1227 AND HIS-1229.
RX   PubMed=9060645;
RA   Stempniak M., Hostomska Z., Nodes B.R., Hostomsky Z.;
RT   "The NS3 proteinase domain of hepatitis C virus is a zinc-containing
RT   enzyme.";
RL   J. Virol. 71:2881-2886(1997).
RN   [12]
RP   SUBCELLULAR LOCATION OF CORE PROTEIN.
RX   PubMed=9621068;
RA   Yasui K., Wakita T., Tsukiyama-Kohara K., Funahashi S., Ichikawa M.,
RA   Kajita T., Moradpour D., Wands J.R., Kohara M.;
RT   "The native form and maturation process of hepatitis C virus core
RT   protein.";
RL   J. Virol. 72:6048-6055(1998).
RN   [13]
RP   DOMAIN ISDR REGION.
RX   PubMed=9525599;
RA   Pawlotsky J.-M., Germanidis G., Neumann A.U., Pellerin M.,
RA   Frainais P.-O., Dhumeaux D.;
RT   "Interferon resistance of hepatitis C virus genotype 1b: relationship
RT   to nonstructural 5A gene quasispecies mutations.";
RL   J. Virol. 72:2795-2805(1998).
RN   [14]
RP   SUBCELLULAR LOCATION OF NS5A.
RX   PubMed=10793006; DOI=10.1006/viro.2000.0287;
RA   Satoh S., Hirota M., Noguchi T., Hijikata M., Handa H., Shimotohno K.;
RT   "Cleavage of hepatitis C virus nonstructural protein 5A by a caspase-
RT   like protease(s) in mammalian cells.";
RL   Virology 270:476-487(2000).
RN   [15]
RP   OLIGOMERIZATION OF NS5B.
RX   PubMed=11907226; DOI=10.1128/JVI.76.8.3865-3872.2002;
RA   Wang Q.M., Hockman M.A., Staschke K., Johnson R.B., Case K.A., Lu J.,
RA   Parsons S., Zhang F., Rathnachalam R., Kirkegaard K., Colacino J.M.;
RT   "Oligomerization and cooperative RNA synthesis activity of hepatitis C
RT   virus RNA-dependent RNA polymerase.";
RL   J. Virol. 76:3865-3872(2002).
RN   [16]
RP   INHIBITION OF P7 BY AMANTADINE.
RX   MEDLINE=22448611; PubMed=12560074; DOI=10.1016/S0014-5793(02)03851-6;
RA   Griffin S.D., Beales L.P., Clarke D.S., Worsfold O., Evans S.D.,
RA   Jaeger J., Harris M.P., Rowlands D.J.;
RT   "The p7 protein of hepatitis C virus forms an ion channel that is
RT   blocked by the antiviral drug, Amantadine.";
RL   FEBS Lett. 535:34-38(2003).
RN   [17]
RP   INTERACTION OF CORE PROTEIN WITH HUMAN SP110.
RX   PubMed=14559998; DOI=10.1128/MCB.23.21.7498-7509.2003;
RA   Watashi K., Hijikata M., Tagawa A., Doi T., Marusawa H.,
RA   Shimotohno K.;
RT   "Modulation of retinoid signaling by a cytoplasmic viral protein via
RT   sequestration of Sp110b, a potent transcriptional corepressor of
RT   retinoic acid receptor, from the nucleus.";
RL   Mol. Cell. Biol. 23:7498-7509(2003).
RN   [18]
RP   CLEAVAGE OF CORE PROTEIN BY THE SIGNAL PEPTIDASE, AND MUTAGENESIS OF
RP   LEU-139; VAL-140; LEU-144; ILE-176; PHE-177; LEU-178; LEU-179;
RP   LEU-181; LEU-182; SER-183 AND CYS-184.
RX   PubMed=15163730; DOI=10.1128/JVI.78.12.6370-6380.2004;
RA   Okamoto K., Moriishi K., Miyamura T., Matsuura Y.;
RT   "Intramembrane proteolysis and endoplasmic reticulum retention of
RT   hepatitis C virus core protein.";
RL   J. Virol. 78:6370-6380(2004).
RN   [19]
RP   FUNCTION OF CORE PROTEIN.
RX   PubMed=15760888; DOI=10.1074/jbc.M501826200;
RA   Boni S., Lavergne J.-P., Boulant S., Cahour A.;
RT   "Hepatitis C virus core protein acts as a trans-modulating factor on
RT   internal translation initiation of the viral RNA.";
RL   J. Biol. Chem. 280:17737-17748(2005).
RN   [20]
RP   INTERACTION OF CORE PROTEIN WITH HUMAN STAT1.
RX   PubMed=15825084; DOI=10.1053/j.gastro.2005.02.006;
RA   Lin W., Choe W.H., Hiasa Y., Kamegaya Y., Blackard J.T., Schmidt E.V.,
RA   Chung R.T.;
RT   "Hepatitis C virus expression suppresses interferon signaling by
RT   degrading STAT1.";
RL   Gastroenterology 128:1034-1041(2005).
RN   [21]
RP   SUBCELLULAR LOCATION OF CORE PROTEIN.
RX   PubMed=15613354; DOI=10.1128/JVI.79.2.1271-1281.2005;
RA   Suzuki R., Sakamoto S., Tsutsumi T., Rikimaru A., Tanaka K.,
RA   Shimoike T., Moriishi K., Iwasaki T., Mizumoto K., Matsuura Y.,
RA   Miyamura T., Suzuki T.;
RT   "Molecular determinants for subcellular localization of hepatitis C
RT   virus core protein.";
RL   J. Virol. 79:1271-1281(2005).
RN   [22]
RP   CHARACTERIZATION OF NS5A.
RX   PubMed=16126720; DOI=10.1074/jbc.M508175200;
RA   Huang L., Hwang J., Sharma S.D., Hargittai M.R., Chen Y., Arnold J.J.,
RA   Raney K.D., Cameron C.E.;
RT   "Hepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding
RT   protein.";
RL   J. Biol. Chem. 280:36417-36428(2005).
RN   [23]
RP   INTERACTION OF NS5A AND NS5B WITH HUMAN VAPB.
RX   PubMed=16227268; DOI=10.1128/JVI.79.21.13473-13482.2005;
RA   Hamamoto I., Nishimura Y., Okamoto T., Aizaki H., Liu M., Mori Y.,
RA   Abe T., Suzuki T., Lai M.M., Miyamura T., Moriishi K., Matsuura Y.;
RT   "Human VAP-B is involved in hepatitis C virus replication through
RT   interaction with NS5A and NS5B.";
RL   J. Virol. 79:13473-13482(2005).
RN   [24]
RP   INTERACTION OF CORE PROTEIN WITH HUMAN STAT1.
RX   PubMed=16940534; DOI=10.1128/JVI.00459-06;
RA   Lin W., Kim S.S., Yeung E., Kamegaya Y., Blackard J.T., Kim K.A.,
RA   Holtzman M.J., Chung R.T.;
RT   "Hepatitis C virus core protein blocks interferon signaling by
RT   interaction with the STAT1 SH2 domain.";
RL   J. Virol. 80:9226-9235(2006).
RN   [25]
RP   INTERACTION OF NS5A WITH HUMAN FKBP8, AND SUBCELLULAR LOCATION OF
RP   NS5A.
RX   PubMed=16844119; DOI=10.1016/j.febslet.2006.07.002;
RA   Wang J., Tong W., Zhang X., Chen L., Yi Z., Pan T., Hu Y., Xiang L.,
RA   Yuan Z.;
RT   "Hepatitis C virus non-structural protein NS5A interacts with FKBP38
RT   and inhibits apoptosis in Huh7 hepatoma cells.";
RL   FEBS Lett. 580:4392-4400(2006).
RN   [26]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [27]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [28]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1027-1213.
RX   MEDLINE=20167193; PubMed=10702283; DOI=10.1074/jbc.275.10.7152;
RA   Di Marco S., Rizzi M., Volpari C., Walsh M.A., Narjes F.,
RA   Colarusso S., De Francesco R., Matassa V.G., Sollazzo M.;
RT   "Inhibition of the hepatitis C virus NS3/4A protease. The crystal
RT   structures of two protease-inhibitor complexes.";
RL   J. Biol. Chem. 275:7152-7157(2000).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1027-1213 IN COMPLEX WITH A
RP   PEPTIDOMIMETIC INHIBITOR.
RX   PubMed=15588076; DOI=10.1021/jm049435d;
RA   Ontoria J.M., Di Marco S., Conte I., Di Francesco M.E., Gardelli C.,
RA   Koch U., Matassa V.G., Poma M., Steinkuehler C., Volpari C.,
RA   Harper S.;
RT   "The design and enzyme-bound crystal structure of indoline based
RT   peptidomimetic inhibitors of hepatitis C virus NS3 protease.";
RL   J. Med. Chem. 47:6443-6446(2004).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex.
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication.
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain.
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain.
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions.
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and transcription. In addition to
CC       blocking the formation of phosphorylated STAT1, the core protein
CC       also promotes ubiquitin-mediated proteasome-dependent degradation
CC       of STAT1. Interacts and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein. Host cytoplasm,
CC       host perinuclear region. Host mitochondrion. Note=Host membrane
CC       insertion occurs after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain two highly variable regions called
CC       hypervariable region 1 and 2 (HVR1 and HVR2). E2 also contain two
CC       segments involved in CD81-binding. HVR1 is implicated in the
CC       SCARB1-mediated cell entry. HVR2 and CD81-binding regions may be
CC       involved in sensitivity and/or resistance to IFN-alpha therapy (By
CC       similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A contains a variable region called interferon
CC       sensitivity determining region (ISDR) and seems to be
CC       intrinsically disordered and interacts with NS5B and host PKR. The
CC       C-terminus of NS5A contains a variable region called variable
CC       region 3 (V3). ISDR and V3 may be involved in sensitivity and/or
CC       resistance to IFN-alpha therapy.
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3.
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication.
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding.
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D90208; BAA14233.1; -; Genomic_RNA.
DR   EMBL; D89872; BAA14035.1; -; Genomic_RNA.
DR   EMBL; D11397; BAA20975.1; -; Genomic_RNA.
DR   PIR; A39253; GNWVCJ.
DR   PDB; 1DXP; X-ray; 2.40 A; A/B=1027-1213.
DR   PDB; 1DY8; X-ray; 2.40 A; A/B=1027-1213.
DR   PDB; 1DY9; X-ray; 2.10 A; A/B=1027-1213.
DR   PDB; 1W3C; X-ray; 2.30 A; A/B=1027-1213.
DR   PDB; 2K8J; NMR; -; X=781-809.
DR   PDBsum; 1DXP; -.
DR   PDBsum; 1DY8; -.
DR   PDBsum; 1DY9; -.
DR   PDBsum; 1W3C; -.
DR   PDBsum; 2K8J; -.
DR   euHCVdb; D89872; -.
DR   euHCVdb; D90208; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; FALSE_NEG.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Disulfide bond; Envelope protein; Fusion protein;
KW   Glycoprotein; Helicase; Host cell membrane; Host cytoplasm;
KW   Host endoplasmic reticulum; Host lipid droplet; Host membrane;
KW   Host mitochondrion; Host nucleus; Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000037637.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000037638.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000037639.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000037640.
FT   CHAIN       384    746       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000037641.
FT   CHAIN       747    809       p7 (By similarity).
FT                                /FTId=PRO_0000037642.
FT   CHAIN       810   1026       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000037643.
FT   CHAIN      1027   1657       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000037644.
FT   CHAIN      1658   1711       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000037645.
FT   CHAIN      1712   1972       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000037646.
FT   CHAIN      1973   2419       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000037647.
FT   CHAIN      2420   3010       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000037648.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    725       Lumenal (Potential).
FT   TRANSMEM    726    746       Potential.
FT   TOPO_DOM    747    757       Lumenal (Potential).
FT   TRANSMEM    758    778       Potential.
FT   TOPO_DOM    779    782       Cytoplasmic (Potential).
FT   TRANSMEM    783    803       Potential.
FT   TOPO_DOM    804    813       Lumenal (Potential).
FT   TRANSMEM    814    834       Potential.
FT   TOPO_DOM    835    881       Cytoplasmic (Potential).
FT   TRANSMEM    882    902       Potential.
FT   TOPO_DOM    903    928       Lumenal (Potential).
FT   TRANSMEM    929    949       Potential.
FT   TOPO_DOM    950   1657       Cytoplasmic (Potential).
FT   TRANSMEM   1658   1678       Potential.
FT   TOPO_DOM   1679   1805       Cytoplasmic (Potential).
FT   TRANSMEM   1806   1826       Potential.
FT   TOPO_DOM   1827   1828       Lumenal (Potential).
FT   TRANSMEM   1829   1849       Potential.
FT   TOPO_DOM   1850   1850       Cytoplasmic (Potential).
FT   TRANSMEM   1851   1871       Potential.
FT   TOPO_DOM   1872   1881       Lumenal (Potential).
FT   TRANSMEM   1882   1902       Potential.
FT   TOPO_DOM   1903   1972       Cytoplasmic (Potential).
FT   TOPO_DOM   1973   2002       In membrane (By similarity).
FT   TOPO_DOM   2003   2989       Cytoplasmic (Potential).
FT   TRANSMEM   2990   3010       By similarity.
FT   DOMAIN     1217   1369       Helicase ATP-binding.
FT   DOMAIN     2633   2751       RdRp catalytic.
FT   NP_BIND    1230   1237       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1.
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      385    411       HVR1 (By similarity).
FT   REGION      475    481       HVR2 (By similarity).
FT   REGION      482    494       CD81-binding 1 (Potential).
FT   REGION      522    553       CD81-binding 2 (Potential).
FT   REGION      660    671       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD).
FT   REGION     1679   1690       NS3-binding (by NS4A) (Potential).
FT   REGION     2120   2332       Transcriptional activation (Potential).
FT   REGION     2120   2208       FKBP8-binding (Potential).
FT   REGION     2200   2250       Basal phosphorylation.
FT   REGION     2210   2275       PKR-binding (Potential).
FT   REGION     2210   2249       ISDR (By similarity).
FT   REGION     2249   2306       NS4B-binding (Potential).
FT   REGION     2351   2419       Basal phosphorylation.
FT   REGION     2354   2377       V3 (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1316   1319       DECH box.
FT   MOTIF      2322   2325       SH3-binding (Potential).
FT   MOTIF      2327   2335       Nuclear localization signal (Potential).
FT   COMPBIAS    796    803       Poly-Leu.
FT   COMPBIAS   1432   1435       Poly-Val.
FT   COMPBIAS   2282   2327       Pro-rich.
FT   COMPBIAS   2993   2998       Poly-Leu.
FT   ACT_SITE    952    952       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    972    972       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    993    993       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1083   1083       Charge relay system; for serine protease
FT                                NS3 activity.
FT   ACT_SITE   1107   1107       Charge relay system; for serine protease
FT                                NS3 activity.
FT   ACT_SITE   1165   1165       Charge relay system; for serine protease
FT                                NS3 activity.
FT   METAL      1123   1123       Zinc.
FT   METAL      1125   1125       Zinc.
FT   METAL      1171   1171       Zinc.
FT   METAL      1175   1175       Zinc.
FT   METAL      2011   2011       Zinc.
FT   METAL      2029   2029       Zinc.
FT   METAL      2031   2031       Zinc.
FT   METAL      2052   2052       Zinc.
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        191    192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        746    747       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        809    810       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1026   1027       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1657   1658       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1711   1712       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1972   1973       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2419   2420       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2194   2194       Phosphoserine; by host; in p56.
FT   MOD_RES    2197   2197       Phosphoserine; by host; in p58.
FT   MOD_RES    2201   2201       Phosphoserine; by host; in p58.
FT   MOD_RES    2204   2204       Phosphoserine; by host; in p58.
FT   LIPID      1968   1968       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   LIPID      1972   1972       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    250    250       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    417    417       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    423    423       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    430    430       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    448    448       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    532    532       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    556    556       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    576    576       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    623    623       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    645    645       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2114   2162       By similarity.
FT   VARIANT     464    464       E -> K.
FT   VARIANT     475    479       DMPES -> VVPNI.
FT   VARIANT     492    492       R -> Q.
FT   VARIANT     522    524       FGA -> SGV.
FT   VARIANT     538    540       LLS -> VLN.
FT   VARIANT     580    580       V -> I.
FT   VARIANT     608    608       M -> L.
FT   VARIANT     622    622       V -> I.
FT   VARIANT     626    626       V -> I.
FT   VARIANT     674    674       I -> V.
FT   VARIANT     694    694       R -> Q.
FT   VARIANT     705    705       I -> V.
FT   VARIANT     708    708       A -> V.
FT   VARIANT     712    713       FA -> VV.
FT   VARIANT     719    719       I -> V.
FT   VARIANT     906    906       I -> M.
FT   VARIANT     983    983       L -> I.
FT   VARIANT    1140   1140       V -> I.
FT   VARIANT    1158   1158       I -> V.
FT   VARIANT    1252   1252       L -> R.
FT   VARIANT    1297   1297       C -> G.
FT   VARIANT    1323   1323       S -> W.
FT   VARIANT    1477   1477       L -> V.
FT   VARIANT    1485   1485       A -> S.
FT   VARIANT    1536   1536       S -> T.
FT   VARIANT    1583   1583       L -> F.
FT   VARIANT    1635   1635       V -> I.
FT   VARIANT    1644   1645       YI -> FV.
FT   VARIANT    1695   1695       I -> V.
FT   VARIANT    1703   1703       Q -> R.
FT   VARIANT    1710   1710       E -> A.
FT   VARIANT    1713   1713       S -> P.
FT   VARIANT    1753   1753       K -> R.
FT   VARIANT    1759   1759       V -> A.
FT   VARIANT    1839   1839       V -> I.
FT   VARIANT    1873   1873       M -> A.
FT   VARIANT    1876   1876       T -> A.
FT   VARIANT    1896   1896       V -> I.
FT   VARIANT    1978   1978       K -> R.
FT   VARIANT    1989   1989       S -> T.
FT   VARIANT    2002   2002       R -> K.
FT   VARIANT    2006   2006       L -> V.
FT   VARIANT    2009   2009       L -> F.
FT   VARIANT    2093   2093       V -> I.
FT   VARIANT    2125   2125       V -> L.
FT   VARIANT    2136   2138       VCK -> ACR.
FT   VARIANT    2143   2146       EEVV -> VDVT.
FT   VARIANT    2190   2190       L -> P.
FT   VARIANT    2196   2196       P -> S.
FT   VARIANT    2199   2199       A -> G.
FT   VARIANT    2199   2199       A -> V.
FT   VARIANT    2200   2200       S -> T.
FT   VARIANT    2204   2204       S -> R.
FT   VARIANT    2205   2205       Q -> H.
FT   VARIANT    2208   2208       A -> T.
FT   VARIANT    2209   2209       P -> H.
FT   VARIANT    2209   2209       P -> L.
FT   VARIANT    2209   2209       P -> S.
FT   VARIANT    2210   2210       S -> P.
FT   VARIANT    2211   2211       L -> S.
FT   VARIANT    2212   2212       K -> E.
FT   VARIANT    2212   2212       K -> R.
FT   VARIANT    2214   2214       T -> A.
FT   VARIANT    2215   2215       C -> Y.
FT   VARIANT    2216   2216       T -> I.
FT   VARIANT    2217   2217       T -> A.
FT   VARIANT    2218   2218       H -> A.
FT   VARIANT    2218   2218       H -> L.
FT   VARIANT    2218   2218       H -> Q.
FT   VARIANT    2218   2218       H -> R.
FT   VARIANT    2218   2218       H -> T.
FT   VARIANT    2219   2219       H -> R.
FT   VARIANT    2219   2219       H -> Y.
FT   VARIANT    2220   2220       D -> G.
FT   VARIANT    2222   2222       P -> L.
FT   VARIANT    2222   2222       P -> S.
FT   VARIANT    2223   2223       D -> G.
FT   VARIANT    2224   2224       A -> V.
FT   VARIANT    2225   2225       D -> G.
FT   VARIANT    2225   2225       D -> N.
FT   VARIANT    2227   2227       I -> V.
FT   VARIANT    2228   2228       E -> A.
FT   VARIANT    2228   2228       E -> D.
FT   VARIANT    2228   2228       E -> G.
FT   VARIANT    2228   2228       E -> K.
FT   VARIANT    2230   2230       N -> D.
FT   VARIANT    2230   2230       N -> S.
FT   VARIANT    2233   2233       W -> R.
FT   VARIANT    2259   2259       I -> L.
FT   VARIANT    2262   2262       V -> E.
FT   VARIANT    2268   2268       I -> V.
FT   VARIANT    2271   2271       P -> A.
FT   VARIANT    2278   2279       PR -> SK.
FT   VARIANT    2303   2303       D -> S.
FT   VARIANT    2310   2310       V -> A.
FT   VARIANT    2318   2321       STKA -> PTTG.
FT   VARIANT    2329   2329       R -> K.
FT   VARIANT    2367   2367       G -> A.
FT   VARIANT    2372   2372       A -> T.
FT   VARIANT    2379   2379       G -> E.
FT   VARIANT    2382   2382       V -> I.
FT   VARIANT    2414   2416       EDV -> DDI.
FT   VARIANT    2673   2673       R -> K.
FT   VARIANT    2681   2681       V -> I.
FT   VARIANT    2754   2754       A -> S.
FT   VARIANT    2757   2757       A -> V.
FT   VARIANT    2950   2950       K -> R.
FT   MUTAGEN     139    139       L->A: Complete loss of core protein
FT                                processing by host signal peptidase, no
FT                                effect on the cleavage at core-E1
FT                                junction; when associated with A-140 and
FT                                A-144.
FT   MUTAGEN     140    140       V->A: Complete loss of core protein
FT                                processing by host signal peptidase, no
FT                                effect on the cleavage at core-E1
FT                                junction; when associated with A-139 and
FT                                A-144.
FT   MUTAGEN     144    144       L->A: Complete loss of core protein
FT                                processing by host signal peptidase, no
FT                                effect on the cleavage at core-E1
FT                                junction; when associated with A-139 and
FT                                A-140.
FT   MUTAGEN     176    176       I->A: Complete loss of core protein
FT                                processing by host signal peptidase; when
FT                                associated with L-177.
FT   MUTAGEN     177    177       F->L: Complete loss of core protein
FT                                processing by host signal peptidase; when
FT                                associated with A-176.
FT   MUTAGEN     178    178       L->V: No effect on processing of the core
FT                                protein; when associated with V-179.
FT   MUTAGEN     179    179       L->V: No effect on processing of the core
FT                                protein; when associated with V-178.
FT   MUTAGEN     181    181       L->V: No effect on processing of the core
FT                                protein.
FT   MUTAGEN     182    182       L->V: No effect on processing of the core
FT                                protein.
FT   MUTAGEN     183    183       S->L: No effect on processing of the core
FT                                protein; when associated with A-184 or V-
FT                                184.
FT   MUTAGEN     184    184       C->A,V: No effect on processing of the
FT                                core protein; when associated with L-183.
FT   MUTAGEN     922    922       C->A: No effect on polyprotein
FT                                processing.
FT   MUTAGEN     932    932       H->A: No effect on polyprotein
FT                                processing.
FT   MUTAGEN     952    952       H->A,R: Complete loss of protease NS2-3
FT                                activity.
FT   MUTAGEN     972    972       E->Q: Reduced protease NS2-3 activity.
FT   MUTAGEN     980    980       E->Q: No effect on polyprotein
FT                                processing.
FT   MUTAGEN     993    993       C->A: Complete loss of protease NS2-3
FT                                activity.
FT   MUTAGEN    1009   1009       E->Q: No effect on polyprotein
FT                                processing.
FT   MUTAGEN    1042   1042       C->A: No effect on zinc-binding by serine
FT                                protease NS3.
FT   MUTAGEN    1058   1058       E->Q: No effect on polyprotein
FT                                processing.
FT   MUTAGEN    1073   1073       C->S: No effect on zinc-binding by serine
FT                                protease NS3.
FT   MUTAGEN    1078   1078       C->L: No effect on zinc-binding by serine
FT                                protease NS3.
FT   MUTAGEN    1083   1083       H->A: Complete loss of serine protease
FT                                NS3 activity. No effect on zinc-binding
FT                                by serine protease NS3.
FT   MUTAGEN    1107   1107       D->A: Complete loss of serine protease
FT                                NS3 activity.
FT   MUTAGEN    1123   1123       C->A: Reduced protease NS2-3 and serine
FT                                protease NS3 activities.
FT   MUTAGEN    1125   1125       C->A: Reduced protease NS2-3 and serine
FT                                protease NS3 activities.
FT   MUTAGEN    1136   1136       H->A: No effect on polyprotein
FT                                processing. No effect on zinc-binding by
FT                                serine protease NS3.
FT   MUTAGEN    1165   1165       S->A: Complete loss of serine protease
FT                                NS3 activity. No effect on zinc-binding
FT                                by serine protease NS3.
FT   MUTAGEN    1171   1171       C->A: Reduced protease NS2-3 and serine
FT                                protease NS3 activities.
FT   MUTAGEN    1175   1175       H->A: No effect on polyprotein
FT                                processing. Reduces zinc-binding by
FT                                serine protease NS3.
FT   MUTAGEN    1185   1185       C->A: No effect on polyprotein
FT                                processing. No effect on zinc-binding by
FT                                serine protease NS3.
FT   MUTAGEN    1199   1199       E->Q: No effect on polyprotein
FT                                processing.
FT   MUTAGEN    1202   1202       E->Q: No effect on polyprotein
FT                                processing.
FT   MUTAGEN    1227   1227       H->A: No effect on polyprotein
FT                                processing. No effect on zinc-binding by
FT                                serine protease NS3.
FT   MUTAGEN    1229   1229       H->A: No effect on polyprotein
FT                                processing. No effect on zinc-binding by
FT                                serine protease NS3.
FT   MUTAGEN    2194   2194       S->A: No effect on NS5A
FT                                hyperphosphorylation.
FT   MUTAGEN    2197   2197       S->A: Loss of NS5A hyperphosphorylation.
FT   MUTAGEN    2200   2200       S->A: No effect on NS5A
FT                                hyperphosphorylation.
FT   MUTAGEN    2201   2201       S->A: Loss of NS5A hyperphosphorylation.
FT   MUTAGEN    2202   2202       S->A: No effect on NS5A
FT                                hyperphosphorylation.
FT   MUTAGEN    2204   2204       S->A: Loss of NS5A hyperphosphorylation.
FT   MUTAGEN    2207   2207       S->A: No effect on NS5A
FT                                hyperphosphorylation.
FT   MUTAGEN    2210   2210       S->A: No effect on NS5A
FT                                hyperphosphorylation.
FT   MUTAGEN    2221   2221       S->A: No effect on NS5A
FT                                hyperphosphorylation.
FT   STRAND     1030   1035
FT   HELIX      1039   1048
FT   STRAND     1057   1063
FT   STRAND     1068   1074
FT   STRAND     1077   1081
FT   HELIX      1082   1085
FT   STRAND     1100   1103
FT   TURN       1104   1107
FT   STRAND     1108   1112
FT   STRAND     1128   1133
FT   STRAND     1139   1146
FT   STRAND     1149   1157
FT   HELIX      1158   1160
FT   TURN       1161   1163
FT   STRAND     1168   1170
FT   STRAND     1176   1186
FT   STRAND     1189   1197
FT   HELIX      1198   1200
FT   STRAND     1680   1689
SQ   SEQUENCE   3010 AA;  327021 MW;  AA993794F46DB185 CRC64;
     MSTNPKPQRK TKRNTNRRPQ DVKFPGGGQI VGGVYLLPRR GPRLGVRATR KTSERSQPRG
     RRQPIPKARR PEGRTWAQPG YPWPLYGNEG MGWAGWLLSP RGSRPSWGPT DPRRRSRNLG
     KVIDTLTCGF ADLMGYIPLV GAPLGGAARA LAHGVRVLED GVNYATGNLP GCSFSIFLLA
     LLSCLTIPAS AYEVRNVSGI YHVTNDCSNS SIVYEAADMI MHTPGCVPCV RESNFSRCWV
     ALTPTLAARN SSIPTTTIRR HVDLLVGAAA LCSAMYVGDL CGSVFLVSQL FTFSPRRYET
     VQDCNCSIYP GHVSGHRMAW DMMMNWSPTT ALVVSQLLRI PQAVVDMVAG AHWGVLAGLA
     YYSMVGNWAK VLIVMLLFAG VDGHTHVTGG RVASSTQSLV SWLSQGPSQK IQLVNTNGSW
     HINRTALNCN DSLQTGFIAA LFYAHRFNAS GCPERMASCR PIDEFAQGWG PITHDMPESS
     DQRPYCWHYA PRPCGIVPAS QVCGPVYCFT PSPVVVGTTD RFGAPTYSWG ENETDVLLLS
     NTRPPQGNWF GCTWMNSTGF TKTCGGPPCN IGGVGNNTLV CPTDCFRKHP EATYTKCGSG
     PWLTPRCMVD YPYRLWHYPC TVNFTVFKVR MYVGGVEHRL NAACNWTRGE RCDLEDRDRS
     ELSPLLLSTT EWQILPCSFT TLPALSTGLI HLHRNIVDVQ YLYGIGSAVV SFAIKWEYIL
     LLFLLLADAR VCACLWMMLL IAQAEATLEN LVVLNAASVA GAHGLLSFLV FFCAAWYIKG
     RLVPGAAYAL YGVWPLLLLL LALPPRAYAM DREMAASCGG AVFVGLVLLT LSPYYKVFLA
     RLIWWLQYFI TRAEAHLQVW VPPLNVRGGR DAIILLTCAV HPELIFDITK LLLAILGPLM
     VLQAGITRVP YFVRAQGLIR ACMLVRKVAG GHYVQMAFMK LAALTGTYVY DHLTPLRDWA
     HAGLRDLAVA VEPVVFSDME TKLITWGADT AACGDIISGL PVSARRGKEI LLGPADSFGE
     QGWRLLAPIT AYSQQTRGLL GCIITSLTGR DKNQVDGEVQ VLSTATQSFL ATCVNGVCWT
     VYHGAGSKTL AGPKGPITQM YTNVDQDLVG WPAPPGARSM TPCTCGSSDL YLVTRHADVV
     PVRRRGDSRG SLLSPRPISY LKGSSGGPLL CPSGHVVGIF RAAVCTRGVA KAVDFIPVES
     METTMRSPVF TDNSSPPAVP QTFQVAHLHA PTGSGKSTKV PAAYAAQGYK VLVLNPSVAA
     TLGFGAYMSK AHGIEPNIRT GVRTITTGGP ITYSTYCKFL ADGGCSGGAY DIIICDECHS
     TDSTTILGIG TVLDQAETAG ARLVVLATAT PPGSITVPHP NIEEVALSNT GEIPFYGKAI
     PIEAIKGGRH LIFCHSKKKC DELAAKLTGL GLNAVAYYRG LDVSVIPTSG DVVVVATDAL
     MTGFTGDFDS VIDCNTCVTQ TVDFSLDPTF TIETTTLPQD AVSRAQRRGR TGRGRSGIYR
     FVTPGERPSG MFDSSVLCEC YDAGCAWYEL TPAETSVRLR AYLNTPGLPV CQDHLEFWES
     VFTGLTHIDA HFLSQTKQAG DNLPYLVAYQ ATVCARAQAP PPSWDQMWKC LIRLKPTLHG
     PTPLLYRLGA VQNEVTLTHP ITKYIMACMS ADLEVVTSTW VLVGGVLAAL AAYCLTTGSV
     VIVGRIILSG RPAVIPDREV LYQEFDEMEE CASHLPYIEQ GMQLAEQFKQ KALGLLQTAT
     KQAEAAAPVV ESKWRALEVF WAKHMWNFIS GIQYLAGLST LPGNPAIASL MAFTASITSP
     LTTQNTLLFN ILGGWVAAQL APPSAASAFV GAGIAGAAVG SIGLGKVLVD ILAGYGAGVA
     GALVAFKVMS GEMPSTEDLV NLLPAILSPG ALVVGVVCAA ILRRHVGPGE GAVQWMNRLI
     AFASRGNHVS PTHYVPESDA AARVTQILSS LTITQLLKRL HQWINEDCST PCSGSWLKDV
     WDWICTVLSD FKTWLQSKLL PRLPGLPFLS CQRGYKGVWR GDGIMQTTCP CGAQITGHVK
     NGSMRIVGPK TCSNTWHGTF PINAYTTGPC TPSPAPNYSR ALWRVAAEEY VEVTRVGDFH
     YVTGMTTDNV KCPCQVPAPE FFTEVDGVRL HRYAPVCKPL LREEVVFQVG LNQYLVGSQL
     PCEPEPDVAV LTSMLTDPSH ITAETAKRRL ARGSPPSLAS SSASQLSAPS LKATCTTHHD
     SPDADLIEAN LLWRQEMGGN ITRVESENKV VILDSFDPIR AVEDEREISV PAEILRKPRK
     FPPALPIWAR PDYNPPLLES WKDPDYVPPV VHGCPLPSTK APPIPPPRRK RTVVLTESTV
     SSALAELATK TFGSSGSSAV DSGTATGPPD QASDDGDKGS DVESYSSMPP LEGEPGDPDL
     SDGSWSTVSG EAGEDVVCCS MSYTWTGALI TPCAAEESKL PINPLSNSLL RHHSMVYSTT
     SRSASLRQKK VTFDRLQVLD DHYRDVLKEM KAKASTVKAR LLSIEEACKL TPPHSAKSKF
     GYGAKDVRSL SSRAVNHIRS VWEDLLEDTE TPIDTTIMAK NEVFCVQPEK GGRKPARLIV
     FPDLGVRVCE KMALYDVVST LPQAVMGPSY GFQYSPGQRV EFLVNTWKSK KCPMGFSYDT
     RCFDSTVTEN DIRTEESIYQ CCDLAPEARQ AIRSLTERLY VGGPLTNSKG QNCGYRRCRA
     SGVLTTSCGN TLTCYLKATA ACRAAKLQDC TMLVNGDDLV VICESAGTQE DAAALRAFTE
     AMTRYSAPPG DPPQPEYDLE LITSCSSNVS VAHDASGKRV YYLTRDPTTP LARAAWETVR
     HTPVNSWLGN IIMYAPTLWA RMILMTHFFS ILLAQEQLEK ALDCQIYGAC YSIEPLDLPQ
     IIERLHGLSA FSLHSYSPGE INRVASCLRK LGVPPLRVWR HRARSVRAKL LSQGGRAATC
     GKYLFNWAVK TKLKLTPIPA ASQLDLSGWF VAGYNGGDIY HSLSRARPRW FMLCLLLLSV
     GVGIYLLPNR
//
ID   POLG_HCVJF              Reviewed;        3033 AA.
AC   Q99IB8;
DT   10-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 68.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 2a (isolate JFH-1) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=356411;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=21316767; PubMed=11424123; DOI=10.1002/jmv.1055;
RA   Kato T., Furusaka A., Miyamoto M., Date T., Yasui K., Hiramoto J.,
RA   Nagayama K., Tanaka T., Wakita T.;
RT   "Sequence analysis of hepatitis C virus isolated from a fulminant
RT   hepatitis patient.";
RL   J. Med. Virol. 64:334-339(2001).
RN   [2]
RP   SUBCELLULAR LOCATION OF P7.
RX   PubMed=17170445; DOI=10.1099/vir.0.82049-0;
RA   Haqshenas G., Mackenzie J.M., Dong X., Gowans E.J.;
RT   "Hepatitis C virus p7 protein is localized in the endoplasmic
RT   reticulum when it is encoded by a replication-competent genome.";
RL   J. Gen. Virol. 88:134-142(2007).
RN   [3]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [4]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [5]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein. Host cell membrane. Note=The C-
CC       terminus of p7 membrane domain acts as a signal sequence. After
CC       cleavage by host signal peptidase, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. Only a fraction localizes to the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein
CC       (Probable). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain a highly variable region called hypervariable
CC       region 1 (HVR1). E2 also contains two segments involved in CD81-
CC       binding. HVR1 is implicated in the SCARB1-mediated cell entry.
CC       CD81-binding regions may be involved in sensitivity and/or
CC       resistance to IFN-alpha therapy (By similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A seems to be intrinsically disordered and
CC       interacts with NS5B and host PKR (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB047639; BAB32872.1; -; Genomic_RNA.
DR   PDB; 3I5K; X-ray; 2.20 A; A/B/C/D=2443-3007.
DR   PDBsum; 3I5K; -.
DR   SMR; Q99IB8; 2-45, 906-1030, 1033-1661, 1977-2007, 2012-2174.
DR   euHCVdb; AB047639; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; FALSE_NEG.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Disulfide bond; Envelope protein; Fusion protein;
KW   Glycoprotein; Helicase; Host cell membrane; Host cytoplasm;
KW   Host endoplasmic reticulum; Host lipid droplet; Host membrane;
KW   Host mitochondrion; Host nucleus; Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000045592.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000045593.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000045594.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000045595.
FT   CHAIN       384    750       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000045596.
FT   CHAIN       751    813       p7 (By similarity).
FT                                /FTId=PRO_0000045597.
FT   CHAIN       814   1030       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000045598.
FT   CHAIN      1031   1661       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000045599.
FT   CHAIN      1662   1715       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000045600.
FT   CHAIN      1716   1976       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000045601.
FT   CHAIN      1977   2442       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000045602.
FT   CHAIN      2443   3033       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000045603.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    729       Lumenal (Potential).
FT   TRANSMEM    730    750       Potential.
FT   TOPO_DOM    751    761       Lumenal (Potential).
FT   TRANSMEM    762    782       Potential.
FT   TOPO_DOM    783    786       Cytoplasmic (Potential).
FT   TRANSMEM    787    807       Potential.
FT   TOPO_DOM    808    817       Lumenal (Potential).
FT   TRANSMEM    818    838       Potential.
FT   TOPO_DOM    839    885       Cytoplasmic (Potential).
FT   TRANSMEM    886    906       Potential.
FT   TOPO_DOM    907    932       Lumenal (Potential).
FT   TRANSMEM    933    953       Potential.
FT   TOPO_DOM    954   1661       Cytoplasmic (Potential).
FT   TRANSMEM   1662   1682       Potential.
FT   TOPO_DOM   1683   1809       Cytoplasmic (Potential).
FT   TRANSMEM   1810   1830       Potential.
FT   TOPO_DOM   1831   1832       Lumenal (Potential).
FT   TRANSMEM   1833   1853       Potential.
FT   TOPO_DOM   1854   1854       Cytoplasmic (Potential).
FT   TRANSMEM   1855   1875       Potential.
FT   TOPO_DOM   1876   1885       Lumenal (Potential).
FT   TRANSMEM   1886   1906       Potential.
FT   TOPO_DOM   1907   1976       Cytoplasmic (Potential).
FT   TOPO_DOM   1977   2006       In membrane (By similarity).
FT   TOPO_DOM   2007   3012       Cytoplasmic (Potential).
FT   TRANSMEM   3013   3033       By similarity.
FT   DOMAIN     1221   1373       Helicase ATP-binding.
FT   DOMAIN     2656   2774       RdRp catalytic.
FT   NP_BIND    1234   1241       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      385    411       HVR1 (By similarity).
FT   REGION      484    496       CD81-binding 1 (Potential).
FT   REGION      524    555       CD81-binding 2 (Potential).
FT   REGION      664    675       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1683   1694       NS3-binding (by NS4A) (Potential).
FT   REGION     2124   2332       Transcriptional activation (Potential).
FT   REGION     2124   2212       FKBP8-binding (Potential).
FT   REGION     2204   2250       Basal phosphorylation (By similarity).
FT   REGION     2214   2275       PKR-binding (Potential).
FT   REGION     2249   2306       NS4B-binding (Potential).
FT   REGION     2351   2442       Basal phosphorylation (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1320   1323       DECH box (By similarity).
FT   MOTIF      2322   2325       SH3-binding (Potential).
FT   MOTIF      2327   2335       Nuclear localization signal (Potential).
FT   COMPBIAS   1436   1439       Poly-Val.
FT   COMPBIAS   2277   2327       Pro-rich.
FT   COMPBIAS   2328   2331       Poly-Arg.
FT   COMPBIAS   3018   3021       Poly-Leu.
FT   ACT_SITE    956    956       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    976    976       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    997    997       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1087   1087       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1111   1111       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1169   1169       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1127   1127       Zinc (By similarity).
FT   METAL      1129   1129       Zinc (By similarity).
FT   METAL      1175   1175       Zinc (By similarity).
FT   METAL      1179   1179       Zinc (By similarity).
FT   METAL      2015   2015       Zinc (By similarity).
FT   METAL      2033   2033       Zinc (By similarity).
FT   METAL      2035   2035       Zinc (By similarity).
FT   METAL      2056   2056       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        191    192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        750    751       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        813    814       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1030   1031       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1661   1662       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1715   1716       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1976   1977       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2442   2443       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2198   2198       Phosphoserine; by host; in p56 (By
FT                                similarity).
FT   MOD_RES    2201   2201       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2205   2205       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2208   2208       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1972   1972       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   LIPID      1976   1976       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    417    417       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    423    423       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    430    430       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    448    448       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    477    477       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    534    534       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    542    542       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    558    558       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    578    578       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    627    627       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    649    649       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2118   2166       By similarity.
SQ   SEQUENCE   3033 AA;  328828 MW;  7E5BEA79702AF95B CRC64;
     MSTNPKPQRK TKRNTNRRPE DVKFPGGGQI VGGVYLLPRR GPRLGVRTTR KTSERSQPRG
     RRQPIPKDRR STGKAWGKPG RPWPLYGNEG LGWAGWLLSP RGSRPSWGPT DPRHRSRNVG
     KVIDTLTCGF ADLMGYIPVV GAPLSGAARA VAHGVRVLED GVNYATGNLP GFPFSIFLLA
     LLSCITVPVS AAQVKNTSSS YMVTNDCSND SITWQLEAAV LHVPGCVPCE RVGNTSRCWV
     PVSPNMAVRQ PGALTQGLRT HIDMVVMSAT FCSALYVGDL CGGVMLAAQV FIVSPQYHWF
     VQECNCSIYP GTITGHRMAW DMMMNWSPTA TMILAYVMRV PEVIIDIVSG AHWGVMFGLA
     YFSMQGAWAK VIVILLLAAG VDAGTTTVGG AVARSTNVIA GVFSHGPQQN IQLINTNGSW
     HINRTALNCN DSLNTGFLAA LFYTNRFNSS GCPGRLSACR NIEAFRIGWG TLQYEDNVTN
     PEDMRPYCWH YPPKPCGVVP ARSVCGPVYC FTPSPVVVGT TDRRGVPTYT WGENETDVFL
     LNSTRPPQGS WFGCTWMNST GFTKTCGAPP CRTRADFNAS TDLLCPTDCF RKHPDATYIK
     CGSGPWLTPK CLVHYPYRLW HYPCTVNFTI FKIRMYVGGV EHRLTAACNF TRGDRCDLED
     RDRSQLSPLL HSTTEWAILP CTYSDLPALS TGLLHLHQNI VDVQYMYGLS PAITKYVVRW
     EWVVLLFLLL ADARVCACLW MLILLGQAEA ALEKLVVLHA ASAANCHGLL YFAIFFVAAW
     HIRGRVVPLT TYCLTGLWPF CLLLMALPRQ AYAYDAPVHG QIGVGLLILI TLFTLTPGYK
     TLLGQCLWWL CYLLTLGEAM IQEWVPPMQV RGGRDGIAWA VTIFCPGVVF DITKWLLALL
     GPAYLLRAAL THVPYFVRAH ALIRVCALVK QLAGGRYVQV ALLALGRWTG TYIYDHLTPM
     SDWAASGLRD LAVAVEPIIF SPMEKKVIVW GAETAACGDI LHGLPVSARL GQEILLGPAD
     GYTSKGWKLL APITAYAQQT RGLLGAIVVS MTGRDRTEQA GEVQILSTVS QSFLGTTISG
     VLWTVYHGAG NKTLAGLRGP VTQMYSSAEG DLVGWPSPPG TKSLEPCKCG AVDLYLVTRN
     ADVIPARRRG DKRGALLSPR PISTLKGSSG GPVLCPRGHV VGLFRAAVCS RGVAKSIDFI
     PVETLDVVTR SPTFSDNSTP PAVPQTYQVG YLHAPTGSGK STKVPVAYAA QGYKVLVLNP
     SVAATLGFGA YLSKAHGINP NIRTGVRTVM TGEAITYSTY GKFLADGGCA SGAYDIIICD
     ECHAVDATSI LGIGTVLDQA ETAGVRLTVL ATATPPGSVT TPHPDIEEVG LGREGEIPFY
     GRAIPLSCIK GGRHLIFCHS KKKCDELAAA LRGMGLNAVA YYRGLDVSII PAQGDVVVVA
     TDALMTGYTG DFDSVIDCNV AVTQAVDFSL DPTFTITTQT VPQDAVSRSQ RRGRTGRGRQ
     GTYRYVSTGE RASGMFDSVV LCECYDAGAA WYDLTPAETT VRLRAYFNTP GLPVCQDHLE
     FWEAVFTGLT HIDAHFLSQT KQAGENFAYL VAYQATVCAR AKAPPPSWDA MWKCLARLKP
     TLAGPTPLLY RLGPITNEVT LTHPGTKYIA TCMQADLEVM TSTWVLAGGV LAAVAAYCLA
     TGCVSIIGRL HVNQRVVVAP DKEVLYEAFD EMEECASRAA LIEEGQRIAE MLKSKIQGLL
     QQASKQAQDI QPAMQASWPK VEQFWARHMW NFISGIQYLA GLSTLPGNPA VASMMAFSAA
     LTSPLSTSTT ILLNIMGGWL ASQIAPPAGA TGFVVSGLVG AAVGSIGLGK VLVDILAGYG
     AGISGALVAF KIMSGEKPSM EDVINLLPGI LSPGALVVGV ICAAILRRHV GPGEGAVQWM
     NRLIAFASRG NHVAPTHYVT ESDASQRVTQ LLGSLTITSL LRRLHNWITE DCPIPCSGSW
     LRDVWDWVCT ILTDFKNWLT SKLFPKLPGL PFISCQKGYK GVWAGTGIMT TRCPCGANIS
     GNVRLGSMRI TGPKTCMNTW QGTFPINCYT EGQCAPKPPT NYKTAIWRVA ASEYAEVTQH
     GSYSYVTGLT TDNLKIPCQL PSPEFFSWVD GVQIHRFAPT PKPFFRDEVS FCVGLNSYAV
     GSQLPCEPEP DADVLRSMLT DPPHITAETA ARRLARGSPP SEASSSVSQL SAPSLRATCT
     THSNTYDVDM VDANLLMEGG VAQTEPESRV PVLDFLEPMA EEESDLEPSI PSECMLPRSG
     FPRALPAWAR PDYNPPLVES WRRPDYQPPT VAGCALPPPK KAPTPPPRRR RTVGLSESTI
     SEALQQLAIK TFGQPPSSGD AGSSTGAGAA ESGGPTSPGE PAPSETGSAS SMPPLEGEPG
     DPDLESDQVE LQPPPQGGGV APGSGSGSWS TCSEEDDTTV CCSMSYSWTG ALITPCSPEE
     EKLPINPLSN SLLRYHNKVY CTTSKSASQR AKKVTFDRTQ VLDAHYDSVL KDIKLAASKV
     SARLLTLEEA CQLTPPHSAR SKYGFGAKEV RSLSGRAVNH IKSVWKDLLE DPQTPIPTTI
     MAKNEVFCVD PAKGGKKPAR LIVYPDLGVR VCEKMALYDI TQKLPQAVMG ASYGFQYSPA
     QRVEYLLKAW AEKKDPMGFS YDTRCFDSTV TERDIRTEES IYQACSLPEE ARTAIHSLTE
     RLYVGGPMFN SKGQTCGYRR CRASGVLTTS MGNTITCYVK ALAACKAAGI VAPTMLVCGD
     DLVVISESQG TEEDERNLRA FTEAMTRYSA PPGDPPRPEY DLELITSCSS NVSVALGPRG
     RRRYYLTRDP TTPLARAAWE TVRHSPINSW LGNIIQYAPT IWVRMVLMTH FFSILMVQDT
     LDQNLNFEMY GSVYSVNPLD LPAIIERLHG LDAFSMHTYS HHELTRVASA LRKLGAPPLR
     VWKSRARAVR ASLISRGGKA AVCGRYLFNW AVKTKLKLTP LPEARLLDLS SWFTVGAGGG
     DIFHSVSRAR PRSLLFGLLL LFVGVGLFLL PAR
//
ID   POLG_HCVJK              Reviewed;        3019 AA.
AC   Q68801;
DT   10-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 82.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 3k (isolate JK049) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=356417;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=96226020; PubMed=8627233;
RA   Tokita H., Okamoto H., Iizuka H., Kishimoto J., Tsuda F.,
RA   Lesmana L.A., Miyakawa Y., Mayumi M.;
RT   "Hepatitis C virus variants from Jakarta, Indonesia classifiable into
RT   novel genotypes in the second (2e and 2f), tenth (10a) and eleventh
RT   (11a) genetic groups.";
RL   J. Gen. Virol. 77:293-301(1996).
RN   [2]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [3]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [4]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain a highly variable region called hypervariable
CC       region 1 (HVR1). E2 also contains two segments involved in CD81-
CC       binding. HVR1 is implicated in the SCARB1-mediated cell entry.
CC       CD81-binding regions may be involved in sensitivity and/or
CC       resistance to IFN-alpha therapy (By similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A seems to be intrinsically disordered and
CC       interacts with NS5B and host PKR (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase C-terminal domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D63821; BAA09890.1; -; Genomic_RNA.
DR   euHCVdb; D63821; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; 1.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Disulfide bond; Envelope protein; Fusion protein;
KW   Glycoprotein; Helicase; Host cell membrane; Host cytoplasm;
KW   Host endoplasmic reticulum; Host lipid droplet; Host membrane;
KW   Host mitochondrion; Host nucleus; Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000045604.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000045605.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000045606.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000045607.
FT   CHAIN       384    751       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000045608.
FT   CHAIN       752    814       p7 (By similarity).
FT                                /FTId=PRO_0000045609.
FT   CHAIN       815   1031       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000045610.
FT   CHAIN      1032   1662       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000045611.
FT   CHAIN      1663   1716       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000045612.
FT   CHAIN      1717   1977       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000045613.
FT   CHAIN      1978   2428       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000045614.
FT   CHAIN      2429   3019       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000045615.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    730       Lumenal (Potential).
FT   TRANSMEM    731    751       Potential.
FT   TOPO_DOM    752    762       Lumenal (Potential).
FT   TRANSMEM    763    783       Potential.
FT   TOPO_DOM    784    787       Cytoplasmic (Potential).
FT   TRANSMEM    788    808       Potential.
FT   TOPO_DOM    809    818       Lumenal (Potential).
FT   TRANSMEM    819    839       Potential.
FT   TOPO_DOM    840    886       Cytoplasmic (Potential).
FT   TRANSMEM    887    907       Potential.
FT   TOPO_DOM    908    933       Lumenal (Potential).
FT   TRANSMEM    934    954       Potential.
FT   TOPO_DOM    955   1662       Cytoplasmic (Potential).
FT   TRANSMEM   1663   1683       Potential.
FT   TOPO_DOM   1684   1810       Cytoplasmic (Potential).
FT   TRANSMEM   1811   1831       Potential.
FT   TOPO_DOM   1832   1833       Lumenal (Potential).
FT   TRANSMEM   1834   1854       Potential.
FT   TOPO_DOM   1855   1855       Cytoplasmic (Potential).
FT   TRANSMEM   1856   1876       Potential.
FT   TOPO_DOM   1877   1886       Lumenal (Potential).
FT   TRANSMEM   1887   1907       Potential.
FT   TOPO_DOM   1908   1977       Cytoplasmic (Potential).
FT   TOPO_DOM   1978   2007       In membrane (By similarity).
FT   TOPO_DOM   2008   2998       Cytoplasmic (Potential).
FT   TRANSMEM   2999   3019       By similarity.
FT   DOMAIN     1366   1543       Helicase C-terminal.
FT   DOMAIN     2642   2760       RdRp catalytic.
FT   NP_BIND    1235   1242       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      385    411       HVR1 (By similarity).
FT   REGION      483    495       CD81-binding 1 (Potential).
FT   REGION      523    554       CD81-binding 2 (Potential).
FT   REGION      665    676       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1684   1695       NS3-binding (by NS4A) (Potential).
FT   REGION     2125   2337       Transcriptional activation (Potential).
FT   REGION     2125   2213       FKBP8-binding (Potential).
FT   REGION     2205   2255       Basal phosphorylation (By similarity).
FT   REGION     2215   2280       PKR-binding (Potential).
FT   REGION     2254   2311       NS4B-binding (Potential).
FT   REGION     2356   2428       Basal phosphorylation (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1321   1324       DECH box (By similarity).
FT   MOTIF      2327   2330       SH3-binding (Potential).
FT   MOTIF      2332   2340       Nuclear localization signal (Potential).
FT   COMPBIAS    801    808       Poly-Leu.
FT   COMPBIAS   2283   2332       Pro-rich.
FT   COMPBIAS   2386   2391       Poly-Asp.
FT   COMPBIAS   3000   3007       Poly-Leu.
FT   ACT_SITE    957    957       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    977    977       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    998    998       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1088   1088       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1112   1112       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1170   1170       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1128   1128       Zinc (By similarity).
FT   METAL      1130   1130       Zinc (By similarity).
FT   METAL      1176   1176       Zinc (By similarity).
FT   METAL      1180   1180       Zinc (By similarity).
FT   METAL      2016   2016       Zinc (By similarity).
FT   METAL      2034   2034       Zinc (By similarity).
FT   METAL      2036   2036       Zinc (By similarity).
FT   METAL      2057   2057       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       ?191   ?192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        751    752       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        814    815       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1031   1032       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1662   1663       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1716   1717       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1977   1978       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2428   2429       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2199   2199       Phosphoserine; by host; in p56 (By
FT                                similarity).
FT   MOD_RES    2202   2202       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2206   2206       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2209   2209       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1977   1977       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    417    417       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    423    423       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    430    430       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    448    448       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    476    476       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    533    533       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    557    557       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    581    581       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    628    628       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    650    650       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    932    932       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2119   2167       By similarity.
SQ   SEQUENCE   3019 AA;  328215 MW;  AF7A6774BC6D95FA CRC64;
     MSTLPKPQRI TKRNINRRPQ DVKFPGGGQI VGGVYVLPRR GPKLGVRAVR KTSERSQPRS
     RRQPIPRARR TEGRSWAQPG YPWPLYGNEG CGWAGWLLSP RGSRPSWGPN DPRRRSRNLG
     KVIDTLTCGF ADLMGYIPLV GAPVGGVARA LAHGVRALED GINFATGNLP GCSFSIFLLA
     LLSCLLTPTA GLEYRNASGL YTVTNDCSNG SIVYEAGDVI LHLPGCIPCV RLNNASKCWT
     PVSPTVAVSR PGAATASLRT HVDMMVGAAT LCSALYVGDL CGALFLVGQG FSWRHRQHWT
     VQDCNCSIYP GHLTGHRMAW DMMMNWSPAM TLIVSQVLRL PQTMFDLVIG AHWGVMAGVA
     YYSMQGNWAK VFLVLCLFSG VDASTTITGG VAASGAFTIT SLFSTGAKQP LHLVNTNGSW
     HINRTALNCN DSLNTGFIAG LLYYHKFNSS GCVERMSACS PLDRFAQGWG PLGPANISGP
     SSEKPYCWHY APRPCDTVPA QSVCGPVYCF TPSPVVVGAT DKRGAPTYTW GENESDVFLL
     ESARPPTEPW FGCTWMNGSG YVKTCGAPPC HIYGGREGKS NNSLVCPTDC FRKHPDATYN
     RCGAGPWLTP RCLVDYPYRL WHYPCTVNYT IFKVRMFVGG LEHRFNAACN WTRGERCNLE
     DRDRSEMYPL LHSTTEQAIL PCSFVPIPAL STGLIHLHQN IVDVQYLYGI SSGLVGWAIK
     WEFVILIFLL LADARVCVVL WMMMLISQAE AALENLIVLN AISAAGTHGI WWSLVAFCVA
     WHVRGRIFPI AVYSIVGLWP LLLLVLMLPY RAYAWTGTDT STLGAGVLSL FALFTLSPWY
     KHWIARLIWW NQYTIARCEA ALQIWVPPLL ARGARDGIIL LAGLFYPALV FDITKLLLAI
     LGPLYILQAS LVRVPYFVRA HAVVRLCILV RNITGGKYVQ MVLLALARGF NTYLYDHLSP
     MTDWAAEGLK DLAVAVEPVI FSPMEVKVIT WGADTTACGD ILCGLPVSAR LGKEVLLGPA
     DDYRSMGWRL LAPITAHAQQ TRGLFGTIVT SLTGRDKNIV TGEIQVLSTS TQTFLGTSVG
     GVMWTVYHGA GSRTLAGNKR PALQMYTNVD QDLVGWPSPP GAKSLVPCTC GSADLYLITR
     DADVLPARRR GDSTASLLSP RPLACLKGSS GGPIMCPSGH VAGIFRAAVC TRGVAKALQF
     IPVESLSAQT RSPSFSDNST PPAVPQTFQV GYLHAPTGSG ESTKVPASYV AQGYTVLVLN
     PSVAATLGFG RFMSHAYGID PNVRTGTRTI TTGAKLTYST YGKFLADGGC SGGAYDVIIC
     DECHAQDATS ILGIGTVLDQ AETAGARLVV LATATPPGSI TVPHSNIEEV ALTGEGEIPF
     YGRAIPLGVI KGGRHLIFCH SKKKCDELAK QLTSLGVNAV AFYRGLDVSV IPTQGDVVVC
     ATDALITGYT GDFDSVIDCN VAVEQYVDFS LDPTFSIETH TVPQDAVSRS QRRGRTGRGK
     SGTYRYVSPG ERPSGMFDSV VLCECYDAGC AWYELTPSET TVRLRAYLST PGLPVCQDHL
     EFWEGVFTGL THIDAHFLSQ TKQQGLNFPY LTAYQATVCA RAAALPPSWD ETWKCLIRLK
     PTLHGPTPLL YRLGAVQNEI CTTHPVTKYI ATCMAADLEV ATSAWVLLGG VMAALTAYCL
     SVGSVVIVGH LVLGGKPALV PDKEVLYQQY DEMEECSRAA PYIEQAQGIA QQFKEKVIGL
     LQQADQKAAD IKPIATPYWQ KLETFWSKHM WNFVSGIQYL AGLSTLPGNP AIASLMAFTA
     SVTSPLTTNQ TLLFNIMGGW VASNLAPPPA STAFVVSGLA GAAVGSIGLG KVLLDILAGY
     GAGVAGALVA FKIMGGEMPS TEDMVNLLPA ILSPGALVVG VICAAILRRH VGPGEGAVQW
     MNRLIAFASR GNHVAPTHYV PESDAAAKVT ALLSSLTVTQ LLRRLHQWIN EDYPTPCDGN
     WLYDIWNWVC TVLADFKLWL GAKILPKMPG IPFLSCQKGY RGTWRGDGVV STRCPCGALL
     SGHVKNGTMR LVGPRWCANT WHGTFPINGY TTGPSTPAPS YAYSRALWRV ASDSYVEVRK
     VGDFHYVTGT TDDGLKCPCQ VPLPEFFTEL DGVRLHRYAP VCRPLLRDDV TFTVGLNSYV
     IGSQLPCEPE PDVAVVTSML QDPSHITVET AKRRLDRGSP PSLASSSASQ LSAPSRKATC
     TTHGRHPDAE LITANLLWRQ EMGSNITRVE SESKVVILDS FEPLRACDDE DELSVAAECF
     KKPPKYPPAL PIWARPDYNP PLVEPWKDPD YVPPTVHGCA LPPQKLPPVP PPRRKRTIVL
     SESTVSKALA SLAEKSFPQP TCSAEDESTS GVGTQSGSLT GPVQLDDDDS DNESHSSMPP
     LEGEPGDPDL SSGSWSTVSG EEQSVVCCSM SYSWTGALIT PCAAEEEKLP ISPLSNSLLR
     HHNLVYSTSS RSAAQRQKKV TFDRLQVLDD HYNTTLKEIK ELASGVKAEL LSVEEACRLV
     PSHSARSKFG YGAKEVRSLS SKAINHINSV WEDLLEDNTT PIPTTIMAKN EVFAVAPHKG
     GRKPARLIVY PDLGVRICEK RALYDVIQKL PSAIMGSAYG FQYSPKQRVE YLLKMWNSKK
     TPLGFSYDTR CFDSTVTEQD IRVEESIYQA CDLKDEARRV ITSLTERLYC GGPMFNSKGQ
     HCGYRRCRAS GVLPTSFGNT VTCYLKAKAA TKAAGIKDPS FLVCGDDLVV IAESAGIDED
     KSALRAFTEA MTRYSAPPGD PPQPTYDLEL ITSCSSNVSV AHDGAGKRYY YLTRDPETPL
     ARAAWETARH TPVNSWLGNI IMYAPTIWVR MVIMTHFFSI LQAQEQLEKA LDFEMYGAVY
     SVTPLDLPAI IERLHGLSAF SLHSYSPVEL NRVAGALRKL GIPPLRAWRH RARAVRAKLI
     SQGGKAKICG LYLFNWAVRT KAKLTPLPQA GLLDLSRWFT VGAGGNDIYH SVSRARSRHL
     LLGLLLLTVG VGIFLLPAR
//
ID   POLG_HCVJL              Reviewed;        3022 AA.
AC   Q68798;
DT   10-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 81.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 6g (isolate JK046) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=356423;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=96226020; PubMed=8627233;
RA   Tokita H., Okamoto H., Iizuka H., Kishimoto J., Tsuda F.,
RA   Lesmana L.A., Miyakawa Y., Mayumi M.;
RT   "Hepatitis C virus variants from Jakarta, Indonesia classifiable into
RT   novel genotypes in the second (2e and 2f), tenth (10a) and eleventh
RT   (11a) genetic groups.";
RL   J. Gen. Virol. 77:293-301(1996).
RN   [2]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [3]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [4]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain a highly variable region called hypervariable
CC       region 1 (HVR1). E2 also contains two segments involved in CD81-
CC       binding. HVR1 is implicated in the SCARB1-mediated cell entry.
CC       CD81-binding regions may be involved in sensitivity and/or
CC       resistance to IFN-alpha therapy (By similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A seems to be intrinsically disordered and
CC       interacts with NS5B and host PKR (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D63822; BAA09891.1; -; Genomic_RNA.
DR   euHCVdb; D63822; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; FALSE_NEG.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Disulfide bond; Envelope protein; Fusion protein;
KW   Glycoprotein; Helicase; Host cell membrane; Host cytoplasm;
KW   Host endoplasmic reticulum; Host lipid droplet; Host membrane;
KW   Host mitochondrion; Host nucleus; Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000045616.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000045617.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000045618.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000045619.
FT   CHAIN       384    750       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000045620.
FT   CHAIN       751    813       p7 (By similarity).
FT                                /FTId=PRO_0000045621.
FT   CHAIN       814   1030       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000045622.
FT   CHAIN      1031   1661       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000045623.
FT   CHAIN      1662   1715       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000045624.
FT   CHAIN      1716   1976       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000045625.
FT   CHAIN      1977   2431       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000045626.
FT   CHAIN      2432   3022       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000045627.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    729       Lumenal (Potential).
FT   TRANSMEM    730    750       Potential.
FT   TOPO_DOM    751    761       Lumenal (Potential).
FT   TRANSMEM    762    782       Potential.
FT   TOPO_DOM    783    786       Cytoplasmic (Potential).
FT   TRANSMEM    787    807       Potential.
FT   TOPO_DOM    808    817       Lumenal (Potential).
FT   TRANSMEM    818    838       Potential.
FT   TOPO_DOM    839    885       Cytoplasmic (Potential).
FT   TRANSMEM    886    906       Potential.
FT   TOPO_DOM    907    932       Lumenal (Potential).
FT   TRANSMEM    933    953       Potential.
FT   TOPO_DOM    954   1661       Cytoplasmic (Potential).
FT   TRANSMEM   1662   1682       Potential.
FT   TOPO_DOM   1683   1809       Cytoplasmic (Potential).
FT   TRANSMEM   1810   1830       Potential.
FT   TOPO_DOM   1831   1832       Lumenal (Potential).
FT   TRANSMEM   1833   1853       Potential.
FT   TOPO_DOM   1854   1854       Cytoplasmic (Potential).
FT   TRANSMEM   1855   1875       Potential.
FT   TOPO_DOM   1876   1885       Lumenal (Potential).
FT   TRANSMEM   1886   1906       Potential.
FT   TOPO_DOM   1907   1976       Cytoplasmic (Potential).
FT   TOPO_DOM   1977   2006       In membrane (By similarity).
FT   TOPO_DOM   2007   3001       Cytoplasmic (Potential).
FT   TRANSMEM   3002   3022       By similarity.
FT   DOMAIN     1221   1373       Helicase ATP-binding.
FT   DOMAIN     2645   2763       RdRp catalytic.
FT   NP_BIND    1234   1241       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      384    410       HVR1 (By similarity).
FT   REGION      482    494       CD81-binding 1 (Potential).
FT   REGION      522    553       CD81-binding 2 (Potential).
FT   REGION      664    675       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1683   1694       NS3-binding (by NS4A) (Potential).
FT   REGION     2124   2337       Transcriptional activation (Potential).
FT   REGION     2124   2212       FKBP8-binding (Potential).
FT   REGION     2204   2254       Basal phosphorylation (By similarity).
FT   REGION     2214   2279       PKR-binding (Potential).
FT   REGION     2253   2311       NS4B-binding (Potential).
FT   REGION     2356   2431       Basal phosphorylation (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1320   1323       DECH box (By similarity).
FT   MOTIF      2327   2330       SH3-binding (Potential).
FT   MOTIF      2332   2340       Nuclear localization signal (Potential).
FT   COMPBIAS    800    807       Poly-Leu.
FT   COMPBIAS   2281   2332       Pro-rich.
FT   COMPBIAS   3003   3010       Poly-Leu.
FT   ACT_SITE    956    956       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    976    976       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    997    997       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1087   1087       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1111   1111       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1169   1169       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1127   1127       Zinc (By similarity).
FT   METAL      1129   1129       Zinc (By similarity).
FT   METAL      1175   1175       Zinc (By similarity).
FT   METAL      1179   1179       Zinc (By similarity).
FT   METAL      2015   2015       Zinc (By similarity).
FT   METAL      2033   2033       Zinc (By similarity).
FT   METAL      2035   2035       Zinc (By similarity).
FT   METAL      2056   2056       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        191    192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        750    751       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        813    814       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1030   1031       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1661   1662       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1715   1716       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2431   2432       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2198   2198       Phosphoserine; by host; in p56 (By
FT                                similarity).
FT   MOD_RES    2201   2201       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2205   2205       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2208   2208       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1976   1976       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    250    250       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    416    416       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    422    422       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    429    429       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    447    447       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    475    475       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    532    532       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    556    556       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    578    578       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    627    627       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    649    649       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2118   2166       By similarity.
SQ   SEQUENCE   3022 AA;  328688 MW;  EE6A21538FEA26E1 CRC64;
     MSTNPKPQRQ TKRNTNRRPQ DVKFPGGGQI VGGVYLLPRR GPRLGVRATR KTSERSQPRG
     RRQPIPKARR QTGRAWGQPG YAWPLYGNEG CGWAGWLLSP RGSRPTWGPN DPRRRSRNLG
     KVIDTLTCGL ADLMGYIPVI GGPLGGVAAA LAHGVRAVED GVNYATGNLP GCSFSIFLLA
     LLSCLTVPAS AVNYANKSGI YHLTNDCPNS SMVYEAEAII LHLPGCVPCI RTGNQSRCWT
     PATPTLAIPN STVPASGFRQ HIDLMVGAAA LCSAMYLGDL CGGVFLVGQL FTFRPRIHQT
     VQDCNCSIYT GHVTGHRMAW DMMMNWSPTA TFVVSSALRA PQVLFDIFAG GHWGIIGALL
     YYSTAANWAK VIIVLLLFAG VDASTYVASS VSQATSGLVS LFSAGARQNL QLINTNGSWH
     INRTALNCND SLQTGFIASL FYRNKFNATG CPERLSACKT LDSFDQGWGP ITYANISGPA
     VEKPYCWHYP PRPCEVVSAL NVCGPVYCFT PSPVVLGTTD RRGNPTYTWG ANETDVFMMS
     SLRPPAGGWY GCTWMNTSGF VKTCGAPPCN IRPNPEENRT ETLRCPTDCF RKHPGATYAK
     CGSGPWLTPR CLVDYPYRLW HYPCTVNYTL HKVRMYIAGS EHRFTAACNW TRGERCDLAD
     RDRIEMSPLL FSTTELAILP CSFTTMPALS TGLIHLHQNV VDVQYLYGLS TSIVNWAIKW
     EYVVLLFLVL ADSRICLALW LMLLIGQAEA ALENLIVLNA ASAAATRGWE CFLLFMCWAW
     YVRGRVVPAV TYGLLNLWPL LLLVLLLPHR AYAYDGVQAG SIGAAVIAAL TIFSLTPAYK
     TLLAHFLWWT QYFIAHIEAK LHVWVPFLRV RGGRDAIILL TCVFHPSLGF EVTKILLALI
     GPLYLLHASL LRVPYYVRAH ALIRICALVQ NVAGGKYVQA AILRAGSWTG TYIYDHLVPL
     RTWASDGLRD LAVAVEPVVF SPMEKKVITW GADTAACGDI LAGLPVSARR GNLILLGPAD
     DVKDKGWSLL APITAYAQQT RGLLGTIVTS LTGRDKNEAA GEIQILSTAT QTFLATCVNG
     VCWTVYHGAG SKTLAGPRGP VCQMYTNVDQ DMVGWPAPAG TRSYTPCTCG ASDLYLITRQ
     ADVIPARRRG DNRAGLISPR PISTLKGSSG GPLLCPSGHV VGLFRAAVCT RGVAKALDFV
     PCEAMDATTR SPTFTDNSTP PAVPQAYQVG YLHAPTGSGK STKVPVAYAS QGYKVLVLNP
     SVAATLSFGS YLSRAHGIDP NIRTGVRTIT TGAPITYSTY GKFLADGGCS GGAYDVIICD
     ECHSTDPTTV LGIGTVLDQA ETAGCRLTVL ATATPPGSVT VPHPNIQETA LPLTGEVPFY
     GKAIPLEYIK GGRHLIFCHS KKKCDELAAQ LRTLGLNAVA FYRGVDVSVI PTSGDVVVCA
     TDALMTGYTG DFDSVIDCNV AVTQIVDFSL DPTFSIETTT VPQDAVARSQ RRGRTGRGKP
     GVYRYVSQGE RPSGMFDTVV LCEAYDTGAA WYELTPAETT VRLRAYLNTP GLPVCQDHLE
     FWEAVFTGLT HIDAHFLSQT KQGGENFAYL VAYQATVCAR AKAPPPSWDT MWKCLLRLKP
     TLTGPTPLLY RLGAVQNEVT PTHPVTKYIM ACMSADLEVI TSTWVVAGGI LAAIAAYCLT
     VGSVVICGRI TTSSRPAVIP DREVMYQQYD EMEECSRHLP YLVEGQQLAE QFKQNVLGLI
     QVTTKQAEEL KPAVHSAWPK LEQFWYKHMW NFISGIQYLA GLSTLPGNPA VAALMSFSAS
     LTSPLTTAQT LLLNVLGGWV ASQLATPVPA TAFVVSGLAG AAIGSIGLGK VIVDILAGYG
     AGVSGALVAF KIMSGETPSV EDMVNLLPAL LSPGALVVGV VRAAILRRHV GPSEGAAQWM
     NRLIAFASRG NHVSPTHYVP ETDASRAVTN ILSSLTITSL LRKLHHWITE DYATPCGSTW
     LRDIWDWVCT VLSDFRVWLK SKLMPSLPGV PFFSCQRGYR GTWRGDGICN TTCPCGASIA
     GHVKNGTMRI VGPRTCSNVW NGTFPINATT TGPSIPIPAP NYKKALWRVS ATEYVEVVRV
     GDSHYITGVT AENTKCPCQV PAPEFFTEVD GVRLHRYAPE CKPILRDEVT FTVGLSTYVV
     GSQLPCEPEP DVLVVTSMLR DPDHITAEEA SRRLKRGSPP SLASSSASQL SAPSLKATCT
     THADHPDAEL VEANLLWRQE MGGNITRVES ENKIVILDSF EPLKAEFDDR EISVAAECHR
     PPRFKYPPAL PVWARPDYNP PLLETWKAPD YDPPVVSGCA LPPQGLPPVP PPRRKKLVQL
     DDSVVGHVLA QLAEKSFPAT PDQPQTNSDS GHGTNGAASL PSAEDDDASD ADSYSSMPPL
     EGEPGDPDLS DGGGSGSWST VSSEETSVVC CSMSYSWTGA LITPCAAEEE KLPISPLSNT
     LIRHHNMVYS TTSRSAALRQ KKVTFDRQQV VDQHYYDTLK EMKARASTVS AKLLSVEEAC
     DLTPAHSARS KFGYGAKDVR GRTSKALNHI NSVWEDLLED NVTPIPTTIM AKNEVFCVDV
     SKGGRKPARL IVYPDLSVRV CEKRALYDVT RKLPVAVMGA AYGFQYSPSQ RVEYLLKIWR
     SKKTPMGFSY DTRCFDSTVT ERDIRTEESI YQCCELDPVA RKAISSLTER LYVGGPMYNS
     QGQSCGYRRC RASGVLPTSM GNTLTCYLKA MAACKAAGLK NFDMLVCGDD LVVISESLGV
     SEDASALRAF TDAMTRYSAP PGDEPHPEYD LEHITSCSSN VSVAHDHTGQ RYYYLTRDPT
     NVLARAAWET ARHTPVNSWL GNIIMYAPTI WVRMVLMTHF FGILQPQEQL HKALDFDMYG
     VTYNITPLDL PQIIQRLHGM AAFSLHGYSP GELNRVGACL RKLGAPPLRA WRHRARAVRA
     KLIAQGGKAA ICGMYLFNWA VKTKLKLTPL RDAHRLDLSG WFVAGYSGGD IFHSVSHARP
     RVLLLCLLLL TVGVGIFFLP PR
//
ID   POLG_HCVJP              Reviewed;        3033 AA.
AC   Q9DHD6;
DT   10-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 71.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 2b (isolate JPUT971017) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=356412;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=21296595; PubMed=11402859; DOI=10.1007/s007050170142;
RA   Murakami K., Abe M., Kageyama T., Kamoshita N., Nomoto A.;
RT   "Down-regulation of translation driven by hepatitis C virus internal
RT   ribosomal entry site by the 3' untranslated region of RNA.";
RL   Arch. Virol. 146:729-741(2001).
RN   [2]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [3]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [4]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain a highly variable region called hypervariable
CC       region 1 (HVR1). E2 also contains two segments involved in CD81-
CC       binding. HVR1 is implicated in the SCARB1-mediated cell entry.
CC       CD81-binding regions may be involved in sensitivity and/or
CC       resistance to IFN-alpha therapy (By similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A seems to be intrinsically disordered and
CC       interacts with NS5B and host PKR (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB030907; BAB08107.1; -; Genomic_RNA.
DR   euHCVdb; AB030907; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; FALSE_NEG.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Disulfide bond; Envelope protein; Fusion protein;
KW   Glycoprotein; Helicase; Host cell membrane; Host cytoplasm;
KW   Host endoplasmic reticulum; Host lipid droplet; Host membrane;
KW   Host mitochondrion; Host nucleus; Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000045628.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000045629.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000045630.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000045631.
FT   CHAIN       384    750       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000045632.
FT   CHAIN       751    813       p7 (By similarity).
FT                                /FTId=PRO_0000045633.
FT   CHAIN       814   1030       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000045634.
FT   CHAIN      1031   1661       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000045635.
FT   CHAIN      1662   1715       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000045636.
FT   CHAIN      1716   1976       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000045637.
FT   CHAIN      1977   2442       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000045638.
FT   CHAIN      2443   3033       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000045639.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    729       Lumenal (Potential).
FT   TRANSMEM    730    750       Potential.
FT   TOPO_DOM    751    761       Lumenal (Potential).
FT   TRANSMEM    762    782       Potential.
FT   TOPO_DOM    783    786       Cytoplasmic (Potential).
FT   TRANSMEM    787    807       Potential.
FT   TOPO_DOM    808    817       Lumenal (Potential).
FT   TRANSMEM    818    838       Potential.
FT   TOPO_DOM    839    885       Cytoplasmic (Potential).
FT   TRANSMEM    886    906       Potential.
FT   TOPO_DOM    907    932       Lumenal (Potential).
FT   TRANSMEM    933    953       Potential.
FT   TOPO_DOM    954   1661       Cytoplasmic (Potential).
FT   TRANSMEM   1662   1682       Potential.
FT   TOPO_DOM   1683   1809       Cytoplasmic (Potential).
FT   TRANSMEM   1810   1830       Potential.
FT   TOPO_DOM   1831   1832       Lumenal (Potential).
FT   TRANSMEM   1833   1853       Potential.
FT   TOPO_DOM   1854   1854       Cytoplasmic (Potential).
FT   TRANSMEM   1855   1875       Potential.
FT   TOPO_DOM   1876   1885       Lumenal (Potential).
FT   TRANSMEM   1886   1906       Potential.
FT   TOPO_DOM   1907   1976       Cytoplasmic (Potential).
FT   TOPO_DOM   1977   2006       In membrane (By similarity).
FT   TOPO_DOM   2007   3012       Cytoplasmic (Potential).
FT   TRANSMEM   3013   3033       By similarity.
FT   DOMAIN     1221   1373       Helicase ATP-binding.
FT   DOMAIN     2656   2774       RdRp catalytic.
FT   NP_BIND    1234   1241       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      385    411       HVR1 (By similarity).
FT   REGION      484    496       CD81-binding 1 (Potential).
FT   REGION      524    555       CD81-binding 2 (Potential).
FT   REGION      664    675       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1683   1694       NS3-binding (by NS4A) (Potential).
FT   REGION     2124   2332       Transcriptional activation (Potential).
FT   REGION     2124   2212       FKBP8-binding (Potential).
FT   REGION     2204   2250       Basal phosphorylation (By similarity).
FT   REGION     2214   2275       PKR-binding (Potential).
FT   REGION     2249   2306       NS4B-binding (Potential).
FT   REGION     2351   2442       Basal phosphorylation (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1320   1323       DECH box (By similarity).
FT   MOTIF      2322   2325       SH3-binding (Potential).
FT   MOTIF      2327   2335       Nuclear localization signal (Potential).
FT   COMPBIAS   1436   1439       Poly-Val.
FT   COMPBIAS   2282   2327       Pro-rich.
FT   COMPBIAS   2328   2333       Poly-Arg.
FT   COMPBIAS   3013   3021       Poly-Leu.
FT   ACT_SITE    956    956       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    976    976       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    997    997       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1087   1087       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1111   1111       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1169   1169       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1127   1127       Zinc (By similarity).
FT   METAL      1129   1129       Zinc (By similarity).
FT   METAL      1175   1175       Zinc (By similarity).
FT   METAL      1179   1179       Zinc (By similarity).
FT   METAL      2015   2015       Zinc (By similarity).
FT   METAL      2033   2033       Zinc (By similarity).
FT   METAL      2035   2035       Zinc (By similarity).
FT   METAL      2056   2056       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       ?191   ?192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        750    751       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        813    814       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1030   1031       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1661   1662       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1715   1716       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1976   1977       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2442   2443       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2198   2198       Phosphoserine; by host; in p56 (By
FT                                similarity).
FT   MOD_RES    2201   2201       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2205   2205       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2208   2208       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1972   1972       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   LIPID      1976   1976       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    233    233       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    299    299       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    417    417       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    423    423       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    430    430       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    448    448       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    477    477       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    534    534       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    542    542       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    558    558       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    578    578       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    627    627       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    649    649       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2118   2166       By similarity.
SQ   SEQUENCE   3033 AA;  329985 MW;  6B183FED090872B4 CRC64;
     MSTNPKPQRK TKRNTNRRPQ DVKFPGGGQI VGGVYLLPRR GPRLGVRATR KTSERSQPRG
     RRQPIPKDRR STGKSWGKPG YPWPLYGNEG CGWAGWLLSP RGSRPTWGPS DPRHRSRNLG
     RVIDTITCGF ADLMGYIPVV GAPVGGVARA LAHGVRVLED GINYATRNLP GCSFSIFLLA
     LLSCVTVPVS SVEIRNISTS YYATNDCSNN SITWQLTNAV LHLPGCVPCE NDNGTLRCWI
     QVTPNVAVKH RGALTHNLRA HVDVIVMAAT VCSALYVGDV CGAVMIVSQA LIVSPERHNF
     TQECNCSIYQ GHITGQRMAW DMMLNWSPTL TMILAYAARV PELVLEIVFG GHWGVVFGLA
     YFSMQGAWAK VIAILLLVAG VDATTYSTGA TVGRTVGSFA GLFKLGAQQN VQLINTNGSW
     HINRTALNCN DSLHTGFMAA LFYANKFNSS GCPERLSSCR GLDDFRIGWG TLEYETNVTN
     VEDMRPYCWH YPPKPCGIVP AQSVCGPVYC FTPSPVVVGT TDRQGVPTYN WGDNETDVFL
     LNSTRPPRGA WFGCTWMNGT GFTKTCGAPP CRIRKDFNST LDLLCPTDCF RKHPDATYVK
     CGAGPWLTPR CLIDYPYRLW HYPCTVNFTI FKVRMYVGGV EHRFSAACNF TRGDRCRLED
     RDRGQQSPLL HSTTEWAVLP CSFSDLPALS TGLLHLHQNI VDVQYLYGLS PAVTKYIVKW
     EWVVLLFLLL ADARICACLW MLIILGQAEA ALEKLIILHS ASAASANGPL WFFIFFTAAW
     YLKGRVVPAA TYSVLGLWSF LLLVLALPQQ AYALDAAEQG ELGLVILMII SIFTLTPAYK
     ILLSRSVWWL SYMLVLAEAQ VQQWVPPLEA RGGRDGIIWV AVILHPHLVF EVTKWLLAIL
     GSAYLLKASL LRVPYFVRAH ALLRVCTLVR HLAGARYIQM LLITMGRWTG TYIYDHLSPL
     STWAAQGLRD LAVAVEPVVF SPMEKKVIVW GAETVACGDI LHGLPVSARL GREVLLGPAD
     GYTSKGWKLL APITAYTQQT RGLLGAIVVS LTGRDKNEQA GQVQVLSSVT QSFLGTSISG
     VLWTVYHGAG NKTLASPRGP VTQMYTSAEG DLVGWPSPPG TKSLDPCTCG AVDLYLVTRN
     ADVIPVRRKD DRRGALLSPR PLSTLKGSSG GPVLCPRGHA VGLFRAAVCA RGVAKSIDFI
     PVESLDIARR TPSFSDNSTP PAVPQTYQVG YLHAPTGSGK STKVPAAYTS QGYKVLVLNP
     SVAATLGFGA YMSKAHGINP NIRTGVRTVT TGDSITYSTY GKFLADGGCS AGAYDIIICD
     ECHSVDATTI LGIGTVLDQA ETAGVRLVVL ATATPPGTVT TPHANIEEVA LGHEGEIPFY
     GKAIPLASIK GGRHLIFCHS KKKCDELAAA LRGMGVNAVA YYRGLDVSVI PTQGDVVVVA
     TDALMTGYTG DFDSVIDCNV AVTQIVDFSL DPTFTITTQT VPQDAVSRSQ RRGRTGRGRL
     GTYRYVSSGE RPSGMFDSVV LCECYDAGAA WYELTPAETT VRLRAYFNTP GLPVCQDHLE
     FWEAVFTGLT HIDAHFLSQT KQGGDNFAYL TAYQATVCAR AKAPPPSWDV MWKCLTRLKP
     TLTGPTPLLY RLGAVTNEIT LTHPVTKYIA TCMQADLEVM TSTWVLAGGV LAAVAAYCLA
     TGCISIIGRI HLNDQVVVAP DKEILYEAFD EMEECASKAA LIEEGQRMAE MLKSKILGLL
     QQATKQAQDI QPAMQSSWPK IEQFWARHMW NFISGIQYLA GLSTLPGNPA VASMMAFSAA
     LTSPLPTSTT ILLNIMGGWL ASQIAPPAGA TGFVVSGLVG AAVGSIGLGK ILVDVLAGYG
     AGISGALVAF KIMSGEKPSV EDVVNLLPAI LSPGALVVGV ICAAILRRHV GQGEGAVQWM
     NRLIAFASRG NHVAPTHYVA ESDASLRVTQ VLSSLTITSL LRRLHAWITE DCPVPCSGSW
     LRDIWEWVCS ILTDFKNWLS AKLLPKMPGL PFISCQKGYR GVWAGTGVMT TRCSCGANIS
     GHVRLGTMKI TGPKTCLNMW QGTFPINCYT EGPCVPKPPP NYKTAIWRVA ASEYVEVTQH
     GSFSYVTGLT SDNLKVPCQV PAPEFFSWVD GVQIHRFAPT PGPFFRDEVT FTVGLNSLVV
     GSQLPCDPEP DTEVLASMLT DPSHITAETA ARRLARGSPP SQASSSASQL SAPSLKATCT
     THKTAYDCDM VDANLFMGGD VTRIESDSKV IVLDSLDSMT EVEDDREPSV PSEYLTRRRK
     FPPALPPWAR PDYNPPVIET WKRPDYEPPT VLGCALPPTP QAPVPPPRRR RARVLTQDNV
     EGVLREMADK VLSPLQDTND SGHSTGADTG GDSVQQPSGE TAASDAGSLS SMPPLEGEPG
     DPDLEFEPAR SAPPSEGECE VIDSDSKSWS TVSDQEDSVI CCSMSYSWTG ALITPCGPEE
     EKLPISPLSN SLMRFHNKVY STTSRSASLR AKKVTFDRVQ VLDAHYDSVL QDVKRAASKV
     SARLLSVEEA CALTPPHSAK SRYGFGAKEV RSLSRGAVNH IRSVWEDLLE DQHTPIDTTA
     MAKNEVFCID PAKGGKKPAR LIVYPDLGVR VCEKMALYDI AQKLPKAIMG PSYGFQYSPA
     ERVDFLLKAW GSKKDPMGFS YDTRCFDSTV TERDIRTEES IYQACSLPQE ARTVIHSITE
     RLYVGGPMTN SKGQSCGYRR CRASGVFTTS MGNTMTCYIK ALAACKAAGI VDPTMLVCGD
     DLVVISESQG NEEDERNLRA FTEAMTRYSA PPGDLPRPEY DLELITSCSS NVSVALDSRG
     RRRYFLTRDP TTPITRAAWE TVRHSPVNSW LGNIIQYAPT IWVRMVIMTH FFSILLAQDT
     LNQNLNFEMY GAVYSVNPLD LPAIIERLHG LDAFSLHTYS PHELSRVAAT LRKLGAPPLR
     AWKSRARAVR ASLIIQGGRA ATCGRYLFNW AVKTKLKLTP LPEASRLDLS GWFTVGAGGG
     DIFHSVSHAR PRLLLLCLLL LSVGVGIFLL PAR
//
ID   POLG_HCVJT              Reviewed;        3010 AA.
AC   Q00269;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 112.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 1b (isolate HC-JT) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=31642;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=92295714; PubMed=1318627; DOI=10.1016/0168-1702(92)90066-I;
RA   Tanaka T., Kato N., Nakagawa M., Ootsuyama Y., Cho M.J., Nakazawa T.,
RA   Hijikata M., Ishimura Y., Shimotohno K.;
RT   "Molecular cloning of hepatitis C virus genome from a single Japanese
RT   carrier: sequence variation within the same individual and among
RT   infected individuals.";
RL   Virus Res. 23:39-53(1992).
RN   [2]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [3]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [4]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain two highly variable regions called
CC       hypervariable region 1 and 2 (HVR1 and HVR2). E2 also contain two
CC       segments involved in CD81-binding. HVR1 is implicated in the
CC       SCARB1-mediated cell entry. HVR2 and CD81-binding regions may be
CC       involved in sensitivity and/or resistance to IFN-alpha therapy (By
CC       similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A contains a variable region called interferon
CC       sensitivity determining region (ISDR) and seems to be
CC       intrinsically disordered and interacts with NS5B and host PKR. The
CC       C-terminus of NS5A contains a variable region called variable
CC       region 3 (V3). ISDR and V3 may be involved in sensitivity and/or
CC       resistance to IFN-alpha therapy (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D11168; BAA01943.1; -; Genomic_RNA.
DR   PIR; A45573; A45573.
DR   euHCVdb; D11168; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; FALSE_NEG.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Disulfide bond; Envelope protein; Fusion protein;
KW   Glycoprotein; Helicase; Host cell membrane; Host cytoplasm;
KW   Host endoplasmic reticulum; Host lipid droplet; Host membrane;
KW   Host mitochondrion; Host nucleus; Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000037649.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000037650.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000037651.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000037652.
FT   CHAIN       384    746       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000037653.
FT   CHAIN       747    809       p7 (By similarity).
FT                                /FTId=PRO_0000037654.
FT   CHAIN       810   1026       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000037655.
FT   CHAIN      1027   1657       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000037656.
FT   CHAIN      1658   1711       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000037657.
FT   CHAIN      1712   1972       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000037658.
FT   CHAIN      1973   2419       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000037659.
FT   CHAIN      2420   3010       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000037660.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    725       Lumenal (Potential).
FT   TRANSMEM    726    746       Potential.
FT   TOPO_DOM    747    757       Lumenal (Potential).
FT   TRANSMEM    758    778       Potential.
FT   TOPO_DOM    779    782       Cytoplasmic (Potential).
FT   TRANSMEM    783    803       Potential.
FT   TOPO_DOM    804    813       Lumenal (Potential).
FT   TRANSMEM    814    834       Potential.
FT   TOPO_DOM    835    881       Cytoplasmic (Potential).
FT   TRANSMEM    882    902       Potential.
FT   TOPO_DOM    903    928       Lumenal (Potential).
FT   TRANSMEM    929    949       Potential.
FT   TOPO_DOM    950   1657       Cytoplasmic (Potential).
FT   TRANSMEM   1658   1678       Potential.
FT   TOPO_DOM   1679   1805       Cytoplasmic (Potential).
FT   TRANSMEM   1806   1826       Potential.
FT   TOPO_DOM   1827   1828       Lumenal (Potential).
FT   TRANSMEM   1829   1849       Potential.
FT   TOPO_DOM   1850   1850       Cytoplasmic (Potential).
FT   TRANSMEM   1851   1871       Potential.
FT   TOPO_DOM   1872   1881       Lumenal (Potential).
FT   TRANSMEM   1882   1902       Potential.
FT   TOPO_DOM   1903   1972       Cytoplasmic (Potential).
FT   TOPO_DOM   1973   2002       In membrane (By similarity).
FT   TOPO_DOM   2003   2989       Cytoplasmic (Potential).
FT   TRANSMEM   2990   3010       By similarity.
FT   DOMAIN     1217   1369       Helicase ATP-binding.
FT   DOMAIN     2633   2751       RdRp catalytic.
FT   NP_BIND    1230   1237       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      385    411       HVR1 (By similarity).
FT   REGION      475    481       HVR2 (By similarity).
FT   REGION      482    494       CD81-binding 1 (Potential).
FT   REGION      522    553       CD81-binding 2 (Potential).
FT   REGION      660    671       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1679   1690       NS3-binding (by NS4A) (Potential).
FT   REGION     2120   2332       Transcriptional activation (Potential).
FT   REGION     2120   2208       FKBP8-binding (Potential).
FT   REGION     2200   2250       Basal phosphorylation (By similarity).
FT   REGION     2210   2275       PKR-binding (Potential).
FT   REGION     2210   2249       ISDR (By similarity).
FT   REGION     2249   2306       NS4B-binding (Potential).
FT   REGION     2351   2419       Basal phosphorylation (By similarity).
FT   REGION     2354   2377       V3 (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1316   1319       DECH box (By similarity).
FT   MOTIF      2322   2325       SH3-binding (Potential).
FT   MOTIF      2327   2335       Nuclear localization signal (Potential).
FT   COMPBIAS    796    803       Poly-Leu.
FT   COMPBIAS   2282   2327       Pro-rich.
FT   COMPBIAS   2995   2998       Poly-Leu.
FT   ACT_SITE    952    952       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    972    972       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    993    993       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1083   1083       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1107   1107       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1165   1165       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1123   1123       Zinc (By similarity).
FT   METAL      1125   1125       Zinc (By similarity).
FT   METAL      1171   1171       Zinc (By similarity).
FT   METAL      1175   1175       Zinc (By similarity).
FT   METAL      2011   2011       Zinc (By similarity).
FT   METAL      2029   2029       Zinc (By similarity).
FT   METAL      2031   2031       Zinc (By similarity).
FT   METAL      2052   2052       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        191    192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        746    747       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        809    810       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1026   1027       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1657   1658       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1711   1712       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1972   1973       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2419   2420       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2194   2194       Phosphoserine; by host; in p56 (By
FT                                similarity).
FT   MOD_RES    2197   2197       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2201   2201       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2204   2204       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1968   1968       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   LIPID      1972   1972       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    250    250       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    417    417       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    423    423       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    430    430       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    448    448       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    532    532       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    540    540       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    556    556       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    576    576       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    623    623       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    645    645       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2114   2162       By similarity.
SQ   SEQUENCE   3010 AA;  326578 MW;  94A1C77435D642BB CRC64;
     MSTNPKPQRK TKRNTYRRPQ DVKFPGGGQI VGGVYVLPRR GPTLGVRATR KTSERSQPRG
     RRQPIPKARR PEGRAWAQPG YPWPLYGNEG LGWAGWLLSP RGSRPSWGPT DPRRRSRNLG
     KVIDTLTCGF ADLMGYIPLV GAPLGGAARA LAHGVRVLED GVNYATGNLP GCSFSIFLLA
     LLSCLTIPAS AYQVRNASGL YHVTNDCSNS SIVYEAAGMI MHTPGCVPCV RENNASRCWV
     ALTPTLAARN TSIPTTTIRR HVDLLVGAAA FCSAMYVGDL CGSVFLVSQL FTFSPRRYET
     VQDCNCSIYP GHVSGHRMAW DMMMNWSPTT ALVVSQLLRI PQAVVDMVAG AHWGVLAGLA
     YYSMVGNWAK VLIVMLLFAG VDGVTYTTGG SQARHTQSVT SFFTQGPAQR IQLINTNGSW
     HINRTALNCN ESLNTGFFAA LFYAHKFNSS GCPERMASCS SIDKFAQGWG PITYTEPRDL
     DQRPYCWHYA PRQCGIVPAS QVCGPVYCFT PSPVVVGTTD RSGAPTYNWG ANETDVLLLN
     NTRPPQGNWF GCTWMNSTGF TKTCGGPPCN IGGVGNLTLT CPTDCFRKHP EATYTKCGSG
     PWLTPRCIVD YPYRLWHYPC TVNFTIFKVR MYVGGVEHRL SAACNWTRGE RCDLEDRDRS
     ELSPLLLSTT EWQTLPCSFT TLPALSTGLI HLHQNIVDVQ YLYGIGSAVV SFVIKWEYIV
     LLFLLLADAR VCACLWMMLL IAQAEAALEN LVVLNAASLA GADGILSFLV FFCAAWYIKG
     RLVPGAAYAL YGVWPLLLLL LALPPRAYAM DREMAASCGG VVFVGLILLT LSPHYKVFLA
     RLIWWLQYFI TRAEAHLCVW VPPLNVRGGR DAIILLTCAA HPELIFDITK LLLAILGPLM
     VLQAAITAMP YFVRAQGLIR ACMLVRKVAG GHYVQMAFMK LAALTGTYVY DHLTPLQDWA
     HAGLRDLAVA VEPVVFSDME TKIITWGADT AACGDIILGL PVSARRGREI LLGPADSIEG
     QGWRLLAPIT AYAQQTRGLL GCIVTSLTGR DKNQVEGEVQ VVSTATQSFL ATCVNGVCWT
     VFHGAGSKTL AGPKGPITQM YTNVDQDLVG WHAPPGARSL TPCTCGSSDL YLVTRHADVI
     PVRRRGDGRG SLLSPRPVSY LKGSSGGPLL CPSGHAVGIF RAAVCTRGVA KAVDFIPVES
     METTMRSPVF TDNSSPPAVP QTFQVAHLHA PTGSGKSTKV PAAYAAQGYK VLVLNPSVAA
     TLGFGAYMSK AHGTDPNIRT GVRTITTGAP ITYSTYGKFL ADGGCSGGAY DIIICDECHS
     TDSTTILGIG TVLDQAETAG ARLVVLATAT PPGSVTVPHP NIEEVALSNT GEIPFYGKAI
     PLEAIKGGRH LIFCHSKKKC DELAAKLSGL GINAVAYYRG LDVSVIPTSG DVVIVATDAL
     MTGYTGDFDS VIDCNTCVTQ TVDFSLDPTF TIETTTVPQD AVSRSQRRGR TGRGRGGIYR
     FVTPGERPSG MFDSSVLCEC YDAGCAWYEL TPAETTVRLR AYLNTPGLPV CQDHLEFWES
     VFTGLTHIDA HFLSQTKQAG DNFPYLVAYQ ATVCARAQAP PPSWDQMWKC LIRLKPTLHG
     PTPLLYRLGA VQNEITLTHP ITKFIMACMS ADLEVVTSTW VLVGGVLAAL AAYCLTTGSV
     VIVGRIILSG RPAVVPDREV LYREFDEMEE CASHLPYIEQ GMQLAEQFKQ KALGLLQTAT
     KQAEAAAPVV ESRWRALEAF WAKHMWNFIS GIQYLAGLST LPGNPAIASL MAFTASITSP
     LTTQNTLLFN ILGGWVAAQL APPSAASAFV GAGIAGAAIG SIGLGKVLVD ILAGYGAGVA
     GALVAFKVMS GEAPSAEDLV NLLPAILSPG ALVVGVVCAA ILRRHVGPGE GAVQWMNRLI
     AFASRGNHVS PTHYVPESDA AARVTQILSS LTITQLLKRL HQWINEDCST PCSGSWLKDV
     WDWICTVLTD FKTWLQSKLL PKLPGVPFFS CQRGYKGVWR GDGIMQTTCP CGAQITGHVK
     NGSMRIVGPK TCSNTWHGTF PINAYTTGPC TPSPAPNYSR ALWRVAAEEY VEITRVGDFH
     YVTGMTTDNV KCPCQVPAPE FFTELDGVRL HRYAPACRPL LREDVTFQVG LNQYLVGSQL
     PCEPEPDVAV LTSMLTDPSH ITAETAKRRL ARGSPPSLAS SSASQLSAPS LKATCTTHHD
     SPDADLIEAN LLWRQEMGGN ITRVESENKV VILDSFDPLR AEEDEREVSV AAEILRKSKK
     FPPALPIWAR PDYNPPLLES WKSPDYVPPA VHGCPLPPTT GPPIPPPRKK RTVVLTESTV
     SSALAELATK TFGSSGSSAV DSGTATAPPD QTSDDGDKES DVESYSSMPP LEGEPGDPDL
     SDGSWSTVSG EASDDIVCCS MSYTWTGALI TPCAAEESKL PINALSNSLL RHHNMVYATT
     SRSASLRQKK VTFDRLQVLD DHYRDVLKEM KAKASTVKAK LLSVEEACKL TPPHSAKSKF
     GYGAKDVRNL SSKAINHIRS VWKDLLEDTE TPIDTTIMAK SEVFCVQPEK GGRKPARLIV
     FPDLGVRVCE KMALYDVVST LPQAVMGSSY GFQYSPGQRV EFLVNAWKSK KSPMGFSYDT
     RCFDSTVTES DIRVEESIYQ CCDLAPEARQ AIKSLTERLY IGGPLTNSKG QNCGYRRCRA
     SGVLTTSCGN TLTCYLKATA ACRAAKLQDC TMLVNGDDLV VICESAGTQE DAASLRVFTE
     AMTRYSAPPG DPPQPEYDLE LITSCSSNVS VAHDASGKRV YYLTRDPTTP LARAAWETAR
     HTPVNSWLGN IIMYAPTLWA RMILMTHFFS ILLAQEQLEK ALDCQIYGAC YSIEPLDLPQ
     IIQRLHGLSA FSLHSYSPGE INRVASCLRK LGVPPLRVWR HRARSVRARL LSQGGRAATC
     GKYLFNWAVR TKLKLTPIPA ASQLDLSSWF VAGYSGGDIY HSLSRARPRW FMWCLLLLSV
     GVGIYLLPNR
//
ID   POLG_HCVK3              Reviewed;        3021 AA.
AC   Q81495;
DT   10-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 80.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 3a (isolate k3a) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=356416;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=95053917; PubMed=7964640;
RA   Yamada N., Manihara K., Mizokami M., Ohba K., Takada A., Tsutsumi M.,
RA   Date T.;
RT   "Full-length sequence of the genome of hepatitis C virus type 3a:
RT   comparative study with different genotypes.";
RL   J. Gen. Virol. 75:3279-3284(1994).
RN   [2]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [3]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [4]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain a highly variable region called hypervariable
CC       region 1 (HVR1). E2 also contains two segments involved in CD81-
CC       binding. HVR1 is implicated in the SCARB1-mediated cell entry.
CC       CD81-binding regions may be involved in sensitivity and/or
CC       resistance to IFN-alpha therapy (By similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A seems to be intrinsically disordered and
CC       interacts with NS5B and host PKR (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- MISCELLANEOUS: Core protein of HCV genotype 3a induces increased
CC       amount of triglyceride accumulation over other genotypes.
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 helicase C-terminal domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D28917; BAA06044.1; -; Genomic_RNA.
DR   euHCVdb; D28917; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; 1.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Disulfide bond; Envelope protein; Fusion protein;
KW   Glycoprotein; Helicase; Host cell membrane; Host cytoplasm;
KW   Host endoplasmic reticulum; Host lipid droplet; Host membrane;
KW   Host mitochondrion; Host nucleus; Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000045640.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000045641.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000045642.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000045643.
FT   CHAIN       384    752       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000045644.
FT   CHAIN       753    815       p7 (By similarity).
FT                                /FTId=PRO_0000045645.
FT   CHAIN       816   1032       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000045646.
FT   CHAIN      1033   1663       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000045647.
FT   CHAIN      1664   1717       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000045648.
FT   CHAIN      1718   1978       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000045649.
FT   CHAIN      1979   2430       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000045650.
FT   CHAIN      2431   3021       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000045651.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    731       Lumenal (Potential).
FT   TRANSMEM    732    752       Potential.
FT   TOPO_DOM    753    763       Lumenal (Potential).
FT   TRANSMEM    764    784       Potential.
FT   TOPO_DOM    785    788       Cytoplasmic (Potential).
FT   TRANSMEM    789    809       Potential.
FT   TOPO_DOM    810    819       Lumenal (Potential).
FT   TRANSMEM    820    840       Potential.
FT   TOPO_DOM    841    887       Cytoplasmic (Potential).
FT   TRANSMEM    888    908       Potential.
FT   TOPO_DOM    909    934       Lumenal (Potential).
FT   TRANSMEM    935    955       Potential.
FT   TOPO_DOM    956   1663       Cytoplasmic (Potential).
FT   TRANSMEM   1664   1684       Potential.
FT   TOPO_DOM   1685   1811       Cytoplasmic (Potential).
FT   TRANSMEM   1812   1832       Potential.
FT   TOPO_DOM   1833   1834       Lumenal (Potential).
FT   TRANSMEM   1835   1855       Potential.
FT   TOPO_DOM   1856   1856       Cytoplasmic (Potential).
FT   TRANSMEM   1857   1877       Potential.
FT   TOPO_DOM   1878   1887       Lumenal (Potential).
FT   TRANSMEM   1888   1908       Potential.
FT   TOPO_DOM   1909   1978       Cytoplasmic (Potential).
FT   TOPO_DOM   1979   2008       In membrane (By similarity).
FT   TOPO_DOM   2009   3000       Cytoplasmic (Potential).
FT   TRANSMEM   3001   3021       By similarity.
FT   DOMAIN     1223   1375       Helicase ATP-binding.
FT   DOMAIN     1382   1544       Helicase C-terminal.
FT   DOMAIN     2644   2762       RdRp catalytic.
FT   NP_BIND    1236   1243       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      385    411       HVR1 (By similarity).
FT   REGION      483    495       CD81-binding 1 (Potential).
FT   REGION      523    554       CD81-binding 2 (Potential).
FT   REGION      666    677       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1685   1696       NS3-binding (by NS4A) (Potential).
FT   REGION     2126   2338       Transcriptional activation (Potential).
FT   REGION     2126   2214       FKBP8-binding (Potential).
FT   REGION     2206   2256       Basal phosphorylation (By similarity).
FT   REGION     2216   2281       PKR-binding (Potential).
FT   REGION     2255   2312       NS4B-binding (Potential).
FT   REGION     2357   2430       Basal phosphorylation (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1322   1325       DECH box (By similarity).
FT   MOTIF      2328   2331       SH3-binding (Potential).
FT   MOTIF      2333   2341       Nuclear localization signal (Potential).
FT   COMPBIAS   2284   2333       Pro-rich.
FT   COMPBIAS   2357   2476       Ser-rich.
FT   COMPBIAS   3002   3009       Poly-Leu.
FT   ACT_SITE    958    958       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    978    978       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    999    999       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1089   1089       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1113   1113       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1171   1171       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1129   1129       Zinc (By similarity).
FT   METAL      1131   1131       Zinc (By similarity).
FT   METAL      1177   1177       Zinc (By similarity).
FT   METAL      1181   1181       Zinc (By similarity).
FT   METAL      2017   2017       Zinc (By similarity).
FT   METAL      2035   2035       Zinc (By similarity).
FT   METAL      2037   2037       Zinc (By similarity).
FT   METAL      2058   2058       Zinc (By similarity).
FT   SITE        164    164       Responsible for increased FAS up-
FT                                regulation (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       ?191   ?192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        752    753       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        815    816       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1032   1033       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1663   1664       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1717   1718       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1978   1979       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2430   2431       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2200   2200       Phosphoserine; by host; in p56 (By
FT                                similarity).
FT   MOD_RES    2203   2203       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2207   2207       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2210   2210       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1978   1978       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    417    417       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    423    423       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    430    430       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    448    448       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    476    476       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    533    533       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    557    557       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    581    581       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    629    629       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    651    651       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2120   2168       By similarity.
SQ   SEQUENCE   3021 AA;  328390 MW;  A97418FF36C062A4 CRC64;
     MSTLPKPQRK TKRNTIRRPQ DVKFPGGGVI YVGVYVLPRR GPRLGVRATR KTSERSQPRG
     RRKPIPKARR SEGRSWAQPG YPWPLYGNEG CGWAGWLLSP RGSRPNWAPN DPRRRSRNLG
     KVIDTLTCGF ADLMGYIPLV GAPLGGAARA LAHGVRALED GINFATGNLP GCSFSIFLLA
     LFSCLIHPAA SLEWRNTSGL YVLTNDCSNS SIVYEADDVI LHTPGCIPCV QDGNTSTCWT
     PVTPTVAVRY VGATTASIRS HVDLLVGAGT MCSALYVGDM CGPVFLVGQA FTFRPRRHRT
     VQTCNCSLYP GHLSGQRMAW DMMMNWSPAV GMVVAHILRL PQTLFDVVAG AHWGIIAGLA
     YYSMQGNWAK VAIIMVMFSG VDASTHVTAG QAARNAYGIT SLFSVGAKQN LQLINTNGSW
     HINRTALNCN ESINTGFIAG LFYYHKFNST GCPQRLSSCK PITFFKQGWG PLTDANITGP
     SDDKPYCWHY APRPCGIVPA LNVCGPVYCF TPSPVVVGTT DAKGAPTYTW GANKTDVFLL
     ESLRPPSGRW FGCTWMNSTG FVKTCGAPPC NIYGDGRDAQ NESDLFCPTD CFRKHPEATY
     SRCGAGPWLT PRCLVDYPYR LWHYPCTVNF TLFKVRMFVG GFEHRFTAAC NWTRGERCDI
     EDRDRSEQHP LLHSTTELAI LPCSFTPMPA LSTGLIHLHQ NIVDVQYLYG IGSGMVGWAL
     KWEFVILIFL LLADARVCVA LWLILTISQA EAALENLVTL NAVAAAGTHG IGWYLVAFCA
     AWYVRGKLVP LVTYSLTGLW SLALLVLLLP QRAYAWSGED SATLGAGILV LFGFFTLSPW
     YKHWIARLIW WNQYTICRCE SALHVWVPPL LARGGRDGVI LLTSLLYPSL IFDITKLLIA
     ALGPLYLIQA TITATPYFVR AHVLVRLCML VRSVMGGKYF QMIILSLADG SNTYLYDHLA
     PMQHWAAAGL KDLAVATEPV IFSPMEIKVI TWGADTAACG DILCGLPVSA RLGREVLLGP
     ADDYREMGWR LLAPITAYAQ QTRGLLGTIV TSLTGRDKNV VAGEVQVLST ATQTFLGTTV
     GGVMWTVYHG AGSRTLAGVK HPALQMYTNV DQDLVGWPAP PGAKSLEPCT CGSADLYLVT
     RDADVIPARR RGDSTASLLS PRPLARLKGS SGGPVMCPSG HVAGIFRAAV CTRGVAKALQ
     FIPVETLSTQ ARSPSFSDNS TPPAVPQSYQ VGYLHAPTGS GKSTKVPAAY VAQGYNVLVL
     NPSVAATLGF GSFMSRAYGI DPNIRTGNRT VTTGAKLTYS TYGKFLAGGG CSGGAYDVII
     CDDCHAQDAT SILGIGTVLD QAETAGVRLT VLATATPPGS ITVPHSNIEE VALGSEGEIP
     FYGKAIPIAC IKGGRHLIFC HSKKKCDKMA SKLRGMGLNA VAYYRGLDVS VIPTTGDVVV
     CATDALMTGF TGDFDSVIDC NVAVEQYVDF SLDPTFSIET CTAPQDAVSR SQRRGRTGRG
     RLGTYRYVTP GERPSGMFDS VVLCECYDAG CSWYDLQPAE TTVRLRAYLS TPGLPVCQDH
     LDLWESVFTG LTHIDAHFLS QTKQAGLNFS YLTAYQATVC ARAQAPPPSW DETWKCLVRL
     KPTLHGPTPL LYRLGPVQNE ICLTHPITKY VMACMSADLE VTTSTWVLLG GVLAAVAAYC
     LSVGCVVIVG HIELGGKPAL VPDKEVLYQQ YDEMEECSQA RPYIEQAQVI AHQFKEKVLG
     LLQRATQQQA VIEPIVVSNW QKLEVLWHKH MWNFVSGIQY LAGLSTLPGN PAVASLMAFT
     ASVTSPLTTN QTMFFNILGG WVATHLAGPQ ASSAFVVSGL AGAAIGGIGL GRVLLDILAG
     YGAGVSGALV AFKIMGGEPP TTEDMVNLLP AILSPGALVV GVICAAILRR HVGPGEGPVQ
     WMNRLIAFAS RGNHVSPAHY VPESDAAARV TALLSSLTVT SLLRRLHQWI NEDYPSPCSG
     DWLRIIWDWV CSVVSDFKTW LSAKIMPALP GLPFISCQKG YKGVWRGDGV MSTRCPCGAS
     IAGHVKNGSM RLAGPRTCAN MCHGTFPINE YTTGPSTPCP PPNYTRALWR VAANSYVEVR
     RVGDFHYITG ATEDGLKCPC QVPATEFFTE VDGVRIHRYA PPCRPLLRDE ITFMVGLNSY
     AIGSQLPCEP EPDVSVLTSM LRDPSHITAE TAARRLARGS PPSEASSSAS QLSAPSLKAT
     CQTHRPHPDA ELVDANLLWR QEMGSNITRV ESETKVVILD SFEPLRAETD DAELSAAAEC
     FKKPPKYPPA LPIWARPDYN PPLLDRWKSP DYVPPTVHGC ALPPKGAPPV PPPRRKRTIQ
     LDGSNVSAAL AALAEKSFPS SKPQEENSSS SGVDTQSSTA SKVLPSPGEE SDSESCSSMP
     PLEGEPGDPD LSCDSWSTVS DSEEQSVVCC SMSYSWTGAL ITPCSAEEEK LPISPLSNSL
     LRHHNLVYST SSRSASQRQK KVTFDRLQVL DDHYKTALQE VKERASRVKA RMLSIEEACA
     LVPPHSARSK FGYSAKDVRS LSSKAINQIR SVWEDLLEDT TTPIPTTIMA KNEVFCVDPA
     KGGRKAARLI VYPDLGVRVC EKRALYDVIQ RLSIETMGSA YGFQYSPRQR VERLLKMWTS
     KKTPLGFSYD TRCFDSTVTG QDIRVEEAVY QCCNLEPEPG QAISSLTERL YCGGPMNNSK
     GAQCGYLRCR ASGVLPTSFG NTITCYIKAT AAARAAGLRN PDFLVCGDDL VVVAESDGVD
     EDRATLRAFT EAMTRYSAPP GDAPQPTYDL ELITSCSSNV SVARDDKGKR YYYLTRDATT
     PLARAAWETA RHTPVNSWLG SIIMYAPTIW VRMVMMTHFF SILQSQEILD RPLDFEMYGA
     TYSVTPLDLP AIIERLHGLS AFSVHSYSPV ELNRVAGTLR KLGCPPLRAW RHRARAVRAK
     LIAQGGRAKI CGLYLFNWAV RTKTKLTPLP AAGQLDLSSW FTVGVGGNDI YHSVSRARTR
     YLLLCLLLLT VGVGIFLLPA R
//
ID   POLG_HCVNZ              Reviewed;        3021 AA.
AC   Q81258;
DT   10-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 79.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 3a (isolate NZL1) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=356415;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=8021605;
RA   Sakamoto M., Akahane Y., Tsuda F., Tanaka T., Woodfield D.G.,
RA   Okamoto H.;
RT   "Entire nucleotide sequence and characterization of a hepatitis C
RT   virus of genotype V/3a.";
RL   J. Gen. Virol. 75:1761-1768(1994).
RN   [2]
RP   SUBCELLULAR LOCATION OF CORE PROTEIN, FUNCTION OF CORE PROTEIN, AND
RP   MUTAGENESIS OF PHE-164.
RX   PubMed=17188392; DOI=10.1016/j.jhep.2006.10.019;
RA   Jackel-Cram C., Babiuk L.A., Liu Q.;
RT   "Up-regulation of fatty acid synthase promoter by hepatitis C virus
RT   core protein: genotype-3a core has a stronger effect than genotype-1b
RT   core.";
RL   J. Hepatol. 46:999-1008(2007).
RN   [3]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [4]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [5]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity (By similarity). Alters lipid metabolism by
CC       interacting with hepatocellular proteins involved in lipid
CC       accumulation and storage. Core protein induces up-regulation of
CC       FAS promoter activity, and thereby probably contributes to the
CC       increased triglyceride accumulation in hepatocytes (steatosis).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein. Host mitochondrion
CC       membrane; Single-pass type I membrane protein. Host lipid droplet.
CC       Note=The C-terminal transmembrane domain of core protein p21
CC       contains an ER signal leading the nascent polyprotein to the ER
CC       membrane. Only a minor proportion of core protein is present in
CC       the nucleus and an unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain a highly variable region called hypervariable
CC       region 1 (HVR1). E2 also contains two segments involved in CD81-
CC       binding. HVR1 is implicated in the SCARB1-mediated cell entry.
CC       CD81-binding regions may be involved in sensitivity and/or
CC       resistance to IFN-alpha therapy (By similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A seems to be intrinsically disordered and
CC       interacts with NS5B and host PKR (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- MISCELLANEOUS: HCV genotype 3a induces increased amount of
CC       triglyceride accumulation (steatosis) over other genotypes. This
CC       could be due to a stronger FAS promoter up-regulation by the core
CC       protein from genotype 3a.
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 helicase C-terminal domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D17763; BAA04609.1; -; Genomic_RNA.
DR   PIR; PQ0401; PQ0401.
DR   PIR; PQ0804; PQ0804.
DR   RefSeq; YP_001469631.1; -.
DR   euHCVdb; D17763; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; 1.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Disulfide bond; Envelope protein; Fusion protein;
KW   Glycoprotein; Helicase; Host cell membrane; Host cytoplasm;
KW   Host endoplasmic reticulum; Host lipid droplet; Host membrane;
KW   Host mitochondrion; Host nucleus; Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000045652.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000045653.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000045654.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000045655.
FT   CHAIN       384    752       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000045656.
FT   CHAIN       753    815       p7 (By similarity).
FT                                /FTId=PRO_0000045657.
FT   CHAIN       816   1032       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000045658.
FT   CHAIN      1033   1663       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000045659.
FT   CHAIN      1664   1717       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000045660.
FT   CHAIN      1718   1978       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000045661.
FT   CHAIN      1979   2430       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000045662.
FT   CHAIN      2431   3021       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000045663.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    731       Lumenal (Potential).
FT   TRANSMEM    732    752       Potential.
FT   TOPO_DOM    753    763       Lumenal (Potential).
FT   TRANSMEM    764    784       Potential.
FT   TOPO_DOM    785    788       Cytoplasmic (Potential).
FT   TRANSMEM    789    809       Potential.
FT   TOPO_DOM    810    819       Lumenal (Potential).
FT   TRANSMEM    820    840       Potential.
FT   TOPO_DOM    841    887       Cytoplasmic (Potential).
FT   TRANSMEM    888    908       Potential.
FT   TOPO_DOM    909    934       Lumenal (Potential).
FT   TRANSMEM    935    955       Potential.
FT   TOPO_DOM    956   1663       Cytoplasmic (Potential).
FT   TRANSMEM   1664   1684       Potential.
FT   TOPO_DOM   1685   1811       Cytoplasmic (Potential).
FT   TRANSMEM   1812   1832       Potential.
FT   TOPO_DOM   1833   1834       Lumenal (Potential).
FT   TRANSMEM   1835   1855       Potential.
FT   TOPO_DOM   1856   1856       Cytoplasmic (Potential).
FT   TRANSMEM   1857   1877       Potential.
FT   TOPO_DOM   1878   1887       Lumenal (Potential).
FT   TRANSMEM   1888   1908       Potential.
FT   TOPO_DOM   1909   1978       Cytoplasmic (Potential).
FT   TOPO_DOM   1979   2008       In membrane (By similarity).
FT   TOPO_DOM   2009   3000       Cytoplasmic (Potential).
FT   TRANSMEM   3001   3021       By similarity.
FT   DOMAIN     1223   1375       Helicase ATP-binding.
FT   DOMAIN     1382   1544       Helicase C-terminal.
FT   DOMAIN     2644   2762       RdRp catalytic.
FT   NP_BIND    1236   1243       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplet localization.
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      385    411       HVR1 (By similarity).
FT   REGION      483    495       CD81-binding 1 (Potential).
FT   REGION      523    554       CD81-binding 2 (Potential).
FT   REGION      666    677       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1685   1696       NS3-binding (by NS4A) (Potential).
FT   REGION     2126   2338       Transcriptional activation (Potential).
FT   REGION     2126   2214       FKBP8-binding (Potential).
FT   REGION     2206   2256       Basal phosphorylation (By similarity).
FT   REGION     2216   2281       PKR-binding (Potential).
FT   REGION     2255   2312       NS4B-binding (Potential).
FT   REGION     2357   2430       Basal phosphorylation (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1322   1325       DECH box (By similarity).
FT   MOTIF      2328   2331       SH3-binding (Potential).
FT   MOTIF      2333   2341       Nuclear localization signal (Potential).
FT   COMPBIAS   2284   2333       Pro-rich.
FT   COMPBIAS   2357   2476       Ser-rich.
FT   COMPBIAS   3002   3009       Poly-Leu.
FT   ACT_SITE    958    958       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    978    978       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    999    999       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1089   1089       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1113   1113       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1171   1171       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1129   1129       Zinc (By similarity).
FT   METAL      1131   1131       Zinc (By similarity).
FT   METAL      1177   1177       Zinc (By similarity).
FT   METAL      1181   1181       Zinc (By similarity).
FT   METAL      2017   2017       Zinc (By similarity).
FT   METAL      2035   2035       Zinc (By similarity).
FT   METAL      2037   2037       Zinc (By similarity).
FT   METAL      2058   2058       Zinc (By similarity).
FT   SITE        164    164       Responsible for increased FAS up-
FT                                regulation.
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       ?191   ?192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        752    753       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        815    816       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1032   1033       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1663   1664       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1717   1718       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1978   1979       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2430   2431       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2200   2200       Phosphoserine; by host; in p56 (By
FT                                similarity).
FT   MOD_RES    2203   2203       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2207   2207       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2210   2210       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1978   1978       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    417    417       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    423    423       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    430    430       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    448    448       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    476    476       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    557    557       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    581    581       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    651    651       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2120   2168       By similarity.
FT   MUTAGEN     164    164       F->Y: Reduced FAS up-regulation by the
FT                                core protein.
SQ   SEQUENCE   3021 AA;  329578 MW;  38712CCBC0C19562 CRC64;
     MSTLPKPQRK TKRNTIRRPQ DVKFPGGGQI VGGVYVLPRR GPRLGVRATR KTSERSQPRG
     RRQPIPKARR SEGRSWAQPG YPWPLYGNEG CGWAGWLLSP RGSRPSWGPN DPRRRSRNLG
     KVIDTLTCGF ADLMGYIPLV GAPVGGVARA LAHGVRALED GINFATGNLP GCSFSIFLLA
     LFSCLIHPAA SLEWRNTSGL YVLTNDCSNS SIVYEADDVI LHTPGCVPCV QDGNTSTCWT
     PVTPTVAVRY VGATTASIRS HVDLLVGAAT MCSALYVGDM CGAVFLVGQA FTFRPRRHQT
     VQTCNCSLYP GHLSGHRMAW DMMMNWSPAV GMVVAHVLRL PQTLFDIMAG AHWGILAGLA
     YYSMQGNWAK VAIIMVMFSG VDAHTYTTGG TASRHTQAFA GLFDIGPQQK LQLVNTNGSW
     HINSTALNCN ESINTGFIAG LFYYHKFNST GCPQRLSSCK PITFFRQGWG PLTDANITGP
     SDDRPYCWHY APRPCDIVPA SSVCGPVYCF TPSPVVVGTT DARGVPTYTW GENEKDVFLL
     KSQRPPSGRW FGCSWMNSTG FLKTCGAPPC NIYGGEGNPH NESDLFCPTD CFRKHPETTY
     SRCGAGPWLT PRCMVDYPYR LWHYPCTVDF RLFKVRMFVG GFEHRFTAAC NWTRGERCDI
     EDRDRSEQHP LLHSTTELAI LPCSFTPMPA LSTGLIHLHQ NIVDVQYLYG VGSGMVGWAL
     KWEFVILVFL LLADARVCVA LWLMLMISQT EAALENLVTL NAVAAAGTHG IGWYLVAFCA
     AWYVRGKLVP LVTYSLTGLW SLALLVLLLP QRAYAWSGED SATLGAGVLV LFGFFTLSPW
     YKHWIGRLMW WNQYTICRCE SALHVWVPPL LARGSRDGVI LLTSLLYPSL IFDITKLLMA
     VLGPLYLIQA TITTTPYFVR AHVLVRLCML VRSVIGGKYF QMIILSIGRW FNTYLYDHLA
     PMQHWAAAGL KDLAVATEPV IFSPMEIKVI TWGADTAACG DILCGLPVSA RLGREVLLGP
     ADDYREMGWR LLAPITAYAQ QTRGLLGTIV TSLTGRDKNV VTGEVQVLST ATQTFLGTTV
     GGVIWTVYHG AGSRTLAGAK HPALQMYTNV DQDLVGWPAP PGAKSLEPCA CGSSDLYLVT
     RDADVIPARR RGDSTASLLS PRPLACLKGS SGGPVMCPSG HVAGIFRAAV CTRGVAKSLQ
     FIPVETLSTQ ARSPSFSDNS TPPAVPQSYQ VGYLHAPTGS GKSTKVPAAY VAQGYNVLVL
     NPSVAATLGF GSFMSRAYGI DPNIRTGNRT VTTGAKLTYS TYGKFLADGG CSGGAYDVII
     CDECHAQDAT SILGIGTVLD QAETAGVRLT VLATATPPGS ITVPHSNIEE VALGSEGEIP
     FYGKAIPIAL LKGGRHLIFC HSKKKCDEIA SKLRGMGLNA VAYYRGLDVS VIPTTGDVVV
     CATDALMTGF TGDFDSVIDC NVAVEQYVDF SLDPTFSIET RTAPQDAVSR SQRRGRTGRG
     RLGTYRYVAS GERPSGMFDS VVLCECYDAG CSWYDLQPAE TTVRLRAYLS TPGLPVCQDH
     LDFWESVFTG LTHIDAHFLS QTKQQGLNFS YLTAYQATVC ARAQAPPPSW DEMWKCLVRL
     KPTLHGPTPL LYRLGPVQNE TCLTHPITKY LMACMSADLE VTTSTWVLLG GVLAALAAYC
     LSVGCVVIVG HIELEGKPAL VPDKEVLYQQ YDEMEECSQA APYIEQAQVI AHQFKEKILG
     LLQRATQQQA VIEPIVTTNW QKLEAFWHKH MWNFVSGIQY LAGLSTLPGN PAVASLMAFT
     ASVTSPLTTN QTMFFNILGG WVATHLAGPQ SSSAFVVSGL AGAAIGGIGL GRVLLDILAG
     YGAGVSGALV AFKIMGGECP TAEDMVNLLP AILSPGALVV GVICAAILRR HVGPGEGAVQ
     WMNRLIAFAS RGNHVSPTHY VPESDAAARV TALLSSLTVT SLLRRLHQWI NEDYPSPCSD
     DWLRTIWDWV CSVLADFKAW LSAKIMPALP GLPFISCQKG YKGVWRGDGV MSTRCPCGAA
     ITGHVKNGSM RLAGPRTCAN MWHGTFPINE YTTGPSTPCP SPNYTRALWR VAANSYVEVR
     RVGDFHYITG ATEDELKCPC QVPAAEFFTE VDGVRLHRYA PPCKPLLRDD ITFMVGLHSY
     TIGSQLPCEP EPDVSVLTSM LRDPSHITAE TAARRLARGS PPSEASSSAS QLSAPSLKAT
     CQTHRPHPDA ELVDANLLWR QEMGSNITRV ESETKVVVLD SFEPLRAETD DVEPSVAAEC
     FKKPPKYPPA LPIWARPDYN PPLLDRWKAP DYVPPTVHGC ALPPRGAPPV PPPRRKRTIQ
     LDGSNVSAAL AALAEKSFPS SKPQEENSSS SGVDTQSSTT SKVPPSPGGE SDSESCSSMP
     PLEGEPGDPD LSCDSWSTVS DSEEQSVVCC SMSYSWTGAL ITPCSAEEEK LPISPLSNSL
     LRHHNLVYST SSRSASQRQK KVTFDRLQVL DDHYKTALKE VKERASRVKA RMLTIEEACA
     LVPPHSARSK FGYSAKDVRS LSSRAINQIR SVWEDLLEDT TTPIPTTIMA KNEVFCVDPA
     KGGRKPARLI VYPDLGVRVC EKRALYDVIQ KLSIETMGPA YGFQYSPQQR VERLLKMWTS
     KKTPLGFSYD TRCFDSTVTE QDIRVEEEIY QCCNLEPEAR KVISSLTERL YCGGPMFNSK
     GAQCGYRRCR ASGVLPTSFG NTITCYIKAT AAAKAANLRN PDFLVCGDDL VVVAESDGVD
     EDRAALRAFT EAMTRYSAPP GDAPQATYDL ELITSCSSNV SVARDDKGRR YYYLTRDATT
     PLARAAWETA RHTPVNSWLG NIIMYAPTIW VRMVMMTHFF SILQSQEILD RPLDFEMYGA
     TYSVTPLDLP AIIERLHGLS AFTLHSYSPV ELNRVAGTLR KLGCPPLRAW RHRARAVRAK
     LIAQGGKAKI CGLYLFNWAV RTKTNLTPLP AAGQLDLSSW FTVGVGGNDI YHSVSRARTR
     HLLLCLLLLT VGVGIFLLPA R
//
ID   POLG_HCVR6              Reviewed;        3010 AA.
AC   Q913V3;
DT   20-FEB-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   02-MAR-2010, entry version 61.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 1b (isolate HCR6) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=421879;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=14747471; DOI=10.1074/jbc.M312822200;
RA   Tsukiyama-Kohara K., Tone S., Maruyama I., Inoue K., Katsume A.,
RA   Nuriya H., Ohmori H., Ohkawa J., Taira K., Hoshikawa Y., Shibasaki F.,
RA   Reth M., Minatogawa Y., Kohara M.;
RT   "Activation of the CKI-CDK-Rb-E2F pathway in full genome hepatitis C
RT   virus-expressing cells.";
RL   J. Biol. Chem. 279:14531-14541(2004).
RN   [2]
RP   CLEAVAGE OF CORE PROTEIN BY SIGNAL PEPTIDASE, AND MASS SPECTROMETRY.
RX   PubMed=15479818; DOI=10.1128/JVI.78.21.11766-11777.2004;
RA   Ogino T., Fukuda H., Imajoh-Ohmi S., Kohara M., Nomoto A.;
RT   "Membrane binding properties and terminal residues of the mature
RT   hepatitis C virus capsid protein in insect cells.";
RL   J. Virol. 78:11766-11777(2004).
RN   [3]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain two highly variable regions called
CC       hypervariable region 1 and 2 (HVR1 and HVR2). E2 also contain two
CC       segments involved in CD81-binding. HVR1 is implicated in the
CC       SCARB1-mediated cell entry. HVR2 and CD81-binding regions may be
CC       involved in sensitivity and/or resistance to IFN-alpha therapy (By
CC       similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A seems to be intrinsically disordered and
CC       interacts with NS5B and host PKR. The C-terminus of NS5A contains
CC       a variable region called variable region 3 (V3) (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY045702; AAK97744.1; -; Genomic_RNA.
DR   PIR; A61196; A61196.
DR   PIR; PS0329; PS0329.
DR   HSSP; P27958; 1CWX.
DR   euHCVdb; AY045702; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; FALSE_NEG.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Envelope protein; Fusion protein; Glycoprotein;
KW   Helicase; Host cell membrane; Host cytoplasm;
KW   Host endoplasmic reticulum; Host lipid droplet; Host membrane;
KW   Host mitochondrion; Host nucleus; Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000278754.
FT   CHAIN         2    177       Core protein p19 (Probable).
FT                                /FTId=PRO_0000278755.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (Probable).
FT                                /FTId=PRO_0000278756.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000278757.
FT   CHAIN       384    746       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000278758.
FT   CHAIN       747    809       p7 (By similarity).
FT                                /FTId=PRO_0000278759.
FT   CHAIN       810   1026       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000278760.
FT   CHAIN      1027   1657       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000278761.
FT   CHAIN      1658   1711       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000278762.
FT   CHAIN      1712   1972       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000278763.
FT   CHAIN      1973   2419       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000278764.
FT   CHAIN      2420   3010       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000278765.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    725       Lumenal (Potential).
FT   TRANSMEM    726    746       Potential.
FT   TOPO_DOM    747    757       Lumenal (Potential).
FT   TRANSMEM    758    778       Potential.
FT   TOPO_DOM    779    782       Cytoplasmic (Potential).
FT   TRANSMEM    783    803       Potential.
FT   TOPO_DOM    804    813       Lumenal (Potential).
FT   TRANSMEM    814    834       Potential.
FT   TOPO_DOM    835    881       Cytoplasmic (Potential).
FT   TRANSMEM    882    902       Potential.
FT   TOPO_DOM    903    928       Lumenal (Potential).
FT   TRANSMEM    929    949       Potential.
FT   TOPO_DOM    950   1657       Cytoplasmic (Potential).
FT   TRANSMEM   1658   1678       Potential.
FT   TOPO_DOM   1679   1805       Cytoplasmic (Potential).
FT   TRANSMEM   1806   1826       Potential.
FT   TOPO_DOM   1827   1828       Lumenal (Potential).
FT   TRANSMEM   1829   1849       Potential.
FT   TOPO_DOM   1850   1850       Cytoplasmic (Potential).
FT   TRANSMEM   1851   1871       Potential.
FT   TOPO_DOM   1872   1881       Lumenal (Potential).
FT   TRANSMEM   1882   1902       Potential.
FT   TOPO_DOM   1903   1972       Cytoplasmic (Potential).
FT   TOPO_DOM   1973   2002       In membrane (By similarity).
FT   TOPO_DOM   2003   2989       Cytoplasmic (Potential).
FT   TRANSMEM   2990   3010       By similarity.
FT   DOMAIN     1217   1369       Helicase ATP-binding.
FT   DOMAIN     2633   2751       RdRp catalytic.
FT   NP_BIND    1230   1237       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      385    411       HVR1 (By similarity).
FT   REGION      475    481       HVR2 (By similarity).
FT   REGION      482    494       CD81-binding 1 (Potential).
FT   REGION      522    553       CD81-binding 2 (Potential).
FT   REGION      660    671       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1679   1690       NS3-binding (by NS4A) (Potential).
FT   REGION     2120   2332       Transcriptional activation (Potential).
FT   REGION     2120   2208       FKBP8-binding (Potential).
FT   REGION     2200   2250       Basal phosphorylation (By similarity).
FT   REGION     2210   2275       PKR-binding (Potential).
FT   REGION     2210   2249       ISDR (By similarity).
FT   REGION     2249   2306       NS4B-binding (Potential).
FT   REGION     2351   2419       Basal phosphorylation (By similarity).
FT   REGION     2354   2377       V3 (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1316   1319       DECH box.
FT   MOTIF      2322   2325       SH3-binding (Potential).
FT   MOTIF      2327   2335       Nuclear localization signal (Potential).
FT   COMPBIAS    572    575       Poly-Gly.
FT   COMPBIAS    796    803       Poly-Leu.
FT   COMPBIAS   1432   1435       Poly-Val.
FT   COMPBIAS   2282   2327       Pro-rich.
FT   COMPBIAS   2993   2998       Poly-Leu.
FT   ACT_SITE    952    952       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    972    972       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    993    993       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1083   1083       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1107   1107       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1165   1165       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1123   1123       Zinc (By similarity).
FT   METAL      1125   1125       Zinc (By similarity).
FT   METAL      1171   1171       Zinc (By similarity).
FT   METAL      1175   1175       Zinc (By similarity).
FT   METAL      2011   2011       Zinc (By similarity).
FT   METAL      2029   2029       Zinc (By similarity).
FT   METAL      2031   2031       Zinc (By similarity).
FT   METAL      2052   2052       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        191    192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        746    747       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        809    810       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1026   1027       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1657   1658       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1711   1712       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1972   1973       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2419   2420       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (Probable).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2194   2194       Phosphoserine; by host; in p56
FT                                (Probable).
FT   MOD_RES    2197   2197       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2201   2201       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2204   2204       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1968   1968       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   LIPID      1972   1972       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    250    250       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    417    417       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    423    423       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    430    430       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    448    448       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    532    532       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    540    540       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    556    556       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    576    576       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    623    623       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    645    645       N-linked (GlcNAc...); by host
FT                                (Potential).
SQ   SEQUENCE   3010 AA;  326942 MW;  D528A329A11F0D92 CRC64;
     MSTNPKPQRK TKRNTNRRPQ DVKFPGGGQI VGGVYLLPRR GPRLGVRATR KTSERSQPRG
     RRQPIPKARQ PEGRAWAQPG YPWPLYGNEG MGWAGWLLSP RGSRPSWGPT DPRRRSRNLG
     KVIDTLTCGF ADLMGYIPLV GAPLGGVARA LAHGVRVVED GVNYATGNLP GCSFSIFLLA
     LLSCLTIPAS AYEVRNVSGI YHVTNDCSNS SIVYEAADMI MHTPGCVPCV REGNSSRCWV
     ALTPTLAARN ASVPTTAIRR HVDLLVGAAA FCSAMYVGDL CGSVFLVSQL FTFSPRRHET
     IQDCNCSIYP GHVSGHRMAW DMMMNWSPTT ALVVSQLLRI PQAIVDMVAG AHWGVLAGLA
     YYSMVGNWAK VLIVMLLFAG VDGETRVTGG QIARNAYSLT TLFSSGSAQN IQLINTNGSW
     HINRTALNCN DSLNTGFLAA LFYTHKFNAS GCPERLASCR PIDKFDQGWG PITYAEQGGQ
     DQRPYCWHYA PKPCGIVSAS KVCGPVYCFT PSPVVVGTTD RFGVPTYSWG ENETDVLLLN
     NTRPPQGNWF GCTWMNGTGF TKTCGGPPCN IGGGGNNTLT CPTDCFRKHP AATYTKCGSG
     PWLTPRCLVD YPYRLWHYPC TANFTIFKVR MYVGGVEHRL DAACNWTRGE RCNLEDRDRL
     ELSPLLLSTT EWQVLPCSFT TLPALSTGLI HLHQNIVDVQ YLYGIGSAVV SFAIKWDYIV
     ILFLLLADAR VCACLWMMLL IAQAEAALEN LVVLNAASVA GAHGILSFLV FFCAAWYIKG
     KLVPGAAYAF YGVWPLLLLL LALPPRAYAM EREMAASCGG AVFVGLVLLT LSPYYKEFLA
     RLIWWLQYFI TRAEAHLQVW IPPLNIRGGR DAIILLACVV HPELIFDITK LLLAILGPLM
     VLQASITQVP YFVRAQGLIR ACMLVRKVAG GHYVQMAFVK LTALTGTYVY DHLTPLRDWA
     HAGLRDLAVA VEPVVFSDME TKVITWGADT AACGDIILGL PVSARRGREI LLGPADSLEG
     QGWRLLAPIT AYSQQTRGLL GCIITSLTGR DKNQVEGEVQ VVSTATQSFL ATCVNGACWT
     VFHGAGSKTL AGPKGPITQM YTNVDLDLVG WQAPPGSRSL TPCTCGSSDL YLVTRHADVI
     PVRRRGDSRG SLLSPRPVSY LKGSSGGPLL CPSRHAVGIF RAAVCTRGVA KAVDFIPVES
     METTMRSPVF TDNSSPPAVP QTFQVAHLHA PTGSGKSTKV PAAYAAQGYK VLVLNPSVAA
     TLGFGAYMSK AHGIDPNIRT GVRAITTGAP ITYSTYGKFL ADGGCSGGAY DIIICDECHS
     TDSTTILGIG TVLDQAETAG ARLVVLATAT PPGSVTVPHP NIEEVALSNA GEIPFYGKAI
     PIEVIKGGRH LIFCHSKKKY DELAAKLSAL GLNAVAYYRG LDVSVIPTNG DVVVVATDAL
     MTGFTGDFDS VIDCNTCVTQ TVDFSLDPTF TIETTTVPQD AVARSQRRGR TGRGRRGIYR
     FVTPGERPSG MFDSSVLCEC YDAGCAWYEL TPAETSVRLR AYLNTPGLPV CQDHLEFWES
     VSTGLTHIDA HFLSQTKQAG DNFPYLVAYQ ATVCARAQAP PPSWDQMWKC LIRLKPTLHG
     PTPLLYRLGA VQNEITLTHP MTKFIMACMS ADLEVVTSTW VLVGGVLAAL AAYCLTTGSV
     VIVGRIILSG RPAVIPDREV LYREFDEMEE CASHLPYIEQ GMQLAEQFKQ KALGLLQTAT
     KQAEAAAPVV ESKWRALETF WAKHMWNFIS GIQYLAGLST LPGNPAIASL MAFTASITSP
     LSTQNTLLFN IWGGWVAAQL APPSAASAFV GAGIAGAAVG SIGLGKVLVD ILAGYGAGVA
     GALVAFKIMS GEVPSTEDLV NLLPAILSPG ALVVGVVCAA ILRRHVGPGE GAVQWMNRLI
     AFASRGNHVS PAHYVPESDA AARVTQILSG LTITQLLKRL HHWINEDCST PCSGSWLRDV
     WDWICTVLTD FKTWLQSKLL PRLPGVPFFS CQRGYKGVWR GDGIMQTTCP CGAQITGHVK
     NGSMRIVGPK TCSSTWHGTF PINAYTTGPC APSPAPNYSR ALWRVAAEEY VEVTRVGDFH
     YVTGMTTDNV KCPCQVPAPE FFTEVDGVRL HRYAPACKPL LREEVTFQVG LNQYLVGSQL
     PCEPEPDVAV LTSMLTDPSH ITAETAKRRL ARGSPPSLAS SSASQLSAPS LKATCTTHHD
     SPDVDLIEAN LLWRQEMGGN ITRVESENKV VILDSFDPLR AEEDEREPSV AAEILRKTKR
     FPPAMPIWAR PDYNPPLLES WKDPDYVPPV VHGCPLPPTK APPIPPPRRK RTVVLTESTV
     SSALAELATK TFGSSGSSAV DSGTATAPPD QASDDGDQGS DVESYSSMPP LEGEPGDPDL
     SDGSWSTVSE EAGEDVICCS MSYTWTGALI TPCAAEESKL PINPLSNSLL RHHNMVYATT
     SRSAGLRQKK VTFDRLQVLD DHYRDVLKEM KAKASTVKAK LLSIEEACKL TPPHSARSKF
     GYGAKDVRNL SSKAVNHIRS VWKDLLEDTE TPIDTTVMAK SEVFCVQPEK GGRKPARLIV
     FPDLGVRVCE KMALYDVVST LPQAVMGSSY GFQYSPGQRV EFLVNAWKSK KCPMGFSYDT
     RCFDSTVTES DIRVEESIYQ CCDLAPEARQ AIKSLTERLY IGGPLTNSKG QNCGYRRCRA
     SGVLTTSCGN TLTCYLKASA ACRAAKLRDC TMLVNGDDLV VICESAGTQE DEANLRVFTE
     AMTRYSAPPG DPPRPEYDLE LITSCSSNVS VAHDASGKRV YYLTRDPSTP LARAAWETAR
     HTPVNSWLGN IIMYAPTLWA RMILMTHFFS ILLAQEQLEK ALDCQIYGAC YSIEPLDLPQ
     IIERLHGLSA FSLHSYSPGE INRVASCLRK LGVPPLRVWR HRARSVRAKL LSQGGRAATC
     GKYLFNWAVR TKLKLTPIPA ASQLDLSSWF VAGYSGGDIY HSLSRARPRW FMLCLLLLSV
     GVGIYLLPNR
//
ID   POLG_HCVSA              Reviewed;        3014 AA.
AC   O91936;
DT   10-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 76.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 5a (isolate SA13) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=356390;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=99023006; PubMed=9806059; DOI=10.1086/515683;
RA   Bukh J., Apgar C.L., Engle R., Govindarajan S., Hegerich P.A.,
RA   Tellier R., Wong D.C., Elkins R., Kew M.C.;
RT   "Experimental infection of chimpanzees with hepatitis C virus of
RT   genotype 5a: genetic analysis of the virus and generation of a
RT   standardized challenge pool.";
RL   J. Infect. Dis. 178:1193-1197(1998).
RN   [2]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [3]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [4]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain a highly variable region called hypervariable
CC       region 1 (HVR1). E2 also contains two segments involved in CD81-
CC       binding. HVR1 is implicated in the SCARB1-mediated cell entry.
CC       CD81-binding regions may be involved in sensitivity and/or
CC       resistance to IFN-alpha therapy (By similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A seems to be intrinsically disordered and
CC       interacts with NS5B and host PKR (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF064490; AAC61696.1; -; Genomic_RNA.
DR   MEROPS; C18.001; -.
DR   euHCVdb; AF064490; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; FALSE_NEG.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Disulfide bond; Envelope protein; Fusion protein;
KW   Glycoprotein; Helicase; Host cell membrane; Host cytoplasm;
KW   Host endoplasmic reticulum; Host lipid droplet; Host membrane;
KW   Host mitochondrion; Host nucleus; Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000045664.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000045665.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000045666.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000045667.
FT   CHAIN       384    747       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000045668.
FT   CHAIN       748    810       p7 (By similarity).
FT                                /FTId=PRO_0000045669.
FT   CHAIN       811   1027       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000045670.
FT   CHAIN      1028   1658       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000045671.
FT   CHAIN      1659   1712       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000045672.
FT   CHAIN      1713   1973       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000045673.
FT   CHAIN      1974   2423       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000045674.
FT   CHAIN      2424   3014       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000045675.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    726       Lumenal (Potential).
FT   TRANSMEM    727    747       Potential.
FT   TOPO_DOM    748    758       Lumenal (Potential).
FT   TRANSMEM    759    779       Potential.
FT   TOPO_DOM    780    783       Cytoplasmic (Potential).
FT   TRANSMEM    784    804       Potential.
FT   TOPO_DOM    805    814       Lumenal (Potential).
FT   TRANSMEM    815    835       Potential.
FT   TOPO_DOM    836    882       Cytoplasmic (Potential).
FT   TRANSMEM    883    903       Potential.
FT   TOPO_DOM    904    929       Lumenal (Potential).
FT   TRANSMEM    930    950       Potential.
FT   TOPO_DOM    951   1658       Cytoplasmic (Potential).
FT   TRANSMEM   1659   1679       Potential.
FT   TOPO_DOM   1680   1806       Cytoplasmic (Potential).
FT   TRANSMEM   1807   1827       Potential.
FT   TOPO_DOM   1828   1829       Lumenal (Potential).
FT   TRANSMEM   1830   1850       Potential.
FT   TOPO_DOM   1851   1851       Cytoplasmic (Potential).
FT   TRANSMEM   1852   1872       Potential.
FT   TOPO_DOM   1873   1882       Lumenal (Potential).
FT   TRANSMEM   1883   1903       Potential.
FT   TOPO_DOM   1904   1973       Cytoplasmic (Potential).
FT   TOPO_DOM   1974   2003       In membrane (By similarity).
FT   TOPO_DOM   2004   2993       Cytoplasmic (Potential).
FT   TRANSMEM   2994   3014       By similarity.
FT   DOMAIN     1218   1370       Helicase ATP-binding.
FT   DOMAIN     2637   2755       RdRp catalytic.
FT   NP_BIND    1231   1238       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      385    411       HVR1 (By similarity).
FT   REGION      483    495       CD81-binding 1 (Potential).
FT   REGION      523    554       CD81-binding 2 (Potential).
FT   REGION      661    672       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1680   1691       NS3-binding (by NS4A) (Potential).
FT   REGION     2121   2334       Transcriptional activation (Potential).
FT   REGION     2121   2209       FKBP8-binding (Potential).
FT   REGION     2201   2251       Basal phosphorylation (By similarity).
FT   REGION     2211   2276       PKR-binding (Potential).
FT   REGION     2250   2307       NS4B-binding (Potential).
FT   REGION     2353   2423       Basal phosphorylation (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1317   1320       DECH box (By similarity).
FT   MOTIF      2323   2326       SH3-binding (Potential).
FT   MOTIF      2328   2337       Nuclear localization signal (Potential).
FT   COMPBIAS    757    761       Poly-Ala.
FT   COMPBIAS    797    804       Poly-Leu.
FT   COMPBIAS   2263   2266       Poly-Asp.
FT   COMPBIAS   2280   2328       Pro-rich.
FT   COMPBIAS   2996   3002       Poly-Leu.
FT   ACT_SITE    953    953       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    973    973       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    994    994       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1084   1084       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1108   1108       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1166   1166       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1124   1124       Zinc (By similarity).
FT   METAL      1126   1126       Zinc (By similarity).
FT   METAL      1172   1172       Zinc (By similarity).
FT   METAL      1176   1176       Zinc (By similarity).
FT   METAL      2012   2012       Zinc (By similarity).
FT   METAL      2030   2030       Zinc (By similarity).
FT   METAL      2032   2032       Zinc (By similarity).
FT   METAL      2053   2053       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        191    192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        747    748       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        810    811       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1027   1028       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1658   1659       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1712   1713       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1973   1974       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2423   2424       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2195   2195       Phosphoserine; by host; in p56 (By
FT                                similarity).
FT   MOD_RES    2198   2198       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2202   2202       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2205   2205       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1973   1973       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    417    417       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    423    423       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    430    430       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    448    448       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    533    533       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    541    541       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    557    557       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    577    577       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    624    624       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    646    646       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2115   2163       By similarity.
SQ   SEQUENCE   3014 AA;  327119 MW;  4D198683058C13D6 CRC64;
     MSTNPKPQRK TKRNTNRRPQ DVKFPGGGQI VGGVYLLPRR GPRLGVRATR KTSERSQPRG
     RRQPIPKARQ PTGRSWGQPG YPWPLYANEG LGWAGWLLSP RGSRPNWGPN DPRRKSRNLG
     KVIDTLTCGF ADLMGYIPLV GGPVGGVARA LAHGVRVLED GVNYATGNLP GCSFSIFILA
     LLSCLTVPTS AVPYRNASGV YHVTNDCPNS SIVYEAEDLI LHAPGCVPCV RQGNVSRCWV
     QITPTLSAPS LGAVTAPLRR AVDYLAGGAA LCSALYVGDA CGAVFLVGQM FTYSPRRHNV
     VQDCNCSIYS GHITGHRMAW DMMMNWSPTT ALVMAQLLRI PQVVIDIIAG AHWGVLFAAA
     YYASAANWAK VVLVLFLFAG VDANTRTVGG SAAQGARGLA SLFTPGPQQN LQLINTNGSW
     HINRTALNCN DSLQTGFVAG LLYYHKFNST GCPQRMASCR PLAAFDQGWG TISYAAVSGP
     SDDKPYCWHY PPRPCGIVPA RGVCGPVYCF TPSPVVVGTT DRKGNPTYSW GENETDIFLL
     NNTRPPTGNW FGCTWMNSTG FVKTCGAPPC NLGPTGNNSL KCPTDCFRKH PDATYTKCGS
     GPWLTPRCLV HYPYRLWHYP CTLNYTIFKV RMYIGGLEHR LEVACNWTRG ERCDLEDRDR
     AELSPLLHTT TQWAILPCSF TPTPALSTGL IHLHQNIVDT QYLYGLSSSI VSWAVKWEYI
     VLAFLLLADA RICTCLWIML LVCQAEAALE NVIVLNAAAA AGTHGFFWGL LVICFAWHFK
     GRLVPGATYL CLGIWPLLLL LFLLPQRALA LDSSDGGTVG CLVLTILTIF TLTPGYKKMV
     VLVIWWLQYF IARVEAFIHV WVPPLQVRGG RDAIIMLTCL FHPALGFEVT KILLGILGPL
     YLLQYSLIKL PYFIRARALL RACLLAKHLA CGRYVQAALL HLGRLTGTYI YDHLAPMKDW
     AASGLRDLAV ATEPIIFSPM ETKVITWGAD TAACGDILAG LPVSARRGHE IFLGPADDIR
     EAGWRLLAPI TAYAQQTRGV LGAIIVSLTG RDKNEAEGEV QVLSTATQTF LGTCINGVMW
     TVFHGAGAKT LAGPKGPVVQ MYTNVDKDLV GWPTPPGTRS LTPCTCGSAD LYLVTRHADV
     VPARRRGDTR ASLLSPRPIS YLKGSSGGPV MCPSGHVVGV FRAAVCTRGV AKALDFIPVE
     NLETTMRSPV FTDNSTPPAV PHEFQVGHLH APTGSGKSTK VPAAYAAQGY KVLVLNPSVA
     ATLGFGAYMS RAYGVDPNIR TGVRTVTTGA AITYSTYGKF LADGGCSGGA YDVIICDECH
     SQDATTILGI GTVLDQAETA GARLVVLATA TPPGSVTTPH PNIEEVALPS EGEIPFYGRA
     IPLALIKGGR HLIFCHSKKK CDELAKQLTS QGVNAVAYYR GLDVAVIPAT GDVVVCSTDA
     LMTGFTGDFD SVIDCNTTVT QTVDFSLDPT FTIETTTVPQ DAVSRSQRRG RTGRGRHGIY
     RYVSSGERPS GIFDSVVLCE CYDAGCAWYD LTPAETTVRL RAYLNTPGLP VCQDHLEFWE
     GVFTGLTNID AHMLSQTKQG GENFPYLVAY QATVCVRAKA PPPSWDTMWK CMLRLKPTLT
     GPTPLLYRLG AVQNEITLTH PITKYIMACM SADLEVITST WVLVGGVVAA LAAYCLTVGS
     VAIVGRIILS GRPAIIPDRE VLYQQFDEME ECSASLPYMD EARAIAEQFK EKVLGLIGTA
     GQKAETLKPA ATSMWNRAEQ FWAKHMWNFV SGIQYLAGLS TLPGNPAVAT LMSFTAAVTS
     PLTTQQTLLF NILGGWVASQ IAPPTAATAF VVSGMAGAAV GSIGLGRVLI DILAGYGAGV
     AGALVAFKIM CGEKPTAEDL VNLLPSILCP GALVVGVICA AVLRRHIGPG EGAVQWMNRL
     IAFASRGNHV SPTHYVPETD ASAKVTQLLS SLTVTSLLKR LHTWIGEDYS TPCDGTWLRA
     IWDWVCTALT DFKAWLQAKL LPQLPGVPFL SCQRGYRGVW RGDGVNSTKC PCGATISGHV
     KNGTMRIVGP KLCSNTWHGT FPINATTTGP SVPAPAPNYK FALWRVGAAD YAEVRRVGDY
     HYITGVTQDN LKCPCQVPSP EFFTELDGVR IHRYAPPCNP LLREEVCFSV GLHSFVVGSQ
     LPCEPEPDVT VLTSMLSDPA HITAETAKRR LDRGSPPSLA SSSASQLSAP SLKATCTTQG
     HHPDADLIEA NLLWRQCMGG NITRVEAENK VVILDSFEPL KADDDDREIS VSADCFRRGP
     AFPPALPIWA RPGYDPPLLE TWKQPDYDPP QVSGCPLPPA GLPPVPPPRR KRKPVVLSDS
     NVSQVLADLA HARFKADTQS IEGQDSAVGT SSQPDSGPEE KRDDDSDAAS YSSMPPLEGE
     PGDPDLSSGS WSTVSDEDSV VCCSMSYSWT GALITPCSAE EEKLPINPLS NTLLRHHNLV
     YSTSSRSAGQ RQKKVTFDRL QVLDDHYREV VDEMKRLASK VKARLLPLEE ACGLTPPHSA
     RSKYGYGAKE VRSLDKKALN HIKGVWQDLL DDSDTPLPTT IMAKNEVFAV EPSKGGKKPA
     RLIVYPDLGV RVCEKRALYD IAQKLPTALM GPSYGFQYSP AQRVEFLLKT WRSKKTPMAF
     SYDTRCFDST VTEHDIMTEE SIYQSCDLQP EARAAIRSLT QRLYCGGPMY NSKGQQCGYR
     RCRASGVFTT SMGNTMTCYI KALASCRAAK LRDCTLLVCG DDLVAICESQ GTHEDEASLR
     AFTEAMTRYS APPGDPPVPA YDLELVTSCS SNVSVAHDAS GNRVYYLTRD PQVPLARAAW
     ETAKHSPVNS WLGNIIMYAP TLWARIVLMT HFFSVLQSQE QLEKALAFEM YGSVYSVTPL
     DLPAIIQRLH GLSAFTLHSY SPSEINRVSS CLRKLGVPPL RAWRHRARAV RAKLIAQGGK
     AAICGIYLFN WAVKTKRKLT PLADADRLDL SSWFTVGAGG GDIYHSMSRA RPRCILLCLL
     LLTVGVGIFL LPAR
//
ID   POLG_HCVT5              Reviewed;        3019 AA.
AC   O92529;
DT   10-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 76.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 6b (isolate Th580) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=356421;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=98378034; PubMed=9714232;
RA   Tokita H., Okamoto H., Iizuka H., Kishimoto J., Tsuda F., Miyakawa Y.,
RA   Mayumi M.;
RT   "The entire nucleotide sequences of three hepatitis C virus isolates
RT   in genetic groups 7-9 and comparison with those in the other eight
RT   genetic groups.";
RL   J. Gen. Virol. 79:1847-1857(1998).
RN   [2]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [3]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [4]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain a highly variable region called hypervariable
CC       region 1 (HVR1). E2 also contains two segments involved in CD81-
CC       binding. HVR1 is implicated in the SCARB1-mediated cell entry.
CC       CD81-binding regions may be involved in sensitivity and/or
CC       resistance to IFN-alpha therapy (By similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A seems to be intrinsically disordered and
CC       interacts with NS5B and host PKR (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D84262; BAA32664.1; -; Genomic_RNA.
DR   RefSeq; YP_001469634.1; -.
DR   euHCVdb; D84262; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; FALSE_NEG.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Disulfide bond; Envelope protein; Fusion protein;
KW   Glycoprotein; Helicase; Host cell membrane; Host cytoplasm;
KW   Host endoplasmic reticulum; Host lipid droplet; Host membrane;
KW   Host mitochondrion; Host nucleus; Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000045676.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000045677.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000045678.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000045679.
FT   CHAIN       384    751       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000045680.
FT   CHAIN       752    814       p7 (By similarity).
FT                                /FTId=PRO_0000045681.
FT   CHAIN       815   1031       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000045682.
FT   CHAIN      1032   1662       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000045683.
FT   CHAIN      1663   1716       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000045684.
FT   CHAIN      1717   1977       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000045685.
FT   CHAIN      1978   2428       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000045686.
FT   CHAIN      2429   3019       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000045687.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    730       Lumenal (Potential).
FT   TRANSMEM    731    751       Potential.
FT   TOPO_DOM    752    762       Lumenal (Potential).
FT   TRANSMEM    763    783       Potential.
FT   TOPO_DOM    784    787       Cytoplasmic (Potential).
FT   TRANSMEM    788    808       Potential.
FT   TOPO_DOM    809    818       Lumenal (Potential).
FT   TRANSMEM    819    839       Potential.
FT   TOPO_DOM    840    886       Cytoplasmic (Potential).
FT   TRANSMEM    887    907       Potential.
FT   TOPO_DOM    908    933       Lumenal (Potential).
FT   TRANSMEM    934    954       Potential.
FT   TOPO_DOM    955   1662       Cytoplasmic (Potential).
FT   TRANSMEM   1663   1683       Potential.
FT   TOPO_DOM   1684   1810       Cytoplasmic (Potential).
FT   TRANSMEM   1811   1831       Potential.
FT   TOPO_DOM   1832   1833       Lumenal (Potential).
FT   TRANSMEM   1834   1854       Potential.
FT   TOPO_DOM   1855   1855       Cytoplasmic (Potential).
FT   TRANSMEM   1856   1876       Potential.
FT   TOPO_DOM   1877   1886       Lumenal (Potential).
FT   TRANSMEM   1887   1907       Potential.
FT   TOPO_DOM   1908   1977       Cytoplasmic (Potential).
FT   TOPO_DOM   1978   2007       In membrane (By similarity).
FT   TOPO_DOM   2008   2998       Cytoplasmic (Potential).
FT   TRANSMEM   2999   3019       By similarity.
FT   DOMAIN     1222   1374       Helicase ATP-binding.
FT   DOMAIN     2642   2760       RdRp catalytic.
FT   NP_BIND    1235   1242       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      384    410       HVR1 (By similarity).
FT   REGION      483    495       CD81-binding 1 (Potential).
FT   REGION      523    554       CD81-binding 2 (Potential).
FT   REGION      665    676       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1684   1695       NS3-binding (by NS4A) (Potential).
FT   REGION     2125   2338       Transcriptional activation (Potential).
FT   REGION     2125   2213       FKBP8-binding (Potential).
FT   REGION     2205   2255       Basal phosphorylation (By similarity).
FT   REGION     2215   2280       PKR-binding (Potential).
FT   REGION     2254   2312       NS4B-binding (Potential).
FT   REGION     2357   2428       Basal phosphorylation (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1321   1324       DECH box (By similarity).
FT   MOTIF      2328   2331       SH3-binding (Potential).
FT   MOTIF      2333   2341       Nuclear localization signal (Potential).
FT   COMPBIAS   2282   2333       Pro-rich.
FT   COMPBIAS   2999   3007       Poly-Leu.
FT   ACT_SITE    957    957       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    977    977       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    998    998       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1088   1088       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1112   1112       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1170   1170       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1128   1128       Zinc (By similarity).
FT   METAL      1130   1130       Zinc (By similarity).
FT   METAL      1176   1176       Zinc (By similarity).
FT   METAL      1180   1180       Zinc (By similarity).
FT   METAL      2016   2016       Zinc (By similarity).
FT   METAL      2034   2034       Zinc (By similarity).
FT   METAL      2036   2036       Zinc (By similarity).
FT   METAL      2057   2057       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        191    192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        751    752       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        814    815       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1031   1032       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1662   1663       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1716   1717       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1977   1978       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2428   2429       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2199   2199       Phosphoserine; by host; in p56 (By
FT                                similarity).
FT   MOD_RES    2202   2202       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2206   2206       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2209   2209       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1977   1977       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    250    250       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    416    416       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    422    422       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    447    447       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    476    476       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    533    533       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    557    557       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    578    578       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    628    628       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    650    650       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2119   2167       By similarity.
SQ   SEQUENCE   3019 AA;  328235 MW;  E26750E07BCBC310 CRC64;
     MSTLPKPQRK TKRNTNRRPM DVKFPGGGQI VGGVYLLPRR GPRLGVRATR KTSERSQPRG
     RRQPIPKARP SQGRTWGQPG YPWPLYGNEG CGWAGWLMSP RGSRPSWGPN DPRRRSRNLG
     KVIDTLTCGL ADLMGYIPVV GGPLGGVAAA LAHGVRAIED GINYATGNLP GCSFSIFILA
     LLSCLTTPAS ALTYGNSSGL YHLTNDCPRS SIVLEAEAMI LHLAGCVPCV RAGNISRCWH
     PVSPTLAVPN ASVPASGFRK HVDLLAGAAV VCSSMYIGDL CGAVFLAGQL ATFSPRIHDI
     TQDCNCSVYT GHVTGHRMAW DMMMNWSPTT TLVLSSILRV PEIVLEVFAG GHWGVLIAIA
     YFGMSGNWLK VIAVLFLFAG VEATTTVGRA AGRSAYLFTS IFSSGPNQKI QLINTNGSWH
     INRTALNCID SLQTGFLSAL FYRSNFNSTG CSERLGACKP LEHFQQGWGP ITHKSNITGP
     SEDRPYCWHY APRECSVVPA SSVCGPVYCF TPSPVVVGTT DRLGNPTYNW GENETDVFML
     ESLRPPQGGW FGCTWMNSTG FTKTCGAPPC QLIPGDYNSS SNQLLCPTDC FRKHPEATYQ
     KCGSGPWLTP RCLVDYPYRL WHYPCTVNYT IHKVRMFIGG VEHRFDAACN WTRGDRCDLY
     DRDRIEMSPL LFSTTQLAIL PCSFTTMPAL STGLIHLHQN IVDVQYLYGV SSSIVSWAVK
     WEYVVLMFLV LADARICTCL WLMLLVGKVE AALERLVVLN AASAAGTAGW CWTLIFLCCV
     WHVKGRLVPA CTYTALGMWP ILLVILALPQ RAYAWDNSQA ASLGVVALLV LTIFTLSPMY
     KQLLTHAIWW NQYMLARAEA MIHDWVPDLR VRGGRDAIIL LTCLLHPHLG FEVTKILLAI
     LAPLYILQHS LLKVPYFVRA HILLRACMFF RKVAAGKYVQ ACLLRLGAWT GTYIYDHLAP
     LSEWASDGLR DLAVAVEPVI FSPMEKKIIT WGADTAACGD ILRGLPVSAR LGDLVLLGPA
     DDMRHGGWKL LAPITAYAQQ TRGLVGTIVT SLTGRDKNEA EGEVQVVSTA TQSFLATTIN
     GVLWTVYHGA GSKNLAGPKG PVCQMYTNVD QDLVGWPAPL GARSLAPCTC GSSDLYLVTR
     GADVIPARRR GDTRAALLSP RPISTLKGSS GGPLMCPSGH VVGLFRAAVC TRGVAKALDF
     IPVENMDTTM RSPVFTDNSS PPAVPQTYQV GYLHAPTGSG KSTRVPAAYA TQGYKVLVLN
     PSVAATLSFG AYMSKAHGID PNIRTGVRTI TTGGPVTYST YGKFLADGGC SGGAYDIIIC
     DECHSTDPTT VLGIGTVLDQ AETAGVRLTV LATATPPGSV TVPHPNITET ALPTTGEIPF
     YGKCIPLEFI KGGRHLIFCH SKKKCDELSK QLTSLGLNAV AFYRGVDVAV IPTSGDVVVC
     ATDALMTGYT GDFDSVIDCN VAVTQVVDFS LDPTFSIETT TVPQDAVSRS QRRGRTGRGK
     PGVYRFVSQG ERPSGMFDSV VLCEAYDTGC AWYELTPAET TVRLRAYLNT PGLPVCQDHL
     EFWEGVFTGL THIDAHFLSQ TKQGGENFAY LVAYQATVCA RAKAPPPSWD VMWKCLTRLK
     PTLTGPTPLL YRLGAVQNEI VTTHPITKYI MTCMSADLEV ITSTWVIVGG VLAALAAYCL
     TVGCVVICGR IVTSGKPAVV PDREVLYQQF DEMEECSKHI PYLVEGQQIA EQFKQKVLGL
     LQAGTKHAEE LKPAIHSTWP RVEEFWRKHM WNFVSGIQYL AGLSTLPGSP AVASLMSFTA
     SLTSPLRTSQ TLLLNILGGW IASQVAPPSA STAFVVSGLA GATVASIGLG RVIVDILAGY
     GAGVAGALVA FKIMSGECPS TEDMVNLLPA LLSPGALVVG VVCAAILRRH VGPSEGANQW
     MNRLIAFASR GNHVSPTHYV PETDASNKVT QILSSLTITS LLRRLHQWIH EDTSTPCASS
     WLRDVWDWVC TVLSDFKTWL KAKITPRIPG IPFISCQAGY RGVWAGDGVC HTTCSCGAQI
     AGHVKNGSMK ITGPRMCSNT WHGTFPINAT TTSPSVPVPA PNYKRALWRV SAEEYVEVER
     HGDRHYVVGV TADGLKCPCQ VPGPEFFTEV DGVRIHRYAP PCKPLLRDEV SFSVGLLEFV
     VGSQLPCEPE PDVTVVTSML TDPSHITAET ASRRLKRGSP PSLASSSASQ LSAPSLKATC
     TANGDHPDAE LIEANLLWRQ EMGSNITRVE SETKVVILDS FDPLVAEYDD REISVSAECH
     RPPRPKFPPA LPIWARPDYN PPLLQKWQMP GYEPPVVSGC ALPPAKPTPI PPPRRKRLIQ
     LDESAVSQAL QQLADKVFVE DTSTSEPSSG LGGSIAGPSS PDPTTADDTC SDAGSFSSMP
     PLEGEPGDPD LSTGSWSTVS EEDDVVCCSM SYTWTGALIT PCAAEEEKLP INPLSNSLIR
     HHNMVYSTTS RSAGLRQKKV TFDRLQVVDQ HYQDVLKEIK LRASTVHARL LSTEEACSLT
     PPHSARSRYG YGARDVRSHT SKAVKHIDSV WEDLLEDNAT PIPTTIMAKN EVFCVDPSKG
     GRKPARLIVY PDLSVRVCEK MALYDVTQKL PKTVMGSAYG FQYSPSQRVE YLLKMWRSKK
     TPMGFSYDTR CFDSTVTERD IRTEEDIYQS CQLDPTARKA ISSLTERLYC GGPMFNSKGE
     SCGYRRCRAS GVLTTSLGNT LTCYLKAQAA CRAANIKNFD MLVCGDDLVV ICESAGVQED
     VVALRAFTDA MIRYSAPPGD APQPTYDLEL ITSCSSNVSV AHDGTGQRYY YLTRDCTTPL
     ARAAWETARH TPVNSWLGNI IMYAPTIWVR MVLMTHFFSI LQCQEQLEAA LNFDMYGVTY
     SVTPLDLPAI IQRLHGMAAF SLHGYSPTEL NRVGASLRKL GAPPLRAWRH RARAVRAKLI
     AQGGKAAICG KYLFNWAVKT KLKLTPLAAA SQLDLSGWFV AGYDGGDIYH SVSRARPRLL
     LLGLLLLTVG VGIFLLPAR
//
ID   POLG_HCVTR              Reviewed;        3023 AA.
AC   Q81487;
DT   10-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 81.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 3b (isolate Tr-Kj) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=357355;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=7996156;
RA   Chayama K., Tsubota A., Koida I., Arase Y., Saitoh S., Ikeda K.,
RA   Kumada H.;
RT   "Nucleotide sequence of hepatitis C virus (type 3b) isolated from a
RT   Japanese patient with chronic hepatitis C.";
RL   J. Gen. Virol. 75:3623-3628(1994).
RN   [2]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [3]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [4]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain a highly variable region called hypervariable
CC       region 1 (HVR1). E2 also contains two segments involved in CD81-
CC       binding. HVR1 is implicated in the SCARB1-mediated cell entry.
CC       CD81-binding regions may be involved in sensitivity and/or
CC       resistance to IFN-alpha therapy (By similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A seems to be intrinsically disordered and
CC       interacts with NS5B and host PKR (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 helicase C-terminal domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D49374; BAA08372.1; -; Genomic_RNA.
DR   MEROPS; S29.001; -.
DR   euHCVdb; D49374; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; 1.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Disulfide bond; Envelope protein; Fusion protein;
KW   Glycoprotein; Helicase; Host cell membrane; Host cytoplasm;
KW   Host endoplasmic reticulum; Host lipid droplet; Host membrane;
KW   Host mitochondrion; Host nucleus; Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000045688.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000045689.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000045690.
FT   CHAIN       192    384       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000045691.
FT   CHAIN       385    754       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000045692.
FT   CHAIN       755    817       p7 (By similarity).
FT                                /FTId=PRO_0000045693.
FT   CHAIN       818   1034       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000045694.
FT   CHAIN      1035   1665       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000045695.
FT   CHAIN      1666   1719       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000045696.
FT   CHAIN      1720   1980       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000045697.
FT   CHAIN      1981   2432       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000045698.
FT   CHAIN      2433   3023       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000045699.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    359       Lumenal (Potential).
FT   TRANSMEM    360    380       Potential.
FT   TOPO_DOM    381    733       Lumenal (Potential).
FT   TRANSMEM    734    754       Potential.
FT   TOPO_DOM    755    765       Lumenal (Potential).
FT   TRANSMEM    766    786       Potential.
FT   TOPO_DOM    787    790       Cytoplasmic (Potential).
FT   TRANSMEM    791    811       Potential.
FT   TOPO_DOM    812    821       Lumenal (Potential).
FT   TRANSMEM    822    842       Potential.
FT   TOPO_DOM    843    889       Cytoplasmic (Potential).
FT   TRANSMEM    890    910       Potential.
FT   TOPO_DOM    911    936       Lumenal (Potential).
FT   TRANSMEM    937    957       Potential.
FT   TOPO_DOM    958   1665       Cytoplasmic (Potential).
FT   TRANSMEM   1666   1686       Potential.
FT   TOPO_DOM   1687   1813       Cytoplasmic (Potential).
FT   TRANSMEM   1814   1834       Potential.
FT   TOPO_DOM   1835   1836       Lumenal (Potential).
FT   TRANSMEM   1837   1857       Potential.
FT   TOPO_DOM   1858   1858       Cytoplasmic (Potential).
FT   TRANSMEM   1859   1879       Potential.
FT   TOPO_DOM   1880   1889       Lumenal (Potential).
FT   TRANSMEM   1890   1910       Potential.
FT   TOPO_DOM   1911   1980       Cytoplasmic (Potential).
FT   TOPO_DOM   1981   2010       In membrane (By similarity).
FT   TOPO_DOM   2011   3002       Cytoplasmic (Potential).
FT   TRANSMEM   3003   3023       By similarity.
FT   DOMAIN     1225   1377       Helicase ATP-binding.
FT   DOMAIN     1387   1546       Helicase C-terminal.
FT   DOMAIN     2646   2764       RdRp catalytic.
FT   NP_BIND    1238   1245       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      266    297       Fusion peptide (Potential).
FT   REGION      386    412       HVR1 (By similarity).
FT   REGION      484    496       CD81-binding 1 (Potential).
FT   REGION      524    555       CD81-binding 2 (Potential).
FT   REGION      668    679       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1687   1698       NS3-binding (by NS4A) (Potential).
FT   REGION     2128   2340       Transcriptional activation (Potential).
FT   REGION     2128   2216       FKBP8-binding (Potential).
FT   REGION     2208   2258       Basal phosphorylation (By similarity).
FT   REGION     2218   2283       PKR-binding (Potential).
FT   REGION     2257   2314       NS4B-binding (Potential).
FT   REGION     2359   2432       Basal phosphorylation (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1324   1327       DECH box (By similarity).
FT   MOTIF      2330   2333       SH3-binding (Potential).
FT   MOTIF      2335   2343       Nuclear localization signal (Potential).
FT   COMPBIAS    831    834       Poly-Leu.
FT   COMPBIAS   2286   2335       Pro-rich.
FT   COMPBIAS   3004   3011       Poly-Leu.
FT   ACT_SITE    960    960       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    980    980       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1001   1001       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1091   1091       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1115   1115       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1173   1173       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1131   1131       Zinc (By similarity).
FT   METAL      1133   1133       Zinc (By similarity).
FT   METAL      1179   1179       Zinc (By similarity).
FT   METAL      1183   1183       Zinc (By similarity).
FT   METAL      2019   2019       Zinc (By similarity).
FT   METAL      2037   2037       Zinc (By similarity).
FT   METAL      2039   2039       Zinc (By similarity).
FT   METAL      2060   2060       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       ?191   ?192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        384    385       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        754    755       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        817    818       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1034   1035       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1665   1666       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1719   1720       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1980   1981       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2432   2433       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2202   2202       Phosphoserine; by host; in p56 (By
FT                                similarity).
FT   MOD_RES    2205   2205       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2209   2209       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2212   2212       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1980   1980       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    235    235       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    236    236       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    306    306       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    418    418       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    424    424       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    431    431       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    449    449       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    497    497       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    534    534       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    558    558       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    583    583       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    631    631       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    653    653       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2122   2170       By similarity.
SQ   SEQUENCE   3023 AA;  329739 MW;  5268D1EC410AC545 CRC64;
     MSTLPKPKRQ TKRNTLRRPK NVKFPAGGQI VGEVYVLPRR GPQLGVREVR KTSERSQPRG
     RRQPTPKARP REGRSWAQPG YPWPLYGNEG CGWAGWLLPP RGSRPSWGQN DPRRRSRNLG
     KVIDTLTCGF ADLMGYIPLI GAPVGGVARA LAHGVRALED GVNYATGNLP GCSFSIFLLA
     LFSCLTCPAS SLEYRNASGL YLLTNDCSNR SIVYEADDVI LHLPGCVPCV ETDNNNTSCW
     TPISPTVAVK HPGVTTASIR NHVNMLVAPP TLCSALYVED AFGAVSLVGQ AFTFRPRQHK
     TVQTCNCSIY PGHVSGHRMA WDMMMNWSPA IGLVISHLMR LPQTFFDLVV GAHWGVMAGL
     AYFSMQGNWA KVVIVLIMFS GVDATTHTTG GSAAQATAGF TSFFTRGPSQ NLQLVNSNGS
     WHINSTALNC NDSLNTGFIA GLFYYHKFNS SGCPERMSSC KPITYFNQGW GPLTDANING
     PSEDRPYCWH YPPRPCNITK PLNVCGPVYC FTPSPVVVGT TDIKGLPTYR FGVNESDVFL
     LTSLRPPQGR WFGCVWMNST GFVKTCGAPP CNIYGGMKDI EANQTHLKCP TDCFRKHHDA
     TFTRCGSGPW LTPRCLVDYP YRLWHYPCTV NFSIFKVRMF VGGHEHRFSA ACNWTRGERC
     DLEDRDRSEQ QPLLHSTTDS LILPCSFTPM RRLSTGLIHL HQNIVDVQYL YGVGSAVVGW
     ALKWEFVVLV FLLLADARVC VALWMMLLIS QAEAAMENLV MLNALSAAGQ QGYVWYLVAF
     CAAWHIRGKL VPLITYGLTG LWPLALLDLL LPQRAYAWTG EDDATIGAGV LLLLGFFTLS
     PWYKHWIGRL IWWNQYAICR GEAALQVWVP PLLVRGSRDS VILLASLLYP SLIFDITKLL
     IAVLGPLYLI QAALTSTPYF VRAHVLIRIC MLVRSAMGGK YVQMAVLTVG RWFNTYLYDH
     LSPIQDWAAE GLKGLAVATE PVIFSPMEIK VITWGADTAA CGDILCGLPV SARLGRELLL
     GPADDYKKMG WRLLSPISAY AQQTRGLFGT IVTSLTGRDK NVVTGEVQVL STATQTFLGT
     TVGGVMWTVY HGAGSRTLAG NKRPALQMYT NVDQDLVGWP APAGTKSLDP CTCGSSDLYL
     VTREADVLPA RRRGDSTASL LSTRPLSCLK GSSGGPVMCP SGHVVGIFRA AVCTRGVAKA
     LQFIPVETLS TQVRSPSFSD NSTPPAVPES YQVGYLHAPT GSGKSTKVPA AYVAQGYSVL
     VLNPSVAATL GFGTYMSKAY GIDPNIRTGT RTITTGAKLT YSTYGKFLAD GGCSGGAYDV
     IICDECHAQD ATSILGIGTV LDQAETAGVR LTVLATATPP GSITVPHPNI EEVGLTSDGE
     IPFYGKALPL AMIKGGRHLV FCHSKEKCDE LASKLRGMGV NAVAFYRGLD VSVIPVSGDV
     VVCATDALMT GYTGDFDTVI DCNVAVEQYV DFSLDPTFSI ETRTVPQDAV SRSQRRGRTG
     RGRPGIYRFV TPGERPSGMF DSVVLCECYD AGCSWYDLQP AETTVRLRAY LSTPGLPVCQ
     DHLDFWERVF TGLTHIDAHF LSQAKQQGLN FAYLVAYQAT VCARAKASPP CWDEMWKCLI
     RLKPTLQGPT PLLYRLGAIQ NDICMTHPIT KYIMACMSAD LEVTTSAWVL VGGVLAALAA
     YCLSVGCVVI VGHIELGGKP ALVPDRQVLY QQYDEMEECS QSAPYIEQAQ AIAQQFKDKV
     LGLLQRASQQ EAEIRPIVQS QWQKAEAFWQ QHMWNFVSGI QYLAGLSTLP GNPAVASLMA
     FTASVTSPLT TNQTMFFNIL GGWVATHLAG PAASSAFVVS GLAGAAVGGI GIGRVLLDVL
     AGYGAGVSGA LVAFKIMGGE LPTTEDMVNL LPAILSPGAL VVGVICAAVL RRHVGPGEGA
     VQWMNRLIAF ASRGNHVSPT HYVPESDAAA KVTALLSSLT VTRLLRRLHQ WINEDYPSPC
     NGDWLHDIWD WVCIVLSDFK TWLSAKIMPK VPGIPFLSCQ KGYKGVWRGD GVMTTRCPCG
     EDFTGHVRNG SMRIAGSGLC ANMWHGTFPI NEYTTGPSTP VPAHNYSRAL WRVTSDSYVE
     VRRVGDTHYV VGATNDGLKI PCQVPAPEFF TELDGVRLHR YAPPCKPLLR DEITFSVGLH
     SYANGSQLSC EPEPDVAVLT SMLRDPAHIT AATAARRLAR GSPPSEASSS ASQLSAPSLK
     ATCQTHRPHP DAELIDANLL WRQEMGSNIT RVESETKVVI LDSFEPLRAE EDDTELSIPA
     ECFKKPPKYP PALPIWARPD YNPPLLPSWK DPTYEPPAVH GCALPPTRPA PVPPPRRKRT
     IKLDGSNVSA ALLALAERSF PSTKPEGTGT SSSGVGTEST AESGDSPETG EESDVESYSS
     MPPLEGEPGD PDLDADSWST VSDSEEQSVV CCSMSYSWTG AIITPCSAEE EKLPISPLSN
     SLLRHHNLVY STSSRSAAAR QKKVTFDRLQ VLDDHYKNVL KEVKERASGV KGRLLSFEEA
     CSLVPPHSGR SKYGYSAKDV RSLSSKAMNQ IRSVWEDLLE DNSTPIPTTI MAKNEVFSVN
     PAKGGRKPAR LIVYPDLGVR VCEKRALYDV IQKLSIATMG PAYGFQYSPK QRVEHLLKMW
     TSKKTPLGFS YDTRCFDSTV TEHDIRTEEG IYQCCDLEPE ARKAISALTE RLYIGGPMYN
     SKGLQCGYRR CRASGVLPTS FGNTITCYIK ATAASRAAGL KNPSFLVCGD DLVVISESCG
     VEEDRTALRA FTEAMTRYSA PPGDAPQPTY DLELISSCSS NVSVACDGAG KRYYYLTRDP
     ETPLARAAWE TARHTPVNSW LGNIIMFAPT IWVRMVLITH FFSILQAQEQ LERALDFEMY
     GATYSVTPLD LPAIIERLHG LSAFSLHGYS PTELNRVAGA LRKLGIPPLR AWRHRARAVR
     AKLIAQGGKA RICGLYLFNW AVRTKTKLTP LPTAGQLDLS SWFTVGVGGN DIYHSVSRAR
     TRHLLLCLLL LTVGVGIFLL PAR
//
ID   POLG_HCVTW              Reviewed;        3010 AA.
AC   P29846;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 110.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 1b (isolate Taiwan) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=31645;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=92230206; PubMed=1314449; DOI=10.1016/0042-6822(92)90739-C;
RA   Chen P.J., Lin M.H., Tai K.F., Liu P.C., Lin C.J., Chen D.S.;
RT   "The Taiwanese hepatitis C virus genome: sequence determination and
RT   mapping the 5' termini of viral genomic and antigenomic RNA.";
RL   Virology 188:102-113(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA] OF 1461-1644.
RC   STRAIN=Isolate T3;
RX   PubMed=1648541; DOI=10.1002/hep.1840140113;
RA   Chen P.J., Lin M.H., Tu S.J., Chen D.S.;
RT   "Isolation of a complementary DNA fragment of hepatitis C virus in
RT   Taiwan revealed significant sequence variations compared with other
RT   isolates.";
RL   Hepatology 14:73-78(1991).
RN   [3]
RP   HOMOMULTIMERIZATION.
RX   MEDLINE=96207393; PubMed=8615040; DOI=10.1006/viro.1996.0164;
RA   Matsumoto M., Hwang S.B., Jeng K.-S., Zhu N., Lai M.M.C.;
RT   "Homotypic interaction and multimerization of hepatitis C virus core
RT   protein.";
RL   Virology 218:43-51(1996).
RN   [4]
RP   INTERACTION OF CORE PROTEIN WITH HUMAN LTBR.
RX   PubMed=8995654;
RA   Matsumoto M., Hsieh T.-Y., Zhu N., VanArsdale T., Hwang S.B.,
RA   Jeng K.-S., Gorbalenya A.E., Lo S.-Y., Ou J.-H., Ware C.F.,
RA   Lai M.M.C.;
RT   "Hepatitis C virus core protein interacts with the cytoplasmic tail of
RT   lymphotoxin-beta receptor.";
RL   J. Virol. 71:1301-1309(1997).
RN   [5]
RP   INTERACTION OF CORE PROTEIN WITH HUMAN TNFRSF1A.
RX   MEDLINE=98216728; PubMed=9557650;
RA   Zhu N., Khoshnan A., Schneider R., Matsumoto M., Dennert G.,
RA   Ware C.F., Lai M.M.C.;
RT   "Hepatitis C virus core protein binds to the cytoplasmic domain of
RT   tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced
RT   apoptosis.";
RL   J. Virol. 72:3691-3697(1998).
RN   [6]
RP   INTERACTION OF CORE PROTEIN WITH HUMAN HNRPK.
RX   MEDLINE=98316333; PubMed=9651361; DOI=10.1074/jbc.273.28.17651;
RA   Hsieh T.-Y., Matsumoto M., Chou H.-C., Schneider R., Hwang S.B.,
RA   Lee A.S., Lai M.M.C.;
RT   "Hepatitis C virus core protein interacts with heterogeneous nuclear
RT   ribonucleoprotein K.";
RL   J. Biol. Chem. 273:17651-17659(1998).
RN   [7]
RP   INTERACTION OF CORE PROTEIN WITH HUMAN APOA2.
RX   PubMed=10498661; DOI=10.1002/hep.510300429;
RA   Sabile A., Perlemuter G., Bono F., Kohara K., Demaugre F., Kohara M.,
RA   Matsuura Y., Miyamura T., Brechot C., Barba G.;
RT   "Hepatitis C virus core protein binds to apolipoprotein AII and its
RT   secretion is modulated by fibrates.";
RL   Hepatology 30:1064-1076(1999).
RN   [8]
RP   INTERACTION OF CORE PROTEIN WITH HUMAN P53.
RX   PubMed=10544138; DOI=10.1006/viro.1999.9979;
RA   Lu W., Lo S.-Y., Chen M., Wu K.-J., Fung Y.K.T., Ou J.-H.;
RT   "Activation of p53 tumor suppressor by hepatitis C virus core
RT   protein.";
RL   Virology 264:134-141(1999).
RN   [9]
RP   INTERACTION OF CORE PROTEIN WITH HUMAN YWHAE.
RX   MEDLINE=20111292; PubMed=10644344;
RX   DOI=10.1128/JVI.74.4.1736-1741.2000;
RA   Aoki H., Hayashi J., Moriyama M., Arakawa Y., Hino O.;
RT   "Hepatitis C virus core protein interacts with 14-3-3 protein and
RT   activates the kinase Raf-1.";
RL   J. Virol. 74:1736-1741(2000).
RN   [10]
RP   INTERACTION OF CORE PROTEIN WITH HUMAN CREB3.
RX   MEDLINE=20141198; PubMed=10675342; DOI=10.1093/emboj/19.4.729;
RA   Jin D.-Y., Wang H.-L., Zhou Y., Chun A.C.S., Kibler K.V., Hou Y.-D.,
RA   Kung H.-F., Jeang K.-T.;
RT   "Hepatitis C virus core protein-induced loss of LZIP function
RT   correlates with cellular transformation.";
RL   EMBO J. 19:729-740(2000).
RN   [11]
RP   INTERACTION OF CORE PROTEIN WITH HUMAN STAT3.
RX   MEDLINE=22198898; PubMed=12208879; DOI=10.1084/jem.20012127;
RA   Yoshida T., Hanada T., Tokuhisa T., Kosai K., Sata M., Kohara M.,
RA   Yoshimura A.;
RT   "Activation of STAT3 by the hepatitis C virus core protein leads to
RT   cellular transformation.";
RL   J. Exp. Med. 196:641-653(2002).
RN   [12]
RP   INTERACTION OF CORE PROTEIN WITH HUMAN CYTOKERATINS AND VIMENTIN.
RX   PubMed=15846844; DOI=10.1002/pmic.200401093;
RA   Kang S.-M., Shin M.-J., Kim J.-H., Oh J.-W.;
RT   "Proteomic profiling of cellular proteins interacting with the
RT   hepatitis C virus core protein.";
RL   Proteomics 5:2227-2237(2005).
RN   [13]
RP   FUNCTION OF CORE PROTEIN.
RX   PubMed=15699147; DOI=174/4/2160;
RA   Chou A.H., Tsai H.F., Wu Y.Y., Hu C.Y., Hwang L.H., Hsu P.I.,
RA   Hsu P.N.;
RT   "Hepatitis C virus core protein modulates TRAIL-mediated apoptosis by
RT   enhancing Bid cleavage and activation of mitochondria apoptosis
RT   signaling pathway.";
RL   J. Immunol. 174:2160-2166(2005).
RN   [14]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [15]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [16]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.34 ANGSTROMS) OF 25-40 IN COMPLEX WITH A
RP   MONOCLONAL ANTIBODY.
RX   PubMed=12574359;
RA   Menez R., Bossus M., Muller B.H., Sibai G., Dalbon P., Ducancel F.,
RA   Jolivet-Reynaud C., Stura E.A.;
RT   "Crystal structure of a hydrophobic immunodominant antigenic site on
RT   hepatitis C virus core protein complexed to monoclonal antibody
RT   19D9D6.";
RL   J. Immunol. 170:1917-1924(2003).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- INTERACTION:
CC       O43889-2:CREB3 (xeno); NbExp=5; IntAct=EBI-909718, EBI-625022;
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain two highly variable regions called
CC       hypervariable region 1 and 2 (HVR1 and HVR2). E2 also contain two
CC       segments involved in CD81-binding. HVR1 is implicated in the
CC       SCARB1-mediated cell entry. HVR2 and CD81-binding regions may be
CC       involved in sensitivity and/or resistance to IFN-alpha therapy (By
CC       similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A contains a variable region called interferon
CC       sensitivity determining region (ISDR) and seems to be
CC       intrinsically disordered and interacts with NS5B and host PKR. The
CC       C-terminus of NS5A contains a variable region called variable
CC       region 3 (V3). ISDR and V3 may be involved in sensitivity and/or
CC       resistance to IFN-alpha therapy (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M84754; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   PIR; A40244; GNWVTW.
DR   PIR; A61196; A61196.
DR   PDB; 1N64; X-ray; 2.34 A; P=25-40.
DR   PDB; 2ZJO; X-ray; 2.50 A; A=1193-1657.
DR   PDBsum; 1N64; -.
DR   PDBsum; 2ZJO; -.
DR   IntAct; P29846; 1.
DR   euHCVdb; M84754; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0043433; P:negative regulation of transcription factor...; IDA:UniProtKB.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; FALSE_NEG.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Apoptosis; ATP-binding; Capsid protein;
KW   Complete proteome; Disulfide bond; Envelope protein; Fusion protein;
KW   Glycoprotein; Helicase; Host cell membrane; Host cytoplasm;
KW   Host endoplasmic reticulum; Host lipid droplet; Host membrane;
KW   Host mitochondrion; Host nucleus; Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000037666.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000037667.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000037668.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000037669.
FT   CHAIN       384    746       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000037670.
FT   CHAIN       747    809       p7 (By similarity).
FT                                /FTId=PRO_0000037671.
FT   CHAIN       810   1026       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000037672.
FT   CHAIN      1027   1657       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000037673.
FT   CHAIN      1658   1711       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000037674.
FT   CHAIN      1712   1972       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000037675.
FT   CHAIN      1973   2419       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000037676.
FT   CHAIN      2420   3010       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000037677.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    725       Lumenal (Potential).
FT   TRANSMEM    726    746       Potential.
FT   TOPO_DOM    747    757       Lumenal (Potential).
FT   TRANSMEM    758    778       Potential.
FT   TOPO_DOM    779    782       Cytoplasmic (Potential).
FT   TRANSMEM    783    803       Potential.
FT   TOPO_DOM    804    813       Lumenal (Potential).
FT   TRANSMEM    814    834       Potential.
FT   TOPO_DOM    835    881       Cytoplasmic (Potential).
FT   TRANSMEM    882    902       Potential.
FT   TOPO_DOM    903    928       Lumenal (Potential).
FT   TRANSMEM    929    949       Potential.
FT   TOPO_DOM    950   1657       Cytoplasmic (Potential).
FT   TRANSMEM   1658   1678       Potential.
FT   TOPO_DOM   1679   1805       Cytoplasmic (Potential).
FT   TRANSMEM   1806   1826       Potential.
FT   TOPO_DOM   1827   1828       Lumenal (Potential).
FT   TRANSMEM   1829   1849       Potential.
FT   TOPO_DOM   1850   1850       Cytoplasmic (Potential).
FT   TRANSMEM   1851   1871       Potential.
FT   TOPO_DOM   1872   1881       Lumenal (Potential).
FT   TRANSMEM   1882   1902       Potential.
FT   TOPO_DOM   1903   1972       Cytoplasmic (Potential).
FT   TOPO_DOM   1973   2002       In membrane (By similarity).
FT   TOPO_DOM   2003   2989       Cytoplasmic (Potential).
FT   TRANSMEM   2990   3010       By similarity.
FT   DOMAIN     1217   1369       Helicase ATP-binding.
FT   DOMAIN     2633   2751       RdRp catalytic.
FT   NP_BIND    1230   1237       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2.
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      385    411       HVR1 (By similarity).
FT   REGION      475    481       HVR2 (By similarity).
FT   REGION      482    494       CD81-binding 1 (Potential).
FT   REGION      522    553       CD81-binding 2 (Potential).
FT   REGION      660    671       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1679   1690       NS3-binding (by NS4A) (Potential).
FT   REGION     2120   2332       Transcriptional activation (Potential).
FT   REGION     2120   2208       FKBP8-binding (Potential).
FT   REGION     2200   2250       Basal phosphorylation (By similarity).
FT   REGION     2210   2275       PKR-binding (Potential).
FT   REGION     2210   2249       ISDR (By similarity).
FT   REGION     2249   2306       NS4B-binding (Potential).
FT   REGION     2351   2419       Basal phosphorylation (By similarity).
FT   REGION     2354   2377       V3 (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1316   1319       DECH box.
FT   MOTIF      2322   2325       SH3-binding (Potential).
FT   MOTIF      2327   2335       Nuclear localization signal (Potential).
FT   COMPBIAS    572    575       Poly-Gly.
FT   COMPBIAS    796    803       Poly-Leu.
FT   COMPBIAS   1432   1435       Poly-Val.
FT   COMPBIAS   2282   2327       Pro-rich.
FT   COMPBIAS   2993   2998       Poly-Leu.
FT   ACT_SITE    952    952       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    972    972       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    993    993       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1083   1083       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1107   1107       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1165   1165       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1123   1123       Zinc (By similarity).
FT   METAL      1125   1125       Zinc (By similarity).
FT   METAL      1171   1171       Zinc (By similarity).
FT   METAL      1175   1175       Zinc (By similarity).
FT   METAL      2011   2011       Zinc (By similarity).
FT   METAL      2029   2029       Zinc (By similarity).
FT   METAL      2031   2031       Zinc (By similarity).
FT   METAL      2052   2052       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        191    192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        746    747       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        809    810       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1026   1027       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1657   1658       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1711   1712       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1972   1973       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2419   2420       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2194   2194       Phosphoserine; by host; in p56 (By
FT                                similarity).
FT   MOD_RES    2197   2197       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2201   2201       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2204   2204       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1968   1968       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   LIPID      1972   1972       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    233    233       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    250    250       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    417    417       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    423    423       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    430    430       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    448    448       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    532    532       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    540    540       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    556    556       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    576    576       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    623    623       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    645    645       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2114   2162       By similarity.
FT   CONFLICT   1492   1492       S -> G (in Ref. 2).
FT   HELIX        33     35
SQ   SEQUENCE   3010 AA;  327051 MW;  AAD267D55CDFE215 CRC64;
     MSTNGKPQRK TKRNTNRRPQ DVKFPGGGQI VGGVYLLPRR GPRLGVRATR KTWERSQPRG
     RRQPIPKARQ PEGRAWAQPG YPWPLYGNEG LGWAGWLVSP RGSRPNWGPT DPRRRSRNLG
     KVIDTLTCGF ADLMGYIPLV GAPLGGVARA LAHGVRVLED GVNYATGNLP GCSFSIFLLA
     LLSCLTIPAS AYEVHNVSGI YHVTNDCSNS SIVYEAADMI MHTPGCVPCV RENNSSRCWV
     ALTPTLAARN NSVPTATIRR HVDLLVGAAA FCSAMYVGDL CGSVFLVSQL FTFSPRRYET
     VQDCNCSIYP GHVTGHRMAW DMMMNWSPTT ALVVSQLLRI PQAVVDMVGG AHWGVLAGLA
     YYSMVGNWAK VLIVMLLFAG VDGSTIVSGG TVARTTHSLA SLFTQGASQK IQLINTNGSW
     HINRTALNCN DSLQTGFLAS LFYAHRFNAS GCPERMASCR SIDKFDQGWG PITYTEADIQ
     DQRPYCWHYA PRPCGIVPAS QVCGPVYCFT PSPVVVGTTD RFGAPTYSWG ENETDVLILN
     NTRPPQGNWF GCTWMNSTGF TKTCGGPPCN IGGGGNNTLV CPTDCFRKHP EATYTKCGSG
     PWLTPRCMVD YPYRLWHYPC TVNFTIFKVR MYVGGVEHRL NAACNWTRGE RCDLEDRDRS
     ELSPLLLSTT EWQILPCSFT GLPALSTGLI HLHQNVVDVQ YLYGIGSAVV SFAIKWEYIL
     LLFLLLADAR VCACLWMMLL IAQAEAALEN LVVFNAASVA GMHGTLSFLV FFCAAWYIKG
     RLVPGAAYAL YGVWPLLLLL LALPPRAYAM DREMAASCGG AVFVGLVLLT LSPHYKMFLA
     RLIWWLQYFI TRAEAHLQVW IPPLNVRGGR DAIILLTCAA YPELIFDITK ILLAILGPLM
     VLQAGLTRIP YFVRAQGLIR ACMLVRKAAG GHYVQMALMK LAALTGTYVY DHLTPLQDWA
     HTGLRDLAVA VEPVVFSDME TKIITWGADT AACGDIILGL PVSARRGREI LLGPADSLEG
     RGWRLLAPIT AYAQQTRGLF GCIITSLTGR DKNQVEGEVQ VVSTATQSFL ATCINGVCWT
     VYHGAGSKTL AGPKGPITQM YTNVDQDLVG WHAPQGARSL TPCTCGSSDL YLVTRHADVI
     PVRRRGDSRG SLLSPRPISY LKGSSGGPLL CPSGHVVGIF RAAVCTRGVA KAVDFVPVES
     METTMRSPVF TDNSSPPAVP QAFQVAHLHA PTGSGKSTKV PAAYAAQGYK VLVLNPSVAA
     TLGFGAYMSK AHGVDPNIRT GVRTITTGAP ITYSTYGKFL ADGGCSGGAY DIIMCDECHS
     TDSTTILGIG TVLDQAETAG ARLVVLATAT PPGSVTVPHP NIEEIALSNT GEIPFYGKAI
     PIETIKGGRH LIFCHSKKKC DELAAKLSAL GIHAVAYYRG LDVSVIPASG NVVVVATDAL
     MTGFTGDFDS VIDCNTCVTQ TVDFSLDPTF TIETTTMPQD AVSRSQRRGR TSRGRRGIYR
     FVTPGERPSG MFDSSVLCEC YDAGCAWYEL TPAETSVRLR AYLNTPGLPV CQDHLEFWES
     VFTGLTHIDA HFLSQTKQAG DNFPYLVAYQ ATVCARAQAP PPSWDQMWKC LTRLKPTLHG
     PTPLLYRLGA VQNEVTLTHP ITKYIMACMS ADLEVVTSTW VLVGGVLAAL AAYCLTTGSV
     VIVGRIILSG KPAVVPDREV LYQEFDEMEE CASHLPYIEQ GMQLAEQFKQ KALGLLQTAT
     KQAEAAAPVV ESKWRTLEAF WANDMWNFIS GIQYLAGLST LPGNPAIASL MAFTASITSP
     LTTQSTLLFN ILGGWVAAQL APPGAASAFV GAGIAGAAVG SIGLGKVLVD MVAGYGAGVA
     GALVAFKVMS GEMPSTEDLV NLLPAILSPG ALVVGVVCAA ILRRHVDPGE GAVQWMNRLI
     AFASRGNHVS PTHYVPESDA AARVTQILSG LTITQLLRRL HQWINEDCST PCSGSWLRDV
     WDWICTVLAD FKTWLQSKLL PRLPGVPFFS CQRGYKGVWR GDGIMQTTCP CGAQLTGHVK
     NGSMRIWGPK TCSNTWHGTF PINAYTTGPC TPSPAPNYSR ALWRVAAEEY VEVRRVGDFH
     YVTGMTTDNV KCPCQVPAPE FFTEVDGVRL HRYAPACKPL LREEVSFQVG LNQYVVGSQL
     PCEPEPDVAV LTSMLTDPSH ITAETAKRRL ARGSPPSLAS SSASQLSALS LKAACTTRHT
     PPDADLIEAN LLWRQEMGGN ITRVESENKV VILDSFDPLR AEEDEREVSV PAEILRKSRK
     FPPALPVWAR PDYNPPLLEP WKDPDYVPPV VHGCPLPPVK APPIPPPRRK RTVVLTESTV
     SSALAELATK TFGSSESSAA GSGTATAPPD QPSDDGDAGS DVESCSSMPP LEGEPGDPDL
     SDGSWSTVSE EDGEGVICCS MSYTWTGALI TPCAAEESKL PINALSNSLL RHHNMVYATT
     SRSASQRQKK VTIDRLQVLD DHYRDVLKEM KAKASTVKAK LLSVEEACKL TPPHSARSKF
     GYGAKDVRNL SGKAINHIRS VWKDLLEDTE TPIDTTIMAK NEVFCVQPEK GGRKPARLIV
     FPDLGVRVCE KMALYDVVST LPQAVMGSSY GFQYSPGQRV EFLVNAWKSK KCPMGFSYDT
     RCFDSTVTES DIRVEESIYQ CCDLAPEARQ AIRSLTERLY IGGPLTNSKG QNCGYRRCRA
     SGVLTTSCGN TLTCYLKASA ACRAAKLQDC TMLVCGDDLV VICESAGTQE DAASLRVFTE
     AMTRYSAPPG DLPQPEYDQE LITSCSSNVS VAHDASGKRV YYLTRDPTTP LARAAWATAR
     HTPVNSWLGN IIMYAPTLWA RMILMTHFFS ILLAQEQLEK ALDCQIYGAC YSIEPLDLPQ
     IIERLHGLSA FSLHSYSPGE INRVASCLRK LGVPPLRAWR HRARSVRAKL LSQGGRAATC
     GRYLFNWAVK TKLKLTPIPA ASQLDLSKWF VAGYGGGDIY HSLSRARPRW FMLCLLLLSV
     GVGIYLLPNR
//
ID   POLG_HCVVA              Reviewed;        3033 AA.
AC   Q9QAX1;
DT   10-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 73.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 2k (isolate VAT96) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=356414;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=20329282; PubMed=10872881; DOI=10.1023/A:1008182901274;
RA   Samokhvalov E.I., Hijikata M., Gylka R.I., Lvov D.K., Mishiro S.;
RT   "Full-genome nucleotide sequence of a hepatitis C virus variant
RT   (isolate name VAT96) representing a new subtype within the genotype 2
RT   (arbitrarily 2k).";
RL   Virus Genes 20:183-187(2000).
RN   [2]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [3]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [4]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain a highly variable region called hypervariable
CC       region 1 (HVR1). E2 also contains two segments involved in CD81-
CC       binding. HVR1 is implicated in the SCARB1-mediated cell entry.
CC       CD81-binding regions may be involved in sensitivity and/or
CC       resistance to IFN-alpha therapy (By similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A seems to be intrinsically disordered and
CC       interacts with NS5B and host PKR (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB031663; BAA88057.1; -; Genomic_RNA.
DR   euHCVdb; AB031663; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; FALSE_NEG.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Apoptosis; ATP-binding; Capsid protein; Disulfide bond;
KW   Envelope protein; Fusion protein; Glycoprotein; Helicase;
KW   Host cell membrane; Host cytoplasm; Host endoplasmic reticulum;
KW   Host lipid droplet; Host membrane; Host mitochondrion; Host nucleus;
KW   Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000045700.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000045701.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000045702.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000045703.
FT   CHAIN       384    750       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000045704.
FT   CHAIN       751    813       p7 (By similarity).
FT                                /FTId=PRO_0000045705.
FT   CHAIN       814   1030       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000045706.
FT   CHAIN      1031   1661       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000045707.
FT   CHAIN      1662   1715       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000045708.
FT   CHAIN      1716   1976       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000045709.
FT   CHAIN      1977   2442       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000045710.
FT   CHAIN      2443   3033       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000045711.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    729       Lumenal (Potential).
FT   TRANSMEM    730    750       Potential.
FT   TOPO_DOM    751    761       Lumenal (Potential).
FT   TRANSMEM    762    782       Potential.
FT   TOPO_DOM    783    786       Cytoplasmic (Potential).
FT   TRANSMEM    787    807       Potential.
FT   TOPO_DOM    808    817       Lumenal (Potential).
FT   TRANSMEM    818    838       Potential.
FT   TOPO_DOM    839    885       Cytoplasmic (Potential).
FT   TRANSMEM    886    906       Potential.
FT   TOPO_DOM    907    932       Lumenal (Potential).
FT   TRANSMEM    933    953       Potential.
FT   TOPO_DOM    954   1661       Cytoplasmic (Potential).
FT   TRANSMEM   1662   1682       Potential.
FT   TOPO_DOM   1683   1809       Cytoplasmic (Potential).
FT   TRANSMEM   1810   1830       Potential.
FT   TOPO_DOM   1831   1832       Lumenal (Potential).
FT   TRANSMEM   1833   1853       Potential.
FT   TOPO_DOM   1854   1854       Cytoplasmic (Potential).
FT   TRANSMEM   1855   1875       Potential.
FT   TOPO_DOM   1876   1885       Lumenal (Potential).
FT   TRANSMEM   1886   1906       Potential.
FT   TOPO_DOM   1907   1976       Cytoplasmic (Potential).
FT   TOPO_DOM   1977   2006       In membrane (By similarity).
FT   TOPO_DOM   2007   3012       Cytoplasmic (Potential).
FT   TRANSMEM   3013   3033       By similarity.
FT   DOMAIN     1221   1373       Helicase ATP-binding.
FT   DOMAIN     2656   2774       RdRp catalytic.
FT   NP_BIND    1234   1241       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      385    411       HVR1 (By similarity).
FT   REGION      484    496       CD81-binding 1 (Potential).
FT   REGION      524    555       CD81-binding 2 (Potential).
FT   REGION      664    675       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1683   1694       NS3-binding (by NS4A) (Potential).
FT   REGION     2124   2332       Transcriptional activation (Potential).
FT   REGION     2124   2212       FKBP8-binding (Potential).
FT   REGION     2204   2250       Basal phosphorylation (By similarity).
FT   REGION     2214   2275       PKR-binding (Potential).
FT   REGION     2249   2306       NS4B-binding (Potential).
FT   REGION     2351   2442       Basal phosphorylation (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1320   1323       DECH box (By similarity).
FT   MOTIF      2322   2325       SH3-binding (Potential).
FT   MOTIF      2327   2335       Nuclear localization signal (Potential).
FT   COMPBIAS    742    745       Poly-Leu.
FT   COMPBIAS    802    807       Poly-Leu.
FT   COMPBIAS   1436   1439       Poly-Val.
FT   COMPBIAS   2277   2327       Pro-rich.
FT   COMPBIAS   2328   2331       Poly-Arg.
FT   COMPBIAS   3014   3021       Poly-Leu.
FT   ACT_SITE    956    956       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    976    976       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    997    997       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1087   1087       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1111   1111       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1169   1169       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1127   1127       Zinc (By similarity).
FT   METAL      1129   1129       Zinc (By similarity).
FT   METAL      1175   1175       Zinc (By similarity).
FT   METAL      1179   1179       Zinc (By similarity).
FT   METAL      2015   2015       Zinc (By similarity).
FT   METAL      2033   2033       Zinc (By similarity).
FT   METAL      2035   2035       Zinc (By similarity).
FT   METAL      2056   2056       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        191    192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        750    751       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        813    814       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1030   1031       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1661   1662       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1715   1716       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1976   1977       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2442   2443       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2198   2198       Phosphoserine; by host; in p56 (By
FT                                similarity).
FT   MOD_RES    2201   2201       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2205   2205       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2208   2208       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1972   1972       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   LIPID      1976   1976       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    417    417       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    423    423       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    430    430       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    448    448       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    477    477       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    534    534       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    542    542       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    558    558       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    578    578       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    627    627       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    649    649       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2118   2166       By similarity.
SQ   SEQUENCE   3033 AA;  329863 MW;  5245F9E0A46A7E50 CRC64;
     MSTNPKPQRK TKRNTNRRPQ DVKFPGGGQI VGGVYLLPRR GPRLGVRATR KTSERSQPRG
     RRQPIPKDRR SAGKSWGRPG YPWPLYGNEG LGWAGWLLSP RGSRPSWGPT DPRHRSRNLG
     KVIDTLTCGF ADLMGYIPVV GAPVGGVARA LAHGVRVLED GINYATGNLP GCSFSIFLLA
     LLSCMSVPVS AVEVKNTSQI YMATNDCSNN SITWQLEGAV LHVPGCVPCE STGNISRCWI
     PVTPNVAVRE RGALTKGLRT HIDLIVVSAT FCSALYIGDV CGAIMIAAQA TIISPQHHTF
     VQDCNCSIYP GHVTGHRMAW DMMMNWSPAT TMIMAYFMRV PEVVLDIITG AHWGVMFGLA
     YFSMQGAWAK VVVILLLTAG VDAQTHTISG HAARTTHGLV SLFTPGSQQN IQLVNTNGSW
     HINRTALNCN DSLKTGFIAA LFYSHKFNSS GCPQRMSSCR SIEEFRIGWG NLEYEENVTN
     DDNMRPYCWH YPPRPCGIVP AQTVCGPVYC FTPSPVVVGT TDRRGVPTYT WGENDTDVFL
     LNSTRPPRGA WFGCTWMNST GFTKTCGAPP CRIRPDFNSS EDLLCPTDCF RKHSEATYTR
     CGAGPWLTPK CLFHYPYRLW HYPCTINFTI HKIRMFIGGV EHRLEAACNF TRGDRCNLED
     RDRSQLSPLL HSTTEWAILP CTFSDMPALS TGLLHLHQNI VDVQYLYGLS PAITKYIVKW
     EWVVLLFLLL ADARVCACLW MLLLLGQAEA ALEKLVILHA ASAASSHGML CFIIFFIAAW
     YIKGRVTPLV TYSYLGMWSF SLLLLALPQQ AYALDTTEQG QIGLVLLVVI SVFTLSPAYK
     ILLCRSLWWL SYLLVRAEAL IQDWVPPWQA RGGRDGIIWA ATIFCPGVLF DITNWLLAIL
     GPGYLLRSVL TSTPYFVRAQ ALLRICAAVR HLSGGKYVQM MLLTLGKWTG TYIYDHLSPM
     SGWAASGLRD LAVAVEPIVF SPMEKKVIVW GAETAACGDI LHGLPVSARL GQEVLLGPAD
     EYTSKGWKLL APITAYAQQT RGLLGTIVVS MTGRDKTEQA GEIQVLSTVT QSFLGTTISG
     ILWTVFHGAG NKTLAGSRGP VTQMYSSAEG DLVGWPSPPG TRSLDPCTCG AVDLYLVTRN
     ADVIPARRQG DRRGALLSPR PLSSLKGSSG GPVLCPRGHA VGIFRAAICT RGAAKSIDFI
     PIESLDVIIR SPNFTDNSSP PAVPQTYQVG YLHAPTGSGK STKVPASYAA QGYKVLVLNP
     SVAATLGFGA YMSKAHGINP NIRTGVRTVT TGESITYSTY GKFLADGGCS GGAYDVIICD
     ECHSVDATTI LGIGTVLDQA ETAGARLTVL ATATPPGSVT TPHPNIEEVA LGHEGEIPFY
     GKAIPLSQIK GGRHLIFCHS KKKCDELAAA LRGMGLNAVA YYRGLDVSVI PTQGDVVVVA
     TDALMTGFTG DFDSVVDCNV AVTQTVDFSL DPTFTVTTQT VPQDAVSRSQ RRGRTGRGRL
     GIYRYVSSGE RASGMFDSVV LCECYDAGAA WYELTPAETT VRLRAYFNTP GLPVCQDHLE
     FWEAVFTGLT HIDAHFLSQT KQAGENFPYL VAYQATVCAR AKAPPPSWDV MWKCLIRLKP
     TLTGPTPLLY RLGPVTNETT LTHPVTKYIA TCMQADLEIM TSTWVLAGGV LAAIAAYCLA
     TGCVVCIGRV NINQKTIVAP DKEVLYEAFD EMEECASRAL LLEEGQRIAE MLKSKIQGLL
     QQATKQAQDI QPAVQATWPK LEQFWAKHMW NFISGIQYLA GLSTLPGNPA VAAMMAFSAA
     LTSPLPTSTT ILLNIMGGWL ASQIAPAAGA TGFVVSGLVG AAVGSIGLGK ILVDVLAGYG
     AGISGALVAF KIMSGEKPSV EDVVNLLPGI LSPGALVVGV ICAAILRRHV GQGEGAVQWM
     NRLIAFASRG NHVAPTHYVA ESDASQRVTQ LLGSLTITSL LRRLHTWITE DCPVPCAGSW
     LRDIWDWACT ILTDFKNWLS TKLLPKMPGL PFISCQRGHK GAWTGTGIMT TRCPCGAVVS
     GNVRHGSMRI TGPKTCMNTW QGTFPINCYT EGQCAPQPTH NYKTAIWKVA AAEYAEVTRH
     GSYAYVTGLT NDNLKVPCQL PAPEFFSWVD GVQIHRFAPT PKPFIRDEVS FTVGLNSFVV
     GSQLPCEPEP DTEVLASMLT DPSHITAEAA ARRLARGSPP SEASSSASQL SAPSLRATCT
     AHAKNYAVEM VDANFFMGSD VTRIESETKV LILDSLDPSV EEEDEREPSV PSEYLLPKKK
     FPQALPVWAR PDYNPPVVET WKRPDYDPPT VSGCALPPRV TAPTPPPRRR RALVLSQSNV
     GEALQALAIK SFGQLPPSCD SGRSTGMDTT DATDQPALKE STDSEAGSDS SMPPLEGEPG
     DPDLESGSVE YHPSSQEGEA APDLDSGSWS TCSEEGGSEV CCSMSYSWTG ALITPCGPEE
     EKLPINPLSN SLLRYHNKVY STTSRSASQR AKKVTFDRVQ LLDSHYDQVL KDIKLAASKV
     SANLLSIEEA CALTPPHSAR SKYGFGAKEV RSLSRKAVDH IKSVWKDLLE DQQTPIPTTI
     MAKNEVFCID PTKGGKKAAR LIVFPDLGVR VCEKMALYDI TQKLPQAVMG ASYGFQYSPA
     QRVDFLLRAW KEKKDPMGFS YDTRCFDSTV TERDIRTEES IYLACSLPEE ARVAIHSLTE
     RLYVGGPMMN SKGQSCGYRR CRASGVLTTS MGNTITCYVK ALAACKAAGI VAPTMLVCGD
     DLVVISESQG AEEDERNLRV FTEAMTRYSA PPGDPPKPEY DLELITSCSS NVSVALDQHG
     RRMYYLTRDP STPLARAAWE TARHSPVNSW LGNIIQYAPT IWVRMVLMTH FFSVLMAQET
     LDQDLNFEMY GAVYSVNPLD LPAIIERLHG LEAFSLHGYS PTELTRVAAA LRKLGAPPLR
     AWKSRARAVR ASLISQGGRA ATCGFYLFNW AVRTKRKLTP LPAARRLDLS GWFTVGAGGG
     DIYHSVSRAR PRFLLLCLLL LSVGVGIFLL PAR
//
ID   POLG_HCVVN              Reviewed;        3013 AA.
AC   O92530;
DT   10-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 77.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 6d (isolate VN235) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=356422;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=98378034; PubMed=9714232;
RA   Tokita H., Okamoto H., Iizuka H., Kishimoto J., Tsuda F., Miyakawa Y.,
RA   Mayumi M.;
RT   "The entire nucleotide sequences of three hepatitis C virus isolates
RT   in genetic groups 7-9 and comparison with those in the other eight
RT   genetic groups.";
RL   J. Gen. Virol. 79:1847-1857(1998).
RN   [2]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [3]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [4]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain a highly variable region called hypervariable
CC       region 1 (HVR1). E2 also contains two segments involved in CD81-
CC       binding. HVR1 is implicated in the SCARB1-mediated cell entry.
CC       CD81-binding regions may be involved in sensitivity and/or
CC       resistance to IFN-alpha therapy (By similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A seems to be intrinsically disordered and
CC       interacts with NS5B and host PKR (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 helicase C-terminal domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D84263; BAA32665.1; -; Genomic_RNA.
DR   euHCVdb; D84263; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; 1.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Apoptosis; ATP-binding; Capsid protein; Disulfide bond;
KW   Envelope protein; Fusion protein; Glycoprotein; Helicase;
KW   Host cell membrane; Host cytoplasm; Host endoplasmic reticulum;
KW   Host lipid droplet; Host membrane; Host mitochondrion; Host nucleus;
KW   Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000045712.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000045713.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000045714.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000045715.
FT   CHAIN       384    744       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000045716.
FT   CHAIN       745    807       p7 (By similarity).
FT                                /FTId=PRO_0000045717.
FT   CHAIN       808   1024       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000045718.
FT   CHAIN      1025   1655       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000045719.
FT   CHAIN      1656   1709       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000045720.
FT   CHAIN      1710   1970       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000045721.
FT   CHAIN      1971   2422       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000045722.
FT   CHAIN      2423   3013       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000045723.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    723       Lumenal (Potential).
FT   TRANSMEM    724    744       Potential.
FT   TOPO_DOM    745    755       Lumenal (Potential).
FT   TRANSMEM    756    776       Potential.
FT   TOPO_DOM    777    780       Cytoplasmic (Potential).
FT   TRANSMEM    781    801       Potential.
FT   TOPO_DOM    802    811       Lumenal (Potential).
FT   TRANSMEM    812    832       Potential.
FT   TOPO_DOM    833    879       Cytoplasmic (Potential).
FT   TRANSMEM    880    900       Potential.
FT   TOPO_DOM    901    926       Lumenal (Potential).
FT   TRANSMEM    927    947       Potential.
FT   TOPO_DOM    948   1655       Cytoplasmic (Potential).
FT   TRANSMEM   1656   1676       Potential.
FT   TOPO_DOM   1677   1803       Cytoplasmic (Potential).
FT   TRANSMEM   1804   1824       Potential.
FT   TOPO_DOM   1825   1826       Lumenal (Potential).
FT   TRANSMEM   1827   1847       Potential.
FT   TOPO_DOM   1848   1848       Cytoplasmic (Potential).
FT   TRANSMEM   1849   1869       Potential.
FT   TOPO_DOM   1870   1879       Lumenal (Potential).
FT   TRANSMEM   1880   1900       Potential.
FT   TOPO_DOM   1901   1970       Cytoplasmic (Potential).
FT   TOPO_DOM   1971   2000       In membrane (By similarity).
FT   TOPO_DOM   2001   2992       Cytoplasmic (Potential).
FT   TRANSMEM   2993   3013       By similarity.
FT   DOMAIN     1215   1367       Helicase ATP-binding.
FT   DOMAIN     1374   1536       Helicase C-terminal.
FT   DOMAIN     2636   2754       RdRp catalytic.
FT   NP_BIND    1228   1235       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      385    411       HVR1 (By similarity).
FT   REGION      483    495       CD81-binding 1 (Potential).
FT   REGION      523    554       CD81-binding 2 (Potential).
FT   REGION      658    669       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1677   1688       NS3-binding (by NS4A) (Potential).
FT   REGION     2118   2331       Transcriptional activation (Potential).
FT   REGION     2118   2206       FKBP8-binding (Potential).
FT   REGION     2198   2248       Basal phosphorylation (By similarity).
FT   REGION     2208   2273       PKR-binding (Potential).
FT   REGION     2247   2305       NS4B-binding (Potential).
FT   REGION     2350   2422       Basal phosphorylation (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1314   1317       DECH box (By similarity).
FT   MOTIF      2321   2324       SH3-binding (Potential).
FT   MOTIF      2326   2334       Nuclear localization signal (Potential).
FT   COMPBIAS    794    801       Poly-Leu.
FT   COMPBIAS   2275   2326       Pro-rich.
FT   COMPBIAS   2994   3001       Poly-Leu.
FT   ACT_SITE    950    950       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    970    970       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    991    991       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1081   1081       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1105   1105       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1163   1163       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1121   1121       Zinc (By similarity).
FT   METAL      1123   1123       Zinc (By similarity).
FT   METAL      1169   1169       Zinc (By similarity).
FT   METAL      1173   1173       Zinc (By similarity).
FT   METAL      2009   2009       Zinc (By similarity).
FT   METAL      2027   2027       Zinc (By similarity).
FT   METAL      2029   2029       Zinc (By similarity).
FT   METAL      2050   2050       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        191    192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        744    745       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        807    808       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1024   1025       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1655   1656       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1709   1710       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1970   1971       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2422   2423       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2192   2192       Phosphoserine; by host; in p56 (By
FT                                similarity).
FT   MOD_RES    2195   2195       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2199   2199       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2202   2202       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1970   1970       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    250    250       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    417    417       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    423    423       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    430    430       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    448    448       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    476    476       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    533    533       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    557    557       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    621    621       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    643    643       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2112   2160       By similarity.
SQ   SEQUENCE   3013 AA;  328200 MW;  C9EE9C0231E86EAF CRC64;
     MSTLPKPQKR NQRNTNRRPQ DVKFPGGGQI VGGVYLLPRR GPRLGVRATR KTSERSQPRG
     RRQPIPKARR QTGRTWAQPG YPWPLYGNEG CGWMGWLLSP RGSRPHWGPN DPRRRSRNLG
     KVIDTLTCGF ADLMGYIPVV GAPLGGVAAA LAHGVRAVED GINYATGNLP GCSFSIFLLA
     LLSCLTTPAS AVHYANKSGI YHLTNDCPNS SIVYEAEDFI MHLPGCVPCI KSGNGSSCWL
     PATLTIAVPN ASIPVRGFRR HVDLMVGAAA FCSAMYVGDL CGGIFLVGQL FSFNPRRHWV
     VQDCNCSIYV GHITGHRMAW DMMMNWSPTA TLVLSYVMRI PQVIMDIFTG GHWGILAGIL
     YYSMVANWAK VLCILFLFAG VDATTRTTGA QAARATLGFT GLFQTGAKQN IHLINTNGSW
     HINRTALNCN DSLNTGFMAA LFYLHKFNST GCPERLSACK SITQFAQGWG PVTYANVSGS
     SEDRPYCWHY APRPCGVVSA RSVCGPVYCF TPSPVVVGTT DRRGVPTYTW GENESDVFLL
     ESLRPPAGAW YGCTWMNSTG YTKTCGAPPC HIGPPDQFCP TDCFRKHPEA TYRKCGSGPW
     LTPRCLVDYP YRLWHYPCTV NYTIHKVRLF INGLEHRFDA ACNWTRGERC ELEDRDRIEM
     SPLLFSTTEL AILPCSFTTM PALSTGLVHL HQNIVDIQYL YGLAPALVSW AVRWEYVVLA
     FLLLADARIC ACLWMVLLIS QVEAALENLI VLNAASAASS QGWIYCLVFI CCAWYIKGRV
     VPGATYAILH LWPLLLLVLA LPQRAYAQDR EQGASIGVVV IAAITIFTLT PAYKTMLVHF
     LWWNQYFIAR SEALIQQWVP SLRVRGGRDA VILLTCLLHP SLGFDITKML LALLGPLYLL
     QVSLLRVPYY VRAHALLRVC ILVRRVAGGK YIQAALLKLG AWTGTYIYDH LAPLSTWASD
     GLRDLAVAVE PVTFSPMEKK IITWGADTAA CGDILAGLPV SARLGHLLFL GPADDMKSMG
     WRLLAPITAY CQQTRGLLGT IVTSLTGRDR NVVEGEIQVL STATQSFLGT AINGVMWTVY
     HGAGSKTLAG PKGPVCQMYT NVDQDMVGWP APPGTRSLTP CTCGASDLYL VTRNADVIPA
     RRRGDTRAGL LSPRPLSTLK GSSGGPLMCP SDHVVGLFRA AVCTRGVAKA LDFVPVENME
     TTMRSPVFTD NSTPPAVPQT YQVGYLHAPT GSGKSTKVPA AYASQGYKVL VLNPSVAATL
     GFGSYMSTAH GIDPNIRTGV RTITTGGPIT YSTYGKFLAD GGCSGGAYDI IICDECHSTD
     PTTVLGIGTV LDQAETAGVR LTVLATATPP GSVTVPHPNI TETALPSTGE VPFYGKAIPL
     ECIKGGRHLI FCHSKKKCDE LAKQLRTLGL NAVAFYRGVD VSVIPTAGDV VVCATDALMT
     GYTGDFDSVI DCNVAVTQIV DFSLDPTFSI ETTTVPQDAV ARSQRRGRTG RGKPGVYRYV
     SQGERPSGMF DTVVLCEAYD VGCAWYELTP SETTVRLRAY LNTPGLPVCQ DHLEFWEGVF
     TGMTHIDAHF LSQTKQGGEN FAYLVAYQAT VCARAKAPPP SWDTMWKCLI RLKPMLTGPT
     PLLYRLGAVQ NEIITTHPIT KYIMTCMAAD LEVITSTWVL AGGIVAALAA YCLTVGSVVI
     CGRIVTSGKP VPLPDREVLY RQFDEMEECS RHIPYLAEGQ QIAEQFKQKI LGLLQNTAKQ
     AEDLKPAVQS AWPKLEQFWQ KHLWNFVSGV QYLAGLSTLP GNPAVASLMS FSAALTSPLS
     TSTTLLLNIL GGWVASQLAP PTASTAFVVS GLAGAAVGSI GLGKVIIDIL AGYGAGVSGA
     LVAFKIMSGE APAVEDMVNL LPALLSPGAL VVGVVCAAVL RRHVGPSEGA TQWMNRLIAF
     ASRGNHVSPT HYVPETDASR AVTTILSSLT ITSLLRRLHE WISGDWSAPC SCSWLKDVWD
     WVCTVLSDFK TWLRAKLVPT LPGIPFISCQ RGFRGVWRGD GVNYTTCSCG ANITGHVKNG
     SMKIVGPKMC SNVWNNRFPI NAITTGPSVP VPEPNYHKAL WRVSAEDYVE VVRVNDHHYI
     VGATADNLKC PCQVPAPEFF TEVDGVRLHR FAPPCRPLMR DDITFSVGLS TYVVGSQLPC
     EPEPDVVILT SMLTDPDHIT AETAARRLAR GSPPSLASSS ASQLSAPSLK ATCTTAGKHP
     DAELIEANLL WRQEVGGNIT RVESENKIIV LDSFDPLIAE TDDREISVGA ECFNPPRPKF
     PPALPVWARP DYNPPLLQPW KAPDYEPPLV HGCALPPKGL PPVPPPRKKR VVQLDEGSAK
     RALAELAQTS FPPSTATLSE DSGRETSTLS SDMTPPREEA DRASDDGSYS SMPPLEGEPG
     DPDLSSGSWS TVSEDHDSVV CCSMSYSWTG ALITPCAAEE EKLPISPLSN ALIRHHNLVY
     STTSRSASLR QKKVTFDRVQ VVDQHYYDVL KEIKTKASGV SAKLLSVEEA CALTPPHSAR
     SKFGYGAKEV RGLASKAVNH INSVWEDLLE DNSTPIPTTI MAKNEVFCVD AQKGGRKPAR
     LIVYPDLGVR VCEKRALYDV TQKLPIAVMG AAYGFQYSPK QRVDYLLKMW RSKKTPMGFS
     YDTRCFDSTV TERDIRTEED IYQCCQLDPV AKKAITSLTE RLYCGGPMYN SRGQSCGYRR
     CRASGVLTTS LGNTLTCYLK AQAACRAAKL KDFDMLVCGD DLVVISESMG VAEDASALRA
     FTEAMTRYSA PPGDDPQPEY DLELITSCSS NVSVAHDGAG QRYYYLTRDP LTPLSRAAWE
     TARHTPVNSW LGNIIMYAPT IWVRMVLMTH FFAILQSQEI LHKALDFDMY GVTYSVTPLD
     LPYIIQRLHG MAAFSLHGYS PGELNRVASC LRKLGAPPLR AWRHRARAVR AKLIAQGGKH
     AICGKYLFNW AVRTKLKLTP LRGAANLDLS GWFVSGGSGG DIFHSVSRAR PRNLLLCLLL
     LTVGVGIFLL PAR
//
ID   POLG_HCVVO              Reviewed;        3016 AA.
AC   O92531;
DT   10-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 76.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 6k (isolate VN405) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=356425;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=98378034; PubMed=9714232;
RA   Tokita H., Okamoto H., Iizuka H., Kishimoto J., Tsuda F., Miyakawa Y.,
RA   Mayumi M.;
RT   "The entire nucleotide sequences of three hepatitis C virus isolates
RT   in genetic groups 7-9 and comparison with those in the other eight
RT   genetic groups.";
RL   J. Gen. Virol. 79:1847-1857(1998).
RN   [2]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [3]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [4]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs act as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain a highly variable region called hypervariable
CC       region 1 (HVR1). E2 also contains two segments involved in CD81-
CC       binding. HVR1 is implicated in the SCARB1-mediated cell entry.
CC       CD81-binding regions may be involved in sensitivity and/or
CC       resistance to IFN-alpha therapy (By similarity).
CC   -!- DOMAIN: The N-terminus of NS5A acts as membrane anchor. The
CC       central part of NS5A seems to be intrinsically disordered and
CC       interacts with NS5B and host PKR (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D84264; BAA32666.1; -; Genomic_RNA.
DR   PIR; PQ0804; PQ0804.
DR   MEROPS; C18.001; -.
DR   euHCVdb; D84264; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; FALSE_NEG.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Apoptosis; ATP-binding; Capsid protein; Disulfide bond;
KW   Envelope protein; Fusion protein; Glycoprotein; Helicase;
KW   Host cell membrane; Host cytoplasm; Host endoplasmic reticulum;
KW   Host lipid droplet; Host membrane; Host mitochondrion; Host nucleus;
KW   Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000045724.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000045725.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000045726.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000045727.
FT   CHAIN       384    748       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000045728.
FT   CHAIN       749    811       p7 (By similarity).
FT                                /FTId=PRO_0000045729.
FT   CHAIN       812   1028       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000045730.
FT   CHAIN      1029   1659       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000045731.
FT   CHAIN      1660   1713       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000045732.
FT   CHAIN      1714   1974       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000045733.
FT   CHAIN      1975   2425       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000045734.
FT   CHAIN      2426   3016       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000045735.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    727       Lumenal (Potential).
FT   TRANSMEM    728    748       Potential.
FT   TOPO_DOM    749    759       Lumenal (Potential).
FT   TRANSMEM    760    780       Potential.
FT   TOPO_DOM    781    784       Cytoplasmic (Potential).
FT   TRANSMEM    785    805       Potential.
FT   TOPO_DOM    806    815       Lumenal (Potential).
FT   TRANSMEM    816    836       Potential.
FT   TOPO_DOM    837    883       Cytoplasmic (Potential).
FT   TRANSMEM    884    904       Potential.
FT   TOPO_DOM    905    930       Lumenal (Potential).
FT   TRANSMEM    931    951       Potential.
FT   TOPO_DOM    952   1659       Cytoplasmic (Potential).
FT   TRANSMEM   1660   1680       Potential.
FT   TOPO_DOM   1681   1807       Cytoplasmic (Potential).
FT   TRANSMEM   1808   1828       Potential.
FT   TOPO_DOM   1829   1830       Lumenal (Potential).
FT   TRANSMEM   1831   1851       Potential.
FT   TOPO_DOM   1852   1852       Cytoplasmic (Potential).
FT   TRANSMEM   1853   1873       Potential.
FT   TOPO_DOM   1874   1883       Lumenal (Potential).
FT   TRANSMEM   1884   1904       Potential.
FT   TOPO_DOM   1905   1974       Cytoplasmic (Potential).
FT   TOPO_DOM   1975   2004       In membrane (By similarity).
FT   TOPO_DOM   2005   2995       Cytoplasmic (Potential).
FT   TRANSMEM   2996   3016       By similarity.
FT   DOMAIN     1219   1371       Helicase ATP-binding.
FT   DOMAIN     2639   2757       RdRp catalytic.
FT   NP_BIND    1232   1239       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      384    410       HVR1 (By similarity).
FT   REGION      482    494       CD81-binding 1 (Potential).
FT   REGION      522    553       CD81-binding 2 (Potential).
FT   REGION      662    673       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1681   1692       NS3-binding (by NS4A) (Potential).
FT   REGION     2122   2335       Transcriptional activation (Potential).
FT   REGION     2122   2210       FKBP8-binding (Potential).
FT   REGION     2202   2252       Basal phosphorylation (By similarity).
FT   REGION     2212   2277       PKR-binding (Potential).
FT   REGION     2251   2309       NS4B-binding (Potential).
FT   REGION     2354   2425       Basal phosphorylation (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1318   1321       DECH box (By similarity).
FT   MOTIF      2325   2328       SH3-binding (Potential).
FT   MOTIF      2330   2338       Nuclear localization signal (Potential).
FT   COMPBIAS    798    805       Poly-Leu.
FT   COMPBIAS   2279   2330       Pro-rich.
FT   COMPBIAS   2998   3004       Poly-Leu.
FT   ACT_SITE    954    954       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    974    974       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    995    995       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1085   1085       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1109   1109       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1167   1167       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1125   1125       Zinc (By similarity).
FT   METAL      1127   1127       Zinc (By similarity).
FT   METAL      1173   1173       Zinc (By similarity).
FT   METAL      1177   1177       Zinc (By similarity).
FT   METAL      2013   2013       Zinc (By similarity).
FT   METAL      2031   2031       Zinc (By similarity).
FT   METAL      2033   2033       Zinc (By similarity).
FT   METAL      2054   2054       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        191    192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        748    749       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        811    812       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1028   1029       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1659   1660       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1713   1714       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1974   1975       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2425   2426       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2196   2196       Phosphoserine; by host; in p56 (By
FT                                similarity).
FT   MOD_RES    2199   2199       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2203   2203       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2206   2206       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1974   1974       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    250    250       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    416    416       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    422    422       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    429    429       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    447    447       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    475    475       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    532    532       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    556    556       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    578    578       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    625    625       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    647    647       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    757    757       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2116   2164       By similarity.
SQ   SEQUENCE   3016 AA;  328035 MW;  4E5CFF96258BCE3B CRC64;
     MSTLPKPQRK TKRNTNRRPM DVKFPGGGQI VGGVYLLPRR GPRLGVRATR KTSERSQPRG
     RRQPIPKARQ SQGRHWAQPG YPWPLYGNEG CGWAGWLLSP RGSRPNWGPN DPRRRSRNLG
     KVIDTLTCGF ADLMGYIPVV GAPLGGVAAA LAHGVRAIED GINYATGNLP GCSFSIFLLA
     LLSCLTTPAS AVHYRNISGI YHLTNDCPNS SIIYEADNII MHTPGCVPCV KTGNKSQCWV
     PVAPTLAVAN ASVPIRGFRS HVDLLVGSAA ACSALYIGDL CGGVFLVGQL FTFRPRQHTT
     VQECNCSIYT GHITGHRMAW DMMMNWSPTV TFITSSLLRV PQLLLEIALE GHWGVIGALL
     YYSMVANWAK VFAVLLLFAG VDATTHIGSS ASATTNRLTS FFSPGSKQNV QLIKTNGSWH
     INRTALNCND SLHTGFIAGL LYAHRFNSSG CPERLSSCRP LHAFEQGWGP LTYANISGPS
     NDKPYCWHYP PRPCDIVPAR SVCGPVYCFT PSPVVVGTTD RKGLPTYTWG ANESDVFLLR
     STRPPRGSWF GCTWMNSTGF VKTCGAPPCN TRPVGSGNDT LVCPTDCFRK HPEATYARCG
     SGPWLTPRCL VNYPYRLWHY PCTVNYTIHK VRMFVGGIEH RFEAACNWTR GERCELDDRD
     RVEMSPLLFS TTQLSILPCS FTTMPALSTG LIHLHQNIVD VQYLYGVSSA VVSWAVKWEY
     IVLAFLVLAV ARVCACLWLM FLVGQAEAAL ENLIVLNATS AAGSQGWVWG VVFICAAWYI
     RGRAAPITTY AILQLWPLLL LVLALPRRAY AYNGEEAASL GMLAIVIITI FTLTPAYKTL
     LISTLWWIQY YIARAEAMLY VWVPSLQVRG GRDAVILLTC LLHPQLGFEV TKAILALLGP
     LYILQYSLLK TPYFVRAHIL LRVCMFLRGV AGGKYVQAAL LRLGAWTGTY IYDHLTPLSD
     WACDGLRDLA VAVEPVVFSP MEKKVITWGA DTVACGDIIS GLPVSARRGN LIFLGPADDI
     RDGGWRLLAP ITAYAQQTRG LVGTIVTSLT GRDKNEVEGE IQVVSTATQS FLATTVNGVL
     WTVYHGAGSK TLAGPKGPIC QMYTNVDQDL VGWPAPPGAR SLTPCTCGSS DLYLVTRNAD
     VIPARRRGDT RAALLSPRPI STLKGSSGGP MLCPSGHVAG IFRAAVCTRG VAKSLDFVPV
     ENMQSTARSP SFSDNTTPPA VPQTYQVGYL HAPTGSGKST KVPAAYAAQG YKVLVLNPSV
     AATLGFGSYM STAHGIDPNI RTGVRTITTG GAITYSTYGK FLADGGCSGG AYDIIICDEC
     HSTDPTTVLG IGTVLDQAET AGVRLTVLAT ATPPGSVTVP HPNITEVALS STGEVPFYGK
     AIPLEYIKGG RHLIFCHSKK KCDELAKQLT SLGLNAVAFY RGVDVSVIPT SGDVVVCATD
     ALMTGYTGDF DSVIDCNVSV TQVVDFSLDP TFTIETTTMP QDAVSRSQRR GRTGRGKHGV
     YRYVSQGERP SGIFDTVVLC EAYDTGCAWY ELTPSETTVR LRAYLNTPGL PVCQDHLEFW
     EGVFTGLTHI DAHLLSQTKQ GGENFAYLVA YQATVCARAK APPPSWDTMW KCLIRLKPML
     TGPTPLLYRL GAVQNEITTT HPITKYIMTC MSADLEVITS TWVLVGGVLA ALAAYCLSVG
     CVVVCGRIST TGKPVLIPDR EVLYQQFDEM EECSRHIPYL VEGQHLAEQF KQKVLGLIQT
     TTRQAEEIEP VVHSAWPKLE QFWQKHLWNF VSGIQYLAGL STLPGNPAVA SLMSFSASLT
     SPLSTSTTLL LNILGGWVAS QLANPTASTA FVVSGLAGAT VGSIGLGRVL VDIIAGYGAG
     VSGALVAFKI MSGETPSAED MVNLLPALLS PGALVVGVVC AAILRRHAGP AEGATQWMNR
     LIAFASRGNH VSPTHYVPET DTSRQVMAIL SSLTVTSLLR KLHEWINSDW STPCSGSWLR
     DIWDWVCTVL SDFKVWLKSK LVPALPGVPF LSCQRGFRGV WRGDGICRTT CPCGADIVGH
     VKNGSMRISG SRWCSNIWHG TFPINATTTG PSVPIPEPNY KRALWRVSAE EYVEVARVGD
     SHFVVGATNQ DLKCPCQVPA PEFFTEVDGV RLHRFAPACK PLLRDEISFL VGLNSYAIGS
     QLPCEPEPDV TVVTSMLVDP SHLTAEAAAR RLARGSPPSC ASSLASQLSA PSLKATCTTH
     CAHPDADLIE ANLLWRQEVG GNITRVESEN KVIVLDSFDP LVPEYDDREP SVPAECHRPN
     RPKFPPALPI WARPDYNPPL LETWKKPDYA PPLVHGCALP SPVQPPVPPP RRKSVVHLDD
     STVATALAEL AEKSFPTQPA STPDSDSGHP TTSKSSDQAD EGEDTPSEAG SYSSMPPLEG
     EPGDPDLSSG SWSTVSEEGD SVVCCSMSYS WTGALVTPCA AEEEKLPINP LSNSLIRHHN
     LVYSTTTRSA AMRQKKVTFD RLQILDQHYN NVVKEVKLRA SGVTAKLLSV EEACSLTPPH
     SARSKFGYGA KDVRSHTSKA INHINSVWED LLEDNQTPIP TTIMAKNEVF CADVSKGGRK
     PARLIVYPDL GVRVCEKRAL YDVTRKLPTA IMGDAYGFQY SPKQRVDQLL KMWRSKKTPM
     GFSYDTRCFD STVTEHDIKT ERDVYLSCKL DPVARKAIES LTERLYIGGP MYNSRGQLCG
     TRRCRASGVL TTSLGNTMTC FIKAEAACRA AGLTNYDMLV CGDDLVVIAE SAGVQEDASN
     LRAFTEAMTR YSAPPGDEPH PAYDLELITS CSSNVSVAHD HTGQRYYYLT RDPTTPLSRA
     AWETARHTPV NSWLGNIIMY APAIWVRMVL MTHFFQILQA QEQLDKVLDF DMYGVTYSVS
     PLQLPAIIQR LHGMAAFSLH GYSPTELNRV GACLRKLGAP PLRAWRHRAR AVRAKLIAQG
     GGAAICGKYL FNWAVKTKLK LTPIPDAARL DLSGWFISGF SGGDIYHSVS RARPRIFLLC
     LLLLSVGVGI FLLPAR
//
ID   POLG_HCVVP              Reviewed;        3015 AA.
AC   O92532;
DT   10-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 76.
DE   RecName: Full=Genome polyprotein;
DE   Contains:
DE     RecName: Full=Core protein p21;
DE     AltName: Full=Capsid protein C;
DE     AltName: Full=p21;
DE   Contains:
DE     RecName: Full=Core protein p19;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E1;
DE     AltName: Full=gp32;
DE     AltName: Full=gp35;
DE   Contains:
DE     RecName: Full=Envelope glycoprotein E2;
DE     AltName: Full=NS1;
DE     AltName: Full=gp68;
DE     AltName: Full=gp70;
DE   Contains:
DE     RecName: Full=p7;
DE   Contains:
DE     RecName: Full=Protease NS2-3;
DE              Short=p23;
DE              EC=3.4.22.-;
DE   Contains:
DE     RecName: Full=Serine protease/NTPase/helicase NS3;
DE              EC=3.4.21.98;
DE              EC=3.6.1.15;
DE              EC=3.6.1.-;
DE     AltName: Full=Hepacivirin;
DE     AltName: Full=NS3P;
DE     AltName: Full=p70;
DE   Contains:
DE     RecName: Full=Non-structural protein 4A;
DE              Short=NS4A;
DE     AltName: Full=p8;
DE   Contains:
DE     RecName: Full=Non-structural protein 4B;
DE              Short=NS4B;
DE     AltName: Full=p27;
DE   Contains:
DE     RecName: Full=Non-structural protein 5A;
DE              Short=NS5A;
DE     AltName: Full=p56;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase;
DE              EC=2.7.7.48;
DE     AltName: Full=NS5B;
DE     AltName: Full=p68;
OS   Hepatitis C virus genotype 6h (isolate VN004) (HCV).
OC   Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC   Hepacivirus.
OX   NCBI_TaxID=356424;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   MEDLINE=98378034; PubMed=9714232;
RA   Tokita H., Okamoto H., Iizuka H., Kishimoto J., Tsuda F., Miyakawa Y.,
RA   Mayumi M.;
RT   "The entire nucleotide sequences of three hepatitis C virus isolates
RT   in genetic groups 7-9 and comparison with those in the other eight
RT   genetic groups.";
RL   J. Gen. Virol. 79:1847-1857(1998).
RN   [2]
RP   REVIEW.
RX   PubMed=10718937; DOI=10.1046/j.1365-2893.2000.00201.x;
RA   McLauchlan J.;
RT   "Properties of the hepatitis C virus core protein: a structural
RT   protein that modulates cellular processes.";
RL   J. Viral Hepat. 7:2-14(2000).
RN   [3]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=14752815; DOI=10.1002/hep.20032;
RA   Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.-M.;
RT   "Structural biology of hepatitis C virus.";
RL   Hepatology 39:5-19(2004).
RN   [4]
RP   INTERACTION WITH HNRNPA1 AND SEPT6.
RX   PubMed=17229681; DOI=10.1128/JVI.01311-06;
RA   Kim C.S., Seol S.K., Song O.-K., Park J.H., Jang S.K.;
RT   "An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6,
RT   facilitate hepatitis C virus replication.";
RL   J. Virol. 81:3852-3865(2007).
CC   -!- FUNCTION: Core protein packages viral RNA to form a viral
CC       nucleocapsid, and promotes virion budding. Modulates viral
CC       translation initiation by interacting with HCV IRES and 40S
CC       ribosomal subunit. Also regulates many host cellular functions
CC       such as signaling pathways and apoptosis. Prevents the
CC       establishment of cellular antiviral state by blocking the
CC       interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling
CC       pathways and by inducing human STAT1 degradation. Thought to play
CC       a role in virus-mediated cell transformation leading to
CC       hepatocellular carcinomas. Interacts with, and activates STAT3
CC       leading to cellular transformation. May repress the promoter of
CC       p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the
CC       cytoplasm. Also represses cell cycle negative regulating factor
CC       CDKN1A, thereby interrupting an important check point of normal
CC       cell cycle regulation. Targets transcription factors involved in
CC       the regulation of inflammatory responses and in the immune
CC       response: suppresses NK-kappaB activation, and activates AP-1.
CC       Could mediate apoptotic pathways through association with TNF-type
CC       receptors TNFRSF1A and LTBR, although its effect on death
CC       receptor-induced apoptosis remains controversial. Enhances TRAIL
CC       mediated apoptosis, suggesting that it might play a role in
CC       immune-mediated liver cell injury. Seric core protein is able to
CC       bind C1QR1 at the T-cell surface, resulting in down-regulation of
CC       T-lymphocytes proliferation. May transactivate human MYC, Rous
CC       sarcoma virus LTR, and SV40 promoters. May suppress the human FOS
CC       and HIV-1 LTR activity. Alters lipid metabolism by interacting
CC       with hepatocellular proteins involved in lipid accumulation and
CC       storage. Core protein induces up-regulation of FAS promoter
CC       activity, and thereby probably contributes to the increased
CC       triglyceride accumulation in hepatocytes (steatosis) (By
CC       similarity).
CC   -!- FUNCTION: E1 and E2 glycoproteins form a heterodimer that is
CC       involved in virus attachment to the host cell, virion
CC       internalization through clathrin-dependent endocytosis and fusion
CC       with host membrane. E1/E2 heterodimer binds to human LDLR, CD81
CC       and SCARB1/SR-BI receptors, but this binding is not sufficient for
CC       infection, some additional liver specific cofactors may be needed.
CC       The fusion function may possibly be carried by E1. E2 inhibits
CC       human EIF2AK2/PKR activation, preventing the establishment of an
CC       antiviral state. E2 is a viral ligand for CD209/DC-SIGN and
CC       CLEC4M/DC-SIGNR, which are respectively found on dendritic cells
CC       (DCs), and on liver sinusoidal endothelial cells and macrophage-
CC       like cells of lymph node sinuses. These interactions allow capture
CC       of circulating HCV particles by these cells and subsequent
CC       transmission to permissive cells. DCs are as sentinels in various
CC       tissues where they entrap pathogens and convey them to local
CC       lymphoid tissue or lymph node for establishment of immunity.
CC       Capture of circulating HCV particles by these SIGN+ cells may
CC       facilitate virus infection of proximal hepatocytes and lymphocyte
CC       subpopulations and may be essential for the establishment of
CC       persistent infection (By similarity).
CC   -!- FUNCTION: P7 seems to be a heptameric ion channel protein
CC       (viroporin) and is inhibited by the antiviral drug amantadine.
CC       Also inhibited by long-alkyl-chain iminosugar derivatives.
CC       Essential for infectivity (By similarity).
CC   -!- FUNCTION: Protease NS2-3 is a cysteine protease responsible for
CC       the autocatalytic cleavage of NS2-NS3. Seems to undergo self-
CC       inactivation following maturation (By similarity).
CC   -!- FUNCTION: NS3 displays three enzymatic activities: serine
CC       protease, NTPase and RNA helicase. NS3 serine protease, in
CC       association with NS4A, is responsible for the cleavages of NS3-
CC       NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B. NS3/NS4A complex also
CC       prevents phosphorylation of human IRF3, thus preventing the
CC       establishment of dsRNA induced antiviral state. NS3 RNA helicase
CC       binds to RNA and unwinds dsRNA in the 3' to 5' direction, and
CC       likely RNA stable secondary structure in the template strand.
CC       Cleaves and inhibits the host antiviral protein MAVS (By
CC       similarity).
CC   -!- FUNCTION: NS4B induces a specific membrane alteration that serves
CC       as a scaffold for the virus replication complex. This membrane
CC       alteration gives rise to the so-called ER-derived membranous web
CC       that contains the replication complex (By similarity).
CC   -!- FUNCTION: NS5A is a component of the replication complex involved
CC       in RNA-binding. Its interaction with Human VAPB may target the
CC       viral replication complex to vesicles. Down-regulates viral IRES
CC       translation initiation. Mediates interferon resistance, presumably
CC       by interacting with and inhibiting human EIF2AK2/PKR. Seems to
CC       inhibit apoptosis by interacting with BIN1 and FKBP8. The
CC       hyperphosphorylated form of NS5A is an inhibitor of viral
CC       replication (By similarity).
CC   -!- FUNCTION: NS5B is a RNA-dependent RNA polymerase that plays an
CC       essential role in the virus replication (By similarity).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of four peptide bonds in the viral
CC       precursor polyprotein, commonly with Asp or Glu in the P6
CC       position, Cys or Thr in P1 and Ser or Ala in P1'.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate.
CC   -!- COFACTOR: Binds 1 zinc ion per NS3 protease domain (By
CC       similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per NS5A N-terminal domain (By
CC       similarity).
CC   -!- ENZYME REGULATION: Activity of auto-protease NS2-3 is dependent on
CC       zinc ions and completely inhibited by EDTA. Serine protease NS3 is
CC       also activated by zinc ions (By similarity).
CC   -!- SUBUNIT: Core protein is a homomultimer that binds the C-terminal
CC       part of E1 and interacts with numerous cellular proteins.
CC       Interaction with human STAT1 SH2 domain seems to result in
CC       decreased STAT1 phosphorylation, leading to decreased IFN-
CC       stimulated gene transcription. In addition to blocking the
CC       formation of phosphorylated STAT1, the core protein also promotes
CC       ubiquitin-mediated proteasome-dependent degradation of STAT1.
CC       Interacts with, and constitutively activates human STAT3.
CC       Associates with human LTBR and TNFRSF1A receptors and possibly
CC       induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK,
CC       C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins.
CC       Interacts with human CREB3 nuclear transcription protein,
CC       triggering cell transformation. May interact with human p53. Also
CC       binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1
CC       and E2 glycoproteins form a heterodimer that binds to human LDLR,
CC       CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human
CC       EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR.
CC       p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing
CC       a pair of composite active sites at the dimerization interface.
CC       NS2 seems to interact with all other non-structural (NS) proteins.
CC       NS4A interacts with NS3 serine protease and stabilizes its
CC       folding. NS3-NS4A complex is essential for the activation of the
CC       latter and allows membrane anchorage of NS3. NS3 interacts with
CC       human TANK-binding kinase TBK1 and MAVS. NS4B and NS5A form
CC       homodimers and seem to interact with all other non-structural (NS)
CC       proteins. NS5A also interacts with human EIF2AK2/PKR, FKBP8, GRB2,
CC       BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B
CC       is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6
CC       (By similarity).
CC   -!- SUBCELLULAR LOCATION: Core protein p21: Host endoplasmic reticulum
CC       membrane; Single-pass membrane protein (By similarity). Host
CC       mitochondrion membrane; Single-pass type I membrane protein (By
CC       similarity). Host lipid droplet (By similarity). Note=The C-
CC       terminal transmembrane domain of core protein p21 contains an ER
CC       signal leading the nascent polyprotein to the ER membrane. Only a
CC       minor proportion of core protein is present in the nucleus and an
CC       unknown proportion is secreted.
CC   -!- SUBCELLULAR LOCATION: Core protein p19: Virion (By similarity).
CC       Host cytoplasm (By similarity). Host nucleus (By similarity).
CC       Secreted (By similarity).
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E1: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E1 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Envelope glycoprotein E2: Virion membrane;
CC       Single-pass type I membrane protein (Potential). Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein (By
CC       similarity). Note=The C-terminal transmembrane domain acts as a
CC       signal sequence and forms a hairpin structure before cleavage by
CC       host signal peptidase. After cleavage, the membrane sequence is
CC       retained at the C-terminus of the protein, serving as ER membrane
CC       anchor. A reorientation of the second hydrophobic stretch occurs
CC       after cleavage producing a single reoriented transmembrane domain.
CC       These events explain the final topology of the protein. ER
CC       retention of E2 is leaky and, in overexpression conditions, only a
CC       small fraction reaches the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: p7: Host endoplasmic reticulum membrane;
CC       Multi-pass membrane protein (By similarity). Host cell membrane
CC       (By similarity). Note=The C-terminus of p7 membrane domain acts as
CC       a signal sequence. After cleavage by host signal peptidase, the
CC       membrane sequence is retained at the C-terminus of the protein,
CC       serving as ER membrane anchor. Only a fraction localizes to the
CC       plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Protease NS2-3: Host endoplasmic reticulum
CC       membrane; Multi-pass membrane protein (Potential).
CC   -!- SUBCELLULAR LOCATION: Serine protease/NTPase/helicase NS3: Host
CC       endoplasmic reticulum membrane; Peripheral membrane protein (By
CC       similarity). Note=NS3 is associated to the ER membrane through its
CC       binding to NS4A.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4A: Host endoplasmic
CC       reticulum membrane; Single-pass type I membrane protein
CC       (Potential). Note=Host membrane insertion occurs after processing
CC       by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 4B: Host endoplasmic
CC       reticulum membrane; Multi-pass membrane protein (By similarity).
CC   -!- SUBCELLULAR LOCATION: Non-structural protein 5A: Host endoplasmic
CC       reticulum membrane; Peripheral membrane protein (By similarity).
CC       Host cytoplasm, host perinuclear region (By similarity). Host
CC       mitochondrion (By similarity). Note=Host membrane insertion occurs
CC       after processing by the NS3 protease.
CC   -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase: Host
CC       endoplasmic reticulum membrane; Single-pass type I membrane
CC       protein (Potential). Note=Host membrane insertion occurs after
CC       processing by the NS3 protease.
CC   -!- DOMAIN: The transmembrane regions of envelope E1 and E2
CC       glycoproteins are involved in heterodimer formation, ER
CC       localization, and assembly of these proteins. Envelope E2
CC       glycoprotein contain a highly variable region called hypervariable
CC       region 1 (HVR1). E2 also contains two segments involved in CD81-
CC       binding. HVR1 is implicated in the SCARB1-mediated cell entry.
CC       CD81-binding regions may be involved in sensitivity and/or
CC       resistance to IFN-alpha therapy (By similarity).
CC   -!- DOMAIN: The N-terminus of NS5A act as membrane anchor. The central
CC       s part of NS5A seems to be intrinsically disordered and interacts
CC       with NS5B and host PKR (By similarity).
CC   -!- DOMAIN: The SH3-binding domain of NS5A is involved in the
CC       interaction with human Bin1, GRB2 and Src-family kinases (By
CC       similarity).
CC   -!- DOMAIN: The N-terminal one-third of serine protease NS3 contains
CC       the protease activity. This region contains a zinc atom that does
CC       not belong to the active site, but may play a structural rather
CC       than a catalytic role. This region is essential for the activity
CC       of protease NS2-3, maybe by contributing to the folding of the
CC       latter. The helicase activity is located in the C-terminus of NS3
CC       (By similarity).
CC   -!- PTM: Specific enzymatic cleavages in vivo yield mature proteins.
CC       The structural proteins, core, E1, E2 and p7 are produced by
CC       proteolytic processing by host signal peptidases. The core protein
CC       is synthesized as a 21 kDa precursor which is retained in the ER
CC       membrane through the hydrophobic signal peptide. Cleavage by the
CC       signal peptidase releases the 19 kDa mature core protein. The
CC       other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS5A and NS5B) are
CC       cleaved by the viral proteases (By similarity).
CC   -!- PTM: Envelope E1 and E2 glycoproteins are highly N-glycosylated
CC       (By similarity).
CC   -!- PTM: Core protein is phosphorylated by host PKC and PKA (By
CC       similarity).
CC   -!- PTM: NS5A is phosphorylated in a basal form termed p56. p58 is an
CC       hyperphosphorylated form of p56. p56 and p58 coexist in the cell
CC       in roughly equivalent amounts. Hyperphosphorylation is dependent
CC       on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1,
CC       MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for
CC       NS5A phosphorylation (By similarity).
CC   -!- PTM: NS4B is palmitoylated. This modification may play a role in
CC       its polymerization or in protein-protein interactions (By
CC       similarity).
CC   -!- PTM: The N-terminus of a fraction of NS4B molecules seems to be
CC       relocated post-translationally from the cytoplasm to the ER lumen,
CC       with a 5th transmembrane segment. The C-terminus of NS2 may be
CC       lumenal with a fourth transmembrane segment (By similarity).
CC   -!- PTM: Core protein is ubiquitinated; mediated by UBE3A and leading
CC       to core protein subsequent proteasomal degradation (By
CC       similarity).
CC   -!- MISCELLANEOUS: Cell culture adaptation of the virus leads to
CC       mutations in NS5A, reducing its inhibitory effect on replication
CC       (By similarity).
CC   -!- MISCELLANEOUS: Core protein exerts viral interference on hepatitis
CC       B virus when HCV and HBV coinfect the same cell, by suppressing
CC       HBV gene expression, RNA encapsidation and budding (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the hepaciviruses polyprotein family.
CC   -!- SIMILARITY: Contains 1 helicase ATP-binding domain.
CC   -!- SIMILARITY: Contains 1 peptidase C18 domain.
CC   -!- SIMILARITY: Contains 1 peptidase S29 domain.
CC   -!- SIMILARITY: Contains 1 RdRp catalytic domain.
CC   -!- CAUTION: The core gene probably also codes for alternative reading
CC       frame proteins (ARFPs). Many functions depicted for the core
CC       protein might belong to the ARFPs.
CC   -!- CAUTION: Lacks the conserved His residue in position 1084
CC       essential for serine protease NS3 activity. Its enzyme activity is
CC       therefore unsure.
CC   -!- WEB RESOURCE: Name=euHCVdb; Note=The European HCV database;
CC       URL="http://euhcvdb.ibcp.fr";
CC   -!- WEB RESOURCE: Name=HCV database;
CC       URL="http://www.hcvdb.org/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D84265; BAA32667.1; -; Genomic_RNA.
DR   MEROPS; S29.001; -.
DR   euHCVdb; D84265; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:InterPro.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044186; C:host cell lipid particle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044191; C:host cell mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0030683; P:evasion by virus of host immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of cellular transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006410; P:cellular transcription, RNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0019087; P:transformation of host cell by virus; IEA:InterPro.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   InterPro; IPR014001; DEAD-like_N.
DR   InterPro; IPR001650; DNA/RNA_helicase_C.
DR   InterPro; IPR002521; HCV_core_C.
DR   InterPro; IPR002519; HCV_env.
DR   InterPro; IPR002531; HCV_NS1.
DR   InterPro; IPR000745; HCV_NS4a.
DR   InterPro; IPR001490; HCV_NS4b.
DR   InterPro; IPR002868; HCV_NS5a.
DR   InterPro; IPR013193; HCV_NS5a_1B_dom.
DR   InterPro; IPR014021; Helicase_SF1/SF2_ATP-bd.
DR   InterPro; IPR002518; Pept_C18_HCV_NS2.
DR   InterPro; IPR004109; Peptidase_S29.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR002166; RNA_pol_HCV.
DR   InterPro; IPR009003; Ser/Cys_Pept_Trypsin-like.
DR   InterPro; IPR013192; Znf_HCV_NS5a.
DR   Pfam; PF01542; HCV_core; 1.
DR   Pfam; PF01539; HCV_env; 1.
DR   Pfam; PF01560; HCV_NS1; 1.
DR   Pfam; PF01538; HCV_NS2; 1.
DR   Pfam; PF01006; HCV_NS4a; 1.
DR   Pfam; PF01001; HCV_NS4b; 1.
DR   Pfam; PF01506; HCV_NS5a; 1.
DR   Pfam; PF08300; HCV_NS5a_1a; 1.
DR   Pfam; PF08301; HCV_NS5a_1b; 1.
DR   Pfam; PF02907; Peptidase_S29; 1.
DR   Pfam; PF00998; RdRP_3; 1.
DR   ProDom; PD001388; HCV_env; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SUPFAM; SSF50494; Pept_Ser_Cys; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; FALSE_NEG.
DR   PROSITE; PS50507; RDRP_SSRNA_POS; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Apoptosis; ATP-binding; Capsid protein; Disulfide bond;
KW   Envelope protein; Fusion protein; Glycoprotein; Helicase;
KW   Host cell membrane; Host cytoplasm; Host endoplasmic reticulum;
KW   Host lipid droplet; Host membrane; Host mitochondrion; Host nucleus;
KW   Host-virus interaction; Hydrolase;
KW   Interferon antiviral system evasion; Lipoprotein; Membrane;
KW   Metal-binding; Multifunctional enzyme; Nucleotide-binding;
KW   Nucleotidyltransferase; Oncogene; Palmitate; Phosphoprotein; Protease;
KW   Ribonucleoprotein; RNA replication; RNA-binding;
KW   RNA-directed RNA polymerase; Secreted; Serine protease; SH3-binding;
KW   Thiol protease; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Ubl conjugation; Viral nucleoprotein; Virion; Zinc.
FT   INIT_MET      1      1       Removed; by host (By similarity).
FT   CHAIN         2    191       Core protein p21 (Potential).
FT                                /FTId=PRO_0000045736.
FT   CHAIN         2    177       Core protein p19 (By similarity).
FT                                /FTId=PRO_0000045737.
FT   PROPEP      178    191       ER anchor for the core protein, removed
FT                                in mature form by host signal peptidase
FT                                (By similarity).
FT                                /FTId=PRO_0000045738.
FT   CHAIN       192    383       Envelope glycoprotein E1 (Potential).
FT                                /FTId=PRO_0000045739.
FT   CHAIN       384    747       Envelope glycoprotein E2 (Potential).
FT                                /FTId=PRO_0000045740.
FT   CHAIN       748    810       p7 (By similarity).
FT                                /FTId=PRO_0000045741.
FT   CHAIN       811   1027       Protease NS2-3 (Potential).
FT                                /FTId=PRO_0000045742.
FT   CHAIN      1028   1658       Serine protease/NTPase/helicase NS3
FT                                (Potential).
FT                                /FTId=PRO_0000045743.
FT   CHAIN      1659   1712       Non-structural protein 4A (Potential).
FT                                /FTId=PRO_0000045744.
FT   CHAIN      1713   1973       Non-structural protein 4B (Potential).
FT                                /FTId=PRO_0000045745.
FT   CHAIN      1974   2424       Non-structural protein 5A (Potential).
FT                                /FTId=PRO_0000045746.
FT   CHAIN      2425   3015       RNA-directed RNA polymerase (Potential).
FT                                /FTId=PRO_0000045747.
FT   TOPO_DOM      2    168       Cytoplasmic (Potential).
FT   TRANSMEM    169    189       Potential.
FT   TOPO_DOM    190    358       Lumenal (Potential).
FT   TRANSMEM    359    379       Potential.
FT   TOPO_DOM    380    726       Lumenal (Potential).
FT   TRANSMEM    727    747       Potential.
FT   TOPO_DOM    748    758       Lumenal (Potential).
FT   TRANSMEM    759    779       Potential.
FT   TOPO_DOM    780    783       Cytoplasmic (Potential).
FT   TRANSMEM    784    804       Potential.
FT   TOPO_DOM    805    814       Lumenal (Potential).
FT   TRANSMEM    815    835       Potential.
FT   TOPO_DOM    836    882       Cytoplasmic (Potential).
FT   TRANSMEM    883    903       Potential.
FT   TOPO_DOM    904    929       Lumenal (Potential).
FT   TRANSMEM    930    950       Potential.
FT   TOPO_DOM    951   1658       Cytoplasmic (Potential).
FT   TRANSMEM   1659   1679       Potential.
FT   TOPO_DOM   1680   1806       Cytoplasmic (Potential).
FT   TRANSMEM   1807   1827       Potential.
FT   TOPO_DOM   1828   1829       Lumenal (Potential).
FT   TRANSMEM   1830   1850       Potential.
FT   TOPO_DOM   1851   1851       Cytoplasmic (Potential).
FT   TRANSMEM   1852   1872       Potential.
FT   TOPO_DOM   1873   1882       Lumenal (Potential).
FT   TRANSMEM   1883   1903       Potential.
FT   TOPO_DOM   1904   1973       Cytoplasmic (Potential).
FT   TOPO_DOM   1974   2003       In membrane (By similarity).
FT   TOPO_DOM   2004   2994       Cytoplasmic (Potential).
FT   TRANSMEM   2995   3015       By similarity.
FT   DOMAIN     1218   1370       Helicase ATP-binding.
FT   DOMAIN     2638   2756       RdRp catalytic.
FT   NP_BIND    1231   1238       ATP (Potential).
FT   REGION        2     59       Interaction with DDX3X (By similarity).
FT   REGION        2     23       Interaction with STAT1 (By similarity).
FT   REGION      122    173       Interaction with APOA2 (By similarity).
FT   REGION      150    159       Mitochondrial targeting signal (By
FT                                similarity).
FT   REGION      164    167       Important for lipid droplets localization
FT                                (By similarity).
FT   REGION      265    296       Fusion peptide (Potential).
FT   REGION      384    410       HVR1 (By similarity).
FT   REGION      482    494       CD81-binding 1 (Potential).
FT   REGION      522    553       CD81-binding 2 (Potential).
FT   REGION      661    672       PKR/eIF2-alpha phosphorylation homology
FT                                domain (PePHD) (By similarity).
FT   REGION     1680   1691       NS3-binding (by NS4A) (Potential).
FT   REGION     2201   2251       Basal phosphorylation (By similarity).
FT   REGION     2211   2276       PKR-binding (Potential).
FT   REGION     2250   2308       NS4B-binding (Potential).
FT   REGION     2353   2424       Basal phosphorylation (By similarity).
FT   MOTIF         5     13       Nuclear localization signal (Potential).
FT   MOTIF        38     43       Nuclear localization signal (Potential).
FT   MOTIF        58     64       Nuclear localization signal (Potential).
FT   MOTIF        66     71       Nuclear localization signal (Potential).
FT   MOTIF      1317   1320       DECH box (By similarity).
FT   MOTIF      2324   2327       SH3-binding (Potential).
FT   MOTIF      2329   2337       Nuclear localization signal (Potential).
FT   COMPBIAS    797    804       Poly-Leu.
FT   COMPBIAS   2278   2329       Pro-rich.
FT   COMPBIAS   2996   3003       Poly-Leu.
FT   ACT_SITE    953    953       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    973    973       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE    994    994       For protease NS2-3 activity; shared with
FT                                dimeric partner (By similarity).
FT   ACT_SITE   1108   1108       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   ACT_SITE   1166   1166       Charge relay system; for serine protease
FT                                NS3 activity (By similarity).
FT   METAL      1124   1124       Zinc (By similarity).
FT   METAL      1126   1126       Zinc (By similarity).
FT   METAL      1172   1172       Zinc (By similarity).
FT   METAL      1176   1176       Zinc (By similarity).
FT   METAL      2012   2012       Zinc (By similarity).
FT   METAL      2030   2030       Zinc (By similarity).
FT   METAL      2032   2032       Zinc (By similarity).
FT   METAL      2053   2053       Zinc (By similarity).
FT   SITE        177    178       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        191    192       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        383    384       Cleavage; by host signal peptidase
FT                                (Potential).
FT   SITE        747    748       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE        810    811       Cleavage; by host signal peptidase (By
FT                                similarity).
FT   SITE       1027   1028       Cleavage; by protease NS2-3 (Potential).
FT   SITE       1658   1659       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1712   1713       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       1973   1974       Cleavage; by serine protease NS3
FT                                (Potential).
FT   SITE       2424   2425       Cleavage; by serine protease NS3
FT                                (Potential).
FT   MOD_RES       2      2       N-acetylserine; by host (By similarity).
FT   MOD_RES      53     53       Phosphoserine; by host (By similarity).
FT   MOD_RES      99     99       Phosphoserine; by host (By similarity).
FT   MOD_RES     116    116       Phosphoserine; by host PKA (By
FT                                similarity).
FT   MOD_RES    2195   2195       Phosphoserine; by host; in p56 (By
FT                                similarity).
FT   MOD_RES    2198   2198       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2202   2202       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   MOD_RES    2205   2205       Phosphoserine; by host; in p58 (By
FT                                similarity).
FT   LIPID      1973   1973       S-palmitoyl cysteine; by host (By
FT                                similarity).
FT   CARBOHYD    196    196       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    209    209       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    234    234       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    250    250       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    305    305       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    416    416       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    422    422       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    429    429       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    447    447       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    475    475       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    532    532       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    556    556       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    576    576       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    624    624       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   CARBOHYD    646    646       N-linked (GlcNAc...); by host
FT                                (Potential).
FT   DISULFID   2115   2163       By similarity.
SQ   SEQUENCE   3015 AA;  327978 MW;  69108DD32B5DA012 CRC64;
     MSTLPKPQRK TKRNTNRRPM DVKFPGGGQI VGGVYLLPRR GPRLGVRATR KTSERSQPRG
     RRQPIPKARQ PIGRSWGQPG YPWPLYGNEG CGWAGWLLSP RGSRPNWGPN DPRRRSRNLG
     KVIDTLTCGL ADLMGYIPVL GGPLGGVAAA LAHGVRAIED GVNYATGNLP GCSFSIFLLA
     LLSCLTTPAS AIQVRNASGI YHLTNDCSNN SIVFEAETII LHLPGCVPCI KVGNGSRCWL
     SVSPTLAVPN SSVPIHGFRR HVDLLVGAAA FCSAMYIGDL CGSVFLVGQL FTFRPKHHQV
     TQDCNCSIYA GHITGHRMAW DMMLNWSPTV SYVVSSALRV PQLLLEVITG AHWGVLGALL
     YFSMVANWAK VIAVLFLFAG ADATTYTGSA VSSTTGAFVS LFSPGPTQNL QLVNSNGSWH
     INRTALNCND SLQTGFIAGL FARYKFNSTG CPERMSKCRP LHSFEQGWGP ISYVNISGSS
     EDKPYCWHYA PRPCGIVPAR NVCGPVYCFT PSPVVVGTTD QRGIPTYTWG ENVSDVFLLH
     SARPPLGAWF GCTWMNSSGF VKTCGAPPCR IKPTINETDL VCPTDCFRKH PDASFVKCGS
     GPWLTPRCMV DYPYRLWHYP CTVNFTIHKV RVFVGGVEHR FNAACNWTRG DRCELDDRDR
     FEMSPLLFST TQLAILPCSF TTMPALSTGL IHLHQNIVDI QYLYGVSTAV VSWAMKWEYV
     VLAFLVLADA RVCACLWLMF LVGQAEAALE NVIVLNAASA ASCQGLLWGL IFICCAWHVR
     GRAVPVTTYA LLQLWPLLLL ILALPRRAYA FDSEQAASAG LLVLGLITIF TLTPAYKQLL
     ISMLWWIQYF IALTEAQLHQ WVPSLLVRGG RDAVILLACL FHPQLGFEVT KILLALLGPL
     YLLQYSLLKT PYFVRAHILL RACMFFRGMA RGRYAQAILL RIGAWTGTYI YDHLAPLSDW
     ACDGLRDLAV AVEPVVFSPM EKKVITWGAD TAACGDIIAG LPVAARRGNL LFLGPADDVK
     GKGWRLLAPI TAYAQQTRGI VGTIVTSLTG RDKNEVEGEI QVVSTATQSF LATAVNGVLW
     TVYYGAGSKT LAGPKGPVCQ MYTNVDQDLV GWPAPAGARS LTPCSCGSSD LYLVTRNADV
     IPARRRGDNR AALLSPRPIS TLKGSSGGPM LCPSGHVAGI FRAAVCTRGV AKSLDFAPVE
     SMQSSQRSPS FSDNTSPPAV PQTYQVGYLH APTGSGKSTK VPAAYAAQGY KVLVLNPSVA
     ATLGFGSYMS TSHGIDPNIR TGVRTITTGG AITYSTYGKF LADGGCSGGA YDVIICDECH
     STDPTTVSGI GTVLDQAETS GVRLTVLATA TPPGSVTVPH PNITESALPT TGEIPFYGKA
     VPLEYIKGGR HLIFCHPKKK CDELAKQLVS LGLNAVAFYR GVDVSVIPTS GDVVVCATDA
     LMTGYTGDFD SVIDCNVTVT QVVDFSLDPT FTIETTTVPQ DAVSRSQRRG RTGRGKHGVY
     RYVSQGERPS GMFDSVILCE AYDTGCAWYE LTPAETTVRL RAYLNTPGLP VCQDHLEFWE
     GVFTGLTHID AHFLSQTKQA EENFAYLVAY QATVCARAKA PPPSWDTMWK CLIRLKPMLT
     GPTPLLYRLG PVQNEVVTTH PITKYIMTCM SADLEVITST WVLVGGVVAA LAAYCLSVGC
     VVICGRISTS GKPVLIPDRE VLYQQFDEME ECSRHIPYLA EGHLIAEQFK QKVLGLIQST
     SKQAEELKPA VHAAWPKLEQ FWQKQLWNFV SGIQYLAGLS TLPGNPAIAS LMSFSASLTS
     PLSTHQTLLL NILGGWVASQ LANPTASTAF VVSGLAGAAV GSIGLGRVIV DVLAGYGAGV
     SGALVAFKIM CGETPSAEDM VNLLPALLSP GALVVGVVCA AILRRHAGPS EGATQWMNRL
     IAFASRGNHV SPTHYVPETD TSRQIMTILS SLTVTSLLRK LHEWINTDWS TPCSSSWLRD
     IWDWVCEVLS DFKTWLKAKL VPALPGVPFL SCQRGFRGTW RGDGICHTTC PCGSEITGHV
     KNGTMKISGP RWCSNVSHRT FPINATTTGP SVPIPEPNYT RALWRVSAEE YVEVKRVGDS
     HFVVGATTDN LKCPCQVPAP EFFTEVDGVR LHRYAPRCKP LLRDEVSFSV GLSSYAVGSQ
     LPCEPEPDVT VVTSMLIDPS HVTAEAAARR LARGSPPSLA SSSASQLSAP SLKATCTMHG
     AHPDAELIEA NLLWRQEMGG NITRVESENK VVILDSFDPL VPEFEEREMS VPAECHRPRR
     PKFPPALPIW ATPGYNPPVL ETWKSPTYEP PVVHGCALPP SGPPPIPPPR RKKVVQLDSS
     NVSAALAQLA AKTFETPSSP TTGYGSDQPD HSTESSEHDR DDGVASEAES YSSMPPLEGE
     PGDPDLSSGS WSTVSEEGDS VVCCSYSYSW TGALVTPCAA EEEKLPINPL SNSLIRHHNL
     VYSTSSRSAA TRQKKVTFDR VQLLDQHYYD TVKEIKLRAS HVKAQLLSTE EACDLTPPHS
     ARSKFGYGAK DVRSHASKAI NHINSVWADL LEDTQTPIPT TIMAKNEVFC VDASKGGRKS
     ARLIVYPDLG VRVCEKRALF DVTRKLPTAI MGDAYGFQYS PQQRVDRLLK MWRSKKTPMG
     FSYDTRCFDS TVTERDIRTE QDIYLSCQLD PEARKVIESL TERLYVGGPM YNSKGQLCGQ
     RRCRASGVLP TSMGNTVTCF LKATAACRAA GFTDYDMLVC GDDLVVVTES AGVNEDIANL
     RAFTEAMTRY SATPGDEPSP TYDLELITSC SSNVSVAHDG DGRRYYYLTR DPVTPLARAA
     WETARHTPVN SWLGNIIMYA PTIWVRMVLM THFFQILQAQ ETLDRALDFD IYGVTYSITP
     LDLPVIIQRL HGMAAFSLHG YSPDELNRVA SCLRKLGAPP LRAWRHRARA VRAKLIAQGG
     KAAVCGKYLF NWAIKTKLRL TPLRGASALD LSGWFTSGYG GGDVYHSASR ARPRFLLLCL
     LLLSVGVGIF LLPAR
//
ID   PRAF1_HUMAN             Reviewed;         185 AA.
AC   Q9UI14; Q7Z4Y2; Q9Y3R1;
DT   07-DEC-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   02-MAR-2010, entry version 65.
DE   RecName: Full=Prenylated Rab acceptor protein 1;
DE   AltName: Full=PRA1 family protein 1;
GN   Name=RABAC1; Synonyms=PRA1, PRAF1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], INTERACTION WITH RAB GTPASES, AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Brain, and Placenta;
RX   MEDLINE=99262153; PubMed=10329441; DOI=10.1006/bbrc.1999.0651;
RA   Bucci C., Chiariello M., Lattero D., Maiorano M., Bruni C.B.;
RT   "Interaction cloning and characterization of the cDNA encoding the
RT   human prenylated rab acceptor (PRA1).";
RL   Biochem. Biophys. Res. Commun. 258:657-662(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Hypothalamus;
RA   Jin W., Huang C., Wu T., Peng Y., Gu Y., Zhang L., Jiang C., Li Y.,
RA   Han Z., Wang Y., Chen Z., Fu G.;
RT   "A novel gene expressed in human hypothalamus.";
RL   Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Fu Q., Yu L., Yue P., Dai F.Y., Wang X.K., Zhao S.Y.;
RT   "Cloning and characterization of a new human cDNA homologous to Rattus
RT   norvegicus prenylated rab acceptor 1 (PRA1) mRNA.";
RL   Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX   PubMed=11520070; DOI=10.1006/bbrc.2001.5466;
RA   Bucci C., De Gregorio L., Bruni C.B.;
RT   "Expression analysis and chromosomal assignment of PRA1 and RILP
RT   genes.";
RL   Biochem. Biophys. Res. Commun. 286:815-819(2001).
RN   [8]
RP   NOMENCLATURE.
RX   PubMed=16481131; DOI=10.1016/j.gene.2005.12.009;
RA   Fo C.S., Coleman C.S., Wallick C.J., Vine A.L., Bachmann A.S.;
RT   "Genomic organization, expression profile, and characterization of the
RT   new protein PRA1 domain family, member 2 (PRAF2).";
RL   Gene 371:154-165(2006).
RN   [9]
RP   IDENTIFICATION [LARGE SCALE ANALYSIS], AND MASS SPECTROMETRY.
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
CC   -!- FUNCTION: General Rab protein regulator required for vesicle
CC       formation from the Golgi complex. May control vesicle docking and
CC       fusion by mediating the action of Rab GTPases to the SNARE
CC       complexes. In addition it inhibits the removal of Rab GTPases from
CC       the membrane by GDI (By similarity).
CC   -!- SUBUNIT: Homodimer. Interacts with VAMP2 (synaptobrevin-2), GDI1,
CC       and PCLO (By similarity). Interacts specifically with prenylated
CC       Rab proteins; strongly with RAB4B, RAB5A and RAB5C, and weakly
CC       with RAB4A, RAB6, RAB7, RAB17 and RAB22.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-712367, EBI-712367;
CC       P51116:FXR2; NbExp=2; IntAct=EBI-712367, EBI-740459;
CC       Q9GZT8:NIF3L1; NbExp=2; IntAct=EBI-712367, EBI-740897;
CC       Q6ZVK8:NUDT18; NbExp=2; IntAct=EBI-712367, EBI-740486;
CC       Q9H8W4:PLEKHF2; NbExp=2; IntAct=EBI-712367, EBI-742388;
CC       Q14088:RAB33A; NbExp=2; IntAct=EBI-712367, EBI-744685;
CC       Q96C03:SMCR7; NbExp=2; IntAct=EBI-712367, EBI-750153;
CC       Q96HA8:WDYHV1; NbExp=2; IntAct=EBI-712367, EBI-741158;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein
CC       (By similarity). Cytoplasm (By similarity). Golgi apparatus (By
CC       similarity). Cytoplasmic vesicle, secretory vesicle, synaptic
CC       vesicle (By similarity). Note=According to some authors, it is an
CC       integral membrane protein, while others showed that it is
CC       cytoplasmic and membrane-associated to Golgi and synaptic vesicles
CC       (By similarity).
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Strongest expression found in
CC       placenta, pituitary gland, kidney, lung and stomach.
CC   -!- DEVELOPMENTAL STAGE: In fetal tissues, it is more abundant in
CC       kidney and lung.
CC   -!- SIMILARITY: Belongs to the PRA1 family.
CC   -!- CAUTION: In contrast to the mouse ortholog, it does not interact
CC       with Ras.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ133534; CAB43107.1; -; mRNA.
DR   EMBL; AF112202; AAF17190.1; -; mRNA.
DR   EMBL; AF112996; AAP97229.1; -; mRNA.
DR   EMBL; CR457214; CAG33495.1; -; mRNA.
DR   EMBL; CR542116; CAG46913.1; -; mRNA.
DR   EMBL; BT019964; AAV38767.1; -; mRNA.
DR   EMBL; BC008950; AAH08950.1; -; mRNA.
DR   IPI; IPI00007909; -.
DR   RefSeq; NP_006414.2; -.
DR   UniGene; Hs.11417; -.
DR   IntAct; Q9UI14; 22.
DR   STRING; Q9UI14; -.
DR   PRIDE; Q9UI14; -.
DR   Ensembl; ENST00000222008; ENSP00000222008; ENSG00000105404; Homo sapiens.
DR   GeneID; 10567; -.
DR   KEGG; hsa:10567; -.
DR   UCSC; uc002osf.1; human.
DR   CTD; 10567; -.
DR   GeneCards; GC19M047152; -.
DR   H-InvDB; HIX0015164; -.
DR   HGNC; HGNC:9794; RABAC1.
DR   HPA; CAB019320; -.
DR   MIM; 604925; gene.
DR   PharmGKB; PA34155; -.
DR   eggNOG; prNOG07096; -.
DR   HOGENOM; HBG277451; -.
DR   HOVERGEN; HBG053660; -.
DR   InParanoid; Q9UI14; -.
DR   OMA; AGGISFP; -.
DR   OrthoDB; EOG9DV85S; -.
DR   PhylomeDB; Q9UI14; -.
DR   NextBio; 40105; -.
DR   ArrayExpress; Q9UI14; -.
DR   Bgee; Q9UI14; -.
DR   CleanEx; HS_RABAC1; -.
DR   Genevestigator; Q9UI14; -.
DR   GermOnline; ENSG00000105404; Homo sapiens.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0008021; C:synaptic vesicle; IEA:UniProtKB-SubCell.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   InterPro; IPR004895; Prenylated_rab_accept_PRA1.
DR   Pfam; PF03208; PRA1; 1.
PE   1: Evidence at protein level;
KW   Cell junction; Cell membrane; Complete proteome; Cytoplasm;
KW   Cytoplasmic vesicle; Golgi apparatus; Membrane; Synapse;
KW   Transmembrane.
FT   CHAIN         1    185       Prenylated Rab acceptor protein 1.
FT                                /FTId=PRO_0000220878.
FT   TOPO_DOM      1     78       Cytoplasmic (By similarity).
FT   TRANSMEM     79     94       By similarity.
FT   TRANSMEM     95    112       By similarity.
FT   TOPO_DOM    113    131       Cytoplasmic (By similarity).
FT   TRANSMEM    132    148       By similarity.
FT   TRANSMEM    149    165       By similarity.
FT   TOPO_DOM    166    185       Cytoplasmic (By similarity).
FT   REGION       30     54       Required for interaction with prenylated
FT                                RAB3A and VAMP2 (By similarity).
FT   REGION      165    185       Required for interaction with GDI1 (By
FT                                similarity).
FT   REGION      175    185       Homodimerization (By similarity).
FT   REGION      175    185       Required for interaction with prenylated
FT                                RAB3A and VAMP2 (By similarity).
FT   CONFLICT      2      2       Missing (in Ref. 3).
FT   CONFLICT     40     41       AT -> GP (in Ref. 3; AAP97229).
FT   CONFLICT    129    129       A -> E (in Ref. 1; CAB43107).
SQ   SEQUENCE   185 AA;  20648 MW;  A85BD5BDCF6C23E4 CRC64;
     MAAQKDQQKD AEAEGLSGTT LLPKLIPSGA GREWLERRRA TIRPWSTFVD QQRFSRPRNL
     GELCQRLVRN VEYYQSNYVF VFLGLILYCV VTSPMLLVAL AVFFGACYIL YLRTLESKLV
     LFGREVSPAH QYALAGGISF PFFWLAGAGS AVFWVLGATL VVIGSHAAFH QIEAVDGEEL
     QMEPV
//
ID   PRAF1_RAT               Reviewed;         185 AA.
AC   O35394;
DT   07-DEC-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   02-MAR-2010, entry version 58.
DE   RecName: Full=Prenylated Rab acceptor protein 1;
DE   AltName: Full=PRA1 family protein 1;
GN   Name=Rabac1; Synonyms=Pra1, Praf1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   MEDLINE=98001672; PubMed=9341137; DOI=10.1074/jbc.272.43.26991;
RA   Martincic I., Peralta M.E., Ngsee J.K.;
RT   "Isolation and characterization of a dual prenylated Rab and VAMP2
RT   receptor.";
RL   J. Biol. Chem. 272:26991-26998(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH GDI1.
RX   MEDLINE=20309810; PubMed=10751420; DOI=10.1074/jbc.M909309199;
RA   Hutt D.M., da Silva L.F., Chang L.-H., Prosser D.C., Ngsee J.K.;
RT   "PRA1 inhibits the extraction of membrane-bound rab GTPase by GDI1.";
RL   J. Biol. Chem. 275:18511-18519(2000).
RN   [4]
RP   MUTAGENESIS OF ASN-70; TYR-73; SER-76; ASN-77; TYR-78; TRP-154;
RP   VAL-161 AND HIS-166, FUNCTION, AND SUBCELLULAR LOCATION.
RX   MEDLINE=22229317; PubMed=12107180; DOI=10.1074/jbc.M205026200;
RA   Gougeon P.-Y., Prosser D.C., Da-Silva L.F., Ngsee J.K.;
RT   "Disruption of Golgi morphology and trafficking in cells expressing
RT   mutant prenylated rab acceptor-1.";
RL   J. Biol. Chem. 277:36408-36414(2002).
RN   [5]
RP   MUTAGENESIS OF ASP-176; GLU-178 AND GLU-179, AND SUBCELLULAR LOCATION.
RX   MEDLINE=21125827; PubMed=11096102; DOI=10.1074/jbc.M009073200;
RA   Abdul-Ghani M., Gougeon P.-Y., Prosser D.C., Da-Silva L.F.,
RA   Ngsee J.K.;
RT   "PRA isoforms are targeted to distinct membrane compartments.";
RL   J. Biol. Chem. 276:6225-6233(2001).
RN   [6]
RP   INTERACTION WITH PCLO, AND SUBCELLULAR LOCATION.
RX   MEDLINE=20170257; PubMed=10707984; DOI=10.1016/S0896-6273(00)80883-1;
RA   Fenster S.D., Chung W.J., Zhai R., Cases-Langhoff C., Voss B.,
RA   Garner A.M., Kaempf U., Kindler S., Gundelfinger E.D., Garner C.C.;
RT   "Piccolo, a presynaptic zinc finger protein structurally related to
RT   bassoon.";
RL   Neuron 25:203-214(2000).
CC   -!- FUNCTION: General Rab protein regulator required for vesicle
CC       formation from the Golgi complex. May control vesicle docking and
CC       fusion by mediating the action of Rab GTPases to the SNARE
CC       complexes. In addition it inhibits the removal of Rab GTPases from
CC       the membrane by GDI1.
CC   -!- SUBUNIT: Homodimers (By similarity). Interacts specifically with
CC       both prenylated Rab proteins (including RAB3A and RAB1), and VAMP2
CC       (synaptobrevin-2), in an exclusive way. Interacts with free GDI1
CC       in the absence of Rab proteins. Also interacts with PCLO.
CC   -!- INTERACTION:
CC       P63012:Rab3a; NbExp=1; IntAct=EBI-2028510, EBI-440126;
CC       P07825:Syp; NbExp=1; IntAct=EBI-2028510, EBI-976085;
CC       P63045:Vamp2; NbExp=1; IntAct=EBI-2028510, EBI-520880;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC       Cytoplasm. Golgi apparatus. Cytoplasmic vesicle, secretory
CC       vesicle, synaptic vesicle. Note=According to some authors, it is
CC       an integral membrane protein, while others showed that it is
CC       cytoplasmic and membrane-associated to Golgi and synaptic
CC       vesicles.
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- SIMILARITY: Belongs to the PRA1 family.
CC   -!- CAUTION: In contrast to the mouse ortholog, it does not interact
CC       with the Ras-like GTPases RAC1 and RHOA.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF025506; AAB81721.1; -; mRNA.
DR   EMBL; BC086387; AAH86387.1; -; mRNA.
DR   IPI; IPI00208565; -.
DR   RefSeq; NP_113962.1; -.
DR   UniGene; Rn.25604; -.
DR   IntAct; O35394; 6.
DR   STRING; O35394; -.
DR   PRIDE; O35394; -.
DR   Ensembl; ENSRNOT00000027435; ENSRNOP00000027435; ENSRNOG00000020233; Rattus norvegicus.
DR   GeneID; 83583; -.
DR   KEGG; rno:83583; -.
DR   UCSC; NM_031774; rat.
DR   CTD; 83583; -.
DR   RGD; 621002; Rabac1.
DR   eggNOG; maNOG18371; -.
DR   HOVERGEN; HBG053660; -.
DR   InParanoid; O35394; -.
DR   OMA; AGGISFP; -.
DR   OrthoDB; EOG9DV85S; -.
DR   PhylomeDB; O35394; -.
DR   NextBio; 616119; -.
DR   ArrayExpress; O35394; -.
DR   Genevestigator; O35394; -.
DR   GermOnline; ENSRNOG00000020233; Rattus norvegicus.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0008021; C:synaptic vesicle; IEA:UniProtKB-SubCell.
DR   GO; GO:0030674; F:protein binding, bridging; NAS:RGD.
DR   GO; GO:0016192; P:vesicle-mediated transport; NAS:RGD.
DR   InterPro; IPR004895; Prenylated_rab_accept_PRA1.
DR   Pfam; PF03208; PRA1; 1.
PE   1: Evidence at protein level;
KW   Cell junction; Cell membrane; Cytoplasm; Cytoplasmic vesicle;
KW   Golgi apparatus; Membrane; Synapse; Transmembrane.
FT   CHAIN         1    185       Prenylated Rab acceptor protein 1.
FT                                /FTId=PRO_0000220880.
FT   TOPO_DOM      1     78       Cytoplasmic (By similarity).
FT   TRANSMEM     79     94       By similarity.
FT   TRANSMEM     95    112       By similarity.
FT   TOPO_DOM    113    131       Cytoplasmic (By similarity).
FT   TRANSMEM    132    148       By similarity.
FT   TRANSMEM    149    165       By similarity.
FT   TOPO_DOM    166    185       Cytoplasmic (By similarity).
FT   REGION       30     54       Required for interaction with prenylated
FT                                RAB3A and VAMP2.
FT   REGION      165    185       Required for interaction with GDI1.
FT   REGION      175    185       Homodimerization (By similarity).
FT   REGION      175    185       Required for interaction with prenylated
FT                                RAB3A and VAMP2.
FT   MUTAGEN      70     70       N->T: Retained in endoplasmic reticulum,
FT                                no interaction with RAB3A or VAMP2.
FT   MUTAGEN      73     73       Y->A: Retained in endoplasmic reticulum,
FT                                Golgi and tubular structures, no
FT                                interaction with RAB3A.
FT   MUTAGEN      76     76       S->A,V: Increased interaction with RAB3A
FT                                or VAMP2, Golgi condensation.
FT   MUTAGEN      77     77       N->A: No effect.
FT   MUTAGEN      78     78       Y->A: Retained in endoplasmic reticulum,
FT                                no interaction with RAB3A or VAMP2.
FT   MUTAGEN     154    154       W->A: No effect.
FT   MUTAGEN     161    161       V->A: Increased interaction with RAB3A or
FT                                VAMP2, Golgi condensation.
FT   MUTAGEN     166    166       H->A: Retained in endoplasmic reticulum,
FT                                Golgi and tubular structures, no
FT                                interaction with RAB3A.
FT   MUTAGEN     176    176       D->A: Retained in endoplasmic reticulum.
FT   MUTAGEN     178    178       E->A: Retained in endoplasmic reticulum.
FT   MUTAGEN     179    179       E->A: Retained in endoplasmic reticulum.
SQ   SEQUENCE   185 AA;  20643 MW;  DA6341AE66F5C2F0 CRC64;
     MAAQKDQQKD AEVEGLSATT LLPKLIPSGA GREWLERRRA TIRPWGTFVD QQRFSRPRNV
     GELCQRLVRN VEYYQSNYVF VFLGLILYCV VTSPMLLVAL AVFFGACYIL YLRTLQSKLV
     LFGREVSPAH QYALAGGVSF PFFWLAGAGS AVFWVLGATL VLIGSHAAFH QIEPADGEEL
     QMEPV
//
ID   PRLR_RAT                Reviewed;         610 AA.
AC   P05710; Q62832; Q63451; Q63479; Q63723; Q64274;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 2.
DT   02-MAR-2010, entry version 107.
DE   RecName: Full=Prolactin receptor;
DE            Short=PRL-R;
DE   AltName: Full=Lactogen receptor;
DE   Flags: Precursor;
GN   Name=Prlr;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   MEDLINE=91155946; PubMed=2293022;
RA   Shirota M., Banville D., Ali S., Jolicoeur C., Boutin J.-M., Edery M.,
RA   Djiane J., Kelly P.A.;
RT   "Expression of two forms of prolactin receptor in rat ovary and
RT   liver.";
RL   Mol. Endocrinol. 4:1136-1143(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   STRAIN=Sprague-Dawley; TISSUE=Ovary;
RX   MEDLINE=90241201; PubMed=2159291; DOI=10.1016/0006-291X(90)92337-Y;
RA   Zhang R., Buczko E., Tsai-Morris C.-H., Hu Z.Z., Dufau M.L.;
RT   "Isolation and characterization of two novel rat ovarian lactogen
RT   receptor cDNA species.";
RL   Biochem. Biophys. Res. Commun. 168:415-422(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE OF 281-610.
RA   Banville D., Stocco R., Murthy K.K., Boie Y., Kelly P.A.;
RL   Submitted (MAR-1996) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Liver;
RX   MEDLINE=88165059; PubMed=2832068; DOI=10.1016/0092-8674(88)90488-6;
RA   Boutin J.-M., Jolicoeur C., Okamura H., Gagnon J., Edery M.,
RA   Shirota M., Banville D., Dusanter-Fourt I., Djiane J., Kelly P.A.;
RT   "Cloning and expression of the rat prolactin receptor, a member of the
RT   growth hormone/prolactin receptor gene family.";
RL   Cell 53:69-77(1988).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RC   TISSUE=Lymphoma;
RX   MEDLINE=92041834; PubMed=1718958;
RA   Ali S., Pelligrini I., Kelly P.A.;
RT   "A prolactin-dependent immune cell line (Nb2) expresses a mutant form
RT   of prolactin receptor.";
RL   J. Biol. Chem. 266:20110-20117(1991).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RX   MEDLINE=95014432; PubMed=7929319;
RA   O'Neal K.D., Yu-Lee L.Y.;
RT   "Differential signal transduction of the short, Nb2, and long
RT   prolactin receptors. Activation of interferon regulatory factor-1 and
RT   cell proliferation.";
RL   J. Biol. Chem. 269:26076-26082(1994).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 20-229 IN COMPLEX WITH
RP   PLACENTAL LACTOGEN, AND DISULFIDE BONDS.
RX   MEDLINE=20423091; PubMed=10966654; DOI=10.1038/79047;
RA   Elkins P.A., Christinger H.W., Sandowski Y., Sakal E., Gertler A.,
RA   de Vos A.M., Kossiakoff A.A.;
RT   "Ternary complex between placental lactogen and the extracellular
RT   domain of the prolactin receptor.";
RL   Nat. Struct. Biol. 7:808-815(2000).
CC   -!- FUNCTION: This is a receptor for the anterior pituitary hormone
CC       prolactin.
CC   -!- SUBUNIT: Interacts with SMARCA1 (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=Long;
CC         IsoId=P05710-1; Sequence=Displayed;
CC       Name=2; Synonyms=Short;
CC         IsoId=P05710-2; Sequence=VSP_001725, VSP_001726;
CC       Name=3; Synonyms=Medium;
CC         IsoId=P05710-3; Sequence=VSP_001727, VSP_001728;
CC       Name=4; Synonyms=NB2;
CC         IsoId=P05710-4; Sequence=VSP_001729;
CC   -!- DOMAIN: The WSXWS motif appears to be necessary for proper protein
CC       folding and thereby efficient intracellular transport and cell-
CC       surface receptor binding.
CC   -!- DOMAIN: The box 1 motif is required for JAK interaction and/or
CC       activation.
CC   -!- SIMILARITY: Belongs to the type I cytokine receptor family. Type 1
CC       subfamily.
CC   -!- SIMILARITY: Contains 2 fibronectin type-III domains.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M57668; AAA41938.1; -; mRNA.
DR   EMBL; M34083; AAA79273.1; -; mRNA.
DR   EMBL; L48060; AAA79274.1; -; mRNA.
DR   EMBL; U34730; AAA92053.1; -; Genomic_DNA.
DR   EMBL; M19304; AAA41937.1; -; mRNA.
DR   EMBL; M74152; AAA41946.1; -; mRNA.
DR   EMBL; U07567; AAA61784.1; -; mRNA.
DR   IPI; IPI00202568; -.
DR   IPI; IPI00231333; -.
DR   IPI; IPI00231334; -.
DR   IPI; IPI00231336; -.
DR   PIR; A29884; A29884.
DR   PIR; A34631; A34631.
DR   PIR; A36116; A36116.
DR   PIR; A41070; A41070.
DR   PIR; B34631; B34631.
DR   RefSeq; NP_001029283.1; -.
DR   RefSeq; NP_036762.1; -.
DR   UniGene; Rn.9757; -.
DR   PDB; 1F6F; X-ray; 2.30 A; B/C=20-229.
DR   PDB; 3EW3; X-ray; 3.80 A; B/C=20-229.
DR   PDBsum; 1F6F; -.
DR   PDBsum; 3EW3; -.
DR   PhosphoSite; P05710; -.
DR   PRIDE; P05710; -.
DR   GeneID; 24684; -.
DR   KEGG; rno:24684; -.
DR   CTD; 24684; -.
DR   RGD; 3407; Prlr.
DR   eggNOG; roNOG08652; -.
DR   HOVERGEN; HBG007314; -.
DR   NextBio; 604105; -.
DR   Genevestigator; P05710; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0004925; F:prolactin receptor activity; IMP:RGD.
DR   InterPro; IPR008957; Fibronectin_typ-III-like_fold.
DR   InterPro; IPR003961; FN_III.
DR   InterPro; IPR003528; Long_hematopoietin_rcpt_CS.
DR   Gene3D; G3DSA:2.60.40.30; FN_III-like; 2.
DR   Pfam; PF00041; fn3; 1.
DR   SMART; SM00060; FN3; 2.
DR   SUPFAM; SSF49265; FN_III-like; 2.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS01352; HEMATOPO_REC_L_F1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Membrane; Metal-binding; Receptor;
KW   Repeat; Signal; Transmembrane; Zinc.
FT   SIGNAL        1     19       Potential.
FT   CHAIN        20    610       Prolactin receptor.
FT                                /FTId=PRO_0000010981.
FT   TOPO_DOM     20    229       Extracellular (By similarity).
FT   TRANSMEM    230    253       By similarity.
FT   TOPO_DOM    254    610       Cytoplasmic (By similarity).
FT   DOMAIN       22    118       Fibronectin type-III 1.
FT   DOMAIN      122    219       Fibronectin type-III 2.
FT   MOTIF       210    214       WSXWS motif.
FT   MOTIF       262    270       Box 1 motif.
FT   METAL       206    206       Zinc (By similarity).
FT   METAL       207    207       Zinc (By similarity).
FT   CARBOHYD     54     54       N-linked (GlcNAc...).
FT   CARBOHYD     99     99       N-linked (GlcNAc...).
FT   CARBOHYD    127    127       N-linked (GlcNAc...) (Potential).
FT   DISULFID     31     41
FT   DISULFID     70     81
FT   VAR_SEQ     131    150       EVKQLKDKKTYLWVKWSPPT -> DYRWEVSCHQEALPKSA
FT                                KLN (in isoform 2).
FT                                /FTId=VSP_001725.
FT   VAR_SEQ     151    610       Missing (in isoform 2).
FT                                /FTId=VSP_001726.
FT   VAR_SEQ     281    310       KGKSEELLSALGCQDFPPTSDCEDLLVEFL -> TGSPSKY
FT                                KVDLYLALPGGFQKLDNAGELDY (in isoform 3).
FT                                /FTId=VSP_001727.
FT   VAR_SEQ     311    610       Missing (in isoform 3).
FT                                /FTId=VSP_001728.
FT   VAR_SEQ     342    539       Missing (in isoform 4).
FT                                /FTId=VSP_001729.
FT   CONFLICT    236    236       V -> A (in Ref. 2; AAA79273).
FT   CONFLICT    345    345       G -> V (in Ref. 2; AAA79273).
FT   CONFLICT    465    465       E -> K (in Ref. 1; AAA41938).
FT   CONFLICT    466    466       Q -> E (in Ref. 2; AAA79273).
FT   CONFLICT    469    469       A -> G (in Ref. 2; AAA79273).
FT   CONFLICT    541    541       T -> M (in Ref. 1; AAA41938).
FT   CONFLICT    555    555       Q -> K (in Ref. 2; AAA79273).
FT   STRAND       27     37
FT   STRAND       39     44
FT   STRAND       54     61
FT   STRAND       64     69
FT   STRAND       80     83
FT   TURN         85     87
FT   STRAND       93    102
FT   STRAND      105    108
FT   STRAND      112    115
FT   HELIX       116    118
FT   STRAND      126    132
FT   STRAND      142    147
FT   TURN        154    157
FT   STRAND      161    171
FT   STRAND      176    181
FT   STRAND      184    188
FT   STRAND      196    208
FT   STRAND      217    220
SQ   SEQUENCE   610 AA;  68599 MW;  83D04D832861295D CRC64;
     MPSALAFVLL VLNISLLKGQ SPPGKPEIHK CRSPDKETFT CWWNPGTDGG LPTNYSLTYS
     KEGEKTTYEC PDYKTSGPNS CFFSKQYTSI WKIYIITVNA TNQMGSSSSD PLYVDVTYIV
     EPEPPRNLTL EVKQLKDKKT YLWVKWSPPT ITDVKTGWFT MEYEIRLKPE EAEEWEIHFT
     GHQTQFKVFD LYPGQKYLVQ TRCKPDHGYW SRWSQESSVE MPNDFTLKDT TVWIIVAILS
     AVICLIMVWA VALKGYSMMT CIFPPVPGPK IKGFDTHLLE KGKSEELLSA LGCQDFPPTS
     DCEDLLVEFL EVDDNEDERL MPSHSKEYPG QGVKPTHLDP DSDSGHGSYD SHSLLSEKCE
     EPQAYPPTLH IPEITEKPEN PEANIPPTVD PQSTNPNFHV DAPKSSTWPL LPGQHMPRSP
     YHSVADVCKL AGSPVNTLDS FLDKAEENVL KLSKALETGE EEVAEQKGAK SFPSDKQNTP
     WPLLQEKSPT VYVKPPDYVE IHKVNKDGVL SLFPKQRENN QTEKPGVPET SKEYAKVSGI
     TDNNILVLVP DSRAQNTALL EESAKKAPPS FEADQSEKDL ASFTATSSNR RLQLGRLDYL
     DPTCFMHSFH
//
ID   RBOHA_SOLTU             Reviewed;         963 AA.
AC   Q948U0;
DT   15-JAN-2008, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   02-MAR-2010, entry version 48.
DE   RecName: Full=Respiratory burst oxidase homolog protein A;
DE            EC=1.6.3.-;
DE            EC=1.11.1.-;
DE   AltName: Full=NADPH oxidase RBOHA;
DE   AltName: Full=StRBOHA;
GN   Name=RBOHA;
OS   Solanum tuberosum (Potato).
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
OC   asterids; lamiids; Solanales; Solanaceae; Solanoideae; Solaneae;
OC   Solanum.
OX   NCBI_TaxID=4113;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RC   STRAIN=cv. Rishiri;
RX   MEDLINE=21279668; PubMed=11386368; DOI=10.1094/MPMI.2001.14.6.725;
RA   Yoshioka H., Sugie K., Park H.-J., Maeda H., Tsuda N., Kawakita K.,
RA   Doke N.;
RT   "Induction of plant gp91 phox homolog by fungal cell wall, arachidonic
RT   acid, and salicylic acid in potato.";
RL   Mol. Plant Microbe Interact. 14:725-736(2001).
RN   [2]
RP   SUBCELLULAR LOCATION, AND INDUCTION.
RC   STRAIN=cv. Rishiri;
RX   PubMed=16551687; DOI=10.1093/jxb/erj113;
RA   Kobayashi M., Kawakita K., Maeshima M., Doke N., Yoshioka H.;
RT   "Subcellular localization of Strboh proteins and NADPH-dependent
RT   O2(-)-generating activity in potato tuber tissues.";
RL   J. Exp. Bot. 57:1373-1379(2006).
RN   [3]
RP   PHOSPHORYLATION.
RX   PubMed=17400895; DOI=10.1105/tpc.106.048884;
RA   Kobayashi M., Ohura I., Kawakita K., Yokota N., Fujiwara M.,
RA   Shimamoto K., Doke N., Yoshioka H.;
RT   "Calcium-dependent protein kinases regulate the production of reactive
RT   oxygen species by potato NADPH oxidase.";
RL   Plant Cell 19:1065-1080(2007).
CC   -!- FUNCTION: Calcium-dependent NADPH oxidase that generates
CC       superoxide. Involved in the rapid and transient phase I oxidative
CC       burst induced by pathogen infection.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- INDUCTION: Expressed constitutively. Not induced by fungal
CC       elicitor.
CC   -!- PTM: Phosphorylated by CPK.
CC   -!- SIMILARITY: Belongs to the RBOH family.
CC   -!- SIMILARITY: Contains 1 EF-hand domain.
CC   -!- SIMILARITY: Contains 1 FAD-binding FR-type domain.
CC   -!- SIMILARITY: Contains 1 ferric oxidoreductase domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB050660; BAB70750.1; -; mRNA.
DR   SMR; Q948U0; 213-347, 639-963.
DR   PeroxiBase; 4549; StRbohA.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005509; F:calcium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0009055; F:electron carrier activity; IEA:InterPro.
DR   GO; GO:0050660; F:FAD binding; IEA:InterPro.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0050664; F:oxidoreductase activity, acting on NADH or ...; IEA:InterPro.
DR   GO; GO:0004601; F:peroxidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0055114; P:oxidation reduction; IEA:UniProtKB-KW.
DR   InterPro; IPR000778; Cyt_b245_heavy_chain.
DR   InterPro; IPR011992; EF-hand-like_dom.
DR   InterPro; IPR018247; EF_Hand_1_Ca_BS.
DR   InterPro; IPR018249; EF_HAND_2.
DR   InterPro; IPR013112; FAD_bd_8.
DR   InterPro; IPR017927; Fd_Rdtase_FAD-bd.
DR   InterPro; IPR013130; Fe3_reduct_TM_N.
DR   InterPro; IPR013121; Fe_red_NAD_bd_6.
DR   InterPro; IPR013623; NADPH_Ox.
DR   InterPro; IPR017938; Riboflavin_synthase-like_b-brl.
DR   Gene3D; G3DSA:1.10.238.10; EF-Hand_type; 1.
DR   Pfam; PF08022; FAD_binding_8; 1.
DR   Pfam; PF01794; Ferric_reduct; 1.
DR   Pfam; PF08030; NAD_binding_6; 1.
DR   Pfam; PF08414; NADPH_Ox; 1.
DR   PRINTS; PR00466; GP91PHOX.
DR   SUPFAM; SSF63380; Riboflavin_synthase_like_b-brl; 1.
DR   PROSITE; PS00018; EF_HAND_1; 1.
DR   PROSITE; PS50222; EF_HAND_2; 1.
DR   PROSITE; PS51384; FAD_FR; 1.
PE   1: Evidence at protein level;
KW   Calcium; Cell membrane; FAD; Membrane; NADP; Oxidoreductase;
KW   Peroxidase; Phosphoprotein; Transmembrane.
FT   CHAIN         1    963       Respiratory burst oxidase homolog protein
FT                                A.
FT                                /FTId=PRO_0000313763.
FT   TOPO_DOM      1    399       Cytoplasmic (Potential).
FT   TRANSMEM    400    420       1 (Potential).
FT   TOPO_DOM    421    435       Extracellular (Potential).
FT   TRANSMEM    436    456       2 (By similarity).
FT   TOPO_DOM    457    482       Cytoplasmic (Potential).
FT   TRANSMEM    483    503       3 (By similarity).
FT   TOPO_DOM    504    535       Extracellular (Potential).
FT   TRANSMEM    536    556       4 (Potential).
FT   TOPO_DOM    557    583       Cytoplasmic (Potential).
FT   TRANSMEM    584    604       5 (Potential).
FT   TOPO_DOM    605    759       Extracellular (Potential).
FT   TRANSMEM    760    780       6 (Potential).
FT   TOPO_DOM    781    963       Cytoplasmic (Potential).
FT   DOMAIN      276    311       EF-hand.
FT   DOMAIN      438    595       Ferric oxidoreductase.
FT   DOMAIN      634    754       FAD-binding FR-type.
FT   CA_BIND     289    300       Potential.
FT   COMPBIAS    251    254       Poly-Arg.
SQ   SEQUENCE   963 AA;  109146 MW;  501BB92E1157A4F9 CRC64;
     MRGLPGHERR WTSDTVSSGK DLSGESSPGT DSGNISGFAS EEFVEVILDL QDDDTIILRS
     VEPATVINID ASDPATGVGI GGVSIETPAS LTSTSGTRSP TMRRSTSNKL RQFSQELKAE
     AVAKAKHFSQ ELKAELRRFS WSHGHASRTF SPASFFQNAV VGTGNGVDSA LAARALRRQR
     AQLDRTRSSA HKALRGLKFI SNNKTNGWNE VENNFAKLAK DGYLYRSDFA QCIGMKDSKE
     FALELFDALS RRRRLKVDKI SKEELYEYWS QITDQSFDSR LQIFFDMVDK NEDGRIGEEE
     VKEIIMLSAS ANKLSRLKEQ AEEYAALIME ELDPERLGYI ELWQLETLLL QKDTYLNYSQ
     ALSYTSQALS QNLQGLRKRS PIRRMSTKLV YSLQENWKRI WVLVLWILIM IGLFLWKFYL
     YKQKSAFQVM GYCLLTAKGA AETLKFNMAL ILLPVCRNTI TFLRSTKLSC FVPFDDNINF
     HKTVAAAIVT GIILHAGNHL VCDFPKLIHA NNTNYQKYLV NDFGPSQPQY IDLVKGVEGV
     TGIIMVILMA IAFTLATRWF RRSLIKFPKP FDRLTGFNAF WYSHHLLIIV YIVLIIHGTF
     LYLVHNWYSK TTWMYLAVPV LLYAGERTLR FFRSGLYTVR LLKVAIYPGN VLTLQMSKPP
     QFRYKSGQYM FVQCPAVSPF EWHPFSITSA PGDDYLSIHI RQLGDWTQEL KRVFSEACEQ
     PEAGKSGLLR ADENTKTSLP KLLIDGPYGA PAQDYRKYDV LLLVGLGIGA TPFISILKDL
     LKNIVTMEEQ ADLVSDFSGN SDMSAATSEQ PALNKISPKK RKSTLKTTNA YFYWVTREQG
     SFDWFKGVMN EVAELDQRGV IEMHNYLTSV YEEGDARSAL ITMVQALNHA KNGVDIVSGT
     SVRTHFARPN WRKVFSKTLT KHANARIGVF YCGAPILAKE LSKLCKEFNQ KGTTKFEFHK
     EHF
//
ID   RBOHB_SOLTU             Reviewed;         867 AA.
AC   Q948T9;
DT   15-JAN-2008, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   02-MAR-2010, entry version 49.
DE   RecName: Full=Respiratory burst oxidase homolog protein B;
DE            EC=1.6.3.-;
DE            EC=1.11.1.-;
DE   AltName: Full=NADPH oxidase RBOHB;
DE   AltName: Full=StRBOHB;
GN   Name=RBOHB;
OS   Solanum tuberosum (Potato).
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
OC   asterids; lamiids; Solanales; Solanaceae; Solanoideae; Solaneae;
OC   Solanum.
OX   NCBI_TaxID=4113;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INDUCTION, AND ENZYME
RP   REGULATION.
RC   STRAIN=cv. Rishiri;
RX   MEDLINE=21279668; PubMed=11386368; DOI=10.1094/MPMI.2001.14.6.725;
RA   Yoshioka H., Sugie K., Park H.-J., Maeda H., Tsuda N., Kawakita K.,
RA   Doke N.;
RT   "Induction of plant gp91 phox homolog by fungal cell wall, arachidonic
RT   acid, and salicylic acid in potato.";
RL   Mol. Plant Microbe Interact. 14:725-736(2001).
RN   [2]
RP   SUBCELLULAR LOCATION, AND INDUCTION.
RC   STRAIN=cv. Rishiri;
RX   PubMed=16551687; DOI=10.1093/jxb/erj113;
RA   Kobayashi M., Kawakita K., Maeshima M., Doke N., Yoshioka H.;
RT   "Subcellular localization of Strboh proteins and NADPH-dependent
RT   O2(-)-generating activity in potato tuber tissues.";
RL   J. Exp. Bot. 57:1373-1379(2006).
RN   [3]
RP   MUTAGENESIS OF SER-82; SER-89 AND SER-97, PHOSPHORYLATION AT SER-82
RP   AND SER-97, AND MASS SPECTROMETRY.
RX   PubMed=17400895; DOI=10.1105/tpc.106.048884;
RA   Kobayashi M., Ohura I., Kawakita K., Yokota N., Fujiwara M.,
RA   Shimamoto K., Doke N., Yoshioka H.;
RT   "Calcium-dependent protein kinases regulate the production of reactive
RT   oxygen species by potato NADPH oxidase.";
RL   Plant Cell 19:1065-1080(2007).
CC   -!- FUNCTION: Calcium-dependent NADPH oxidase that generates
CC       superoxide. Involved in the massive phase II oxidative burst
CC       induced by pathogen infection.
CC   -!- ENZYME REGULATION: Inhibited by diphenylene iodinium (DPI).
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- INDUCTION: By fungal elicitor, arachidonic acid and salicylic
CC       acid.
CC   -!- PTM: Phosphorylation at Ser-82 and Ser-97 is required for full
CC       activity of RBOHB. Not phosphorylated at Ser-89. Phosphorylation
CC       at Ser-82 is induced by fungal elicitor treatment.
CC   -!- MISCELLANEOUS: K252a and staurosporine, two protein kinase
CC       inhibitors, completely block the RBOHB induction by fungal
CC       elicitor.
CC   -!- SIMILARITY: Belongs to the RBOH family.
CC   -!- SIMILARITY: Contains 2 EF-hand domains.
CC   -!- SIMILARITY: Contains 1 FAD-binding FR-type domain.
CC   -!- SIMILARITY: Contains 1 ferric oxidoreductase domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB050661; BAB70751.1; -; mRNA.
DR   SMR; Q948T9; 133-276, 562-748.
DR   PeroxiBase; 4546; StRbohB.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005509; F:calcium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0009055; F:electron carrier activity; IEA:InterPro.
DR   GO; GO:0050660; F:FAD binding; IEA:InterPro.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0050664; F:oxidoreductase activity, acting on NADH or ...; IEA:InterPro.
DR   GO; GO:0004601; F:peroxidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0055114; P:oxidation reduction; IEA:UniProtKB-KW.
DR   InterPro; IPR000778; Cyt_b245_heavy_chain.
DR   InterPro; IPR011992; EF-hand-like_dom.
DR   InterPro; IPR018247; EF_Hand_1_Ca_BS.
DR   InterPro; IPR018249; EF_HAND_2.
DR   InterPro; IPR013112; FAD_bd_8.
DR   InterPro; IPR017927; Fd_Rdtase_FAD-bd.
DR   InterPro; IPR013130; Fe3_reduct_TM_N.
DR   InterPro; IPR013121; Fe_red_NAD_bd_6.
DR   InterPro; IPR013623; NADPH_Ox.
DR   InterPro; IPR017938; Riboflavin_synthase-like_b-brl.
DR   Gene3D; G3DSA:1.10.238.10; EF-Hand_type; 1.
DR   Pfam; PF08022; FAD_binding_8; 1.
DR   Pfam; PF01794; Ferric_reduct; 1.
DR   Pfam; PF08030; NAD_binding_6; 1.
DR   Pfam; PF08414; NADPH_Ox; 1.
DR   PRINTS; PR00466; GP91PHOX.
DR   SUPFAM; SSF63380; Riboflavin_synthase_like_b-brl; 1.
DR   PROSITE; PS00018; EF_HAND_1; 1.
DR   PROSITE; PS50222; EF_HAND_2; 2.
DR   PROSITE; PS51384; FAD_FR; 1.
PE   1: Evidence at protein level;
KW   Calcium; Cell membrane; FAD; Membrane; NADP; Oxidoreductase;
KW   Peroxidase; Phosphoprotein; Repeat; Transmembrane.
FT   CHAIN         1    867       Respiratory burst oxidase homolog protein
FT                                B.
FT                                /FTId=PRO_0000313764.
FT   TOPO_DOM      1    322       Cytoplasmic (Potential).
FT   TRANSMEM    323    343       1 (Potential).
FT   TOPO_DOM    344    358       Extracellular (Potential).
FT   TRANSMEM    359    379       2 (By similarity).
FT   TOPO_DOM    380    407       Cytoplasmic (Potential).
FT   TRANSMEM    408    428       3 (Potential).
FT   TOPO_DOM    429    463       Extracellular (Potential).
FT   TRANSMEM    464    484       4 (Potential).
FT   TOPO_DOM    485    506       Cytoplasmic (Potential).
FT   TRANSMEM    507    527       5 (Potential).
FT   TOPO_DOM    528    686       Extracellular (Potential).
FT   TRANSMEM    687    707       6 (Potential).
FT   TOPO_DOM    708    867       Cytoplasmic (Potential).
FT   DOMAIN      198    233       EF-hand 1.
FT   DOMAIN      242    277       EF-hand 2.
FT   DOMAIN      361    519       Ferric oxidoreductase.
FT   DOMAIN      558    681       FAD-binding FR-type.
FT   CA_BIND     211    222       1 (Potential).
FT   MOD_RES      82     82       Phosphoserine; by CPK.
FT   MOD_RES      97     97       Phosphoserine; by CPK.
FT   MUTAGEN      82     82       S->A: Decreased activity.
FT   MUTAGEN      89     89       S->A: No effect.
FT   MUTAGEN      97     97       S->A: Decreased activity.
SQ   SEQUENCE   867 AA;  99051 MW;  F1D64A8DC6AC6E78 CRC64;
     MEIENTRDSD SMRGSRVGFS GSLVSGKKSA RFKDDESYVE ITLDVRDDSV SVQNIKGADH
     EAALLASRLE KRPNNTLGSQ LSFHLRQVSK ELKRMTSSNK FQKIDRSKSG AARALRGLQF
     MNKNVGTEGW SEVESRFDQL AVNGMLTKSL FGQCIGMKES SEFAEELFDA LARKRCITSP
     AVTKDELREF WEQITDTSFD ARLQTFFDMV DKDADGRITQ EEVKEIISLS ASANKLSKIQ
     DNSDEYAALI MEELDPGNVG YIELYNLETL LLQAPSHSMN LSTNSRVLSR MLSQKLKPTK
     ERNPFKRCKR RLDYFIEDNW KRIWVMALWL SICAGLFTWK FIQYKRRAVF DVMGYCVSVA
     KGGAETTKFN MALVLLPVCR NTITWLRSRT KLGKIIPFDD NINFHKVIAF GIAVGVGLHA
     ISHLTCDFPR LLHATDEEYE PMKPFFGDER PNNYWWFVKG TEGWTGVVMV VLMIIAYVLA
     QPWFRRNRLN LPSTIKKLTG FNAFWYSHHL FVIVYVLFII HGYFLYLSKK WYKKTTWMYI
     AVPMILYACE RLLRAFRSGY KAVKILKVAV YPGNVMAVHM SKPQGFKYTS GQYIFVNCSD
     VSSFQWHPFT ISSAPGDDYL SMHIRTLGDW TSQLKTLFSK VCEPPTGDQS GLLRADVAKA
     DYKPRLPKLL IDGPYGAPAQ DYKKYDVVLL VGLGIGATPL ISIVKDVLNN IKQQKNIEDG
     TKGSKRSPFA TKRAYFYWVT REQGSFEWFK GVMDEVSEND QEGLIELHNY CTSVYEEGDA
     RSALITMLQS IQQAKSGVDI VSGTRVKTHF ARPNWRQVFK RVTINHPDQR IGVFYCGPQG
     LVGELRHLSQ DFSHKTGTKF EFHKENF
//
ID   RBOHD_ARATH             Reviewed;         921 AA.
AC   Q9FIJ0; O81212;
DT   15-JAN-2008, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 1.
DT   02-MAR-2010, entry version 65.
DE   RecName: Full=Respiratory burst oxidase homolog protein D;
DE            EC=1.6.3.-;
DE            EC=1.11.1.-;
DE   AltName: Full=NADPH oxidase RBOHD;
DE            Short=AtRBOHD;
GN   Name=RBOHD; OrderedLocusNames=At5g47910; ORFNames=MCA23.25;
OS   Arabidopsis thaliana (Mouse-ear cress).
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
OC   rosids; malvids; Brassicales; Brassicaceae; Arabidopsis.
OX   NCBI_TaxID=3702;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   STRAIN=cv. Landsberg erecta;
RX   MEDLINE=98291500; PubMed=9628030;
RX   DOI=10.1046/j.1365-313X.1998.00136.x;
RA   Torres M.A., Onouchi H., Hamada S., Machida C., Hammond-Kosack K.E.,
RA   Jones J.D.G.;
RT   "Six Arabidopsis thaliana homologues of the human respiratory burst
RT   oxidase (gp91phox).";
RL   Plant J. 14:365-370(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=cv. Columbia;
RX   MEDLINE=99156233; PubMed=10048488; DOI=10.1093/dnares/5.6.379;
RA   Asamizu E., Sato S., Kaneko T., Nakamura Y., Kotani H., Miyajima N.,
RA   Tabata S.;
RT   "Structural analysis of Arabidopsis thaliana chromosome 5. VIII.
RT   Sequence features of the regions of 1,081,958 bp covered by seventeen
RT   physically assigned P1 and TAC clones.";
RL   DNA Res. 5:379-391(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=cv. Columbia;
RX   MEDLINE=22954850; PubMed=14593172; DOI=10.1126/science.1088305;
RA   Yamada K., Lim J., Dale J.M., Chen H., Shinn P., Palm C.J.,
RA   Southwick A.M., Wu H.C., Kim C.J., Nguyen M., Pham P.K., Cheuk R.F.,
RA   Karlin-Newmann G., Liu S.X., Lam B., Sakano H., Wu T., Yu G.,
RA   Miranda M., Quach H.L., Tripp M., Chang C.H., Lee J.M., Toriumi M.J.,
RA   Chan M.M., Tang C.C., Onodera C.S., Deng J.M., Akiyama K., Ansari Y.,
RA   Arakawa T., Banh J., Banno F., Bowser L., Brooks S.Y., Carninci P.,
RA   Chao Q., Choy N., Enju A., Goldsmith A.D., Gurjal M., Hansen N.F.,
RA   Hayashizaki Y., Johnson-Hopson C., Hsuan V.W., Iida K., Karnes M.,
RA   Khan S., Koesema E., Ishida J., Jiang P.X., Jones T., Kawai J.,
RA   Kamiya A., Meyers C., Nakajima M., Narusaka M., Seki M., Sakurai T.,
RA   Satou M., Tamse R., Vaysberg M., Wallender E.K., Wong C., Yamamura Y.,
RA   Yuan S., Shinozaki K., Davis R.W., Theologis A., Ecker J.R.;
RT   "Empirical analysis of transcriptional activity in the Arabidopsis
RT   genome.";
RL   Science 302:842-846(2003).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-39; SER-152; SER-163 AND
RP   SER-343, AND MASS SPECTROMETRY.
RX   PubMed=17317660; DOI=10.1074/mcp.M600429-MCP200;
RA   Benschop J.J., Mohammed S., O'Flaherty M., Heck A.J.R., Slijper M.,
RA   Menke F.L.H.;
RT   "Quantitative phosphoproteomics of early elicitor signaling in
RT   Arabidopsis.";
RL   Mol. Cell. Proteomics 6:1198-1214(2007).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-26; SER-343 AND SER-347,
RP   AND MASS SPECTROMETRY.
RX   PubMed=17651370; DOI=10.1111/j.1365-313X.2007.03192.x;
RA   Nuehse T.S., Bottrill A.R., Jones A.M.E., Peck S.C.;
RT   "Quantitative phosphoproteomic analysis of plasma membrane proteins
RT   reveals regulatory mechanisms of plant innate immune responses.";
RL   Plant J. 51:931-940(2007).
RN   [6]
RP   FUNCTION.
RX   PubMed=11756663; DOI=10.1073/pnas.012452499;
RA   Torres M.A., Dangl J.L., Jones J.D.G.;
RT   "Arabidopsis gp91phox homologues AtrbohD and AtrbohF are required for
RT   accumulation of reactive oxygen intermediates in the plant defense
RT   response.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:517-522(2002).
RN   [7]
RP   FUNCTION, INDUCTION BY ABSCISIC ACID, AND TISSUE SPECIFICITY.
RX   PubMed=12773379; DOI=10.1093/emboj/cdg277;
RA   Kwak J.M., Mori I.C., Pei Z.-M., Leonhardt N., Torres M.A.,
RA   Dangl J.L., Bloom R.E., Bodde S., Jones J.D.G., Schroeder J.I.;
RT   "NADPH oxidase AtrbohD and AtrbohF genes function in ROS-dependent ABA
RT   signaling in Arabidopsis.";
RL   EMBO J. 22:2623-2633(2003).
RN   [8]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=15608336; DOI=10.1105/tpc.104.026971;
RA   Davletova S., Rizhsky L., Liang H., Shengqiang Z., Oliver D.J.,
RA   Coutu J., Shulaev V., Schlauch K., Mittler R.;
RT   "Cytosolic ascorbate peroxidase 1 is a central component of the
RT   reactive oxygen gene network of Arabidopsis.";
RL   Plant Cell 17:268-281(2005).
RN   [9]
RP   FUNCTION.
RX   PubMed=16913867; DOI=10.1111/j.1365-3040.2006.01555.x;
RA   Kalbina I., Strid A.;
RT   "The role of NADPH oxidase and MAP kinase phosphatase in UV-B-
RT   dependent gene expression in Arabidopsis.";
RL   Plant Cell Environ. 29:1783-1793(2006).
RN   [10]
RP   FUNCTION.
RX   PubMed=16428598; DOI=10.1104/pp.105.073072;
RA   Song C.J., Steinebrunner I., Wang X., Stout S.C., Roux S.J.;
RT   "Extracellular ATP induces the accumulation of superoxide via NADPH
RT   oxidases in Arabidopsis.";
RL   Plant Physiol. 140:1222-1232(2006).
RN   [11]
RP   GENE FAMILY, AND NOMENCLATURE.
RX   PubMed=16760484; DOI=10.1104/pp.106.078089;
RA   Sagi M., Fluhr R.;
RT   "Production of reactive oxygen species by plant NADPH oxidases.";
RL   Plant Physiol. 141:336-340(2006).
RN   [12]
RP   FUNCTION, ENZYME REGULATION, AND INDUCTION.
RX   PubMed=17601167; DOI=10.1094/MPMI-20-7-0794;
RA   Fagard M., Dellagi A., Roux C., Perino C., Rigault M., Boucher V.,
RA   Shevchik V.E., Expert D.;
RT   "Arabidopsis thaliana expresses multiple lines of defense to
RT   counterattack Erwinia chrysanthemi.";
RL   Mol. Plant Microbe Interact. 20:794-805(2007).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-39, AND MASS
RP   SPECTROMETRY.
RX   PubMed=19245862; DOI=10.1016/j.jprot.2009.02.004;
RA   Jones A.M.E., MacLean D., Studholme D.J., Serna-Sanz A.,
RA   Andreasson E., Rathjen J.P., Peck S.C.;
RT   "Phosphoproteomic analysis of nuclei-enriched fractions from
RT   Arabidopsis thaliana.";
RL   J. Proteomics 72:439-451(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-8 AND SER-39, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Seedling;
RX   PubMed=19376835; DOI=10.1104/pp.109.138677;
RA   Reiland S., Messerli G., Baerenfaller K., Gerrits B., Endler A.,
RA   Grossmann J., Gruissem W., Baginsky S.;
RT   "Large-scale Arabidopsis phosphoproteome profiling reveals novel
RT   chloroplast kinase substrates and phosphorylation networks.";
RL   Plant Physiol. 150:889-903(2009).
CC   -!- FUNCTION: Calcium-dependent NADPH oxidase that generates
CC       superoxide. Involved in the generation of reactive oxygen species
CC       (ROS) during incompatible interactions with pathogens and in UV-B
CC       and abscissic acid ROS-dependent signaling. Might be required for
CC       ROS signal amplification during light stress.
CC   -!- ENZYME REGULATION: Inhibited by diphenylene iodinium (DPI).
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein
CC       (Potential).
CC   -!- TISSUE SPECIFICITY: More abundant in roots than in leaves, stems
CC       or inflorescences. Expressed in mesophyll and guard cells.
CC   -!- INDUCTION: Up-regulated by pathogen infection and by abscisic
CC       acid.
CC   -!- PTM: Phosphorylation level varies significantly during early
CC       response to general elicitors.
CC   -!- DISRUPTION PHENOTYPE: Plants do not accumulate reactive oxygen
CC       species during disease-resistance reactions, do not up-regulate
CC       UV-B-dependent gene expression and are impaired in abscisic acid-
CC       induced stomatal closing and in root growth and seed germination
CC       inhibitions.
CC   -!- SIMILARITY: Belongs to the RBOH family.
CC   -!- SIMILARITY: Contains 2 EF-hand domains.
CC   -!- SIMILARITY: Contains 1 FAD-binding FR-type domain.
CC   -!- SIMILARITY: Contains 1 ferric oxidoreductase domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF055357; AAC39479.1; -; mRNA.
DR   EMBL; AB016886; BAB11338.1; -; Genomic_DNA.
DR   EMBL; AF424625; AAL11618.1; -; mRNA.
DR   EMBL; BT002651; AAO11567.1; -; mRNA.
DR   IPI; IPI00522047; -.
DR   PIR; T51804; T51804.
DR   RefSeq; NP_199602.1; -.
DR   UniGene; At.23270; -.
DR   UniGene; Rsa.875; -.
DR   SMR; Q9FIJ0; 185-331, 615-920.
DR   STRING; Q9FIJ0; -.
DR   PeroxiBase; 3286; AtRbohD.
DR   PRIDE; Q9FIJ0; -.
DR   GeneID; 834842; -.
DR   GenomeReviews; BA000015_GR; AT5G47910.
DR   KEGG; ath:AT5G47910; -.
DR   NMPDR; fig|3702.1.peg.26608; -.
DR   TAIR; At5g47910; -.
DR   eggNOG; KOG0039; -.
DR   HOGENOM; HBG591219; -.
DR   InParanoid; Q9FIJ0; -.
DR   OMA; ALYACER; -.
DR   PhylomeDB; Q9FIJ0; -.
DR   Genevestigator; Q9FIJ0; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IDA:TAIR.
DR   GO; GO:0005509; F:calcium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0009055; F:electron carrier activity; IEA:InterPro.
DR   GO; GO:0050660; F:FAD binding; IEA:InterPro.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0016174; F:NAD(P)H oxidase activity; IMP:TAIR.
DR   GO; GO:0004601; F:peroxidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0050832; P:defense response to fungus; IMP:TAIR.
DR   GO; GO:0043069; P:negative regulation of programmed cell death; IGI:TAIR.
DR   GO; GO:0055114; P:oxidation reduction; IEA:UniProtKB-KW.
DR   GO; GO:0006800; P:oxygen and reactive oxygen species metaboli...; IMP:TAIR.
DR   GO; GO:0009408; P:response to heat; IMP:TAIR.
DR   InterPro; IPR000778; Cyt_b245_heavy_chain.
DR   InterPro; IPR011992; EF-hand-like_dom.
DR   InterPro; IPR018247; EF_Hand_1_Ca_BS.
DR   InterPro; IPR018249; EF_HAND_2.
DR   InterPro; IPR013112; FAD_bd_8.
DR   InterPro; IPR017927; Fd_Rdtase_FAD-bd.
DR   InterPro; IPR013130; Fe3_reduct_TM_N.
DR   InterPro; IPR013121; Fe_red_NAD_bd_6.
DR   InterPro; IPR013623; NADPH_Ox.
DR   InterPro; IPR017938; Riboflavin_synthase-like_b-brl.
DR   Gene3D; G3DSA:1.10.238.10; EF-Hand_type; 1.
DR   Pfam; PF08022; FAD_binding_8; 1.
DR   Pfam; PF01794; Ferric_reduct; 1.
DR   Pfam; PF08030; NAD_binding_6; 1.
DR   Pfam; PF08414; NADPH_Ox; 1.
DR   PRINTS; PR00466; GP91PHOX.
DR   SUPFAM; SSF63380; Riboflavin_synthase_like_b-brl; 1.
DR   PROSITE; PS00018; EF_HAND_1; 1.
DR   PROSITE; PS50222; EF_HAND_2; 2.
DR   PROSITE; PS51384; FAD_FR; 1.
PE   1: Evidence at protein level;
KW   Calcium; Complete proteome; FAD; Membrane; NADP; Oxidoreductase;
KW   Peroxidase; Phosphoprotein; Repeat; Transmembrane.
FT   CHAIN         1    921       Respiratory burst oxidase homolog protein
FT                                D.
FT                                /FTId=PRO_0000313756.
FT   TOPO_DOM      1    376       Cytoplasmic (Potential).
FT   TRANSMEM    377    397       1 (Potential).
FT   TOPO_DOM    398    461       Extracellular (Potential).
FT   TRANSMEM    462    482       2 (By similarity).
FT   TOPO_DOM    483    516       Cytoplasmic (Potential).
FT   TRANSMEM    517    537       3 (Potential).
FT   TOPO_DOM    538    559       Extracellular (Potential).
FT   TRANSMEM    560    580       4 (Potential).
FT   TOPO_DOM    581    588       Cytoplasmic (Potential).
FT   TRANSMEM    589    606       5 (By similarity).
FT   TOPO_DOM    607    734       Extracellular (Potential).
FT   TRANSMEM    735    755       6 (Potential).
FT   TOPO_DOM    756    921       Cytoplasmic (Potential).
FT   DOMAIN      253    288       EF-hand 1.
FT   DOMAIN      297    332       EF-hand 2.
FT   DOMAIN      415    572       Ferric oxidoreductase.
FT   DOMAIN      611    732       FAD-binding FR-type.
FT   CA_BIND     266    277       1 (Potential).
FT   COMPBIAS     98    101       Poly-Gly.
FT   MOD_RES       8      8       Phosphoserine.
FT   MOD_RES      26     26       Phosphoserine.
FT   MOD_RES      39     39       Phosphoserine.
FT   MOD_RES     152    152       Phosphoserine.
FT   MOD_RES     163    163       Phosphoserine.
FT   MOD_RES     343    343       Phosphoserine.
FT   MOD_RES     347    347       Phosphoserine.
SQ   SEQUENCE   921 AA;  103909 MW;  1A822569A7AB1817 CRC64;
     MKMRRGNSSN DHELGILRGA NSDTNSDTES IASDRGAFSG PLGRPKRASK KNARFADDLP
     KRSNSVAGGR GDDDEYVEIT LDIRDDSVAV HSVQQAAGGG GHLEDPELAL LTKKTLESSL
     NNTTSLSFFR STSSRIKNAS RELRRVFSRR PSPAVRRFDR TSSAAIHALK GLKFIATKTA
     AWPAVDQRFD KLSADSNGLL LSAKFWECLG MNKESKDFAD QLFRALARRN NVSGDAITKE
     QLRIFWEQIS DESFDAKLQV FFDMVDKDED GRVTEEEVAE IISLSASANK LSNIQKQAKE
     YAALIMEELD PDNAGFIMIE NLEMLLLQAP NQSVRMGDSR ILSQMLSQKL RPAKESNPLV
     RWSEKIKYFI LDNWQRLWIM MLWLGICGGL FTYKFIQYKN KAAYGVMGYC VCVAKGGAET
     LKFNMALILL PVCRNTITWL RNKTKLGTVV PFDDSLNFHK VIASGIVVGV LLHAGAHLTC
     DFPRLIAADE DTYEPMEKYF GDQPTSYWWF VKGVEGWTGI VMVVLMAIAF TLATPWFRRN
     KLNLPNFLKK LTGFNAFWYT HHLFIIVYAL LIVHGIKLYL TKIWYQKTTW MYLAVPILLY
     ASERLLRAFR SSIKPVKMIK VAVYPGNVLS LHMTKPQGFK YKSGQFMLVN CRAVSPFEWH
     PFSITSAPGD DYLSVHIRTL GDWTRKLRTV FSEVCKPPTA GKSGLLRADG GDGNLPFPKV
     LIDGPYGAPA QDYKKYDVVL LVGLGIGATP MISILKDIIN NMKGPDRDSD IENNNSNNNS
     KGFKTRKAYF YWVTREQGSF EWFKGIMDEI SELDEEGIIE LHNYCTSVYE EGDARVALIA
     MLQSLQHAKN GVDVVSGTRV KSHFAKPNWR QVYKKIAVQH PGKRIGVFYC GMPGMIKELK
     NLALDFSRKT TTKFDFHKEN F
//
ID   RBOHF_ARATH             Reviewed;         944 AA.
AC   O48538; O80342; Q0WR97; Q9SH56;
DT   15-JAN-2008, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1998, sequence version 1.
DT   02-MAR-2010, entry version 61.
DE   RecName: Full=Respiratory burst oxidase homolog protein F;
DE            EC=1.6.3.-;
DE            EC=1.11.1.-;
DE   AltName: Full=NADPH oxidase RBOHF;
DE            Short=AtRBOHF;
DE   AltName: Full=Cytochrome b245 beta chain homolog RbohAp108;
GN   Name=RBOHF; Synonyms=RBOHAP108; OrderedLocusNames=At1g64060;
GN   ORFNames=F22C12.18;
OS   Arabidopsis thaliana (Mouse-ear cress).
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
OC   rosids; malvids; Brassicales; Brassicaceae; Arabidopsis.
OX   NCBI_TaxID=3702;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   STRAIN=cv. Landsberg erecta;
RX   MEDLINE=98291500; PubMed=9628030;
RX   DOI=10.1046/j.1365-313X.1998.00136.x;
RA   Torres M.A., Onouchi H., Hamada S., Machida C., Hammond-Kosack K.E.,
RA   Jones J.D.G.;
RT   "Six Arabidopsis thaliana homologues of the human respiratory burst
RT   oxidase (gp91phox).";
RL   Plant J. 14:365-370(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 2-3, TISSUE
RP   SPECIFICITY, SUBCELLULAR LOCATION, CALCIUM-BINDING DATA, AND LACK OF
RP   GLYCOSYLATION.
RC   STRAIN=cv. Columbia;
RX   MEDLINE=98158692; PubMed=9490748; DOI=10.1105/tpc.10.2.255;
RA   Keller T., Damude H.G., Werner D., Doerner P., Dixon R.A., Lamb C.;
RT   "A plant homolog of the neutrophil NADPH oxidase gp91phox subunit gene
RT   encodes a plasma membrane protein with Ca2+ binding motifs.";
RL   Plant Cell 10:255-266(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=cv. Columbia;
RX   MEDLINE=21016719; PubMed=11130712; DOI=10.1038/35048500;
RA   Theologis A., Ecker J.R., Palm C.J., Federspiel N.A., Kaul S.,
RA   White O., Alonso J., Altafi H., Araujo R., Bowman C.L., Brooks S.Y.,
RA   Buehler E., Chan A., Chao Q., Chen H., Cheuk R.F., Chin C.W.,
RA   Chung M.K., Conn L., Conway A.B., Conway A.R., Creasy T.H., Dewar K.,
RA   Dunn P., Etgu P., Feldblyum T.V., Feng J.-D., Fong B., Fujii C.Y.,
RA   Gill J.E., Goldsmith A.D., Haas B., Hansen N.F., Hughes B., Huizar L.,
RA   Hunter J.L., Jenkins J., Johnson-Hopson C., Khan S., Khaykin E.,
RA   Kim C.J., Koo H.L., Kremenetskaia I., Kurtz D.B., Kwan A., Lam B.,
RA   Langin-Hooper S., Lee A., Lee J.M., Lenz C.A., Li J.H., Li Y.-P.,
RA   Lin X., Liu S.X., Liu Z.A., Luros J.S., Maiti R., Marziali A.,
RA   Militscher J., Miranda M., Nguyen M., Nierman W.C., Osborne B.I.,
RA   Pai G., Peterson J., Pham P.K., Rizzo M., Rooney T., Rowley D.,
RA   Sakano H., Salzberg S.L., Schwartz J.R., Shinn P., Southwick A.M.,
RA   Sun H., Tallon L.J., Tambunga G., Toriumi M.J., Town C.D.,
RA   Utterback T., Van Aken S., Vaysberg M., Vysotskaia V.S., Walker M.,
RA   Wu D., Yu G., Fraser C.M., Venter J.C., Davis R.W.;
RT   "Sequence and analysis of chromosome 1 of the plant Arabidopsis
RT   thaliana.";
RL   Nature 408:816-820(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=cv. Columbia;
RA   Totoki Y., Seki M., Ishida J., Nakajima M., Enju A., Kamiya A.,
RA   Narusaka M., Shin-i T., Nakagawa M., Sakamoto N., Oishi K., Kohara Y.,
RA   Kobayashi M., Toyoda A., Sakaki Y., Sakurai T., Iida K., Akiyama K.,
RA   Satou M., Toyoda T., Konagaya A., Carninci P., Kawai J.,
RA   Hayashizaki Y., Shinozaki K.;
RT   "Large-scale analysis of RIKEN Arabidopsis full-length (RAFL) cDNAs.";
RL   Submitted (JUL-2006) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   FUNCTION.
RX   PubMed=11756663; DOI=10.1073/pnas.012452499;
RA   Torres M.A., Dangl J.L., Jones J.D.G.;
RT   "Arabidopsis gp91phox homologues AtrbohD and AtrbohF are required for
RT   accumulation of reactive oxygen intermediates in the plant defense
RT   response.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:517-522(2002).
RN   [6]
RP   FUNCTION, INDUCTION BY ABSCISIC ACID, AND TISSUE SPECIFICITY.
RX   PubMed=12773379; DOI=10.1093/emboj/cdg277;
RA   Kwak J.M., Mori I.C., Pei Z.-M., Leonhardt N., Torres M.A.,
RA   Dangl J.L., Bloom R.E., Bodde S., Jones J.D.G., Schroeder J.I.;
RT   "NADPH oxidase AtrbohD and AtrbohF genes function in ROS-dependent ABA
RT   signaling in Arabidopsis.";
RL   EMBO J. 22:2623-2633(2003).
RN   [7]
RP   FUNCTION, AND ENZYME REGULATION.
RX   PubMed=16961732; DOI=10.1111/j.1365-313X.2006.02842.x;
RA   Desikan R., Last K., Harrett-Williams R., Tagliavia C., Harter K.,
RA   Hooley R., Hancock J.T., Neill S.J.;
RT   "Ethylene-induced stomatal closure in Arabidopsis occurs via AtrbohF-
RT   mediated hydrogen peroxide synthesis.";
RL   Plant J. 47:907-916(2006).
RN   [8]
RP   FUNCTION.
RX   PubMed=16913867; DOI=10.1111/j.1365-3040.2006.01555.x;
RA   Kalbina I., Strid A.;
RT   "The role of NADPH oxidase and MAP kinase phosphatase in UV-B-
RT   dependent gene expression in Arabidopsis.";
RL   Plant Cell Environ. 29:1783-1793(2006).
RN   [9]
RP   FUNCTION.
RX   PubMed=16428598; DOI=10.1104/pp.105.073072;
RA   Song C.J., Steinebrunner I., Wang X., Stout S.C., Roux S.J.;
RT   "Extracellular ATP induces the accumulation of superoxide via NADPH
RT   oxidases in Arabidopsis.";
RL   Plant Physiol. 140:1222-1232(2006).
RN   [10]
RP   GENE FAMILY, AND NOMENCLATURE.
RX   PubMed=16760484; DOI=10.1104/pp.106.078089;
RA   Sagi M., Fluhr R.;
RT   "Production of reactive oxygen species by plant NADPH oxidases.";
RL   Plant Physiol. 141:336-340(2006).
CC   -!- FUNCTION: Calcium-dependent NADPH oxidase that generates
CC       superoxide. Generates reactive oxygen species (ROS) during
CC       incompatible interactions with pathogens and is important in the
CC       regulation of the hypersensitive response (HR). Involved in
CC       abscisic acid-induced stomatal closing and in UV-B and abscissic
CC       acid ROS-dependent signaling.
CC   -!- ENZYME REGULATION: Inhibited by diphenylene iodonium (DPI).
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Expressed in roots, stems, seedlings,
CC       inflorescences, leaves and guard cells.
CC   -!- INDUCTION: Up-regulated by abscisic acid.
CC   -!- PTM: Not glycosylated.
CC   -!- SIMILARITY: Belongs to the RBOH family.
CC   -!- SIMILARITY: Contains 1 EF-hand domain.
CC   -!- SIMILARITY: Contains 1 FAD-binding FR-type domain.
CC   -!- SIMILARITY: Contains 1 ferric oxidoreductase domain.
CC   -!- CAUTION: Was originally (PubMed:9490748) called RBOHA.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF24574.1; Type=Erroneous gene model prediction;
CC       Sequence=BAF00352.1; Type=Miscellaneous discrepancy; Note=Intron retention;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB008111; BAA28953.1; -; mRNA.
DR   EMBL; AF015301; AAB87789.1; -; mRNA.
DR   EMBL; AC007764; AAF24574.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AK228418; BAF00352.1; ALT_SEQ; mRNA.
DR   IPI; IPI00533584; -.
DR   PIR; T03826; T03826.
DR   RefSeq; NP_564821.1; -.
DR   UniGene; At.235; -.
DR   SMR; O48538; 202-335, 602-849, 650-944.
DR   PRIDE; O48538; -.
DR   GeneID; 842710; -.
DR   GenomeReviews; CT485782_GR; AT1G64060.
DR   KEGG; ath:AT1G64060; -.
DR   NMPDR; fig|3702.1.peg.5817; -.
DR   TAIR; At1g64060; -.
DR   eggNOG; KOG0039; -.
DR   HOGENOM; HBG591219; -.
DR   InParanoid; O48538; -.
DR   OMA; HKTIAGA; -.
DR   PhylomeDB; O48538; -.
DR   Genevestigator; O48538; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IDA:TAIR.
DR   GO; GO:0005509; F:calcium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0009055; F:electron carrier activity; IEA:InterPro.
DR   GO; GO:0050660; F:FAD binding; IEA:InterPro.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0016174; F:NAD(P)H oxidase activity; IMP:TAIR.
DR   GO; GO:0004601; F:peroxidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0009738; P:abscisic acid mediated signaling pathway; TAS:TAIR.
DR   GO; GO:0052542; P:callose deposition during defense response; IMP:TAIR.
DR   GO; GO:0009873; P:ethylene mediated signaling pathway; TAS:TAIR.
DR   GO; GO:0050665; P:hydrogen peroxide biosynthetic process; IMP:TAIR.
DR   GO; GO:0043069; P:negative regulation of programmed cell death; IMP:TAIR.
DR   GO; GO:0055114; P:oxidation reduction; IEA:UniProtKB-KW.
DR   GO; GO:0010119; P:regulation of stomatal movement; IMP:TAIR.
DR   GO; GO:0002679; P:respiratory burst during defense response; IMP:TAIR.
DR   InterPro; IPR000778; Cyt_b245_heavy_chain.
DR   InterPro; IPR011992; EF-hand-like_dom.
DR   InterPro; IPR018247; EF_Hand_1_Ca_BS.
DR   InterPro; IPR018249; EF_HAND_2.
DR   InterPro; IPR013112; FAD_bd_8.
DR   InterPro; IPR017927; Fd_Rdtase_FAD-bd.
DR   InterPro; IPR013130; Fe3_reduct_TM_N.
DR   InterPro; IPR013121; Fe_red_NAD_bd_6.
DR   InterPro; IPR013623; NADPH_Ox.
DR   InterPro; IPR017938; Riboflavin_synthase-like_b-brl.
DR   Gene3D; G3DSA:1.10.238.10; EF-Hand_type; 1.
DR   Pfam; PF08022; FAD_binding_8; 1.
DR   Pfam; PF01794; Ferric_reduct; 1.
DR   Pfam; PF08030; NAD_binding_6; 1.
DR   Pfam; PF08414; NADPH_Ox; 1.
DR   PRINTS; PR00466; GP91PHOX.
DR   SUPFAM; SSF63380; Riboflavin_synthase_like_b-brl; 1.
DR   PROSITE; PS00018; EF_HAND_1; 1.
DR   PROSITE; PS50222; EF_HAND_2; 1.
DR   PROSITE; PS51384; FAD_FR; 1.
PE   1: Evidence at protein level;
KW   Calcium; Coiled coil; Complete proteome; Direct protein sequencing;
KW   FAD; Membrane; NADP; Oxidoreductase; Peroxidase; Repeat;
KW   Transmembrane.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    944       Respiratory burst oxidase homolog protein
FT                                F.
FT                                /FTId=PRO_0000313758.
FT   TOPO_DOM      2    387       Cytoplasmic (Potential).
FT   TRANSMEM    388    408       1 (Potential).
FT   TOPO_DOM    409    475       Extracellular (Potential).
FT   TRANSMEM    476    492       2 (By similarity).
FT   TOPO_DOM    493    527       Cytoplasmic (Potential).
FT   TRANSMEM    528    548       3 (Potential).
FT   TOPO_DOM    549    570       Extracellular (Potential).
FT   TRANSMEM    571    591       4 (Potential).
FT   TOPO_DOM    592    599       Cytoplasmic (Potential).
FT   TRANSMEM    600    617       5 (Potential).
FT   TOPO_DOM    618    744       Extracellular (Potential).
FT   TRANSMEM    745    765       6 (Potential).
FT   TOPO_DOM    766    944       Cytoplasmic (Potential).
FT   DOMAIN      264    299       EF-hand 1.
FT   DOMAIN      308    343       EF-hand 2.
FT   DOMAIN      426    583       Ferric oxidoreductase.
FT   DOMAIN      622    742       FAD-binding FR-type.
FT   CA_BIND     277    288       1.
FT   CA_BIND     321    332       2.
FT   COILED      102    126       Potential.
FT   COILED      157    184       Potential.
FT   COMPBIAS    239    242       Poly-Arg.
FT   CONFLICT    908    908       I -> T (in Ref. 1; BAA28953).
SQ   SEQUENCE   944 AA;  108418 MW;  1ABAEC316AE80F9B CRC64;
     MKPFSKNDRR RWSFDSVSAG KTAVGSASTS PGTEYSINGD QEFVEVTIDL QDDDTIVLRS
     VEPATAINVI GDISDDNTGI MTPVSISRSP TMKRTSSNRF RQFSQELKAE AVAKAKQLSQ
     ELKRFSWSRS FSGNLTTTST AANQSGGAGG GLVNSALEAR ALRKQRAQLD RTRSSAQRAL
     RGLRFISNKQ KNVDGWNDVQ SNFEKFEKNG YIYRSDFAQC IGMKDSKEFA LELFDALSRR
     RRLKVEKINH DELYEYWSQI NDESFDSRLQ IFFDIVDKNE DGRITEEEVK EIIMLSASAN
     KLSRLKEQAE EYAALIMEEL DPERLGYIEL WQLETLLLQK DTYLNYSQAL SYTSQALSQN
     LQGLRGKSRI HRMSSDFVYI MQENWKRIWV LSLWIMIMIG LFLWKFFQYK QKDAFHVMGY
     CLLTAKGAAE TLKFNMALIL FPVCRNTITW LRSTRLSYFV PFDDNINFHK TIAGAIVVAV
     ILHIGDHLAC DFPRIVRATE YDYNRYLFHY FQTKQPTYFD LVKGPEGITG ILMVILMIIS
     FTLATRWFRR NLVKLPKPFD RLTGFNAFWY SHHLFVIVYI LLILHGIFLY FAKPWYVRTT
     WMYLAVPVLL YGGERTLRYF RSGSYSVRLL KVAIYPGNVL TLQMSKPTQF RYKSGQYMFV
     QCPAVSPFEW HPFSITSAPE DDYISIHIRQ LGDWTQELKR VFSEVCEPPV GGKSGLLRAD
     ETTKKSLPKL LIDGPYGAPA QDYRKYDVLL LVGLGIGATP FISILKDLLN NIVKMEEHAD
     SISDFSRSSE YSTGSNGDTP RRKRILKTTN AYFYWVTREQ GSFDWFKGVM NEVAELDQRG
     VIEMHNYLTS VYEEGDARSA LITMVQALNH AKNGVDIVSG TRVRTHFARP NWKKVLTKLS
     SKHCNARIGV FYCGVPVLGK ELSKLCNTFN QKGSTKFEFH KEHF
//
ID   S1PR1_HUMAN             Reviewed;         382 AA.
AC   P21453; Q9BYY4; Q9NYN8;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   02-SEP-2008, sequence version 2.
DT   02-MAR-2010, entry version 102.
DE   RecName: Full=Sphingosine 1-phosphate receptor 1;
DE            Short=S1P receptor 1;
DE            Short=S1P1;
DE   AltName: Full=Sphingosine 1-phosphate receptor Edg-1;
DE            Short=S1P receptor Edg-1;
DE   AltName: Full=Endothelial differentiation G-protein coupled receptor 1;
GN   Name=S1PR1; Synonyms=CHEDG1, EDG1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Umbilical vein endothelial cell;
RX   MEDLINE=90264425; PubMed=2160972;
RA   Hla T., Maciag T.;
RT   "An abundant transcript induced in differentiating human endothelial
RT   cells encodes a polypeptide with structural similarities to G-protein-
RT   coupled receptors.";
RL   J. Biol. Chem. 265:9308-9313(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lung;
RX   MEDLINE=98072391; PubMed=9409733; DOI=10.1016/S0014-5793(97)01301-X;
RA   An S., Bleu T., Huang W., Hallmark O.G., Coughlin S.R., Goetzl E.J.;
RT   "Identification of cDNAs encoding two G protein-coupled receptors for
RT   lysosphingolipids.";
RL   FEBS Lett. 417:279-282(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND MUTAGENESIS OF ARG-120; GLU-121 AND
RP   ARG-292.
RX   MEDLINE=20564308; PubMed=10982820; DOI=10.1074/jbc.M007680200;
RA   Parrill A.L., Wang D., Bautista D.L., Van Brocklyn J.R., Lorincz Z.,
RA   Fischer D.J., Baker D.L., Liliom K., Spiegel S., Tigyi G.;
RT   "Identification of Edg1 receptor residues that recognize sphingosine
RT   1-phosphate.";
RL   J. Biol. Chem. 275:39379-39384(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Substantia nigra;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S.,
RA   Neubert P., Kstrang K., Schatten R., Shen B., Henze S., Mar W.,
RA   Korn B., Zuo D., Hu Y., LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PHARMACOLOGICAL CHARACTERIZATION.
RX   PubMed=8626678; DOI=10.1074/jbc.271.19.11272;
RA   Lee M.-J., Evans M., Hla T.;
RT   "The inducible G protein-coupled receptor edg-1 signals via the
RT   G(i)/mitogen-activated protein kinase pathway.";
RL   J. Biol. Chem. 271:11272-11279(1996).
RN   [10]
RP   FUNCTION.
RX   PubMed=9488656; DOI=10.1126/science.279.5356.1552;
RA   Lee M.-J., Van Brocklyn J.R., Thangada S., Liu C.H., Hand A.R.,
RA   Menzeleev R., Spiegel S., Hla T.;
RT   "Sphingosine-1-phosphate as a ligand for the G protein-coupled
RT   receptor EDG-1.";
RL   Science 279:1552-1555(1998).
RN   [11]
RP   PHARMACOLOGICAL CHARACTERIZATION.
RX   PubMed=10383399; DOI=10.1074/jbc.274.27.18997;
RA   Ancellin N., Hla T.;
RT   "Differential pharmacological properties and signal transduction of
RT   the sphingosine 1-phosphate receptors EDG-1, EDG-3, and EDG-5.";
RL   J. Biol. Chem. 274:18997-19002(1999).
RN   [12]
RP   PHOSPHORYLATION AT THR-236, AND MUTAGENESIS OF THR-236.
RX   PubMed=11583630; DOI=10.1016/S1097-2765(01)00324-0;
RA   Lee M.-J., Thangada S., Paik J.-H., Sapkota G.P., Ancellin N.,
RA   Chae S.-S., Wu M., Morales-Ruiz M., Sessa W.C., Alessi D.R., Hla T.;
RT   "Akt-mediated phosphorylation of the G protein-coupled receptor EDG-1
RT   is required for endothelial cell chemotaxis.";
RL   Mol. Cell 8:693-704(2001).
RN   [13]
RP   FUNCTION.
RX   PubMed=11230698; DOI=10.1126/science.1057559;
RA   Hobson J.P., Rosenfeldt H.M., Barak L.S., Olivera A., Poulton S.,
RA   Caron M.G., Milstien S., Spiegel S.;
RT   "Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-induced
RT   cell motility.";
RL   Science 291:1800-1803(2001).
CC   -!- FUNCTION: Receptor for the lysosphingolipid sphingosine 1-
CC       phosphate (S1P). S1P is a bioactive lysophospholipid that elicits
CC       diverse physiological effect on most types of cells and tissues.
CC       This inducible epithelial cell G-protein-coupled receptor may be
CC       involved in the processes that regulate the differentiation of
CC       endothelial cells. Seems to be coupled to the G(i) subclass of
CC       heteromeric G proteins.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Endothelial cells, and to a lesser extent, in
CC       vascular smooth muscle cells, fibroblasts, melanocytes, and cells
CC       of epithelioid origin.
CC   -!- INDUCTION: By the tumor promoter phorbol 12-myristate 13-acetate
CC       (PME) in the presence of cycloheximide.
CC   -!- PTM: S1P-induced endothelial cell migration requires the PKB/AKT1-
CC       mediated phosphorylation of the third intracellular loop at the
CC       Thr-236 residue.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M31210; AAA52336.1; -; mRNA.
DR   EMBL; AF022137; AAC51905.1; -; mRNA.
DR   EMBL; AF233365; AAF43420.1; -; mRNA.
DR   EMBL; AK312493; BAG35395.1; -; mRNA.
DR   EMBL; CR541786; CAG46585.1; -; mRNA.
DR   EMBL; CR542269; CAG47065.1; -; mRNA.
DR   EMBL; AL109741; CAI21861.1; -; Genomic_DNA.
DR   EMBL; CH471097; EAW72927.1; -; Genomic_DNA.
DR   EMBL; BC018650; AAH18650.1; -; mRNA.
DR   IPI; IPI00015343; -.
DR   PIR; A35300; A35300.
DR   RefSeq; NP_001391.2; -.
DR   UniGene; Hs.154210; -.
DR   SMR; P21453; 50-333.
DR   STRING; P21453; -.
DR   PhosphoSite; P21453; -.
DR   PRIDE; P21453; -.
DR   Ensembl; ENST00000305352; ENSP00000305416; ENSG00000170989; Homo sapiens.
DR   GeneID; 1901; -.
DR   KEGG; hsa:1901; -.
DR   CTD; 1901; -.
DR   GeneCards; GC01P101475; -.
DR   H-InvDB; HIX0000822; -.
DR   HGNC; HGNC:3165; S1PR1.
DR   HPA; CAB010104; -.
DR   MIM; 601974; gene.
DR   PharmGKB; PA27605; -.
DR   HOVERGEN; HBG103071; -.
DR   InParanoid; P21453; -.
DR   OrthoDB; EOG9W3W6J; -.
DR   PhylomeDB; P21453; -.
DR   Pathway_Interaction_DB; fcer1pathway; Fc-epsilon receptor I signaling in mast cells.
DR   Pathway_Interaction_DB; pdgfrbpathway; PDGFR-beta signaling pathway.
DR   Pathway_Interaction_DB; s1p_s1p1_pathway; S1P1 pathway.
DR   Pathway_Interaction_DB; s1p_s1p3_pathway; S1P3 pathway.
DR   Pathway_Interaction_DB; vegfr1_2_pathway; Signaling events mediated by VEGFR1 and VEGFR2.
DR   Pathway_Interaction_DB; s1p_meta_pathway; Sphingosine 1-phosphate (S1P) pathway.
DR   Reactome; REACT_14797; Signaling by GPCR.
DR   ArrayExpress; P21453; -.
DR   Bgee; P21453; -.
DR   CleanEx; HS_S1PR1; -.
DR   Genevestigator; P21453; -.
DR   GermOnline; ENSG00000170989; Homo sapiens.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; TAS:ProtInc.
DR   GO; GO:0001619; F:lysosphingolipid and lysophosphatidic acid ...; IEA:InterPro.
DR   GO; GO:0007155; P:cell adhesion; TAS:ProtInc.
DR   GO; GO:0007186; P:G-protein coupled receptor protein signalin...; TAS:ProtInc.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR000987; EDG1_rcpt.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   InterPro; IPR004061; S1P_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00642; EDG1RECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01523; S1PRECEPTOR.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Complete proteome; G-protein coupled receptor;
KW   Glycoprotein; Lipoprotein; Membrane; Palmitate; Phosphoprotein;
KW   Polymorphism; Receptor; Transducer; Transmembrane.
FT   CHAIN         1    382       Sphingosine 1-phosphate receptor 1.
FT                                /FTId=PRO_0000069412.
FT   TOPO_DOM      1     46       Extracellular (By similarity).
FT   TRANSMEM     47     71       1 (By similarity).
FT   TOPO_DOM     72     78       Cytoplasmic (By similarity).
FT   TRANSMEM     79    107       2 (By similarity).
FT   TOPO_DOM    108    121       Extracellular (By similarity).
FT   TRANSMEM    122    140       3 (By similarity).
FT   TOPO_DOM    141    159       Cytoplasmic (By similarity).
FT   TRANSMEM    160    185       4 (By similarity).
FT   TOPO_DOM    186    201       Extracellular (By similarity).
FT   TRANSMEM    202    222       5 (By similarity).
FT   TOPO_DOM    223    255       Cytoplasmic (By similarity).
FT   TRANSMEM    256    277       6 (By similarity).
FT   TOPO_DOM    278    293       Extracellular (By similarity).
FT   TRANSMEM    294    314       7 (By similarity).
FT   TOPO_DOM    315    382       Cytoplasmic (By similarity).
FT   MOD_RES     236    236       Phosphothreonine; by PKB/AKT1.
FT   MOD_RES     353    353       Phosphoserine (Potential).
FT   LIPID       328    328       S-palmitoyl cysteine (By similarity).
FT   CARBOHYD     30     30       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     36     36       N-linked (GlcNAc...) (Potential).
FT   VARIANT      15     15       S -> L (in dbSNP:rs4987250).
FT                                /FTId=VAR_046158.
FT   VARIANT     115    115       A -> T (in dbSNP:rs11542632).
FT                                /FTId=VAR_046159.
FT   VARIANT     332    332       P -> R (in dbSNP:rs7549921).
FT                                /FTId=VAR_046160.
FT   MUTAGEN     120    120       R->A: Drastically reduced affinity for
FT                                sphingosine 1-phosphate.
FT   MUTAGEN     121    121       E->A: Drastically reduced affinity for
FT                                sphingosine 1-phosphate.
FT   MUTAGEN     121    121       E->Q: Slight activation of the receptor
FT                                at maximal ligand concentration.
FT   MUTAGEN     236    236       T->A: Acts as a dominant negative GPCR
FT                                and inhibits S1P-induced Rac activation,
FT                                chemotaxis, and angiogenesis.
FT   MUTAGEN     292    292       R->A,V: Drastically reduced affinity for
FT                                sphingosine 1-phosphate.
FT   CONFLICT    250    252       KSL -> NV (in Ref. 1; AAA52336 and 2;
FT                                AAC51905).
SQ   SEQUENCE   382 AA;  42811 MW;  0CCE8685A5E1BAD2 CRC64;
     MGPTSVPLVK AHRSSVSDYV NYDIIVRHYN YTGKLNISAD KENSIKLTSV VFILICCFII
     LENIFVLLTI WKTKKFHRPM YYFIGNLALS DLLAGVAYTA NLLLSGATTY KLTPAQWFLR
     EGSMFVALSA SVFSLLAIAI ERYITMLKMK LHNGSNNFRL FLLISACWVI SLILGGLPIM
     GWNCISALSS CSTVLPLYHK HYILFCTTVF TLLLLSIVIL YCRIYSLVRT RSRRLTFRKN
     ISKASRSSEK SLALLKTVII VLSVFIACWA PLFILLLLDV GCKVKTCDIL FRAEYFLVLA
     VLNSGTNPII YTLTNKEMRR AFIRIMSCCK CPSGDSAGKF KRPIIAGMEF SRSKSDNSSH
     PQKDEGDNPE TIMSSGNVNS SS
//
ID   S1PR2_DANRE             Reviewed;         370 AA.
AC   Q9I8K8;
DT   16-FEB-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   02-MAR-2010, entry version 62.
DE   RecName: Full=Sphingosine 1-phosphate receptor 2;
DE            Short=S1P receptor 2;
DE            Short=S1P2;
DE   AltName: Full=Sphingosine 1-phosphate receptor Edg-5;
DE            Short=S1P receptor Edg-5;
GN   Name=s1pr2; Synonyms=edg5;
OS   Danio rerio (Zebrafish) (Brachydanio rerio).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
OC   Cyprinidae; Danio.
OX   NCBI_TaxID=7955;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS MIL HIS-150 AND CYS-167.
RX   MEDLINE=20365730; PubMed=10910360; DOI=10.1038/35018092;
RA   Kupperman E., An S., Osborne N., Waldron S., Stainier D.Y.R.;
RT   "A sphingosine-1-phosphate receptor regulates cell migration during
RT   vertebrate heart development.";
RL   Nature 406:192-195(2000).
CC   -!- FUNCTION: Receptor for the lysosphingolipid sphingosine 1-
CC       phosphate (S1P). S1P receptor is critical for cell migration and
CC       epithlial integrity during vertebrate embryogenesis.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- DEVELOPMENTAL STAGE: The expression pattern is complex and
CC       dynamic. Maternal expression is found in a diffuse pattern
CC       throughout the blastoderm, and this pattern persists through the
CC       onset of gastrulation. More pronounced expression can be seen at
CC       tailbud stage in the anterior portion of the embryo and along the
CC       embryonic axis, and at the 16-somite stage in the
CC       midbrain/hindbrain boundary and the tip of the tail where blisters
CC       later develop in receptor mutants. At the 18-somite stage,
CC       expression appears just lateral to the midline, and as the
CC       myocardial precursors migrate to the midline, their location
CC       overlaps with this domain of receptor expression.
CC   -!- DISEASE: Defects in s1pr2 are a cause of heart development
CC       abnormality named miles apart (mil). In all vertebrates, the
CC       myocardial progenitors involute early during gastrulation and come
CC       to occupy bilateral positions in the anterior lateral plate
CC       mesoderm (LPM). During somitogenesis, these cells undergo a second
CC       phase of migration toward the midline and fuse to form the
CC       definitive heart tube. Defects in S1PR2 disrupt this process,
CC       leading to the formation of two laterally positioned hearts
CC       (cardia bifida). The mil phenotype for which two recessive alleles
CC       exist, mil(m93) and mil(te273) are fully penetrant.
CC       Mil(m93)/mil(te273) transheterozygous embryos display the same
CC       phenotype as homozygotes for either single mutant allele. In
CC       addition to cardia bifida, mil mutants display epithelial tail
CC       blisters, indicative of a defect in epithelial integrity.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF260256; AAF88001.1; -; mRNA.
DR   IPI; IPI00492275; -.
DR   RefSeq; NP_001153442.1; -.
DR   UniGene; Dr.110802; -.
DR   SMR; Q9I8K8; 53-334.
DR   STRING; Q9I8K8; -.
DR   Ensembl; ENSDART00000053106; ENSDARP00000053105; ENSDARG00000036548; Danio rerio.
DR   GeneID; 170457; -.
DR   KEGG; dre:170457; -.
DR   CTD; 170457; -.
DR   ZFIN; ZDB-GENE-020123-2; s1pr2.
DR   eggNOG; fiNOG06747; -.
DR   HOGENOM; HBG714382; -.
DR   HOVERGEN; HBG103071; -.
DR   InParanoid; Q9I8K8; -.
DR   OMA; AYIANIF; -.
DR   OrthoDB; EOG9W3W6J; -.
DR   PhylomeDB; Q9I8K8; -.
DR   ArrayExpress; Q9I8K8; -.
DR   Bgee; Q9I8K8; -.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0001619; F:lysosphingolipid and lysophosphatidic acid ...; IEA:InterPro.
DR   GO; GO:0060027; P:convergent extension involved in gastrulation; IDA:ZFIN.
DR   GO; GO:0007186; P:G-protein coupled receptor protein signalin...; IEA:UniProtKB-KW.
DR   GO; GO:0003007; P:heart morphogenesis; IMP:ZFIN.
DR   GO; GO:0008078; P:mesodermal cell migration; IGI:ZFIN.
DR   GO; GO:0030336; P:negative regulation of cell migration; IGI:ZFIN.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR000987; EDG1_rcpt.
DR   InterPro; IPR004063; EDG5_rcpt.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   InterPro; IPR004061; S1P_rcpt.
DR   PANTHER; PTHR22750:SF17; EDG5_rcpt; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00642; EDG1RECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01523; S1PRECEPTOR.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Disease mutation; G-protein coupled receptor;
KW   Glycoprotein; Lipoprotein; Membrane; Palmitate; Receptor; Transducer;
KW   Transmembrane.
FT   CHAIN         1    370       Sphingosine 1-phosphate receptor 2.
FT                                /FTId=PRO_0000069430.
FT   TOPO_DOM      1     57       Extracellular (By similarity).
FT   TRANSMEM     58     78       1 (By similarity).
FT   TOPO_DOM     79     87       Cytoplasmic (By similarity).
FT   TRANSMEM     88    108       2 (By similarity).
FT   TOPO_DOM    109    128       Extracellular (By similarity).
FT   TRANSMEM    129    149       3 (By similarity).
FT   TOPO_DOM    150    167       Cytoplasmic (By similarity).
FT   TRANSMEM    168    193       4 (By similarity).
FT   TOPO_DOM    194    219       Extracellular (By similarity).
FT   TRANSMEM    220    230       5 (By similarity).
FT   TOPO_DOM    231    254       Cytoplasmic (By similarity).
FT   TRANSMEM    255    275       6 (By similarity).
FT   TOPO_DOM    276    289       Extracellular (By similarity).
FT   TRANSMEM    290    310       7 (By similarity).
FT   TOPO_DOM    311    370       Cytoplasmic (By similarity).
FT   LIPID       325    325       S-palmitoyl cysteine (By similarity).
FT   CARBOHYD     24     24       N-linked (GlcNAc...) (Potential).
FT   VARIANT     150    150       R -> H (in mil; allele m93; lack of S1P-
FT                                mediated signaling).
FT   VARIANT     167    167       R -> C (in mil; allele te273; lack of
FT                                S1P-mediated signaling).
SQ   SEQUENCE   370 AA;  41777 MW;  8C6B3A06DEEA6757 CRC64;
     MTTCRLFAGF CQAVTMSKYS QYFNKTLIQV HYLTAKEMTA EELRDRIESK QSLSSLNILF
     VVICSIIILE NLLVLIAVFR NKKFHSAMFF FIGNLAFSDL LAGSAYIANI FLSGPRTFHL
     TPVQWFIREG TAFIALSASV FSLLAIAIER YIAITKVKVY GSNKTCRMFL LIGACWVMSI
     LLGGLPIIGW NCINNLDDCS AVLPLNTRYY IRFVVTIFSI ILLSIVILYV RIYLIVRTSH
     QEATNSPAYA LLKTVTIVLG VFIICWLPAF TILLLDTSCK MKQCPILNNA GIFFSFATLN
     SALNPLIYTL RSKDMRKEFL RVLCCWGLLN CGRPPHRCMV PLKSSSSMEH CTNKHEHQSI
     PIMQDCTTCV
//
ID   S1PR2_HUMAN             Reviewed;         353 AA.
AC   O95136; Q86UN8;
DT   07-NOV-2003, integrated into UniProtKB/Swiss-Prot.
DT   07-NOV-2003, sequence version 2.
DT   02-MAR-2010, entry version 82.
DE   RecName: Full=Sphingosine 1-phosphate receptor 2;
DE            Short=S1P receptor 2;
DE            Short=S1P2;
DE   AltName: Full=Sphingosine 1-phosphate receptor Edg-5;
DE            Short=S1P receptor Edg-5;
DE   AltName: Full=Endothelial differentiation G-protein coupled receptor 5;
GN   Name=S1PR2; Synonyms=EDG5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Fetal brain;
RX   PubMed=10617617; DOI=10.1074/jbc.275.1.288;
RA   An S., Zheng Y., Bleu T.;
RT   "Sphingosine 1-phosphate-induced cell proliferation, survival, and
RT   related signaling events mediated by G protein-coupled receptors Edg3
RT   and Edg5.";
RL   J. Biol. Chem. 275:288-296(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction
RT   sequenced by the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (MAR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-343, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
CC   -!- FUNCTION: Receptor for the lysosphingolipid sphingosine 1-
CC       phosphate (S1P). S1P is a bioactive lysophospholipid that elicits
CC       diverse physiological effect on most types of cells and tissues.
CC       When expressed in rat HTC4 hepatoma cells, is capable of mediating
CC       S1P-induced cell proliferation and suppression of apoptosis.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF034780; AAC98919.1; -; mRNA.
DR   EMBL; AY262688; AAP20652.1; -; Genomic_DNA.
DR   EMBL; BC069598; AAH69598.1; -; mRNA.
DR   IPI; IPI00003501; -.
DR   RefSeq; NP_004221.3; -.
DR   UniGene; Hs.655405; -.
DR   PDB; 1ZTI; Model; -; A=1-353.
DR   PDBsum; 1ZTI; -.
DR   SMR; O95136; 7-307.
DR   STRING; O95136; -.
DR   PRIDE; O95136; -.
DR   Ensembl; ENST00000317726; ENSP00000322049; ENSG00000175898; Homo sapiens.
DR   GeneID; 9294; -.
DR   KEGG; hsa:9294; -.
DR   UCSC; uc002mnl.2; human.
DR   CTD; 9294; -.
DR   GeneCards; GC19M010193; -.
DR   H-InvDB; HIX0039949; -.
DR   HGNC; HGNC:3169; S1PR2.
DR   HPA; HPA014307; -.
DR   MIM; 605111; gene.
DR   PharmGKB; PA27609; -.
DR   eggNOG; prNOG05755; -.
DR   HOGENOM; HBG714382; -.
DR   HOVERGEN; HBG103071; -.
DR   InParanoid; O95136; -.
DR   OMA; REGSAFI; -.
DR   OrthoDB; EOG9W3W6J; -.
DR   PhylomeDB; O95136; -.
DR   Pathway_Interaction_DB; s1p_s1p2_pathway; S1P2 pathway.
DR   Pathway_Interaction_DB; s1p_s1p3_pathway; S1P3 pathway.
DR   Pathway_Interaction_DB; s1p_meta_pathway; Sphingosine 1-phosphate (S1P) pathway.
DR   Reactome; REACT_14797; Signaling by GPCR.
DR   NextBio; 34823; -.
DR   ArrayExpress; O95136; -.
DR   Bgee; O95136; -.
DR   CleanEx; HS_S1PR2; -.
DR   Genevestigator; O95136; -.
DR   GermOnline; ENSG00000175898; Homo sapiens.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0008289; F:lipid binding; TAS:ProtInc.
DR   GO; GO:0001619; F:lysosphingolipid and lysophosphatidic acid ...; IEA:InterPro.
DR   GO; GO:0000187; P:activation of MAPK activity; TAS:ProtInc.
DR   GO; GO:0007186; P:G-protein coupled receptor protein signalin...; TAS:ProtInc.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; TAS:ProtInc.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR004063; EDG5_rcpt.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   InterPro; IPR004061; S1P_rcpt.
DR   PANTHER; PTHR22750:SF17; EDG5_rcpt; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01525; EDG5RECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01523; S1PRECEPTOR.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Complete proteome;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane;
KW   Palmitate; Phosphoprotein; Receptor; Transducer; Transmembrane.
FT   CHAIN         1    353       Sphingosine 1-phosphate receptor 2.
FT                                /FTId=PRO_0000069427.
FT   TOPO_DOM      1     34       Extracellular (By similarity).
FT   TRANSMEM     35     59       1 (By similarity).
FT   TOPO_DOM     60     66       Cytoplasmic (By similarity).
FT   TRANSMEM     67     95       2 (By similarity).
FT   TOPO_DOM     96    109       Extracellular (By similarity).
FT   TRANSMEM    110    128       3 (By similarity).
FT   TOPO_DOM    129    147       Cytoplasmic (By similarity).
FT   TRANSMEM    148    173       4 (By similarity).
FT   TOPO_DOM    174    189       Extracellular (By similarity).
FT   TRANSMEM    190    210       5 (By similarity).
FT   TOPO_DOM    211    233       Cytoplasmic (By similarity).
FT   TRANSMEM    234    255       6 (By similarity).
FT   TOPO_DOM    256    271       Extracellular (By similarity).
FT   TRANSMEM    272    292       7 (By similarity).
FT   TOPO_DOM    293    353       Cytoplasmic (By similarity).
FT   MOD_RES     333    333       Phosphoserine (By similarity).
FT   MOD_RES     343    343       Phosphoserine.
FT   LIPID       305    305       S-palmitoyl cysteine (By similarity).
FT   CARBOHYD     19     19       N-linked (GlcNAc...) (Potential).
FT   CONFLICT    113    113       F -> S (in Ref. 1; AAC98919).
FT   CONFLICT    318    318       G -> V (in Ref. 1; AAC98919).
FT   STRAND        3      6
FT   STRAND       11     13
FT   TURN         19     21
FT   TURN         25     27
FT   HELIX        30     39
FT   STRAND       40     43
FT   HELIX        44     60
FT   HELIX        67     85
FT   TURN         91     96
FT   HELIX       102    134
FT   STRAND      138    140
FT   HELIX       145    168
FT   STRAND      173    176
FT   TURN        177    180
FT   STRAND      181    184
FT   HELIX       188    196
FT   HELIX       199    211
FT   STRAND      214    216
FT   HELIX       226    258
FT   HELIX       266    278
FT   TURN        279    282
FT   HELIX       283    291
FT   HELIX       293    304
FT   TURN        333    335
FT   STRAND      344    346
SQ   SEQUENCE   353 AA;  38867 MW;  8E37084284ABF7E8 CRC64;
     MGSLYSEYLN PNKVQEHYNY TKETLETQET TSRQVASAFI VILCCAIVVE NLLVLIAVAR
     NSKFHSAMYL FLGNLAASDL LAGVAFVANT LLSGSVTLRL TPVQWFAREG SAFITLSASV
     FSLLAIAIER HVAIAKVKLY GSDKSCRMLL LIGASWLISL VLGGLPILGW NCLGHLEACS
     TVLPLYAKHY VLCVVTIFSI ILLAIVALYV RIYCVVRSSH ADMAAPQTLA LLKTVTIVLG
     VFIVCWLPAF SILLLDYACP VHSCPILYKA HYFFAVSTLN SLLNPVIYTW RSRDLRREVL
     RPLQCWRPGV GVQGRRRGGT PGHHLLPLRS SSSLERGMHM PTSPTFLEGN TVV
//
ID   S1PR2_MOUSE             Reviewed;         352 AA.
AC   P52592; Q9R236;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   07-NOV-2003, sequence version 2.
DT   02-MAR-2010, entry version 73.
DE   RecName: Full=Sphingosine 1-phosphate receptor 2;
DE            Short=S1P receptor 2;
DE            Short=S1P2;
DE   AltName: Full=Sphingosine 1-phosphate receptor Edg-5;
DE            Short=S1P receptor Edg-5;
DE   AltName: Full=Endothelial differentiation G-protein coupled receptor 5;
DE   AltName: Full=Lysophospholipid receptor B2;
GN   Name=S1pr2; Synonyms=Edg5, Gpcr13, Lpb2;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND TISSUE SPECIFICITY.
RC   STRAIN=129/SvJ;
RX   MEDLINE=99132320; PubMed=9931453; DOI=10.1016/S0378-1119(98)00589-7;
RA   Zhang G., Contos J.J.A., Weiner J.A., Fukushima N., Chun J.;
RT   "Comparative analysis of three murine G-protein coupled receptors
RT   activated by sphingosine-1-phosphate.";
RL   Gene 227:89-99(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 62-241.
RC   TISSUE=Testis;
RX   MEDLINE=94116980; PubMed=8288218; DOI=10.1006/geno.1993.1452;
RA   Wilkie T.M., Chen Y., Gilbert D.J., Moore K.J., Yu L., Simon M.I.,
RA   Copeland N.G., Jenkins N.A.;
RT   "Identification, chromosomal location, and genome organization of
RT   mammalian G-protein-coupled receptors.";
RL   Genomics 18:175-184(1993).
RN   [3]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-332, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Macrophage;
RX   PubMed=19144319; DOI=10.1016/j.immuni.2008.11.006;
RA   Trost M., English L., Lemieux S., Courcelles M., Desjardins M.,
RA   Thibault P.;
RT   "The phagosomal proteome in interferon-gamma-activated macrophages.";
RL   Immunity 30:143-154(2009).
RN   [4]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-19, AND MASS SPECTROMETRY.
RC   TISSUE=Myoblast;
RX   PubMed=19656770; DOI=10.1074/mcp.M900195-MCP200;
RA   Gundry R.L., Raginski K., Tarasova Y., Tchernyshyov I.,
RA   Bausch-Fluck D., Elliott S.T., Boheler K.R., Van Eyk J.E.,
RA   Wollscheid B.;
RT   "The mouse C2C12 myoblast cell surface N-linked glycoproteome:
RT   identification, glycosite occupancy, and membrane orientation.";
RL   Mol. Cell. Proteomics 8:2555-2569(2009).
RN   [5]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-19, AND MASS SPECTROMETRY.
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-
RT   linked cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
CC   -!- FUNCTION: Receptor for the lysosphingolipid sphingosine 1-
CC       phosphate (S1P). S1P is a bioactive lysophospholipid that elicits
CC       diverse physiological effect on most types of cells and tissues.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Most abundant in heart and lung; low, but
CC       clearly observed in kidney, liver and thymus; much lower but
CC       detectable in brain, testis, stomach and intestine. Not
CC       significantly detected in any of the sections of embryonic day (E)
CC       14-18, except in embryonic brain.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF108020; AAD16976.1; -; Genomic_DNA.
DR   EMBL; L20334; AAA16846.1; -; mRNA.
DR   IPI; IPI00128628; -.
DR   PIR; E48909; E48909.
DR   UniGene; Mm.46493; -.
DR   SMR; P52592; 35-308.
DR   STRING; P52592; -.
DR   PRIDE; P52592; -.
DR   Ensembl; ENSMUST00000054197; ENSMUSP00000053394; ENSMUSG00000043895; Mus musculus.
DR   MGI; MGI:99569; S1pr2.
DR   HOGENOM; HBG714382; -.
DR   HOVERGEN; HBG103071; -.
DR   InParanoid; P52592; -.
DR   ArrayExpress; P52592; -.
DR   Bgee; P52592; -.
DR   Genevestigator; P52592; -.
DR   GermOnline; ENSMUSG00000043895; Mus musculus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0001619; F:lysosphingolipid and lysophosphatidic acid ...; IEA:InterPro.
DR   GO; GO:0007610; P:behavior; IMP:MGI.
DR   GO; GO:0007186; P:G-protein coupled receptor protein signalin...; IEA:UniProtKB-KW.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR004063; EDG5_rcpt.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   InterPro; IPR004061; S1P_rcpt.
DR   PANTHER; PTHR22750:SF17; EDG5_rcpt; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01525; EDG5RECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01523; S1PRECEPTOR.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; PARTIAL.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; G-protein coupled receptor; Glycoprotein; Lipoprotein;
KW   Membrane; Palmitate; Phosphoprotein; Receptor; Transducer;
KW   Transmembrane.
FT   CHAIN         1    352       Sphingosine 1-phosphate receptor 2.
FT                                /FTId=PRO_0000069428.
FT   TOPO_DOM      1     34       Extracellular (By similarity).
FT   TRANSMEM     35     59       1 (By similarity).
FT   TOPO_DOM     60     66       Cytoplasmic (By similarity).
FT   TRANSMEM     67     95       2 (By similarity).
FT   TOPO_DOM     96    109       Extracellular (By similarity).
FT   TRANSMEM    110    128       3 (By similarity).
FT   TOPO_DOM    129    147       Cytoplasmic (By similarity).
FT   TRANSMEM    148    173       4 (By similarity).
FT   TOPO_DOM    174    189       Extracellular (By similarity).
FT   TRANSMEM    190    210       5 (By similarity).
FT   TOPO_DOM    211    233       Cytoplasmic (By similarity).
FT   TRANSMEM    234    255       6 (By similarity).
FT   TOPO_DOM    256    271       Extracellular (By similarity).
FT   TRANSMEM    272    292       7 (By similarity).
FT   TOPO_DOM    293    352       Cytoplasmic (By similarity).
FT   MOD_RES     332    332       Phosphoserine.
FT   MOD_RES     342    342       Phosphoserine (By similarity).
FT   LIPID       305    305       S-palmitoyl cysteine (By similarity).
FT   CARBOHYD     19     19       N-linked (GlcNAc...).
FT   CONFLICT    166    166       P -> S (in Ref. 2; AAA16846).
FT   CONFLICT    175    175       Q -> K (in Ref. 2; AAA16846).
FT   CONFLICT    189    189       H -> R (in Ref. 2; AAA16846).
SQ   SEQUENCE   352 AA;  38871 MW;  9A3E456DD488FE6B CRC64;
     MGGLYSEYLN PEKVLEHYNY TKETLDMQET TSRKVASAFI IILCCAIVVE NLLVLIAVAR
     NSKFHSAMYL FLGNLAASDL LAGVAFVANT LLSGHVTLSL TPVQWFAREV SAFITLSASV
     FSLLAIAIER QVALAKVKLY GSDKSCRMLM LIGASWLISL ILGGLPILGW NCLNQLEACS
     TVLPLYAKHY VLCVVTIFSV ILLAIVALYV RIYFVVRSSH ADVAGPQTLA LLKTVTIVLG
     VFIICWLPAF SILLLDSTCP VRACPVLYKA HYFFAFATLN SLLNPVIYTW RSRDLRREVL
     RPLQCWRRGK GVTGRRGGNP GHRLLPLRSS SSLERGMHMP TSPTFLEGNT VV
//
ID   S1PR2_RAT               Reviewed;         352 AA.
AC   P47752; Q54AI6;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 1.
DT   02-MAR-2010, entry version 77.
DE   RecName: Full=Sphingosine 1-phosphate receptor 2;
DE            Short=S1P receptor 2;
DE            Short=S1P2;
DE   AltName: Full=Sphingosine 1-phosphate receptor Edg-5;
DE            Short=S1P receptor Edg-5;
DE   AltName: Full=Endothelial differentiation G-protein coupled receptor 5;
DE   AltName: Full=G-protein coupled receptor H218;
DE   AltName: Full=AGR16;
GN   Name=S1pr2; Synonyms=Edg5;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Aortic smooth muscle;
RX   MEDLINE=93176155; PubMed=8382486; DOI=10.1006/bbrc.1993.1163;
RA   Okazaki H., Ishizaka N., Sakurai T., Kurokawa K., Goto K., Kumada M.,
RA   Takuwa Y.;
RT   "Molecular cloning of a novel putative G protein-coupled receptor
RT   expressed in the cardiovascular system.";
RL   Biochem. Biophys. Res. Commun. 190:1104-1109(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain, and Lung;
RX   MEDLINE=94373324; PubMed=8087418; DOI=10.1006/mcne.1994.1024;
RA   Maclennan A.J., Browe C.S., Gaskin A.A., Lado D.C., Shaw G.;
RT   "Cloning and characterization of a putative G-protein coupled receptor
RT   potentially involved in development.";
RL   Mol. Cell. Neurosci. 5:201-209(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   MEDLINE=98072391; PubMed=9409733; DOI=10.1016/S0014-5793(97)01301-X;
RA   An S., Bleu T., Huang W., Hallmark O.G., Coughlin S.R., Goetzl E.J.;
RT   "Identification of cDNAs encoding two G protein-coupled receptors for
RT   lysosphingolipids.";
RL   FEBS Lett. 417:279-282(1997).
RN   [4]
RP   PHARMACOLOGICAL CHARACTERIZATION.
RX   PubMed=10383399; DOI=10.1074/jbc.274.27.18997;
RA   Ancellin N., Hla T.;
RT   "Differential pharmacological properties and signal transduction of
RT   the sphingosine 1-phosphate receptors EDG-1, EDG-3, and EDG-5.";
RL   J. Biol. Chem. 274:18997-19002(1999).
CC   -!- FUNCTION: Receptor for the lysosphingolipid sphingosine 1-
CC       phosphate (S1P). S1P is a bioactive lysophospholipid that elicits
CC       diverse physiological effect on most types of cells and tissues.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Expressed in all developing tissues with
CC       highest levels detected in primitive, transformed cells. Relative
CC       abundance: lung > kidney = skin = gut > spleen > brain > liver.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB016931; BAA32454.1; -; mRNA.
DR   EMBL; U10699; AAA19241.1; -; mRNA.
DR   EMBL; AF022138; AAC53494.1; -; mRNA.
DR   IPI; IPI00190100; -.
DR   PIR; JC1465; JC1465.
DR   RefSeq; NP_058888.1; -.
DR   UniGene; Rn.2491; -.
DR   SMR; P47752; 36-308.
DR   STRING; P47752; -.
DR   Ensembl; ENSRNOT00000028034; ENSRNOP00000028034; ENSRNOG00000020653; Rattus norvegicus.
DR   GeneID; 29415; -.
DR   KEGG; rno:29415; -.
DR   UCSC; NM_017192; rat.
DR   CTD; 29415; -.
DR   RGD; 68334; S1pr2.
DR   HOVERGEN; HBG103071; -.
DR   InParanoid; P47752; -.
DR   OMA; REGSAFI; -.
DR   OrthoDB; EOG9W3W6J; -.
DR   PhylomeDB; P47752; -.
DR   NextBio; 609092; -.
DR   ArrayExpress; P47752; -.
DR   Genevestigator; P47752; -.
DR   GermOnline; ENSRNOG00000020653; Rattus norvegicus.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0001619; F:lysosphingolipid and lysophosphatidic acid ...; IEA:InterPro.
DR   GO; GO:0007186; P:G-protein coupled receptor protein signalin...; IEA:UniProtKB-KW.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR004063; EDG5_rcpt.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   InterPro; IPR004061; S1P_rcpt.
DR   PANTHER; PTHR22750:SF17; EDG5_rcpt; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01525; EDG5RECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01523; S1PRECEPTOR.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; FALSE_NEG.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; G-protein coupled receptor; Glycoprotein; Lipoprotein;
KW   Membrane; Palmitate; Phosphoprotein; Receptor; Transducer;
KW   Transmembrane.
FT   CHAIN         1    352       Sphingosine 1-phosphate receptor 2.
FT                                /FTId=PRO_0000069429.
FT   TOPO_DOM      1     34       Extracellular (By similarity).
FT   TRANSMEM     35     59       1 (By similarity).
FT   TOPO_DOM     60     66       Cytoplasmic (By similarity).
FT   TRANSMEM     67     95       2 (By similarity).
FT   TOPO_DOM     96    109       Extracellular (By similarity).
FT   TRANSMEM    110    128       3 (By similarity).
FT   TOPO_DOM    129    147       Cytoplasmic (By similarity).
FT   TRANSMEM    148    173       4 (By similarity).
FT   TOPO_DOM    174    189       Extracellular (By similarity).
FT   TRANSMEM    190    210       5 (By similarity).
FT   TOPO_DOM    211    233       Cytoplasmic (By similarity).
FT   TRANSMEM    234    255       6 (By similarity).
FT   TOPO_DOM    256    271       Extracellular (By similarity).
FT   TRANSMEM    272    292       7 (By similarity).
FT   TOPO_DOM    293    352       Cytoplasmic (By similarity).
FT   MOD_RES     332    332       Phosphoserine (By similarity).
FT   MOD_RES     342    342       Phosphoserine (By similarity).
FT   LIPID       305    305       S-palmitoyl cysteine (By similarity).
FT   CARBOHYD     19     19       N-linked (GlcNAc...) (Potential).
SQ   SEQUENCE   352 AA;  38735 MW;  9C933A18E756CE1E CRC64;
     MGGLYSEYLN PEKVQEHYNY TKETLDMQET PSRKVASAFI IILCCAIVVE NLLVLIAVAR
     NSKFHSAMYL FLGNLAASDL LAGVAFVANT LLSGPVTLSL TPLQWFAREG SAFITLSASV
     FSLLAIAIER QVAIAKVKLY GSDKSCRMLM LIGASWLISL ILGGLPILGW NCLDHLEACS
     TVLPLYAKHY VLCVVTIFSV ILLAIVALYV RIYFVVRSSH ADVAGPQTLA LLKTVTIVLG
     VFIICWLPAF SILLLDSTCP VRACPVLYKA HYFFAFATLN SLLNPVIYTW RSRDLRREVL
     RPLLCWRQGK GATGRRGGNP GHRLLPLRSS SSLERGLHMP TSPTFLEGNT VV
//
ID   S1PR3_HUMAN             Reviewed;         378 AA.
AC   Q99500; Q5SQD8; Q7Z5I2;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   16-FEB-2004, sequence version 2.
DT   02-MAR-2010, entry version 89.
DE   RecName: Full=Sphingosine 1-phosphate receptor 3;
DE            Short=S1P receptor 3;
DE            Short=S1P3;
DE   AltName: Full=Sphingosine 1-phosphate receptor Edg-3;
DE            Short=S1P receptor Edg-3;
DE   AltName: Full=Endothelial differentiation G-protein coupled receptor 3;
GN   Name=S1PR3; Synonyms=EDG3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RX   MEDLINE=97032811; PubMed=8878560; DOI=10.1006/bbrc.1996.1553;
RA   Yamaguchi F., Tokuda M., Hatase O., Brenner S.;
RT   "Molecular cloning of the novel human G protein-coupled receptor
RT   (GPCR) gene mapped on chromosome 9.";
RL   Biochem. Biophys. Res. Commun. 227:608-614(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   MEDLINE=98072391; PubMed=9409733; DOI=10.1016/S0014-5793(97)01301-X;
RA   An S., Bleu T., Huang W., Hallmark O.G., Coughlin S.R., Goetzl E.J.;
RT   "Identification of cDNAs encoding two G protein-coupled receptors for
RT   lysosphingolipids.";
RL   FEBS Lett. 417:279-282(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction
RT   sequenced by the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PHARMACOLOGICAL CHARACTERIZATION.
RX   PubMed=10383399; DOI=10.1074/jbc.274.27.18997;
RA   Ancellin N., Hla T.;
RT   "Differential pharmacological properties and signal transduction of
RT   the sphingosine 1-phosphate receptors EDG-1, EDG-3, and EDG-5.";
RL   J. Biol. Chem. 274:18997-19002(1999).
RN   [9]
RP   FUNCTION.
RX   PubMed=10617617; DOI=10.1074/jbc.275.1.288;
RA   An S., Zheng Y., Bleu T.;
RT   "Sphingosine 1-phosphate-induced cell proliferation, survival, and
RT   related signaling events mediated by G protein-coupled receptors Edg3
RT   and Edg5.";
RL   J. Biol. Chem. 275:288-296(2000).
RN   [10]
RP   SPHINGOSINE 1-PHOSPHATE ACTIVATION.
RX   MEDLINE=20368609; PubMed=10908314;
RA   Himmel H.M., Meyer Zu Heringdorf D., Graf E., Dobrev D., Kortner A.,
RA   Schueler S., Jakobs K.H., Ravens U.;
RT   "Evidence for Edg-3 receptor-mediated activation of I(K.ACh) by
RT   sphingosine-1-phosphate in human atrial cardiomyocytes.";
RL   Mol. Pharmacol. 58:449-454(2000).
CC   -!- FUNCTION: Receptor for the lysosphingolipid sphingosine 1-
CC       phosphate (S1P). S1P is a bioactive lysophospholipid that elicits
CC       diverse physiological effect on most types of cells and tissues.
CC       When expressed in rat HTC4 hepatoma cells, is capable of mediating
CC       S1P-induced cell proliferation and suppression of apoptosis.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Expressed in all tissues, but most abundantly
CC       in heart, placenta, kidney, and liver.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X83864; CAA58744.1; -; Genomic_DNA.
DR   EMBL; AF022139; AAC51906.1; -; mRNA.
DR   EMBL; AY322540; AAP84353.1; -; Genomic_DNA.
DR   EMBL; AK312798; BAG35658.1; -; mRNA.
DR   EMBL; AL772202; CAI16743.1; -; Genomic_DNA.
DR   EMBL; CH471089; EAW62758.1; -; Genomic_DNA.
DR   EMBL; BC060827; AAH60827.1; -; mRNA.
DR   EMBL; BC069579; AAH69579.1; -; mRNA.
DR   IPI; IPI00015983; -.
DR   PIR; JC5245; JC5245.
DR   RefSeq; NP_005217.2; -.
DR   UniGene; Hs.585118; -.
DR   SMR; Q99500; 43-320.
DR   STRING; Q99500; -.
DR   PhosphoSite; Q99500; -.
DR   PRIDE; Q99500; -.
DR   Ensembl; ENST00000358157; ENSP00000350878; ENSG00000213694; Homo sapiens.
DR   Ensembl; ENST00000375846; ENSP00000365006; ENSG00000213694; Homo sapiens.
DR   GeneID; 1903; -.
DR   KEGG; hsa:1903; -.
DR   UCSC; uc004aqe.1; human.
DR   CTD; 1903; -.
DR   GeneCards; GC09P090797; -.
DR   H-InvDB; HIX0021793; -.
DR   HGNC; HGNC:3167; S1PR3.
DR   MIM; 601965; gene.
DR   PharmGKB; PA27607; -.
DR   HOGENOM; HBG714382; -.
DR   HOVERGEN; HBG103071; -.
DR   InParanoid; Q99500; -.
DR   OMA; DCSTILP; -.
DR   OrthoDB; EOG9W3W6J; -.
DR   PhylomeDB; Q99500; -.
DR   Pathway_Interaction_DB; s1p_s1p3_pathway; S1P3 pathway.
DR   Pathway_Interaction_DB; s1p_meta_pathway; Sphingosine 1-phosphate (S1P) pathway.
DR   Reactome; REACT_14797; Signaling by GPCR.
DR   NextBio; 7753; -.
DR   ArrayExpress; Q99500; -.
DR   Bgee; Q99500; -.
DR   CleanEx; HS_S1PR3; -.
DR   Genevestigator; Q99500; -.
DR   GermOnline; ENSG00000186354; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0008289; F:lipid binding; TAS:ProtInc.
DR   GO; GO:0001619; F:lysosphingolipid and lysophosphatidic acid ...; IEA:InterPro.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; TAS:ProtInc.
DR   GO; GO:0007204; P:elevation of cytosolic calcium ion concentr...; TAS:ProtInc.
DR   GO; GO:0006954; P:inflammatory response; TAS:ProtInc.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; TAS:ProtInc.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR004062; EDG3_rcpt.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   InterPro; IPR004061; S1P_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01524; EDG3RECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01523; S1PRECEPTOR.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Complete proteome; G-protein coupled receptor;
KW   Glycoprotein; Membrane; Polymorphism; Receptor; Transducer;
KW   Transmembrane.
FT   CHAIN         1    378       Sphingosine 1-phosphate receptor 3.
FT                                /FTId=PRO_0000069421.
FT   TOPO_DOM      1     40       Extracellular (By similarity).
FT   TRANSMEM     41     65       1 (By similarity).
FT   TOPO_DOM     66     72       Cytoplasmic (By similarity).
FT   TRANSMEM     73    101       2 (By similarity).
FT   TOPO_DOM    102    115       Extracellular (By similarity).
FT   TRANSMEM    116    134       3 (By similarity).
FT   TOPO_DOM    135    153       Cytoplasmic (By similarity).
FT   TRANSMEM    154    179       4 (By similarity).
FT   TOPO_DOM    180    195       Extracellular (By similarity).
FT   TRANSMEM    196    216       5 (By similarity).
FT   TOPO_DOM    217    243       Cytoplasmic (By similarity).
FT   TRANSMEM    244    265       6 (By similarity).
FT   TOPO_DOM    266    281       Extracellular (By similarity).
FT   TRANSMEM    282    302       7 (By similarity).
FT   TOPO_DOM    303    378       Cytoplasmic (By similarity).
FT   CARBOHYD     15     15       N-linked (GlcNAc...) (Potential).
FT   VARIANT     243    243       R -> Q (in dbSNP:rs34075341).
FT                                /FTId=VAR_033465.
FT   CONFLICT    359    359       A -> D (in Ref. 1; CAA58744 and 2;
FT                                AAC51906).
SQ   SEQUENCE   378 AA;  42250 MW;  79A00300968F439F CRC64;
     MATALPPRLQ PVRGNETLRE HYQYVGKLAG RLKEASEGST LTTVLFLVIC SFIVLENLMV
     LIAIWKNNKF HNRMYFFIGN LALCDLLAGI AYKVNILMSG KKTFSLSPTV WFLREGSMFV
     ALGASTCSLL AIAIERHLTM IKMRPYDANK RHRVFLLIGM CWLIAFTLGA LPILGWNCLH
     NLPDCSTILP LYSKKYIAFC ISIFTAILVT IVILYARIYF LVKSSSRKVA NHNNSERSMA
     LLRTVVIVVS VFIACWSPLF ILFLIDVACR VQACPILFKA QWFIVLAVLN SAMNPVIYTL
     ASKEMRRAFF RLVCNCLVRG RGARASPIQP ALDPSRSKSS SSNNSSHSPK VKEDLPHTAP
     SSCIMDKNAA LQNGIFCN
//
ID   S1PR4_HUMAN             Reviewed;         384 AA.
AC   O95977;
DT   16-FEB-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   02-MAR-2010, entry version 84.
DE   RecName: Full=Sphingosine 1-phosphate receptor 4;
DE            Short=S1P receptor 4;
DE            Short=S1P4;
DE   AltName: Full=Sphingosine 1-phosphate receptor Edg-6;
DE            Short=S1P receptor Edg-6;
DE   AltName: Full=Endothelial differentiation G-protein coupled receptor 6;
GN   Name=S1PR4; Synonyms=EDG6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Dendritic cell;
RX   MEDLINE=99009331; PubMed=9790765; DOI=10.1006/geno.1998.5491;
RA   Graeler M.H., Bernhardt G., Lipp M.;
RT   "EDG6, a novel G protein-coupled receptor related to receptors for
RT   bioactive lysophospholipids, is specifically expressed in lymphoid
RT   tissue.";
RL   Genomics 53:164-169(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction
RT   sequenced by the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Blood;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   FUNCTION.
RX   MEDLINE=20145476; PubMed=10679247; DOI=10.1006/bbrc.2000.2162;
RA   Yamazaki Y., Kon J., Sato K., Tomura H., Sato M., Yoneya T.,
RA   Okazaki H., Okajima F., Ohta H.;
RT   "Edg-6 as a putative sphingosine 1-phosphate receptor coupling to
RT   Ca(2+) signaling pathway.";
RL   Biochem. Biophys. Res. Commun. 268:583-589(2000).
RN   [5]
RP   FUNCTION.
RX   MEDLINE=20218747; PubMed=10753843;
RA   Van Brocklyn J.R., Graeler M.H., Bernhardt G., Hobson J.P., Lipp M.,
RA   Spiegel S.;
RT   "Sphingosine-1-phosphate is a ligand for the G protein-coupled
RT   receptor EDG-6.";
RL   Blood 95:2624-2629(2000).
RN   [6]
RP   STRUCTURE BY NMR OF 105-122.
RX   PubMed=17443712; DOI=10.1002/bip.20745;
RA   Pham T.-C.T., Kriwacki R.W., Parrill A.L.;
RT   "Peptide design and structural characterization of a GPCR loop
RT   mimetic.";
RL   Biopolymers 86:298-310(2007).
CC   -!- FUNCTION: Receptor for the lysosphingolipid sphingosine 1-
CC       phosphate (S1P). S1P is a bioactive lysophospholipid that elicits
CC       diverse physiological effect on most types of cells and tissues.
CC       May be involved in cell migration processes that are specific for
CC       lymphocytes.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Specifically expressed in fetal and adult
CC       lymphoid and hematopoietic tissue as well as in lung. Considerable
CC       level of expression in adult and fetal spleen as well as adult
CC       peripheral leukocytes and lung. Lower expression in adult thymus,
CC       lymph node, bone marrow, and appendix as well as in fetal liver,
CC       thymus, and lung.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ000479; CAA04118.1; -; mRNA.
DR   EMBL; AY322537; AAP84350.1; -; Genomic_DNA.
DR   EMBL; BC014970; AAH14970.1; -; mRNA.
DR   IPI; IPI00021534; -.
DR   RefSeq; NP_003766.1; -.
DR   UniGene; Hs.662006; -.
DR   PDB; 2DCO; NMR; -; A=105-118.
DR   PDBsum; 2DCO; -.
DR   SMR; O95977; 54-326.
DR   STRING; O95977; -.
DR   PRIDE; O95977; -.
DR   Ensembl; ENST00000246115; ENSP00000246115; ENSG00000125910; Homo sapiens.
DR   GeneID; 8698; -.
DR   KEGG; hsa:8698; -.
DR   UCSC; uc002lxg.1; human.
DR   CTD; 8698; -.
DR   GeneCards; GC19P003130; -.
DR   H-InvDB; HIX0014635; -.
DR   HGNC; HGNC:3170; S1PR4.
DR   MIM; 603751; gene.
DR   PharmGKB; PA27610; -.
DR   eggNOG; prNOG14306; -.
DR   HOGENOM; HBG714382; -.
DR   HOVERGEN; HBG103071; -.
DR   InParanoid; O95977; -.
DR   OMA; AFVVCWG; -.
DR   OrthoDB; EOG9W3W6J; -.
DR   PhylomeDB; O95977; -.
DR   Pathway_Interaction_DB; s1p_s1p4_pathway; S1P4 pathway.
DR   Pathway_Interaction_DB; s1p_meta_pathway; Sphingosine 1-phosphate (S1P) pathway.
DR   Reactome; REACT_14797; Signaling by GPCR.
DR   NextBio; 32617; -.
DR   ArrayExpress; O95977; -.
DR   Bgee; O95977; -.
DR   CleanEx; HS_S1PR4; -.
DR   Genevestigator; O95977; -.
DR   GermOnline; ENSG00000125910; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0008289; F:lipid binding; TAS:ProtInc.
DR   GO; GO:0001619; F:lysosphingolipid and lysophosphatidic acid ...; IEA:InterPro.
DR   GO; GO:0007202; P:activation of phospholipase C activity; TAS:ProtInc.
DR   GO; GO:0007204; P:elevation of cytosolic calcium ion concentr...; TAS:ProtInc.
DR   GO; GO:0006955; P:immune response; TAS:ProtInc.
DR   InterPro; IPR000276; 7TM_GPCR_Rhodpsn.
DR   InterPro; IPR004064; EDG6_rcpt.
DR   InterPro; IPR017452; GPCR_Rhodpsn_supfam.
DR   InterPro; IPR004061; S1P_rcpt.
DR   PANTHER; PTHR22750:SF13; EDG6_rcpt; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01526; EDG6RECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01523; S1PRECEPTOR.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; FALSE_NEG.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Complete proteome;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane;
KW   Palmitate; Polymorphism; Receptor; Transducer; Transmembrane.
FT   CHAIN         1    384       Sphingosine 1-phosphate receptor 4.
FT                                /FTId=PRO_0000069431.
FT   TOPO_DOM      1     50       Extracellular (By similarity).
FT   TRANSMEM     51     71       1 (By similarity).
FT   TOPO_DOM     72     84       Cytoplasmic (By similarity).
FT   TRANSMEM     85    105       2 (By similarity).
FT   TOPO_DOM    106    117       Extracellular (By similarity).
FT   TRANSMEM    118    138       3 (By similarity).
FT   TOPO_DOM    139    161       Cytoplasmic (By similarity).
FT   TRANSMEM    162    182       4 (By similarity).
FT   TOPO_DOM    183    206       Extracellular (By similarity).
FT   TRANSMEM    207    227       5 (By similarity).
FT   TOPO_DOM    228    252       Cytoplasmic (By similarity).
FT   TRANSMEM    253    273       6 (By similarity).
FT   TOPO_DOM    274    288       Extracellular (By similarity).
FT   TRANSMEM    289    309       7 (By similarity).
FT   TOPO_DOM    310    384       Cytoplasmic (By similarity).
FT   LIPID       323    323       S-palmitoyl cysteine (By similarity).
FT   CARBOHYD      2      2       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     30     30       N-linked (GlcNAc...) (Potential).
FT   VARIANT     365    365       R -> L (in dbSNP:rs3746072).
FT                                /FTId=VAR_022066.
FT   HELIX       108    111
FT   STRAND      113    116
SQ   SEQUENCE   384 AA;  41623 MW;  369A7BC56AB46A47 CRC64;
     MNATGTPVAP ESCQQLAAGG HSRLIVLHYN HSGRLAGRGG PEDGGLGALR GLSVAASCLV
     VLENLLVLAA ITSHMRSRRW VYYCLVNITL SDLLTGAAYL ANVLLSGART FRLAPAQWFL
     REGLLFTALA ASTFSLLFTA GERFATMVRP VAESGATKTS RVYGFIGLCW LLAALLGMLP
     LLGWNCLCAF DRCSSLLPLY SKRYILFCLV IFAGVLATIM GLYGAIFRLV QASGQKAPRP
     AARRKARRLL KTVLMILLAF LVCWGPLFGL LLADVFGSNL WAQEYLRGMD WILALAVLNS
     AVNPIIYSFR SREVCRAVLS FLCCGCLRLG MRGPGDCLAR AVEAHSGAST TDSSLRPRDS
     FRGSRSLSFR MREPLSSISS VRSI
//
ID   SCN1A_HUMAN             Reviewed;        2009 AA.
AC   P35498; Q16172; Q585T7; Q96LA3; Q9C008;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   08-DEC-2000, sequence version 2.
DT   02-MAR-2010, entry version 109.
DE   RecName: Full=Sodium channel protein type 1 subunit alpha;
DE   AltName: Full=Sodium channel protein type I subunit alpha;
DE   AltName: Full=Voltage-gated sodium channel subunit alpha Nav1.1;
DE   AltName: Full=Sodium channel protein brain I subunit alpha;
GN   Name=SCN1A; Synonyms=NAC1, SCN1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS GEFS+2 MET-875
RP   AND HIS-1648.
RX   MEDLINE=20206553; PubMed=10742094; DOI=10.1038/74159;
RA   Escayg A., MacDonald B.T., Meisler M.H., Baulac S., Huberfeld G.,
RA   An-Gourfinkel I., Brice A., LeGuern E., Moulard B., Chaigne D.,
RA   Buresi C., Malafosse A.;
RT   "Mutations of SCN1A, encoding a neuronal sodium channel, in two
RT   families with GEFS+2.";
RL   Nat. Genet. 24:343-345(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Jeong S.-Y., Goto J., Kanazawa I.;
RT   "Cloning of cDNA for human voltage-gated sodium channel alpha subunit,
RT   SCN1A.";
RL   Submitted (JAN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RA   Sugawara T., Mazaki E.M., Yamakawa K.;
RT   "Homo sapiens neuronal voltage-gated sodium channel type I (Nav1.1)
RT   mRNA.";
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND VARIANT THR-1067.
RA   Ouchida M., Ohmori I.;
RT   "Isoforms of human sodium channel SCN1A gene.";
RL   Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1335-1428.
RX   MEDLINE=94340991; PubMed=8062593;
RA   Malo M.S., Blanchard B.J., Andresen J.M., Srivastava K., Chen X.N.,
RA   Li X., Jabs E.W., Korenberg J.R., Ingram V.M.;
RT   "Localization of a putative human brain sodium channel gene (SCN1A) to
RT   chromosome band 2q24.";
RL   Cytogenet. Cell Genet. 67:178-186(1994).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1518-1940.
RC   TISSUE=Brain;
RX   MEDLINE=92275082; PubMed=1317301; DOI=10.1016/0014-5793(92)80476-W;
RA   Lu C.-M., Han J., Rado T.A., Brown G.B.;
RT   "Differential expression of two sodium channel subtypes in human
RT   brain.";
RL   FEBS Lett. 303:53-58(1992).
RN   [8]
RP   VARIANTS GEFS+2 VAL-188; LEU-1353 AND MET-1656.
RX   MEDLINE=21152274; PubMed=11254444; DOI=10.1086/319516;
RA   Wallace R.H., Scheffer I.E., Barnett S., Richards M., Dibbens L.,
RA   Desai R.R., Lerman-Sagie T., Lev D., Mazarib A., Brand N.,
RA   Ben-Zeev B., Goikhman I., Singh R., Kremmidiotis G., Gardner A.,
RA   Sutherland G.R., George A.L. Jr., Mulley J.C., Berkovic S.F.;
RT   "Neuronal sodium-channel alpha1-subunit mutations in generalized
RT   epilepsy with febrile seizures plus.";
RL   Am. J. Hum. Genet. 68:859-865(2001).
RN   [9]
RP   VARIANT GEFS+2 ARG-1204.
RX   MEDLINE=21152275; PubMed=11254445; DOI=10.1086/319524;
RA   Escayg A., Heils A., MacDonald B.T., Haug K., Sander T., Meisler M.H.;
RT   "A novel SCN1A mutation associated with generalized epilepsy with
RT   febrile seizures plus -- and prevalence of variants in patients with
RT   epilepsy.";
RL   Am. J. Hum. Genet. 68:866-873(2001).
RN   [10]
RP   VARIANT SMEI PHE-986.
RX   MEDLINE=21257503; PubMed=11359211; DOI=10.1086/320609;
RA   Claes L., Del-Favero J., Ceulemans B., Lagae L., Van Broeckhoven C.,
RA   De Jonghe P.;
RT   "De novo mutations in the sodium-channel gene SCN1A cause severe
RT   myoclonic epilepsy of infancy.";
RL   Am. J. Hum. Genet. 68:1327-1332(2001).
RN   [11]
RP   VARIANTS GEFS+2 ALA-1428 AND VAL-1685.
RX   PubMed=11524484;
RA   Sugawara T., Mazaki-Miyazaki E., Ito M., Nagafuji H., Fukuma G.,
RA   Mitsudome A., Wada K., Kaneko S., Hirose S., Yamakawa K.;
RT   "Na(v)1.1 mutations cause febrile seizures associated with afebrile
RT   partial seizures.";
RL   Neurology 57:703-705(2001).
RN   [12]
RP   VARIANT GEFS+2 THR-1270.
RX   MEDLINE=21630138; PubMed=11756608;
RA   Abou-Khalil B., Ge Q., Desai R., Ryther R., Bazyk A., Bailey R.,
RA   Haines J.L., Sutcliffe J.S., George A.L. Jr.;
RT   "Partial and generalized epilepsy with febrile seizures plus and a
RT   novel SCN1A mutation.";
RL   Neurology 57:2265-2272(2001).
RN   [13]
RP   VARIANTS SMEI CYS-902; CYS-931; PRO-1265; PHE-1289 DEL; MET-1390;
RP   ARG-1434; ARG-1450; CYS-1648 AND ARG-1674 AND ILE-1909, AND VARIANT
RP   THR-1067.
RX   PubMed=12083760; DOI=10.1016/S0006-291X(02)00617-4;
RA   Ohmori I., Ouchida M., Ohtsuka Y., Oka E., Shimizu K.;
RT   "Significant correlation of the SCN1A mutations and severe myoclonic
RT   epilepsy in infancy.";
RL   Biochem. Biophys. Res. Commun. 295:17-23(2002).
RN   [14]
RP   VARIANTS SMEI GLY-103; ILE-112; TRP-265; GLU-343; SER-808; VAL-960;
RP   ARG-979; ALA-983; ILE-985; ILE-1011; ARG-1231; LEU-1263; PHE-1611;
RP   SER-1632; ASP-1685; ILE-1709; 1807-MET--GLU-1810 DEL; LEU-1808;
RP   GLY-1812 AND SER-1831, AND VARIANT THR-1067.
RX   PubMed=12566275; DOI=10.1093/brain/awg053;
RA   Fujiwara T., Sugawara T., Mazaki-Miyazaki E., Takahashi Y.,
RA   Fukushima K., Watanabe M., Hara K., Morikawa T., Yagi K., Yamakawa K.,
RA   Inoue Y.;
RT   "Mutations of sodium channel alpha subunit type 1 (SCN1A) in
RT   intractable childhood epilepsies with frequent generalized tonic-
RT   clonic seizures.";
RL   Brain 126:531-546(2003).
RN   [15]
RP   VARIANTS GEFS+2 CYS-790 AND THR-1852.
RX   PubMed=12919402; DOI=10.1046/j.1528-1157.2003.22503.x;
RA   Annesi G., Gambardella A., Carrideo S., Incorpora G., Labate A.,
RA   Pasqua A.A., Civitelli D., Polizzi A., Annesi F., Spadafora P.,
RA   Tarantino P., Ciro Candiano I.C., Romeo N., De Marco E.V., Ventura P.,
RA   LePiane E., Zappia M., Aguglia U., Pavone L., Quattrone A.;
RT   "Two novel SCN1A missense mutations in generalized epilepsy with
RT   febrile seizures plus.";
RL   Epilepsia 44:1257-1258(2003).
RN   [16]
RP   VARIANTS SMEI HIS-393; GLN-939; ARG-959; ARG-1434; SER-1661 AND
RP   GLU-1749.
RX   PubMed=12754708; DOI=10.1002/humu.10217;
RA   Claes L., Ceulemans B., Audenaert D., Smets K., Loefgren A.,
RA   Del-Favero J., Ala-Mello S., Basel-Vanagaite L., Plecko B., Raskin S.,
RA   Thiry P., Wolf N.I., Van Broeckhoven C., De Jonghe P.;
RT   "De novo SCN1A mutations are a major cause of severe myoclonic
RT   epilepsy of infancy.";
RL   Hum. Mutat. 21:615-621(2003).
RN   [17]
RP   VARIANT GEFS+2 CYS-1657, CHARACTERIZATION OF VARIANTS GEFS+2 LEU-1353;
RP   MET-1656; CYS-1657 AND VAL-1685, AND CHARACTERIZATION OF VARIANT SMEI
RP   PHE-986.
RX   PubMed=14672992;
RA   Lossin C., Rhodes T.H., Desai R.R., Vanoye C.G., Wang D., Carniciu S.,
RA   Devinsky O., George A.L. Jr.;
RT   "Epilepsy-associated dysfunction in the voltage-gated neuronal sodium
RT   channel SCN1A.";
RL   J. Neurosci. 23:11289-11295(2003).
RN   [18]
RP   VARIANTS GLN-542; THR-1034; LEU-1038; THR-1067 AND THR-1955.
RX   PubMed=12610651; DOI=10.1038/sj.mp.4001241;
RA   Weiss L.A., Escayg A., Kearney J.A., Trudeau M., MacDonald B.T.,
RA   Mori M., Reichert J., Buxbaum J.D., Meisler M.H.;
RT   "Sodium channels SCN1A, SCN2A and SCN3A in familial autism.";
RL   Mol. Psychiatry 8:186-194(2003).
RN   [19]
RP   VARIANTS SMEI ASP-78; GLU-177; SER-227; ARG-280; ILE-297; ASN-426;
RP   ARG-1233; ILE-1461; SER-1463; ALA-1668; THR-1780 AND
RP   1812-TRP--LYS-1815 DELINS CYS.
RX   PubMed=12821740;
RA   Nabbout R., Gennaro E., Dalla Bernardina B., Dulac O., Madia F.,
RA   Bertini E., Capovilla G., Chiron C., Cristofori G., Elia M.,
RA   Fontana E., Gaggero R., Granata T., Guerrini R., Loi M., La Selva L.,
RA   Lispi M.L., Matricardi A., Romeo A., Tzolas V., Valseriati D.,
RA   Veggiotti P., Vigevano F., Vallee L., Dagna Bricarelli F., Bianchi A.,
RA   Zara F.;
RT   "Spectrum of SCN1A mutations in severe myoclonic epilepsy of
RT   infancy.";
RL   Neurology 60:1961-1967(2003).
RN   [20]
RP   VARIANTS SMEI PRO-1326 AND ASP-1881, AND VARIANT INFANTILE SPASMS
RP   GLY-1957.
RX   PubMed=14504318;
RA   Wallace R.H., Hodgson B.L., Grinton B.E., Gardiner R.M., Robinson R.,
RA   Rodriguez-Casero V., Sadleir L., Morgan J., Harkin L.A., Dibbens L.M.,
RA   Yamamoto T., Andermann E., Mulley J.C., Berkovic S.F., Scheffer I.E.;
RT   "Sodium channel alpha1-subunit mutations in severe myoclonic epilepsy
RT   of infancy and infantile spasms.";
RL   Neurology 61:765-769(2003).
RN   [21]
RP   VARIANTS SMEI GLN-101; ARG-190; ILE-934; ALA-944; CYS-946; HIS-946;
RP   PRO-1355; MET-1559 DEL; CYS-1684; SER-1692; PHE-1766 DEL AND CYS-1781.
RX   PubMed=14738421; DOI=10.1111/j.0013-9580.2004.15103.x;
RA   Fukuma G., Oguni H., Shirasaka Y., Watanabe K., Miyajima T.,
RA   Yasumoto S., Ohfu M., Inoue T., Watanachai A., Kira R., Matsuo M.,
RA   Muranaka H., Sofue F., Zhang B., Kaneko S., Mitsudome A., Hirose S.;
RT   "Mutations of neuronal voltage-gated Na+ channel alpha 1 subunit gene
RT   SCN1A in core severe myoclonic epilepsy in infancy (SMEI) and in
RT   borderline SMEI (SMEB).";
RL   Epilepsia 45:140-148(2004).
RN   [22]
RP   VARIANT GEFS+2 TYR-1866, AND CHARACTERIZATION OF VARIANT GEFS+2
RP   TYR-1866.
RX   PubMed=15525788; DOI=10.1523/JNEUROSCI.2034-04.2004;
RA   Spampanato J., Kearney J.A., de Haan G., McEwen D.P., Escayg A.,
RA   Aradi I., MacDonald B.T., Levin S.I., Soltesz I., Benna P.,
RA   Montalenti E., Isom L.L., Goldin A.L., Meisler M.H.;
RT   "A novel epilepsy mutation in the sodium channel SCN1A identifies a
RT   cytoplasmic domain for beta subunit interaction.";
RL   J. Neurosci. 24:10022-10034(2004).
RN   [23]
RP   VARIANT SMEI ASN-252.
RX   PubMed=15087100; DOI=10.1016/j.pediatrneurol.2003.10.012;
RA   Ceulemans B.P.G.M., Claes L.R.F., Lagae L.G.;
RT   "Clinical correlations of mutations in the SCN1A gene: from febrile
RT   seizures to severe myoclonic epilepsy in infancy.";
RL   Pediatr. Neurol. 30:236-243(2004).
RN   [24]
RP   VARIANT GEFS+2 LEU-1857.
RX   PubMed=15715999; DOI=10.1016/j.eplepsyres.2004.11.005;
RA   Nagao Y., Mazaki-Miyazaki E., Okamura N., Takagi M., Igarashi T.,
RA   Yamakawa K.;
RT   "A family of generalized epilepsy with febrile seizures plus type 2-a
RT   new missense mutation of SCN1A found in the pedigree of several
RT   patients with complex febrile seizures.";
RL   Epilepsy Res. 63:151-156(2005).
RN   [25]
RP   VARIANT FHM3 LYS-1489.
RX   PubMed=16054936; DOI=10.1016/S0140-6736(05)66786-4;
RA   Dichgans M., Freilinger T., Eckstein G., Babini E.,
RA   Lorenz-Depiereux B., Biskup S., Ferrari M.D., Herzog J.,
RA   van den Maagdenberg A.M.J.M., Pusch M., Strom T.M.;
RT   "Mutation in the neuronal voltage-gated sodium channel SCN1A in
RT   familial hemiplegic migraine.";
RL   Lancet 366:371-377(2005).
RN   [26]
RP   VARIANT SMEI SER-946.
RX   PubMed=15944908; DOI=10.1055/s-2005-865607;
RA   Ebach K., Joos H., Doose H., Stephani U., Kurlemann G., Fiedler B.,
RA   Hahn A., Hauser E., Hundt K., Holthausen H., Mueller U.,
RA   Neubauer B.A.;
RT   "SCN1A mutation analysis in myoclonic astatic epilepsy and severe
RT   idiopathic generalized epilepsy of infancy with generalized tonic-
RT   clonic seizures.";
RL   Neuropediatrics 36:210-213(2005).
RN   [27]
RP   VARIANT FEB3 THR-145, AND CHARACTERIZATION OF VARIANT FEB3 THR-145.
RX   PubMed=16326807; DOI=10.1073/pnas.0506818102;
RA   Mantegazza M., Gambardella A., Rusconi R., Schiavon E., Annesi F.,
RA   Cassulini R.R., Labate A., Carrideo S., Chifari R., Canevini M.P.,
RA   Canger R., Franceschetti S., Annesi G., Wanke E., Quattrone A.;
RT   "Identification of an Nav1.1 sodium channel (SCN1A) loss-of-function
RT   mutation associated with familial simple febrile seizures.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:18177-18182(2005).
RN   [28]
RP   VARIANT GEFS+2 GLY-1742.
RX   PubMed=15694566; DOI=10.1016/j.seizure.2004.12.007;
RA   Pineda-Trujillo N., Carrizosa J., Cornejo W., Arias W., Franco C.,
RA   Cabrera D., Bedoya G., Ruiz-Linares A.;
RT   "A novel SCN1A mutation associated with severe GEFS+ in a large South
RT   American pedigree.";
RL   Seizure 14:123-128(2005).
RN   [29]
RP   VARIANTS CYS-84; MET-226; CYS-393; PRO-395; GLU-422; GLY-626; VAL-973;
RP   VAL-1480; SER-1543; CYS-1596; GLN-1636 AND HIS-1657, AND VARIANTS SMEI
RP   THR-239 AND ASP-1238.
RX   PubMed=17347258; DOI=10.1093/brain/awm002;
RG   The infantile epileptic encephalopathy referral consortium;
RA   Harkin L.A., McMahon J.M., Iona X., Dibbens L., Pelekanos J.T.,
RA   Zuberi S.M., Sadleir L.G., Andermann E., Gill D., Farrell K.,
RA   Connolly M., Stanley T., Harbord M., Andermann F., Wang J.,
RA   Batish S.D., Jones J.G., Seltzer W.K., Gardner A., Sutherland G.,
RA   Berkovic S.F., Mulley J.C., Scheffer I.E.;
RT   "The spectrum of SCN1A-related infantile epileptic encephalopathies.";
RL   Brain 130:843-852(2007).
RN   [30]
RP   VARIANT GEFS+2/ICEGTC ILE-1366.
RX   PubMed=17507202; DOI=10.1016/j.eplepsyres.2007.03.018;
RA   Osaka H., Ogiwara I., Mazaki E., Okamura N., Yamashita S., Iai M.,
RA   Yamada M., Kurosawa K., Iwamoto H., Yasui-Furukori N., Kaneko S.,
RA   Fujiwara T., Inoue Y., Yamakawa K.;
RT   "Patients with a sodium channel alpha 1 gene mutation show wide
RT   phenotypic variation.";
RL   Epilepsy Res. 75:46-51(2007).
RN   [31]
RP   VARIANTS SMEI SER-118; GLU-366; PRO-1207; MET-1335; SER-1358; CYS-1462
RP   AND GLY-1928, AND VARIANT GEFS+2 GLN-377.
RX   PubMed=18413471; DOI=10.1001/archneur.65.4.489;
RA   Zucca C., Redaelli F., Epifanio R., Zanotta N., Romeo A., Lodi M.,
RA   Veggiotti P., Airoldi G., Panzeri C., Romaniello R., De Polo G.,
RA   Bonanni P., Cardinali S., Baschirotto C., Martorell L., Borgatti R.,
RA   Bresolin N., Bassi M.T.;
RT   "Cryptogenic epileptic syndromes related to SCN1A: twelve novel
RT   mutations identified.";
RL   Arch. Neurol. 65:489-494(2008).
RN   [32]
RP   VARIANTS FHM3 HIS-1489 AND LEU-1499.
RX   PubMed=19332696; DOI=10.1212/01.wnl.0000345393.53132.8c;
RA   Vahedi K., Depienne C., Le Fort D., Riant F., Chaine P.,
RA   Trouillard O., Gaudric A., Morris M.A., LeGuern E.,
RA   Tournier-Lasserve E., Bousser M.-G.;
RT   "Elicited repetitive daily blindness: a new phenotype associated with
RT   hemiplegic migraine and SCN1A mutations.";
RL   Neurology 72:1178-1183(2009).
CC   -!- FUNCTION: Mediates the voltage-dependent sodium ion permeability
CC       of excitable membranes. Assuming opened or closed conformations in
CC       response to the voltage difference across the membrane, the
CC       protein forms a sodium-selective channel through which Na(+) ions
CC       may pass in accordance with their electrochemical gradient.
CC   -!- SUBUNIT: The sodium channel consists of a large polypeptide and 2-
CC       3 smaller ones. This sequence represents a large polypeptide.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P35498-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P35498-2; Sequence=VSP_001031;
CC   -!- DOMAIN: The sequence contains 4 internal repeats, each with 5
CC       hydrophobic segments (S1,S2,S3,S5,S6) and one positively charged
CC       segment (S4). Segments S4 are probably the voltage-sensors and are
CC       characterized by a series of positively charged amino acids at
CC       every third position.
CC   -!- DISEASE: Defects in SCN1A are the cause of generalized epilepsy
CC       with febrile seizures plus type 2 (GEFS+2) [MIM:604233].
CC       Generalized epilepsy with febrile seizures-plus refers to a rare
CC       autosomal dominant, familial condition with incomplete penetrance
CC       and large intrafamilial variability. Patients display febrile
CC       seizures persisting sometimes beyond the age of 6 years and/or a
CC       variety of afebrile seizure types. GEFS+ is a disease combining
CC       febrile seizures, generalized seizures often precipitated by fever
CC       at age 6 years or more, and partial seizures, with a variable
CC       degree of severity.
CC   -!- DISEASE: Defects in SCN1A are a cause of severe myoclonic epilepsy
CC       in infancy (SMEI) [MIM:607208]; also called Dravet syndrome. SMEI
CC       is a rare disorder characterized by generalized tonic, clonic, and
CC       tonic-clonic seizures that are initially induced by fever and
CC       begin during the first year of life. Later, patients also manifest
CC       other seizure types, including absence, myoclonic, and simple and
CC       complex partial seizures. Psychomotor development delay is
CC       observed around the second year of life. SMEI is considered to be
CC       the most severe phenotype within the spectrum of generalized
CC       epilepsies with febrile seizures-plus.
CC   -!- DISEASE: Defects in SCN1A are a cause of intractable childhood
CC       epilepsy with generalized tonic-clonic seizures (ICEGTC)
CC       [MIM:607208]. ICEGTC is a disorder characterized by generalized
CC       tonic-clonic seizures beginning usually in infancy and induced by
CC       fever. Seizures are associated with subsequent mental decline, as
CC       well as ataxia or hypotonia. ICEGTC is similar to SMEI, except for
CC       the absence of myoclonic seizures.
CC   -!- DISEASE: Defects in SCN1A are the cause of familial hemiplegic
CC       migraine type 3 (FHM3) [MIM:609634]. FHM3 is an autosomal dominant
CC       severe subtype of migraine with aura characterized by some degree
CC       of hemiparesis during the attacks. The episodes are associated
CC       with variable features of nausea, vomiting, photophobia, and
CC       phonophobia. Age at onset ranges from 6 to 15 years. FHM is
CC       occasionally associated with other neurologic symptoms such as
CC       cerebellar ataxia or epileptic seizures. A unique eye phenotype of
CC       elicited repetitive daily blindness has also been reported to be
CC       cosegregating with FHM in a single Swiss family.
CC   -!- DISEASE: Defects in SCN1A are the cause of familial febrile
CC       convulsions type 3 (FEB3) [MIM:604403]; also known as familial
CC       febrile seizures 3. Febrile convulsions are seizures associated
CC       with febrile episodes in childhood without any evidence of
CC       intracranial infection or defined pathologic or traumatic cause.
CC       It is a common condition, affecting 2-5% of children aged 3 months
CC       to 5 years. The majority are simple febrile seizures (generally
CC       defined as generalized onset, single seizures with a duration of
CC       less than 30 minutes). Complex febrile seizures are characterized
CC       by focal onset, duration greater than 30 minutes, and/or more than
CC       one seizure in a 24 hour period. The likelihood of developing
CC       epilepsy following simple febrile seizures is low. Complex febrile
CC       seizures are associated with a moderately increased incidence of
CC       epilepsy.
CC   -!- SIMILARITY: Belongs to the sodium channel family.
CC   -!- SIMILARITY: Contains 1 IQ domain.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/SCN1A";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF225985; AAK00217.1; -; mRNA.
DR   EMBL; AY043484; AAK95360.1; -; mRNA.
DR   EMBL; AB093548; BAC21101.1; -; mRNA.
DR   EMBL; AB093549; BAC21102.1; -; mRNA.
DR   EMBL; AC010127; AAX81984.1; -; Genomic_DNA.
DR   EMBL; S71446; AAB31605.1; -; Genomic_DNA.
DR   EMBL; X65362; CAA46439.1; -; mRNA.
DR   EMBL; M91803; -; NOT_ANNOTATED_CDS; mRNA.
DR   IPI; IPI00018934; -.
DR   IPI; IPI00748990; -.
DR   PIR; I52964; I52964.
DR   PIR; S29184; S29184.
DR   RefSeq; NP_001159435.1; -.
DR   RefSeq; NP_008851.3; -.
DR   UniGene; Hs.22654; -.
DR   SMR; P35498; 1212-1343.
DR   STRING; P35498; -.
DR   TCDB; 1.A.1.10.7; voltage-gated ion channel (VIC) superfamily.
DR   PhosphoSite; P35498; -.
DR   PRIDE; P35498; -.
DR   Ensembl; ENST00000303395; ENSP00000303540; ENSG00000144285; Homo sapiens.
DR   GeneID; 6323; -.
DR   KEGG; hsa:6323; -.
DR   CTD; 6323; -.
DR   GeneCards; GC02M166553; -.
DR   H-InvDB; HIX0002563; -.
DR   HGNC; HGNC:10585; SCN1A.
DR   MIM; 182389; gene.
DR   MIM; 604233; phenotype.
DR   MIM; 604403; phenotype.
DR   MIM; 607208; phenotype.
DR   MIM; 609634; phenotype.
DR   Orphanet; 33069; Dravet syndrome.
DR   Orphanet; 36387; Generalized epilepsy with febrile seizures-plus context.
DR   Orphanet; 569; Hemiplegic migraine, familial or sporadic.
DR   PharmGKB; PA301; -.
DR   eggNOG; prNOG05196; -.
DR   HOGENOM; HBG358468; -.
DR   HOVERGEN; HBG053100; -.
DR   InParanoid; P35498; -.
DR   OMA; RFKCCQI; -.
DR   DrugBank; DB00555; Lamotrigine.
DR   DrugBank; DB01202; Levetiracetam.
DR   DrugBank; DB01121; Phenacemide.
DR   DrugBank; DB00252; Phenytoin.
DR   DrugBank; DB00273; Topiramate.
DR   DrugBank; DB00909; Zonisamide.
DR   NextBio; 24538; -.
DR   ArrayExpress; P35498; -.
DR   Bgee; P35498; -.
DR   CleanEx; HS_SCN1A; -.
DR   Genevestigator; P35498; -.
DR   GermOnline; ENSG00000144285; Homo sapiens.
DR   GO; GO:0001518; C:voltage-gated sodium channel complex; IEA:InterPro.
DR   GO; GO:0031402; F:sodium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005248; F:voltage-gated sodium channel activity; NAS:UniProtKB.
DR   GO; GO:0006814; P:sodium ion transport; NAS:UniProtKB.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR005821; Ion_trans.
DR   InterPro; IPR000048; IQ_CaM_bd_region.
DR   InterPro; IPR001696; Na_channel.
DR   InterPro; IPR008051; Na_channel1.
DR   InterPro; IPR010526; Na_trans_assoc.
DR   PANTHER; PTHR10037:SF29; Na_channel1; 1.
DR   Pfam; PF00520; Ion_trans; 4.
DR   Pfam; PF06512; Na_trans_assoc; 1.
DR   PRINTS; PR00170; NACHANNEL.
DR   PRINTS; PR01664; NACHANNEL1.
DR   SMART; SM00015; IQ; 1.
DR   PROSITE; PS50096; IQ; FALSE_NEG.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Disease mutation; Epilepsy;
KW   Glycoprotein; Ion transport; Ionic channel; Membrane; Polymorphism;
KW   Repeat; Sodium; Sodium channel; Sodium transport; Transmembrane;
KW   Transport; Voltage-gated channel.
FT   CHAIN         1   2009       Sodium channel protein type 1 subunit
FT                                alpha.
FT                                /FTId=PRO_0000048489.
FT   TRANSMEM    124    147       S1 of repeat I (By similarity).
FT   TRANSMEM    156    175       S2 of repeat I (By similarity).
FT   TRANSMEM    189    207       S3 of repeat I (By similarity).
FT   TRANSMEM    214    233       S4 of repeat I (By similarity).
FT   TRANSMEM    250    273       S5 of repeat I (By similarity).
FT   TRANSMEM    400    425       S6 of repeat I (By similarity).
FT   TRANSMEM    763    787       S1 of repeat II (By similarity).
FT   TRANSMEM    799    822       S2 of repeat II (By similarity).
FT   TRANSMEM    831    850       S3 of repeat II (By similarity).
FT   TRANSMEM    857    876       S4 of repeat II (By similarity).
FT   TRANSMEM    893    913       S5 of repeat II (By similarity).
FT   TRANSMEM    967    992       S6 of repeat II (By similarity).
FT   TRANSMEM   1214   1237       S1 of repeat III (By similarity).
FT   TRANSMEM   1251   1276       S2 of repeat III (By similarity).
FT   TRANSMEM   1283   1304       S3 of repeat III (By similarity).
FT   TRANSMEM   1309   1330       S4 of repeat III (By similarity).
FT   TRANSMEM   1350   1377       S5 of repeat III (By similarity).
FT   TRANSMEM   1457   1483       S6 of repeat III (By similarity).
FT   TRANSMEM   1537   1560       S1 of repeat IV (By similarity).
FT   TRANSMEM   1572   1595       S2 of repeat IV (By similarity).
FT   TRANSMEM   1602   1625       S3 of repeat IV (By similarity).
FT   TRANSMEM   1636   1657       S4 of repeat IV (By similarity).
FT   TRANSMEM   1673   1695       S5 of repeat IV (By similarity).
FT   TRANSMEM   1762   1786       S6 of repeat IV (By similarity).
FT   REPEAT      110    454       I.
FT   REPEAT      750   1022       II.
FT   REPEAT     1200   1514       III.
FT   REPEAT     1523   1821       IV.
FT   CARBOHYD    211    211       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    284    284       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    295    295       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    301    301       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    306    306       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    338    338       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    601    601       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    621    621       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    681    681       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    892    892       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1064   1064       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1080   1080       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1146   1146       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1378   1378       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1392   1392       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1403   1403       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1788   1788       N-linked (GlcNAc...) (Potential).
FT   VAR_SEQ     671    681       Missing (in isoform 2).
FT                                /FTId=VSP_001031.
FT   VARIANT      78     78       E -> D (in SMEI).
FT                                /FTId=VAR_029660.
FT   VARIANT      84     84       Y -> C.
FT                                /FTId=VAR_043349.
FT   VARIANT     101    101       R -> Q (in SMEI).
FT                                /FTId=VAR_029661.
FT   VARIANT     103    103       S -> G (in SMEI).
FT                                /FTId=VAR_029662.
FT   VARIANT     112    112       T -> I (in SMEI).
FT                                /FTId=VAR_029663.
FT   VARIANT     118    118       R -> S (in SMEI).
FT                                /FTId=VAR_043350.
FT   VARIANT     145    145       M -> T (in FEB3; loss of function).
FT                                /FTId=VAR_025366.
FT   VARIANT     177    177       G -> E (in SMEI).
FT                                /FTId=VAR_029664.
FT   VARIANT     188    188       D -> V (in GEFS+2).
FT                                /FTId=VAR_014267.
FT   VARIANT     190    190       W -> R (in SMEI).
FT                                /FTId=VAR_029665.
FT   VARIANT     226    226       T -> M (in a patient with cryptogenic
FT                                generalized epilepsy).
FT                                /FTId=VAR_043351.
FT   VARIANT     227    227       I -> S (in SMEI).
FT                                /FTId=VAR_029666.
FT   VARIANT     239    239       A -> T (in SMEI).
FT                                /FTId=VAR_043352.
FT   VARIANT     252    252       I -> N (in SMEI).
FT                                /FTId=VAR_029667.
FT   VARIANT     265    265       G -> W (in SMEI).
FT                                /FTId=VAR_029668.
FT   VARIANT     280    280       W -> R (in SMEI).
FT                                /FTId=VAR_029669.
FT   VARIANT     297    297       T -> I (in SMEI).
FT                                /FTId=VAR_029670.
FT   VARIANT     343    343       G -> E (in SMEI).
FT                                /FTId=VAR_029671.
FT   VARIANT     366    366       D -> E (in SMEI).
FT                                /FTId=VAR_043353.
FT   VARIANT     377    377       R -> Q (in GEFS+2).
FT                                /FTId=VAR_043354.
FT   VARIANT     393    393       R -> C (in a patient with myoclonic
FT                                astatic epilepsy).
FT                                /FTId=VAR_043355.
FT   VARIANT     393    393       R -> H (in SMEI).
FT                                /FTId=VAR_029672.
FT   VARIANT     395    395       A -> P (in a patient with cryptogenic
FT                                generalized epilepsy).
FT                                /FTId=VAR_043356.
FT   VARIANT     422    422       V -> E (in a patient with cryptogenic
FT                                generalized epilepsy).
FT                                /FTId=VAR_043357.
FT   VARIANT     426    426       Y -> N (in SMEI).
FT                                /FTId=VAR_029673.
FT   VARIANT     542    542       R -> Q (associated with autism).
FT                                /FTId=VAR_029674.
FT   VARIANT     626    626       S -> G (in a patient with cryptogenic
FT                                generalized epilepsy).
FT                                /FTId=VAR_043358.
FT   VARIANT     790    790       Y -> C (in GEFS+2).
FT                                /FTId=VAR_029675.
FT   VARIANT     808    808       T -> S (in SMEI).
FT                                /FTId=VAR_029676.
FT   VARIANT     875    875       T -> M (in GEFS+2).
FT                                /FTId=VAR_010110.
FT   VARIANT     902    902       F -> C (in SMEI).
FT                                /FTId=VAR_029677.
FT   VARIANT     931    931       R -> C (in SMEI).
FT                                /FTId=VAR_029678.
FT   VARIANT     934    934       M -> I (in SMEI).
FT                                /FTId=VAR_029679.
FT   VARIANT     939    939       H -> Q (in SMEI).
FT                                /FTId=VAR_029680.
FT   VARIANT     944    944       V -> A (in SMEI).
FT                                /FTId=VAR_029681.
FT   VARIANT     946    946       R -> C (in SMEI).
FT                                /FTId=VAR_029682.
FT   VARIANT     946    946       R -> H (in SMEI).
FT                                /FTId=VAR_029683.
FT   VARIANT     946    946       R -> S (in SMEI; or severe idiopathic
FT                                generalized epilepsy of infancy).
FT                                /FTId=VAR_057995.
FT   VARIANT     959    959       C -> R (in SMEI).
FT                                /FTId=VAR_029684.
FT   VARIANT     960    960       M -> V (in SMEI).
FT                                /FTId=VAR_029685.
FT   VARIANT     973    973       M -> V (in a patient with cryptogenic
FT                                generalized epilepsy).
FT                                /FTId=VAR_043359.
FT   VARIANT     979    979       G -> R (in SMEI).
FT                                /FTId=VAR_029686.
FT   VARIANT     983    983       V -> A (in SMEI).
FT                                /FTId=VAR_029687.
FT   VARIANT     985    985       N -> I (in SMEI).
FT                                /FTId=VAR_029688.
FT   VARIANT     986    986       L -> F (in SMEI; complete loss of
FT                                function).
FT                                /FTId=VAR_014268.
FT   VARIANT    1011   1011       N -> I (in SMEI).
FT                                /FTId=VAR_029689.
FT   VARIANT    1034   1034       I -> T (associated with autism).
FT                                /FTId=VAR_029690.
FT   VARIANT    1038   1038       F -> L (associated with autism).
FT                                /FTId=VAR_029691.
FT   VARIANT    1067   1067       A -> T (in dbSNP:rs2298771).
FT                                /FTId=VAR_014269.
FT   VARIANT    1204   1204       W -> R (in GEFS+2).
FT                                /FTId=VAR_014270.
FT   VARIANT    1207   1207       L -> P (in SMEI).
FT                                /FTId=VAR_043360.
FT   VARIANT    1231   1231       S -> R (in SMEI).
FT                                /FTId=VAR_029692.
FT   VARIANT    1233   1233       G -> R (in SMEI).
FT                                /FTId=VAR_029693.
FT   VARIANT    1238   1238       E -> D (in SMEI).
FT                                /FTId=VAR_043361.
FT   VARIANT    1263   1263       F -> L (in SMEI).
FT                                /FTId=VAR_029694.
FT   VARIANT    1265   1265       L -> P (in SMEI).
FT                                /FTId=VAR_029695.
FT   VARIANT    1270   1270       K -> T (in GEFS+2).
FT                                /FTId=VAR_014271.
FT   VARIANT    1289   1289       Missing (in SMEI).
FT                                /FTId=VAR_029696.
FT   VARIANT    1326   1326       A -> P (in SMEI).
FT                                /FTId=VAR_029698.
FT   VARIANT    1335   1335       V -> M (in SMEI).
FT                                /FTId=VAR_043362.
FT   VARIANT    1353   1353       V -> L (in GEFS+2; complete loss of
FT                                function).
FT                                /FTId=VAR_014272.
FT   VARIANT    1355   1355       L -> P (in SMEI).
FT                                /FTId=VAR_029697.
FT   VARIANT    1358   1358       W -> S (in SMEI).
FT                                /FTId=VAR_043363.
FT   VARIANT    1366   1366       V -> I (in GEFS+2 and ICEGTC).
FT                                /FTId=VAR_043364.
FT   VARIANT    1390   1390       V -> M (in SMEI).
FT                                /FTId=VAR_029699.
FT   VARIANT    1428   1428       V -> A (in GEFS+2).
FT                                /FTId=VAR_029700.
FT   VARIANT    1434   1434       W -> R (in SMEI).
FT                                /FTId=VAR_029701.
FT   VARIANT    1450   1450       Q -> R (in SMEI).
FT                                /FTId=VAR_029702.
FT   VARIANT    1461   1461       L -> I (in SMEI).
FT                                /FTId=VAR_029703.
FT   VARIANT    1462   1462       Y -> C (in SMEI).
FT                                /FTId=VAR_043365.
FT   VARIANT    1463   1463       F -> S (in SMEI).
FT                                /FTId=VAR_029704.
FT   VARIANT    1480   1480       G -> V (in a patient with myoclonic
FT                                astatic epilepsy).
FT                                /FTId=VAR_043366.
FT   VARIANT    1489   1489       Q -> H (in FHM3).
FT                                /FTId=VAR_057996.
FT   VARIANT    1489   1489       Q -> K (in FHM3).
FT                                /FTId=VAR_025281.
FT   VARIANT    1499   1499       F -> L (in FHM3).
FT                                /FTId=VAR_057997.
FT   VARIANT    1543   1543       F -> S (in a patient with cryptogenic
FT                                focal epilepsy).
FT                                /FTId=VAR_043367.
FT   VARIANT    1559   1559       Missing (in SMEI).
FT                                /FTId=VAR_029705.
FT   VARIANT    1596   1596       R -> C (in a patient with cryptogenic
FT                                focal epilepsy).
FT                                /FTId=VAR_043368.
FT   VARIANT    1611   1611       V -> F (in SMEI).
FT                                /FTId=VAR_029706.
FT   VARIANT    1632   1632       P -> S (in SMEI).
FT                                /FTId=VAR_029707.
FT   VARIANT    1636   1636       R -> Q (in a patient with Lennon-Gastaut
FT                                syndrome).
FT                                /FTId=VAR_043369.
FT   VARIANT    1648   1648       R -> C (in SMEI).
FT                                /FTId=VAR_029708.
FT   VARIANT    1648   1648       R -> H (in GEFS+2).
FT                                /FTId=VAR_010111.
FT   VARIANT    1656   1656       I -> M (in GEFS+2; exhibits a
FT                                depolarizing shift in the voltage
FT                                dependence of activation).
FT                                /FTId=VAR_014273.
FT   VARIANT    1657   1657       R -> C (in GEFS+2; exhibits a
FT                                depolarizing shift in the voltage
FT                                dependence of activation; shows a 50%
FT                                reduction in current density and
FT                                accelerates recovery from slow
FT                                inactivation).
FT                                /FTId=VAR_029709.
FT   VARIANT    1657   1657       R -> H (in a patient with cryptogenic
FT                                focal epilepsy).
FT                                /FTId=VAR_043370.
FT   VARIANT    1661   1661       F -> S (in SMEI).
FT                                /FTId=VAR_029710.
FT   VARIANT    1668   1668       P -> A (in SMEI).
FT                                /FTId=VAR_029711.
FT   VARIANT    1674   1674       G -> R (in SMEI).
FT                                /FTId=VAR_029712.
FT   VARIANT    1684   1684       Y -> C (in SMEI).
FT                                /FTId=VAR_029713.
FT   VARIANT    1685   1685       A -> D (in SMEI).
FT                                /FTId=VAR_029714.
FT   VARIANT    1685   1685       A -> V (in GEFS+2; complete loss of
FT                                function).
FT                                /FTId=VAR_029715.
FT   VARIANT    1692   1692       F -> S (in SMEI).
FT                                /FTId=VAR_029716.
FT   VARIANT    1709   1709       T -> I (in SMEI).
FT                                /FTId=VAR_029717.
FT   VARIANT    1742   1742       D -> G (in GEFS+2).
FT                                /FTId=VAR_057998.
FT   VARIANT    1749   1749       G -> E (in SMEI).
FT                                /FTId=VAR_029718.
FT   VARIANT    1766   1766       Missing (in SMEI).
FT                                /FTId=VAR_029719.
FT   VARIANT    1780   1780       M -> T (in SMEI).
FT                                /FTId=VAR_029720.
FT   VARIANT    1781   1781       Y -> C (in SMEI).
FT                                /FTId=VAR_029721.
FT   VARIANT    1807   1810       Missing (in SMEI).
FT                                /FTId=VAR_029722.
FT   VARIANT    1808   1808       F -> L (in SMEI).
FT                                /FTId=VAR_029723.
FT   VARIANT    1812   1815       WEKF -> C (in SMEI).
FT                                /FTId=VAR_029725.
FT   VARIANT    1812   1812       W -> G (in SMEI).
FT                                /FTId=VAR_029724.
FT   VARIANT    1831   1831       F -> S (in SMEI).
FT                                /FTId=VAR_029726.
FT   VARIANT    1852   1852       M -> T (in GEFS+2).
FT                                /FTId=VAR_029727.
FT   VARIANT    1857   1857       V -> L (in GEFS+2).
FT                                /FTId=VAR_057999.
FT   VARIANT    1866   1866       D -> Y (in GEFS+2; causes a positive
FT                                shift in the voltage dependence of sodium
FT                                channel fast inactivation; causes an
FT                                increase in the magnitude of the
FT                                persistent current and a delay in the
FT                                kinetics of inactivation).
FT                                /FTId=VAR_058000.
FT   VARIANT    1881   1881       E -> D (in SMEI).
FT                                /FTId=VAR_029728.
FT   VARIANT    1909   1909       T -> I (in SMEI).
FT                                /FTId=VAR_029729.
FT   VARIANT    1928   1928       R -> G (in SMEI).
FT                                /FTId=VAR_043371.
FT   VARIANT    1955   1955       I -> T (associated with autism).
FT                                /FTId=VAR_029730.
FT   VARIANT    1957   1957       E -> G (in infantile spasms).
FT                                /FTId=VAR_029731.
FT   CONFLICT    670    670       E -> G (in Ref. 2).
FT   CONFLICT    746    746       L -> S (in Ref. 2; AAK00217).
FT   CONFLICT    930    930       P -> PQ (in Ref. 2; AAK00217).
FT   CONFLICT   1158   1161       DIGA -> GHRR (in Ref. 2; AAK00217).
FT   CONFLICT   1537   1537       F -> L (in Ref. 7).
SQ   SEQUENCE   2009 AA;  228972 MW;  0593A6730F33C9A2 CRC64;
     MEQTVLVPPG PDSFNFFTRE SLAAIERRIA EEKAKNPKPD KKDDDENGPK PNSDLEAGKN
     LPFIYGDIPP EMVSEPLEDL DPYYINKKTF IVLNKGKAIF RFSATSALYI LTPFNPLRKI
     AIKILVHSLF SMLIMCTILT NCVFMTMSNP PDWTKNVEYT FTGIYTFESL IKIIARGFCL
     EDFTFLRDPW NWLDFTVITF AYVTEFVDLG NVSALRTFRV LRALKTISVI PGLKTIVGAL
     IQSVKKLSDV MILTVFCLSV FALIGLQLFM GNLRNKCIQW PPTNASLEEH SIEKNITVNY
     NGTLINETVF EFDWKSYIQD SRYHYFLEGF LDALLCGNSS DAGQCPEGYM CVKAGRNPNY
     GYTSFDTFSW AFLSLFRLMT QDFWENLYQL TLRAAGKTYM IFFVLVIFLG SFYLINLILA
     VVAMAYEEQN QATLEEAEQK EAEFQQMIEQ LKKQQEAAQQ AATATASEHS REPSAAGRLS
     DSSSEASKLS SKSAKERRNR RKKRKQKEQS GGEEKDEDEF QKSESEDSIR RKGFRFSIEG
     NRLTYEKRYS SPHQSLLSIR GSLFSPRRNS RTSLFSFRGR AKDVGSENDF ADDEHSTFED
     NESRRDSLFV PRRHGERRNS NLSQTSRSSR MLAVFPANGK MHSTVDCNGV VSLVGGPSVP
     TSPVGQLLPE VIIDKPATDD NGTTTETEMR KRRSSSFHVS MDFLEDPSQR QRAMSIASIL
     TNTVEELEES RQKCPPCWYK FSNIFLIWDC SPYWLKVKHV VNLVVMDPFV DLAITICIVL
     NTLFMAMEHY PMTDHFNNVL TVGNLVFTGI FTAEMFLKII AMDPYYYFQE GWNIFDGFIV
     TLSLVELGLA NVEGLSVLRS FRLLRVFKLA KSWPTLNMLI KIIGNSVGAL GNLTLVLAII
     VFIFAVVGMQ LFGKSYKDCV CKIASDCQLP RWHMNDFFHS FLIVFRVLCG EWIETMWDCM
     EVAGQAMCLT VFMMVMVIGN LVVLNLFLAL LLSSFSADNL AATDDDNEMN NLQIAVDRMH
     KGVAYVKRKI YEFIQQSFIR KQKILDEIKP LDDLNNKKDS CMSNHTAEIG KDLDYLKDVN
     GTTSGIGTGS SVEKYIIDES DYMSFINNPS LTVTVPIAVG ESDFENLNTE DFSSESDLEE
     SKEKLNESSS SSEGSTVDIG APVEEQPVVE PEETLEPEAC FTEGCVQRFK CCQINVEEGR
     GKQWWNLRRT CFRIVEHNWF ETFIVFMILL SSGALAFEDI YIDQRKTIKT MLEYADKVFT
     YIFILEMLLK WVAYGYQTYF TNAWCWLDFL IVDVSLVSLT ANALGYSELG AIKSLRTLRA
     LRPLRALSRF EGMRVVVNAL LGAIPSIMNV LLVCLIFWLI FSIMGVNLFA GKFYHCINTT
     TGDRFDIEDV NNHTDCLKLI ERNETARWKN VKVNFDNVGF GYLSLLQVAT FKGWMDIMYA
     AVDSRNVELQ PKYEESLYMY LYFVIFIIFG SFFTLNLFIG VIIDNFNQQK KKFGGQDIFM
     TEEQKKYYNA MKKLGSKKPQ KPIPRPGNKF QGMVFDFVTR QVFDISIMIL ICLNMVTMMV
     ETDDQSEYVT TILSRINLVF IVLFTGECVL KLISLRHYYF TIGWNIFDFV VVILSIVGMF
     LAELIEKYFV SPTLFRVIRL ARIGRILRLI KGAKGIRTLL FALMMSLPAL FNIGLLLFLV
     MFIYAIFGMS NFAYVKREVG IDDMFNFETF GNSMICLFQI TTSAGWDGLL APILNSKPPD
     CDPNKVNPGS SVKGDCGNPS VGIFFFVSYI IISFLVVVNM YIAVILENFS VATEESAEPL
     SEDDFEMFYE VWEKFDPDAT QFMEFEKLSQ FAAALEPPLN LPQPNKLQLI AMDLPMVSGD
     RIHCLDILFA FTKRVLGESG EMDALRIQME ERFMASNPSK VSYQPITTTL KRKQEEVSAV
     IIQRAYRRHL LKRTVKQASF TYNKNKIKGG ANLLIKEDMI IDRINENSIT EKTDLTMSTA
     ACPPSYDRVT KPIVEKHEQE GKDEKAKGK
//
ID   SCNBA_HUMAN             Reviewed;        1791 AA.
AC   Q9UI33; A6NN05; Q68K15; Q8NDX3; Q9UHE0; Q9UHM0;
DT   21-DEC-2004, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   02-MAR-2010, entry version 70.
DE   RecName: Full=Sodium channel protein type 11 subunit alpha;
DE   AltName: Full=Sodium channel protein type XI subunit alpha;
DE   AltName: Full=Voltage-gated sodium channel subunit alpha Nav1.9;
DE   AltName: Full=Sensory neuron sodium channel 2;
DE   AltName: Full=Peripheral nerve sodium channel 5;
DE            Short=PN5;
DE   AltName: Full=hNaN;
GN   Name=SCN11A; Synonyms=SCN12A, SNS2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION IN VOLTAGE-EVOKED
RP   DEPOLARIZATION.
RC   TISSUE=Spinal ganglion;
RX   MEDLINE=20047838; PubMed=10580103; DOI=10.1016/S0014-5793(99)01519-7;
RA   Dib-Hajj S.D., Tyrrell L., Cummins T.R., Black J.A., Wood P.M.,
RA   Waxman S.G.;
RT   "Two tetrodotoxin-resistant sodium channels in human dorsal root
RT   ganglion neurons.";
RL   FEBS Lett. 462:117-120(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   MEDLINE=20090626; PubMed=10623608; DOI=10.1006/bbrc.1999.1916;
RA   Jeong S.-Y., Goto J., Hashida H., Suzuki T., Ogata K., Masuda M.,
RA   Hirai M., Isahara K., Uchiyama Y., Kanazawa I.;
RT   "Identification of a novel human voltage-gated sodium channel alpha
RT   subunit gene, SCN12A.";
RL   Biochem. Biophys. Res. Commun. 267:262-270(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION IN
RP   NEUROTROPHIN-EVOKED DEPOLARIZATION.
RC   TISSUE=Neuroblastoma;
RX   MEDLINE=22272672; PubMed=12384689; DOI=10.1038/nature01085;
RA   Blum R., Kafitz K.W., Konnerth A.;
RT   "Neurotrophin-evoked depolarization requires the sodium channel
RT   Nav1.9.";
RL   Nature 419:687-693(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 924-1114 (ISOFORM 3), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Spinal ganglion;
RX   PubMed=15302875; DOI=10.1074/jbc.M406387200;
RA   Raymond C.K., Castle J.C., Garrett-Engele P.W., Armour C.D., Kan Z.G.,
RA   Tsinoremas N.T., Johnson J.M.;
RT   "Expression of alternatively spliced sodium channel alpha-subunit
RT   genes: unique splicing patterns are observed in dorsal root ganglia.";
RL   J. Biol. Chem. 279:46234-46241(2004).
RN   [6]
RP   REVIEW.
RX   MEDLINE=22424164; PubMed=12536125; DOI=10.1016/S0166-2236(02)00030-9;
RA   Delmas P., Coste B.;
RT   "Na+ channel Nav1.9: in search of a gating mechanism.";
RL   Trends Neurosci. 26:55-57(2003).
CC   -!- FUNCTION: This protein mediates the voltage-dependent sodium ion
CC       permeability of excitable membranes. Assuming opened or closed
CC       conformations in response to the voltage difference across the
CC       membrane, the protein forms a sodium-selective channel through
CC       which sodium ions may pass in accordance with their
CC       electrochemical gradient. It is a tetrodotoxin-resistant sodium
CC       channel isoform. Also involved, with the contribution of the
CC       receptor tyrosine kinase NTRK2, in rapid BDNF-evoked neuronal
CC       depolarization.
CC   -!- SUBUNIT: The voltage-resistant sodium channel consists of an ion
CC       conducting pore forming alpha-subunit regulated by one or more
CC       auxiliary subunits SCN1B, SCN2B and SCN3B.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein (By
CC       similarity).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9UI33-1; Sequence=Displayed;
CC       Name=2; Synonyms=Scn12a-s;
CC         IsoId=Q9UI33-2; Sequence=VSP_012260, VSP_012261;
CC       Name=3;
CC         IsoId=Q9UI33-3; Sequence=VSP_012259;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Expressed in the dorsal root ganglia and
CC       trigeminal ganglia, olfactory bulb, hippocampus, cerebellar
CC       cortex, spinal cord, spleen, small intestine and placenta.
CC   -!- DOMAIN: The sequence contains 4 internal repeats, each with 5
CC       hydrophobic segments (S1,S2,S3,S5,S6) and one positively charged
CC       segment (S4). Segments S4 are probably the voltage-sensors and are
CC       characterized by a series of positively charged amino acids at
CC       every third position.
CC   -!- SIMILARITY: Belongs to the sodium channel family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF188679; AAF17480.1; -; mRNA.
DR   EMBL; AF109737; AAF24976.1; -; mRNA.
DR   EMBL; AF150882; AAF24980.1; -; mRNA.
DR   EMBL; AJ417790; CAD10507.1; -; mRNA.
DR   EMBL; AC116038; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AY686224; AAT95434.1; -; mRNA.
DR   IPI; IPI00296063; -.
DR   IPI; IPI00513973; -.
DR   IPI; IPI00514134; -.
DR   RefSeq; NP_054858.2; -.
DR   UniGene; Hs.591657; -.
DR   SMR; Q9UI33; 1050-1313, 1360-1433.
DR   STRING; Q9UI33; -.
DR   PhosphoSite; Q9UI33; -.
DR   PRIDE; Q9UI33; -.
DR   Ensembl; ENST00000302328; ENSP00000307599; ENSG00000168356; Homo sapiens.
DR   Ensembl; ENST00000450244; ENSP00000400945; ENSG00000168356; Homo sapiens.
DR   GeneID; 11280; -.
DR   KEGG; hsa:11280; -.
DR   UCSC; uc010hhm.1; human.
DR   CTD; 11280; -.
DR   GeneCards; GC03M038862; -.
DR   H-InvDB; HIX0030716; -.
DR   HGNC; HGNC:10583; SCN11A.
DR   MIM; 604385; gene.
DR   PharmGKB; PA35001; -.
DR   eggNOG; prNOG12028; -.
DR   HOGENOM; HBG358468; -.
DR   HOVERGEN; HBG053100; -.
DR   InParanoid; Q9UI33; -.
DR   OMA; LVMDLPM; -.
DR   OrthoDB; EOG9V7225; -.
DR   DrugBank; DB00907; Cocaine.
DR   NextBio; 42941; -.
DR   ArrayExpress; Q9UI33; -.
DR   Bgee; Q9UI33; -.
DR   CleanEx; HS_SCN11A; -.
DR   Genevestigator; Q9UI33; -.
DR   GermOnline; ENSG00000168356; Homo sapiens.
DR   GO; GO:0001518; C:voltage-gated sodium channel complex; IEA:InterPro.
DR   GO; GO:0031402; F:sodium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005248; F:voltage-gated sodium channel activity; TAS:ProtInc.
DR   GO; GO:0042493; P:response to drug; TAS:ProtInc.
DR   GO; GO:0006814; P:sodium ion transport; TAS:ProtInc.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR005821; Ion_trans.
DR   InterPro; IPR001696; Na_channel.
DR   InterPro; IPR010526; Na_trans_assoc.
DR   Pfam; PF00520; Ion_trans; 4.
DR   Pfam; PF06512; Na_trans_assoc; 1.
DR   PRINTS; PR00170; NACHANNEL.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Glycoprotein; Ion transport;
KW   Ionic channel; Membrane; Phosphoprotein; Polymorphism; Repeat; Sodium;
KW   Sodium channel; Sodium transport; Transmembrane; Transport;
KW   Voltage-gated channel.
FT   CHAIN         1   1791       Sodium channel protein type 11 subunit
FT                                alpha.
FT                                /FTId=PRO_0000048510.
FT   TRANSMEM    127    148       S1 of repeat I (By similarity).
FT   TRANSMEM    157    180       S2 of repeat I (By similarity).
FT   TRANSMEM    193    212       S3 of repeat I (By similarity).
FT   TRANSMEM    220    239       S4 of repeat I (By similarity).
FT   TRANSMEM    256    269       S5 of repeat I (By similarity).
FT   TRANSMEM    377    402       S6 of repeat I (By similarity).
FT   TRANSMEM    573    596       S1 of repeat II (By similarity).
FT   TRANSMEM    608    631       S2 of repeat II (By similarity).
FT   TRANSMEM    640    659       S3 of repeat II (By similarity).
FT   TRANSMEM    668    687       S4 of repeat II (By similarity).
FT   TRANSMEM    703    725       S5 of repeat II (By similarity).
FT   TRANSMEM    786    811       S6 of repeat II (By similarity).
FT   TRANSMEM   1052   1074       S1 of repeat III (By similarity).
FT   TRANSMEM   1089   1114       S2 of repeat III (By similarity).
FT   TRANSMEM   1121   1138       S3 of repeat III (By similarity).
FT   TRANSMEM   1140   1161       S4 of repeat III (By similarity).
FT   TRANSMEM   1181   1202       S5 of repeat III (By similarity).
FT   TRANSMEM   1282   1308       S6 of repeat III (By similarity).
FT   TRANSMEM   1362   1385       S1 of repeat IV (By similarity).
FT   TRANSMEM   1397   1420       S2 of repeat IV (By similarity).
FT   TRANSMEM   1427   1450       S3 of repeat IV (By similarity).
FT   TRANSMEM   1462   1484       S4 of repeat IV (By similarity).
FT   TRANSMEM   1500   1522       S5 of repeat IV (By similarity).
FT   TRANSMEM   1580   1604       S6 of repeat IV (By similarity).
FT   REPEAT      126    403       I.
FT   REPEAT      572    812       II.
FT   REPEAT     1051   1309       III.
FT   REPEAT     1361   1605       IV.
FT   MOD_RES    1269   1269       Phosphoserine (By similarity).
FT   CARBOHYD    290    290       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    338    338       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    781    781       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1209   1209       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1216   1216       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1222   1222       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1230   1230       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1568   1568       N-linked (GlcNAc...) (Potential).
FT   VAR_SEQ     946    983       Missing (in isoform 3).
FT                                /FTId=VSP_012259.
FT   VAR_SEQ    1444   1444       T -> K (in isoform 2).
FT                                /FTId=VSP_012260.
FT   VAR_SEQ    1445   1791       Missing (in isoform 2).
FT                                /FTId=VSP_012261.
FT   VARIANT     481    481       G -> E (in dbSNP:rs13059805).
FT                                /FTId=VAR_030002.
FT   VARIANT     777    777       M -> R (in dbSNP:rs4302324).
FT                                /FTId=VAR_030003.
FT   VARIANT     909    909       V -> I (in dbSNP:rs33985936).
FT                                /FTId=VAR_048697.
FT   VARIANT    1198   1198       Y -> H (in dbSNP:rs12638601).
FT                                /FTId=VAR_030004.
FT   CONFLICT    576    576       D -> G (in Ref. 3; CAD10507).
FT   CONFLICT    703    703       S -> N (in Ref. 2; AAF24976/AAF24980).
FT   CONFLICT    847    847       R -> G (in Ref. 3; CAD10507).
FT   CONFLICT   1086   1086       I -> T (in Ref. 5; AAT95434).
SQ   SEQUENCE   1791 AA;  204922 MW;  DE38680BFB639ED1 CRC64;
     MDDRCYPVIF PDERNFRPFT SDSLAAIEKR IAIQKEKKKS KDQTGEVPQP RPQLDLKASR
     KLPKLYGDIP RELIGKPLED LDPFYRNHKT FMVLNRKRTI YRFSAKHALF IFGPFNSIRS
     LAIRVSVHSL FSMFIIGTVI INCVFMATGP AKNSNSNNTD IAECVFTGIY IFEALIKILA
     RGFILDEFSF LRDPWNWLDS IVIGIAIVSY IPGITIKLLP LRTFRVFRAL KAISVVSRLK
     VIVGALLRSV KKLVNVIILT FFCLSIFALV GQQLFMGSLN LKCISRDCKN ISNPEAYDHC
     FEKKENSPEF KMCGIWMGNS ACSIQYECKH TKINPDYNYT NFDNFGWSFL AMFRLMTQDS
     WEKLYQQTLR TTGLYSVFFF IVVIFLGSFY LINLTLAVVT MAYEEQNKNV AAEIEAKEKM
     FQEAQQLLKE EKEALVAMGI DRSSLTSLET SYFTPKKRKL FGNKKRKSFF LRESGKDQPP
     GSDSDEDCQK KPQLLEQTKR LSQNLSLDHF DEHGDPLQRQ RALSAVSILT ITMKEQEKSQ
     EPCLPCGENL ASKYLVWNCC PQWLCVKKVL RTVMTDPFTE LAITICIIIN TVFLAMEHHK
     MEASFEKMLN IGNLVFTSIF IAEMCLKIIA LDPYHYFRRG WNIFDSIVAL LSFADVMNCV
     LQKRSWPFLR SFRVLRVFKL AKSWPTLNTL IKIIGNSVGA LGSLTVVLVI VIFIFSVVGM
     QLFGRSFNSQ KSPKLCNPTG PTVSCLRHWH MGDFWHSFLV VFRILCGEWI ENMWECMQEA
     NASSSLCVIV FILITVIGKL VVLNLFIALL LNSFSNEERN GNLEGEARKT KVQLALDRFR
     RAFCFVRHTL EHFCHKWCRK QNLPQQKEVA GGCAAQSKDI IPLVMEMKRG SETQEELGIL
     TSVPKTLGVR HDWTWLAPLA EEEDDVEFSG EDNAQRITQP EPEQQAYELH QENKKPTSQR
     VQSVEIDMFS EDEPHLTIQD PRKKSDVTSI LSECSTIDLQ DGFGWLPEMV PKKQPERCLP
     KGFGCCFPCC SVDKRKPPWV IWWNLRKTCY QIVKHSWFES FIIFVILLSS GALIFEDVHL
     ENQPKIQELL NCTDIIFTHI FILEMVLKWV AFGFGKYFTS AWCCLDFIIV IVSVTTLINL
     MELKSFRTLR ALRPLRALSQ FEGMKVVVNA LIGAIPAILN VLLVCLIFWL VFCILGVYFF
     SGKFGKCING TDSVINYTII TNKSQCESGN FSWINQKVNF DNVGNAYLAL LQVATFKGWM
     DIIYAAVDST EKEQQPEFES NSLGYIYFVV FIIFGSFFTL NLFIGVIIDN FNQQQKKLGG
     QDIFMTEEQK KYYNAMKKLG SKKPQKPIPR PLNKCQGLVF DIVTSQIFDI IIISLIILNM
     ISMMAESYNQ PKAMKSILDH LNWVFVVIFT LECLIKIFAL RQYYFTNGWN LFDCVVVLLS
     IVSTMISTLE NQEHIPFPPT LFRIVRLARI GRILRLVRAA RGIRTLLFAL MMSLPSLFNI
     GLLLFLIMFI YAILGMNWFS KVNPESGIDD IFNFKTFASS MLCLFQISTS AGWDSLLSPM
     LRSKESCNSS SENCHLPGIA TSYFVSYIII SFLIVVNMYI AVILENFNTA TEESEDPLGE
     DDFDIFYEVW EKFDPEATQF IKYSALSDFA DALPEPLRVA KPNKYQFLVM DLPMVSEDRL
     HCMDILFAFT ARVLGGSDGL DSMKAMMEEK FMEANPLKKL YEPIVTTTKR KEEERGAAII
     QKAFRKYMMK VTKGDQGDQN DLENGPHSPL QTLCNGDLSS FGVAKGKVHC D
//
ID   SCNBA_MOUSE             Reviewed;        1765 AA.
AC   Q9R053; Q9JMD4;
DT   21-DEC-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   02-MAR-2010, entry version 64.
DE   RecName: Full=Sodium channel protein type 11 subunit alpha;
DE   AltName: Full=Sodium channel protein type XI subunit alpha;
DE   AltName: Full=Voltage-gated sodium channel subunit alpha Nav1.9;
DE   AltName: Full=Sensory neuron sodium channel 2;
DE   AltName: Full=NaN;
GN   Name=Scn11a; Synonyms=Nan, Nat, Sns2;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=ICR; TISSUE=Trigeminal ganglion;
RX   MEDLINE=99375324; PubMed=10444332; DOI=10.1006/geno.1999.5890;
RA   Dib-Hajj S.D., Tyrrell L., Escayg A., Wood P.M., Meisler M.H.,
RA   Waxman S.G.;
RT   "Coding sequence, genomic organization, and conserved chromosomal
RT   localization of the mouse gene Scn11a encoding the sodium channel
RT   NaN.";
RL   Genomics 59:309-318(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND DEVELOPMENTAL
RP   STAGE.
RC   TISSUE=Testis;
RX   MEDLINE=20090627; PubMed=10623609; DOI=10.1006/bbrc.1999.1858;
RA   Ogata K., Jeong S.-Y., Murakami H., Hashida H., Suzuki T., Masuda N.,
RA   Hirai M., Isahara K., Uchiyama Y., Goto J., Kanazawa I.;
RT   "Cloning and expression study of the mouse tetrodotoxin-resistant
RT   voltage-gated sodium channel alpha subunit NaT/Scn11a.";
RL   Biochem. Biophys. Res. Commun. 267:271-277(2000).
RN   [3]
RP   INDUCTION.
RX   PubMed=14515348; DOI=10.1002/jnr.10768;
RA   Klein J.P., Tendi E.A., Dib-Hajj S.D., Fields R.D., Waxman S.G.;
RT   "Patterned electrical activity modulates sodium channel expression in
RT   sensory neurons.";
RL   J. Neurosci. Res. 74:192-198(2003).
RN   [4]
RP   REVIEW.
RX   MEDLINE=22424164; PubMed=12536125; DOI=10.1016/S0166-2236(02)00030-9;
RA   Delmas P., Coste B.;
RT   "Na+ channel Nav1.9: in search of a gating mechanism.";
RL   Trends Neurosci. 26:55-57(2003).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-734 AND SER-1250, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=17203969; DOI=10.1021/pr0604155;
RA   Dai J., Jin W.-H., Sheng Q.-H., Shieh C.-H., Wu J.-R., Zeng R.;
RT   "Protein phosphorylation and expression profiling by Yin-yang
RT   multidimensional liquid chromatography (Yin-yang MDLC) mass
RT   spectrometry.";
RL   J. Proteome Res. 6:250-262(2007).
CC   -!- FUNCTION: This protein mediates the voltage-dependent sodium ion
CC       permeability of excitable membranes. Assuming opened or closed
CC       conformations in response to the voltage difference across the
CC       membrane, the protein forms a sodium-selective channel through
CC       which sodium ions may pass in accordance with their
CC       electrochemical gradient. It is a tetrodotoxin-resistant sodium
CC       channel isoform. Also involved, with the contribution of the
CC       receptor tyrosine kinase NTRK2, in rapid BDNF-evoked neuronal
CC       depolarization (By similarity).
CC   -!- SUBUNIT: The voltage-resistant sodium channel consists of an ion
CC       conducting pore forming alpha-subunit regulated by one or more
CC       auxiliary subunits SCN1B, SCN2B and SCN3B.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein (By
CC       similarity).
CC   -!- TISSUE SPECIFICITY: Expressed in the dorsal root ganglia (C-fiber
CC       neurons), spinal cord, trigeminal ganglia, testis, ovary, uterus
CC       and small intestine.
CC   -!- DEVELOPMENTAL STAGE: Expressed in embryo at 15 dpc onwards.
CC   -!- DOMAIN: The sequence contains 4 internal repeats, each with 5
CC       hydrophobic segments (S1,S2,S3,S5,S6) and one positively charged
CC       segment (S4). Segments S4 are probably the voltage-sensors and are
CC       characterized by a series of positively charged amino acids at
CC       every third position.
CC   -!- SIMILARITY: Belongs to the sodium channel family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF118044; AAD53403.1; -; mRNA.
DR   EMBL; AB031389; BAA92154.1; -; mRNA.
DR   IPI; IPI00126898; -.
DR   UniGene; Mm.89981; -.
DR   SMR; Q9R053; 1029-1152, 1341-1414.
DR   STRING; Q9R053; -.
DR   PhosphoSite; Q9R053; -.
DR   PRIDE; Q9R053; -.
DR   Ensembl; ENSMUST00000070617; ENSMUSP00000065466; ENSMUSG00000034115; Mus musculus.
DR   UCSC; uc009sbk.1; mouse.
DR   MGI; MGI:1345149; Scn11a.
DR   eggNOG; roNOG15247; -.
DR   HOGENOM; HBG358468; -.
DR   HOVERGEN; HBG053100; -.
DR   InParanoid; Q9R053; -.
DR   ArrayExpress; Q9R053; -.
DR   Bgee; Q9R053; -.
DR   CleanEx; MM_SCN11A; -.
DR   Genevestigator; Q9R053; -.
DR   GermOnline; ENSMUSG00000034115; Mus musculus.
DR   GO; GO:0001518; C:voltage-gated sodium channel complex; IEA:InterPro.
DR   GO; GO:0031402; F:sodium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005248; F:voltage-gated sodium channel activity; IEA:InterPro.
DR   GO; GO:0006814; P:sodium ion transport; IEA:UniProtKB-KW.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR005821; Ion_trans.
DR   InterPro; IPR001696; Na_channel.
DR   InterPro; IPR010526; Na_trans_assoc.
DR   Pfam; PF00520; Ion_trans; 4.
DR   Pfam; PF06512; Na_trans_assoc; 1.
DR   PRINTS; PR00170; NACHANNEL.
PE   1: Evidence at protein level;
KW   Glycoprotein; Ion transport; Ionic channel; Membrane; Phosphoprotein;
KW   Repeat; Sodium; Sodium channel; Sodium transport; Transmembrane;
KW   Transport; Voltage-gated channel.
FT   CHAIN         1   1765       Sodium channel protein type 11 subunit
FT                                alpha.
FT                                /FTId=PRO_0000048511.
FT   TRANSMEM    127    148       S1 of repeat I (By similarity).
FT   TRANSMEM    160    179       S2 of repeat I (By similarity).
FT   TRANSMEM    192    211       S3 of repeat I (By similarity).
FT   TRANSMEM    220    239       S4 of repeat I (By similarity).
FT   TRANSMEM    256    269       S5 of repeat I (By similarity).
FT   TRANSMEM    375    400       S6 of repeat I (By similarity).
FT   TRANSMEM    571    594       S1 of repeat II (By similarity).
FT   TRANSMEM    606    629       S2 of repeat II (By similarity).
FT   TRANSMEM    638    659       S3 of repeat II (By similarity).
FT   TRANSMEM    665    684       S4 of repeat II (By similarity).
FT   TRANSMEM    700    722       S5 of repeat II (By similarity).
FT   TRANSMEM    774    799       S6 of repeat II (By similarity).
FT   TRANSMEM   1031   1053       S1 of repeat III (By similarity).
FT   TRANSMEM   1068   1093       S2 of repeat III (By similarity).
FT   TRANSMEM   1100   1117       S3 of repeat III (By similarity).
FT   TRANSMEM   1119   1140       S4 of repeat III (By similarity).
FT   TRANSMEM   1160   1181       S5 of repeat III (By similarity).
FT   TRANSMEM   1263   1289       S6 of repeat III (By similarity).
FT   TRANSMEM   1343   1366       S1 of repeat IV (By similarity).
FT   TRANSMEM   1378   1401       S2 of repeat IV (By similarity).
FT   TRANSMEM   1408   1431       S3 of repeat IV (By similarity).
FT   TRANSMEM   1441   1463       S4 of repeat IV (By similarity).
FT   TRANSMEM   1479   1501       S5 of repeat IV (By similarity).
FT   TRANSMEM   1560   1584       S6 of repeat IV (By similarity).
FT   REPEAT      126    401       I.
FT   REPEAT      570    800       II.
FT   REPEAT     1030   1290       III.
FT   REPEAT     1342   1585       IV.
FT   MOD_RES     734    734       Phosphoserine.
FT   MOD_RES    1250   1250       Phosphoserine.
FT   CARBOHYD    149    149       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    217    217       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    303    303       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    327    327       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    336    336       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    662    662       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    725    725       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1188   1188       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1197   1197       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1203   1203       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1211   1211       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1676   1676       N-linked (GlcNAc...) (Potential).
FT   CONFLICT    400    400       A -> G (in Ref. 2; BAA92154).
FT   CONFLICT    427    427       R -> K (in Ref. 2; BAA92154).
FT   CONFLICT    489    489       N -> K (in Ref. 2; BAA92154).
FT   CONFLICT    738    738       W -> R (in Ref. 2; BAA92154).
FT   CONFLICT    761    761       N -> T (in Ref. 2; BAA92154).
FT   CONFLICT    764    764       E -> D (in Ref. 2; BAA92154).
FT   CONFLICT    843    843       C -> R (in Ref. 2; BAA92154).
FT   CONFLICT   1023   1024       NL -> IF (in Ref. 2; BAA92154).
FT   CONFLICT   1054   1054       F -> L (in Ref. 2; BAA92154).
FT   CONFLICT   1212   1212       Y -> H (in Ref. 2; BAA92154).
FT   CONFLICT   1376   1376       K -> Q (in Ref. 2; BAA92154).
FT   CONFLICT   1496   1496       N -> S (in Ref. 2; BAA92154).
FT   CONFLICT   1572   1572       F -> L (in Ref. 2; BAA92154).
SQ   SEQUENCE   1765 AA;  201427 MW;  E3F99FA896DD50A1 CRC64;
     MEERYYPVIF PDERNFRPFT FDSLAAIEKR ITIQKEKKKS KDKAATEPQP RPQLDLKASR
     KLPKLYGDVP PDLIAKPLED LDPFYKDHKT FMVLNKKRTI YRFSAKRALF ILGPFNPIRS
     FMIRISVHSV FSMFIICTVI INCMFMANNS SVDSRPSSNI PEYVFIGIYV LEAVIKILAR
     GFIVDEFSYL RDPWNWLDFI VIGTAIAPCF LGNKVNNLST LRTFRVLRAL KAISVISGLK
     VIVGALLRSV KKLVDVMVLT LFCLSIFALV GQQLFMGILS QKCIKDDCGP NAFSNKDCFV
     KENDSEDFIM CGNWLGRRSC PDGSTCNKTT FNPDYNYTNF DSFGWSFLAM FRVMTQDSWE
     KLYRQILRTS GIYFVFFFVV VIFLGSFYLL NLTLAVVTMA YEEQNRNVAA ETEAKEKMFQ
     EAQQLLREEK EALVAMGIDR TSLNSLQASS FSPKKRKFFG SKTRKSFFMR GSKTARASAS
     DSEDDASKNP QLLEQTKRLS QNLPVELFDE HVDPLHRQRA LSAVSILTIT MQEQEKSQEP
     CFPCGKNLAS KYLVWECSPP WLCIKKVLQT IMTDPFTELA ITICIIVNTV FLAMEHHNMD
     NSLKDILKIG NWVFTGIFIA EMCLKIIALD PYHYFRHGWN IFDSIVALVS LADVLFHKLS
     KNLSFLASLR VLRVFKLAKS WPTLNTLIKI IGHSVGALGN LTVVLTIVVF IFSVVGMRLF
     GAKFNKTCST SPESLRRWHM GDFYHSFLVV FRILCGEWIE NMWECMQEME GSPLCVIVFV
     LIMVVGKLVV LNLFIALLLN SFSNEEKDGN PEGETRKTKV QLALDRFSRA FYFMARALQN
     FCCKRCRRQN SPKPNEATES FAGESRDTAT LDTRSWKEYD SEMTLYTGQA GAPLAPLAKE
     EDDMECCGEC DASPTSQPSE EAQACDLPLK TKRLPSPDDH GVEMEVFSEE DPNLTIQSAR
     KKSDAASMLS ECSTIDLNDI FRNLQKTVSP QKQPDRCFPK GLSCIFLCCK TIKKKSPWVL
     WWNLRKTCYQ IVKHSWFESF IIFVILLSSG ALIFEDVNLP SRPQVEKLLK CTDNIFTFIF
     LLEMILKWVA FGFRKYFTSA WCWLDFLIVV VSVLSLTNLP NLKSFRNLRA LRPLRALSQF
     EGMKVVVNAL MSAIPAILNV LLVCLIFWLI FCILGVNFFS GKFGRCINGT DINKYFNASN
     VPNQSQCLVS NYTWKVPNVN FDNVGNAYLA LLQVATYKGW LDIMNAAVDS RGKDEQPAFE
     ANLYAYLYFV VFIIFGSFFT LNLFIGVIID NFNQQQKKLG GQDIFMTEEQ KKYYNAMKKL
     GTKKPQKPIP RPLNKCQAFV FDLVTSQVFD VIILGLIVTN MIIMMAESEG QPNEVKKIFD
     ILNIVFVVIF TVECLIKVFA LRQHYFTNGW NLFDCVVVVL SIISTLVSGL ENSNVFPPTL
     FRIVRLARIG RILRLVRAAR GIRTLLFALM MSLPSLFNIG LLLFLVMFIY AIFGMNWFSK
     VKRGSGIDDI FNFDTFSGSM LCLFQITTSA GWDALLNPML ESKASCNSSS QESCQQPQIA
     IVYFVSYIII SFLIVVNMYI AVILENFNTA TEESEDPLGE DDFEIFYEIW EKFDPEATQF
     IQYSSLSDFA DALPEPLRVA KPNRFQFLMM DLPMVMGDRL HCMDVLFAFT TRVLGNSSGL
     DTMKAMMEEK FMEANPFKKL YEPIVTTTKR KEEEECAAVI QRAYRRHMEK MIKLKLKGRS
     SSSLQVFCNG DLSSLDVPKI KVHCD
//
ID   SCNBA_RAT               Reviewed;        1765 AA.
AC   O88457;
DT   21-DEC-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1998, sequence version 1.
DT   02-MAR-2010, entry version 64.
DE   RecName: Full=Sodium channel protein type 11 subunit alpha;
DE   AltName: Full=Sodium channel protein type XI subunit alpha;
DE   AltName: Full=Voltage-gated sodium channel subunit alpha Nav1.9;
DE   AltName: Full=Sensory neuron sodium channel 2;
DE   AltName: Full=NaN;
GN   Name=Scn11a; Synonyms=Nan, Sns2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND INDUCTION.
RC   STRAIN=Sprague-Dawley; TISSUE=Spinal ganglion;
RX   MEDLINE=98338024; PubMed=9671787; DOI=10.1073/pnas.95.15.8963;
RA   Dib-Hajj S.D., Tyrrell L., Black J.A., Waxman S.G.;
RT   "NaN, a novel voltage-gated Na channel, is expressed preferentially in
RT   peripheral sensory neurons and down-regulated after axotomy.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:8963-8968(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION IN VOLTAGE-EVOKED DEPOLARIZATION,
RP   TISSUE SPECIFICITY, AND INDUCTION.
RC   STRAIN=Sprague-Dawley; TISSUE=Spinal ganglion;
RX   MEDLINE=99212311; PubMed=10196578; DOI=10.1038/3652;
RA   Tate S.N., Benn S.C., Hick C.A., Trezise D., John V.H., Mannion R.J.,
RA   Costigan M., Plumpton C., Grose D., Gladwell Z., Kendall G., Dale K.,
RA   Bountra C., Woolf C.J.;
RT   "Two sodium channels contribute to the TTX-R sodium current in primary
RT   sensory neurons.";
RL   Nat. Neurosci. 1:653-655(1998).
RN   [3]
RP   TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX   MEDLINE=21380282; PubMed=11487631;
RA   Benn S.C., Costigan M., Tate S., Fitzgerald M., Woolf C.J.;
RT   "Developmental expression of the TTX-resistant voltage-gated sodium
RT   channels Nav1.8 (SNS) and Nav1.9 (SNS2) in primary sensory neurons.";
RL   J. Neurosci. 21:6077-6085(2001).
RN   [4]
RP   REVIEW.
RX   MEDLINE=22424164; PubMed=12536125; DOI=10.1016/S0166-2236(02)00030-9;
RA   Delmas P., Coste B.;
RT   "Na+ channel Nav1.9: in search of a gating mechanism.";
RL   Trends Neurosci. 26:55-57(2003).
CC   -!- FUNCTION: This protein mediates the voltage-dependent sodium ion
CC       permeability of excitable membranes. Assuming opened or closed
CC       conformations in response to the voltage difference across the
CC       membrane, the protein forms a sodium-selective channel through
CC       which sodium ions may pass in accordance with their
CC       electrochemical gradient. It is a tetrodotoxin-resistant sodium
CC       channel isoform. Also involved, with the contribution of the
CC       receptor tyrosine kinase NTRK2, in rapid BDNF-evoked neuronal
CC       depolarization (By similarity).
CC   -!- SUBUNIT: The voltage-resistant sodium channel consists of an ion
CC       conducting pore forming alpha-subunit regulated by one or more
CC       auxiliary subunits SCN1B, SCN2B and SCN3B.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein (By
CC       similarity).
CC   -!- TISSUE SPECIFICITY: Expressed (at protein level) in myenteric
CC       sensory neurons. Expressed in small sensory neurons of the dorsal
CC       root ganglia (C-fiber neurons) and trigeminal ganglia.
CC   -!- DEVELOPMENTAL STAGE: Expressed in dorsal root ganglia at 17 dpc
CC       onwards.
CC   -!- INDUCTION: Down-regulated after axotomy and up-regulated following
CC       hind paw inflammation. Down-regulated in vitro by electrical
CC       stimulation and by deprivation of NGF.
CC   -!- DOMAIN: The sequence contains 4 internal repeats, each with 5
CC       hydrophobic segments (S1,S2,S3,S5,S6) and one positively charged
CC       segment (S4). Segments S4 are probably the voltage-sensors and are
CC       characterized by a series of positively charged amino acids at
CC       every third position.
CC   -!- SIMILARITY: Belongs to the sodium channel family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF059030; AAC40199.1; -; mRNA.
DR   EMBL; AJ237852; CAB41850.1; -; mRNA.
DR   IPI; IPI00392165; -.
DR   PIR; T42388; T42388.
DR   RefSeq; NP_062138.1; -.
DR   UniGene; Rn.30023; -.
DR   SMR; O88457; 1028-1146, 1340-1477.
DR   STRING; O88457; -.
DR   PhosphoSite; O88457; -.
DR   Ensembl; ENSRNOT00000034025; ENSRNOP00000033224; ENSRNOG00000032884; Rattus norvegicus.
DR   GeneID; 29701; -.
DR   KEGG; rno:29701; -.
DR   UCSC; NM_019265; rat.
DR   CTD; 29701; -.
DR   RGD; 3630; Scn11a.
DR   eggNOG; maNOG15914; -.
DR   HOVERGEN; HBG053100; -.
DR   InParanoid; O88457; -.
DR   PhylomeDB; O88457; -.
DR   NextBio; 610107; -.
DR   ArrayExpress; O88457; -.
DR   Genevestigator; O88457; -.
DR   GermOnline; ENSRNOG00000032884; Rattus norvegicus.
DR   GO; GO:0001518; C:voltage-gated sodium channel complex; IEA:InterPro.
DR   GO; GO:0031402; F:sodium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005248; F:voltage-gated sodium channel activity; IEA:InterPro.
DR   GO; GO:0006814; P:sodium ion transport; IEA:UniProtKB-KW.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR005821; Ion_trans.
DR   InterPro; IPR001696; Na_channel.
DR   InterPro; IPR010526; Na_trans_assoc.
DR   Pfam; PF00520; Ion_trans; 4.
DR   Pfam; PF06512; Na_trans_assoc; 1.
DR   PRINTS; PR00170; NACHANNEL.
PE   1: Evidence at protein level;
KW   Glycoprotein; Ion transport; Ionic channel; Membrane; Phosphoprotein;
KW   Repeat; Sodium; Sodium channel; Sodium transport; Transmembrane;
KW   Transport; Voltage-gated channel.
FT   CHAIN         1   1765       Sodium channel protein type 11 subunit
FT                                alpha.
FT                                /FTId=PRO_0000048512.
FT   TRANSMEM    127    148       S1 of repeat I (By similarity).
FT   TRANSMEM    158    177       S2 of repeat I (By similarity).
FT   TRANSMEM    190    209       S3 of repeat I (By similarity).
FT   TRANSMEM    217    236       S4 of repeat I (By similarity).
FT   TRANSMEM    253    266       S5 of repeat I (By similarity).
FT   TRANSMEM    372    397       S6 of repeat I (By similarity).
FT   TRANSMEM    568    591       S1 of repeat II (By similarity).
FT   TRANSMEM    603    626       S2 of repeat II (By similarity).
FT   TRANSMEM    635    656       S3 of repeat II (By similarity).
FT   TRANSMEM    663    682       S4 of repeat II (By similarity).
FT   TRANSMEM    698    720       S5 of repeat II (By similarity).
FT   TRANSMEM    773    798       S6 of repeat II (By similarity).
FT   TRANSMEM   1030   1052       S1 of repeat III (By similarity).
FT   TRANSMEM   1067   1092       S2 of repeat III (By similarity).
FT   TRANSMEM   1099   1116       S3 of repeat III (By similarity).
FT   TRANSMEM   1118   1139       S4 of repeat III (By similarity).
FT   TRANSMEM   1159   1180       S5 of repeat III (By similarity).
FT   TRANSMEM   1262   1288       S6 of repeat III (By similarity).
FT   TRANSMEM   1342   1365       S1 of repeat IV (By similarity).
FT   TRANSMEM   1377   1400       S2 of repeat IV (By similarity).
FT   TRANSMEM   1407   1430       S3 of repeat IV (By similarity).
FT   TRANSMEM   1441   1463       S4 of repeat IV (By similarity).
FT   TRANSMEM   1479   1501       S5 of repeat IV (By similarity).
FT   TRANSMEM   1560   1584       S6 of repeat IV (By similarity).
FT   REPEAT      126    398       I.
FT   REPEAT      567    799       II.
FT   REPEAT     1029   1289       III.
FT   REPEAT     1341   1585       IV.
FT   MOD_RES    1249   1249       Phosphoserine (By similarity).
FT   CARBOHYD    214    214       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    319    319       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    333    333       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    660    660       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    723    723       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1187   1187       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1202   1202       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1207   1207       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1210   1210       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD   1547   1547       N-linked (GlcNAc...) (Potential).
SQ   SEQUENCE   1765 AA;  201845 MW;  AE8C67397CC60BD9 CRC64;
     MEERYYPVIF PDERNFRPFT SDSLAAIEKR IAIQKERKKS KDKAAAEPQP RPQLDLKASR
     KLPKLYGDIP PELVAKPLED LDPFYKDHKT FMVLNKKRTI YRFSAKRALF ILGPFNPLRS
     LMIRISVHSV FSMFIICTVI INCMFMANSM ERSFDNDIPE YVFIGIYILE AVIKILARGF
     IVDEFSFLRD PWNWLDFIVI GTAIATCFPG SQVNLSALRT FRVFRALKAI SVISGLKVIV
     GALLRSVKKL VDVMVLTLFC LSIFALVGQQ LFMGILNQKC IKHNCGPNPA SNKDCFEKEK
     DSEDFIMCGT WLGSRPCPNG STCDKTTLNP DNNYTKFDNF GWSFLAMFRV MTQDSWERLY
     RQILRTSGIY FVFFFVVVIF LGSFYLLNLT LAVVTMAYEE QNRNVAAETE AKEKMFQEAQ
     QLLREEKEAL VAMGIDRSSL NSLQASSFSP KKRKFFGSKT RKSFFMRGSK TAQASASDSE
     DDASKNPQLL EQTKRLSQNL PVDLFDEHVD PLHRQRALSA VSILTITMQE QEKFQEPCFP
     CGKNLASKYL VWDCSPQWLC IKKVLRTIMT DPFTELAITI CIIINTVFLA VEHHNMDDNL
     KTILKIGNWV FTGIFIAEMC LKIIALDPYH YFRHGWNVFD SIVALLSLAD VLYNTLSDNN
     RSFLASLRVL RVFKLAKSWP TLNTLIKIIG HSVGALGNLT VVLTIVVFIF SVVGMRLFGT
     KFNKTAYATQ ERPRRRWHMD NFYHSFLVVF RILCGEWIEN MWGCMQDMDG SPLCIIVFVL
     IMVIGKLVVL NLFIALLLNS FSNEEKDGSL EGETRKTKVQ LALDRFRRAF SFMLHALQSF
     CCKKCRRKNS PKPKETTESF AGENKDSILP DARPWKEYDT DMALYTGQAG APLAPLAEVE
     DDVEYCGEGG ALPTSQHSAG VQAGDLPPET KQLTSPDDQG VEMEVFSEED LHLSIQSPRK
     KSDAVSMLSE CSTIDLNDIF RNLQKTVSPK KQPDRCFPKG LSCHFLCHKT DKRKSPWVLW
     WNIRKTCYQI VKHSWFESFI IFVILLSSGA LIFEDVNLPS RPQVEKLLRC TDNIFTFIFL
     LEMILKWVAF GFRRYFTSAW CWLDFLIVVV SVLSLMNLPS LKSFRTLRAL RPLRALSQFE
     GMKVVVYALI SAIPAILNVL LVCLIFWLVF CILGVNLFSG KFGRCINGTD INMYLDFTEV
     PNRSQCNISN YSWKVPQVNF DNVGNAYLAL LQVATYKGWL EIMNAAVDSR EKDEQPDFEA
     NLYAYLYFVV FIIFGSFFTL NLFIGVIIDN FNQQQKKLGG QDIFMTEEQK KYYNAMKKLG
     TKKPQKPIPR PLNKCQAFVF DLVTSQVFDV IILGLIVLNM IIMMAESADQ PKDVKKTFDI
     LNIAFVVIFT IECLIKVFAL RQHYFTNGWN LFDCVVVVLS IISTLVSRLE DSDISFPPTL
     FRVVRLARIG RILRLVRAAR GIRTLLFALM MSLPSLFNIG LLLFLVMFIY AIFGMSWFSK
     VKKGSGIDDI FNFETFTGSM LCLFQITTSA GWDTLLNPML EAKEHCNSSS QDSCQQPQIA
     VVYFVSYIII SFLIVVNMYI AVILENFNTA TEESEDPLGE DDFEIFYEVW EKFDPEASQF
     IQYSALSDFA DALPEPLRVA KPNKFQFLVM DLPMVMGDRL HCMDVLFAFT TRVLGDSSGL
     DTMKTMMEEK FMEANPFKKL YEPIVTTTKR KEEEQGAAVI QRAYRKHMEK MVKLRLKDRS
     SSSHQVFCNG DLSSLDVAKV KVHND
//
ID   SIPB_SALTI              Reviewed;         593 AA.
AC   Q56134; Q7AME0; Q7C7N1;
DT   01-FEB-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   02-MAR-2010, entry version 53.
DE   RecName: Full=Cell invasion protein sipB;
DE   AltName: Full=Effector protein sipB;
GN   Name=sipB; OrderedLocusNames=STY3008, t2787;
OS   Salmonella typhi.
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC   Enterobacteriaceae; Salmonella.
OX   NCBI_TaxID=90370;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=ATCC 700931 / Ty2;
RX   MEDLINE=96111497; PubMed=8801431;
RX   DOI=10.1111/j.1365-2958.1995.mmi_17040781.x;
RA   Hermant D., Menard R., Arricau N., Parsot C., Popoff M.Y.;
RT   "Functional conservation of the Salmonella and Shigella effectors of
RT   entry into epithelial cells.";
RL   Mol. Microbiol. 17:781-789(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=CT18;
RX   MEDLINE=21534947; PubMed=11677608; DOI=10.1038/35101607;
RA   Parkhill J., Dougan G., James K.D., Thomson N.R., Pickard D., Wain J.,
RA   Churcher C.M., Mungall K.L., Bentley S.D., Holden M.T.G., Sebaihia M.,
RA   Baker S., Basham D., Brooks K., Chillingworth T., Connerton P.,
RA   Cronin A., Davis P., Davies R.M., Dowd L., White N., Farrar J.,
RA   Feltwell T., Hamlin N., Haque A., Hien T.T., Holroyd S., Jagels K.,
RA   Krogh A., Larsen T.S., Leather S., Moule S., O'Gaora P., Parry C.,
RA   Quail M.A., Rutherford K.M., Simmonds M., Skelton J., Stevens K.,
RA   Whitehead S., Barrell B.G.;
RT   "Complete genome sequence of a multiple drug resistant Salmonella
RT   enterica serovar Typhi CT18.";
RL   Nature 413:848-852(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 700931 / Ty2;
RX   MEDLINE=22531367; PubMed=12644504;
RX   DOI=10.1128/JB.185.7.2330-2337.2003;
RA   Deng W., Liou S.-R., Plunkett G. III, Mayhew G.F., Rose D.J.,
RA   Burland V., Kodoyianni V., Schwartz D.C., Blattner F.R.;
RT   "Comparative genomics of Salmonella enterica serovar Typhi strains Ty2
RT   and CT18.";
RL   J. Bacteriol. 185:2330-2337(2003).
RN   [4]
RP   FUNCTION IN CASPASE-1-DEPENDENT APOPTOSIS.
RC   STRAIN=ATCC 700931 / Ty2;
RX   PubMed=10051653; DOI=10.1073/pnas.96.5.2396;
RA   Hersh D., Monack D.M., Smith M.R., Ghori N., Falkow S., Zychlinsky A.;
RT   "The Salmonella invasin SipB induces macrophage apoptosis by binding
RT   to caspase-1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:2396-2401(1999).
CC   -!- FUNCTION: Required for entry into the host cell through
CC       presentation or delivery of sipC at the host cell plasma membrane.
CC       Along with sipC, is necessary for the transfer of other effector
CC       proteins into the host cell. Induces macrophage apoptosis either
CC       by binding and activating the proapoptotic enzyme caspase-1
CC       (caspase-1 dependent), resulting in the release of interleukin-1
CC       beta active form, or by disrupting mitochondria and inducing
CC       autophagy (caspase-1 independent). The former is dependent of its
CC       membrane-fusion activity. The sipBC complex, in association with
CC       its chaperone sicA, is regulated by binding of invE (By
CC       similarity).
CC   -!- SUBUNIT: Homotrimer (By similarity).
CC   -!- INTERACTION:
CC       P29452:Casp1 (xeno); NbExp=2; IntAct=EBI-489689, EBI-489700;
CC   -!- SUBCELLULAR LOCATION: Secreted (By similarity). Host cell
CC       membrane; Multi-pass membrane protein (By similarity).
CC       Note=Secreted via the type III secretion system 1 (SPI-1 TTSS) and
CC       inserted into the host cell plasma membrane (By similarity).
CC   -!- DOMAIN: SipB membrane integration requires both hydrophobic
CC       domains and the helical C-terminal region (By similarity).
CC   -!- SIMILARITY: Belongs to the invasin protein B family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X82670; CAA57988.1; -; Genomic_DNA.
DR   EMBL; AL627276; CAD05992.1; -; Genomic_DNA.
DR   EMBL; AE014613; AAO70348.1; -; Genomic_DNA.
DR   PIR; S70216; S70216.
DR   RefSeq; NP_457279.1; -.
DR   RefSeq; NP_806488.1; -.
DR   IntAct; Q56134; 1.
DR   GeneID; 1068872; -.
DR   GeneID; 1249314; -.
DR   GenomeReviews; AE014613_GR; t2787.
DR   GenomeReviews; AL513382_GR; STY3008.
DR   KEGG; stt:t2787; -.
DR   KEGG; sty:STY3008; -.
DR   HOGENOM; HBG673809; -.
DR   OMA; NTIQAAN; -.
DR   ProtClustDB; CLSK862848; -.
DR   BioCyc; SENT209261:T2787-MONOMER; -.
DR   BioCyc; SENT220341:STY3008-MONOMER; -.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0009405; P:pathogenesis; IEA:UniProtKB-KW.
DR   InterPro; IPR003895; T3SS_invasion_prot_B.
DR   PRINTS; PR01375; BACINVASINB.
PE   1: Evidence at protein level;
KW   Coiled coil; Complete proteome; Host cell membrane; Host membrane;
KW   Membrane; Secreted; Transmembrane; Virulence.
FT   CHAIN         1    593       Cell invasion protein sipB.
FT                                /FTId=PRO_0000219855.
FT   TRANSMEM    320    354       By similarity.
FT   TRANSMEM    408    427       By similarity.
FT   COILED      151    208       Potential.
FT   COILED      287    314       Potential.
SQ   SEQUENCE   593 AA;  62421 MW;  8570D64343276639 CRC64;
     MVNDASSISR SGYTQNPRLA EAAFEGVRKN TDFLKAADKA FKDVVATKAG DLKAGTKSGE
     SAINTVGLKP PTDAAREKLS SEGQLTLLLG KLMTLLGDVS LSQLESRLAV WQAMIESQKE
     MGIQVSKEFQ TALGEAQEAT DLYEASIKKT DTAKSVYDAA AKKLTQAQNK LQSLDPADPG
     YAQAEAAVEQ AGKEATEAKE ALDKATDATV KAGTDAKAKA EKADNILTKF QGTANAASQN
     QVSQGEQDNL SNVARLTMLM AMFIEIVGKN TEESLQNDLA LFNALQEGRQ AEMEKKSAEF
     QEETRKAEET NRIMGCIGKV LGALLTIVSV VAAVFTGGAS LALAAVGLAV MVADEIVKAA
     TGVSFIQQAL NPIMEHVLKP LMELIGKAIT KALEGLGVDK KTAEMAGSIV GAIVAAIAMV
     AVIVVVAVVG KGAAAKLGNA LSKMMGETIK KLVPNVLKQL AQNGSKLFTQ GMQRITSGLG
     NVGSKMGLQT NALSKELVGN TLNKVALGME VTNTAAQSAG GVAEGVFIKN ASEALADFML
     ARFAMDQIQQ WLKQSVEIFG ENQKVTAELQ KAMSSAVQQN ADASRFILRQ SRA
//
ID   STS_RAT                 Reviewed;         577 AA.
AC   P15589;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 2.
DT   02-MAR-2010, entry version 80.
DE   RecName: Full=Steryl-sulfatase;
DE            EC=3.1.6.2;
DE   AltName: Full=Steroid sulfatase;
DE   AltName: Full=Steryl-sulfate sulfohydrolase;
DE   AltName: Full=Arylsulfatase C;
DE            Short=ASC;
DE   Flags: Precursor;
GN   Name=Sts;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley;
RA   Li X.M., Salido E.C., Gong Y., Yen P.H., Kitada Y., Serikawa T.,
RA   Shapiro L.J.;
RL   Submitted (NOV-1995) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   PROTEIN SEQUENCE OF 20-45.
RC   TISSUE=Liver;
RX   MEDLINE=89352671; PubMed=2765556; DOI=10.1016/0167-4838(89)90187-8;
RA   Kawano J., Kotani T., Ohtaki S., Minamino N., Matsuo H., Oinuma T.,
RA   Aikawa E.;
RT   "Characterization of rat and human steroid sulfatases.";
RL   Biochim. Biophys. Acta 997:199-205(1989).
CC   -!- FUNCTION: Conversion of sulfated steroid precursors to estrogens
CC       during pregnancy.
CC   -!- CATALYTIC ACTIVITY: 3-beta-hydroxyandrost-5-en-17-one 3-sulfate +
CC       H(2)O = 3-beta-hydroxyandrost-5-en-17-one + sulfate.
CC   -!- COFACTOR: Binds 1 calcium ion per subunit (By similarity).
CC   -!- SUBUNIT: Homodimer.
CC   -!- SUBCELLULAR LOCATION: Microsome membrane; Multi-pass membrane
CC       protein. Endoplasmic reticulum membrane; Multi-pass membrane
CC       protein (Potential). Note=The sequence shows several membrane-
CC       spanning domains that could serve to anchor the protein in the
CC       microsomal membrane.
CC   -!- PTM: The conversion to 3-oxoalanine (also known as C-
CC       formylglycine, FGly), of a serine or cysteine residue in
CC       prokaryotes and of a cysteine residue in eukaryotes, is critical
CC       for catalytic activity (By similarity).
CC   -!- SIMILARITY: Belongs to the sulfatase family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U37138; AAC53097.1; -; mRNA.
DR   IPI; IPI00210494; -.
DR   PIR; S05414; S05414.
DR   RefSeq; NP_036793.1; -.
DR   UniGene; Rn.6312; -.
DR   SMR; P15589; 26-573.
DR   STRING; P15589; -.
DR   PRIDE; P15589; -.
DR   Ensembl; ENSRNOT00000051897; ENSRNOP00000043915; ENSRNOG00000032487; Rattus norvegicus.
DR   GeneID; 24800; -.
DR   KEGG; rno:24800; -.
DR   UCSC; NM_012661; rat.
DR   CTD; 24800; -.
DR   RGD; 3783; Sts.
DR   eggNOG; maNOG06076; -.
DR   HOVERGEN; HBG004283; -.
DR   InParanoid; P15589; -.
DR   PhylomeDB; P15589; -.
DR   BRENDA; 3.1.6.2; 248.
DR   NextBio; 604458; -.
DR   ArrayExpress; P15589; -.
DR   Genevestigator; P15589; -.
DR   GermOnline; ENSRNOG00000032487; Rattus norvegicus.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:RGD.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0000299; C:integral to membrane of membrane fraction; IDA:RGD.
DR   GO; GO:0005792; C:microsome; IDA:RGD.
DR   GO; GO:0005635; C:nuclear envelope; IDA:RGD.
DR   GO; GO:0005509; F:calcium ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004773; F:steryl-sulfatase activity; IDA:RGD.
DR   GO; GO:0007565; P:female pregnancy; IEA:UniProtKB-KW.
DR   GO; GO:0007611; P:learning or memory; IMP:RGD.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:RGD.
DR   GO; GO:0043627; P:response to estrogen stimulus; IDA:RGD.
DR   GO; GO:0014070; P:response to organic cyclic substance; IDA:RGD.
DR   GO; GO:0043434; P:response to peptide hormone stimulus; IDA:RGD.
DR   GO; GO:0009268; P:response to pH; IDA:RGD.
DR   GO; GO:0043588; P:skin development; IEP:RGD.
DR   GO; GO:0008202; P:steroid metabolic process; IEA:UniProtKB-KW.
DR   InterPro; IPR017849; Alkaline_Pase-like_a/b/a.
DR   InterPro; IPR017850; Alkaline_phosphatase_core.
DR   InterPro; IPR000917; Sulfatase.
DR   Gene3D; G3DSA:3.40.720.10; Alk_phosphtse; 1.
DR   Pfam; PF00884; Sulfatase; 1.
DR   SUPFAM; SSF53649; Alkaline_phosphatase_core; 1.
DR   PROSITE; PS00523; SULFATASE_1; 1.
DR   PROSITE; PS00149; SULFATASE_2; 1.
PE   1: Evidence at protein level;
KW   Calcium; Direct protein sequencing; Disulfide bond;
KW   Endoplasmic reticulum; Glycoprotein; Hydrolase; Lipid metabolism;
KW   Membrane; Metal-binding; Microsome; Pregnancy; Signal;
KW   Steroid metabolism; Transmembrane.
FT   SIGNAL        1     19
FT   CHAIN        20    577       Steryl-sulfatase.
FT                                /FTId=PRO_0000033416.
FT   TOPO_DOM     21    183       Lumenal (By similarity).
FT   TRANSMEM    184    207       By similarity.
FT   TOPO_DOM    208    211       Cytoplasmic (By similarity).
FT   TRANSMEM    212    233       By similarity.
FT   TOPO_DOM    234    577       Lumenal (By similarity).
FT   ACT_SITE    135    135       By similarity.
FT   METAL        34     34       Calcium (By similarity).
FT   METAL        35     35       Calcium (By similarity).
FT   METAL        74     74       Calcium; via 3-oxoalanine (By
FT                                similarity).
FT   METAL       341    341       Calcium (By similarity).
FT   METAL       342    342       Calcium (By similarity).
FT   MOD_RES      74     74       3-oxoalanine (Cys) (By similarity).
FT   CARBOHYD     46     46       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    332    332       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    458    458       N-linked (GlcNAc...) (Potential).
FT   DISULFID    140    147       By similarity.
FT   DISULFID    169    241       By similarity.
FT   DISULFID    445    488       By similarity.
FT   DISULFID    480    486       By similarity.
FT   DISULFID    561    571       By similarity.
SQ   SEQUENCE   577 AA;  62679 MW;  07562EADEDCDB716 CRC64;
     MLWPCLLALL LSQLNFLCAA RPGPGPNFLL IMADDLGIGD LGCYGNRTLR TPHIDRLALE
     GVKLTQHLAA APLCTPSRAA FLTGRYPVRS GMASHGRLGV FLFSASSGGL PPNEVTFAKL
     LKGQGYTTGL VGKWHLGLSC QAASDFCHHP GRHGFDRFLG TPTTNLRDCK PGGGTVFGSA
     QQVFVVLPMN ILGAVLLAMA LARWAGLARP PGWVFGVTVA AMAAVGGAYV AFLYHFRPAN
     CFLMADFTIT QQPTDYKGLT QRLASEAGDF LRRNRDTPFL LFLSFMHVHT AHFANPEFAG
     QSLHGAYGDA VEEMDWAVGQ VLATLDKLGL ANNTLVYLTS DHGAHVEELG PNGERHGGSN
     GIYRGGKANT WEGGIRVPGL VRWPGVIVPG QEVEEPTSNM DVFPTVARLA GAELPTDRVI
     DGRDLMPLLL GHVQHSEHEF LFHYCNAYLS AVAWRPHNSS SVWKAFYFTP NFDPPGSNGC
     FSTHVCMCHG HHVTHHDPPL LFDIARDPRE RHPLTPETEP RHGEILRNMD AAARAHVATL
     EEAPNQLSMS NVAWKPWLQL CLPSKPHPLA CRCAGDG
//
ID   TAAC_ARATH              Reviewed;         415 AA.
AC   Q9M024; Q8LCT8;
DT   15-JAN-2008, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   02-MAR-2010, entry version 66.
DE   RecName: Full=Thylakoid ADP,ATP carrier protein, chloroplastic;
DE   AltName: Full=Thylakoid ADP/ATP translocase;
DE   Flags: Precursor;
GN   Name=TAAC; OrderedLocusNames=At5g01500; ORFNames=F7A7.20;
OS   Arabidopsis thaliana (Mouse-ear cress).
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
OC   rosids; malvids; Brassicales; Brassicaceae; Arabidopsis.
OX   NCBI_TaxID=3702;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=cv. Columbia;
RX   MEDLINE=21016721; PubMed=11130714; DOI=10.1038/35048507;
RA   Tabata S., Kaneko T., Nakamura Y., Kotani H., Kato T., Asamizu E.,
RA   Miyajima N., Sasamoto S., Kimura T., Hosouchi T., Kawashima K.,
RA   Kohara M., Matsumoto M., Matsuno A., Muraki A., Nakayama S.,
RA   Nakazaki N., Naruo K., Okumura S., Shinpo S., Takeuchi C., Wada T.,
RA   Watanabe A., Yamada M., Yasuda M., Sato S., de la Bastide M.,
RA   Huang E., Spiegel L., Gnoj L., O'Shaughnessy A., Preston R.,
RA   Habermann K., Murray J., Johnson D., Rohlfing T., Nelson J.,
RA   Stoneking T., Pepin K., Spieth J., Sekhon M., Armstrong J., Becker M.,
RA   Belter E., Cordum H., Cordes M., Courtney L., Courtney W., Dante M.,
RA   Du H., Edwards J., Fryman J., Haakensen B., Lamar E., Latreille P.,
RA   Leonard S., Meyer R., Mulvaney E., Ozersky P., Riley A., Strowmatt C.,
RA   Wagner-McPherson C., Wollam A., Yoakum M., Bell M., Dedhia N.,
RA   Parnell L., Shah R., Rodriguez M., Hoon See L., Vil D., Baker J.,
RA   Kirchoff K., Toth K., King L., Bahret A., Miller B., Marra M.A.,
RA   Martienssen R., McCombie W.R., Wilson R.K., Murphy G., Bancroft I.,
RA   Volckaert G., Wambutt R., Duesterhoeft A., Stiekema W., Pohl T.,
RA   Entian K.-D., Terryn N., Hartley N., Bent E., Johnson S.,
RA   Langham S.-A., McCullagh B., Robben J., Grymonprez B., Zimmermann W.,
RA   Ramsperger U., Wedler H., Balke K., Wedler E., Peters S.,
RA   van Staveren M., Dirkse W., Mooijman P., Klein Lankhorst R.,
RA   Weitzenegger T., Bothe G., Rose M., Hauf J., Berneiser S., Hempel S.,
RA   Feldpausch M., Lamberth S., Villarroel R., Gielen J., Ardiles W.,
RA   Bents O., Lemcke K., Kolesov G., Mayer K.F.X., Rudd S., Schoof H.,
RA   Schueller C., Zaccaria P., Mewes H.-W., Bevan M., Fransz P.F.;
RT   "Sequence and analysis of chromosome 5 of the plant Arabidopsis
RT   thaliana.";
RL   Nature 408:823-826(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=cv. Columbia;
RX   MEDLINE=22954850; PubMed=14593172; DOI=10.1126/science.1088305;
RA   Yamada K., Lim J., Dale J.M., Chen H., Shinn P., Palm C.J.,
RA   Southwick A.M., Wu H.C., Kim C.J., Nguyen M., Pham P.K., Cheuk R.F.,
RA   Karlin-Newmann G., Liu S.X., Lam B., Sakano H., Wu T., Yu G.,
RA   Miranda M., Quach H.L., Tripp M., Chang C.H., Lee J.M., Toriumi M.J.,
RA   Chan M.M., Tang C.C., Onodera C.S., Deng J.M., Akiyama K., Ansari Y.,
RA   Arakawa T., Banh J., Banno F., Bowser L., Brooks S.Y., Carninci P.,
RA   Chao Q., Choy N., Enju A., Goldsmith A.D., Gurjal M., Hansen N.F.,
RA   Hayashizaki Y., Johnson-Hopson C., Hsuan V.W., Iida K., Karnes M.,
RA   Khan S., Koesema E., Ishida J., Jiang P.X., Jones T., Kawai J.,
RA   Kamiya A., Meyers C., Nakajima M., Narusaka M., Seki M., Sakurai T.,
RA   Satou M., Tamse R., Vaysberg M., Wallender E.K., Wong C., Yamamura Y.,
RA   Yuan S., Shinozaki K., Davis R.W., Theologis A., Ecker J.R.;
RT   "Empirical analysis of transcriptional activity in the Arabidopsis
RT   genome.";
RL   Science 302:842-846(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Brover V.V., Troukhan M.E., Alexandrov N.A., Lu Y.-P., Flavell R.B.,
RA   Feldmann K.A.;
RT   "Full-length cDNA from Arabidopsis thaliana.";
RL   Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   IDENTIFICATION, FUNCTION, DISRUPTION PHENOTYPE, DEVELOPMENTAL STAGE,
RP   TISSUE SPECIFICITY, SUBCELLULAR LOCATION, ENZYME REGULATION, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=17261580; DOI=10.1074/jbc.M609130200;
RA   Thuswaldner S., Lagerstedt J.O., Rojas-Stuetz M., Bouhidel K., Der C.,
RA   Leborgne-Castel N., Mishra A., Marty F., Schoefs B., Adamska I.,
RA   Persson B.L., Spetea C.;
RT   "Identification, expression, and functional analyses of a thylakoid
RT   ATP/ADP carrier from Arabidopsis.";
RL   J. Biol. Chem. 282:8848-8859(2007).
CC   -!- FUNCTION: Specifically transports adenine nucleotides. Involved in
CC       the uptake of ATP into thylakoids in exchange for lumenal ADP.
CC   -!- ENZYME REGULATION: KM and Vmax values toward ATP only are
CC       increased by m-chlorocarbonyl cyanide phenylhydrazone (CCCP). The
CC       corresponding values for ADP are not affected.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=47 uM for ATP (for the recombinant protein);
CC         KM=0.5 uM for ATP (in vivo);
CC         KM=45 uM for ADP (for the recombinant protein);
CC         Vmax=0.71 nmol/h/mg enzyme toward ATP (for the recombinant
CC         protein);
CC         Vmax=0.53 nmol/h/mg enzyme toward ADP (for the recombinant
CC         protein);
CC   -!- SUBCELLULAR LOCATION: Plastid, chloroplast thylakoid membrane;
CC       Multi-pass membrane protein. Plastid, chloroplast envelope.
CC       Note=Detected only in low amounts in the chloroplast envelope and
CC       in non-photosynthetic plastids.
CC   -!- TISSUE SPECIFICITY: Highly expressed in developing photosynthetic
CC       organs such as leaves, flower buds and green siliques. Also
CC       detected in roots, flowers, mature leaves and stems.
CC   -!- DEVELOPMENTAL STAGE: Expressed in dark-grown seedlings and remains
CC       stable throughout the greening process. Highest expression in
CC       developing green tissues and in leaves undergoing senescence or
CC       abiotic stress, with the exception of heat shock conditions that
CC       induced a drastic reduction of expression.
CC   -!- DISRUPTION PHENOTYPE: Plants show a 30-40% reduction in the
CC       thylakoid ATP transport and metabolism.
CC   -!- SIMILARITY: Belongs to the mitochondrial carrier family.
CC   -!- SIMILARITY: Contains 3 Solcar repeats.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AL161946; CAB82266.1; -; Genomic_DNA.
DR   EMBL; AY074566; AAL67106.1; -; mRNA.
DR   EMBL; BT006336; AAP21144.1; -; mRNA.
DR   EMBL; AY086408; AAM64475.1; -; mRNA.
DR   IPI; IPI00523181; -.
DR   PIR; T48171; T48171.
DR   RefSeq; NP_195770.1; -.
DR   UniGene; At.43427; -.
DR   HSSP; P02722; 1OKC.
DR   SMR; Q9M024; 118-383.
DR   TCDB; 2.A.29.23.3; mitochondrial carrier (MC) family.
DR   PRIDE; Q9M024; -.
DR   GeneID; 831861; -.
DR   GenomeReviews; BA000015_GR; AT5G01500.
DR   KEGG; ath:AT5G01500; -.
DR   NMPDR; fig|3702.1.peg.22216; -.
DR   GeneFarm; 3876; 393.
DR   TAIR; At5g01500; -.
DR   eggNOG; KOG0752; -.
DR   HOGENOM; HBG735918; -.
DR   InParanoid; Q9M024; -.
DR   OMA; NFCVFDL; -.
DR   PhylomeDB; Q9M024; -.
DR   Genevestigator; Q9M024; -.
DR   GO; GO:0009941; C:chloroplast envelope; IDA:TAIR.
DR   GO; GO:0009535; C:chloroplast thylakoid membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IEA:InterPro.
DR   GO; GO:0005347; F:ATP transmembrane transporter activity; IDA:TAIR.
DR   GO; GO:0005488; F:binding; IEA:InterPro.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR002067; Mit_carrier.
DR   InterPro; IPR001993; Mitochondria_substrate_carrier.
DR   InterPro; IPR018108; Mitochondrial_sb/sol_carrier.
DR   PANTHER; PTHR11896; Mitoch_carrier; 1.
DR   Pfam; PF00153; Mito_carr; 3.
DR   PRINTS; PR00926; MITOCARRIER.
DR   SUPFAM; SSF103506; Mitoch_carrier; 1.
DR   PROSITE; PS50920; SOLCAR; 3.
PE   1: Evidence at protein level;
KW   Chloroplast; Complete proteome; Membrane; Plastid; Repeat; Thylakoid;
KW   Transit peptide; Transmembrane; Transport.
FT   TRANSIT       1     61       Chloroplast (Potential).
FT   CHAIN        62    415       Thylakoid ADP,ATP carrier protein,
FT                                chloroplastic.
FT                                /FTId=PRO_0000313084.
FT   TRANSMEM    106    126       1 (By similarity).
FT   TRANSMEM    182    207       2 (By similarity).
FT   TRANSMEM    219    239       3 (By similarity).
FT   TRANSMEM    273    293       4 (By similarity).
FT   TRANSMEM    309    329       5 (Potential).
FT   TRANSMEM    362    388       6 (By similarity).
FT   REPEAT      113    205       Solcar 1.
FT   REPEAT      213    296       Solcar 2.
FT   REPEAT      307    387       Solcar 3.
FT   COMPBIAS     74     78       Poly-Gly.
FT   BINDING     187    187       Nucleotide (By similarity).
FT   CONFLICT    411    411       I -> T (in Ref. 3; AAM64475).
SQ   SEQUENCE   415 AA;  45090 MW;  D32B575A04994C2B CRC64;
     MGEEKSLLQF RSFPSLKTSD FALTEEPSWR LENNVSSNRR RGNKRSGGVF TNFASLSVAI
     RRDRRESTFN GRNGGGGGAF ASVSVVIPKE EDEFAPTSAQ LLKNPIALLS IVPKDAALFF
     AGAFAGAAAK SVTAPLDRIK LLMQTHGVRA GQQSAKKAIG FIEAITLIGK EEGIKGYWKG
     NLPQVIRIVP YSAVQLFAYE TYKKLFRGKD GQLSVLGRLG AGACAGMTST LITYPLDVLR
     LRLAVEPGYR TMSQVALNML REEGVASFYN GLGPSLLSIA PYIAINFCVF DLVKKSLPEK
     YQQKTQSSLL TAVVAAAIAT GTCYPLDTIR RQMQLKGTPY KSVLDAFSGI IAREGVVGLY
     RGFVPNALKS MPNSSIKLTT FDIVKKLIAA SEKEIQRIAD DNRKKASPNT IDEQT
//
ID   US9_BHV1S               Reviewed;         158 AA.
AC   Q08098;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   02-MAR-2010, entry version 39.
DE   RecName: Full=Envelope protein US9;
GN   ORFNames=US9;
OS   Bovine herpesvirus 1.2 (strain ST) (BoHV-1) (Infectious bovine
OS   rhinotracheitis virus).
OC   Viruses; dsDNA viruses, no RNA stage; Herpesvirales; Herpesviridae;
OC   Alphaherpesvirinae; Varicellovirus.
OX   NCBI_TaxID=45407;
OH   NCBI_TaxID=9913; Bos taurus (Bovine).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=94167875; PubMed=8122370; DOI=10.1006/viro.1994.1139;
RA   Leung-Tack P., Audonnet J.F., Riviere M.;
RT   "The complete DNA sequence and the genetic organization of the short
RT   unique region (US) of the bovine herpesvirus type 1 (ST strain).";
RL   Virology 199:409-421(1994).
RN   [2]
RP   TOPOLOGY, AND SUBCELLULAR LOCATION.
RC   STRAIN=Jura;
RX   PubMed=19420087; DOI=10.1128/JVI.00598-09;
RA   Lyman M.G., Kemp C.D., Taylor M.P., Enquist L.W.;
RT   "Comparison of the pseudorabies virus Us9 protein with homologs from
RT   other veterinary and human alphaherpesviruses.";
RL   J. Virol. 83:6978-6986(2009).
CC   -!- FUNCTION: Essential for the anterograde spread of the infection
CC       throughout the host nervous system. Together with the gE/gI
CC       heterodimer, US9 is involved in the sorting and transport of viral
CC       structural components toward axon tips (By similarity).
CC   -!- SUBCELLULAR LOCATION: Virion membrane; Single-pass type II
CC       membrane protein (By similarity). Host Golgi apparatus membrane;
CC       Single-pass type II membrane protein. Host smooth endoplasmic
CC       reticulum membrane; Single-pass type II membrane protein (By
CC       similarity). Host cell membrane; Single-pass type II membrane
CC       protein (Potential). Note=During virion morphogenesis, this
CC       protein probably accumulates in the endosomes and trans-Golgi
CC       where secondary envelopment occurs. It is probably transported to
CC       the cell surface from where it is endocytosed and directed to the
CC       trans-Golgi network (TGN), maybe through an interaction with PACS-
CC       1 sorting protein.
CC   -!- PTM: Phosphorylated on serines within the acidic cluster, possibly
CC       by host CK2 (Potential). Phosphorylation determines whether
CC       endocytosed viral US9 traffics to the trans-Golgi network or
CC       recycles to the cell membrane (Potential).
CC   -!- SIMILARITY: Belongs to the alphaherpesvirinae envelope protein US9
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z23068; CAA80607.1; -; Genomic_DNA.
DR   PIR; S35787; S35787.
DR   GO; GO:0044178; C:host cell Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044171; C:host cell smooth endoplasmic reticulum memb...; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0019033; C:viral tegument; IEA:InterPro.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   InterPro; IPR009278; Herpes_US9.
DR   Pfam; PF06072; Herpes_US9; 1.
PE   1: Evidence at protein level;
KW   Envelope protein; Host cell membrane; Host endoplasmic reticulum;
KW   Host Golgi apparatus; Host membrane; Membrane; Phosphoprotein;
KW   Signal-anchor; Transmembrane; Virion.
FT   CHAIN         1    158       Envelope protein US9.
FT                                /FTId=PRO_0000116138.
FT   TOPO_DOM      1    134       Cytoplasmic (By similarity).
FT   TRANSMEM    135    155       Signal-anchor for type II membrane
FT                                protein (By similarity).
FT   TOPO_DOM    156    158       Extracellular (By similarity).
FT   REGION       93    108       Acidic.
FT   MOTIF        86     89       Internalization motif (Potential).
FT   COMPBIAS     68     73       Poly-Ala.
FT   COMPBIAS    118    125       Arg-rich (basic).
FT   COMPBIAS    139    148       Poly-Ala.
FT   MOD_RES      99     99       Phosphoserine; by host CK2 (Potential).
FT   MOD_RES     101    101       Phosphoserine; by host CK2 (Potential).
SQ   SEQUENCE   158 AA;  16266 MW;  01870BECC322B2F4 CRC64;
     MERSHKASCG CFEGMESPRS VVNENYRGAD EADAAPPSPP PEGSIVSIPI LELTIEDAPA
     SAEATGTAAA APAGRTPDAN AAPGGYVPVP AADADCYYSE SDSETAGEFL IRMGRQQRRR
     HRRRRCMIAA ALTCIGLGAC AAAAAAGAVL ALEVVPRP
//
ID   US9_EHV1K               Reviewed;         219 AA.
AC   P32513;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1993, sequence version 1.
DT   02-MAR-2010, entry version 42.
DE   RecName: Full=Envelope protein US9 homolog;
DE   AltName: Full=Envelope protein 76;
DE   AltName: Full=ORF76 protein;
GN   OrderedLocusNames=76;
OS   Equine herpesvirus 1 (strain Kentucky A) (EHV-1) (Equine abortion
OS   virus).
OC   Viruses; dsDNA viruses, no RNA stage; Herpesvirales; Herpesviridae;
OC   Alphaherpesvirinae; Varicellovirus.
OX   NCBI_TaxID=10329;
OH   NCBI_TaxID=9796; Equus caballus (Horse).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=92410608; PubMed=1326805; DOI=10.1016/0042-6822(92)91217-I;
RA   Flowers C.C., O'Callaghan D.J.;
RT   "The equine herpesvirus type 1 (EHV-1) homolog of herpes simplex virus
RT   type 1 US9 and the nature of a major deletion within the unique short
RT   segment of the EHV-1 KyA strain genome.";
RL   Virology 190:307-315(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=92263758; PubMed=1316673; DOI=10.1016/0042-6822(92)90509-N;
RA   Colle C.F. III, Flowers C.C., O'Callaghan D.J.;
RT   "Open reading frames encoding a protein kinase, homolog of
RT   glycoprotein gX of pseudorabies virus, and a novel glycoprotein map
RT   within the unique short segment of equine herpesvirus type 1.";
RL   Virology 188:545-557(1992).
RN   [3]
RP   TOPOLOGY, AND SUBCELLULAR LOCATION.
RX   PubMed=19420087; DOI=10.1128/JVI.00598-09;
RA   Lyman M.G., Kemp C.D., Taylor M.P., Enquist L.W.;
RT   "Comparison of the pseudorabies virus Us9 protein with homologs from
RT   other veterinary and human alphaherpesviruses.";
RL   J. Virol. 83:6978-6986(2009).
CC   -!- FUNCTION: Essential for the anterograde spread of the infection
CC       throughout the host nervous system. Together with the gE/gI
CC       heterodimer, US9 is involved in the sorting and transport of viral
CC       structural components toward axon tips (By similarity).
CC   -!- SUBCELLULAR LOCATION: Virion membrane; Single-pass type II
CC       membrane protein (By similarity). Host Golgi apparatus membrane;
CC       Single-pass type II membrane protein. Host smooth endoplasmic
CC       reticulum membrane; Single-pass type II membrane protein (By
CC       similarity). Host cell membrane; Single-pass type II membrane
CC       protein (Potential). Note=During virion morphogenesis, this
CC       protein probably accumulates in the endosomes and trans-Golgi
CC       where secondary envelopment occurs. It is probably transported to
CC       the cell surface from where it is endocytosed and directed to the
CC       trans-Golgi network (TGN), maybe through an interaction with PACS-
CC       1 sorting protein.
CC   -!- PTM: Phosphorylated on serines within the acidic cluster
CC       (Potential). Phosphorylation determines whether endocytosed viral
CC       US9 traffics to the trans-Golgi network or recycles to the cell
CC       membrane (Potential).
CC   -!- SIMILARITY: Belongs to the alphaherpesvirinae envelope protein US9
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M86931; AAA46105.1; -; Genomic_DNA.
DR   EMBL; M87497; AAA46074.1; -; Genomic_DNA.
DR   PIR; A43378; TEBEKA.
DR   GO; GO:0044178; C:host cell Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044171; C:host cell smooth endoplasmic reticulum memb...; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0019033; C:viral tegument; IEA:InterPro.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   InterPro; IPR009278; Herpes_US9.
DR   Pfam; PF06072; Herpes_US9; 1.
PE   1: Evidence at protein level;
KW   Envelope protein; Host cell membrane; Host endoplasmic reticulum;
KW   Host Golgi apparatus; Host membrane; Membrane; Phosphoprotein;
KW   Signal-anchor; Transmembrane; Virion.
FT   CHAIN         1    219       Envelope protein US9 homolog.
FT                                /FTId=PRO_0000116135.
FT   TOPO_DOM      1    193       Cytoplasmic (By similarity).
FT   TRANSMEM    194    214       Signal-anchor for type II membrane
FT                                protein (By similarity).
FT   TOPO_DOM    215    219       Extracellular (By similarity).
FT   REGION      153    168       Acidic.
FT   MOTIF       145    146       Di-leucine internalization motif
FT                                (Potential).
FT   COMPBIAS     43     55       Poly-Ala.
FT   COMPBIAS    175    189       Arg-rich (basic).
FT   MOD_RES     163    163       Phosphoserine; by host CK2 (Potential).
FT   MOD_RES     165    165       Phosphoserine; by host CK2 (Potential).
SQ   SEQUENCE   219 AA;  22358 MW;  20B2313D27CE18C5 CRC64;
     MEKAEAAAVV IPLSVSNPSY RGSGMSDQEV SEEQSAGDAW VSAAMAAAEA VAAAATSTGI
     DNTNDYTYTA ASENGDPGFT LGDNTYGPNG AASGCPSPPS PEVVGLEMVV VSSLAPEIAA
     AVPADTISAS AAAPATRVDD GNAPLLGPGQ AQDYDSESGC YYSESDNETA SMFIRRVGRR
     QARRHRRRRV ALTVAGVILV VVLCAISGIV GAFLARVFP
//
ID   US9_HHV11               Reviewed;          90 AA.
AC   P06481; B9VQK4; Q09I67;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1988, sequence version 1.
DT   02-MAR-2010, entry version 59.
DE   RecName: Full=Envelope protein US9;
DE   AltName: Full=10 kDa protein;
GN   ORFNames=US9;
OS   Human herpesvirus 1 (strain 17) (HHV-1) (Human herpes simplex virus
OS   1).
OC   Viruses; dsDNA viruses, no RNA stage; Herpesvirales; Herpesviridae;
OC   Alphaherpesvirinae; Simplexvirus.
OX   NCBI_TaxID=10299;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=85160822; PubMed=2984429; DOI=10.1016/0022-2836(85)90320-1;
RA   McGeoch D.J., Dolan A., Donald S., Rixon F.J.;
RT   "Sequence determination and genetic content of the short unique region
RT   in the genome of herpes simplex virus type 1.";
RL   J. Mol. Biol. 181:1-13(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   MEDLINE=88274327; PubMed=2839594;
RA   McGeoch D.J., Dalrymple M.A., Davison A.J., Dolan A., Frame M.C.,
RA   McNab D., Perry L.J., Scott J.E., Taylor P.;
RT   "The complete DNA sequence of the long unique region in the genome of
RT   herpes simplex virus type 1.";
RL   J. Gen. Virol. 69:1531-1574(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Nonneuroinvasive mutant HF10;
RX   PubMed=17218138; DOI=10.1016/j.micinf.2006.10.019;
RA   Ushijima Y., Luo C., Goshima F., Yamauchi Y., Kimura H., Nishiyama Y.;
RT   "Determination and analysis of the DNA sequence of highly attenuated
RT   herpes simplex virus type 1 mutant HF10, a potential oncolytic
RT   virus.";
RL   Microbes Infect. 9:142-149(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=17 syn+;
RA   Cunningham C., Davison A.J.;
RT   "Herpes simplex virus type 1 bacterial artificial chromosome.";
RL   Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RC   STRAIN=F;
RX   PubMed=17382478; DOI=10.1016/j.neuroscience.2007.02.010;
RA   LaVail J.H., Tauscher A.N., Sucher A., Harrabi O., Brandimarti R.;
RT   "Viral regulation of the long distance axonal transport of herpes
RT   simplex virus nucleocapsid.";
RL   Neuroscience 146:974-985(2007).
RN   [6]
RP   FUNCTION.
RC   STRAIN=F;
RX   PubMed=18753205; DOI=10.1128/JVI.01241-08;
RA   Snyder A., Polcicova K., Johnson D.C.;
RT   "Herpes simplex virus gE/gI and US9 proteins promote transport of both
RT   capsids and virion glycoproteins in neuronal axons.";
RL   J. Virol. 82:10613-10624(2008).
RN   [7]
RP   SUBCELLULAR LOCATION.
RC   STRAIN=F;
RX   PubMed=18596102; DOI=10.1128/JVI.00904-08;
RA   Loret S., Guay G., Lippe R.;
RT   "Comprehensive characterization of extracellular herpes simplex virus
RT   type 1 virions.";
RL   J. Virol. 82:8605-8618(2008).
RN   [8]
RP   TOPOLOGY, AND SUBCELLULAR LOCATION.
RX   PubMed=19420087; DOI=10.1128/JVI.00598-09;
RA   Lyman M.G., Kemp C.D., Taylor M.P., Enquist L.W.;
RT   "Comparison of the pseudorabies virus Us9 protein with homologs from
RT   other veterinary and human alphaherpesviruses.";
RL   J. Virol. 83:6978-6986(2009).
CC   -!- FUNCTION: Essential for the anterograde spread of the infection
CC       throughout the host nervous system. Together with the gE/gI
CC       heterodimer, US9 is involved in the sorting and transport of viral
CC       structural components toward axon tips.
CC   -!- SUBCELLULAR LOCATION: Virion membrane; Single-pass type II
CC       membrane protein. Host Golgi apparatus membrane; Single-pass type
CC       II membrane protein. Host smooth endoplasmic reticulum membrane;
CC       Single-pass type II membrane protein (Probable). Host cell
CC       membrane; Single-pass type II membrane protein (Potential).
CC       Note=During virion morphogenesis, this protein probably
CC       accumulates in the endosomes and trans-Golgi where secondary
CC       envelopment occurs. It is probably transported to the cell surface
CC       from where it is endocytosed and directed to the trans-Golgi
CC       network (TGN), maybe through an interaction with PACS-1 sorting
CC       protein (Potential).
CC   -!- PTM: Phosphorylated on serines within the acidic cluster, possibly
CC       by host CK2 (Potential). Phosphorylation determines whether
CC       endocytosed viral US9 traffics to the trans-Golgi network or
CC       recycles to the cell membrane (Potential).
CC   -!- SIMILARITY: Belongs to the alphaherpesvirinae envelope protein US9
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L00036; AAA96679.1; -; Genomic_DNA.
DR   EMBL; X14112; CAA32274.1; -; Genomic_DNA.
DR   EMBL; X02138; CAA26063.1; -; Genomic_DNA.
DR   EMBL; DQ889502; ABI63528.1; -; Genomic_DNA.
DR   EMBL; FJ593289; ACM62299.1; -; Genomic_DNA.
DR   PIR; A05241; QQBE79.
DR   RefSeq; NP_044672.1; -.
DR   GeneID; 2703452; -.
DR   ProtClustDB; CLSP2510183; -.
DR   GO; GO:0044178; C:host cell Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044171; C:host cell smooth endoplasmic reticulum memb...; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0019033; C:viral tegument; IEA:InterPro.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   InterPro; IPR009278; Herpes_US9.
DR   Pfam; PF06072; Herpes_US9; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Envelope protein; Host cell membrane;
KW   Host endoplasmic reticulum; Host Golgi apparatus; Host membrane;
KW   Membrane; Phosphoprotein; Signal-anchor; Transmembrane; Virion;
KW   Virus reference strain.
FT   CHAIN         1     90       Envelope protein US9.
FT                                /FTId=PRO_0000116132.
FT   TOPO_DOM      1     67       Cytoplasmic (By similarity).
FT   TRANSMEM     68     88       Signal-anchor for type II membrane
FT                                protein (By similarity).
FT   TOPO_DOM     89     90       Extracellular (By similarity).
FT   REGION       30     39       Acidic.
FT   MOTIF        21     24       Internalization motif (Potential).
FT   COMPBIAS     56     63       Arg-rich (basic).
FT   MOD_RES      34     34       Phosphoserine; by host CK2 (Potential).
FT   MOD_RES      36     36       Phosphoserine; by host CK2 (Potential).
FT   VARIANT      29     29       V -> A (in strain: Nonneuroinvasive
FT                                mutant HF10).
SQ   SEQUENCE   90 AA;  10027 MW;  F4D4DC2608BB38F7 CRC64;
     MTSRLSDPNS SARSDMSVPL YPTASPVSVE AYYSESEDEA ANDFLVRMGR QQSVLRRRRR
     RTRCVGMVIA CLLVAVLSGG FGALLMWLLR
//
ID   US9_VZVD                Reviewed;         102 AA.
AC   P09312;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   02-MAR-2010, entry version 49.
DE   RecName: Full=Envelope protein US9;
DE   AltName: Full=Envelope protein 65;
DE   AltName: Full=ORF65 protein;
GN   ORFNames=ORF65;
OS   Varicella-zoster virus (strain Dumas) (HHV-3) (Human herpesvirus 3).
OC   Viruses; dsDNA viruses, no RNA stage; Herpesvirales; Herpesviridae;
OC   Alphaherpesvirinae; Varicellovirus.
OX   NCBI_TaxID=10338;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=84131932; PubMed=6321154;
RA   Davison A.J.;
RT   "DNA sequence of the US component of the varicella-zoster virus
RT   genome.";
RL   EMBO J. 2:2203-2209(1983).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   MEDLINE=86306657; PubMed=3018124;
RA   Davison A.J., Scott J.E.;
RT   "The complete DNA sequence of varicella-zoster virus.";
RL   J. Gen. Virol. 67:1759-1816(1986).
RN   [3]
RP   SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=11162819; DOI=10.1006/viro.2000.0741;
RA   Cohen J.I., Sato H., Srinivas S., Lekstrom K.;
RT   "Varicella-zoster virus (VZV) ORF65 virion protein is dispensable for
RT   replication in cell culture and is phosphorylated by casein kinase II,
RT   but not by the VZV protein kinases.";
RL   Virology 280:62-71(2001).
RN   [4]
RP   TOPOLOGY, AND SUBCELLULAR LOCATION.
RX   PubMed=19420087; DOI=10.1128/JVI.00598-09;
RA   Lyman M.G., Kemp C.D., Taylor M.P., Enquist L.W.;
RT   "Comparison of the pseudorabies virus Us9 protein with homologs from
RT   other veterinary and human alphaherpesviruses.";
RL   J. Virol. 83:6978-6986(2009).
CC   -!- FUNCTION: Essential for the anterograde spread of the infection
CC       throughout the host nervous system. Together with the gE/gI
CC       heterodimer, US9 is involved in the sorting and transport of viral
CC       structural components toward axon tips.
CC   -!- SUBCELLULAR LOCATION: Virion membrane; Single-pass type II
CC       membrane protein (By similarity). Host Golgi apparatus membrane;
CC       Single-pass type II membrane protein. Host smooth endoplasmic
CC       reticulum membrane; Single-pass type II membrane protein (By
CC       similarity). Host cell membrane; Single-pass type II membrane
CC       protein (Potential). Note=During virion morphogenesis, this
CC       protein probably accumulates in the endosomes and trans-Golgi
CC       where secondary envelopment occurs. It is probably transported to
CC       the cell surface from where it is endocytosed and directed to the
CC       trans-Golgi network (TGN), maybe through an interaction with PACS-
CC       1 sorting protein.
CC   -!- PTM: Phosphorylated on serines within the acidic cluster, possibly
CC       by host CK2 (Potential). Phosphorylation determines whether
CC       endocytosed viral US9 traffics to the trans-Golgi network or
CC       recycles to the cell membrane (Potential).
CC   -!- SIMILARITY: Belongs to the alphaherpesvirinae envelope protein US9
CC       family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X04370; CAA27948.1; -; Genomic_DNA.
DR   EMBL; X00208; CAA25030.1; -; Genomic_DNA.
DR   PIR; D27345; WZBE65.
DR   RefSeq; NP_040187.1; -.
DR   GeneID; 1487702; -.
DR   ProtClustDB; CLSP2509642; -.
DR   GO; GO:0044178; C:host cell Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044171; C:host cell smooth endoplasmic reticulum memb...; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR   GO; GO:0019033; C:viral tegument; IEA:InterPro.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   InterPro; IPR009278; Herpes_US9.
DR   Pfam; PF06072; Herpes_US9; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Envelope protein; Host cell membrane;
KW   Host endoplasmic reticulum; Host Golgi apparatus; Host membrane;
KW   Membrane; Phosphoprotein; Signal-anchor; Transmembrane; Virion;
KW   Virus reference strain.
FT   CHAIN         1    102       Envelope protein US9.
FT                                /FTId=PRO_0000116142.
FT   TOPO_DOM      1     75       Cytoplasmic (By similarity).
FT   TRANSMEM     76     96       Signal-anchor for type II membrane
FT                                protein (By similarity).
FT   TOPO_DOM     97    102       Extracellular (By similarity).
FT   REGION       41     55       Acidic.
FT   MOTIF        14     15       Di-leucine internalization motif
FT                                (Potential).
FT   MOD_RES      46     46       Phosphoserine; by host CK2 (Potential).
FT   MOD_RES      48     48       Phosphoserine; by host CK2 (Potential).
SQ   SEQUENCE   102 AA;  11436 MW;  18801A669057A3A3 CRC64;
     MAGQNTMEGE AVALLMEAVV TPRAQPNNTT ITAIQPSRSA EKCYYSDSEN ETADEFLRRI
     GKYQHKIYHR KKFCYITLII VFVFAMTGAA FALGYITSQF VG
//
ID   VDAC1_BOVIN             Reviewed;         283 AA.
AC   P45879; Q3ZCK0; Q71SW7;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-MAR-2010, entry version 73.
DE   RecName: Full=Voltage-dependent anion-selective channel protein 1;
DE            Short=VDAC-1;
DE   AltName: Full=Plasmalemmal porin;
DE   AltName: Full=Brain-derived voltage-dependent anion channel 1;
DE            Short=BR1-VDAC;
GN   Name=VDAC1;
OS   Bos taurus (Bovine).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Ruminantia;
OC   Pecora; Bovidae; Bovinae; Bos.
OX   NCBI_TaxID=9913;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Brain;
RX   MEDLINE=94119914; PubMed=7507248; DOI=10.1073/pnas.91.2.499;
RA   Dermietzel R., Hwang T.-K., Buettner R., Hofer A., Dotzler E.,
RA   Kremer M., Deutzmann R., Thinnes F.P., Fishman G.I., Spray D.C.,
RA   Siemen D.;
RT   "Cloning and in situ localization of a brain-derived porin that
RT   constitutes a large-conductance anion channel in astrocytic plasma
RT   membranes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:499-503(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lens;
RA   Rae J.L.;
RT   "Ion channels in the lens.";
RL   Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=Crossbred X Angus; TISSUE=Ileum;
RG   NIH - Mammalian Gene Collection (MGC) project;
RL   Submitted (AUG-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   ACTIVE SITE.
RX   PubMed=7685355;
RA   De Pinto V., Al Jamal J.A., Palmieri F.;
RT   "Location of the dicyclohexylcarbodiimide-reactive glutamate residue
RT   in the bovine heart mitochondrial porin.";
RL   J. Biol. Chem. 268:12977-12982(1993).
CC   -!- FUNCTION: Forms a channel through the mitochondrial outer membrane
CC       and also the plasma membrane. The channel at the outer
CC       mitochondrial membrane allows diffusion of small hydrophilic
CC       molecules; in the plasma membrane it is involved in cell volume
CC       regulation and apoptosis. It adopts an open conformation at low or
CC       zero membrane potential and a closed conformation at potentials
CC       above 30-40 mV. The open state has a weak anion selectivity
CC       whereas the closed state is cation-selective. May participate in
CC       the formation of the permeability transition pore complex (PTPC)
CC       responsible for the release of mitochondrial products that
CC       triggers apoptosis.
CC   -!- SUBUNIT: Interacts with hexokinases (Probable). Interacts with
CC       BCL2L1 (By similarity).
CC   -!- SUBCELLULAR LOCATION: Mitochondrion outer membrane. Cell membrane.
CC   -!- TISSUE SPECIFICITY: Predominantly in brain astrocytes.
CC   -!- DOMAIN: Consists mainly of a membrane-spanning beta-barrel formed
CC       by 19 beta-strands. The helical N-terminus folds back into the
CC       pore opening and plays a role in voltage-gated channel activity
CC       (By similarity).
CC   -!- MISCELLANEOUS: Dicyclohexylcarbodiimide (DCCD) binding on Glu-73
CC       inhibits hexokinase binding in vitro.
CC   -!- SIMILARITY: Belongs to the eukaryotic mitochondrial porin family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X75068; CAA52962.1; -; mRNA.
DR   EMBL; AF268464; AAF80101.1; -; mRNA.
DR   EMBL; BC102113; AAI02114.1; -; mRNA.
DR   IPI; IPI00703129; -.
DR   PIR; A36875; A36875.
DR   RefSeq; NP_776910.2; -.
DR   UniGene; Bt.49674; -.
DR   STRING; P45879; -.
DR   TCDB; 1.B.8.1.3; mitochondrial and plastid porin (MPP) family.
DR   Ensembl; ENSBTAT00000017430; ENSBTAP00000017430; ENSBTAG00000013113; Bos taurus.
DR   Ensembl; ENSBTAT00000053816; ENSBTAP00000049262; ENSBTAG00000013113; Bos taurus.
DR   GeneID; 282119; -.
DR   KEGG; bta:282119; -.
DR   CTD; 282119; -.
DR   eggNOG; maNOG11150; -.
DR   HOVERGEN; HBG054036; -.
DR   InParanoid; P45879; -.
DR   OrthoDB; EOG92FW36; -.
DR   PhylomeDB; P45879; -.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0046930; C:pore complex; IEA:UniProtKB-KW.
DR   GO; GO:0000166; F:nucleotide binding; IEA:UniProtKB-KW.
DR   GO; GO:0008308; F:voltage-gated anion channel activity; ISS:UniProtKB.
DR   GO; GO:0006820; P:anion transport; IEA:InterPro.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR001925; Porin_Euk.
DR   Pfam; PF01459; Porin_3; 1.
DR   PRINTS; PR00185; EUKARYTPORIN.
DR   PROSITE; PS00558; EUKARYOTIC_PORIN; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Apoptosis; Cell membrane; Direct protein sequencing;
KW   Ion transport; Membrane; Mitochondrion; Mitochondrion outer membrane;
KW   NAD; Nucleotide-binding; Phosphoprotein; Porin; Transmembrane;
KW   Transport.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    283       Voltage-dependent anion-selective channel
FT                                protein 1.
FT                                /FTId=PRO_0000050498.
FT   TRANSMEM     26     35       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     39     47       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     54     64       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     69     76       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     80     89       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     95    104       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    111    120       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    123    130       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    137    145       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    150    158       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    163    175       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    178    185       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    189    198       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    202    211       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    218    227       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    231    238       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    242    251       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    254    263       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    273    282       Transmembrane beta-strand (By
FT                                similarity).
FT   NP_BIND     242    244       NAD (By similarity).
FT   NP_BIND     260    264       NAD (By similarity).
FT   SITE         73     73       Involved in hexokinase binding
FT                                (Probable).
FT   MOD_RES       2      2       N-acetylalanine (By similarity).
FT   MOD_RES      13     13       Phosphoserine (By similarity).
FT   MOD_RES      20     20       N6-acetyllysine (By similarity).
FT   MOD_RES      28     28       N6-acetyllysine (By similarity).
FT   MOD_RES      61     61       N6-acetyllysine (By similarity).
FT   MOD_RES      67     67       Phosphotyrosine (By similarity).
FT   MOD_RES     101    101       Phosphoserine (By similarity).
FT   MOD_RES     104    104       Phosphoserine (By similarity).
FT   MOD_RES     107    107       Phosphothreonine (By similarity).
FT   MOD_RES     137    137       Phosphoserine (By similarity).
FT   MOD_RES     195    195       Phosphotyrosine (By similarity).
FT   MOD_RES     224    224       N6-acetyllysine (By similarity).
FT   MOD_RES     266    266       N6-acetyllysine (By similarity).
FT   CONFLICT      4      6       PPT -> VRP (in Ref. 1; AA sequence).
FT   CONFLICT    109    109       K -> R (in Ref. 1; CAA52962).
FT   CONFLICT    246    246       G -> R (in Ref. 3; AAI02114).
SQ   SEQUENCE   283 AA;  30741 MW;  9CAE6D8D50A18BD5 CRC64;
     MAVPPTYADL GKSARDVFTK GYGFGLIKLD LKTKSENGLE FTSSGSANTE TTKVTGSLET
     KYRWTEYGLT FTEKWNTDNT LGTEITVEDQ LARGLKLTFD SSFSPNTGKK NAKIKTGYKR
     EHINLGCDVD FDIAGPSIRG ALVLGYEGWL AGYQMNFETA KSRVTQSNFA VGYKTDEFQL
     HTNVNDGTEF GGSIYQKVNK KLETAVNLAW TAGNSNTRFG IAAKYQIDPD ACFSAKVNNS
     SLIGLGYTQT LKPGIKLTLS ALLDGKNVNA GGHKLGLGLE FQA
//
ID   VDAC1_RAT               Reviewed;         283 AA.
AC   Q9Z2L0; A1L125; Q3MHT8; Q5M944; Q5M972; Q6IN28; Q6P9W9;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   02-MAR-2010, entry version 73.
DE   RecName: Full=Voltage-dependent anion-selective channel protein 1;
DE            Short=VDAC-1;
DE            Short=rVDAC1;
DE   AltName: Full=Outer mitochondrial membrane protein porin 1;
GN   Name=Vdac1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Heart;
RX   MEDLINE=98390268; PubMed=9714728; DOI=10.1016/S0167-4781(98)00088-8;
RA   Anflous K., Blondel O., Bernard A., Khrestchatisky M.,
RA   Ventura-Clapier R.;
RT   "Characterization of rat porin isoforms: cloning of a cardiac type-3
RT   variant encoding an additional methionine at its putative N-terminal
RT   region.";
RL   Biochim. Biophys. Acta 1399:47-50(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Ascitic tumor;
RX   MEDLINE=20453129; PubMed=10998068;
RX   DOI=10.1046/j.1432-1327.2000.01687.x;
RA   Shinohara Y., Ishida T., Hino M., Yamazaki N., Baba Y., Terada H.;
RT   "Characterization of porin isoforms expressed in tumor cells.";
RL   Eur. J. Biochem. 267:6067-6073(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Lens;
RA   Rae J.L.;
RT   "Ion channels in the lens.";
RL   Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, Embryonic brain, Heart, Ovary, Pituitary, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PROTEIN SEQUENCE OF 2-14 AND 135-138, ACETYLATION AT ALA-2,
RP   PHOSPHORYLATION AT SER-13 AND SER-137, AND MASS SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=17478130; DOI=10.1016/j.bbapap.2007.03.012;
RA   Distler A.M., Kerner J., Hoppel C.L.;
RT   "Post-translational modifications of rat liver mitochondrial outer
RT   membrane proteins identified by mass spectrometry.";
RL   Biochim. Biophys. Acta 1774:628-636(2007).
RN   [6]
RP   PROTEIN SEQUENCE OF 21-28; 33-53; 64-74; 75-93; 97-109; 121-139;
RP   164-197; 201-218 AND 225-266, AND MASS SPECTROMETRY.
RC   STRAIN=Sprague-Dawley; TISSUE=Brain, Hippocampus, and Spinal cord;
RA   Lubec G., Chen W.-Q., Afjehi-Sadat L., Kang S.U.;
RL   Submitted (JUL-2007) to UniProtKB.
CC   -!- FUNCTION: Forms a channel through the mitochondrial outer membrane
CC       and also the plasma membrane. The channel at the outer
CC       mitochondrial membrane allows diffusion of small hydrophilic
CC       molecules; in the plasma membrane it is involved in cell volume
CC       regulation and apoptosis. It adopts an open conformation at low or
CC       zero membrane potential and a closed conformation at potentials
CC       above 30-40 mV. The open state has a weak anion selectivity
CC       whereas the closed state is cation-selective. May participate in
CC       the formation of the permeability transition pore complex (PTPC)
CC       responsible for the release of mitochondrial products that
CC       triggers apoptosis (By similarity).
CC   -!- SUBUNIT: Interacts with hexokinases (By similarity). Interacts
CC       with BCL2L1 (By similarity).
CC   -!- SUBCELLULAR LOCATION: Mitochondrion outer membrane (By
CC       similarity). Cell membrane (By similarity).
CC   -!- TISSUE SPECIFICITY: Widely expressed. High levels in heart and
CC       kidney with lower levels in brain and ascitic tumor. Very low
CC       levels in liver.
CC   -!- DOMAIN: Consists mainly of a membrane-spanning beta-barrel formed
CC       by 19 beta-strands. The helical N-terminus folds back into the
CC       pore opening and plays a role in voltage-gated channel activity
CC       (By similarity).
CC   -!- SIMILARITY: Belongs to the eukaryotic mitochondrial porin family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF048828; AAD02476.1; -; mRNA.
DR   EMBL; AB039662; BAB13473.1; -; mRNA.
DR   EMBL; AF268467; AAF80115.1; -; mRNA.
DR   EMBL; BC060558; AAH60558.1; ALT_INIT; mRNA.
DR   EMBL; BC072484; AAH72484.2; -; mRNA.
DR   EMBL; BC087573; AAH87573.2; -; mRNA.
DR   EMBL; BC087657; AAH87657.2; -; mRNA.
DR   EMBL; BC104684; AAI04685.2; -; mRNA.
DR   EMBL; BC127491; AAI27492.1; -; mRNA.
DR   IPI; IPI00421874; -.
DR   RefSeq; NP_112643.1; -.
DR   UniGene; Rn.54594; -.
DR   STRING; Q9Z2L0; -.
DR   PhosphoSite; Q9Z2L0; -.
DR   PRIDE; Q9Z2L0; -.
DR   Ensembl; ENSRNOT00000008477; ENSRNOP00000008477; ENSRNOG00000006375; Rattus norvegicus.
DR   GeneID; 83529; -.
DR   KEGG; rno:83529; -.
DR   UCSC; NM_031353; rat.
DR   CTD; 83529; -.
DR   RGD; 621575; Vdac1.
DR   eggNOG; roNOG10550; -.
DR   HOVERGEN; HBG054036; -.
DR   InParanoid; Q9Z2L0; -.
DR   OrthoDB; EOG92FW36; -.
DR   PhylomeDB; Q9Z2L0; -.
DR   NextBio; 616021; -.
DR   ArrayExpress; Q9Z2L0; -.
DR   Genevestigator; Q9Z2L0; -.
DR   GermOnline; ENSRNOG00000006375; Rattus norvegicus.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IDA:RGD.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0046930; C:pore complex; IEA:UniProtKB-KW.
DR   GO; GO:0000166; F:nucleotide binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0008308; F:voltage-gated anion channel activity; ISS:UniProtKB.
DR   GO; GO:0006820; P:anion transport; IEA:InterPro.
DR   GO; GO:0006915; P:apoptosis; IEA:UniProtKB-KW.
DR   GO; GO:0006851; P:mitochondrial calcium ion transport; IDA:RGD.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR001925; Porin_Euk.
DR   Pfam; PF01459; Porin_3; 1.
DR   PRINTS; PR00185; EUKARYTPORIN.
DR   PROSITE; PS00558; EUKARYOTIC_PORIN; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Apoptosis; Cell membrane; Direct protein sequencing;
KW   Ion transport; Membrane; Mitochondrion; Mitochondrion outer membrane;
KW   NAD; Nucleotide-binding; Phosphoprotein; Porin; Transmembrane;
KW   Transport.
FT   INIT_MET      1      1       Removed (By similarity).
FT   CHAIN         2    283       Voltage-dependent anion-selective channel
FT                                protein 1.
FT                                /FTId=PRO_0000050503.
FT   TRANSMEM     26     35       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     39     47       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     54     64       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     69     76       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     80     89       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     95    104       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    111    120       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    123    130       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    137    145       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    150    158       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    163    175       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    178    185       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    189    198       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    202    211       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    218    227       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    231    238       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    242    251       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    254    263       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    273    282       Transmembrane beta-strand (By
FT                                similarity).
FT   NP_BIND     242    244       NAD (By similarity).
FT   NP_BIND     260    264       NAD (By similarity).
FT   SITE         73     73       Involved in hexokinase binding (By
FT                                similarity).
FT   MOD_RES       2      2       N-acetylalanine.
FT   MOD_RES      13     13       Phosphoserine.
FT   MOD_RES      20     20       N6-acetyllysine (By similarity).
FT   MOD_RES      28     28       N6-acetyllysine (By similarity).
FT   MOD_RES      61     61       N6-acetyllysine (By similarity).
FT   MOD_RES      67     67       Phosphotyrosine (By similarity).
FT   MOD_RES     101    101       Phosphoserine (By similarity).
FT   MOD_RES     104    104       Phosphoserine (By similarity).
FT   MOD_RES     107    107       Phosphothreonine (By similarity).
FT   MOD_RES     137    137       Phosphoserine.
FT   MOD_RES     195    195       Phosphotyrosine (By similarity).
FT   MOD_RES     224    224       N6-acetyllysine (By similarity).
FT   MOD_RES     266    266       N6-acetyllysine (By similarity).
FT   CONFLICT     55     55       N -> T (in Ref. 1; AAD02476).
FT   CONFLICT     83     83       T -> S (in Ref. 1; AAD02476).
FT   CONFLICT    129    129       V -> M (in Ref. 1; AAD02476).
FT   CONFLICT    148    148       G -> GFDIAGPSIRGALVLGYEG (in Ref. 1;
FT                                AAD02476).
SQ   SEQUENCE   283 AA;  30756 MW;  D32B05B8A8D75732 CRC64;
     MAVPPTYADL GKSARDVFTK GYGFGLIKLD LKTKSENGLE FTSSGSANTE TTKVNGSLET
     KYRWTEYGLT FTEKWNTDNT LGTEITVEDQ LARGLKLTFD SSFSPNTGKK NAKIKTGYKR
     EHINLGCDVD FDIAGPSIRG ALVLGYEGWL AGYQMNFETS KSRVTQSNFA VGYKTDEFQL
     HTNVNDGTEF GGSIYQKVNK KLETAVNLAW TAGNSNTRFG IAAKYQVDPD ACFSAKVNNS
     SLIGLGYTQT LKPGIKLTLS ALLDGKNVNA GGHKLGLGLE FQA
//
ID   VDAC2_HUMAN             Reviewed;         294 AA.
AC   P45880; Q5VWK1; Q5VWK3; Q6IB40; Q7L3J5; Q9BWK8; Q9Y5I6;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   11-SEP-2007, sequence version 2.
DT   02-MAR-2010, entry version 96.
DE   RecName: Full=Voltage-dependent anion-selective channel protein 2;
DE            Short=VDAC-2;
DE            Short=hVDAC2;
DE   AltName: Full=Outer mitochondrial membrane protein porin 2;
GN   Name=VDAC2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=B-cell;
RX   MEDLINE=93280191; PubMed=7685033;
RA   Ha H., Hajek P., Bedwell D.M., Burrows P.D.;
RT   "A mitochondrial porin cDNA predicts the existence of multiple human
RT   porins.";
RL   J. Biol. Chem. 268:12143-12149(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND VARIANT VAL-24.
RC   TISSUE=Liver;
RX   MEDLINE=93131931; PubMed=8420959;
RA   Blachly-Dyson E., Zambronicz E.B., Yu W.H., Adams V., McCabe E.R.,
RA   Adelman J.P., Colombini M., Forte M.A.;
RT   "Cloning and functional expression in yeast of two human isoforms of
RT   the outer mitochondrial membrane channel, the voltage-dependent anion
RT   channel.";
RL   J. Biol. Chem. 268:1835-1841(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 3).
RX   MEDLINE=99431679; PubMed=10501981; DOI=10.1007/s003359901158;
RA   Decker W.K., Bowles K.R., Schatte E.C., Towbin J.A., Craigen W.J.;
RT   "Revised fine mapping of the human voltage-dependent anion channel
RT   loci by radiation hybrid analysis.";
RL   Mamm. Genome 10:1041-1042(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Cervix, and Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 86-120; 178-229 AND 248-267, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Vishwanath V., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [8]
RP   PROTEIN SEQUENCE OF 11-23 (ISOFORM 3), PROTEIN SEQUENCE OF 46-64;
RP   75-85; 108-120; 178-185; 236-263 AND 268-277 (ISOFORMS 1/2/3), AND
RP   MASS SPECTROMETRY.
RC   TISSUE=B-cell lymphoma;
RA   Bienvenut W.V.;
RL   Submitted (JUN-2005) to UniProtKB.
RN   [9]
RP   SUBCELLULAR LOCATION.
RX   MEDLINE=95294003; PubMed=7539795; DOI=10.1074/jbc.270.23.13998;
RA   Yu W.H., Wolfgang W., Forte M.A.;
RT   "Subcellular localization of human voltage-dependent anion channel
RT   isoforms.";
RL   J. Biol. Chem. 270:13998-14006(1995).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-115, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Epithelium;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-115, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-115, AND MASS
RP   SPECTROMETRY.
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-115, AND MASS
RP   SPECTROMETRY.
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-115, AND MASS SPECTROMETRY.
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-31; LYS-39; LYS-72 AND
RP   LYS-74, AND MASS SPECTROMETRY.
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
CC   -!- FUNCTION: Forms a channel through the mitochondrial outer membrane
CC       that allows diffusion of small hydrophilic molecules. The channel
CC       adopts an open conformation at low or zero membrane potential and
CC       a closed conformation at potentials above 30-40 mV. The open state
CC       has a weak anion selectivity whereas the closed state is cation-
CC       selective.
CC   -!- SUBUNIT: Interacts with hexokinases (By similarity).
CC   -!- INTERACTION:
CC       Q16611:BAK1; NbExp=1; IntAct=EBI-354022, EBI-519866;
CC       Q13530:SERINC3; NbExp=1; IntAct=EBI-354022, EBI-1045571;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion outer membrane.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=3;
CC         IsoId=P45880-3; Sequence=Displayed;
CC       Name=1;
CC         IsoId=P45880-1; Sequence=VSP_005077;
CC         Note=Ref.1 (AAA60144) sequence differs from that shown due to a
CC         frameshift in position 303;
CC       Name=2;
CC         IsoId=P45880-2; Sequence=VSP_005076;
CC         Note=Ref.1 (AAA60145) sequence differs from that shown due to a
CC         frameshift in position 277;
CC   -!- TISSUE SPECIFICITY: Expressed in all tissues examined.
CC   -!- DOMAIN: Consists mainly of a membrane-spanning beta-barrel formed
CC       by 19 beta-strands (By similarity).
CC   -!- SIMILARITY: Belongs to the eukaryotic mitochondrial porin family.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAH73106.1; Type=Erroneous gene model prediction;
CC       Sequence=CAI40910.1; Type=Erroneous gene model prediction;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L08666; AAA60144.1; ALT_FRAME; mRNA.
DR   EMBL; L08666; AAA60145.1; ALT_FRAME; mRNA.
DR   EMBL; L06328; AAB59457.1; -; mRNA.
DR   EMBL; AF152227; AAD40241.1; -; Genomic_DNA.
DR   EMBL; AF152220; AAD40241.1; JOINED; Genomic_DNA.
DR   EMBL; AF152221; AAD40241.1; JOINED; Genomic_DNA.
DR   EMBL; AF152222; AAD40241.1; JOINED; Genomic_DNA.
DR   EMBL; AF152223; AAD40241.1; JOINED; Genomic_DNA.
DR   EMBL; AF152224; AAD40241.1; JOINED; Genomic_DNA.
DR   EMBL; AF152225; AAD40241.1; JOINED; Genomic_DNA.
DR   EMBL; AF152226; AAD40241.1; JOINED; Genomic_DNA.
DR   EMBL; CR456964; CAG33245.1; -; mRNA.
DR   EMBL; AL390034; CAH73108.1; -; Genomic_DNA.
DR   EMBL; AL392111; CAH73108.1; JOINED; Genomic_DNA.
DR   EMBL; AL392111; CAI40914.1; -; Genomic_DNA.
DR   EMBL; AL390034; CAI40914.1; JOINED; Genomic_DNA.
DR   EMBL; AL390034; CAH73107.1; -; Genomic_DNA.
DR   EMBL; AL392111; CAH73107.1; JOINED; Genomic_DNA.
DR   EMBL; AL392111; CAI40911.1; -; Genomic_DNA.
DR   EMBL; AL390034; CAI40911.1; JOINED; Genomic_DNA.
DR   EMBL; AL390034; CAH73106.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL392111; CAH73106.1; JOINED; Genomic_DNA.
DR   EMBL; AL392111; CAI40910.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL390034; CAI40910.1; JOINED; Genomic_DNA.
DR   EMBL; BC000165; AAH00165.2; -; mRNA.
DR   EMBL; BC012883; AAH12883.2; -; mRNA.
DR   EMBL; BC072407; AAH72407.1; -; mRNA.
DR   IPI; IPI00024145; -.
DR   IPI; IPI00216026; -.
DR   IPI; IPI00902560; -.
DR   PIR; A45972; A45972.
DR   PIR; B44422; B44422.
DR   RefSeq; NP_003366.2; -.
DR   UniGene; Hs.355927; -.
DR   IntAct; P45880; 6.
DR   STRING; P45880; -.
DR   PhosphoSite; P45880; -.
DR   SWISS-2DPAGE; P45880; -.
DR   DOSAC-COBS-2DPAGE; P45880; -.
DR   OGP; P45880; -.
DR   REPRODUCTION-2DPAGE; P45880; -.
DR   PRIDE; P45880; -.
DR   Ensembl; ENST00000332211; ENSP00000361686; ENSG00000165637; Homo sapiens.
DR   GeneID; 7417; -.
DR   KEGG; hsa:7417; -.
DR   UCSC; uc001jwz.1; human.
DR   UCSC; uc001jxa.1; human.
DR   CTD; 7417; -.
DR   GeneCards; GC10P076640; -.
DR   H-InvDB; HIX0008945; -.
DR   H-InvDB; HIX0029994; -.
DR   HGNC; HGNC:12672; VDAC2.
DR   MIM; 193245; gene.
DR   PharmGKB; PA37295; -.
DR   HOVERGEN; HBG054036; -.
DR   OMA; LETKYKR; -.
DR   DrugBank; DB01375; Dihydroxyaluminium.
DR   NextBio; 29042; -.
DR   ArrayExpress; P45880; -.
DR   Bgee; P45880; -.
DR   CleanEx; HS_VDAC2; -.
DR   Genevestigator; P45880; -.
DR   GermOnline; ENSG00000165637; Homo sapiens.
DR   GO; GO:0042645; C:mitochondrial nucleoid; IDA:UniProtKB.
DR   GO; GO:0005741; C:mitochondrial outer membrane; TAS:ProtInc.
DR   GO; GO:0046930; C:pore complex; IEA:UniProtKB-KW.
DR   GO; GO:0000166; F:nucleotide binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0008308; F:voltage-gated anion channel activity; TAS:UniProtKB.
DR   GO; GO:0006820; P:anion transport; TAS:ProtInc.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR001925; Porin_Euk.
DR   Pfam; PF01459; Porin_3; 1.
DR   PRINTS; PR00185; EUKARYTPORIN.
DR   PROSITE; PS00558; EUKARYOTIC_PORIN; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Complete proteome;
KW   Direct protein sequencing; Ion transport; Membrane; Mitochondrion;
KW   Mitochondrion outer membrane; NAD; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Porin; Transmembrane; Transport.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    294       Voltage-dependent anion-selective channel
FT                                protein 2.
FT                                /FTId=PRO_0000050505.
FT   TRANSMEM     37     46       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     50     58       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     65     75       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     80     87       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     91    100       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    106    115       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    122    131       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    134    141       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    148    156       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    161    169       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    174    186       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    189    196       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    200    209       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    213    222       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    229    238       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    242    249       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    253    262       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    265    274       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    284    293       Transmembrane beta-strand (By
FT                                similarity).
FT   NP_BIND     253    255       NAD (By similarity).
FT   NP_BIND     271    275       NAD (By similarity).
FT   SITE         84     84       Involved in hexokinase binding (By
FT                                similarity).
FT   MOD_RES       2      2       N-acetylalanine.
FT   MOD_RES      31     31       N6-acetyllysine.
FT   MOD_RES      39     39       N6-acetyllysine.
FT   MOD_RES      72     72       N6-acetyllysine.
FT   MOD_RES      74     74       N6-acetyllysine.
FT   MOD_RES     115    115       Phosphoserine.
FT   MOD_RES     206    206       Phosphotyrosine (By similarity).
FT   MOD_RES     236    236       Phosphotyrosine (By similarity).
FT   VAR_SEQ       1     11       MATHGQTCARP -> MSWCNELRLPALKQHSIGRGLESHIT
FT                                (in isoform 1).
FT                                /FTId=VSP_005077.
FT   VAR_SEQ       1     11       Missing (in isoform 2).
FT                                /FTId=VSP_005076.
FT   VARIANT      24     24       A -> V.
FT                                /FTId=VAR_006380.
SQ   SEQUENCE   294 AA;  31567 MW;  F4EAE732E653637E CRC64;
     MATHGQTCAR PMCIPPSYAD LGKAARDIFN KGFGFGLVKL DVKTKSCSGV EFSTSGSSNT
     DTGKVTGTLE TKYKWCEYGL TFTEKWNTDN TLGTEIAIED QICQGLKLTF DTTFSPNTGK
     KSGKIKSSYK RECINLGCDV DFDFAGPAIH GSAVFGYEGW LAGYQMTFDS AKSKLTRNNF
     AVGYRTGDFQ LHTNVNDGTE FGGSIYQKVC EDLDTSVNLA WTSGTNCTRF GIAAKYQLDP
     TASISAKVNN SSLIGVGYTQ TLRPGVKLTL SALVDGKSIN AGGHKVGLAL ELEA
//
ID   VDAC2_MELGA             Reviewed;         282 AA.
AC   P82013;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   02-MAR-2010, entry version 42.
DE   RecName: Full=Voltage-dependent anion-selective channel protein 2;
DE            Short=VDAC-2;
DE   AltName: Full=Outer mitochondrial membrane protein porin 2;
GN   Name=VDAC2;
OS   Meleagris gallopavo (Common turkey).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Archosauria; Dinosauria; Saurischia; Theropoda; Coelurosauria; Aves;
OC   Neognathae; Galliformes; Phasianidae; Meleagridinae; Meleagris.
OX   NCBI_TaxID=9103;
RN   [1]
RP   PROTEIN SEQUENCE.
RC   TISSUE=Skeletal muscle;
RA   Hesse D., Strutz N., Kratzin H.D., Thinnes F.P., Hilschmann N.;
RL   Submitted (SEP-1999) to UniProtKB.
CC   -!- FUNCTION: Forms a channel through the cell membrane that allows
CC       diffusion from small hydrophilic molecules (By similarity).
CC   -!- SUBUNIT: Interacts with hexokinases (By similarity).
CC   -!- SUBCELLULAR LOCATION: Mitochondrion outer membrane (By
CC       similarity).
CC   -!- DOMAIN: Consists mainly of a membrane-spanning beta-barrel formed
CC       by 19 beta-strands (By similarity).
CC   -!- SIMILARITY: Belongs to the eukaryotic mitochondrial porin family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   HOVERGEN; HBG054036; -.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0046930; C:pore complex; IEA:UniProtKB-KW.
DR   GO; GO:0000166; F:nucleotide binding; IEA:UniProtKB-KW.
DR   GO; GO:0008308; F:voltage-gated anion channel activity; IEA:InterPro.
DR   GO; GO:0006820; P:anion transport; IEA:InterPro.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR001925; Porin_Euk.
DR   Pfam; PF01459; Porin_3; 1.
DR   PRINTS; PR00185; EUKARYTPORIN.
DR   PROSITE; PS00558; EUKARYOTIC_PORIN; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Direct protein sequencing; Ion transport; Membrane;
KW   Mitochondrion; Mitochondrion outer membrane; NAD; Nucleotide-binding;
KW   Porin; Transmembrane; Transport.
FT   CHAIN         1    282       Voltage-dependent anion-selective channel
FT                                protein 2.
FT                                /FTId=PRO_0000050510.
FT   TRANSMEM     25     34       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     38     46       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     53     63       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     68     75       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     79     88       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     94    103       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    110    119       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    122    129       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    136    144       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    149    157       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    162    174       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    177    184       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    188    197       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    201    210       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    217    226       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    230    237       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    241    250       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    253    262       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    272    281       Transmembrane beta-strand (By
FT                                similarity).
FT   NP_BIND     241    243       NAD (By similarity).
FT   NP_BIND     259    263       NAD (By similarity).
FT   SITE         72     72       Involved in hexokinase binding (By
FT                                similarity).
FT   MOD_RES       1      1       N-acetylalanine.
SQ   SEQUENCE   282 AA;  30067 MW;  88ECCF19ABCA004F CRC64;
     AIPPSYADLG KSARDIFNKG YGFGLVKLDV KTKSASGVEF TTSGSSNTDT GKVNGSLETK
     YKWAEYGLTF TEKWNTDNTL GTEIAIEDQI AKGLKLTFDT TFSPNTGKKS GKIKSAYKRE
     CLNLGCDVDF DFAGPAIHGS AVFGYEGWLA GYQMTFDSAK SKLTRNNFSV GYKTGDFQLH
     TNVNDGSEFG GSIYQKVSDN LETAVNLAWT AGSNSTRFGI AAKYKLDSTA SISAKVNNSS
     LVGVGYTQTL RPGVKLTLSA LIDGKSINAG GHKLGLGLEL EA
//
ID   VDAC2_MOUSE             Reviewed;         295 AA.
AC   Q60930; Q78MH6; Q99L98;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1998, sequence version 2.
DT   02-MAR-2010, entry version 77.
DE   RecName: Full=Voltage-dependent anion-selective channel protein 2;
DE            Short=VDAC-2;
DE            Short=mVDAC2;
DE   AltName: Full=Voltage-dependent anion-selective channel protein 6;
DE            Short=VDAC-6;
DE            Short=mVDAC6;
DE   AltName: Full=Outer mitochondrial membrane protein porin 2;
GN   Name=Vdac2; Synonyms=Vdac6;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   MEDLINE=96301405; PubMed=8660977; DOI=10.1006/geno.1996.0193;
RA   Sampson M.J., Lovell R.S., Craigen W.J.;
RT   "Isolation, characterization, and mapping of two mouse mitochondrial
RT   voltage-dependent anion channel isoforms.";
RL   Genomics 33:283-288(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=BALB/c, and C57BL/6J; TISSUE=Bone marrow;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RA   Brathwaite M.E., Waeltz P., Qian Y., Dudekula D., Schlessinger D.,
RA   Nagaraja R.;
RT   "Genomic sequence analysis in the mouse T-complex region.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=FVB/N; TISSUE=Mammary tumor;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PROTEIN SEQUENCE OF 33-40; 47-65; 76-121; 179-230 AND 237-278, AND
RP   MASS SPECTROMETRY.
RC   STRAIN=C57BL/6; TISSUE=Brain, and Hippocampus;
RA   Lubec G., Klug S., Kang S.U.;
RL   Submitted (APR-2007) to UniProtKB.
RN   [6]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-32 AND LYS-75, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=16916647; DOI=10.1016/j.molcel.2006.06.026;
RA   Kim S.C., Sprung R., Chen Y., Xu Y., Ball H., Pei J., Cheng T.,
RA   Kho Y., Xiao H., Xiao L., Grishin N.V., White M., Yang X.-J., Zhao Y.;
RT   "Substrate and functional diversity of lysine acetylation revealed by
RT   a proteomics survey.";
RL   Mol. Cell 23:607-618(2006).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-207, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Brain;
RX   PubMed=18034455; DOI=10.1021/pr0701254;
RA   Ballif B.A., Carey G.R., Sunyaev S.R., Gygi S.P.;
RT   "Large-scale identification and evolution indexing of tyrosine
RT   phosphorylation sites from murine brain.";
RL   J. Proteome Res. 7:311-318(2008).
CC   -!- FUNCTION: Forms a channel through the mitochondrial outer membrane
CC       that allows diffusion of small hydrophilic molecules. The channel
CC       adopts an open conformation at low or zero membrane potential and
CC       a closed conformation at potentials above 30-40 mV. The open state
CC       has a weak anion selectivity whereas the closed state is cation-
CC       selective (By similarity).
CC   -!- SUBUNIT: Interacts with hexokinases (By similarity).
CC   -!- SUBCELLULAR LOCATION: Mitochondrion outer membrane.
CC   -!- TISSUE SPECIFICITY: Highest levels of expression detected in
CC       testis, less but still abundant expression in heart, kidney,
CC       brain, and skeletal muscle.
CC   -!- DOMAIN: Consists mainly of a membrane-spanning beta-barrel formed
CC       by 19 beta-strands (By similarity).
CC   -!- SIMILARITY: Belongs to the eukaryotic mitochondrial porin family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U30838; AAC13321.1; -; mRNA.
DR   EMBL; AK168199; BAE40159.1; -; mRNA.
DR   EMBL; AK159561; BAE35185.1; -; mRNA.
DR   EMBL; AK152274; BAE31090.1; -; mRNA.
DR   EMBL; AK150940; BAE29975.1; -; mRNA.
DR   EMBL; AK150627; BAE29717.1; -; mRNA.
DR   EMBL; AK150504; BAE29617.1; -; mRNA.
DR   EMBL; AK012359; BAE43231.1; -; mRNA.
DR   EMBL; AY294423; AAQ01516.1; -; Genomic_DNA.
DR   EMBL; BC003731; AAH03731.2; -; mRNA.
DR   IPI; IPI00122547; -.
DR   RefSeq; NP_035825.1; -.
DR   UniGene; Mm.262327; -.
DR   STRING; Q60930; -.
DR   PhosphoSite; Q60930; -.
DR   REPRODUCTION-2DPAGE; Q60930; -.
DR   PRIDE; Q60930; -.
DR   Ensembl; ENSMUST00000022293; ENSMUSP00000022293; ENSMUSG00000021771; Mus musculus.
DR   GeneID; 22334; -.
DR   KEGG; mmu:22334; -.
DR   UCSC; uc007sls.1; mouse.
DR   CTD; 22334; -.
DR   MGI; MGI:106915; Vdac2.
DR   eggNOG; roNOG11568; -.
DR   HOGENOM; HBG396026; -.
DR   HOVERGEN; HBG054036; -.
DR   InParanoid; Q60930; -.
DR   OMA; LETKYKR; -.
DR   OrthoDB; EOG92FW36; -.
DR   PhylomeDB; Q60930; -.
DR   NextBio; 302579; -.
DR   ArrayExpress; Q60930; -.
DR   Bgee; Q60930; -.
DR   CleanEx; MM_VDAC2; -.
DR   Genevestigator; Q60930; -.
DR   GermOnline; ENSMUSG00000021771; Mus musculus.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IDA:MGI.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0046930; C:pore complex; IEA:UniProtKB-KW.
DR   GO; GO:0000166; F:nucleotide binding; IEA:UniProtKB-KW.
DR   GO; GO:0008308; F:voltage-gated anion channel activity; IEA:InterPro.
DR   GO; GO:0006820; P:anion transport; IEA:InterPro.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR001925; Porin_Euk.
DR   Pfam; PF01459; Porin_3; 1.
DR   PRINTS; PR00185; EUKARYTPORIN.
DR   PROSITE; PS00558; EUKARYOTIC_PORIN; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Direct protein sequencing; Ion transport; Membrane;
KW   Mitochondrion; Mitochondrion outer membrane; NAD; Nucleotide-binding;
KW   Phosphoprotein; Porin; Transmembrane; Transport.
FT   CHAIN         1    295       Voltage-dependent anion-selective channel
FT                                protein 2.
FT                                /FTId=PRO_0000050506.
FT   TRANSMEM     38     47       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     51     59       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     66     76       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     81     88       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     92    101       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    107    116       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    123    132       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    135    142       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    149    157       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    162    170       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    175    187       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    190    197       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    201    210       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    214    223       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    230    239       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    243    250       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    254    263       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    266    275       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    285    294       Transmembrane beta-strand (By
FT                                similarity).
FT   NP_BIND     254    256       NAD (By similarity).
FT   NP_BIND     272    276       NAD (By similarity).
FT   SITE         85     85       Involved in hexokinase binding (By
FT                                similarity).
FT   MOD_RES      32     32       N6-acetyllysine.
FT   MOD_RES      40     40       N6-acetyllysine (By similarity).
FT   MOD_RES      73     73       N6-acetyllysine (By similarity).
FT   MOD_RES      75     75       N6-acetyllysine.
FT   MOD_RES     116    116       Phosphoserine (By similarity).
FT   MOD_RES     207    207       Phosphotyrosine.
FT   MOD_RES     237    237       Phosphotyrosine (By similarity).
FT   CONFLICT    260    260       T -> A (in Ref. 4; AAH03731).
SQ   SEQUENCE   295 AA;  31733 MW;  7BBCDC625AD013C7 CRC64;
     MAECCVPVCP RPMCIPPPYA DLGKAARDIF NKGFGFGLVK LDVKTKSCSG VEFSTSGSSN
     TDTGKVSGTL ETKYKWCEYG LTFTEKWNTD NTLGTEIAIE DQICQGLKLT FDTTFSPNTG
     KKSGKIKSAY KRECINLGCD VDFDFAGPAI HGSAVFGYEG WLAGYQMTFD SAKSKLTRSN
     FAVGYRTGDF QLHTNVNNGT EFGGSIYQKV CEDFDTSVNL AWTSGTNCTR FGIAAKYQLD
     PTASISAKVN NSSLIGVGYT QTLRPGVKLT LSALVDGKSF NAGGHKLGLA LELEA
//
ID   VDAC2_RAT               Reviewed;         295 AA.
AC   P81155; Q9JI32;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   13-APR-2004, sequence version 2.
DT   02-MAR-2010, entry version 72.
DE   RecName: Full=Voltage-dependent anion-selective channel protein 2;
DE            Short=VDAC-2;
DE   AltName: Full=Outer mitochondrial membrane protein porin 2;
DE   AltName: Full=B36-VDAC;
GN   Name=Vdac2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 63-96 AND 190-203.
RC   TISSUE=Hippocampus;
RX   MEDLINE=92235102; PubMed=1373732;
RA   Bureau M.H., Khrestchatisky M., Heeren M.A., Zambrowicz E.B., Kim H.,
RA   Grisar T.M., Colombini M., Tobin A.J., Olsen R.W.;
RT   "Isolation and cloning of a voltage-dependent anion channel-like Mr
RT   36,000 polypeptide from mammalian brain.";
RL   J. Biol. Chem. 267:8679-8684(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Ascitic tumor;
RX   MEDLINE=20453129; PubMed=10998068;
RX   DOI=10.1046/j.1432-1327.2000.01687.x;
RA   Shinohara Y., Ishida T., Hino M., Yamazaki N., Baba Y., Terada H.;
RT   "Characterization of porin isoforms expressed in tumor cells.";
RL   Eur. J. Biochem. 267:6067-6073(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Lens;
RA   Rae J.L.;
RT   "Ion channels in the lens.";
RL   Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pituitary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PROTEIN SEQUENCE OF 47-121; 179-230 AND 237-278, AND MASS
RP   SPECTROMETRY.
RC   STRAIN=Sprague-Dawley; TISSUE=Brain, Hippocampus, and Spinal cord;
RA   Lubec G., Afjehi-Sadat L., Chen W.-Q., Kang S.U., Lubec S.;
RL   Submitted (SEP-2007) to UniProtKB.
RN   [6]
RP   PROTEIN SEQUENCE OF 236-243, PHOSPHORYLATION AT TYR-237, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=17478130; DOI=10.1016/j.bbapap.2007.03.012;
RA   Distler A.M., Kerner J., Hoppel C.L.;
RT   "Post-translational modifications of rat liver mitochondrial outer
RT   membrane proteins identified by mass spectrometry.";
RL   Biochim. Biophys. Acta 1774:628-636(2007).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND TISSUE SPECIFICITY.
RX   PubMed=19423663; DOI=10.1530/REP-09-0052;
RA   Khan S.A., Suryawanshi A.R., Ranpura S.A., Jadhav S.V., Khole V.V.;
RT   "Identification of novel immunodominant epididymal sperm proteins
RT   using combinatorial approach.";
RL   Reproduction 138:81-93(2009).
CC   -!- FUNCTION: Forms a channel through the mitochondrial outer membrane
CC       that allows diffusion of small hydrophilic molecules. The channel
CC       adopts an open conformation at low or zero membrane potential and
CC       a closed conformation at potentials above 30-40 mV. The open state
CC       has a weak anion selectivity whereas the closed state is cation-
CC       selective (By similarity).
CC   -!- SUBUNIT: Interacts with hexokinases (By similarity).
CC   -!- SUBCELLULAR LOCATION: Mitochondrion outer membrane.
CC   -!- TISSUE SPECIFICITY: Highly expressed in heart, kidney, brain and
CC       ascitic tumor with very low levels in liver. Expressed in the head
CC       region of epididymal sperm.
CC   -!- DOMAIN: Consists mainly of a membrane-spanning beta-barrel formed
CC       by 19 beta-strands (By similarity).
CC   -!- SIMILARITY: Belongs to the eukaryotic mitochondrial porin family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB039663; BAB13474.1; -; mRNA.
DR   EMBL; AF268468; AAF80116.1; -; mRNA.
DR   EMBL; BC063164; AAH63164.1; -; mRNA.
DR   IPI; IPI00198327; -.
DR   PIR; A38102; A38102.
DR   RefSeq; NP_112644.1; -.
DR   UniGene; Rn.162037; -.
DR   STRING; P81155; -.
DR   PhosphoSite; P81155; -.
DR   PRIDE; P81155; -.
DR   Ensembl; ENSRNOT00000018462; ENSRNOP00000018462; ENSRNOG00000013505; Rattus norvegicus.
DR   GeneID; 83531; -.
DR   KEGG; rno:83531; -.
DR   UCSC; NM_031354; rat.
DR   CTD; 83531; -.
DR   RGD; 621576; Vdac2.
DR   eggNOG; roNOG11568; -.
DR   HOVERGEN; HBG054036; -.
DR   InParanoid; P81155; -.
DR   PhylomeDB; P81155; -.
DR   NextBio; 616025; -.
DR   ArrayExpress; P81155; -.
DR   Genevestigator; P81155; -.
DR   GermOnline; ENSRNOG00000013505; Rattus norvegicus.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0046930; C:pore complex; IEA:UniProtKB-KW.
DR   GO; GO:0000166; F:nucleotide binding; IEA:UniProtKB-KW.
DR   GO; GO:0008308; F:voltage-gated anion channel activity; IEA:InterPro.
DR   GO; GO:0006820; P:anion transport; IEA:InterPro.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR001925; Porin_Euk.
DR   Pfam; PF01459; Porin_3; 1.
DR   PRINTS; PR00185; EUKARYTPORIN.
DR   PROSITE; PS00558; EUKARYOTIC_PORIN; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Direct protein sequencing; Ion transport; Membrane;
KW   Mitochondrion; Mitochondrion outer membrane; NAD; Nucleotide-binding;
KW   Phosphoprotein; Porin; Transmembrane; Transport.
FT   CHAIN         1    295       Voltage-dependent anion-selective channel
FT                                protein 2.
FT                                /FTId=PRO_0000050509.
FT   TRANSMEM     38     47       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     51     59       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     66     76       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     81     88       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     92    101       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    107    116       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    123    132       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    135    142       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    149    157       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    162    170       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    175    187       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    190    197       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    201    210       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    214    223       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    230    239       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    243    250       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    254    263       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    266    275       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    285    294       Transmembrane beta-strand (By
FT                                similarity).
FT   NP_BIND     254    256       NAD (By similarity).
FT   NP_BIND     272    276       NAD (By similarity).
FT   SITE         85     85       Involved in hexokinase binding (By
FT                                similarity).
FT   MOD_RES      32     32       N6-acetyllysine (By similarity).
FT   MOD_RES      40     40       N6-acetyllysine (By similarity).
FT   MOD_RES      73     73       N6-acetyllysine (By similarity).
FT   MOD_RES      75     75       N6-acetyllysine (By similarity).
FT   MOD_RES     116    116       Phosphoserine (By similarity).
FT   MOD_RES     207    207       Phosphotyrosine (By similarity).
FT   MOD_RES     237    237       Phosphotyrosine.
FT   CONFLICT     12     12       P -> A (in Ref. 1; AA sequence).
SQ   SEQUENCE   295 AA;  31746 MW;  59582738AF84507F CRC64;
     MAECCVPVCQ RPICIPPPYA DLGKAARDIF NKGFGFGLVK LDVKTKSCSG VEFSTSGSSN
     TDTGKVSGTL ETKYKWCEYG LTFTEKWNTD NTLGTEIAIE DQICQGLKLT FDTTFSPNTG
     KKSGKIKSAY KRECINLGCD VDFDFAGPAI HGSAVFGYEG WLAGYQMTFD SAKSKLTRSN
     FAVGYRTGDF QLHTNVNNGT EFGGSIYQKV CEDFDTSVNL AWTSGTNCTR FGIAAKYQLD
     PTASISAKVN NSSLIGVGYT QTLRPGVKLT LSALVDGKSF NAGGHKLGLA LELEA
//
ID   VDAC2_XENLA             Reviewed;         282 AA.
AC   P81004;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 1.
DT   02-MAR-2010, entry version 49.
DE   RecName: Full=Voltage-dependent anion-selective channel protein 2;
DE            Short=VDAC-2;
DE   AltName: Full=Outer mitochondrial membrane protein porin;
GN   Name=vdac2;
OS   Xenopus laevis (African clawed frog).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Amphibia; Batrachia; Anura; Mesobatrachia; Pipoidea; Pipidae;
OC   Xenopodinae; Xenopus; Xenopus.
OX   NCBI_TaxID=8355;
RN   [1]
RP   PROTEIN SEQUENCE.
RC   TISSUE=Skeletal muscle;
RA   Reymann S., Kratzin H.D., Hesse D., Hesse J.-O., Klebert S.,
RA   Kiafard Z., Zimmermann B., Spengler B., Metzger S., Thinnes F.P.,
RA   Hilschmann N.;
RL   Submitted (JUL-1997) to UniProtKB.
RN   [2]
RP   PROTEIN SEQUENCE OF 84-90 AND 274-282, AND TISSUE SPECIFICITY.
RC   TISSUE=Oocyte;
RX   MEDLINE=20150664; PubMed=10687956; DOI=10.1016/S1357-2725(99)00124-7;
RA   Steinacker P., Awni L.A., Becker S., Cole T., Reymann S., Hesse D.,
RA   Kratzin H.D., Morris-Wortmann C., Schwarzer C., Thinnes F.P.,
RA   Hilschmann N.;
RT   "The plasma membrane of Xenopus laevis oocytes contains voltage-
RT   dependent anion-selective porin channels.";
RL   Int. J. Biochem. Cell Biol. 32:225-234(2000).
CC   -!- FUNCTION: Forms a channel through the mitochondrial outer membrane
CC       that allows diffusion of small hydrophilic molecules. The channel
CC       adopts an open conformation at low or zero membrane potential and
CC       a closed conformation at potentials above 30-40 mV. The open state
CC       has a weak anion selectivity whereas the closed state is cation-
CC       selective (By similarity).
CC   -!- SUBUNIT: Interacts with hexokinases (By similarity).
CC   -!- SUBCELLULAR LOCATION: Mitochondrion outer membrane (Potential).
CC   -!- TISSUE SPECIFICITY: Expressed in skeletal muscle and oocytes.
CC   -!- DOMAIN: Consists mainly of a membrane-spanning beta-barrel formed
CC       by 19 beta-strands (By similarity).
CC   -!- SIMILARITY: Belongs to the eukaryotic mitochondrial porin family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   RefSeq; NP_001089399.1; -.
DR   UniGene; Xl.24385; -.
DR   GeneID; 734449; -.
DR   KEGG; xla:734449; -.
DR   CTD; 734449; -.
DR   Xenbase; XB-FEAT-954838; vdac2.
DR   HOVERGEN; HBG054036; -.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0046930; C:pore complex; IEA:UniProtKB-KW.
DR   GO; GO:0000166; F:nucleotide binding; IEA:UniProtKB-KW.
DR   GO; GO:0008308; F:voltage-gated anion channel activity; IEA:InterPro.
DR   GO; GO:0006820; P:anion transport; IEA:InterPro.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR001925; Porin_Euk.
DR   Pfam; PF01459; Porin_3; 1.
DR   PRINTS; PR00185; EUKARYTPORIN.
DR   PROSITE; PS00558; EUKARYOTIC_PORIN; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Direct protein sequencing; Ion transport; Membrane;
KW   Mitochondrion; Mitochondrion outer membrane; NAD; Nucleotide-binding;
KW   Porin; Transmembrane; Transport.
FT   CHAIN         1    282       Voltage-dependent anion-selective channel
FT                                protein 2.
FT                                /FTId=PRO_0000050518.
FT   TRANSMEM     25     34       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     38     46       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     53     63       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     68     75       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     79     88       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     94    103       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    110    119       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    122    129       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    136    144       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    149    157       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    162    174       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    177    184       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    188    197       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    201    210       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    217    226       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    230    237       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    241    250       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    253    262       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    272    281       Transmembrane beta-strand (By
FT                                similarity).
FT   NP_BIND     241    243       NAD (By similarity).
FT   NP_BIND     259    263       NAD (By similarity).
FT   SITE         72     72       Involved in hexokinase binding (By
FT                                similarity).
FT   MOD_RES       1      1       N-acetylalanine.
SQ   SEQUENCE   282 AA;  30071 MW;  B0309215D81FF313 CRC64;
     AVPPSYADLG KSARDIFNKG YGFGLVKLDV KTKSATGVEF TTSGTSNTDS GKVNGSLETK
     YKWGEYGLTF TEKWNTDNTL GTEIAIEDQI AKGLKLTFDT TFSPNTGKKS GKVKAAYKQE
     YVNLGCDVDF DFAGPAIHGS AVVGYEGWLA GYQMTFDSAK SKLTKNNFAV GYKTGDFQLH
     TNVNDGSEFA GSIYQKVSDK METAVNLAWT SGNNSTRFGI AAKYQLDSHA AISAKVNNSS
     LVGVGYTQTL RPGVKLTLSA LVDGKNINAG GHKLGLGLEL EA
//
ID   VDAC3_HUMAN             Reviewed;         283 AA.
AC   Q9Y277; Q9UIS0;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   02-MAR-2010, entry version 86.
DE   RecName: Full=Voltage-dependent anion-selective channel protein 3;
DE            Short=VDAC-3;
DE            Short=hVDAC3;
DE   AltName: Full=Outer mitochondrial membrane protein porin 3;
GN   Name=VDAC3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=98454325; PubMed=9781040; DOI=10.1038/sj.ejhg.5200198;
RA   Rahmani Z., Maunoury C., Siddiqui A.;
RT   "Isolation of a novel human voltage-dependent anion channel gene.";
RL   Eur. J. Hum. Genet. 6:337-340(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Umbilical cord blood;
RX   MEDLINE=98318631; PubMed=9653160; DOI=10.1073/pnas.95.14.8175;
RA   Mao M., Fu G., Wu J.-S., Zhang Q.-H., Zhou J., Kan L.-X., Huang Q.-H.,
RA   He K.-L., Gu B.-W., Han Z.-G., Shen Y., Gu J., Yu Y.-P., Xu S.-H.,
RA   Wang Y.-X., Chen S.-J., Chen Z.;
RT   "Identification of genes expressed in human CD34(+) hematopoietic
RT   stem/progenitor cells by expressed sequence tags and efficient full-
RT   length cDNA cloning.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:8175-8180(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-253.
RX   MEDLINE=99431679; PubMed=10501981; DOI=10.1007/s003359901158;
RA   Decker W.K., Bowles K.R., Schatte E.C., Towbin J.A., Craigen W.J.;
RT   "Revised fine mapping of the human voltage-dependent anion channel
RT   loci by radiation hybrid analysis.";
RL   Mamm. Genome 10:1041-1042(1999).
RN   [5]
RP   ALTERNATIVE SPLICING.
RX   MEDLINE=20295349; PubMed=10833333; DOI=10.1006/mgme.2000.2987;
RA   Decker W.K., Craigen W.J.;
RT   "The tissue-specific, alternatively spliced single ATG exon of the
RT   type 3 voltage-dependent anion channel gene does not create a
RT   truncated protein isoform in vivo.";
RL   Mol. Genet. Metab. 70:69-74(2000).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-195, AND MASS
RP   SPECTROMETRY.
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [7]
RP   IDENTIFICATION [LARGE SCALE ANALYSIS], AND MASS SPECTROMETRY.
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [8]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-20; LYS-28; LYS-61; LYS-63
RP   AND LYS-90, AND MASS SPECTROMETRY.
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
CC   -!- FUNCTION: Forms a channel through the mitochondrial outer membrane
CC       that allows diffusion of small hydrophilic molecules (By
CC       similarity).
CC   -!- INTERACTION:
CC       P49662:CASP4; NbExp=1; IntAct=EBI-354196, EBI-1057327;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion outer membrane.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9Y277-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9Y277-2; Sequence=VSP_005079;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Highest in testis.
CC   -!- DOMAIN: Consists mainly of a membrane-spanning beta-barrel formed
CC       by 19 beta-strands (By similarity).
CC   -!- SIMILARITY: Belongs to the eukaryotic mitochondrial porin family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U90943; AAB93872.1; -; mRNA.
DR   EMBL; AF038962; AAC39876.1; -; mRNA.
DR   EMBL; BC056870; AAH56870.1; -; mRNA.
DR   EMBL; AF151682; AAD49610.1; -; Genomic_DNA.
DR   EMBL; AF151679; AAD49610.1; JOINED; Genomic_DNA.
DR   EMBL; AF151681; AAD49610.1; JOINED; Genomic_DNA.
DR   IPI; IPI00031804; -.
DR   IPI; IPI00294779; -.
DR   RefSeq; NP_001129166.1; -.
DR   RefSeq; NP_005653.3; -.
DR   UniGene; Hs.655340; -.
DR   UniGene; Hs.699301; -.
DR   IntAct; Q9Y277; 9.
DR   STRING; Q9Y277; -.
DR   PhosphoSite; Q9Y277; -.
DR   PeptideAtlas; Q9Y277; -.
DR   PRIDE; Q9Y277; -.
DR   Ensembl; ENST00000022615; ENSP00000022615; ENSG00000078668; Homo sapiens.
DR   GeneID; 7419; -.
DR   KEGG; hsa:7419; -.
DR   UCSC; uc003xpc.1; human.
DR   CTD; 7419; -.
DR   GeneCards; GC08P042368; -.
DR   H-InvDB; HIX0007479; -.
DR   HGNC; HGNC:12674; VDAC3.
DR   HPA; HPA026864; -.
DR   MIM; 610029; gene.
DR   PharmGKB; PA37297; -.
DR   eggNOG; prNOG11276; -.
DR   HOVERGEN; HBG054036; -.
DR   InParanoid; Q9Y277; -.
DR   OMA; CFSLGSN; -.
DR   PhylomeDB; Q9Y277; -.
DR   DrugBank; DB01375; Dihydroxyaluminium.
DR   NextBio; 29048; -.
DR   ArrayExpress; Q9Y277; -.
DR   Bgee; Q9Y277; -.
DR   CleanEx; HS_VDAC3; -.
DR   Genevestigator; Q9Y277; -.
DR   GermOnline; ENSG00000078668; Homo sapiens.
DR   GO; GO:0005741; C:mitochondrial outer membrane; TAS:ProtInc.
DR   GO; GO:0046930; C:pore complex; IEA:UniProtKB-KW.
DR   GO; GO:0000166; F:nucleotide binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0008308; F:voltage-gated anion channel activity; TAS:UniProtKB.
DR   GO; GO:0015853; P:adenine transport; TAS:ProtInc.
DR   GO; GO:0006820; P:anion transport; IEA:InterPro.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR001925; Porin_Euk.
DR   Pfam; PF01459; Porin_3; 1.
DR   PRINTS; PR00185; EUKARYTPORIN.
DR   PROSITE; PS00558; EUKARYOTIC_PORIN; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Complete proteome; Ion transport;
KW   Membrane; Mitochondrion; Mitochondrion outer membrane; NAD;
KW   Nucleotide-binding; Phosphoprotein; Porin; Transmembrane; Transport.
FT   CHAIN         1    283       Voltage-dependent anion-selective channel
FT                                protein 3.
FT                                /FTId=PRO_0000050512.
FT   TRANSMEM     26     35       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     39     47       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     54     64       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     69     76       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     80     89       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     95    104       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    111    120       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    123    130       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    137    145       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    150    158       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    163    175       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    178    185       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    189    198       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    202    211       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    218    227       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    231    238       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    242    251       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    254    263       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    273    282       Transmembrane beta-strand (By
FT                                similarity).
FT   NP_BIND     242    244       NAD (By similarity).
FT   NP_BIND     260    264       NAD (By similarity).
FT   MOD_RES      20     20       N6-acetyllysine.
FT   MOD_RES      28     28       N6-acetyllysine.
FT   MOD_RES      33     33       Phosphothreonine (By similarity).
FT   MOD_RES      48     48       Phosphotyrosine (By similarity).
FT   MOD_RES      61     61       N6-acetyllysine.
FT   MOD_RES      63     63       N6-acetyllysine.
FT   MOD_RES      90     90       N6-acetyllysine.
FT   MOD_RES     195    195       Phosphotyrosine.
FT   MOD_RES     241    241       Phosphoserine (By similarity).
FT   VAR_SEQ      39     39       V -> VM (in isoform 2).
FT                                /FTId=VSP_005079.
SQ   SEQUENCE   283 AA;  30659 MW;  E03CBCEDA72A9783 CRC64;
     MCNTPTYCDL GKAAKDVFNK GYGFGMVKID LKTKSCSGVE FSTSGHAYTD TGKASGNLET
     KYKVCNYGLT FTQKWNTDNT LGTEISWENK LAEGLKLTLD TIFVPNTGKK SGKLKASYKR
     DCFSVGSNVD IDFSGPTIYG WAVLAFEGWL AGYQMSFDTA KSKLSQNNFA LGYKAADFQL
     HTHVNDGTEF GGSIYQKVNE KIETSINLAW TAGSNNTRFG IAAKYMLDCR TSLSAKVNNA
     SLIGLGYTQT LRPGVKLTLS ALIDGKNFSA GGHKVGLGFE LEA
//
ID   VDAC3_MOUSE             Reviewed;         283 AA.
AC   Q60931; Q8BNG2;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   02-MAR-2010, entry version 74.
DE   RecName: Full=Voltage-dependent anion-selective channel protein 3;
DE            Short=VDAC-3;
DE            Short=mVDAC3;
DE   AltName: Full=Outer mitochondrial membrane protein porin 3;
GN   Name=Vdac3;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   MEDLINE=96411667; PubMed=8812436; DOI=10.1006/geno.1996.0445;
RA   Sampson M.J., Lovell R.S., Davison D.B., Craigen W.J.;
RT   "A novel mouse mitochondrial voltage-dependent anion channel gene
RT   localizes to chromosome 8.";
RL   Genomics 36:192-196(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Spinal ganglion;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=FVB/N; TISSUE=Mammary gland;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PROTEIN SEQUENCE OF 257-266, AND MASS SPECTROMETRY.
RC   STRAIN=C57BL/6; TISSUE=Brain;
RA   Lubec G., Kang S.U.;
RL   Submitted (APR-2007) to UniProtKB.
RN   [5]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-20; LYS-61 AND LYS-226, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=16916647; DOI=10.1016/j.molcel.2006.06.026;
RA   Kim S.C., Sprung R., Chen Y., Xu Y., Ball H., Pei J., Cheng T.,
RA   Kho Y., Xiao H., Xiao L., Grishin N.V., White M., Yang X.-J., Zhao Y.;
RT   "Substrate and functional diversity of lysine acetylation revealed by
RT   a proteomics survey.";
RL   Mol. Cell 23:607-618(2006).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-48, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Brain;
RX   PubMed=18034455; DOI=10.1021/pr0701254;
RA   Ballif B.A., Carey G.R., Sunyaev S.R., Gygi S.P.;
RT   "Large-scale identification and evolution indexing of tyrosine
RT   phosphorylation sites from murine brain.";
RL   J. Proteome Res. 7:311-318(2008).
CC   -!- FUNCTION: Forms a channel through the mitochondrial outer membrane
CC       that allows diffusion of small hydrophilic molecules (By
CC       similarity).
CC   -!- SUBCELLULAR LOCATION: Mitochondrion outer membrane.
CC   -!- TISSUE SPECIFICITY: Highest levels of expression detected in
CC       testis, less but still abundant expression in heart, kidney,
CC       brain, and skeletal muscle.
CC   -!- DOMAIN: Consists mainly of a membrane-spanning beta-barrel formed
CC       by 19 beta-strands (By similarity).
CC   -!- SIMILARITY: Belongs to the eukaryotic mitochondrial porin family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U30839; AAB47776.1; -; mRNA.
DR   EMBL; AK083785; BAC39019.1; -; mRNA.
DR   EMBL; BC004743; AAH04743.1; -; mRNA.
DR   IPI; IPI00876341; -.
DR   RefSeq; NP_035826.1; -.
DR   UniGene; Mm.227704; -.
DR   STRING; Q60931; -.
DR   TCDB; 1.B.8.1.2; mitochondrial and plastid porin (MPP) family.
DR   PhosphoSite; Q60931; -.
DR   PRIDE; Q60931; -.
DR   Ensembl; ENSMUST00000009036; ENSMUSP00000009036; ENSMUSG00000008892; Mus musculus.
DR   GeneID; 22335; -.
DR   KEGG; mmu:22335; -.
DR   UCSC; uc009ldh.1; mouse.
DR   CTD; 22335; -.
DR   MGI; MGI:106922; Vdac3.
DR   HOVERGEN; HBG054036; -.
DR   PhylomeDB; Q60931; -.
DR   NextBio; 302583; -.
DR   ArrayExpress; Q60931; -.
DR   Bgee; Q60931; -.
DR   CleanEx; MM_VDAC3; -.
DR   Genevestigator; Q60931; -.
DR   GermOnline; ENSMUSG00000008892; Mus musculus.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IDA:MGI.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0046930; C:pore complex; IEA:UniProtKB-KW.
DR   GO; GO:0000166; F:nucleotide binding; IEA:UniProtKB-KW.
DR   GO; GO:0008308; F:voltage-gated anion channel activity; IEA:InterPro.
DR   GO; GO:0006820; P:anion transport; IEA:InterPro.
DR   GO; GO:0001662; P:behavioral fear response; IMP:MGI.
DR   GO; GO:0007612; P:learning; IMP:MGI.
DR   GO; GO:0007270; P:nerve-nerve synaptic transmission; IMP:MGI.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR001925; Porin_Euk.
DR   Pfam; PF01459; Porin_3; 1.
DR   PRINTS; PR00185; EUKARYTPORIN.
DR   PROSITE; PS00558; EUKARYOTIC_PORIN; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Direct protein sequencing; Ion transport; Membrane;
KW   Mitochondrion; Mitochondrion outer membrane; NAD; Nucleotide-binding;
KW   Phosphoprotein; Porin; Transmembrane; Transport.
FT   CHAIN         1    283       Voltage-dependent anion-selective channel
FT                                protein 3.
FT                                /FTId=PRO_0000050513.
FT   TRANSMEM     26     35       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     39     47       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     54     64       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     69     76       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     80     89       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     95    104       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    111    120       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    123    130       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    137    145       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    150    158       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    163    175       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    178    185       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    189    198       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    202    211       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    218    227       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    231    238       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    242    251       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    254    263       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    273    282       Transmembrane beta-strand (By
FT                                similarity).
FT   NP_BIND     242    244       NAD (By similarity).
FT   NP_BIND     260    264       NAD (By similarity).
FT   MOD_RES      20     20       N6-acetyllysine.
FT   MOD_RES      28     28       N6-acetyllysine (By similarity).
FT   MOD_RES      33     33       Phosphothreonine (By similarity).
FT   MOD_RES      48     48       Phosphotyrosine.
FT   MOD_RES      61     61       N6-acetyllysine.
FT   MOD_RES      63     63       N6-acetyllysine (By similarity).
FT   MOD_RES      90     90       N6-acetyllysine (By similarity).
FT   MOD_RES     195    195       Phosphotyrosine (By similarity).
FT   MOD_RES     226    226       N6-acetyllysine.
FT   MOD_RES     241    241       Phosphoserine (By similarity).
FT   CONFLICT     39     39       V -> VM (in Ref. 2; BAC39019).
FT   CONFLICT    174    174       K -> E (in Ref. 2; BAC39019).
SQ   SEQUENCE   283 AA;  30753 MW;  A95AFD67C611228C CRC64;
     MCNTPTYCDL GKAAKDVFNK GYGFGMVKID LKTKSCSGVE FSTSGHAYTD TGKASGNLET
     KYKVCNYGLT FTQKWNTDNT LGTEISWENK LAEGLKLTLD TIFVPNTGKK SGKLKASYRR
     DCFSLGSNVD IDFSGPTIYG WAVLAFEGWL AGYQMSFDTA KSKLSQNNFA LGYKAADFQL
     HTHVNDGTEF GGSIYQKVNE RIETSINLAW TAGSNNTRFG IAAKYKLDCR TSLSAKVNNA
     SLIGLGYTQT LRPGVKLTLS ALIDGKNFNA GGHKVGLGFE LEA
//
ID   VDAC3_RAT               Reviewed;         283 AA.
AC   Q9R1Z0; Q6GSZ1; Q9ESR2; Q9JI31; Q9WTU2;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   14-AUG-2001, sequence version 2.
DT   02-MAR-2010, entry version 69.
DE   RecName: Full=Voltage-dependent anion-selective channel protein 3;
DE            Short=VDAC-3;
DE            Short=rVDAC3;
DE   AltName: Full=Outer mitochondrial membrane protein porin 3;
GN   Name=Vdac3;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Ascitic tumor;
RX   MEDLINE=20453129; PubMed=10998068;
RX   DOI=10.1046/j.1432-1327.2000.01687.x;
RA   Shinohara Y., Ishida T., Hino M., Yamazaki N., Baba Y., Terada H.;
RT   "Characterization of porin isoforms expressed in tumor cells.";
RL   Eur. J. Biochem. 267:6067-6073(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   STRAIN=Sprague-Dawley; TISSUE=Lens;
RA   Rae J.L.;
RT   "Ion channels in the lens.";
RL   Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 10-283 (ISOFORMS 1 AND 2).
RC   TISSUE=Heart;
RX   MEDLINE=98390268; PubMed=9714728; DOI=10.1016/S0167-4781(98)00088-8;
RA   Anflous K., Blondel O., Bernard A., Khrestchatisky M.,
RA   Ventura-Clapier R.;
RT   "Characterization of rat porin isoforms: cloning of a cardiac type-3
RT   variant encoding an additional methionine at its putative N-terminal
RT   region.";
RL   Biochim. Biophys. Acta 1399:47-50(1998).
RN   [5]
RP   PROTEIN SEQUENCE OF 29-34 AND 236-245, PHOSPHORYLATION AT THR-33 AND
RP   SER-241, AND MASS SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=17478130; DOI=10.1016/j.bbapap.2007.03.012;
RA   Distler A.M., Kerner J., Hoppel C.L.;
RT   "Post-translational modifications of rat liver mitochondrial outer
RT   membrane proteins identified by mass spectrometry.";
RL   Biochim. Biophys. Acta 1774:628-636(2007).
RN   [6]
RP   PROTEIN SEQUENCE OF 54-63; 97-109 AND 257-266, AND MASS SPECTROMETRY.
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RA   Lubec G., Kang S.U., Lubec S.;
RL   Submitted (SEP-2007) to UniProtKB.
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND TISSUE SPECIFICITY.
RX   PubMed=19423663; DOI=10.1530/REP-09-0052;
RA   Khan S.A., Suryawanshi A.R., Ranpura S.A., Jadhav S.V., Khole V.V.;
RT   "Identification of novel immunodominant epididymal sperm proteins
RT   using combinatorial approach.";
RL   Reproduction 138:81-93(2009).
CC   -!- FUNCTION: Forms a channel through the mitochondrial outer membrane
CC       that allows diffusion of small hydrophilic molecules (By
CC       similarity).
CC   -!- SUBCELLULAR LOCATION: Mitochondrion outer membrane.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=RVDAC3;
CC         IsoId=Q9R1Z0-1; Sequence=Displayed;
CC       Name=2; Synonyms=RVDAC3V;
CC         IsoId=Q9R1Z0-2; Sequence=VSP_005080;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is widely expressed with strong
CC       expression in atrium and ascitic tumor, lower levels in brain and
CC       very low levels in liver and kidney. Isoform 2 is also widely
CC       expressed with highest levels in brain but no expression in
CC       kidney. Also expressed in flagella of epididymal sperm.
CC   -!- DOMAIN: Consists mainly of a membrane-spanning beta-barrel formed
CC       by 19 beta-strands (By similarity).
CC   -!- SIMILARITY: Belongs to the eukaryotic mitochondrial porin family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB039664; BAB13475.1; -; mRNA.
DR   EMBL; AF268469; AAF80117.1; -; mRNA.
DR   EMBL; BC061780; AAH61780.1; -; mRNA.
DR   EMBL; AF048829; AAD22722.1; -; mRNA.
DR   EMBL; AF048830; AAD22723.1; -; mRNA.
DR   IPI; IPI00231067; -.
DR   IPI; IPI00556929; -.
DR   RefSeq; NP_112645.1; -.
DR   UniGene; Rn.107287; -.
DR   STRING; Q9R1Z0; -.
DR   PhosphoSite; Q9R1Z0; -.
DR   Ensembl; ENSRNOT00000026197; ENSRNOP00000026197; ENSRNOG00000019277; Rattus norvegicus.
DR   GeneID; 83532; -.
DR   KEGG; rno:83532; -.
DR   UCSC; NM_031355; rat.
DR   CTD; 83532; -.
DR   RGD; 621577; Vdac3.
DR   eggNOG; roNOG07651; -.
DR   HOVERGEN; HBG054036; -.
DR   PhylomeDB; Q9R1Z0; -.
DR   NextBio; 616029; -.
DR   ArrayExpress; Q9R1Z0; -.
DR   Genevestigator; Q9R1Z0; -.
DR   GermOnline; ENSRNOG00000019277; Rattus norvegicus.
DR   GO; GO:0005741; C:mitochondrial outer membrane; TAS:RGD.
DR   GO; GO:0046930; C:pore complex; IEA:UniProtKB-KW.
DR   GO; GO:0019718; C:rough microsome; IDA:RGD.
DR   GO; GO:0000166; F:nucleotide binding; IEA:UniProtKB-KW.
DR   GO; GO:0008308; F:voltage-gated anion channel activity; IEA:InterPro.
DR   GO; GO:0006820; P:anion transport; IEA:InterPro.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR001925; Porin_Euk.
DR   Pfam; PF01459; Porin_3; 1.
DR   PRINTS; PR00185; EUKARYTPORIN.
DR   PROSITE; PS00558; EUKARYOTIC_PORIN; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Direct protein sequencing;
KW   Ion transport; Membrane; Mitochondrion; Mitochondrion outer membrane;
KW   NAD; Nucleotide-binding; Phosphoprotein; Porin; Transmembrane;
KW   Transport.
FT   CHAIN         1    283       Voltage-dependent anion-selective channel
FT                                protein 3.
FT                                /FTId=PRO_0000050517.
FT   TRANSMEM     26     35       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     39     47       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     54     64       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     69     76       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     80     89       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM     95    104       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    111    120       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    123    130       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    137    145       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    150    158       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    163    175       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    178    185       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    189    198       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    202    211       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    218    227       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    231    238       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    242    251       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    254    263       Transmembrane beta-strand (By
FT                                similarity).
FT   TRANSMEM    273    282       Transmembrane beta-strand (By
FT                                similarity).
FT   NP_BIND     242    244       NAD (By similarity).
FT   NP_BIND     260    264       NAD (By similarity).
FT   MOD_RES      20     20       N6-acetyllysine (By similarity).
FT   MOD_RES      28     28       N6-acetyllysine (By similarity).
FT   MOD_RES      33     33       Phosphothreonine.
FT   MOD_RES      48     48       Phosphotyrosine (By similarity).
FT   MOD_RES      61     61       N6-acetyllysine (By similarity).
FT   MOD_RES      63     63       N6-acetyllysine (By similarity).
FT   MOD_RES      90     90       N6-acetyllysine (By similarity).
FT   MOD_RES     195    195       Phosphotyrosine (By similarity).
FT   MOD_RES     241    241       Phosphoserine.
FT   VAR_SEQ      39     39       V -> VM (in isoform 2).
FT                                /FTId=VSP_005080.
FT   CONFLICT    128    128       K -> N (in Ref. 2; AAF80117 and 3;
FT                                AAH61780).
SQ   SEQUENCE   283 AA;  30798 MW;  38002466B6557864 CRC64;
     MCSTPTYCDL GKAAKDVFNK GYGFGMVKID LKTKSCSGVE FSTSGHAYTD TGKASGNLET
     KYKVCNYGLI FTQKWNTDNT LGTEISWENK LAEGLKLTVD TIFVPNTGKK SGKLKASYRR
     DCFSVGSKVD IDFSGPTIYG WAVLAFEGWL AGYQMSFDTA KSKLCQNNFA LGYKAEDFQL
     HTHVNDGTEF GGSIYQRVNE KIETSINLAW TAGSNNTRFG IAAKYRLDCR TSLSAKVNNA
     SLIGLGYTQS LRPGVKLTLS ALVDGKNFNA GGHKVGLGFE LEA
//
ID   YBR6_SCHPO              Reviewed;         780 AA.
AC   O94464;
DT   23-SEP-2008, integrated into UniProtKB/Swiss-Prot.
DT   22-SEP-2009, sequence version 2.
DT   02-MAR-2010, entry version 41.
DE   RecName: Full=Uncharacterized protein C23G7.06c;
GN   ORFNames=SPBC23G7.06c;
OS   Schizosaccharomyces pombe (Fission yeast).
OC   Eukaryota; Fungi; Dikarya; Ascomycota; Taphrinomycotina;
OC   Schizosaccharomycetes; Schizosaccharomycetales;
OC   Schizosaccharomycetaceae; Schizosaccharomyces.
OX   NCBI_TaxID=4896;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 38366 / 972;
RX   MEDLINE=21848401; PubMed=11859360; DOI=10.1038/nature724;
RA   Wood V., Gwilliam R., Rajandream M.A., Lyne M.H., Lyne R., Stewart A.,
RA   Sgouros J.G., Peat N., Hayles J., Baker S.G., Basham D., Bowman S.,
RA   Brooks K., Brown D., Brown S., Chillingworth T., Churcher C.M.,
RA   Collins M., Connor R., Cronin A., Davis P., Feltwell T., Fraser A.,
RA   Gentles S., Goble A., Hamlin N., Harris D.E., Hidalgo J., Hodgson G.,
RA   Holroyd S., Hornsby T., Howarth S., Huckle E.J., Hunt S., Jagels K.,
RA   James K.D., Jones L., Jones M., Leather S., McDonald S., McLean J.,
RA   Mooney P., Moule S., Mungall K.L., Murphy L.D., Niblett D., Odell C.,
RA   Oliver K., O'Neil S., Pearson D., Quail M.A., Rabbinowitsch E.,
RA   Rutherford K.M., Rutter S., Saunders D., Seeger K., Sharp S.,
RA   Skelton J., Simmonds M.N., Squares R., Squares S., Stevens K.,
RA   Taylor K., Taylor R.G., Tivey A., Walsh S.V., Warren T., Whitehead S.,
RA   Woodward J.R., Volckaert G., Aert R., Robben J., Grymonprez B.,
RA   Weltjens I., Vanstreels E., Rieger M., Schaefer M., Mueller-Auer S.,
RA   Gabel C., Fuchs M., Duesterhoeft A., Fritzc C., Holzer E., Moestl D.,
RA   Hilbert H., Borzym K., Langer I., Beck A., Lehrach H., Reinhardt R.,
RA   Pohl T.M., Eger P., Zimmermann W., Wedler H., Wambutt R., Purnelle B.,
RA   Goffeau A., Cadieu E., Dreano S., Gloux S., Lelaure V., Mottier S.,
RA   Galibert F., Aves S.J., Xiang Z., Hunt C., Moore K., Hurst S.M.,
RA   Lucas M., Rochet M., Gaillardin C., Tallada V.A., Garzon A., Thode G.,
RA   Daga R.R., Cruzado L., Jimenez J., Sanchez M., del Rey F., Benito J.,
RA   Dominguez A., Revuelta J.L., Moreno S., Armstrong J., Forsburg S.L.,
RA   Cerutti L., Lowe T., McCombie W.R., Paulsen I., Potashkin J.,
RA   Shpakovski G.V., Ussery D., Barrell B.G., Nurse P.;
RT   "The genome sequence of Schizosaccharomyces pombe.";
RL   Nature 415:871-880(2002).
RN   [2]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-473, AND MASS
RP   SPECTROMETRY.
RX   PubMed=18257517; DOI=10.1021/pr7006335;
RA   Wilson-Grady J.T., Villen J., Gygi S.P.;
RT   "Phosphoproteome analysis of fission yeast.";
RL   J. Proteome Res. 7:1088-1097(2008).
RN   [3]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RX   PubMed=16823372; DOI=10.1038/nbt1222;
RA   Matsuyama A., Arai R., Yashiroda Y., Shirai A., Kamata A., Sekido S.,
RA   Kobayashi Y., Hashimoto A., Hamamoto M., Hiraoka Y., Horinouchi S.,
RA   Yoshida M.;
RT   "ORFeome cloning and global analysis of protein localization in the
RT   fission yeast Schizosaccharomyces pombe.";
RL   Nat. Biotechnol. 24:841-847(2006).
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Single-pass
CC       type II membrane protein.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; CU329671; CAA22622.2; -; Genomic_DNA.
DR   PIR; T39952; T39952.
DR   RefSeq; NP_595864.1; -.
DR   GeneID; 2540553; -.
DR   KEGG; spo:SPBC23G7.06c; -.
DR   NMPDR; fig|4896.1.peg.1730; -.
DR   GeneDB_Spombe; SPBC23G7.06c; -.
DR   eggNOG; fuNOG05100; -.
DR   OrthoDB; EOG9GB8PQ; -.
DR   ArrayExpress; O94464; -.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0033554; P:cellular response to stress; IEP:GeneDB_SPombe.
PE   1: Evidence at protein level;
KW   Complete proteome; Endoplasmic reticulum; Glycoprotein; Membrane;
KW   Phosphoprotein; Signal-anchor; Transmembrane.
FT   CHAIN         1    780       Uncharacterized protein C23G7.06c.
FT                                /FTId=PRO_0000350757.
FT   TOPO_DOM      1      2       Cytoplasmic (By similarity).
FT   TRANSMEM      3     23       Signal-anchor for type II membrane
FT                                protein (By similarity).
FT   TOPO_DOM     24    780       Lumenal (By similarity).
FT   MOD_RES     473    473       Phosphoserine.
FT   CARBOHYD    233    233       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    489    489       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    536    536       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    640    640       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    660    660       N-linked (GlcNAc...) (Potential).
SQ   SEQUENCE   780 AA;  87177 MW;  D5A5363FFC927D9D CRC64;
     MFFAFLITYL LGGVTFLPFI LFIYLLTRPT HKSEELRIIE PNNDCLTKLD KDIRIQGWIR
     VTTKFLQGKS GSVKVQEIPQ DQLPKSSSDN AVTDRKTISP SGINNQYVIR NPKDVYYATV
     QAGKLHLFDP VKTSELLHVI NLHEYLVVFY PGTVTENELF SNRNAIFLKY PAVSHKKESS
     TKSLLNKDLY VYGRTPSNKE DWDYALLSYS KISPAIKPLE APIDFDYASV HHNLTALSSP
     DTDWLNAFIG RIFLGIHKTE GFKSLVVEKL TKKLSRIKTP GIMTDVKVID VDVGEAIPTV
     NGLKFESLSN GGELIVSADI WYEGDCSFKA ETTANIKFGS HFPSKTVPLA LVIRLTHVSG
     KVRLLIKPPP SNRVWYAFYE KPRLHLIVEP MVARKQLTNN YLINFITQKL VELVHETIVM
     PNMNDLAFFI DNEAPIKGGL WDIELFRAPT IQKPAEKDAK AERKKSGLSS STSEESLNRH
     ISKRSSNSND TAPSSHIIAD KNLEPTSNIQ LKKNPDGNLV ETSELSDSDE NSVLSNKSST
     LSKKVVENTS PLKYTHSASK SFIGEVQDSL QALKTKAHKP RSIGGDSSQT TLSETTKKYG
     SVAKKSFFQG VSDAKSFVKK IKSTYIDDSS SNSPSDIESN YSADDNEISK SKAQNAIDFN
     VTNTHSPSRS ISSEKSYKAA ERGQQDKHND VLVDLNPNVE AEKSNPHSNS QKTSKNDMSR
     NQRNKYAKEI MTGQPTLHPQ GQLPIQNVEQ RATHKPLPRP PVQVETREPV RPVPPIPKLL
//
ID   YBT1_YEAST              Reviewed;        1661 AA.
AC   P32386; Q07882;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   15-DEC-1998, sequence version 2.
DT   02-MAR-2010, entry version 94.
DE   RecName: Full=ATP-dependent bile acid permease;
GN   Name=YBT1; Synonyms=BAT1; OrderedLocusNames=YLL048C;
OS   Saccharomyces cerevisiae (Baker's yeast).
OC   Eukaryota; Fungi; Dikarya; Ascomycota; Saccharomycotina;
OC   Saccharomycetes; Saccharomycetales; Saccharomycetaceae; Saccharomyces.
OX   NCBI_TaxID=4932;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 204511 / S288c / AB972;
RX   MEDLINE=97313267; PubMed=9169871;
RA   Johnston M., Hillier L.W., Riles L., Albermann K., Andre B.,
RA   Ansorge W., Benes V., Brueckner M., Delius H., Dubois E.,
RA   Duesterhoeft A., Entian K.-D., Floeth M., Goffeau A., Hebling U.,
RA   Heumann K., Heuss-Neitzel D., Hilbert H., Hilger F., Kleine K.,
RA   Koetter P., Louis E.J., Messenguy F., Mewes H.-W., Miosga T.,
RA   Moestl D., Mueller-Auer S., Nentwich U., Obermaier B., Piravandi E.,
RA   Pohl T.M., Portetelle D., Purnelle B., Rechmann S., Rieger M.,
RA   Rinke M., Rose M., Scharfe M., Scherens B., Scholler P., Schwager C.,
RA   Schwarz S., Underwood A.P., Urrestarazu L.A., Vandenbol M.,
RA   Verhasselt P., Vierendeels F., Voet M., Volckaert G., Voss H.,
RA   Wambutt R., Wedler E., Wedler H., Zimmermann F.K., Zollner A.,
RA   Hani J., Hoheisel J.D.;
RT   "The nucleotide sequence of Saccharomyces cerevisiae chromosome XII.";
RL   Nature 387:87-90(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-378.
RX   MEDLINE=94188141; PubMed=8139928; DOI=10.1093/nar/22.5.869;
RA   Cusick M.E.;
RT   "RNP1, a new ribonucleoprotein gene of the yeast Saccharomyces
RT   cerevisiae.";
RL   Nucleic Acids Res. 22:869-877(1994).
RN   [3]
RP   CHARACTERIZATION.
RX   MEDLINE=97326114; PubMed=9182565; DOI=10.1074/jbc.272.24.15358;
RA   Ortiz D.F., St Pierre M.V., Abdulmessih A., Arias I.M.;
RT   "A yeast ATP-binding cassette-type protein mediating ATP-dependent
RT   bile acid transport.";
RL   J. Biol. Chem. 272:15358-15365(1997).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-940; SER-944; SER-1516
RP   AND THR-1517, AND MASS SPECTROMETRY.
RX   MEDLINE=21864552; PubMed=11875433; DOI=10.1038/nbt0302-301;
RA   Ficarro S.B., McCleland M.L., Stukenberg P.T., Burke D.J., Ross M.M.,
RA   Shabanowitz J., Hunt D.F., White F.M.;
RT   "Phosphoproteome analysis by mass spectrometry and its application to
RT   Saccharomyces cerevisiae.";
RL   Nat. Biotechnol. 20:301-305(2002).
RN   [5]
RP   LEVEL OF PROTEIN EXPRESSION [LARGE SCALE ANALYSIS].
RX   MEDLINE=22923965; PubMed=14562106; DOI=10.1038/nature02046;
RA   Ghaemmaghami S., Huh W.-K., Bower K., Howson R.W., Belle A.,
RA   Dephoure N., O'Shea E.K., Weissman J.S.;
RT   "Global analysis of protein expression in yeast.";
RL   Nature 425:737-741(2003).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-940; SER-944 AND
RP   THR-954, AND MASS SPECTROMETRY.
RX   PubMed=15665377; DOI=10.1074/mcp.M400219-MCP200;
RA   Gruhler A., Olsen J.V., Mohammed S., Mortensen P., Faergeman N.J.,
RA   Mann M., Jensen O.N.;
RT   "Quantitative phosphoproteomics applied to the yeast pheromone
RT   signaling pathway.";
RL   Mol. Cell. Proteomics 4:310-327(2005).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-936, AND MASS
RP   SPECTROMETRY.
RX   PubMed=17330950; DOI=10.1021/pr060559j;
RA   Li X., Gerber S.A., Rudner A.D., Beausoleil S.A., Haas W., Villen J.,
RA   Elias J.E., Gygi S.P.;
RT   "Large-scale phosphorylation analysis of alpha-factor-arrested
RT   Saccharomyces cerevisiae.";
RL   J. Proteome Res. 6:1190-1197(2007).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-936, AND MASS
RP   SPECTROMETRY.
RX   PubMed=17563356; DOI=10.1073/pnas.0701622104;
RA   Smolka M.B., Albuquerque C.P., Chen S.H., Zhou H.;
RT   "Proteome-wide identification of in vivo targets of DNA damage
RT   checkpoint kinases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:10364-10369(2007).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-81; SER-936; SER-937;
RP   SER-940; SER-944; SER-952; SER-953; THR-954; SER-955; SER-1516;
RP   THR-1517 AND SER-1519, AND MASS SPECTROMETRY.
RX   PubMed=18407956; DOI=10.1074/mcp.M700468-MCP200;
RA   Albuquerque C.P., Smolka M.B., Payne S.H., Bafna V., Eng J., Zhou H.;
RT   "A multidimensional chromatography technology for in-depth
RT   phosphoproteome analysis.";
RL   Mol. Cell. Proteomics 7:1389-1396(2008).
CC   -!- FUNCTION: Exhibits ATP-dependent bile acid transport.
CC   -!- INTERACTION:
CC       P38310:FTH1; NbExp=1; IntAct=EBI-21511, EBI-20959;
CC       Q02205:MEH1; NbExp=1; IntAct=EBI-21511, EBI-27062;
CC       P38929:PMC1; NbExp=1; IntAct=EBI-21511, EBI-3097;
CC       Q07549:SNA4; NbExp=1; IntAct=EBI-21511, EBI-22078;
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein
CC       (Potential).
CC   -!- MISCELLANEOUS: Present with 3000 molecules/cell in log phase SD
CC       medium.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCC
CC       family. Conjugate transporter (TC 3.A.1.208) subfamily.
CC   -!- SIMILARITY: Contains 2 ABC transmembrane type-1 domains.
CC   -!- SIMILARITY: Contains 2 ABC transporter domains.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z73153; CAA97500.1; -; Genomic_DNA.
DR   EMBL; M88608; AAA20992.1; -; Genomic_DNA.
DR   PIR; S64800; S64800.
DR   RefSeq; NP_013052.1; -.
DR   SMR; P32386; 1110-1636.
DR   DIP; DIP-6474N; -.
DR   IntAct; P32386; 10.
DR   STRING; P32386; -.
DR   TCDB; 3.A.1.208.12; ATP-binding cassette (ABC) superfamily.
DR   PRIDE; P32386; -.
DR   Ensembl; YLL048C; YLL048C; YLL048C; Saccharomyces cerevisiae.
DR   GeneID; 850678; -.
DR   GenomeReviews; Y13138_GR; YLL048C.
DR   KEGG; sce:YLL048C; -.
DR   NMPDR; fig|4932.3.peg.4043; -.
DR   CYGD; YLL048c; -.
DR   SGD; S000003971; YBT1.
DR   eggNOG; fuNOG05955; -.
DR   HOGENOM; HBG734884; -.
DR   OMA; EACGLKR; -.
DR   OrthoDB; EOG9MKPZR; -.
DR   PhylomeDB; P32386; -.
DR   NextBio; 966677; -.
DR   ArrayExpress; P32386; -.
DR   Genevestigator; P32386; -.
DR   GermOnline; YLL048C; Saccharomyces cerevisiae.
DR   GO; GO:0000324; C:fungal-type vacuole; IDA:SGD.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042626; F:ATPase activity, coupled to transmembrane m...; IEA:InterPro.
DR   GO; GO:0015125; F:bile acid transmembrane transporter activity; IMP:SGD.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0015721; P:bile acid and bile salt transport; IMP:SGD.
DR   GO; GO:0055085; P:transmembrane transport; IEA:InterPro.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR017940; ABC_transporter_type1.
DR   InterPro; IPR001140; ABC_transptr_TM_dom.
DR   InterPro; IPR011527; ABC_transptrTM_dom_typ1.
DR   InterPro; IPR003593; ATPase_AAA+_core.
DR   Pfam; PF00664; ABC_membrane; 2.
DR   Pfam; PF00005; ABC_tran; 2.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF90123; ABC_TM_1; 2.
DR   PROSITE; PS50929; ABC_TM1F; 2.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 2.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
PE   1: Evidence at protein level;
KW   ATP-binding; Complete proteome; Glycoprotein; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Repeat; Transmembrane; Transport.
FT   CHAIN         1   1661       ATP-dependent bile acid permease.
FT                                /FTId=PRO_0000093447.
FT   TOPO_DOM      1     33       Extracellular (By similarity).
FT   TRANSMEM     34     54       1 (By similarity).
FT   TOPO_DOM     55     74       Cytoplasmic (By similarity).
FT   TRANSMEM     75     95       2 (By similarity).
FT   TOPO_DOM     96    133       Extracellular (By similarity).
FT   TRANSMEM    134    154       3 (By similarity).
FT   TOPO_DOM    155    166       Cytoplasmic (By similarity).
FT   TRANSMEM    167    187       4 (By similarity).
FT   TOPO_DOM    188    205       Extracellular (By similarity).
FT   TRANSMEM    206    226       5 (By similarity).
FT   TOPO_DOM    227    345       Cytoplasmic (By similarity).
FT   TRANSMEM    346    366       6 (By similarity).
FT   TOPO_DOM    367    393       Extracellular (By similarity).
FT   TRANSMEM    394    414       7 (By similarity).
FT   TOPO_DOM    415    495       Cytoplasmic (By similarity).
FT   TRANSMEM    496    516       8 (By similarity).
FT   TOPO_DOM    517    519       Extracellular (By similarity).
FT   TRANSMEM    520    540       9 (By similarity).
FT   TOPO_DOM    541    602       Cytoplasmic (By similarity).
FT   TRANSMEM    603    623       10 (By similarity).
FT   TOPO_DOM    624    644       Extracellular (By similarity).
FT   TRANSMEM    645    665       11 (By similarity).
FT   TOPO_DOM    666   1053       Cytoplasmic (By similarity).
FT   TRANSMEM   1054   1074       12 (By similarity).
FT   TOPO_DOM   1075   1114       Extracellular (By similarity).
FT   TRANSMEM   1115   1135       13 (By similarity).
FT   TOPO_DOM   1136   1178       Cytoplasmic (By similarity).
FT   TRANSMEM   1179   1199       14 (By similarity).
FT   TOPO_DOM   1200   1200       Extracellular (By similarity).
FT   TRANSMEM   1201   1221       15 (By similarity).
FT   TOPO_DOM   1222   1292       Cytoplasmic (By similarity).
FT   TRANSMEM   1293   1313       16 (By similarity).
FT   TOPO_DOM   1314   1315       Extracellular (By similarity).
FT   TRANSMEM   1316   1336       17 (By similarity).
FT   TOPO_DOM   1337   1661       Cytoplasmic (By similarity).
FT   DOMAIN      354    662       ABC transmembrane type-1 1.
FT   DOMAIN      694    935       ABC transporter 1.
FT   DOMAIN     1026   1345       ABC transmembrane type-1 2.
FT   DOMAIN     1381   1636       ABC transporter 2.
FT   NP_BIND     729    736       ATP 1 (Potential).
FT   NP_BIND    1415   1422       ATP 2 (Potential).
FT   MOD_RES      81     81       Phosphoserine.
FT   MOD_RES     936    936       Phosphoserine.
FT   MOD_RES     937    937       Phosphoserine.
FT   MOD_RES     940    940       Phosphoserine.
FT   MOD_RES     944    944       Phosphoserine.
FT   MOD_RES     952    952       Phosphoserine.
FT   MOD_RES     953    953       Phosphoserine.
FT   MOD_RES     954    954       Phosphothreonine.
FT   MOD_RES     955    955       Phosphoserine.
FT   MOD_RES    1516   1516       Phosphoserine.
FT   MOD_RES    1517   1517       Phosphothreonine.
FT   MOD_RES    1519   1519       Phosphoserine.
FT   CARBOHYD      6      6       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     97     97       N-linked (GlcNAc...) (Potential).
FT   CONFLICT    172    174       TIT -> QIH (in Ref. 2; AAA20992).
FT   CONFLICT    188    189       LR -> FS (in Ref. 2; AAA20992).
SQ   SEQUENCE   1661 AA;  189162 MW;  E71D3D57A3013C38 CRC64;
     MHHVLNSTRP DHRFWFYDDV TQYGRTKYLN YYTPLVLLIF TVLFITYNIW KHYYYYDVLH
     LKQKNPIDEL LYSSTDEDEQ SPLINNNTIT TNYVDNNCTK DALKNRHFSL EKLKSVKVNG
     EPHGTPEIVR RGFIEKSRII LEFFLVLSQV IIHSFILLHY VNKNPEFTQQ GTITGLVEWC
     ALFIIVSLRL ANVNQNFKFI NKYPGNLWSV SFINYLALFI SMILPFRSIF IHHINSPISR
     KYYISQISIN LALFLLLFFA RIRNNFAIIY KTDSWITPSP EPVTSIAGFI CWAWLDSFVW
     KAHKVSIKVK DIWGLMMQDY SFFVVKKFRY FVDHKVKRKR IFSLNLFFFF SNYLVLQCFW
     AFLGSVLSFI PTVLLKRILE YVEDQSSAPS NLAWFYVTVM FVGRILVAIC QAQALFFGRR
     VCIRMKSIII SEIYTKALRR KISTNKTKPS NEDPQEINDQ KSINGDEEST SSANLGAIIN
     LMAIDAFKVS EICGYLHSFL EAFVMTVVAL ALLYRLLGFA AIVGVLIIVA MLPLNYKLAK
     YIGDLQKKNL AVTDNRIQKL NEAFQAIRII KYFSWEENFE KDINTIRENE LSLLLMRSIV
     WSISSFLWFV TPTIVTAASF AYYIYVQGEV LTTPVAFTAL SLFTLLRDPL DRLSDMLSFV
     VQSKVSLDRV QDFLNENDTK KYDQLTIDPN GNRFAFENST ISWDKDNQDF KLKDLNIEFK
     TGKLNVVIGP TGSGKTSLLM ALLGEMYLLN GKVVVPALEP RQELIVDANG TTNSIAYCSQ
     AAWLLNDTVK NNILFNSPFN EARYKAVVEA CGLKRDFEIL KAGDLTEIGE KGITLSGGQK
     QRVSLARALY SNARHVLLDD CLSAVDSHTA SWIYDNCITG PLMEDRTCIL VSHNIALTLR
     NAELVVLLED GRVKDQGDPI DMLQKGLFGE DELVKSSILS RANSSANLAA KSSTSLSNLP
     AVKEQQVSVN NNSSHFEAKK LQKSLRTEAE RTEDGKLIKE ETKEEGVVGL DVYKWYLKIF
     GGWKIVSFLA SLFLIAQLLY IGQSWWVRAW ASHNVIAKII PRAQRAIAFI SKKASHLIDW
     RGSSQISMAS AENQPSSGHS TMYYLVLYLI IGFAQALLGA GKTILNFVAG INASRKIFNM
     ILNKVLHSKI RFFDATPTGR IMNRFSKDIE AIDQELTPYI QGAFYSLIEC LSTVILITFI
     TPQFLSVAIV VSILYYFVGY FYMAGSRELK RFESISRSPI YQHFSETLVG VTTIRAFGDE
     GRFMQENLHK IDENNKPFFY LWVANRWLAF RIDMIGSLVI FGAGLFILFN INNLDSGMAG
     ISLTYAISFT EGALWLVRLY SEVEMNMNSV ERVKEYMEIE QEPYNEHKEI PPPQWPQDGK
     IEVNDLSLRY APNLPRVIKN VSFSVDAQSK IGIVGRTGAG KSTIITALFR FLEPETGHIK
     IDNIDISGVD LQRLRRSITI IPQDPTLFSG TIKTNLDPYD EFSDRQIFEA LKRVNLISEE
     QLQQGATRET SNEASSTNSE NVNKFLDLSS EISEGGSNLS QGQRQLMCLA RSLLRSPKII
     LLDEATASID YSSDAKIQET IRKEFQGSTI LTIAHRLRSV IDYDKILVMD AGEVKEYDHP
     YSLLLNKQSA FYSMCEHSGE LDILIELAKK AFVEKLNSKK D
//
